PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	JOHNSON, VG; NICHOLLS, PJ				JOHNSON, VG; NICHOLLS, PJ			HISTIDINE-21 DOES NOT PLAY A MAJOR ROLE IN DIPHTHERIA-TOXIN CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLTRANSFERASE ACTIVITY; AERUGINOSA EXOTOXIN-A; NAD BINDING-SITE; ESCHERICHIA-COLI; ASPARTIC-ACID; FULL-LENGTH; MUTANT; FRAGMENT; TRANSLATION; EXPRESSION	It has been proposed that the histidine at position 21 (H21) of the diphtheria toxin A subunit (DTA) plays an important role in the ADP-ribosyltransferase (ADPRT) activity of the toxin. The region of DT encompassing H21 demonstrates sequence similarity with other toxins exhibiting ADPRT activity, is located along the catalytic cleft of DTA, and when H21 is chemically modified, ADPRT activity is abolished. H21 was mutagenized by a polymerase chain reaction-based system whereby all alternative amino acids were substituted in place of the histidine. The majority of the substitutions virtually abolished enzymatic activity, the exception being a mutant in which H21 was replaced with asparagine (DTA-H21N). This mutant demonstrated only a slight increase in K-m and relatively small decreases in both reaction rate (k(cat)) and catalytic efficiency (k(cat)/K-m). Asparagine is a sterically conserved substitution, but its side-chain is unable to replace the imidazole group of histidine in general acid-base mechanisms or to participate in electrostatic interactions. This suggests that H21 is important in maintaining a steric conformation required for catalysis rather than in participating in an electrostatic or acid-base type of exchange.	NIDR,MICROBIAL ECOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	JOHNSON, VG (corresponding author), US FDA,CBER,DIV BACTERIAL PROD,BACTERIAL TOXINS LAB,BLDG 29,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							ASHKENAZI A, 1990, P NATL ACAD SCI USA, V87, P7150, DOI 10.1073/pnas.87.18.7150; BARBIERI JT, 1987, INFECT IMMUN, V55, P1647, DOI 10.1128/IAI.55.7.1647-1651.1987; BLANKE S, 1992, ZBL BAKT S, V23, P349; CARROLL SF, 1984, P NATL ACAD SCI-BIOL, V81, P3307, DOI 10.1073/pnas.81.11.3307; CARROLL SF, 1988, MOL MICROBIOL, V2, P293, DOI 10.1111/j.1365-2958.1988.tb00031.x; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; DOMENIGHINI M, 1991, MOL MICROBIOL, V5, P23, DOI 10.1111/j.1365-2958.1991.tb01822.x; EMERICK A, 1985, DNA-J MOLEC CELL BIO, V4, P78; GILL DM, 1988, BACTERIAL PROTEIN TO, P315; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; HONJO T, 1968, J BIOL CHEM, V243, P3553; JOHNSON VG, 1988, J BIOL CHEM, V263, P1295; JOHNSON VG, 1993, J BIOL CHEM, V268, P3514; KANDEL J, 1974, J BIOL CHEM, V249, P2088; KASLOW HR, 1989, J BIOL CHEM, V264, P6386; KILLEEN KP, 1992, P NATL ACAD SCI USA, V89, P6207, DOI 10.1073/pnas.89.13.6207; KOZAK M, 1990, NUCLEIC ACIDS RES, V18, P2828, DOI 10.1093/nar/18.9.2828; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILES EW, 1989, J BIOL CHEM, V264, P6280; NICHOLLS PJ, 1993, J BIOL CHEM, V268, P5302; NICOLLS PJ, 1992, GENETICALLY ENG TOXI, P339; OKEEFE DO, 1992, ARCH BIOCHEM BIOPHYS, V296, P678, DOI 10.1016/0003-9861(92)90626-8; PAPINI E, 1987, FEBS LETT, V215, P73, DOI 10.1016/0014-5793(87)80116-3; PAPINI E, 1989, J BIOL CHEM, V264, P12385; PAPINI E, 1990, TOXICON, V28, P631, DOI 10.1016/0041-0101(90)90251-2; PORATH J, 1992, PROTEIN EXP PURIF, V2, P95; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TWETEN RK, 1985, J BIOL CHEM, V260, P392; UCHIDA T, 1973, J BIOL CHEM, V248, P3838; WILLIAMS DP, 1990, J BIOL CHEM, V265, P20673; WILSON BA, 1990, BIOCHEMISTRY-US, V29, P8643, DOI 10.1021/bi00489a021; WILSON BA, 1992, CURR TOP MICROBIOL, V175, P27; 1986, FED REGISTER, V51, P16971; 1986, FED REG 3, V51, P16961	35	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4349	4354						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308004				2022-12-27	WOS:A1994MW98900071
J	KAPLAN, DL; BORON, WF				KAPLAN, DL; BORON, WF			LONG-TERM EXPRESSION OF C-H-RAS STIMULATES NA-H AND NA+-DEPENDENT CL-HCO3 EXCHANGE IN NIH-3T3 FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR MESANGIAL CELLS; INTRACELLULAR-PH; CYTOPLASMIC-PH; GROWTH-FACTORS; 3T3 CELLS; EXTRACELLULAR PH; PROXIMAL TUBULE; ANGIOTENSIN-II; ACID-EXTRUSION; ALKALINIZATION	In a study of intracellular pH (pH(i)) regulation, we compared c-H-ras-transformed fibroblasts (FT9s) with parental NIH 3T3 cells. Cells were grown on a coverslip and placed in a flow-through cuvette; pH(i) was monitored using a fluorescent dye. Whether cells were in a CO2-free or CO2-containing solution, steady-state pH(i) was similar to 0.5 higher in FT9s than in 3T3s. Rates of pH(i) recovery from acid loads in the presence of CO2 indicate that total net acid extrusion (J(total)) was far greater in FT9s than 3T3s in the pH(i) range 6.3-7.4. In both FT9s and 3T3s, pH(i) recovery was blocked by removing Na+. In FT9s, most of (J)(total), was blocked by ethyl isopropyl amiloride (EIPA) and was probably due to Na-H exchange. A smaller component was inhibited by 4,4'-diisothiocyanostilbene-2,2'-disulfonate (DIDS) and required Cl- and was probably due to Na+-dependent Cl-HCO3 exchange. In 3T3s, the DIDS-sensitive and Cl--dependent components of (J)(total), were very small. The dominant acid extruder in 3T3s appears to be a Na-H exchanger insensitive to 50 mu M EIPA. We determined the flux-pH(i) relationships for both the Na-H and Na+-dependent Cl-HCO3 exchangers in both FT9s and 3T3s. p21(ras) alkaline shifts the pH(i) profile of each transporter by similar to 0.7, without affecting the V-max. These shifts in the flux-pH(i) relationships provide a mechanism for the large increase in steady-state pH(i) produced by long-term expression of p21(ras).			KAPLAN, DL (corresponding author), YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510, USA.		Boron, Walter/ABI-1564-2020	Boron, Walter/0000-0003-4741-7287; Kaplan, Daniel/0000-0003-2760-7745	NIDDK NIH HHS [DK17433] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK017433] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADLER S, 1965, J CLIN INVEST, V44, P21, DOI 10.1172/JCI105123; ADLER S, 1965, J CLIN INVEST, V44, P8, DOI 10.1172/JCI105129; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BIERMAN AJ, 1988, J BIOL CHEM, V263, P15253; BORON WF, 1983, J GEN PHYSIOL, V81, P29, DOI 10.1085/jgp.81.1.29; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BORON WF, 1992, J GEN PHYSIOL, V99, P817, DOI 10.1085/jgp.99.5.817; BORON WF, 1979, AM J PHYSIOL, V237, pC185, DOI 10.1152/ajpcell.1979.237.3.C185; BOS JL, 1989, CANCER RES, V49, P4682; BOYARSKY G, 1990, P NATL ACAD SCI USA, V87, P5921, DOI 10.1073/pnas.87.15.5921; BOYARSKY G, 1993, GLIA, V8, P241, DOI 10.1002/glia.440080404; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC857, DOI 10.1152/ajpcell.1988.255.6.C857; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; CASSEL D, 1983, P NATL ACAD SCI-BIOL, V80, P6224, DOI 10.1073/pnas.80.20.6224; CHEN LK, 1991, THESIS YALE U; DEUTSCH C, 1984, J CELL BIOL, V98, P885, DOI 10.1083/jcb.98.3.885; DOPPLER W, 1987, GENE, V54, P147, DOI 10.1016/0378-1119(87)90357-X; GANZ MB, 1990, AM J PHYSIOL, V259, pF269, DOI 10.1152/ajprenal.1990.259.2.F269; GANZ MB, 1989, NATURE, V337, P648, DOI 10.1038/337648a0; GANZ MB, 1988, AM J PHYSIOL, V254, pF787, DOI 10.1152/ajprenal.1988.254.6.F787; GEIBEL J, 1990, P NATL ACAD SCI USA, V87, P7917, DOI 10.1073/pnas.87.20.7917; GILLIES RJ, 1991, J BIOL CHEM, V266, P1551; GRIFFITHS JR, 1991, BRIT J CANCER, V64, P425, DOI 10.1038/bjc.1991.326; GRINSTEIN S, 1985, P NATL ACAD SCI USA, V82, P1429, DOI 10.1073/pnas.82.5.1429; HAGAG N, 1987, MOL CELL BIOL, V7, P1984, DOI 10.1128/MCB.7.5.1984; JOHNSON JD, 1976, NATURE, V262, P661, DOI 10.1038/262661a0; KAPLAN DL, 1992, FASEB J, V6, pA1639; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MOOLENAAR WH, 1984, NATURE, V312, P371, DOI 10.1038/312371a0; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; NAKHOUL NL, 1994, IN PRESS J GEN PHYSL; OLSNES S, 1986, J CELL BIOL, V102, P967, DOI 10.1083/jcb.102.3.967; PERONA R, 1988, NATURE, V334, P438, DOI 10.1038/334438a0; POUYSSEGUR J, 1985, FEBS LETT, V190, P115, DOI 10.1016/0014-5793(85)80439-7; RALEYSUSMAN KM, 1991, J BIOL CHEM, V266, P2739; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SCHULDINER S, 1982, P NATL ACAD SCI-BIOL, V79, P7778, DOI 10.1073/pnas.79.24.7778; SCHWARTZ GJ, 1985, J CLIN INVEST, V75, P1638, DOI 10.1172/JCI111871; SZWERGOLD BS, 1989, J CELL PHYSIOL, V138, P227, DOI 10.1002/jcp.1041380203; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VAUPEL P, 1989, CANCER RES, V49, P6449; YAMADA H, 1990, MOL CELL BIOL, V10, P1822, DOI 10.1128/MCB.10.4.1822	44	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4116	4124						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307971				2022-12-27	WOS:A1994MW98900036
J	LEJOHN, HB; CAMERON, LE; YANG, B; RENNIE, SL				LEJOHN, HB; CAMERON, LE; YANG, B; RENNIE, SL			MOLECULAR CHARACTERIZATION OF AN NAD-SPECIFIC GLUTAMATE-DEHYDROGENASE GENE INDUCIBLE BY L-GLUTAMINE - ANTISENSE GENE PAIR ARRANGEMENT WITH L-GLUTAMINE-INDUCIBLE HEAT-SHOCK 70-LIKE PROTEIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; CORTICOTROPIN ACTH RECEPTOR; ESCHERICHIA-COLI; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; BINDING-SITE; AMINO-ACIDS; COMPLEMENTARY; DNA; EXPRESSION	The gene for an NAD-specific glutamate dehydrogenase (NAD-GDH) that is allosterically activated by NADP(+) (non-substrate) was cloned, and its physical structure and nucleotide sequence was determined. The gene consists of 9 introns and 10 exons; the 10th and largest exon, which is 1863 nucleotides long, is at the 3'-end of the gene. The shortest exon of 33 base pairs is the first and is located at the 5'-end of the gene. The large exon is in perfect register along the complementary strand with a heat shock 70 (HSP)-like protein gene. The NAD-GDH gene is inducible with L-glutamine, just as the HSP 70-like protein gene (LeJohn, H. B., Cameron, L. E., Yang, B., MacBeath, G., Barker, D. S., and Williams, S. A (1994) J. Biol. Chem. 269, 4513-4522). The phenomenon of antiparallel coupling of two genes is named antisense gene pair. By Northern and Western blotting techniques, we obtained indirect evidence that the gene is expressed in vivo. The gene encodes a protein of M(r) 118,740 which consists of 1063 amino acid residues. The 5' and 3' borders of the gene display typical but unproven promoter motifs of CCAAT, TATAAT, and AAATAAAA polyadenylation signal bounded by a pyrimidine-rich transcription termination-type format. Restriction endonuclease site mapping of all the genomic clones isolated that carry most or all of the gene, and of the genome itself, gave hybridization patterns that are consistent with the interpretation that the organism, Achlya klebsiana, has only one form of the gene. 3'-End-labeling of a 5.2-kb XbaI DNA fragment (carrying the antisense gene pair) that was then asymmetrically cleaved to produce two single 3'-end-labeled pieces that were used as probes on L-glutamine-induced cell poly(A)(+) RNA, showed that the end-labeled DNA equivalent to the HSP 70-like protein mRNA hybridized to a 3.4-kb transcript and the end-labeled DNA equivalent to the NAD-GDH mRNA hybridized to a 2.4-kb transcript.	UNIV MANITOBA,FAC MED,DEPT HUMAN GENET,WINNIPEG R3E 0W3,MB,CANADA; MANITOBA INST CELL BIOL,WINNIPEG R3E 0V9,MB,CANADA	University of Manitoba	LEJOHN, HB (corresponding author), UNIV MANITOBA,DEPT MICROBIOL,WINNIPEG R3T 2N2,MB,CANADA.							AMURO N, 1990, BIOCHIM BIOPHYS ACTA, V1049, P216, DOI 10.1016/0167-4781(90)90043-2; ANG D, 1991, J BIOL CHEM, V266, P24333; AUSTEN BM, 1977, J BIOL CHEM, V252, P8142; AUSUBEL F, 1989, SHORT PROTOCOLS MOL, P4; AVIV H, 1972, P NATL ACAD SCI USA, V74, P5463; BLALOCK JE, 1984, BIOCHEM BIOPH RES CO, V121, P203, DOI 10.1016/0006-291X(84)90707-1; BLALOCK JE, 1986, BIOCHEM J, V234, P679, DOI 10.1042/bj2340679; BOST KL, 1986, MOL CELL ENDOCRINOL, V44, P1, DOI 10.1016/0303-7207(86)90099-7; BOST KL, 1985, P NATL ACAD SCI USA, V82, P1372, DOI 10.1073/pnas.82.5.1372; BRENTANI RR, 1988, J THEOR BIOL, V135, P495, DOI 10.1016/S0022-5193(88)80272-8; BRENTANI RR, 1988, P NATL ACAD SCI USA, V85, P364, DOI 10.1073/pnas.85.2.364; BRENTANI RR, 1990, J MOL EVOL, V3, P239; BRITTON KL, 1992, EUR J BIOCHEM, V209, P851, DOI 10.1111/j.1432-1033.1992.tb17357.x; CARR DJJ, 1986, J NEUROIMMUNOL, V12, P329, DOI 10.1016/0165-5728(86)90039-1; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLON AD, 1986, J NEUROCHEM, V46, P1811; DAS AT, 1989, NUCLEIC ACIDS RES, V17, P2355, DOI 10.1093/nar/17.6.2355; DESOUZA SJ, 1992, J BIOL CHEM, V267, P13763; ELTON TS, 1988, P NATL ACAD SCI USA, V85, P2518, DOI 10.1073/pnas.85.8.2518; GOLDSTEIN A, 1989, P NATL ACAD SCI USA, V86, P42, DOI 10.1073/pnas.86.1.42; HAWKINS AR, 1989, MOL GEN GENET, V218, P105, DOI 10.1007/BF00330572; HELLING RB, 1990, MOL GEN GENET, V223, P508, DOI 10.1007/BF00264460; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENIKOFF S, 1984, GENE, V28, P521; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; KAPOOR M, 1993, BIOCHEM CELL BIOL, V71, P205, DOI 10.1139/o93-032; KINNAIRD JH, 1983, GENE, V26, P253, DOI 10.1016/0378-1119(83)90195-6; KORNELUK RG, 1985, GENE, V40, P317, DOI 10.1016/0378-1119(85)90055-1; LEE YM, 1988, ANAL BIOCHEM, V175, P156; LEJOHN HB, 1989, J BIOL CHEM, V264, P19366; LEJOHN HB, 1994, J BIOL CHEM, V269, P4513; LEJOHN HB, 1970, J BIOL CHEM, V245, P3890; MAVROTHALASSITIS G, 1988, P NATL ACAD SCI USA, V85, P3494, DOI 10.1073/pnas.85.10.3494; MILLER SM, 1990, J BACTERIOL, V172, P4927, DOI 10.1128/jb.172.9.4927-4935.1990; MULCHAHEY JJ, 1986, P NATL ACAD SCI USA, V83, P9714, DOI 10.1073/pnas.83.24.9714; NAGASU T, 1985, GENE, V37, P247, DOI 10.1016/0378-1119(85)90279-3; PAPADOPOULOU D, 1990, BIOCHEM GENET, V28, P337; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Smith E.L., 1975, ENZYMES, P293, DOI DOI 10.1016/S1874-6047(08)60213-9; STEVENSON RM, 1971, J BIOL CHEM, V246, P2127; TELLER JK, 1992, EUR J BIOCHEM, V206, P151, DOI 10.1111/j.1432-1033.1992.tb16912.x; VALLE F, 1984, GENE, V27, P193, DOI 10.1016/0378-1119(84)90140-9; YANG BH, 1994, J BIOL CHEM, V269, P4506	46	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4523	4531						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308022				2022-12-27	WOS:A1994MW98900094
J	NAIM, HY; ROTH, MG				NAIM, HY; ROTH, MG			CHARACTERISTICS OF THE INTERNALIZATION SIGNAL IN THE Y543 INFLUENZA-VIRUS HEMAGGLUTININ SUGGEST A MODEL FOR RECOGNITION OF INTERNALIZATION SIGNALS CONTAINING TYROSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN DETERMINANT; DENSITY-LIPOPROTEIN RECEPTOR; MANNOSE 6-PHOSPHATE RECEPTOR; HUMAN TRANSFERRIN RECEPTOR; FACTOR-II RECEPTOR; AMINO-ACID CHANGE; COATED PITS; RAPID INTERNALIZATION; PLASMA-MEMBRANE; PEPTIDE BINDING	Several proteins, including the hemagglutinin (HA)-Y543 mutant influenza virus hemagglutinin, are internalized by clathrin coated pits but do not have a sequence that fits a recently proposed consensus for internalization signals containing tyrosine. To determine whether or not the HA-543 signal is a degenerate form of the internalization signal found in proteins such as the transferrin receptor and mannose 6-phosphate/insulin-like growth factor (IGF) II receptor, we have mutated amino acid positions of HA-Y543 shown to be important for internalization of the two receptors. Our results indicate that the HA-Y543 mutant contains a suboptimum sequence for a tyrosine-based internalization signal similar to those found in the receptors for transferrin, low density lipoprotein, and mannose 6-phosphate/IGFII. However, amino acids with side chains having very different chemical properties functioned well in positions that are important for the internalization signal. The variety of amino acid side chains found in known internalization sequences suggests that atoms of the polypeptide chain backbone may contribute important interactions for binding proteins to clathrin coats, with many of the side chains serving mainly to permit these interactions, a situation similar to that observed for the binding of peptides by histocompatibility proteins.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Roth, Michael/0000-0002-9056-332X	NIGMS NIH HHS [GM37547] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037547] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ E, 1990, BIOCHEM J, V267, P31, DOI 10.1042/bj2670031; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DOYLE C, 1985, J CELL BIOL, V100, P704, DOI 10.1083/jcb.100.3.704; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; FIRE E, 1991, J CELL BIOL, V115, P1585, DOI 10.1083/jcb.115.6.1585; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; GIRONES N, 1991, J BIOL CHEM, V266, P19006; HAMMER J, 1993, CELL, V74, P197, DOI 10.1016/0092-8674(93)90306-B; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; JADOT M, 1992, J BIOL CHEM, V267, P11069; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KRUSKAL BA, 1992, J EXP MED, V176, P1673, DOI 10.1084/jem.176.6.1673; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LAZAROVITS J, 1990, J BIOL CHEM, V265, P4760; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; MIETTINEN HM, 1992, J CELL BIOL, V116, P875, DOI 10.1083/jcb.116.4.875; NAIM HY, 1993, J VIROL, V67, P4831, DOI 10.1128/JVI.67.8.4831-4841.1993; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; ROTH MG, 1993, CELL BIOL BIOTECHNOL, P137; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOSA MA, 1993, J BIOL CHEM, V268, P12537; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; VEGA MA, 1989, P NATL ACAD SCI USA, V86, P2688, DOI 10.1073/pnas.86.8.2688; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	50	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3928	3933						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307947				2022-12-27	WOS:A1994MW98900007
J	OGIERDENIS, E; BLAIS, A; HOURI, JJ; VOISIN, T; TRUGNAN, G; CODOGNO, P				OGIERDENIS, E; BLAIS, A; HOURI, JJ; VOISIN, T; TRUGNAN, G; CODOGNO, P			THE EMERGENCE OF A BASOLATERAL 1-DEOXYMANNOJIRIMYCIN-SENSITIVE MANNOSE CARRIER IS A FUNCTION OF INTESTINAL EPITHELIAL-CELL DIFFERENTIATION - EVIDENCE FOR A NEW INHIBITORY EFFECT OF 1-DEOXYMANNOJIRIMYCIN ON FACILITATIVE MANNOSE TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; VILLUS-CRYPT AXIS; LIVER GOLGI MEMBRANES; RAT-LIVER; CACO-2 CELLS; ENDOPLASMIC-RETICULUM; ALPHA-MANNOSIDASE; MESSENGER-RNA; PEPTIDE-YY; GLUCOSE TRANSPORTERS	We have previously reported that 1-deoxymannojiri-mycin (dMM), a specific cy-mannosidase I inhibitor interfered with the uptake of D-[2-H-3]mannose in differentiated HT-29 cells (a cell line derived from a human colon adenocarcinoma) (Ogier Denis, E., Trugnan, G., Sapin, C., Aubery, M., and Codogno, P. (1990) J. Biol. Chem. 265, 5366-5369). In the present work, we have used another cell line derived from a human colon adenocarcinoma, Caco-2 cells, which has the capacity to grow and to dif ferentiate on porous filters. We have determined that mannose could enter the cells by two distinct transporters. One sensitive to dMM, present at the basolateral membrane of differentiated Caco-2 cells, and one insensitive to the drug localized at the brush border membrane of these cells. The basolateral mannose uptake is mediated by a Na+-independent transporter whereas the apical entry of mannose is under the dependence of Na+. We have focused our studies on the basolateral dMM-sensitive mannose carrier. Kinetic studies indicated that this facilitative mannose transporter has a K-m and a V-max of 55 +/- 8 mu m and 0.144 +/- 0.005 mu mol/mg of protein/ min, respectively. This basolateral transporter is clearly distinct from facilitative glucose transporters. Moreover, this dMM-sensitive mannose transport accurately follows the differentiation process of intestinal epithelial cells as well in vitro as shown using Caco-2 cells as in vivo when experiments were done on crypt cells and villus cells isolated from rat jejunum.	INSERM, U239, UNITE RECH BIOL & PHYSIOPATHOL CELLULES DIGEST, F-75018 PARIS, FRANCE; FAC PHARM CHATENAY MALABRY, DIPARTIMENTO MICROBIOL, F-92296 CHATENAY MALABRY, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay			voisin, thierry/R-1241-2017; Ogier-Denis, Eric/E-5030-2016; Codogno, Patrice/G-1384-2013	voisin, thierry/0000-0002-4320-5183; Codogno, Patrice/0000-0002-5492-3180; Ogier-Denis, Eric/0000-0002-0057-7593				ALVAREZHERNANDE.X, 1991, BIOCHIM BIOPHYS ACTA, V1070, P2205; BELL GI, 1993, J BIOL CHEM, V268, P19161; BISCHOFF J, 1984, BIOCHEM BIOPH RES CO, V125, P324, DOI 10.1016/S0006-291X(84)80371-X; BISCHOFF J, 1986, J BIOL CHEM, V261, P4758; BLAIS A, 1987, J MEMBRANE BIOL, V99, P113, DOI 10.1007/BF01871231; BOLLER K, 1988, DIFFERENTIATION, V39, P51, DOI 10.1111/j.1432-0436.1988.tb00080.x; BONAY P, 1991, EUR J BIOCHEM, V197, P229, DOI 10.1111/j.1432-1033.1991.tb15903.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURANT CF, 1992, J BIOL CHEM, V267, P14523; BURNHAM DB, 1989, AM J PHYSIOL, V256, pG808, DOI 10.1152/ajpgi.1989.256.4.G808; BURTON PS, 1993, BIOCHEM BIOPH RES CO, V190, P760, DOI 10.1006/bbrc.1993.1114; CHANDRASENA G, 1992, CELL MOL BIOL, V38, P243; DARMOUL D, 1991, AM J PHYSIOL, V261, pG763, DOI 10.1152/ajpgi.1991.261.5.G763; DAVIDSON NO, 1992, AM J PHYSIOL, V262, pC795, DOI 10.1152/ajpcell.1992.262.3.C795; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ELLWOOD KC, 1993, P SOC EXP BIOL MED, V202, P440, DOI 10.3181/00379727-202-43556; ELSAS LJ, 1992, ANNU REV MED, V43, P377, DOI 10.1146/annurev.me.43.020192.002113; FORSEE WT, 1989, J BIOL CHEM, V264, P3869; FUHRMANN U, 1984, NATURE, V307, P755, DOI 10.1038/307755a0; FUHRMANN U, 1985, BIOCHIM BIOPHYS ACTA, V825, P95, DOI 10.1016/0167-4781(85)90095-8; GORDON JI, 1992, FASEB J, V6, P3039, DOI 10.1096/fasebj.6.12.1521737; HARRIS DS, 1992, P NATL ACAD SCI USA, V89, P7556, DOI 10.1073/pnas.89.16.7556; HIRAIZUMI S, 1993, J BIOL CHEM, V268, P9927; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HUGHES TE, 1988, J BIOL CHEM, V263, P3425; KAYANO T, 1990, J BIOL CHEM, V265, P13276; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LABURTHE M, 1986, ENDOCRINOLOGY, V118, P1910, DOI 10.1210/endo-118-5-1910; LABURTHE M, 1988, AM J PHYSIOL, V254, pG457, DOI 10.1152/ajpgi.1988.254.3.G457; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; MAHRAOUI L, 1992, AM J PHYSIOL, V263, pG312, DOI 10.1152/ajpgi.1992.263.3.G312; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MENDELSSOHN DC, 1989, AM J PHYSIOL, V257, pF1100, DOI 10.1152/ajprenal.1989.257.6.F1100; NEEFJES JJ, 1989, J BIOL CHEM, V264, P10271; OGIERDENIS E, 1990, J BIOL CHEM, V265, P5366; PINTO M, 1983, BIOL CELL, V47, P323; RAND EB, 1993, AM J PHYSIOL, V264, pG1169, DOI 10.1152/ajpgi.1993.264.6.G1169; RINDLER MJ, 1988, J CELL BIOL, V107, P471, DOI 10.1083/jcb.107.2.471; RIZZOLO LJ, 1988, J BIOL CHEM, V263, P9520; SAUNIER B, 1982, J BIOL CHEM, V257, P4155; SCHWEDEN J, 1986, EUR J BIOCHEM, V157, P563, DOI 10.1111/j.1432-1033.1986.tb09703.x; SIMON PM, 1979, BIOCHEM J, V178, P407, DOI 10.1042/bj1780407; TABAS I, 1979, J BIOL CHEM, V254, P1655; THORENS B, 1990, AM J PHYSIOL, V259, pC279; THWAITES DT, 1993, J BIOL CHEM, V268, P7640; TULSIANI DRP, 1988, J BIOL CHEM, V263, P5408; TULSIANI DRP, 1977, J BIOL CHEM, V252, P3227; VOISIN T, 1990, AM J PHYSIOL, V258, pG753, DOI 10.1152/ajpgi.1990.258.5.G753; VOISIN T, 1990, ANN NY ACAD SCI, V611, P343; Zweibaum A., 1991, HDB PHYSL GASTROINTE, P223	50	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4285	4290						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307994				2022-12-27	WOS:A1994MW98900061
J	XU, QH; NAKANISHI, T; SEKIMIZU, K; NATORI, S				XU, QH; NAKANISHI, T; SEKIMIZU, K; NATORI, S			CLONING AND IDENTIFICATION OF TESTIS-SPECIFIC TRANSCRIPTION ELONGATION FACTOR-S-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ASCITES TUMOR-CELLS; FACTOR-SII; STIMULATORY FACTORS; EXPRESSION; GENE; PURIFICATION; PROTEIN; TFIIS; DNA	A new S-II cDNA clone was isolated from a rat testis library. This cDNA contained an open reading frame encoding 299 amino acid residues. The deduced amino- and carboxyl-terminal regions were very similar with those of Ehrlich cell S-II, which we reported previously, but the sequence of the intervening 46 amino acid residues was unique. This new S-II was expressed in the testis but not in the other rat tissues examined, suggesting that it was a testis-specific S-II. Recombinant testis-specific S-II produced in Escherichia coli was shown to stimulate RNA polymerase II.	UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN HC, 1992, GENE, V116, P253, DOI 10.1016/0378-1119(92)90522-Q; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Hecht NB., 1986, EXPT APPROACHES MAMM, P151; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; HORIKOSHI M, 1985, J BIOL CHEM, V260, P5739; HORIKOSHI N, 1990, J BIOL CHEM, V265, P11854; KANAI A, 1991, J BIOCHEM-TOKYO, V109, P674, DOI 10.1093/oxfordjournals.jbchem.a123439; MARSHALL TK, 1990, NUCLEIC ACIDS RES, V18, P6293, DOI 10.1093/nar/18.21.6293; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; NATORI S, 1982, MOL CELL BIOCHEM, V46, P173; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADOGO M, 1980, J BIOL CHEM, V255, P12; SEKIMIZU K, 1979, BIOCHEMISTRY-US, V18, P1582, DOI 10.1021/bi00575a031; SEKIMIZU K, 1982, J BIOL CHEM, V257, P2719; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; UENO K, 1979, NATURE, V277, P145, DOI 10.1038/277145a0; WILLISON K, 1987, TRENDS GENET, V3, P351, DOI 10.1016/0168-9525(87)90296-4; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073	30	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3100	3103						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300645				2022-12-27	WOS:A1994MV43200106
J	HAYES, BK; FREEZE, HH; VARKI, A				HAYES, BK; FREEZE, HH; VARKI, A			BIOSYNTHESIS OF OLIGOSACCHARIDES IN INTACT GOLGI PREPARATIONS FROM RAT-LIVER - ANALYSIS OF N-LINKED GLYCANS LABELED BY UDP-[6-H-3]N-ACETYLGLUCOSAMINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; GAL-BETA-1->3(4)GLCNAC ALPHA-2->3 SIALYLTRANSFERASE; COMPLEX-TYPE OLIGOSACCHARIDES; VIRUS-G PROTEIN; TERMINAL GLYCOSYLATION; SUGAR CHAINS; ACETYLGLUCOSAMINYLTRANSFERASE-III; GLYCOPROTEIN OLIGOSACCHARIDES; MOLECULAR DISSECTION; SIALIC ACIDS	During short incubations of a Golgi apparatus-enriched subcellular fraction from rat liver with UDP-[H-3]GlcNAc, label is efficiently transferred to endogenous acceptors. Most of the macromolecular radioactivity is specifically released by peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase, indicating that it is mainly associated with N-linked oligosaccharides. The glycoprotein acceptors are resistant to proteases unless detergent is added in amounts greater than the critical micellar concentration. This shows that the acceptors are within the lumen of intact compartments, which have the correct topological orientation expected for the Golgi apparatus in intact cells. Structural characterization of the radiolabeled N-linked oligosaccharides shows a variety of distinct neutral and anionic species. The neutral chains include bi-, tri-, and tetra-antennary molecules with terminal beta-[H-3] GlcNAc residues. In vitro sialylation shows that some of the tetra-antennary chains have beta1,3-linked Gal residues on their unlabeled antennae. An unknown modification appears to block the action of beta-galactosidase on these galactosylated oligosaccharides. Chasing the labeling reaction with a mixtures of UDP-Gal, CMP-Neu5Ac, and adenosine 3'-phosphate,5'-phosphosulfate causes an increase in the percent of radiolabeled anionic oligosaccharides. Most of the negative charge is due to sialic acid (Sia), and some appears to be in phosphodiester-linked [H-3]GlcNAc. The sialylated oligosaccharides are a mixture of bi-, tri-, and tetra-antennary species with 1-3-Sia residues, and some of the [H-3]GlcNAc residues are directly covered with unlabeled Gal and Sia residues. This in vitro approach should recapitulate reactions that occur in the biosynthesis of N-linked oligosaccharides in the Golgi apparatus of the intact cell. Since the conditions during labeling do not permit inter-compartmental transport, the oligosaccharides produced should represent the biosynthetic capabilities of individual Golgi compartments. Evidence is presented for a functional association of GlcNAc transferases I, II, and alpha-mannosidase II, with separation from GlcNAc transferase IV and/or V. The structures also indicate co-compartmentalization of several GlcNAc transferase(s) with beta-galactosyltransferase(s) and sialyltransferase(s). The compartmental organization of the Golgi apparatus is discussed in light of these findings.	UNIV CALIF SAN DIEGO,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093; LA JOLLA CANC RES FDN,GLYCOBIOL CHEM PROGRAM,LA JOLLA,CA 92037	University of California System; University of California San Diego; Sanford Burnham Prebys Medical Discovery Institute				Freeze, Hudson/0000-0001-6316-0501	NCI NIH HHS [R01-CA38701] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038701] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGER EG, 1985, P NATL ACAD SCI USA, V82, P4736, DOI 10.1073/pnas.82.14.4736; BERGERON JJM, 1985, BIOCHIM BIOPHYS ACTA, V821, P393, DOI 10.1016/0005-2736(85)90043-4; BERGERON JJM, 1982, J CELL BIOL, V92, P139, DOI 10.1083/jcb.92.1.139; BERNARD N, 1983, BIOCHIMIE, V65, P185, DOI 10.1016/S0300-9084(83)80083-2; BLOUIN A, 1977, J CELL BIOL, V72, P441, DOI 10.1083/jcb.72.2.441; BROCKHAUSEN I, 1988, BIOCHEM CELL BIOL, V66, P1134, DOI 10.1139/o88-131; BROWN WJ, 1987, P NATL ACAD SCI USA, V84, P9001, DOI 10.1073/pnas.84.24.9001; BURKE J, 1992, J BIOL CHEM, V267, P24433; BUTOR C, 1993, J BIOL CHEM, V268, P10197; CARDINI CE, 1957, J BIOL CHEM, V200, P317; CAREY DJ, 1981, J BIOL CHEM, V256, P989; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CUMMINGS RD, 1992, GLYCOCONJUGATES COMP, P333; DEWAARD P, 1991, J BIOL CHEM, V266, P4237; DEWALD B, 1973, J BIOL CHEM, V248, P7223; DIAZ S, 1989, J BIOL CHEM, V264, P19416; DUNPHY WG, 1981, P NATL ACAD SCI-BIOL, V78, P7453, DOI 10.1073/pnas.78.12.7453; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; GONATAS JO, 1989, J BIOL CHEM, V264, P646; GREEN ED, 1986, J BIOL CHEM, V261, P6309; GREEN SA, 1990, J BIOL CHEM, V265, P21269; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HAYES BK, 1992, ANAL BIOCHEM, V201, P140, DOI 10.1016/0003-2697(92)90186-B; HAYES BK, 1993, J BIOL CHEM, V268, P16155; HAYES BK, 1993, J BIOL CHEM, V268, P16170; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HOOGEWERF AJ, 1991, J BIOL CHEM, V266, P1048; KAGIWADA S, 1993, J BIOL CHEM, V268, P1430; KOBATA A, 1979, ANAL BIOCHEM, V100, P1, DOI 10.1016/0003-2697(79)90102-7; KOBATA A, 1992, CELL SURFACE CARBOHY, P1; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1978, J BIOL CHEM, V253, P7771; LEE EU, 1989, J BIOL CHEM, V264, P13848; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LEVERY SB, 1992, BIOCHEMISTRY-US, V31, P5335, DOI 10.1021/bi00138a013; LI E, 1978, J BIOL CHEM, V253, P7762; LIDHOLT K, 1988, BIOCHEM J, V254, P571, DOI 10.1042/bj2540571; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MELLIS SJ, 1981, ANAL BIOCHEM, V114, P276, DOI 10.1016/0003-2697(81)90480-2; MERKLE RK, 1987, METHOD ENZYMOL, V138, P232; MIZUOCHI T, 1980, J BIOL CHEM, V255, P3526; MIZUOCHI T, 1979, J BIOL CHEM, V254, P6419; NARASIMHAN S, 1988, J BIOL CHEM, V263, P1273; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; NISHIKAWA A, 1988, ANAL BIOCHEM, V170, P349, DOI 10.1016/0003-2697(88)90641-0; PAIEMENT J, 1982, J CELL BIOL, V92, P147, DOI 10.1083/jcb.92.1.147; PAVELKA M, 1991, J ELECTRON MICR TECH, V17, P35, DOI 10.1002/jemt.1060170106; PEREZ M, 1987, METHOD ENZYMOL, V138, P709; PEREZ M, 1985, J BIOL CHEM, V260, P4671; PILLER F, 1982, ANAL BIOCHEM, V127, P171, DOI 10.1016/0003-2697(82)90161-0; PLUMMER T H JR, 1991, Glycobiology, V1, P257, DOI 10.1093/glycob/1.3.257; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROUX L, 1988, J BIOL CHEM, V263, P8879; SABESAN S, 1991, CARBOHYD RES, V218, P27, DOI 10.1016/0008-6215(91)84084-R; SADLER JE, 1982, METHOD ENZYMOL, V83, P458; SAMPATH D, 1992, J BIOL CHEM, V267, P4440; SCHACHTER H, 1991, Glycobiology, V1, P453, DOI 10.1093/glycob/1.5.453; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; SNIDER MD, 1986, J CELL BIOL, V103, P265, DOI 10.1083/jcb.103.1.265; SWANSON MA, 1955, METHOD ENZYMOL, V2, P541, DOI 10.1016/S0076-6879(55)02247-7; TABAS I, 1979, J BIOL CHEM, V254, P1655; TARENTINO AL, 1987, METHOD ENZYMOL, V138, P770; TORRES CR, 1984, J BIOL CHEM, V259, P3308; TOWNSEND RR, 1986, BIOCHEMISTRY-US, V25, P5716, DOI 10.1021/bi00367a055; TULSIANI DRP, 1983, J BIOL CHEM, V258, P7578; VARKI A, 1991, FASEB J, V5, P226, DOI 10.1096/fasebj.5.2.2004668; VARKI A, 1983, J BIOL CHEM, V258, P2808; VARKI A, 1980, J BIOL CHEM, V255, P8398; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WEN DX, 1992, J BIOL CHEM, V267, P21011; YAMASHITA K, 1989, J BIOL CHEM, V264, P17873; YAMASHITA K, 1980, J BIOL CHEM, V255, P5635; YUAN L, 1987, J CELL BIOL, V105, P215, DOI 10.1083/jcb.105.1.215; Yurchenco P D, 1978, Methods Enzymol, V50, P175	78	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16139	16154						16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344899				2022-12-27	WOS:A1993LQ33600014
J	KAZAMA, Y; PASTUSZYN, A; WILDGOOSE, P; HAMAMOTO, T; KISIEL, W				KAZAMA, Y; PASTUSZYN, A; WILDGOOSE, P; HAMAMOTO, T; KISIEL, W			ISOLATION AND CHARACTERIZATION OF PROTEOLYTIC FRAGMENTS OF HUMAN FACTOR-VIIA WHICH INHIBIT THE TISSUE FACTOR-ENHANCED AMIDOLYTIC ACTIVITY OF FACTOR-VIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-VII; FACTOR-DEPENDENT AUTOACTIVATION; EXTRINSIC PATHWAY INHIBITOR; CLOTTING FACTOR-VII; BOVINE FACTOR-VII; BLOOD-COAGULATION; FACTOR-X; FACTOR-IX; PHOSPHOLIPID-VESICLES; COFACTOR FUNCTION	The interaction of circulating factor VII/VIIa with tissue factor presented by cells in extravascular tissues represents the initial event in the extrinsic pathway of blood coagulation. To determine the tissue factor binding domains in human factor VIIa, we have subjected recombinant human factor VIIa to tryptic digestion and isolated two proteolytic fragments (molecular mass = 32 and 20 kDa) by a combination of immunoaffinity chromatography and reversed phase high performance liquid chromatography (HPLC) which strongly inhibits the tissue factor-enhanced amidolytic activity of factor VIIa and inhibits the activation of factor X by factor VIIa in the presence of tissue factor. The 32-kDa factor VIIa fragment consisted of residues 1-137/143 from the light chain of factor VIIa connected by a disulfide bond to residues 153-277 from the heavy chain. The 20-kDa factor VIIa fragment consisted of residues 1-137 of the light chain of factor VIIa in disulfide linkage with residues 248-266 of the heavy chain. The 32-and 20-kDa factor VIIa fragments inhibited the tissue factor apoprotein-enhanced factor VIIa amidolytic activity with K(i) values of 35 and 65 nM, respectively. The K(i) values for the inhibition of relipidated tissue factor apoprotein-enhanced factor VIIa amidolytic activity by the 32- and 20-kDa factor VIIa fragments were 70 and 610 nM, respectively. Factor X activation by factor VIIa-relipidated tissue factor was inhibited half-maximally by the 32- and 20-kDa factor VIIa fragments at 65 and 680 nM concentrations, respectively. Equilibrium binding studies indicated that the 32- and 20-kDa factor VIIa fragments interacted with cell surface tissue factor expressed on J82 cells in a specific and saturable manner with K(d) values of 30 and 64 nM, respectively. In addition, a peptide consisting of residues 1-109 from the light chain of factor VIIa obtained by reduction and HPLC of the 20-kDa factor VIIa fragment retained inhibitory activity, but the selective removal of the gamma-carboxyglutamic acid domain from the 20-kDa factor VIIa fragment by cathepsin G cleavage resulted in the complete loss of inhibitory activity in this fragment. Our data strongly suggest that the epidermal growth factor-like domains covalently linked to the gamma-carboxyglutamic acid domain in factor VIIa constitute the high affinity tissue factor binding domain in this molecule.	UNIV NEW MEXICO,SCH MED,DEPT PATHOL,BLOOD SYST RES FDN LAB,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,SCH MED,DEPT BIOCHEM,ALBUQUERQUE,NM 87131; NOVO NORDISK A-S,DK-2820 GENTOFTE,DENMARK	University of New Mexico; University of New Mexico; Novo Nordisk					NHLBI NIH HHS [HL35246] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035246] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BJOERN S, 1991, J BIOL CHEM, V266, P11051; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROZE GJ, 1980, J BIOL CHEM, V255, P1242; BROZE GJ, 1985, J BIOL CHEM, V260, P917; BROZE GJ, 1980, METHOD ENZYMOL, V80, P228; CLARKE BJ, 1992, FEBS LETT, V298, P206, DOI 10.1016/0014-5793(92)80058-O; FRACKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P4189, DOI 10.1021/bi00638a009; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; KONDO S, 1987, BLOOD, V70, P1947; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; KUMAR A, 1991, J BIOL CHEM, V266, P915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; MASYS DR, 1982, BLOOD, V60, P1143; Monroe Dougald M., 1992, Circulation, V86, pI681; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NEMERSON Y, 1985, THROMB RES, V40, P351, DOI 10.1016/0049-3848(85)90270-1; NEMERSON Y, 1988, BLOOD, V71, P1; NEUENSCHWANDER PF, 1992, J BIOL CHEM, V267, P14477; NICOLAISEN EM, 1992, FEBS LETT, V306, P157, DOI 10.1016/0014-5793(92)80989-T; NISHIMURA H, 1989, J BIOL CHEM, V264, P20320; OBRIEN DP, 1991, BLOOD, V78, P132; OHLIN AK, 1990, BIOCHEMISTRY-US, V29, P644; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; RADCLIFFE R, 1976, J BIOL CHEM, V251, P4797; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; SAKAI T, 1989, J BIOL CHEM, V264, P9980; SAKAI T, 1990, J BIOL CHEM, V265, P1890; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; TURKINGTON PT, 1992, THROMB RES, V67, P147, DOI 10.1016/0049-3848(92)90134-V; WILDGOOSE P, 1990, BIOCHEMISTRY-US, V29, P3413, DOI 10.1021/bi00465a039; WILDGOOSE P, 1993, BIOCHEMISTRY-US, V32, P114, DOI 10.1021/bi00052a016; WILDGOOSE P, 1989, BLOOD, V73, P1888; WILDGOOSE P, 1990, P NATL ACAD SCI USA, V87, P7290, DOI 10.1073/pnas.87.18.7290; WILDGOOSE P, 1992, THROMB HAEMOSTASIS, V67, P679; YAMAMOTO M, 1992, J BIOL CHEM, V267, P19089	49	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16231	16240						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344908				2022-12-27	WOS:A1993LQ33600024
J	MILTENBERGER, RJ; CORTNER, J; FARNHAM, PJ				MILTENBERGER, RJ; CORTNER, J; FARNHAM, PJ			AN INHIBITORY RAF-1 MUTANT SUPPRESSES EXPRESSION OF A SUBSET OF V-RAF-ACTIVATED GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SERUM RESPONSE ELEMENT; PROTEIN-KINASE; C-FOS; MAP KINASE; SIGNAL TRANSDUCTION; MOUSE FIBROBLASTS; EGR-1 PROMOTER; BINDING-SITE; 3T3 CELLS	The Proto-oncogene Raf-1 is a cytoplasmic serine/threonine kinase implicated in the signaling process in cell proliferation. To determine if Raf-1 is sufficient and necessary to transmit mitogenic signals to growth-responsive genes, we examined the effect of constitutively activated (v-raf) or inhibitory (Raf-C4) Raf-1 proteins on reporter gene activation in transient expression assays of NIH 3T3 cells. In serum-starved cells, v-raf strongly activated transcription from the promoters of the immediate-early genes c-fos and egr-2, as well as the proximal or B promoter of the late growth response gene rep-3 (rep-3b). Two other late response gene promoters, cad and dhfr, were only modestly activated by v-raf, however. An individual serum response element from the c-fos or egr-2 promoter conferred both serum-inducibility and v-raf-responsiveness to a heterologous promoter. Consistent with the degree to which antisense c-raf-1 RNA and dominant-negative Raf-1 proteins interfere with NIH 3T3 cell proliferation, Raf-C4 reduced serum-induced transcription from the egr-2 and rep-3b promoters in a dose-dependent manner by 50%. In contrast, Raf-C4 did not significantly reduce transcription from the c-fos or cad promoters or the serum response element-driven heterologous promoters. We conclude that Raf-1 is both sufficient and necessary to activate a subset of early and late growth response genes.	UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Farnham, Peggy/0000-0003-4469-7914	NATIONAL CANCER INSTITUTE [T32CA009135, P30CA007175, P01CA023076] Funding Source: NIH RePORTER; NCI NIH HHS [CA07175, CA23076, CA09135] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CORTNER J, 1990, MOL CELL BIOL, V10, P3788, DOI 10.1128/MCB.10.7.3788; CORTNER J, 1991, THESIS U WISCONSIN M; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANNINK M, 1990, ONCOGENE, V5, P1843; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IZUMI T, 1991, J BIOL CHEM, V266, P7933; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KIZAKAKONDOH S, 1992, MOL CELL BIOL, V12, P5078, DOI 10.1128/MCB.12.11.5078; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LIAO WSL, 1986, J BIOL CHEM, V261, P5577; LIM K, 1989, BIOTECHNIQUES, V7, P576; LINTON JP, 1989, MOL CELL BIOL, V9, P3058, DOI 10.1128/MCB.9.7.3058; MAMON H, 1991, COLD SPRING HARB SYM, V56, P251; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PERRIMON N, 1985, DEV BIOL, V110, P480, DOI 10.1016/0012-1606(85)90105-8; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; RAO GN, 1988, EXP CELL RES, V178, P449, DOI 10.1016/0014-4827(88)90413-2; RIM M, 1992, ONCOGENE, V7, P2065; RIVERA V M, 1990, New Biologist, V2, P751; Sambrook J, 1989, MOL CLONING LABORATO; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SPRENGER F, 1993, MOL CELL BIOL, V13, P1163, DOI 10.1128/MCB.13.2.1163; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	50	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15674	15680						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340392				2022-12-27	WOS:A1993LN30500054
J	UNNO, M; YONEKURA, H; NAKAGAWARA, K; WATANABE, T; MIYASHITA, H; MORIIZUMI, S; OKAMOTO, H; ITOH, T; TERAOKA, H				UNNO, M; YONEKURA, H; NAKAGAWARA, K; WATANABE, T; MIYASHITA, H; MORIIZUMI, S; OKAMOTO, H; ITOH, T; TERAOKA, H			STRUCTURE, CHROMOSOMAL LOCALIZATION, AND EXPRESSION OF MOUSE REG GENES, REG-I AND REG-II - A NOVEL TYPE OF REG GENE, REG-II, EXISTS IN THE MOUSE GENOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC STONE PROTEIN; MESSENGER-RNA; REGENERATING ISLETS; NUCLEOTIDE-SEQUENCE; RAT; CELLS; ENHANCER; INSULIN; ACID; PITUITARY	We previously identified a gene, reg (i.e. regenerating gene), in the screening of a regenerating islet-derived cDNA library of rat (Terazono, K., Yamamoto, H., Takasawa, S., Shiga, K., Yonemura, Y., Tochino, Y., and Okamoto, H. (1988) J. Biol. Chem. 263, 2111-2114), and isolated a human reg cDNA and gene (Watanabe, T., Yonekura, H., Terazono, K., Yamamoto, H., and Okamoto, H. (1990) J. Biol. Chem. 265, 7432-7439); the rat and human cDNAs encode 165- and 166- amino acid proteins, respectively. Until now, it was thought that there is a single locus for Reg protein in the mammalian genome. In this study, we isolated two distinct cDNAs and genes, one of which was a mouse homologue to rat and human reg gene, the other a novel type of reg gene. We designated them reg I and reg II, respectively. The two proteins encoded by these genes share 76% amino acid sequence identity with each other. Both genes span about 3 kilobase pairs, and the genomic organization of six exons and five introns is conserved between them. Chromosomal mapping studies indicate that the reg I gene is localized on mouse chromosome 12, whereas the reg II gene is localized on chromosome 3. By Northern blot analysis, both reg I and reg II mRNAs are detected in the normal pancreas and hyperplastic islets of aurothioglucose-treated mice, but not in the normal islets. It is remarkable that in the gallbladder reg I is expressed, but reg II is not.	TOHOKU UNIV,SCH MED,DEPT BIOCHEM,2-1 SEIRYO MACHI,AOBA KU,SENDAI,MIYAGI 980,JAPAN; SHIONOGI & CO LTD,SHIONOGI RES LAB,FUKUSHIMA KU,OSAKA 553,JAPAN	Tohoku University; Shionogi & Company Limited			Unno, Michiaki/AAX-5246-2020; Unno, Michiaki/A-8633-2010	Unno, Michiaki/0000-0002-2145-6416; Unno, Michiaki/0000-0002-2145-6416				BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BOULET AM, 1986, P NATL ACAD SCI USA, V83, P3599, DOI 10.1073/pnas.83.11.3599; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DECARO AM, 1989, BIOCHIM BIOPHYS ACTA, V994, P281, DOI 10.1016/0167-4838(89)90305-1; DECARO AM, 1987, EUR J BIOCHEM, V168, P201; DELAMONTE SM, 1990, J CLIN INVEST, V86, P1004, DOI 10.1172/JCI114762; DRICKAMER K, 1987, J BIOL CHEM, V262, P2582; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FODOR E, 1991, BIOCHEMISTRY-US, V30, P8102, DOI 10.1021/bi00247a002; FRANCIS PJ, 1992, DIABETOLOGIA, V35, P238, DOI 10.1007/BF00400923; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GROSS J, 1985, J CLIN INVEST, V76, P2115, DOI 10.1172/JCI112216; HAGENBUCHLE O, 1980, CELL, V21, P179, DOI 10.1016/0092-8674(80)90125-7; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; IOVANNA J, 1991, J BIOL CHEM, V266, P24664; KAWAGUCHI N, 1991, DEV BIOL, V144, P86, DOI 10.1016/0012-1606(91)90481-H; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LASSERRE C, 1992, CANCER RES, V52, P5089; Maniatis T, 1989, DECONTAMINATION DILU; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MIYAURA C, 1991, MOL ENDOCRINOL, V5, P226, DOI 10.1210/mend-5-2-226; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; NIR U, 1986, P NATL ACAD SCI USA, V83, P3180, DOI 10.1073/pnas.83.10.3180; OKAMOTO H, 1981, MOL CELL BIOCHEM, V37, P43, DOI 10.1007/BF02355886; Okamoto H., 2008, MOL BIOL ISLETS LANG, P209; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; ROSENBERG L, 1983, J SURG RES, V35, P63, DOI 10.1016/0022-4804(83)90127-0; ROUQUIER S, 1991, J BIOL CHEM, V266, P786; SHARON N, 1989, LECTINS; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEVENSON BJ, 1986, NUCLEIC ACIDS RES, V14, P8307, DOI 10.1093/nar/14.21.8307; TACHIBANA K, 1988, MOL ENDOCRINOL, V2, P973, DOI 10.1210/mend-2-10-973; TAKASAWA S, 1992, FEBS LETT, V307, P318, DOI 10.1016/0014-5793(92)80704-K; TERAZONO K, 1988, J BIOL CHEM, V263, P2111; TERAZONO K, 1990, DIABETOLOGIA, V33, P250, DOI 10.1007/BF00404804; Terazono K., 2008, MOL BIOL ISLETS LANG, P301; TOCHINO Y, 1983, DIABETES MICROANGIOP, P423; TRASK BJ, 1992, METHOD CELL BIOL, V35, P3; UNNO M, 1992, PANCREATIC ISLET CEL, P61; WATANABE T, 1990, J BIOL CHEM, V265, P7432; YAMAMOTO T, 1992, J HISTOCHEM CYTOCHEM, V40, P221, DOI 10.1177/40.2.1348066; YAMAOKA K, 1991, BIOCHEM BIOPH RES CO, V179, P272, DOI 10.1016/0006-291X(91)91365-J; YONEKURA H, 1988, J BIOL CHEM, V263, P2990; YONEMURA Y, 1984, DIABETES, V33, P401, DOI 10.2337/diabetes.33.4.401	45	128	139	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15974	15982						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340418				2022-12-27	WOS:A1993LN30500092
J	GEE, SH; BLACHER, RW; DOUVILLE, PJ; PROVOST, PR; YURCHENCO, PD; CARBONETTO, S				GEE, SH; BLACHER, RW; DOUVILLE, PJ; PROVOST, PR; YURCHENCO, PD; CARBONETTO, S			LAMININ-BINDING PROTEIN-120 FROM BRAIN IS CLOSELY-RELATED TO THE DYSTROPHIN-ASSOCIATED GLYCOPROTEIN, DYSTROGLYCAN, AND BINDS WITH HIGH-AFFINITY TO THE MAJOR HEPARIN-BINDING DOMAIN OF LAMININ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE PROTEOGLYCAN; COMPLETE SEQUENCE; CELL-MEMBRANES; RECEPTOR; COMPONENTS; NEURONS; MUSCLE; CHAIN; FORM	When brain proteins separated by SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to nitrocellulose are probed with I-125-labeled laminin, a single broad band of approximately 120 kDa binds laminin specifically. We show here by two-dimensional electrophoresis and protein microsequencing that this band consists of two distinct laminin-binding proteins. One of these is the amyloid precursor protein. The other, laminin-binding protein (LBP) 120, is closely related to the dystrophin-associated glycoprotein, dystroglycan (156 kDa); 5 peptides from purified bovine brain LBP120, ranging in size from 7 to 19 residues, are up to 100% identical to the predicted amino acid sequence of muscle dystroglycan (Ibraghimov-Beskrovnaya, O., Ervasti, J. M., Leveille, C. J., Slaughter, C. A., Sernett, S. W., and Campbell, K. P. (1992) Nature 355, 696-702). These protein microsequence data support the data of Ibraghimov-Beskrovnaya et al., which suggest that the dystroglycan precursor is processed into 120/156- and 43-kDa proteins. Moreover, the data suggest a revision in the position of the proposed cleavage site of the precursor. The glycosylation and extracellular localization of LBP120/dystroglycan are consistent with it being a cell surface laminin receptor. LBP120/dystroglycan, either as a native protein, or following SDS-PAGE and transfer to nitrocellulose, binds with high affinity (K(d) = 90 nM) to a proteolytic fragment of laminin (E3) containing the major heparin binding domain. This binding is Ca2+-dependent and inhibited by low concentrations of heparin. Thus, LBP120/dystroglycan is a major non-integrin laminin receptor whose high affinity interaction with laminin may reflect a structural role in brain and muscle.	MCGILL UNIV,MONTREAL GEN HOSP,RES INST,CTR RES NEUROSCI,1650 CEDAR AVE,MONTREAL H3G 1A4,QUEBEC,CANADA; ATHENA NEUROSCI,S SAN FRANCISCO,CA 94080; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,PISCATAWAY,NJ 08854	McGill University; Rutgers State University New Brunswick; Rutgers State University Medical Center				Yurchenco, Peter/0000-0003-0387-2317	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK036425, R01DK036425] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 36425] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; DOUVILLE PJ, 1988, J BIOL CHEM, V263, P14964; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FRENETTE GP, 1989, J BIOL CHEM, V264, P3078; FRIEDMAN M, 1970, J BIOL CHEM, V245, P3868; HARLOW E, 1988, ANTIBODIES LABORATOR, P494; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JOSEPH DR, 1992, FASEB J, V6, P2477, DOI 10.1096/fasebj.6.7.1532944; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; KLEINMAN HK, 1991, ARCH BIOCHEM BIOPHYS, V290, P320, DOI 10.1016/0003-9861(91)90547-V; KLEINMAN HK, 1988, P NATL ACAD SCI USA, V85, P1282, DOI 10.1073/pnas.85.4.1282; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESOT H, 1983, EMBO J, V2, P861, DOI 10.1002/j.1460-2075.1983.tb01514.x; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; LIESI P, 1985, EMBO J, V4, P1163, DOI 10.1002/j.1460-2075.1985.tb03755.x; LINDENBAUM MH, 1993, CURR BIOL, V3, P109, DOI 10.1016/0960-9822(93)90167-M; MALINOFF HL, 1983, J CELL BIOL, V96, P1475, DOI 10.1083/jcb.96.5.1475; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; NARINDRASORASAK S, 1992, LAB INVEST, V67, P643; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; POMERANZ HD, 1991, J COMP NEUROL, V313, P625, DOI 10.1002/cne.903130408; RAO CN, 1983, BIOCHEM BIOPH RES CO, V111, P804; RUNYAN RB, 1986, J CELL BIOL, V102, P432, DOI 10.1083/jcb.102.2.432; RUPP F, 1992, J NEUROSCI, V12, P3535; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SCHITTNY JC, 1990, J CELL BIOL, V110, P825, DOI 10.1083/jcb.110.3.825; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SHIH YJ, 1990, J BIOL CHEM, V265, P19077; SMALHEISER NR, 1987, P NATL ACAD SCI USA, V84, P6457, DOI 10.1073/pnas.84.18.6457; TIMPL R, 1982, METHOD ENZYMOL, V82, P831; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; WARD LD, 1990, CURRENT RES PROTEIN, P179; WOO HJ, 1990, J BIOL CHEM, V265, P7097; YURCHENCO PD, 1990, J BIOL CHEM, V265, P3981	46	272	272	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14972	14980						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325873				2022-12-27	WOS:A1993LL75900066
J	JUNG, G; FUKUI, Y; MARTIN, B; HAMMER, JA				JUNG, G; FUKUI, Y; MARTIN, B; HAMMER, JA			SEQUENCE, EXPRESSION PATTERN, INTRACELLULAR-LOCALIZATION, AND TARGETED DISRUPTION OF THE DICTYOSTELIUM MYOSIN ID HEAVY-CHAIN ISOFORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACANTHAMOEBA-CASTELLANII; HOMOLOGOUS RECOMBINATION; CELL MOTILITY; GENE; DISCOIDEUM; CHEMOTAXIS; CLONING; ACTIN; IA; IB	The complete sequence of the Dictyostelium myosin ID (DMID) heavy chain isoform has been determined from cDNA and genomic clones. Like the DMIB isoform characterized previously, the DMID isoform is up-regulated during starvation-induced chemotatic aggregation, and its 124-kDa heavy chain contains the tail domain sequences that correspond to both the membrane and second actin-binding sites. An antibody that is specific for the DMID isoform was found to stain the actin-rich pseudopods at the leading edge of migrating cells. Protein microsequencing data reveals that the myosin I isoform localized to leading edge pseudopods in a previous study (Fukui, Y., Lynch, T. J., Brzeska, H., and Korn, E. D. (1989) Nature 341, 328-33 1) was DMIB, indicating that DMID and DMIB also colocalize and that both should influence the dynamics of actin-rich cortical structures. This and other data indicate that the DMID and DMIB isoforms are closely related and are distinct from the DMIA and DMIE isoforms, which possess truncated tail domains and are not up-regulated during chemotactic aggregation. Cells in which the DMID gene was rendered nonfunctional by targeted gene disruption do not show obvious behavioral defects, suggesting that another myosin I isoform(s) (possibly DMIB) might compensate for DMID. Finally, Southern blot data indicate that Dictyostelium may contain as many as nine myosin I isoforms.	NHLBI, CELL BIOL LAB, 9000 ROCKVILLE PIKE, 3-B1-22, BETHESDA, MD 20892 USA; NORTHWESTERN UNIV, SCH MED, DEPT CELL MOLEC & STRUCT BIOL, CHICAGO, IL 60611 USA; NIMH, CLIN NEUROSCI BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Northwestern University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)								ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; ADAMS RJ, 1989, CELL MOTIL CYTOSKEL, V14, P178, DOI 10.1002/cm.970140203; BAINES IC, 1992, J CELL BIOL, V119, P1193, DOI 10.1083/jcb.119.5.1193; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CONDEELIS J, 1990, DEV GENET, V11, P333, DOI 10.1002/dvg.1020110504; COTE GP, 1985, J BIOL CHEM, V260, P4543; DELOZANNE A, 1987, METHOD CELL BIOL, V28, P489; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DELOZANNE A, 1985, P NATL ACAD SCI USA, V82, P6807, DOI 10.1073/pnas.82.20.6807; DOBERSTEIN SK, 1992, J CELL BIOL, V117, P1241, DOI 10.1083/jcb.117.6.1241; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; FUJISAKI H, 1985, J BIOL CHEM, V260, P1183; FUKUI Y, 1987, METHOD CELL BIOL, V28, P347; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; Hammer J A, 1991, Trends Cell Biol, V1, P50, DOI 10.1016/0962-8924(91)90089-R; HAMMER JA, 1983, J BIOL CHEM, V258, P168; HOROWITZ JA, 1990, J BIOL CHEM, V265, P20646; Janmey PA, 1991, CURR OPIN CELL BIOL, V3, P4, DOI 10.1016/0955-0674(91)90159-V; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; JUNG G, 1989, GENE, V82, P269, DOI 10.1016/0378-1119(89)90052-8; JUNG G, 1989, P NATL ACAD SCI USA, V86, P6186, DOI 10.1073/pnas.86.16.6186; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; Korn ED, 1990, CURR OPIN CELL BIOL, V2, P57, DOI 10.1016/S0955-0674(05)80031-6; KORN ED, 1988, J CELL BIOCHEM, V36, P37, DOI 10.1002/jcb.240360105; LYNCH T J, 1988, Journal of Cell Biology, V107, p7A; LYNCH TJ, 1990, BIOPHYS J, V57, pA536; LYNCH TJ, 1986, J BIOL CHEM, V261, P7156; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; NELLEN W, 1988, BIOCHEM BIOPH RES CO, V154, P54, DOI 10.1016/0006-291X(88)90648-1; OSTER GF, 1987, J CELL SCI, P35; PODOLSKI JL, 1990, J BIOL CHEM, V265, P1312; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; RUBINO S, 1987, PROTOPLASMA, V136, P63, DOI 10.1007/BF01276319; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPUDICH JA, 1989, CELL REGUL, V1, P1; TITUS M A, 1990, Journal of Cell Biology, V111, p168A; TITUS MA, 1989, CELL REGUL, V1, P55, DOI 10.1091/mbc.1.1.55; TITUS MA, 1993, MOL BIOL CELL, V4, P233, DOI 10.1091/mbc.4.2.233; URRUTIA RA, 1993, IN PRESS BIOCH BIOPH; VARNUM B, 1986, DEV BIOL, V113, P218, DOI 10.1016/0012-1606(86)90124-7; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; WESSELS D, 1991, CELL MOTIL CYTOSKEL, V20, P301, DOI 10.1002/cm.970200406; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	48	83	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14981	14990						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325874				2022-12-27	WOS:A1993LL75900067
J	WANG, CK; LIAO, RL; CHEUNG, HC				WANG, CK; LIAO, RL; CHEUNG, HC			ROTATIONAL-DYNAMICS OF SKELETAL-MUSCLE TROPONIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTANCE DISTRIBUTIONS; ENERGY-TRANSFER; FLUORESCENCE; CALCIUM; COMPLEX; RESOLUTION; CALMODULIN; BINDING; DOMAIN; SITES	Upon excitation by 280 nm, the intensity decay of the 2 tyrosine residues (residues 10 and 109) of rabbit skeletal muscle troponin C is resolved into three components. The anisotropy decay in the absence of divalent cation is biphasic with a short correlation time of 0.67 ns and a long correlation time of 9.23 ns. The limiting anisotropy is 0.225, considerably lower than the value expected for immobilized tyrosine. Upon excitation by 290 nm, the anisotropy decay is also biphasic, and the limiting anisotropy increases to 0.274. The recovery of anisotropy by excitation at a wavelength near the red edge of the tyrosine absorption spectrum is evidence of fluorescence resonance energy transfer between the two tyrosines. For energy transfer to occur, the average separation between the 2 tyrosines is unlikely much larger than the Forster distance R(o), congruent-to 10 angstrom, and this close proximity of the residues would require a highly distorted dumbbell shape of troponin C in solution. These results are consistent with a flexible central helix, which either has a segmental flexibility with large amplitude or results in a spectrum of conformations including those in which the two globular domains are in a very close proximity.	UNIV ALABAMA,DEPT BIOCHEM,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR025193] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR25193] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BLECHNER SL, 1992, BIOCHEMISTRY-US, V31, P11326, DOI 10.1021/bi00161a010; CHEUNG HC, 1991, BIOCHEMISTRY-US, V30, P5238, DOI 10.1021/bi00235a018; CHEUNG HC, 1982, BIOCHEMISTRY-US, V21, P5135, DOI 10.1021/bi00264a005; CHEUNG HC, 1987, BIOCHEMISTRY-US, V26, P5904, DOI 10.1021/bi00392a049; GAUDUCHON P, 1978, BIOPHYS CHEM, V8, P87, DOI 10.1016/0301-4622(78)85026-1; GRABAREK Z, 1986, J BIOL CHEM, V261, P608; GRYCZYNSKI I, 1988, BIOPHYS CHEM, V30, P49, DOI 10.1016/0301-4622(88)85003-8; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JOHNSON JD, 1978, J BIOL CHEM, V253, P3775; KASPRZAK A, 1982, BIOCHEMISTRY-US, V21, P5924, DOI 10.1021/bi00266a030; KINOSITA K, 1977, BIOPHYS J, V20, P289, DOI 10.1016/S0006-3495(77)85550-1; LAKOWICZ JR, 1988, BIOCHEMISTRY-US, V27, P9149, DOI 10.1021/bi00426a012; LEAVIS PC, 1978, ARCH BIOCHEM BIOPHYS, V187, P243, DOI 10.1016/0003-9861(78)90030-9; LIAO RL, 1992, BIOPHYS J, V63, P986, DOI 10.1016/S0006-3495(92)81685-5; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; LUDESCHER RD, 1987, BIOPHYS CHEM, V28, P59, DOI 10.1016/0301-4622(87)80075-3; PERRY SV, 1974, BIOCHEM J, V141, P733, DOI 10.1042/bj1410733; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; RUGGIERO A, 1989, BIOPHYS J, V55, P1111, DOI 10.1016/S0006-3495(89)82908-X; SMALL EW, 1984, REV SCI INSTRUM, V55, P879, DOI 10.1063/1.1137850; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; SWENSON CA, 1992, BIOCHEMISTRY-US, V31, P3420, DOI 10.1021/bi00128a017; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; TOROK K, 1992, BIOCHEMISTRY-US, V31, P3452, DOI 10.1021/bi00128a020; WANG CK, 1985, BIOPHYS J, V48, P727, DOI 10.1016/S0006-3495(85)83831-5; WANG CK, 1986, J MOL BIOL, V191, P509, DOI 10.1016/0022-2836(86)90145-2; WANG CK, 1989, PROTEINS, V6, P424, DOI 10.1002/prot.340060409; WANG CK, 1988, BIOPHYS J, V53, pA73; WANG CLA, 1983, J BIOL CHEM, V258, P9175; WEBER G, 1970, P NATL ACAD SCI USA, V65, P823, DOI 10.1073/pnas.65.4.823	32	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14671	14677						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325844				2022-12-27	WOS:A1993LL75900024
J	FIELDS, CG; MICKELSON, DJ; DRAKE, SL; MCCARTHY, JB; FIELDS, GB				FIELDS, CG; MICKELSON, DJ; DRAKE, SL; MCCARTHY, JB; FIELDS, GB			MELANOMA CELL-ADHESION AND SPREADING ACTIVITIES OF A SYNTHETIC 124-RESIDUE TRIPLE-HELICAL MINI-COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE PEPTIDE-SYNTHESIS; IV-COLLAGEN; BINDING-SITE; POLYTRIPEPTIDES; ATTACHMENT; SEQUENCE; MULTIPLE; HYDROXYPYROLINE; IDENTIFICATION; STABILIZATION	A great variety of cells, such as melanoma cells, fibroblasts, platelets, keratinocytes, and epithelial cells, adhere to and migrate on specific regions within the triple-helical domains of types I, III, and IV collagen. The relative importance of collagen primary, secondary, and tertiary structures on these cellular activities has not been ascertained, as no general synthetic methodology exists to allow for the study of peptides incorporating biologically active sequences in triple-helical conformation. We have thus developed a novel, generally applicable solid-phase branching methodology for the synthesis of aligned, triple-helical collagen-model polypeptides (i.e. ''mini-collagens''). Three nascent peptide chains are carboxyl-terminally linked through one N(alpha)-amino and two N(epsilon)-amino groups of Lys, while repeating Gly-Pro-Hyp triplets induce triple helicity. A homotrimeric triple-helical polypeptide (THP) of 124 amino acids, incorporating residues 1263-1277 of alpha1(IV) collagen, was synthesized. Highly metastatic mouse melanoma cells showed a profound preference for adhesion to this THP as compared with a single-stranded peptide (SSP) incorporating the same type IV collagen sequence or a branched peptide containing eight repeats of Gly-Pro-Hyp (designated GPP*). Specifically, 50% cell adhesion occurred at a THP concentration of 1.12 muM, while comparable levels of adhesion required [SSP] = 170 muM or [GPP*] > 100 muM. Melanoma cells also spread on the THP to a greater extent than on the SSP or GPP*. These results are the first direct demonstrations of the significance of triple helicity for cell adhesion to and spreading on a specific collagen sequence and support earlier conclusions of conformational dependency for cell adhesion to and migration on types I and IV collagen. In addition, the melanoma cell THP activities support the concept that tumor cell adhesion and spreading on type IV collagen involves multiple, distinct domains in triple-helical conformation. The triple-helical peptide synthetic protocol developed here will allow eventually for the study of both structure and biological activity of specific, glycosylated collagen sequences in homotrimeric and heterotrimeric forms.	UNIV MINNESOTA,DEPT LAB MED & PATHOL,BOX 107,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,CTR BIOMED ENGN,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL CANCER INSTITUTE [R01CA043924, R55CA054263] Funding Source: NIH RePORTER; NCI NIH HHS [CA 54263, CA 43924] Funding Source: Medline; PHS HHS [KD 44494] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMSON JG, 1992, ANAL BIOCHEM, V202, P210; ANDREEVA NS, 1963, ASPECTS PROTEIN STRU, P137; AUMAILLEY M, 1986, J CELL BIOL, V103, P1569, DOI 10.1083/jcb.103.4.1569; BABEL W, 1984, EUR J BIOCHEM, V143, P545, DOI 10.1111/j.1432-1033.1984.tb08404.x; BABIARZ B, 1992, EXP CELL RES, V203, P276, DOI 10.1016/0014-4827(92)90065-G; BARANY G, 1977, J AM CHEM SOC, V99, P7363, DOI 10.1021/ja00464a050; BARANY G, 1985, J AM CHEM SOC, V107, P4936, DOI 10.1021/ja00303a019; BLANKEMEYERMENGE B, 1988, TETRAHEDRON LETT, V29, P5871, DOI 10.1016/S0040-4039(00)82212-1; BRODSKY B, 1992, BIOPOLYMERS, V32, P447, DOI 10.1002/bip.360320423; CAMERON JD, 1991, INVEST OPHTH VIS SCI, V32, P2766; CHELBERG MK, 1989, CANCER RES, V49, P4796; CHELBERG MK, 1990, J CELL BIOL, V111, P261, DOI 10.1083/jcb.111.1.261; ENGEL J, 1977, BIOPOLYMERS, V16, P601, DOI 10.1002/bip.1977.360160310; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; FIELDS C G, 1991, Peptide Research, V4, P95; FIELDS CG, 1993, PEPTIDE RES, V6, P39; FIELDS CG, 1989, INT J PEPT PROT RES, V33, P298; FIELDS CG, 1992, ANAL BIOCHEM, V203, P245, DOI 10.1016/0003-2697(92)90309-U; Fields G. B., 1992, SYNTHETIC PEPTIDES U, P77; FIELDS GB, 1991, J THEOR BIOL, V153, P585, DOI 10.1016/S0022-5193(05)80157-2; FIELDS GB, 1992, J PHYS CHEM-US, V96, P3974, DOI 10.1021/j100189a013; FIELDS GB, 1991, J AM CHEM SOC, V113, P4202, DOI 10.1021/ja00011a023; GOLDMAN R, 1992, EUR J IMMUNOL, V22, P1109, DOI 10.1002/eji.1830220502; GUIBE F, 1989, TETRAHEDRON LETT, V30, P2641, DOI 10.1016/S0040-4039(00)99087-7; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; HAHN KW, 1990, SCIENCE, V248, P1544, DOI 10.1126/science.2360048; HEIDEMANN E, 1982, ADV POLYM SCI, V43, P143; KLEINMAN HK, 1978, J BIOL CHEM, V253, P5642; KUNZ H, 1988, ANGEW CHEM INT EDIT, V27, P711, DOI 10.1002/anie.198807111; KUNZ H, 1989, PEPTIDES 1988, P154; LEGRAND YJ, 1980, BIOCHEM BIOPH RES CO, V96, P1579, DOI 10.1016/0006-291X(80)91354-6; LLOYDWILLIAMS P, 1991, TETRAHEDRON LETT, V32, P4207, DOI 10.1016/S0040-4039(00)79906-0; LONG CG, 1992, J MOL BIOL, V225, P1, DOI 10.1016/0022-2836(92)91020-P; MAYO KH, 1991, BIOCHEMISTRY-US, V30, P8251, DOI 10.1021/bi00247a022; MILLIONOVA MI, 1963, BIOPHYS-USSR, V8, P478; MUTTER M, 1992, J AM CHEM SOC, V114, P1463, DOI 10.1021/ja00030a049; NEMETHY G, 1986, BIOCHEMISTRY-US, V25, P3184, DOI 10.1021/bi00359a016; OLSEN BR, 1971, J MOL BIOL, V57, P589, DOI 10.1016/0022-2836(71)90111-2; RAMACHAN.GN, 1973, BIOCHIM BIOPHYS ACTA, V322, P166, DOI 10.1016/0005-2795(73)90187-6; ROTH W, 1979, MAKROMOL CHEM, V180, P905; RUBIN K, 1981, CELL, V24, P463, DOI 10.1016/0092-8674(81)90337-8; SAKAKIBARA S, 1973, BIOCHIM BIOPHYS ACTA, V303, P198, DOI 10.1016/0005-2795(73)90164-5; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SCHARFFETTERKOCHANEK K, 1992, J INVEST DERMATOL, V98, P3, DOI 10.1111/1523-1747.ep12493266; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; WADE J D, 1991, Peptide Research, V4, P194; WILKE MS, 1990, J INVEST DERMATOL, V95, P264, DOI 10.1111/1523-1747.ep12484883; ZIJENAH LS, 1990, THROMB RES, V59, P553, DOI 10.1016/0049-3848(90)90415-9	50	108	115	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14153	14160						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314781				2022-12-27	WOS:A1993LJ82500056
J	ALBERTA, JA; RUNDELL, K; STILES, CD				ALBERTA, JA; RUNDELL, K; STILES, CD			IDENTIFICATION OF AN ACTIVITY THAT INTERACTS WITH THE 3'-UNTRANSLATED REGION OF C-MYC MESSENGER-RNA AND THE ROLE OF ITS TARGET SEQUENCE IN MEDIATING RAPID MESSENGER-RNA DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; 3' UNTRANSLATED REGION; URIDINE BINDING-FACTOR; CELL-FREE SYSTEM; RICH SEQUENCES; NUCLEOTIDE-SEQUENCE; STABILITY INVITRO; GENE-EXPRESSION; CODING REGION; 1ST STEP	Single or multiple copies of the pentameric motif, AUUUA, are found in the 3'-untranslated domain of most immediate early mRNAs. A broad body of data links this 5-base element to the selective degradation of these mRNAs. However, AUUUA motifs are neither always necessary nor always sufficient to tag an mRNA for rapid degradation. Here, we describe a cytoplasmic, protease-sensitive factor in Balb/c3T3 cells that interacts with the 3'-untranslated region of c-myc mRNA. The factor recognizes a 39-base uridine-rich domain adjacent to, but distinct from, the c-mye AUUUA motif. In chimeric mRNA constructs, the 39-base binding element cooperates with adjacent sequence material to destabilize beta-globin mRNA.	DANA FARBER CANC INST, DIV CELLULAR & MOLEC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, PROGRAM CELL & DEV BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; NORTHWESTERN UNIV, SCH MED, DEPT MICROBIOL IMMUNOL, CHICAGO, IL 60611 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Northwestern University					NATIONAL CANCER INSTITUTE [R01CA022042] Funding Source: NIH RePORTER; NCI NIH HHS [CA22042] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BICKEL M, 1992, P NATL ACAD SCI USA, V89, P10001, DOI 10.1073/pnas.89.21.10001; BLOBEL G, 1973, P NATL ACAD SCI USA, V70, P924, DOI 10.1073/pnas.70.3.924; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BONNIEU A, 1988, ONCOGENE RES, V3, P155; BONNIEU A, 1990, ONCOGENE, V5, P1585; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GRAHAM FL, 1973, J VIROL, V52, P455; GREENBERG JR, 1972, NATURE, V242, P102; HAN JH, 1991, BIOCHIM BIOPHYS ACTA, V1090, P22, DOI 10.1016/0167-4781(91)90032-H; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAIRDOFFRINGA IA, 1991, NUCLEIC ACIDS RES, V19, P2387, DOI 10.1093/nar/19.9.2387; LIEBERMAN AP, 1990, J EXP MED, V172, P989, DOI 10.1084/jem.172.3.989; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PEI R, 1988, MOL CELL BIOL, V8, P2860, DOI 10.1128/MCB.8.7.2860; PERRY RP, 1973, J MOL BIOL, V79, P681, DOI 10.1016/0022-2836(73)90071-5; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; RAYMOND V, 1989, ONCOGENE RES, V5, P1; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SINGER RH, 1973, J MOL BIOL, V78, P321, DOI 10.1016/0022-2836(73)90119-8; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WHITTEMORE LA, 1990, MOL CELL BIOL, V10, P1329, DOI 10.1128/MCB.10.4.1329; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931	48	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4532	4538						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308023				2022-12-27	WOS:A1994MW98900095
J	MASON, GGF; WITTE, AM; WHITELAW, ML; ANTONSSON, C; MCGUIRE, J; WILHELMSSON, A; POELLINGER, L; GUSTAFSSON, JA				MASON, GGF; WITTE, AM; WHITELAW, ML; ANTONSSON, C; MCGUIRE, J; WILHELMSSON, A; POELLINGER, L; GUSTAFSSON, JA			PURIFICATION OF THE DNA-BINDING FORM OF DIOXIN RECEPTOR - ROLE OF THE ARNT COFACTOR IN REGULATION OF DIOXIN RECEPTOR FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOBIOTIC RESPONSIVE ELEMENTS; HEAT-SHOCK PROTEIN; AH-RECEPTOR; TRANSCRIPTION FACTOR; IMMUNOGLOBULIN-ENHANCER; NUCLEAR RECEPTORS; RETINOIC ACID; P-450C GENE; IDENTIFICATION; CLONING	The basic region/helix-loop-helix dioxin receptor mediates signal transduction by dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin). Upon ligand binding the dioxin receptor is converted from a latent, non-DNA binding form to a form that directly interacts with target genes by binding to dioxin-responsive transcriptional control elements. We have purified by conventional and DNA affinity chromatographic procedures the ligand-activated, DNA binding form of dioxin receptor to examine its architecture and functional properties. We observed that the DNA binding activity of the receptor was labile. Most notably, this activity was lost following DNA affinity purification. In complementation experiments we have identified an auxiliary factor(s) that exhibited very poor, if any, intrinsic affinity for the DNA target sequence in vitro but strongly increased the DNA binding activity of the purified receptor-containing material identified by immunoblot analysis. In a similar fashion the in vitro expressed basic region/helix-loop-helix factor Arnt (that has been postulated to modulate the nuclear translocation function of the receptor) reconstituted the DNA binding function of the purified receptor, and the purified auxiliary factor reconstituted receptor activity upon addition to an extract from mutant, Arnt-deficient hepatoma cells. Conversely, purified dioxin receptor reconstituted DNA binding activity in extracts from receptor deficient hepatoma cells which express bona fide levels of Arnt. Interestingly, UV cross-linking studies using a BrdU-substituted DNA target sequence indicated that primarily the receptor protein was bound to DNA. Moreover, we demonstrate that purified receptor or Arnt exhibited virtually no detectable affinity for the target sequence individually but, in the presence of one another, showed a strong synergy in DNA binding activity in vitro. Importantly, simultaneous expression of the receptor and Arnt resulted in synergistic induction of gene expression in vivo. These data demonstrate that Arnt plays a central role in control of dioxin receptor function by cooperatively modulating the DNA binding activity of the receptor in vitro and dioxin-dependent transactivation in vivo.	KAROLINSKA INST,HUDDINGE HOSP,NOVUM,DEPT MED NUTR,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet								ANDERSSON S, 1991, J BIOL CHEM, V264, P10078; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Bailar J C 3rd, 1991, N Engl J Med, V324, P260, DOI 10.1056/NEJM199101243240409; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; BLANAR MA, 1992, SCIENCE, V251, P1211; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CUTHILL S, 1991, MOL CELL BIOL, V11, P412; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GRADIN K, 1993, J BIOL CHEM, V268, P4061; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HANKINSON O, 1983, SOMATIC CELL GENET, V9, P97; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HAPGOOD J, 1991, MOL CELL BIOL, V11, P4314, DOI 10.1128/MCB.11.9.4314; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; NEMOTO T, 1990, J BIOL CHEM, V265, P2269; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; PAULSON KE, 1990, MOL CELL BIOL, V10, P1841, DOI 10.1128/MCB.10.5.1841; PERDEW GH, 1988, J BIOL CHEM, V263, P1382; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; POELLINGER L, 1992, TRENDS PHARMACOL SCI, V13, P241, DOI 10.1016/0165-6147(92)90076-I; POELLINGER L, 1985, ANAL BIOCHEM, V144, P371, DOI 10.1016/0003-2697(85)90130-7; POELLINGER L, 1989, MOL CELL BIOL, V9, P747, DOI 10.1128/MCB.9.2.747; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1986, J BIOL CHEM, V261, P6352; POLAND A, 1991, MOL PHARMACOL, V39, P20; PONGRATZ I, 1991, J BIOL CHEM, V266, P16813; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; PRATT WB, 1992, TRENDS ENDOCRIN MET, V3, P326, DOI 10.1016/1043-2760(92)90111-D; PROKIPCAK RD, 1988, ARCH BIOCHEM BIOPHYS, V261, P6352; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; TAKAHASHI JS, 1992, SCIENCE, V258, P238, DOI 10.1126/science.1384127; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WANG X, 1991, ARCH BIOCHEM BIOPHYS, V287, P186, DOI 10.1016/0003-9861(91)90405-8; WEINBERGER J, 1986, NATURE, V322, P846, DOI 10.1038/322846a0; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	54	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4438	4449						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308014				2022-12-27	WOS:A1994MW98900084
J	METZLER, WJ; BELL, AJ; ERNST, E; LAVOIE, TB; MUELLER, L				METZLER, WJ; BELL, AJ; ERNST, E; LAVOIE, TB; MUELLER, L			IDENTIFICATION OF THE POLY-L-PROLINE-BINDING SITE ON HUMAN PROFILIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; N-15-LABELED PROTEINS; NUCLEOTIDE-SEQUENCE; ACTIN; GENE; CLONING; DOMAIN; CDNA; RECEPTOR	Profilin is a ubiquitous protein that has been implicated in the signaling pathway leading to cytoskeletal rearrangement in cells. An unusual property of profilin is its high binding affinity for poly-L-proline (PLP). This binding property is conserved in the profilins from diverse species with little sequence homology. We have monitored the binding of PLP to profilin by fluorescence and nuclear magnetic resonance spectroscopies. NMR spectroscopy has identified several residues whose amide nitrogen and amide hydrogen chemical shifts are significantly perturbed by binding of PLP. The affected residues are located at various locations throughout profilin's primary structure; however, mapping the location of the affected residues onto the recently determined three dimensional solution structure of human profilin indicates that the effects of PLP binding are highly localized. Poly-L-proline binds profilin at the hydrophobic interface between profilin's NH2- and COOH-terminal helices and the upper face of its antiparallel beta-sheet. In contrast, residues located on the opposite side of the profilin structure are unaffected. The extent of the potential interaction surface of the PLP-profilin complex suggests that as few as 6 contiguous prolines would be sufficient for binding profilin. Examination of sequence data bases indicates that stretches of prolines of this length and longer occur in numerous regulatory proteins, suggesting that the ability of profilin to bind polyproline may be an important component of its signaling capabilities.	BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT MACROMOLEC BIOCHEM,PRINCETON,NJ 08543	Bristol-Myers Squibb	METZLER, WJ (corresponding author), BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT MACROMOLEC NMR,POB 4000,PRINCETON,NJ 08543, USA.							AMPE C, 1987, EMBO J, V6, P4149, DOI 10.1002/j.1460-2075.1987.tb02761.x; BABA T, 1989, FEBS LETT, V244, P296, DOI 10.1016/0014-5793(89)80549-6; BABCOCK G, 1989, CELL MOTIL CYTOSKEL, V14, P230, DOI 10.1002/cm.970140209; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BANERJI J, 1990, P NATL ACAD SCI USA, V87, P2374, DOI 10.1073/pnas.87.6.2374; BLAKE TJ, 1991, ONCOGENE, V6, P653; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; CARLSSON L, 1976, J MOL BIOL, V105, P353, DOI 10.1016/0022-2836(76)90098-X; CHAMPE MA, 1989, NUCLEIC ACIDS RES, V17, P3304, DOI 10.1093/nar/17.8.3304; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; FEIGL G, 1989, NUCLEIC ACIDS RES, V17, P7167, DOI 10.1093/nar/17.18.7167; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOLDSCHMIDTCLERMONT PJ, 1991, CELL, V66, P419, DOI 10.1016/0092-8674(81)90002-7; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; HAARER BK, 1990, CELL MOTIL CYTOSKEL, V17, P71, DOI 10.1002/cm.970170202; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KAISER DA, 1989, CELL MOTIL CYTOSKEL, V14, P251, DOI 10.1002/cm.970140211; KATAKAMI Y, 1992, BIOCHIM BIOPHYS ACTA, V1122, P123, DOI 10.1016/0167-4838(92)90314-4; LINDBERG U, 1988, BIOCHIM BIOPHYS ACTA, V967, P391, DOI 10.1016/0304-4165(88)90102-X; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; METZLER WJ, 1993, IN PRESS BIOCHEMISTR, V32; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; MUELLER L, 1992, J MAGN RESON, V96, P408, DOI 10.1016/0022-2364(92)90096-P; MUELLER L, 1979, MOL PHYS, V38, P963; RAGHUNATHAN V, 1992, FEBS LETT, V297, P46, DOI 10.1016/0014-5793(92)80324-A; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11383, DOI 10.1093/nar/16.23.11383; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SUDHOF TC, 1990, J BIOL CHEM, V265, P7849; TAN JL, 1990, MOL CELL BIOL, V10, P3578, DOI 10.1128/MCB.10.7.3578; TANAKA M, 1985, EUR J BIOCHEM, V151, P291, DOI 10.1111/j.1432-1033.1985.tb09099.x; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	40	94	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4620	4625						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308034				2022-12-27	WOS:A1994MW98900106
J	NICULESCU, F; RUS, H; SHINO, ML				NICULESCU, F; RUS, H; SHINO, ML			RECEPTOR-INDEPENDENT ACTIVATION OF GUANINE-NUCLEOTIDE-BINDING REGULATORY PROTEINS BY TERMINAL COMPLEMENT COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; CATALYZED ADP-RIBOSYLATION; GTP-BINDING; SIGNAL TRANSDUCTION; HUMAN-ERYTHROCYTES; PLASMA-MEMBRANES; NUCLEATED CELLS; PHOSPHOLIPASE-C; MASTOPARAN; ATTACK	Activation of heterotrimeric guanine nucleotide-binding proteins (G proteins) by terminal complement complexes (TCC) was investigated on human lymphoblastoid B-cell line JY25 and its mutant JY5 deficient in glycosylphosphatidylinositol-anchored proteins. TCC assembly achieved by antibody dependent activation of C7-deficient serum reconstituted with C7 increased specific guanosine-5'-(gamma-thio)triphosphate (GTP gamma S) binding, 4- and 8-fold, in JY25 and JY5 membranes, respectively, between 2 and 10 min, over the level without C7. TCC also increased GTPase activity 5- and 4-fold in JY25 and JY5, respectively, between 5 and 10 min. Increased GTPase activity was noted first with C5b-7 assembly, which increased further with C5b-8 and C5b-9. The presence of G proteins in anti TCC immunoprecipitates of cell lysates was investigated by demonstration of Ga subunit that can be ADP-ribosylated by pertussis toxin (PTX). Immunoprecipitated TCC complexes contained a PTX-sensitive 41-kDa Gi alpha/Go alpha subunit, as shown by SDS PAGE and Western blotting. These complexes were functionally active as determined by GTP gamma S binding. We have further shown that enhanced TCC elimination from the plasma membrane induced by TCC-generated signals was inhibited by PTX. In conclusion the biological activities induced by TCC in nucleated cells may be mediated in part by activation of PTX-sensitive G proteins.	UNIV MARYLAND,SCH MED,DEPT PATHOL,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore			Rus, Horea/AAF-2583-2020		FIC NIH HHS [FO5 TWO 4624] Funding Source: Medline; NIAID NIH HHS [R01-AI19622] Funding Source: Medline; NINDS NIH HHS [R01-NS15662] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004624] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015662] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANTONNY B, 1992, J BIOL CHEM, V267, P6710; BHAKDI S, 1983, BIOCHIM BIOPHYS ACTA, V737, P343, DOI 10.1016/0304-4157(83)90006-0; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOMMAKANTI RK, 1992, J BIOL CHEM, V267, P7576; CARNEY DF, 1990, J IMMUNOL, V145, P623; CARNEY DF, 1986, J IMMUNOL, V137, P263; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; HALPERIN JA, 1993, J CLIN INVEST, V91, P1974, DOI 10.1172/JCI116418; HANSCH GM, 1992, IMMUNOPHARMACOLOGY, V24, P107, DOI 10.1016/0162-3109(92)90017-7; HANSCH MG, 1981, P NATL ACAD SCI USA, V78, P5112; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P12655; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HOLLANDER N, 1988, J IMMUNOL, V141, P4283; HOLLANDER N, 1989, J IMMUNOL, V142, P3913; IMAMURA K, 1988, J BIOL CHEM, V263, P14093; KOCH G, 1991, FEBS LETT, V291, P336, DOI 10.1016/0014-5793(91)81315-Y; KOSKI CL, 1987, J CLIN INVEST, V80, P1492, DOI 10.1172/JCI113231; KUPPER RW, 1992, BIOCHEM J, V282, P429, DOI 10.1042/bj2820429; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; LILLIE THW, 1992, BIOCHEM J, V288, P181, DOI 10.1042/bj2880181; MORGAN BP, 1989, BIOCHEM J, V264, P1; NICHOLSONWELLER A, 1982, J IMMUNOL, V129, P184; NICULESCU F, 1992, AM J PATHOL, V140, P1039; NICULESCU F, 1993, J IMMUNOL, V150, P214; ONEILL LAJ, 1990, J BIOL CHEM, V265, P3146; RAMM LE, 1983, BIOL RESPONSE MEDIAT, P117; ROLLINS TE, 1991, P NATL ACAD SCI USA, V88, P971, DOI 10.1073/pnas.88.3.971; RUS HG, 1987, IMMUNOL LETT, V16, P15, DOI 10.1016/0165-2478(87)90054-X; SANDERS ME, 1986, J RHEUMATOL, V13, P1028; SCHEPERS TM, 1993, BIOCHEM J, V289, P469, DOI 10.1042/bj2890469; SCHONERMARK S, 1986, J IMMUNOL, V136, P1772; SEEGER W, 1986, J IMMUNOL, V137, P1286; SHIN ML, 1988, PROG ALLERGY, V40, P44; SICILIANO SJ, 1990, J BIOL CHEM, V265, P16873; STEINBUCH M, 1969, ARCH BIOCHEM BIOPHYS, V134, P279, DOI 10.1016/0003-9861(69)90285-9; SUGITA Y, 1988, J BIOCHEM-TOKYO, V104, P633, DOI 10.1093/oxfordjournals.jbchem.a122524; TAKEI Y, 1992, J BIOL CHEM, V267, P5085; THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187; TSCHOPP J, 1988, CYTOLYTIC LYMPHOCYTE, V1, P185; VANGURI P, 1988, J BIOL CHEM, V263, P7228; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; WIEDMER T, 1987, J BIOL CHEM, V262, P13674; WU DQ, 1992, J BIOL CHEM, V267, P1811; YANAGA F, 1992, J BIOL CHEM, V267, P5114; YANG LJ, 1993, J BIOL CHEM, V268, P3739; YATANI A, 1991, J BIOL CHEM, V266, P22872	49	68	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4417	4423						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308012				2022-12-27	WOS:A1994MW98900081
J	BISSIG, M; HAGENBUCH, B; STIEGER, B; KOLLER, T; MEIER, PJ				BISSIG, M; HAGENBUCH, B; STIEGER, B; KOLLER, T; MEIER, PJ			FUNCTIONAL EXPRESSION CLONING OF THE CANALICULAR SULFATE TRANSPORT-SYSTEM OF RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; EXCHANGE	We have cloned a single cDNA encoding the canalicular sulfate transporter of rat liver using Xenopus laevis oocytes as a functional expression system. The cloned cDNA sulfate anion transporter-1 (sat-1) expresses saturable Na+-independent sulfate uptake (K(m) approximately 0.14 mM) that can be inhibited by, 4,4'-diisothiocyano-2,2'-disulfonic acid stilbene (DIDS, IC50 = 28 muM) and oxalate, but not by succinate or cholate. These properties are very similar to sulfate uptake expressed in oocytes injected with total rat liver mRNA and to the bicarbonate/sulfate exchange system previously characterized in canalicular rat liver plasma membrane vesicles. The cloned sat-1 cDNA has a total length of 3726 base pairs (bp) with an open reading frame encompassing 2109 bp, a 5'-untranslated region of 367 bp, and a 3'-untranslated region of 1250 bp. The coding region predicts a protein of 703 amino acids with a calculated molecular mass of 75.4 kDa. Computer-based hydrophobicity analysis suggests the presence of 12 putative transmembrane spanning domains. Furthermore, three potential glycosylation sites are detected (Asn-158, Asn-163, Asn-587). Northern blot analysis indicates that similar sulfate anion transporters are also present in the kidney, muscle, and brain of rat and in the liver of the mouse. Using antisense oligonucleotides the mRNA-species of the sat-1 analogue in rat kidney has been characterized by hybrid depletion experiments (Markovich, D., Bissig, M., Sorribas, V., Hagenbuch, B., Meier, P. J., and Murer, H. (1994) J. Biol. Chem. 269, 3022-3026).	UNIV HOSP ZURICH,DEPT MED,DIV CLIN PHARMACOL & TOXICOL,CH-8091 ZURICH,SWITZERLAND; SWISS FED INST TECHNOL,INST CELL BIOL,CH-8092 ZURICH,SWITZERLAND	University of Zurich; University Zurich Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich			Stieger, Bruno/U-6323-2017; Hagenbuch, Bruno/M-5294-2016	Stieger, Bruno/0000-0002-7190-5785; Hagenbuch, Bruno/0000-0002-2938-8630				COLMAN A, 1986, TRANSCRIPTION TRANSL, P271; HAGENBUCH B, 1990, J BIOL CHEM, V265, P5357; HUGENTOBLER G, 1986, AM J PHYSIOL, V251, pG656, DOI 10.1152/ajpgi.1986.251.5.G656; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MARKOVICH D, 1994, J BIOL CHEM, V269, P3022; McCormick M, 1987, Methods Enzymol, V151, P445, DOI 10.1016/S0076-6879(87)51036-9; Meier Peter J., 1993, P587; MEIER PJ, 1987, AM J PHYSIOL, V253, pG461, DOI 10.1152/ajpgi.1987.253.4.G461; PALACIN M, 1990, J BIOL CHEM, V265, P7142; Sambrook J, 1989, MOL CLONING LABORATO; Stremmel Wolfgang, 1993, P225; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F	14	168	174	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3017	3021						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300633				2022-12-27	WOS:A1994MV43200093
J	XING, MZ; WILKINS, PL; MCCONNELL, BK; MATTERA, R				XING, MZ; WILKINS, PL; MCCONNELL, BK; MATTERA, R			REGULATION OF PHOSPHOLIPASE-A(2) ACTIVITY IN UNDIFFERENTIATED AND NEUTROPHIL-LIKE HL-60 CELLS - LINKAGE BETWEEN IMPAIRED RESPONSES TO AGONISTS AND ABSENCE OF PROTEIN-KINASE C-DEPENDENT PHOSPHORYLATION OF CYTOSOLIC PHOSPHOLIPASE-A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; PROMYELOCYTIC LEUKEMIA-CELLS; ARACHIDONIC-ACID RELEASE; DIMETHYL-SULFOXIDE; HL-60 CELLS; SIGNAL TRANSDUCTION; DIFFERENTIATION; RECEPTORS; PURIFICATION; CULTURE	We compared the regulation of cytosolic phospholipase A2 (cPLA2) activity in undifferentiated and neutrophil-like HL60 cells. Although Ca2+-mobilizing P2-purinergic receptors are expressed in both cell types, arachidonic acid (AA) release stimulated by P2-purinergic agonists was 5-7-fold higher in the differentiated cells. Similarly, the stimulation of AA release by AlF4- in intact cells or by ATP and guanosine 5'-3-O-(thio)triphosphate (GTPgammaS) in electropermeabilized cells was significantly higher in the differentiated cells. Treatment with phorbol 12-myristate 13-acetate (PMA) enhanced A23187-stimulated AA release in intact HL60 granulocytes with minimal effects in the undifferentiated cells. Immunoblotting experiments showed similar levels of cPLA2 and of agonist-mediated activation of mitogen-activated protein kinase in both cell types. Experiments measuring stimulation of AA release by either melittin, using endogenously labeled intact cells, or Ca2+, using homogenates and exogenous substrate, indicated that undifferentiated cells do not lack an activatable PLA2. The stimulatory effects of GTPgammaS and Ca2+ on AA release in homogenates from endogenously labeled cells suggested that undifferentiated cells display G protein-cPLA2 coupling. Basal and PMA-stimulated phosphorylation of cPLA2 was detected in differentiated, but not in undifferentiated cells. However, the two cell types displayed only subtle differences in the time courses of phosphorylation of mitogen-activated protein kinase triggered by agonists and PMA. The observed defect in cPLA2 phosphorylation may represent the alteration preventing agonist-mediated stimulation of AA release in undifferentiated HL60 cells.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106	Case Western Reserve University					NIGMS NIH HHS [GM 46552-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM046552] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXELROD J, 1990, BIOCHEM SOC T, V18, P503, DOI 10.1042/bst0180503; BILLAH MM, 1986, J BIOL CHEM, V261, P5824; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONSER RW, 1981, BIOCHEM BIOPH RES CO, V98, P614, DOI 10.1016/0006-291X(81)91158-X; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COCKCROFT S, 1989, BIOCHEM J, V263, P715, DOI 10.1042/bj2630715; COCKCROFT S, 1991, BIOCHEM SOC T, V19, P333, DOI 10.1042/bst0190333; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COWEN DS, 1989, J CLIN INVEST, V83, P1651, DOI 10.1172/JCI114064; COWEN DS, 1990, BIOCHIM BIOPHYS ACTA, V1053, P195, DOI 10.1016/0167-4889(90)90014-5; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DUBYAK GR, 1988, J BIOL CHEM, V263, P18108; FLOWER RJ, 1976, BIOCHEM PHARMACOL, V25, P285, DOI 10.1016/0006-2952(76)90216-1; FURTH EE, 1989, J BIOL CHEM, V264, P18494; GAO G, 1990, J BIOL CHEM, V265, P2431; GARCIA MD, 1991, BIOCHEM J, V273, P573, DOI 10.1042/bj2730573; GODSON C, 1990, J BIOL CHEM, V265, P8369; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HO AK, 1987, J BIOL CHEM, V262, P11764; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HONG SL, 1976, P NATL ACAD SCI USA, V73, P1730, DOI 10.1073/pnas.73.5.1730; INSEL PA, 1991, BIOCHEM SOC T, V19, P329, DOI 10.1042/bst0190329; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MOLLAY C, 1974, FEBS LETT, V46, P141, DOI 10.1016/0014-5793(74)80354-6; MURAYAMA T, 1990, J BIOL CHEM, V265, P4290; MURPHY PM, 1987, FEBS LETT, V221, P81, DOI 10.1016/0014-5793(87)80356-3; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; POSADA J, 1992, MOL BIOL CELL, V3, P583, DOI 10.1091/mbc.3.6.583; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHIER WT, 1979, P NATL ACAD SCI USA, V76, P195, DOI 10.1073/pnas.76.1.195; STEINER MR, 1993, BIOCHIM BIOPHYS ACTA, V1166, P124, DOI 10.1016/0005-2760(93)90292-H; SUGA K, 1990, J BIOL CHEM, V265, P12363; TAKAYAMA K, 1991, FEBS LETT, V282, P326, DOI 10.1016/0014-5793(91)80506-X; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P83; WINKLER JD, 1993, BIOCHEM J, V291, P825, DOI 10.1042/bj2910825; XIE MS, 1991, J CLIN INVEST, V88, P45, DOI 10.1172/JCI115303; XING MZ, 1992, J BIOL CHEM, V267, P25966; XING MZ, 1992, J BIOL CHEM, V267, P6602; YORIO T, 1978, NATURE, V271, P79, DOI 10.1038/271079a0	55	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3117	3124						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300648				2022-12-27	WOS:A1994MV43200109
J	DELAFONTAINE, P; LOU, H				DELAFONTAINE, P; LOU, H			ANGIOTENSIN-II REGULATES INSULIN-LIKE GROWTH FACTOR-I GENE-EXPRESSION IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C ACTIVATION; MESSENGER-RNA; PROTEIN-SYNTHESIS; TRANSCRIPTION; MOBILIZATION; HYPERTROPHY; SECRETION; INDUCTION; CALCIUM; INJURY	The potent vasoconstrictor peptide angiotensin II (ang II) has been shown to promote growth of vascular smooth muscle cells (VSMC) in vitro and in vivo. We have previously demonstrated that VSMC synthesize insulin-like growth factor I (IGF I), an important autocrine/paracrine growth factor. Exposure of quiescent VSMC to ang II caused a marked increase in IGF I mRNA levels, peaking at 6 h (199 +/- 26% above control) and sustained for at least 24 h. This increase was completely inhibited by actinomycin D. Nuclear run-on assays indicated that ang II stimulated IGF I gene transcription 3.6-fold. Protein synthesis inhibition with cycloheximide increased basal IGF I mRNA levels but blocked ang II-induced IGF I expression. Immunoreactive IGF I levels in VSMC-conditioned medium were increased by 2.7-fold 24 h following ang II exposure. Measurements of [H-3]thymidine incorporation showed that ang II caused a 117% increase in DNA synthesis at 24 h that was almost completely inhibited in the presence of an anti-IGF I antibody. Thus, ang II regulates transcription of the IGF I gene in VSMC and IGF I is required for ang II-induced DNA synthesis. These findings suggest a potentially important role for IGF I as a mediator of the vascular growth responses induced by activation of the renin-angiotensin system in vivo.			DELAFONTAINE, P (corresponding author), EMORY UNIV, DEPT MED, DIV CARDIOL, PO DRAWER LL, ATLANTA, GA 30322 USA.			Delafontaine, Patrice/0000-0003-3744-3617	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045317, R01HL045317, R01HL047035] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47035, HL45317] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMO ML, 1991, BIOCHEM BIOPH RES CO, V176, P887, DOI 10.1016/S0006-291X(05)80269-4; ALEXANDER RW, 1985, HYPERTENSION, V7, P447, DOI 10.1161/01.HYP.7.3.447; [Anonymous], 1991, INSULIN LIKE GROWTH; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BERK BC, 1987, J BIOL CHEM, V262, P5057; BROCK TA, 1985, HYPERTENSION, V7, pI105, DOI 10.1161/01.HYP.7.3_Pt_2.I105; CERCEK B, 1990, CIRC RES, V66, P1755, DOI 10.1161/01.RES.66.6.1755; CHATELAIN P, 1991, ACTA PAEDIATR SCAND, P92; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEMMONS DR, 1985, CIRC RES, V56, P418, DOI 10.1161/01.RES.56.3.418; CLEMMONS DR, 1985, J CLIN INVEST, V75, P1914, DOI 10.1172/JCI111906; CLEMMONS DR, 1985, ENDOCRINOLOGY, V117, P77, DOI 10.1210/endo-117-1-77; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DAZU VJ, 1987, J CARDIOVASC PHAR S7, V10, pS9; DELAFONTAINE P, 1991, HYPERTENSION, V17, P693, DOI 10.1161/01.HYP.17.5.693; DELAFONTAINE P, 1991, HYPERTENSION, V18, P742, DOI 10.1161/01.HYP.18.6.742; DUBEY RK, 1992, CIRC RES, V71, P1143, DOI 10.1161/01.RES.71.5.1143; DZAU VJ, 1991, FOCUS HYPERTENSION, V1, P5; FATH KA, 1993, CIRC RES, V72, P271, DOI 10.1161/01.RES.72.2.271; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GADJUSEK CM, 1993, J CELL PHYSL, V154, P192; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GLUCKMAN PD, 1991, ACTA PAEDIATR SCAND, P97; GRIFFIN SA, 1991, HYPERTENSION, V17, P626, DOI 10.1161/01.HYP.17.5.626; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUYTON AC, 1991, TXB MED PHYSL, P205; Hall JE, 1990, HYPERTENSION PATHOPH, P1105; HANSSON HA, 1987, ACTA PHYSIOL SCAND, V129, P165, DOI 10.1111/j.1748-1716.1987.tb08055.x; HANSSON HA, 1987, CELL TISSUE RES, V250, P499; KAUFFMAN RF, 1991, LIFE SCI, V49, pPL223, DOI 10.1016/0024-3205(91)90298-P; KAWAHARA Y, 1988, BIOCHEM BIOPH RES CO, V150, P52, DOI 10.1016/0006-291X(88)90485-8; LANG U, 1989, BIOCHEM J, V259, P477, DOI 10.1042/bj2590477; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; NAGAOKA I, 1990, J CLIN INVEST, V85, P448, DOI 10.1172/JCI114458; PENHOAT A, 1989, J BIOL CHEM, V264, P6858; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; ROTWEIN P, 1988, P NATL ACAD SCI USA, V85, P265, DOI 10.1073/pnas.85.1.265; STOUFFER GA, 1992, CIRC RES, V70, P820, DOI 10.1161/01.RES.70.4.820; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526	41	128	133	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16866	16870						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344966				2022-12-27	WOS:A1993LQ33600110
J	HUTH, JR; PERINI, F; LOCKRIDGE, O; BEDOWS, E; RUDDON, RW				HUTH, JR; PERINI, F; LOCKRIDGE, O; BEDOWS, E; RUDDON, RW			PROTEIN-FOLDING AND ASSEMBLY IN-VITRO PARALLEL INTRACELLULAR FOLDING AND ASSEMBLY - CATALYSIS OF FOLDING AND ASSEMBLY OF THE HUMAN CHORIONIC-GONADOTROPIN ALPHA-BETA DIMER BY PROTEIN DISULFIDE-ISOMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; PANCREATIC TRYPSIN-INHIBITOR; ENDOPLASMIC-RETICULUM; BOND FORMATION; CHORIOCARCINOMA CELLS; MICROSOMAL-MEMBRANES; BIOLOGICAL-ACTIVITY; SERUM-ALBUMIN; SUBUNIT; SECRETION	Although purified proteins will refold and assemble in vitro, it is not known if cellular factors change the mechanisms of these processes. Based on the gel migration of folding intermediates, the kinetic relationships between these intermediates, and on the order of formation of six disulfide bonds, we have found that the in vitro folding pathway of the human chorionic gonadotropin beta subunit (hCG-beta) is indistinguishable from the intracellular folding pathway. The same rate-limiting event was found in both folding environments; however, the t1/2 for this step in a cell is 4 min, whereas in vitro the t1/2 was greater-than-or-equal-to 80 min. Protein disulfide isomerase (PDI) increased the in vitro rate of this event (t1/2 = 25 min) without changing the order of disulfide bond formation. PDI also catalyzed the in vitro rate of assembly of hCG subunits. In intact cells, assembly of the alphabeta heterodimer occurs before all of the intramolecular disulfide bonds of beta are formed. In vitro, assembly was increased after reduction of two of the carboxyl-terminal disulfide bonds of hCG-beta by PDI. These results strongly suggest that both in intact cells and in vitro, partially unfolded hCG-beta is more assembly-competent than is fully folded hCG-beta. The comparison of in vitro and intracellular hCG-beta folding and hCG subunit assembly which is shown in this report indicates that the assisted folding and assembly pathway that occurs in cells, where proteins such as PDI play a role, differs only in rate but not in the order of disulfide bond formation or in the precursor-product relationships among the folding intermediates.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,600 S 42ND ST,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT PHARMACOL,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT BIOCHEM,OMAHA,NE 68198; UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [R01CA032949] Funding Source: NIH RePORTER; NCI NIH HHS [CA32949] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANFINSEN CB, 1972, BIOCHEM J, V128, P737, DOI 10.1042/bj1280737; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BEDOWS E, 1992, J BIOL CHEM, V267, P8880; BEDOWS E, 1993, J BIOL CHEM, V268, P11655; BEEBE JS, 1990, ENDOCRINOLOGY, V126, P384, DOI 10.1210/endo-126-1-384; BEEBE JS, 1990, J BIOL CHEM, V265, P312; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CHATRENET B, 1992, J BIOL CHEM, V267, P3038; CHEN F, 1991, J BIOL CHEM, V266, P6904; CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; EWBANK J J, 1992, Current Biology, V2, P347, DOI 10.1016/0960-9822(92)90051-B; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FUCHS A, 1991, BIOCHEMISTRY-US, V30, P6598, DOI 10.1021/bi00240a032; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOVERMAN JM, 1982, J BIOL CHEM, V257, P5059; HTUH JR, 1992, J BIOL CHEM, V267, P8870; HUTH JR, 1992, J BIOL CHEM, V267, P21396; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P88; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; Matthews CR, 1991, CURR OPIN STRUC BIOL, V1, P28; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; MATZUK MM, 1988, J BIOL CHEM, V263, P17106; MISE T, 1981, J BIOL CHEM, V256, P6587; MITRAKI A, 1992, FEBS LETT, V307, P20, DOI 10.1016/0014-5793(92)80894-M; NOIVA R, 1992, J BIOL CHEM, V267, P3553; PAVER JL, 1989, BIOCHEM J, V257, P657, DOI 10.1042/bj2570657; PETERS BP, 1984, J BIOL CHEM, V259, P5123; PETERS T, 1982, J BIOL CHEM, V257, P8847; RUDDON RW, 1979, P NATL ACAD SCI USA, V76, P5143, DOI 10.1073/pnas.76.10.5143; RUDDON RW, 1989, ENDOCRINOLOGY, V124, P862, DOI 10.1210/endo-124-2-862; RUDDON RW, 1987, J BIOL CHEM, V262, P12533; RUDDON RW, 1993, IN PRESS GLYCOPROTEI; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; SCHLAFF S, 1976, ENDOCRINOLOGY, V98, P527, DOI 10.1210/endo-98-2-527; SCHONBRUNNER ER, 1992, P NATL ACAD SCI USA, V89, P4510, DOI 10.1073/pnas.89.10.4510; STRICKLAND TW, 1982, J BIOL CHEM, V257, P2954; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; TAKAHASHI N, 1992, J BIOL CHEM, V267, P11565; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; WETLAUFER DB, 1984, METHOD ENZYMOL, V107, P301; WILSON JM, 1980, J AM CHEM SOC, V102, P359, DOI 10.1021/ja00521a058; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104; ZIEGLER DM, 1977, TRENDS BIOCHEM SCI, V2, P79, DOI 10.1016/0968-0004(77)90042-1	57	71	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16472	16482						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344931				2022-12-27	WOS:A1993LQ33600058
J	LINDBLOM, G; HAUKSSON, JB; RILFORS, L; BERGENSTAHL, B; WIESLANDER, A; ERIKSSON, PO				LINDBLOM, G; HAUKSSON, JB; RILFORS, L; BERGENSTAHL, B; WIESLANDER, A; ERIKSSON, PO			MEMBRANE LIPID REGULATION IN ACHOLEPLASMA-LAIDLAWII GROWN WITH SATURATED FATTY-ACIDS - BIOSYNTHESIS OF A TRIACYLGLUCOLIPID FORMING REVERSED MICELLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; X-RAY-DIFFRACTION; PHYSICAL-PROPERTIES; PHASE-EQUILIBRIA; GLYCOSYL DIACYLGLYCEROLS; HOMOLOGOUS SERIES; WATER-SYSTEMS; EF 22; CHOLESTEROL; LIQUID	The membrane lipid composition in several strains of Acholeplasma laidlawii is regulated upon a change in the growth conditions. Monoglucosyldiacylglycerol (MGlcDAG) and diglucosyldiacylglycerol (DGlcDAG) are the most abundant lipids in the A. laidlawii membrane. A third glucolipid, 3-O-acyl-monoglucosyldiacylglycerol (MAMGlcDAG) is synthesized by strain A-EF22 when the membrane lipids contain large amounts of saturated acyl chains. The lipid regulation can be understood from a simple theoretical model, in which the cells strive to maintain a balance between the lipids constituting a bilayer and those forming reversed non-lamellar liquid crystalline phases. Thus, the physical chemistry of membrane lipids, in particular their ability to form different aggregate structures, constitutes the basis for the lipid regulation, and therefore an understanding of the phase equilibria of membrane lipids is crucial. MGlcDAG and MAMGlcDAG isolated from A. laidlawii strain A-EF22 membranes were studied mainly by H-2 NMR, H-1 NMR, and H-1 NMR diffusion measurements. MAMGlcDAG, containing 96 mol % saturated acyl chains formed a gel/crystalline phase up to about 80-degrees-C, where a transition occurred to a reversed micellar (L2) phase. This is an unexpected finding for a membrane lipid. However, this lipid homogeneously mixes with the other membrane lipids at physiological temperatures. Previous and new data on MGlcDAG show that the lamellar phase is stabilized when the length and the degree of unsaturation of the acyl chains are decreased. The physicochemical properties of MAMGlcDAG and MGlcDAG were compared and found to be of great significance for the physiological regulation of the lipids in the membrane. MAMGlcDAG is synthesized under conditions when the phase equilibria of MGlcDAG are shifted from a non-lamellar toward a lamellar phase. Apart from MAMGlcDAG, MGlcDAG is the major lipid in A. laidlawii strain A-EF22 which is able to form reversed aggregate structures. MAMGlcDAG probably assists MGlcDAG in maintaining an optimal molecular packing, or negative curvature, of the lipids in the membrane.	UMEA UNIV,DEPT BIOCHEM,S-90187 UMEA,SWEDEN; INST SURFACE CHEM,S-11486 STOCKHOLM,SWEDEN	Umea University	LINDBLOM, G (corresponding author), UMEA UNIV,DEPT PHYS CHEM,S-90187 UMEA,SWEDEN.		Bergenståhl, Björn A/B-4663-2016					ABRAGAM A, 1961, PRINCIPLES NUCLEAR M; Adams W. F., 1985, EMULGATOREN LEBENSMI; BHAKOO M, 1987, BIOCHIM BIOPHYS ACTA, V922, P34, DOI 10.1016/0005-2760(87)90242-6; BHAKOO M, 1988, BIOCHIM BIOPHYS ACTA, V945, P307, DOI 10.1016/0005-2736(88)90493-2; BLOOM M, 1965, J CHEM PHYS, V42, P1615, DOI 10.1063/1.1696168; BLOOM M, 1978, BIOCHEMISTRY-US, V17, P5750, DOI 10.1021/bi00619a024; BRENTEL I, 1985, BIOCHIM BIOPHYS ACTA, V812, P816, DOI 10.1016/0005-2736(85)90277-9; CEBULA DJ, 1992, J AM OIL CHEM SOC, V69, P130, DOI 10.1007/BF02540562; CHRISTIANSSON A, 1978, EUR J BIOCHEM, V85, P65, DOI 10.1111/j.1432-1033.1978.tb12212.x; CHRISTIANSSON A, 1980, BIOCHIM BIOPHYS ACTA, V595, P189, DOI 10.1016/0005-2736(80)90083-8; DAVIS JH, 1976, CHEM PHYS LETT, V42, P390, DOI 10.1016/0009-2614(76)80392-2; DEKRUIJFF B, 1987, NATURE, V329, P587, DOI 10.1038/329587a0; EFRATI H, 1986, ARCH BIOCHEM BIOPHYS, V248, P282, DOI 10.1016/0003-9861(86)90425-X; ERIKSSON PO, 1991, BIOCHEMISTRY-US, V30, P4916, DOI 10.1021/bi00234a012; FONTELL K, 1968, ACTA POLYTECH SCA 74, V3, P2; GRUNER SM, 1989, J PHYS CHEM-US, V93, P7562, DOI 10.1021/j100359a011; Israelachvili J.N., 1991, INTERMOLECULAR SURFA; JANES N, 1990, BIOCHEMISTRY-US, V29, P8385, DOI 10.1021/bi00488a027; KARGER J, 1988, ADV MAGNETIC OPTICAL, V13, P1; KHAN A, 1981, EUR J BIOCHEM, V116, P215, DOI 10.1111/j.1432-1033.1981.tb05321.x; LARSSON K, 1979, J COLLOID INTERF SCI, V72, P152, DOI 10.1016/0021-9797(79)90194-2; LARSSON K, 1992, J AM OIL CHEM SOC, V69, P835, DOI 10.1007/BF02635928; LEWIS RNAH, 1990, BIOCHIM BIOPHYS ACTA, V1026, P21, DOI 10.1016/0005-2736(90)90327-K; LINDBLOM G, 1970, J COLLOID INTERF SCI, V34, P262, DOI 10.1016/0021-9797(70)90177-3; LINDBLOM G, 1989, BIOCHIM BIOPHYS ACTA, V988, P221, DOI 10.1016/0304-4157(89)90020-8; LINDBLOM G, 1986, BIOCHEMISTRY-US, V25, P7502, DOI 10.1021/bi00371a037; LINDBLOM G, 1990, NATO ADV SCI I H-CEL, V40, P43; LINDBLOM G, 1977, BIOPHYS CHEM, V6, P167, DOI 10.1016/0301-4622(77)87006-3; LINDBLOM G, 1976, ADV CHEM SER, V152, P121; MANNOCK DA, 1990, BIOCHEMISTRY-US, V29, P7790, DOI 10.1021/bi00486a003; MCELHANEY RN, 1989, CRIT REV MICROBIOL, V17, P1, DOI 10.3109/10408418909105720; MILLS R, 1973, J PHYS CHEM-US, V77, P685, DOI 10.1021/j100624a025; Rilfors L., 1984, Biomembranes, V12, P205; Rilfors L, 1993, Subcell Biochem, V20, P109; ROSEVEAR FB, 1968, J SOC COSMET CHEM, V19, P581; ROSEVEAR FB, 1954, J AM OIL CHEM SOC, V31, P628, DOI 10.1007/BF02545595; SEN A, 1990, BIOCHEMISTRY-US, V29, P7799, DOI 10.1021/bi00486a004; SJOLUND M, 1989, BIOCHEMISTRY-US, V28, P1323; SJOLUND M, 1987, BIOPHYS J, V52, P145, DOI 10.1016/S0006-3495(87)83202-2; Slichter CP., 1989, PRINCIPLES MAGNETIC; Small D.M., 1986, HDB LIPID RES, V4; SMITH ICP, 1979, FEBS LETT, V100, P57, DOI 10.1016/0014-5793(79)81130-8; SMITH PF, 1986, BIOCHIM BIOPHYS ACTA, V879, P107, DOI 10.1016/0005-2760(86)90091-3; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; ULMIUS J, 1977, BIOCHEMISTRY-US, V16, P5742, DOI 10.1021/bi00645a014; VEERKAMP JH, 1972, BIOCHIM BIOPHYS ACTA, V273, P359, DOI 10.1016/0304-4165(72)90227-9; WENNERSTROM H, 1974, CHEM SCRIPTA, V6, P97; WIESLANDER A, 1978, BIOCHIM BIOPHYS ACTA, V512, P241, DOI 10.1016/0005-2736(78)90250-X; WIESLANDER A, 1977, BIOCHIM BIOPHYS ACTA, V466, P336, DOI 10.1016/0005-2736(77)90229-2; WIESLANDER A, 1980, BIOCHEMISTRY-US, V19, P3650, DOI 10.1021/bi00557a002; WIESLANDER A, 1986, BIOCHEMISTRY-US, V25, P7511, DOI 10.1021/bi00371a038; WIESLANDER A, 1979, BIOCHIM BIOPHYS ACTA, V550, P1, DOI 10.1016/0005-2736(79)90111-1; [No title captured]; [No title captured]	54	57	57	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16198	16207						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344904				2022-12-27	WOS:A1993LQ33600020
J	MURPHY, G; SEGAIN, JP; OSHEA, M; COCKETT, M; IOANNOU, C; LEFEBVRE, O; CHAMBON, P; BASSET, P				MURPHY, G; SEGAIN, JP; OSHEA, M; COCKETT, M; IOANNOU, C; LEFEBVRE, O; CHAMBON, P; BASSET, P			THE 28-KDA N-TERMINAL DOMAIN OF MOUSE STROMELYSIN-3 HAS THE GENERAL-PROPERTIES OF A WEAK METALLOPROTEINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE GELS; TISSUE INHIBITOR; ACTIVATION; PURIFICATION; COLLAGENASE; MECHANISMS; IV; PROCOLLAGENASE; RECOMBINANT; EXPRESSION	The putative matrix metalloproteinase mouse stromelysin-3 was expressed from Escherichia coli and from a mouse myeloma cell line. In the former case a single major protein of 58-kDa was detectable by immunoblotting, but no proteolytic activity could be elicited by zymography or trypsin or organomercurial treatment as would be expected for a typical matrix metalloproteinase. In the latter case immunodetectable proteins of 55-58 and 27-28-kDa were produced. The effect of trypsin or organomercurial treatment of the 55-58-kDa forms was to generate a 51-kDa form and lower molecular mass fragments. Upon zymographic analysis only the 27-28-kDa forms showed caseinolytic activity. N-terminal sequencing and immunoblotting analysis with antibodies specific to distinct domains of stromelysin-3 indicated that the 27-28-Da stromelysin-3 forms had lost the predicted propeptide and the majority of the C-terminal domain. The purified 28-kDa form of stromelysin-3 could weakly degrade a number of extracellular matrix proteins and was inhibited by TIMP. However, the evidence that mature full-length stromelysin-3 is a metalloproteinase could not be substantiated and the precise role of this protein in vivo remains to be elucidated. By partial analogy with interstitial collagenase, one hypothesis is that stromelysin-3 with an intact C-terminal domain has specific properties for an as yet undefined substrate.	CELLTECH LTD, SLOUGH SL1 4EN, ENGLAND; FAC MED STRASBOURG, INST CHIM BIOL,GENET MOLEC EUCARYOTES LAB,CNRS, UA 184,INSERM, F-67085 STRASBOURG, FRANCE	Celltech Group Ltd; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	MURPHY, G (corresponding author), STRANGEWAYS RES LAB, WORTS CAUSEWAY, CAMBRIDGE CB1 4RN, ENGLAND.		Lefebvre, Olivier/I-2388-2016; Lefebvre, Olivier/S-6436-2019	Lefebvre, Olivier/0000-0001-9130-9174; Lefebvre, Olivier/0000-0001-9130-9174	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BASSET P, 1993, BREAST CANCER RES TR, V24, P185, DOI 10.1007/BF01833259; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BEBBINGTON CR, 1992, BIO-TECHNOL, V10, P169, DOI 10.1038/nbt0292-169; BIRKEDALHANSEN B, 1988, BIOCHEMISTRY-US, V27, P6751, DOI 10.1021/bi00418a016; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; DOCHERTY AJP, 1990, ANN RHEUM DIS, P469; DOCHERTY AJP, 1992, TRENDS BIOTECHNOL, V10, P200, DOI 10.1016/0167-7799(92)90214-G; Flaumenhaft R, 1991, CURR OPIN CELL BIOL, V3, P817, DOI 10.1016/0955-0674(91)90055-4; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; HECHT P M, 1992, Trends in Cell Biology, V2, P197, DOI 10.1016/0962-8924(92)90246-J; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEFEBVRE O, 1992, J CELL BIOL, V119, P997, DOI 10.1083/jcb.119.4.997; LEVY A, 1992, GENOMICS, V13, P881, DOI 10.1016/0888-7543(92)90175-R; Matrisian L M, 1990, Semin Cancer Biol, V1, P107; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MULLER D, 1993, CANCER RES, V53, P165; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1992, J BIOL CHEM, V267, P9612; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; MURPHY G, 1981, BIOCHEM J, V199, P807, DOI 10.1042/bj1990807; MURPHY GJP, 1991, FEBS LETT, V289, P4, DOI 10.1016/0014-5793(91)80895-A; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OKADA Y, 1988, BIOCHEM J, V254, P731, DOI 10.1042/bj2540731; OSHEA M, 1992, BIOCHEMISTRY-US, V31, P10146, DOI 10.1021/bi00157a002; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; STETLERSTEVENSON WG, 1990, CANCER METAST REV, V9, P289, DOI 10.1007/BF00049520; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WOLF C, 1992, J INVEST DERMATOL, V99, P870, DOI 10.1111/1523-1747.ep12614846	38	119	122	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15435	15441						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340372				2022-12-27	WOS:A1993LN30500021
J	ZHU, LQ; MCKAY, RR; SHORTRIDGE, RD				ZHU, LQ; MCKAY, RR; SHORTRIDGE, RD			TISSUE-SPECIFIC EXPRESSION OF PHOSPHOLIPASE-C ENCODED BY THE NORPA GENE OF DROSOPHILA-MELANOGASTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE; SIGNAL TRANSDUCTION; NERVOUS-SYSTEM; RECEPTOR; PURIFICATION; PROTEINS; SEQUENCE; ISOZYMES; CALCIUM; CLONING	Mutations in the norpA gene of Drosophila melanogaster severely affect the light-evoked photoreceptor potential with strong mutations rendering the fly blind. Molecular cloning of the norpA gene revealed that it encodes phosphatidylinositol-specific phospholipase C, which enzymes play a pivotal role in one of the largest classes of signaling pathways known. We have used Northern analysis, Western blots, phospholipase C activity assays, and immunohistochemical staining of tissues to examine the tissue-specific expression of the norpA gene and found that it is expressed in a variety of tissues besides the eye. Hybridization of norpA cRNA probe to blots of poly(A+) RNA reveals that the gene encodes at least four transcripts: a 7.5-kilobase (kb) transcript that is expressed in eye and 6.5-, 5.5-, and 5.0-kb transcripts that are expressed in adult body or early stages of development. Antiserum generated against the major gene product of norpA recognizes a 130-kDa protein that is abundant in eyes but severely reduced or absent in norpA mutants, a result which is consistent with previous conclusions that the norpA gene encodes an essential component of the visual system. However, the norpA antiserum also recognizes a 130-kDa protein in adult legs, thorax, and male abdomen, but not female abdomen. These localizations are supported by results of phospholipase C activity assays which show that the norpA mutation reduces phospholipase C activity in each of the tissues in which norpA protein can be detected. Furthermore, immunohistochemical staining of tissue sections with the norpA antiserum demonstrates that the norpA protein is abundant in the retina and ocelli and is present to a lesser extent in the brain and thoracic nervous system. Since some of the above mentioned tissues that express norpA (such as thorax, legs, and abdomen) have no known photoreceptor tissue, we conclude that the norpA gene product is also likely to have a role in signaling pathways other than phototransduction.	SUNY Buffalo, DEPT BIOL SCI, COOKE HALL, RM 109, BUFFALO, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; COLLINGRIDGE G, 1987, NATURE, V330, P604, DOI 10.1038/330604a0; DUERR JS, 1982, P NATL ACAD SCI-BIOL, V79, P3646, DOI 10.1073/pnas.79.11.3646; Gall JG, 1971, METHOD ENZYMOL, V21, P470; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARLOW E, 1988, ANTIBODIES LABORATOR; HOTTA Y, 1970, P NATL ACAD SCI USA, V67, P1156, DOI 10.1073/pnas.67.3.1156; HU KG, 1978, J COMP PHYSIOL, V126, P15, DOI 10.1007/BF01342646; INOUE H, 1988, J BIOCHEM-TOKYO, V103, P91, DOI 10.1093/oxfordjournals.jbchem.a122246; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MARKOW TA, 1980, BEHAV NEURAL BIOL, V29, P276, DOI 10.1016/S0163-1047(80)90612-3; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; MICHELL RH, 1989, BIOCHEM SOC T, V17, P1; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; PAK WL, 1970, NATURE, V227, P518, DOI 10.1038/227518b0; PAK WL, 1991, PHOTOCHEM PHOTOBIOL, V53, P871, DOI 10.1111/j.1751-1097.1991.tb09901.x; PANDIELLA A, 1989, TRENDS PHARMACOL SCI, V10, P411; PUTNEY JW, 1988, J EXP BIOL, V139, P135; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROSS CA, 1989, P NATL ACAD SCI USA, V86, P2923, DOI 10.1073/pnas.86.8.2923; SCHNEUWLY S, 1991, J BIOL CHEM, V266, P24314; SHORTRIDGE RD, 1991, J BIOL CHEM, V266, P12474; SLACK BE, 1986, AM J PHYSIOL, V250, pC340, DOI 10.1152/ajpcell.1986.250.2.C340; STULL JT, 1988, AM J MED SCI, V296, P241, DOI 10.1016/S0002-9629(15)40865-1; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUZUKI E, 1992, NEUROSCI RES, V13, P155, DOI 10.1016/0168-0102(92)90096-U; Sved J, 1986, DROSOPH INF SERV, V63, P169; TOMPKINS L, 1982, BEHAV GENET, V12, P295, DOI 10.1007/BF01067849; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOYOSHIMA S, 1990, J BIOL CHEM, V265, P14842; VOLPE P, 1986, FEBS LETT, V197, P1, DOI 10.1016/0014-5793(86)80285-X; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; YOSHIKAWA S, 1992, J BIOL CHEM, V267, P16613; YOSHIOKA T, 1985, J BIOCHEM-TOKYO, V97, P1251, DOI 10.1093/oxfordjournals.jbchem.a135171	37	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15994	16001						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340420				2022-12-27	WOS:A1993LN30500094
J	GARRICK, MD; GNIECKO, K; LIU, YH; COHAN, DS; GARRICK, LM				GARRICK, MD; GNIECKO, K; LIU, YH; COHAN, DS; GARRICK, LM			TRANSFERRIN AND THE TRANSFERRIN CYCLE IN BELGRADE RAT RETICULOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON UPTAKE; RABBIT RETICULOCYTES; RECEPTOR; BINDING; RELEASE; ANEMIA; CELLS	Belgrade rats have an autosomal recessive anemia with hypochromia and microcytosis. Iron uptake into reticulocytes is approximately 20% of normal, but transferrin uptake is unimpaired. We have systematically compared the transferrin cycle in Belgrade versus normal reticulocytes to locate the defect more precisely. Belgrade transferrin was functionally normal as purified transferrin or whole plasma. Transferrin affinity of Belgrade receptors was indistinguishable from normal, but Belgrade reticulocytes had twice as many receptors. Belgrade transferrin endocytosis was 1.5 times faster than normal, whereas exocytosis is about twice as fast. Initially Belgrade reticulocytes internalize iron at an unimpaired rate, but they lag behind normal by 5 min. During reincubation, they release 25-33% of iron taken up during a 30-min preincubation, whereas normal cells do not lose a detectable fraction. Unexpectedly, transferrin cycle time was unchanged. Hence another kinetic step of the cycle is slower, compensating for increases in Belgrade endocytosis and exocytosis. After one cycle, Belgrade reticulocytes retain only half of the iron that entered, but over 90% of iron entering normal cells remains within. Iron unloading is ineffective inside the Belgrade vesicle; 85% of iron that entered on transferrin returned to the medium after exocytosis, whereas only 45% of iron entering normal reticulocytes exits. Ineffective utilization of iron in or near Belgrade endosomes accounts for the Belgrade defect.	SUNY Buffalo, DEPT PEDIAT, BUFFALO, NY 14214 USA; SUNY Buffalo, DEPT MED, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	GARRICK, MD (corresponding author), SUNY Buffalo, DEPT BIOCHEM, 140 FARBER HALL, 3435 MAIN ST, BUFFALO, NY 14214 USA.			Garrick, Michael/0000-0001-7342-6983				BALI PK, 1991, BIOCHEMISTRY-US, V30, P324, DOI 10.1021/bi00216a003; BOWEN BJ, 1987, BLOOD, V70, P38; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; EDWARDS J, 1986, BLOOD, V67, P623; EDWARDS JA, 1978, BLOOD, V51, P347; FARCICH EA, 1992, AM J HEMATOL, V39, P9, DOI 10.1002/ajh.2830390104; GARRICK L, 1988, BLOOD, V72, pA41; GARRICK L M, 1990, Experimental Hematology (Charlottesville), V18, P573; GARRICK LM, 1975, BIOCHEM J, V149, P245, DOI 10.1042/bj1490245; GARRICK LM, 1991, J CELL PHYSIOL, V146, P460, DOI 10.1002/jcp.1041460317; GARRICK LM, 1993, IN PRESS BLOOD; GARRICK M, 1990, Experimental Hematology (Charlottesville), V18, P573; GARRICK M, 1988, BLOOD, V72, pA42; GARRICK M D, 1990, Journal of Cell Biology, V111, p82A; GARRICK MD, 1990, BLOOD, V76, pA8; GARRICK MD, 1990, BLOOD, V111, pA8; GARRICK MD, 1990, BLOOD, V111, pA82; HRADILEK A, 1987, J CELL PHYSIOL, V133, P192, DOI 10.1002/jcp.1041330126; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORGAN EH, 1981, MOL ASPECTS MED, V4, P1, DOI 10.1016/0098-2997(81)90003-0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NUNEZ MT, 1983, J BIOL CHEM, V258, P9676; NUNEZ MT, 1990, J BIOL CHEM, V265, P6688; OKADA S, 1979, J LAB CLIN MED, V93, P189; PAVLOVICKENTERA V, 1989, EXP HEMATOL, V17, P812; RAPOPORT SM, 1986, RETICULOCYTE, P145; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SELIGMAN PA, 1983, PROG HEMATOL, V13, P131; SIPE DM, 1991, J BIOL CHEM, V266, P8002; SLADICSIMIC D, 1969, ANN NY ACAD SCI, V165, P93, DOI 10.1111/j.1749-6632.1969.tb27779.x; SLADICSIMIC D, 1966, GENETICS, V53, P1079; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; YOUNG SP, 1984, BIOCHEM J, V219, P505, DOI 10.1042/bj2190505	33	77	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14867	14874						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325865				2022-12-27	WOS:A1993LL75900052
J	KIM, SK; NORDEN, B; TAKAHASHI, M				KIM, SK; NORDEN, B; TAKAHASHI, M			ROLE OF DNA INTERCALATORS IN THE BINDING OF RECA TO DOUBLE-STRANDED DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINEAR DICHROISM SPECTROSCOPY; FLOW-ORIENTED SOLUTION; ESCHERICHIA-COLI; PROTEIN-BINDING; DUPLEX DNA; ELECTRON-MICROSCOPY; NEUTRON-SCATTERING; COMPLEXES; STOICHIOMETRY; RECOMBINATION	RecA protein can bind to double-stranded DNA even without the cofactor ATP if a DNA intercalator such as ethidium bromide is present (Thresher R. J., and Griffith, J. D. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 5056-5060). We have studied the structure and association kinetics of the ethidium-promoted DNA-RecA complex in order to understand the role of this intercalator in the DNA-RecA association process, information that could provide insight about the binding mechanism of RecA to DNA. Both linear dichroism and fluorescence measurements show that ethidium remains intercalated between the DNA bases in the RecA-DNA complex in the absence of ATP. Even in the presence of the ATP analog, adenosine 5'-O-(3-thiotriphosphate) (ATPgammaS), ethidium bromide shows some stimulating effect on the binding of RecA to DNA. The results indicate that the destacking of DNA bases is an important limiting step in the association of RecA to DNA (DNA is stretched in the ATPgammaS-RecA-DNA complex). In the presence of ATPgammaS, however, ethidium was extruded from DNA upon the binding of RecA. This result suggests that the binding mechanism of RecA to DNA may involve intercalation of one or more amino acid residues of RecA between the DNA bases. Such an intercalation would also be consistent with the stretching of DNA and the observation that the DNA bases remain in a (virtually stacked) perpendicular geometry (Takahashi, M., Kubista, M., and Norden, B. (1991) Biochemie (Paris) 73, 219-226; Norden, B., Elvingson, C., Kubista, M., Sjoberg, B., Ryberg, H., Ryberg, M., Mortensen, K., and Takahashi, M. (1992b) J. Mol. Biol. 226, 1175-1191).	UNIV PARIS 11,INST CURIE,CNRS,URA 1342,F-91405 ORSAY,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	KIM, SK (corresponding author), CHALMERS UNIV TECHNOL,DEPT PHYS CHEM,S-41296 GOTHENBURG,SWEDEN.		Norden, Bengt/ABE-3675-2020	Norden, Bengt/0000-0002-7946-200X				CHABBERT M, 1987, BIOCHEMISTRY-US, V26, P2218, DOI 10.1021/bi00382a022; CHABBERT M, 1991, J BIOL CHEM, V266, P5395; CHRYSOGELOS S, 1983, J BIOL CHEM, V258, P2624; DICAPUA E, 1989, BIOCHEMISTRY-US, V28, P3287, DOI 10.1021/bi00434a025; DICAPUA E, 1982, J MOL BIOL, V157, P87, DOI 10.1016/0022-2836(82)90514-9; DOMBROSKI DF, 1983, NUCLEIC ACIDS RES, V11, P7487, DOI 10.1093/nar/11.21.7487; ERIKSSON S, 1993, J BIOL CHEM, V268, P1805; ERIKSSON S, 1993, J BIOL CHEM, V268, P1811; GRIFFITH JD, 1988, CRC CR REV BIOCH MOL, V23, pS43, DOI 10.3109/10409238809083375; HAGMAR P, 1992, J MOL BIOL, V226, P1193, DOI 10.1016/0022-2836(92)91061-S; KOBAYASHI N, 1987, BIOCHEMISTRY-US, V26, P6801, DOI 10.1021/bi00395a033; KUBISTA M, 1990, J BIOL CHEM, V265, P18891; KURAMITSU S, 1981, J BIOCHEM-TOKYO, V90, P1033, DOI 10.1093/oxfordjournals.jbchem.a133555; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; NORDEN B, 1990, J MOL BIOL, V216, P223, DOI 10.1016/S0022-2836(05)80311-0; NORDEN B, 1985, APPL SPECTROSC, V39, P647, DOI 10.1366/0003702854250356; NORDEN B, 1992, Q REV BIOPHYS, V25, P51, DOI 10.1017/S0033583500004728; NORDEN B, 1992, J MOL BIOL, V226, P1175, DOI 10.1016/0022-2836(92)91060-3; PUGH BF, 1989, J MOL BIOL, V205, P487, DOI 10.1016/0022-2836(89)90219-2; PUGH BF, 1988, J MOL BIOL, V203, P479, DOI 10.1016/0022-2836(88)90014-9; RADDING CM, 1989, BIOCHIM BIOPHYS ACTA, V1008, P131, DOI 10.1016/0167-4781(80)90001-9; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SMITH GR, 1989, CELL, V58, P807, DOI 10.1016/0092-8674(89)90929-X; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; TAKAHASHI M, 1989, J BIOL CHEM, V264, P8568; TAKAHASHI M, 1991, FEBS LETT, V279, P270, DOI 10.1016/0014-5793(91)80165-Y; TAKAHASHI M, 1987, J BIOL CHEM, V262, P8109; TAKAHASHI M, 1989, J MOL BIOL, V205, P137, DOI 10.1016/0022-2836(89)90371-9; TAKAHASHI M, 1991, BIOCHIMIE, V73, P219, DOI 10.1016/0300-9084(91)90205-F; THRESHER RJ, 1990, P NATL ACAD SCI USA, V87, P5056, DOI 10.1073/pnas.87.13.5056; WADA A, 1964, J POLYM SCI PART A, V2, P853, DOI 10.1002/pol.1964.100020222; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WILLIAMS RC, 1986, J MOL BIOL, V187, P109, DOI 10.1016/0022-2836(86)90410-9	33	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14799	14804						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325858				2022-12-27	WOS:A1993LL75900043
J	SHAKARJIAN, MP; EISEMAN, E; PENHALLOW, RC; BOLEN, JB				SHAKARJIAN, MP; EISEMAN, E; PENHALLOW, RC; BOLEN, JB			3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE INHIBITION IN A RAT MAST-CELL LINE - IMPAIRMENT OF TYROSINE KINASE-DEPENDENT SIGNAL-TRANSDUCTION AND THE SUBSEQUENT DEGRANULATION RESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; HIGH-AFFINITY; RECEPTOR; IGE; PHOSPHORYLATION; PROTEINS; RBL-2H3	IgE molecules bind mast cells via a heterotetrameric receptor termed Fc(epsilon)RI. Cross-linking of bound IgE by specific allergen (Ag) initiates a signal transduction cascade resulting in a degranulation response. Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in isoprenoid and sterol biosynthesis, by the cholesterol-lowering drug, lovastatin, blocks Fc(epsilon)RI-dependent [H-3] serotonin ([H-3]5HT) release from the mast cell line, RBL-2H3. We studied the mode and locus of action of lovastatin in these cells. Lovastatin inhibited Ag-stimulated degranulation, as well as that evoked by ionomycin or by phorbol 12-myristate 13-acetate and ionomycin, stimuli which bypass early receptor events. Inhibition was concentration-dependent, occurred at levels which reduce lipid synthesis, and was reversible by addition of mevalonic acid, the product of the reductase reaction. The effects of lovastatin were not mimicked by treatment with the sterol demethylase inhibitor, econazole, suggesting that nonsterol isoprenoid synthesis is required for the degranulation response. Conversely, tyrosine kinase inhibitors from three disparate chemical classes reduced stimulus-evoked [H-3]5HT release in a manner similar to lovastatin, suggesting that these agents share similar loci of action. Accordingly, lovastatin altered the phosphorylation pattern in unstimulated RBL-2H3, and reduced the phosphorylation response to IgE cross-linking. By analogy to 5HT release, this effect was concentration-dependent and mevalonic acid-reversible. The tyrosine kinase inhibitor, geldanamycin, also reduced the phosphorylation response to Ag. Lyn, a Src-related tyrosine kinase activated upon IgE cross-linking, was little influenced by either lovastatin or geldanamycin. Thus, lipid synthesis inhibition by lovastatin results in impaired tyrosine phosphorylation in RBL-2H3. This impairment is reflected in the subsequent exocytotic response. While lovastatin may inhibit tyrosine phosphorylation via an indirect mechanism, our results with tyrosine kinase inhibitors support the concept that multiple tyrosine kinases participate in the Fc(epsilon)RI-dependent signal transduction process.			SHAKARJIAN, MP (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, PRINCETON, NJ 08543 USA.							ALBER G, 1991, J BIOL CHEM, V266, P22613; ALBERTS AW, 1988, AM J CARDIOL, V62, pJ10, DOI 10.1016/0002-9149(88)90002-1; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; COLIGAN JE, 1983, METHOD ENZYMOL, V91, P413; CONNELLY PA, 1991, BIOCHEM BIOPH RES CO, V177, P192, DOI 10.1016/0006-291X(91)91967-H; DEANIN GG, 1991, J IMMUNOL, V146, P3528; DEANIN GG, 1991, CELL REGUL, V2, P627, DOI 10.1091/mbc.2.8.627; EISEMAN E, 1992, NATURE, V355, P78; FUKAMACHI H, 1992, P NATL ACAD SCI USA, V89, P9524, DOI 10.1073/pnas.89.20.9524; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KAWAKAMI T, 1992, J IMMUNOL, V148, P3513; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; OKADA M, 1991, J BIOL CHEM, V266, P24249; PARK DJ, 1991, J BIOL CHEM, V266, P24237; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; SCHNEIDER H, 1992, INT IMMUNOL, V4, P447, DOI 10.1093/intimm/4.4.447; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WHITE KN, 1988, J IMMUNOL, V141, P942; YU KT, 1991, J BIOL CHEM, V266, P22564	29	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15252	15259						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325896				2022-12-27	WOS:A1993LL75900102
J	MIYAZAKI, K; FUNAHASHI, K; NUMATA, Y; KOSHIKAWA, N; AKAOGI, K; KIKKAWA, Y; YASUMITSU, H; UMEDA, M				MIYAZAKI, K; FUNAHASHI, K; NUMATA, Y; KOSHIKAWA, N; AKAOGI, K; KIKKAWA, Y; YASUMITSU, H; UMEDA, M			PURIFICATION AND CHARACTERIZATION OF A 2-CHAIN FORM OF TISSUE INHIBITOR OF METALLOPROTEINASES (TIMP) TYPE-2 AND A LOW-MOLECULAR-WEIGHT TIMP-LIKE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-DEGRADING METALLOPROTEINASE; ERYTHROID-POTENTIATING ACTIVITY; CELL-LINE; 72-KDA PROGELATINASE; ENDOTHELIAL-CELLS; TUMOR INVASION; COLLAGENASE; EXPRESSION; IDENTIFICATION; CARCINOMA	Multiple forms of metalloproteinase inhibitors were found in the serum-free conditioned medium of the EJ-1 human bladder carcinoma cell line by reverse zymography assay with gelatinase A as the indicator enzyme. Two novel forms of inhibitor with apparent molecular masses of 18 and 22 kDa on nonreducing SDS-polyacrylamide gel electrophoresis (PAGE), together with tissue inhibitor of metalloproteinases (TIMP) and TIMP-2, were purified from the conditioned medium by a series of chromatographic steps. Structural analysis showed that the 18-kDa inhibitor is a two-chain form of TIMP-2 (tc-TIMP-2) produced by proteolytic processing, and the 22-kDa inhibitor may be a partially glycosylated form of TIMP. The purified tc-TIMP-2 was separated into a 17-kDa peptide and a small peptide of about 2.5 kDa by reducing SDS-PAGE and into four isoforms with pI 7.6, 7.3, 7.2, and 6.8 by isoelectric focusing. tc-TIMP-2 has essentially the same inhibitory activity as TIMP-2 toward gelatinase A, collagenase, stromelysin, and matrilysin. Unlike TIMP-2, however, tc-TIMP-2 does not bind to the latent precursor of gelatinase A. Similar two-chain forms of TIMP-2 were produced by its partial digestion with trypsin or less effectively with plasmin. These results suggest that proteolytic processing of TIMP-2 plays a role in the regulation of gelatinase A activity in the extracellular matrix.			MIYAZAKI, K (corresponding author), YOKOHAMA CITY UNIV,KIHARA INST BIOL RES,DIV CELL BIOL,2-120-3 NAKAMURA CHO,MINAMI KU,YOKOHAMA,KANAGAWA 232,JAPAN.		Kikkawa, Yamato/D-1503-2010					ALVAREZ OA, 1990, J NATL CANCER I, V82, P589, DOI 10.1093/jnci/82.7.589; APODACA G, 1990, CANCER RES, V50, P2322; CAWSTON TE, 1981, BIOCHEM J, V195, P159, DOI 10.1042/bj1950159; DECLERCK YA, 1989, J BIOL CHEM, V264, P17445; DECLERCK YA, 1992, CANCER RES, V52, P701; DOCHERTY AJP, 1992, TRENDS BIOTECHNOL, V10, P200, DOI 10.1016/0167-7799(92)90214-G; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; KHOKHA R, 1992, J NATL CANCER I, V84, P1017, DOI 10.1093/jnci/84.13.1017; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KOIVUNEN E, 1991, INT J CANCER, V47, P592, DOI 10.1002/ijc.2910470419; KOLKENBROCK H, 1991, EUR J BIOCHEM, V198, P775, DOI 10.1111/j.1432-1033.1991.tb16080.x; KOSHIKAWA N, 1992, CANCER RES, V52, P5046; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MIYAZAKI K, 1990, CANCER RES, V50, P7758; MIYAZAKI K, 1993, NATURE, V362, P839, DOI 10.1038/362839a0; MIYAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P852, DOI 10.1016/0006-291X(92)91705-U; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; NAKANISHI Y, 1986, DEV BIOL, V113, P201, DOI 10.1016/0012-1606(86)90122-3; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; SCHULTZ RM, 1988, CANCER RES, V48, P5539; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; UMENISHI F, 1991, J BIOCHEM-TOKYO, V110, P189, DOI 10.1093/oxfordjournals.jbchem.a123555; UMENISHI F, 1990, J BIOCHEM-TOKYO, V108, P537, DOI 10.1093/oxfordjournals.jbchem.a123238; WESTBROOK CA, 1984, J BIOL CHEM, V259, P9992; WILLIAMSON RA, 1990, BIOCHEM J, V268, P267, DOI 10.1042/bj2680267; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YASUMITSU H, 1992, J BIOCHEM-TOKYO, V267, P11424	35	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14387	14393						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314798				2022-12-27	WOS:A1993LJ82500086
J	NAKAGOSHI, H; TAKEMOTO, Y; ISHII, S				NAKAGOSHI, H; TAKEMOTO, Y; ISHII, S			FUNCTIONAL DOMAINS OF THE HUMAN-B-MYB GENE-PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; HUMAN HEMATOPOIETIC-CELLS; C-MYB; V-MYB; MYELOMONOCYTIC CELLS; PROTO-ONCOGENE; NUCLEOTIDE-SEQUENCE; CELLULAR PROGENITOR; CDNA CLONES; A-MYB	Three members of the human myb gene family (c-myb, A-myb, and B-myb) encode transcriptional regulators that can bind to specific DNA sequences. High levels of c-myb expression are usually found in immature hemopoietic cells, but the B-myb is more commonly expressed in many types of cells. To understand the regulation of the activity of B-myb gene product (B-Myb), its functional domains were analyzed. Like c-Myb, B-Myb also has a transcriptional activation domain containing a cluster of acidic amino acids in the region downstream of the DNA-binding domain, which consists of three tandem repeats of 51-52 amino acids. In contrast to c-Myb, B-Myb does not contain a negative regulatory domain. Furthermore, the multiple nuclear localization signals are in at least two regions in the COOH-terminal half of B-Myb, and one of them is adjacent to a potential cdc2 kinase site. These results indicate that B-Myb contains DNA-binding and transcriptional activation domains similar to those of c-Myb, but a regulatory mechanism of B-Myb activity is quite different from that for c-Myb.	INST PHYS & CHEM RES RIKEN,TSUKUBA LIFE SCI CTR,MOLEC GENET LAB,TSUKUBA,IBARAKI 305,JAPAN	RIKEN			Ishii, Shunsuke/A-5271-2016; NAKAGOSHI, Hideki/B-2145-2011	Ishii, Shunsuke/0000-0002-6530-2478; NAKAGOSHI, Hideki/0000-0003-0850-1814				ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; ARSURA M, 1992, BLOOD, V79, P2708; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DANG CV, 1989, J BIOL CHEM, V264, P18019; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1991, BLOOD, V77, P149; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HU YL, 1991, ONCOGENE, V6, P1549; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; Moscovici C., 1982, ADV VIRAL ONCOL, V1, P83; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	51	55	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14161	14167						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314782				2022-12-27	WOS:A1993LJ82500057
J	WALKER, RK; KRISHNASWAMY, S				WALKER, RK; KRISHNASWAMY, S			THE INFLUENCE OF FACTOR VA ON THE ACTIVE-SITE OF FACTOR-XA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE CHLOROMETHYL KETONE; COAGULATION FACTOR-XA; PROTHROMBINASE COMPLEX; PHOSPHOLIPID-VESICLES; BLOOD-COAGULATION; PROTEIN-C; ANALYTICAL ULTRACENTRIFUGATION; CONFORMATIONAL SENSITIVITY; CATALYZED ACTIVATION; COFACTOR DEPENDENCE	The interaction of factor Xa with factor Va on the membrane surface results in a 3,000-fold increase in the k(cat) for the activation of prothrombin catalyzed by factor Xa. The reaction between the transition state irreversible inhibitor dansylglutamyl-glycyl-arginyl chloromethyl ketone (DEGRck) and factor Xa was characterized and employed to evaluate changes in the active site of factor Xa resulting from its interaction with factor Va, which may account for the increased catalytic efficiency of the enzyme complex. Inhibition studies indicated a two-step inhibition reaction involving a reversible binding step (K(i) = 1.13 muM) and an irreversible alkylation step (k(i) = 0.65 s-1). The interaction between factors Va and Xa in solution or on membranes resulted in a small decrease in the overall second-order rate constant (k(i)/K(i)) for the inhibition reaction. The incorporation of DEGRck into the active site of factor Xa results in a large change in the fluorescence intensity of the dansyl moiety. The fluorescence change was employed to study the reaction between enzyme and inhibitor directly by stopped-flow fluorescence measurements. The fluorescence traces were biphasic, indicating that the association of DEGRck with factor Xa and the subsequent covalent modification of the active site could be resolved because of differences in fluorescence intensities of the intermediate and product. This interpretation was verified by rapid chemical quench experiments. The reaction between DEGRck and factor Xa was characterized by a second-order association rate constant of 8.38 +/- 0.28 x 10(5) M-1.s-1 and an intrinsic rate constant for the alkylation step of 1.67 +/- 0.25 s-1. The rate constant for the alkylation step was unchanged in the presence of factor Va and membranes, whereas the association rate constant was modestly decreased by approximately 50%. The decrease in the association rate constant did not result from the partitioning of factor Xa to the membrane surface and could therefore be ascribed to an effect of factor Va on the protease. The data suggest that the interaction between factors Va and Xa on the membrane surface does not detectably alter the catalytic residues but may result in changes in the binding or accessibility of substrate to extended macromolecular recognition sites on the protease.	EMORY UNIV,DEPT MED,DIV HEMATOL ONCOL,DRAWER AR,ATLANTA,GA 30322	Emory University					NHLBI NIH HHS [HL-47465, HL-38337] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047465, R29HL038337] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; Bevington P. R, 1969, DATA REDUCTION ERROR; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; CARLISLE TL, 1990, J BIOL CHEM, V265, P22044; CHASE T, 1970, METHOD ENZYMOL, V19, P20; CORNISHBOWDEN A, 1979, FUNDAMENTALS ENZYME, P177; ESMON CT, 1974, J BIOL CHEM, V249, P7798; ESMON CT, 1974, J BIOL CHEM, V249, P7791; FERSHT A, 1977, ENZYME STRUCTURE MEC, P111; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P5290, DOI 10.1021/bi00723a006; GIESEN PLA, 1991, J BIOL CHEM, V266, P1379; Gomori G, 1942, J LAB CLIN MED, V27, P955; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; HIGGINS DL, 1985, J BIOL CHEM, V260, P3604; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; JACKSON CM, 1968, BIOCHEMISTRY-US, V7, P4492, DOI 10.1021/bi00852a046; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; JAKUBOWSKI HV, 1986, J BIOL CHEM, V261, P3876; JENCKS WP, 1987, CATALYSIS CHEM ENZYM, P571; Jesty J, 1976, Methods Enzymol, V45, P95; KETTNER C, 1981, METHOD ENZYMOL, V80, P826; KETTNER C, 1981, THROMB RES, V22, P645, DOI 10.1016/0049-3848(81)90062-1; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; LEE J, 1989, BIOPHYS CHEM, V33, P99, DOI 10.1016/0301-4622(89)80012-2; LEE J, 1989, BIOCHEMISTRY-US, V28, P4263, DOI 10.1021/bi00436a022; LEYTUS SP, 1984, BIOCHIM BIOPHYS ACTA, V788, P74, DOI 10.1016/0167-4838(84)90299-1; LIU W, 1986, BIOCHIM BIOPHYS ACTA, V870, P185, DOI 10.1016/0167-4838(86)90220-7; LU RL, 1989, J BIOL CHEM, V264, P12956; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; MANN KG, 1987, TRENDS BIOCHEM SCI, V12, P229, DOI 10.1016/0968-0004(87)90115-0; MOORE JW, 1981, KINETICS MECHANISM, P290; NEISHEIM ME, 1979, J BIOL CHEM, V254, P10952; NESHEIM ME, 1981, J BIOL CHEM, V256, P6537; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NESHEIM ME, 1981, J BIOL CHEM, V256, P9874; NESHEIM ME, 1983, J BIOL CHEM, V258, P5386; ODEGAARD B, 1987, J BIOL CHEM, V262, P11233; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; POULOS TL, 1976, J BIOL CHEM, V251, P1097; Powers J C, 1977, Methods Enzymol, V46, P197; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; ROSING J, 1980, J BIOL CHEM, V255, P274; RUF W, 1991, J BIOL CHEM, V266, P2158; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Segel IH, 1975, ENZYME KINETICS, P113; STRAUME M, 1992, METHOD ENZYMOL, V210, P87; TSOU CL, 1988, ADV ENZYMOL RAMB, V61, P381; VANRIJN JLML, 1984, BIOCHEMISTRY-US, V23, P4557, DOI 10.1021/bi00315a008; WALKER RK, 1992, CIRCULATION, V86, P466; YE J, 1991, J BIOL CHEM, V266, P23016; YE J, 1992, J BIOL CHEM, V267, P11023	64	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13920	13929						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314758				2022-12-27	WOS:A1993LJ82500025
J	DAVIS, LH; BENNETT, V				DAVIS, LH; BENNETT, V			IDENTIFICATION OF 2 REGIONS OF BETA(G) SPECTRIN THAT BIND TO DISTINCT SITES IN BRAIN MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE SPECTRIN; ANKYRIN; CYTOSKELETON; ASSOCIATION; PROTEINS; ISOFORM; PURIFICATION; CALMODULIN; ANALOGS; CELLS	This study analyzed the complex interactions of intact spectrin with bovine brain membranes by evaluating membrane associations of defined regions of beta(G) spectrin, the subunit responsible for high affinity membrane binding. Two regions of beta(G) spectrin were expressed in bacteria and demonstrated to contain fully functional binding site(s) for a subset of spectrin-binding sites in brain membranes depleted of peripheral proteins. One region, located near the NH2 terminus, was comprised of 106-residue repeats and required repeats 2-7 for full activity. The other binding domain was located at the COOH terminus, which is the most variable between beta(G) and beta(R) spectrins, is distinct from the 106-residue repeats, and contains a pleckstrin homology domain. NH2-terminal beta spectrin polypeptides interacted with a membrane site(s) that recognized both brain and erythrocyte isoforms of spectrin, was inhibited by calcium/calmodulin, and was not blocked by the COOH-terminal polypeptide. The COOH-terminal region associated with a membrane site(s) that was specific for brain spectrin, was not inhibited by calcium/calmodulin, and was not blocked by the NH2-terminal polypeptide. These observations demonstrate membrane association of spectrin with at least two independent sites, which differ with regard to regulation by calcium/calmodulin and in selectivity for spectrin isoforms.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University	DAVIS, LH (corresponding author), DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA.							BENNETT V, 1981, P NATL ACAD SCI-BIOL, V78, P7550, DOI 10.1073/pnas.78.12.7550; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1986, METHOD ENZYMOL, V134, P55; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BENNETT V, 1982, NATURE, V299, P126, DOI 10.1038/299126a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIS JQ, 1986, J BIOL CHEM, V261, P6198; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; DUBREUIL RR, 1990, J CELL BIOL, V111, P1849, DOI 10.1083/jcb.111.5.1849; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HU RJ, 1992, J BIOL CHEM, V267, P18715; HU RJ, 1991, J BIOL CHEM, V266, P18200; LAMBERT S, 1993, J NEUROSCI, V13, P3725; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P21551; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; POLLERBERG GE, 1987, CELL TISSUE RES, V250, P227, DOI 10.1007/BF00214676; RIEDERER BM, 1986, J CELL BIOL, V102, P2088, DOI 10.1083/jcb.102.6.2088; Sambrook J, 1989, MOL CLONING LABORATO; STEINER JP, 1988, J BIOL CHEM, V263, P14417; STEINER JP, 1989, J BIOL CHEM, V264, P2783; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WINKELMANN JC, 1990, J BIOL CHEM, V265, P20449; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788	26	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4409	4416						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308011				2022-12-27	WOS:A1994MW98900080
J	FISCHER, WH; BEHAN, DP; PARK, MY; POTTER, E; LOWRY, PJ; VALE, W				FISCHER, WH; BEHAN, DP; PARK, MY; POTTER, E; LOWRY, PJ; VALE, W			ASSIGNMENT OF DISULFIDE BONDS IN CORTICOTROPIN-RELEASING FACTOR-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA; PREGNANCY; HORMONE; SECRETION	We have previously isolated, cloned, and characterized a protein that specifically binds and inactivates the peptide corticotropin-releasing factor. The integrity of the disulfide bonds in the binding protein is essential for this activity as reduction abolishes the protein's ability to bind corticotropin-releasing factor. The disulfide arrangement of the 10 cysteines present in the mature protein was established by analysis of proteolytically cleaved protein and sequence analysis of cystine containing fragments. A pattern is observed where each cysteine is connected to the next one in a sequential manner. Inspection of the genomic DNA encoding for this protein reveals that four of the domains defined by disulfide linkage coincide with four different exons.	UNIV READING,DEPT BIOCHEM & PHYSIOL,READING RG6 2AJ,BERKS,ENGLAND	University of Reading	FISCHER, WH (corresponding author), SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,LA JOLLA,CA 92037, USA.				NICHD NIH HHS [HD 13527] Funding Source: Medline; NIDDK NIH HHS [DK 26741] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD013527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK026741] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEHAN DP, 1993, GENOMICS, V16, P63, DOI 10.1006/geno.1993.1141; BEHAN DP, 1993, ANN NY ACAD SCI, V697, P1, DOI 10.1111/j.1749-6632.1993.tb49918.x; BEHAN DP, 1989, J ENDOCRINOL, V122, P28; BURNS JA, 1991, J ORG CHEM, V56, P2648, DOI 10.1021/jo00008a014; CAMPBELL EA, 1987, J CLIN ENDOCR METAB, V64, P1054, DOI 10.1210/jcem-64-5-1054; FISCHER WH, 1993, RAPID COMMUN MASS SP, V7, P225, DOI 10.1002/rcm.1290070312; GOLAND RS, 1986, J CLIN ENDOCR METAB, V63, P1199, DOI 10.1210/jcem-63-5-1199; LINTON EA, 1987, J CLIN ENDOCR METAB, V64, P1047, DOI 10.1210/jcem-64-5-1047; PETRAGLIA F, 1987, NATURE, V328, P717, DOI 10.1038/328717a0; POTTER E, 1991, NATURE, V349, P423, DOI 10.1038/349423a0; POTTER E, 1992, P NATL ACAD SCI USA, V89, P4192, DOI 10.1073/pnas.89.9.4192; SASAKI A, 1984, J CLIN ENDOCR METAB, V59, P812; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; WILLIAMS AF, 1987, IMMUNOL TODAY, V8, P298, DOI 10.1016/0167-5699(87)90016-8	14	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4313	4316						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307998				2022-12-27	WOS:A1994MW98900065
J	JEFFERIES, HBJ; THOMAS, G; THOMAS, G				JEFFERIES, HBJ; THOMAS, G; THOMAS, G			ELONGATION FACTOR-1-ALPHA MESSENGER-RNA IS SELECTIVELY TRANSLATED FOLLOWING MITOGENIC STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRIEND-ERYTHROLEUKEMIA CELLS; S-ADENOSYLMETHIONINE DECARBOXYLASE; MESSENGER-RNA; PROTEIN-SYNTHESIS; FACTOR-TU; NUCLEOTIDE-SEQUENCE; RIBOSOMAL-SUBUNITS; FACTOR 1-ALPHA; ACTIN GENES; MOUSE	Stimulation of quiescent Swiss 3T3 cells to proliferate leads to a selective 6-fold increase in the rate of translation of protein synthesis elongation factor eEF-1 alpha. Northern blot and solution hybridization protection studies show that levels of eEF-1 alpha mRNA remain constant following serum stimulation, demonstrating that eEF-1 alpha transcripts are not degraded following mitogenic stimulation and that the increase in eEF-1 alpha synthesis is accounted for by pre-existing mRNA. Localization of these transcripts in resting cells shows that they are largely distributed equally between stored mRNA protein particles and monosomes/disomes. Following serum addition, eEF-1 alpha transcripts present in mRNA protein particles redistribute to large polysomes rather than to monosomes and disomes as would be expected. The same is true for those transcripts present in monosomes and disomes. Salt shift and translational runoff studies indicate that eEF-1 alpha transcripts sedimenting with monosomes and disomes in quiescent cells are associated with actively translating ribosomes. The results suggest that a specific transcript can move within polysome profile as a function of the affinity of translational apparatus for that transcript.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND; VOLLUM INST, PORTLAND, OR 97201 USA	Friedrich Miescher Institute for Biomedical Research								AGRAWAL MG, 1987, J BIOL CHEM, V262, P4868; ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BAG J, 1991, TRANSLATION EUKARYOT, V3, P71; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BANDMAN E, 1975, EXP CELL RES, V90, P159, DOI 10.1016/0014-4827(75)90369-9; BERGMANN JE, 1979, J BIOL CHEM, V254, P1927; BOHM H, 1989, BIOCHEM INT, V19, P277; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; CAVALLIUS J, 1986, EXP GERONTOL, V21, P149, DOI 10.1016/0531-5565(86)90068-9; CHITPATIMA ST, 1988, NUCLEIC ACIDS RES, V16, P2350, DOI 10.1093/nar/16.5.2350; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COLOMBO B, 1968, P NATL ACAD SCI USA, V61, P651, DOI 10.1073/pnas.61.2.651; DEGEN JL, 1983, J BIOL CHEM, V258, P2153; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; FALVEY AK, 1970, J MOL BIOL, V53, P21, DOI 10.1016/0022-2836(70)90043-4; FALVEY AK, 1970, J MOL BIOL, V53, P1, DOI 10.1016/0022-2836(70)90042-2; HAMMOND ML, 1988, J BIOL CHEM, V263, P17785; HERRERA F, 1991, EUR J BIOCHEM, V200, P321, DOI 10.1111/j.1432-1033.1991.tb16188.x; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HERSHKO A, 1971, NATURE-NEW BIOL, V232, P206, DOI 10.1038/newbio232206a0; JOHNSON LF, 1974, CELL, V1, P95, DOI 10.1016/0092-8674(74)90068-3; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; KASPAR RL, 1992, J BIOL CHEM, V267, P508; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; MACH M, 1986, J BIOL CHEM, V261, P1697; MARIOTTINI P, 1990, MOL CELL BIOL, V10, P816, DOI 10.1128/MCB.10.2.816; MARKS PA, 1965, P NATL ACAD SCI USA, V53, P1437, DOI 10.1073/pnas.53.6.1437; MATTAJ IW, 1987, EMBO J, V6, P2409, DOI 10.1002/j.1460-2075.1987.tb02519.x; MORLEY SJ, 1990, BIOCHIMIE, V72, P259, DOI 10.1016/0300-9084(90)90081-Q; MORLEY SJ, 1991, PHARMACOL THERAPEUT, V50, P291, DOI 10.1016/0163-7258(91)90047-P; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; RAO TR, 1987, MOL CELL BIOL, V7, P687, DOI 10.1128/MCB.7.2.687; RAO TR, 1988, MOL CELL BIOL, V8, P1085, DOI 10.1128/MCB.8.3.1085; ROTH WW, 1987, MOL CELL BIOL, V7, P3929, DOI 10.1128/MCB.7.11.3929; RUDLAND PS, 1974, P NATL ACAD SCI USA, V71, P750, DOI 10.1073/pnas.71.3.750; RUDLAND PS, 1975, J MOL BIOL, V96, P745, DOI 10.1016/0022-2836(75)90150-3; Sambrook J, 1989, MOL CLONING LABORATO; SHEPHERD JCW, 1989, P NATL ACAD SCI USA, V86, P7520, DOI 10.1073/pnas.86.19.7520; SPIRIN AS, 1985, TRENDS BIOCHEM SCI, V10, P162, DOI 10.1016/0968-0004(85)90158-6; STAEHELIN T, 1971, METHOD ENZYMOL, V20, P433; SUNITHA I, 1987, BIOCHEM BIOPH RES CO, V144, P560, DOI 10.1016/S0006-291X(87)80003-7; TAMM I, 1978, ADV VIRUS RES, V22, P188; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; THOMAS G, 1986, J CELL BIOL, V103, P2137, DOI 10.1083/jcb.103.6.2137; THOMAS G, 1981, P NATL ACAD SCI-BIOL, V78, P5712, DOI 10.1073/pnas.78.9.5712; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; VAZQUEZ D, 1979, MOL BIOL BIOCH BIOPH, V30, P34; WHITE MW, 1990, BIOCHEM J, V268, P657, DOI 10.1042/bj2680657; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x; XIANG L, 1989, NUCLEIC ACIDS RES, V17, P442; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; YENOFSKY R, 1983, MOL CELL BIOL, V3, P1197, DOI 10.1128/MCB.3.7.1197	59	101	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4367	4372						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308006				2022-12-27	WOS:A1994MW98900074
J	KAMADA, S; TOYOSHIMA, K; AKIYAMA, T				KAMADA, S; TOYOSHIMA, K; AKIYAMA, T			SERUM-INDEPENDENT PHOSPHORYLATION OF C-JUN AND ALTERATIONS IN AP-1 COMPONENTS BY TRANSFORMATION WITH VARIOUS ONCOGENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC INHIBITOR; DNA-BINDING ACTIVITY; PROTEIN-KINASE-C; TRANSCRIPTION FACTOR; MOUSE FIBROBLASTS; LEUCINE ZIPPER; GENE FAMILY; V-JUN; FOS; GROWTH	To understand the mechanisms regulating the trans activating activity of Jun/AP-1, we analyzed alterations in c-Jun induced by growth stimulation and cell transformation. Serum stimulation of quiescent NIH3T3 cells induced a marked increase in phosphorylation of c-Jun in its amino-terminal activation domain. On the other hand, this domain was highly phosphorylated, in a se rum-independent manner, in cells transformed with various oncogenes, including active c-raf-1, v-src, active Ha ras, and active erbB-2. There were no obvious differences in the phosphorylation states of c-Jun in exponentially growing normal and transformed cells. However, in the exponentially growing state, the TRECAT activity in transformed cells was markedly higher than that in normal cells. Gel retardation analysis indicated that the AP-1 components in transformed cells were significantly different from those in normal cells. These results suggest that some other alterations besides phosphorylation of c-Jun are involved in enhancement of AP-1 activity in exponentially growing transformed cells.	OSAKA UNIV, MICROBIAL DIS RES INST, DEPT ONCOGENE RES, SUITA, OSAKA 565, JAPAN	Osaka University								ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FUJIMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P724, DOI 10.1016/0006-291X(91)90168-7; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KAMADA S, 1992, GENE, V119, P229, DOI 10.1016/0378-1119(92)90276-U; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUI M, 1990, ONCOGENE, V5, P249; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	52	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4565	4570						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308027				2022-12-27	WOS:A1994MW98900099
J	MAKEH, I; THOMAS, M; HARDELIN, JP; BRIAND, P; KAHN, A; SKALA, H				MAKEH, I; THOMAS, M; HARDELIN, JP; BRIAND, P; KAHN, A; SKALA, H			ANALYSIS OF A BRAIN-SPECIFIC ISOZYME - EXPRESSION AND CHROMATIN STRUCTURE OF THE RAT ALDOLASE-C GENE AND TRANSGENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; HYPERSENSITIVE SITES; MOLECULAR-CLONING; MESSENGER-RNAS; PROMOTER; DOMAIN; CELLS; TRANSCRIPTION; PHOSPHORYLASE; ISOENZYME	Aldolase C mRNA is detected by Northern blot in all fetal tissues in rat; it is very abundant in the adult brain and undetectable in the other adult tissues. However, reverse transcriptase polymerase chain reaction amplification indicates that this gene is not totally repressed in these tissues. A DNase-I hypersensitivity site located in a 115-base pair proximal promoter fragment is detectable in the brain as well as in other adult tissues. Two MspI/HpaII restriction sites located at -3800 and -450 base pairs are demethylated in the brain and totally or partially methylated in other tissues. In transgenic mice, a 12.5-kilobase genomic fragment is strongly and tissue specifically expressed in different lines, with conservation of a methylation pattern similar to that of the endogenous gene. A chloramphenicol acetyltransferase gene directed by either 800 or 115 base pairs of aldolase C 5'-flanking sequences is tissue specifically expressed in transgenic mice, but the level of expression is very low. This level is greatly increased when the transgene consists of a chloramphenicol acetyltransferase hybrid gene directed by 5.5 kilobases of aldolase C 5'-flanking sequences. We propose therefore that the chromatin structure around the aldolase C promoter is accessible in fetal tissues, then remains open in the adult brain, where the gene is very active, as well as in tissues in which it is practically inactive. The specificity of expression in the brain is conferred by a short 115-base pair proximal promoter fragment that needs more upstream sequences to be fully active.	INST COCHIN GENET MOLEC, INSERM, U129, RECH GENET & PATHOL MOLEC LAB, F-75014 PARIS, FRANCE; INST COCHIN GENET MOLEC, INSERM, U380, RECH GENET & PATHOL EXPTL LAB, F-75014 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			Thomas, Muriel/D-9164-2015	Thomas, Muriel/0000-0002-7608-3274				BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BODE J, 1988, BIOCHEMISTRY-US, V27, P4706, DOI 10.1021/bi00413a019; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; DELAIN D, 1973, Differentiation, V1, P349, DOI 10.1111/j.1432-0436.1973.tb00131.x; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; GAZDAR AF, 1981, CANCER RES, V41, P2773; GODBOUT R, 1988, GENE DEV, V2, P949, DOI 10.1101/gad.2.8.949; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; KAHN A, 1981, EUR J BIOCHEM, V116, P7, DOI 10.1111/j.1432-1033.1981.tb05293.x; KAHN A, 1980, PEDIATR RES, V14, P1162, DOI 10.1203/00006450-198011000-00003; KEYSER YD, 1985, J CLIN INVEST, V76, P1892; LEBHERZ HG, 1969, BIOCHEMISTRY-US, V8, P109, DOI 10.1021/bi00829a016; MEEHAN R, 1992, J CELL SCI, P9; MIQUEROL L, 1994, IN PRESS J BIOL CHEM; MUKAI T, 1991, BIOCHEM BIOPH RES CO, V174, P1035, DOI 10.1016/0006-291X(91)91523-F; NOONAN KE, 1988, NUCLEIC ACIDS RES, V16, P10366, DOI 10.1093/nar/16.21.10366; NUMAZAKI M, 1984, EUR J BIOCHEM, V142, P165, DOI 10.1111/j.1432-1033.1984.tb08265.x; OPDECAMP K, 1992, NUCLEIC ACIDS RES, V20, P171, DOI 10.1093/nar/20.2.171; PEEK R, 1991, NUCLEIC ACIDS RES, V19, P77, DOI 10.1093/nar/19.1.77; PENHOET E, 1966, P NATL ACAD SCI USA, V56, P1275, DOI 10.1073/pnas.56.4.1275; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; POPOVICI T, 1990, FEBS LETT, V268, P189, DOI 10.1016/0014-5793(90)81005-9; SATO K, 1972, SCIENCE, V178, P879, DOI 10.1126/science.178.4063.879; SCHAPIRA F, 1970, BIOCHEM BIOPH RES CO, V40, P321, DOI 10.1016/0006-291X(70)91012-0; SKALA H, 1987, EUR J BIOCHEM, V163, P513, DOI 10.1111/j.1432-1033.1987.tb10898.x; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; SUSOR WA, 1971, ANAL BIOCHEM, V43, P147, DOI 10.1016/0003-2697(71)90119-9; SZYF M, 1990, MOL CELL BIOL, V10, P4396, DOI 10.1128/MCB.10.8.4396; TAKASHI M, 1990, AM J CLIN PATHOL, V93, P631, DOI 10.1093/ajcp/93.5.631; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; THOMAS M, 1993, IN PRESS EUR J BIOCH; THOMPSON RJ, 1982, BRAIN RES, V232, P489, DOI 10.1016/0006-8993(82)90294-3; TILGHMAN SM, 1982, P NATL ACAD SCI-BIOL, V79, P5254, DOI 10.1073/pnas.79.17.5254; TSUTSUMI K, 1985, J MOL BIOL, V181, P153, DOI 10.1016/0022-2836(85)90081-6; VIBERT M, 1989, EUR J BIOCHEM, V181, P33, DOI 10.1111/j.1432-1033.1989.tb14690.x; VILLEPONTEAU B, 1984, CELL, V39, P469, DOI 10.1016/0092-8674(84)90454-9; ZENNO S, 1990, J BIOCHEM, V107, P810, DOI 10.1093/oxfordjournals.jbchem.a123130	42	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4194	4200						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307981				2022-12-27	WOS:A1994MW98900047
J	GAN, K; GUPTA, SD; SANKARAN, K; SCHMID, MB; WU, HC				GAN, K; GUPTA, SD; SANKARAN, K; SCHMID, MB; WU, HC			ISOLATION AND CHARACTERIZATION OF A TEMPERATURE-SENSITIVE MUTANT OF SALMONELLA-TYPHIMURIUM DEFECTIVE IN PROLIPOPROTEIN MODIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE LIPOPROTEIN; ESCHERICHIA-COLI; CYTOPLASMIC MEMBRANE; MUREIN-LIPOPROTEIN; PROTEIN; GLOBOMYCIN; BINDING; EXPORT; IDENTIFICATION; DIGLYCERIDE	A temperature-sensitive (ts) mutant of Salmonella typhimurium that accumulated unmodified murein prolipoprotein at 42-degrees-C but not at 30-degrees-C was identified. In vivo and in vitro studies of the biosynthesis of Braun's lipoprotein revealed that this mutant (SE5221) was defective in the glyceryl modification of prolipoprotein. The ts mutation was mapped to 60.6 min of the S. typhimurium chromosome and was linked to argA and cysH. A clone with a 1.4-kilobase S. typhimurium DNA insert that complemented the ts mutation and restored the prolipoprotein modification activity both in vivo and in vitro was isolated. DNA sequencing of the complementing region revealed an open reading frame encoding a protein with 291 amino acids lacking NH2-terminal signal sequence. This open reading frame is immediately 5' to the thyA gene and is allelic to umpA of Escherichia coli. Wild-type strains harboring the cloned gene exhibited elevated levels of prolipoprotein modification activity. At the non-permissive temperature, the mutation affected both growth and viability, and the mutant cells exhibited anomalous cell morphology. The ts phenotype was suppressed by the introduction of a lpp=Tn10 mutation. These results suggest that the cloned gene encodes prolipoprotein glyceryl transferase (lgt), and in the wild-type background, this prolipoprotein modification enzyme is essential for the growth and viability of S. typhimurium.	UNIFORMED SERV UNIV HLTH SCI,DEPT MICROBIOL,BETHESDA,MD 20814; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Uniformed Services University of the Health Sciences - USA; Princeton University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028811] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-28811] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASAI Y, 1989, J BACTERIOL, V171, P6867, DOI 10.1128/jb.171.12.6867-6869.1989; BELFORT M, 1983, P NATL ACAD SCI-BIOL, V80, P4914, DOI 10.1073/pnas.80.16.4914; BENSON NR, 1992, J BACTERIOL, V174, P1673, DOI 10.1128/jb.174.5.1673-1681.1992; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATTOPADHYAY PK, 1977, P NATL ACAD SCI USA, V74, P5318, DOI 10.1073/pnas.74.12.5318; GUPTA SD, 1993, J BIOL CHEM, V268, P16551; HANTKE K, 1973, EUR J BIOCHEM, V34, P284, DOI 10.1111/j.1432-1033.1973.tb02757.x; HAYASHI S, 1992, LIPID MODIFICATION P, P261; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; ICHIHARA S, 1982, J BIOL CHEM, V257, P495; INUKAI M, 1983, EUR J BIOCHEM, V130, P27; INUKAI M, 1978, J ANTIBIOT, V31, P1203, DOI 10.7164/antibiotics.31.1203; INUKAI M, 1979, J BACTERIOL, V140, P1098, DOI 10.1128/JB.140.3.1098-1101.1979; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAI JS, 1981, J BACTERIOL, V145, P657, DOI 10.1128/JB.145.1.657-660.1981; ROTERING H, 1984, FEMS MICROBIOL LETT, V22, P61; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANKARAN K, 1992, LIPID MODIFICATIONS, P163; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMID MB, 1989, GENETICS, V123, P625; SHANABRUCH WG, 1981, J BACTERIOL, V147, P827, DOI 10.1128/JB.147.3.827-835.1981; SUGAI M, 1992, J BACTERIOL, V174, P2511, DOI 10.1128/jb.174.8.2511-2516.1992; TIAN GL, 1989, J BACTERIOL, V171, P1987, DOI 10.1128/jb.171.4.1987-1997.1989; TOKUNAGA M, 1982, P NATL ACAD SCI-BIOL, V79, P2255, DOI 10.1073/pnas.79.7.2255; TOKUNAGA M, 1984, J BIOL CHEM, V259, P3825; WATANABE T, 1988, J BACTERIOL, V170, P4001, DOI 10.1128/jb.170.9.4001-4007.1988; WILLIAMS MG, 1989, J BACTERIOL, V171, P565, DOI 10.1128/jb.171.1.565-568.1989; YAMAGATA H, 1982, J BACTERIOL, V152, P1163	29	45	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16544	16550						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344935				2022-12-27	WOS:A1993LQ33600067
J	LIN, F; WORMAN, HJ				LIN, F; WORMAN, HJ			STRUCTURAL ORGANIZATION OF THE HUMAN GENE ENCODING NUCLEAR LAMIN-A AND NUCLEAR LAMIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEIN; AMINO-ACID SEQUENCE; B-TYPE LAMIN; XENOPUS-LAEVIS; NEUROFILAMENT SUBUNIT; VIMENTIN GENE; CHICKEN LAMIN-B2; KERATIN GENES; CDNA CLONING; IF PROTEINS	We have determined the structural organization of the human gene that encodes nuclear lamins A and C, intermediate filament proteins of the nuclear lamina. Sequencing and restriction mapping show that the coding region spans approximately 24 kilobases. The 5'-proximal promoter region contains several GC-rich stretches, a CCAAT box, and a TATA-like element of sequence TATTA. The lamin A/C gene contains 12 exons. Alternative splicing within exon 10 gives rise to two different mRNAs that code for pre-lamin A and lamin C. Consequently, two proteins are generated, only one of which, pre-lamin A, can be modified by isoprenylation. The intron positions in the human lamin A/C gene are generally conserved in the previously characterized genes for Xenopus lamin LIII and mouse lamin B2, but differ from those in a Drosophila lamin gene. In the regions coding for the central rod domains, the intron positions are also conserved when compared with the intron positions in the genes for most cytoplasmic intermediate filament proteins except those for nestin and neurofilaments. Analysis of the intron positions in these genes supports the hypothesis that the nuclear lamins and other intermediate filament proteins arose from a common ancestor.	CUNY MT SINAI SCH MED,DEPT MED,BOX 1039,ONE GUSTAVE L LEVY PL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; BADER BL, 1986, EMBO J, V5, P1865, DOI 10.1002/j.1460-2075.1986.tb04438.x; BALCAREK J, 1985, NUCLEIC ACIDS RES, V173, P159; BECK LA, 1990, J CELL BIOL, V110, P1489, DOI 10.1083/jcb.110.5.1489; CANCE WG, 1992, J EXP CLIN CANC RES, V11, P233; DODEMONT H, 1990, EMBO J, V9, P4083, DOI 10.1002/j.1460-2075.1990.tb07630.x; DORING V, 1990, EMBO J, V9, P4073, DOI 10.1002/j.1460-2075.1990.tb07629.x; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; FERRARI S, 1986, MOL CELL BIOL, V6, P3614, DOI 10.1128/MCB.6.11.3614; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; FUCHS E, 1983, CELL, V34, P332, DOI 10.1016/0092-8674(83)90367-7; GEORGATOS SD, 1988, P NATL ACAD SCI USA, V85, P4325, DOI 10.1073/pnas.85.12.4325; GERACE L, 1978, J CELL BIOL, V79, P546, DOI 10.1083/jcb.79.2.546; GLASS JR, 1990, J CELL BIOL, V111, P1047, DOI 10.1083/jcb.111.3.1047; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRUENBAUM Y, 1988, J CELL BIOL, V106, P585, DOI 10.1083/jcb.106.3.585; GUILLY MN, 1990, EXP CELL RES, V189, P145, DOI 10.1016/0014-4827(90)90267-E; GUILLY MN, 1987, EMBO J, V6, P3795, DOI 10.1002/j.1460-2075.1987.tb02715.x; HEITLINGER E, 1991, J CELL BIOL, V113, P485, DOI 10.1083/jcb.113.3.485; HOGER TH, 1990, CHROMOSOMA, V99, P379, DOI 10.1007/BF01726689; HOGER TH, 1988, EUR J CELL BIOL, V47, P283; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; JULIEN JP, 1988, GENE, V68, P307, DOI 10.1016/0378-1119(88)90033-9; KAUFMANN SH, 1989, J BIOL CHEM, V264, P13946; KLINGE EM, 1987, J MOL EVOL, V24, P319, DOI 10.1007/BF02134130; KRAUSS S, 1990, GENE, V86, P241, DOI 10.1016/0378-1119(90)90285-Y; KRIEG TM, 1985, J BIOL CHEM, V260, P5867; KROHNE G, 1987, EMBO J, V6, P3801, DOI 10.1002/j.1460-2075.1987.tb02716.x; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; LEBEL S, 1987, J CELL BIOL, V105, P1099, DOI 10.1083/jcb.105.3.1099; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LEHNER CF, 1986, J BIOL CHEM, V261, P3293; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LEVY E, 1987, EUR J BIOCHEM, V166, P71, DOI 10.1111/j.1432-1033.1987.tb13485.x; LEWIS SA, 1986, MOL CELL BIOL, V6, P1529, DOI 10.1128/MCB.6.5.1529; LUTZ RJ, 1992, P NATL ACAD SCI USA, V89, P3000, DOI 10.1073/pnas.89.7.3000; MARCHUK D, 1984, CELL, V39, P491, DOI 10.1016/0092-8674(84)90456-2; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; MIYATANI S, 1986, J CELL BIOL, V103, P1957, DOI 10.1083/jcb.103.5.1957; MYERS MW, 1987, EMBO J, V6, P1617, DOI 10.1002/j.1460-2075.1987.tb02409.x; OSMAN M, 1990, GENOMICS, V8, P217, DOI 10.1016/0888-7543(90)90274-X; PETER M, 1989, J MOL BIOL, V208, P393, DOI 10.1016/0022-2836(89)90504-4; POLLARD KM, 1990, MOL CELL BIOL, V10, P2164, DOI 10.1128/MCB.10.5.2164; QUAX W, 1985, CELL, V43, P327, DOI 10.1016/0092-8674(85)90038-8; QUAX W, 1983, CELL, V35, P215, DOI 10.1016/0092-8674(83)90224-6; RACKWITZ HR, 1984, GENE, V30, P195, DOI 10.1016/0378-1119(84)90120-3; RAYCHAUDHURY A, 1986, MOL CELL BIOL, V6, P539, DOI 10.1128/MCB.6.2.539; RIEGER M, 1985, EMBO J, V4, P2261, DOI 10.1002/j.1460-2075.1985.tb03924.x; ROBER RA, 1989, DEVELOPMENT, V105, P365; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEINERT PM, 1985, CELL, V42, P411, DOI 10.1016/0092-8674(85)90098-4; STEWART C, 1987, CELL, V51, P383, DOI 10.1016/0092-8674(87)90634-9; STICK R, 1988, EMBO J, V7, P3189, DOI 10.1002/j.1460-2075.1988.tb03186.x; THOMPSON MA, 1989, NEURON, V2, P1043, DOI 10.1016/0896-6273(89)90228-6; TYNER AL, 1985, P NATL ACAD SCI USA, V82, P4683, DOI 10.1073/pnas.82.14.4683; VORBURGER K, 1989, J MOL BIOL, V208, P405, DOI 10.1016/0022-2836(89)90505-6; WEBER K, 1989, FEBS LETT, V257, P411, DOI 10.1016/0014-5793(89)81584-4; WOLIN SL, 1987, EMBO J, V6, P3809, DOI 10.1002/j.1460-2075.1987.tb02717.x; WORMAN HJ, 1988, J BIOL CHEM, V263, P12135; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; YUAN J, 1991, J BIOL CHEM, V266, P9211; ZEHNER ZE, 1987, J BIOL CHEM, V262, P8112; ZEWE M, 1991, EUR J CELL BIOL, V56, P342	67	480	498	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16321	16326						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344919				2022-12-27	WOS:A1993LQ33600038
J	PHILIP, R; LIGGITT, D; PHILIP, M; DAZIN, P; DEBS, R				PHILIP, R; LIGGITT, D; PHILIP, M; DAZIN, P; DEBS, R			IN-VIVO GENE DELIVERY - EFFICIENT TRANSFECTION OF T-LYMPHOCYTES IN ADULT MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EXPRESSION INVIVO; ENHANCER-PROMOTER; CELLS; MOUSE	We have demonstrated that a single intraperitoneal injection of cationic liposomes complexed to a chloramphenicol acetyltransferase (CAT) gene expression plasmid can transfect the majority of splenic Thy 1.2+ T lymphocytes, as well as significant numbers of bone marrow-derived hematopoietic cells, in adult mice. CAT activity was detected in the spleen for at least 2 weeks, and there was no evidence of treatment-related toxicity. Some degree of tissue-specific transgene expression was achieved by varying the cationic lipid used.	UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV WASHINGTON,SCH MED,DEPT COMPARAT MED,SEATTLE,WA 98195	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of Washington; University of Washington Seattle								BENVENISTY N, 1986, P NATL ACAD SCI USA, V83, P9551, DOI 10.1073/pnas.83.24.9551; BRIGHAM KL, 1989, AM J MED SCI, V298, P278, DOI 10.1097/00000441-198910000-00013; DEBS RJ, 1990, J BIOL CHEM, V265, P10189; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P8413; FOECKING MK, 1986, GENE, V45, P101, DOI 10.1016/0378-1119(86)90137-X; FURTH PA, 1991, NUCLEIC ACIDS RES, V19, P6205, DOI 10.1093/nar/19.22.6205; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; JARNAGIN WR, 1992, NUCLEIC ACIDS RES, V20, P4205, DOI 10.1093/nar/20.16.4205; KAY MA, 1992, HUM GENE THER, V3, P641, DOI 10.1089/hum.1992.3.6-641; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; PARKER RJ, 1981, CANCER RES, V41, P1311; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; ROSENBERG SA, 1991, CANCER RES, V51, pS5074; Sambrook J, 1989, MOL CLONING LABORATO; STAMATATOS L, 1988, BIOCHEMISTRY-US, V27, P3917, DOI 10.1021/bi00411a005; STRIBLING R, 1992, P NATL ACAD SCI USA, V89, P11277, DOI 10.1073/pnas.89.23.11277; WANG CY, 1987, P NATL ACAD SCI USA, V84, P7851, DOI 10.1073/pnas.84.22.7851; WEISSMAN IL, 1975, TRANSPLANT REV, V24, P159; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; WU GY, 1988, J BIOL CHEM, V263, P14621	21	85	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16087	16090						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344890				2022-12-27	WOS:A1993LQ33600002
J	SPUDICH, EN; SPUDICH, JL				SPUDICH, EN; SPUDICH, JL			THE PHOTOCHEMICAL-REACTIONS OF SENSORY RHODOPSIN-I ARE ALTERED BY ITS TRANSDUCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RESONANCE RAMAN-SPECTROSCOPY; METARHODOPSIN-II; PROTEIN; BACTERIORHODOPSIN	The sopI gene, which encodes the phototaxis receptor sensory rhodopsin I (SR-I), was expressed in Halobacterium salinarium strains with chromosomal deletions of (i) sopI only or of (ii) the region containing sopI and htrI. The htrI gene encodes a transducer protein for SR-I signals. Transformation of the sopI deletion mutant containing the htrI gene by a multicopy expression plasmid for sopI results in normal physiological and photochemical properties of SR-I. Transformation by the same plasmid of the mutant lacking the htrI gene as well as sopI results in production of pigment with a normal absorption spectrum but altered photochemical properties, and no phototaxis by the transformants. Analysis of flash-induced absorbance changes shows that the transducer protein increases light-induced production of the photocycle intermediate S373, the SR-I signaling conformation, and modulates the rate Of S373 return to the prestimulus state, rendering this return pH-independent. These effects are interpreted in terms of receptor/transducer interactions that influence proton transfer reactions occurring in the photoactive site.			SPUDICH, EN (corresponding author), UNIV TEXAS, SCH MED, DEPT MICROBIOL & MOLEC GENET, HOUSTON, TX 77030 USA.				NIGMS NIH HHS [R01GM27750] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027750] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANCK A, 1989, EMBO J, V8, P3963, DOI 10.1002/j.1460-2075.1989.tb08579.x; BOGOMOLNI RA, 1987, BIOPHYS J, V52, P1071, DOI 10.1016/S0006-3495(87)83301-5; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BOUSCHE O, 1991, BIOCHEMISTRY-US, V30, P5395, DOI 10.1021/bi00236a010; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOUKAS AG, 1978, BIOCHEMISTRY-US, V17, P2430, DOI 10.1021/bi00605a028; EMEIS D, 1982, FEBS LETT, V143, P29, DOI 10.1016/0014-5793(82)80266-4; FODOR SPA, 1989, J BIOL CHEM, V264, P18280; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; HOFMANN KP, 1993, HDB EXPT PHARM; KREBS MP, 1993, P NATL ACAD SCI USA, V90, P3486, DOI 10.1073/pnas.90.8.3486; LEWIS A, 1974, P NATL ACAD SCI USA, V71, P4462, DOI 10.1073/pnas.71.11.4462; LONGSTAFF C, 1986, P NATL ACAD SCI USA, V83, P4209, DOI 10.1073/pnas.83.12.4209; OESTERHELT D, 1990, S SOC GEN MICROBIOL, V46, P219; OLSON KD, 1992, PHOTOCHEM PHOTOBIOL, V56, P1181, DOI 10.1111/j.1751-1097.1992.tb09743.x; SPUDICH E N, 1986, Proteins Structure Function and Genetics, V1, P239, DOI 10.1002/prot.340010306; SPUDICH EN, 1989, P NATL ACAD SCI USA, V86, P7746, DOI 10.1073/pnas.86.20.7746; SPUDICH EN, 1988, J BACTERIOL, V170, P4280, DOI 10.1128/jb.170.9.4280-4285.1988; SPUDICH JL, 1988, ANNU REV BIOPHYS BIO, V17, P193; SPUDICH JL, 1984, NATURE, V312, P509, DOI 10.1038/312509a0; YAN B, 1991, PHOTOCHEM PHOTOBIOL, V54, P1023, DOI 10.1111/j.1751-1097.1991.tb02125.x; YAO VJ, 1992, P NATL ACAD SCI USA, V89, P11915, DOI 10.1073/pnas.89.24.11915	22	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16095	16097						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344892				2022-12-27	WOS:A1993LQ33600004
J	ZIMMERMAN, JW; ROBBINS, PW				ZIMMERMAN, JW; ROBBINS, PW			THE HYDROPHOBIC DOMAIN OF DOLICHYL-PHOSPHATE-MANNOSE SYNTHASE IS NOT ESSENTIAL FOR ENZYME-ACTIVITY OR GROWTH IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED OLIGOSACCHARIDES; ENDOPLASMIC-RETICULUM; PROTEIN GLYCOSYLATION; SHUTTLE VECTORS; YEAST; MEMBRANES; CELLS; PHOSPHOLIPIDS; TOPOGRAPHY; ACTIVATION	Dolichyl-phosphate-mannose synthase is a membrane-bound enzyme of the endoplasmic reticulum that catalyzes the formation of dolichyl phosphate mannose from dolichyl phosphate and GDP-mannose. It is an essential enzyme for growth of Saccharomyces cerevisiae, visiae, and, like other enzymes that utilize some form of the lipid dolichol as substrate, dolichyl-phosphate-mannose synthase contains a putative ''dolichol recognition sequence'' in the predicted membrane-spanning domain. To investigate the importance of this sequence in particular and the hydrophobic region in general, a series of mutants of dolichyl-phosphate-mannose synthase were constructed that contained successive deletions or mutations of the hydrophobic region, and their in vivo functions and in vitro activities were examined. While all of the mutant proteins exhibited decreased transferase activities in vitro compared to the wild-type enzyme, the sequence was not essential for growth or for protein glycosylation in S. cerevisiae. Interestingly, although deletion of the entire hydrophobic region resulted in a soluble protein, mutant proteins containing 3 or 8 hydrophobic residues at the carboxyl terminus were still membrane-associated. These mutant proteins could be released from membranes by treatment with sodium carbonate, indicating peripheral associations.			ZIMMERMAN, JW (corresponding author), MIT,CTR CANC RES,E17-236,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.			Robbins, Phillips/0000-0002-5121-1524	NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045188] Funding Source: NIH RePORTER; NCI NIH HHS [CA14051] Funding Source: Medline; NIGMS NIH HHS [GM45188] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; ALBRIGHT CF, 1989, P NATL ACAD SCI USA, V86, P7366, DOI 10.1073/pnas.86.19.7366; BRAELL WA, 1976, ANAL BIOCHEM, V74, P484, DOI 10.1016/0003-2697(76)90229-3; BULAWA CE, 1992, MOL CELL BIOL, V12, P1764, DOI 10.1128/MCB.12.4.1764; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HASELBECK A, 1982, P NATL ACAD SCI-BIOL, V79, P1520, DOI 10.1073/pnas.79.5.1520; HASELBECK A, 1984, FEMS MICROBIOL LETT, V21, P305, DOI 10.1016/0378-1097(84)90088-0; HELLER L, 1992, P NATL ACAD SCI USA, V89, P7013, DOI 10.1073/pnas.89.15.7013; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HUBBARD SC, 1980, J BIOL CHEM, V255, P1782; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENSEN JW, 1985, EUR J BIOCHEM, V153, P41, DOI 10.1111/j.1432-1033.1985.tb09264.x; KEAN EL, 1992, BIOCHEM CELL BIOL, V70, P413, DOI 10.1139/o92-064; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHLE L, 1983, BIOCHEM SOC T, V11, P568, DOI 10.1042/bst0110568; LEHRMAN M A, 1991, Glycobiology, V1, P553, DOI 10.1093/glycob/1.6.553; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; SCHEIN CH, 1989, BIO-TECHNOL, V7, P1141; SCHUTZBACH JS, 1992, BIOCHEM CELL BIOL, V70, P460, DOI 10.1139/o92-070; SCOCCA JR, 1990, J BIOL CHEM, V265, P20621; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; STECK TL, 1973, J SUPRAMOL STRUCT, V1, P221; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5	33	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16746	16753						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344954				2022-12-27	WOS:A1993LQ33600094
J	DAVODEAU, F; HOUDE, I; BOULOT, G; ROMAGNE, F; NECKER, A; CANAVO, N; PEYRAT, MA; HALLET, MM; VIE, H; JACQUES, Y; MARIUZZA, R; BONNEVILLE, M				DAVODEAU, F; HOUDE, I; BOULOT, G; ROMAGNE, F; NECKER, A; CANAVO, N; PEYRAT, MA; HALLET, MM; VIE, H; JACQUES, Y; MARIUZZA, R; BONNEVILLE, M			SECRETION OF DISULFIDE-LINKED HUMAN T-CELL RECEPTOR-GAMMA-DELTA HETERODIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; MONOCLONAL-ANTIBODIES; MOLECULAR-GENETICS; CHIMERIC PROTEIN; EXPRESSION; TCR	The availability of soluble forms of T-cell antigen receptors (sTCR) should be of great use in the detailed characterization of their interactions with ligands, for the generation of anti-TCR monoclonal antibodies (mAb), and for the eventual determination of their three-dimensional structures by x-ray crystallography. Here, we show that efficient secretion of nonchimeric disulfide-linked human gammadelta TCR could be achieved by simply introducing translational termination codons upstream from the sequences encoding TCR chain transmembrane regions. This recombinant protein appeared to be correctly folded, as judged by its reactivity with a panel of anti-gamma and anti-delta mAbs, and proved to be a powerful immunogen, allowing generation of mAb that are able to recognize both soluble- and membrane-bound gammadelta TCR. While variable and constant domains of gammadelta sTCR seem to be folded into compact conformations, the extreme sensitivity of its interchain disulfide bridge to digestion with papain suggests that sTCR C-terminal portions are in a more extended configuration than the corresponding region in immunoglobulins. Finally, the gammadelta heterodimer remains stable even after removal of the interchain disulfide link, suggesting the existence of strong noncovalent forces holding the two chains together.	INST BIOL NANTES,INSERM,U211,9 QUAI MONCOUSU,F-44035 NANTES 01,FRANCE; INST PASTEUR,F-75024 PARIS,FRANCE; IMMUNOTECH SA,F-13276 MARSEILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Davodeau, Francois/M-1888-2015; Vie, Henri/L-2651-2015	Davodeau, Francois/0000-0001-8181-0192				BASI GS, 1992, J IMMUNOL METHODS, V155, P175, DOI 10.1016/0022-1759(92)90284-Z; BISMUTH G, 1990, MOL IMMUNOL, V27, P1127, DOI 10.1016/0161-5890(90)90101-5; COUSIN MA, 1985, LYMPHOKINE RES, V4, P319; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DAVODEAU F, 1993, EUR J IMMUNOL, V23, P804, DOI 10.1002/eji.1830230405; DEVAUX B, 1991, EUR J IMMUNOL, V21, P2111, DOI 10.1002/eji.1830210920; EILAT D, 1992, P NATL ACAD SCI USA, V89, P6871, DOI 10.1073/pnas.89.15.6871; ENGEL I, 1992, SCIENCE, V256, P1318, DOI 10.1126/science.1598575; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GASCOIGNE NRJ, 1987, P NATL ACAD SCI USA, V84, P2936, DOI 10.1073/pnas.84.9.2936; GREGOIRE C, 1991, P NATL ACAD SCI USA, V88, P8077, DOI 10.1073/pnas.88.18.8077; HARLOW E, 1988, ANTIBODIES LABORATOR, P580; HATA S, 1987, SCIENCE, V238, P678, DOI 10.1126/science.3499667; JAMESON SC, 1990, J IMMUNOL, V145, P1324; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; LEFRANC MP, 1986, P NATL ACAD SCI USA, V83, P9596, DOI 10.1073/pnas.83.24.9596; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; MALISSEN M, 1992, IMMUNOL TODAY, V13, P49; MARIUZZA RA, 1989, J BIOL CHEM, V264, P7310; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MIOSSEC C, 1990, J EXP MED, V171, P1171, DOI 10.1084/jem.171.4.1171; NOVOTNY J, 1991, P NATL ACAD SCI USA, V88, P8646, DOI 10.1073/pnas.88.19.8646; RAULET DH, 1989, ANNU REV IMMUNOL, V7, P175, DOI 10.1146/annurev.iy.07.040189.001135; SLANETZ AE, 1991, EUR J IMMUNOL, V21, P179, DOI 10.1002/eji.1830210127; TRAUNECKER A, 1989, IMMUNOL TODAY, V10, P29, DOI 10.1016/0167-5699(89)90062-5; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WARD ES, 1992, J MOL BIOL, V224, P885, DOI 10.1016/0022-2836(92)90455-S; WEBER S, 1992, NATURE, V356, P93; WIGLERR M, 1979, CELL, V16, P177	29	26	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15455	15460						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340374				2022-12-27	WOS:A1993LN30500023
J	DRAKE, SL; VARNUM, J; MAYO, KH; LETOURNEAU, PC; FURCHT, LT; MCCARTHY, JB				DRAKE, SL; VARNUM, J; MAYO, KH; LETOURNEAU, PC; FURCHT, LT; MCCARTHY, JB			STRUCTURAL FEATURES OF FIBRONECTIN SYNTHETIC PEPTIDE FN-C/H II, RESPONSIBLE FOR CELL-ADHESION, NEURITE EXTENSION, AND HEPARAN-SULFATE BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; SURFACE RECEPTORS; PLATELET FACTOR-4; CYTOCHROME-C; IV COLLAGEN; N-CAM; PROTEIN; PROTEOGLYCAN; DOMAIN; IDENTIFICATION	FN-C/H II (KNNQKSEPLIGRKKT), a heparin-binding peptide derived from the COOH-terminal heparin-binding domain of fibronectin, mediates cell adhesion for a variety of cell types and promotes neurite out-growth. By systematic amino acid substitution of synthetic peptide analogues of FN-C/H II, the basic structural features necessary for activity have been identified in the COOH-terminal residues LIGRKK. This biologically ''active'' sequence has been located in several other heparin/heparan sulfate-binding proteins and may represent a potential binding motif for sulfated polyanions. NMR structural studies indicate that the COOH-terminal segment of FN-C/H II displays significant multiple-turn or helix-like character suggesting that the RKK sequence may lie on the same surface of the protein, as opposed to alternating in an extended chain motif.	UNIV MINNESOTA,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,CTR BIOMED ENGN,MINNEAPOLIS,MN 55455; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Jefferson University; Jefferson University			Letourneau, Paul C/A-6764-2009		NATIONAL CANCER INSTITUTE [R55CA054263, R01CA043924] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043194, K99HL143194] Funding Source: NIH RePORTER; NCI NIH HHS [CA43924, CA54263] Funding Source: Medline; NHLBI NIH HHS [HL-43194] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARKALOW FJ, 1991, J BIOL CHEM, V12, P7812; BARON M, 1992, BIOCHEMISTRY-US, V31, P2068, DOI 10.1021/bi00122a025; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CAREY DJ, 1990, J CELL BIOL, V111, P2053, DOI 10.1083/jcb.111.5.2053; CHARONIS AS, 1988, J CELL BIOL, V107, P1253, DOI 10.1083/jcb.107.3.1253; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; COLE GJ, 1986, J CELL BIOL, V102, P403, DOI 10.1083/jcb.102.2.403; COLE GJ, 1989, EXP CELL RES, V182, P44, DOI 10.1016/0014-4827(89)90278-4; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DRAKE SL, 1992, J CELL BIOL, V117, P1331, DOI 10.1083/jcb.117.6.1331; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; HAUGEN PK, 1992, J NEUROSCI, V12, P2034; HAUGEN PK, 1992, J NEUROSCI, V12, P2597; HAUGEN PK, 1990, J CELL BIOL, V111, P2733, DOI 10.1083/jcb.111.6.2733; HEIMER R, 1987, ANAL BIOCHEM, V165, P448, DOI 10.1016/0003-2697(87)90295-8; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; JEERNER J, 1979, J CHEM PHYS, V71, P4546; JULIANO RL, 1987, BIOCHIM BIOPHYS ACTA, V907, P261, DOI 10.1016/0304-419X(87)90009-6; KLEIN DJ, 1989, DEV BIOL, V133, P515, DOI 10.1016/0012-1606(89)90054-7; KOLIAKOS GG, 1989, J BIOL CHEM, V264, P2313; KOUZIKOLIAKOS K, 1989, J BIOL CHEM, V264, P17971; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LEHRMAN SR, 1990, BIOCHEMISTRY-US, V29, P5590, DOI 10.1021/bi00475a025; MAYO KH, 1991, BIOCHEMISTRY-US, V30, P925, DOI 10.1021/bi00218a007; MAYO KH, 1989, BIOCHEMISTRY-US, V28, P9469, DOI 10.1021/bi00450a034; MCCARTHY JB, 1988, BIOCHEMISTRY-US, V27, P1380, DOI 10.1021/bi00404a044; MCCARTHY JB, 1990, J CELL BIOL, V110, P777, DOI 10.1083/jcb.110.3.777; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; MERENMIES J, 1990, J BIOL CHEM, V265, P16271; MIZZEN LA, 1988, J CELL BIOL, V106, P1105, DOI 10.1083/jcb.106.4.1105; MURRAY BA, 1992, J CELL BIOL, V117, P1311, DOI 10.1083/jcb.117.6.1311; OEGEMA TR, 1979, J BIOL CHEM, V254, P1312; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REYES AA, 1990, CELL REGUL, V1, P567, DOI 10.1091/mbc.1.8.567; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SALMIVIRTA M, 1992, EXP CELL RES, V200, P444, DOI 10.1016/0014-4827(92)90194-D; SAMPSON PM, 1985, ANAL BIOCHEM, V151, P304, DOI 10.1016/0003-2697(85)90180-0; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SKUBITZ APN, 1991, J CELL BIOL, V115, P1137, DOI 10.1083/jcb.115.4.1137; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; TSILIBARY EC, 1990, J CELL BIOL, V111, P1583, DOI 10.1083/jcb.111.4.1583; UNGEWICKELL E, 1985, EMBO J, V4, P3385, DOI 10.1002/j.1460-2075.1985.tb04094.x; WAGNER R, 1988, BIOCHEMISTRY-US, V27, P7167; WILKE MS, 1991, J INVEST DERMATOL, V97, P573, DOI 10.1111/1523-1747.ep12481915; WRIGHT PE, 1988, BIOCHEMISTRY-US, V27, P7167, DOI 10.1021/bi00419a001; Wuthrich K, 1986, NMR PROTEINS NUCL AC, P117; YANAGISHITA M, 1984, J BIOL CHEM, V259, P260	60	44	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15859	15867						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340411				2022-12-27	WOS:A1993LN30500078
J	RUTENBER, E; FAUMAN, EB; KEENAN, RJ; FONG, S; FURTH, PS; DEMONTELLANO, PRO; MENG, E; KUNTZ, ID; DECAMP, DL; SALTO, R; ROSE, JR; CRAIK, CS; STROUD, RM				RUTENBER, E; FAUMAN, EB; KEENAN, RJ; FONG, S; FURTH, PS; DEMONTELLANO, PRO; MENG, E; KUNTZ, ID; DECAMP, DL; SALTO, R; ROSE, JR; CRAIK, CS; STROUD, RM			STRUCTURE OF A NONPEPTIDE INHIBITOR COMPLEXED WITH HIV-1 PROTEASE - DEVELOPING A CYCLE OF STRUCTURE-BASED DRUG DESIGN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN IMMUNODEFICIENCY VIRUS-1; MULTIWIRE AREA DETECTOR; 3-DIMENSIONAL STRUCTURE; TYPE-1 PROTEASE; RESOLUTION; PROTEINASE; RETRIEVAL	A stable, non-peptide inhibitor of the protease from type 1 human immunodeficiency virus has been developed, and the stereochemistry of binding defined through crystallographic three-dimensional structure determination. The initial compound, haloperidol, was discovered through computational screening of the Cambridge Structural Database using a shape complementarity algorithm. The subsequent modification is a non-peptidic lateral lead, which belongs to a family of compounds with well characterized pharmacological properties. This thioketal derivative of haloperidol and a halide counterion are bound within the enzyme active site in a mode distinct from that observed for peptide-based inhibitors. A variant of the protease cocrystallized with this inhibitor shows binding in the manner predicted during the initial computer-based search. The structures provide the context for subsequent synthetic modifications of the inhibitor.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Salto, Rafael/A-6486-2011; Fauman, Eric/AAC-8275-2020	Salto, Rafael/0000-0002-7044-3611; Fauman, Eric/0000-0002-9739-0249; Keenan, Robert/0000-0003-1466-0889	NIGMS NIH HHS [GM 39552] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM039552] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN FH, 1973, J CHEM DOC, V13, P119, DOI 10.1021/c160050a006; ALLEN FH, 1979, ACTA CRYSTALLOGR B, V35, P2331, DOI 10.1107/S0567740879009249; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BLUNDELL TL, 1990, TRENDS BIOCHEM SCI, V15, P425, DOI 10.1016/0968-0004(90)90280-O; BROWNER MF, 1992, BIOCHEMISTRY-US, V31, P11297, DOI 10.1021/bi00161a006; DATTA N, 1979, ACTA CRYSTALLOGR B, V35, P1486, DOI 10.1107/S0567740879006828; DESJARLAIS RL, 1990, P NATL ACAD SCI USA, V87, P6644, DOI 10.1073/pnas.87.17.6644; DESJARLAIS RL, 1988, J MED CHEM, V31, P722, DOI 10.1021/jm00399a006; FISANICK W, 1990, J CHEM INF COMP SCI, V30, P145, DOI 10.1021/ci00066a008; FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209; FURGUSON G, 1991, ACTA CRYSTALLOGR B, V47, P479; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNTZ ID, 1982, J MOL BIOL, V161, P269, DOI 10.1016/0022-2836(82)90153-X; LAPATTO R, 1989, NATURE, V342, P299, DOI 10.1038/342299a0; MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486; MENG EC, 1992, J COMPUT CHEM, V13, P505, DOI 10.1002/jcc.540130412; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; PERRY KM, 1990, PROTEINS, V8, P315, DOI 10.1002/prot.340080406; PREUTZ M, 1992, PROTEIN STRUCTURE NE; ROSE JR, 1993, J BIOL CHEM, V268, P11939; RUSINKO A, 1989, J CHEM INF COMP SCI, V29, P251, DOI 10.1021/ci00064a004; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SWAIN AL, 1990, P NATL ACAD SCI USA, V87, P8805, DOI 10.1073/pnas.87.22.8805; TILTON RF, 1986, J MOL BIOL, V192, P443, DOI 10.1016/0022-2836(86)90374-8; VERHOEF JC, 1990, EUR J DRUG METAB PH, V15, P83, DOI 10.1007/BF03190191; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279	30	127	134	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15343	15346						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340363				2022-12-27	WOS:A1993LN30500006
J	BULET, P; DIMARCQ, JL; HETRU, C; LAGUEUX, M; CHARLET, M; HEGY, G; VANDORSSELAER, A; HOFFMANN, JA				BULET, P; DIMARCQ, JL; HETRU, C; LAGUEUX, M; CHARLET, M; HEGY, G; VANDORSSELAER, A; HOFFMANN, JA			A NOVEL INDUCIBLE ANTIBACTERIAL PEPTIDE OF DROSOPHILA CARRIES AN O-GLYCOSYLATED SUBSTITUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSECT IMMUNITY; ANTIMICROBIAL PEPTIDES; PROTEINS; CDNA; SEQUENCE; CECROPIA; CLONING; FAMILY; MEMBER; CELLS	One of the facets of the host defense of higher insects is the rapid and transient synthesis, following bacterial challenge or trauma, of a battery of potent antibacterial peptides (Steiner, H., Hultmark, D., Engstrom, A., Bennich, H., and Boman, H. G. (1981) Nature 292, 246-248). The best characterized of these peptides are the cecropins (ibid.), 4-kDa peptides devoid of cysteines, and the insect defensins (Hoffmann, J. A., and Hetru, C. (1992) Immunol. Today 13, 411-415), 4-kDa peptides with three intramolecular disulfide bridges. Several other inducible antibacterial peptides have been characterized only at the level of their amino acid sequences (Hoffmann, J. A., Dimarcq, J. L., and Bulet, P. (1992) Medecine & Sciences 8, 432-439). We report here the isolation of a novel 19-residue proline-rich inducible antibacterial peptide from Drosophila. In contrast to all previous reports on antibacterial peptides, this molecule carries a substitution as evidenced by molecular mass determinations; our data show that this reflects the O-glycosylation of a Thr residue by an N-acetylgalactosamine plus a galactose. A synthetic nonsubstituted peptide of identical amino acid sequence has an activity several times lower (5-10) than the native compound. Our data suggest that this substitution represents a post-translational modification essential for the full biological activity of this novel peptide.	UNIV STRASBOURG 1,BIOL GEN LAB,CNRS,F-67070 STRASBOURG,FRANCE; UNIV STRASBOURG 1,SPECTROMETRIE MASSE BIOORGAN,CNRS,URA CHIM ORGAN SUBST NAT 31,F-67008 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			BULET, Philippe/C-8557-2014	BULET, Philippe/0000-0001-9016-265X				AGERBERTH B, 1991, EUR J BIOCHEM, V202, P849, DOI 10.1111/j.1432-1033.1991.tb16442.x; ANDO K, 1988, BIOCHEMISTRY-US, V27, P1715, DOI 10.1021/bi00405a050; BOHLMANN H, 1988, EMBO J, V7, P1559, DOI 10.1002/j.1460-2075.1988.tb02980.x; BOMAN HG, 1991, EUR J BIOCHEM, V201, P23, DOI 10.1111/j.1432-1033.1991.tb16252.x; BONMATIN JM, 1992, J BIOMOL NMR, V2, P235, DOI 10.1007/BF01875319; BULET P, 1991, J BIOL CHEM, V266, P24520; CASTEELS P, 1989, EMBO J, V8, P2387, DOI 10.1002/j.1460-2075.1989.tb08368.x; CASTEELS P, 1990, EUR J BIOCHEM, V187, P381, DOI 10.1111/j.1432-1033.1990.tb15315.x; CORCES V, 1981, P NATL ACAD SCI-BIOL, V78, P7038, DOI 10.1073/pnas.78.11.7038; DIMARCQ JL, 1988, EUR J BIOCHEM, V171, P17, DOI 10.1111/j.1432-1033.1988.tb13752.x; HAN JH, 1987, NUCLEIC ACIDS RES, V15, P6304, DOI 10.1093/nar/15.15.6304; HOFFMANN JA, 1992, M S-MED SCI, V8, P432, DOI 10.4267/10608/3159; HOFFMANN JA, 1992, IMMUNOL TODAY, V13, P411, DOI 10.1016/0167-5699(92)90092-L; KOCKUM K, 1984, EMBO J, V3, P2071, DOI 10.1002/j.1460-2075.1984.tb02093.x; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; Mason PJ, 1985, NUCLEIC ACID HYBRIDI, P113; MOORE KS, 1991, J BIOL CHEM, V266, P19851; REICHHART JM, 1992, EMBO J, V11, P1469, DOI 10.1002/j.1460-2075.1992.tb05191.x; SAMAKOVLIS C, 1990, EMBO J, V9, P2969, DOI 10.1002/j.1460-2075.1990.tb07489.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER MP, 1983, ANAL BIOCHEM, V128, P66, DOI 10.1016/0003-2697(83)90345-7; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANDORSSELAER A, 1990, BIOMED ENVIRON MASS, V19, P692, DOI 10.1002/bms.1200191108; WICKER C, 1990, J BIOL CHEM, V265, P22493; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; YANNISCHPERRON C, 1985, GENE, V33, P103; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	28	322	349	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14893	14897						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325867				2022-12-27	WOS:A1993LL75900056
J	MARKLUND, U; BRATTSAND, G; SHINGLER, V; GULLBERG, M				MARKLUND, U; BRATTSAND, G; SHINGLER, V; GULLBERG, M			SERINE-25 OF ONCOPROTEIN-18 IS A MAJOR CYTOSOLIC TARGET FOR THE MITOGEN-ACTIVATED PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LYMPHOCYTES-T; PHOSPHORYLATION SITE; MAP KINASES; C-MYC; SUBSTRATE; GENE; PHOSPHOPROTEIN; STATHMIN; BRAIN; IDENTIFICATION	Oncoprotein 18 (Op18) is an 18-19-kDa cytoplasmic phosphoprotein, of unknown function, that is frequently up-regulated in transformed cells. Stimulation of various cell-surface receptors results in extensive phosphorylation of Op18 and this protein has, therefore, previously been implicated in intracellular signaling. In the present study, by expression of specific Op18 cDNA mutant constructs and phosphopeptide mapping, we have identified in vivo phosphorylation sites. In conjunction with in vitro phosphorylation experiments, using purified wild-type and mutant Op18 proteins in combination with a series of kinases, these results have identified two distinct proline-directed kinase families that phosphorylate Op 1 8 with overlapping but distinct site preference. These two kinase families, mitogen activated protein (MAP) kinases and cyclin dependent cdc2 kinases, are involved in receptor and cell cycle-regulated phosphorylation events, respectively. Therefore, Op18 may reside at a junction where receptor and cell cycle-regulated kinase families interact with the same substrate. The present study shows that the MAP kinase has a 20-fold preference for Ser25 as opposed to Ser38 of Op18, while cdc2 kinases have a 5-fold preference for the Ser38 residue. Only a minor fraction of the 4.5 x 10(6)Op18 molecules/cell in a leukemic T-cell line are normally in their Ser25 phosphorylated form. However, antigen receptor stimulation of this cell line is shown to result in a rapid conversion of 35-45% of all Op18 molecules to the Ser25 phosphorylated form. These results suggest that Ser25 of Op18 may be a major cytoplasmic target for the MAP kinase in cells with high expression of Op18.	UMEA UNIV, DEPT CELL & MOLEC BIOL, S-90187 UMEA, SWEDEN	Umea University				Shingler, Victoria/0000-0002-7349-1678; Gullberg, Martin/0000-0002-3984-4572				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BEVERLEY PCL, 1981, EUR J IMMUNOL, V11, P329, DOI 10.1002/eji.1830110412; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRATTSAND G, 1993, LEUKEMIA, V7, P569; BRATTSAND G, 1989, SCAND J IMMUNOL, V30, P233, DOI 10.1111/j.1365-3083.1989.tb01206.x; BRATTSAND G, 1990, J IMMUNOL, V144, P3651; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CHNEIWEISS H, 1989, J NEUROCHEM, V53, P856, DOI 10.1111/j.1471-4159.1989.tb11783.x; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DOYE V, 1989, J BIOL CHEM, V264, P12134; DOYE V, 1990, J BIOL CHEM, V265, P11650; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FRIEDRICH B, 1988, IMMUNOBIOLOGY, V176, P465, DOI 10.1016/S0171-2985(88)80027-5; FRIEDRICH B, 1989, EUR J IMMUNOL, V19, P17, DOI 10.1002/eji.1830190104; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GULLBERG M, 1990, J BIOL CHEM, V265, P17499; HAILAT N, 1990, ONCOGENE, V5, P1615; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HOSHI M, 1989, EUR J BIOCHEM, V184, P477, DOI 10.1111/j.1432-1033.1989.tb15040.x; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LABDON JE, 1992, J BIOL CHEM, V267, P3506; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LUO KX, 1991, METHOD ENZYMOL, V201, P149; Maniatis T, 1989, MOL CLONING; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NAKIELNY S, 1992, FEBS LETT, V308, P183, DOI 10.1016/0014-5793(92)81271-M; NEL AE, 1990, J IMMUNOL, V144, P2683; PILON M, 1991, J IMMUNOL, V146, P1047; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SCHUBART UK, 1989, DNA-J MOLEC CELL BIO, V8, P389, DOI 10.1089/dna.1.1989.8.389; SCHUBART UK, 1987, J BIOL CHEM, V262, P11871; SETH A, 1991, J BIOL CHEM, V266, P23521; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHU XX, 1989, J BIOL CHEM, V264, P14556	49	129	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15039	15049						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325880				2022-12-27	WOS:A1993LL75900074
J	PAVLIAK, V; BRISSON, JR; MICHON, F; UHRIN, D; JENNINGS, HJ				PAVLIAK, V; BRISSON, JR; MICHON, F; UHRIN, D; JENNINGS, HJ			STRUCTURE OF THE SIALYLATED L3 LIPOPOLYSACCHARIDE OF NEISSERIA-MENINGITIDIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSULAR POLYSACCHARIDE; MAGNETIC-RESONANCE; ANTIGENS; OLIGOSACCHARIDES; SPECTROSCOPY; LIPOOLIGOSACCHARIDES; GLYCOPROTEINS; GLYCOLIPIDS; INHIBITION; COMPONENTS	The L3 immunotype lipopolysaccharide (LPS) of Neisseria meningitidis was subjected to degradation procedures, which produced a number of different oligosaccharide fragments. The high resolution H-1 and C-13 NMR spectroscopic analyses of these oligosaccharides yielded structural information on a number of different regions of the LPS. For example, from one oligosaccharide, it was found that the endogenous sialylation of the meningococcal LPS occurs at O-3 of the terminal beta-D-galactopyranosyl residue of its lacto-N-neotetraose antenna in the alpha-D-configuration. From another, it was also established that the dominant structural feature responsible for L3 epitope specificity is the presence of a phosphorylethanolamine substituent at O-3 of the penultimate heptopyranosyl residue of its other antenna. In addition from information obtained with another oligosaccharide the structure of the 3-deoxy-D-manno-octulosonic acid disaccharide region of the L3 LPS was also elucidated. From all the above cumulative data plus some published data, it was then possible to reconstruct the complete structure of the entire native L3 LPS.	NATL RES COUNCIL CANADA, INST BIOL SCI, OTTAWA K1A 0R6, ONTARIO, CANADA; SLOVAK ACAD SCI, INST CHEM, CS-84238 BRATISLAVA, CZECHOSLOVAKIA	National Research Council Canada; Slovak Academy of Sciences								ALTMAN E, 1987, EUR J BIOCHEM, V170, P185, DOI 10.1111/j.1432-1033.1987.tb13685.x; ALTMAN E, 1992, EUR J BIOCHEM, V204, P225, DOI 10.1111/j.1432-1033.1992.tb16628.x; BAUMANN H, 1992, BIOCHEMISTRY-US, V31, P4081, DOI 10.1021/bi00131a026; BHATTACHARJEE AK, 1978, BIOCHEMISTRY-US, V17, P645, DOI 10.1021/bi00597a013; BIRNBAUM GI, 1987, J CARBOHYD CHEM, V6, P17, DOI 10.1080/07328308708058858; DIFABIO JL, 1989, BIOCHEM CELL BIOL, V67, P78; DIFABIO JL, 1990, CAN J CHEM, V68, P1029, DOI 10.1139/v90-160; FEIZI T, 1985, TRENDS BIOCHEM SCI, V10, P24, DOI 10.1016/0968-0004(85)90012-X; FUKUDA MN, 1985, J BIOL CHEM, V260, P1067; GAMIAN A, 1992, J BIOL CHEM, V267, P922; GU XX, 1991, ANAL BIOCHEM, V196, P311, DOI 10.1016/0003-2697(91)90472-6; HAKOMORI SI, 1981, SEMIN HEMATOL, V18, P39; HOLST O, 1991, J BACTERIOL, V173, P1862, DOI 10.1128/jb.173.6.1862-1866.1991; INAGAKI F, 1989, J MAGN RESON, V81, P186, DOI 10.1016/0022-2364(89)90278-3; JANSSON PE, 1989, CARBOHYD RES, V188, P169, DOI 10.1016/0008-6215(89)84069-8; JENNINGS HJ, 1984, INFECT IMMUN, V43, P407, DOI 10.1128/IAI.43.1.407-412.1984; JENNINGS HJ, 1983, CARBOHYD RES, V121, P233, DOI 10.1016/0008-6215(83)84020-8; JENNINGS HJ, 1987, A VAN LEEUW J MICROB, V53, P519, DOI 10.1007/BF00415511; KAMERLING JP, 1975, BIOCHEM J, V151, P491, DOI 10.1042/bj1510491; KESSLER H, 1989, J MAGN RESON, V85, P1, DOI 10.1016/0022-2364(89)90314-4; KNIREL YA, 1988, BIOORG KHIM+, V14, P77; KOSMA P, 1987, CARBOHYD RES, V167, P39, DOI 10.1016/0008-6215(87)80266-5; KRASIKOVA IN, 1982, EUR J BIOCHEM, V126, P349; KULSHIN VA, 1992, J BACTERIOL, V174, P1793, DOI 10.1128/jb.174.6.1793-1800.1992; LERNER L, 1986, J MAGN RESON, V69, P375, DOI 10.1016/0022-2364(86)90091-0; MANDRELL RE, 1991, J BACTERIOL, V173, P2823, DOI 10.1128/JB.173.9.2823-2832.1991; MANDRELL RE, 1977, INFECT IMMUN, V16, P471, DOI 10.1128/IAI.16.2.471-475.1977; MICHON F, 1990, J BIOL CHEM, V265, P7243; POZSGAY V, 1991, BIOORG MED CHEM LETT, V1, P391, DOI 10.1016/S0960-894X(00)80262-0; SABESAN S, 1986, J AM CHEM SOC, V108, P2068, DOI 10.1021/ja00268a056; TSAI CM, 1991, INFECT IMMUN, V59, P3604, DOI 10.1128/IAI.59.10.3604-3609.1991; ZOLLINGER WD, 1980, INFECT IMMUN, V28, P451; ZOLLINGER WD, 1977, INFECT IMMUN, V18, P424, DOI 10.1128/IAI.18.2.424-433.1977	33	87	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14146	14152						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314780				2022-12-27	WOS:A1993LJ82500055
J	HISCOCK, DRR; YANAGISHITA, M; HASCALL, VC				HISCOCK, DRR; YANAGISHITA, M; HASCALL, VC			NUCLEAR-LOCALIZATION OF GLYCOSAMINOGLYCANS IN RAT OVARIAN GRANULOSA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCAN; INTRACELLULAR DEGRADATIVE PATHWAYS; BINDING; LIVER; IDENTIFICATION; TRANSCRIPTION; HEPATOCYTES; METABOLISM; RECEPTOR	In rat ovarian granulosa cell cultures, internalized cell surface heparan sulfate is processed by either a fast lysosome-mediated pathway or by a slow pathway which generates glycosaminoglycan fragments. Cell-associated dermatan sulfate proteoglycans also undergo processing through analogous pathways, although the slow pathway does not involve endoglycosidic cleavage of the dermatan sulfate chains. In the present study we tested whether intracellular glycosaminoglycan fragments in rat ovarian granulosa cells were transient residents of the nuclei. A technique for isolating nuclei was devised in which cells were lysed with a hypo-osmotic extraction buffer containing detergent. Nuclei were then purified by conventional methods, and final preparations gave excellent recovery of the starting DNA (similar to 90%). The technique was used to isolate glycosaminoglycans from nuclei after cells were metabolically radiolabeled with [S-35]sulfate. The results indicated the possible presence of dermatan sulfate, but not heparan sulfate, glycosaminoglycans at this location. Failure to remove cell surface proteoglycans with trypsin before preparation of nuclei resulted in nuclear contamination with significant amounts of intact dermatan sulfate proteoglycans. Nuclei preparations obtained using traditional homogenization steps from cells either treated without or with trypsin gave identical results except that recoveries of DNA were much lower (similar to 30%). The results demonstrate the difficulty in isolating pure nuclei and therefore also of firm conclusions pertaining to the nuclear association of glycosaminoglycans.			HISCOCK, DRR (corresponding author), NIDR,BONE RES BRANCH,PROTEOGLYCAN CHEM SECT,BETHESDA,MD 20892, USA.							BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BUSCH SJ, 1992, J CELL BIOL, V116, P31, DOI 10.1083/jcb.116.1.31; CAREY DJ, 1987, J BIOL CHEM, V262, P3376; CARLSON DM, 1968, J BIOL CHEM, V243, P616; FEDARKO NS, 1989, J CELL PHYSIOL, V139, P287, DOI 10.1002/jcp.1041390210; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; FURUKAWA K, 1983, BIOCHIM BIOPHYS ACTA, V740, P466, DOI 10.1016/0167-4781(83)90096-9; FURUKAWA K, 1977, BIOCHIM BIOPHYS ACTA, V499, P278, DOI 10.1016/0304-4165(77)90010-1; GALLAGHER JT, 1992, GLYCOBIOLOGY, V2, P523, DOI 10.1093/glycob/2.6.523; GRAHAM JM, 1990, ANAL BIOCHEM, V187, P318, DOI 10.1016/0003-2697(90)90463-J; HEUSER JE, 1980, J CELL BIOL, V86, P212, DOI 10.1083/jcb.86.1.212; ISHIHARA M, 1989, J CELL PHYSIOL, V138, P467, DOI 10.1002/jcp.1041380305; ISHIHARA M, 1986, J BIOL CHEM, V261, P3575; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TYRRELL DJ, 1993, J BIOL CHEM, V268, P4684; WESTERGRENTHORSSON G, 1991, J CELL PHYSIOL, V147, P523, DOI 10.1002/jcp.1041470319; YANAGISHITA M, 1989, J BIOL CHEM, V264, P17551; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9505; YANAGISHITA M, 1979, J BIOL CHEM, V254, P2355; YANAGISHITA M, 1984, J BIOL CHEM, V259, P270; YANAGISHITA M, 1987, BIOL PROTEOGLYCANS, P105; YANAGISHITA M, 1984, J BIOL CHEM, V259, P1260; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	30	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4539	4546						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308024				2022-12-27	WOS:A1994MW98900096
J	QUEST, AFG; BARDES, ESG; BELL, RM				QUEST, AFG; BARDES, ESG; BELL, RM			A PHORBOL ESTER BINDING DOMAIN OF PROTEIN KINASE-C-GAMMA - HIGH-AFFINITY BINDING TO A GLUTATHIONE-S-TRANSFERASE/CYS2 FUSION PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-100 MIXED MICELLES; REGULATORY DOMAIN; 2ND MESSENGERS; DILUTE-SOLUTION; LIPID-BINDING; N-CHIMAERIN; ACTIVATION; DIACYLGLYCEROL; PHOSPHATIDYLSERINE; CALCIUM	Cysteine-rich regions of protein kinase C (PKC) are implicated in diacylglycerol-dependent regulation of kinase activity. The second cysteine-rich region (residues 92-173) of PKCgamma was expressed as a fusion protein with glutathione-S-transferase in Escherichia coli and purified to homogeneity by affinity chromatography. This fusion protein displayed high affinity phorbol dibutyrate (PDBu) binding (K(d) 23 nM). The phosphatidylserine dependence of PDBu binding was highly cooperative with Hill numbers (near 4.5) similar to those previously reported for PKCgamma (Burns, D. J., and Bell, R. M. (1991) J. Biol. Chem. 266,18330-18338). The fusion protein specifically bound 4beta-hydroxy-PDBu but not the 4alpha-stereoisomer. Furthermore, sn-1,2-dioctanoylglycerol (diC8) stereoselectively competed for PDBu binding. The cysteine-rich region was sufficient for association of the fusion protein to liposome preparations containing phosphatidylserine and phosphatidylcholine. Association was significantly enhanced in a stereospecific manner by the presence of PDBu as well as diC8. These results establish that a single cysteine-rich domain (residues 92-173) of PKCgamma contains regions necessary and sufficient for lipid-dependent stereospecific interactions with PDBu and diC8. Furthermore, the region is sufficient to confer translocation of a fusion protein to liposomes in a PDBu- and diC8-dependent fashion. Thus, a single cysteine-rich region of PKCgamma displays many of the properties characteristic of PKC.	DUKE UNIV, MED CTR, CELL GROWTH REGULAT & ONCOGENESIS SECT, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University; Duke University					NIGMS NIH HHS [GM 38737] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038737] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; BELL RM, 1991, J BIOL CHEM, V266, P4661; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BONI LT, 1985, J BIOL CHEM, V260, P819; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; BURNS DJ, 1992, PROTEIN KINASE C CUR, P25; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; EBELING JG, 1985, P NATL ACAD SCI USA, V82, P815, DOI 10.1073/pnas.82.3.815; EXTON JH, 1990, J BIOL CHEM, V265, P1; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; GANONG BR, 1986, P NATL ACAD SCI USA, V83, P1184, DOI 10.1073/pnas.83.5.1184; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HANNUN YA, 1987, METHOD ENZYMOL, V141, P287; HANNUN YA, 1986, J BIOL CHEM, V261, P9341; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; HUBBARD SR, 1991, SCIENCE, V254, P1776; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KISHIMOTO A, 1980, J BIOL CHEM, V255, P2273; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MH, 1986, J BIOL CHEM, V261, P4867; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; LEYTON L, 1989, J CELL BIOL, V108, P2163, DOI 10.1083/jcb.108.6.2163; MAKOWSKE M, 1989, J BIOL CHEM, V264, P16155; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MICHELL RH, 1992, TRENDS BIOCHEM SCI, V17, P274, DOI 10.1016/0968-0004(92)90433-A; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PREISS J, 1986, J BIOL CHEM, V261, P8597; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; RANDO RR, 1988, FASEB J, V2, P2348, DOI 10.1096/fasebj.2.8.3282960; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; SIMONS PC, 1977, ANAL BIOCHEM, V82, P334, DOI 10.1016/0003-2697(77)90169-5; SOSSIN WS, 1992, J NEUROSCI, V12, P1160; SOUVIGNET C, 1991, J BIOL CHEM, V266, P40; TAKAI Y, 1979, BIOCHEM BIOPH RES CO, V91, P1218, DOI 10.1016/0006-291X(79)91197-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WELLING GW, 1985, FEBS LETT, V188, P215, DOI 10.1016/0014-5793(85)80374-4; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; White DA, 1973, FORM FUNCTION PHOSPH, P441; WILLOTT E, 1992, AM J PHYSIOL, V262, pC1119, DOI 10.1152/ajpcell.1992.262.5.C1119; WOLF M, 1985, NATURE, V317, P546, DOI 10.1038/317546a0	62	90	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2953	2960						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300627				2022-12-27	WOS:A1994MV43200086
J	KOMATSU, H; TAWADA, K				KOMATSU, H; TAWADA, K			MICROHETEROGENEITY AROUND THE REACTIVE LYSINE RESIDUE IN THE MYOSIN HEAVY-CHAIN FROM RABBIT SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBFRAGMENT-1; SEQUENCE; FRAGMENT	A molecule of myosin subfragment 1 (S1) from rabbit skeletal muscle has one highly reactive lysine residue, Lys-83 (RLR), in the heavy chain, which is rapidly and stoichiometrically modified by trinitrobenzenesulfonate. Our previous kinetic study (Komatsu, H., Emoto, Y., and Tawada, K. (1993) J. Biol. Chem. 268, 7799-7808) showed that although MgPP(i) reduces the maximum number of trinitrophenylated RLR down to about 0.5 mol/mol of S1, this half-stoichiometric modification of RLR is not the result of any heterogeneity in the primary structure of S1. However, this result conflicts with a previous report in which the half-stoichiometric trinitrophenylation has been reported to be related to Pro/Ser microheterogeneity at the 78th residue position in the heavy chain of rabbit skeletal muscle myosin. To resolve the conflict, we isolated peptides containing both the 78th residue and RLR from the two different preparations of S1, one whose RLR was trinitrophenylated in the presence of MgPP(i) and the other whose RLR was not trinitrophenylated in the presence of MgPP(i), and then we determined the amino acid sequences of the peptides. We found the same Pro/Ser microheterogeneity at the 78th position in the peptides from these S1s and thus concluded that this microheterogeneity has no correlation to the half-stoichiometric trinitrophenylation of RLR.	KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN; KYUSHU UNIV,GRAD SCH MED SCI,DEPT MOLEC BIOL,FUKUOKA 812,JAPAN	Kyushu University; Kyushu University								FABIAN F, 1968, BIOCHIM BIOPHYS ACTA, V162, P596, DOI 10.1016/0005-2728(68)90065-0; Inoue A, 1979, Adv Biophys, V13, P1; KOMATSU H, 1993, J BIOL CHEM, V268, P7799; KUBO S, 1960, J BIOL CHEM, V235, P2835; MIYANISHI T, 1981, J BIOCHEM, V89, P831, DOI 10.1093/oxfordjournals.jbchem.a133266; MIYANISHI T, 1982, J BIOCHEM-TOKYO, V91, P1845, DOI 10.1093/oxfordjournals.jbchem.a133881; MIYANISHI T, 1979, J BIOCHEM, V85, P747; MORNET D, 1989, J MUSCLE RES CELL M, V10, P10, DOI 10.1007/BF01739853; OKUYAMA T, 1960, J BIOCHEM-TOKYO, V47, P454, DOI 10.1093/oxfordjournals.jbchem.a127083; PERRY SV, 1955, METHOD ENZYMOL, V2, P582, DOI 10.1016/S0076-6879(55)02258-1; SETTON A, 1988, J MUSCLE RES CELL M, V9, P132, DOI 10.1007/BF01773735; TONG SW, 1983, J BIOL CHEM, V258, P3100; TONG SW, 1990, J BIOL CHEM, V265, P4893; TONOMURA Y, 1986, ENERGY TRANSDUCING A, P5; TRAYER HR, 1988, BIOCHEMISTRY-US, V27, P5718, DOI 10.1021/bi00415a049; WAGNER PD, 1977, J MOL BIOL, V109, P455, DOI 10.1016/S0022-2836(77)80023-5; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0	17	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16974	16978						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349587				2022-12-27	WOS:A1993LQ98800017
J	MORRISON, DK; HEIDECKER, G; RAPP, UR; COPELAND, TD				MORRISON, DK; HEIDECKER, G; RAPP, UR; COPELAND, TD			IDENTIFICATION OF THE MAJOR PHOSPHORYLATION SITES OF THE RAF-1 KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; COMPLETE CODING SEQUENCE; PROTEIN-KINASE; MAP KINASE; SIGNAL TRANSDUCTION; TYROSINE PHOSPHORYLATION; REGULATORY PHOSPHORYLATION; TRANSFORMING ACTIVITY; 3T3 CELLS; V-RAF	Treatment of cells with various growth factors and mitogens results in the rapid hyperphosphorylation and activation of the Raf-1 kinase. To determine if phosphorylation events affect Raf-1 activity, we have initiated experiments to identify the phosphorylation sites of Raf-1. In this report, we find that Ser43, Ser259, and Ser621 are the major sites of Raf-1 which are phosphorylated in mammalian cells and in Sf9 insect cells infected with a recombinant baculovirus encoding human Raf-1. Mutant Raf-1 proteins lacking kinase activity are also phosphorylated on these sites in vivo, indicating that these phosphorylation events are not a consequence of autophosphorylation. Furthermore, we find that Thr268 is the predominant Raf-1 residue phosphorylated in in vitro autokinase assays. In addition, we have examined the biochemical activity of baculovirus-expressed Raf-1 proteins containing mutations at these phosphorylation sites. In in vitro protein kinase assays Ser259 mutant proteins were 2-fold more active than wild-type Raf-1 and Ser621 mutant proteins were inactive as kinases. Analysis of the residues surrounding Ser259 and Ser621 indicates that RSXSAP may be a consensus sequence for the kinase responsible for phosphorylation of Raf-1 at these sites. Interestingly, these RSXSXP sequences are completely conserved throughout evolution in all Raf family members.	NCI, FREDERICK CANC RES & DEV CTR, VIRAL CARCINOGENESIS LAB, VIRAL PATHOL SECT, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	MORRISON, DK (corresponding author), NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA.				NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; COPELAND TD, 1986, J IMMUNOL, V137, P2945; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HEIDECKER G, 1989, GENES SIGNAL TRANSDU, P339; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; ISHIKAWA F, 1988, ONCOGENE, V3, P653; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEGUELLEC R, 1991, BIOL CELL, V72, P39, DOI 10.1016/0248-4900(91)90076-Y; MCGEW BR, 1992, ONCOGENE, V7, P33; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORRISON DK, 1990, CANCER CELL-MON REV, V2, P377; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1987, ONCOGENES CANCER, P55; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SMITH MR, 1990, MOL CELL BIOL, V10, P3828, DOI 10.1128/MCB.10.7.3828; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; STORM SM, 1990, ONCOGENE, V5, P345; Summers MD, 1987, MANUAL METHODS BACUL; SWEET LJ, 1990, MOL CELL BIOL, V10, P2413, DOI 10.1128/MCB.10.5.2413; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922	59	293	298	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17309	17316						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349614				2022-12-27	WOS:A1993LQ98800064
J	ORDENTLICH, A; BARAK, D; KRONMAN, C; FLASHNER, Y; LEITNER, M; SEGALL, Y; ARIEL, N; COHEN, S; VELAN, B; SHAFFERMAN, A				ORDENTLICH, A; BARAK, D; KRONMAN, C; FLASHNER, Y; LEITNER, M; SEGALL, Y; ARIEL, N; COHEN, S; VELAN, B; SHAFFERMAN, A			DISSECTION OF THE HUMAN ACETYLCHOLINESTERASE ACTIVE-CENTER DETERMINANTS OF SUBSTRATE-SPECIFICITY - IDENTIFICATION OF RESIDUES CONSTITUTING THE ANIONIC SITE, THE HYDROPHOBIC SITE, AND THE ACYL POCKET	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN ACETYLCHOLINESTERASE; CATALYTIC CENTER; BINDING; ENZYME; MUTAGENESIS; HYDROLYSIS; ASSOCIATION; EXPRESSION; TRIMETHYL; SECRETION	Substrate specificity determinants of human acetylcholinesterase (HuAChE) were identified by combination of molecular modeling and kinetic studies with enzymes mutated in residues Trp-86, Trp-286, Phe-295, Phe-297, Tyr-337, and Phe-338. The substitution of Trp-86 by alanine resulted in a 660-fold decrease in affinity for acetythiocholine but had no effect on affinity for the isosteric uncharged substrate (3,3-dimethylbutylthioacetate). The results demonstrate that residue Trp-86 is the anionic site which binds, through cation-pi interactions, the quaternary ammonium of choline, and that of active center inhibitors such as edrophonium. The results also suggest that in the non-covalent complex, charged and uncharged substrates with a common acyl moiety (acetyl) bind to different molecular environments. The hydrophobic site for the alcoholic portion of the covalent adduct (tetrahedral intermediate) includes residues Trp-86, Tyr-337, and Phe-338, which operate through nonpolar and/or stacking interactions, depending on the substrate. Substrates containing choline but differing in the acyl moiety (acetyl, propyl, and butyryl) revealed that residues Phe-295 and Phe-297 determine substrate specificity of the acyl pocket for the covalent adducts. Phe-295 also determines substrate specificity in the non-covalent enzyme substrate complex and thus, the HuAChE F295A mutant exhibits over 130-fold increase in the apparent bimolecular rate constant for butyrylthiocholine compared with wild type enzyme. Reactivity toward specific butyrylcholinesterase inhibitors is similarly dependent on the nature of residues at positions 295 and 297. Amino acid Trp-286 at the rim of the active site ''gorge'' and Trp-86, in the active center, are essential elements in the mechanism of inhibition by propidium, a peripheral anionic site ligand. Molecular modeling and kinetic data suggest that a cross-talk between Trp-286 and Trp-86 can result in reorientation of Trp-86 which may then interfere with stabilization of substrate enzyme complexes. It is proposed that the conformational flexibility of aromatic residues generates a plasticity in the active center that contributes to the high efficiency of AChE and its ability to respond to external stimuli.	ISRAEL INST BIOL RES, DEPT BIOCHEM, IL-70450 NESS ZIONA, ISRAEL; ISRAEL INST BIOL RES, DEPT ORGAN CHEM, IL-70450 NESS ZIONA, ISRAEL									AUGUSTINSSON KB, 1949, SCIENCE, V110, P98, DOI 10.1126/science.110.2847.98; BARAK D, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P195; BARNETT P, 1977, J BIOL CHEM, V252, P7200; BAZELYANSKY M, 1986, BIOCHEMISTRY-US, V25, P125, DOI 10.1021/bi00349a019; BENSCHOP HP, 1988, ACCOUNTS CHEM RES, V21, P368, DOI 10.1021/ar00154a003; BERMAN HA, 1981, BIOCHEMISTRY-US, V20, P4803, DOI 10.1021/bi00519a043; BERMAN HA, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P149; BERMAN HA, 1986, BIOCHIM BIOPHYS ACTA, V872, P125, DOI 10.1016/0167-4838(86)90155-X; BERMAN HA, 1990, BIOCHEMISTRY-US, V29, P10640, DOI 10.1021/bi00499a010; BONE R, 1991, METHOD ENZYMOL, V202, P643; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CHANGEUX JP, 1966, MOL PHARMACOL, V2, P369; COHEN SG, 1985, J MED CHEM, V28, P1309, DOI 10.1021/jm00147a033; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FOURNIER D, 1992, J BIOL CHEM, V267, P14270; GIBNEY G, 1990, P NATL ACAD SCI USA, V87, P7546, DOI 10.1073/pnas.87.19.7546; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAREL M, 1992, P NATL ACAD SCI USA, V89, P10827, DOI 10.1073/pnas.89.22.10827; HAREL M, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P189; HASAN FB, 1980, J BIOL CHEM, V255, P3898; HOBBIGER F, 1969, BRIT J PHARMACOL, V37, P258, DOI 10.1111/j.1476-5381.1969.tb09543.x; HUCHO F, 1991, TRENDS PHARMACOL SCI, V12, P422; JARV J, 1976, EUR J BIOCHEM, V67, P315, DOI 10.1111/j.1432-1033.1976.tb10694.x; JARV J, 1984, BIOORG CHEM, V12, P259, DOI 10.1016/0045-2068(84)90010-5; KIEFFER B, 1986, FEBS LETT, V202, P91, DOI 10.1016/0014-5793(86)80655-X; KREIENKAMP HJ, 1991, P NATL ACAD SCI USA, V88, P6117, DOI 10.1073/pnas.88.14.6117; KRONMAN C, 1992, GENE, V121, P295, DOI 10.1016/0378-1119(92)90134-B; KRUPKA RM, 1966, BIOCHEMISTRY-US, V5, P1988, DOI 10.1021/bi00870a029; MACPHEEQUIGLEY K, 1985, J BIOL CHEM, V260, P2185; MASSOULIE J, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P285; MCCURDY A, 1992, J AM CHEM SOC, V114, P10314, DOI 10.1021/ja00052a031; NOLTE HJ, 1980, BIOCHEMISTRY-US, V19, P3705, DOI 10.1021/bi00557a011; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1992, BIOCHEMISTRY-US, V31, P9760, DOI 10.1021/bi00155a032; ROSENBERRY TL, 1975, P NATL ACAD SCI USA, V72, P3834, DOI 10.1073/pnas.72.10.3834; SALIH E, 1992, BIOCHEM J, V285, P451, DOI 10.1042/bj2850451; SAREL S, 1956, J AM CHEM SOC, V78, P5416, DOI 10.1021/ja01601a068; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHALK I, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P117; SCHNEIDER HJ, 1991, ANGEW CHEM INT EDIT, V30, P1417, DOI 10.1002/anie.199114171; SEPP A, 1991, BIOCHIM BIOPHYS ACTA, V1077, P407, DOI 10.1016/0167-4838(91)90558-H; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; SHAFFERMAN A, 1992, J BIOL CHEM, V267, P17640; SHAFFERMAN A, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P165; SOREQ H, 1990, P NATL ACAD SCI USA, V87, P9688, DOI 10.1073/pnas.87.24.9688; Strating J, 1936, RECL TRAV CHIM PAY-B, V55, P903; SUSSMAN JL, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P95; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; VELAN B, 1991, J BIOL CHEM, V266, P23977; VELAN B, 1991, CELL MOL NEUROBIOL, V11, P143, DOI 10.1007/BF00712806; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003; WEISE C, 1990, EMBO J, V9, P3885, DOI 10.1002/j.1460-2075.1990.tb07607.x; Wenzel FW, 1937, J AM CHEM SOC, V59, P1089, DOI 10.1021/ja01285a037	55	290	298	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17083	17095						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349597				2022-12-27	WOS:A1993LQ98800033
J	AGARWAL, A; SALEM, P; ROBBINS, KC				AGARWAL, A; SALEM, P; ROBBINS, KC			INVOLVEMENT OF P72(SYK), A PROTEIN-TYROSINE KINASE, IN FC-GAMMA RECEPTOR SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; T-CELL; CROSS-LINKING; ZETA-CHAIN; MONOCLONAL-ANTIBODIES; HUMAN-MONOCYTES; SRC FAMILY; U937 CELLS; PHOSPHORYLATION; ACTIVATION	Previous studies have demonstrated that multichain immune recognition receptors, such as the T-cell receptor, signal their occupancy by inducing tyrosine phosphorylation of cellular protein substrates. Type I and II receptors for the Fc portion of IgG are single-chain immune recognition receptors having external, trans-membrane, and cytoplasmic domains. In the present study, we have investigated the possibility that, upon engagement, Fcgamma receptors induce protein-tyrosine phosphorylation. Our findings reveal increased phosphorylation of a number of proteins on tyrosine residues after cross-linking of either high (FcgammaRI) or low (FcgammaRII) affinity receptors expressed on HL60 cells. Engagement of FcgammaRII induced rapid tyrosine phosphorylation that decayed to basal levels by 40 min. In contrast, phosphorylation induced by FcgammaRI cross-linking was more delayed, peaking at 5-10 min, and returning to basal levels by 60 min. Kinase assays of cellular proteins immunoprecipitated from lysates of activated cells by antibody to phosphotyrosine revealed phosphorylation of a 72-kDa molecule that was not present in lysates of resting cells. This phosphoprotein was identified as p72syk by immunoprecipitation with antibodies directed against two different regions of the syk gene product. Immunoprecipitation with antibodies against p72syk followed by immunoblotting with anti-phosphotyrosine antibodies revealed an activation-dependent tyrosine phosphorylation of p72syk. Thus, our present findings demonstrate induction of protein-tyrosine phosphorylation following engagement of monomeric immune recognition receptors and identify p72syk as a tyrosine kinase substrate involved in signaling by FcgammaRI and FcgammaRII.	NIDR, CELLULAR DEV & ONCOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								ANDERSON CL, 1986, J BIOL CHEM, V261, P2856; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; CAMBIER JC, 1992, CURR OPIN IMMUNOL, V4, P257, DOI 10.1016/0952-7915(92)90074-O; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; EINSPAHR KJ, 1991, P NATL ACAD SCI USA, V88, P6279, DOI 10.1073/pnas.88.14.6279; EISEMAN E, 1992, NATURE, V355, P78; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; GUYRE PM, 1989, J IMMUNOL, V143, P1650; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; LOONEY RJ, 1986, J IMMUNOL, V136, P1641; MACINTYRE EA, 1989, J IMMUNOL, V142, P2377; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P350, DOI 10.1073/pnas.88.2.350; RANKIN BM, 1993, J IMMUNOL, V150, P605; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; STENGELIN S, 1988, EMBO J, V7, P1053, DOI 10.1002/j.1460-2075.1988.tb02913.x; STUART SG, 1989, EMBO J, V8, P3657, DOI 10.1002/j.1460-2075.1989.tb08540.x; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; VANDEWINKEL JGJ, 1990, SCAND J IMMUNOL, V31, P315; VIVIER E, 1991, J IMMUNOL, V146, P206; WANGE RL, 1992, J BIOL CHEM, V267, P11685; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	37	138	143	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15900	15905						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340414				2022-12-27	WOS:A1993LN30500082
J	MUNCHPETERSEN, B; TYRSTED, G; CLOOS, L				MUNCHPETERSEN, B; TYRSTED, G; CLOOS, L			REVERSIBLE ATP-DEPENDENT TRANSITION BETWEEN 2 FORMS OF HUMAN CYTOSOLIC THYMIDINE KINASE WITH DIFFERENT ENZYMATIC-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED HUMAN-LYMPHOCYTES; HUMAN DEOXYTHYMIDINE KINASE; ACUTE MYELOCYTIC-LEUKEMIA; CELL-CYCLE; SUBSTRATE-SPECIFICITY; MESSENGER-RNA; DNA-SYNTHESIS; BLAST CELLS; PURIFICATION; PLACENTA	Human cytosolic thymidine kinase, subunit molecular mass about 24 kDa, is a tetramer in the presence of ATP but a dimer in the presence of thymidine or without substrates. The pure, substrate-free enzyme showed complex, non-hyperbolic thymidine substrate kinetics with an apparent K(m) of 15 muM. Incubation with ATP at 4-degrees-C induced a time-dependent transition to an enzyme form with hyperbolic kinetics and a 20-fold lower K(m) value for thymidine (0.7 muM) but the same maximal velocity as for cytosolic thymidine kinase (TK1) without ATP. Removal of the ATP by carboxymethyl chromatography reestablished the non-hyperbolic kinetics with the low affinity for thymidine (K(m(app)) = 12 muM), and this enzyme form could be reversed once more by ATP incubation to the high affinity enzyme form. Similar shifts could not be induced by thymidine. The activating effect of ATP depended on the concentration of enzyme protein in a linear manner. These results indicate that ATP is a positive effector of cytosolic thymidine kinase, controlling a kinetically slow transition between two molecular forms of the enzyme. A hypothetical reaction mechanism is presented to explain the complex kinetic behavior.	UNIV COPENHAGEN,PANUM INST,DEPT MED BIOCHEM & GENET BIOCHEM LAB C,DK-2200 COPENHAGEN,DENMARK	University of Copenhagen	MUNCHPETERSEN, B (corresponding author), ROSKILDE UNIV CTR,DEPT BIOL & CHEM 1,BOX 260,DK-4000 ROSKILDE,DENMARK.							COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; ELLIMS PH, 1982, MOL CELL BIOCHEM, V45, P113; FERRARO P, 1992, EXP CELL RES, V199, P349, DOI 10.1016/0014-4827(92)90444-D; GAN TE, 1983, J BIOL CHEM, V258, P7000; HOLDEN L, 1980, EUR J CANCER, V16, P115, DOI 10.1016/0014-2964(80)90116-4; ITO M, 1990, J BIOL CHEM, V265, P6954; KAUFFMAN MG, 1991, MOL CELL BIOL, V11, P2538, DOI 10.1128/MCB.11.5.2538; KAUFFMAN MG, 1991, ONCOGENE, V6, P1427; KIT S, 1976, MOL CELL BIOCHEM, V11, P161, DOI 10.1007/BF01744997; KOFOED ML, 1986, PHOTODERMATOLOGY, V3, P158; LEE LS, 1976, J BIOL CHEM, V251, P2600; LEE LS, 1976, BIOCHEMISTRY-US, V15, P3686, DOI 10.1021/bi00662a007; MUNCHPETERSEN B, 1984, MOL CELL BIOCHEM, V64, P173; MUNCHPETERSEN B, 1991, J BIOL CHEM, V266, P9032; MUNCHPETERSEN B, 1977, BIOCHIM BIOPHYS ACTA, V478, P364, DOI 10.1016/0005-2787(77)90152-6; MUNCHPETERSEN B, 1990, LEUKEMIA RES, V14, P39, DOI 10.1016/0145-2126(90)90144-X; PIPER AA, 1980, BIOCHIM BIOPHYS ACTA, V633, P400, DOI 10.1016/0304-4165(80)90198-1; Plagemann P.G.W., 1980, CURR TOP MEMBR TRANS, P225; SHERLEY JL, 1988, J BIOL CHEM, V263, P375; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; TAMIYA N, 1989, BIOCHIM BIOPHYS ACTA, V995, P28, DOI 10.1016/0167-4838(89)90229-X; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025	22	70	74	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15621	15625						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340387				2022-12-27	WOS:A1993LN30500046
J	VASU, SK; KEDERSHA, NL; ROME, LH				VASU, SK; KEDERSHA, NL; ROME, LH			CDNA CLONING AND DISRUPTION OF THE MAJOR VAULT PROTEIN-ALPHA GENE (MVPA) IN DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN GENE; TRANSFORMATION; EXPRESSION; SEQUENCE; GENERATION; NUMBER; CELLS; RNA	Vaults are large cytoplasmic ribonucleoprotein particles found in nearly all eukaryotic cells. Dictyostelium vaults contain two major proteins, MVPalpha (94.2 kDa) and MVPbeta (approximately 92 kDa). Using an anti-rat vault antibody, we screened a Dictyostelium cDNA expression library and isolated a 2.8-kilobase pair clone that contained a single full-length reading frame. The identity of the clone was established by the presence of a predicted 20-amino acid sequence identical to that found in a peptide sequenced from purified MVPalpha. We have disrupted the single copy gene using homologous recombination and have demonstrated a loss of MVPalpha. Although the cells still produce MVPbeta, they do not contain characteristic vault particles, suggesting that MVPalpha is required for normal vault structure. These cells should be a valuable tool for elucidating the function of vaults.	UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, 33-257 CHS, LOS ANGELES, CA 90024 USA; IMMUNOGEN INC, CAMBRIDGE, MA 02139 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; ImmunoGen, Inc.			Rome, Leonard H/E-8786-2016	Rome, Leonard H/0000-0002-1236-2063	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038097] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38097] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHUGANI D C, 1991, Journal of Cell Biology, V115, p458A; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COHEN SM, 1986, EMBO J, V5, P3361, DOI 10.1002/j.1460-2075.1986.tb04651.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DORING V, 1991, J BIOL CHEM, V266, P17509; EGELHOFF TT, 1991, METHOD ENZYMOL, V196, P319; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; KEDERSHA NL, 1991, J CELL BIOL, V112, P225, DOI 10.1083/jcb.112.2.225; KEDERSHA NL, 1990, J CELL BIOL, V110, P895, DOI 10.1083/jcb.110.4.895; KEDERSHA NL, 1986, J CELL BIOL, V103, P699, DOI 10.1083/jcb.103.3.699; KICKHOEFER VA, 1993, J BIOL CHEM, V268, P7868; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KNECHT DA, 1990, DEV GENET, V11, P403, DOI 10.1002/dvg.1020110513; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; NELLEN W, 1985, GENE, V39, P155, DOI 10.1016/0378-1119(85)90309-9; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; Rome L, 1991, Trends Cell Biol, V1, P47, DOI 10.1016/0962-8924(91)90088-Q; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPUDICH JA, 1987, METHOD CELL BIOL, V28, P9; VIERA J, 1987, METHOD ENZYMOL, V153, P3	24	42	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15356	15360						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340365				2022-12-27	WOS:A1993LN30500009
J	HSU, LC; HU, MC; CHENG, HC; LU, JC; CHUNG, BC				HSU, LC; HU, MC; CHENG, HC; LU, JC; CHUNG, BC			THE N-TERMINAL HYDROPHOBIC DOMAIN OF P450C21 IS REQUIRED FOR MEMBRANE INSERTION AND ENZYME STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID 21-HYDROXYLASE DEFICIENCY; ESCHERICHIA-COLI; AMINO-ACIDS; CYTOCHROME-P-450; EXPRESSION; PROTEINS; SIGNAL; MUTATION; ORIENTATION; SEQUENCE	Microsomal cytochromes P-450 are known to be integrated into smooth endoplasmic reticulum through their hydrophobic sequences located at the N termini. The length requirement of the membrane insertion signal was determined by the generation of six plasmids encoding mutant P450c21 that lacked various portions of the N-terminal hydrophobic domains. When they were transcribed and translated in vitro in the presence of endoplasmic reticulum membranes, mutant protein lacking more than a third of the first hydrophobic domain gradually lost the ability to insert into the membrane and stayed mostly in the soluble fraction when the first N-terminal hydrophobic domain was removed. The steady-state amount of the truncated proteins was progressively reduced in parallel to the extent of their N-terminal deletions, due to their fast degradation. This process was accompanied by a decrease in the enzymatic activity. Therefore, the first hydrophobic domain of P450c21 not only serves as a membrane targeting and anchoring domain, but it is also important for the in vivo protein stability.	ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN	Academia Sinica - Taiwan				Chung, Bon-chu/0000-0002-8612-0219; HU, MENG-CHUN/0000-0002-2783-5687; Hsu, Li-Chung/0000-0001-7206-5231; Cheng, Hsu-Chen/0000-0002-6586-6425				AMOR M, 1988, P NATL ACAD SCI USA, V85, P1600, DOI 10.1073/pnas.85.5.1600; BARNES HJ, 1992, J BASIC CLIN PHYSL S, V3, P13; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; CHIOU SH, 1990, J BIOL CHEM, V265, P3549; CLARK BJ, 1991, J BIOL CHEM, V266, P5898; DASMAHAPATRA B, 1987, NUCLEIC ACIDS RES, V15, P3933, DOI 10.1093/nar/15.9.3933; ELIASSON E, 1992, J BIOL CHEM, V267, P15765; FALETTO MB, 1992, J BIOL CHEM, V267, P2032; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HIGASHI Y, 1988, P NATL ACAD SCI USA, V85, P7486, DOI 10.1073/pnas.85.20.7486; HU MC, 1990, MOL ENDOCRINOL, V4, P893, DOI 10.1210/mend-4-6-893; LARSON JR, 1991, J BIOL CHEM, V266, P7321; LI YC, 1991, J BIOL CHEM, V266, P19186; MILLER WL, 1989, ANNU REV GENET, V23, P371, DOI 10.1146/annurev.ge.23.120189.002103; MILLER WL, 1987, J PEDIATR-US, V111, P1, DOI 10.1016/S0022-3476(87)80334-7; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; NELSON DR, 1988, J BIOL CHEM, V263, P6038; PAKULA AA, 1989, ANNU REV GENET, V23, P289, DOI 10.1146/annurev.ge.23.120189.001445; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RICKETTS MH, 1992, BIOCHEM BIOPH RES CO, V186, P426, DOI 10.1016/S0006-291X(05)80825-3; SAKAGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P3361, DOI 10.1073/pnas.81.11.3361; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; SPEISER PW, 1992, J CLIN INVEST, V90, P584, DOI 10.1172/JCI115897; SZCZESNASKORUPA E, 1988, P NATL ACAD SCI USA, V85, P738, DOI 10.1073/pnas.85.3.738; SZCZESNASKORUPA E, 1989, J CELL BIOL, V108, P1237, DOI 10.1083/jcb.108.4.1237; TUSIELUNA MT, 1991, MOL ENDOCRINOL, V5, P685, DOI 10.1210/mend-5-5-685; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WEDELL A, 1992, P NATL ACAD SCI USA, V89, P7232, DOI 10.1073/pnas.89.15.7232; WHITE PC, 1988, P NATL ACAD SCI USA, V85, P4436, DOI 10.1073/pnas.85.12.4436; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WU DA, 1991, J CLIN INVEST, V88, P519, DOI 10.1172/JCI115334	31	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14682	14686						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325846				2022-12-27	WOS:A1993LL75900026
J	BOKMAN, AM; JIMENEZBARBERO, J; LLINAS, M				BOKMAN, AM; JIMENEZBARBERO, J; LLINAS, M			H-1-NMR CHARACTERIZATION OF THE UROKINASE KRINGLE MODULE - STRUCTURAL, BUT NOT FUNCTIONAL, RELATEDNESS TO HOMOLOGOUS DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON MAGNETIC-RESONANCE; HUMAN-PLASMINOGEN KRINGLE-4; AROMATIC H-1-NMR SPECTRUM; BINDING-SITE; ESCHERICHIA-COLI; LIGAND-BINDING; LYSINE-BINDING; FIBRIN-BINDING; OVERHAUSER EXPERIMENTS; MOLECULAR-CLONING	The human urokinase (uPA) kringle (K) domain has been characterized via high resolution NMR spectroscopy. The H-1 spectrum is analogous to that of the K2 domain of tissue-type plasminogen activator (tPA) and other homologous domains from the plasminogen (Pgn) heavy chain. This indicates a similar folding for the uPA/K. Comparisons of the high-field methyl and aromatic regions of the uPA/K and tPA/K2 spectra against those from the Pgn/K1 and K4 homologues afford the immediate assignment of signals stemming from conserved residues, such as the characteristic high-field shifted Leu46 delta,delta'-methyl doublets, and the aromatic side chains at the hydrophobic core, in particular those from Trp25, His48a, Tyr50, and Trp62. Resonances unresolved due to spectral overlaps in the H-1-H-1 correlated two-dimensional spectra were identified via a natural abundance H-1-C-13 single/multiple quantum correlated experiment. Spin systems unique to the uPA/K, such as His7, His37, His40, and His78, were assigned from Overhauser experiments and sequence information. Acid/base titrations of His imidazole signals in (H2O)-H-2 yielded pK(a)* (pK(a) determined from acid/base titration in (H2O)-H-2, uncorrected for deuterium isotope effects) values of 6.2 for His7, 6.3 for His37, 6.4 for His40, 4.1 for His48a, and 6.2 for His78, which suggests a significant structural protection for His48a, consistent with a buried location within the hydrophobic core. Binding of low molecular weight heparin to the uPA/K in (H2O)-H-2 affects mainly the His37, His40, His48a, and Tyr 50 resonances, in a concerted and saturable fashion (association constant approximately 58 mM-1). The absence of perturbation of the His7 and His78 side chains indicates that segment 37-50 is selectively sensitive to heparin binding. Thus, the kringle outer B-loop is likely to be proximal to the basic residues responsible for the interaction with the polyanion ligand.	CARNEGIE MELLON UNIV, DEPT CHEM, PITTSBURGH, PA 15213 USA; CSIC, INST QUIM ORGAN, JUAN CIERVA 3, E-28006 MADRID, SPAIN	Carnegie Mellon University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Organica General (IQOG)			JIMENEZ-BARBERO, JESUS/D-4431-2014	JIMENEZ-BARBERO, JESUS/0000-0001-5421-8513	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029409] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-29409] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATKINSON RA, 1990, J MOL BIOL, V212, P541, DOI 10.1016/0022-2836(90)90330-O; BLASI F, 1988, Fibrinolysis, V2, P73, DOI 10.1016/0268-9499(88)90370-0; BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; BOGUSKY MJ, 1989, BIOCHEMISTRY-US, V28, P6728, DOI 10.1021/bi00442a028; BRUNGER AT, 1988, X PLOR VERSION 3 0 U; BYEON IJL, 1989, BIOCHEMISTRY-US, V28, P9350, DOI 10.1021/bi00450a016; BYEON IJL, 1991, J MOL BIOL, V222, P1035, DOI 10.1016/0022-2836(91)90592-T; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CASTELLINO FJ, 1981, J BIOL CHEM, V256, P4778; CLEARY S, 1989, BIOCHEMISTRY-US, V28, P1884, DOI 10.1021/bi00430a068; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEMARCO A, 1985, BIOCHEMISTRY-US, V24, P748, DOI 10.1021/bi00324a032; DEMARCO A, 1977, J MAGN RESON, V26, P527, DOI 10.1016/0022-2364(77)90104-4; DEMARCO A, 1985, BIOCHIM BIOPHYS ACTA, V827, P369, DOI 10.1016/0167-4838(85)90221-3; DEMARCO A, 1987, EUR BIOPHYS J BIOPHY, V14, P359, DOI 10.1007/BF00262321; DESERRANO VS, 1992, BIOCHEMISTRY-US, V31, P3326, DOI 10.1021/bi00128a004; DESERRANO VS, 1992, BIOCHEMISTRY-US, V31, P11698, DOI 10.1021/bi00162a005; DEVOS AM, 1992, BIOCHEMISTRY-US, V31, P270, DOI 10.1021/bi00116a037; FORSGREN M, 1987, FEBS LETT, V213, P254, DOI 10.1016/0014-5793(87)81501-6; GETTINS P, 1987, BIOCHEMISTRY-US, V26, P1391, DOI 10.1021/bi00379a027; GIRALT E, 1985, BIOORG CHEM, V13, P171, DOI 10.1016/0045-2068(85)90019-7; GLASOE PK, 1960, J PHYS CHEM-US, V64, P188, DOI 10.1021/j100830a521; GUNZLER WA, 1982, H-S Z PHYSIOL CHEM, V363, P1155, DOI 10.1515/bchm2.1982.363.2.1155; HOSCHWENDER SM, 1981, J BIOL CHEM, V256, P11172; KELLEY RF, 1989, BIOCHEMISTRY-US, V28, P4047, DOI 10.1021/bi00435a062; LERCH PG, 1980, BIOCHIM BIOPHYS ACTA, V625, P374, DOI 10.1016/0005-2795(80)90302-5; LI X, 1992, BIOCHEMISTRY-US, V31, P9562, DOI 10.1021/bi00155a008; LIJNEN HR, 1991, THROMB HAEMOSTASIS, V66, P88; LLINAS M, 1985, J BIOSCIENCE, V8, P121, DOI 10.1007/BF02703971; LLINAS M, 1983, EUR J BIOCHEM, V135, P379, DOI 10.1111/j.1432-1033.1983.tb07665.x; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MARKLEY JL, 1975, ACCOUNTS CHEM RES, V8, P70, DOI 10.1021/ar50086a004; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MENHART N, 1991, BIOCHEMISTRY-US, V30, P1948, DOI 10.1021/bi00221a031; MOTTA A, 1986, J BIOL CHEM, V261, P3684; MOTTA A, 1987, BIOCHEMISTRY-US, V26, P3827, DOI 10.1021/bi00387a014; MOTTA A, 1986, BIOCHEMISTRY-US, V25, P7924, DOI 10.1021/bi00372a021; MULICHAK AM, 1991, BIOCHEMISTRY-US, V30, P10576, DOI 10.1021/bi00107a029; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NOVOKHATNY VV, 1984, J MOL BIOL, V179, P215, DOI 10.1016/0022-2836(84)90466-2; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; PETROS AM, 1989, BIOCHEMISTRY-US, V28, P1368, DOI 10.1021/bi00429a064; PETROS AM, 1988, ARCH BIOCHEM BIOPHYS, V264, P192, DOI 10.1016/0003-9861(88)90585-1; POLLANEN J, 1991, ADV CANCER RES, V57, P273; RAMESH V, 1986, EUR J BIOCHEM, V159, P581, DOI 10.1111/j.1432-1033.1986.tb09925.x; RAMESH V, 1987, J MOL BIOL, V198, P481, DOI 10.1016/0022-2836(87)90295-6; REJANTE M, 1991, FIBRINOLYSIS, V5, P87, DOI 10.1016/0268-9499(91)90048-9; REJANTE MR, 1991, BIOCHEMISTRY-US, V30, P11081, DOI 10.1021/bi00110a010; REJANTE MR, 1992, THESIS CARNEGIE MELL; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; STEPHENS RW, 1992, BIOCHEMISTRY-US, V31, P7572, DOI 10.1021/bi00148a019; TALPAS CJ, 1991, BIOCHIM BIOPHYS ACTA, V1078, P208, DOI 10.1016/0167-4838(91)99011-G; THEWES T, 1987, BIOCHIM BIOPHYS ACTA, V912, P254, DOI 10.1016/0167-4838(87)90096-3; THEWES T, 1990, J BIOL CHEM, V265, P3906; THEWES T, 1988, EUR J BIOCHEM, V175, P237, DOI 10.1111/j.1432-1033.1988.tb14189.x; TREXLER M, 1982, J BIOL CHEM, V257, P7401; TREXLER M, 1983, P NATL ACAD SCI-BIOL, V80, P2457, DOI 10.1073/pnas.80.9.2457; TULINSKY A, 1988, J MOL BIOL, V202, P885, DOI 10.1016/0022-2836(88)90565-7; TULINSKY A, 1988, PROTEINS, V3, P85, DOI 10.1002/prot.340030203; VALI Z, 1984, J BIOL CHEM, V259, P3690; VANZONNEVELD AJ, 1986, J BIOL CHEM, V261, P14214; VERHEIJEN JH, 1986, EMBO J, V5, P3525, DOI 10.1002/j.1460-2075.1986.tb04678.x; WINKLER ME, 1985, BIO-TECHNOL, V3, P990, DOI 10.1038/nbt1185-990; WU TP, 1991, BIOCHEMISTRY-US, V30, P10589, DOI 10.1021/bi00107a030; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZUIDERWEG ERP, 1990, J MAGN RESON, V86, P346, DOI 10.1016/0022-2364(90)90265-B	68	16	16	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13858	13868						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314753				2022-12-27	WOS:A1993LJ82500017
J	HARDUINLEPERS, A; SHAPER, JH; SHAPER, NL				HARDUINLEPERS, A; SHAPER, JH; SHAPER, NL			CHARACTERIZATION OF 2 CIS-REGULATORY REGIONS IN THE MURINE BETA-1,4-GALACTOSYLTRANSFERASE GENE - EVIDENCE FOR A NEGATIVE REGULATORY ELEMENT THAT CONTROLS INITIATION AT THE PROXIMAL SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REPRESSION; GENOMIC STRUCTURE; MESSENGER-RNAS; MAMMARY-GLAND; EXPRESSION; PROTEIN; PROMOTER; BINDING; MOUSE; HORMONE	The beta1,4-galactosyltransferase (beta1,4-GT) gene is unusual in that it specifies, two mRNAs in somatic cells of 3.9 and 4.1 kilobases (kb). These two transcripts arise as a consequence of initiation at two different sets of start sites that are separated by approximately 200 base pairs. Translation of each mRNA results in the predicted synthesis of two related protein isoforms that differ only in the length of their NH2-terminal cytoplasmic domain (Russo, R. N., Shaper, N. L., and Shaper, J. H. (1990) J. Biol. Chem. 265, 3324-3331). In this study we show that the cellular requirement for beta1,4-GT correlate with the transcriptional start site used. In cells and tissues that express low transcript levels, the 4.1-kb transcriptional start site is apparently used exclusively. Increased transcription from the 4.1-kb start site plus low levels of transcription from the 3.9-kb start site result in the intermediate, beta1,4-GT transcript levels that are found in almost all somatic cell types. However, in mid- to late pregnant and lactating mammary glands very high transcript levels are observed, which correlate with the predominant use of the 3.9-kb transcriptional start site. To identify the cis-acting elements that regulate the use of the two transcriptional start sites, we constructed a series of beta1,4-GT/CAT hybrids and carried out transient transfection assays using mouse L cells and Drosophila SL2 cells. These studies have delineated both a distal and proximal regulatory region just upstream of the 4.1- and 3.9-kb transcriptional start sites, respectively. In addition, a negative cis-acting regulatory region was identified that represses transcription from the proximal site. These results suggest a model of transcriptional regulation in which the distal region functions as a housekeeping promoter while the proximal region functions as a mammary cell-specific promoter. Differential initiation from the two promoters is a mechanism for regulation of beta1,4-GT enzyme levels. The predictions from this model are consistent with the conclusion that both protein isoforms are functionally equivalent resident trans-Golgi membrane-bound enzymes.	JOHNS HOPKINS UNIV,CTR ONCOL,SCH MED,CELL STRUCT & FUNCT LAB,RM 1-127,600 N WOLFE ST,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University			Harduin-Lepers, Anne/O-7503-2017	Harduin-Lepers, Anne/0000-0002-1233-3799	NCI NIH HHS [CA45799] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045799] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BEYER TA, 1982, GLYCOCONJUGATES, V3, P25; Brew K, 1970, Essays Biochem, V6, P93; BRODBECK U, 1967, J BIOL CHEM, V242, P1391; BURDON T, 1991, J BIOL CHEM, V266, P6909; CATO ACB, 1992, PROG NUCLEIC ACID RE, V43, P1, DOI 10.1016/S0079-6603(08)61042-9; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU JL, 1991, J BIOL CHEM, V266, P24471; CHRETIEN S, 1988, P NATL ACAD SCI USA, V85, P6, DOI 10.1073/pnas.85.1.6; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DOPPLER W, 1991, MOL ENDOCRINOL, V5, P1624, DOI 10.1210/mend-5-11-1624; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; Hamprecht B, 1977, Int Rev Cytol, V49, P99; HARDUINLEPERS A, 1992, GLYCOBIOLOGY, V2, P361, DOI 10.1093/glycob/2.4.361; HATHAWAY HJ, 1992, J CELL BIOL, V117, P369, DOI 10.1083/jcb.117.2.369; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Hill R L, 1968, Brookhaven Symp Biol, V21, P139; HOLLIS GF, 1989, BIOCHEM BIOPH RES CO, V162, P1069, DOI 10.1016/0006-291X(89)90782-1; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LOPEZ LC, 1991, J BIOL CHEM, V266, P15984; LUBON H, 1988, BIOCHEM J, V256, P391, DOI 10.1042/bj2560391; MASIBAY AS, 1989, P NATL ACAD SCI USA, V86, P5733, DOI 10.1073/pnas.86.15.5733; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MENGLEGAW L, 1991, BIOCHEM BIOPH RES CO, V176, P1269, DOI 10.1016/0006-291X(91)90423-5; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MUNOZ B, 1989, MOL CELL ENDOCRINOL, V62, P23, DOI 10.1016/0303-7207(89)90109-3; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; NOWOCK J, 1985, NUCLEIC ACIDS RES, V13, P2045, DOI 10.1093/nar/13.6.2045; PIAGGIO G, 1990, FOCUS, V12, P83; PIETRINI G, 1992, J CELL BIOL, V117, P975, DOI 10.1083/jcb.117.5.975; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; RUSSO RN, 1990, J BIOL CHEM, V265, P3324; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; SCHIBLER U, 1987, ANNU REV GENET, V21, P237, DOI 10.1146/annurev.ge.21.120187.001321; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SHAH NP, 1991, MOL CELL BIOL, V11, P1854, DOI 10.1128/MCB.11.4.1854; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1990, P NATL ACAD SCI USA, V87, P791, DOI 10.1073/pnas.87.2.791; SHAPER NL, 1990, CYTOGENET CELL GENET, V54, P172, DOI 10.1159/000132987; SHUR B D, 1991, Glycobiology, V1, P563, DOI 10.1093/glycob/1.6.563; STRANGE R, 1991, CELL GROWTH DIFFER, V2, P549; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; TURKINGTON RW, 1968, J BIOL CHEM, V243, P3382; VILOTTE JL, 1992, GENE, V119, P287, DOI 10.1016/0378-1119(92)90285-W; WATSON CJ, 1991, NUCLEIC ACIDS RES, V19, P6603, DOI 10.1093/nar/19.23.6603; Zhou Ming-Dong, 1992, Gene Expression, V2, P127; ZUCKER M, 1981, NUCLEIC ACIDS RES, V9, P133	63	81	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14348	14359						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314795				2022-12-27	WOS:A1993LJ82500082
J	CARR, FE; WONG, NCW				CARR, FE; WONG, NCW			CHARACTERISTICS OF A NEGATIVE THYROID-HORMONE RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT GENE; RETINOIC ACID RECEPTORS; AUXILIARY PROTEIN; NUCLEAR RECEPTORS; PROMOTER ACTIVITY; T3 RECEPTOR; X-RECEPTOR; HALF-SITE; TATA BOX; BINDING	Thyroid hormones may stimulate or repress transcriptional activity depending upon the specific gene. Whereas, a palindromic DNA sequence, TREpal, mediates positive regulation by thyroid hormone, the negative response element (nT(3)RE) remains undefined. Therefore, we have examined the DNA sequences that mediate the inhibitory effects of thyroid hormone on the transcription of the beta-subunit gene of rat thyrotropin (rTSH beta). In rat pituitary tumor cells (GH(3)), transient expression of plasmid constructs containing the putative nT(3)RE of rTSH beta mediated negative regulation by L-triiodothyronine (T-3). Since this nT(3)RE contained sequences which resembled a half-site motif of the consensus T(3)RE and the idealized palindrome (TREpal), we tested a construct containing this half-site motif in the same cells. T-3 decreased the activity of this plasmid. Cotransfection studies in T-3-receptor (T(3)R)-deficient cells indicated that either alpha or beta isoforms of T(3)R were required for the inhibitory effects of the hormone. Both T(3)R isomers bind to DNA sequences containing the nT(3)RE from rTSH beta DNA or the half-site motif of TREpal. In summary, our results show that the repressive properties of T-3 are mediated by a nT(3)RE from rTSH beta. Unexpectedly, this motif resembles a half-site component of TREpal which enhances promoter activity in response to T-3.	UNIV CALGARY,DEPT MED & MED BIOCHEM,CALGARY T2N 4N1,AB,CANADA	University of Calgary	CARR, FE (corresponding author), WALTER REED ARMY MED CTR,DEPT CLIN INVEST,RES LABS,KYLE METAB UNIT,6800 GEORGIA AVE,WASHINGTON,DC 20307, USA.							BODENNER DL, 1991, J BIOL CHEM, V266, P21666; BRENT G A, 1989, New Biologist, V1, P329; BRENT GA, 1991, MOL ENDOCRINOL, V5, P542, DOI 10.1210/mend-5-4-542; BRENT GA, 1992, MOL ENDOCRINOL, V6, P502, DOI 10.1210/me.6.4.502; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1989, J BIOL CHEM, V264, P6886; CARR FE, 1992, J BIOL CHEM, V267, P18689; CARR FE, 1989, MOL ENDOCRINOL, V3, P709, DOI 10.1210/mend-3-4-709; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CHIN WW, 1993, RECENT PROG HORM RES, V48, P393; CRONE DE, 1990, J BIOL CHEM, V265, P10851; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; ROSEN ED, 1991, MOL CELL ENDOCRINOL, V78, pC83, DOI 10.1016/0303-7207(91)90175-R; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; THOMPSON KL, 1992, MOL ENDOCRINOL, V6, P627, DOI 10.1210/me.6.4.627; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WANG M, 1992, 74TH ANN M END SOC S; WONDISFORD FE, 1989, J BIOL CHEM, V264, P14601; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YEN PM, 1992, J BIOL CHEM, V267, P3565; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG X, 1991, MOL ENDOCRINOL, V5, P1909, DOI 10.1210/mend-5-12-1909; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	33	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4175	4179						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307979				2022-12-27	WOS:A1994MW98900044
J	DERUITER, GA; VANBRUGGENVANDERLUGT, AW; MISCHNICK, P; SMID, P; VANBOOM, JH; NOTERMANS, SHW; ROMBOUTS, FM				DERUITER, GA; VANBRUGGENVANDERLUGT, AW; MISCHNICK, P; SMID, P; VANBOOM, JH; NOTERMANS, SHW; ROMBOUTS, FM			2-O-METHYL-D-MANNOSE RESIDUES ARE IMMUNODOMINANT IN EXTRACELLULAR POLYSACCHARIDES OF MUCOR RACEMOSUS AND RELATED MOLDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-EXCHANGE CHROMATOGRAPHY; LINKED IMMUNOSORBENT-ASSAY; ABSIDIA-CYLINDROSPORA; LIQUID-CHROMATOGRAPHY; CARBOHYDRATE ANALYSIS; LIPOPOLYSACCHARIDES; PURIFICATION; STRAINS; LINKAGE; ELISA	In this study, the structure of the immunodominant carbohydrate epitope of the extracellular polysaccharides from mold species belonging to the order Mucorales reactive with rabbit IgG antibodies was elucidated. An exo-alpha-D-mannanase which was able to abolish the antigenicity of these polysaccharides completely was purified and characterized, and the activity was compared with that of an alpha-D-mannosidase. Analysis of the monomeric reaction products after enzymatic treatment revealed the presence of 2-O-methyl D-mannose residues. This compound is a constituent of the polysaccharides from the mold genera Mucor, Rhizopus, Rhizomucor, Absidia, Syncephalastrum, and Thamnidium, and its occurrence in fungi has not been reported until now. Two mannan fractions which are highly reactive with rabbit IgG were isolated from the extracellular polysaccharides of Mucor racemosus and characterized with ethylation analysis. The role of the newly found 2-O-methyl-D-mannose residues in the immunoreactivity was assessed by specific degradation of these mannans with the exo-alpha-D-mannanase and subsequent ethylation analysis. It was concluded that the immunodominant carbo hydrates reactive with rabbit IgG are chains composed of a single terminal non-reducing 2-O-methyl-D-mannose residue, alpha(1-2)-linked to a short sequence of alpha(1-2)linked D-mannose residues.	AGR UNIV WAGENINGEN,DEPT FOOD SCI,6703 HD WAGENINGEN,NETHERLANDS; UNIV HAMBURG,DEPT ORGAN CHEM,D-20146 HAMBURG,GERMANY; GORLAEUS LABS,DEPT ORGAN CHEM,2300 RA LEIDEN,NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT,WATER & FOOD MICROBIOL LAB,3720 BA BILTHOVEN,NETHERLANDS	Wageningen University & Research; University of Hamburg; Netherlands National Institute for Public Health & the Environment			Rombouts, Frans/F-9882-2011					BARTNICKI-GARCIA S, 1972, Carbohydrate Research, V23, P75, DOI 10.1016/S0008-6215(00)81579-7; BOWIE JU, 1984, CARBOHYD RES, V125, P301, DOI 10.1016/0008-6215(84)85165-4; CLAMP JR, 1965, BIOCHEM J, V94, P17, DOI 10.1042/bj0940017; Cole G. T., 1991, The fungal spore and disease initiation in plants and animals., P403; DERUITER GA, 1992, CARBOHYD POLYM, V18, P1, DOI 10.1016/0144-8617(92)90181-O; DERUITER GA, 1993, MYCOL RES, V97, P690, DOI 10.1016/S0953-7562(09)80149-4; DERUITER GA, 1993, TRENDS FOOD SCI TECH, V4, P91, DOI 10.1016/0924-2244(93)90089-S; DERUITER GA, 1992, ANAL BIOCHEM, V207, P176, DOI 10.1016/0003-2697(92)90520-H; DERUITER GA, 1993, J GEN MICROBIOL, V139, P1557, DOI 10.1099/00221287-139-7-1557; DERUITER GA, 1991, CARBOHYD RES, V215, P47, DOI 10.1016/0008-6215(91)84006-Z; DERUITER GA, 1992, ANTON LEEUW INT J G, V62, P189, DOI 10.1007/BF00582579; DERUITER GA, 1991, NATO ASI SERIES H, V53, P169; ENGLYST HN, 1984, ANALYST, V109, P937, DOI 10.1039/an9840900937; HAYASHI O, 1978, J GEN MICROBIOL, V108, P345, DOI 10.1099/00221287-108-2-345; HAYASHI O, 1978, J GEN MICROBIOL, V106, P289, DOI 10.1099/00221287-106-2-289; HEARN VM, 1980, MOL IMMUNOL, V17, P1097, DOI 10.1016/0161-5890(80)90106-6; JANSSON PE, 1976, PRACTICAL GUIDE METH, V8; KAUFMAN L, 1989, J CLIN MICROBIOL, V27, P1979, DOI 10.1128/JCM.27.9.1979-1982.1989; KEMPER MS, 1988, THESIS U MINNESOTA M; LEE YC, 1990, ANAL BIOCHEM, V189, P151, DOI 10.1016/0003-2697(90)90099-U; LINDBERG B, 1990, ADV CARBOHYD CHEM BI, V48, P279, DOI 10.1016/S0065-2318(08)60033-5; MIYAZAKI T, 1979, J GEN MICROBIOL, V111, P417, DOI 10.1099/00221287-111-2-417; MIYAZAKI T, 1977, Kitasato Archives of Experimental Medicine, V50, P1; MIYAZAKI T, 1971, CHEM PHARM BULL, V19, P1450; MIYAZAKI T, 1972, CHEM PHARM BULL, V20, P330; MIYAZAKI T, 1980, ACS SYM SER, V126, P81; MORT A, 1983, CAN J MICROBIOL, V29, P993, DOI 10.1139/m83-156; NOTERMANS S, 1985, INT J FOOD MICROBIOL, V2, P247, DOI 10.1016/0168-1605(85)90015-7; OGNER G, 1980, SOIL SCI, V129, P1, DOI 10.1097/00010694-198001000-00001; Pitt J.I., 1985, FUNGI FOOD SPOILAGE, P143; SCHMIDT W, 1980, ARCH MICROBIOL, V127, P217, DOI 10.1007/BF00427196; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SMID P, 1993, THESIS STATE U LEIDE, P35; SNAITH SM, 1973, ADV CARBOHYD CHEM BI, V28, P401; SUGAR AM, 1992, CLIN INFECT DIS, V14, pS126, DOI 10.1093/clinids/14.Supplement_1.S126; VANBRUGGENVANDERLUGT AW, 1992, J BACTERIOL, V174, P6096; VANLANGENHOVE A, 1985, CARBOHYD RES, V143, P1, DOI 10.1016/S0008-6215(00)90691-8; WECKESSER J, 1979, ANNU REV MICROBIOL, V33, P215, DOI 10.1146/annurev.mi.33.100179.001243; YAMADA H, 1982, CHEM PHARM BULL, V30, P1784; YAMADA H, 1982, J GEN MICROBIOL, V128, P189; YAMADA H, 1982, CARBOHYD RES, V110, P113, DOI 10.1016/0008-6215(82)85030-1	41	9	9	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4299	4306						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307996				2022-12-27	WOS:A1994MW98900063
J	PONATH, PD; FASS, D; LIOU, HC; GLIMCHER, LH; STROMINGER, JL				PONATH, PD; FASS, D; LIOU, HC; GLIMCHER, LH; STROMINGER, JL			THE REGULATORY GENE, HXBP-1, AND ITS TARGET, HLA-DRA, UTILIZE BOTH COMMON AND DISTINCT REGULATORY ELEMENTS AND PROTEIN COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-II GENES; B-CELL LINES; TRANSCRIPTIONAL CONTROL ELEMENTS; MACROPHAGE-IA EXPRESSION; BARE LYMPHOCYTE SYNDROME; ANTIGEN EXPRESSION; IMMUNE INTERFERON; BINDING-PROTEIN; FUNCTIONAL-ANALYSIS	hXBP-1 is a transcription factor of the leucine zipper (b-zip) family important in the expression of the class II major histocompatibility complex gene, DRA. Studies with mouse-human hybrids have mapped hXBP-1 hybridizing fragments to human chromosomes 5 and 22 and the frequent detection of two mRNA transcripts suggested that hXBP-1 may be a member of a small gene family. To analyze the structure and regulation of hXBP-1 further, cosmid clones from both chromosomes were isolated. Mapping and sequence analyses reveal that chromosome 22 contains the functional hXBP-1 gene while chromosome 5 contains a processed pseudogene. hXBP-1 promoter analysis has revealed that cis-active elements within the 5'-untranslated region of hXBP-1 are essential for full promoter activity. One such element, hX2, is identical to the hXBP-1 target sequence in the DRA promoter. Mutagenesis of the hX2 site substantially decreases promoter activity. This element interacts with four distinct protein complexes in mature B cells and cross-competition experiments show that two of these complexes (complex 1 and complex 4) also interact with the hXBP-1 target sequence (X2) from the DRA promoter. The similarities of the hXBP-1 promoter and of the DRA promoter (the gene that the hXBP-1 protein regulates) are further emphasized by the fact that a Y box element is located 3' of both hX2 and X2.	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R35CA047554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030241, R01DK030241] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036864] Funding Source: NIH RePORTER; NCI NIH HHS [CA47554] Funding Source: Medline; NIDDK NIH HHS [DK30241] Funding Source: Medline; NIGMS NIH HHS [GM 36864] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAROGRACIA JM, 1989, J EXP MED, V170, P865, DOI 10.1084/jem.170.3.865; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BLACKMAN MA, 1989, SCIENCE, V244, P214, DOI 10.1126/science.2784868; BOSS JM, 1986, P NATL ACAD SCI USA, V83, P9139, DOI 10.1073/pnas.83.23.9139; BOTTAZZO GF, 1983, LANCET, V2, P1115; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; DEPREVAL C, 1985, NATURE, V318, P291, DOI 10.1038/318291a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, P NATL ACAD SCI USA, V84, P6249, DOI 10.1073/pnas.84.17.6249; FROHMAN EM, 1988, P NATL ACAD SCI USA, V85, P1292, DOI 10.1073/pnas.85.4.1292; GEBELLE AP, 1986, CELL, V46, P865; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GROSVELD FG, 1982, NUCLEIC ACIDS RES, V10, P6715, DOI 10.1093/nar/10.21.6715; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; HUME CR, 1989, HUM IMMUNOL, V25, P1, DOI 10.1016/0198-8859(89)90065-7; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KARA CJ, 1990, MOL CELL BIOL, V10, P1347, DOI 10.1128/MCB.10.4.1347; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LING PD, 1985, J IMMUNOL, V135, P1857; LIOU HC, 1990, SCIENCE, V247, P1581, DOI 10.1126/science.2321018; LIOU HC, 1991, IMMUNOGENETICS, V34, P286, DOI 10.1007/BF00211992; LIOU HC, 1989, SCIENCE, V244, P69; MANSOUR SL, 1985, MOL CELL BIOL, V5, P2633; MASSA PT, 1987, P NATL ACAD SCI USA, V84, P4219, DOI 10.1073/pnas.84.12.4219; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; ONO SJ, 1991, P NATL ACAD SCI USA, V88, P4309, DOI 10.1073/pnas.88.10.4309; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; POBER JS, 1983, NATURE, V305, P726, DOI 10.1038/305726a0; POLLA BS, 1986, P NATL ACAD SCI USA, V83, P4878, DOI 10.1073/pnas.83.13.4878; PUJOLBORRELL R, 1987, NATURE, V326, P304, DOI 10.1038/326304a0; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3; SAKURAI M, 1989, TISSUE ANTIGENS, V34, P64, DOI 10.1111/j.1399-0039.1989.tb01718.x; SAKURAI M, 1988, P NATL ACAD SCI USA, V85, P6909, DOI 10.1073/pnas.85.18.6909; SAMPLE J, 1991, P NATL ACAD SCI USA, V88, P6343, DOI 10.1073/pnas.88.14.6343; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHAEFER BC, 1991, P NATL ACAD SCI USA, V88, P6550, DOI 10.1073/pnas.88.15.6550; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SLOAN JH, 1988, P NATL ACAD SCI USA, V85, P8186, DOI 10.1073/pnas.85.21.8186; SNYDER DS, 1982, NATURE, V299, P163, DOI 10.1038/299163a0; SNYDER DS, 1982, J IMMUNOL, V129, P1803; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; STEEG PS, 1982, J IMMUNOL, V129, P2402; STERNBERG EM, 1986, J IMMUNOL, V137, P276; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; THEILL LE, 1987, MOL CELL BIOL, V7, P4329, DOI 10.1128/MCB.7.12.4329; TSANG SY, 1988, P NATL ACAD SCI USA, V85, P8598, DOI 10.1073/pnas.85.22.8598; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; WARREN MK, 1985, J IMMUNOL, V134, P2462; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WILLMAN CL, 1989, J EXP MED, V170, P1559, DOI 10.1084/jem.170.5.1559; WILUSZ J, 1989, NUCLEIC ACIDS RES, V17, P3899, DOI 10.1093/nar/17.10.3899; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YANG Z, 1988, EMBO J, V7, P1965, DOI 10.1002/j.1460-2075.1988.tb03034.x	64	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17074	17082						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349596				2022-12-27	WOS:A1993LQ98800032
J	CAMPBELL, CG; SPRAY, DC; WOLKOFF, AW				CAMPBELL, CG; SPRAY, DC; WOLKOFF, AW			EXTRACELLULAR ATP(4-) MODULATES ORGANIC ANION TRANSPORT BY RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER PLASMA-MEMBRANE; ECTO-ATPASE; CONJUGATED HYPERBILIRUBINEMIA; MOUSE MACROPHAGES; CELL; SULFOBROMOPHTHALEIN; FIBROBLASTS; BILIRUBIN; RESPONSES; RECEPTORS	The hepatocyte has an organic anion transport system that recognizes compounds such as bilirubin and sulfobromophthalein. These anions circulate bound tightly to albumin from which they are extracted rapidly by hepatocytes by an electroneutral process that requires extracellular inorganic anions such as Cl- for activity. Transport activity is reduced by depletion of intracellular ATP, but whether ATP interacts directly with this transporter is not known. In this study, the influence of extracellular ATP on the hepatocyte organic anion transport mechanism has been characterized. In the presence of 2.5 mM Ca2+ and 2 mM Mg2+, initial uptake of [S-35]sulfobromophthalein was reduced by 50% at 1 mM ATP. In the absence of divalent cations sensitivity to ATP was 10-fold greater. Other nucleotides including UTP, CTP, GTP, ADP, AMP, and AMP-PCP (adenosine 5'-(beta,gamma-methylene)triphosphate) were inactive. Decreased transport activity was rapidly reversible, was non-competitive with respect to ATP, did not require ATP hydrolysis, and did not correlate with P2y purinergic receptor activity. Differential activity of ATP on sulfobromophthalein transport in the presence and absence of divalent cations was not due to ecto-ATPase activity but rather to alteration in [ATP4-]. Although an ATP4- receptor in macrophages mediates increased cellular permeability, reduced organic anion permeability is seen in hepatocytes. This effect is not seen in the hepatoma cell line HepG2. Modulation of activity of the organic anion transporter by extracellular ATP may have important pathophysiological consequences in conditions resulting in liver cell injury.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,LIVER RES CTR,1300 MORRIS PK AVE,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT NEUROSCI,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine				Spray, David/0000-0001-8368-5073	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041296, R01DK023026] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-23026, DK-41296] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTY RA, 1968, J BIOL CHEM, V243, P1337; BUISMAN HP, 1988, P NATL ACAD SCI USA, V85, P7988, DOI 10.1073/pnas.85.21.7988; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; CAO CX, 1992, J INFECT DIS, V165, P322, DOI 10.1093/infdis/165.2.322; CHAREST R, 1985, J BIOL CHEM, V260, P5789; CHE MX, 1992, J BIOL CHEM, V267, P9684; CHRIST GJ, 1992, AM J PHYSIOL, V263, pC373, DOI 10.1152/ajpcell.1992.263.2.C373; COCKCROFT S, 1980, BIOCHEM J, V188, P789, DOI 10.1042/bj1880789; DAHLQUIST R, 1974, ACTA PHARMACOL TOX, V34, P368, DOI 10.1111/j.1600-0773.1974.tb03533.x; DIXON CJ, 1990, BIOCHEM J, V269, P499, DOI 10.1042/bj2690499; DUBYAK GR, 1990, ANN NY ACAD SCI, V603; ELMOATASSIM C, 1992, BIOCHIM BIOPHYS ACTA, V1134, P31, DOI 10.1016/0167-4889(92)90025-7; GARTNER U, 1982, GASTROENTEROLOGY, V83, P1163; GONZALEZ FA, 1989, BIOCHEM BIOPH RES CO, V164, P706, DOI 10.1016/0006-291X(89)91517-9; GONZALEZ FA, 1989, J CELL PHYSL, V139, P105; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HAUSSINGER D, 1987, EUR J BIOCHEM, V167, P65; HAUSSINGER D, 1988, EUR J BIOCHEM, V178, P249, DOI 10.1111/j.1432-1033.1988.tb14450.x; KITAMURA T, 1990, P NATL ACAD SCI USA, V87, P3557, DOI 10.1073/pnas.87.9.3557; KITAMURA T, 1991, HEPATOLOGY, V14, P640, DOI 10.1016/0270-9139(91)90051-V; KURISU H, 1989, ANAL BIOCHEM, V179, P72, DOI 10.1016/0003-2697(89)90202-9; LIN SH, 1988, J BIOL CHEM, V263, P12253; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; LIN SH, 1989, J BIOL CHEM, V264, P14408; LIN SH, 1989, J BIOL CHEM, V264, P14403; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARGOLIS RN, 1990, BIOCHEM BIOPH RES CO, V166, P562, DOI 10.1016/0006-291X(90)90845-E; MIN AD, 1991, HEPATOLOGY, V14, P1217, DOI 10.1002/hep.1840140642; MIN AD, 1991, J CLIN INVEST, V87, P1496, DOI 10.1172/JCI115159; OKAJIMA F, 1987, J BIOL CHEM, V262, P13483; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100; STEINBERG TH, 1987, J BIOL CHEM, V262, P3118; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; STIEGER B, 1992, BIOCHEM J, V284, P67, DOI 10.1042/bj2840067; STOLLMAN YR, 1983, J CLIN INVEST, V72, P718, DOI 10.1172/JCI111021; SUNG SSJ, 1985, J BIOL CHEM, V260, P3442; WEISMAN GA, 1989, J CELL PHYSIOL, V138, P375, DOI 10.1002/jcp.1041380221; WOLKOFF AW, 1985, J CLIN INVEST, V76, P454, DOI 10.1172/JCI111993; WOLKOFF AW, 1987, J CLIN INVEST, V79, P1259, DOI 10.1172/JCI112946; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2484, DOI 10.1021/bi00789a009; ZIMNIAK P, 1992, ARCH BIOCHEM BIOPHYS, V292, P534, DOI 10.1016/0003-9861(92)90027-T	41	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15399	15404						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340370				2022-12-27	WOS:A1993LN30500016
J	HAMEL, CP; TSILOU, E; PFEFFER, BA; HOOKS, JJ; DETRICK, B; REDMOND, TM				HAMEL, CP; TSILOU, E; PFEFFER, BA; HOOKS, JJ; DETRICK, B; REDMOND, TM			MOLECULAR-CLONING AND EXPRESSION OF RPE65, A NOVEL RETINAL-PIGMENT EPITHELIUM-SPECIFIC MICROSOMAL PROTEIN THAT IS POSTTRANSCRIPTIONALLY REGULATED IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; SEQUENCE-ANALYSIS; BOVINE RETINA; CELLS; IDENTIFICATION; DIFFERENTIATION; 11-CIS-RETINYL; NITROCELLULOSE; PURIFICATION; TRANSLATION	Studies reported previously from this laboratory have shown that microsomal membranes of the vertebrate retinal pigment epithelium (RPE) contain an RPE-specific 65-kDa protein, RPE65, which bears the determinant recognized by the strictly tissue-specific monoclonal antibody RPE9, and which is developmentally regulated (Hamel, C. P., Tsilou, E., Harris, E., Pfeffer, B. A., Hooks, J. J., Detrick, B., and Redmond, T. M. (1993) J. Neurosci. Res. 34, 414-425). Microsequencing of 17 tryptic and chymotryptic peptides obtained from the in situ digestion of the RPE65 blotted on nitrocellulose yielded primary sequences that were used to generate oligonucleotide probes. An 84-nucleotide guessmer was used to isolate two clones from a bovine RPE lambdaZap II cDNA library. Rapid amplification of cDNA ends was used to complete the 5' and 3' ends, resulting in a 3,115-base pair composite cDNA. The open reading frame encodes a novel protein of 533 amino acid residues with a computed molecular weight of 60,940. This protein does not match any other sequence in the data bases. The 231 amino acids obtained from peptide sequencing match 43% of the amino acid sequence deduced from the cDNA. The protein has a calculated pI of 6.41 and is not predicted to have any transmembrane segments. The open reading frame expressed in Escherichia coli has an apparent molecular weight identical to that of the native protein and is recognized by the monoclonal antibody RPE9, further corroborating its validity. Northern blot analysis detected a major mRNA species of 3.15 kilobases for RPE65, as well as shorter species, only in RPE and not in other tissues (including other ocular tissues). Cultured RPE cells (7 weeks in primary culture) contained RPE65 mRNA in amounts equivalent to fresh RPE. Such cells, however, contained no immunodetectable RPE65. The possible structure of this RPE-specific protein and hypotheses for the absence of translation in vitro are discussed.	NEI, RETINAL CELL & MOLEC BIOL LAB,BLDG 6,RM 339, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA; NEI, IMMUNOL & VIROL LAB, BETHESDA, MD 20892 USA; GEORGE WASHINGTON UNIV, MED CTR, DEPT PATHOL, WASHINGTON, DC 20037 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); George Washington University				Redmond, T. Michael/0000-0002-1813-5291				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASLANIDIS C, 1990, NUCLEIC ACIDS RES, V18, P6069, DOI 10.1093/nar/18.20.6069; BARRY RJ, 1989, J BIOL CHEM, V264, P9231; BAVIK CO, 1991, J BIOL CHEM, V266, P14978; BERMAN ER, 1991, BIOCH EYE, P380; BERNSTEIN PS, 1987, P NATL ACAD SCI USA, V84, P1849, DOI 10.1073/pnas.84.7.1849; BLANER WS, 1987, J BIOL CHEM, V262, P53; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENT A, 1990, P NATL ACAD SCI USA, V87, P318, DOI 10.1073/pnas.87.1.318; CRABB JW, 1988, J BIOL CHEM, V263, P18678; CRABB JW, 1988, J BIOL CHEM, V263, P18688; DAS A, 1990, METHOD ENZYMOL, V182, P93; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLANNERY JG, 1990, EXP EYE RES, V51, P717, DOI 10.1016/0014-4835(90)90057-2; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIESER L, 1992, GENOMICS, V13, P873, DOI 10.1016/0888-7543(92)90173-P; HAMEL CP, 1993, J NEUROSCI RES, V34, P414, DOI 10.1002/jnr.490340406; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOOKS JJ, 1989, INVEST OPHTH VIS SCI, V30, P2106; JIANG MS, 1991, P NATL ACAD SCI USA, V88, P3907, DOI 10.1073/pnas.88.9.3907; JOSEPH DP, 1991, J PHYSIOL-LONDON, V435, P439, DOI 10.1113/jphysiol.1991.sp018518; KANEHISA M, 1982, NUCLEIC ACIDS RES, V10, P183, DOI 10.1093/nar/10.1.183; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEIGHTON J, 1969, SCIENCE, V163, P472, DOI 10.1126/science.163.3866.472; MATA NL, 1992, J BIOL CHEM, V267, P9794; MAYERSON PL, 1986, J CELL BIOL, V103, P299, DOI 10.1083/jcb.103.1.299; MULLEN RJ, 1976, SCIENCE, V192, P799, DOI 10.1126/science.1265483; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pfeffer BA, 1991, PROG RETINAL RES, V10, P251; PIDGEON C, 1991, ANAL BIOCHEM, V194, P163, DOI 10.1016/0003-2697(91)90164-O; SAARI JC, 1989, J BIOL CHEM, V264, P8636; SAARI JC, 1982, J BIOL CHEM, V257, P13329; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SHALLAL A, 1988, EYE, V2, pS180, DOI 10.1038/eye.1988.143; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SPOERRI PE, 1988, EUR J CELL BIOL, V46, P362; STRAMM LE, 1990, EXP EYE RES, V50, P521, DOI 10.1016/0014-4835(90)90041-R; TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG N, 1992, CURR EYE RES, V11, P783, DOI 10.3109/02713689209000751; YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392	49	270	292	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15751	15757						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340400				2022-12-27	WOS:A1993LN30500064
J	MATHAI, JC; SAUNA, ZE; JOHN, O; SITARAMAM, V				MATHAI, JC; SAUNA, ZE; JOHN, O; SITARAMAM, V			RATE-LIMITING STEP IN ELECTRON-TRANSPORT - OSMOTICALLY SENSITIVE DIFFUSION OF QUINONES THROUGH VOIDS IN THE BILAYER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL INNER MEMBRANE; LATERAL DIFFUSION; OXIDATIVE-PHOSPHORYLATION; PHOTOSYNTHETIC ACTIVITY; PHOSPHOLIPID-VESICLES; BIOLOGICAL-MEMBRANES; VARIABLE POROSITY; FLUORESCENCE; UBIQUINONE; PERMEABILITY	Respiration in mitochondria and photosynthesis in chloroplasts varied with the osmotic stretch of the membrane such that these processes were uniformly inhibited at higher osmolalities. A systematic evaluation of segmental electron transport in these intact particles showed that no individual complex exhibited osmotic sensitivity, whereas osmotic sensitivity appeared wherever the assay involved crossing over the corresponding quinone in the electron transport chain. The evidence was consistent with the rate-limiting step in electron transport being the availability of voids for quinone migration rather than any of the components of electron transport chain per se. Evidence based on quinone reconstitution in mitochondria depleted of quinone by acetone treatment clearly distinguished the kinetic control in the hypotonic domain and diffusive control via availability of voids in the hypertonic domain. Influence as well as the presence of voids was further confirmed in quinone-depleted mitochondria reconstituted with quinone as well as cholesterol. Decrease in lateral diffusion of the fluorescent probe, 12-(9-anthroyl)stearic acid, on osmotic compression of the bilayer is consistent with a change in void size distribution on osmotic compression of the bilayer. A direct correlation between succinate cytochrome c oxidoreductase activity and diffusivity of fluorescent probe 12-(9-anthroyl)stearic acid confirmed the availability of voids as the rate-limiting step in electron transport.			MATHAI, JC (corresponding author), UNIV POONA,DEPT ZOOL,POONA 411007,MAHARASHTRA,INDIA.		Sauna, Zuben E./AAA-7149-2019					AMENTA JS, 1964, J LIPID RES, V5, P270; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BEAVIS AD, 1986, EUR J BIOCHEM, V158, P315, DOI 10.1111/j.1432-1033.1986.tb09753.x; BLUME A, 1983, BIOCHEMISTRY-US, V22, P5436, DOI 10.1021/bi00292a027; BONDI A, 1964, J PHYS CHEM-US, V68, P441, DOI 10.1021/j100785a001; BREHM P, 1984, J PHYSIOL-LONDON, V350, P631, DOI 10.1113/jphysiol.1984.sp015222; CHALPIN DB, 1983, BIOCHIM BIOPHYS ACTA, V731, P465, DOI 10.1016/0005-2736(83)90042-1; CHAZOTTE B, 1989, J BIOL CHEM, V264, P4978; CHONG PLG, 1985, J BIOL CHEM, V260, P4484; COHEN MH, 1959, J CHEM PHYS, V31, P1164, DOI 10.1063/1.1730566; Crofts A. R., 1978, CURR TOP BIOENERG, V7, P175; DEAMER DW, 1983, P NATL ACAD SCI-BIOL, V80, P165, DOI 10.1073/pnas.80.1.165; FATO R, 1986, BIOCHEMISTRY-US, V25, P3378, DOI 10.1021/bi00359a043; GALLA HJ, 1979, J MEMBRANE BIOL, V48, P215, DOI 10.1007/BF01872892; GAVISH B, 1979, BIOCHEMISTRY-US, V18, P1269, DOI 10.1021/bi00574a023; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GOULD JM, 1975, BIOCHIM BIOPHYS ACTA, V387, P135; GOULD JM, 1973, EUR J BIOCHEM, V37, P185, DOI 10.1111/j.1432-1033.1973.tb02974.x; GRAHAM JM, 1970, EUR J BIOCHEM, V12, P58, DOI 10.1111/j.1432-1033.1970.tb00820.x; GRIENSTEIN S, 1985, AM J PHYSIOL, V246, pC204; GUTMAN M, 1980, BIOCHIM BIOPHYS ACTA, V594, P53, DOI 10.1016/0304-4173(80)90013-0; HACKENBROCK CR, 1986, J BIOENERG BIOMEMBR, V18, P331, DOI 10.1007/BF00743010; HATEFI Y, 1979, METHOD ENZYMOL, V55, P35; HERON C, 1978, BIOCHEM J, V179, P791; IZAWA S, 1974, BIOCHIM BIOPHYS ACTA, V357, P127, DOI 10.1016/0005-2728(74)90118-2; Izawa S., 1980, METHODS ENZYMOL    C, P413; KAISER WM, 1982, PLANTA, V154, P538, DOI 10.1007/BF00402997; KAISER WM, 1981, PLANTA, V1151, P375; KRAUSE GH, 1982, BIOCHIM BIOPHYS ACTA, V679, P116, DOI 10.1016/0005-2728(82)90262-6; KRISHNAMOORTHY G, 1984, BIOCHEMISTRY-US, V23, P1640, DOI 10.1021/bi00303a009; KROGER A, 1973, EUR J BIOCHEM, V39, P313, DOI 10.1111/j.1432-1033.1973.tb03129.x; LAVERGNE J, 1991, TRENDS BIOCHEM SCI, V16, P129, DOI 10.1016/0968-0004(91)90054-Y; LAWFORD AG, 1973, BIOCHEM J, V136, P711; LENAZ G, 1986, J BIOENERG BIOMEMBR, V18, P369, DOI 10.1007/BF00743011; LESTER RL, 1961, BIOCHIM BIOPHYS ACTA, V47, P358, DOI 10.1016/0006-3002(61)90297-9; LI W, 1986, BIOCHEMISTRY-US, V25, P8220, DOI 10.1021/bi00373a015; LILLEY RM, 1975, NEW PHYTOL, V75, P1, DOI 10.1111/j.1469-8137.1975.tb01365.x; MARSH D, 1974, BIOCHIM BIOPHYS ACTA, V363, P373, DOI 10.1016/0005-2736(74)90076-5; MATHAI JC, 1989, BIOCHIM BIOPHYS ACTA, V976, P214, DOI 10.1016/S0005-2728(89)80233-6; MAYER H, 1971, METHODS ENZYMOL C, V18, P182; MCGRATH AE, 1976, BIOCHIM BIOPHYS ACTA, V426, P173, DOI 10.1016/0005-2736(76)90330-8; OLEARY TJ, 1987, P NATL ACAD SCI USA, V84, P429, DOI 10.1073/pnas.84.2.429; PETERS R, 1983, P NATL ACAD SCI-BIOL, V80, P7183, DOI 10.1073/pnas.80.23.7183; PU LC, 1967, METHOD ENZYMOL, V10, P33; PUMPHREY AM, 1960, BIOCHEM J, V76, P61, DOI 10.1042/bj0760061; ROBINSON J, 1970, ANAL BIOCHEM, V33, P390, DOI 10.1016/0003-2697(70)90310-6; SAMBASIVARAO D, 1983, BIOCHIM BIOPHYS ACTA, V722, P256, DOI 10.1016/0005-2728(83)90072-5; SAMBASIVARAO D, 1986, BIOCHIM BIOPHYS ACTA, V857, P48, DOI 10.1016/0005-2736(86)90097-0; SAMBASIVARAO D, 1988, BIOCHIM BIOPHYS ACTA, V933, P200, DOI 10.1016/0005-2728(88)90071-0; SAMBASIVARAO D, 1985, BIOCHIM BIOPHYS ACTA, V806, P195, DOI 10.1016/0005-2728(85)90097-0; SITARAMAM V, 1981, P NATL ACAD SCI-BIOL, V78, P3441, DOI 10.1073/pnas.78.6.3441; SITARAMAM V, 1989, BIOCHIM BIOPHYS ACTA, V975, P252, DOI 10.1016/S0005-2728(89)80256-7; SITARAMAM V, 1989, MOL CELL BIOCHEM, V91, P91, DOI 10.1007/BF00228083; SITARAMAM V, 1991, INDIAN J BIOCH BIOPH, V29, P103; SITARAMAM V, 1991, MEMBRANE STRUCTURE F, P123; SITARAMAM V, 1984, EBEC REP, V3, P555; SITARAMAM V, 1988, INDIAN J BIOCH BIOPH, V47, P395; SOZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194; TAKANAKA K, 1975, ARCH BIOCHEM BIOPHYS, V169, P420; Trebst A, 1972, Methods Enzymol, V24, P146; ULRICH EL, 1985, BIOCHEMISTRY-US, V24, P2501, DOI 10.1021/bi00331a016; WALKER DA, 1981, PLANTA, V153, P273, DOI 10.1007/BF00383899; WALKER DA, 1980, METHOD ENZYMOL, V69, P94, DOI DOI 10.1016/S0076-6879(80)69011-9; WELCH G R, 1982, Progress in Biophysics and Molecular Biology, V39, P109; WILLIAMSON P, 1983, BIOCHIM BIOPHYS ACTA, V732, P387, DOI 10.1016/0005-2736(83)90055-X; YOCUM CF, 1980, METHOD ENZYMOL, V69, P576	66	33	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15442	15454						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340373				2022-12-27	WOS:A1993LN30500022
J	ROMANI, A; MARFELLA, C; SCARPA, A				ROMANI, A; MARFELLA, C; SCARPA, A			HORMONAL-STIMULATION OF MG(2+) UPTAKE IN HEPATOCYTES - REGULATION BY PLASMA-MEMBRANE AND INTRACELLULAR ORGANELLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC FREE MAGNESIUM; PROTEIN-KINASE-C; RAT-LIVER; MG-2+ EFFLUX; INOSITOL TRISPHOSPHATE; ISOLATED-MITOCHONDRIA; ANION TRANSPORT; 2ND MESSENGERS; CELLS; CALCIUM	Collagenase dispersed rat liver hepatocytes release Mg2+ when stimulated with norepinephrine or accumulate Mg2+ when stimulated with vasopressin, respectively. Mg2+ fluxes in either direction account for a net loss or gain of approximately 10% of total cell magnesium and are rapidly reversible. Both stimulated Mg2+ efflux and Mg2+ influx require physiological concentration of extracellular NaCl and Ca2+. In the absence of extracellular Na+, Mg2+ efflux, but not influx, can be observed in the presence of extracellular Cl-. Under these conditions, the efflux is inhibited by the Cl-/HCO3- exchanger inhibitor 4,4'-dinitrostilbene-2,2'-disulfonic acid. In hepatocytes, Mg2+ influx, but not efflux, is completely inhibited by thapsigargin, a specific inhibitor of the endoplasmic reticulum Ca2+ ATPase. Several lines of evidence, such as measurements of cytosolic Ca2+ or of cytosolic Ca2+ buffering, indicate that the effect of thapsigargin in inhibiting Mg2+ influx could not be explained by an increase in cytosolic Ca2+. Instead, the inhibition of hepatocyte Mg2+ influx was found to be the result of the depletion of the Ca2+ stored within the endoplasmic reticulum.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106	Case Western Reserve University				Romani, Andrea/0000-0001-9864-4848	NHLBI NIH HHS [HL 18708] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018708] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APRILLE JR, 1988, FASEB J, V2, P2547, DOI 10.1096/fasebj.2.10.3290024; ARIAS IM, 1988, LIVER BIOL PATHOBIOL, P9; BAUMANN O, 1991, P NATL ACAD SCI USA, V88, P741, DOI 10.1073/pnas.88.3.741; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BLACKMORE PF, 1982, J BIOL CHEM, V257, P190; BOND M, 1987, J BIOL CHEM, V262, P15630; BOYNTON AL, 1983, BIOCHEM BIOPH RES CO, V115, P383, DOI 10.1016/0006-291X(83)91015-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAYDEN DJ, 1989, BRIT J PHARMACOL, V98, P809, DOI 10.1111/j.1476-5381.1989.tb14609.x; BURGESS GM, 1984, NATURE, V309, P63, DOI 10.1038/309063a0; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; CSERMELY P, 1987, CARCINOGENESIS, V8, P1663, DOI 10.1093/carcin/8.11.1663; DEYOUNG MB, 1989, AM J PHYSIOL, V257, pC750, DOI 10.1152/ajpcell.1989.257.4.C750; DIPOLO R, 1988, BIOCHIM BIOPHYS ACTA, V946, P424, DOI 10.1016/0005-2736(88)90418-X; DRANSFIELD DT, 1991, J CELL BIOL, V115, P300; FLATMAN PW, 1984, J MEMBRANE BIOL, V80, P1, DOI 10.1007/BF01868686; GARFINKEL L, 1986, J MOL CELL CARDIOL, V18, P1003, DOI 10.1016/S0022-2828(86)80289-9; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GRUBBS RD, 1987, MAGNESIUM, V6, P113; GUNTHER T, 1991, MAGNESIUM-B, V13, P122; GUNTHER T, 1984, BIOCHEM BIOPH RES CO, V119, P124, DOI 10.1016/0006-291X(84)91627-9; GUNTHER T, 1985, BIOCHEM BIOPH RES CO, V130, P540, DOI 10.1016/0006-291X(85)90450-4; GUNTHER T, 1992, FEBS LETT, V297, P132, DOI 10.1016/0014-5793(92)80343-F; HARMAN AW, 1990, BIOCHEM BIOPH RES CO, V170, P477, DOI 10.1016/0006-291X(90)92116-H; JAKOB A, 1989, FEBS LETT, V246, P127, DOI 10.1016/0014-5793(89)80267-4; JELICKS LA, 1990, J BIOL CHEM, V265, P1394; JENNINGS ML, 1985, ANNU REV PHYSIOL, V47, P519; KAIBUCHI K, 1983, J BIOL CHEM, V258, P6701; KRAUSFRIEDMANN N, 1986, P NATL ACAD SCI USA, V83, P8943, DOI 10.1073/pnas.83.23.8943; MURPHY E, 1989, J BIOL CHEM, V264, P5622; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOSEK MT, 1990, J BIOL CHEM, V265, P8444; OTTO DA, 1983, ISOLATION CHARACTERI, P41; ROMANI A, 1992, FEBS LETT, V296, P135, DOI 10.1016/0014-5793(92)80364-M; ROMANI A, 1991, J BIOL CHEM, V266, P24376; ROMANI A, 1990, NATURE, V346, P841, DOI 10.1038/346841a0; ROMANI A, 1990, FEBS LETT, V269, P37, DOI 10.1016/0014-5793(90)81113-3; ROTEVATN S, 1989, AM J PHYSIOL, V257, pC141, DOI 10.1152/ajpcell.1989.257.1.C141; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SIMCHOWITZ L, 1990, ANNU REV PHYSIOL, V52, P381; SOMLYO AV, 1985, J BIOL CHEM, V260, P6801; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; VORMANN J, 1987, MAGNESIUM, V6, P220; WHITE RE, 1989, BIOCHEM PHARMACOL, V38, P859, DOI 10.1016/0006-2952(89)90272-4	46	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15489	15495						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340377				2022-12-27	WOS:A1993LN30500028
J	CASTELLO, A; CADEFAU, J; CUSSO, R; TESTAR, X; HESKETH, JE; PALACIN, M; ZORZANO, A				CASTELLO, A; CADEFAU, J; CUSSO, R; TESTAR, X; HESKETH, JE; PALACIN, M; ZORZANO, A			GLUT-4 AND GLUT-1 GLUCOSE-TRANSPORTER EXPRESSION IS DIFFERENTIALLY REGULATED BY CONTRACTILE ACTIVITY IN SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIABETIC RATS; PRETRANSLATIONAL SUPPRESSION; INSULIN RESISTANCE; GENE-EXPRESSION; SOLEUS MUSCLE; DNA-BINDING; PROTEIN; DENERVATION; STIMULATION; INVIVO	Mammalian skeletal muscle expresses GLUT-4 and GLUT-1 glucose transporters. Here, we have investigated whether GLUT- 1 and GLUT-4 expression is regulated in muscle by contractile activity. GLUT-1 mRNA levels were high in skeletal muscle at days 16 and 17 of fetal life and decreased markedly by days 19 and 21. In contrast, GLUT-4 mRNA levels were clearly detectable at day 21 of fetal life, and they increased progressively during postnatal life. The timing data for GLUT-4 induction and GLUT- 1 repression suggest that these processes are related to skeletal muscle innervation. GLUT-4 mRNA decreased markedly in adult rat and rabbit tibialis anterior muscle after severage of peroneal nerve. In contrast, GLUT-1 mRNA levels showed a 9-fold increase in rat muscle 3 days after denervation. Direct stimulation of rabbit tibialis anterior muscle with extracellular electrodes protected GLUT-4 mRNA levels against the effect of denervation. This indicates that the repression of GLUT-4 mRNA associated with denervation is due, at least in part, to electrical activity. Increased contractile activity induced for 24 h by indirect electrical stimulation at low frequency caused a marked and specific increase in GLUT-1 mRNA levels in rabbit tibialis anterior muscle. Our results indicate that (a) innervation-dependent basal contractile activity regulates in an inverse manner the expression of GLUT-1 and GLUT-4 in skeletal muscle, and (b) enhanced contractile activity stimulates GLUT-1 expression in the absence of modifications to GLUT-4 expression. This suggests the existence of different factors which depend on contractile activity and which control GLUT-1 and GLUT-4 glucose transporter expression in skeletal muscle.	UNIV BARCELONA, FAC BIOL, DEPT BIOQUIM & FISIOL, AVE DIAGONAL 645, E-08028 BARCELONA, SPAIN; UNIV BARCELONA, FAC MED, DEPT CIENCIES FISIOL HUMANES & NUTR, E-08028 BARCELONA, SPAIN; ROWETT RES INST, DEPT BIOCHEM SCI, BUCKSBURN AB2 9SB, ABERDEEN, SCOTLAND	University of Barcelona; University of Barcelona; University of Aberdeen			Palacín, Manuel/G-9786-2015; Cadefau, Joan Aureli/G-2906-2016; Zorzano, Antonio/R-5479-2018; Farré, Anna Castelló/K-9637-2015; Cadefau, Joan AurelI/M-7934-2018	Cadefau, Joan Aureli/0000-0001-6020-189X; Farré, Anna Castelló/0000-0001-8497-6251; Cadefau, Joan AurelI/0000-0001-6020-189X; Palacin, Manuel/0000-0002-8670-293X				AUGERT G, 1985, DIABETOLOGIA, V28, P295, DOI 10.1007/BF00271689; BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BLOCK NE, 1991, J CLIN INVEST, V88, P1546, DOI 10.1172/JCI115465; BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BORNEMANN A, 1992, DIABETES, V41, P215, DOI 10.2337/diabetes.41.2.215; BOUREY RE, 1990, J CLIN INVEST, V86, P542, DOI 10.1172/JCI114742; BUONANNO A, 1992, NUCLEIC ACIDS RES, V20, P539, DOI 10.1093/nar/20.3.539; BURANT CF, 1984, AM J PHYSIOL, V247, pE657, DOI 10.1152/ajpendo.1984.247.5.E657; CAMPS M, 1992, BIOCHEM J, V282, P765, DOI 10.1042/bj2820765; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CODERRE L, 1992, ENDOCRINOLOGY, V131, P1821, DOI 10.1210/en.131.4.1821; CONDON K, 1990, DEV BIOL, V138, P256, DOI 10.1016/0012-1606(90)90196-P; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; DOUEN AG, 1990, FEBS LETT, V261, P256, DOI 10.1016/0014-5793(90)80566-2; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349; EVANS S, 1987, J BIOL CHEM, V262, P4911; FRIEDMAN JE, 1991, DIABETES, V40, P150, DOI 10.2337/diabetes.40.1.150; FURLER SM, 1991, AM J PHYSIOL, V261, pE337, DOI 10.1152/ajpendo.1991.261.3.E337; GARVEY WT, 1991, J CLIN INVEST, V87, P1072, DOI 10.1172/JCI115068; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; GREEN HJ, 1990, DYNAMIC STATE OF MUSCLE FIBERS, P617; HABER RS, 1992, DIABETES, V41, P728, DOI 10.2337/diabetes.41.6.728; HANDBERG A, 1992, AM J PHYSIOL, V262, pE721, DOI 10.1152/ajpendo.1992.262.5.E721; HARRIS AJ, 1989, DEVELOPMENT, V107, P751; HENRIKSEN EJ, 1991, J APPL PHYSIOL, V70, P2322, DOI 10.1152/jappl.1991.70.5.2322; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; HOOD DA, 1989, EUR J BIOCHEM, V179, P275, DOI 10.1111/j.1432-1033.1989.tb14551.x; JAMES DE, 1985, AM J PHYSIOL, V248, pE567, DOI 10.1152/ajpendo.1985.248.5.E567; KAHN BB, 1989, J CLIN INVEST, V84, P404, DOI 10.1172/JCI114180; KAHN BB, 1991, J CLIN INVEST, V87, P2197, DOI 10.1172/JCI115254; KLIP A, 1992, J CELL BIOCHEM, V48, P51, DOI 10.1002/jcb.240480109; KLIP A, 1990, BIOCHEM BIOPH RES CO, V172, P728, DOI 10.1016/0006-291X(90)90735-6; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; MARETTE A, 1992, AM J PHYSIOL, V263, pC443, DOI 10.1152/ajpcell.1992.263.2.C443; MERLIE JP, 1989, NEURON, V2, P1295, DOI 10.1016/0896-6273(89)90067-6; ONTELL M, 1984, AM J ANAT, V171, P133, DOI 10.1002/aja.1001710202; ONTELL M, 1988, AM J ANAT, V181, P279, DOI 10.1002/aja.1001810306; PETTE D, 1992, AM J PHYSIOL, V262, pR333, DOI 10.1152/ajpregu.1992.262.3.R333; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; RICHARDSON JM, 1991, J BIOL CHEM, V266, P12690; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; Rosen K., 1990, FOCUS, V12, P23; SANTALUCIA T, 1992, ENDOCRINOLOGY, V130, P837, DOI 10.1210/en.130.2.837; SCHWARZ G, 1983, PFLUG ARCH EUR J PHY, V398, P130, DOI 10.1007/BF00581060; SINHA MK, 1991, DIABETES, V40, P472, DOI 10.2337/diabetes.40.4.472; SIVITZ WI, 1989, NATURE, V340, P72, DOI 10.1038/340072a0; SLOT JW, 1990, NATURE, V346, P369, DOI 10.1038/346369a0; SMITH RL, 1984, J BIOL CHEM, V259, P2201; STROUT HV, 1990, ENDOCRINOLOGY, V126, P2728, DOI 10.1210/endo-126-5-2728; TSAY HJ, 1989, J CELL BIOL, V108, P1523, DOI 10.1083/jcb.108.4.1523; WALLACE S, 1992, FEBS LETT, V301, P69, DOI 10.1016/0014-5793(92)80212-Y; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WHITELAW PF, 1992, BIOCHEM J, V281, P143, DOI 10.1042/bj2810143; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764	58	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14998	15003						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325875				2022-12-27	WOS:A1993LL75900069
J	FAUCHER, C; CAPDEVIELLE, J; CANAL, I; FERRARA, P; MAZARGUIL, H; MCGUIRE, WL; DARBON, JM				FAUCHER, C; CAPDEVIELLE, J; CANAL, I; FERRARA, P; MAZARGUIL, H; MCGUIRE, WL; DARBON, JM			THE 28-KDA PROTEIN WHOSE PHOSPHORYLATION IS INDUCED BY PROTEIN-KINASE-C ACTIVATORS IN MCF-7 CELLS BELONGS TO THE FAMILY OF LOW-MOLECULAR-MASS HEAT-SHOCK PROTEINS AND IS THE ESTROGEN-REGULATED 24-KDA PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST CANCER-CELLS; STRESS PROTEINS; PHOSPHOLIPASE-C; PHORBOL ESTERS; GROWTH; RECEPTOR; ELECTROPHORESIS; INHIBITION; COMPONENT	We have previously reported the presence of a 28-kDa protein in human mammary adenocarcinoma MCF-7 cells, whose phosphorylation by phorbol ester 12-O-tetradecanoylphorbol-13-acetate(TPA) and permeant diacylglycerol 1,2-dioctanoyl-sn-glycerol was correlated to growth arrest induced by the protein kinase C (PKC) activators. We now investigate the possible identity of this protein with the estrogen-regulated ''24-kDa'' protein shown as related to the mammalian heat shock protein 27 (Fuqua, S. A. W., Blum-Salingaros, M., and McGuire, W. L. (1989) Cancer Res 49, 4126-4129). P-32-Labeled 28-kDa protein from TPA-treated MCF-7 cells was immunoprecipitated with a 24-kDa-specific monoclonal antibody. Immunoblots from cell extracts fractionated by two-dimensional isoelectric focusing/SDS-polyacrylamide gel electrophoresis demonstrated that TPA induced the conversion of a 28-kDa isoform ''a'' (pI 6.7) to a more acidic isoform ''b'' (pI 6.2). Two-dimensional gel analysis of [H-3]leucine-labeled MCF-7 cell extracts demonstrated that conversely to TPA, which induced only phosphorylation of 28-kDa protein, heat shock induced both synthesis (increase of isoform a) and phosphorylation (conversion of isoforms a to b) of the protein. P-32 labeling of MCF-7 cells allowed demonstration of the presence of an extra phosphoisoform ''c'' (pI 5.9) upon TPA as well as heat shock treatment. When cells were pretreated with the bisindolylmaleimide GF109203X, a selective inhibitor of PKC, the heat shock-induced phosphorylation was unchanged, while the TPA effect was almost abolished, suggesting that the heat shock-activated protein kinase was very likely different from PKC. However, peptide mapping of the 28-kDa phosphoprotein suggested identical sites of phosphorylation upon TPA and heat shock stimulation. Partial amino acid sequencing of the 28-kDa protein revealed identity with both the 24-kDa protein and the mammalian HSP27. The fact that estrogens and PKC, respectively, regulate expression and phosphorylation of this 24/28-kDa protein strongly argues for its key role in MCF-7 cell proliferation and differentiation.	FAC MED TOULOUSE,INSERM,U133,F-31062 TOULOUSE,FRANCE; SANOFI ELF BIORECH,F-31328 LABEGE,FRANCE; CNRS,PHARMACOL & TOXICOL MOLEC LAB,F-31077 TOULOUSE,FRANCE; UNIV TEXAS,HLTH SCI CTR,DEPT MED,DIV ONCOL,SAN ANTONIO,TX 78284	Institut National de la Sante et de la Recherche Medicale (Inserm); Sanofi-Aventis; Centre National de la Recherche Scientifique (CNRS); University of Texas System; University of Texas Health San Antonio								ANG D, 1991, J BIOL CHEM, V266, P24233; ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CHRETIEN P, 1988, J CELL PHYSIOL, V137, P157, DOI 10.1002/jcp.1041370119; CIOCCA DR, 1991, BREAST CANCER RES TR, V20, P33, DOI 10.1007/BF01833355; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COFFER AI, 1985, CANCER RES, V45, P3686; DARBON JM, 1990, BIOCHEM BIOPH RES CO, V168, P527, DOI 10.1016/0006-291X(90)92353-2; EDWARDS DP, 1980, BIOCHEM BIOPH RES CO, V93, P804, DOI 10.1016/0006-291X(80)91148-1; FUQUA SAW, 1989, CANCER RES, V49, P4126; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; ISSANDOU M, 1986, FEBS LETT, V200, P337, DOI 10.1016/0014-5793(86)81164-4; ISSANDOU M, 1988, CANCER RES, V48, P6943; ISSANDOU M, 1991, J BIOL CHEM, V266, P21037; JOZAN S, 1985, BIOCHEM BIOPH RES CO, V107, P1566; KAGEYAMA M, 1991, J PHARMACOL EXP THER, V259, P1019; KIM YJ, 1984, MOL CELL BIOL, V4, P468, DOI 10.1128/MCB.4.3.468; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LEE YJ, 1990, BIOCHEM BIOPH RES CO, V172, P119, DOI 10.1016/S0006-291X(05)80181-0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SECRIST JP, 1990, J BIOL CHEM, V265, P20394; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WELCH WJ, 1985, J BIOL CHEM, V260, P3058	30	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15168	15173						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325890				2022-12-27	WOS:A1993LL75900090
J	HENDERSON, LA; QURESHI, MN				HENDERSON, LA; QURESHI, MN			A PEPTIDE INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION BINDS TO NOVEL HUMAN CELL-SURFACE POLYPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL-MYRISTATE ACETATE; ENVELOPE GLYCOPROTEIN; SOLUBLE CD4; SYNTHETIC PEPTIDE; HIV-INFECTION; TRANSMEMBRANE PROTEIN; CYTOPLASMIC DOMAIN; SEQUENCE IDENTITY; AIDS RETROVIRUS; T4 ANTIGEN	Putative cell surface human immunodeficiency virus (HIV) gp41 receptor proteins of 45 and 80 kDa (p45 and p80, respectively) were identified on human cells using a 17-amino acid peptide, referred to as CS3. In contrast, murine P815 cells expressed a peptide binding protein of 80 kDa only. A segment of 8 amino acids within CS3 contains the minimum sequence able to inhibit binding of radiolabeled CS3 to p80 and p45, as shown by competitive binding studies. Human p45 was purified from CD4+ RH9 cells by CS3 peptide affinity chromatography. Human p80 was partially purified from RH9 cell lysates by size exclusion chromatography followed by SDS-polyacrylamide gel electrophoresis; a rabbit polyclonal antibody was raised against this preparation. Anti-p80 antibody inhibited HIV infection in a dose-dependent manner. The CS3 region of gp41 has been been shown previously to be exposed on viral particles and envelope-expressing cells predominately after conformational changes in the HIV envelope occur due to the interaction of CD4 with gp120. These results, together with those from previous studies, suggest that following the interaction of gp120 with CD4, there may be a second receptor interaction necessary for virus entry/fusion.	BETH ISRAEL MED CTR,DEPT PATHOL & LAB MED,NEW YORK,NY 10003	Harvard University; Beth Israel Deaconess Medical Center	HENDERSON, LA (corresponding author), GUTHRIE RES INST,SAYRE,PA 18840, USA.							ACRES RB, 1986, J BIOL CHEM, V261, P6210; BEDINGER P, 1988, NATURE, V334, P162, DOI 10.1038/334162a0; BRIGHTY DW, 1991, P NATL ACAD SCI USA, V88, P7802, DOI 10.1073/pnas.88.17.7802; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; CELADA F, 1990, J EXP MED, V172, P1143, DOI 10.1084/jem.172.4.1143; CIANCIOLO GJ, 1985, SCIENCE, V230, P453, DOI 10.1126/science.2996136; CIANCIOLO GJ, 1988, IMMUNOL LETT, V19, P7, DOI 10.1016/0165-2478(88)90112-5; CLEMENTS GJ, 1991, AIDS RES HUM RETROV, V7, P3, DOI 10.1089/aid.1991.7.3; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DIAMOND DC, 1990, P NATL ACAD SCI USA, V87, P5001, DOI 10.1073/pnas.87.13.5001; DYSON HJ, 1988, ANNU REV BIOPHYS BIO, V17, P305; GABUZDA DH, 1992, J VIROL, V66, P3306, DOI 10.1128/JVI.66.6.3306-3315.1992; GALLAHER WR, 1987, CELL, V50, P327, DOI 10.1016/0092-8674(87)90485-5; GALLAHER WR, 1989, AIDS RES HUM RETROV, V5, P431, DOI 10.1089/aid.1989.5.431; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233; HOXIE JA, 1988, J IMMUNOL, V140, P786; HOXIE JA, 1986, J IMMUNOL, V137, P1194; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; KOWALSKI M, 1991, J VIROL, V65, P281, DOI 10.1128/JVI.65.1.281-291.1991; LEVY JA, 1986, SCIENCE, V232, P998, DOI 10.1126/science.3010461; LORES P, 1992, AIDS RES HUM RETROV, V8, P2063, DOI 10.1089/aid.1992.8.2063; MADDON PJ, 1988, CELL, V54, P865, DOI 10.1016/S0092-8674(88)91241-X; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCKEATING JA, 1991, J VIROL, V65, P852, DOI 10.1128/JVI.65.2.852-860.1991; MOORE JP, 1991, J VIROL, V65, P1133, DOI 10.1128/JVI.65.3.1133-1140.1991; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; MOORE JP, 1992, J VIROL, V66, P235, DOI 10.1128/JVI.66.1.235-243.1992; MOORE JP, 1991, SCIENCE, V56, P1133; MULLIGAN MJ, 1992, J VIROL, V66, P3971, DOI 10.1128/JVI.66.6.3971-3975.1992; NGO TT, 1981, J BIOL CHEM, V256, P1313; OBRIEN WA, 1992, J VIROL, V66, P3125, DOI 10.1128/JVI.66.5.3125-3130.1992; QURESHI NM, 1990, AIDS, V4, P553, DOI 10.1097/00002030-199006000-00009; RICHARDSON NE, 1986, P NATL ACAD SCI USA, V85, P6102; RUEGG CL, 1989, J VIROL, V63, P3257, DOI 10.1128/JVI.63.8.3257-3260.1989; RUEGG CL, 1990, J IMMUNOL, V144, P3928; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SLECKMAN BP, 1989, J IMMUNOL, V142, P1457; SOLBACH W, 1982, J EXP MED, V1156, P1250; TRUNEH A, 1991, J BIOL CHEM, V266, P5942; TURNER S, 1992, P NATL ACAD SCI USA, V89, P1335, DOI 10.1073/pnas.89.4.1335; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; WILSON C, 1990, J VIROL, V64, P3240, DOI 10.1128/JVI.64.7.3240-3248.1990	46	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15291	15297						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325899				2022-12-27	WOS:A1993LL75900107
J	SEVERINOV, K; SOUSHKO, M; GOLDFARB, A; NIKIFOROV, V				SEVERINOV, K; SOUSHKO, M; GOLDFARB, A; NIKIFOROV, V			RIFAMPICIN REGION REVISITED - NEW RIFAMPICIN-RESISTANT AND STREPTOLYDIGIN-RESISTANT MUTANTS IN THE BETA-SUBUNIT OF ESCHERICHIA-COLI RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RPOB GENE; NUCLEOTIDE-SEQUENCE; TRANSCRIPTION; DNA; TERMINATION; MUTATION; PROTEIN; ORGANIZATION; PHENOTYPES; OPERON	Mutations to rifampicin resistance (Rif(R)) in Escherichia coli alter the beta subunit of RNA polymerase (RNAP). A series of new point Rif(R) mutations was isolated with the aid of random polymerase chain reaction-mediated mutagenesis followed by selection on rifampicin (Rif). All of the new Rif(R) mutants, including changes in two novel positions, fell into the two principal clusters previously identified in the middle section of beta. Disruption of the spacer between the two clusters with deletions and insertions led to RNAP that was functional and sensitive to Rif in vitro, indicating that the spacer is not directly involved in Rif binding. However, most of the spacer mutants were strongly resistant to streptolydigin, suggesting that this area is involved in the binding of streptolydigin. An insertion of six consecutive histidines into the spacer was constructed that could be used to anchor RNAP on a Ni-chelate matrix without the loss of enzymatic activity, indicating that this region is looped out of the RNAP molecule.	PUBL HLTH RES INST CITY NEW YORK INC, 455 1ST AVE, NEW YORK, NY 10016 USA; RUSSIAN ACAD SCI, INST MOLEC GENET, MOSCOW 123182, RUSSIA	Russian Academy of Sciences			Severinov, Konstantin/C-8545-2016		NIGMS NIH HHS [GM-30717] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030717] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALIKHANIAN SI, 1970, 2ND P LEP C, P28; BORODIN AM, 1988, DOKL AKAD NAUK SSSR+, V302, P1261; BRIAT JF, 1979, EUR J BIOCHEM, V98, P285, DOI 10.1111/j.1432-1033.1979.tb13187.x; CASSANI G, 1971, NATURE-NEW BIOL, V230, P197, DOI 10.1038/newbio230197a0; CLARK MA, 1992, CURR MICROBIOL, V25, P283, DOI 10.1007/BF01575863; DAS A, 1978, P NATL ACAD SCI USA, V75, P4828, DOI 10.1073/pnas.75.10.4828; ENGEL JN, 1990, J BACTERIOL, V172, P5732, DOI 10.1128/jb.172.10.5732-5741.1990; GARDNER MJ, 1991, MOL BIOCHEM PARASIT, V44, P115, DOI 10.1016/0166-6851(91)90227-W; GUARENTE LP, 1978, P NATL ACAD SCI USA, V75, P294, DOI 10.1073/pnas.75.1.294; HARTMANN G, 1967, BIOCHIM BIOPHYS ACTA, V145, P843, DOI 10.1016/0005-2787(67)90147-5; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HUDSON GS, 1988, J MOL BIOL, V200, P639, DOI 10.1016/0022-2836(88)90477-9; IGLOI GL, 1990, MOL GEN GENET, V221, P379, DOI 10.1007/BF00259403; IWAKURA Y, 1973, MOL GEN GENET, V121, P181, DOI 10.1007/BF00277531; JIN DJ, 1989, J BACTERIOL, V171, P5229, DOI 10.1128/jb.171.9.5229-5231.1989; JIN DJ, 1988, J MOL BIOL, V202, P245, DOI 10.1016/0022-2836(88)90455-X; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; JOHNSTON DE, 1976, RNA POLYM, P101; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; KASHLEV M, 1993, IN PRESS GENE AMST; KIDD GH, 1980, BIOCHIM BIOPHYS ACTA, V609, P14, DOI 10.1016/0005-2787(80)90197-5; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; LISITSYN NA, 1984, MOL GEN GENET, V196, P173, DOI 10.1007/BF00334112; LISITSYN NA, 1985, BIOORG KHIM+, V11, P132; LISITSYN NA, 1988, EUR J BIOCHEM, V177, P363, DOI 10.1111/j.1432-1033.1988.tb14385.x; MCCLURE WR, 1978, J BIOL CHEM, V253, P8949; MINDLIN SZ, 1972, MOL GEN GENET, V115, P115, DOI 10.1007/BF00277290; MORROW TO, 1979, J BACTERIOL, V137, P374, DOI 10.1128/JB.137.1.374-383.1979; NENE V, 1982, MOL GEN GENET, V188, P399, DOI 10.1007/BF00330040; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; OVCHINNIKOV YA, 1981, MOL GEN GENET, V184, P536, DOI 10.1007/BF00352535; OVCHINNIKOV YA, 1983, MOL GEN GENET, V190, P344, DOI 10.1007/BF00330662; Sambrook J, 1989, MOL CLONING LABORATO; SCHLEIF R, 1969, NATURE, V223, P1068, DOI 10.1038/2231068a0; SCHULTZ W, 1981, NUCLEIC ACIDS RES, V24, P6889; SEVERINOV K, 1992, J BIOL CHEM, V267, P12813; STENDER W, 1977, EUR J BIOCHEM, V76, P591, DOI 10.1111/j.1432-1033.1977.tb11629.x; SZYBALSKI W, 1952, SCIENCE, V116, P46; VONDERHELM K, 1972, NATURE-NEW BIOL, V235, P82, DOI 10.1038/newbio235082a0; WEHRLI W, 1968, P NATL ACAD SCI USA, V61, P667, DOI 10.1073/pnas.61.2.667; YEPIZPLASCENCIA GM, 1990, NUCLEIC ACIDS RES, V18, P1869, DOI 10.1093/nar/18.7.1869; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052; ZILLIG W, 1970, COLD SPRING HARB SYM, V35, P47, DOI 10.1101/SQB.1970.035.01.010	45	176	183	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14820	14825						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325861				2022-12-27	WOS:A1993LL75900046
J	VANDAM, M; MULLBERG, J; SCHOOLTINK, H; STOYAN, T; BRAKENHOFF, JPJ; GRAEVE, L; HEINRICH, PC; ROSEJOHN, S				VANDAM, M; MULLBERG, J; SCHOOLTINK, H; STOYAN, T; BRAKENHOFF, JPJ; GRAEVE, L; HEINRICH, PC; ROSEJOHN, S			STRUCTURE-FUNCTION ANALYSIS OF INTERLEUKIN-6 UTILIZING HUMAN MURINE CHIMERIC MOLECULES - INVOLVEMENT OF 2 SEPARATE DOMAINS IN RECEPTOR-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; AMINO-ACIDS; HUMAN IL-6; BIOLOGIC ACTIVITIES; INTERNAL DELETIONS; SIGNAL TRANSDUCER; ESCHERICHIA-COLI; HIGH-AFFINITY; EXPRESSION; CYTOKINES	As an approach to understanding the interaction of interleukin-6 (IL-6) and its 80-kDa receptor (gp80), we have constructed chimeric human/murine IL-6-molecules, which were expressed in Escherichia coli and analyzed for biological activity and receptor binding. This experimental strategy was based on the observation that human IL-6 acts on human and murine cells, whereas murine IL-6 stimulates only murine cells. The regions to be exchanged were chosen according to the four antiparallel helix model of the hematopoietic cytokine family. All 14 chimeras constructed showed biological activity on murine cells. From the differential biological activities on human cells we deduced that three out of four domains of IL-6 are involved in species specificity, whereas only two domains are necessary for specific recognition by the gp80 IL-6-receptor protein.	NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV, CLB, CENT LAB, 1066 CX AMSTERDAM, NETHERLANDS		VANDAM, M (corresponding author), RHEIN WESTFAL TH AACHEN KLINIKUM, INST BIOCHEM, PAUWELSSTR 30, W-5100 AACHEN, GERMANY.		Rose-John, Stefan/A-7998-2010	Rose-John, Stefan/0000-0002-7519-3279				AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; ARCONE R, 1991, FEBS LETT, V288, P197, DOI 10.1016/0014-5793(91)81033-5; BAUER J, 1991, ANN HEMATOL, V62, P203, DOI 10.1007/BF01729833; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; BRAKENHOFF JPJ, 1989, J IMMUNOL, V143, P1175; COULIE PG, 1989, EUR J IMMUNOL, V19, P2107, DOI 10.1002/eji.1830191121; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FIORILLO MT, 1992, EUR J IMMUNOL, V22, P799, DOI 10.1002/eji.1830220325; FONTAINE V, 1991, GENE, V104, P227, DOI 10.1016/0378-1119(91)90254-9; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HAEGEMAN G, 1986, EUR J BIOCHEM, V159, P625, DOI 10.1111/j.1432-1033.1986.tb09931.x; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; IDA N, 1989, BIOCHEM BIOPH RES CO, V165, P728, DOI 10.1016/S0006-291X(89)80027-0; KRUTTGEN A, 1990, FEBS LETT, V273, P95, DOI 10.1016/0014-5793(90)81059-W; KRUTTGEN A, 1990, FEBS LETT, V262, P323, DOI 10.1016/0014-5793(90)80219-9; LAURELL CB, 1972, SCAND J CLIN LAB INV, V29, P21, DOI 10.3109/00365517209102748; LEEBEEK FWG, 1992, J BIOL CHEM, V267, P14832; LUTTICKEN C, 1991, FEBS LETT, V282, P265, DOI 10.1016/0014-5793(91)80491-K; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; MACKIEWICZ A, 1990, P NATL ACAD SCI USA, V87, P1491, DOI 10.1073/pnas.87.4.1491; Roberts A. B., 1990, PEPTIDE GROWTH FACTO, P633; ROSEJOHN S, 1991, J BIOL CHEM, V266, P3841; SAITO M, 1992, J IMMUNOL, V148, P4066; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHANAFELT AB, 1991, J BIOL CHEM, V266, P13804; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SNOUWAERT JN, 1991, J IMMUNOL, V146, P585; STUDIER FW, 1990, METHOD ENZYMOL, V185, P517; SUGITA T, 1990, J EXP MED, V171, P2001, DOI 10.1084/jem.171.6.2001; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAL M, 1985, J BIOL CHEM, V260, P9976; VANSNICK J, 1988, EUR J IMMUNOL, V18, P193; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZHANG XG, 1990, BLOOD, V76, P2599; ZILBERSTEIN A, 1986, EMBO J, V5, P2529, DOI 10.1002/j.1460-2075.1986.tb04531.x; ZOHLNHOFER D, 1992, FEBS LETT, V306, P219, DOI 10.1016/0014-5793(92)81004-6	46	102	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15285	15290						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325898				2022-12-27	WOS:A1993LL75900106
J	KITABAYASHI, I; KAWAKAMI, Z; MATSUOKA, T; CHIU, R; GACHELIN, G; YOKOYAMA, K				KITABAYASHI, I; KAWAKAMI, Z; MATSUOKA, T; CHIU, R; GACHELIN, G; YOKOYAMA, K			2 CIS-REGULATORY ELEMENTS THAT MEDIATE DIFFERENT SIGNALING PATHWAYS FOR SERUM-DEPENDENT ACTIVATION OF THE JUNB GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FOS; CELLS	Transcription of the junB gene is rapidly and transiently induced by a variety of extracellular signals We report here that expression directed by a jun promoter/chloramphenicol acetyltransferase reporter construct (junB/CAT) is induced by fetal bovine serum, 12-O-tetradecanoylphorbol-13-acetate (TPA), epidermal growth factor (EGF), platelet-derived growth factor, and fibroblast growth factor in mouse fibroblast 3T6 cells. Deletion analysis of the promoter region of the junB gene indicates that there are at least two cis-regulatory elements that confer the capacity for serum-dependent induction. These two serum response elements (SRE1 and SRE2) are mapped between nucleotides -1451 and -1425 and between nucleotides -3100 and -2500, respectively, relative to the site of initiation of transcription. SRE1, the nucleotide sequence of which resembles that of the serum response element of the c-fos gene, is activated by TPA, platelet-derived growth factor, and fibroblast growth factor, but these growth-stimulating factors do not induce SRE2-mediated transcription. Pretreatment of the cells with phorbol dibutyrate, which reduces the level of protein kinase C activity in cells, almost completely abolishes the activation of SRE1 by TPA. Pretreatment with phorbol dibutyrate also reduces (but does not eliminate) the serum-dependent activation of SRE1. By contrast, the induction of SRE2 by serum is not affected by this pretreatment. Herbimycin A, an inhibitor of protein kinases, inhibits the activity of SRE2, but not that of SRE1. These results suggest that transcription of the junB gene can be induced by at least two distinct signaling pathways, which are mediated by SRE1 and SRE2, respectively. In addition, EGF induces expression of junB/CAT as strongly as does serum, but neither SRE1 nor SRE2 is sufficient for responsiveness to EGF.	INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, 3-1-1 KOYADAI, TSUKUBA, IBARAKI 305, JAPAN; UNIV CALIF LOS ANGELES, SCH MED, DEPT SURG ONCOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90024 USA; INST PASTEUR, DEPT IMMUNOL, F-75724 PARIS 15, FRANCE	RIKEN; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Kitabayashi, Issay/G-2204-2017	Kitabayashi, Issay/0000-0002-8409-0407	NCI NIH HHS [CA54381] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA054381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DENHERTOG J, 1992, NUCLEIC ACIDS RES, V20, P125, DOI 10.1093/nar/20.1.125; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISH TM, 1987, MOL CELL BIOL, V7, P3490; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; KAWAKAMI Z, 1992, NUCLEIC ACIDS RES, V20, P914, DOI 10.1093/nar/20.4.914; KITABAYASHI I, 1992, EMBO J, V11, P167, DOI 10.1002/j.1460-2075.1992.tb05039.x; KITABAYASHI I, 1991, NUCLEIC ACIDS RES, V19, P649, DOI 10.1093/nar/19.3.649; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Treisman R, 1990, Semin Cancer Biol, V1, P47; VOGT PK, 1990, ADV CANCER RES, V55, P2	24	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14482	14489						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314805				2022-12-27	WOS:A1993LJ82500099
J	WEBB, JR; MCMASTER, WR				WEBB, JR; MCMASTER, WR			MOLECULAR-CLONING AND EXPRESSION OF A LEISHMANIA-MAJOR GENE ENCODING A SINGLE-STRANDED DNA-BINDING PROTEIN CONTAINING 9 CCHC ZINC-FINGER MOTIFS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; RNA-POLYMERASE-II; C-TERMINAL DOMAIN; NUCLEOCAPSID PROTEIN; TRYPANOSOMA-BRUCEI; DISCONTINUOUS TRANSCRIPTION; SURFACE GLYCOPROTEIN; LARGEST SUBUNIT; MESSENGER-RNAS; NUCLEIC-ACIDS	The genes encoding GP63, the major surface glycoprotein of the protozoan parasite Leishmania, are highly conserved across diverse species of Leishmania both within the protein coding region and in the immediate 5'-untranslated region. Located between the 3' trans-spliced leader acceptor site and the translational initiation codon of the GP63 gene is an area of conserved hexanucleotide direct repeats (CTCGCC) which vary in number according to species. To determine whether these repeats represent a site of protein DNA interaction, a Leishmania major lambdagt11 expression library was screened with a radiolabeled synthetic oligodeoxynucleotide probe containing multiple CTCGCC repeats to detect clones expressing functional DNA-binding proteins. Using this approach a gene was isolated which encodes a sequence-specific DNA-binding protein referred to as HEXBP (hexamer-binding protein). Sequence analysis of the HEXBP gene showed that HEXBP contains nine cysteine-rich motifs which are identical to a consensus sequence known as the ''CCHC type'' zinc finger. This motif is present in a number of nucleic acid-binding proteins including the nucleocapsid protein of retroviruses. In accordance with the activity exhibited by other proteins containing the ''CCHC'' motif, HEXBP binds to single-stranded nucleic acids as demonstrated by gel mobility shift assays and Southwestern blot assays.	UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER V6T 1W5,BC,CANADA	University of British Columbia								BENAMAR MF, 1988, MOL CELL BIOL, V8, P2166, DOI 10.1128/MCB.8.5.2166; BESS JW, 1992, J VIROL, V66, P840, DOI 10.1128/JVI.66.2.840-847.1992; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BUTTON LL, 1989, MOL BIOCHEM PARASIT, V32, P271, DOI 10.1016/0166-6851(89)90076-5; CAMPBELL DA, 1984, NATURE, V311, P350, DOI 10.1038/311350a0; CORNILLE F, 1990, INT J PEPT PROT RES, V36, P551; COVEY SN, 1986, NUCLEIC ACIDS RES, V14, P623, DOI 10.1093/nar/14.2.623; Curotto da Lafaille M.A., 1992, Proceedings of the National Academy of Sciences of the United States of America, V89, P2703; EVERS R, 1989, CELL, V56, P585, DOI 10.1016/0092-8674(89)90581-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FITZGERALD DW, 1991, BIOCHEMISTRY-US, V30, P5195, DOI 10.1021/bi00235a012; FRANK D, 1992, GENE DEV, V6, P2112, DOI 10.1101/gad.6.11.2112; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GLASS DJ, 1986, MOL CELL BIOL, V6, P4657, DOI 10.1128/MCB.6.12.4657; GORELICK RJ, 1988, P NATL ACAD SCI USA, V85, P8420, DOI 10.1073/pnas.85.22.8420; GREEN LM, 1990, P NATL ACAD SCI USA, V87, P6403, DOI 10.1073/pnas.87.16.6403; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Huang X Y, 1992, Genet Eng (N Y), V14, P211; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; IMBODEN MA, 1987, NUCLEIC ACIDS RES, V15, P7357, DOI 10.1093/nar/15.18.7357; JENTOFT JE, 1988, P NATL ACAD SCI USA, V85, P7094, DOI 10.1073/pnas.85.19.7094; KARPEL RL, 1987, J BIOL CHEM, V262, P4961; KATZ RA, 1989, BIOESSAYS, V11, P176, DOI 10.1002/bies.950110605; LABAN A, 1989, P NATL ACAD SCI USA, V86, P9119, DOI 10.1073/pnas.86.23.9119; LABAN A, 1990, NATURE, V343, P572, DOI 10.1038/343572a0; LANDFEAR SM, 1983, MOL CELL BIOL, V3, P1070, DOI 10.1128/MCB.3.6.1070; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MEADE JC, 1987, MOL CELL BIOL, V7, P3937, DOI 10.1128/MCB.7.11.3937; MERIC C, 1989, J VIROL, V63, P1558; MERIC C, 1988, J VIROL, V62, P3328; MILLER RA, 1990, MOL BIOCHEM PARASIT, V39, P267, DOI 10.1016/0166-6851(90)90065-T; MOUNT SM, 1985, MOL CELL BIOL, V5, P1630, DOI 10.1128/MCB.5.7.1630; MUHICH ML, 1988, MOL CELL BIOL, V8, P3837, DOI 10.1128/MCB.8.9.3837; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PRATS AC, 1991, NUCLEIC ACIDS RES, V19, P3533, DOI 10.1093/nar/19.13.3533; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; ROBERTS WJ, 1989, BIOCHEMISTRY-US, V28, P10043, DOI 10.1021/bi00452a024; RUDENKO G, 1992, NUCLEIC ACIDS RES, V20, P303, DOI 10.1093/nar/20.2.303; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO SM, 1991, DEVELOPMENT, V112, P747; SMITH JL, 1989, CELL, V56, P815, DOI 10.1016/0092-8674(89)90686-7; SOUTH TL, 1989, J AM CHEM SOC, V111, P395, DOI 10.1021/ja00183a074; SOUTH TL, 1991, BIOCHEMISTRY-US, V30, P6342, DOI 10.1021/bi00239a036; SOUTH TL, 1990, BIOCHEM PHARMACOL, V40, P123, DOI 10.1016/0006-2952(90)90187-P; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUMMERS MF, 1991, J CELL BIOCHEM, V45, P41, DOI 10.1002/jcb.240450110; TENASBROEK ALMA, 1990, NATURE, V348, P174, DOI 10.1038/348174a0; TSCHUDI C, 1985, P NATL ACAD SCI USA, V82, P3998, DOI 10.1073/pnas.82.12.3998; TSCHUDI C, 1988, EMBO J, V7, P455, DOI 10.1002/j.1460-2075.1988.tb02833.x; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WALLIS AE, 1987, J EXP MED, V166, P1814, DOI 10.1084/jem.166.6.1814; WEBB JR, 1991, MOL BIOCHEM PARASIT, V48, P173, DOI 10.1016/0166-6851(91)90113-K; WEINER AM, 1990, CELL, V61, P917, DOI 10.1016/0092-8674(90)90053-H; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P5153, DOI 10.1093/nar/19.19.5153; ZOMERDIJK JCBM, 1991, NATURE, V353, P772, DOI 10.1038/353772a0	56	41	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13994	14002						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314766				2022-12-27	WOS:A1993LJ82500035
J	GORDON, JA; HELLER, SK; KADUCE, TL; SPECTOR, AA				GORDON, JA; HELLER, SK; KADUCE, TL; SPECTOR, AA			FORMATION AND RELEASE OF A PEROXISOME-DEPENDENT ARACHIDONIC-ACID METABOLITE BY HUMAN SKIN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; TUBULAR EPITHELIAL-CELLS; RAT-LIVER PEROXISOMES; SMOOTH-MUSCLE CELLS; BETA-OXIDATION; 12-HYDROXYEICOSATETRAENOIC ACID; ENDOTHELIAL-CELLS; PATHWAY; IDENTIFICATION; REDUCTASE	Human skin fibroblasts labeled with [5,6,8,9,11,12,14,15-H-3]arachidonic acid produce a radioactive metabolite that has a shorter retention time on reverse-phase high-performance liquid chromatography than arachidonic acid. This product is not retained in the cells; it is released entirely into the extracellular fluid in a time dependent manner. The metabolite does not cochromatograph with any of the eicosanoid standards, and its formation is not prevented by the addition of cyclooxygenase, lipoxygenase, or cytochrome P-450 inhibitors. The compound is not produced by fibroblasts labeled with [1-C-14]arachidonic acid, suggesting that it is formed through an oxidative process. Chemical analyses indicated that the metabolite is 4,7,10-hexadecatrienoic acid (16:3). Peroxisome-deficient human skin fibroblasts did not produce 16:3, indicating that it probably is formed through peroxisomal beta-oxidation. Human umbilical vein endothelial cells and porcine pulmonary artery smooth muscle cells also release radioactive 16:3 following labeling with [H-3]arachidonic acid. Therefore, the production of this metabolite is not limited only to fibroblasts. The fact that 16:3 is released into the extracellular fluid suggests that it may be a new type of lipid mediator derived from arachidonic acid, formed through a peroxisome-dependent oxidative process.	UNIV IOWA,COLL MED,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa	GORDON, JA (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,E 300 G GH,200 HAWKINS DR,IOWA CITY,IA 52242, USA.		Spector, Arthur/AAG-9860-2020		NHLBI NIH HHS [HL 49264] Funding Source: Medline; NIDDK NIH HHS [DK 28516] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049264] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028516] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DEDUVE C, 1966, PHYSIOL REV, V46, P323, DOI 10.1152/physrev.1966.46.2.323; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DOMMES V, 1981, J BIOL CHEM, V256, P8259; FALES HM, 1973, ANAL CHEM, V45, P2302, DOI 10.1021/ac60335a020; FITZPATRICK FA, 1989, PHARMACOL REV, V40, P229; GORDON JA, 1989, J LIPID RES, V30, P731; GORDON JA, 1987, AM J PHYSIOL, V253, pC277, DOI 10.1152/ajpcell.1987.253.2.C277; GORDON JA, 1990, J CLIN INVEST, V85, P1173, DOI 10.1172/JCI114550; GORDON JA, 1993, J CLIN INVEST, V92, P169, DOI 10.1172/JCI116545; GORDON JA, 1991, BIOCHIM BIOPHYS ACTA, V1085, P21, DOI 10.1016/0005-2760(91)90227-9; HADJIAGAPIOU C, 1987, PROSTAG OTH LIPID M, V34, P579, DOI 10.1016/0090-6980(87)90100-6; HADJIAGAPIOU C, 1990, J BIOL CHEM, V265, P4369; HILTUNEN JK, 1986, J BIOL CHEM, V261, P6484; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; ISAACS WB, 1989, J BIOL CHEM, V264, P17953; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LEWIS RA, 1984, J CLIN INVEST, V73, P889, DOI 10.1172/JCI111312; MAAS RL, 1982, J BIOL CHEM, V257, P7055; MATHUR SN, 1990, J BIOL CHEM, V265, P21048; MOORE SA, 1988, J CELL PHYSIOL, V137, P75, DOI 10.1002/jcp.1041370109; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; OSMUNDSEN H, 1985, BIOCHEM J, V230, P329, DOI 10.1042/bj2300329; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; RAZ A, 1989, P NATL ACAD SCI USA, V86, P1657, DOI 10.1073/pnas.86.5.1657; RAZ A, 1988, J BIOL CHEM, V263, P3022; SCHEPERS L, 1988, J BIOL CHEM, V263, P2724; SCHULZ H, 1987, LIFE SCI, V40, P1443, DOI 10.1016/0024-3205(87)90375-4; SCHULZ H, 1991, BIOCHIM BIOPHYS ACTA, V1081, P109, DOI 10.1016/0005-2760(91)90015-A; SCHULZ H, 1987, TRENDS BIOCHEM SCI, V12, P403, DOI 10.1016/0968-0004(87)90196-4; SHEN XY, 1988, BIOCHEMISTRY-US, V27, P996, DOI 10.1021/bi00403a024; SPECTOR AA, 1988, PROG LIPID RES, V27, P271, DOI 10.1016/0163-7827(88)90009-4; STOLL LL, 1989, J CELL PHYSIOL, V139, P253, DOI 10.1002/jcp.1041390206; VANROLLINS M, 1985, BIOCHIM BIOPHYS ACTA, V833, P272, DOI 10.1016/0005-2760(85)90199-7; WANG LX, 1990, J LIPID RES, V31, P2265; WIGREN J, 1993, J LIPID RES, V34, P625	36	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4103	4109						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307970				2022-12-27	WOS:A1994MW98900034
J	GREENWOOD, JA; SCOTT, CW; SPREEN, RC; CAPUTO, CB; JOHNSON, GVW				GREENWOOD, JA; SCOTT, CW; SPREEN, RC; CAPUTO, CB; JOHNSON, GVW			CASEIN KINASE-II PREFERENTIALLY PHOSPHORYLATES HUMAN TAU ISOFORMS CONTAINING AN AMINO-TERMINAL INSERT - IDENTIFICATION OF THREONINE-39 AS THE PRIMARY PHOSPHATE ACCEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; PAIRED HELICAL FILAMENTS; EPIDERMAL GROWTH-FACTOR; HEAT-SHOCK PROTEIN; NEUROFIBRILLARY TANGLES; ALZHEIMERS-DISEASE; BINDING DOMAIN; TUBULIN; NEUROFILAMENTS; CALMODULIN	The in vitro phosphorylation of the microtubule-associated protein tau by casein kinase II was studied. Purified human brain tau was phosphorylated by casein kinase II to a stoichiometry of 0.7 mol of P-32/mol of tau. Individual recombinant human tau isoforms were phosphorylated to stoichiometries ranging from 0.2 to 0.8 mol of P-32/mol of tau. Casein kinase II catalyzed a 4-fold greater incorporation of phosphate into the tau isoform containing a 58-amino acid insert near its amino terminus (T4L) than the isoforms without the 58-amino acid insert (T3 and T4). Phosphopeptide mapping of casein kinase II phosphorylated human tau and recombinant tau isoforms suggested that the isoforms containing an amino-terminal insert constitute the major substrates for casein kinase II within the tau family. The sites of phosphorylation on T4L were identified by digesting phosphorylated T4L with the protease Asp-N, separating the peptides by reversed phase high performance liquid chromatography, and analyzing the isolated peptides by liquid-secondary ion mass spectrometry and solid-phase amino-terminal sequencing. Thr(39) was identified as the predominant phosphorylation site, which is located 5 residues from the amino-terminal insert in T4L. Phosphopeptide mapping of tau isolated from LA-N-5 neuroblastoma cells indicates that Thr(39) is phosphorylated in situ. To our knowledge, this is the first demonstration of a differential phosphorylation of the human tau isoforms, with the isoforms containing the acidic aminoterminal insert being the preferred substrates of casein kinase II.	UNIV ALABAMA, DEPT PSYCHIAT & BEHAV NEUROBIOL, BIRMINGHAM, AL 35294 USA; ICI AMER INC, ICI PHARMACEUT GRP, WILMINGTON, DE 19897 USA	University of Alabama System; University of Alabama Birmingham			Johnson, Gail V.W./K-4723-2012	Johnson, Gail V.W./0000-0003-3464-0404; Greenwood, Juliet/0000-0001-6438-964X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027538, R29NS027538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG006569] Funding Source: NIH RePORTER; NIA NIH HHS [AG06569] Funding Source: Medline; NINDS NIH HHS [NS27538] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AAMODT EJ, 1984, BIOCHEMISTRY-US, V23, P6023, DOI 10.1021/bi00320a019; ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; BAUM L, 1992, BRAIN RES, V573, P126, DOI 10.1016/0006-8993(92)90121-O; BINART N, 1989, BIOCHEM BIOPH RES CO, V159, P140, DOI 10.1016/0006-291X(89)92415-7; CAPUTO CB, 1989, BIOCHIM BIOPHYS ACTA, V1012, P299, DOI 10.1016/0167-4889(89)90112-2; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; CORREAS I, 1992, J BIOL CHEM, V267, P15721; CRUTE BE, 1992, J NEUROCHEM, V59, P2017; DELACOURTE A, 1986, J NEUROL SCI, V76, P173, DOI 10.1016/0022-510X(86)90167-X; DIAZNIDO J, 1988, MOL CELL BIOCHEM, V79, P73, DOI 10.1007/BF00229400; DIAZNIDO J, 1988, J CELL BIOL, V106, P2057, DOI 10.1083/jcb.106.6.2057; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; FLAMENT S, 1990, BRAIN RES, V516, P15, DOI 10.1016/0006-8993(90)90891-E; FUJITAYAMAGUCHI Y, 1989, P NATL ACAD SCI USA, V86, P7306, DOI 10.1073/pnas.86.19.7306; GATICA M, 1987, P NATL ACAD SCI USA, V84, P324, DOI 10.1073/pnas.84.2.324; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HATHAWAY GM, 1984, J BIOL CHEM, V259, P7011; HEIMANN R, 1985, J BIOL CHEM, V260, P2160; IIMOTO DS, 1990, BRAIN RES, V507, P273, DOI 10.1016/0006-8993(90)90282-G; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; JOHNSON GVW, 1989, BIOCHEM BIOPH RES CO, V163, P1505, DOI 10.1016/0006-291X(89)91150-9; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KHILKO S, 1992, PROTEIN EXPRES PURIF, V3, P355, DOI 10.1016/S1046-5928(05)80035-X; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASLIAH E, 1992, AM J PATHOL, V140, P263; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; MEGGIO F, 1987, FEBS LETT, V215, P241, DOI 10.1016/0014-5793(87)80154-0; MEGGIO F, 1983, FEBS LETT, V160, P203, DOI 10.1016/0014-5793(83)80967-3; MIYATA Y, 1986, J BIOL CHEM, V261, P3026; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; POLLARD TD, 1984, J CELL BIOL, V99, pS33, DOI 10.1083/jcb.99.1.33s; RUNGE MS, 1981, P NATL ACAD SCI-BIOL, V78, P1431, DOI 10.1073/pnas.78.3.1431; SACKS DB, 1988, J BIOL CHEM, V263, P2377; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; SCOTT CW, 1991, J NEUROSCI RES, V30, P154, DOI 10.1002/jnr.490300116; SERRANO L, 1987, J CELL BIOL, V105, P1731, DOI 10.1083/jcb.105.4.1731; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; SIHAG RK, 1990, J BIOL CHEM, V265, P4166; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; Speicher D.W., 1989, TECHNIQUES PROTEIN C, P24; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WOOD JG, 1986, P NATL ACAD SCI USA, V83, P4040, DOI 10.1073/pnas.83.11.4040	58	90	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4373	4380						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308007				2022-12-27	WOS:A1994MW98900075
J	MUSTAFI, D; MAKINEN, MW				MUSTAFI, D; MAKINEN, MW			CATALYTIC CONFORMATION OF CARBOXYPEPTIDASE-A - STRUCTURE OF A TRUE ENZYME REACTION INTERMEDIATE DETERMINED BY ELECTRON-NUCLEAR DOUBLE-RESONANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LABELED AMINO-ACIDS; METAL-ION; COMPUTER-GRAPHICS; CRYSTAL-STRUCTURE; ESTER HYDROLYSIS; ACTIVE-SITE; MECHANISM; BINDING; SPECTROSCOPY; ENVIRONMENT	The structure of a catalytically competent reaction intermediate of carboxypeptidase A (CPA) formed with the specific spin-label ester substrate O-[3-(2,2,5,5-tetramethyl-1-oxypyrrolinyl)propen-2-oyl]- -L-beta-phenyllactate through application of cryoenzymological methods has been determined by electron nuclear double resonance (ENDOR) and molecular modeling. It is shown that the reaction intermediate is best identified as a mixed anhydride acylenzyme derivative in which the side chain of Glu-270 is acylated by the spin-label substrate, in agreement with previous cryoenzymological and spectroscopic studies from this laboratory. From the observed proton ENDOR shifts corresponding to principal hyperfine coupling components and assigned by selective deuteration, the dipolar hyperfine coupling components were calculated to estimate electron-proton distances. With these ENDOR-determined distances as constraints, the conformation of the substrate free in solution and in the active site of CPA has been determined on the basis of torsion angle search calculations. With a catalytically active, acetylated form of CPA, we have also assigned the position of the side chain of Tyr-198 with respect to the nitroxyl group. The positional assignments of both substrate and active-site residues in a true reaction intermediate provide important constraints in defining the structural basis of action of CPA.	UNIV CHICAGO,CUMMINGS LIFE SCI CTR,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	University of Chicago					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021900] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21900] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOWITZ N, 1967, BIOCHEM BIOPH RES CO, V29, P862, DOI 10.1016/0006-291X(67)90299-9; BERLINER L J, 1976, P592; BRESLOW R, 1977, P NATL ACAD SCI USA, V74, P1303, DOI 10.1073/pnas.74.4.1303; BYERS LD, 1973, BIOCHEMISTRY-US, V12, P2070, DOI 10.1021/bi00735a008; CAPIOMONT A, 1974, J CHEM PHYS, V60, P2530, DOI 10.1063/1.1681393; CARTWRIGHT SJ, 1981, CRC CRIT REV BIOCH, V11, P145; CESARIO M, 1975, CRYST STRUCT COMMUN, V4, P245; CHIARI G, 1981, ACTA CRYSTALLOGR B, V37, P1623, DOI 10.1107/S0567740881006729; CHRISTIANSON DW, 1986, P NATL ACAD SCI USA, V83, P7568, DOI 10.1073/pnas.83.20.7568; COX DJ, 1964, BIOCHEMISTRY-US, V3, P44, DOI 10.1021/bi00889a008; DAYRINGER HE, 1986, J MOL GRAPHICS, V4, P82; DESLONGCHAMPS P, 1975, TETRAHEDRON, V31, P2463, DOI 10.1016/0040-4020(75)80257-2; Deslongchamps P, 1983, STEREOELECTRONIC EFF, P54; DOUZOU P, 1977, CRYOBIOCHEMISTRY, P286; GALDES A, 1983, BIOCHEMISTRY-US, V22, P1888, DOI 10.1021/bi00277a023; GARDELL SJ, 1987, J BIOL CHEM, V262, P576; GEOGHEGAN KF, 1983, BIOCHEMISTRY-US, V22, P2255, DOI 10.1021/bi00278a031; GLOVSKY J, 1972, BIOCHEM BIOPH RES CO, V47, P244, DOI 10.1016/S0006-291X(72)80034-2; GRIFFITH OH, 1965, J CHEM PHYS, V43, P2909, DOI 10.1063/1.1697233; IIJIMA H, 1987, PROTEINS, V2, P330, DOI 10.1002/prot.340020408; JOELA H, 1991, J PHYS CHEM-US, V95, P9135, DOI 10.1021/j100176a021; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KOCH TR, 1979, J BIOL CHEM, V254, P2310; KUO LC, 1985, J AM CHEM SOC, V107, P5255, DOI 10.1021/ja00304a036; KUO LC, 1982, J BIOL CHEM, V257, P24; KUO LC, 1983, J MOL BIOL, V163, P63, DOI 10.1016/0022-2836(83)90030-X; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIPSCOMB WN, 1974, TETRAHEDRON, V30, P1725, DOI 10.1016/S0040-4020(01)97306-5; LUMRY R, 1951, J AM CHEM SOC, V73, P4330, DOI 10.1021/ja01153a090; Makinen M W, 1984, Adv Inorg Biochem, V6, P1; MAKINEN MW, 1979, J BIOL CHEM, V254, P356; MAKINEN MW, 1989, J MOL BIOL, V207, P201, DOI 10.1016/0022-2836(89)90451-8; MAKINEN MW, 1982, J AM CHEM SOC, V104, P2667, DOI 10.1021/ja00373a070; MAKINEN MW, 1977, ANNU REV BIOPHYS BIO, V6, P301, DOI 10.1146/annurev.bb.06.060177.001505; MOCK WL, 1976, BIOORG CHEM, V5, P403, DOI 10.1016/0045-2068(76)90025-0; MUSTAFI D, 1990, J AM CHEM SOC, V112, P2558, DOI 10.1021/ja00163a012; MUSTAFI D, 1990, BIOPOLYMERS, V29, P45, DOI 10.1002/bip.360290108; MUSTAFI D, 1991, J MAGN RESON, V91, P497, DOI 10.1016/0022-2364(91)90376-5; MUSTAFI D, 1993, J AM CHEM SOC, V115, P3674, DOI 10.1021/ja00062a037; NARUTO S, 1985, J AM CHEM SOC, V107, P5262, DOI 10.1021/ja00304a037; Quiocho F A, 1971, Adv Protein Chem, V25, P1, DOI 10.1016/S0065-3233(08)60278-8; REES DC, 1981, P NATL ACAD SCI-BIOL, V78, P5455, DOI 10.1073/pnas.78.9.5455; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; REES DC, 1981, P NATL ACAD SCI-BIOL, V78, P3408, DOI 10.1073/pnas.78.6.3408; RIORDAN JF, 1963, BIOCHEMISTRY-US, V2, P1460, DOI 10.1021/bi00906a045; Rozantsev E.G., 1970, FREE NITROXYL RADICA, P203; SANDER ME, 1985, BIOCHEM BIOPH RES CO, V132, P681, DOI 10.1016/0006-291X(85)91186-6; SANDER ME, 1986, ZINC ENZYMES, P207; SCHECHTE.I, 1970, EUR J BIOCHEM, V14, P516, DOI 10.1111/j.1432-1033.1970.tb00318.x; SIMPSON RT, 1963, BIOCHEMISTRY-US, V2, P616, DOI 10.1021/bi00903a039; SUH J, 1976, J AM CHEM SOC, V98, P1940, DOI 10.1021/ja00423a048; TURLEY JW, 1972, ACTA CRYSTALL B-STRU, VB 28, P1641, DOI 10.1107/S0567740872004765; VALLEE BL, 1984, ADV ENZYMOL, V56, P284; WELLS GB, 1994, J BIOL CHEM, V269, P4577; WELLS GB, 1988, J AM CHEM SOC, V110, P6343, DOI 10.1021/ja00227a012; WELLS GB, 1990, J AM CHEM SOC, V112, P2566, DOI 10.1021/ja00163a013	56	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4587	4595						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308030				2022-12-27	WOS:A1994MW98900102
J	UEDA, N; INIGUEZLLUHI, JA; LEE, E; SMRCKA, AV; ROBISHAW, JD; GILMAN, AG				UEDA, N; INIGUEZLLUHI, JA; LEE, E; SMRCKA, AV; ROBISHAW, JD; GILMAN, AG			G-PROTEIN BETA-GAMMA-SUBUNITS - SIMPLIFIED PURIFICATION AND PROPERTIES OF NOVEL ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; MUSCARINIC K+-CHANNEL; GTP-BINDING; ADENYLATE-CYCLASE; PHOSPHOLIPASE-C; MOLECULAR-CLONING; ALPHA-SUBUNITS; EXPRESSION; CDNA; TRANSDUCIN	The beta and gamma subunits of heterotrimeric guanine nucleotide-binding regulatory proteins (G proteins) form tightly associated complexes. To examine functional differences among the large number of possible combinations of unique beta and gamma subunits, we have synthesized and characterized beta gamma complexes containing gamma(5) and gamma(7), two widely distributed gamma subunits. When either gamma(5) or gamma(7) is expressed concurrently with beta 1 or beta(2) subunits in a baculovirus/Sf9 cell system, all four subunit complexes support pertussis toxin-catalyzed ADP-ribosylation of rG(i alpha 1) (where ''r'' indicates recombinant), indicating formation of functional complexes. Each of the complexes was purified by subunit exchange chromatography, using the G203A mutant of rG(i alpha 1) as the immobilized ligand. The purified preparations were compared with other recombinant beta gamma subunits, including beta(1) gamma(1) and beta(1) gamma(2), for their ability to modulate type I and II adenylyl cyclase activities; stimulate phosphoinositide-specific phospholipase C beta; support pertussis toxin-catalyzed ADP-ribosylation of rG(i alpha 1) and G(o alpha); and inhibit steady-state GTP hydrolysis catalyzed by G(s alpha), G(o alpha), and myristoylated rG(i alpha 2) The results emphasize the unique properties of beta(1) gamma(1). The properties of the complexes containing gamma(5) or gamma(7) were similar to each other and to those of beta(1) gamma(2).	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; GEISINGER MED CLIN,WEIS CTR RES,DANVILLE,PA 17822	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Geisinger Medical Center				Iniguez-Lluhi, Jorge/0000-0001-7010-089X	NIGMS NIH HHS [GM31954, GM34497, GM39867] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R01GM039867, R01GM031954, R29GM039867, R37GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BRANDT DR, 1985, J BIOL CHEM, V260, P266; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CERIONE RA, 1987, BIOCHEMISTRY-US, V26, P1485, DOI 10.1021/bi00379a041; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GAO B, 1987, J BIOL CHEM, V262, P17254; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRABER SG, 1992, J BIOL CHEM, V267, P13123; GRAF R, 1992, J BIOL CHEM, V267, P24307; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HAGA K, 1992, J BIOL CHEM, V267, P2222; HEKMAN M, 1987, EUR J BIOCHEM, V169, P431, DOI 10.1111/j.1432-1033.1987.tb13630.x; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; ITO H, 1992, J GEN PHYSIOL, V99, P961, DOI 10.1085/jgp.99.6.961; ITOH H, 1991, J BIOL CHEM, V266, P16226; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; LAW SF, 1991, J BIOL CHEM, V266, P17885; LEE E, 1992, J BIOL CHEM, V267, P1212; LEE E, 1993, IN PRESS METHODS ENZ; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LOGOTHETIS DE, 1988, P NATL ACAD SCI USA, V85, P5814, DOI 10.1073/pnas.85.16.5814; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; PENG YW, 1992, P NATL ACAD SCI USA, V89, P10882, DOI 10.1073/pnas.89.22.10882; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; ROBISHAW JD, 1992, BIOCHEM J, V286, P677, DOI 10.1042/bj2860677; ROOF DJ, 1985, J BIOL CHEM, V260, P6242; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; STERNWEIS PC, 1990, RECEPTOR EFFECTOR CO, P1; SUGIMOTO K, 1985, FEBS LETT, V191, P235, DOI 10.1016/0014-5793(85)80015-6; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3	62	169	172	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4388	4395						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308009				2022-12-27	WOS:A1994MW98900077
J	FIALKOW, L; CHAN, CK; GRINSTEIN, S; DOWNEY, GP				FIALKOW, L; CHAN, CK; GRINSTEIN, S; DOWNEY, GP			REGULATION OF TYROSINE PHOSPHORYLATION IN NEUTROPHILS BY THE NADPH OXIDASE - ROLE OF REACTIVE OXYGEN INTERMEDIATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RESPIRATORY BURST; ACTIVATION; INHIBITION; CELLS; NUCLEOTIDES; RECEPTOR; MEMBRANE; PATHWAY; DIAMIDE	Neutrophils possess a multicomponent NADPH-oxidase that produces large quantities of superoxide, which can in turn generate other reactive oxygen intermediates. Superoxide and its dismutation product, hydrogen peroxide, are powerful oxidants. Because the activity of certain tyrosine kinases and phosphatases can be affected by their redox state, we considered the possibility that endogenously generated reactive oxygen intermediates (ROI) may alter phosphotyrosine formation and thereby function as intra- or intercellular messengers in neutrophils. Exposure of human neutrophils to exogenous oxidants such as diamide induced marked tyrosine phosphorylation of several cellular proteins. More importantly, activation of the NADPH oxidase in permeabilized neutrophils, by direct stimulation of GTP-binding proteins, also resulted in enhanced tyrosine phosphorylation. The latter was NADPH-dependent, paralleled by production of superoxide, and was inhibited by diphenylene iodonium, an inhibitor of the flavoprotein component of the oxidase. Neutrophils, from a patient with chronic granulomatous disease, which are deficient in the production of ROI, demonstrated no such phosphotyrosine accumulation. We conclude that ROI produced by the NADPH oxidase can regulate tyrosine phosphorylation in granulocytes, possibly by effects on oxidation-sensitive tyrosine kinases and/or phosphatases.	UNIV TORONTO,DEPT MED,DIV CLIN SCI,RM 6264,MED SCI BLDG,1 KINGS COLL CIRCLE,TORONTO M5S 1A8,ONTARIO,CANADA; TORONTO HOSP,DIV RESP,TORONTO,ON,CANADA; HOSP SICK CHILDREN,RES INST,DEPT CELL BIOL,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)				Downey, Gregory P/0000-0003-3253-5862				BABIOR BM, 1976, J CLIN INVEST, V58, P989, DOI 10.1172/JCI108553; BAUSKIN AR, 1991, CELL, V66, P1; BERKOW RL, 1990, BLOOD, V75, P2445; COLLETTE J, 1956, J AM CHEM SOC, V78, P3819, DOI 10.1021/ja01596a070; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; CROSS AR, 1989, NEUTROPHIL CELLULAR, P97; DEWALD B, 1989, BIOCHEM J, V264, P879, DOI 10.1042/bj2640879; DOWNEY GP, 1992, J CELL BIOL, V116, P695, DOI 10.1083/jcb.116.3.695; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; GRINSTEIN S, 1991, AM J PHYSIOL, V260, pC1019, DOI 10.1152/ajpcell.1991.260.5.C1019; Halliwell B., 1985, FREE RADICALS BIOL M, DOI 10.1016/0748-5514(85)90140-0; HASLETT C, 1985, AM J PATHOL, V119, P101; HUANG CK, 1988, BIOCHEM BIOPH RES CO, V151, P794, DOI 10.1016/S0006-291X(88)80351-6; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMAS S, 1991, AM J PHYSIOL, V261, pC634, DOI 10.1152/ajpcell.1991.261.4.C634; MARGOLIASH E, 1960, BIOCHEM J, V74, P339, DOI 10.1042/bj0740339; MONTEIRO HP, 1991, FEBS LETT, V295, P146, DOI 10.1016/0014-5793(91)81405-W; NASMITH PE, 1986, FEBS LETT, V202, P79, DOI 10.1016/0014-5793(86)80653-6; NASMITH PE, 1989, BIOCHEM J, V257, P893, DOI 10.1042/bj2570893; NOLDEUS P, 1986, RESPIRATION S1, V50, P5; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; PETERSGOLDEN M, 1984, AM REV RESPIR DIS, V130, P803; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SEIFERT R, 1989, BIOCHEM J, V259, P813, DOI 10.1042/bj2590813; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; SKLAR LA, 1985, J BIOL CHEM, V260, P1461; SMITH RM, 1991, BLOOD, V77, P673; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TRUDEL S, 1991, BIOCHEM J, V276, P611, DOI 10.1042/bj2760611	36	138	140	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17131	17137						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349602				2022-12-27	WOS:A1993LQ98800040
J	BODE, AM; NORDLIE, RC				BODE, AM; NORDLIE, RC			RECIPROCAL EFFECTS OF PROLINE AND GLUTAMINE ON GLYCOGENESIS FROM GLUCOSE AND UREAGENESIS IN ISOLATED, PERFUSED RAT LIVERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMYL-PHOSPHATE; AMINO-ACIDS; HEPATOCYTES; STIMULATION	L-Proline and L-glutamine were used to probe the inverse relationship between glycogenesis and ureagenesis in isolated, perfused livers from 48-h fasted rats. Both amino acids may provide nitrogen in the form of NH4+ for carbamyl-P synthesis. However, one molecule of glutamine may provide additionally for the synthesis of one molecule of the urea cycle substrate L-aspartate, but proline can provide for the synthesis of a molecule of NH4+ or one molecule of aspartate on an either/or basis only. In all perfusates, glucose was initially 30 mM (to favor phosphotransferase activity of glucose-6-phosphatase) and 0.5 mM 3-mercaptopicolinate was present (to inhibit glyconeogenesis from endogenous substrates, from the added amino acids, and via the indirect pathway). Glycogenesis from glucose, perfusate and hepatic urea formation, and levels of hepatic glucose-6-P, citrulline, PP(i), and carbamyl-P were measured. The addition of glutamine to the perfusate markedly stimulated the urea cycle, but not glycogenesis. Hepatic urea level, perfusate urea concentration, and hepatic citrulline and PP(i) increased while carbamyl-P content decreased. In contrast, proline stimulated glycogenesis from glucose, but not ureagenesis. In the proline-supplemented compared with glutamine group, hepatic glycogenesis and carbamyl-P content increased; hepatic glucose-6-P levels showed a tendency toward increase; and hepatic urea formation, hepatic citrulline, and PP(i) levels were decreased. These observations are interpreted to support an hepatic mechanism whereby the relative availability of carbamyl-P to the urea cycle and as a substrate for glucose phosphorylation via phosphotransferase activity of the glucose-6-phosphatase system preliminary to glycogenesis from glucose is a major metabolic determinant.	UNIV N DAKOTA,SCH MED,DEPT BIOCHEM & MOLEC BIOL,IRELAND RES LAB,GRAND FORKS,ND 58202; UNIV N DAKOTA,SCH MED,DEPT PHYSIOL,GRAND FORKS,ND 58202	University of North Dakota Grand Forks; University of North Dakota Grand Forks					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK007141] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07141] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVARES FL, 1977, J BIOL CHEM, V252, P8404; BAQUET A, 1990, J BIOL CHEM, V265, P955; BODE AM, 1992, J BIOL CHEM, V267, P2860; BODE AM, 1993, IN PRESS BIOCH CELL, V71; CARREY EA, 1986, BIOCHEM J, V236, P327, DOI 10.1042/bj2360327; CHEN KS, 1985, J BIOL CHEM, V260, P4683; CHEUNG CW, 1989, J BIOL CHEM, V264, P4038; COHEN NS, 1980, J BIOL CHEM, V255, P248; COHEN PP, 1962, ENZYMES, P477; COHEN PP, 1964, MANOMETRIC TECHNIQUE, P149; COOK GA, 1978, ANAL BIOCHEM, V91, P557, DOI 10.1016/0003-2697(78)90543-2; DITULLIO NW, 1974, BIOCHEM J, V138, P387, DOI 10.1042/bj1380387; DIXON WJ, 1957, INTRO STATISTICAL AN, P19; FOSTER JD, 1993, FASEB J, V7, pA848; HEMS DA, 1972, BIOCHEM J, V129, P529, DOI 10.1042/bj1290529; Hohorst H.-J., 1965, METHOD ENZYMAT AN, P134, DOI DOI 10.1016/B978-0-12-395630-9.50025-6; JORGENSON RA, 1980, J BIOL CHEM, V255, P5907; KATZ J, 1976, P NATL ACAD SCI USA, V73, P3433, DOI 10.1073/pnas.73.10.3433; KATZ J, 1983, BIOCHEM J, V214, P795, DOI 10.1042/bj2140795; Keppler D., 1974, METHOD ENZYMAT AN, V3, P1127, DOI DOI 10.1242/JEB.037275; KERSCHER L, 1985, METHOD ENZYMAT AN, P444; Lehninger A. L., 1993, PRINCIPLES BIOCH, P514; LUECK JD, 1972, BIOCHEMISTRY-US, V11, P2792, DOI 10.1021/bi00765a010; LUECK JD, 1972, FEBS LETT, V20, P195, DOI 10.1016/0014-5793(72)80792-0; LUECK JD, 1970, BIOCHEM BIOPH RES CO, V39, P190, DOI 10.1016/0006-291X(70)90776-X; MEIJER AJ, 1982, METABOLIC COMPARTMEN, P259; MURRAY RK, 1990, HARPERS BIOCH, P276; NATALE PJ, 1969, BIOCHEM BIOPH RES CO, V37, P512, DOI 10.1016/0006-291X(69)90945-0; Nordlie R C, 1974, Curr Top Cell Regul, V8, P33; NORDLIE RC, 1980, J BIOL CHEM, V255, P1834; NORDLIE RC, 1985, TRENDS BIOCHEM SCI, V10, P70, DOI 10.1016/0968-0004(85)90236-1; NORDLIE RC, 1983, BIOCH METABOLIC PROC, P125; PLOMP PJAM, 1990, EUR J BIOCHEM, V191, P237, DOI 10.1111/j.1432-1033.1990.tb19115.x; REICHARD P, 1957, ACTA CHEM SCAND, V11, P523, DOI 10.3891/acta.chem.scand.11-0523; ROGNSTAD R, 1985, BIOCHEM BIOPH RES CO, V130, P229, DOI 10.1016/0006-291X(85)90406-1; SHAH PC, 1991, ALCOHOL, V8, P25, DOI 10.1016/0741-8329(91)91184-4; SMITH EL, 1983, PRINCIPLES BIOCH GEN, P649; SMITH EL, 1983, PRINCIPLES BIOCH GEN, P615; SZWEDA LI, 1990, J BIOL CHEM, V265, P20869; TREMBLAY GC, 1977, ARCH BIOCHEM BIOPHYS, V178, P264, DOI 10.1016/0003-9861(77)90191-6; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P179	41	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16298	16301						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344917				2022-12-27	WOS:A1993LQ33600034
J	SHOREIBAH, M; PERNG, GS; ADLER, B; WEINSTEIN, J; BASU, R; CUPPLES, R; WEN, DZ; BROWNE, JK; BUCKHAULTS, P; FREGIEN, N; PIERCE, M				SHOREIBAH, M; PERNG, GS; ADLER, B; WEINSTEIN, J; BASU, R; CUPPLES, R; WEN, DZ; BROWNE, JK; BUCKHAULTS, P; FREGIEN, N; PIERCE, M			ISOLATION, CHARACTERIZATION, AND EXPRESSION OF A CDNA-ENCODING N-ACETYLGLUCOSAMINYLTRANSFERASE-V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL MEMBRANE-GLYCOPROTEINS; ASN-LINKED OLIGOSACCHARIDES; HAMSTER-KIDNEY CELLS; NIH 3T3; TRANSFORMATION; GLYCOSYLATION; SURFACE; GLYCOSYLTRANSFERASES; PHYTOHEMAGGLUTININ; GLYCOPEPTIDES	A cDNA clone for the complete coding sequence for alpha-1,3(6)-mannosylglycoprotein beta-1,6-N-acetylglucosaminyltransferase V (GlcNAc-T V, EC 2.4.1.155) was isolated and expressed in COS-7 cells. Degenerate oligonucleotide primers for polymerase chain reaction were synthesized based on the amino acid sequence of three tryptic peptides isolated from affinity-purified GlcNAc-T V. Polymerase chain reaction amplimers were isolated from rat and mouse mRNA. A cDNA-encoding full-length enzyme was isolated from a rat 1 cell (EJ-ras-transformed) library and sequenced. Transient expression of this clone in COS-7 cells, followed by enzymatic activity assays, demonstrated that this cDNA sequence encodes GlcNAc-T V. Northern analysis of rat kidney mRNA revealed a single band corresponding to a length of about 7 kilobases. Sequence analysis of the cDNA clone demonstrated an open reading frame that encoded a type II membrane protein of 740 amino acids.	UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602; UNIV GEORGIA,CTR COMPLEX CARBOHYDRATE RES,ATHENS,GA 30602; AMGEN INC,THOUSAND OAKS,CA 91320; UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,MIAMI,FL 33101	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Amgen; University of Miami					NCI NIH HHS [CA 49926] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049926] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CHANEY W, 1989, J CELL BIOL, V109, P2089, DOI 10.1083/jcb.109.5.2089; CRAWLEY SC, 1990, ANAL BIOCHEM, V185, P112, DOI 10.1016/0003-2697(90)90264-A; CUMMINGS RD, 1982, J BIOL CHEM, V257, P13421; DENNIS JW, 1989, ONCOGENE, V4, P853; DENNIS JW, 1989, CANCER RES, V49, P945; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; EASTON EW, 1991, J BIOL CHEM, V266, P21674; GLICK MC, 1974, J VIROL, V13, P967, DOI 10.1128/JVI.13.5.967-974.1974; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MOREMEN KW, 1989, P NATL ACAD SCI USA, V86, P5276, DOI 10.1073/pnas.86.14.5276; NISKIKAWA A, 1992, J BIOL CHEM, V267, P18199; PALCIC MM, 1990, J BIOL CHEM, V265, P6759; PIERCE M, 1987, BIOCHEM BIOPH RES CO, V146, P679, DOI 10.1016/0006-291X(87)90582-1; PIERCE M, 1986, J BIOL CHEM, V261, P772; SAITOH O, 1992, J BIOL CHEM, V267, P5700; Sambrook J, 1989, MOL CLONING LABORATO; SANTER UV, 1984, CANCER RES, V44, P3730; Schachter H, 1991, CURR OPIN STRUC BIOL, V1, P755, DOI 10.1016/0959-440X(91)90175-S; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; Shur BD, 1989, CURR OPIN CELL BIOL, V1, P905, DOI 10.1016/0955-0674(89)90057-4; STANLEY P, 1975, P NATL ACAD SCI USA, V72, P3323, DOI 10.1073/pnas.72.9.3323; WARREN L, 1978, BIOCHIM BIOPHYS ACTA, V516, P97, DOI 10.1016/0304-419X(78)90005-7; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; ZHOU Q, 1991, CELL SURFACE CARBOHY, P99	28	117	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15381	15385						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340368				2022-12-27	WOS:A1993LN30500013
J	CRECHET, JB; POULLET, P; BERNARDI, A; FASANO, O; PARMEGGIANI, A				CRECHET, JB; POULLET, P; BERNARDI, A; FASANO, O; PARMEGGIANI, A			PROPERTIES OF THE SDC25 C-DOMAIN, A GDP TO GTP EXCHANGE FACTOR OF RAS PROTEINS AND IN-VITRO MODULATION OF ADENYLYL-CYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ACTIVATING PROTEIN; CDC25 GENE; ELONGATION-FACTORS; KINETIC-PROPERTIES; CALF BRAIN; YEAST; KIRROMYCIN; PRODUCT; MUTANTS	The SDC25 C-domain, the product encoded by the 3'-terminal part of the Saccharomyces cerevisiae SDC25 gene, acts as a GDP dissociation stimulator on RAS proteins (Crechet, J. B., Poullet, P., Mistou, M. Y., Parmeggiani, A., Camonis, J., Boy-Marcotte, E., Damak, F., and Jacquet, M. (1990b) Science 248, 866-868). To define further its role in the RAS-adenylyl cyclase pathway, an in vitro system was used, which utilized cell membranes from yeast strains with appropriate genotypes carrying alterations in the positive regulators of adenylyl cyclase activity. The SDC25 C-domain was able to stimulate the adenylyl cyclase activity of membranes from RAS2 cdc25 strains. Our results indicate that the SDC25 C-domain activates adenylyl cyclase by rapidly recycling the active RAS2. or RAS1.GTP complex from the respective GDP complex. This is also supported by the observation that the stimulation of adenylyl cyclase activity by RAS2T152I, a mutant characterized by a constitutively fast GDP to GTP exchange, was insensitive to the action of the SDC25 C-domain. No direct influence of this GDP dissociation stimulator on adenylyl cyclase was detected. Biochemical evidence was obtained, showing that in the presence of the functional target of RAS, the adenylyl cyclase, the effects of SDC25 C-domain and the catalytic domain of GTPase-activating protein are antagonistic. This in vitro system allowed a quantitative evaluation of the effects of positive and negative effectors of RAS on adenylyl cyclase and the biochemical analysis of conditions inducing a phenotype of permanently activated adenylyl cyclase.	UNIV PALERMO,DIPARTIMENTO BIOL CELLULARE & SVILUPPO,I-90123 PALERMO,ITALY; CNRS,ENZYMOL LAB,F-91198 GIF SUR YVETTE,FRANCE	University of Palermo; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	CRECHET, JB (corresponding author), ECOLE POLYTECH,BIOCHIM LAB,CNRS,SDI 61840,F-91128 PALAISEAU,FRANCE.							BARONI MD, 1989, MOL CELL BIOL, V9, P2715, DOI 10.1128/MCB.9.6.2715; BOYMARCOTTE E, 1989, GENE, V77, P21, DOI 10.1016/0378-1119(89)90355-7; BREVIARIO D, 1988, EMBO J, V7, P1805, DOI 10.1002/j.1460-2075.1988.tb03012.x; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; CAMONIS JH, 1988, MOL CELL BIOL, V8, P2980, DOI 10.1128/MCB.8.7.2980; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CRECHET JB, 1986, EUR J BIOCHEM, V161, P647, DOI 10.1111/j.1432-1033.1986.tb10489.x; CRECHET JB, 1990, J BIOL CHEM, V265, P1563; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; CRECHET JB, 1986, EUR J BIOCHEM, V161, P655, DOI 10.1111/j.1432-1033.1986.tb10490.x; DAMAK F, 1991, MOL CELL BIOL, V11, P202, DOI 10.1128/MCB.11.1.202; DANIEL J, 1987, MOL CELL BIOL, V7, P3857, DOI 10.1128/MCB.7.10.3857; DEVENDITTIS E, 1986, EMBO J, V5, P3657, DOI 10.1002/j.1460-2075.1986.tb04696.x; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; ENGELBERG D, 1990, EMBO J, V9, P641, DOI 10.1002/j.1460-2075.1990.tb08156.x; FASANO O, 1978, EUR J BIOCHEM, V89, P557, DOI 10.1111/j.1432-1033.1978.tb12560.x; FEGER G, 1991, EMBO J, V10, P349, DOI 10.1002/j.1460-2075.1991.tb07956.x; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GIDEON P, 1991, J BIOL CHEM, V266, P2962; HORIUCHI H, 1992, MOL CELL BIOL, V12, P4515, DOI 10.1128/MCB.12.10.4515; HUGHES DA, 1990, NATURE, V344, P355, DOI 10.1038/344355a0; JONES S, 1984, CELL, V37, P437; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MATSUMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P2355, DOI 10.1073/pnas.79.7.2355; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; REY I, 1991, ONCOGENE, V6, P347; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TATCHELL K, 1985, P NATL ACAD SCI USA, V82, P3785, DOI 10.1073/pnas.82.11.3785; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624	39	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14836	14841						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325863				2022-12-27	WOS:A1993LL75900048
J	GEMMELL, CH; SEFTON, MV; YEO, EL				GEMMELL, CH; SEFTON, MV; YEO, EL			PLATELET-DERIVED MICROPARTICLE FORMATION INVOLVES GLYCOPROTEIN-IIB-IIIA - INHIBITION BY RGDS AND A GLANZMANN THROMBASTHENIA DEFECT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACTIVATED PLATELETS; PLASMA-MEMBRANE; PROCOAGULANT ACTIVITY; FIBRINOGEN BINDING; WHOLE-BLOOD; FACTOR-VA; COMPLEX; VESICULATION; VESICLES; RECEPTOR	While the physiologic role of platelet microparticles may include a stable, physical dispersion of concentrated surface procoagulant activity the mechanism(s) of platelet vesiculation remains unknown. We demonstrate using flow cytometric methods a central role for the beta3 integrin glycoprotein (GP) IIb-IIIa complex and its ligand tetrapeptide Arg-Gly-Asp-Ser (RGDS) binding site in platelet vesiculation. Time- and calcium-dependent vesiculation of platelets in response to ADP, collagen, thrombin, phorbol myristate acetate, and the thrombin peptide SFLLRN were dramatically inhibited, in a concentration-dependent manner, by monoclonal antibodies to GPIIb-IIIa (A2A9, 7E3, PAC1) and RGDS. Complete inhibition with A2A9 and RGDS occurred at 7.5 mug/ml and 75 muM, respectively, while control antibodies and a mock peptide had no effect. Platelet vesiculation requires intact GPIIb-IIIa and is fully supported by the intracellular pool of GPIIb-IIIa alone since de-complexing of this heterodimer by calcium chelation completely abolished microparticle formation in response to collagen (no alpha-granule release) but not to thrombin or SFLLRN. A central role for GPIIb-IIIa is supported by the near total inability of Glanzmann's thrombasthenic (type I) platelets to vesiculate in response to thrombin, ADP, collagen, and phorbol 12-myristate 13-acetate. This extends the biologic roles of GPIIb-IIIa to include platelet vesiculation and suggests that one or all of its binding ligands play a role.	UNIV TORONTO, DEPT MED, TORONTO M5S 1A4, ONTARIO, CANADA; UNIV TORONTO, DEPT CHEM ENGN & APPL CHEM, TORONTO M5S 1A4, ONTARIO, CANADA	University of Toronto; University of Toronto								ABRAMS CS, 1990, BLOOD, V75, P128; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BERMAN CL, 1989, METHOD ENZYMOL, V169, P311; BEVERS EM, 1986, BRIT J HAEMATOL, V63, P335; BODE AP, 1991, BLOOD, V77, P887; COLLER BS, 1989, J CLIN INVEST, V7, P101; COMFURIUS P, 1985, BIOCHIM BIOPHYS ACTA, V815, P143, DOI 10.1016/0005-2736(85)90485-7; GILBERT GE, 1991, J BIOL CHEM, V266, P17261; HOFFMAN M, 1992, THROMB HAEMOSTASIS, V68, P74; ISENBERG WM, 1987, J CELL BIOL, V104, P1655, DOI 10.1083/jcb.104.6.1655; JY W, 1991, CLIN RES, V39, pA268; LEE Y, 1992, CLIN RES, V40, pA358; MONTGOMERY RR, 1983, J CLIN INVEST, V71, P385, DOI 10.1172/JCI110780; NURDEN AT, 1989, PLATELET IMMUNOBIOLO, P63; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PHILLIPS DR, 1988, BLOOD, V71, P831; PIDARD D, 1986, BLOOD, V67, P604; PLOW EF, 1987, BLOOD, V70, P110; PLOW EF, 1992, J LAB CLIN MED, V120, P198; POLASEK J, 1982, THROMB RES, V28, P433, DOI 10.1016/0049-3848(82)90125-6; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; ROSING J, 1985, BLOOD, V65, P1557, DOI 10.1182/blood.V65.6.1557.bloodjournal6561557; SANDBERG H, 1985, THROMB RES, V39, P63, DOI 10.1016/0049-3848(85)90122-7; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SHATTIL S, 1991, CURR STUD HEMATOL BL, V58, P26, DOI DOI 10.1159/000419332; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHATTIL SJ, 1987, BLOOD, V70, P307; SIMS PJ, 1989, J BIOL CHEM, V264, P17049; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; SKAER RJ, 1981, PLATELETS BIOL PATHO, V2, P321; SUTHERLAND DR, 1991, BLOOD, V77, P84; TANS G, 1991, BLOOD, V77, P2641; THIAGARAJAN P, 1991, J BIOL CHEM, V266, P24302; WARREN BA, 1972, BRIT J EXP PATHOL, V53, P206; WARREN BA, 1972, MICROVASC RES, V4, P159, DOI 10.1016/0026-2862(72)90062-3; WEISS HJ, 1979, AM J MED, V67, P206, DOI 10.1016/0002-9343(79)90392-9; WENCELDRAKE JD, 1986, AM J PATHOL, V124, P324; WIEDMER T, 1990, BIOCHEMISTRY-US, V29, P623, DOI 10.1021/bi00455a005; WIEDMER T, 1991, BLOOD, V78, P2880	39	118	120	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14586	14589						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325838				2022-12-27	WOS:A1993LL75900010
J	HEMRIC, ME; LU, FWM; SHRAGER, R; CAREY, J; CHALOVICH, JM				HEMRIC, ME; LU, FWM; SHRAGER, R; CAREY, J; CHALOVICH, JM			REVERSAL OF CALDESMON BINDING TO MYOSIN WITH CALCIUM-CALMODULIN OR BY PHOSPHORYLATING CALDESMON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALDESMON; PROTEIN-KINASE-C; CHICKEN GIZZARD CALDESMON; INTACT HUMAN-PLATELETS; LIGHT-CHAIN KINASE; ATPASE ACTIVITY; HEAVY-MEROMYOSIN; SKELETAL-MUSCLE; CROSS-LINKING; F-ACTIN	Caldesmon, an actin-binding protein from smooth muscle and non-muscle cells, has previously been shown to bind stoichiometrically to smooth muscle myosin in an ATP-dependent manner. We now show quantitatively the effects of Ca2+-calmodulin and phosphorylation on the binding of caldesmon to myosin. Ca2+-calmodulin reduces the binding of caldesmon to myosin with the same effectiveness as it does the binding of caldesmon to actin. However, Ca2+-calmodulin is ineffective in antagonizing the binding of the purified myosin-binding region of caldesmon to myosin. These and other results suggest that Ca2+-calmodulin binding to the COOH-terminal region of caldesmon is responsible for reversal of binding to myosin. Phosphorylation of the NH2-terminal region of caldesmon by the co-purifying kinase, calmodulin-dependent protein kinase II, weakens but does not eliminate the binding of caldesmon to smooth muscle myosin. Finally, phosphorylation of smooth muscle myosin by smooth muscle myosin light chain kinase has no effect on the binding of caldesmon to myosin. Since Ca2+-calmodulin and phosphorylation of caldesmon weaken the binding of caldesmon to both actin and myosin, these events may be coordinately regulated.	E CAROLINA UNIV,SCH MED,DEPT BIOCHEM,GREENVILLE,NC 27858; NIH,BETHESDA,MD 20892	University of North Carolina; East Carolina University; National Institutes of Health (NIH) - USA				Chalovich, Joseph/0000-0002-1243-4055	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035216] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR035216, AR35216] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABOUGOU JC, 1989, FEBS LETT, V257, P408, DOI 10.1016/0014-5793(89)81583-2; ADAM L P, 1991, Biophysical Journal, V59, p56A; ADAM L P, 1992, Biophysical Journal, V61, pA7; ADAM LP, 1989, J BIOL CHEM, V264, P7698; ADELSTEIN RS, 1982, METHOD ENZYMOL, V85, P298; BARANY M, 1991, FEBS LETT, V279, P65, DOI 10.1016/0014-5793(91)80252-X; BRENNER B, 1991, P NATL ACAD SCI USA, V88, P5739, DOI 10.1073/pnas.88.13.5739; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CHALOVICH JM, 1992, J BIOL CHEM, V267, P16644; CHALOVICH JM, 1991, J MUSCLE RES CELL M, V12, P503, DOI 10.1007/BF01738438; CHILDS TJ, 1992, J BIOL CHEM, V267, P22853; DABROWSKA R, 1985, BIOCHIM BIOPHYS ACTA, V842, P70, DOI 10.1016/0304-4165(85)90295-8; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FUJII T, 1987, J BIOL CHEM, V262, P2757; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HEGMANN TE, 1991, CELL MOTIL CYTOSKEL, V20, P109, DOI 10.1002/cm.970200204; HEMRIC M E, 1991, Biophysical Journal, V59, p57A; HEMRIC M E, 1992, Biophysical Journal, V61, pA6; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HEMRIC ME, 1990, J BIOL CHEM, V265, P19672; HETTASCH JM, 1991, J BIOL CHEM, V266, P11876; IKEBE M, 1991, ARCH BIOCHEM BIOPHYS, V288, P538, DOI 10.1016/0003-9861(91)90232-8; IKEBE M, 1988, J BIOL CHEM, V263, P3055; IKEBE M, 1990, J BIOL CHEM, V265, P17607; KATAYAMA E, 1989, Biophysical Journal, V55, p232A; KATSUYAMA H, 1992, J BIOL CHEM, V267, P14555; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASH JA, 1986, J BIOL CHEM, V261, P6155; LIN JJC, 1991, CELL MOTIL CYTOSKEL, V20, P95, DOI 10.1002/cm.970200203; LITCHFIELD DW, 1987, J BIOL CHEM, V262, P8056; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU FWM, 1993, BIOPHYS J, V64, pA29; LYNCH WP, 1987, J BIOL CHEM, V262, P7429; MARSTON S, 1992, J MUSCLE RES CELL M, V13, P206, DOI 10.1007/BF01874158; MARSTON SB, 1986, BIOCHEM J, V237, P605, DOI 10.1042/bj2370605; MORNET D, 1988, BIOCHEM BIOPH RES CO, V154, P564, DOI 10.1016/0006-291X(88)90177-5; NGAI PK, 1987, BIOCHEM J, V244, P417, DOI 10.1042/bj2440417; NGAI PK, 1985, BIOCHEM J, V230, P695, DOI 10.1042/bj2300695; PERSECHINI A, 1983, BIOCHEMISTRY-US, V22, P470, DOI 10.1021/bi00271a033; PFITZER G, 1992, Biophysical Journal, V61, pA7; REDWOOD CS, 1990, FEBS LETT, V270, P53, DOI 10.1016/0014-5793(90)81233-E; SCOTTWOO GC, 1990, BIOCHEM J, V268, P367, DOI 10.1042/bj2680367; SELLERS JR, 1982, J BIOL CHEM, V257, P3880; SMITH CWJ, 1985, FEBS LETT, V184, P115, DOI 10.1016/0014-5793(85)80665-7; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SOBUE K, 1985, BIOCHEM BIOPH RES CO, V132, P645, DOI 10.1016/0006-291X(85)91181-7; SUTHERLAND C, 1989, J BIOL CHEM, V264, P578; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; VELAZ L, 1990, J BIOL CHEM, V265, P2929; VELAZ L, 1989, J BIOL CHEM, V264, P9602; WALKER G, 1989, J BIOL CHEM, V264, P496; WALSH MP, 1983, METHOD ENZYMOL, V99, P279; WANG CLA, 1989, BIOCHEM BIOPH RES CO, V162, P746, DOI 10.1016/0006-291X(89)92373-5; WANG CLA, 1991, J BIOL CHEM, V266, P13956; WAWRZYNOW A, 1991, FEBS LETT, V289, P213, DOI 10.1016/0014-5793(91)81072-G; WELLS C, 1984, J MUSCLE RES CELL M, V5, P97, DOI 10.1007/BF00713154; YAMAKITA Y, 1992, J BIOL CHEM, V267, P12022; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0; YAZAWA M, 1987, J BIOCHEM-TOKYO, V102, P1065, DOI 10.1093/oxfordjournals.jbchem.a122144; YAZAWA M, 1980, J BIOCHEM, V87, P1313, DOI 10.1093/oxfordjournals.jbchem.a132869	62	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15305	15311						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325900				2022-12-27	WOS:A1993LL75900109
J	KANG, HA; SCHWELBERGER, HG; HERSHEY, JWB				KANG, HA; SCHWELBERGER, HG; HERSHEY, JWB			TRANSLATION INITIATION FACTOR-EIF-5A, THE HYPUSINE-CONTAINING PROTEIN, IS PHOSPHORYLATED ON SERINE IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR EIF-4D; FACTOR 4D; PURIFICATION; BIOSYNTHESIS; RIBOSOMES; YEAST; CELLS	Translation initiation factor eIF-5A (formerly called eIF-4D) is a small, highly conserved protein in eukaryotic cells that undergoes a unique modification at one of its lysine residues to form hypusine. eIF-5A stimulates in vitro the synthesis of methionyl-puromycin, a model reaction for formation of the first peptide bond. In Saccharomyces cerevisiae eIF-5A is encoded by two highly homologous genes, TIF51A and TIF51B, and each gene gives rise to two hypusinated isoelectric variants, eIF-5Aa (more acidic) and eIF-5Ab (more basic). In order to study the structural and functional differences between the two isoforms, both isoelectric forms were purified from a yeast strain overexpressing TIF51A and were shown to stimulate identically the synthesis of methionyl-puromycin in a heterologous mammalian assay system. Pulse-chase labeling of yeast cells with [S-35]methionine showed that the basic form, eIF-5Ab, is a precursor form of the acidic form, eIF-5Aa. Immunoprecipitation of P-32-labeled cell lysates with rabbit antibodies specific for yeast eIF-5A, phosphoprotein phosphatase treatment of eIF-5Aa, and phosphoamino acid analysis demonstrated that eIF-5Aa is generated by phosphorylation of eIF-5Ab on serine. Therefore eIF-5A undergoes two post-translational modifications, hypusination and phosphorylation, where the activity of the factor is dependent on the first but is not influenced in vitro by the second.			KANG, HA (corresponding author), UNIV CALIF DAVIS, SCH MED, DEPT BIOL CHEM, DAVIS, CA 95616 USA.				NIGMS NIH HHS [GM22135] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTIG D, 1992, EUR J BIOCHEM, V204, P751, DOI 10.1111/j.1432-1033.1992.tb16690.x; BENNE R, 1978, J BIOL CHEM, V253, P3070; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; CHAMOT D, 1992, NUCLEIC ACIDS RES, V20, P665, DOI 10.1093/nar/20.4.665; COOPER HL, 1983, P NATL ACAD SCI-BIOL, V80, P1854, DOI 10.1073/pnas.80.7.1854; DUNCAN RF, 1986, J BIOL CHEM, V261, P2903; GORDON ED, 1987, J BIOL CHEM, V262, P16590; GORDON ED, 1987, J BIOL CHEM, V262, P16585; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KANG HA, 1992, MOL GEN GENET, V233, P487, DOI 10.1007/BF00265449; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAURIDES PA, 1989, ANAL BIOCHEM, V183, P144, DOI 10.1016/0003-2697(89)90182-6; MEHTA KD, 1990, J BIOL CHEM, V265, P8802; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARK MH, 1984, J BIOL CHEM, V259, P2123; PARK MH, 1989, J BIOL CHEM, V264, P18531; PARK MH, 1987, J BIOL CHEM, V262, P12730; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; SCHWELBERGER HG, 1993, J BIOL CHEM, V268, P14018; Sherman F., 1986, METHODS YEAST GENETI; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P18527; THOMAS A, 1979, EUR J BIOCHEM, V98, P329, DOI 10.1111/j.1432-1033.1979.tb13192.x; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; WOLFF EC, 1992, J BIOL CHEM, V267, P6107	28	38	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14750	14756						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325852				2022-12-27	WOS:A1993LL75900035
J	BELL, PA; KASPER, CB				BELL, PA; KASPER, CB			EXPRESSION OF RAT MICROSOMAL EPOXIDE HYDROLASE IN ESCHERICHIA-COLI - IDENTIFICATION OF A HISTIDYL RESIDUE ESSENTIAL FOR CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-ENVELOPE; ARENE OXIDES; COMPLEMENTARY-DNA; HYDRASE ACTIVITY; LIVER; METABOLISM; PURIFICATION; HYDRATASE; MECHANISM; MEMBRANE	The cDNA containing the complete coding region for rat microsomal epoxide hydrolase (EC 3.3.2.3) was cloned into the expression/secretion vector pIN-III-OmpA3 and expressed in Escherichia coli strain TG1. Recombinant epoxide hydrolase was found to represent 4-9% of total bacterial protein and catalyzed the hydrolysis of styrene oxide and benzo[a]pyrene 4,5-oxide with specific activities of 421 and 734 nmol min-1 mg of epoxide hydrolase-1, respectively. Previous work implicated a histidyl residue at or near the active site of the enzyme (DuBois, G. C., Appella, E., Levin, W., Lu, A. Y. H., and Jerina, D. M. (1978) J. Biol. Chem. 253, 2932-2939). Comparison of the amino acid sequences of rat, human, and rabbit epoxide hydrolases revealed the presence of 14 conserved histidyl residues. To investigate the role of these residues in epoxide hydrolysis, site-specific mutants were generated and expressed in E. coli. Mutants H64L, H82L, H115N, H126N, H129L, H148N, H170L, H176L, H242L, H247L, H301L, H385L, K386M-H387L, DELTA385-391, and H407L catalyzed the hydrolysis of benzo[a]pyrene 4,5-oxide with specific activities between 115 and 830 nmol min-1 mg-1. Mutants H431L, H431N, and H431R were all found to have activities of <5 nmol min-1 mg-1, which is at least 150-fold less than the activity of the wild type enzyme. A V(m) versus pH profile for the recombinant wild type epoxide hydrolase revealed a broad pH optimum of 6.5 to 8.5 and the presence of three ionizable groups with pK(a) values of 5.8 +/- 0.2, 9.2 +/- 0.1, and 9.7 +/- 0.4. The group with a pK(a) of 5.8 is preferentially unprotonated, while the other two groups are preferentially protonated for catalysis. We propose that histidine 431 corresponds to the group with a pK(a) of 5.8, while the others, with pK(a) values of 9.2 and 9.7 likely represent lysyl, cysteinyl, or tyrosyl residues. Thus, the data are consistent with a model where His-431 acts as a general base, abstracting a proton from water, while another residue(s), perhaps lysine, act as a general acid protonating the alkoxide anion that forms upon cleavage of the carbon-oxygen bond.	UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL CANCER INSTITUTE [T32CA009020, T32CA009135, P01CA022484] Funding Source: NIH RePORTER; NCI NIH HHS [CA22484, CA09135, CA09020] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTER GM, 1990, BIOCHEMISTRY-US, V29, P7557, DOI 10.1021/bi00485a003; CHRISTOU M, 1989, CARCINOGENESIS, V10, P1883, DOI 10.1093/carcin/10.10.1883; Cleland W W, 1979, Methods Enzymol, V63, P103; CRAFT JA, 1990, BIOCHIM BIOPHYS ACTA, V1046, P32, DOI 10.1016/0005-2760(90)90091-B; DALY JW, 1972, EXPERIENTIA, V28, P1129, DOI 10.1007/BF01946135; DANSETTE PM, 1979, ANAL BIOCHEM, V97, P340, DOI 10.1016/0003-2697(79)90083-6; DEONARAIN MP, 1989, BIOCHEMISTRY-US, V28, P9602, DOI 10.1021/bi00451a008; DUBOIS GC, 1978, J BIOL CHEM, V253, P2932; EHRIG T, 1991, BIOCHEMISTRY-US, V30, P1062, DOI 10.1021/bi00218a026; FAHL WE, 1978, J BIOL CHEM, V253, P3106; FINDLAY D, 1962, BIOCHEM J, V85, P152, DOI 10.1042/bj0850152; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; GONZALEZ FJ, 1982, MOL PHARMACOL, V21, P511; HANZLIK RP, 1976, J AM CHEM SOC, V98, P1952, DOI 10.1021/ja00423a050; HARLOW E, 1988, COLD SPRING HARBOR L; HASSETT C, 1989, ARCH BIOCHEM BIOPHYS, V271, P380, DOI 10.1016/0003-9861(89)90287-7; JERINA DM, 1974, SCIENCE, V185, P573, DOI 10.1126/science.185.4151.573; KNOWLES RG, 1977, BIOCHEM J, V163, P381, DOI 10.1042/bj1630381; LEVIN W, 1978, P NATL ACAD SCI USA, V75, P3240, DOI 10.1073/pnas.75.7.3240; LU AYH, 1975, J BIOL CHEM, V250, P8283; LU AYH, 1977, J BIOL CHEM, V252, P3715; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; OESCH F, 1971, BIOCHIM BIOPHYS ACTA, V227, P685, DOI 10.1016/0005-2744(71)90017-9; OESCH F, 1971, BIOCHIM BIOPHYS ACTA, V227, P692, DOI 10.1016/0005-2744(71)90018-0; PORTER TD, 1986, ARCH BIOCHEM BIOPHYS, V248, P121, DOI 10.1016/0003-9861(86)90408-X; ROBERTS GCK, 1969, P NATL ACAD SCI USA, V62, P1151, DOI 10.1073/pnas.62.4.1151; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIDEGARD J, 1983, BIOCHIM BIOPHYS ACTA, V695, P251, DOI 10.1016/0304-419X(83)90014-8; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SKODA RC, 1988, J BIOL CHEM, V263, P1549; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSANG VCW, 1983, METHOD ENZYMOL, V92, P377; YANG SK, 1977, SCIENCE, V196, P1199, DOI 10.1126/science.870975; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3; ZIMMERMAN JJ, 1978, ARCH BIOCHEM BIOPHYS, V190, P726, DOI 10.1016/0003-9861(78)90333-8	37	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14011	14017						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314768				2022-12-27	WOS:A1993LJ82500037
J	DIAMOND, AM; CHOI, IS; CRAIN, PF; HASHIZUME, T; POMERANTZ, SC; CRUZ, R; STEER, CJ; HILL, KE; BURK, RF; MCCLOSKEY, JA; HATFIELD, DL				DIAMOND, AM; CHOI, IS; CRAIN, PF; HASHIZUME, T; POMERANTZ, SC; CRUZ, R; STEER, CJ; HILL, KE; BURK, RF; MCCLOSKEY, JA; HATFIELD, DL			DIETARY SELENIUM AFFECTS METHYLATION OF THE WOBBLE NUCLEOSIDE IN THE ANTICODON OF SELENOCYSTEINE TRANSFER RNA[SER]SEC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATOGRAPHY-MASS-SPECTROMETRY; TRANSFER-RNA; ESCHERICHIA-COLI; MAMMALIAN-CELLS; INSERTS SELENOCYSTEINE; RIBOSE METHYLATION; SEQUENCE-ANALYSIS; AMINO-ACID; GENE; UGA	We reported previously that the presence of selenium in culture media of mammalian cells influences both the steady-state levels and distributions of two tRNA isoacceptors involved in the insertion of selenocysteine into protein in response to certain UGA codons. In this study, we demonstrate an increase in the levels of these isoacceptors in rats fed a selenium-adequate diet compared to animals fed a selenium-deficient diet, as well as a shift in the relative distribution toward the tRNA which elutes later from an RPC-5 column. These effects were found to occur in a tissue-specific manner. Both selenocysteine tRNAs were isolated from rat liver, sequenced, analyzed by mass spectrometry, and shown to differ only by ribose 2'-O-methylation of 5-methylcarboxymethyluridine that occurs in the wobble position of the anticodon. This modified nucleoside has been documented previously only in yeast tRNA while the corresponding 2'-O-methylribose derivative has not been observed. The structure of these nucleosides was established by mass spectrometry and confirmed by chemical synthesis. Although the role of methylation of the wobble nucleotide is not known, the differences in elution properties from RPC-5 columns are consistent with other experimental observations indicating that a change in tRNA conformation accompanies this methylation.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT MED,NASHVILLE,TN 37232; UNIV MINNESOTA,MED CTR,DEPT MED,MINNEAPOLIS,MN 55455; NCI,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20892; VANDERBILT UNIV,MED CTR,SCH MED,CTR MOLEC TOXICOL,NASHVILLE,TN 37232; UNIV UTAH,DEPT MED CHEM,SALT LAKE CITY,UT 84112	Vanderbilt University; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Vanderbilt University; Utah System of Higher Education; University of Utah	DIAMOND, AM (corresponding author), UNIV CHICAGO,DEPT RADIAT & CELLULAR ONCOL,CHICAGO,IL 60637, USA.			Pomerantz, Steven/0000-0003-2173-7442	NATIONAL CANCER INSTITUTE [R01CA054364] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029812] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA54364] Funding Source: Medline; NIEHS NIH HHS [R01 ES02497] Funding Source: Medline; NIGMS NIH HHS [R01 GM29812] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; BROWN DG, 1973, J NUTR, V103, P102, DOI 10.1093/jn/103.1.102; BURK RF, 1972, J NUTR, V102, P1049, DOI 10.1093/jn/102.8.1049; BURK RF, 1987, METHOD ENZYMOL, V143, P307; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; DIAMOND A, 1981, CELL, V25, P497, DOI 10.1016/0092-8674(81)90068-4; DIAMOND A, 1983, METHOD ENZYMOL, V100, P431; DIAMOND AM, 1990, NUCLEIC ACIDS RES, V18, P6727, DOI 10.1093/nar/18.22.6727; EDMONDS CG, 1988, ANAL CHEM, V60, P2314, DOI 10.1021/ac00171a034; EDMONDS CG, 1985, NUCLEIC ACIDS RES, V13, P8197, DOI 10.1093/nar/13.22.8197; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6324; GARCIA GE, 1991, J BACTERIOL, V173, P2093, DOI 10.1128/jb.173.6.2093-2098.1991; GEHRKE CW, 1990, CHROMATOGRAPHY MOD A, pA3; HATFIELD D, 1979, BIOCHIM BIOPHYS ACTA, V564, P414, DOI 10.1016/0005-2787(79)90032-7; HATFIELD D, 1982, P NATL ACAD SCI-BIOL, V79, P6215, DOI 10.1073/pnas.79.20.6215; HATFIELD D, 1970, P NATL ACAD SCI USA, V67, P1200, DOI 10.1073/pnas.67.3.1200; HATFIELD D, 1991, NUCLEIC ACIDS RES, V19, P939, DOI 10.1093/nar/19.4.939; HATFIELD D, 1992, BIOCHEM BIOPH RES CO, V184, P254, DOI 10.1016/0006-291X(92)91186-T; HATFIELD D, 1992, TRANSFER RNA PROTEIN, P269; HATFIELD D, 1972, P NATL ACAD SCI USA, V67, P3014; HATFIELD DL, 1990, CRIT REV BIOCHEM MOL, V25, P71, DOI 10.3109/10409239009090606; HATFIELD DL, 1991, MOL MICROBIOL, V5, P1183, DOI 10.1111/j.1365-2958.1991.tb01891.x; HEIDER J, 1989, NUCLEIC ACIDS RES, V17, P2529, DOI 10.1093/nar/17.7.2529; HILL KE, 1991, J BIOL CHEM, V266, P10050; KATO N, 1983, BIOCH INT, V5, P835; KAWAI G, 1992, BIOCHEMISTRY-US, V31, P1040, DOI 10.1021/bi00119a012; KELMERS AD, 1971, ANAL BIOCHEM, V44, P486, DOI 10.1016/0003-2697(71)90236-3; KUMAGAI I, 1982, J BIOL CHEM, V257, P7388; KUNTZEL B, 1975, BIOCHIMIE, V57, P61, DOI 10.1016/S0300-9084(75)80110-6; LEE BJ, 1990, MOL CELL BIOL, V10, P1940, DOI 10.1128/MCB.10.5.1940; LEE BJ, 1989, J BIOL CHEM, V264, P9724; LEINFELDER W, 1988, NATURE, V331, P723, DOI 10.1038/331723a0; LEINFELDER W, 1989, J BIOL CHEM, V264, P9720; Maxam A M, 1980, Methods Enzymol, V65, P499; McCloskey J. A., 1974, BASIC PRINCIPLES NUC, V1, P209; MULLENBACH GT, 1988, PROTEIN ENG, V2, P239, DOI 10.1093/protein/2.3.239; POMERANTZ SC, 1990, METHOD ENZYMOL, V193, P796, DOI 10.1016/0076-6879(90)93452-Q; RANDERATH E, 1981, CANCER RES, V41, P2863; ROE BA, 1974, NUCLEIC ACIDS RES, V2, P21; ROGG H, 1977, P NATL ACAD SCI USA, V74, P4243, DOI 10.1073/pnas.74.10.4243; Silberklang M, 1979, Methods Enzymol, V59, P58; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; STADTMAN TC, 1991, BIOFACTORS, V3, P21; TUMAITIS T D, 1970, Biochimica et Biophysica Acta, V224, P391, DOI 10.1016/0005-2787(70)90572-1	45	121	124	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14215	14223						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314785				2022-12-27	WOS:A1993LJ82500064
J	DUSETTI, NJ; FRIGERIO, JM; KEIM, V; DAGORN, JC; IOVANNA, JL				DUSETTI, NJ; FRIGERIO, JM; KEIM, V; DAGORN, JC; IOVANNA, JL			STRUCTURAL ORGANIZATION OF THE GENE ENCODING THE RAT PANCREATITIS-ASSOCIATED PROTEIN - ANALYSIS OF ITS EVOLUTIONARY HISTORY REVEALS AN ANCIENT DIVERGENCE FROM THE OTHER CARBOHYDRATE-RECOGNITION DOMAIN-CONTAINING GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION MOLECULE-1; BINDING-RECEPTOR UNIQUE; ASIALOGLYCOPROTEIN RECEPTOR; KUPFFER CELLS; EXPRESSION; ENHANCER; SEQUENCES; INTRONS; REGION; EXONS	Rat pancreatitis-associated protein (PAP) mRNA is barely detectable in normal pancreas and overexpressed during acute pancreatitis (Iovanna, J., Orelle, B., Keim, V., and Dagorn J.-C. (1991) J. Biol. Chem. 266, 24664-24669). RNA amplification by reverse-transcriptase-coupled polymerase chain reaction showed that PAP mRNA was constitutively expressed in duodenum, jejunum, and ileum, at similar levels as in pancreas during the acute phase of pancreatitis. A weak expression was also detected in several other tissues. The rat PAP gene was isolated from a genomic library and characterized over 3.2 kilobases of gene sequence and 1.2 kilobases of 5'-flanking sequence. The 5' end of the coding sequence was determined by primer extension of the PAP transcript. Several potential regulatory elements were identified in the promoter region, including a pancreas-specific consensus sequence, two Pan1 (pancreas-specific) transcription activators, two IL-6 response elements, and one glucocorticoid response element. The PAP coding sequence spanned over six exons. The first three exons encoded the 5'-untranslated region of the mRNA, the signal peptide, and 39 amino acids of the NH2-terminal end of the mature protein, respectively. The other three exons encoded a domain of the protein with significant homology to the carbohydrate-recognition domain of animal lectins. Sequence comparison of the PAP gene with 13 carbohydrate-recognition domain-containing genes revealed that they derived from the same ancestor gene. Position of introns within the carbohydrate-recognition domain were different, however, suggesting that PAP belongs to a new group of lectins. These results support the hypothesis that genes encoding PAP and other lectins evolved from a common ancestor gene by intron gain.	INSERM,U315,46 BD GAYE,F-13009 MARSEILLE,FRANCE; UNIV HEIDELBERG,MED KLIN 1,W-6800 MANNHEIM,GERMANY	Institut National de la Sante et de la Recherche Medicale (Inserm); Ruprecht Karls University Heidelberg			Dusetti, Nelson/O-7919-2017; Iovanna, Juan/M-9805-2017	Dusetti, Nelson/0000-0002-6161-8483; Iovanna, Juan/0000-0003-1822-2237				BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERGLUND L, 1992, FEBS LETT, V309, P15, DOI 10.1016/0014-5793(92)80729-Z; BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; BLAKE CCF, 1985, INT REV CYTOL, V93, P149, DOI 10.1016/S0074-7696(08)61374-1; BOULET AM, 1986, P NATL ACAD SCI USA, V83, P3599, DOI 10.1073/pnas.83.11.3599; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS T, 1991, J BIOL CHEM, V266, P2466; DIBB NJ, 1989, EMBO J, V8, P2015, DOI 10.1002/j.1460-2075.1989.tb03609.x; DOWBENKO DJ, 1991, GENOMICS, V9, P270, DOI 10.1016/0888-7543(91)90252-A; DRICKAMER K, 1987, J BIOL CHEM, V262, P2582; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GILBERT W, 1985, SCIENCE, V228, P823, DOI 10.1126/science.4001923; GILBERT W, 1986, CELL, V46, P151, DOI 10.1016/0092-8674(86)90730-0; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HOYLE GW, 1991, J BIOL CHEM, V266, P1850; HOYLE GW, 1988, J BIOL CHEM, V263, P7487; HUMPHRIES S, 1976, CELL, V7, P267, DOI 10.1016/0092-8674(76)90026-X; IOVANNA J, 1991, J BIOL CHEM, V266, P24664; IOVANNA JL, 1991, AM J PHYSIOL, V261, pG485, DOI 10.1152/ajpgi.1991.261.3.G485; JACKMAN RW, 1987, P NATL ACAD SCI USA, V84, P6425, DOI 10.1073/pnas.84.18.6425; JOHNSTON GI, 1990, J BIOL CHEM, V265, P21381; KEIM V, 1991, GASTROENTEROLOGY, V100, P775, DOI 10.1016/0016-5085(91)80025-5; KRUSE F, 1988, MOL CELL BIOL, V8, P893, DOI 10.1128/MCB.8.2.893; KUNZ D, 1989, NUCLEIC ACIDS RES, V17, P1121, DOI 10.1093/nar/17.3.1121; LEUNG JO, 1985, J BIOL CHEM, V260, P2523; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; MEISTER A, 1989, J BIOL CHEM, V264, P20744; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; ORD DC, 1990, J BIOL CHEM, V265, P7760; ORELLE B, 1992, J CLIN INVEST, V90, P2284, DOI 10.1172/JCI116115; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PETROPOULOS I, 1991, J BIOL CHEM, V266, P24220; Sambrook J., 1982, MOL CLONING LAB MANU, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPECK NA, 1987, MOL CELL BIOL, V7, P1101, DOI 10.1128/MCB.7.3.1101; SUTER U, 1987, NUCLEIC ACIDS RES, V15, P7295, DOI 10.1093/nar/15.18.7295; TANAKA T, 1988, J BIOL CHEM, V263, P15831; TAYLOR ME, 1989, BIOCHEM J, V262, P763, DOI 10.1042/bj2620763; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0	42	55	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14470	14475						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314803				2022-12-27	WOS:A1993LJ82500097
J	WLASICHUK, KB; KASHEM, MA; NIKRAD, PV; BIRD, P; JIANG, C; VENOT, AP				WLASICHUK, KB; KASHEM, MA; NIKRAD, PV; BIRD, P; JIANG, C; VENOT, AP			DETERMINATION OF THE SPECIFICITIES OF RAT-LIVER GAL(BETA-1-4)GLCNAC ALPHA-2,6-SIALYLTRANSFERASE AND GAL(BETA-1-3/4)GLCNAC ALPHA-2,3-SIALYLTRANSFERASE USING SYNTHETIC MODIFIED ACCEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAL-BETA-1->3(4)GLCNAC ALPHA-2->3 SIALYLTRANSFERASE; GLYCOPROTEIN OLIGOSACCHARIDES; LINKED OLIGOSACCHARIDES; GRIFFONIA-SIMPLICIFOLIA; MOLECULAR RECOGNITION; LECTIN-IV; LEWIS-B; BIOSYNTHESIS; GLYCOSYLTRANSFERASES; SEQUENCES	Apparent kinetic parameters have been measured for the transfer of N-acetyl-D-neuraminic acid (Neu5Ac) from CMP-Neu5Ac to analogues of the Gal(beta1-4)GlcNAc (type II) and Gal(beta1-3)GlcNAc (type I) substrates by the rat liver Gal(beta1-4)GlcNAc alpha2,6-sialyltransferase and the Gal(beta1-3/4)GlcNAc alpha2,3-sialyltransferase. In these acceptor analogues, the substituents of the pyranose rings were modified, particularly by deoxygenation, to identify (i) the key polar groups required for efficient transfer and (ii) the substituents that can be removed or modified. A topography including the 6-hydroxyl of the betaGal and the 2-acetamido of the GlcNAc unit is required for transfer to a terminal type II disaccharide by the alpha2,6-sialyltransferase. The other hydroxyls can be replaced by hydrogen without a substantial decrease in activity. The alpha2,3-sialyltransferase requires the 3-, 4-, and 6-hydroxyls of the terminal betaGal and some contribution from the subterminal sugar. This may explain the cross-reactivity of this enzyme for the type I and type II acceptors. For both enzymes, an influence of the hydrophobic nature of the aglycone is noticed. The results allow an evaluation of the efficiency of the transfer of Neu5Ac to modified substrates.	ALBERTA RES COUNCIL, CARBOHYDRATE RES PROGRAM, POB 8330, STN F, EDMONTON T6H 5X2, AB, CANADA	Alberta Innovates								ALAIS J, 1990, CARBOHYD RES, V207, P11, DOI 10.1016/0008-6215(90)80002-K; BERLINER LJ, 1984, MOL CELL BIOCHEM, V62, P37, DOI 10.1007/BF00230075; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; BEYER TA, 1979, J BIOL CHEM, V254, P2531; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKHAUSEN I, 1992, BIOCHEM CELL BIOL, V70, P99, DOI 10.1139/o92-015; CHESTER MA, 1976, EUR J BIOCHEM, V69, P583, DOI 10.1111/j.1432-1033.1976.tb10944.x; FUKUDA M, 1984, BIOCHIM BIOPHYS ACTA, V780, P119, DOI 10.1016/0304-419X(84)90002-7; GROSS HJ, 1989, BIOCHEMISTRY-US, V28, P7386, DOI 10.1021/bi00444a036; HANSSON GC, 1985, J BIOL CHEM, V260, P9388; HIGA HH, 1985, J BIOL CHEM, V260, P8838; HINDSGAUL O, 1991, J BIOL CHEM, V266, P17858; HINDSGAUL O, 1991, ACS SYM SER, V466, P38; HOKKE CH, 1991, 11TH INT S GLYC TOR; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; ICHIKAWA Y, 1992, J AM CHEM SOC, V114, P9283, DOI 10.1021/ja00050a007; ICHIKAWA Y, 1992, ANAL BIOCHEM, V202, P215, DOI 10.1016/0003-2697(92)90099-S; IMBERTY A, 1991, GLYCOCONJUGATE J, V8, P456, DOI 10.1007/BF00769847; KAJIHARA Y, 1992, CARBOHYD RES, V229, pC5, DOI 10.1016/S0008-6215(00)90494-4; KAJIHARA Y, 1992, 16TH P INT CARB S PA, pA133; KHARE DP, 1985, CARBOHYD RES, V136, P285, DOI 10.1016/0008-6215(85)85204-6; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LEMIEUX RU, 1988, CAN J CHEM, V66, P3083, DOI 10.1139/v88-477; LEMIEUX RU, 1975, J AM CHEM SOC, V97, P4076, DOI 10.1021/ja00847a035; LEMIEUX RU, 1989, CHEM SOC REV, V18, P347, DOI 10.1039/cs9891800347; MATSUMOTO I, 1981, ANAL BIOCHEM, V116, P103, DOI 10.1016/0003-2697(81)90329-8; MATTA KL, 1984, CARBOHYD RES, V132, P119, DOI 10.1016/0008-6215(84)85069-7; MAZID MA, 1990, Patent No. 12090; MEYER B, 1990, TOP CURR CHEM, V154, P141; MOLLER G, 1992, GLYCOCONJUGATE J, V9, P180, DOI 10.1007/BF00731163; NEMANSKY M, 1992, BIOCHEM J, V287, P311, DOI 10.1042/bj2870311; NIKRAD PV, 1992, CAN J CHEM, V70, P241, DOI 10.1139/v92-035; PALCIC M M, 1991, Glycobiology, V1, P205, DOI 10.1093/glycob/1.2.205; PALCIC MM, 1987, CARBOHYD RES, V159, P315, DOI 10.1016/S0008-6215(00)90224-6; PALCIC MM, 1989, CARBOHYD RES, V190, P1, DOI 10.1016/0008-6215(89)84141-2; PAULSEN H, 1984, CARBOHYD RES, V125, P21, DOI 10.1016/0008-6215(84)85140-X; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1978, J BIOL CHEM, V253, P5617; POZSGAY V, 1991, BIOORG MED CHEM LETT, V1, P391, DOI 10.1016/S0960-894X(00)80262-0; SABESAN S, 1991, CARBOHYD RES, V218, P27, DOI 10.1016/0008-6215(91)84084-R; SPOHR U, 1988, CARBOHYD RES, V174, P211, DOI 10.1016/0008-6215(88)85093-6; SRIVASTAVA OP, 1988, CARBOHYD RES, V179, P137, DOI 10.1016/0008-6215(88)84115-6; STICHER U, 1988, BIOCHEM J, V253, P577, DOI 10.1042/bj2530577; TAKASE K, 1984, CURR TOP CELL REGUL, V24, P51; Thorgensen H., 1982, CAN J CHEM, V60, P44; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WEN DX, 1992, J BIOL CHEM, V267, P21011; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; WONG CH, 1991, J AM CHEM SOC, V113, P8137, DOI 10.1021/ja00021a045; YAN ZY, 1990, BIOPOLYMERS, V29, P799, DOI 10.1002/bip.360290414; YAZAWA S, 1990, ANAL BIOCHEM, V187, P374, DOI 10.1016/0003-2697(90)90472-L	54	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13971	13977						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314763				2022-12-27	WOS:A1993LJ82500032
J	BARKER, CW; FAGAN, JB; PASCO, DS				BARKER, CW; FAGAN, JB; PASCO, DS			DOWN-REGULATION OF P4501A1 AND P4501A2 MESSENGER-RNA EXPRESSION IN ISOLATED HEPATOCYTES BY OXIDATIVE STRESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR KAPPA-B; HYDROGEN-PEROXIDE; TRANSCRIPTIONAL REGULATION; N-ACETYLCYSTEINE; RECEPTOR KINASE; MESSENGER-RNAS; RAT ADIPOCYTES; INTACT-CELLS; AH RECEPTOR; ACTIVATION	We have previously shown that the inflammatory mediator interleukin-1 suppressed transcription of CYP1A1 and CYP1A2 mRNAs (Barker, C. W., Fagan, J. B., and Pasco, D. S. (1992) J. Biol. Chem. 267, 8050-8055). Since many of the actions of inflammatory mediators are mimicked by oxidative stress, we treated isolated hepatocytes with 0.25-1.0 mM H2O2 to determine whether expression of these genes is also modulated by oxidative stress. Inducer dependent accumulation of CYP1A1 and CYP1A2 mRNAs were maximally reduced approximately 50 and 70%, respectively, by 1.0 mM H2O2. Run-on transcription analysis suggested that the effect of H2O2 was mediated transcriptionally. The reduction in CYP1A mRNA levels was not due to a reduction in the levels of all mRNAs due to some general toxic effect since H2O2 did not reduce glyceraldehyde-3-phosphate dehydrogenase, alpha-tubulin, beta-fibrinogen, or albumin mRNA levels, and did not increase lactate dehydrogenase released into the medium. Insulin-mimicked H2O2 action, reducing the expression of both mRNAs, and N-acetylcysteine, which increases intracellular glutathione levels, completely reversed the insulin effect on both mRNAs and the H2O2 effect on CYP1A1 mRNA, but only partially reversed the H2O2 effect on CYP1A2 mRNA. This study indicates that the CYP1A1 and CYP1A2 genes are responsive to oxidative stress and that the majority of this responsiveness can be modified by cellular redox potential.	MAHARISHI INT UNIV,MOLEC BIOL LAB,FAIRFIELD,IA 52557						NCI NIH HHS [R01-CA55228] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055228] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON GM, 1992, ARCH BIOCHEM BIOPHYS, V294, P223, DOI 10.1016/0003-9861(92)90161-O; ALWINE JC, 1977, P NATL ACAD SCI USA, V74, P5350, DOI 10.1073/pnas.74.12.5350; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AOYAMA T, 1990, P NATL ACAD SCI USA, V87, P4790, DOI 10.1073/pnas.87.12.4790; BARKER CW, 1992, J BIOL CHEM, V267, P8050; BRADFIELD CA, 1991, MOL PHARMACOL, V39, P13; BUTLER MA, 1989, P NATL ACAD SCI USA, V86, P7696, DOI 10.1073/pnas.86.20.7696; BUTLER MA, 1989, CANCER RES, V49, P25; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CZECH MP, 1974, P NATL ACAD SCI USA, V71, P4173, DOI 10.1073/pnas.71.10.4173; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; FAGAN JB, 1986, ARCH BIOCHEM BIOPHYS, V244, P261, DOI 10.1016/0003-9861(86)90116-5; FALETTO MB, 1988, J BIOL CHEM, V263, P12187; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GATTI S, 1993, CLIN EXP IMMUNOL, V91, P456; GELBOIN HV, 1980, PHYSIOL REV, V60, P1107, DOI 10.1152/physrev.1980.60.4.1107; GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HANKINSON O, 1993, ARCH BIOCHEM BIOPHYS, V300, P1, DOI 10.1006/abbi.1993.1001; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; JIANG ZY, 1992, ANAL BIOCHEM, V202, P384, DOI 10.1016/0003-2697(92)90122-N; KALEBIC T, 1991, P NATL ACAD SCI USA, V88, P986, DOI 10.1073/pnas.88.3.986; KOJ A, 1985, ACUTE PHASE RESPONSE, pR22; KREAMER BL, 1986, IN VITRO CELL DEV B, V22, P201; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; KUKIELKA E, 1991, DRUG METAB DISPOS, V19, P1108; KURIEKA E, 1990, ARCH BIOCHEM BIOPHYS, V283, P326; LAWRENCE JC, 1978, J BIOL CHEM, V253, P2104; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LITTLE SA, 1990, J BIOL CHEM, V255, P10888; LIU PT, 1993, TOXICOLOGY, V80, P37, DOI 10.1016/0300-483X(93)90075-4; LU AYH, 1980, PHARMACOL REV, V31, P277; MANNERING GJ, 1986, ANNU REV PHARMACOL, V26, P455, DOI 10.1146/annurev.pa.26.040186.002323; MAY JM, 1979, J BIOL CHEM, V254, P9017; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; PASCO DS, 1988, J BIOL CHEM, V263, P8671; PASCO DS, 1993, J BIOL CHEM, V268, P1053; PELKONEN O, 1982, PHARMACOL REV, V34, P190; PERISTERIS P, 1992, CELL IMMUNOL, V140, P390, DOI 10.1016/0008-8749(92)90205-4; POELLINGER L, 1992, TRENDS PHARMACOL SCI, V13, P241, DOI 10.1016/0165-6147(92)90076-I; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; SAATCIOGLU F, 1990, J BIOL CHEM, V265, P9251; SANTHANAM K, 1989, CANCER LETT, V45, P129, DOI 10.1016/0304-3835(89)90147-X; SCHRAUFSTATTER I, 1988, J CLIN INVEST, V82, P1040, DOI 10.1172/JCI113660; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SHIBANUMA M, 1990, ONCOGENE, V5, P1025; SHIMM DS, 1992, RADIAT RES, V129, P149, DOI 10.2307/3578151; STARKE PE, 1985, J BIOL CHEM, V260, P86; SUGAWA K, 1985, J BIOL CHEM, V280, P5026; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	59	103	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3985	3990						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307954				2022-12-27	WOS:A1994MW98900016
J	HUG, P; SLEIGHT, RG				HUG, P; SLEIGHT, RG			FUSOGENIC VIROSOMES PREPARED BY PARTITIONING OF VESICULAR STOMATITIS-VIRUS G-PROTEIN INTO PREFORMED VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PH-SENSITIVE LIPOSOMES; MEMBRANE-FUSION; UNILAMELLAR VESICLES; INTRACELLULAR FATE; DEPENDENT FUSION; ENCAPSULATED DNA; COATED VESICLES; CELLS; RECONSTITUTION; FLUORESCENCE	Virosomes were prepared by the insertion of vesicular stomatitis virus glycoprotein, a pH-sensitive fusion protein, into preformed liposomes. The fusogenic activity of these virosomes was characterized in cell-free fusion assays using liposomal targets. Fusion was monitored by concentration-dependent changes in the efficiency of resonance energy transfer between N-(lissamine rhodamine B sulfonyl)-phosphatidylethanolamine and N-(4-nitrobenzo-2-oxa-1,3-diazol)-phosphatidylethanolamine and by electron microscopy. The fusogenic activity was dependent on the presence of vesicular stomatitis virus glycoprotein, was pH-sensitive, and had a pH threshold of activation similar to that of the native virus. The ex tent of fusion was dependent upon the lipid composition of the vesicles. This technique will allow vesicles prepared by any method to be made fusogenic.	UNIV CINCINNATI, COLL MED, DEPT MOLEC GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati					NIGMS NIH HHS [GM-39035] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039035] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLUMENTHAL R, 1988, CELL BIOPHYS, V12, P1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNS M, 1984, VIROLOGY, V137, P49, DOI 10.1016/0042-6822(84)90007-2; COLLINS D, 1990, BIOCHIM BIOPHYS ACTA, V1025, P234, DOI 10.1016/0005-2736(90)90102-T; COLLINS D, 1987, CANCER RES, V47, P735; CONNOR J, 1984, P NATL ACAD SCI-BIOL, V81, P1715, DOI 10.1073/pnas.81.6.1715; CUDD A, 1985, BIOCHIM BIOPHYS ACTA, V845, P477, DOI 10.1016/0167-4889(85)90214-9; EIDELMAN O, 1984, J BIOL CHEM, V259, P4622; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; GOULDFOGERITE S, 1985, ANAL BIOCHEM, V148, P15, DOI 10.1016/0003-2697(85)90622-0; GUY HR, 1992, BIOPHYS J, V62, P113; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HUANG L, 1983, METHOD ENZYMOL, V149, P88; HUG P, 1991, BIOCHIM BIOPHYS ACTA, V1097, P1, DOI 10.1016/0925-4439(91)90016-3; KREMER JMH, 1977, BIOCHEMISTRY-US, V16, P3932, DOI 10.1021/bi00636a033; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPIDOT M, 1989, BIOCHIM BIOPHYS ACTA, V980, P281, DOI 10.1016/0005-2736(89)90314-3; LIU D, 1989, BIOCHEM BIOPH RES CO, V163, P326; LIU DX, 1990, BIOCHIM BIOPHYS ACTA, V1022, P348, DOI 10.1016/0005-2736(90)90284-U; MAGEE WE, 1974, J CELL BIOL, V63, P492, DOI 10.1083/jcb.63.2.492; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; METSIKKO K, 1986, EMBO J, V5, P3429, DOI 10.1002/j.1460-2075.1986.tb04665.x; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MORGAN DO, 1988, IMMUNOL TODAY, V9, P84, DOI 10.1016/0167-5699(88)91270-4; NANDI PK, 1986, J BIOL CHEM, V261, P6722; PATERNOSTRE MT, 1989, FEBS LETT, V243, P251, DOI 10.1016/0014-5793(89)80139-5; PETRI WA, 1979, J BIOL CHEM, V254, P4313; PETRI WA, 1980, VIROLOGY, V107, P543, DOI 10.1016/0042-6822(80)90323-2; POLLARD HB, 1992, BIOPHYS J, V62, P15, DOI 10.1016/S0006-3495(92)81764-2; ROSIER RN, 1979, ANAL BIOCHEM, V96, P384, DOI 10.1016/0003-2697(79)90596-7; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SCHEULE RK, 1987, BIOCHIM BIOPHYS ACTA, V899, P185, DOI 10.1016/0005-2736(87)90399-3; SCHLEGEL R, 1983, CELL, V32, P639, DOI 10.1016/0092-8674(83)90483-X; STRAUBINGER RM, 1983, CELL, V32, P1069, DOI 10.1016/0092-8674(83)90291-X; STRAUBINGER RM, 1983, METHOD ENZYMOL, V101, P512; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; THOMAS D, 1985, J VIROL, V54, P598, DOI 10.1128/JVI.54.2.598-607.1985; VAINSTEIN A, 1983, METHOD ENZYMOL, V101, P492; WALTER A, 1993, BIOCHEMISTRY-US, V32, P3271, DOI 10.1021/bi00064a009; WHITE J, 1981, J CELL BIOL, V89, P674, DOI 10.1083/jcb.89.3.674; WHITE JM, 1992, J CELL BIOCH C SJ, V16, P111; WILLIAMS MC, 1991, AM J RESP CELL MOL, V5, P41, DOI 10.1165/ajrcmb/5.1.41; YATVIN MB, 1980, SCIENCE, V210, P1253, DOI 10.1126/science.7434025; ZAKIM D, 1989, METHOD ENZYMOL, V171, P253; ZON G, 1988, PHARM RES-DORDR, V5, P539, DOI 10.1023/A:1015985728434	48	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4050	4056						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307962				2022-12-27	WOS:A1994MW98900026
J	AUTHIER, F; RACHUBINSKI, RA; POSNER, BI; BERGERON, JJM				AUTHIER, F; RACHUBINSKI, RA; POSNER, BI; BERGERON, JJM			ENDOSOMAL PROTEOLYSIS OF INSULIN BY AN ACIDIC THIOL METALLOPROTEASE UNRELATED TO INSULIN DEGRADING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY VESICLES; RAT-LIVER ENDOSOMES; DEGRADATION PRODUCTS; HUMAN-ERYTHROCYTES; RECEPTOR KINASE; MAMMALIAN-CELLS; HEPATOMA-CELLS; GLUCAGON; MEMBRANE; PROTEIN	Although insulin is degraded as a consequence of receptor-mediated endocytosis, the location and nature of the responsible proteinase(s) remain controversial. Insulin degrading enzyme (IDE; EC 3.4.22.11), a mainly cytosolic neutral thiol metalloendopeptidase of 110 kDa, has been proposed to be the main cellular clearance mechanism. However, endosomes concentrate and degrade internalized insulin demonstrating that IDE is unlikely to be the relevant-enzyme for endosomal proteolysis of internalized insulin in liver parenchyma. In purified endosomal fractions insulin was actively degraded at acid pH and IDE was undetectable as evaluated by immunoblotting, immunoprecipitation, or chemical cross-linking procedures. Affinity purified endosomal acidic insulinase displayed a pH optimum of 4-5.5, a lack of inhibition by EDTA and N-ethylmaleimide, and a partial metal-ion requirement (for Mn2+) all of which distinguished it from IDE. A small but detectable presence of IDE in particulate nuclear (N) and large granule (ML) fractions was observed by differential centrifugation. By analytical centrifugation, IDE cosedimented with the organelle containing the peroxisomal marker proteins catalase and thiolase (median density, 1.21 g . cm-3). By preparative centrifugation, highly purified peroxisomes were observed to be enriched in IDE. Since all cloned cDNAs of IDE (human, rat, and Drosophila) reveal a deduced classical peroxisomal targeting sequence A/SKL at their carboxyl termini this may account for the peroxisomal location of IDE. Taken together, our studies identify an insulin-degrading enzyme in endosomes which is distinct from IDE. The latter's presence in peroxisomes suggests that its physiological substrate(s) in vivo are polypeptides other than insulin.	MCGILL UNIV, DEPT ANAT & CELL BIOL, MONTREAL H3A 2B2, QUEBEC, CANADA; MCGILL UNIV, DEPT MED, MONTREAL H3A 2B2, QUEBEC, CANADA; MCMASTER UNIV, DEPT BIOCHEM, HAMILTON L8N 3Z5, ONTARIO, CANADA	McGill University; McGill University; McMaster University			Bergeron, John/AAW-1893-2021; Posner, Barry/B-6733-2008					AFFHOLTER JA, 1990, MOL ENDOCRINOL, V4, P1125, DOI 10.1210/mend-4-8-1125; AFFHOLTER JA, 1988, SCIENCE, V242, P1415, DOI 10.1126/science.3059494; ALEXSON SEH, 1985, J CELL BIOL, V101, P294, DOI 10.1083/jcb.101.1.294; AMARCOSTESEC A, 1974, J CELL BIOL, V61, P201, DOI 10.1083/jcb.61.1.201; AUTHIER F, 1990, BIOCHEM J, V272, P703, DOI 10.1042/bj2720703; AUTHIER F, 1991, BIOCHEM J, V280, P211, DOI 10.1042/bj2800211; AUTHIER F, 1992, ENDOCRINOLOGY, V131, P447, DOI 10.1210/en.131.1.447; BACKER JM, 1990, J BIOL CHEM, V265, P14828; BAUDHUIN P, 1964, BIOCHEM J, V92, P179, DOI 10.1042/bj0920179; BAUMEISTER H, 1993, FEBS LETT, V317, P250, DOI 10.1016/0014-5793(93)81286-9; BERGERON JJM, 1986, BIOCHEMISTRY-US, V25, P1756, DOI 10.1021/bi00355a046; BERGERON JJM, 1982, J CELL BIOL, V92, P139, DOI 10.1083/jcb.92.1.139; BERGERON JJM, 1985, ANNU REV PHYSIOL, V47, P383; BODNAR AG, 1991, BIOCHEM CELL BIOL, V69, P499, DOI 10.1139/o91-074; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLOT JP, 1990, MOL CELL ENDOCRINOL, V72, P175, DOI 10.1016/0303-7207(90)90142-U; DIMENT S, 1988, J BIOL CHEM, V263, P6901; DOHERTY JJ, 1990, J CELL BIOL, V110, P35, DOI 10.1083/jcb.110.1.35; DUCKWORT.WC, 1972, P NATL ACAD SCI USA, V69, P3698, DOI 10.1073/pnas.69.12.3698; DUCKWORTH WC, 1988, ENDOCR REV, V9, P319, DOI 10.1210/edrv-9-3-319; DUCKWORTH WC, 1974, DIABETES, V23, P536, DOI 10.2337/diab.23.6.536; DUVE CD, 1975, SCIENCE, V189, P186, DOI 10.1126/science.1138375; FUCHS R, 1989, J BIOL CHEM, V264, P2212; GEUZE HJ, 1985, J CELL BIOL, V101, P2253, DOI 10.1083/jcb.101.6.2253; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; GRIFFITHS G, 1990, J CELL SCI, V95, P441; HAMEL FG, 1991, DIABETES, V40, P436, DOI 10.2337/diabetes.40.4.436; HAMEL FG, 1988, J BIOL CHEM, V263, P6703; HARADA S, 1993, ENDOCRINOLOGY, V132, P2293, DOI 10.1210/en.132.6.2293; JASPAN JB, 1981, AM J PHYSIOL, V240, pE233, DOI 10.1152/ajpendo.1981.240.3.E233; KHAN MN, 1986, J BIOL CHEM, V261, P8462; KHAN MN, 1989, J BIOL CHEM, V264, P12931; KHAN MN, 1985, DIABETES, V34, P1025, DOI 10.2337/diabetes.34.10.1025; KIRSCHNER RJ, 1983, J BIOL CHEM, V258, P967; KUO WL, 1990, MOL ENDOCRINOL, V4, P1580, DOI 10.1210/mend-4-10-1580; KUO WL, 1993, ENDOCRINOLOGY, V132, P604, DOI 10.1210/en.132.2.604; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; MISBIN RI, 1989, DIABETES, V38, P152, DOI 10.2337/diabetes.38.2.152; MOLLAT P, 1992, BIO-TECHNOL, V10, P1151, DOI 10.1038/nbt1092-1151; MULLER D, 1992, BIOCHEMISTRY-US, V31, P11138; MULLER D, 1991, EUR J BIOCHEM, V202, P285, DOI 10.1111/j.1432-1033.1991.tb16374.x; NEVILLE DM, 1968, BIOCHIM BIOPHYS ACTA, V154, P540, DOI 10.1016/0005-2795(68)90014-7; OU WJ, 1992, J BIOL CHEM, V267, P23789; PEASE RJ, 1985, BIOCHEM J, V228, P137, DOI 10.1042/bj2280137; PEASE RJ, 1987, EUR J BIOCHEM, V164, P251, DOI 10.1111/j.1432-1033.1987.tb11018.x; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; POSNER BI, 1979, J BIOL CHEM, V254, P2494; POSNER BI, 1982, J BIOL CHEM, V257, P5789; RACHUBINSKI RA, 1984, J CELL BIOL, V99, P2241, DOI 10.1083/jcb.99.6.2241; ROSE K, 1988, BIOCHEM J, V256, P847, DOI 10.1042/bj2560847; SHII K, 1986, P NATL ACAD SCI USA, V83, P4147, DOI 10.1073/pnas.83.12.4147; SHII K, 1985, J BIOL CHEM, V260, P6503; SHII K, 1986, DIABETES, V35, P675, DOI 10.2337/diabetes.35.6.675; SMITH GD, 1989, EUR J BIOCHEM, V181, P287, DOI 10.1111/j.1432-1033.1989.tb14723.x; TERRIS S, 1975, J BIOL CHEM, V250, P8389; TERRIS S, 1976, J CLIN INVEST, V57, P885, DOI 10.1172/JCI108365; UNQUIST EA, 1991, J BIOL CHEM, V266, P22557; WADA I, 1991, J BIOL CHEM, V266, P19599; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTON PA, 1992, MOL CELL BIOL, V12, P531, DOI 10.1128/MCB.12.2.531	62	90	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3010	3016						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300632				2022-12-27	WOS:A1994MV43200092
J	GROSSMAN, L; THIAGALINGAM, S				GROSSMAN, L; THIAGALINGAM, S			NUCLEOTIDE EXCISION-REPAIR, A TRACKING MECHANISM IN SEARCH OF DAMAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ESCHERICHIA-COLI UVRAB; PROTEIN COMPLEX; ENZYMATIC-PROPERTIES; DNA-REPAIR; ENDONUCLEASE; PURIFICATION; BINDING; STRAND; GENE; MUTATIONS				GROSSMAN, L (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21205, USA.			Thiagalingam, Sam/0000-0001-5211-266X	NIGMS NIH HHS [GM22846] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022846, R37GM022846] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; BECK DJ, 1985, NUCLEIC ACIDS RES, V13, P7395, DOI 10.1093/nar/13.20.7395; BOHR VA, 1986, P NATL ACAD SCI USA, V83, P3830, DOI 10.1073/pnas.83.11.3830; CARON PR, 1988, NUCLEIC ACIDS RES, V16, P9651, DOI 10.1093/nar/16.20.9651; CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; CARON PR, 1988, NUCLEIC ACIDS RES, V16, P7855, DOI 10.1093/nar/16.16.7855; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11380; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11388; FERSHT A, 1977, ENZYME STRUCTURE MEC, P196; GROSSMAN L, 1988, FASEB J, V2, P2696, DOI 10.1096/fasebj.2.11.3294078; GROSSMAN L, 1990, MUTAT RES, V236, P213, DOI 10.1016/0921-8777(90)90006-Q; GROSSMAN L, 1991, ENCY HUMAN BIOL, V6, P547; HILDEBRAND E, 1993, J CELL BIOCHEM     S, V17, P164; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; OH EY, 1989, NUCLEIC ACIDS RES, V17, P4145, DOI 10.1093/nar/17.11.4145; OH EY, 1986, NUCLEIC ACIDS RES, V14, P8557, DOI 10.1093/nar/14.21.8557; OH EY, 1989, J BIOL CHEM, V264, P1336; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; OLIVER DB, 1993, MOL MICROBIOL, V7, P159, DOI 10.1111/j.1365-2958.1993.tb01107.x; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SEEBERG E, 1982, P NATL ACAD SCI-BIOL, V79, P988, DOI 10.1073/pnas.79.4.988; SEELEY TW, 1990, J BIOL CHEM, V265, P7158; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; THIAGALINGAM S, 1991, J BIOL CHEM, V266; THIAGALINGAM S, 1993, IN PRESS J BIOL CHEM, V268; VANHOUTEN B, 1993, BIOESSAYS, V15, P51, DOI 10.1002/bies.950150108; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VISSE R, 1992, J BIOL CHEM, V267, P6736; WANG JT, 1993, J BIOL CHEM, V268, P5323; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P2567, DOI 10.1093/nar/14.6.2567; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157	40	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16871	16874						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349576				2022-12-27	WOS:A1993LQ98800001
J	SHETTY, M; LOEB, JN; VIKSTROM, K; ISMAILBEIGI, F				SHETTY, M; LOEB, JN; VIKSTROM, K; ISMAILBEIGI, F			RAPID ACTIVATION OF GLUT-1 GLUCOSE-TRANSPORTER FOLLOWING INHIBITION OF OXIDATIVE-PHOSPHORYLATION IN CLONE-9 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE 3T3-L1 ADIPOCYTES; CYTOCHALASIN-B BINDING; HEXOSE-TRANSPORT; THYROID-HORMONE; MAMMALIAN-CELLS; INSULIN; STIMULATION; MEMBRANE; TRANSLOCATION; ENHANCEMENT	Exposure of Clone 9 cells to inhibitors of oxidative phosphorylation results in a rapid and striking stimulation of facilitated glucose transport (7.5-fold at 2 h) that is mediated by the GLUT-1 transporter. We have previouslY shown that this rapid stimulation of glucose transport occurs in the absence of any detectable increase in cell GLUT-1 or GLUT-1 mRNA content. To determine whether this early enhancement of transport is attributable to a translocation of glucose transporters to the plasma membrane, or instead to an activation of transporters already present in the plasma membrane, we have employed four different approaches to determine whether the stimulation of transport is accompanied by a corresponding increase in plasma membrane GLUT-1 sites: 1) immunofluorescence microscopy; 2) quantitation of GLUT-1 sites in plasma membrane fractions isolated by differential centrifugation and subsequent Western blotting; 3) cell surface biotinylation followed by isolation of plasma membranes and quantitation of GLUT-1 sites by Western blotting; and 4) quantitation of GLUT-1 sites in plasma membrane fractions by [H-3]cytochalasin B binding. Each of these experimental approaches led to the same conclusion, namely that the large stimulation of glucose transport observed during the early phase of the response to azide is associated with only a slight increase in the abundance of GLUT-1 sites in the plasma membrane. These results strongly suggest that activation of GLUT-1 sites pre-existing in the plasma membrane is the dominant mechanism mediating the early glucose transport response to inhibition of oxidative phosphorylation.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	SHETTY, M (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032, USA.				NICHD NIH HHS [HD-05506] Funding Source: Medline; NIDDK NIH HHS [DK-07328] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD005506, R01HD005506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007328] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AXELROD JD, 1983, BIOCHEMISTRY-US, V22, P2222, DOI 10.1021/bi00278a025; BALY DL, 1987, J BIOL CHEM, V262, P21; BASHAN N, 1992, AM J PHYSIOL, V262, pC682, DOI 10.1152/ajpcell.1992.262.3.C682; Battey, 1986, BASIC METHODS MOL BI; CARRUTHERS A, 1986, J BIOL CHEM, V261, P1028; CARTEE GD, 1991, J APPL PHYSIOL, V70, P1593, DOI 10.1152/jappl.1991.70.4.1593; CHEN SR, 1988, BIOCHEM J, V251, P63, DOI 10.1042/bj2510063; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; ELBRINK J, 1975, SCIENCE, V188, P1177, DOI 10.1126/science.1096301; GIBBS EM, 1988, BIOCHEMISTRY-US, V27, P6681, DOI 10.1021/bi00418a006; GORGA FR, 1981, BIOCHEMISTRY-US, V20, P5108, DOI 10.1021/bi00521a003; HAKIMIAN J, 1991, J MEMBRANE BIOL, V120, P29, DOI 10.1007/BF01868588; HARRISON SA, 1991, P NATL ACAD SCI USA, V88, P7839, DOI 10.1073/pnas.88.17.7839; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; HARRISON SA, 1991, J BIOL CHEM, V266, P19438; HASPEL HC, 1988, J BIOL CHEM, V263, P398; HEBERT DN, 1992, J BIOL CHEM, V267, P23829; ISMAILBEIGI F, 1971, J GEN PHYSIOL, V57, P710, DOI 10.1085/jgp.57.6.710; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KURUVILLA AK, 1991, BIOCHIM BIOPHYS ACTA, V1094, P300, DOI 10.1016/0167-4889(91)90090-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN S, 1974, J BIOL CHEM, V249, P5778; LOIKE JD, 1992, AM J PHYSIOL, V263, pC326, DOI 10.1152/ajpcell.1992.263.2.C326; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERCADO CL, 1989, AM J PHYSIOL, V257, pC19, DOI 10.1152/ajpcell.1989.257.1.C19; MIZEL SB, 1972, J BIOL CHEM, V247, P4102; Morgan H E, 1965, Fed Proc, V24, P1040; MORGAN H. E., 1965, P347; MORGAN HE, 1959, BIOCHEM J, V73, P573, DOI 10.1042/bj0730573; MORGAN HE, 1973, CURRENT TOPICS MEMBR, V4, P255; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; RANDLE PJ, 1958, BIOCHEM J, V70, P501, DOI 10.1042/bj0700501; RANDLE PJ, 1958, BIOCHEM J, V70, P490, DOI 10.1042/bj0700490; REEVES JP, 1975, J BIOL CHEM, V250, P9413; REUSCH JEB, 1993, J BIOL CHEM, V268, P3348; SHETTY M, 1992, AM J PHYSIOL, V262, pC527, DOI 10.1152/ajpcell.1992.262.2.C527; Shetty Mangala, 1992, Journal of General Physiology, V100, p56A; SNEDECOR GW, 1976, STATISTICAL METHODS; WEINSTEIN EB, 1975, GENE EXPRESSION CARC, P441; WHEELER TJ, 1988, J BIOL CHEM, V263, P19447; WHEELER TJ, 1985, ANNU REV PHYSIOL, V47, P503, DOI 10.1146/annurev.ph.47.030185.002443; WHITFIELD CF, 1973, BIOCHIM BIOPHYS ACTA, V307, P181, DOI 10.1016/0005-2736(73)90036-9; WOOD RE, 1969, J BIOL CHEM, V244, P1451	45	111	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17225	17232						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349608				2022-12-27	WOS:A1993LQ98800054
J	DONG, DLY; XU, ZS; CHEVRIER, MR; COTTER, RJ; CLEVELAND, DW; HART, GW				DONG, DLY; XU, ZS; CHEVRIER, MR; COTTER, RJ; CLEVELAND, DW; HART, GW			GLYCOSYLATION OF MAMMALIAN NEUROFILAMENTS - LOCALIZATION OF MULTIPLE O-LINKED N-ACETYLGLUCOSAMINE MOIETIES ON NEUROFILAMENT POLYPEPTIDES-L AND POLYPEPTIDES-M	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXY-TERMINAL EXTENSION; FILAMENT GENE FAMILY; AMINO-ACID SEQUENCE; PHOSPHORYLATION SITES; CYTOPLASMIC GLYCOPROTEINS; INTERMEDIATE FILAMENTS; TRIPLET PROTEINS; AXONAL-TRANSPORT; IDENTIFICATION; EXPRESSION	Neurofilaments are neuronal intermediate filaments that play an important role in the growth and maintenance of large myelinated axons. Mammalian neurofilaments are composed of three polypeptide subunits, designed as NF-L, NF-M, and NF-H, all of which are phosphorylated. Here, we demonstrate by several criteria that neurofilament polypeptides are also modified by an abundant type of intracellular protein glycosylation in which single N-acetylglucosamine monosaccharides are O-glycosidically (O-GlcNAc) linked to serine or threonine residues. In purified neurofilament proteins, the O-GlcNAc modifications occur at a stoichiometry of approximately 0.1 and 0.15 mol of GlcNAc/mol of NF-L and NF-M, respectively. The predominant sites of O-GlcNAc attachment on NF-L and NF-M are identified using proteolysis, purification of the glycopeptides, and subsequent analysis by automated gas-phase sequencing, manual Edman degradation, and laser desorption mass spectrometry. For NF-L, both major sites of glycosylation (Thr21 and Ser27) are located at the NH2-terminal head domain. For NF-M, one major site (Thr48) lies within the NH2-terminal head domain, whereas the other (Thr431) is located at the tail domain. Deletions encompassing these sites have been shown previously to have a dominant detrimental effect upon neurofilament assembly, raising questions about the specific function(s) of the saccharide moieties at these sites. Specific identification of these O-GlcNAc attachment sites has set the stage for more detailed mutagenic analysis of O-GlcNAc functions on neurofilaments.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Cleveland, Don/AAN-9783-2021	Cleveland, Don/0000-0002-1934-3682	NICHD NIH HHS [HD13563] Funding Source: Medline; NINDS NIH HHS [NS27036] Funding Source: Medline; PHS HHS [1P30A128748] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013563, R37HD013563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027036, R37NS027036] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIGNAMI A, 1986, BRAIN RES, V375, P73, DOI 10.1016/0006-8993(86)90960-1; CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; CHARNAS LR, 1992, J NEUROSCI, V12, P3010, DOI 10.1523/JNEUROSCI.12-08-03010.1992; CHEVRIER MR, 1991, RAPID COMMUN MASS SP, V5, P611, DOI 10.1002/rcm.1290051209; CHIN SSM, 1989, EUR J CELL BIOL, V50, P475; CHOU CF, 1992, J BIOL CHEM, V267, P3901; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; GEISLER N, 1984, EMBO J, V3, P2701, DOI 10.1002/j.1460-2075.1984.tb02196.x; GEISLER N, 1983, EMBO J, V2, P1295, DOI 10.1002/j.1460-2075.1983.tb01584.x; GEISLER N, 1985, FEBS LETT, V182, P475, DOI 10.1016/0014-5793(85)80357-4; GEISLER N, 1985, EMBO J, V4, P57, DOI 10.1002/j.1460-2075.1985.tb02317.x; GILL SR, 1990, J CELL BIOL, V111, P2005, DOI 10.1083/jcb.111.5.2005; HAGMANN J, 1992, J BIOL CHEM, V267, P14424; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P1; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HIRANO A, 1988, AMYOTROPHIC LATERAL, P193; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; HOFFMAN PN, 1985, J CELL BIOL, V101, P1332, DOI 10.1083/jcb.101.4.1332; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; HOLT GD, 1987, J BIOL CHEM, V262, P14847; HOLT GD, 1986, J BIOL CHEM, V261, P8049; INABA M, 1989, J BIOL CHEM, V264, P18149; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JULIEN JP, 1982, J BIOL CHEM, V257, P467; JULIEN JP, 1983, J BIOL CHEM, V258, P4019; JULIEN JP, 1987, BIOCHIM BIOPHYS ACTA, V909, P10, DOI 10.1016/0167-4781(87)90041-8; KARLSSON JE, 1987, J NEUROCHEM, V49, P1375, DOI 10.1111/j.1471-4159.1987.tb01002.x; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KELLY WG, 1993, J BIOL CHEM, V268, P10416; KING IA, 1989, J BIOL CHEM, V264, P14022; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY E, 1987, EUR J BIOCHEM, V166, P71, DOI 10.1111/j.1432-1033.1987.tb13485.x; LEWIS SA, 1986, MOL CELL BIOL, V6, P1529, DOI 10.1128/MCB.6.5.1529; LUTHI T, 1991, J NEUROCHEM, V56, P1493; MYERS MW, 1987, EMBO J, V6, P1617, DOI 10.1002/j.1460-2075.1987.tb02409.x; NAPOLITANO EW, 1987, J NEUROSCI, V7, P2590; NIXON RA, 1992, CELL MOTIL CYTOSKEL, V22, P81, DOI 10.1002/cm.970220202; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; REASON AJ, 1992, J BIOL CHEM, V267, P16911; ROQUEMORE EP, 1992, J BIOL CHEM, V267, P555; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHAW G, 1991, NEURONAL CYTOSKELETO, P185; SIHAG RK, 1989, J BIOL CHEM, V264, P457; SIHAG RK, 1991, J BIOL CHEM, V266, P18861; SIHAG RK, 1990, J BIOL CHEM, V265, P4166; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; TORRES CR, 1984, J BIOL CHEM, V259, P3308; WILEY CA, 1987, ACTA NEUROPATHOL, V72, P369, DOI 10.1007/BF00687269; WONG PC, 1990, J CELL BIOL, V111, P1987, DOI 10.1083/jcb.111.5.1987; XU ZS, 1990, J NEUROSCI, V10, P1838; XU ZS, 1992, J BIOL CHEM, V267, P4467; XU ZS, 1993, IN PRESS CELL; YAMASAKI H, 1992, LAB INVEST, V66, P734; ZOPF D, 1990, NUCLEIC ACIDS RES, V18, P521, DOI 10.1093/nar/18.3.521	58	184	195	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16679	16687						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344946				2022-12-27	WOS:A1993LQ33600085
J	WERLEN, G; BELIN, D; CONNE, B; ROCHE, E; LEW, DP; PRENTKI, M				WERLEN, G; BELIN, D; CONNE, B; ROCHE, E; LEW, DP; PRENTKI, M			INTRACELLULAR CA2+ AND THE REGULATION OF EARLY RESPONSE GENE-EXPRESSION IN HL-60 MYELOID-LEUKEMIA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FOS GENE; HUMAN-NEUTROPHILS; FREE CALCIUM; TRANSIENT INCREASE; PROLACTIN GENE; MESSENGER-RNAS; TRANSCRIPTION; CA-2+; MACROPHAGES	To gain direct insight into the action of the second messenger Ca2+ on transcriptional regulation, we have developed an intact cell model in which the intracellular free Ca2+ concentration ([Ca2+]i) can be measured, set, and varied at any level within the physiological range and in which the expression of early response genes is assayed in parallel. Using promyelocytic HL-60 cells, we have observed an exquisite sensitivity to Ca2+ of c-fos, c-jun, and zif268 mRNA accumulation, since early and maximal inductions were observed at 200-300 nm [Ca2+]i. At early times (10-20 min), the [Ca2+]i dose dependence of c-fos transcription and mRNA accumulation displayed a bell shape since c-fos expression was barely modified at high (700-1,250 nM) [Ca2+]i. The threshold [Ca2+]i concentration for prolonged (60 min) c-fos mRNA accumulation was greater than 200 nM. This indicates that the quantitative effects of Ca2+ on a given gene can vary markedly as a function of both the [Ca2+]i concentration and the duration of stimulation. Strikingly, a [Ca2+]i perturbation of only 1 min was sufficient for full induction of c-fos and zif268 transcripts. This demonstrates that a transient perturbation of [Ca2+]i has long term effects on gene expression. The half-life of c-fos mRNA (16 min) was unaltered by Ca2+. Nuclear run-on analysis of the distribution of RNA polymerase II along the c-fos locus indicated that Ca2+ promotes a small increase in transcriptional initiation and a pronounced relief of a block to transcriptional elongation beyond intron 1. The extreme sensitivity to [Ca2+]i, in terms of both the length of time and the dose of [Ca2+]i required for maximal gene induction, demonstrates that Ca2+ is a major physiological regulator of early response gene expression. In addition, the results indicate that a c-fos intragenic element is the main target of Ca2+-regulated transcriptional activation.	UNIV GENEVA,SCH MED,DEPT MED,CH-1211 GENEVA 4,SWITZERLAND; UNIV GENEVA,SCH MED,DEPT PATHOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva; University of Geneva			Roche, Enrique/V-5738-2017	Roche, Enrique/0000-0001-5128-1672				BANDYOPADHYAY SK, 1989, J BIOL CHEM, V264, P14216; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BUSSO N, 1986, J BIOL CHEM, V261, P9309; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COFFIN JM, 1976, J MOL BIOL, V100, P293, DOI 10.1016/S0022-2836(76)80065-4; COLLART MA, 1989, ONCOGENE, V4, P237; COLLART MA, 1987, J IMMUNOL, V139, P949; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; DAVIS JRE, 1991, MOL ENDOCRINOL, V5, P8, DOI 10.1210/mend-5-1-8; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Karin M, 1991, CURR OPIN CELL BIOL, V3, P467, DOI 10.1016/0955-0674(91)90075-A; KLEY N, 1987, J BIOL CHEM, V262, P4083; KNIGHT DE, 1986, BIOCHEM J, V234, P497, DOI 10.1042/bj2340497; KRUSKAL BA, 1986, P NATL ACAD SCI USA, V83, P2919, DOI 10.1073/pnas.83.9.2919; LAVERRIERE JN, 1988, ENDOCRINOLOGY, V122, P333, DOI 10.1210/endo-122-1-333; Lee KAW, 1991, CURR OPIN CELL BIOL, V3, P953, DOI 10.1016/0955-0674(91)90113-D; LEW PD, 1986, J CELL BIOL, V102, P2197, DOI 10.1083/jcb.102.6.2197; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MORGAN JI, 1988, CELL CALCIUM, V9, P303, DOI 10.1016/0143-4160(88)90011-5; PITTET D, 1989, J BIOL CHEM, V264, P7251; PRENTKI M, 1984, J BIOL CHEM, V259, P3777; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; TREJO J, 1991, J BIOL CHEM, V266, P7876; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; WOLLHEIM CB, 1987, BIOSCIENCE REP, V7, P443, DOI 10.1007/BF01362507; ZIEGLER A, 1990, J BIOL CHEM, V265, P21194	37	77	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16596	16601						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344941				2022-12-27	WOS:A1993LQ33600075
J	HOLMES, DF; WATSON, RB; STEINMANN, B; KADLER, KE				HOLMES, DF; WATSON, RB; STEINMANN, B; KADLER, KE			EHLERS-DANLOS SYNDROME TYPE-VIIB - MORPHOLOGY OF TYPE-I COLLAGEN FIBRILS FORMED IN-VIVO AND IN-VITRO IS DETERMINED BY THE CONFORMATION OF THE RETAINED N-PROPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMISSION ELECTRON-MICROSCOPY; CHICK-EMBRYO TENDONS; LENGTH CDNA CLONE; PRO-ALPHA-2(I) CHAIN; CONNECTIVE-TISSUE; STAINING PATTERN; PC-COLLAGEN; PROCOLLAGEN; PROTEINASE; GENE	Previously we showed that fibrils generated from collagen and pNcollagen(-ex6) from fibroblasts of an individual with Ehlers-Danlos syndrome (EDS) type VIIB were hieroglyphic in cross-section and all N-propeptides were located at the fibril surface. Hieroglyphs were resolved to near-cylindrical fibrils (that were similar in appearance to the fibrils seen in the. tissues of individuals with EDS type VIIB) by treatment with N-proteinase which cleaved the pNalpha1(I) chains but not the pNalpha2(I)-ex6 chains (Watson, R. B., Wallis, G. A., Holmes, D. F., Viljoen, D., Byers, P. H., and Kadler, K. E. (1992) J. Biol. Chem. 267, 9093-9100). Here, quantitative scanning transmission electron microscopy (STEM) showed that N-propeptides in hieroglyphs were in a ''bent-back'' conformation and thus located exclusively in the overlap zone of the fibril D-period (D = 67 nm). In contrast, STEM of fibrils from the dermis of an individual with EDS type VIIB showed that partially cleaved N-propeptides (in which cleaved pNalpha1(I) remained in noncovalent association with pNalpha2(I)-ex6 chains) were distributed equally between the gap and overlap zones of the fibrils. Comparison of experimental data with theoretical mass distributions of the fibril based on amino acid sequence data gave a consistent value of 33 nm for the total axial extent for the N-propeptides in hieroglyphic and tissue fibrils irrespective of the location of N-propeptides to the gap or overlap zone. These data exclude the possibility that N-propeptides adopt a random configuration, but rather, that they locate to specific sites in the gap and overlap zones. The results demonstrated that cleavage of pNalpha1(I) chains in vivo releases the N-propeptides from the constraints of the bent-back conformation. Co-distribution of partially cleaved N-propeptides between gap and overlap zones allows a higher surface packing density of N-propeptides and explains how circularity of large diameter fibrils can be achieved despite the retention of N-propeptides in tissues of individuals with EDS type VIIB.	UNIV MANCHESTER,SCH BIOL SCI,DEPT BIOCHEM & MOLEC BIOL,OXFORD RD,MANCHESTER M13 9PT,LANCS,ENGLAND; UNIV MANCHESTER,SCH BIOL SCI,DEPT MED BIOPHYS,MANCHESTER M13 9PT,LANCS,ENGLAND; UNIV ZURICH,CHILDRENS HOSP,DEPT PEDIAT,DIV METAB,CH-8032 ZURICH,SWITZERLAND	University of Manchester; University of Manchester; University Children's Hospital Zurich; University of Zurich			KADLER, KARL/ABI-2403-2020	KADLER, KARL/0000-0003-4977-4683	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEIGHTON P, 1988, AM J MED GENET, V29, P581, DOI 10.1002/ajmg.1320290316; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; BYERS PH, 1989, METABOLIC BASIS INHE, P2805; CAPALDI MJ, 1982, BIOPOLYMERS, V21, P2291, DOI 10.1002/bip.360211115; CHAPMAN JA, 1974, CONNECT TISSUE RES, V2, P151, DOI 10.3109/03008207409152100; CHAPMAN JA, 1989, BIOPOLYMERS, V28, P2201, DOI 10.1002/bip.360281212; CHAPMAN JA, 1989, BIOPOLYMERS, V28, P1367, DOI 10.1002/bip.360280803; COUNTS DF, 1980, J INVEST DERMATOL, V74, P96, DOI 10.1111/1523-1747.ep12519991; DALESSIO M, 1988, GENE, V67, P105, DOI 10.1016/0378-1119(88)90013-3; DEWET W, 1987, J BIOL CHEM, V262, P16032; ENGEL A, 1982, MICRON, V13, P425, DOI 10.1016/0047-7206(82)90094-2; ENGEL A, 1978, ULTRAMICROSCOPY, V3, P273, DOI 10.1016/S0304-3991(78)80037-0; ENGEL A, 1981, ULTRAMICROSCOPY, V7, P45, DOI 10.1016/0304-3991(81)90022-X; ENGEL A, 1984, J ULTRA MOL STRUCT R, V88, P105, DOI 10.1016/S0022-5320(84)80003-9; ENGEL J, 1977, BIOCHEMISTRY-US, V16, P4026, DOI 10.1021/bi00637a014; EYRE DR, 1985, J BIOL CHEM, V260, P1322; FIEDLERNAGY C, 1981, ARCH BIOCHEM BIOPHYS, V212, P668, DOI 10.1016/0003-9861(81)90411-2; FJOLSTAD M, 1974, J PATHOL, V112, P183, DOI 10.1002/path.1711120309; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HELSETH DL, 1979, BIOPOLYMERS, V18, P3005, DOI 10.1002/bip.1979.360181208; HOJIMA Y, 1989, J BIOL CHEM, V264, P11336; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HOLBROOK KA, 1980, J INVEST DERMATOL, V74, P100, DOI 10.1111/1523-1747.ep12520000; HOLMES DF, 1991, J MOL BIOL, V220, P111, DOI 10.1016/0022-2836(91)90385-J; HOLMES DF, 1991, BIOCHEM SOC T, V19, P808, DOI 10.1042/bst0190808; HOLMES DF, 1991, J MOL BIOL, V19, P808; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KUIVANIEMI H, 1988, BIOCHEM J, V252, P633, DOI 10.1042/bj2520633; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENAERS A, 1971, EUR J BIOCHEM, V23, P533, DOI 10.1111/j.1432-1033.1971.tb01651.x; MEEK KM, 1979, J BIOL CHEM, V254, P710; MOULD AP, 1987, J MOL BIOL, V197, P543; NUSGENS BV, 1992, NAT GENET, V1, P214, DOI 10.1038/ng0692-214; PELTONEN L, 1980, P NATL ACAD SCI USA, V71, P6179; SCOTT JE, 1981, BIOCHEM J, V197, P213, DOI 10.1042/bj1970213; SMITH LT, 1992, AM J HUM GENET, V51, P235; STEINMANN B, 1985, ANN NY ACAD SCI, V460, P506, DOI 10.1111/j.1749-6632.1985.tb51224.x; STEINMANN B, 1980, J BIOL CHEM, V255, P8887; Steinmann Beat, 1993, P351; TROMP G, 1988, BIOCHEM J, V253, P919, DOI 10.1042/bj2530919; VASAN NS, 1991, AM J HUM GENET, V48, P305; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WATSON RB, 1992, J BIOL CHEM, V267, P9093; WIRTZ MK, 1990, J BIOL CHEM, V265, P6312; WIRTZ MK, 1987, J BIOL CHEM, V262, P16376; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0	46	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15758	15765						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340401				2022-12-27	WOS:A1993LN30500065
J	KUMAR, GB; BLACK, PN				KUMAR, GB; BLACK, PN			BACTERIAL LONG-CHAIN FATTY-ACID TRANSPORT - IDENTIFICATION OF AMINO-ACID-RESIDUES WITHIN THE OUTER-MEMBRANE PROTEIN FADL REQUIRED FOR ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENE-PRODUCT; BINDING; PURIFICATION; DEGRADATION; MUTATIONS; MUTANTS; CLONING; SYSTEM	The outer membrane protein FadL (product of the fadL gene) of Escherichia coli is required for the specific binding and transport of exogenous long-chain fatty acids prior to metabolic utilization. The carboxyl end of FadL has been proposed to play a crucial role by facilitating the transport of long-chain fatty acids. In an attempt to define specific amino acid residues within carboxyl region of FadL essential for activity, a series of deletion and point mutations within the 3' end of the fadL+ gene have been constructed and characterized. These fadL mutants were classified into three categories based on functional properties attributable to the altered FadL proteins: (i) those that had essentially wild-type levels of long-chain fatty acid binding and transport, (ii) those that had wild-type levels of long-chain fatty acid binding but were defective in transport, and (iii) those that were defective for both long-chain fatty acid binding and transport. These findings demonstrate that amino acid residues Phe448, Pro428, Val410, and Ser397 are required for optimal levels of long-chain fatty acid transport and that amino acid residues Pro428 and Val410 are essential for long-chain fatty acid binding.	UNIV TENNESSEE, CTR HLTH SCI,COLL MED,DEPT BIOCHEM,SUITE G01, MOLEC SCI BLDG,858 MADISON AVE, MEMPHIS, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center				Black, Paul/0000-0002-6272-6881				BLACK PN, 1987, J BIOL CHEM, V262, P1412; BLACK PN, 1990, BIOCHIM BIOPHYS ACTA, V1046, P97, DOI 10.1016/0005-2760(90)90099-J; BLACK PN, 1991, J BACTERIOL, V173, P435, DOI 10.1128/jb.173.2.435-442.1991; BLACK PN, 1988, J BACTERIOL, V170, P2850, DOI 10.1128/jb.170.6.2850-2854.1988; BLACK PN, 1985, J BIOL CHEM, V260, P1780; BLUNDELL T, 1986, SCIENCE, V234, P1005, DOI 10.1126/science.3775369; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; GINSBURGH CL, 1984, J BIOL CHEM, V259, P8437; ISACKSON PJ, 1985, P NATL ACAD SCI USA, V82, P6226, DOI 10.1073/pnas.82.18.6226; KAMEDA K, 1987, BIOCHEM INT, V14, P227; KAMEDA K, 1986, BIOCHEM INT, V13, P343; KLEIN K, 1971, EUR J BIOCHEM, V19, P442, DOI 10.1111/j.1432-1033.1971.tb01334.x; KUMAR GB, 1991, J BIOL CHEM, V266, P1348; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALOY SR, 1981, J BACTERIOL, V145, P1110, DOI 10.1128/JB.145.2.1110-1111.1981; MANGROO D, 1992, J BIOL CHEM, V267, P17095; Maniatis T., 1982, MOL CLONING; Miller J. H., 1972, EXPT MOL GENETICS, P433; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NUNN WD, 1978, P NATL ACAD SCI USA, V75, P3377, DOI 10.1073/pnas.75.7.3377; NUNN WD, 1986, J BIOL CHEM, V261, P167; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; OVERATH P, 1969, EUR J BIOCHEM, V7, P559; RICHARDSON JS, 1989, PREDICTION PROTEIN S, P2; ROCK CO, 1985, J BIOL CHEM, V260, P2720; SALEMME FR, 1983, PROG BIOPHYS MOL BIO, V42, P95, DOI 10.1016/0079-6107(83)90005-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMONS RW, 1980, J BACTERIOL, V142, P621, DOI 10.1128/JB.142.2.621-632.1980; STRUYVE M, 1991, J MOL BIOL, V218, P141, DOI 10.1016/0022-2836(91)90880-F	31	48	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15469	15476						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340375				2022-12-27	WOS:A1993LN30500025
J	BARKER, PA; LOMENHOERTH, C; GENSCH, EM; MEAKIN, SO; GLASS, DJ; SHOOTER, EM				BARKER, PA; LOMENHOERTH, C; GENSCH, EM; MEAKIN, SO; GLASS, DJ; SHOOTER, EM			TISSUE-SPECIFIC ALTERNATIVE SPLICING GENERATES 2 ISOFORMS OF THE TRKA RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; AFFINITY NGF RECEPTOR; NEUROTROPHIC FACTOR; PROTOONCOGENE PRODUCT; MOLECULAR-CLONING; MELANOMA-CELLS; GENE-TRANSFER; EXPRESSION; BRAIN	The trkA receptor functions as a signal transducing receptor for nerve growth factor. In this report, we show that alternative splicing results in the production of two distinct trkA isoforms in both rats and humans. These isoforms differ by virtue of a 6-amino acid insertion in their extracellular domain, the placement of which corresponds exactly with the breakpoint found in several human trkA oncogenes. When tested in fibroblasts, the presence (trkAII) or absence (trkAI) of the 6-amino acid insert does not affect the receptor's ligand binding specificity or its ability to transduce functional signals in response to nerve growth factor. In rats and humans, trkAII is the only isoform expressed within neuronal tissues at appreciable levels whereas trkAI, the form of trkA originally cloned, appears to be expressed mainly in non-neuronal tissues.	STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305; REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591	Stanford University; Regeneron			Meakin, Susan/K-8823-2013; Glass, David/AAI-3910-2021; Glass, David/C-4782-2012	Meakin, Susan/0000-0003-2469-6615; Glass, David/0000-0001-6187-4164	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS004270] Funding Source: NIH RePORTER; NINDS NIH HHS [NS04270] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; AYERLELIEVE C, 1988, P NATL ACAD SCI USA, V88, P2628; BARBACID M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1115; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BARKER PA, 1991, J BIOL CHEM, V266, P19113; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BUXSER SE, 1983, J CELL BIOCHEM, V22, P219, DOI 10.1002/jcb.240220404; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DIAMOND J, 1992, J NEUROSCI, V12, P1454; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOLTZMAN DM, 1992, NEURON, V9, P465, DOI 10.1016/0896-6273(92)90184-F; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MARANO N, 1987, J NEUROCHEM, V48, P225, DOI 10.1111/j.1471-4159.1987.tb13151.x; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MEAKIN SO, 1992, P NATL ACAD SCI USA, V89, P2374, DOI 10.1073/pnas.89.6.2374; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MILLER FD, 1991, J CELL BIOL, V112, P303, DOI 10.1083/jcb.112.2.303; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; PARVINEN M, 1992, J CELL BIOL, V117, P629, DOI 10.1083/jcb.117.3.629; PIAETTA E, 1992, J BIOL CHEM, V267, P11078; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SARIOLA H, 1991, SCIENCE, V254, P571, DOI 10.1126/science.1658930; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; SONNENFELD KH, 1982, J NEUROSCI RES, V8, P375, DOI 10.1002/jnr.490080226; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WRIGHT EM, 1992, NEURON, V9, P139, DOI 10.1016/0896-6273(92)90229-7; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	61	180	184	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15150	15157						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325889				2022-12-27	WOS:A1993LL75900088
J	KRUDE, T; KNIPPERS, R				KRUDE, T; KNIPPERS, R			NUCLEOSOME ASSEMBLY DURING COMPLEMENTARY-DNA STRAND SYNTHESIS IN EXTRACTS FROM MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; SIMIAN VIRUS 40; REPLICATION INVITRO; POLYACRYLAMIDE GELS; CHROMATIN; PROTEIN; HISTONES; INITIATION; MINICHROMOSOMES; PURIFICATION	Circular single-stranded phage M13 DNA is used as a template for complementary strand synthesis in cytosolic extracts from proliferating HeLa cells. DNA synthesis is initiated by one or maximally two priming events and typically leads to covalently closed double-stranded reaction products. When carried out in the presence of the nuclear chromatin assembly factor CAF-1, complementary strand synthesis is accompanied by nucleosome assembly. This novel system is very useful for the study of basic biochemical aspects concerning the assembly of nucleosomes. The activity of CAF-1 completely depends on complementary strand synthesis and acts stoichiometrically to promote the assembly of nucleosomes in a noncooperative manner. Apparently, CAF-1 activity is coupled to DNA synthesis via a structural feature of replicating DNA, most likely its partial single strandedness.	UNIV CONSTANCE,FAK BIOL,W-7750 CONSTANCE,GERMANY	University of Konstanz				Krude, Torsten/0000-0002-1842-1933				ALMOUZNI G, 1988, EMBO J, V7, P665, DOI 10.1002/j.1460-2075.1988.tb02861.x; ALMOUZNI G, 1990, NUCLEIC ACIDS RES, V18, P5767, DOI 10.1093/nar/18.19.5767; BANERJEE S, 1990, MOL CELL BIOL, P2863; BONNEANDREA C, 1984, EMBO J, V3, P1193, DOI 10.1002/j.1460-2075.1984.tb01950.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; CUSICK ME, 1984, J MOL BIOL, V178, P249, DOI 10.1016/0022-2836(84)90143-8; DILWORTH SM, 1988, BIOESSAYS, V9, P44, DOI 10.1002/bies.950090203; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; GRUSS C, 1990, EMBO J, V9, P2911, DOI 10.1002/j.1460-2075.1990.tb07482.x; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; KLEINSCHMIDT JA, 1982, CELL, V29, P799, DOI 10.1016/0092-8674(82)90442-1; KLEINSCHMIDT JA, 1991, EMBO J, V10, P3043, DOI 10.1002/j.1460-2075.1991.tb07855.x; KRUDE T, 1991, MOL CELL BIOL, V11, P6257, DOI 10.1128/MCB.11.12.6257; KRUDE T, 1993, MOL CELL BIOL, V13, P1059, DOI 10.1128/MCB.13.2.1059; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LASKEY RA, 1980, NATURE, V286, P763, DOI 10.1038/286763a0; LASSLE M, 1992, BIOCHIM BIOPHYS ACTA, V1132, P1, DOI 10.1016/0167-4781(92)90045-2; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MECHALI M, 1982, CELL, V30, P93, DOI 10.1016/0092-8674(82)90015-0; NELSON T, 1981, BIOCHEMISTRY-US, V20, P2594, DOI 10.1021/bi00512a035; OUDET P, 1975, CELL, V4, P281, DOI 10.1016/0092-8674(75)90149-X; OUDET P, 1977, COLD SPRING HARB SYM, V47, P287; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; SENSHU T, 1978, J BIOCHEM-TOKYO, V84, P985, DOI 10.1093/oxfordjournals.jbchem.a132213; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SMITH S, 1991, J BIOL CHEM, V266, P12041; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; STEIN A, 1979, P NATL ACAD SCI USA, V76, P5000, DOI 10.1073/pnas.76.10.5000; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P3839, DOI 10.1128/MCB.9.9.3839; van Holde K.E., 1988, CHROMATIN; VOLLENWEIDER HJ, 1975, P NATL ACAD SCI USA, V72, P83, DOI 10.1073/pnas.72.1.83; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WESSEL R, 1992, VIROLOGY, V189, P293, DOI 10.1016/0042-6822(92)90705-T; WOLFFE A, 1992, CHROMATIN STRUCTURE; WORCEL A, 1978, CELL, V15, P969, DOI 10.1016/0092-8674(78)90280-5; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZUCKER K, 1990, J BIOL CHEM, V265, P14487	53	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14432	14442						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314801				2022-12-27	WOS:A1993LJ82500093
J	BISSINGER, PH; KUCHLER, K				BISSINGER, PH; KUCHLER, K			MOLECULAR-CLONING AND EXPRESSION OF THE SACCHAROMYCES-CEREVISIAE STS1 GENE-PRODUCT - A YEAST ABC TRANSPORTER CONFERRING MYCOTOXIN RESISTANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLEIOTROPIC DRUG-RESISTANCE; MULTIDRUG RESISTANCE; DROSOPHILA-MELANOGASTER; SHUTTLE VECTORS; PLASMA-MEMBRANE; P-GLYCOPROTEIN; DNA-SEQUENCE; TUMOR-CELLS; PROTEIN; PATHWAY	We have cloned a yeast gene that confers a multidrug resistance phenotype on Saccharomyces cerevisiae when present in multiple copies. The STS1 (for Sporidesmin Toxicity Suppressor) gene encodes a 1511-residue protein whose predicted structural organization is characterized by 12 alpha-helical membrane segments and two domains containing consensus sites for ATP binding, indicating that STS1 is a new yeast ATP-binding cassette (ABC) transporter. A chromosomal deletion of STS1 leads to viable Delta sts1 cells of both mating types, suggesting that STS1 is not essential for cell growth. However, Delta sts1 cells exhibit supersensitivity to sporidesmin and to other structurally unrelated drugs such as cycloheximide. Conversely, overexpression of STS1 leads to increased resistance to the same drugs. Although Northern analysis showed that STS1 mRNA is present in all yeast cell types, its drastically reduced level in a-factor-arrested cells indicates that expression of STS1 is regulated by mating pheromones. Subcellular fractionation and immunoblotting using monoclonal antibodies, which recognize a fully functional epitope-tagged Sts1 protein, showed that Sts1 is a 175-kDa membrane protein localized mainly to intracellular membranes.	UNIV & BIOCTR VIENNA,DEPT MOLEC GENET,A-1030 VIENNA,AUSTRIA; AG RES LTD,CROWN RES INST PASTORAL AGR RES,HAMILTON 3123,NEW ZEALAND	University of Vienna			kuchler, karl/AAL-6937-2020	kuchler, karl/0000-0003-2719-5955				BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1991, BIOCHIM BIOPHYS ACTA, V1073, P241, DOI 10.1016/0304-4165(91)90128-4; BALZI E, 1994, IN PRESS J BIOL CHEM; BISSINGER PH, 1989, MOL CELL BIOL, V9, P1309, DOI 10.1128/MCB.9.3.1309; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; CANGELOSI GA, 1989, J BACTERIOL, V171, P1609, DOI 10.1128/jb.171.3.1609-1615.1989; Cowman Alan F., 1993, Seminars in Cell Biology, V4, P29, DOI 10.1006/scel.1993.1004; DELAVEAU T, 1992, YEAST, V8, P761, DOI 10.1002/yea.320080909; DONAHUE TF, 1990, METHOD ENZYMOL, V185, P366; DREESEN TD, 1988, MOL CELL BIOL, V8, P5206, DOI 10.1128/MCB.8.12.5206; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; FERGUSON LR, 1992, MUTAT RES, V268, P199, DOI 10.1016/0027-5107(92)90225-Q; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GUILFOILE PG, 1991, P NATL ACAD SCI USA, V88, P8553, DOI 10.1073/pnas.88.19.8553; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENIKOFF S, 1983, CELL, V33, P607, DOI 10.1016/0092-8674(83)90441-5; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HERTLE K, 1991, CURR GENET, V19, P429, DOI 10.1007/BF00312733; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; KUCHLER K, 1993, J CELL BIOL, V120, P1203, DOI 10.1083/jcb.120.5.1203; KUCHLER K, 1992, ENDOCR REV, V13, P499, DOI 10.1210/er.13.3.499; KUCHLER K, 1992, P NATL ACAD SCI USA, V89, P2302, DOI 10.1073/pnas.89.6.2302; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEPPERT G, 1990, GENETICS, V125, P13; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; NASMYTH KA, 1980, CELL, V19, P753, DOI 10.1016/S0092-8674(80)80051-1; OHARE K, 1984, J MOL BIOL, V180, P437, DOI 10.1016/0022-2836(84)90021-4; OUELLETTE M, 1990, EMBO J, V9, P1027, DOI 10.1002/j.1460-2075.1990.tb08206.x; PURNELLE B, 1991, YEAST, V7, P867, DOI 10.1002/yea.320070813; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROEMER T, 1993, MOL CELL BIOL, V13, P4039, DOI 10.1128/MCB.13.7.4039; ROSS JI, 1990, MOL MICROBIOL, V4, P1207, DOI 10.1111/j.1365-2958.1990.tb00696.x; ROSS MD, 1990, METHODS YEAST GENETI; RUTTKAY NB, 1992, CURR GENET, V22, P337; Sambrook J, 1989, MOL CLONING LABORATO; SANDBAKEN M, 1990, BIOCHIM BIOPHYS ACTA, V1050, P230, DOI 10.1016/0167-4781(90)90172-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNELL N, 1991, EUR J BIOCHEM, V200, P487, DOI 10.1111/j.1432-1033.1991.tb16209.x; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; SIKORSKI RS, 1989, GENETICS, V122, P19; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; STANFIELD SW, 1988, J BACTERIOL, V170, P3523, DOI 10.1128/jb.170.8.3523-3530.1988; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WILSON KL, 1984, MOL CELL BIOL, V4, P2420, DOI 10.1128/MCB.4.11.2420; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	59	214	220	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4180	4186						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307980				2022-12-27	WOS:A1994MW98900045
J	CRAFT, CM; WHITMORE, DH; WIECHMANN, AF				CRAFT, CM; WHITMORE, DH; WIECHMANN, AF			CONE ARRESTIN IDENTIFIED BY TARGETING EXPRESSION OF A FUNCTIONAL FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL S-ANTIGEN; BETA-ADRENERGIC-RECEPTOR; PINEAL-GLAND; 48-KDA PROTEIN; CYCLIC-GMP; ALPHA-TRANSDUCIN; CDNA; PHOTORECEPTORS; ANTIBODIES; RHODOPSIN	High acuity, color vision in humans is initiated in cones by a receptor/G-protein-linked phototransduction cascade. G-protein-linked receptors are rapidly deactivated by receptor phosphorylation and the binding of a member of the ''arrestin'' family of proteins. Divergence in amino acid sequence at the carboxyl terminus of S-antigen (rod photoreceptor arrestin) and beta-arrestin 1 and beta-arrestin 2 (beta-adrenergic receptors) suggests that receptor specificity may be coded within this region. An anchor primer strategy was utilized to screen for carboxyl-terminal variability with a rat pineal library, identifying three known arrestins plus three unknowns (C-arrestin, D-arrestin, and E-arrestin). cDNA was prepared by reverse transcription of mRNA from 12 rat tissues, and members of the arrestin family were amplified by polymerase chain reaction using the anchor primer and customized 3'-primers for the individual arrestins. The amplified arrestins were then digested by selected restriction endonucleases, producing a pattern of characteristic cleavage products for each arrestin isoform. The procedural combination of epitope domain anchor and tissue screening demonstrated that C-arrestin is enriched in the retina. C-arrestin was isolated from a lambda MAX1 human retinal cDNA library and sequenced, revealing significant identity to known arrestins and divergence within the 3'-region. The mRNA for C-arrestin was visualized by in situ hybridization, localizing in the retina with cone photoreceptors and in the pineal to a subpopulation of pinealocytes. A gene for human C-arrestin was mapped to the X chromosome, making C-arrestin a candidate for several inherited X-linked retinopathies. The localization of C-arrestin to cone photoreceptors suggests that it, like others in the arrestin family, may bind to phosphorylated receptors and participate in deactivation of the phototransduction cascade.	UNIV TEXAS,DEPT BIOL,ARLINGTON,TX 76019; BOWMAN GRAY MED SCH,DEPT NEUROBIOL & ANAT,WINSTON SALEM,NC 27157	University of Texas System; University of Texas Arlington; Wake Forest University	CRAFT, CM (corresponding author), UNIV TEXAS,SW MED SCH,VET AFFAIRS MED CTR,DEPT PSYCHIAT,MOLEC NEUROGENET LAB,DALLAS,TX 75235, USA.				NINDS NIH HHS [R29 NS28126] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS028126] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BAYLOR DA, 1987, J PHYSIOL-LONDON, V390, P145, DOI 10.1113/jphysiol.1987.sp016691; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; CARCAMO B, 1993, INVEST OPHTH VIS SCI, V32, P3249; COBBS WH, 1985, NATURE, V317, P64, DOI 10.1038/317064a0; CRAFT CM, 1990, J NEUROCHEM, V55, P1461, DOI 10.1111/j.1471-4159.1990.tb04927.x; CRAFT CM, 1991, GENOMICS, V10, P400, DOI 10.1016/0888-7543(91)90325-9; CRAFT CM, 1993, MELATONIN BIOSYNTHES, P17; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; DONOSO LA, 1990, CURR EYE RES, V9, P343, DOI 10.3109/02713689008999622; DONOSO LA, 1985, INVEST OPHTH VIS SCI, V26, P561; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; HAYNES L, 1985, NATURE, V317, P61, DOI 10.1038/317061a0; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HURWITZ RL, 1985, J BIOL CHEM, V260, P568; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEREA CL, 1989, NEURON, V3, P367, DOI 10.1016/0896-6273(89)90261-4; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LOLLEY RN, 1992, NEUROCHEM RES, V17, P81, DOI 10.1007/BF00966868; LOLLEY RN, 1990, FASEB J, V4, P3001, DOI 10.1096/fasebj.4.12.1697545; MANDEL JL, 1992, SCIENCE, V258, P103, DOI 10.1126/science.1439756; MIRSHAHI M, 1984, BIOL CELL, V52, P195; NEITZ J, 1986, J COMP PSYCHOL, V100, P21, DOI 10.1037/0735-7036.100.1.21; NIR I, 1992, J HISTOCHEM CYTOCHEM, V40, P343, DOI 10.1177/40.3.1372630; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5678; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P15334; RAPOPORT B, 1992, MOL CELL ENDOCRINOL, V84, pR39, DOI 10.1016/0303-7207(92)90038-8; Sambrook J, 1989, MOL CLONING LABORATO; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; SZEL A, 1992, EXP EYE RES, V55, P47; VANVEEN T, 1986, EXP BIOL, V45, P15; WACKER WB, 1977, J IMMUNOL, V119, P1949; WEICHMANN AF, 1993, NEUROSCI LETT, V150, P207; YAMAKI K, 1988, FEBS LETT, V234, P39, DOI 10.1016/0014-5793(88)81298-5; YAMAKI K, 1990, J BIOL CHEM, V265, P20757	38	134	141	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4613	4619						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308033				2022-12-27	WOS:A1994MW98900105
J	JAKUBOWSKI, M; ROBERTS, JL				JAKUBOWSKI, M; ROBERTS, JL			PROCESSING OF GONADOTROPIN-RELEASING-HORMONE GENE TRANSCRIPTS IN THE RAT-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE; MESSENGER-RNA; ESTROUS-CYCLE; PROESTROUS SURGE; ANTISENSE RNA; FEMALE RAT; EXPRESSION; NEURONS; PROTEIN; CDNA	The precursor of gonadotropin-releasing hormone (GnRH) and the 56-amino acid GnRH-associated peptide is encoded in an mRNA of about 560 bases in length. This mRNA derives from an similar to-4300-base pair-long gene consisting of four relatively short exons (denoted 1, 2, 3, and 4) and three large introns (A,B, and C). In this study, we characterized the order by which the three introns are spliced from the primary transcript and processing intermediates to give rise to a mature mRNA and evaluated the potential role of gene transcription and pre-mRNA processing in the control of proGnRH mRNA levels in vivo. Nuclear and cytoplasmic RNA fractions isolated from rat preoptic area anterior hypothalamus (POA-AH) and basal olfactory area (located rostral to the POA) were analyzed by 1) solution hybridization-RNase protection mapping using several RNA probes directed at various regions of the proGnRH gene and 2) reverse transcription-polymerase chain reaction using several oligonucleotide primers. Both types of analysis showed that proGnRH pre-mRNA processing begins with the splicing of intron B from the primary gene transcript. Hence, intron B is the ideal target for studying proGnRH primary transcript by in situ hybridization. Subsequent splicing of introns A and C appeared to take place in two alternative, although not equally prevalent pathways. Quantitative analysis indicated that the proGnRH hnRNA species constituted, ore a mole basis, about 20% of the total gene transcripts in the POA-AH. The primary transcript alone constituted about 10% of the total gene transcripts in the POA-AH and as much as 20% in the basal olfactory area. The prospect of blockade of proGnRH hnRNA processing by means of hybridization with endogenous antisense RNAs (transcribed from the SH gene on the opposite strand of the same DNA locus) did not prove to be likely, as the SH transcripts were present at very low levels compared to any of the proGnRH RNA species. We conclude that the relatively large pool of proGnRH hnRNA may reflect a high rate of gene transcription and/or slow RNA processing.	CUNY MT SINAI SCH MED,DR ARTHUR M FISHBERG RES CTR NEUROBIOL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NIDDK NIH HHS [DK 39029] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039029] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELMAN JP, 1986, P NATL ACAD SCI USA, V83, P179, DOI 10.1073/pnas.83.1.179; ADELMAN JP, 1987, SCIENCE, V235, P1514, DOI 10.1126/science.3547652; BINHAM PM, 1988, TRENDS GENET, V5, P134; BOND CT, 1989, MOL ENDOCRINOL, V3, P1257, DOI 10.1210/mend-3-8-1257; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; FREMEAU RT, 1989, MOL BRAIN RES, V6, P197, DOI 10.1016/0169-328X(89)90054-5; GOUBAU S, 1992, ENDOCRINOLOGY, V130, P3098, DOI 10.1210/en.130.5.3098; HIATT ES, 1992, ENDOCRINOLOGY, V130, P1030, DOI 10.1210/en.130.2.1030; HOFFMAN GE, 1990, ENDOCRINOLOGY, V126, P1736, DOI 10.1210/endo-126-3-1736; JAKUBOWSKI M, 1992, J NEUROENDOCRINOL, V4, P79, DOI 10.1111/j.1365-2826.1992.tb00349.x; KING JC, 1987, PEPTIDES, V8, P721, DOI 10.1016/0196-9781(87)90049-0; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LEE WS, 1992, ENDOCRINOLOGY, V130, P3101, DOI 10.1210/en.130.5.3101; LEE WS, 1990, P NATL ACAD SCI USA, V87, P5163, DOI 10.1073/pnas.87.13.5163; LEVIN N, 1991, FRONT NEUROENDOCRIN, V12, P1; LEVIN N, 1991, 73RD ANN M END SOC, P42; MALIK KF, 1991, ANAT REC, V231, P457, DOI 10.1002/ar.1092310408; MERCHENTHALER I, 1988, BRAIN RES BULL, V20, P713, DOI 10.1016/0361-9230(88)90082-2; MUNROE SH, 1988, EMBO J, V7, P2523, DOI 10.1002/j.1460-2075.1988.tb03100.x; PAGESY P, 1992, MOL ENDOCRINOL, V6, P523, DOI 10.1210/me.6.4.523; Palkovits M., 1988, MAPS GUIDE MICRODISS; PARK OK, 1990, ENDOCRINOLOGY, V127, P365, DOI 10.1210/endo-127-1-365; RADOVICK S, 1990, MOL ENDOCRINOL, V4, P476, DOI 10.1210/mend-4-3-476; RONNEKLEIV OK, 1986, NEUROENDOCRINOLOGY, V43, P564, DOI 10.1159/000124583; SEEBURG PH, 1984, NATURE, V311, P666, DOI 10.1038/311666a0; SHIVERS BD, 1983, NEUROENDOCRINOLOGY, V36, P1, DOI 10.1159/000123522; TOSIC M, 1990, EMBO J, V9, P401, DOI 10.1002/j.1460-2075.1990.tb08124.x	27	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4078	4083						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307966				2022-12-27	WOS:A1994MW98900030
J	LEJOHN, HB; CAMERON, LE; YANG, BH; MACBEATH, G; BARKER, DS; WILLIAMS, SA				LEJOHN, HB; CAMERON, LE; YANG, BH; MACBEATH, G; BARKER, DS; WILLIAMS, SA			CLONING AND ANALYSIS OF A CONSTITUTIVE HEAT-SHOCK (COGNATE) PROTEIN-70 GENE INDUCIBLE BY L-GLUTAMINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA; EXPRESSION; CALCIUM	An intronless gene encoding a protein of 652 amino acid residues with an M(r), of 71,266, showing between 79% and 59% identity in nucleotide sequence with heat shock protein 70 (HSP 70) genes of Bremia lactucae (a parasitic Oomycete of lettuce) and a wide range of organisms that include humans, was isolated from the nonparasitic Oomycete Achlya klebsiana. While the gene appears to be constitutively expressed, L-glutamine augmented its expression particularly under conditions of nutritional stress. L-Glutamine enhanced the transcription of a 2.4-kilobas poly(A)(+) RNA simultaneously in the same way as it elevated the cellular level of the HSP 70-like protein. A polyclonal antibody (affinity-purified) raised in rabbit against the purified monomeric (M(r) 120,000) form of an NAD-specific glutamate dehydrogenase (Yang, B., and LeJohn, H. B. (1994) J. Biol. Chem. 269, 4506-4512) immunoprecipitated the HSP 70-like protein, and it was used to study the kinetics of induction of this stress related protein and the effect of proteinase inhibitors on its metabolism. By using as probes four partial length cDNA clones, nine overlapping DNA fragments of the organism's genome carrying the HSP 70-like protein gene were isolated from a genomic library. The nucleotide sequence of the gene, including its boundaries, was determined by using these genomic clones. The 5'-untranslated boundary of the gene displayed the classical nucleotide arrangement of heat shock elements as well as CCAAT and TATA box motifs. Within the coding region are the typical conserved amino acid heat shock protein signatures 1 and 2 at the predicted locations. By primer extension and S1 nuclease protection mapping system, we estimated that the gene is probably transcribed into a message of 2.2 kilobases.	UNIV MANITOBA, FAC MED, DEPT HUMAN GENET, WINNIPEG R3E 0W3, MB, CANADA; MANITOBA INST CELL BIOL, WINNIPEG R3E 0V9, MB, CANADA; SCRIPPS RES INST, DEPT CHEM & MOLEC BIOL, LA JOLLA, CA 92037 USA	University of Manitoba; Scripps Research Institute	LEJOHN, HB (corresponding author), UNIV MANITOBA, DEPT MICROBIOL, WINNIPEG R3T 2N2, MB, CANADA.							AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; ANG D, 1991, J BIOL CHEM, V266, P24233; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIENZ M, 1987, ADV GENET, V24, P31, DOI 10.1016/S0065-2660(08)60006-1; BRAITHWAITE CE, 1987, THESIS U MANITOBA; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P327; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENIKOFF S, 1984, GENE, V28, P521; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; JUDELSON HS, 1989, GENE, V79, P207, DOI 10.1016/0378-1119(89)90203-5; KAPOOR M, 1993, BIOCHEM CELL BIOL, V71, P205, DOI 10.1139/o93-032; KORNELUK RG, 1985, GENE, V40, P317, DOI 10.1016/0378-1119(85)90055-1; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LEE YM, 1988, ANAL BIOCHEM, V175, P156; LEJOHN HB, 1989, J BIOL CHEM, V264, P19366; LEJOHN HB, 1994, J BIOL CHEM, V269, P4523; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINGH DP, 1975, CAN J BIOCHEM CELL B, V53, P975, DOI 10.1139/o75-134; YANG BH, 1994, J BIOL CHEM, V269, P4506	24	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4513	4522						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308021				2022-12-27	WOS:A1994MW98900093
J	DITTMANN, J; WENGER, RM; KLEINKAUF, H; LAWEN, A				DITTMANN, J; WENGER, RM; KLEINKAUF, H; LAWEN, A			MECHANISM OF CYCLOSPORINE-A BIOSYNTHESIS - EVIDENCE FOR SYNTHESIS VIA A SINGLE LINEAR UNDECAPEPTIDE PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIENZYME POLYPEPTIDE; TOLYPOCLADIUM-INFLATUM; MULTIFUNCTIONAL ENZYME; SYNTHETASE	Cyclosporin A is synthesized by cyclosporin synthetase, a multienzyme polypeptide. This enzyme catalyzes at least 40 reaction steps in an assembly belt-like mechanism. It activates all constituent amino acids of cyclosporin A to thioesters via amino acyladenylates and carries out specific N-methylation reactions. During elongation, the activated amino acids are linked by peptide bonds leading to enzyme-bound nascent peptide chains. Some of the linear peptides of the growing cyclosporin A chain were isolated and their N-terminal amino acid was determined. D-Alanine at position 8 of the cyclosporin A molecule was found to be a starting amino acid in the biosynthetic process of cyclosporin A formation. Four intermediate peptides of the growing peptide chain of cyclosporin A could be isolated and identified. All of them represent partial sequences of cyclosporin A starting with D-alanine. That these intermediate peptides were bound by thioester linkage to cyclosporin synthetase could be demonstrated by liberation of the peptides with performic acid. The peptides strongly suggest the stepwise synthesis of a single linear peptide precursor of cyclosporin A.	TECH UNIV BERLIN,INST BIOCHEM & MOLEK BIOL,FRANKLINSTR 29,D-10587 BERLIN,GERMANY; SANDOZ PHARMA LTD,PRECLIN RES,CH-4002 BASEL,SWITZERLAND	Technical University of Berlin; Novartis; Sandoz			Lawen, Alfons/A-6598-2008	Lawen, Alfons/0000-0001-6553-9945				BERG P, 1958, J BIOL CHEM, V233, P608; BOREL JF, 1986, PROG ALLERGY, V38, P9; DITTMANN J, 1990, BIOL CHEM H-S, V371, P829, DOI 10.1515/bchm3.1990.371.2.829; GEVERS W, 1968, P NATL ACAD SCI USA, V60, P269, DOI 10.1073/pnas.60.1.269; Gray W R, 1972, Methods Enzymol, V25, P121, DOI 10.1016/S0076-6879(72)25010-8; KAHAN BD, 1984, CYCLOSPORIN BIOL ACT; KLEINKAUF H, 1987, ANNU REV MICROBIOL, V41, P259, DOI 10.1146/annurev.mi.41.100187.001355; LAWEN A, 1991, J BIOL CHEM, V266, P15567; LAWEN A, 1989, J ANTIBIOT, V42, P1283, DOI 10.7164/antibiotics.42.1283; LAWEN A, 1990, J BIOL CHEM, V265, P11355; LAWEN A, 1993, J BIOL CHEM, V268, P20452; LIPMANN F, 1971, SCIENCE, V173, P875, DOI 10.1126/science.173.4000.875; ROSKOSKI R, 1970, BIOCHEMISTRY-US, V9, P4846; SCHINDLER R, 1985, CYCLOSPORIN AUTOIMMU; SCHLUMBOHM W, 1991, J BIOL CHEM, V266, P23135; SCHMIDT B, 1992, FEBS LETT, V307, P355, DOI 10.1016/0014-5793(92)80712-P; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; VANLIEMPT H, 1989, J BIOL CHEM, V264, P3680; WENGER RM, 1984, HELV CHIM ACTA, V67, P502, DOI 10.1002/hlca.19840670220; WENGER RM, 1983, HELV CHIM ACTA, V66, P2672, DOI 10.1002/hlca.19830660836; ZOCHER R, 1986, BIOCHEMISTRY-US, V25, P550, DOI 10.1021/bi00351a005; ZOCHER R, 1982, BIOCHEMISTRY-US, V21, P43, DOI 10.1021/bi00530a008	22	62	62	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2841	2846						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300618				2022-12-27	WOS:A1994MV43200072
J	HAYES, BK; VARKI, A				HAYES, BK; VARKI, A			THE BIOSYNTHESIS OF OLIGOSACCHARIDES IN INTACT GOLGI PREPARATIONS FROM RAT-LIVER - ANALYSIS OF N-LINKED AND O-LINKED GLYCANS LABELED BY UDP-[6-H-3]N-ACETYLGALACTOSAMINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAMM-HORSFALL GLYCOPROTEIN; BLOOD-GROUP; SULFATED OLIGOSACCHARIDES; NEUTRAL OLIGOSACCHARIDES; MONOCLONAL-ANTIBODIES; LIQUID-CHROMATOGRAPHY; CARBOHYDRATE CHAINS; ACETYLGALACTOSAMINE; LUTROPIN; RECEPTOR	Endogenous acceptors in a Golgi apparatus-enriched subcellular fraction from rat liver were labeled with UDP-[H-3]GalNAc. The great majority of these acceptors were protected from protease degradation in the absence of detergent. These molecules are therefore present in intact vesicles of the correct topological orientation, which are likely to be similar to the Golgi compartments of the intact cell. Several distinct glycoproteins are labeled, but most are different from those labeled with UDP-[H-3]GlcNAc. The enzyme peptide-N4(N-acetyl-beta-glucosiminyl)asparagine amidase releases label from a few specific proteins, indicating that [H-3]GalNAc is transferred to N-linked oligosaccharides. Both neutral and anionic N-linked oligosaccharides are found, the great majority of which do not bind to ConA-Sepharose. Most of the [H-3]GalNAc found in neutral oligosaccharides is terminal and beta-linked. The negative charge on the anionic molecules is due to sialic acid, and phosphate. A major portion of the [H-3] GalNAc in this fraction is acid labile, and is released with kinetics consistent with it being in a phosphodiester linkage. These results show the existence of a whole new class of GalNAc-containing N-linked oligosaccharides, and demonstrates that this in vitro approach can detect previously undescribed structures. O-Linked oligosaccharide biosynthesis was also studied in the same labeled rat liver Golgi apparatus preparations. Beta-elimination releases approximately 95% of the peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase (PNGase F)-resistant label which, in the absence of other added nucleotides, is almost exclusively [H-3] GalNAcitol. If other unlabeled sugar nucleotides and adenosine 3'-phosphate,5'-phosphosulfate are added during the chase period two anionic O-linked oligosaccharides are synthesized, indicating that the UDP-GalNAc:peptide-N-acetylgalactosaminyltransferase is at least in part functionally co-localized with enzymes that extend and modify O-linked oligosaccharides.	UNIV CALIF SAN DIEGO,SCH MED,CTR CANC,GLYCOBIOL PROGRAM,0063,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R01CA038701] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA38701] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BALSAMO J, 1986, BIOCHEMISTRY-US, V25, P5402, DOI 10.1021/bi00367a009; BALSAMO J, 1990, J BIOL CHEM, V265, P2923; BLANCHARD D, 1983, J BIOL CHEM, V258, P7691; BLANKEN WM, 1985, ANAL BIOCHEM, V145, P322, DOI 10.1016/0003-2697(85)90369-0; BROCKHAUSEN I, 1992, BIOCHEM CELL BIOL, V70, P99, DOI 10.1139/o92-015; CARDINI CE, 1957, J BIOL CHEM, V200, P317; CHAN A L, 1991, Glycobiology, V1, P173, DOI 10.1093/glycob/1.2.173; CHILDS RA, 1984, EMBO J, V3, P2227, DOI 10.1002/j.1460-2075.1984.tb02120.x; CUMMINGS RD, 1992, GLYCOCONJUGATES COMP, P333; CUMMINGS RD, 1945, J BIOL CHEM, V260, P11944; DICKENSON JM, 1990, BIOCHEM J, V269, P55, DOI 10.1042/bj2690055; ELHAMMER A, 1984, J CELL BIOL, V98, P327; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; FINNE J, 1989, J BIOL CHEM, V264, P5720; GREEN ED, 1988, J BIOL CHEM, V263, P25; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HAYES BK, 1992, ANAL BIOCHEM, V201, P140, DOI 10.1016/0003-2697(92)90186-B; HAYES BK, 1993, J BIOL CHEM, V268, P16139; HAYES BK, 1993, J BIOL CHEM, V268, P16155; HIRAIWA N, 1990, CANCER RES, V50, P5497; HULL SR, 1989, J CELL BIOCHEM, V40, P67, DOI 10.1002/jcb.240400108; IYER RN, 1971, ARCH BIOCHEM BIOPHYS, V142, P101, DOI 10.1016/0003-9861(71)90263-3; KOBATA A, 1992, CELL SURFACE CARBOHY, P1; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAMBLIN G, 1991, BIOCHEM J, V275, P199, DOI 10.1042/bj2750199; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MAWHINNEY TP, 1987, J BIOL CHEM, V262, P2994; MELLIS SJ, 1981, ANAL BIOCHEM, V114, P276, DOI 10.1016/0003-2697(81)90480-2; MERKLE RK, 1987, METHOD ENZYMOL, V138, P232; NYAME K, 1989, J BIOL CHEM, V264, P3235; ROUX L, 1988, J BIOL CHEM, V263, P8879; SCHACHTER H, 1991, Glycobiology, V1, P453, DOI 10.1093/glycob/1.5.453; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; SLOMIANY BL, 1988, BIOCHEM BIOPH RES CO, V157, P61, DOI 10.1016/S0006-291X(88)80011-1; SMITH PL, 1992, J BIOL CHEM, V267, P19140; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SRIVATSAN J, 1992, GLYCOBIOLOGY, V2, P445, DOI 10.1093/glycob/2.5.445; TOMIYA N, 1993, J BIOL CHEM, V268, P113; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VARKI A, 1983, J BIOL CHEM, V258, P2808; VARKI A, 1980, J BIOL CHEM, V255, P847; WEISSHAAR G, 1991, EUR J BIOCHEM, V195, P257, DOI 10.1111/j.1432-1033.1991.tb15702.x; WHITE T, 1990, BIOCHEMISTRY-US, V29, P2740, DOI 10.1021/bi00463a017; WILLIAMS J, 1984, CARBOHYD RES, V134, P141, DOI 10.1016/0008-6215(84)85029-6	48	25	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16170	16178						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344901				2022-12-27	WOS:A1993LQ33600016
J	HIDALGO, FJ; ZAMORA, R				HIDALGO, FJ; ZAMORA, R			FLUORESCENT PYRROLE PRODUCTS FROM CARBONYL-AMINE REACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; LIPOFUSCIN; BROMOTRICHLOROMETHANE; ANTIOXIDANTS; INVOLVEMENT; COMPONENTS; OXIDATION; PROTEINS; SLICES; DAMAGE	The reaction of (E)-4,5-epoxy-(E)-2-heptenal with butylamine and glycine methyl ester produced brown macromolecular pigments, which showed fluorescent characteristics similar to lipofuscins. This polymerization reaction implies in the first step the formation of 1-alkyl-2-(1'-hydroxyalkyl)pyrroles (IV, VI). Compounds IV and VI have been isolated and characterized from the above reactions, and their structures confirmed with the synthesis of 2-(1'-hydroxyethyl)-1-methylpyrrole (V). Compounds IV-VI resulted very unstable and even diluted solutions of them polymerized with time. The first step was the production of a dipyrrymethane VIII, which evolved more stable dipyrrylmethenes IX and X by intramolecular dehydration. These dimers continued polymerizing to produce 16H-tripyrrin derivatives XI and XII, and, in the next step, hexahydroglobins XIII and XIV. All these compounds have been characterized by H-1 NMR and/or gas chromatography coupled with mass spectrometry or mass spectrometry. Additional polymerization produced higher molecular weight polymers that were the responsible for the brown color and the fluorescence. The above results suggest that the fluorescence produced by reaction between some oxidized lipids and amino acids may be related to polymerization more than to the formation of single structures.			HIDALGO, FJ (corresponding author), CSIC, INST GRASA & DERIVADOS, AVDA PADRE GARCIA TEJERO 4, E-41012 SEVILLE, SPAIN.		Zamora, Renato/ABE-6898-2020	Zamora, Renato/0000-0002-2223-3361; Zamora, Rosario/0000-0003-3016-2177; Hidalgo, Francisco J./0000-0003-2098-728X				CHIO KS, 1969, SCIENCE, V166, P1535, DOI 10.1126/science.166.3912.1535; CHIO KS, 1969, BIOCHEMISTRY-US, V8, P2821, DOI 10.1021/bi00835a019; CHRISTIE WW, 1992, ADV LIPID METHODOLOG, P132; DAVIES KJA, 1988, LIPID PEROXIDATION B, P100; DILLARD CJ, 1988, CELLULAR ANTIOXIDANT, P103; ESTERBAUER H, 1986, BIOCHEM J, V239, P405, DOI 10.1042/bj2390405; Esterbauer H., 1982, FREE RADICAL LIPID P, P101; FIORITI JA, 1968, J CHROMATOGR, V32, P761, DOI 10.1016/S0021-9673(01)80563-X; FLETCHER BL, 1971, LIPIDS, V6, P172, DOI 10.1007/BF02533033; FRANCIS FJ, 1975, FOOD COLORIMETRY THE; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; GARDNER HW, 1978, LIPIDS, V13, P246, DOI 10.1007/BF02533664; GARDNER HW, 1979, J AGR FOOD CHEM, V27, P220, DOI 10.1021/jf60222a034; Guilbault G.G., 1973, PRACTICAL FLUORESCEN; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; HIDALGO FJ, 1992, CHEM PHYS LIPIDS, V60, P225, DOI 10.1016/0009-3084(92)90074-Y; HIDALGO FJ, 1990, BIOCHIM BIOPHYS ACTA, V1037, P313, DOI 10.1016/0167-4838(90)90031-A; HIDALGO FJ, 1992, INFORM, V3, P544; Hunter R. S, 1973, MEASUREMENT APPEARAN; IVY GO, 1984, SCIENCE, V226, P985, DOI 10.1126/science.6505679; KAREL M, 1984, J CHEM EDUC, V61, P335, DOI 10.1021/ed061p335; KIKUGAWA K, 1984, LIPIDS, V19, P600, DOI 10.1007/BF02534718; KIKUGAWA K, 1991, LIPIDS, V26, P922, DOI 10.1007/BF02535978; KIKUGAWA K, 1987, CHEM PHYS LIPIDS, V44, P277, DOI 10.1016/0009-3084(87)90054-5; MACHLIN LJ, 1987, FASEB J, V1, P441, DOI 10.1096/fasebj.1.6.3315807; MAGA JA, 1981, J AGR FOOD CHEM, V29, P691, DOI 10.1021/jf00106a001; SHIMASAKI H, 1977, J AM OIL CHEM SOC, V54, P119, DOI 10.1007/BF02894387; SHIMASAKI H, 1988, LIPID PEROXIDATION B, P144; Sies H., 1985, OXIDATIVE STRESS, V501, P1, DOI DOI 10.1016/B978-0-12-642760-8.50005-3; SLATER TF, 1984, BIOCHEM J, V222, P1; SONNTAG NO, 1968, FATTY ACIDS THEIR CH, P3561; SWOBODA PAT, 1976, CHEM IND-LONDON, P160; SWOBODA PAT, 1978, J SCI FOOD AGR, V29, P803, DOI 10.1002/jsfa.2740290910; TAPPEL AL, 1973, FED PROC, V32, P1870; TAUBOLD RD, 1975, LIPIDS, V10, P383, DOI 10.1007/BF02532441; Udenfriend S, 1962, FLUORESCENCE ASSAY B, V1; Young D.W., 1975, HETEROCYCLIC CHEM; ZAMORA R, 1990, CHEM-BIOL INTERACT, V76, P293, DOI 10.1016/0009-2797(90)90097-7; ZAMORA R, 1992, J AGR FOOD CHEM, V40, P2269, DOI 10.1021/jf00023a043; 1978, CIE PUBLICATION S2, V15	40	70	71	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16190	16197						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344903				2022-12-27	WOS:A1993LQ33600019
J	KIJIMA, Y; MAYRLEITNER, M; TIMERMAN, AP; SAITO, A; SCHINDLER, H; FLEISCHER, S				KIJIMA, Y; MAYRLEITNER, M; TIMERMAN, AP; SAITO, A; SCHINDLER, H; FLEISCHER, S			A CARDIAC CLATHRIN ASSEMBLY PROTEIN FORMS A POTASSIUM CHANNEL IN PLANAR LIPID BILAYERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL POLYPHOSPHATE RECEPTOR; COATED VESICLE PROTEINS; SARCOPLASMIC-RETICULUM; MICROGRAM QUANTITIES; PLASMA-MEMBRANE; ION CHANNELS; GOLGI; AP-2; BINDING; ANTIBODIES	A novel clathrin assembly protein (designated cardiac AP-3) has been isolated from dog heart which forms a K+ channel in planar lipid bilayers. AP-3 facilitated the in vitro formation of clathrin cages, which is diagnostic for clathrin assembly proteins. AP-3 consists mainly of 100-, 97-, and 55-kDa bands. A GTP-binding protein of approximately 25 kDa also co-purifies. The 100-kDa band was recognized by a monoclonal antibody to the gamma-adaptin of bovine brain clathrin assembly protein AP-1. A polyclonal antibody to the approximately 100-kDa doublet (alpha- and beta-adaptins) of bovine brain AP-2 did not cross-react with the purified protein. Western blot analysis of cardiac subcellular fractions showed that anti-AP-1 immunoreactivity was strongest in a sarcolemma-enriched fraction. Little immunoreactivity was detected in other cardiac subfractions, including sarcoplasmic reticulum, intercalated discs, and mitochondria. When reconstituted into planar lipid bilayers, AP-3 displays ion channel activity. Permeability ratios were P(K)/P(Cl) approximately 16 and P(K)/P(Na) approximately 3, indicating a cation-selective channel somewhat selective for K+ versus Na+. The K+ channel displays several subconductance states (9 and 12 picosiemens in the main) and was blocked by CaCl2 (mM), inositol 1,3,4,5-tetrakisphosphate (20 muM), inositol 1,4,5-trisphosphate (40 muM), and guanosine 5'-O-(3-thiotrisphosphate) (mM). Thus, the cardiac AP-3 appears to act as a K+ channel modulated by inositol polyphosphates and a small GTP-binding protein.	VANDERBILT UNIV, DEPT MOLEC BIOL, BOX 1820, STN B, NASHVILLE, TN 37235 USA; JOHANNES KEPLER UNIV, A-4040 LINZ, AUSTRIA	Vanderbilt University; Johannes Kepler University Linz					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046681, R01HL032711] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32711, P01-HL46681] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; BECK KA, 1991, J BIOL CHEM, V266, P4442; BOCK, 1974, METHOD ENZYMOL, V31, P374; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHADWICK CC, 1992, J BIOL CHEM, V267, P3473; CHAMBERLAIN BK, 1983, J BIOL CHEM, V258, P6602; Fleischer B, 1974, Methods Enzymol, V31, P180; Fleischer S, 1974, Methods Enzymol, V31, P6; INUI M, 1988, J BIOL CHEM, V263, P10843; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KEEN JH, 1989, BIOCHEM BIOPH RES CO, V158, P17, DOI 10.1016/S0006-291X(89)80170-6; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KIJIMA Y, 1993, J BIOL CHEM, V268, P3499; KIJIMA Y, 1992, BIOCHEM BIOPH RES CO, V189, P728, DOI 10.1016/0006-291X(92)92262-V; KIJIMA Y, 1993, BIOPHYS J, V64, pA9; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS CA, 1979, J PHYSIOL-LONDON, V286, P417, DOI 10.1113/jphysiol.1979.sp012629; MERRIL CR, 1983, METHOD ENZYMOL, V96, P230; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PALADE P, 1989, MOL PHARMACOL, V36, P664; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; SCHINDLER H, 1989, METHOD ENZYMOL, V171, P225; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; TIMERMAN AP, 1992, P NATL ACAD SCI USA, V89, P8976, DOI 10.1073/pnas.89.19.8976; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGNER P, 1992, METHOD ENZYMOL, V219, P369; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0	36	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16253	16258						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344911				2022-12-27	WOS:A1993LQ33600027
J	MAUCUER, A; MOREAU, J; MECHALI, M; SOBEL, A				MAUCUER, A; MOREAU, J; MECHALI, M; SOBEL, A			STATHMIN GENE FAMILY - PHYLOGENETIC CONSERVATION AND DEVELOPMENTAL REGULATION IN XENOPUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURON-ENRICHED PHOSPHOPROTEIN; PROTEIN-PHOSPHORYLATION; TRANSLATIONAL CONTROL; DISTINCT PATTERNS; CELL REGULATIONS; MESSENGER-RNAS; SCG10 GENE; EXPRESSION; ACTIVATION; SEQUENCES	The ubiquitous cytoplasmic phosphoprotein stathmin was proposed to play a general role as an intracellular relay integrating diverse signals regulating the proliferation, differentiation, and functions of cells (Sobel, A. (1991) Trends Biol. Sci. 16, 301-305). It was originally identified in mammalian cells and tissues, but antibodies directed against the mammalian protein also recognized a stathmin-like 19-kDa protein in all vertebrate classes. The immunoreactive protein in Xenopus laevis displayed, like mammalian stathmin, several nonphosphorylated and phosphorylated heat-soluble forms with distinct migration on two-dimensional polyacrylamide gel electrophoresis. Screening of Xenopus oocyte and brain cDNA libraries with a rat stathmin cDNA probe allowed us to isolate several stathmin-related cDNA clones, among which clone XO35 encodes the Xenopus homologue of stathmin whose deduced amino acid sequence is 79% identical to and displays most of the characteristic structural features of the mammalian protein. In particular, one of the cAMP-dependent protein kinase and the two ''proline-directed'' kinase-specific sites known to be phosphorylated in rat stathmin are also present in the Xenopus protein. Furthermore, two other sets of clones coding for related proteins belonging to the stathmin gene family were also isolated; clone SC 15 encodes the Xenopus homologue of SCG10, a rat protein specifically related to neuronal differentiation; clone XB3 encodes a protein which, as SCG10 or SC15, possesses a stathmin-like domain and an additional N-terminal extension but is more distant from SCG10 than SC15. Interestingly, the mRNA transcripts of Xenopus stathmin (XO35) appear ubiquitous, like stathmin in mammals, whereas the SC15 and XB3 mRNAs appeared as markers of the nervous tissue in Xenopus. During Xenopus oogenesis, stathmin accumulates and remains stable as a maternal product throughout early development. Concurrently, its phosphorylation is regulated from essentially unphosphorylated forms to highly phosphorylated ones in the mature egg, which are then progressively dephosphorylated again from the mid-blastula to the tailbud stage. Altogether, our results demonstrate the high evolutionary conservation of stathmin together with the members of its related gene family, not only at the level of their molecular structures, but also of their biochemical and biological regulation. These observations are thus further in favor of a very general and likely essential role of stathmin in the normal control of cells throughout development and in the adult.	INST JACQUES MONOD, CNRS, UMR3, F-75005 PARIS, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	MAUCUER, A (corresponding author), CNRS, URA614, INSERM, U153, 17 RUE FER MOULIN, F-75005 PARIS, FRANCE.		Maucuer, Alexandre/B-1069-2019	Maucuer, Alexandre/0000-0003-2947-6654				ANDEOL Y, 1990, DEV BIOL, V139, P24, DOI 10.1016/0012-1606(90)90275-N; ANDERSON DJ, 1985, CELL, V42, P649, DOI 10.1016/0092-8674(85)90122-9; BERETTA L, 1989, J BIOL CHEM, V264, P9932; BERETTA L, 1993, IN PRESS J BIOL CHEM; BISBEE CA, 1977, SCIENCE, V195, P785, DOI 10.1126/science.65013; BRACHET J, 1963, NATURE, V198, P205, DOI 10.1038/198205a0; BRAVERMAN R, 1986, J BIOL CHEM, V261, P14342; CHNEIWEISS H, 1992, J NEUROCHEM, V58, P282, DOI 10.1111/j.1471-4159.1992.tb09308.x; CHNEIWEISS H, 1989, J NEUROCHEM, V53, P856, DOI 10.1111/j.1471-4159.1989.tb11783.x; COOPER HL, 1991, J IMMUNOL, V146, P3689; Davidson E. H., 1986, GENE ACTIVITY EARLY; DAVIDSON EH, 1987, MOL APPROACHES DEV B; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DOYE V, 1992, DIFFERENTIATION, V50, P89, DOI 10.1111/j.1432-0436.1992.tb00489.x; DOYE V, 1989, J BIOL CHEM, V264, P12134; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; GOODMAN M, 1975, NATURE, V253, P603, DOI 10.1038/253603a0; GRAHAM CF, 1966, DEV BIOL, V14, P439, DOI 10.1016/0012-1606(66)90024-8; GULLBERG M, 1990, J BIOL CHEM, V265, P17499; Gurdon J. B., 1967, METHODS DEV BIOL, P75; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; HAILAT N, 1990, ONCOGENE, V5, P1615; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HEIN J, 1990, METHOD ENZYMOL, V183, P626; KIMELMAN D, 1987, CELL, V48, P399, DOI 10.1016/0092-8674(87)90191-7; KIRSCHNER M, 1985, TRENDS GENET, V1, P41, DOI 10.1016/0168-9525(85)90021-6; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; KOPPEL J, 1990, J BIOL CHEM, V265, P3703; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1977, CELL, V10, P237, DOI 10.1016/0092-8674(77)90217-3; LEGOUVELLO S, 1991, FEBS LETT, V287, P80, DOI 10.1016/0014-5793(91)80020-4; LEIBOVICI M, 1990, DEV BIOL, V141, P183, DOI 10.1016/0012-1606(90)90113-W; LUO XN, 1991, J BIOL CHEM, V266, P21004; MALLER J, 1977, DEV BIOL, V58, P295, DOI 10.1016/0012-1606(77)90093-8; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MAUCUER A, 1990, FEBS LETT, V264, P275, DOI 10.1016/0014-5793(90)80266-L; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; MELHEM RF, 1991, BIOCHEM BIOPH RES CO, V179, P1649, DOI 10.1016/0006-291X(91)91764-4; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; PEYRON JF, 1989, BIOCHEM J, V258, P505, DOI 10.1042/bj2580505; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; SAGATA N, 1980, DEV BIOL, V77, P431, DOI 10.1016/0012-1606(80)90486-8; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUBART UK, 1988, J BIOL CHEM, V263, P12156; SCHUBART UK, 1989, DNA-J MOLEC CELL BIO, V8, P389, DOI 10.1089/dna.1.1989.8.389; SIGNORET J, 1971, Annales d'Embryologie et de Morphogenese, V4, P113; SMITH LD, 1987, MOL APPROACHES DEV B, P3; SOBEL A, 1983, J BIOL CHEM, V258, P312; SOBEL A, 1989, J BIOL CHEM, V264, P3765; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; SOBEL A, 1989, SEP EMBO WORKSH CELL; STEIN R, 1988, NEURON, V1, P463, DOI 10.1016/0896-6273(88)90177-8; STRAHLER JR, 1992, BIOCHEM BIOPH RES CO, V185, P197, DOI 10.1016/S0006-291X(05)80975-1; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; TOUTANT M, 1987, DEV BIOL, V124, P370, DOI 10.1016/0012-1606(87)90489-1; VARNUM SM, 1990, GENE DEV, V4, P2278, DOI 10.1101/gad.4.12b.2278; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X	63	63	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16420	16429						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344928				2022-12-27	WOS:A1993LQ33600051
J	SHADEL, GS; CLAYTON, DA				SHADEL, GS; CLAYTON, DA			MITOCHONDRIAL TRANSCRIPTION INITIATION - VARIATION AND CONSERVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							YEAST SACCHAROMYCES-CEREVISIAE; 2 BIDIRECTIONAL PROMOTERS; RNA-POLYMERASE; INVITRO TRANSCRIPTION; DNA REPLICATION; FACTOR-I; REGULATORY ELEMENTS; SPECIFICITY FACTOR; IDENTIFICATION; SEQUENCE				SHADEL, GS (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033088, R37GM033088] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33088-23] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BISWAS TK, 1986, P NATL ACAD SCI USA, V83, P270, DOI 10.1073/pnas.83.2.270; BISWAS TK, 1990, P NATL ACAD SCI USA, V87, P9338, DOI 10.1073/pnas.87.23.9338; BISWAS TK, 1990, J BIOL CHEM, V265, P19053; BISWAS TK, 1987, J BIOL CHEM, V262, P13690; BISWAS TK, 1985, P NATL ACAD SCI USA, V82, P1954, DOI 10.1073/pnas.82.7.1954; BISWAS TK, 1992, J MOL BIOL, V226, P335, DOI 10.1016/0022-2836(92)90951-F; BOGENHAGEN DF, 1988, MOL CELL BIOL, V8, P2910, DOI 10.1128/MCB.8.7.2910; BOGENHAGEN DF, 1986, MOL CELL BIOL, V6, P2543, DOI 10.1128/MCB.6.7.2543; BOGENHAGEN DF, 1988, MOL CELL BIOL, V8, P2917, DOI 10.1128/MCB.8.7.2917; CHANG DD, 1985, P NATL ACAD SCI USA, V82, P351, DOI 10.1073/pnas.82.2.351; CHANG DD, 1984, CELL, V36, P635, DOI 10.1016/0092-8674(84)90343-X; CHANG DD, 1985, EMBO J, V4, P1559, DOI 10.1002/j.1460-2075.1985.tb03817.x; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CHANG DD, 1986, MOL CELL BIOL, V6, P294, DOI 10.1128/MCB.6.1.294; CHANG DD, 1987, SCIENCE, V235, P1178, DOI 10.1126/science.2434997; CHANG DD, 1985, ACHIEVEMENTS PERSPEC, V2, P135; CHRISTIANSON T, 1983, J BIOL CHEM, V258, P4025; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573; CLAYTON DA, 1991, TRENDS BIOCHEM SCI, V16, P107, DOI 10.1016/0968-0004(91)90043-U; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; CONSTANZO MC, 1990, ANNU REV GENET, V24, P91; DEZAMAROCZY M, 1985, GENE, V37, P1, DOI 10.1016/0378-1119(85)90252-5; DIFFLEY JFX, 1992, J BIOL CHEM, V267, P3368; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; FISHER RP, 1985, J BIOL CHEM, V260, P1330; FISHER RP, 1992, J BIOL CHEM, V267, P3358; FISHER RP, 1988, MOL CELL BIOL, V8, P3496, DOI 10.1128/MCB.8.8.3496; FISHER RP, 1991, J BIOL CHEM, V266, P9153; FISHER RP, 1987, CELL, V50, P247, DOI 10.1016/0092-8674(87)90220-0; FISHER RP, 1989, GENE DEV, V3, P2202, DOI 10.1101/gad.3.12b.2202; GRAY MW, 1989, ANNU REV CELL BIOL, V5, P25, DOI 10.1146/annurev.cb.05.110189.000325; GREENLEAF AL, 1986, P NATL ACAD SCI USA, V83, P3391, DOI 10.1073/pnas.83.10.3391; HIXSON JE, 1985, P NATL ACAD SCI USA, V82, P2660, DOI 10.1073/pnas.82.9.2660; JANG SH, 1991, J BIOL CHEM, V266, P22671; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; KELLY JL, 1986, J BIOL CHEM, V261, P348; LABBE D, 1991, J BIOL CHEM, V266, P10844; LISOWSKY T, 1988, MOL GEN GENET, V214, P218, DOI 10.1007/BF00337714; LISOWSKY T, 1989, MOL GEN GENET, V219, P125, DOI 10.1007/BF00261167; MARCZYNSKI GT, 1989, MOL CELL BIOL, V9, P3193, DOI 10.1128/MCB.9.8.3193; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; MUELLER DM, 1986, J BIOL CHEM, V261, P1756; NER S S, 1992, Current Biology, V2, P208, DOI 10.1016/0960-9822(92)90541-H; OSINGA KA, 1982, NUCLEIC ACIDS RES, V10, P3617, DOI 10.1093/nar/10.12.3617; OSINGA KA, 1984, NUCLEIC ACIDS RES, V12, P1889, DOI 10.1093/nar/12.4.1889; PARISI MA, 1993, MOL CELL BIOL, V13, P1951, DOI 10.1128/MCB.13.3.1951; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; RIEMEN G, 1993, MOL GEN GENET, V237, P49, DOI 10.1007/BF00282783; SCHINKEL AH, 1989, TRENDS GENET, V5, P149, DOI 10.1016/0168-9525(89)90056-5; SCHINKEL AH, 1987, J BIOL CHEM, V262, P12785; SCHINKEL AH, 1988, EMBO J, V7, P3255, DOI 10.1002/j.1460-2075.1988.tb03192.x; SCHINKEL AH, 1988, NUCLEIC ACIDS RES, V19, P9147; SCHMITT ME, 1992, GENE DEV, V6, P1975, DOI 10.1101/gad.6.10.1975; STOHL LL, 1992, MOL CELL BIOL, V12, P2561, DOI 10.1128/MCB.12.6.2561; TOPPER JN, 1989, MOL CELL BIOL, V9, P1200, DOI 10.1128/MCB.9.3.1200; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; WALBERG MW, 1983, J BIOL CHEM, V258, P1268; WETTSTEINEDWARDS J, 1986, J BIOL CHEM, V261, P2905; XU BJ, 1992, NUCLEIC ACIDS RES, V20, P1053, DOI 10.1093/nar/20.5.1053	62	160	167	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16083	16086						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344889				2022-12-27	WOS:A1993LQ33600001
J	SWARTZMAN, E; MEIGHEN, EA				SWARTZMAN, E; MEIGHEN, EA			PURIFICATION AND CHARACTERIZATION OF A POLY(DA-DT) LUX-SPECIFIC DNA-BINDING PROTEIN FROM VIBRIO-HARVEYI AND IDENTIFICATION AS LUXR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISCHERI LUMINESCENCE SYSTEM; ESCHERICHIA-COLI; STRUCTURAL IDENTIFICATION; TRANSCRIPTIONAL ACTIVATOR; NUCLEOTIDE-SEQUENCE; GENE-PRODUCT; AUTOINDUCER; BIOLUMINESCENCE; EXPRESSION; RIBOFLAVIN	A lux-specific DNA-binding protein was purified to homogeneity from Vibrio harveyi by chromatography on DEAE-Sepharose, DNA-cellulose, Superose 12, and Mono Q. A single polypeptide of M(r) = 23,000 was found on SDS-polyacrylamide gel electrophoresis with an amino-terminal sequence corresponding to that predicted for luxR, a gene that causes a shift in the transcriptional start site from position -123 to -26 base pairs upstream of the initiation codon of luxC in the V. harveyi lux operon and is required for high expression of lux mRNA in recombinant Escherichia coli. Identification of the DNA-binding protein as LuxR was confirmed by showing its absence in V. harveyi luxR-mutants and its synthesis in recombinant E. coli containing V. harveyi luxR. The LuxR protein was shown to bind to two specific (A + T)-rich regions of DNA upstream of the V. harveyi luxC gene: region A, -290 to -253 base pairs, and region B, -170 to -116 base pairs. Synthetic poly(dA-dT) but not poly(dA)-poly(dT) competed with the lux DNA for binding to LuxR suggesting that this protein may be a novel poly(dA-dT)-binding protein in prokaryotes. The LuxR protein inhibited transcription from the -123 promoter in vitro; however, transcription from the -26 promoter was not reconstituted suggesting the possible requirement for other factors in lux gene regulation. LuxR shared sequence identity with two proteins linked to the regulation of enzymes involved in electron transport indicating that it may be a member of a family of regulators of metabolic functions responsible for diverting electrons from the respiratory chain.	MCGILL UNIV,DEPT BIOCHEM,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA	McGill University								ANDREWS SC, 1992, FEBS LETT, V302, P247, DOI 10.1016/0014-5793(92)80452-M; CAO JG, 1989, J BIOL CHEM, V264, P21670; DUNLAP PV, 1992, J BACTERIOL, V174, P2440, DOI 10.1128/jb.174.8.2440-2448.1992; EBERHARD A, 1981, BIOCHEMISTRY-US, V20, P2444, DOI 10.1021/bi00512a013; ENGEBRECHT J, 1984, P NATL ACAD SCI-BIOL, V81, P4154, DOI 10.1073/pnas.81.13.4154; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARREAU H, 1983, NUCLEIC ACIDS RES, V11, P8473, DOI 10.1093/nar/11.23.8473; HASTINGS JW, 1985, ADV MICROB PHYSIOL, V26, P235, DOI 10.1016/S0065-2911(08)60398-7; KAPLAN HB, 1987, P NATL ACAD SCI USA, V84, P6639, DOI 10.1073/pnas.84.19.6639; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMARK T, 1991, MOL MICROBIOL, V5, P1049, DOI 10.1111/j.1365-2958.1991.tb01877.x; LEE CY, 1992, BIOCHEM BIOPH RES CO, V186, P690, DOI 10.1016/0006-291X(92)90802-R; LEVINGER L, 1982, P NATL ACAD SCI-BIOL, V79, P7152, DOI 10.1073/pnas.79.23.7152; MARKWELL MA, 1981, METHOD ENZYMOL, V171, P296; MARTIN M, 1989, J BACTERIOL, V171, P2406, DOI 10.1128/jb.171.5.2406-2414.1989; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; MIYAMOTO C, 1987, J BACTERIOL, V169, P247, DOI 10.1128/jb.169.1.247-253.1987; MIYAMOTO CM, 1990, J BACTERIOL, V172, P2046, DOI 10.1128/jb.172.4.2046-2054.1990; MIYAMOTO CM, 1988, NUCLEIC ACIDS RES, V16, P1551, DOI 10.1093/nar/16.4.1551; RICHTER G, 1992, J BACTERIOL, V174, P4050, DOI 10.1128/jb.174.12.4050-4056.1992; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; SHADEL GS, 1990, J BIOLUM CHEMILUM, V5, P99, DOI 10.1002/bio.1170050205; SHADEL GS, 1990, J BACTERIOL, V172, P3980, DOI 10.1128/jb.172.7.3980-3987.1990; SHOWALTER RE, 1990, J BACTERIOL, V172, P2946, DOI 10.1128/jb.172.6.2946-2954.1990; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; SWARTZMAN E, 1992, J BACTERIOL, V174, P7490, DOI 10.1128/jb.174.22.7490-7493.1992; SWARTZMAN E, 1992, BIOCHEM CELL BIOL, V70, P698, DOI 10.1139/o92-106; SWARTZMAN E, 1991, BIOLUMINESCENCE AND CHEMILUMINESCENCE, P27; SWARTZMAN E, 1993, THESIS MCGILL U; WATENABE H, 1991, BIOLUMINESCENCE CHEM, P43; WINTER E, 1989, EMBO J, V8, P1867, DOI 10.1002/j.1460-2075.1989.tb03583.x	31	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16706	16716						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344950				2022-12-27	WOS:A1993LQ33600089
J	GEISER, T; DEWALD, B; EHRENGRUBER, MU; CLARKLEWIS, I; BAGGIOLINI, M				GEISER, T; DEWALD, B; EHRENGRUBER, MU; CLARKLEWIS, I; BAGGIOLINI, M			THE INTERLEUKIN-8-RELATED CHEMOTACTIC CYTOKINES GRO-ALPHA, GRO-BETA, AND GRO-GAMMA ACTIVATE HUMAN NEUTROPHIL AND BASOPHIL LEUKOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATORY ACTIVITY; RESPIRATORY BURST; PEPTIDE-1 INTERLEUKIN-8; RECEPTOR-BINDING; HUMAN MONOCYTES; HIGH-AFFINITY; EXPRESSION; PROTEIN; CELLS; PURIFICATION	GROalpha, a protein structurally related to interleukin-8 (IL-8) and originally described as a melanoma growth stimulatory factor, possesses potent neutrophil-stimulating activity. Recently, two closely related genes, grobeta and grogamma, were identified. In the present work, the three GRO proteins were chemically synthesized, and their biological activities on human neutrophils and other leukocytes were compared. GROalpha, GRObeta, and GROgamma, like IL-8, induced chemotaxis, shape change, a rise in intracellular free calcium levels, exocytosis, and the respiratory burst in neutrophils. The GRO proteins were also active toward basophils as shown by chemotaxis and intracellular calcium concentration changes. The order of potency in neutrophils and basophils was IL-8 > GROalpha greater-than-or-equal-to GROgamma > GRObeta. Of the two IL-8 receptors expressed on human neutrophils, one binds GROalpha with high and the other with low affinity. Competition binding experiments using radiolabeled IL-8 and GROalpha revealed the same characteristics for GRObeta and GROgamma. Similarly, cross-desensitization, as assessed by the stimulus-dependent changes in intracellular calcium concentration, indicated that all three GRO proteins interact with common receptors. From these results, it can be concluded that GROalpha, GRObeta, and GROgamma have the same pattern of activity toward human granulocytes and that the differences in amino acid sequence among these proteins have only minor effects on biological activity.	UNIV BRITISH COLUMBIA,CTR BIOMED RES,VANCOUVER V6T 1W5,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1W5,BC,CANADA	University of British Columbia; University of British Columbia	GEISER, T (corresponding author), UNIV BERN,THEODOR KOCHER INST,POB 99,CH-3000 BERN 9,SWITZERLAND.							ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BISCHOFF SC, 1992, J EXP MED, V175, P1271, DOI 10.1084/jem.175.5.1271; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; GOLDS EE, 1989, BIOCHEM J, V259, P585, DOI 10.1042/bj2590585; GRONENBORN AM, 1991, PROTEIN ENG, V4, P263, DOI 10.1093/protein/4.3.263; HARVATH L, 1980, J IMMUNOL METHODS, V37, P39, DOI 10.1016/0022-1759(80)90179-9; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; IIDA N, 1990, MOL CELL BIOL, V10, P5596, DOI 10.1128/MCB.10.10.5596; KERNEN P, 1991, J CLIN INVEST, V87, P2012, DOI 10.1172/JCI115230; KRIEGER M, 1992, J IMMUNOL, V149, P2662; LEE J, 1992, J BIOL CHEM, V267, P16283; LEONARD EJ, 1990, J IMMUNOL, V144, P1323; MOSER B, 1990, J EXP MED, V171, P1797, DOI 10.1084/jem.171.5.1797; MOSER B, 1991, J BIOL CHEM, V266, P10666; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; RANGNEKAR VV, 1991, J BIOL CHEM, V266, P2415; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; Sager R, 1992, Cytokines, V4, P96; SCHRODER JM, 1990, J EXP MED, V171, P1091, DOI 10.1084/jem.171.4.1091; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; THOMAS HG, 1988, MOL CELL ENDOCRINOL, V57, P69, DOI 10.1016/0303-7207(88)90033-0; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; WALZ A, 1991, J LEUKOCYTE BIOL, V50, P279, DOI 10.1002/jlb.50.3.279; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; WEN DZ, 1989, EMBO J, V8, P1761, DOI 10.1002/j.1460-2075.1989.tb03569.x; WYMANN MP, 1987, J BIOL CHEM, V262, P12048; WYMANN MP, 1987, ANAL BIOCHEM, V165, P371, DOI 10.1016/0003-2697(87)90284-3; WYMANN MP, 1987, BIOCHEM BIOPH RES CO, V147, P361, DOI 10.1016/S0006-291X(87)80130-4	34	249	253	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15419	15424						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340371				2022-12-27	WOS:A1993LN30500019
J	HAIMOVICH, B; LIPFERT, L; BRUGGE, JS; SHATTIL, SJ				HAIMOVICH, B; LIPFERT, L; BRUGGE, JS; SHATTIL, SJ			TYROSINE PHOSPHORYLATION AND CYTOSKELETAL REORGANIZATION IN PLATELETS ARE TRIGGERED BY INTERACTION OF INTEGRIN RECEPTORS WITH THEIR IMMOBILIZED LIGANDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; CELL-ADHESION; SIGNAL TRANSDUCTION; CYTOCHALASIN-D; EXTRACELLULAR-MATRIX; STIMULATED PLATELETS; LYMPHOCYTE ADHESION; ACTIVATED PLATELETS; DEPENDENT ADHESION; THROMBUS FORMATION	Agonist-induced platelet activation causes fibrinogen binding to integrin alpha(IIb)beta3 (glycoprotein (GP) IIb-IIIa) and platelet aggregation. This is associated with the phosphorylation of specific platelet proteins on tyrosine residues. Since fibrinogen immobilized on a solid matrix can bind platelet GP IIb-IIIa without the need for exogenous agonists, we examined whether platelet adhesion to a fibrinogen matrix induces tyrosine phosphorylation. Platelets adhered to fibrinogen in a GP IIb-IIIa-dependent manner and assumed a spread morphology. This change in cell shape was associated with tyrosine phosphorylation of multiple proteins, most prominently two unidentified proteins (101 and 105 kDa) and pp125FAK, a focal adhesion protein-tyrosine kinase. Pretreatment of platelets with prostaglandin I2 to increase cAMP, with cytochalasin D to inhibit actin polymerization, or with ADP scavengers to remove ADP did not affect initial adhesion, but inhibited both platelet spreading and tyrosine phosphorylation of pp125FAK and the 101- and 105-kDa proteins. This suggested that adhesion to fibrinogen caused cytoskeletal reorganization and the local release of ADP from platelet-dense granules, which potentiated the biochemical and morphological responses of the platelets to fibrinogen. Platelet adhesion to a collagen matrix also led to the induction of tyrosine phosphorylation of the 101- and 105-kDa proteins and pp125FAK. In this case, tyrosine phosphorylation was dependent on the interaction of collagen with integrin alpha2beta1 (GP Ia-IIa), and it was independent of both GP IIb-IIIa and ADP. These results indicate that platelet adhesion to fibrinogen or collagen induces signal transduction that is initiated through integrins GP IIb-IIIa and alpha2beta1, respectively. In both cases, tyrosine phosphorylation is accompanied by cytoskeletal reorganization and changes in cell shape. However, different regulatory components may be interposed between each of these integrins and the enzymes that control the level of protein tyrosine phosphorylation.	UNIV PENN, SCH MED, HOWARD HUGHES MED INST, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT MICROBIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT MED, HEMATOL ONCOL SECT, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania					NCI NIH HHS [CA47572] Funding Source: Medline; NHLBI NIH HHS [HL40387] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047572] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CARROLL RC, 1982, CELL, V30, P385, DOI 10.1016/0092-8674(82)90236-7; CHEN WT, 1982, J CELL BIOL, V95, P205, DOI 10.1083/jcb.95.1.205; COLLER BS, 1989, BLOOD, V74, P182; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; DAMLE NK, 1991, P NATL ACAD SCI USA, V88, P6403, DOI 10.1073/pnas.88.15.6403; DHAR A, 1991, J BIOL CHEM, V266, P18797; DRUCKER BJ, 1989, NEW ENGL J MED, V321, P1383; DUBAND JL, 1988, J CELL BIOL, V107, P1385, DOI 10.1083/jcb.107.4.1385; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HAIMOVICH B, 1991, CELL REGUL, V2, P271, DOI 10.1091/mbc.2.4.271; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HERMANOWSKIVOSATKA A, 1992, CELL, V68, P341, DOI 10.1016/0092-8674(92)90475-R; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; Huang E. M., 1986, BIOCH PLATELETS, P1; HUANG MM, 1993, IN PRESS J CELL BIOL; JEN CJ, 1987, AM J PHYSIOL, V253, pH745, DOI 10.1152/ajpheart.1987.253.4.H745; KIEFFER N, 1990, ANNU REV CELL BIOL, V6, P329; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; NACHMIAS VT, 1991, CELL MOTIL CYTOSKEL, V20, P190, DOI 10.1002/cm.970200303; OLORUNDARE OE, 1992, BLOOD, V79, P99, DOI 10.1182/blood.V79.1.99.bloodjournal79199; PEERSCHKE EIB, 1985, AM J PHYSIOL, V248, pC466, DOI 10.1152/ajpcell.1985.248.5.C466; PEERSCHKE EIB, 1984, P SOC EXP BIOL MED, V175, P109; PELLETIER AJ, 1992, MOL BIOL CELL, V3, P989, DOI 10.1091/mbc.3.9.989; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; SANTORO SA, 1991, CELL REGUL, V2, P905, DOI 10.1091/mbc.2.11.905; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHATTIL SJ, 1989, BLOOD, V73, P150; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHATTIL SJ, 1987, BLOOD, V70, P307; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1990, ANNU REV CELL BIOL, V6, P359, DOI 10.1146/annurev.cellbio.6.1.359; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TANGEN O, 1971, THROMB DIATH HAEMOST, V25, P268; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; WEISS HJ, 1986, BLOOD, V67, P322; WEISS HJ, 1978, BLOOD, V51, P267; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; YUROCHKO AD, 1992, P NATL ACAD SCI USA, V89, P9034, DOI 10.1073/pnas.89.19.9034; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	56	260	263	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15868	15877						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340412				2022-12-27	WOS:A1993LN30500079
J	HOCKENSMITH, JW; KUBASEK, WL; EVERTSZ, EM; MESNER, LD; VONHIPPEL, PH				HOCKENSMITH, JW; KUBASEK, WL; EVERTSZ, EM; MESNER, LD; VONHIPPEL, PH			LASER CROSS-LINKING OF PROTEINS TO NUCLEIC-ACIDS .2. INTERACTIONS OF THE BACTERIOPHAGE-T4 DNA-REPLICATION POLYMERASE ACCESSORY PROTEINS COMPLEX WITH DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMER-TEMPLATE JUNCTION; ATP HYDROLYSIS; III HOLOENZYME; 45 PROTEINS; T4; SYSTEM; STIMULATION; GENE-44	In this paper we examine the interactions of the polymerase accessory proteins subassembly of the bacteriophage T4 DNA replication complex, using single-pulse ultraviolet laser excitation to induce protein-nucleic acid cross-links. The laser-induced cross-linking permits effective ''freezing'' of the instantaneous equilibrium state of the complex and thus provides a mechanism to dissect the individual protein-nucleic acid interactions involved in complex assembly. We find that the binding of the gene 44, 62, and 45 proteins is dependent not only on the presence of each of the other proteins, but also on the presence of adenine nucleotide cofactors. We find that the nonhydrolyzable analogs of ATP often behave more like ADP than ATP in these experiments. Gene 45 protein is able to induce an increase in cross-linking of the gp44/62 complex to nucleic acids, and this increased cross-linking correlates with changes in the apparent K(m) of the gp44/62 complex for polynucleotides and with changes in V(max) during ATP hydrolysis. Our results suggest that the enhanced DNA binding is predominately through the gene 62 protein and not the ATPase catalytic subunit (gene 44 protein). Thus the gene 62 protein seems to play an integral role in gp45-mediated enhancement of the ATP hydrolytic activity of gp44. These results are summarized and integrated in the form of a model for the multiple interactions of the accessory proteins with DNA and one another in the presence of mononucleotide cofactors and substrates.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403; UNIV OREGON,DEPT BIOL,EUGENE,OR 97403	University of Oregon; University of Oregon; University of Oregon	HOCKENSMITH, JW (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,BOX 440,CHARLOTTESVILLE,VA 22908, USA.			von Hippel, Peter H./0000-0003-2512-8097	NIGMS NIH HHS [GM-29158, GM-43569, GM-15792] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015792, R37GM015792, R01GM029158] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1975, DNA SYNTHESIS ITS RE, V3, P241; BEDINGER P, 1983, J BIOL CHEM, V258, P9649; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; HOCKENSMITH JW, 1991, METHOD ENZYMOL, V208, P211; HOCKENSMITH JW, 1986, J BIOL CHEM, V261, P3512; HOCKENSMITH JW, 1993, J BIOL CHEM, V268, P15712; HOCKENSMITH JW, 1987, UCLA S MOL CELL BIOL, V47, P111; JARVIS TC, 1991, J BIOL CHEM, V266, P1830; JARVIS TC, 1990, J BIOL CHEM, V265, P15160; JARVIS TC, 1989, J BIOL CHEM, V264, P12717; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KUBASEK WL, 1988, THESIS U OREGON; KUBASEK WL, 1993, IN PRESS PHOTOCHEM P; MACE DC, 1984, J MOL BIOL, V177, P279, DOI 10.1016/0022-2836(84)90457-1; MESNER LD, 1992, P NATL ACAD SCI USA, V89, P2521, DOI 10.1073/pnas.89.7.2521; MORRIS CF, 1979, J BIOL CHEM, V254, P6787; MUNN MM, 1991, J BIOL CHEM, V266, P20034; MUNN MM, 1991, J BIOL CHEM, V266, P20024; NOSSAL NG, 1979, J BIOL CHEM, V254, P6032; PIPERNO JR, 1978, J BIOL CHEM, V253, P5174; REDDY MK, 1993, P NATL ACAD SCI USA, V90, P3211, DOI 10.1073/pnas.90.8.3211; RUSH J, 1989, J BIOL CHEM, V264, P10943; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	28	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15721	15730						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340396				2022-12-27	WOS:A1993LN30500060
J	HERREN, B; ROONEY, B; WEYER, KA; IBERG, N; SCHMID, G; PECH, M				HERREN, B; ROONEY, B; WEYER, KA; IBERG, N; SCHMID, G; PECH, M			DIMERIZATION OF EXTRACELLULAR DOMAINS OF PLATELET-DERIVED GROWTH-FACTOR RECEPTORS - A REVISED MODEL OF RECEPTOR-LIGAND INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR PDGF RECEPTORS; SIMIAN SARCOMA-VIRUS; B-CHAIN; BETA-RECEPTOR; V-SIS; MONOCLONAL-ANTIBODY; KINASE ACTIVATION; CDNA CLONING; BINDING; EXPRESSION	The alpha- and beta-subunits of the receptor for platelet-derived growth factor (PDGFR) were found to be autophosphorylated in the absence of ligands at high expression levels which suggests a propensity of PDGFRs to dimerize spontaneously. When the extracellular domains (ED) of both receptors were expressed and purified to homogeneity, they could be dimerized specifically by the different PDGF isoforms. PDGF-BB-induced dimerization was dependent on uncleaved loop I sequences present on both chains. Whereas, in solution, the EDs were weak competitors for PDGF binding to cellular PDGFRs, they formed high and low affinity complexes upon immobilization on solid phase. Cross-competition experiments defined two distinct binding sites on PDGFRalpha-ED. PDGF-AB bound only to the low affinity form of immobilized PDGFRbeta-ED and could not dimerize PDGFRbeta-ED. Cross-linking studies, however, revealed that both chains of PDGF-AB can interact with a PDGFRbeta-ED monomer. Cross-linking of PDGF homodimers with EDs also yielded complexes which contained more than two ligand chains. These results led to a revised model of receptor-ligand interaction and indicate that monomeric PDGF should be able to dimerize PDGF receptors.	F HOFFMANN LA ROCHE & CO LTD,PRECLIN RES,DIV PHARMA,GRENZACHERSTR 124,CH-4002 BASEL,SWITZERLAND	Roche Holding				Rooney, Barrie/0000-0002-5540-9431				ANDERSSON M, 1992, J BIOL CHEM, V267, P11260; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BOWENPOPE DF, 1985, METHOD ENZYMOL, V109, P69; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLEMENTS JM, 1991, EMBO J, V10, P4113, DOI 10.1002/j.1460-2075.1991.tb04988.x; COOK AL, 1992, BIOCHEM J, V281, P57, DOI 10.1042/bj2810057; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DROZDOFF V, 1991, J BIOL CHEM, V266, P17165; DUAN DSR, 1991, J BIOL CHEM, V266, P413; ESCOBEDO JA, 1988, SCIENCE, V240, P1532, DOI 10.1126/science.2836953; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GIESE N, 1990, MOL CELL BIOL, V10, P5496, DOI 10.1128/MCB.10.10.5496; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HART CE, 1987, J BIOL CHEM, V262, P10780; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HEIDARAN MA, 1992, J BIOL CHEM, V267, P2884; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; IIDA H, 1991, P NATL ACAD SCI USA, V88, P6560, DOI 10.1073/pnas.88.15.6560; JAUMANN M, 1992, FEBS LETT, V302, P265, DOI 10.1016/0014-5793(92)80456-Q; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KELLY JD, 1985, EMBO J, V4, P3399, DOI 10.1002/j.1460-2075.1985.tb04096.x; KELLY JD, 1991, J BIOL CHEM, V266, P8987; LAROCHELLE WJ, 1989, MOL CELL BIOL, V9, P3538, DOI 10.1128/MCB.9.8.3538; LROCHELLE WJ, 1992, J BIOL CHEM, V267, P17074; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MAIORELLA B, 1988, BIO-TECHNOL, V6, P1406, DOI 10.1038/nbt1288-1406; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; OSTMAN A, 1991, J BIOL CHEM, V266, P10073; PECH M, 1989, P NATL ACAD SCI USA, V86, P2693, DOI 10.1073/pnas.86.8.2693; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; RUBIN K, 1988, LANCET, V1, P1353; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SEVERINSSON L, 1989, EUR J BIOCHEM, V182, P679, DOI 10.1111/j.1432-1033.1989.tb14879.x; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; Summers MD, 1987, TEXAS AGR EXPT STATI; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	51	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15088	15095						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325884				2022-12-27	WOS:A1993LL75900080
J	HEPLER, JR; KOZASA, T; SMRCKA, AV; SIMON, MI; RHEE, SG; STERNWEIS, PC; GILMAN, AG				HEPLER, JR; KOZASA, T; SMRCKA, AV; SIMON, MI; RHEE, SG; STERNWEIS, PC; GILMAN, AG			PURIFICATION FROM SF9 CELLS AND CHARACTERIZATION OF RECOMBINANT GQ-ALPHA AND G11-ALPHA - ACTIVATION OF PURIFIED PHOSPHOLIPASE-C ISOZYMES BY G-ALPHA SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; EPIDERMAL GROWTH-FACTOR; ESCHERICHIA-COLI; BETA-GAMMA; IMMUNOLOGICAL IDENTIFICATION; PERTUSSIS TOXIN; BOVINE BRAIN; 2 FORMS; EXPRESSION; RECEPTOR	Members of the G(qalpha) subfamily of heterotrimeric guanine nucleotide-binding proteins (G proteins) activate phospholipase C (PLC). The complementary DNAs (cDNAs) for the G protein alpha subunits G(qalpha) and G11alpha were expressed in insect (Sf9) cells using recombinant baculovirus. Active, nonaggregated, and membrane-associated protein was generated only when the alpha subunit cDNA was expressed together with cDNAs encoding G protein beta and gamma subunits. Recombinant alpha subunits (rG(qalpha) and rG11alpha) were purified by three-step procedures, as was a PLC-activating alpha subunit(s) endogenous to Sf9 cells. Guanosine 5'-3-(thio)triphosphate (GTPgammaS) activated rG(qalpha) and rG11alpha with an apparent K0.5 of 30 muM; similarly high concentrations of the nucleotide were required to observe [S-35]GTPgammaS binding to rG(qalpha). Activated rG(qalpha) and rG11alpha each stimulated all three isoforms of purified PLC-beta with the rank order of potency PLC-beta1 = PLC-beta3 greater-than-or-equal-to PLC-beta2; both alpha subunits also stimulated PLC-beta1 and PLC-beta3 to a much greater extent (10-fold) than they did PLC-beta2. In contrast, activated rG(qalpha) and rG11alpha failed to stimulate either PLC-delta1 or PLCg-gamma1. Recombinant G(ialpha1), G(ialpha2), G(ialpha3), G(oalpha(A)), G(salpha), and G(zalpha) all failed to stimulate any of the isoforms of PLC. The apparent affinities of rG(qalpha) and rG11alpha for PLC-beta1 and their capacities to activate the enzyme were similar to values observed for purified brain G(qalpha/11alpha). Purified brain betagamma subunits also stimulated the three isoforms of PLC-beta. The capacities of rG(qalpha) and rG11alpha to activate PLC-beta1 and PLC-beta3 greatly exceeded those of betagamma, whereas G(qalpha), G11alpha and betagamma were roughly equiefficacious with PLC-beta2; the alpha subunits were more potent than betagamma in all cases. The effects of alpha and betagamma together were nonadditive for both PLC-beta1 and PLC-beta2. These results demonstrate that G(qalpha) and G11alpha specifically and selectively stimulate beta isoforms of PLC and confirm the idea that these members of the G(qalpha) subfamily of G proteins are physiological regulators of this signaling pathway.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; CALTECH, DEPT BIOL, PASADENA, CA 91125 USA; NATL HEART LUNG & BLOOD INST, BETHESDA, MD 20892 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; California Institute of Technology; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034236, R37GM034236, R37GM034497, R01GM031954, R01GM034497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31954, GM34497, GM34236] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BEAMES B, 1991, BIOTECHNIQUES, V11, P378; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRABER SG, 1992, J BIOL CHEM, V267, P1271; GRAZIANO MP, 1987, J BIOL CHEM, V262, P11375; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JHON DY, 1993, J BIOL CHEM, V268, P6654; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KRIZ R, 1990, CIBA F SYMP, V150, P112; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CH, 1992, J BIOL CHEM, V267, P16044; LIANG M, 1991, J BIOL CHEM, V266, P13342; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MUMBY S, 1988, J BIOL CHEM, V263, P2020; NAKAMURA F, 1991, J BIOL CHEM, V266, P12676; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PANG IH, 1990, J BIOL CHEM, V265, P18707; PARK D, 1992, J BIOL CHEM, V267, P16048; PARK DG, 1993, J BIOL CHEM, V268, P4573; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; RYU SH, 1987, J BIOL CHEM, V262, P12511; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SMRCKA AV, 1993, IN PRESS METHODS NEU; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; Summers MD, 1987, TEXAS AGR EXPT STATI; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0	62	255	258	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14367	14375						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314796				2022-12-27	WOS:A1993LJ82500084
J	INCE, BA; ZHUANG, Y; WRENN, CK; SHAPIRO, DJ; KATZENELLENBOGEN, BS				INCE, BA; ZHUANG, Y; WRENN, CK; SHAPIRO, DJ; KATZENELLENBOGEN, BS			POWERFUL DOMINANT-NEGATIVE MUTANTS OF THE HUMAN ESTROGEN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; BREAST-CANCER CELLS; TRANSCRIPTIONAL ACTIVATION; BINDING PROTEIN; V-ERBA; GENE; DNA; EXPRESSION; PROMOTER; ELEMENT	We have identified and characterized three human estrogen receptor (ER) mutants, which, at low concentrations, are capable of blocking the intracellular activity of wild type ER. The mutants, a truncated ER (ER1-530), a point mutant (L540Q), and a frameshift (S554fs), were generated by random chemical mutagenesis of the ER hormone binding domain and screened first for low activity in a yeast selection system. In transient co-transfection assays using ER-deficient Chinese hamster ovary cells, all three mutants exhibited less than 10% of the transcription activation activity of wild type ER, and when co-expressed with wild type ER, each of the mutants effectively suppressed the ability of wild type ER to activate transcription of an estrogen-regulated reporter plasmid. When equal amounts of plasmid encoding the ER mutants and wild type ER were used, S554fs, ER1-530, and L540Q suppressed the activity of wild type ER by 80, 55, and 75%, respectively. At a ratio of 1 part S554fs to 10 parts wild type ER, transcription was still inhibited by 40%. Western blot analysis showed that all three mutants were expressed at approximately the same level as wild type ER. Suppression of transcription was specific for ER, since the mutants did not inhibit progesterone receptor-mediated transcription. Not all mutations leading to inactive ER confer the dominant negative phenotype, as five ER mutants rendered transcriptionally inactive by point mutations between residues 516 and 524 of the ER hormone binding domain were poor inhibitors of wild type ER activity. Binding studies showed that the L540Q and S554fs dominant negative mutants bound 17beta-estradiol with wild type affinity (K(d) = 0.3-0.5 nM), whereas ER1-530 exhibited a 15-fold reduction in affinity for estradiol. The three dominant negative ERs showed significant ability to interact with the estrogen response element (ERE) in promoter interference assays, but ER1-530 and S554fs displayed little or no binding to the ERE in gel mobility shift assays where higher affinity for the DNA may be required for the receptor-ERE complex to remain associated during the electrophoresis. These data support the idea that, in all three mutants, it is loss of function of the COOH-terminal transactivation domain which leads to the dominant negative phenotype. S554fs, a powerful dominant negative mutant, is a good candidate for further studies aimed at suppressing the estrogen-dependent growth of human breast cancer cells.	UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,524 BURRILL HALL,407 S GOODWIN AVE,URBANA,IL 61801; UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801; UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NCI NIH HHS [CA18119] Funding Source: Medline; NICHD NIH HHS [HD16720] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016720] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA018119, R37CA018119] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Ausubel FM, 1991, CURRENT PROTOCOLS MO, V1; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BITTER GA, 1984, GENE, V32, P263, DOI 10.1016/0378-1119(84)90002-7; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CHANG TC, 1990, J BIOL CHEM, V265, P8176; CHANG TC, 1992, MOL ENDOCRINOL, V6, P346, DOI 10.1210/me.6.3.346; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FUQUA SAW, 1992, CANCER RES, V52, P483; GREEN S, 1991, NUCLEAR HORMONE RECE, P15; GREENE GL, 1984, BIOCHEM ACTION HORM, V11, P207; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HARLOW KW, 1989, J BIOL CHEM, V264, P17476; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; ING NH, 1992, J BIOL CHEM, V267, P17617; KATZENELLENBOGEN BS, 1987, BIOCHEMISTRY-US, V26, P2364, DOI 10.1021/bi00382a043; KATZENELLENBOGEN BS, 1991, J NATL CANCER I, V83, P1434, DOI 10.1093/jnci/83.20.1434; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MARTINEZ E, 1989, EMBO J, V8, P3781, DOI 10.1002/j.1460-2075.1989.tb08555.x; MCGUIRE WL, 1991, MOL ENDOCRINOL, V5, P1571, DOI 10.1210/mend-5-11-1571; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MUKHERJEE R, 1990, NUCLEIC ACIDS RES, V18, P5713, DOI 10.1093/nar/18.19.5713; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; PAKDEL F, 1992, J BIOL CHEM, V267, P3429; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; READ LD, 1991, GENES ONCOGENES HORM, P277; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; REESE JC, 1991, NUCLEIC ACIDS RES, V19, P6595, DOI 10.1093/nar/19.23.6595; REESE JC, 1992, J BIOL CHEM, V267, P9868; REESE JC, 1991, J BIOL CHEM, V266, P10880; ROSE M, 1984, GENE, V29, P113, DOI 10.1016/0378-1119(84)90172-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTEN RJ, 1990, ENDOCR REV, V11, P221, DOI 10.1210/edrv-11-2-221; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SELMI S, 1991, J BIOL CHEM, V266, P11589; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; WANG Y, 1991, MOL ENDOCRINOL, V11, P1707; WRENN CK, 1990, MOL ENDOCRINOL, V4, P1647, DOI 10.1210/mend-4-11-1647; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	54	114	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14026	14032						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314770				2022-12-27	WOS:A1993LJ82500039
J	SABERWAL, G; NAGARAJ, R				SABERWAL, G; NAGARAJ, R			CONFORMATIONS OF PEPTIDE-FRAGMENTS COMPRISING THE AMINO-TERMINAL, CENTRAL, AND CARBOXYL-TERMINAL REGIONS OF A MEMBRANE-ACTIVE POLYPEPTIDE - BUILDUP OF SECONDARY STRUCTURE IN PARDAXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLATFISH PARDACHIRUS-MARMORATUS; NUCLEAR MAGNETIC-RESONANCE; SOLID-PHASE SYNTHESIS; RED-SEA FLATFISH; CIRCULAR-DICHROISM; SIGNAL SEQUENCE; WILD-TYPE; HELIX; ALAMETHICIN; SECRETION	The conformations of synthetic peptides of different lengths corresponding to the amino-terminal, central, and carboxyl-terminal regions of pardaxin (GFFALIPKIISSPLFKTLLSAVGSALSSSGEQE) have been studied by circular dichroism spectroscopy. The peptides GFFALIPKIISSPLF-OMe, GFFALIPKIISSPLFK-OMe corresponding to the amino-terminal region, as well as peptides KIISSPLFKTLLSAV and IISSPLFKTLLSAV corresponding to the central region of the toxin have a marked tendency to adopt helical conformation. Ordered conformation is also discernible in the 8- and 7-residue peptides GFFALIPK-OMe and IISSPLF-OMe. Peptides corresponding to the central segments KTLLSAV, LSAVGSAL, and the carboxyl-terminal segment SSSGEQE, however, exhibit very little secondary structure. The peptide segments that adopt ordered conformation show similar conformation when present in the entire toxin as suggested by proton magnetic resonance data (Zagorski, M. G., Norman, D. G., Barrow, C. J., Iwashita, T., Tachibana, K., and Patel, D. J. (1991) Biochemistry 30, 8009-8017). The observation that peptide segments corresponding to the amino-terminal and central regions of the toxin adopt ordered conformations compared to the carboxyl-terminal segment in isolation as well as in the toxin, indicates a role for these regions in initiating and maintaining ordered conformation of pardaxin.	CTR CELLULAR & MOLEC BIOL, UPPAL RD, HYDERABAD 500007, INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)								ANDERSEN OS, 1989, METHOD ENZYMOL, V171, P62; ANDREU D, 1992, FEBS LETT, V296, P190, DOI 10.1016/0014-5793(92)80377-S; BLAGDON DE, 1975, BIOPOLYMERS, V14, P241, DOI 10.1002/bip.1975.360140118; BOMAN HG, 1989, FEBS LETT, V259, P103, DOI 10.1016/0014-5793(89)81505-4; BRUCH MD, 1990, J BIOL CHEM, V265, P3851; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; DYSON HJ, 1992, J MOL BIOL, V226, P795, DOI 10.1016/0022-2836(92)90633-U; FOX RO, 1982, NATURE, V300, P325, DOI 10.1038/300325a0; GREEN WN, 1991, ANNU REV PHYSIOL, V53, P341, DOI 10.1146/annurev.ph.53.030191.002013; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HOYT DW, 1991, BIOCHEMISTRY-US, V30, P10155, DOI 10.1021/bi00106a012; KAISER ET, 1987, ANNU REV BIOPHYS BIO, V16, P561; KELLER RCA, 1992, BIOCHEMISTRY-US, V31, P1672, DOI 10.1021/bi00121a014; LEE KH, 1987, BIOCHIM BIOPHYS ACTA, V911, P144, DOI 10.1016/0167-4838(87)90003-3; LELKES PI, 1988, FEBS LETT, V230, P131, DOI 10.1016/0014-5793(88)80656-2; LODISH HF, 1988, TRENDS BIOCHEM SCI, V13, P332, DOI 10.1016/0968-0004(88)90101-6; MANNING MC, 1988, BIOPHYS CHEM, V31, P77, DOI 10.1016/0301-4622(88)80011-5; MATTICE WL, 1975, BIOPOLYMERS, V14, P2025, DOI 10.1002/bip.1975.360141004; NAGARAJ R, 1981, ACCOUNTS CHEM RES, V14, P356, DOI 10.1021/ar00071a005; NAGARAJ R, 1979, J AM CHEM SOC, V101, P16, DOI 10.1021/ja00495a003; NAGARAJ R, 1981, BIOCHEMISTRY-US, V20, P2828, DOI 10.1021/bi00513a019; NAGARAJ R, 1981, TETRAHEDRON, V37, P1263, DOI 10.1016/S0040-4020(01)92061-7; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; PAL R, 1981, J BIOL CHEM, V256, P209; PRIMOR N, 1984, BRIT J PHARMACOL, V82, P43, DOI 10.1111/j.1476-5381.1984.tb16440.x; PRIMOR N, 1975, TOXICON, V13, P227, DOI 10.1016/0041-0101(75)90128-2; PRIMOR N, 1980, J EXP ZOOL, V211, P33, DOI 10.1002/jez.1402110105; PRIMOR N, 1981, TOXICON, V19, P573, DOI 10.1016/0041-0101(81)90018-0; PRIMOR N, 1980, BIOCHIM BIOPHYS ACTA, V626, P299, DOI 10.1016/0005-2795(80)90124-5; PRIMOR N, 1984, COMP BIOCH PHYSL, V78, P484; PRIMOR N, 1976, ANIMAL PLANT MICROBI, V1, P287; PRIMOR N, 1983, SHARK REPELLENTS SEA, P183; PRIMOR N, 1978, ANIMAL PLANT MICROBI, P287; RAMACHANDRAN GN, 1968, ADV PROTEIN CHEM, V23, P238; REDDY GL, 1986, P INDIAN AS-CHEM SCI, V97, P71; REDDY GL, 1985, TETRAHEDRON LETT, V26, P4257, DOI 10.1016/S0040-4039(00)99008-7; REDDY GL, 1989, J BIOL CHEM, V264, P16591; SABERWAL G, 1989, BIOCHIM BIOPHYS ACTA, V984, P360, DOI 10.1016/0005-2736(89)90303-9; SHAI Y, 1990, J BIOL CHEM, V265, P20202; SHAI Y, 1988, FEBS LETT, V242, P161, DOI 10.1016/0014-5793(88)81007-X; TAYLOR JW, 1987, METHOD ENZYMOL, V154, P473; THOMPSON SA, 1986, SCIENCE, V233, P341, DOI 10.1126/science.233.4761.341; TONIOLO C, 1979, MACROMOLECULES, V12, P620, DOI 10.1021/ma60070a014; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZAGORSKI MG, 1991, BIOCHEMISTRY-US, V30, P8009, DOI 10.1021/bi00246a019	47	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14081	14089						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314775				2022-12-27	WOS:A1993LJ82500046
J	WANG, XD; BRIGGS, MR; HUA, XX; YOKOYAMA, C; GOLDSTEIN, JL; BROWN, MS				WANG, XD; BRIGGS, MR; HUA, XX; YOKOYAMA, C; GOLDSTEIN, JL; BROWN, MS			NUCLEAR-PROTEIN THAT BINDS STEROL REGULATORY ELEMENT OF LOW-DENSITY-LIPOPROTEIN RECEPTOR PROMOTER .2. PURIFICATION AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; TRANSCRIPTION FACTOR; SEQUENCE; IDENTIFICATION; REPRESSION; PATHWAY; GENE	This paper describes the purification and characterization of a sterol regulatory element binding protein (SREBP) that recognizes the SRE-1 sequence in the 5' flanking region of the gene for the low density lipoprotein (LDL) receptor. The protein was purified more than 38,000-fold from nuclear extracts of human HeLa cells by ion exchange, gel filtration, and DNA-affinity chromatography. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the purified preparation revealed a cluster of bands at 59-68 kDa, each of which bound to the SRE-1 element as revealed by cross-linking experiments. Binding of SREBP correlated perfectly with transcriptional activity in a series of 16 sterol regulatory elements with point mutations. In the LDL receptor promoter, the 10-base pair SRE-1 is embedded in a 16-base pair sequence designated Repeat 2, which is adjacent to Repeat 3, a binding site for nuclear factor Sp1. Oligonucleotides containing Repeat 2 + 3 bound SREBP and Sp1 as revealed by mobility shift assays. SREBP produced a DNase I footprint over the SRE-1 sequence, which was immediately adjacent to the footprint produced by Sp1. The current data are consistent with the concept that SREBP acts in concert with Sp1 to achieve high level, sterol-suppressible transcription of the gene for the LDL receptor.			WANG, XD (corresponding author), UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA.				NHLBI NIH HHS [5F32HL07833, HL 20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, F32HL007833] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEHTA KD, 1991, J BIOL CHEM, V266, P10415; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; SMITH JR, 1990, J BIOL CHEM, V265, P2306; SMITH JR, 1988, J BIOL CHEM, V263, P18480; STARK HC, 1992, P NATL ACAD SCI USA, V89, P2180, DOI 10.1073/pnas.89.6.2180; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773	19	264	271	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14497	14504						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314806				2022-12-27	WOS:A1993LJ82500101
J	AKITA, Y; OHNO, S; YAJIMA, Y; KONNO, Y; SAIDO, TC; MIZUNO, K; CHIDA, K; OSADA, S; KUROKI, T; KAWASHIMA, S; SUZUKI, K				AKITA, Y; OHNO, S; YAJIMA, Y; KONNO, Y; SAIDO, TC; MIZUNO, K; CHIDA, K; OSADA, S; KUROKI, T; KAWASHIMA, S; SUZUKI, K			OVERPRODUCTION OF A CA2+-INDEPENDENT PROTEIN-KINASE-C ISOZYME, NPKC-EPSILON, INCREASES THE SECRETION OF PROLACTIN FROM THYROTROPIN-RELEASING HORMONE-STIMULATED RAT PITUITARY GH(4)C(1) CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GH4C1 CELLS; GH3 CELLS; DIFFERENTIAL REGULATION; DOWN-REGULATION; RECEPTOR; TRH; BINDING; FAMILY; EXPRESSION; BRAIN	Rat pituitary GH(4)C(1) cells express protein kinase C (PKC) transcripts for cPKC alpha, cPKC beta II, nPKC delta, nPKC epsilon, nPKC eta, and aPKC xi, but not for cPKC gamma or nPKC theta. Of the transcripts produced, the nPKC epsilon isoform is the most abundant. Transfection of GH(4)C(1) cells with an expression plasmid containing nPKC epsilon cDNA leads to the transient overexpression of cellular nPKC epsilon and confers enhanced phorbol ester binding activity. Transient expression of an inactive point mutant (nPKC epsilon(K-->R)) Of nPKC epsilon, where Lys(436) at the putative ATP-binding site is replaced with Arg, also confers elevated binding activity. However, only overproduction of the wild type in transfected cells increases the basal levels and stimulates the secretion of prolactin (PRL) by 12-O-tetradecanoylphorbol-13-acetate or thyrotropin-releasing hormone (TRH). In stable clones overexpressing nPKC epsilon, immunocytofluorescence and immunoblot experiments indicated that TRH causes the rapid translocation and down-regulation of an appreciable fraction of nPKC epsilon. Both the basal and TRH-stimulated levels of PRL secretion are clearly correlated with the expression level of nPKC epsilon but not with the TRH receptor densities in these clones. The dose dependence of TRH-stimulated secretion were similar in all cells overexpressing cPKC alpha, cPKC beta II, nPKC epsilon, and nPKC delta, but the enhancement of PRL secretion was specific for the overproduction of nPKC epsilon; no effect was found when other isozymes were overproduced. These findings clearly demonstrate that the expression level of nPKC epsilon in GH(4)C(1) cells is rate-limiting for basal and TRH-stimulated PRL secretion, and they provide the first direct evidence that nPKC epsilon plays a key role in hormonal secretory processes.	YOKOHAMA CITY UNIV,SCH MED,DEPT MOLEC BIOL,KANAZAWA KU,YOKOHAMA 236,JAPAN; UNIV TOKYO,INST MED SCI,DEPT CANC CELL RES,MINATO KU,TOKYO 108,JAPAN; UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN	Yokohama City University; University of Tokyo; University of Tokyo	AKITA, Y (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC BIOL,BUNKYO KU,3-18-22 HONKOMAGOME,TOKYO 113,JAPAN.		Saido, Takaomi C/N-5472-2015; Kuroki, Toshio/A-9500-2011; Sado, Takaomi/AAN-2759-2021; Ohno, Shigeo/B-1768-2010	Saido, Takaomi C/0000-0003-1970-6903; Kuroki, Toshio/0000-0001-6369-4351; Sado, Takaomi/0000-0003-1970-6903; Ohno, Shigeo/0000-0002-1294-5269; Osada, Shin-Ichi/0000-0001-5387-085X				AKITA Y, 1990, BIOCHEM BIOPH RES CO, V172, P184, DOI 10.1016/S0006-291X(05)80191-3; AKITA Y, 1990, J BIOL CHEM, V265, P354; ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P7589, DOI 10.1021/bi00420a003; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CASTILLO ARD, 1992, J CELL BIOL, V119, P797; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; FUJIMOTO J, 1991, MOL ENDOCRINOL, V5, P1527, DOI 10.1210/mend-5-10-1527; GERSHENGORN MC, 1986, ANNU REV PHYSIOL, V48, P515; GUADAGNO SN, 1992, J BIOL CHEM, V267, P2697; HA KS, 1993, J BIOL CHEM, V268, P10534; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KILEY SC, 1992, MOL ENDOCRINOL, V6, P120, DOI 10.1210/me.6.1.120; KONNO Y, 1989, J BIOCHEM-TOKYO, V106, P673, DOI 10.1093/oxfordjournals.jbchem.a122915; LEIBERSPERGER H, 1991, J BIOL CHEM, V266, P1477; LOPEZBARNEO J, 1990, P NATL ACAD SCI USA, V87, P8150, DOI 10.1073/pnas.87.20.8150; MARTIN TFJ, 1990, J BIOL CHEM, V265, P7623; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MIZUNO K, 1993, FEBS LETT, V330, P114, DOI 10.1016/0014-5793(93)80254-R; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBEID LM, 1990, J BIOL CHEM, V265, P2370; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1990, J BIOL CHEM, V265, P6296; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; OSADA S, 1990, J BIOL CHEM, V265, P22434; OZAWA K, 1993, J BIOL CHEM, V268, P2280; PACHTER JA, 1992, J BIOL CHEM, V267, P9826; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; RAMSDELL JS, 1986, J BIOL CHEM, V261, P5301; RAMSDELL JS, 1986, J BIOL CHEM, V261, P7073; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SUZUKI K, 1993, RECENT ADV MOL BIOCH; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TRILIVAS I, 1989, J BIOL CHEM, V264, P3102; VANDEMOORTELE S, 1991, J CELL SCI, V99, P79; YAJIMA Y, 1982, IN VITRO CELL DEV B, V18, P1009, DOI 10.1007/BF02796376; YAJIMA Y, 1990, BIOCHEM BIOPH RES CO, V173, P571, DOI 10.1016/S0006-291X(05)80073-7; YAJIMA Y, 1988, MOL PHARMACOL, V33, P592	44	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4653	4660						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308036				2022-12-27	WOS:A1994MW98900111
J	MURAGAKI, Y; ABE, N; NINOMIYA, Y; OLSEN, BR; OOSHIMA, A				MURAGAKI, Y; ABE, N; NINOMIYA, Y; OLSEN, BR; OOSHIMA, A			THE HUMAN ALPHA-1(XV) COLLAGEN CHAIN CONTAINS A LARGE AMINO-TERMINAL NON-TRIPLE HELICAL DOMAIN WITH A TANDEM REPEAT STRUCTURE AND HOMOLOGY TO ALPHA-1(XVIII) COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IX COLLAGEN; CARTILAGE; REGION; XII	We have cloned and characterized cDNAs encoding the alpha 1 chain of type XV collagen from a human placenta library. Using primer extension cloning we extended the cDNAs to the 5' end of the mRNA and determined the complete deduced primary structure of the human alpha 1(XV) chain. The polypeptide chain contains nine triple helical domains separated by eight non-triple helical regions and flanked by large amino terminal (555 amino acid residues) and carboxyl-terminal (256 amino acid residues) non-triple helical domains. Comparison of amino acid sequences of the human alpha 1(XV) chain with those of mouse alpha 1(XVIII) collagen showed remarkable similarity within both amino- and carboxyl-terminal non-triple helical domains. Within the carboxyl third of the amino-terminal domain a tandem repeat structure is found with an about 45-amino acid residue sequence repeated four times. This amino acid sequence has a strikingly high similarity to rat cartilage proteoglycan core protein. Northern blot analysis of human embryonic RNA revealed that alpha 1(XV) mRNA is expressed predominantly in internal organs such as the adrenal gland, kidney, and pancreas.	OKAYAMA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,OKAYAMA 700,JAPAN; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Okayama University; Harvard University; Harvard Medical School	MURAGAKI, Y (corresponding author), WAKAYAMA MED COLL,DEPT PATHOL,9-BANCHO,WAKAYAMA 640,JAPAN.				NEI NIH HHS [EY07334] Funding Source: Medline; NHLBI NIH HHS [HL33014] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007334] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033014] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE N, 1994, IN PRESS BIOCH BIOPH; ADAMS SL, 1979, J BIOL CHEM, V254, P4935; BOUDON MA, 1990, EXTRACELLULAR MATRIX, P157; BROWN JC, 1993, J CELL BIOL, V120, P557, DOI 10.1083/jcb.120.2.557; BRUCKNER P, 1985, P NATL ACAD SCI USA, V82, P2608, DOI 10.1073/pnas.82.9.2608; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOEGE K, 1987, J BIOL CHEM, V262, P17757; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P343; JACENKO O, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P327; LI KH, 1993, J BIOL CHEM, V268, P8825; MARCHANT JK, 1991, P NATL ACAD SCI USA, V88, P1560, DOI 10.1073/pnas.88.4.1560; MYERS JC, 1992, P NATL ACAD SCI USA, V89, P10144, DOI 10.1073/pnas.89.21.10144; OH SP, 1994, IN PRESS P NATL ACAD; PAN TC, 1992, P NATL ACAD SCI USA, V89, P6565, DOI 10.1073/pnas.89.14.6565; PATERSON TE, 1983, P NATL ACAD SCI USA, V80, P137; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WALCHLI C, 1993, EUR J BIOCHEM, V212, P483, DOI 10.1111/j.1432-1033.1993.tb17685.x; WATT SL, 1992, J BIOL CHEM, V267, P20093; YAMAGATA M, 1991, J CELL BIOL, V115, P209, DOI 10.1083/jcb.115.1.209; YOSHIOKA H, 1992, GENOMICS, V13, P884, DOI 10.1016/0888-7543(92)90176-S	23	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4042	4046						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307960				2022-12-27	WOS:A1994MW98900024
J	SCHWEIZER, A; CLAUSEN, H; VAN MEER, G; HAURI, HP				SCHWEIZER, A; CLAUSEN, H; VAN MEER, G; HAURI, HP			LOCALIZATION OF O-GLYCAN INITIATION, SPHINGOMYELIN SYNTHESIS, AND GLUCOSYLCERAMIDE SYNTHESIS IN VERO CELLS WITH RESPECT TO THE ENDOPLASMIC RETICULUM-GOLGI INTERMEDIATE COMPARTMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE SUBMAXILLARY-GLANDS; UDPGLUCOSE-CERAMIDE GLUCOSYLTRANSFERASE; TERMINAL N-ACETYLGALACTOSAMINE; TN-ANTIGEN; SUBCELLULAR-LOCALIZATION; INTRACELLULAR-TRANSPORT; MONOCLONAL-ANTIBODY; RECYCLING PATHWAY; PLASMA-MEMBRANE; BREFELDIN-A	The identification of an endoplasmic reticulum-Golgi intermediate compartment (ERGIC), defined by the 53-kDa transmembrane marker protein ERGIC-53, has added to the complexity of the exocytic pathway of higher eukaryotic cells. Recently, a subcellular fractionation procedure was established for the isolation of the ERGIC from Vero cells (Schweizer, A., Matter, K., Ketcham, C. M., and Hauri, H.-P. (1991) J. Cell Biol, 113, 45-54) which provides a means to study more precisely the compartmentalization of the various enzymic functions along the early secretory pathway. Here, we have investigated if O-glycan initiation and sphingomyelin synthesis are associated with the ERGIC by analyzing both the responsible enzyme activities and their corresponding products. Moreover, the synthesis of glucosylceramide, the precursor of most glycosphingolipids, was also analyzed. In the purified ERGIC fraction UDP. GalNAc:polypeptide N-acetylgalactosaminyltransferase (GalNAc transferase) was only minimally enriched, sphingomyelin synthase was not enriched, and UDP-glucose:ceramide glucosyl transferase specific activity was lower than in the homogenate. On Percoll gradients all three enzymes cofractionated with Golgi markers rather than ERGIC-53. Accordingly, sphingomyelin concentrations were extremely low in the ERGIC fraction. Double immunofluorescence localization of core N-acetylgalactosamine, the product of GalNAc transferase, by monoclonal antibodies against GalNAc-Ser/Thr (Tn antigen) revealed only little apparent overlap with ERGIC-53. This was particularly evident in brefeldin A-treated cells which showed entirely different patterns of Tn antigens and ERGIC-53. The results suggest that in the secretory pathway of Vero cells O-glycan initiation and sphingomyelin as well as glucosylceramide synthesis mainly occur beyond the ERGIC in the Golgi apparatus.	UNIV BASEL, BIOZENTRUM, DEPT PHARMACOL, CH-4056 BASEL, SWITZERLAND; FAC HLTH SCI COPENHAGEN, SCH DENT, DK-2200 COPENHAGEN, DENMARK; UNIV UTRECHT, SCH MED, DEPT CELL BIOL, 3584 CX UTRECHT, NETHERLANDS	University of Basel; Utrecht University			van Meer, Gerrit/AAH-1560-2021; clausen, henrik/AAD-8016-2021	van Meer, Gerrit/0000-0002-5976-6436				Balch WE, 1990, CURR OPIN CELL BIOL, V2, P634, DOI 10.1016/0955-0674(90)90104-M; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BERNERT JT, 1981, BIOCHIM BIOPHYS ACTA, V666, P99, DOI 10.1016/0005-2760(81)90095-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; COLLINS RN, 1992, J BIOL CHEM, V267, P24906; COSTE H, 1985, BIOCHIM BIOPHYS ACTA, V814, P1, DOI 10.1016/0005-2736(85)90412-2; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; DAHR W, 1974, VOX SANG, V27, P29, DOI 10.1111/j.1423-0410.1974.tb02386.x; DESCHUYTENEER M, 1988, J BIOL CHEM, V263, P2452; DURIEUX I, 1990, BIOCHIM BIOPHYS ACTA, V1024, P263, DOI 10.1016/0005-2736(90)90352-O; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; ELLINGER A, 1992, J HISTOCHEM CYTOCHEM, V40, P919, DOI 10.1177/40.7.1607641; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; HIROHASHI S, 1985, P NATL ACAD SCI USA, V82, P7039, DOI 10.1073/pnas.82.20.7039; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; HOMA FL, 1993, J BIOL CHEM, V268, P12609; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; KALLEN KJ, 1993, BIOCHEM J, V289, P307, DOI 10.1042/bj2890307; KJELDSEN T, 1988, CANCER RES, V48, P2214; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KOVAL M, 1991, BIOCHIM BIOPHYS ACTA, V1082, P113, DOI 10.1016/0005-2760(91)90184-J; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LOTTI LV, 1992, J CELL BIOL, V118, P43, DOI 10.1083/jcb.118.1.43; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MARGGRAF WD, 1984, BIOCHIM BIOPHYS ACTA, V793, P346, DOI 10.1016/0005-2760(84)90248-0; MARGGRAF WD, 1981, BIOCHIM BIOPHYS ACTA, V664, P61, DOI 10.1016/0005-2760(81)90028-X; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MOREAU P, 1993, BIOCHIM BIOPHYS ACTA, V1146, P9, DOI 10.1016/0005-2736(93)90332-T; OCONNELL BC, 1992, J BIOL CHEM, V267, P25010; PASCALE MC, 1992, J BIOL CHEM, V267, P25196; PATHAK RK, 1988, J CELL BIOL, V106, P1831, DOI 10.1083/jcb.106.6.1831; PEREZVILAR J, 1991, J BIOL CHEM, V266, P23967; PILLER V, 1990, J BIOL CHEM, V265, P9264; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTH J, 1984, J CELL BIOL, V98, P399, DOI 10.1083/jcb.98.2.399; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; SCHWEIZER A, 1993, J CELL SCI, V104, P671; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SODEIK B, 1993, J CELL BIOL, V121, P521, DOI 10.1083/jcb.121.3.521; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; STIEGER B, 1988, J CELL BIOL, V106, P1853, DOI 10.1083/jcb.106.6.1853; TAKAHASHI HK, 1988, CANCER RES, V48, P4361; THURNHER M, 1993, IN PRESS IMMUNOL LET; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; TRINCHERA M, 1991, J BIOL CHEM, V266, P20907; VAN MEER G, 1993, J CELL SCI, V104, P833; Van Meer Gerrit, 1992, Trends in Cell Biology, V2, P332; van Meer G, 1993, CURR OPIN CELL BIOL, V5, P661, DOI 10.1016/0955-0674(93)90137-F; VANHELVOORT A, 1994, IN PRESS J BIOL CHEM; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; WANG YC, 1992, J BIOL CHEM, V267, P2728; ZAMBRANO F, 1975, BIOCHIM BIOPHYS ACTA, V380, P357, DOI 10.1016/0005-2760(75)90104-6	61	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4035	4041						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307959				2022-12-27	WOS:A1994MW98900023
J	BRANDT, ME; VICKERY, LE				BRANDT, ME; VICKERY, LE			CHARGE PAIR INTERACTIONS STABILIZING FERREDOXIN-FERREDOXIN REDUCTASE COMPLEXES - IDENTIFICATION BY COMPLEMENTARY SITE-SPECIFIC MUTATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; AMINO-ACID SEQUENCE; ADRENODOXIN REDUCTASE; MOLECULAR-CLONING; EXPRESSION; PEPTIDE; PROTEINS; BINDING; TISSUES	Ferredoxin reductase (Fd-reductase) supplies electrons to mitochondrial steroid hydroxylase cytochrome P450 enzymes via a [2Fe-2S] ferredoxin. Chemical labeling studies with bovine Fd-reductase have implicated Lys-243 as important in binding to bovine ferredoxin (Hamamoto, I., Kazutaka, K., Tanaka, S., and Ichikawa, Y. (1988) Biochim. Biophys. Acta 953, 207-213). We have used site-directed mutagenesis to examine the role of charged residues in this region of human Fd-reductase in ferredoxin binding. Mutant proteins were expressed in Escherichia coli and were assayed for activity by ferredoxin-mediated electron transfer to cytochrome c. Replacement of Lys-242 (homologous to Lys-243 in bovine Fd-reductase) with Gln and replacement of Arg-241 with Ser had little effect (2.7- and 3.6-fold increased K(m), respectively). In contrast, mutants at positions 239 and 243 (R239S and R243Q) exhibited markedly lower affinity for ferredoxin (17.5- and 1,600-fold increased K(m), respectively). Studies were also carried out with two ferredoxin charge mutants shown previously to have lowered affinity for Fd-reductase (Coghlan, V. M., and Vickery, L. E. (1991) J. Biol. Chem. 266, 18606-18612). Comparisons of the binding of ferredoxin mutants D76N and D79N to Fd-reductase mutants R239S and R243Q suggest that Arg-239 and Arg-243 of Fd-reductase each interact directly with both Asp-76 and Asp-79 of ferredoxin during formation of the complex between the two proteins. These results support the hypothesis that specific electrostatic interactions involving this region are important in stabilizing the ferredoxin-Fd-reductase complex.	UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717	University of California System; University of California Irvine					NIDDK NIH HHS [DK30109] Funding Source: Medline; NIGMS NIH HHS [GM13942] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013942] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON DE, 1990, BIOCHEMISTRY-US, V29, P2403, DOI 10.1021/bi00461a025; BRANDT ME, 1992, ARCH BIOCHEM BIOPHYS, V29, P735; CHU JW, 1973, J BIOL CHEM, V248, P2089; COGHLAN VM, 1991, J BIOL CHEM, V266, P18606; COGHLAN VM, 1989, P NATL ACAD SCI USA, V86, P835, DOI 10.1073/pnas.86.3.835; COGHLAN VM, 1992, J BIOL CHEM, V267, P8932; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P301, DOI 10.1016/0968-0004(87)90146-0; GEREN LM, 1984, J BIOL CHEM, V259, P2155; HAMAMOTO I, 1988, BIOCHIM BIOPHYS ACTA, V953, P207, DOI 10.1016/0167-4838(88)90026-X; HARA T, 1991, J BIOCHEM-TOKYO, V110, P261, DOI 10.1093/oxfordjournals.jbchem.a123568; JANIN J, 1978, J MOL BIOL, V125, P357, DOI 10.1016/0022-2836(78)90408-4; KAGIMOTO K, 1988, BIOCHEM BIOPH RES CO, V155, P379, DOI 10.1016/S0006-291X(88)81096-9; LAMBETH JD, 1979, J BIOL CHEM, V254, P7255; MATSUO Y, 1992, FEBS LETT, V301, P132, DOI 10.1016/0014-5793(92)81232-B; MELLON SH, 1991, DNA CELL BIOL, V10, P339, DOI 10.1089/dna.1991.10.339; MITTAL S, 1988, ARCH BIOCHEM BIOPHYS, V264, P383, DOI 10.1016/0003-9861(88)90303-7; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; OKAMURA T, 1985, P NATL ACAD SCI USA, V82, P5705, DOI 10.1073/pnas.82.17.5705; OMDAHL JL, 1992, ARCH BIOCHEM BIOPHYS, V293, P213, DOI 10.1016/0003-9861(92)90387-C; SAGARA Y, 1989, J BIOCHEM-TOKYO, V105, P1333; Sambrook J, 1989, MOL CLONING LABORATO; SOLISH SB, 1988, P NATL ACAD SCI USA, V85, P7104, DOI 10.1073/pnas.85.19.7104	23	42	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17126	17130						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349601				2022-12-27	WOS:A1993LQ98800039
J	NOVOKHATNY, VV; MEDVED, LV; MAZAR, A; INGHAM, KC				NOVOKHATNY, VV; MEDVED, LV; MAZAR, A; INGHAM, KC			EFFECT OF TETHERED PEPTIDYLCHLOROMETHYLKETONE INHIBITORS ON THERMAL-STABILITY AND DOMAIN INTERACTIONS OF UROKINASE AND OTHER SERINE PROTEASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL STABILITY; PLASMINOGEN-ACTIVATOR; PROTEIN-STRUCTURE; THROMBIN; PURIFICATION; ANTITHROMBIN; AFFINITY; SERPINS	The melting of several serine proteases that had been reacted with different peptidylchloromethylketone (cmk) inhibitors was studied by fluorescence spectroscopy and calorimetry. These inhibitors, which cross-link the two domains of the proteases, invariably increased the melting temperature by as much as 28.5-degrees-C. The magnitude of the effect was dependent on the size and composition of the peptide moieties. The DELTAG of unfolding of tosyl-Phe-cmk-chymotrypsin was 13.5 kcal/mol compared to only 8.3 kcal/mol for chymotrypsin. Binding of cmk inhibitors also protected the two interacting domains of urokinase from acid-induced decooperation and caused them to merge into a highly cooperative structure upon refolding at low pH. Fluorescence-detected melting curves of Glu-Gly-Arg-cmk-urokinase indicated that unfolding/refolding at pH 4.5 is characterized by dramatic hysteresis; the cooling curves fell close to those obtained upon heating or cooling of the uninhibited enzyme. Upon second heating, the melting curves were similar to those of the original. The hysteresis effects are interpreted as follows. The tethered tripeptide binds to the active site, causing the protein to melt at much higher temperature in a single cooperative step, as if the two domains are merged into one cooperative unit. Upon cooling, the unfolded protein, with the inhibitor still attached, refolds at the same temperature as the underivatized protein. Only after the native structure is formed does the peptide moiety again bind and stabilize toward a second heating. At lower pH, second heating produced biphasic or triphasic melting curves that were attributed to differential protonation of acid-titratable groups on the enzyme and/or inhibitor at the time of refolding. Similar effects were observed with other trypsin-like proteases, indicating that the hysteresis and bi- and triphasic refolding at low pH are rather general for this class of enzyme.	AMER RED CROSS,HOLLAND LAB,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855; ABBOTT LABS,ABBOTT PK,IL 60064	American Red Cross; Abbott Laboratories				Medved, Leonid/0000-0002-3665-9849	NHLBI NIH HHS [HL21791] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021791] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AN-ZHI W, 1988, Febs Letters, V234, P367, DOI 10.1016/0014-5793(88)80118-2; ATHA DH, 1984, BIOCHIM BIOPHYS ACTA, V785, P1, DOI 10.1016/0167-4838(84)90226-7; BAJAJ SP, 1973, J BIOL CHEM, V248, P7729; BJORK I, 1992, J BIOL CHEM, V267, P1976; BODE W, 1992, PROTEIN SCI, V1, P426; BRUCH M, 1988, J BIOL CHEM, V263, P16626; CREIGHTON TE, 1992, NATURE, V356, P194, DOI 10.1038/356194a0; HOLMBERG L, 1976, BIOCHIM BIOPHYS ACTA, V445, P215, DOI 10.1016/0005-2744(76)90174-1; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; LENNICK M, 1985, BIOCHEMISTRY-US, V24, P2561, DOI 10.1021/bi00331a025; MEYER E, 1988, ACTA CRYSTALLOGR B, V44, P26, DOI 10.1107/S0108768187007559; NOVOKHATNY V, 1992, J BIOL CHEM, V267, P3878; NOVOKHATNY VV, 1984, J MOL BIOL, V179, P215, DOI 10.1016/0022-2836(84)90466-2; NOVOKHATNY VV, 1991, J BIOL CHEM, V266, P12994; PACE CN, 1988, J BIOL CHEM, V263, P11820; POULOS TL, 1976, J BIOL CHEM, V251, P1097; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; PRIVALOV PL, 1974, J MOL BIOL, V86, P665, DOI 10.1016/0022-2836(74)90188-0; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SHAW E, 1967, METHOD ENZYMOL, V11, P677; Shotton D. M., 1970, METHOD ENZYMOL, V19, P113, DOI 10.1016/0076-6879(70)19009-4; STROUD RM, 1977, ANNU REV BIOPHYS BIO, V6, P177, DOI 10.1146/annurev.bb.06.060177.001141; VYSOTCHIN A, 1993, J BIOL CHEM, V268, P8436	24	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17211	17218						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349606				2022-12-27	WOS:A1993LQ98800052
J	NEERMANARBEZ, M; HALBAN, PA				NEERMANARBEZ, M; HALBAN, PA			NOVEL, NON-CRINOPHAGIC, DEGRADATION OF CONNECTING PEPTIDE IN TRANSFORMED PANCREATIC BETA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RELATED PEPTIDES; C-PEPTIDE; INTRACELLULAR DEGRADATION; SECRETORY GRANULES; B-CELL; PROINSULIN; PATHWAY; ISLETS; BIOSYNTHESIS; AGGREGATION	Proinsulin is converted to equimolar amounts of insulin and connecting peptide (C-peptide) in pancreatic beta cell secretory granules. The fate of C-peptide, which remains soluble in granules while insulin is crystallized, was studied in a rat insulinoma cell line (INS cells). A pulse-chase approach demonstrated that insulin to C-peptide ratios (I/CP) began to rise in INS cells as soon as conversion took place, reaching 2.2:1 at 6 h of chase, and 5.3:1 by 24 h. During the first 4 h of chase, this ratio was inverted in the medium under basal conditions, possibly reflecting preferential secretion of C-peptide via the post granular constitutive-like pathway. However, the amount of C-peptide secreted to the medium (1.4%/h) was trivial compared with the net loss of C-peptide from the INS cells, estimated to be approximately 33% during the 1st h. As no extracellular degradation of insulin or C-peptide was observed, the data show progressive, extensive intracellular degradation of C-peptide. Stimulation of INS granule exocytosis revealed that the I/CP ratio in secretory granules is representative of that of cell extracts, indicating that C-peptide, but not insulin, is lost from functionally competent granules with time. This particular degradative route for C-peptide is thus distinct from crinophagy (fusion of granules and lysosomes) and was found to be much more active in INS cells than in primary islet beta cells.			NEERMANARBEZ, M (corresponding author), UNIV GENEVA,MED CTR,LAB RECH LOUIS JEANTET,1 RUE MICHEL SERVET,CH-1211 GENEVA 4,SWITZERLAND.			Neerman-Arbez, Marguerite/0000-0002-9351-4195	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035292] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-35292] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARVAN P, 1991, J BIOL CHEM, V266, P14171; Arvan Peter, 1992, Trends in Cell Biology, V2, P327; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; GAZDAR AF, 1980, P NATL ACAD SCI-BIOL, V77, P3519, DOI 10.1073/pnas.77.6.3519; GRIMES M, 1992, J CELL BIOL, V117, P539, DOI 10.1083/jcb.117.3.539; HALBAN PA, 1991, DIABETOLOGIA, V34, P767, DOI 10.1007/BF00408349; HALBAN PA, 1983, DIABETES, V32, P254, DOI 10.2337/diabetes.32.3.254; HALBAN PA, 1987, DIABETOLOGIA, V30, P348, DOI 10.1007/BF00299029; HALBAN PA, 1986, DIABETOLOGIA, V29, P893, DOI 10.1007/BF00870146; HALBAN PA, 1980, J BIOL CHEM, V255, P6003; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; MICHAEL J, 1987, J BIOL CHEM, V262, P16531; NAGAMATSU S, 1992, ENDOCRINOLOGY, V130, P748, DOI 10.1210/en.130.2.748; ORCI L, 1985, CELL, V42, P671, DOI 10.1016/0092-8674(85)90124-2; ORCI L, 1984, J CELL BIOL, V98, P222, DOI 10.1083/jcb.98.1.222; ORCI L, 1982, DIABETES, V31, P538, DOI 10.2337/diab.31.6.538; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PRAZ GA, 1983, BIOCHEM J, V210, P345, DOI 10.1042/bj2100345; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; RHODES CJ, 1988, BIOCHEM J, V251, P23, DOI 10.1042/bj2510023; ROUILLER DG, 1990, EXP CELL RES, V191, P305, DOI 10.1016/0014-4827(90)90019-7; STEINER DF, 1989, ENDOCRINOLOGY, P1263; SWENNE I, 1992, DIABETOLOGIA, V35, P193, DOI 10.1007/BF00400917; TAGER HS, 1972, J BIOL CHEM, V247, P7936; TURNER RC, 1977, DIABETOLOGIA, V13, P571, DOI 10.1007/BF01236309; ZASTROW MV, 1987, J CELL BIOL, V105, P2675	32	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16248	16252						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344910				2022-12-27	WOS:A1993LQ33600026
J	LEE, FJS; MOSS, J				LEE, FJS; MOSS, J			AN RNA-BINDING PROTEIN GENE (RBP1) OF SACCHAROMYCES-CEREVISIAE ENCODES A PUTATIVE GLUCOSE-REPRESSIBLE PROTEIN CONTAINING 2 RNA RECOGNITION MOTIFS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; NUCLEOTIDE-SEQUENCE; CONSENSUS SEQUENCE; PARTICLE CONTAINS; SNRNP PROTEIN; SEX-LETHAL; DROSOPHILA; YEAST; EXPRESSION; DOMAIN	A gene, termed RNA-binding protein (RBP1), was cloned from Saccharomyces cerevisiae. RBP1 contains an open reading frame of 2016 nucleotides that encodes a 672-amino acid protein with a calculated M(r) of approximately 75,000. Southern blots of genomic DNA from wild-type and RBP1-disrupted strains were consistent with the presence of homologous genes. RNA blots revealed a major 2.7-kb RNA band and two minor bands of 1.5 and 1.1 kb. The sequence of the putative RBP1 protein contains two copies of an RNA recognition motif, two glutamine stretches, an asparagine-rich region, a methionine-rich region, and two long potential alpha-helixes. In addition, recombinant RBP1 fusion protein can bind to RNA and single-stranded DNA but not double-stranded DNA. RBP1 is a glucose-repressible gene. Disruption of RBP1 increased cell growth rate in the early log phase. Overexpression of RBP1 or reduction in its translation by expression of antisense RNA decreased or increased the cell growth rate, respectively. From these observations, we infer that RBP1 may be involved in growth regulation, possibly through its participation in RNA metabolism.			LEE, FJS (corresponding author), NHLBI, CELLULAR METAB LAB, ROOM 5N-307, BLDG 10, BETHESDA, MD 20892 USA.			LEE, FANG-JEN/0000-0002-2167-2426				ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BOURBON HM, 1988, J MOL BIOL, V200, P627, DOI 10.1016/0022-2836(88)90476-7; BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; BRENNAN CA, 1991, J BIOL CHEM, V266, P17296; BRUHN L, 1992, MOL CELL BIOL, V12, P3563, DOI 10.1128/MCB.12.8.3563; CHEREST H, 1990, NUCLEIC ACIDS RES, V18, P659, DOI 10.1093/nar/18.3.659; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CREUSOT F, 1988, J MOL BIOL, V204, P263, DOI 10.1016/0022-2836(88)90574-8; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; HAUN RS, 1992, GENE, V112, P37, DOI 10.1016/0378-1119(92)90300-E; HUDSPETH MES, 1982, CELL, V30, P617, DOI 10.1016/0092-8674(82)90258-6; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONG AYS, 1987, MOL CELL BIOL, V7, P2947, DOI 10.1128/MCB.7.8.2947; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KUMA K, 1990, FEBS LETT, V260, P67, DOI 10.1016/0014-5793(90)80067-S; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE FJS, 1989, J BACTERIOL, V171, P5795, DOI 10.1128/jb.171.11.5795-5802.1989; LEE FJS, 1992, BIOTECHNIQUES, V12, P677; LEE FJS, 1992, BIOTECHNIQUES, V13, P844; LEE WC, 1992, MOL CELL BIOL, V12, P3865, DOI 10.1128/MCB.12.9.3865; Maniatis T., 1982, MOL CLONING; MATTOX W, 1992, J BIOL CHEM, V267, P19023; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MISHIMA K, 1993, J BIOL CHEM, V268, P8801; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; PINKHAM JL, 1987, MOL CELL BIOL, V7, P578, DOI 10.1128/MCB.7.2.578; PIRROTTA V, 1987, EMBO J, V6, P791, DOI 10.1002/j.1460-2075.1987.tb04821.x; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SACHS AB, 1986, CELL, V45, P527; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAPP M, 1986, NUCLEIC ACIDS RES, V14, P6803, DOI 10.1093/nar/14.17.6803; SHANNON KW, 1991, GENE DEV, V5, P773, DOI 10.1101/gad.5.5.773; SHERMAN F, 1986, METHODS YEAST GENETI, P79; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUZUKI Y, 1988, MOL CELL BIOL, V8, P4991, DOI 10.1128/MCB.8.11.4991; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WAHLGREN M, 1986, P NATL ACAD SCI USA, V83, P2677, DOI 10.1073/pnas.83.8.2677; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	60	27	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15080	15087						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325883				2022-12-27	WOS:A1993LL75900079
J	ADACHI, Y; COPELAND, TD; HATANAKA, M; OROSZLAN, S				ADACHI, Y; COPELAND, TD; HATANAKA, M; OROSZLAN, S			NUCLEOLAR TARGETING SIGNAL OF REX PROTEIN OF HUMAN T-CELL LEUKEMIA-VIRUS TYPE-I SPECIFICALLY BINDS TO NUCLEOLAR SHUTTLE PROTEIN-B-23	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MESSENGER-RNA; HTLV-I; TRANS-ACTIVATION; GENE-EXPRESSION; SEQUENCES; IDENTIFICATION; P40X; PHOSPHORYLATION; LOCALIZATION	Rex protein, the post-transcriptional regulator of human T-cell leukemia virus type I, is located predominantly in the cell nucleolus and is associated with the cytoplasmic accumulation of unspliced and singly spliced viral mRNAs. The N-terminal 19-amino acid segment of Rex has been identified as the nucleolar targeting signal (NOS) and shown to be important for Rex function. To study the molecular interaction between the NOS region of Rex and its binding host protein(s) in the nucleolus, we chemically synthesized a functional NOS peptide (wild type) and mutant NOS peptides. Fluorescein isothiocyanate-conjugated functional NOS peptide was rapidly taken up by human cells and was transported to the nucleolus. Using affinity chromatography, we identified nucleolar protein B-23 as the major protein that binds to NOS. We also identified two highly acidic regions of B-23 (amino acids 120-132 and 161-188) as acceptor regions for NOS. Previous experiments have suggested that B-23 functions as a shuttle protein for the nucleolar transport of ribosomal components. Our results suggest that B-23 may also serve as a shuttle for the import of Rex from the cytoplasm to the nucleolus coupled to the export of viral mRNAs containing the Rex-responsive element.	NCI,FREDERICK CANC RES & DEV CTR,MOLEC VIROL & CARCINOGENESIS LAB,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,PROT STRUCT GRP,FREDERICK,MD 21702; KYOTO UNIV,INST VIRUS RES,SAKYO KU,KYOTO 606,JAPAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Kyoto University					OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI Y, 1990, J CHROMATOGR-BIOMED, V530, P39, DOI 10.1016/S0378-4347(00)82300-2; ADACHI Y, 1992, J BIOL CHEM, V267, P21977; ADACHI Y, 1990, BIOCHEM BIOPH RES CO, V169, P469, DOI 10.1016/0006-291X(90)90355-Q; ADACHI Y, 1992, J BIOL CHEM, V267, P19373; ADACHI Y, 1991, J BIOL CHEM, V266, P3968; ADACHI Y, 1990, BIOL MED SIGNAL TRAN, P478; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOURGEOIS CA, 1988, INT REV CYTOL, V111, P1, DOI 10.1016/S0074-7696(08)61730-1; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CHAN PK, 1986, J BIOL CHEM, V261, P1868; CHANG JH, 1988, J BIOL CHEM, V263, P12824; CULLEN BR, 1988, J VIROL, V62, P2498, DOI 10.1128/JVI.62.7.2498-2501.1988; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FELBER BK, 1988, SCIENCE, V239, P184, DOI 10.1126/science.3422113; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GESSAIN A, 1985, LANCET, V2, P407; GEY GO, 1952, CANCER RES, V12, P264; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; GREEN M, 1989, CELL, V58, P215, DOI 10.1016/0092-8674(89)90417-0; Hadjiolov AA, 1985, NUCLEOLUS RIBOSOME B; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; INOUE J, 1987, P NATL ACAD SCI USA, V84, P3653, DOI 10.1073/pnas.84.11.3653; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0; NAGASHIMA K, 1986, J VIROL, V60, P394, DOI 10.1128/JVI.60.2.394-399.1986; NOSAKA T, 1989, P NATL ACAD SCI USA, V86, P9798, DOI 10.1073/pnas.86.24.9798; OHE Y, 1989, J BIOCHEM-TOKYO, V106, P844, DOI 10.1093/oxfordjournals.jbchem.a122941; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RHIM JS, 1975, INT J CANCER, V15, P23, DOI 10.1002/ijc.2910150104; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SHIRAKAWA H, 1992, J BIOL CHEM, V267, P6641; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SODROSKI JG, 1985, J VIROL, V55, P831, DOI 10.1128/JVI.55.3.831-835.1985; SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327; TOYOSHIMA H, 1990, J VIROL, V64, P2825, DOI 10.1128/JVI.64.6.2825-2832.1990; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; WACHSMAN W, 1984, SCIENCE, V226, P177, DOI 10.1126/science.6091270; ZHANG XT, 1989, BIOCHEM BIOPH RES CO, V164, P176, DOI 10.1016/0006-291X(89)91699-9	47	112	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13930	13934						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314759				2022-12-27	WOS:A1993LJ82500026
J	CHAPPELL, DA; FRY, GL; WAKNITZ, MA; MUHONEN, LE; PLADET, MW; IVERIUS, PH; STRICKLAND, DK				CHAPPELL, DA; FRY, GL; WAKNITZ, MA; MUHONEN, LE; PLADET, MW; IVERIUS, PH; STRICKLAND, DK			LIPOPROTEIN-LIPASE INDUCES CATABOLISM OF NORMAL TRIGLYCERIDE-RICH LIPOPROTEINS VIA THE LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN/ALPHA-2-MACROGLOBULIN RECEPTOR IN-VITRO - A PROCESS FACILITATED BY CELL-SURFACE PROTEOGLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN C-II; ALPHA-2-MACROGLOBULIN RECEPTOR; MONOCLONAL-ANTIBODIES; CHYLOMICRON REMNANTS; HIGH-AFFINITY; PLASMA-LIPOPROTEINS; HEYMANN NEPHRITIS; LDL-RECEPTOR; BOVINE-MILK; PROTEIN	Bovine milk lipoprotein lipase (LPL) induced binding, uptake, and degradation of I-125-labeled normal human triglyceride-rich lipoproteins by cultured mutant fibroblasts lacking LDL receptors. The induction was dose-dependent and occurred whether LPL and I-125-lipoproteins were added to incubation media simultaneously or LPL was allowed to bind to cell surfaces, and unbound LPL was removed by washing prior to the assay. Lipolytic modification of lipoproteins did not appear to be necessary for increased catabolism because the effect of LPL was not prevented by inhibitors of LPL's enzymatic activity, p-nitrophenyl N-dodecylcarbamate or phenylmethylsulfonyl fluoride. However, the effect was abolished by boiling LPL prior to the assay suggesting that major structural features of LPL were required. Also, LPL-induced binding to cells was blocked by an anti-LPL monoclonal antibody but not by antibodies that are known to block apolipoprotein E- or B-100-mediated binding to low density lipoprotein (LDL) receptors. This indicates that LPL itself mediated I-125-lipoprotein binding to cells. Cellular degradation of I-125-lipoproteins was partially or completely blocked by two previously described ligands for the LDL receptor-related protein/alpha2-macroglobulin receptor (LRP): activated alpha2-macroglobulin (alpha2M*), and the 39-kDa receptor-associated protein. These data implicated LRP as mediating LPL-induced lipoprotein degradation and were confirmed by showing that LPL's effects were prevented by an immunoaffinity-isolated polyclonal antibody against LRP. Furthermore, LPL promoted binding of I-125-lipoproteins to highly purified LRP in a solid-phase assay. Heparin or heparinase treatment of cells markedly decreased LPL-induced binding, uptake, and degradation of lipoproteins, but had no effect on catabolism of alpha2M*. Thus, cell-surface proteoglycans were obligatory participants in the effects of LPL but were not required for LRP-mediated catabolism of alpha2M*. Taken together, these in vitro findings establish that through interaction with cell-surface proteoglycans, LPL induces catabolism of normal human triglyceride-rich lipoproteins via LRP.	UNIV UTAH,VET AFFAIRS MED CTR,DEPT INTERNAL MED,SALT LAKE CITY,UT 84148; AMER RED CROSS,BIOCHEM LAB,ROCKVILLE,MD 20855	US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; American Red Cross	CHAPPELL, DA (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,E318 GH,IOWA CITY,IA 52242, USA.				NHLBI NIH HHS [HL49264, T32 HLO7413] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049264, T32HL007413] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1989, J CLIN INVEST, V84, P1906, DOI 10.1172/JCI114378; CHAPPELL DA, 1988, J CLIN INVEST, V82, P628, DOI 10.1172/JCI113642; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; EVANS AJ, 1992, J BIOL CHEM, V267, P10743; FELTS JM, 1975, BIOCHEM BIOPH RES CO, V66, P1467, DOI 10.1016/0006-291X(75)90524-0; GARFINKEL AS, 1983, J LIPID RES, V24, P775; GOLDBERG IJ, 1986, J CLIN INVEST, V78, P1523, DOI 10.1172/JCI112744; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOBBS HH, 1987, NEW ENGL J MED, V317, P734, DOI 10.1056/NEJM198709173171204; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; Iverius P H, 1986, Methods Enzymol, V129, P691; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; LINDGREN FT, 1972, BLOOD LIPIDS LIPOPRO, P181; MILNE RW, 1982, FEBS LETT, V146, P97, DOI 10.1016/0014-5793(82)80712-6; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; MUSLINER TA, 1979, BIOCHIM BIOPHYS ACTA, V575, P277, DOI 10.1016/0005-2760(79)90029-8; NILSSONEHLE P, 1980, ANNU REV BIOCHEM, V49, P667, DOI 10.1146/annurev.bi.49.070180.003315; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OSTLUNDLINDQVIST AM, 1983, ARTERIOSCLEROSIS, V3, P433, DOI 10.1161/01.ATV.3.5.433; PACKARD CJ, 1984, J CLIN INVEST, V74, P2178, DOI 10.1172/JCI111644; PETERSON J, 1985, BIOCHIM BIOPHYS ACTA, V837, P262, DOI 10.1016/0005-2760(85)90049-9; QUINN DM, 1982, BIOCHEMISTRY-US, V21, P6872, DOI 10.1021/bi00269a038; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; SEHAYEK E, 1991, J CLIN INVEST, V88, P553, DOI 10.1172/JCI115339; SHIN HC, 1992, BIOCHEMISTRY-US, V31, P811, DOI 10.1021/bi00118a025; STIFANI S, 1991, J BIOL CHEM, V266, P19079; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; VILARO S, 1988, BIOCHIM BIOPHYS ACTA, V959, P106, DOI 10.1016/0005-2760(88)90021-5; VILARO S, 1986, BIOCHEM J, V236, P273, DOI 10.1042/bj2360273; VOYTA JC, 1985, J BIOL CHEM, V260, P893; WALLINDER L, 1984, BIOCHIM BIOPHYS ACTA, V795, P513, DOI 10.1016/0005-2760(84)90181-4; WEISGRABER KH, 1978, J BIOL CHEM, V253, P6281; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	55	187	189	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14168	14175						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314783				2022-12-27	WOS:A1993LJ82500058
J	ROTROSEN, D; YEUNG, CL; KATKIN, JP				ROTROSEN, D; YEUNG, CL; KATKIN, JP			PRODUCTION OF RECOMBINANT CYTOCHROME-B558 ALLOWS RECONSTITUTION OF THE PHAGOCYTE NADPH OXIDASE SOLELY FROM RECOMBINANT PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST; HUMAN-NEUTROPHILS; PLASMA-MEMBRANE; EXPRESSION; COMPONENT; BACULOVIRUS; ACTIVATION; CLONING; SUBUNIT	Phagocytic white blood cells contain a multicomponent oxidase that generates microbicidal products by catalyzing electron transfer from NADPH to molecular oxygen. Activation of this oxidase requires interactions of a unique membrane flavocytochrome with the cytosolic proteins p47phox, p67phox, and p21Rac. This flavocytochrome, designated cytochrome b558, is a heteromer comprising a 22-kDa alpha-subunit (p22phox) and a glycosylated almost-equal-to 91-kDa beta-subunit (gp91phox). Cytochrome b558 was expressed in Sf9 insect cells coinfected with recombinant baculoviruses carrying cDNAs for p22phox and gp91phox. Membranes of these cells contained a b-type cytochrome with a dithionite-reduced minus oxidized difference spectrum similar to that of neutrophil cytochrome b558. The recombinant cytochrome b558 beta-subunit was heterogeneously N-glycosylated as demonstrated by its susceptibility to cleavage with endoglycosidases F and H. In contrast to the neutrophil cytochrome b558, a portion of the N-linked oligosaccharide was of the high mannose type. Recombinant cytochrome b558 supported superoxide production in a cell-free assay containing recombinant p47phox, p67phox, and p21Rac. The enzymatic turnover of the partially purified recombinant cytochrome b558 and neutrophil cytochrome b558 were similar (almost-equal-to 100-160 mol of superoxide generated/s/mol of cytochrome heme, range of two experiments) and the native and recombinant cytochromes showed similar requirements for NADPH and exogenous FAD. These studies represent the first reconstitution of the NADPH oxidase solely from recombinant proteins and define a model system to explore the structure and function of cytochrome b558.			ROTROSEN, D (corresponding author), NIAID,HOST DEF LAB,BLDG 10,RM 11N112,BETHESDA,MD 20892, USA.							ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ASSEFFA A, 1989, ARCH BIOCHEM BIOPHYS, V274, P481, DOI 10.1016/0003-9861(89)90461-X; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; CARILLO N, 1992, J BIOL CHEM, V267, P15537; CROSS AR, 1981, BIOCHEM J, V194, P599, DOI 10.1042/bj1940599; Fuhrhop J. H., 1975, PORPHYRINS METALLOPO, P804; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HARPER AM, 1985, BIOCHEM J, V227, P783, DOI 10.1042/bj2270783; IMAJOHOHMI S, 1992, J BIOL CHEM, V267, P180; ISOGAI Y, 1993, J BIOL CHEM, V268, P4025; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KATKIN JP, 1992, INFLAMMATION, V16, P393, DOI 10.1007/BF00917630; KLEINBERG ME, 1989, J IMMUNOL, V143, P4152; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; KURODA K, 1990, VIROLOGY, V174, P418, DOI 10.1016/0042-6822(90)90095-9; KWONG CH, 1993, IN PRESS BIOCHEMISTR; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LETO TL, 1991, J BIOL CHEM, V266, P19812; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MALY FE, 1988, J IMMUNOL, V140, P2334; NAKAMURA M, 1988, BLOOD, V72, P1550; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P221; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; QUINN MT, 1992, J BIOL CHEM, V267, P7303; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; ROTROSEN D, 1992, INFLAMMATION BASIC P, P589; Sambrook J, 1989, MOL CLONING LABORATO; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SEGAL AW, 1989, J CLIN INVEST, V326, P88; UENO I, 1991, FEBS LETT, V281, P130, DOI 10.1016/0014-5793(91)80375-D; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195	36	78	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14256	14260						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314788				2022-12-27	WOS:A1993LJ82500070
J	STRAVITZ, RT; HYLEMON, PB; HEUMAN, DM; HAGEY, LR; SCHTEINGART, CD; TONNU, HT; HOFMANN, AF; VLAHCEVIC, ZR				STRAVITZ, RT; HYLEMON, PB; HEUMAN, DM; HAGEY, LR; SCHTEINGART, CD; TONNU, HT; HOFMANN, AF; VLAHCEVIC, ZR			TRANSCRIPTIONAL REGULATION OF CHOLESTEROL 7-ALPHA-HYDROXYLASE MESSENGER-RNA BY CONJUGATED BILE-ACIDS IN PRIMARY CULTURES OF RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIARY LIPID SECRETION; HEPATIC TRANSPORT; CHENODEOXYCHOLIC ACID; SIDE-CHAIN; METABOLISM; ENZYMES; STIMULATION; ABSORPTION; KINETICS; HAMSTER	The role of bile acids in the regulation of cholesterol 7alpha-monooxygenase (EC 1.14.13.17) was characterized using primary cultures of rat hepatocytes supplemented with dexamethasone and thyroxine. Taurocholate and taurodeoxycholate (50 muM) repressed cholesterol 7alpha-hydroxylase mRNA to 44 +/- 9 and 52 +/- 4%, respectively, of control values. Repression by these natural, relatively hydrophobic bile acids was concentration dependent, with an IC50 of about 50 muM, and time dependent with a t1/2 for repression of 22 h. In contrast, two natural hydrophilic bile acids, tauroursodeoxycholate and taurohyodeoxycholate, had no effect on cholesterol 7alpha-hydroxylase mRNA levels. Taurochenodeoxycholate and taurolithocholate also had no effect, but these hydrophobic bile acids were rapidly hydroxylated to more hydrophilic bile acids. Hydrophilic bile acid analogues (nor (C23) bile acids and beta-hydroxy epimers) repressed cholesterol 7alpha-hydroxylase mRNA less potently than their corresponding and more hydrophobic C24 or alpha-hydroxy derivatives. Cholesterol 7alpha-hydroxylase specific activity was decreased by taurocholate or taurodeoxycholate (50 muM) to 26 +/-9 and 56 +/- 3% of control, respectively; its transcriptional activity was repressed to 52 +/- 5% of control by taurocholate (50 muM). The addition of cholesterol or the induction of cholesterol biosynthesis did not influence repression of cholesterol 7alpha-hydroxylase mRNA levels by taurocholate. Based on several lines of evidence, cAMP was not involved in bile acid-induced repression. In rat hepatocytes cultured under conditions in which cholesterol 7alpha-hydroxylase gene expression is maintained at in vivo levels, hydrophobic bile acids repress this enzyme at the level of gene transcription independently of cholesterol availability.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MICROBIOL IMMUNOL,DIV GASTROENTEROL,MCV STN,RICHMOND,VA 23298; HUNTER HOLMES MCGUIRE VET ADM MED CTR,GASTROENTEROL SECT,RICHMOND,VA 23298; UNIV CALIF SAN DIEGO,DIV GASTROENTEROL,LA JOLLA,CA 92093	Virginia Commonwealth University; Hunter Holmes McGuire Veterinary Affairs Medical Center; University of California System; University of California San Diego					NIDDK NIH HHS [P01 DK-38030-06, DK-32130, DK-21506] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021506, R01DK032130, P01DK038030] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERLUND JE, 1990, J LIPID RES, V31, P2159; BERGSTROM S, 1958, ACTA PHYSIOL SCAND, V43, P1, DOI 10.1111/j.1748-1716.1958.tb01572.x; Bissell D M, 1980, Ann N Y Acad Sci, V349, P85, DOI 10.1111/j.1749-6632.1980.tb29518.x; BJORKHEM I, 1991, BIOCHIM BIOPHYS ACTA, V1085, P329, DOI 10.1016/0005-2760(91)90137-7; BOTHAM KM, 1981, BIOCHIM BIOPHYS ACTA, V666, P236; CLAYTON LM, 1989, J PHARMACOL EXP THER, V248, P1130; CRONHOLM T, 1967, EUR J BIOCHEM, V2, P375, DOI 10.1111/j.1432-1033.1967.tb00148.x; DANZINGE.RG, 1973, J CLIN INVEST, V52, P2809, DOI 10.1172/JCI107477; DAVIS RA, 1983, J BIOL CHEM, V258, P3661; DAVIS RA, 1983, J BIOL CHEM, V258, P4079; EINARSSON K, 1974, CLIN SCI MOL MED, V46, P183, DOI 10.1042/cs0460183; FUJII T, 1988, DIGESTION, V41, P207, DOI 10.1159/000199790; GURANTZ D, 1984, AM J PHYSIOL, V247, pG736, DOI 10.1152/ajpgi.1984.247.6.G736; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HEUMAN DM, 1989, J LIPID RES, V30, P1161; HEUMAN DM, 1989, J LIPID RES, V30, P719; HEUMAN DM, 1988, HEPATOLOGY, V8, P892, DOI 10.1002/hep.1840080431; HOFMANN AF, 1992, J LIPID RES, V33, P599; HOFMANN AF, 1962, J LIPID RES, V3, P127; HYLEMON PB, 1989, ANAL BIOCHEM, V182, P212, DOI 10.1016/0003-2697(89)90581-2; HYLEMON PB, 1990, HEPATOLOGY, V11, P982, DOI 10.1002/hep.1840110612; HYLEMON PB, 1992, J BIOL CHEM, V267, P16866; IIDA T, 1982, J ORG CHEM, V47, P2966, DOI 10.1021/jo00136a030; JUSTE C, 1988, DIGEST DIS SCI, V33, P67, DOI 10.1007/BF01536633; KITANI K, 1981, LIFE SCI, V29, P269, DOI 10.1016/0024-3205(81)90243-5; KUBASKA WM, 1985, J BIOL CHEM, V260, P3459; LARUSSO NF, 1975, GASTROENTEROLOGY, V69, P1301; MARCUS SN, 1991, GASTROENTEROLOGY, V100, P212; NAKAGAKI M, 1984, GASTROENTEROLOGY, V87, P647; NILSELL K, 1983, GASTROENTEROLOGY, V85, P1248; PALMER KR, 1987, AM J PHYSIOL, V252, pG219, DOI 10.1152/ajpgi.1987.252.2.G219; PANDAK WM, 1991, J BIOL CHEM, V266, P3416; PANDAK WM, 1992, J LIPID RES, V33, P659; ROSSI SS, 1987, J LIPID RES, V28, P589; SCHMASSMANN A, 1990, GASTROENTEROLOGY, V99, P1092, DOI 10.1016/0016-5085(90)90630-J; SCHOENFIELD LJ, 1973, J LAB CLIN MED, V82, P858; SCHTEINGART CD, 1988, J LIPID RES, V29, P1387; SHEFER S, 1969, J LIPID RES, V10, P646; SHEFER S, 1982, J BIOL CHEM, V257, P1401; SPADY DK, 1992, J BIOL CHEM, V267, P5584; STANGE EF, 1989, J CLIN INVEST, V84, P173, DOI 10.1172/JCI114137; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TSERNG KY, 1977, J LIPID RES, V18, P404; TUCHWEBER B, 1986, PROG LIVER DIS, V8, P161; VLAHCEVIC ZR, 1991, HEPATOLOGY, V13, P590, DOI 10.1002/hep.1840130331; WHITING MJ, 1989, BIOCHIM BIOPHYS ACTA, V1005, P137, DOI 10.1016/0005-2760(89)90179-3; YOON YB, 1986, GASTROENTEROLOGY, V90, P837, DOI 10.1016/0016-5085(86)90859-0	47	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13987	13993						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314765				2022-12-27	WOS:A1993LJ82500034
J	HALLBERG, B; RAYTER, SI; DOWNWARD, J				HALLBERG, B; RAYTER, SI; DOWNWARD, J			INTERACTION OF RAS AND RAF IN INTACT MAMMALIAN-CELLS UPON EXTRACELLULAR STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE-C	It has recently been shown that Ras proteins interact directly with Raf serine/threonine kinases in vitro and in the yeast two-hybrid system, leading to speculation that Raf proteins function as effecters for Res. Here it is demonstrated that the endogenous Raf-1 protein co-immunoprecipitates with Ras from mammalian cells when the non-neutralizing anti-Ras monoclonal antibody Y13-238 is used. The formation of a Ras-Raf complex is absolutely dependent on prior treatment of the cells with a stimulus that activates Ras: phorbol ester or anti-T cell receptor antibody in the case of human peripheral blood T lymphoblasts, or epidermal growth factor in the case of Rat-1 fibroblasts. Up to 3% of cellular Raf-1 can be found in association with Ras. The association is not competed by addition of exogenous GST-Raf to the cell lysates and is therefore unlikely to be due to Ras-Raf binding after cell lysis. Specific interaction of Ras and Raf therefore occurs in intact mammalian cells in response to stimuli that cause Res to become GTP-bound.			HALLBERG, B (corresponding author), IMPERIAL CANC RES FUND,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.			Downward, Julian/0000-0002-2331-4729				AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HARLOW E, 1988, ANTIBODIES LABORATOR; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; RAPP UR, 1991, ONCOGENE, V6, P495; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; TRAVERSE S, 1993, ONCOGENE, V8, P3175; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	25	179	182	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3913	3916						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307946				2022-12-27	WOS:A1994MW98900003
J	LEBART, MC; MEJEAN, C; CASANOVA, D; AUDEMARD, E; DERANCOURT, J; ROUSTAN, C; BENYAMIN, Y				LEBART, MC; MEJEAN, C; CASANOVA, D; AUDEMARD, E; DERANCOURT, J; ROUSTAN, C; BENYAMIN, Y			CHARACTERIZATION OF THE ACTIN-BINDING SITE ON SMOOTH-MUSCLE FILAMIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL REGION; ALPHA-ACTININ; SKELETAL-MUSCLE; SEQUENCE; PROTEIN; DOMAIN; DYSTROPHIN; IDENTIFICATION; CALMODULIN; SPECTRIN	We have isolated an NH2-terminal fragment of filamin (M(r) = 70,000) after digestion with Staphylococus aureus V8 protease. This fragment was shown to interact with filamentous actin in cosedimentation assays. Using cross-reactive anti-peptides antibodies directed against the strongly conserved 27-mer sequence of alpha-actinin, already implicated as an actin binding site (Kuhlman, P. A., Hemmings, L., and Critchley, D, R. (1992) FEBS Lett. 304, 201-206), we obtained evidence suggesting that the homologous sequence of filamin (121-147 sequence) is the major element in the interaction with actin. In particular, we used enzyme-linked immunosorbent assay experiments, in conjunction with a synthetic peptide approach, and found that the hydrophobic part of the 27-mer peptide (141-147 sequence) is largely involved in actin binding. Thus, the filamin sequence 121-147 (or the alpha-actinin sequence 108-134) and the actin counterpart composed of residues 112-125 and 360-372 (we have already implicated) could constitute the main interface between actin and these cytoskeletal proteins. However, the divergent behavior of filamin and alpha-actinin toward conformational changes of actin argues in favor of distinctive interfaces. Finally, the ionic strength dependence of the filamin-actin interaction, in contrast to that with alpha-actinin, strongly suggests that, besides hydrophobic interactions conferred by the 27-mer sequence, more hydrophilic region(s) of filamin participate(s) in the binding.	UNIV MONTPELLIER 1,ECOLE PRAT HAUTES ETUD,RECH MOTIL CELLULAIRE LAB,CNRS,F-34033 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Universite de Montpellier								BARON MD, 1987, J BIOL CHEM, V262, P17623; BENYAMIN Y, 1986, J IMMUNOL METHODS, V86, P21, DOI 10.1016/0022-1759(86)90260-7; BETTACHE N, 1989, P NATL ACAD SCI USA, V86, P6028, DOI 10.1073/pnas.86.16.6028; BRESNICK AR, 1990, J BIOL CHEM, V265, P9236; BRESNICKAR, 1991, J BIOL CHEM, V266, P12989; Bretscher A, 1991, CURR OPIN STRUC BIOL, V1, P281, DOI 10.1016/0959-440X(91)90074-4; BULINSKI JC, 1983, P NATL ACAD SCI-BIOL, V80, P1506, DOI 10.1073/pnas.80.6.1506; BYERS TJ, 1989, J CELL BIOL, V109, P1633, DOI 10.1083/jcb.109.4.1633; DABROWSKA R, 1985, J MUSCLE RES CELL M, V6, P29, DOI 10.1007/BF00712309; DAVIES P, 1977, FEBS LETT, V77, P228, DOI 10.1016/0014-5793(77)80240-8; DAVIES PJA, 1978, J BIOL CHEM, V253, P4036; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; DEARRUDA MV, 1990, J CELL BIOL, V111, P1069, DOI 10.1083/jcb.111.3.1069; Engvall E, 1980, Methods Enzymol, V70, P419; FRIEDEN C, 1982, J BIOL CHEM, V257, P2882; GORLIN J, 1989, Journal of Cell Biology, V109, p272A; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; HAMMONDS RG, 1987, CELL, V51, P1, DOI 10.1016/0092-8674(87)90002-X; HANIN V, 1989, Peptide Research, V2, P367; HARTWIG JH, 1975, J BIOL CHEM, V250, P5696; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; HOCK RS, 1990, BIOCHEMISTRY-US, V29, P9441, DOI 10.1021/bi00492a019; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HOUMEIDA A, 1991, BIOCHEM J, V274, P753, DOI 10.1042/bj2740753; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KUHLMAN PA, 1992, FEBS LETT, V304, P201, DOI 10.1016/0014-5793(92)80619-R; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBART MC, 1990, BIOCHEM BIOPH RES CO, V173, P120, DOI 10.1016/S0006-291X(05)81030-7; LEBART MC, 1993, J BIOL CHEM, V268, P5642; LEVINE BA, 1992, FEBS LETT, V298, P44, DOI 10.1016/0014-5793(92)80019-D; MALHOTRA A, 1986, BIOCHIM BIOPHYS ACTA, V874, P347, DOI 10.1016/0167-4838(86)90034-8; MARUYAMA K, 1985, J BIOCHEM-TOKYO, V97, P1517, DOI 10.1093/oxfordjournals.jbchem.a135207; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; MEJEAN C, 1992, EUR J BIOCHEM, V209, P555, DOI 10.1111/j.1432-1033.1992.tb17320.x; MEJEAN C, 1988, BIOCHEM BIOPH RES CO, V152, P368, DOI 10.1016/S0006-291X(88)80723-X; MIMURA N, 1986, J BIOL CHEM, V261, P680; MONTGELARD C, 1990, EXPERIENTIA, V46, P303, DOI 10.1007/BF01951773; NOEGEL AA, 1989, J CELL BIOL, V109, P607, DOI 10.1083/jcb.109.2.607; PACAUD M, 1993, BIOCHEMISTRY-US, V32, P363, DOI 10.1021/bi00052a045; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866	42	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4279	4284						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307993				2022-12-27	WOS:A1994MW98900060
J	PIETRINI, G; SUH, YJ; EDELMANN, L; RUDNICK, G; CAPLAN, MJ				PIETRINI, G; SUH, YJ; EDELMANN, L; RUDNICK, G; CAPLAN, MJ			THE AXONAL GAMMA-AMINOBUTYRIC-ACID TRANSPORTER GAT-1 IS SORTED TO THE APICAL MEMBRANES OF POLARIZED EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN ALTERS; HIPPOCAMPAL-NEURONS; RAT-BRAIN; GABA TRANSPORTER; IMMUNOCYTOCHEMICAL LOCALIZATION; MDCK CELLS; EXPRESSION; PROTEINS; CULTURE; CLONING	Recent studies suggest that epithelial cells and neu neurons employ similar mechanisms to target proteins to the distinct subdomains of their polarized cell surface membranes. We have examined the sorting behavior of the neuronal gamma-aminobutyric acid (GABA) transporter CAT-1 expressed by transfection in the polarized epithelial Madin-Darby canine kidney (MDCK) cell line. We find that the GABA transporters endogenously expressed by polarized hippocampal neurons in culture are restricted to axonal plasma membranes. In transfected MDCK cells, the GABA transporter is found to be localized primarily to the apical cell surface when examined by immunocytochemistry, cell surface biotinylation, and transport assay. MDCK cells exposed to hyperosmotic stress express a close relative of GAT-1, the betaine transporter (BGT-1). We find that BGT-1 expressed by transfection in MDCK cells accumulates predominantly at the basolateral cell surface. These observations suggest that the sorting information required for axonal targeting may be similar to that which mediates apical localization in epithelia. Furthermore, it would appear that despite their high degree of homology, the BGT-1 and GAT-1 transporters manifest sorting signals which specify their targeting to distinct cell surface domains.	YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; CNR,CTR CYTOPHARMACOL,I-20129 MILAN,ITALY; UNIV MILAN,DEPT PHARMACOL,I-20129 MILAN,ITALY	Yale University; Yale University; Consiglio Nazionale delle Ricerche (CNR); University of Milan				Caplan, Michael/0000-0001-5768-4405	NIGMS NIH HHS [GM-42136] Funding Source: Medline; PHS HHS [7259] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042136] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGNASCO S, 1986, J BIOL CHEM, V261, P5872; BLACK MM, 1989, TRENDS NEUROSCI, V12, P211, DOI 10.1016/0166-2236(89)90124-0; BORDEN LA, 1992, J BIOL CHEM, V267, P21098; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CACERES A, 1986, J NEUROSCI, V6, P714; CAPLAN M, 1989, FUNCTIONAL EPITHELIA, P71; CAPLAN MJ, 1986, CELL, V46, P623, DOI 10.1016/0092-8674(86)90888-3; CLARK JA, 1992, NEURON, V9, P337, DOI 10.1016/0896-6273(92)90172-A; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; Goslin K., 1991, CULTURING NERVE CELL, P251; GOTTARDI CJ, 1993, SCIENCE, V260, P552, DOI 10.1126/science.8386395; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KORDELI E, 1991, J CELL BIOL, V114, P1243, DOI 10.1083/jcb.114.6.1243; KUMINOTO M, 1991, J CELL BIOL, V115, P1319; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; LIU QR, 1993, J BIOL CHEM, V268, P2106; MABJEESH NJ, 1992, FEBS LETT, V299, P99, DOI 10.1016/0014-5793(92)80109-T; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; Mugnaini E., 1985, HDB CHEM NEUROANAT 1, V4; NAKANISHI T, 1990, AM J PHYSIOL, V258, pF1061, DOI 10.1152/ajprenal.1990.258.4.F1061; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; PFALLER W, 1990, J CELL PHYSIOL, V142, P247, DOI 10.1002/jcp.1041420205; PIETRINI G, 1992, P NATL ACAD SCI USA, V89, P8414, DOI 10.1073/pnas.89.18.8414; PUDDINGTON L, 1987, P NATL ACAD SCI USA, V84, P2756; RADIAN R, 1990, J NEUROSCI, V10, P1319; RADIAN R, 1983, BIOCHEMISTRY-US, V22, P1236, DOI 10.1021/bi00274a038; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; SIEMERS KA, 1993, SCIENCE, V260, P552; SIMONS K, 1985, ANN REV CELL BIOL, V1, P295; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649; YAMAUCHI A, 1991, AM J PHYSIOL, V261, pF197, DOI 10.1152/ajprenal.1991.261.1.F197; ZURZOLO C, 1993, SCIENCE, V260, P550, DOI 10.1126/science.8386394	39	92	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4668	4674						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308038				2022-12-27	WOS:A1994MW98900113
J	INUI, H; KITAMI, Y; KONDO, T; INAGAMI, T				INUI, H; KITAMI, Y; KONDO, T; INAGAMI, T			TRANSDUCTION OF MITOGENIC ACTIVITY OF PLATELET-DERIVED GROWTH-FACTOR (PDGF) AB BY PDGF-BETA RECEPTOR WITHOUT PARTICIPATION OF PDGF-ALPHA RECEPTOR IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENT ISOFORMS; KINASE ACTIVATION; LIGAND-BINDING; B-CHAIN; PHOSPHORYLATION; PURIFICATION; DIMERIZATION; EXPRESSION; MECHANISM; GENE	In cultured rat vascular smooth muscle cells, platelet-derived growth factor (PDGF) beta receptor was expressed at a high level, whereas PDGF-alpha receptor was not detected. PDGF-BB showed a high binding activity at 4-degrees-C in the cells and was not displaced by PDGF-AA or -AB. This result indicates that PDGF-AB as well as PDGF-AA does not bind to the cells lacking PDGF-alpha receptor at 4-degrees-C. However, at 37-degrees-C, PDGF-AB bound to the cells and induced the internalization of PDGF-beta receptor. DNA synthesis was also stimulated potentially by PDGF-AB as well as PDGF-BB in the cells, although PDGF-AA was completely inactive. At 37-degrees-C, PDGF-AB caused tyrosine phosphorylation of a group of proteins including PDGF-beta receptor and phospholipase C-gamma1, but at a slower rate than PDGF-BB. At 4-degrees-C, PDGF-AB did not stimulate protein tyrosine phosphorylation, whereas PDGF-BB did. A chemical cross-linking experiment showed that PDGF-beta receptor was dimerized by PDGF-AB as well as PDGF-BB. These results indicate that PDGF-beta receptor binds PDGF-AB without participation of PDGF-alpha receptor at 37-degrees-C (but not at 4-degrees-C), and PDGF-AB as well as PDGF-BB acts as a potent mitogen in the vascular smooth muscle cells.			INUI, H (corresponding author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232, USA.		Inui, Hiroshi/C-7721-2011		NHLBI NIH HHS [HL-14192, HL-35323] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035323, P50HL014192] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; DROZDOFF V, 1991, J BIOL CHEM, V266, P17165; GOTENDORST GR, 1991, J CELL PHYSL, V149, P235; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KITAMI Y, 1991, CLIN SCI, V81, P387, DOI 10.1042/cs0810387; KONDO T, 1992, J BIOL CHEM, V267, P23609; KONDO T, 1993, J BIOL CHEM, V268, P4458; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KH, 1990, MOL CELL BIOL, V10, P2237, DOI 10.1128/MCB.10.5.2237; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SCHOLLMANN C, 1992, J BIOL CHEM, V267, P18032; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SEJERSEN T, 1986, P NATL ACAD SCI USA, V83, P6844, DOI 10.1073/pnas.83.18.6844; SEVERINSSON L, 1989, EUR J BIOCHEM, V182, P679, DOI 10.1111/j.1432-1033.1989.tb14879.x; Sjolund M, 1990, GROWTH FACTORS, V3, P191, DOI 10.3109/08977199009043904; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; STROOBANT P, 1984, EMBO J, V3, P2963, DOI 10.1002/j.1460-2075.1984.tb02241.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	29	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17045	17050						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349593				2022-12-27	WOS:A1993LQ98800027
J	LOTAN, O; COHEN, Y; MICHAELI, D; NECHUSHTAI, R				LOTAN, O; COHEN, Y; MICHAELI, D; NECHUSHTAI, R			HIGH-LEVELS OF PHOTOSYSTEM-I SUBUNIT-II (PSAD) MESSENGER-RNA RESULT IN THE ACCUMULATION OF THE PSAD POLYPEPTIDE ONLY IN THE PRESENCE OF LIGHT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ILLUMINATED BARLEY SEEDLINGS; CHLOROPHYLL-A-APOPROTEINS; DEPENDENT ACCUMULATION; GENE-EXPRESSION; HIGHER-PLANTS; TRANSLATIONAL CONTROL; CHLOROPLAST PROTEINS; TRANSCRIPT LEVELS; AUREA MUTANT; RED-LIGHT	The light-regulated mRNA and polypeptide accumulation of the nuclear encoded subunit II (PsaD) of the photosystem I reaction center was studied during the greening of etiolated spinach seedlings. Upon exposure to continuous white light, the mRNA, detected at low levels in etiolated seedlings, accumulated in a specific pattern. In contrast, the PsaD subunit could not be detected in the etiolated seedlings; the polypeptide could first be detected in thylakoid membranes approximately 4 h after exposure to continuous light. A pulse of red light induced the expression of the PsaD mRNA, but the polypeptide could not be detected unless the seedlings were exposed to light. In the light (but not in the dark), the PsaD mRNA was found associated with the polysomal fraction. Taken together, the data suggest a dual regulatory mechanism in which both the level of mRNA and the presence of light control the accumulation of the PsaD polypeptide.	HEBREW UNIV JERUSALEM,DEPT BOT,IL-91904 JERUSALEM,ISRAEL	Hebrew University of Jerusalem								ADAMSKA I, 1991, PLANT MOL BIOL, V17, P1055, DOI 10.1007/BF00037144; BERRY JO, 1990, PLANT CELL, V2, P795, DOI 10.1105/tpc.2.8.795; BRUNNER H, 1991, J PHOTOCH PHOTOBIO B, V11, P129, DOI 10.1016/1011-1344(91)80255-G; BRYANT DA, 1992, TOP PHOTOSYNTH, V11, P501; BUTLER WL, 1959, P NATL ACAD SCI USA, V45, P1703, DOI 10.1073/pnas.45.12.1703; CHITNIS PR, 1989, J BIOL CHEM, V264, P18381; CHOQUET Y, 1988, CELL, V52, P903, DOI 10.1016/0092-8674(88)90432-1; COHEN L, 1988, PHYSIOL PLANTARUM, V72, P57, DOI 10.1111/j.1399-3054.1988.tb06622.x; EICHACKER LA, 1990, J BIOL CHEM, V265, P13566; GIULIANO G, 1988, EMBO J, V7, P3635, DOI 10.1002/j.1460-2075.1988.tb03244.x; GOLBECK JH, 1992, ANNU REV PLANT PHYS, V43, P293, DOI 10.1146/annurev.pp.43.060192.001453; GRUISSEM W, 1988, TRENDS GENET, V4, P258, DOI 10.1016/0168-9525(88)90033-9; Herrmann R.G., 1985, MOL FORM FUNCTION PL, P233; IWASAKI Y, 1990, PLANT CELL PHYSIOL, V31, P871; KAUFMAN LS, 1984, SCIENCE, V226, P1447, DOI 10.1126/science.226.4681.1447; KENDROR S, 1990, PLANT PHYSIOL, V92, P1004, DOI 10.1104/pp.92.4.1004; KITTSTEINER U, 1991, PHYSIOL PLANTARUM, V81, P190, DOI 10.1111/j.1399-3054.1991.tb02128.x; KLEIN RR, 1987, J BIOL CHEM, V262, P4341; KLEIN RR, 1988, J CELL BIOL, V106, P289, DOI 10.1083/jcb.106.2.289; KLEIN RR, 1988, PLANT PHYSIOL, V88, P1246, DOI 10.1104/pp.88.4.1246; KREUZ K, 1986, EUR J BIOCHEM, V159, P459, DOI 10.1111/j.1432-1033.1986.tb09908.x; KUHLEMEIER C, 1987, ANNU REV PLANT PHYS, V38, P221; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAING W, 1988, PLANTA, V176, P269, DOI 10.1007/BF00392455; LEUTWILER LS, 1986, NUCLEIC ACIDS RES, V14, P4051, DOI 10.1093/nar/14.10.4051; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; MULLET JE, 1990, P NATL ACAD SCI USA, V87, P4038, DOI 10.1073/pnas.87.11.4038; MUNCH S, 1988, CURR GENET, V14, P511, DOI 10.1007/BF00521277; NECHUSHTAI R, 1985, PLANT MOL BIOL, V4, P377, DOI 10.1007/BF02418259; NECHUSHTAI R, 1981, J BIOL CHEM, V256, P1624; OELMULLER R, 1989, PLANT MOL BIOL, V13, P223, DOI 10.1007/BF00016140; PAUNCZ Y, 1992, PLANT PHYSIOL, V100, P1934, DOI 10.1104/pp.100.4.1934; RODERMEL SR, 1985, J CELL BIOL, V100, P463, DOI 10.1083/jcb.100.2.463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHAH DM, 1982, P NATL ACAD SCI-BIOL, V79, P1022, DOI 10.1073/pnas.79.4.1022; SUTTON A, 1987, EUR J BIOCHEM, V164, P571, DOI 10.1111/j.1432-1033.1987.tb11165.x; THOMPSON WF, 1991, ANNU REV PLANT PHYS, V42, P423, DOI 10.1146/annurev.pp.42.060191.002231; TOBIN EM, 1985, ANNU REV PLANT PHYS, V36, P569, DOI 10.1146/annurev.pp.36.060185.003033; WESTHOFF P, 1988, EUR J BIOCHEM, V171, P551, DOI 10.1111/j.1432-1033.1988.tb13824.x	39	8	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16185	16189						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344902				2022-12-27	WOS:A1993LQ33600018
J	WEN, DY; LAURSEN, RA				WEN, DY; LAURSEN, RA			STRUCTURE-FUNCTION-RELATIONSHIPS IN AN ANTIFREEZE POLYPEPTIDE - THE EFFECT OF ADDED BULKY GROUPS ON ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDES; ICE	We have proposed that the antifreeze activity of an alanine-rich alpha-helical antifreeze polypeptide (AFP) is due in part to side-by-side hydrophobic interactions of AFP molecules bound on the ice surface (Wen, D., and Laursen, R. A. (1992b) Biophys. J. 63, 1659-1662). To test this hypothesis and to assess the importance of a hydrophobic surface on the outward facing (non-ice-binding) portions of the helix, we synthesized several AFP analogs with up to four Ala --> Gln or Ala --> Leu replacements and determined the effect of these changes on antifreeze activity and helix stability. Although Gln replacements caused some helix destabilization and resultant reduction of antifreeze activity, they were in general well tolerated, suggesting that the bulk hydrophobicity of the non-ice-binding faces of the AFP, per se, is probably not a major factor determining AFP activity. However, placement of either Gln or Leu in position 17 on one side of the helix completely abolished activity, demonstrating that the specific location of bulky groups can dramatically alter activity. We conclude from molecular modeling studies that the effect seen by placing bulky groups in position 17 is due to steric hindrance that prevents effective association or packing of AFP molecules on the ice surface, in support of our hypothesis.	BOSTON UNIV,DEPT CHEM,590 COMMONWEALTH AVE,BOSTON,MA 02215	Boston University								CHAKRABARTTY A, 1991, EUR J BIOCHEM, V202, P1057, DOI 10.1111/j.1432-1033.1991.tb16470.x; CHAKRABARTTY A, 1989, J BIOL CHEM, V264, P11313; CHAKRABARTTY A, 1989, J BIOL CHEM, V264, P11307; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; FEENEY RE, 1986, ANNU REV BIOPHYS BIO, V15, P59; KNIGHT CA, 1991, BIOPHYS J, V59, P409, DOI 10.1016/S0006-3495(91)82234-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; SONNICHSEN FD, 1993, SCIENCE, V259, P1154, DOI 10.1126/science.8438165; WEN DY, 1992, BIOPHYS J, V63, P1659, DOI 10.1016/S0006-3495(92)81750-2; WEN DY, 1993, J BIOL CHEM, V268, P16396; WEN DY, 1993, FEBS LETT, V317, P31, DOI 10.1016/0014-5793(93)81485-I; WEN DY, 1992, J BIOL CHEM, V267, P14102; YANG DSC, 1988, NATURE, V333, P232, DOI 10.1038/333232a0	14	34	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16401	16405						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344925				2022-12-27	WOS:A1993LQ33600048
J	ROONEY, TA; HAGER, R; STUBBS, CD; THOMAS, AP				ROONEY, TA; HAGER, R; STUBBS, CD; THOMAS, AP			HALOTHANE REGULATES G-PROTEIN-DEPENDENT PHOSPHOLIPASE-C ACTIVITY IN TURKEY ERYTHROCYTE-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; GH3 PITUITARY-CELLS; ADENYLATE-CYCLASE; GUANINE-NUCLEOTIDES; ADRENERGIC-RECEPTOR; GENERAL-ANESTHESIA; CALCIUM CURRENT; MUSCLE-CELLS; RAT-HEART; ACTIVATION	The ability of halothane to stimulate phospholipase C (PLC) was examined in turkey erythrocyte membranes prepared from [H-3]inositol-labeled turkey erythrocytes by measuring [H-3]inositol phosphate formation ([H-3]InsP) in the presence and absence of G-protein activation. In the presence of guanosine 5'-3-O-(thio)triphosphate) (GTPgammaS), halothane (0.5-10 mM) caused a dose-dependent activation of PLC. The EC50 value for halothane-induced PLC activation was 2.8 +/- 0.3 mM. Halothane (0.1-30 mM) had no effect on PLC activity in the absence of G-protein activation and did not affect Ca2+-dependent PLC activity. The activation of PLC by GTPgammaS occurred after an initial lag period of 60 s which was followed by a linear increase in [H-3]InsP. Halothane dose-dependently decreased the lag period for GTPgammaS-induced PLC activation (minimal value 15 s) and increased the rate of [H-3]InsP formation at all time points following this lag. As a result, halothane shifted the EC50 value for GTPgammaS-induced PLC activation to the left (4-fold) and increased its maximal response. Halothane also caused a dose-dependent activation of PLC in the presence of AlF4-. Half-maximal stimulation of AlF4--activated PLC occurred with an EC50 value of 2.9 +/- 0.4 mM halothane, which is similar to the halothane dose giving half-maximal stimulation of PLC in the presence of GTPgammaS. At low doses (0.1-0.3 mM) halothane inhibited both isoproterenol- and adenosine 5'-O-(2-thiodiphosphate) (ADPbetaS)-induced [H-3]InsP formation, whereas at higher concentrations it stimulated PLC independent of the presence of these agonists. At concentrations chosen to reflect their different membrane/buffer partition coefficients, both hexanol (5 mM) and benzyl alcohol (20 mM) fluidized turkey erythrocyte membranes to the same degree as halothane (5 mM). However, these agents had no effect on GTPgammaS- or AlF4-induced PLC activity, indicating that halothane-induced PLC activation was not secondary to changes in bulk lipid fluidity properties. Halothane also stimulated [H-3]inositol bisphosphate and [H-3]inositol trisphosphate formation in intact erythrocytes. These data demonstrate that the anesthetic halothane can stimulate G-protein-dependent PLC activity and modify the responsiveness of this signaling system to activation by receptor-linked agonists.	THOMAS JEFFERSON UNIV,DEPT PATHOL & CELL BIOL,RM 271 JAH,1020 LOCUST ST,PHILADELPHIA,PA 19107	Jefferson University			Thomas, Andrew/C-6755-2013	Thomas, Andrew/0000-0002-9026-7467	NIAAA NIH HHS [AA07215, AA08022] Funding Source: Medline; NIDDK NIH HHS [DK38422] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038422, R01DK038422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R29AA008022, R01AA008022] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BEAN BP, 1981, J GEN PHYSIOL, V77, P233, DOI 10.1085/jgp.77.3.233; BEECHEM JM, 1989, CHEM PHYS LIPIDS, V50, P237, DOI 10.1016/0009-3084(89)90052-2; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOSNJAK ZJ, 1991, ANESTHESIOLOGY, V74, P340, DOI 10.1097/00000542-199102000-00022; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BOYER JL, 1989, J BIOL CHEM, V264, P13917; BOYER JL, 1989, J BIOL CHEM, V264, P884; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; DANIELL LC, 1988, J PHARMACOL EXP THER, V245, P1; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; FRANKS NP, 1987, TRENDS PHARMACOL SCI, V8, P169, DOI 10.1016/0165-6147(87)90160-X; FRANKS NP, 1982, NATURE, V300, P487, DOI 10.1038/300487a0; FRANKS NP, 1991, SCIENCE, V254, P427, DOI 10.1126/science.1925602; FRANKS NP, 1988, NATURE, V333, P662, DOI 10.1038/333662a0; GRATTON E, 1983, BIOPHYS J, V44, P315, DOI 10.1016/S0006-3495(83)84305-7; HARDEN TK, 1987, J BIOL CHEM, V262, P9057; HARDEN TK, 1988, BIOCHEM J, V252, P583, DOI 10.1042/bj2520583; HAYDON DA, 1983, J PHYSIOL-LONDON, V341, P429, DOI 10.1113/jphysiol.1983.sp014814; HERRINGTON J, 1991, J NEUROSCI, V11, P2226; IAIZZO PA, 1990, CELL CALCIUM, V11, P515, DOI 10.1016/0143-4160(90)90027-R; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KLIP A, 1990, J PHARMACOL EXP THER, V254, P552; LAKOWICZ JR, 1985, BIOPHYS CHEM, V21, P61, DOI 10.1016/0301-4622(85)85007-9; MILLER KW, 1985, INT REV NEUROBIOL, V27, P1, DOI 10.1016/S0074-7742(08)60555-3; MORRIS AJ, 1990, J BIOL CHEM, V265, P13501; MORRIS AJ, 1990, J BIOL CHEM, V265, P13508; NAKAHIRO M, 1989, FASEB J, V3, P1850, DOI 10.1096/fasebj.3.7.2541038; NARAYANAN TK, 1988, BIOCHEM PHARMACOL, V37, P1219, DOI 10.1016/0006-2952(88)90774-5; NICOLL RA, 1982, SCIENCE, V217, P1055, DOI 10.1126/science.7112112; PUIL E, 1990, J PHARMACOL EXP THER, V255, P955; ROONEY TA, 1991, J BIOL CHEM, V266, P15068; ROONEY TA, 1989, J BIOL CHEM, V264, P6817; SCHRAMM M, 1975, J BIOL CHEM, V250, P2232; SEEMAN P, 1972, PHARMACOL REV, V24, P583; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; SILL JC, 1991, MOL PHARMACOL, V40, P1006; STERN RC, 1991, J NEUROSCI, V11, P2217; STUBBS CD, 1980, BIOCHEMISTRY-US, V19, P2756, DOI 10.1021/bi00553a034; STUBBS CD, 1984, BIOCHIM BIOPHYS ACTA, V775, P374, DOI 10.1016/0005-2736(84)90193-7; STUBBS CD, 1983, ESSAYS BIOCHEM, V19, P1; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TOLKOVSKY AM, 1978, BIOCHEMISTRY-US, V17, P3795, DOI 10.1021/bi00611a020; VAZIRI C, 1992, BIOCHEM J, V284, P917, DOI 10.1042/bj2840917; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WHEELER DM, 1988, ANESTHESIOLOGY, V69, P578, DOI 10.1097/00000542-198810000-00019	46	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15550	15556						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340382				2022-12-27	WOS:A1993LN30500037
J	HURLBURT, BK; YANOFSKY, C				HURLBURT, BK; YANOFSKY, C			ANALYSIS OF HETERODIMER FORMATION BY THE ESCHERICHIA-COLI TRP REPRESSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL GENE; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; BINDING; APOREPRESSOR; DNA; PURIFICATION; RESOLUTION; EXPRESSION; K-12	The trp repressor of Escherichia coli is a dimeric DNA-binding protein that regulates transcription of several operons concerned with tryptophan metabolism. Although heterodimer formation between mutant and wild type subunits occurs readily in vivo, comparable heterodimers could be formed in vitro only under extreme conditions. To explain this difference we analyzed trp repressor dimer formation and dissociation using an in vitro transcription/translation system. Nascent wild type or mutant repressor polypeptides, synthesized in the presence of an excess of a second repressor, were invariably incorporated into heterodimers. In contrast, previously synthesized and assembled wild type dimers appeared to be refractory to dissociation, since they did not form heterodimers. However, previously synthesized mutant dimeric repressors that were defective in tryptophan binding readily dissociated and formed heterodimers. We noted that the ability of a dimeric repressor to dissociate under our conditions correlated inversely with its affinity for tryptophan. Consistent with this conclusion, we found that dissociation of the wild type aporepressor (no added tryptophan) was appreciably more rapid than dissociation of the tryptophan-saturated wild type repressor.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM011980] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM11980] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARROWSMITH C, 1991, EUR J BIOCHEM, V202, P53, DOI 10.1111/j.1432-1033.1991.tb16344.x; ARROWSMITH CH, 1990, BIOCHEMISTRY-US, V29, P6332, DOI 10.1021/bi00479a002; CAREY J, 1989, J BIOL CHEM, V264, P1941; GRADDIS TJ, 1988, PROTEINS, V4, P173, DOI 10.1002/prot.340040304; GUNSALUS RP, 1980, P NATL ACAD SCI-BIOL, V77, P7117, DOI 10.1073/pnas.77.12.7117; HEATWOLE VM, 1991, J BACTERIOL, V173, P108, DOI 10.1128/jb.173.1.108-115.1991; HURLBURT BK, 1992, NUCLEIC ACIDS RES, V20, P337, DOI 10.1093/nar/20.2.337; HURLBURT BK, 1990, J BIOL CHEM, V265, P7853; JOACHIMIAK A, 1983, P NATL ACAD SCI-BIOL, V80, P668, DOI 10.1073/pnas.80.3.668; KELLEY RL, 1985, P NATL ACAD SCI USA, V82, P483, DOI 10.1073/pnas.82.2.483; KLIG LS, 1988, J MOL BIOL, V202, P769, DOI 10.1016/0022-2836(88)90557-8; LAWSON CL, 1988, PROTEINS, V3, P18, DOI 10.1002/prot.340030103; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PALUH JL, 1986, NUCLEIC ACIDS RES, V14, P7851, DOI 10.1093/nar/14.20.7851; SARSERO JP, 1991, J BACTERIOL, V173, P4133, DOI 10.1128/jb.173.13.4133-4143.1991; SCHEVITZ RW, 1985, NATURE, V317, P782, DOI 10.1038/317782a0; SIGLER PB, 1992, TRANSCRIPTIONAL REGU, P475; SQUIRES CL, 1975, J MOL BIOL, V92, P93, DOI 10.1016/0022-2836(75)90093-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0; ZUBAY G, 1970, LACTOSE OPERON, P375; ZURAWSKI G, 1981, J MOL BIOL, V145, P47, DOI 10.1016/0022-2836(81)90334-X	22	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14794	14798						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325857				2022-12-27	WOS:A1993LL75900042
J	JANKOWSKI, JA; SCHROEDER, TJ; CIOLKOWSKI, EL; WIGHTMAN, RM				JANKOWSKI, JA; SCHROEDER, TJ; CIOLKOWSKI, EL; WIGHTMAN, RM			TEMPORAL CHARACTERISTICS OF QUANTAL SECRETION OF CATECHOLAMINES FROM ADRENAL-MEDULLARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDIVIDUAL CHROMAFFIN CELLS; EXOCYTOTIC FUSION PORE; SEA-URCHIN EGGS; GRANULE MATRIX; CHROMOGRANIN-A; CONFORMATIONAL CHANGE; MEMBRANE-FUSION; AGGREGATION; PROTEIN; BINDING	Exocytotic release of vesicular catecholamine from individual bovine adrenal medullary cells was detected with carbon fiber microelectrodes. Release was elicited from cells permeabilized with 20 muM digitonin in extracellular solutions of pH 5.5, 7.4, or 8.2, and with 100 muM nicotine at pH 7.4. Release detected amperometrically with a 6-mum radius electrode and 1-mum cell-electrode spacing was qualitatively similar for each pH and stimulus. However, amperometric detection with smaller electrodes (radius = 1 mum), cyclic voltammetry, or increased cell-electrode spacing with the larger electrode all resulted in a severe reduction in size and frequency of spikes detected at pH 5.5. Thus, the existence of a steep catecholamine concentration gradient at the cell surface is necessary to cause dissociation of the vesicular matrix at low extracellular pH. At an extracellular pH of 7.4, the distribution of amperometric spike widths measured with a 1-mum cell-electrode spacing was found to be inconsistent with that predicted for diffusional dispersion during transport from the cell surface to the electrode. Both of these results agree with the hypotheses that the chromaffin vesicle matrix normally exists in an aggregated state that can be dissociated by a chemical driving force. Some of the spikes exhibit a pre-spike feature. These were present more often following permeabilization in acidic pH as opposed to more alkaline solutions, and were most prevalent following exposure to nicotine at pH 7.4. The variability in the occurrence of the pre-spike feature suggests it originates from free catecholamine within the vesicle, since the molar fraction bound by the vesicular matrix is regulated by the pH-dependent conformation and Ca2+-dependent binding affinity of chromogranin A, a major protein in the vesicle.	UNIV N CAROLINA, DEPT CHEM, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill								ALMERS W, 1990, ANNU REV PHYSIOL, V52, P607, DOI 10.1146/annurev.ph.52.030190.003135; BAUR JE, 1988, ANAL CHEM, V60, P1268, DOI 10.1021/ac00164a006; BURGOYNE RD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P174, DOI 10.1016/0304-4157(91)90024-Q; CASEY RP, 1977, BIOCHEMISTRY-US, V16, P972, DOI 10.1021/bi00624a025; CHANDLER DE, 1989, J CELL BIOL, V109, P1269, DOI 10.1083/jcb.109.3.1269; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; CIOLKOWSKI EL, 1992, J AM CHEM SOC, V114, P2815, DOI 10.1021/ja00034a009; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; DUNN LA, 1983, J BIOL CHEM, V258, P4989; ENGSTROM RC, 1987, ANAL CHEM, V59, P2005, DOI 10.1021/ac00142a024; GERHARDT G, 1982, ANAL CHEM, V54, P2618, DOI 10.1021/ac00251a054; GORR SU, 1988, BONE MINER, V4, P17; HELLE KB, 1973, BIOCHIM BIOPHYS ACTA, V318, P181, DOI 10.1016/0005-2736(73)90112-0; HOLZ RW, 1983, J BIOL CHEM, V258, P7506; JANKOWSKI JA, 1992, J BIOL CHEM, V267, P18329; JOHNSON RG, 1979, J BIOL CHEM, V254, P3750; KAWAGOE KT, 1991, ANAL CHEM, V63, P1589, DOI 10.1021/ac00015a017; KNIGHT DE, 1985, J MEMBRANE BIOL, V83, P147, DOI 10.1007/BF01868746; KOPELL WN, 1982, J BIOL CHEM, V257, P5707; KUIJPERS GAJ, 1989, J BIOL CHEM, V264, P698; LESZCZYSZYN DJ, 1990, J BIOL CHEM, V265, P14736; LESZCZYSZYN DJ, 1991, J NEUROCHEM, V56, P1855, DOI 10.1111/j.1471-4159.1991.tb03441.x; MERKLE CJ, 1991, DEV BIOL, V148, P429, DOI 10.1016/0012-1606(91)90262-2; MONCK JR, 1991, BIOPHYS J, V59, P39, DOI 10.1016/S0006-3495(91)82196-8; MONCK JR, 1992, J CELL BIOL, V119, P1395, DOI 10.1083/jcb.119.6.1395; MONCK JR, 1990, P NATL ACAD SCI USA, V87, P7804, DOI 10.1073/pnas.87.20.7804; MORO MA, 1990, ANAL BIOCHEM, V185, P243, DOI 10.1016/0003-2697(90)90287-J; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; OCONNOR DT, 1991, BRAIN RES, V567, P188, DOI 10.1016/0006-8993(91)90795-W; PLETSCHE.A, 1973, BRAIN RES, V62, P317, DOI 10.1016/0006-8993(73)90692-6; SCHAFER T, 1987, BIOSCIENCE REP, V7, P269, DOI 10.1007/BF01121448; SCHMIDT W, 1983, EUR J CELL BIOL, V32, P31; SCHROEDER TJ, 1992, ANAL CHEM, V64, P3077, DOI 10.1021/ac00048a003; SEN R, 1979, BIOCHIM BIOPHYS ACTA, V587, P75, DOI 10.1016/0304-4165(79)90222-8; SPRUCE AE, 1991, P NATL ACAD SCI USA, V88, P3623, DOI 10.1073/pnas.88.9.3623; STREIN TG, 1992, ANAL CHEM, V64, P1368, DOI 10.1021/ac00037a012; TERAKAWA S, 1991, NEUROSCI LETT, V123, P82, DOI 10.1016/0304-3940(91)90163-N; UNVAS B, 1977, ACTA PHYSL SCAND, V99, P476; UNVAS B, 1980, ACTA PHYSL SCAND, V109, P345; VERDUGO P, 1991, AM REV RESPIR DIS, V144, pS33, DOI 10.1164/ajrccm/144.3_pt_2.S33; VIDEEN JS, 1992, J BIOL CHEM, V267, P3066; VIVEROS OH, 1969, SCIENCE, V165, P911, DOI 10.1126/science.165.3896.911; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; WILSON SP, 1983, J BIOL CHEM, V258, P4994; WINKLER H, 1977, NEUROSCIENCE, V2, P657, DOI 10.1016/0306-4522(77)90022-7; WINKLER H, 1976, NEUROSCIENCE, V1, P65, DOI 10.1016/0306-4522(76)90001-4; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; YOO SH, 1992, J BIOL CHEM, V267, P11236; YOO SH, 1990, J BIOL CHEM, V265, P14414; YOO SH, 1991, J BIOL CHEM, V266, P7740; ZIMMERBERG J, 1987, BIOSCIENCE REP, V7, P251, DOI 10.1007/BF01121447; [No title captured]	53	123	125	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14694	14700						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325848				2022-12-27	WOS:A1993LL75900028
J	NAKAYAMA, M; YAZAKI, K; KUSANO, A; NAGATA, K; HANAI, N; ISHIHAMA, A				NAKAYAMA, M; YAZAKI, K; KUSANO, A; NAGATA, K; HANAI, N; ISHIHAMA, A			STRUCTURE OF MOUSE MX1 PROTEIN - MOLECULAR ASSEMBLY AND GTP-DEPENDENT CONFORMATIONAL CHANGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS; GENE; RESISTANCE; CELLS; SEQUENCE; CLONING; NUCLEI; FAMILY	Mouse Mx1 protein is an interferon-inducible nuclear protein and confers resistance to influenza virus infection. The Mx1 protein purified from interferon-induced A2G mouse liver exhibited GTPase activity as did the Mx1 protein purified from the Mx1 cDNA-expressing Escherichia coli (Nakayama, M., Nagata, K., Kato, A., and Ishihama, A. (1991) J. Biol. Chem. 266, 21404-21408; Nakayama, M., Nagata, K., and Ishihama, A. (1992) Virus Res. 22, 227-234). The Mx1 protein purified from both mouse liver and Mx1-cDNA expressing E. coli was found to exist as assembled polymeric states judged from gel filtration pattern. By making a set of deletion derivatives of the Mx1 cDNA, the main motif for self-assembly of the Mx1 protein was mapped between amino acid residues 51-99. This motif is highly conserved not only in the Mx family of proteins but also in Mx-related proteins. The polymeric form of Mx1 from E. coli was observed as ''horseshoe''-like structure by negative staining microscopy. When the Mx1 protein was incubated with GTP, this horseshoe structure was transformed to larger and tightly stacked helical forms. Electron microscopic analysis of immunostained liver of the interferon-induced mice indicated that the Mx1 protein exists in nuclei, forming giant complexes of about half the size of nucleoli.	NATL INST GENET,DEPT MOLEC GENET,MISHIMA,SHIZUOKA 411,JAPAN; NAGOYA UNIV,FAC SCI,DEPT BIOL,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; TOKYO METROPOLITAN INST MED SCI,BUNKYO KU,TOKYO 113,JAPAN; TOKYO RES LABS,DIV IMMUNOL,TOKYO 194,JAPAN	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Nagoya University; Tokyo Metropolitan Institute of Medical Science								AEBI M, 1989, MOL CELL BIOL, V9, P5062, DOI 10.1128/MCB.9.11.5062; ARNHEITER H, 1988, EMBO J, V7, P1315, DOI 10.1002/j.1460-2075.1988.tb02946.x; ARNHEITER H, 1990, CELL, V62, P51, DOI 10.1016/0092-8674(90)90239-B; BRONI B, 1990, J VIROL, V64, P6335, DOI 10.1128/JVI.64.12.6335-6340.1990; Collins C A, 1991, Trends Cell Biol, V1, P57, DOI 10.1016/0962-8924(91)90090-V; DREIDING P, 1985, VIROLOGY, V140, P192, DOI 10.1016/0042-6822(85)90460-X; HORISBERGER MA, 1990, J VIROL, V64, P1171, DOI 10.1128/JVI.64.3.1171-1181.1990; JONES BA, 1992, GENE DEV, V6, P386; KOLB E, 1992, J VIROL, V66, P1709, DOI 10.1128/JVI.66.3.1709-1716.1992; KRUG RM, 1985, J VIROL, V56, P201, DOI 10.1128/JVI.56.1.201-206.1985; MEIER E, 1988, J VIROL, V62, P2386, DOI 10.1128/JVI.62.7.2386-2393.1988; MEIER E, 1990, J VIROL, V64, P6263, DOI 10.1128/JVI.64.12.6263-6269.1990; MELEN K, 1992, J BIOL CHEM, V267, P25898; NAKAYAMA M, 1991, J BIOL CHEM, V266, P21404; NAKAYAMA M, 1992, VIRUS RES, V22, P227, DOI 10.1016/0168-1702(92)90054-D; NOTEBORN M, 1987, J INTERFERON RES, V7, P657, DOI 10.1089/jir.1987.7.657; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; PAVLOVIC J, 1990, J VIROL, V64, P3379; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; STAEHELI P, 1989, MOL CELL BIOL, V9, P3117, DOI 10.1128/MCB.9.7.3117; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; STAEHELI P, 1988, MOL CELL BIOL, V8, P4524, DOI 10.1128/MCB.8.10.4524; STAEHELI P, 1990, ADV VIRUS RES, V38, P140; WEITZ G, 1989, J INTERFERON RES, V9, P679, DOI 10.1089/jir.1989.9.679; YEH E, 1991, NATURE, V349, P713, DOI 10.1038/349713a0	25	70	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15033	15038						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325879				2022-12-27	WOS:A1993LL75900073
J	SHINITZKY, M; FRIEDMAN, P; HAIMOVITZ, R				SHINITZKY, M; FRIEDMAN, P; HAIMOVITZ, R			FORMATION OF 1,3-CYCLIC GLYCEROPHOSPHATE BY THE ACTION OF PHOSPHOLIPASE-C ON PHOSPHATIDYLGLYCEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CEREUS; PHOSPHATIDYLINOSITOL; PURIFICATION; PHOSPHATE; MESSENGER	The action of phospholipase C (PLC) from Bacillus cereus on phosphatidylglycerol (PG), derived from egg yolk phosphatidylcholine (PC), was examined in an ether-water mixture. The PLC cleavage of PG and PC followed a Michaelis-Menten kinetics with apparent V(max) values per 1 mug enzyme of 0.26 and 0.91 mumol.min-1 and K(m) values of 10 and 12 mM, respectively. When the same enzymic reaction was carried out in minimally buffered aqueous solution of 1% Triton X-100, the decrease in pH with respect to phospholipid cleavage was as expected with PC but much less pronounced with PG. This could be accounted for by the formation of a cyclic glycerophosphate, rather than alpha-glycerophosphate, in the PLC hydrolysis of PG. Examination of the chemical nature of the water-soluble product of PG by phosphorus nuclear magnetic resonance (P-31 NMR) revealed a single band at 2.31 ppm, while the bands of alpha-glycerophosphate and beta-glycerophosphate appeared at 5.12 and 4.57 ppm, respectively. Basic hydrolysis of the phospholipase cleavage product of PG (0.1 M NaOH for 1 min at 80-degrees-C) followed by neutralization shifted its P-31 NMR band to 5.18 ppm, which practically coincided with that of alpha-glycerophosphate. Analogous experiments were carried out with PG labeled with H-3 at the carbon 2 of the glycerol headgroup ([H-3]PG). Autoradiography of thin layer chromatography (TLC) of the [H-3]PG enzymic hydrolyzate displayed a single H-3-labeled compound, which could be converted to alpha-glycerophosphate by basic hydrolysis. These results strongly suggest that the phosphate headgroup of PG is cleaved off by PLC as 1,3-cyclic glycerophosphate. A series of PLC experiments with phosphatidyl dihydroxyacetone and phosphatidyl 1,3-propanediol as model substrates supported this assignment. Two-dimensional homonuclear H-1 NMR correlated spectra as well as infrared spectra carried out on the isolated sodium salt of this product could further confirm such a structure. The unique structure and chemical nature of 1,3-cyclic glycerophosphate may bear a distinct physiological function.			SHINITZKY, M (corresponding author), WEIZMANN INST SCI, DEPT MEMBRANE RES & BIOPHYS, IL-76100 REHOVOT, ISRAEL.							BAILLY O, 1922, B SOC CHIM FR, V31, P848; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLACKBUR.GM, 1971, TETRAHEDRON, V27, P2903, DOI 10.1016/S0040-4020(01)98082-2; BOLCKINO SB, 1985, J BIOL CHEM, V260, P14201; DAWSON RMC, 1971, BIOCHEM J, V122, P605, DOI 10.1042/bj1220605; Dennis EA, 1983, ENZYMES, P307; DEROME AE, 1990, J MAGN RESON, V88, P177, DOI 10.1016/0022-2364(90)90123-Q; Eibl H, 1981, Methods Enzymol, V72, P632; EXTON JH, 1990, J BIOL CHEM, V265, P1; FRIEDMAN P, 1992, THESIS WEIZMANN I RE; GALLAGHER G, 1987, METHODS STEREOCHEMIC, V8, P297; GRIFFITH OH, 1991, METHOD ENZYMOL, V197, P493; HAVERKATE F, 1965, BIOCHIM BIOPHYS ACTA, V106, P78; IKEZAWA H, 1978, BIOCHIM BIOPHYS ACTA, V528, P247; Ikezawa H, 1981, METHODS ENZYMOLOGY C, P731, DOI [10.1016/0076-6879(81)71086-3, DOI 10.1016/0076-6879(81)71086-3]; KHORANA HG, 1957, J AM CHEM SOC, V79, P430, DOI 10.1021/ja01559a054; KHORANA HG, 1961, SOME RECENT DEV CHEM, P44; KUMAMOTO J, 1956, J AM CHEM SOC, V78, P4858, DOI 10.1021/ja01600a012; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; Little C., 1981, METHOD ENZYMOL, V71, P725; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; OTNAESS AB, 1977, EUR J BIOCHEM, V79, P459, DOI 10.1111/j.1432-1033.1977.tb11828.x; OTTOLENGHI AC, 1969, METHOD ENZYMOL, V14, P188; ROBERTS MF, 1978, J BIOL CHEM, V253, P1252; ROSS TS, 1986, J BIOL CHEM, V261, P1119; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; VOLWERK JJ, 1989, J CELL BIOCHEM, V39, P315, DOI 10.1002/jcb.240390311; WILSON DB, 1985, J BIOL CHEM, V260, P3496; Zwaal R F, 1974, Methods Enzymol, V32, P154	29	22	24	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14109	14115						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314778				2022-12-27	WOS:A1993LJ82500050
J	STRONGIN, AY; MARMER, BL; GRANT, GA; GOLDBERG, GI				STRONGIN, AY; MARMER, BL; GRANT, GA; GOLDBERG, GI			PLASMA MEMBRANE-DEPENDENT ACTIVATION OF THE 72-KDA TYPE-IV COLLAGENASE IS PREVENTED BY COMPLEX-FORMATION WITH TIMP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASE-3 STROMELYSIN; SKIN FIBROBLAST PROCOLLAGENASE; 72 KDA PROGELATINASE; TISSUE INHIBITOR; INTERSTITIAL COLLAGENASE; SEQUENCE IDENTIFICATION; PURIFICATION; EXPRESSION; MECHANISMS; CELLS	Human 72-kDa type IV collagenase (72T4Cl) is secreted as a proenzyme that can form a specific stoichiometric complex with the tissue inhibitor of metalloproteases TIMP-2 via interaction with the carboxyl-terminal domain of the enzyme. Both complexed an free enzymes can be activated by treatment with organomercurials. The mechanism of the 72T4Cl activation under physiological conditions is not known. Here we describe a ''plasma membrane-dependent'' activation of inhibitor-free 72T4Cl and identify the first conversion intermediate as a 64-kDa species resulting from cleavage of the Asn37-Leu peptide bond in the presence of plasma membranes from 12-O-tetradecanoylphorbol-13-acetate-induced HT1080 cells. This reaction is specific for 72T4Cl in that a closely related proenzyme (92-kDa type IV collagenase) is resistant to activation under the same conditions. Formation of the 72T4Cl.TIMP-2 complex inhibits activation at the level of the initial Asn37-Leu cleavage. Addition of TIMP-1 has no effect on this reaction, but blocks the autocatalytic conversion of the Leu38 intermediate into a 62-kDa active enzyme with an amino-terminal Tyr81. Membrane-dependent activation of 72T4Cl is competitively inhibited in the presence of a 26-kDa peptide derived from the carboxyl-terminal domain of the enzyme. The results suggest that interaction of the carboxyl-terminal domain of the enzyme with a membrane-associated component(s) causes initiation of enzyme activation through an autoproteolytic mechanism.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)	STRONGIN, AY (corresponding author), WASHINGTON UNIV,SCH MED,DIV DERMATOL,ST LOUIS,MO 63110, USA.		Strongin, Alex/R-6609-2019	Strongin, Alex/0000-0003-3765-3016	NIAMS NIH HHS [T32 AR07284, R01 AR39472, R01 AR40618] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039472, R01AR040618, T32AR007284] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BROWN PD, 1990, CANCER RES, V50, P6184; COLLIER IE, 1992, J BIOL CHEM, V267, P6776; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DOCHERTY AJP, 1992, TRENDS BIOTECHNOL, V10, P200, DOI 10.1016/0167-7799(92)90214-G; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FRISCH SM, 1990, ONCOGENE, V5, P75; Goldberg G I, 1992, Matrix Suppl, V1, P25; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; GOLDBERG GI, 1991, REGULATORY MECHANISM, P421; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRANT GA, 1987, J BIOL CHEM, V262, P5886; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; KESKIOJA J, 1992, EXP CELL RES, V202, P471, DOI 10.1016/0014-4827(92)90101-D; KLEINER DE, 1992, BIOCHEMISTRY-US, V31, P1665, DOI 10.1021/bi00121a013; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; STRICKLIN GP, 1983, BIOCHEMISTRY-US, V22, P61, DOI 10.1021/bi00270a009; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213	34	319	332	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14033	14039						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314771				2022-12-27	WOS:A1993LJ82500040
J	TONG, HX; DAVIS, L				TONG, HX; DAVIS, L			2-AMINO 3-KETOBUTYRATE-COA LIGASE FROM BEEF-LIVER MITOCHONDRIA - PURIFICATION AND PARTIAL SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMATE 1-SEMIALDEHYDE AMINOTRANSFERASE; 2-AMINO-3-KETOBUTYRATE COA LIGASE; PYRIDOXAL-PHOSPHATE-BINDING; ESCHERICHIA-COLI; L-THREONINE; NUCLEOTIDE-SEQUENCE; ENZYME; GENE; DEHYDROGENASE; DEGRADATION	2-Amino-3-ketobutyrate-CoA ligase (EC 2.3.1.29), or aminoacetone synthetase, has been purified by a nine-step procedure from 1.0 kg of beef liver to yield 8.8 mg of homogeneous enzyme. The homogeneous form of the enzyme, a monomer of M(r) = 44,000, shows unusually high absorption at 430 nm, with a ratio of absorbance at 280 and 430 nm of 2.6. On storage a species with an additional absorption peak at 332 is formed. Neither the 430-nm peak nor the 332-430 ratio is affected by pH or substrates. The peak at 430 nm and enzyme activity are both reduced by borohydride reduction and treatment with cysteine. The first 21 amino acids at the NH2-terminal of the ligase occur in the sequence Ser-Ala-Leu-Ala-Gln-Leu-Arg- Gly-Ile-Leu-Glu-Glu-Glu-Leu-Glu-Ser-Ile-Arg- Gly-Ala-Gly. No homology is detectable in the first 20 amino acids of the Escherichia coli and beef liver mitochondria enzymes. However, homology is found around the lysine residue to which the pyridoxal 5'-phosphate is attached in the two enzymes. A very hydrophobic peptide containing pyridoxal phosphate having the following sequence Leu-Leu-Gly-Val-Met-Asp-Gln-Val-Thr-Ile-Ile-Asn- Ser-Thr-Leu-Gly-Lys(Pxy)-Ala-Leu-Gly-Gly-Ala-Ser- Gly-Gly-Tyr-Thr-Thr-Gly-Pro-Gly-Ala-Leu-Val has been isolated from the ligase. Fourteen residues around the lysine to which the pyridoxal 5'-phosphate is bound are completely identical with the pyridoxal 5'-phosphate containing peptide isolated from the E. coli 2-amino-3 ketobutyrate-CoA ligase.	UNIV IOWA, DEPT CHEM, IOWA CITY, IA 52242 USA	University of Iowa					NIDDK NIH HHS [DK 16950] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016950] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AITEN A, 1989, PROTEIN SEQUENCING P, P43; ANGELACCIO S, 1992, BIOCHEMISTRY-US, V31, P155, DOI 10.1021/bi00116a023; AOYAMA Y, 1981, J BIOL CHEM, V256, P2367; ARONSON BD, 1988, NUCLEIC ACIDS RES, V16, P3586, DOI 10.1093/nar/16.8.3586; BELL SC, 1976, BIOCHEM J, V156, P449, DOI 10.1042/bj1560449; BELL SC, 1976, BIOCHEM SOC T, V4, P497, DOI 10.1042/bst0040497; BIRD MI, 1983, BIOCHEM J, V214, P687, DOI 10.1042/bj2140687; BIRD MI, 1984, BIOCHIM BIOPHYS ACTA, V802, P229, DOI 10.1016/0304-4165(84)90166-1; Bird MI, 1979, BIOCHEM SOC T, V7, P1276, DOI 10.1042/bst0071276; BORTHWICK IA, 1985, EUR J BIOCHEM, V150, P481, DOI 10.1111/j.1432-1033.1985.tb09047.x; DALE RA, 1978, BIOCHIM BIOPHYS ACTA, V544, P496, DOI 10.1016/0304-4165(78)90324-0; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GIBSON KD, 1958, BIOCHEM J, V70, P71, DOI 10.1042/bj0700071; GRIMM B, 1990, P NATL ACAD SCI USA, V87, P4169, DOI 10.1073/pnas.87.11.4169; GRIMM B, 1991, MOL GEN GENET, V225, P1; HANSSON M, 1991, J BACTERIOL, V173, P2590, DOI 10.1128/jb.173.8.2590-2599.1991; HIRS CHW, 1956, J BIOL CHEM, V219, P611; HORNBERGER U, 1990, MOL GEN GENET, V221, P371, DOI 10.1007/BF00259402; INANA G, 1986, P NATL ACAD SCI USA, V83, P1203, DOI 10.1073/pnas.83.5.1203; KOMATSUBARA S, 1978, J BACTERIOL, V135, P318, DOI 10.1128/JB.135.2.318-323.1978; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAUZERALL D, 1956, J BIOL CHEM, V219, P435; MCGILVRAY D, 1969, BIOCHEM J, V112, P657, DOI 10.1042/bj1120657; MORINO Y, 1984, METHOD ENZYMOL, V106, P116; MUKHERJEE JJ, 1990, BIOCHIM BIOPHYS ACTA, V1037, P24, DOI 10.1016/0167-4838(90)90097-Y; MUKHERJEE JJ, 1987, J BIOL CHEM, V262, P14441; OTSUKA AJ, 1988, J BIOL CHEM, V263, P19577; RAVNIKAR PD, 1987, J BACTERIOL, V169, P2611, DOI 10.1128/jb.169.6.2611-2617.1987; RITCHEY JM, 1977, BIOCHEMISTRY-US, V16, P4584, DOI 10.1021/bi00640a008; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEIDER WC, 1950, J BIOL CHEM, V183, P123; SCHOENHAUT DS, 1986, GENE, V48, P55, DOI 10.1016/0378-1119(86)90351-3; SPECTOR T, 1978, ANAL BIOCHEM, V86, P142, DOI 10.1016/0003-2697(78)90327-5; STRAUSBAUCH PH, 1967, METHOD ENZYMOL, V11, P671; TURNER JM, 1966, BIOCHEM J, V99, P427, DOI 10.1042/bj0990427; ULEVITCH RJ, 1977, BIOCHEMISTRY-US, V16, P5342, DOI 10.1021/bi00643a027; URATA G, 1963, J BIOL CHEM, V238, P811	37	6	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4057	4064						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307963				2022-12-27	WOS:A1994MW98900027
J	WANG, L; LIN, XH; CUI, DF; WANG, ZY; CHI, CW				WANG, L; LIN, XH; CUI, DF; WANG, ZY; CHI, CW			ASSIGNMENT OF THE BINDING-SITE FOR TISSUE-PLASMINOGEN ACTIVATOR ON HUMAN FIBRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLD-INSOLUBLE GLOBULIN; CROSS-LINKING; COLLAGEN; FRAGMENTS; PROTEIN; FIBRIN; INVITRO; PLASMA; CHAIN; CELLS	The tissue-type plasminogen activator (t-PA) has been found to bind reversibly to human fibronectin (Fn). To locate the binding site on Fn for t-PA, the Fn was de graded with N-tosyl-L-phenylalanyl chloromethyl ketone treated trypsin, and the resulting fragments were monitored by the enzyme-linked immunosorbent assay method for t-PA binding activities. A 20-kDa fragment with t-PA binding activity was identified, separated, and purified. It was subjected to further degradation with Staphylococcus aureus proteinase V8. An active 10-kDa fragment was finally purified by reverse-phase high pressure liquid chromatography on a C-3 column. The dissociation constants of the binding of Fn and the 10-kDa fragment to t-PA were estimated by Scatchard plot to be 1.13 x 10(-8) and 2.08 x 10(-8) M, respectively. The 10- kDa fragment was sequenced and proved to be located at the 8-9th domains of type I homology of Fn. Based on the structural analysis of the 8-9th domains, a heptadecapeptide corresponding to the sequence Thr(535)-Gly(551) Of Fn, which resided at the large disulfide loop of domain (I-9), was designed and synthesized. Both the 10-kDa fragment and the synthetic peptide could com petitively inhibit the binding of Fn to t-PA. The synthetic peptide showed about one-tenth of the binding activity of Fn to BPA with a dissociation constant of 1.35 x 10(-7) M and was proved to be the binding region of Fn for t-PA. In addition, like the intact Fn, both the 10-kDa fragment and the synthetic peptide could remarkably enhance the amidolytic activity of t-PA in a dose-dependent manner,as shown by using S-2288 as a chromogenic substrate.	ACAD SINICA, SHANGHAI INST BIOCHEM, SHANGHAI 200031, PEOPLES R CHINA; SHANGHAI MED UNIV 2, SHANGHAI INST HEMATOL, SHANGHAI 200025, PEOPLES R CHINA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University								BANYAI L, 1983, FEBS LETT, V163, P37, DOI 10.1016/0014-5793(83)81157-0; DEBEER FC, 1981, J EXP MED, V154, P1134, DOI 10.1084/jem.154.4.1134; DODD I, 1986, THROMB HAEMOSTASIS, V55, P94; EMMERLING MR, 1981, BIOCHEMISTRY-US, V20, P3242, DOI 10.1021/bi00514a040; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; GILBOA N, 1985, THROMB HAEMOSTASIS, V54, P639; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; HYNES RO, 1976, BIOCHIM BIOPHYS ACTA, V458, P73, DOI 10.1016/0304-419X(76)90015-9; HYNES RO, 1990, FIBRONECTIN, P5; INGHAM KC, 1989, J BIOL CHEM, V264, P16977; INGHAM KC, 1988, J BIOL CHEM, V263, P4624; KESKIOJA J, 1980, J CELL BIOL, V85, P527, DOI 10.1083/jcb.85.3.527; KLEINMAN HK, 1979, P NATL ACAD SCI USA, V76, P3367, DOI 10.1073/pnas.76.7.3367; LITVINOVICH SV, 1991, J MOL BIOL, V217, P563, DOI 10.1016/0022-2836(91)90758-X; MCGUIRE PG, 1989, J CELL BIOCHEM, V40, P215, DOI 10.1002/jcb.240400210; MENZEL EJ, 1981, FEBS LETT, V129, P188, DOI 10.1016/0014-5793(81)80787-9; MOSESSON MW, 1975, BIOCHIM BIOPHYS ACTA, V386, P509, DOI 10.1016/0005-2795(75)90294-9; MOSHER DF, 1986, ANN NY ACAD SCI, V485, P264, DOI 10.1111/j.1749-6632.1986.tb34588.x; MOSHER DF, 1975, J BIOL CHEM, V250, P6614; MOSHER DF, 1980, SCIENCE, V209, P927, DOI 10.1126/science.7403857; NIEUWENHUIZEN W, 1988, EUR J BIOCHEM, V174, P163, DOI 10.1111/j.1432-1033.1988.tb14077.x; OWENS RJ, 1986, EMBO J, V5, P2825, DOI 10.1002/j.1460-2075.1986.tb04575.x; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; QUIGLEY JP, 1987, P NATL ACAD SCI USA, V84, P2776, DOI 10.1073/pnas.84.9.2776; SALONEN EM, 1985, J BIOL CHEM, V260, P2302; SEKIGUCHI K, 1980, P NATL ACAD SCI-BIOL, V77, P2661, DOI 10.1073/pnas.77.5.2661; STEMBERGER A, 1976, H-S Z PHYSIOL CHEM, V357, P1003; VARTIO T, 1982, EUR J BIOCHEM, V123, P223, DOI 10.1111/j.1432-1033.1982.tb19757.x; VERHEIJEN JH, 1985, THROMB RES, V39, P281, DOI 10.1016/0049-3848(85)90223-3; XUE JC, 1991, ACTA BIOCH BIOPH SIN, V22, P281; ZARDI L, 1979, CELL, V18, P649, DOI 10.1016/0092-8674(79)90120-X	32	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4332	4336						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308001				2022-12-27	WOS:A1994MW98900068
J	YADAV, SP; BREW, K; MAJERCIK, MH; PUETT, D				YADAV, SP; BREW, K; MAJERCIK, MH; PUETT, D			A LABEL SELECTION APPROACH TO ASSESS THE ROLE OF INDIVIDUAL AMINO-GROUPS IN HUMAN CHORIOGONADOTROPIN RECEPTOR-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; LEYDIG TUMOR-CELLS; SITE-DIRECTED MUTAGENESIS; BETA-SUBUNIT; ALPHA-SUBUNIT; GLYCOPROTEIN HORMONES; BIOLOGICAL-ACTIVITY; HUMAN CHORIOTROPIN; TERMINAL REGION; LUTROPIN	Human choriogonadotropin (hCG) was trace-labeled with [H-3]acetic anhydride and then incubated with transformed murine Leydig cells (MA-10). The bound hormone was recovered, subunits (alpha and beta) were separated and then cleaved, and the peptides were purified by high performance liquid chromatography. Analysis of the labeling patterns of peptides from the initial preparation and the bound hCG fraction enabled us to determine the protection factor of several amino groups, which is a measure of the effects of acetylation on receptor binding. The largest protection factors, indicating lower labeling in the bound fraction, were found on beta and involved the alpha-amino group/Lys(2) (analyzed together) and Lys(104), which exhibited 6 fold and 5-fold selections against binding, respectively. Thus, acetylation at either of these amino groups does not prevent binding but results in selection against hormone association with receptor. Other amino groups were analyzed (e.g. Lys(122) on beta; the alpha-amino group and lysines 44/45 (analyzed as a pair), 51, and 75 on alpha), and the selection factors indicated either no change or only modest changes (2-fold) in selection for or against binding. These results indicate that the alpha-amino group/Lys(2) and Lys(104) of the hormone-specific beta subunit participate, either directly or indirectly, in receptor binding.	UNIV GEORGIA, DEPT BIOCHEM, ATHENS, GA 30602 USA; UNIV MIAMI, SCH MED, DEPT BIOCHEM & MOLEC BIOL, MIAMI, FL 33101 USA; UNIV MIAMI, SCH MED, REPROD SCI & ENDOCRINOL LABS, MIAMI, FL 33101 USA	University System of Georgia; University of Georgia; University of Miami; University of Miami			Brew, Keith/W-1643-2019; Brew, Keith/A-6746-2009	Brew, Keith/0000-0003-1306-1032	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007129] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033973] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07129] Funding Source: Medline; NIDDK NIH HHS [DK33973] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASCOLI M, 1974, BIOCHIM BIOPHYS ACTA, V371, P203, DOI 10.1016/0005-2795(74)90169-X; ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; ASCOLI M, 1982, J BIOL CHEM, V257, P13306; AZUMA C, 1990, J MOL ENDOCRINOL, V5, P97, DOI 10.1677/jme.0.0050097; BIRKEN S, 1987, ENDOCRINOLOGY, V121, P657, DOI 10.1210/endo-121-2-657; BIRKEN S, 1986, J BIOL CHEM, V261, P719; Bosshard H R, 1979, Methods Biochem Anal, V25, P273, DOI 10.1002/9780470110454.ch4; BOUSFIELD GR, 1988, J BIOL CHEM, V263, P12602; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; CHARLESWORTH MC, 1987, J BIOL CHEM, V262, P13409; CHEN F, 1991, J BIOL CHEM, V266, P19357; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; CHEN F, 1991, BIOCHEMISTRY-US, V30, P10171, DOI 10.1021/bi00106a014; CHEN F, 1991, J BIOL CHEM, V266, P6904; CHEN WY, 1991, J BIOL CHEM, V266, P6246; CHENG KW, 1973, J BIOL CHEM, V248, P7930; CHIN D, 1989, J BIOL CHEM, V264, P15367; COMBARNOUS Y, 1992, ENDOCR REV, V13, P670, DOI 10.1210/edrv-13-4-670; ELDEIRY S, 1989, MOL ENDOCRINOL, V3, P1523, DOI 10.1210/mend-3-10-1523; ERICKSON LD, 1990, ENDOCRINOLOGY, V126, P2555, DOI 10.1210/endo-126-5-2555; Gordon WL, 1985, LUTEINIZING HORMONE, P173; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HUANG JN, 1993, MOL CELL ENDOCRINOL, V90, P211, DOI 10.1016/0303-7207(93)90154-C; HUANG JN, 1993, J BIOL CHEM, V268, P9311; JACKSON AE, 1987, PROTEINS, V2, P202, DOI 10.1002/prot.340020305; KAPLAN H, 1971, BIOCHEM J, V124, P289, DOI 10.1042/bj1240289; KEUTMANN HT, 1988, BIOCHEMISTRY-US, V27, P8939, DOI 10.1021/bi00425a010; KEUTMANN HT, 1992, MOL CELL ENDOCRINOL, V86, pC1, DOI 10.1016/0303-7207(92)90168-6; KEUTMANN HT, 1987, P NATL ACAD SCI USA, V84, P2038, DOI 10.1073/pnas.84.7.2038; KEUTMANN HT, 1992, PEPTIDES CHEM BIOL, P74; LLOSA PDL, 1974, BIOCHIM BIOPHYS ACTA, V342, P97, DOI 10.1016/0005-2795(74)90110-X; LUSTBADER JW, 1993, ENDOCR REV, V14, P291, DOI 10.1210/er.14.3.291; MAJERCIK MH, 1989, STEROIDS, V54, P627, DOI 10.1016/0039-128X(89)90085-8; MATZUK MM, 1990, ENDOCRINOLOGY, V126, P376, DOI 10.1210/endo-126-1-376; MERZ WE, 1984, SECRETION ACTION GON, P59; PARSONS TF, 1984, ENDOCRINOLOGY, V114, P2223, DOI 10.1210/endo-114-6-2223; PUETT D, 1989, J PROTEIN CHEM, V8, P779, DOI 10.1007/BF01024902; REED DK, 1991, J BIOL CHEM, V266, P14251; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; SALESSE R, 1990, MOL CELL ENDOCRINOL, V68, P113, DOI 10.1016/0303-7207(90)90183-9; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; XIA H, 1993, J MOL ENDOCRINOL, V10, P337, DOI 10.1677/jme.0.0100337; XIA HY, 1993, MOL CELL ENDOCRINOL, V92, pR1, DOI 10.1016/0303-7207(93)90086-Y; YADAV S, 1990, J BIOL CHEM, V265, P14163; YADAV SP, 1991, J BIOL CHEM, V266, P698; YADAV SP, 1991, FASEB J, V5, pA1521; YOO J, 1991, J BIOL CHEM, V266, P17741; YOO JK, 1993, J BIOL CHEM, V268, P13034	48	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3991	3998						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307955				2022-12-27	WOS:A1994MW98900017
J	COMSTOCK, KE; JOHNSON, KJ; RIFENBERY, D; HENNER, WD				COMSTOCK, KE; JOHNSON, KJ; RIFENBERY, D; HENNER, WD			ISOLATION AND ANALYSIS OF THE GENE AND CDNA FOR A HUMAN MU CLASS GLUTATHIONE-S-TRANSFERASE, GSTM4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; TRANS-STILBENE OXIDE; HUMAN-LIVER; LUNG-CANCER; CYTOGENETIC DAMAGE; HUMAN-LEUKOCYTES; HUMAN-MUSCLE; ALPHA-CLASS; RAT-LIVER; EXPRESSION	We have isolated the human gene and cDNA that encode the fourth member of the Mu class glutathione S-transferases (GSTs). The complete gene sequence (GenBank M96233) and the cDNA sequence (M96234) are reported and named GSTM4. The gene, located on chromosome 1, is comprised of eight exons with an organization similar to that of other Mu class genes. GSTM4 differs from a partial gene sequence, termed GSTmu2 (Taylor, J. B., Oliver, J., Sherrington, R., and Pemble, S. E. (1991) Biochem. J. 274, 587-593), in exons 3 through 5 by only 11 nucleotides within introns. The cDNA for GSTM4 was isolated from a library derived from the cervical carcinoma cell line, HeLa. Northern blots demonstrate the presence of GSTM4 mRNA in human heart, placenta, lung, brain, liver, skeletal muscle, pancreas, testis, cerebral cortex, uterus, ovary, a lymphoblastoid cell line, and four carcinoma cell lines. The deduced amino acid sequence of GSTM4 is 87% (GSTM1), 83% (GSTM2), and 70% (GSTM3) identical to the previously described human Mu class GSTs. The polypeptide encoded by the GSTM4 cDNA, produced in a bacterial expression system, conjugates 1-chloro-2,4-dinitrobenzene to GSH with a specific activity of 1.39 +/- 0.21 mumol/min/mg.	OREGON HLTH SCI UNIV,DIV HEMATOL & MED ONCOL,MAIL CODE L586,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University								Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BECKETT GJ, 1990, BIOCHIM BIOPHYS ACTA, V1036, P176, DOI 10.1016/0304-4165(90)90031-Q; BELL D, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P291; BOARD PG, 1988, BIOCHIM BIOPHYS ACTA, V953, P214, DOI 10.1016/0167-4838(88)90027-1; BOYER TG, 1989, J BIOL CHEM, V264, P5177; BOYER TG, 1990, J BIOL CHEM, V265, P20524; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL E, 1990, J BIOL CHEM, V265, P9188; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COMSTOCK KE, 1990, NUCLEIC ACIDS RES, V18, P3670, DOI 10.1093/nar/18.12.3670; DAVIDSON NE, 1990, CANCER RES, V50, P2251; DEJONG JL, 1988, NUCLEIC ACIDS RES, V16, P8541, DOI 10.1093/nar/16.17.8541; DEJONG JL, 1991, BIOCHEM BIOPH RES CO, V180, P15, DOI 10.1016/S0006-291X(05)81248-3; DING VDH, 1985, ARCH BIOCHEM BIOPHYS, V240, P553, DOI 10.1016/0003-9861(85)90062-1; DIONNE CA, 1990, BIOTECHNIQUES, V8, P190; FAN WM, 1992, P NATL ACAD SCI USA, V89, P6104, DOI 10.1073/pnas.89.13.6104; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HECKBERT SR, 1992, J NATL CANCER I, V84, P414, DOI 10.1093/jnci/84.6.414; HUSSEY AJ, 1991, BIOCHEM J, V273, P323, DOI 10.1042/bj2730323; ISLAM MQ, 1989, HUM GENET, V82, P338; KETTERER B, 1988, MUTAT RES, V202, P343, DOI 10.1016/0027-5107(88)90197-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI HCJ, 1988, J BIOL CHEM, V263, P11389; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCLELLAN LI, 1991, BIOCHEM J, V276, P461, DOI 10.1042/bj2760461; MEAD DA, 1985, NUCLEIC ACIDS RES, V13, P1103, DOI 10.1093/nar/13.4.1103; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; MORTON MR, 1990, ARCH BIOCHEM BIOPHYS, V277, P56, DOI 10.1016/0003-9861(90)90549-E; PEARSON WR, 1988, J BIOL CHEM, V263, P13324; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Sambrook J, 1989, MOL CLONING LABORATO; SEIDEGARD J, 1985, HUM GENET, V69, P66, DOI 10.1007/BF00295531; SEIDEGARD J, 1986, CARCINOGENESIS, V7, P751, DOI 10.1093/carcin/7.5.751; SEIDEGARD J, 1988, P NATL ACAD SCI USA, V85, P7293, DOI 10.1073/pnas.85.19.7293; SHEA TC, 1988, CANCER RES, V48, P527; SHEA TC, 1990, CANCER RES, V50, P6848; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; Simons P C, 1981, Methods Enzymol, V77, P235; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; SUZUKI T, 1991, BIOCHEM J, V274, P405, DOI 10.1042/bj2740405; TAYLOR JB, 1991, BIOCHEM J, V274, P587, DOI 10.1042/bj2740587; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUCHIDA S, 1990, J BIOL CHEM, V265, P7150; VANDENBERGHE Y, 1991, FEBS LETT, V284, P103, DOI 10.1016/0014-5793(91)80772-U; VANPOPPEL G, 1992, CARCINOGENESIS, V13, P303, DOI 10.1093/carcin/13.2.303; VORACHEK WR, 1991, P NATL ACAD SCI USA, V88, P4443, DOI 10.1073/pnas.88.10.4443; WARHOLM M, 1983, BIOCHEMISTRY-US, V22, P3610, DOI 10.1021/bi00284a011; WARHOLM M, 1980, ACTA CHEM SCAND B, V34, P607, DOI 10.3891/acta.chem.scand.34b-0607; WIENCKE JK, 1990, CANCER RES, V50, P1585; ZHONG S, 1991, CARCINOGENESIS, V12, P1533, DOI 10.1093/carcin/12.9.1533; [No title captured]	53	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16958	16965						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349586				2022-12-27	WOS:A1993LQ98800015
J	NI, F; JACKSON, CM; FENTON, JW				NI, F; JACKSON, CM; FENTON, JW			THROMBIN EXOSITE FOR FIBRINOGEN RECOGNITION IS PARTIALLY ACCESSIBLE IN PROTHROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN ALPHA-THROMBIN; CLOTTING ACTIVITY; BINDING-SITE; HIRUDIN; ACTIVATION; INHIBITOR; PEPTIDES; PRETHROMBIN-1; RECEPTOR; DOMAIN	The procoagulant alpha-thrombin is produced by the proteolytic cleavages of a minimum of two peptide bonds Arg274-Thr275 and Arg323-Ile324 in prothrombin. The Arg323-Ile324 cleavage is required for the expression of the active site of thrombin (Morita, T., Iwanaga, S. Suzuki, T. (1976) J. Biochem. (Tokyo) 79, 1089-1108; Hibbard, L. S., Nesheim, M. E., and Mann, K. G. (1982) Biochemistry 21, 2285-2292). It is not yet clear to what extent the proteolytic events are responsible for exposing protein recognition exosites on thrombin. We employed high resolution NMR spectroscopy to examine interactions of prothrombin and thrombin with synthetic hirudin peptides targeted toward the fibrinogen recognition exosite of thrombin. The hirudin tail synthetic analogues (acetyl-Asp55-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln65/Gly65-OH) exhibited similar NMR relaxation enhancements (line broadening patterns and transferred nuclear Overhauser effects) with human prothrombin as with human alpha-thrombin, indicating that both proteins bind the peptide in a similar manner. The protein-induced relaxation enhancements are specific to the interaction of the hirudin peptides with the fibrinogen recognition exosite of thrombin since no significant effects were observed with either human serum albumin or with human gamma-thrombin, which has an impaired recognition exosite. The binding affinities were determined from NMR relaxation time measurements, which gave approximate K(d) values of 500 muM and <100 muM for prothrombin and alpha-thrombin, respectively. Since the hirudin tail fragment binds specifically to the fibrinogen recognition exosite in alpha-thrombin, this exosite appears to be partially accessible in prothrombin in a proenzyme form.	AMER RED CROSS BLOOD SERV, S EASTERN MICHIGAN REG, DETROIT, MI 48232 USA; NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, ALBANY, NY 12201 USA	American Red Cross; State University of New York (SUNY) System; Wadsworth Center	NI, F (corresponding author), NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, 6100 ROYALMOUNT AVE, MONTREAL H4P 2R2, PQ, CANADA.		Ni, Feng/AAN-6388-2020; Jackson, Craig M/AAC-6338-2020	Jackson, Craig/0000-0001-9484-4420	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL013160] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-13160-22] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; BING DH, 1977, J BIOL CHEM, V252, P8027; BREZNIAK DV, 1990, BIOCHEMISTRY-US, V29, P3536, DOI 10.1021/bi00466a017; CARLISLE TL, 1990, J BIOL CHEM, V265, P22044; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; DWEK RA, 1973, NUCLEAR MAGNETIC RES; Fenton J W 2nd, 1981, Ann N Y Acad Sci, V370, P468, DOI 10.1111/j.1749-6632.1981.tb29757.x; FENTON JW, 1986, ANN NY ACAD SCI, V485, P5, DOI 10.1111/j.1749-6632.1986.tb34563.x; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; FRAENKEL Y, 1990, BIOCHEMISTRY-US, V29, P2617, DOI 10.1021/bi00462a027; HIBBARD LS, 1982, BIOCHEMISTRY-US, V21, P2285, DOI 10.1021/bi00539a003; HOPFNER KP, 1993, BIOCHEMISTRY-US, V32, P2947, DOI 10.1021/bi00063a004; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; KACZMAREK E, 1987, BIOCHIM BIOPHYS ACTA, V914, P275, DOI 10.1016/0167-4838(87)90286-X; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; LIU LW, 1991, J BIOL CHEM, V266, P23632; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MAO SJT, 1988, BIOCHEMISTRY-US, V27, P8170, DOI 10.1021/bi00421a027; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; MORITA T, 1976, J BIOCHEM, V79, P1089, DOI 10.1093/oxfordjournals.jbchem.a131150; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NI F, 1992, BIOCHEMISTRY-US, V31, P2545, DOI 10.1021/bi00124a015; NI F, 1992, J MAGN RESON, V99, P391, DOI 10.1016/0022-2364(92)90192-A; NI F, 1990, BIOCHEMISTRY-US, V29, P4479, DOI 10.1021/bi00470a030; NI F, 1992, BIOCHEMISTRY-US, V31, P11551, DOI 10.1021/bi00161a037; NI F, 1989, BIOCHEMISTRY-US, V28, P3082, DOI 10.1021/bi00433a052; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; STONE SR, 1991, BIOCHEMISTRY-US, V30, P3950, DOI 10.1021/bi00230a021; YUE SY, 1992, PROTEIN ENG, V5, P77, DOI 10.1093/protein/5.1.77	31	24	25	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16899	16902						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349581				2022-12-27	WOS:A1993LQ98800008
J	ORLANDI, PA; FISHMAN, PH				ORLANDI, PA; FISHMAN, PH			ORIENTATION OF CHOLERA-TOXIN BOUND TO TARGET-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-LABILE ENTEROTOXIN; ESCHERICHIA-COLI; MEMBRANE; SUBUNITS; BINDING; INTERNALIZATION; ARRANGEMENT; GENERATION; RECEPTOR; INVITRO	Cholera toxin (CT) consists of a pentameric B subunit that binds to specific cell surface receptors identified as ganglioside G(M1) and an A subunit that activates adenylylcyclase. The A subunit consists of A1 and A2 peptides linked by a disulfide bond; A2 acts to connect A to B, whereas A1 is an ADP-ribosyltransferase that modifies the alpha subunit of the stimulatory G protein (G(s)). How the toxin is oriented when it binds to the cell surface and the related issue of the mechanism by which A1 gains access to G(salpha) are not known. In the present study, we used subunit-specific antibodies and their corresponding Fab fragments to assess their affects on holotoxin binding to target cells and their immunoreactivity to cell-bound toxin. Our results suggest that CT binds with A1 facing away from the membrane. Our hypothesis is further supported by the ability to assemble active CT on the cell surface of cultured human intestinal and neurotumor cells by the sequential addition of purified B and A subunits. We also observed that when cells containing bound CT were incubated at 37-degrees-C, both subunits rapidly became inaccessible to their respective antibodies. We propose that the holotoxin binds with its A subunit facing away from the membrane and must enter the cell in order for A1 to be released, gain access to G(salpha), and activate adenylylcyclase.	NINCDS, MOLEC & CELLULAR NEUROBIOL LAB, MEMBRANE BIOCHEM SECT, PK BLDG, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)								DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DWYER JD, 1982, BIOCHEMISTRY-US, V21, P3227, DOI 10.1021/bi00256a030; FINKELSTEIN RA, 1988, IMMUNOCHEMICAL MOL G, P85; FISHMAN PH, 1992, FEBS LETT, V314, P371, DOI 10.1016/0014-5793(92)81508-J; FISHMAN PH, 1978, BIOCHEMISTRY-US, V17, P711, DOI 10.1021/bi00597a024; FISHMAN PH, 1982, J CELL BIOL, V93, P860, DOI 10.1083/jcb.93.3.860; FISHMAN PH, 1990, ADP RIBOSYLATING TOX, P127; GILL DM, 1976, BIOCHEMISTRY-US, V15, P1242, DOI 10.1021/bi00651a011; HARDY SJS, 1988, P NATL ACAD SCI USA, V85, P7109, DOI 10.1073/pnas.85.19.7109; HIDALGO IJ, 1989, GASTROENTEROLOGY, V96, P736; HOLMGREN J, 1981, NATURE, V292, P413, DOI 10.1038/292413a0; HUDSON L, 1980, PRACTICAL IMMUNOLOGY, P192; JANICOT M, 1988, BIOCHEM J, V253, P735, DOI 10.1042/bj2530735; KASSIS S, 1982, J BIOL CHEM, V257, P2148; MCDANIEL RV, 1986, BIOPHYS J, V49, P94, DOI 10.1016/S0006-3495(86)83606-2; MOSS J, 1981, J BIOL CHEM, V256, P2861; PACUSZKA T, 1990, J BIOL CHEM, V265, P7673; Reichlin M, 1980, Methods Enzymol, V70, P159; RIBI HO, 1988, SCIENCE, V239, P1272, DOI 10.1126/science.3344432; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SIXMA TK, 1992, NATURE, V355, P561, DOI 10.1038/355561a0; TAKEDA Y, 1981, INFECT IMMUN, V34, P341, DOI 10.1128/IAI.34.2.341-346.1981; TOMASI M, 1981, J BIOL CHEM, V256, P1177; TRAN D, 1987, P NATL ACADA SCI US, V84, P7109; TSURU S, 1982, J GEN MICROBIOL, V128, P497; VANHEYNINGEN S, 1991, NATURE, V351, P351, DOI 10.1038/351351a0; VANHEYNINGEN S, 1983, CURR TOP MEMBR TRANS, V18, P445; WISNIESKI BJ, 1981, NATURE, V289, P319, DOI 10.1038/289319a0	28	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17038	17044						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349592				2022-12-27	WOS:A1993LQ98800026
J	HAYES, BK; VARKI, A				HAYES, BK; VARKI, A			BIOSYNTHESIS OF OLIGOSACCHARIDES IN INTACT GOLGI PREPARATIONS FROM RAT-LIVER - ANALYSIS OF N-LINKED GLYCANS LABELED BY UDP-[6-H-3]GALACTOSE, CMP-[9-H-3]N-ACETYLNEURAMINIC ACID, AND [ACETYL-H-3]ACETYL-COENZYME-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-ORTHO-ACETYLATION; GAL-BETA-1->3(4)GLCNAC ALPHA-2->3 SIALYLTRANSFERASE; PULSED AMPEROMETRIC DETECTION; ROUGH ENDOPLASMIC-RETICULUM; SIALIC ACIDS; O-ACETYLATION; ACETYLGLUCOSAMINYLTRANSFERASE-III; GLYCOPROTEIN OLIGOSACCHARIDES; TERMINAL GLYCOSYLATION; LIQUID-CHROMATOGRAPHY	When a rat liver Golgi apparatus-enriched subcellular fraction is incubated with UDP-[H-3]Gal, CMP-[H-3] Neu5Ac, or [acetyl-H-3]acetyl (Ac)-CoA, label is efficiently transferred to endogenous acceptors, which are resistant to added proteases, unless detergent is added at a sufficiently high concentration. Thus, the acceptors are within the lumen of intact compartments of correct topological orientation, which are likely to be similar to those of the Golgi apparatus in the intact cell. In each case, approximately 90% of the macromolecular radioactivity is specifically released by peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase digestion, as labeled N-linked oligosaccharides. Label from UDP-[H-3]Gal is transferred to several distinct N-linked oligosaccharides, and many of these carry sialic acid (Sia) residues. This amount increases if the transfer reaction is chased with CMP-Neu5Ac. A major fraction of the [H-3]Gal is directly ''covered'' with Sia residues, indicating that at least a portion of the beta-galactosyltransferase(s) are co-localized with one or more sialyltransferases. The majority of the [H-3]Gal is found in a beta1,3-linkage, rather than the more common beta1,4-linkage. The N-linked oligosaccharides labeled by CMP-[H-3] Neu5Ac carry labeled Sia residues in either alpha2,3 or alpha2,6 linkage, and showed a range of charge distribution. The transferred [H-3]Neu5Ac is not O-acetylated even when Ac-CoA is added at saturating concentrations, implying that the sialyltransferases and the O-acetyltransferase(s) are not functionally co-localized. However, approximately 20% of label released from N-linked oligosaccharides by sialidase does not co-migrate with authentic Neu5Ac in high performance liquid chromatography analysis, indicating that transferred [H-3] Neu5Ac is modified by unknown enzymes in the Golgi. Most of the [H-3]acetate transferred from [acetyl-H-3] Ac-CoA to N-linked oligosaccharides is on Sia residues that are exclusively alpha2,6-linked, and is enriched on tri- and tetra-antennary chains that do not appear to carry any 2,3-linked Sia residues. These data indicate a restricted substrate preference of the O-acetyltransferase(s). About one-quarter of the [H-3]acetate transferred is sialidase-resistant, indicating either transfer to monosaccharides other than sialic acid, or to sialidase-resistant sialic acids. While most of these sialidase-resistant oligosaccharides remain negatively charged, about 10% are neutralized by sialidase, confirming transfer of [H-3]acetate to monosaccharides other than sialic acid.	UNIV CALIF SAN DIEGO, SCH MED, DEPT CANC, GLYCOBIOL PROGRAM, 0063, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DIV CELLULAR & MOLEC MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R01CA038701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA38701] Funding Source: Medline; NIGMS NIH HHS [R01-GM32373] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BAENZIGER JU, 1980, CELL, V22, P611, DOI 10.1016/0092-8674(80)90371-2; BERGER EG, 1985, P NATL ACAD SCI USA, V82, P4736, DOI 10.1073/pnas.82.14.4736; BERGERON JJM, 1985, BIOCHIM BIOPHYS ACTA, V821, P393, DOI 10.1016/0005-2736(85)90043-4; BERMAN E, 1984, BIOCHEMISTRY-US, V23, P3754, DOI 10.1021/bi00311a029; BERNARD N, 1983, BIOCHIMIE, V65, P185, DOI 10.1016/S0300-9084(83)80083-2; BROWN WJ, 1987, P NATL ACAD SCI USA, V84, P9001, DOI 10.1073/pnas.84.24.9001; BUTOR C, 1993, J BIOL CHEM, V268, P10197; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CORFIELD AP, 1986, BIOL CHEM H-S, V367, P433, DOI 10.1515/bchm3.1986.367.1.433; DIAZ S, 1989, J BIOL CHEM, V264, P19416; DRICKAMER K, 1991, CELL, V67, P1029, DOI 10.1016/0092-8674(91)90278-7; DUNPHY WG, 1981, P NATL ACAD SCI-BIOL, V78, P7453, DOI 10.1073/pnas.78.12.7453; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; GREEN ED, 1987, J BIOL CHEM, V262, P12018; GREEN SA, 1990, J BIOL CHEM, V265, P21269; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HAYES BK, 1992, ANAL BIOCHEM, V201, P140, DOI 10.1016/0003-2697(92)90186-B; HAYES BK, 1989, J BIOL CHEM, V264, P19443; HAYES BK, 1993, J BIOL CHEM, V268, P16139; HAYES BK, 1993, J BIOL CHEM, V268, P16170; HERRLER G, 1985, EMBO J, V4, P1503, DOI 10.1002/j.1460-2075.1985.tb03809.x; HIGA HH, 1985, J BIOL CHEM, V260, P8838; HIGA HH, 1989, J BIOL CHEM, V264, P19427; HIGA HH, 1985, VIROLOGY, V144, P279, DOI 10.1016/0042-6822(85)90325-3; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; KOBATA A, 1992, CELL SURFACE CARBOHY, P1; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; MANZI AE, 1990, J BIOL CHEM, V265, P13091; McEver Rodger P., 1992, Current Opinion in Cell Biology, V4, P840, DOI 10.1016/0955-0674(92)90109-P; MELLIS SJ, 1981, ANAL BIOCHEM, V114, P276, DOI 10.1016/0003-2697(81)90480-2; MERKLE RK, 1987, METHOD ENZYMOL, V138, P232; MIZUOCHI T, 1980, J BIOL CHEM, V255, P3526; MIZUOCHI T, 1979, J BIOL CHEM, V254, P6419; NARASIMHAN S, 1988, J BIOL CHEM, V263, P1273; NISHIKAWA A, 1988, ANAL BIOCHEM, V170, P349, DOI 10.1016/0003-2697(88)90641-0; PAIEMENT J, 1982, J CELL BIOL, V92, P147, DOI 10.1083/jcb.92.1.147; PAULSON JC, 1984, EUR J BIOCHEM, V140, P523, DOI 10.1111/j.1432-1033.1984.tb08133.x; PAULSON JC, 1982, J BIOL CHEM, V257, P4034; PAULSON JC, 1979, J BIOL CHEM, V254, P2120; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PAVELKA M, 1991, J ELECTRON MICR TECH, V17, P35, DOI 10.1002/jemt.1060170106; PEREZ M, 1987, METHOD ENZYMOL, V138, P709; PERSAT F, 1992, J BIOL CHEM, V267, P8764; PILLER F, 1982, ANAL BIOCHEM, V127, P171, DOI 10.1016/0003-2697(82)90161-0; POPPE L, 1992, J BIOMOL NMR, V2, P109, DOI 10.1007/BF01875524; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; SADLER JE, 1982, METHOD ENZYMOL, V83, P458; SCHAUER R, 1982, CELL BIOL MONOGR, V10, P1; SCHWARTZ AL, 1991, INTRACELLULAR TRAFFI; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; SHEARES BT, 1982, J BIOL CHEM, V257, P599; SPARROW JR, 1988, J NEUROSCI RES, V21, P398, DOI 10.1002/jnr.490210231; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; TOWNSEND RR, 1986, BIOCHEMISTRY-US, V25, P5716, DOI 10.1021/bi00367a055; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; VARKI A, 1991, CELL, V65, P65, DOI 10.1016/0092-8674(91)90408-Q; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; VARKI A, 1985, J BIOL CHEM, V260, P6600; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; Weiss P, 1989, Prog Clin Biol Res, V300, P169; WEN DX, 1992, J BIOL CHEM, V267, P21011; YAMASHITA K, 1989, J BIOL CHEM, V264, P17873	69	30	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16155	16169						15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344900				2022-12-27	WOS:A1993LQ33600015
J	JARVIS, DL; SUMMERS, MD; GARCIA, A; BOHLMEYER, DA				JARVIS, DL; SUMMERS, MD; GARCIA, A; BOHLMEYER, DA			INFLUENCE OF DIFFERENT SIGNAL PEPTIDES AND PROSEQUENCES ON EXPRESSION AND SECRETION OF HUMAN TISSUE-PLASMINOGEN ACTIVATOR IN THE BACULOVIRUS SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR POLYHEDROSIS-VIRUS; HUMAN INSULIN-RECEPTOR; GLUCOSE-REGULATED PROTEIN; CHAIN-BINDING-PROTEIN; HIGH-LEVEL EXPRESSION; AMINO-ACID-SEQUENCE; INSECT CELLS; NUCLEOTIDE-SEQUENCE; RECOMBINANT BACULOVIRUS; HONEYBEE PREPROMELITTIN	Foreign secretory pathway proteins are often produced in surprisingly low amounts in the baculovirus/insect cell expression system. One possible reason for this is that heterologous signal peptides might be inefficiently recognized by the insect cell protein translocation machinery. This idea was supported by a recent study showing that secretion of a plant protein in the baculovirus system was enhanced when its signal peptide was replaced with an insect-derived signal peptide (Tessier, D. C., Thomas, D. Y., Khouri, H. E., Laliberte, F., and Vernet, T. (1991) Gene (Amst.) 98, 177-183). We have extended these observations by measuring the effects of different signal peptide and signal peptide-prosequence combinations on baculovirus-mediated expression and secretion of human tissue plasminogen activator (t-PA). Replacement of the native prepropeptide with signal peptides from a lepidopteran insect secretory protein (cecropin B), a major baculovirus structural glycoprotein (64K), or an abundant, highly conserved lumenal protein of the rough endoplasmic reticulum (GRP78/BiP, a 78-kDa glucose-regulated protein/immunoglobulin heavy chain-binding protein), had no significant effect on t-PA expression or secretion. The same results were obtained with the signal peptide from honeybee prepromellitin, which was able to enhance secretion of plant propapain (Tessier et al., 1991 (above)). Similar results were obtained when heterologous signal peptides were combined with the native prosequence or when the intact cecropin B preprosequence was used. Translational initiation at an upstream, in-frame ATT, which could functionally inactivate any signal peptide, did not explain the low efficiency of t-PA secretion. Finally, deletion of the native signal peptide, prosequence, or both, failed to increase t-PA production. These results showed that insect-derived signal peptides and/or prosequences cannot always enhance the expression and/or secretion of foreign secretory pathway proteins in the baculovirus system. They also suggested that the inability of insect cells to recognize the processing signals in human t-PA efficiently is probably not the major factor preventing its high level production in this system.	TEXAS A&M UNIV SYST, INST BIOSCI & TECHNOL, DEPT BIOL, COLL STN, TX 77843 USA; TEXAS A&M UNIV SYST, INST BIOSCI & TECHNOL, CTR ADV INVETEBRATE MOLEC SCI, COLL STN, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	JARVIS, DL (corresponding author), TEXAS A&M UNIV SYST, INST BIOSCI & TECHNOL, DEPT ENTOMOL, COLL STN, TX 77843 USA.			Jarvis, Donald/0000-0002-8104-7155				BEAMES B, 1991, BIOTECHNIQUES, V11, P378; BINDER BR, 1979, J BIOL CHEM, V254, P1998; BUSTOS MM, 1988, PLANT MOL BIOL, V10, P475, DOI 10.1007/BF00033603; DEVLIN JJ, 1989, BIO-TECHNOL, V7, P286, DOI 10.1038/nbt0389-286; ELLIS L, 1988, J VIROL, V62, P1634, DOI 10.1128/JVI.62.5.1634-1639.1988; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FURLONG AM, 1988, BIOTECHNOL APPL BIOC, V10, P454; GETHING MJ, 1982, NATURE, V300, P598, DOI 10.1038/300598a0; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRANELLIPIPERNO A, 1978, J EXP MED, V148, P223, DOI 10.1084/jem.148.1.223; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; JABBAR MA, 1987, MOL CELL BIOL, V7, P1476, DOI 10.1128/MCB.7.4.1476; JARVIS DL, 1990, BIO-TECHNOL, V8, P950, DOI 10.1038/nbt1090-950; JARVIS DL, 1989, MOL CELL BIOL, V9, P214, DOI 10.1128/MCB.9.1.214; JARVIS DL, 1991, VIROLOGY, V185, P795, DOI 10.1016/0042-6822(91)90551-L; JARVIS DL, 1990, J CELL BIOCHEM, V42, P181, DOI 10.1002/jcb.240420402; JARVIS DL, 1992, RECOMBINANT DNA VACC, P265; KING LA, 1991, GENE, V106, P151, DOI 10.1016/0378-1119(91)90194-G; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; KURODA K, 1991, VIROLOGY, V180, P159, DOI 10.1016/0042-6822(91)90019-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANFORD RE, 1989, J VIROL, V63, P1549, DOI 10.1128/JVI.63.4.1549-1557.1989; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; Luckow V. A, 1991, Recombinant DNA technology and applications., P97; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; LUCKOW VA, 1988, VIROLOGY, V167, P56, DOI 10.1016/0042-6822(88)90054-2; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; MURHAMMER DW, 1988, BIO-TECHNOL, V6, P1411, DOI 10.1038/nbt1288-1411; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; POHL G, 1984, BIOCHEMISTRY-US, V23, P3701, DOI 10.1021/bi00311a020; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; Sambrook J, 1989, MOL CLONING LABORATO; SISSOM J, 1989, BIOCHEM J, V261, P119, DOI 10.1042/bj2610119; SISSOM JF, 1991, BIOCHEM BIOPH RES CO, V177, P764, DOI 10.1016/0006-291X(91)91854-6; STEINER H, 1988, GENE, V73, P449, DOI 10.1016/0378-1119(88)90509-4; SUCHANEK G, 1978, P NATL ACAD SCI USA, V75, P701, DOI 10.1073/pnas.75.2.701; SUMMERS MD, 1978, VIROLOGY, V84, P390, DOI 10.1016/0042-6822(78)90257-X; Summers MD, 1987, TEXAS AGR EXPT STATI; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; TING J, 1987, GENE, V55, P147, DOI 10.1016/0378-1119(87)90258-7; VANHOFSTEN P, 1985, P NATL ACAD SCI USA, V82, P2240; VANIDDEKINGE BJLH, 1983, VIROLOGY, V131, P561, DOI 10.1016/0042-6822(83)90522-6; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213; VLASAK R, 1983, EUR J BIOCHEM, V135, P123, DOI 10.1111/j.1432-1033.1983.tb07626.x; VOLKMAN LE, 1986, CURR TOP MICROBIOL, V131, P103; WALLEN P, 1983, EUR J BIOCHEM, V132, P681, DOI 10.1111/j.1432-1033.1983.tb07418.x; WEBB N R, 1990, Technique (Philadelphia), V2, P173; WHITFORD M, 1989, J VIROL, V63, P1393, DOI 10.1128/JVI.63.3.1393-1399.1989	53	72	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16754	16762						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344955				2022-12-27	WOS:A1993LQ33600095
J	PIARD, JC; KUIPERS, OP; ROLLEMA, HS; DESMAZEAUD, MJ; DEVOS, WM				PIARD, JC; KUIPERS, OP; ROLLEMA, HS; DESMAZEAUD, MJ; DEVOS, WM			STRUCTURE, ORGANIZATION, AND EXPRESSION OF THE LCT GENE FOR LACTICIN 481, A NOVEL LANTIBIOTIC PRODUCED BY LACTOCOCCUS-LACTIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; STREPTOCOCCUS-LACTIS; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; LACTACIN-F; BACTERIOCIN; NISIN; PURIFICATION; PROTEIN; EPIDERMIN	The structural gene for the lactococcal lantibiotic lacticin 481 (lct) has been identified and cloned using a degenerated 20-mer DNA oligonucleotide based on the amino-terminal 7 amino acid residues of the purified protein. The transcription of the lct gene was analyzed, and its promoter was mapped. DNA sequence analysis of the lct gene revealed an open reading frame encoding a peptide of 51 amino acids. Comparison of its deduced amino acid sequence with the amino-terminal sequence and the amino acid composition of lacticin 481 indicates that the 51-residue peptide is prelacticin 481, containing a 27-residue carboxyl-terminal propeptide and a 24-residue amino-terminal leader peptide which lacks the properties of a typical signal sequence and which is significantly different from the leaders of other lantibiotics. The predicted amino acid sequence of prolacticin 481 contains 3 cysteines, 2 serines, and 2 threonines which were not detectable in amino acid analyses of mature lacticin 481. Based on these results and on characterization by two-dimensional NMR techniques, a structural model is proposed in which 2 cysteine residues are involved in lanthionine and one in beta-methyllanthionine formation, and a 4th threonine residue is dehydrated. This model predicts a molecular mass for lacticin 481 of 2,901, which is in excellent agreement with that obtained from mass spectrometry.	NIZO, DEPT BIOPHYS CHEM, 6710 BA EDE, NETHERLANDS	NIZO Food Research	PIARD, JC (corresponding author), INRA, RECH LAITIERES STN, F-78352 JOUY EN JOSAS, FRANCE.		Kuipers, Oscar/B-6752-2009	Kuipers, Oscar/0000-0001-5596-7735				ALLGAIER H, 1986, EUR J BIOCHEM, V160, P9, DOI 10.1111/j.1432-1033.1986.tb09933.x; BANERJEE S, 1988, J BIOL CHEM, V263, P9508; BUCHMAN GW, 1988, J BIOL CHEM, V263, P16260; CARAFA YD, 1990, J MOL BIOL, V216, P835, DOI 10.1016/S0022-2836(99)80005-9; CHAN WC, 1989, J CHEM SOC PERK T 1, P2359, DOI 10.1039/p19890002359; DEVOS WM, 1989, J GEN MICROBIOL, V135, P1833; DEVOS WM, 1993, APPL ENVIRON MICROB, V59, P213, DOI 10.1128/AEM.59.1.213-218.1993; GASSON MJ, 1983, J BACTERIOL, V154, P1; Gibson T.J., 1984, THESIS CAMBRIDGE U U; HASTINGS JW, 1991, J BACTERIOL, V173, P7491, DOI 10.1128/jb.173.23.7491-7500.1991; HOLO H, 1991, J BACTERIOL, V173, P3879, DOI 10.1128/JB.173.12.3879-3887.1991; Hurst A., 1981, ADV APPL MICROBIOL, V27, P85, DOI [10.1016/s0065-2164(08)70342-3, DOI 10.1016/S0065-2164(08)70342-3, 10.1016/S0065-2164(08)70342-3]; JACK RW, 1991, NISIN NOVEL LANTIBIO, P171; Jung G, 1991, NISIN NOVEL LANTIBIO; KELLNER R, 1988, EUR J BIOCHEM, V177, P53, DOI 10.1111/j.1432-1033.1988.tb14344.x; Kellner R, 1991, NISIN NOVEL LANTIBIO, P141; KUIPERS OP, 1992, J BIOL CHEM, V267, P24340; KUIPERS OP, 1991, NISIN NOVEL LANTIBIO, P250; LIAN LY, 1992, BIOCHEM J, V283, P413, DOI 10.1042/bj2830413; MARUGG JD, 1992, APPL ENVIRON MICROB, V58, P2360, DOI 10.1128/AEM.58.8.2360-2367.1992; MORTVEDT CI, 1991, APPL ENVIRON MICROB, V57, P1829; MULDERS JWM, 1991, EUR J BIOCHEM, V201, P581, DOI 10.1111/j.1432-1033.1991.tb16317.x; MURIANA PM, 1991, APPL ENVIRON MICROB, V57, P114, DOI 10.1128/AEM.57.1.114-121.1991; MURIANA PM, 1991, J BACTERIOL, V173, P1779, DOI 10.1128/jb.173.5.1779-1788.1991; PIARD JC, 1990, NETH MILK DAIRY J, V44, P143; PIARD JC, 1992, APPL ENVIRON MICROB, V58, P279, DOI 10.1128/AEM.58.1.279-284.1992; PIARD JC, 1992, LAIT, V72, P113; PIARD JC, 1993, IN PRESS FEMS MICROB; RAUCH PJG, 1992, J BACTERIOL, V174, P1280, DOI 10.1128/jb.174.4.1280-1287.1992; RAUCH PJG, 1991, NISIN NOVEL LANTIBIO, P243; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNELL N, 1988, NATURE, V333, P276, DOI 10.1038/333276a0; SIMON D, 1988, BIOCHIMIE, V70, P559, DOI 10.1016/0300-9084(88)90093-4; TERZAGHI BE, 1975, APPL MICROBIOL, V29, P807, DOI 10.1128/AEM.29.6.807-813.1975; VANBELKUM MJ, 1992, APPL ENVIRON MICROB, V58, P572, DOI 10.1128/AEM.58.2.572-577.1992; VANBELKUM MJ, 1991, APPL ENVIRON MICROB, V57, P492, DOI 10.1128/AEM.57.2.492-498.1991; VANDEGUCHTE M, 1992, FEMS MICROBIOL LETT, V88, P73, DOI 10.1016/0378-1097(92)90685-H; VANDERMEER JR, 1993, J BACTERIOL, V175, P2578, DOI 10.1128/JB.175.9.2578-2588.1993; VANDEVEN FJM, 1991, EUR J BIOCHEM, V202, P1181, DOI 10.1111/j.1432-1033.1991.tb16488.x; VANDORSSELAER A, 1990, BIOMED ENVIRON MASS, V19, P692, DOI 10.1002/bms.1200191108; VANROOIJEN RJ, 1990, J BIOL CHEM, V265, P18499; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; VOS P, 1989, J BIOL CHEM, V264, P13579	45	125	134	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16361	16368						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344922				2022-12-27	WOS:A1993LQ33600043
J	WANG, Z; BROWN, DD				WANG, Z; BROWN, DD			THYROID HORMONE-INDUCED GENE-EXPRESSION PROGRAM FOR AMPHIBIAN TAIL RESORPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS; RECEPTOR; METAMORPHOSIS; CELLS; ENCODES; FAMILY; ACID	The changes in gene expression leading to tail resorption that are initiated by thyroid hormone (TH) were studied in Xenopus laevis. Four of the less than 10 genes that are down-regulated during this period have been isolated; their mRNAs decay with identical kinetics. Twenty of the approximately 35 genes that are up-regulated in the first 48 h have been isolated. The up-regulated genes fall into two kinetic patterns. After a lag of several hours, the direct response genes (including thyroid hormone receptor beta) increase their mRNA level steadily for 24-48 h. The delayed genes respond mainly in the second 24 h after TH addition. The importance of these genes for tail resorption is supported by the fact that they are all regulated developmentally during normal metamorphosis in tail and respond to hormone induction when the tail becomes competent to respond to TH. The relatively simple gene expression program leading to tail resorption is contrasted with the complex and multiple periods of gene expression during limb development. The gene expression screen defines the tail resorption program and has isolated the majority of TH-regulated genes.			WANG, Z (corresponding author), CARNEGIE INST WASHINGTON, DEPT EMBRYOL, 115 W UNIV PKWY, BALTIMORE, MD 21210 USA.							ASHBURNER M, 1973, COLD SPRING HARB SYM, V38, P655; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BECKINGHAMSMITH K, 1976, EXP CELL RES, V100, P129, DOI 10.1016/0014-4827(76)90335-9; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BUCKBINDER L, 1992, J BIOL CHEM, V267, P25786; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; DODD MHI, 1976, PHYSIOLOGY AMPHIBIA, V3, P467; ELLISON TR, 1985, DEV BIOL, V112, P329, DOI 10.1016/0012-1606(85)90403-8; Etkin W, 1935, J EXP ZOOL, V71, P317, DOI 10.1002/jez.1400710208; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUKUOKA SI, 1992, P NATL ACAD SCI USA, V89, P1189, DOI 10.1073/pnas.89.4.1189; Galton VA, 1983, MOL BASIS THYROID HO, P445; GROSS J, 1965, P NATL ACAD SCI USA, V54, P1197, DOI 10.1073/pnas.54.4.1197; Gudernatsch JF, 1912, ARCH ENTWICKLUNG ORG, V35, P457, DOI 10.1007/BF02277051; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KANAMORI A, 1992, J BIOL CHEM, V267, P739; KROTOSKI DM, 1985, J EXP ZOOL, V233, P443, DOI 10.1002/jez.1402330313; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LELOUP J, 1977, CR ACAD SCI D NAT, V284, P2261; Maniatis T., 1982, MOL CLONING; MATHISEN PM, 1987, GENE DEV, V1, P1107, DOI 10.1101/gad.1.10.1107; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; QUINN CO, 1990, J BIOL CHEM, V265, P22342; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SHAFFER BM, 1963, J EMBRYOL EXP MORPH, V11, P77; SHI YB, 1990, GENE DEV, V4, P1107, DOI 10.1101/gad.4.7.1107; SMITH EL, PRINCIPLES BIOCH GEN, P796; Steinberg M, 1957, CARNEGIE I WASHINGTO, V56, P347; TATA JR, 1968, DEV BIOL, V18, P415, DOI 10.1016/0012-1606(68)90050-X; TATA JR, 1966, DEV BIOL, V13, P77, DOI 10.1016/0012-1606(66)90050-9; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; WEBER R, 1965, EXPERIENTIA, V21, P665, DOI 10.1007/BF02144069; WEBER R, 1962, EXPERIENTIA, V18, P84, DOI 10.1007/BF02138272; WEBER R, 1967, BIOCHEMISTRY ANIMAL, V2, P227; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YAOITA Y, 1990, GENE DEV, V4, P1917, DOI 10.1101/gad.4.11.1917; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; YOSHIZATO K, 1989, INT REV CYTOL, V119, P97	41	241	248	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16270	16278						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344914				2022-12-27	WOS:A1993LQ33600030
J	KYRIAKIS, JM; FORCE, TL; RAPP, UR; BONVENTRE, JV; AVRUCH, J				KYRIAKIS, JM; FORCE, TL; RAPP, UR; BONVENTRE, JV; AVRUCH, J			MITOGEN REGULATION OF C-RAF-1 PROTEIN-KINASE ACTIVITY TOWARD MITOGEN-ACTIVATED PROTEIN KINASE-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; THREONINE TYROSINE KINASE; ERK-1 GENE-PRODUCT; MAP KINASE; SIGNAL TRANSDUCTION; RAF-1 KINASE; S6 KINASE; PHOSPHORYLATION; INSULIN; SERINE	The c-raf-1 protooncogene encodes a Ser/Thr protein kinase. A mitogen-activated protein kinase-kinase (MAPKK) purified from bovine brain is phosphorylated and activated 4-9-fold in vitro by c-Raf-1 from mitogen-treated cells. c-Raf-1 protein kinase activity, measured by the phosphorylation of brain MAPKK substrate, is detectably activated within 1 min after addition of platelet-derived growth factor (PDGF) to 3T3 cells, increasing more rapidly than the endogenous NIH 3T3 cell MAPKK activity. c-Raf-1 activation is also induced by insulin, phorbol ester, thrombin, and endothelin. PDGF-, epidermal groth factor-, and insulin-stimulated P-32-c-Raf-1 yield very similar, complex tryptic P-32-peptide maps, wherein only 2 of 10 P-32-peptides appear entirely de novo after growth factor addition. Mitogen-activated protein kinase/extracellular signal-regulated kinase-2 can phosphorylate c-Raf-1 in vitro on 4-6 tryptic P-32-peptides, all of which comigrate with tryptic P-32-peptides derived from c-Raf-1 labeled in situ. Mitogen-activated protein kinase phosphorylation of c-Raf-1 in vitro, however, does not 1) generate P-32-peptides that comigrate with those that appear de novo after PDGF or insulin treatment in situ; 2) does not convert c-Raf-1 polypeptides to a slower mobility on SDS-polyacrylamide gel electrophoresis as is seen after PDGF or insulin; 3) does not alter c-Raf-1 kinase activity toward MAPKK. Thus, based on overlapping site specificity, Erk-2 is a viable candidate to be among the PDGF-stimulated c-Raf-1 kinases. Although PDGF/insulin-stimulated c-Raf-1 Ser/Thr phosphorylation may be necessary to sustain the active state, a role for mitogen-activated protein kinase/extracellular signal-regulated kinase-2 phosphorylation in the initiation of c-Raf-1 activation is unlikely.	MASSACHUSETTS GEN HOSP, DIABET UNIT, BOSTON, MA 02129 USA; MASSACHUSETTS GEN HOSP, MED SERV, CARDIOL UNIT, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02129 USA; NCI, FREDERICK CANC RES & DEV CTR, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21702 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Force, Thomas/0000-0002-0450-8659	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK001986, P01DK038452] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046577, R01GM046577] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38452, DK01986] Funding Source: Medline; NIGMS NIH HHS [GM46577] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ASHWORTH A, 1992, ONCOGENE, V7, P2555; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HSI ED, 1989, J BIOL CHEM, V264, P10836; IZUMI T, 1991, J BIOL CHEM, V266, P7933; JAISWAL RK, 1993, J BIOL CHEM, V268, P7055; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1990, BIOCHIM BIOPHYS ACTA, V1054, P73, DOI 10.1016/0167-4889(90)90207-T; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LEE RM, 1992, J BIOL CHEM, V267, P1088; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1988, HDB ONCOGENES, P213; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIRAKABE K, 1992, J BIOL CHEM, V267, P16685; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173	40	100	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					16009	16019						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340422				2022-12-27	WOS:A1993LN30500096
J	ARCIERO, DM; HOOPER, AB				ARCIERO, DM; HOOPER, AB			HYDROXYLAMINE OXIDOREDUCTASE FROM NITROSOMONAS-EUROPAEA IS A MULTIMER OF AN OCTA-HEME SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; RESONANCE SPECTROSCOPY; REDOX POTENTIOMETRY; CYTOCHROME-C; RESOLUTION; REDUCTION; CLEAVAGE; P460	A fully active form of hydroxylamine oxidoreductase from Nitrosomonas has been purified with high recovery and shown by reverse-phase high performance liquid chromatography and N-terminal analysis to contain only a 63-kDa subunit and to lack the 11-kDa protein previously thought to be a second subunit. Based on the previously published values of molecular weight in solution, hydroxylamine oxidoreductase probably has an alpha2 or alpha3 oligomeric structure. The enzyme was digested separately with trypsin and chymotrypsin and peptides which contained covalently bound heme were separated by high performance liquid chromatography and their amino acid sequences determined. A total of seven heme-containing peptides of unique amino acid sequence were obtained. Six of these heme-containing peptides clearly contained a single c-heme with optical properties indistinguishable from the tryptic heme-containing peptide from horse heart cytochrome c. No noncovalently bound heme was observed. One of the seven heme-containing peptides (T7) was unusual in that it released 2 amino acid residues after each cycle of the Edman degradation due to a nondisulfide cross-link and exhibited a Soret band that was broadened in both the ferric form at neutral pH and the pyridine ferrohemochrome. Subdigestion of peptide T7 with nonspecific proteases (Pronase, bromelain, or pepsin) resulted in the isolation of two smaller heme-containing peptides of unique sequences. One of these was spectrally identical to the other c-heme containing peptides, whereas the second was still apparently cross-linked, again releasing 2 amino acid residues after each Edman cycle. This second peptide possessed a heme-like chromophore with absorption bands (Soret, alpha and beta) red-shifted about 6 nm relative to the spectrum of c-heme-containing peptides. Thus, hydroxylamine oxidoreductase contains a total of eight covalently bound hemes per subunit, seven of which are c-hemes. The eighth, which is attached to a cross-linked peptide, is probably the unusual P460 heme which is unique to hydroxylamine oxidoreductase and thought to be at the active site.	UNIV MINNESOTA,DEPT GENET & CELL BIOL,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities								AMBLER RP, 1969, FEBS LETT, V5, P115, DOI 10.1016/0014-5793(69)80308-X; AMBLER RP, 1968, BIOCHEM J, V109, pP47; ANDERSSON KK, 1991, BIOCHEM BIOPH RES CO, V174, P358, DOI 10.1016/0006-291X(91)90528-F; ANDERSSON KK, 1984, J BIOL CHEM, V259, P6833; ANDERSSON KK, 1983, FEBS LETT, V164, P236, DOI 10.1016/0014-5793(83)80292-0; ARCIERO DM, 1991, BIOCHEMISTRY-US, V30, P11466, DOI 10.1021/bi00112a014; ARCIERO DM, 1989, J CELL BIOL, V107, pA619; DISPIRITO AA, 1986, J BIOL CHEM, V261, P7048; ERICKSON RH, 1972, BIOCHIM BIOPHYS ACTA, V275, P231, DOI 10.1016/0005-2728(72)90044-8; FONTANA A, 1973, FEBS LETT, V32, P135, DOI 10.1016/0014-5793(73)80756-2; Fuhrhop J.H., 1975, LABORATORY METHODS P, P48; HILL GC, 1975, EUR J BIOCHEM, V57, P265, DOI 10.1111/j.1432-1033.1975.tb02298.x; HOOPER AB, 1978, BIOCHEMISTRY-US, V17, P2984, DOI 10.1021/bi00608a007; HOOPER AB, 1984, EUR J BIOCHEM, V141, P565, DOI 10.1111/j.1432-1033.1984.tb08230.x; HOOPER AB, 1965, J BIOL CHEM, V240, P4044; HOOPER AB, 1989, AUTOTROPHIC BACTERIA, P239; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN D K, 1973, Nature (London), V241, P533, DOI 10.1038/241533a0; LIPSCOMB JD, 1982, BIOCHEMISTRY-US, V21, P3965, DOI 10.1021/bi00260a010; LIPSCOMB JD, 1982, BIOCHEMISTRY-US, V21, P3973, DOI 10.1021/bi00260a011; LOGAN MSP, 1991, THESIS U MINNESOTA S; MASSON P, 1990, ELECTROPHORESIS, V11, P128, DOI 10.1002/elps.1150110205; NASRI H, 1987, J AM CHEM SOC, V109, P2549, DOI 10.1021/ja00242a069; PETTIGRE.GW, 1972, FEBS LETT, V22, P64, DOI 10.1016/0014-5793(72)80220-5; PETTIGREW GW, 1973, NATURE, V241, P531, DOI 10.1038/241531a0; PRINCE RC, 1987, BIOCHEMISTRY-US, V26, P970, DOI 10.1021/bi00377a043; PRINCE RC, 1983, FEBS LETT, V163, P25, DOI 10.1016/0014-5793(83)81154-5; REES MK, 1968, BIOCHEMISTRY-US, V7, P366, DOI 10.1021/bi00841a046; TERRY KR, 1981, BIOCHEMISTRY-US, V20, P7026, DOI 10.1021/bi00527a039; VICKERY LE, 1981, BIOCHIM BIOPHYS ACTA, V670, P291, DOI 10.1016/0005-2795(81)90022-2; YAMANAKA T, 1979, J BIOCHEM, V86, P1101, DOI 10.1093/oxfordjournals.jbchem.a132604; YAMANAKA T, 1974, J BIOCHEM-TOKYO, V75, P1265, DOI 10.1093/oxfordjournals.jbchem.a130510	32	78	82	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14645	14654						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325841				2022-12-27	WOS:A1993LL75900021
J	ZHAO, GP; SOMERVILLE, RL				ZHAO, GP; SOMERVILLE, RL			AN AMINO-ACID SWITCH (GLY(281)ASTERISK-ARG) WITHIN THE HINGE REGION OF THE TRYPTOPHAN SYNTHASE BETA-SUBUNIT CREATES A NOVEL CLEAVAGE SITE FOR THE OMPT PROTEASE AND SELECTIVITY DIMINISHES AFFINITY TOWARD A SPECIFIC MONOCLONAL-ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; PROTEOLYTIC CLEAVAGE; BINDING; GENE; BETA-2-SUBUNIT; PURIFICATION; DOMAINS; INVITRO; PEPTIDE	The in vitro susceptibility to endogenous proteases of the beta subunit of Escherichia coli tryptophan synthase was studied immunochemically. Whereas the wild-type beta subunit was apparently very stable, the missense mutant beta(BS), carrying an amino acid switch from Gly to Arg at residue 281, underwent specific proteolytic cleavage. Polyclonal chicken antibodies and monoclonal antibodies specific for the N terminus (monoclonal antibody (mAb) 15-1), the C terminus (mAb 93-6), and the ''hinge'' region (mAb 164-2) were used to study the hydrolysis of the beta(B8) polypeptide. Cleavage products of 30 kDa, from the N terminus, and 13 kDa, from the C terminus, were observed. These two polypeptides correspond to the well characterized F1 (N-terminal) and F2 (C-terminal) fragments that are generated during the limited tryptic proteolysis of the wild-type beta subunit. The outer membrane-associated protease OmpT was shown to be responsible for the cleavage of the beta(B8) mutant protein. Proteolytic cleavage, observed only under neutral non-denaturing conditions, was specific for the peptide bond between Arg281 and Met282. The Arg-Met peptide bond has not previously been reported to be susceptible to cleavage by the OmpT protease. The beta(B8) polypeptide had dramatically reduced affinity for mAb 164-2. This antibody interacted more strongly with the OmpT-generated F1-like fragment than with the intact beta(B8) protein. These results strongly suggest that the G281R mutation alters the conformation of the hinge region of the mutant beta subunit, particularly the beta-turn around Gly281. The implications with respect to the epitope recognized by mAb 164-2 are discussed.	PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NIGMS NIH HHS [GM22131] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022131] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED SA, 1986, BIOCHEMISTRY-US, V25, P3118, DOI 10.1021/bi00359a008; AKIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V167, P711, DOI 10.1016/0006-291X(90)92083-C; ALEXANDER L, 1975, BIOCHEM BIOPH RES CO, V67, P1055, DOI 10.1016/0006-291X(75)90781-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRAWFORD IP, 1964, GENETICS, V49, P267; CRAWFORD IP, 1963, GENETICS, V48, P725; CRAWFORD IP, 1978, BIOCHEM BIOPH RES CO, V85, P309, DOI 10.1016/S0006-291X(78)80044-8; CREIGHTON TE, 1970, METHODS ENZYMOLOGY A, V17, P365, DOI DOI 10.1021/ACS.BIOCHEM.8B00167; DELEPIERRE M, 1991, EUR J BIOCHEM, V201, P681, DOI 10.1111/j.1432-1033.1991.tb16329.x; DJAVADIOHANIANCE L, 1986, BIOCHEMISTRY-US, V25, P2502, DOI 10.1021/bi00357a033; DJAVADIOHANIANCE L, 1984, BIOCHEMISTRY-US, V23, P97, DOI 10.1021/bi00296a016; Friedrich P., 1984, SUPRAMOLECULAR ENZYM; FRIGUET B, 1989, RES IMMUNOL, V140, P355, DOI 10.1016/0923-2494(89)90142-9; GENTRY D R, 1990, Protein Expression and Purification, V1, P81, DOI 10.1016/1046-5928(90)90050-9; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; GRODBERG J, 1988, NUCLEIC ACIDS RES, V16, P1209, DOI 10.1093/nar/16.3.1209; HARLOW E, 1988, ANTIBODIES LABORATOR; HATZFELD M, 1992, FEBS LETT, V302, P239, DOI 10.1016/0014-5793(92)80450-U; HOGBERGRAIBAUD A, 1977, P NATL ACAD SCI USA, V74, P442, DOI 10.1073/pnas.74.2.442; HYDE CC, 1988, J BIOL CHEM, V263, P17857; LARVOR MP, 1991, MOL IMMUNOL, V28, P523, DOI 10.1016/0161-5890(91)90167-I; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1985, PYRIDOXAL PHOSPHATE, P253; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEDGWICK B, 1989, J BACTERIOL, V171, P2249, DOI 10.1128/jb.171.4.2249-2251.1989; SONG CS, 1985, J IMMUNOL, V135, P3354; SUGIMURA K, 1988, J BACTERIOL, V170, P5625, DOI 10.1128/jb.170.12.5625-5632.1988; SUGIMURA K, 1988, J BACTERIOL, V170, P3650, DOI 10.1128/jb.170.8.3650-3654.1988; SUGIMURA K, 1988, BIOCHEM BIOPH RES CO, V153, P753, DOI 10.1016/S0006-291X(88)81159-8; YANOFSKY C, 1956, J BIOL CHEM, V223, P171; YANOFSKY C, 1972, ENZYMES, V7, P1; ZHAO GP, 1993, J BIOL CHEM, V268, P14921; ZHAO GP, 1992, J BIOL CHEM, V267, P526	35	11	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14912	14920						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325868				2022-12-27	WOS:A1993LL75900059
J	RAJAGOPALAN, K; CHAVAN, AJ; HALEY, BE; WATT, DS				RAJAGOPALAN, K; CHAVAN, AJ; HALEY, BE; WATT, DS			SYNTHESIS AND APPLICATION OF BIDENTATE PHOTOAFFINITY CROSS-LINKING REAGENTS - NUCLEOTIDE PHOTOAFFINITY PROBES WITH 2 PHOTOACTIVE GROUPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITES; GLUTAMATE-DEHYDROGENASE; 5'-TRIPHOSPHATE; GLYCOSYLATION; PURIFICATION; TRIPHOSPHATE; PROTEINS; CHAIN	Two ''targeted bidentate'' photoaffinity cross-linking reagents, the monoanhydride of 8-N3ADP with N-(4-(benzoyl)phenylmethyl)phosphoramide ([gamma-P-32]8-N3ATPgammaBP) and the monoanhydride of 8-N3GDP with N-(4-(benzoyl)phenylmethyl)-phosphoramide ([gamma-P-32] 8-N3GTPgammaBP), were developed for studying the inter- and intramolecular interactions of nucleotide-binding proteins. Experiments using these bidentate reagents with two photoactive groups led to specific cross-linking: [gamma-P-32]8-N3GTPgammaBP and [gamma-P-32]8-N3ATPgammaBP showed intersubunit cross-linking of glutamate dehydrogenase and [gamma-P-32]8-N3GTPgammaBP appeared to cross-link the alpha- and beta-subunits of tubulin. The non-azido ''monodentate'' versions of these reagents, the monoanhydride of ADP with N-(4-(benzoyl)phenylmethyl)-phosphoramide ([gamma-P-32]ATPgammaBP) and the monoanhydride of GDP with N-(4-(benzoyl)phenylmethyl)-phosphoramide ([gamma-P-32]GTPgammaBP), were also synthesized and characterized. The ability of these monodentate reagents with one photoactive group to serve as photoaffinity probes was established by photolabeling specifically the exchangeable GTP-binding domain of tubulin with [gamma-P-32[GTPgammaBP and the ATP-binding domain of purified adenylate kinase and several nucleotide-binding proteins in human brain homogenate with [gamma-P-32]ATPgammaBP.	UNIV KENTUCKY, DEPT CHEM, LEXINGTON, KY 40506 USA; UNIV KENTUCKY, COLL PHARM, LUCILLE P MARKEY CANC CTR, DIV MED CHEM & PHARMACEUT, LEXINGTON, KY 40506 USA	University of Kentucky; University of Kentucky					NIGMS NIH HHS [GM 35766, GM 47427] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035766, R01GM047427] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABKINA GT, 1975, BIOORG KHIM+, V1, P611; BAYLEY H, 1983, PHOTOGENERATED REAGE, P114; Boyer P.D, 1973, ENZYMES, P279; CALVERT JG, 1966, PHOTOCHEMISTRY, P300; CAMPBELL S, 1990, P NATL ACAD SCI USA, V87, P1243, DOI 10.1073/pnas.87.3.1243; CHAVAN AJ, 1992, J BIOL CHEM, V267, P14866; Chavan AJ, 1990, BIOCONJUGATE CHEM, V1, P337, DOI 10.1021/bc00005a007; CHIBA S, 1990, J BIOL CHEM, V265, P19777; CROCKER PJ, 1991, BIOCONJUGATE CHEM, V2, P419; Czarnecki J, 1979, Methods Enzymol, V56, P642; DALZIEL K, 1972, BIOCHEM J, V126, P975, DOI 10.1042/bj1260975; DOUKAS MA, 1992, BIOCONJUGATE CHEM, V3, P484, DOI 10.1021/bc00018a004; GALARDY RE, 1973, NATURE-NEW BIOL, V242, P127, DOI 10.1038/newbio242127a0; GEAHLEN RL, 1977, P NATL ACAD SCI USA, V74, P4375, DOI 10.1073/pnas.74.10.4375; Girshovich A S, 1977, Methods Enzymol, V46, P656; GLONEK T, 1974, SCIENCE, V185, P352, DOI 10.1126/science.185.4148.352; GOLDIN BF, 1972, CURRENT TOPICS CELLU, V4, P77; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; Imai N, 1990, BIOCONJUGATE CHEM, V1, P138, DOI 10.1021/bc00002a008; KHATOON S, 1989, ANN NEUROL, V26, P210, DOI 10.1002/ana.410260205; KIM H, 1987, FASEB J, V46, P2229; KIM HJ, 1990, BIOCHEMISTRY-US, V29, P1107, DOI 10.1021/bi00457a002; KING SM, 1991, METHOD ENZYMOL, V196, P449; KNORRE DG, 1976, FEBS LETT, V70, P105, DOI 10.1016/0014-5793(76)80736-3; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEVYA E, 1991, PHOTOCHEM PHOTOBIOL, V54, P329; MAHMOOD R, 1987, J BIOL CHEM, V262, P14479; PAL PK, 1979, BIOCHEMISTRY-US, V18, P838, DOI 10.1021/bi00572a016; PANTALONI D, 1969, EUR J BIOCHEM, V11, P510, DOI 10.1111/j.1432-1033.1969.tb00803.x; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; SALVUCCI ME, 1992, BIOCHEMISTRY-US, V31, P4479, DOI 10.1021/bi00133a014; SALVUCCI ME, 1993, J BIOL CHEM, V268, P14239; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; STRAHLBOLSINGER S, 1991, EUR J BIOCHEM, V196, P185, DOI 10.1111/j.1432-1033.1991.tb15802.x; TAKAHITO I, 1990, MACROMOLECULES, V23, P4879; TANNER W, 1987, BIOCHIM BIOPHYS ACTA, V906, P81, DOI 10.1016/0304-4157(87)90006-2; THALMANN E, 1991, BIOCHIM BIOPHYS ACTA, V1088, P301, DOI 10.1016/0167-4781(91)90067-V; WILLIAMS N, 1982, J BIOL CHEM, V257, P2834; YAN HG, 1991, BIOCHEMISTRY-US, V30, P5539, DOI 10.1021/bi00236a029	39	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14230	14238						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314786				2022-12-27	WOS:A1993LJ82500066
J	WANG, YK; LIAO, PC; ALLISON, J; GAGE, DA; ANDREWS, PC; LUBMAN, DM; HANASH, SM; STRAHLER, JR				WANG, YK; LIAO, PC; ALLISON, J; GAGE, DA; ANDREWS, PC; LUBMAN, DM; HANASH, SM; STRAHLER, JR			PHORBOL 12-MYRISTATE 13-ACETATE-INDUCED PHOSPHORYLATION OF OP18 IN JURKAT T-CELLS - IDENTIFICATION OF PHOSPHORYLATION SITES BY MATRIX-ASSISTED LASER-DESORPTION IONIZATION MASS-SPECTROMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURON-ENRICHED PHOSPHOPROTEIN; 2 CYTOSOLIC PROTEINS; ACTIVATION; STATHMIN; KINASE; GENE; ELECTROPHORESIS; PROLIFERATION; DIGESTION; LEUKEMIA	Op18 is a widely expressed, cell cycle-regulated, phosphoprotein involved in signal transduction of a variety of stimuli. In actively proliferating Jurkat T cells which express Op18 at high level, phorbol 12-myristate 13-acetate (PMA) treatment induces a rapid increase in the level of several Op18 phosphorylated forms. To determine phosphorylation sites involved in the PMA effect, the major Op18 phosphorylated forms were resolved in Jurkat T cells, before and after treatment with PMA, using preparative immobilized pH gradient-based two-dimensional polyacrylamide gel electrophoresis. Tryptic fragments of phosphorylated Op18 were analyzed by two-dimensional thin layer peptide mapping and were resolved by reverse-phase high performance liquid chromatography prior to analysis by matrix-assisted laser desorption ionization mass spectrometry. Phosphorylation sites were identified by further treatment of the proteolytic fragments with different enzymes and determination of the mass shifts by matrix-assisted laser desorption ionization mass spectrometry. Two major phosphorylation sites were identified. Low constitutive levels of phosphorylation at Ser25 and Ser38 in Op18a and Op18b was demonstrated. Treatment with PMA resulted in enhanced phosphorylation of Ser25 in Op18a and of both Ser25 and Ser38 in Op18b. Taken together with prior studies of Op18 phosphorylation, the data suggest that Op18 phosphorylation occurs at identical sites in different tissues and organisms.	UNIV MICHIGAN,SCH MED,DEPT PEDIAT,R4451 KRESGE I,BOX 0510,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT BIOCHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT CHEM,ANN ARBOR,MI 48109; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT CHEM,E LANSING,MI 48824	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Michigan State University; Michigan State University				Andrews, Philip/0000-0001-6843-5420	NCI NIH HHS [CA32146] Funding Source: Medline; NCRR NIH HHS [RR0480-23] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA032146] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000480] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; CHAIT BT, 1992, 40TH P ASMS C MASS S, P1939; COOPER HL, 1990, J IMMUNOL, V145, P1205; DOYE V, 1989, J BIOL CHEM, V264, P12134; DOYE V, 1990, J BIOL CHEM, V265, P11650; GULLBERG M, 1990, J BIOL CHEM, V265, P17499; HAILAT N, 1990, ONCOGENE, V5, P1615; HANASH SM, 1991, P NATL ACAD SCI USA, V88, P5709, DOI 10.1073/pnas.88.13.5709; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; KARAS M, 1991, MASS SPECTROM REV, V10, P335, DOI 10.1002/mas.1280100503; LABDON JE, 1992, J BIOL CHEM, V267, P3506; LEGOUVELLO S, 1991, FEBS LETT, V287, P80, DOI 10.1016/0014-5793(91)80020-4; MARY D, 1989, J BIOL CHEM, V264, P14498; MELHEM RF, 1991, BIOCHEM BIOPH RES CO, V179, P1649, DOI 10.1016/0006-291X(91)91764-4; PEYRON JF, 1989, BIOCHEM J, V258, P505, DOI 10.1042/bj2580505; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; SCHAR M, 1991, RAPID COMMUN MASS SP, V5, P319, DOI 10.1002/rcm.1290050705; SCHAR M, 1991, CHIMIA, V45, P123; SCHUBART UK, 1982, J BIOL CHEM, V257, P2231; SCHUBART UK, 1989, DNA-J MOLEC CELL BIO, V8, P389, DOI 10.1089/dna.1.1989.8.389; SOBEL A, 1989, J BIOL CHEM, V264, P3765; SPENGLER B, 1992, RAPID COMMUN MASS SP, V6, P105, DOI 10.1002/rcm.1290060207; STRAHLER J R, 1991, Methods (Orlando), V3, P109, DOI 10.1016/S1046-2023(05)80202-6; STRAHLER JR, 1992, J IMMUNOL, V149, P1191; STRAHLER JR, 1992, BIOCHEM BIOPH RES CO, V185, P197, DOI 10.1016/S0006-291X(05)80975-1; ZHU XX, 1989, J BIOL CHEM, V264, P14556	30	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14269	14277						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314790				2022-12-27	WOS:A1993LJ82500072
J	COSKUNARI, FF; SKOKOTAS, A; MOE, GR; HILL, TM				COSKUNARI, FF; SKOKOTAS, A; MOE, GR; HILL, TM			BIOPHYSICAL CHARACTERISTICS OF TUS, THE REPLICATION ARREST PROTEIN OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS CHROMOSOME; DNA-BINDING PROTEIN; TERMINATOR PROTEIN; SECONDARY-STRUCTURE; CIRCULAR-DICHROISM; ANTIGEN HELICASE; SEQUENCE; IDENTIFICATION; REGION; GENE	Tus, a DNA-binding protein, mediates arrest of DNA replication in Escherichia coli. Tus binds to DNA sequences called Ter sites, located in the terminus region of the chromosome, and forms replication-arrest complexes that block movement of DNA replication forks in a polar fashion. We have analyzed Tus to determine some of its physical parameters and biochemical characteristics. Native Tus had an 8(20,w) of 3.2, a Stokes' radius of 23 Angstrom, an axial ratio of 2, and a molar absorption coefficient of 39,700 M(-1) cm(-1). The data also indicated that Tus existed as a monomeric protein in solution and when complexed with its cognate DNA binding site. Secondary structure estimated from the circular dichroism spectrum suggested that Tus consisted of 40% alpha-helix, 0% beta-sheet, 15% turn, and 45% aperiodic structure. The isoeletric point of native Tus (pH 7.5) was significantly different than that calculated from its amino acid sequence (pH 10.1), possibly because the tertiary structure of Tus perturbs the ionization of several residues. In addition, partial proteolytic digests of free Tus protein did not produce a subfragment of Tus that retained DNA binding activity, but did demonstrate that Tus was resistant to proteolysis when complexed with a Ter site.	DREXEL UNIV,DEPT BIOSCI & BIOTECHNOL,PHILADELPHIA,PA 19104; UNIV DELAWARE,DEPT CHEM & BIOCHEM,NEWARK,DE 19716	Drexel University; University of Delaware					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043193, R01GM043193] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43193] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BADING H, 1988, NUCLEIC ACIDS RES, V16, P5241, DOI 10.1093/nar/16.12.5241; BEDROSIAN CL, 1991, P NATL ACAD SCI USA, V88, P2618, DOI 10.1073/pnas.88.7.2618; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARRIGAN CM, 1987, NUCLEIC ACIDS RES, V15, P8501, DOI 10.1093/nar/15.20.8501; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DEMASSY B, 1987, P NATL ACAD SCI USA, V84, P1759; FREIFELDER D, 1982, PHYSICAL BIOCH, P466; GARNER MM, 1982, BIOCHEMISTRY-US, V21, P6032, DOI 10.1021/bi00267a001; GOTTLIEB PA, 1992, J BIOL CHEM, V267, P7434; HIASA H, 1992, J BIOL CHEM, V267, P11379; HIDAKA M, 1989, J BIOL CHEM, V264, P21031; HIDAKA M, 1992, J BIOL CHEM, V267, P5361; HIDAKA M, 1988, CELL, V55, P467, DOI 10.1016/0092-8674(88)90033-5; HILL TM, 1987, P NATL ACAD SCI USA, V84, P1754, DOI 10.1073/pnas.84.7.1754; HILL TM, 1989, P NATL ACAD SCI USA, V86, P1593, DOI 10.1073/pnas.86.5.1593; HILL TM, 1990, P NATL ACAD SCI USA, V87, P2481, DOI 10.1073/pnas.87.7.2481; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; HILL TM, 1992, ANNU REV MICROBIOL, V46, P603, DOI 10.1146/annurev.micro.46.1.603; HO YS, 1982, J BIOL CHEM, V257, P9128; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KOBAYASHI T, 1989, EMBO J, V8, P2435, DOI 10.1002/j.1460-2075.1989.tb08374.x; LANE D, 1992, MICROBIOL REV, V56, P509, DOI 10.1128/MMBR.56.4.509-528.1992; LAURENT TC, 1964, J CHROMATOGR, V14, P317, DOI 10.1016/S0021-9673(00)86637-6; LEE EH, 1992, J BIOL CHEM, V267, P8778; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LEWIS PJ, 1990, J MOL BIOL, V214, P73, DOI 10.1016/0022-2836(90)90147-E; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; NATARAJAN S, 1991, P NATL ACAD SCI USA, V88, P3867, DOI 10.1073/pnas.88.9.3867; NATARAJAN S, 1993, CELL, V72, P113, DOI 10.1016/0092-8674(93)90055-U; ROECKLEIN B, 1991, RES MICROBIOL, V142, P169, DOI 10.1016/0923-2508(91)90026-7; SALAMAN MR, 1971, BIOCHEM J, V122, P93, DOI 10.1042/bj1220093; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; SHARMA B, 1992, J BACTERIOL, V174, P7854, DOI 10.1128/JB.174.23.7854-7858.1992; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SISTA P, 1990, GENE DEV, V5, P74; SISTA PR, 1989, P NATL ACAD SCI USA, V86, P3026, DOI 10.1073/pnas.86.9.3026; SMITH MT, 1992, J MOL BIOL, V227, P648, DOI 10.1016/0022-2836(92)90214-5; SOBER HA, 1970, HDB BIOCH, pC10; TOMBS MP, 1959, BIOCHEM J, V73, P167, DOI 10.1042/bj0730167; VANIERSEL J, 1985, ANAL BIOCHEM, V151, P196, DOI 10.1016/0003-2697(85)90072-7; WADDELL WJ, 1956, J LAB CLIN MED, V48, P311; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; YANG JT, 1986, METHOD ENZYMOL, V130, P208	46	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4027	4034						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307958				2022-12-27	WOS:A1994MW98900022
J	KRECK, ML; UHLINGER, DJ; TYAGI, SR; INGE, KL; LAMBETH, JD				KRECK, ML; UHLINGER, DJ; TYAGI, SR; INGE, KL; LAMBETH, JD			PARTICIPATION OF THE SMALL MOLECULAR-WEIGHT GTP-BINDING PROTEIN RAC1 IN CELL-FREE ACTIVATION AND ASSEMBLY OF THE RESPIRATORY BURST OXIDASE - INHIBITION BY A CARBOXYL-TERMINAL RAC PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL NADPH OXIDASE; ADENINE-DINUCLEOTIDE PHOSPHATE; FREE SYSTEM; PLASMA-MEMBRANE; CYTOSOLIC COMPONENTS; RECOMBINANT P47-PHOX; ANIONIC AMPHIPHILE; EXCHANGE PROTEINS; CYTOCHROME-B558; RECONSTITUTION	NADPH-dependent superoxide generation was activated by anionic amphiphiles plus GTP gamma S in a cell-free system consisting of plasma membranes plus recombinant p47-phox, p67-phox, and the small GTP-binding protein Rac1. Rac1 was expressed in Escherichia coli both as the native form and as a mutant form (Rac1(C189S)) lacking the prenylation site. When preloaded with GTP gamma S, both Rac proteins supported activity to a level comparable to that seen using cytosol. A peptide corresponding to the carboxyl-terminal region of Rad was used to investigate oxidase assembly and activation. Rac1(178-188), but not several control peptides, inhibited activity. The peptide inhibited competitively (K-i = 15 mu M) with respect to Rac1(C189S), while inhibition was noncompetitive or mixed with respect to p47-phox and p67-phox. This indicated specific inhibition of the interaction of the Rac protein with its target, possibly cytochrome b(558) The peptide was effective only when added prior to activation with arachidonic acid, suggesting that it affects assembly rather than activity. Consistent with this possibility the peptide prevented translocation of p47-phox and p67-phox to the plasma membrane. Thus, Rac plays a central role in the assembly of the neutrophil NADPH oxidase.	EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University					NCI NIH HHS [CA 46508] Funding Source: Medline; NIAID NIH HHS [AI22809] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022809] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; ANDO S, 1992, J BIOL CHEM, V267, P25709; BABIOR BM, 1987, TRENDS BIOCHEM SCI, V12, P241, DOI 10.1016/0968-0004(87)90118-6; BOKOCH GM, 1992, J CLIN INVEST, V89, P402, DOI 10.1172/JCI115599; BOKOCH GM, 1991, SCIENCE, V254, P1794, DOI 10.1126/science.1763330; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; FUJIMOTO S, 1989, J BIOL CHEM, V264, P21629; GABIG TG, 1987, J BIOL CHEM, V262, P1685; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; KLEINBERG ME, 1990, J BIOL CHEM, V265, P15577; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LAMBETH JD, 1988, J BIOENERG BIOMEMBR, V20, P709, DOI 10.1007/BF00762549; LIGETI E, 1989, BIOCHEMISTRY-US, V28, P7116, DOI 10.1021/bi00443a050; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MIKI T, 1992, J BIOL CHEM, V267, P18695; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; NAKANISHI A, 1992, J BIOL CHEM, V267, P19072; PARK JW, 1992, J BIOL CHEM, V267, P17327; PEMBER SO, 1983, ARCH BIOCHEM BIOPHYS, V221, P391, DOI 10.1016/0003-9861(83)90158-3; PEVERI P, 1990, BLOOD, V76, P751; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SEIFERT R, 1988, EUR J BIOCHEM, V175, P51, DOI 10.1111/j.1432-1033.1988.tb14165.x; SMITH RM, 1991, BLOOD, V77, P673; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TYAGI SR, 1992, BIOCHEMISTRY-US, V31, P2765, DOI 10.1021/bi00125a017; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V186, P509, DOI 10.1016/S0006-291X(05)80837-X; UHLINGER DJ, 1993, J BIOL CHEM, V268, P8624; VANGELDER BF, 1962, BIOCHIM BIOPHYS ACTA, V58, P593, DOI 10.1016/0006-3002(62)90073-2	41	86	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4161	4168						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307977				2022-12-27	WOS:A1994MW98900042
J	ZHANG, JS; MACRAE, TH				ZHANG, JS; MACRAE, TH			NUCLEOTIDE DEPENDENCE AND CYTOPLASMIC LOCALIZATION OF A 49-KDA MICROTUBULE CROSS-LINKING PROTEIN FROM THE BRINE SHRIMP, ARTEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINESIN HEAVY-CHAIN; ACTIVATED ATPASE; MITOTIC SPINDLE; MECHANOCHEMICAL ENZYME; MONOCLONAL-ANTIBODIES; CHICKEN ERYTHROCYTES; TRYPANOSOMA-BRUCEI; GROWTH CONES; DYNEIN; IDENTIFICATION	Many different proteins associate with microtubules, influencing their spatial organization and function. These include proteins of a structural nature, which link microtubules to one another or to other cellular organelles and which may stimulate tubulin assembly. The second group, the so-called dynamic microtubule-associated proteins, move subcellular components along microtubules through nucleotidase action. In this report the effects of nucleotides on a 49-kDa protein which appears to associate with ordered arrays of microtubules within Artemia are described, revealing a protein with novel characteristics. Efficient removal of the 49-kDa protein from microtubules assembled in cell-free extracts of Artemia occurred with GTP and some analogues of ATP, nonhydrolyzable or otherwise, but not with ATP itself. The latter nucleotide had a greater impact on cross-linking when microtubules were assembled from purified tubulin. The 49-kDa protein possessed a low level of nucleotidase activity, preferring either ATP or GTP as substrate. Unlike other microtubule-associated proteins, the enzymatic activity of the 49-kDa protein was not stimulated by microtubules, at least under assay conditions in which cross-linking was disrupted by nucleotides. Immunofluorescent staining of Artemia larvae by affinity-purified antibodies indicated that the 49-kDa protein is located in mitotic spindles, midbodies, and setal cells, all regions containing organized microtubules. The 49-kDa microtubule cross-linking protein from Artemia, through its unusual response to nucleotides and its cytoplasmic location, has a unique position within the heterogeneous family of microtubule-associated proteins described to date.	DALHOUSIE UNIV,DEPT BIOL,HALIFAX B3H 4J1,NS,CANADA	Dalhousie University								AAMODT EJ, 1986, J CELL BIOL, V103, P23, DOI 10.1083/jcb.103.1.23; AMOS LA, 1989, J CELL SCI, V93, P19; BALABAN N, 1989, CELL MOTIL CYTOSKEL, V14, P393, DOI 10.1002/cm.970140309; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; BRAMBLETT GT, 1989, CELL MOTIL CYTOSKEL, V13, P145, DOI 10.1002/cm.970130303; CAMPBELL EJ, 1989, J CELL SCI, V93, P29; CHAPIN SJ, 1992, CELL MOTIL CYTOSKEL, V23, P236, DOI 10.1002/cm.970230403; COHN SA, 1989, J BIOL CHEM, V264, P4290; FEICK P, 1991, J CELL BIOL, V112, P689, DOI 10.1083/jcb.112.4.689; GARD DL, 1991, DEV BIOL, V143, P346, DOI 10.1016/0012-1606(91)90085-H; GOLDSTEIN LSB, 1993, J CELL BIOL, V120, P1, DOI 10.1083/jcb.120.1.1; GRISSOM PM, 1992, CELL MOTIL CYTOSKEL, V21, P281, DOI 10.1002/cm.970210404; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HARLOW E, 1988, ANTIBODIES LAB MANUA, P498; HATSUMI M, 1992, J CELL SCI, V103, P1013; HIROKAWA N, 1985, J CELL BIOL, V101, P1858, DOI 10.1083/jcb.101.5.1858; HIROKAWA N, 1990, J CELL BIOL, V111, P1027, DOI 10.1083/jcb.111.3.1027; HOLLENBECK PJ, 1986, J CELL BIOL, V103, P1539, DOI 10.1083/jcb.103.4.1539; HOLLENBECK PJ, 1984, J CELL BIOL, V99, P1251, DOI 10.1083/jcb.99.4.1251; HUITOREL P, 1985, EUR J BIOCHEM, V150, P265, DOI 10.1111/j.1432-1033.1985.tb09016.x; JENSEN CG, 1991, EUR J CELL BIOL, V54, P121; JENSEN CG, 1991, PROTOPLASMA, V161, P137, DOI 10.1007/BF01322726; JONES BA, 1992, GENE DEV, V6, P380, DOI 10.1101/gad.6.3.380; KALLAJOKI M, 1992, J CELL SCI, V102, P91; KNOPS J, 1991, J CELL BIOL, V114, P725, DOI 10.1083/jcb.114.4.725; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; KOONCE MP, 1990, CELL MOTIL CYTOSKEL, V15, P51, DOI 10.1002/cm.970150108; KUZNETSOV SA, 1989, J BIOL CHEM, V264, P589; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8530, DOI 10.1073/pnas.83.22.8530; MACRAE TH, 1991, CELL MOTIL CYTOSKEL, V18, P189, DOI 10.1002/cm.970180305; MACRAE TH, 1992, BIOCHIM BIOPHYS ACTA, V1160, P145, DOI 10.1016/0167-4838(92)90001-T; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; MANDELKOW EM, 1992, CELL MOTIL CYTOSKEL, V22, P235, DOI 10.1002/cm.970220403; MCINTOSH JR, 1991, J CELL BIOL, V115, P577, DOI 10.1083/jcb.115.3.577; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MITHIEUX G, 1988, BIOCHIM BIOPHYS ACTA, V971, P29; MITHIEUX G, 1989, J BIOL CHEM, V264, P4664; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OCONNELL MJ, 1993, J CELL BIOL, V120, P153, DOI 10.1083/jcb.120.1.153; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; PRESCOTT AR, 1992, J CELL SCI, V102, P103; RODIONOV VI, 1990, J BIOL CHEM, V265, P5702; SABRY JH, 1991, J CELL BIOL, V115, P381, DOI 10.1083/jcb.115.2.381; SANCHEZ I, 1990, EUR J CELL BIOL, V52, P349; SAWIN KE, 1992, J CELL SCI, V101, P303; SAXTON WM, 1988, P NATL ACAD SCI USA, V85, P1109, DOI 10.1073/pnas.85.4.1109; SCHROEDER CC, 1990, J CELL BIOL, V111, P2553, DOI 10.1083/jcb.111.6.2553; SHIMIZU T, 1991, J CELL BIOL, V112, P1189, DOI 10.1083/jcb.112.6.1189; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; SHPETNER HS, 1988, J CELL BIOL, V107, P1001, DOI 10.1083/jcb.107.3.1001; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; STEWART RJ, 1991, P NATL ACAD SCI USA, V88, P8470, DOI 10.1073/pnas.88.19.8470; TABLIN F, 1991, EUR J CELL BIOL, V56, P415; TAKEMURA R, 1992, J CELL SCI, V103, P953; TANAKA EM, 1991, J CELL BIOL, V115, P345, DOI 10.1083/jcb.115.2.345; UMEYAMA T, 1993, J CELL BIOL, V120, P451, DOI 10.1083/jcb.120.2.451; URRUTIA R, 1991, P NATL ACAD SCI USA, V88, P6701, DOI 10.1073/pnas.88.15.6701; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALLEE RB, 1983, P NATL ACAD SCI-BIOL, V80, P6259, DOI 10.1073/pnas.80.20.6259; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; VONMASSOW A, 1989, CELL MOTIL CYTOSKEL, V14, P562, DOI 10.1002/cm.970140413; WINCKLER B, 1991, P NATL ACAD SCI USA, V88, P6033, DOI 10.1073/pnas.88.14.6033; WOODS A, 1989, J CELL SCI, V93, P491; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; ZHANG JS, 1992, BIOCHEM CELL BIOL, V70, P1055, DOI 10.1139/o92-150	72	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3053	3062						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300639				2022-12-27	WOS:A1994MV43200099
J	GUREVICH, VV; RICHARDSON, RM; KIM, CM; HOSEY, MM; BENOVIC, JL				GUREVICH, VV; RICHARDSON, RM; KIM, CM; HOSEY, MM; BENOVIC, JL			BINDING OF WILD-TYPE AND CHIMERIC ARRESTINS TO THE M2 MUSCARINIC CHOLINERGIC RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-ADRENERGIC-RECEPTOR; LIGHT-DEPENDENT PHOSPHORYLATION; 48-KDA PROTEIN; RHODOPSIN KINASE; PHOTOEXCITED RHODOPSIN; DESENSITIZATION; FAMILY; EXPRESSION; DROSOPHILA; SIGNAL	Arrestins play an important role in regulating the activity of the G protein-coupled receptors rhodopsin and the beta2-adrenergic receptor. Recently, we described the expression and functional characterization of visual arrestin using an in vitro translation system. Here we report the expression of beta-arrestin and development of a direct binding assay to study the interaction of arrestins with a muscarinic cholinergic receptor. In vitro translated beta-arrestin was found to specifically bind to purified reconstituted human m2 muscarinic cholinergic receptor (hm2 mAChR) in an agonist- and phosphorylation-dependent manner. Visual arrestin also bound to the hm2 mAChR, albeit to a lesser extent and with lower affinity. In an attempt to dissect the major domains responsible for determining the receptor binding specificity of arrestin and beta-arrestin, we generated several chimeric arrestins. One contained the first 340 residues of beta-arrestin followed by residues 346-404 of arrestin (BRV4), another consisted of the first 207 residues of beta-arrestin and residues 214-404 of visual arrestin (BV3), and a third had residues 1-43 of beta-arrestin replaced by residues 1-47 of arrestin (VIN1). All of these arrestins were able to specifically bind to the activated and phosphorylated form of both the hm2 mAChR and rhodopsin, with a clear preference for the muscarinic receptor. The K(d) values for beta-arrestin, BRV4, BV3, VIN1, and visual arrestin binding to the hm2 mAChR were 0.48 +/- 0.06, 0.51 +/- 0.19, 1.38 +/- 0.26, 1.13 +/- 0.26, and 7.2 +/- 1.2 nM, respectively. These data demonstrate that: 1) beta-arrestin binds to the hm2 mAChR in an activation- and phosphorylation-dependent fashion, 2) visual arrestin has 15-fold lower affinity for the hm2 mAChR as compared to beta-arrestin, and 3) the N-terminal half of beta-arrestin plays a key role in determining receptor binding specificity. The use of in vitro translated arrestins to directly assess receptor binding may serve as a viable approach for elucidating the specificity and molecular mechanisms involved in receptor-arrestin interaction.	THOMAS JEFFERSON UNIV,DEPT PHARMACOL,233 S 10TH ST,PHILADELPHIA,PA 19107; NORTHWESTERN UNIV,SCH MED,DEPT PHARMACOL,CHICAGO,IL 60611	Jefferson University; Northwestern University			Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031601, R01HL045964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45964, HL31601] Funding Source: Medline; NIGMS NIH HHS [GM44944] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BENOVIC JL, 1993, IN PRESS J BIOL CHEM, V268; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; GILMAN AG, 1992, CELL, V70, P869; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; KIM CM, 1993, IN PRESS RECEPTOR; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE H, 1991, MECH DEVELOP, V33, P19; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1170; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; ZOZULYA SA, 1988, Patent No. 1547313	36	80	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16879	16882						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349577				2022-12-27	WOS:A1993LQ98800003
J	SHIRAISHI, F; SAVAGEAU, MA				SHIRAISHI, F; SAVAGEAU, MA			THE TRICARBOXYLIC-ACID CYCLE IN DICTYOSTELIUM-DISCOIDEUM - SYSTEMIC EFFECTS OF INCLUDING PROTEIN-TURNOVER IN THE CURRENT MODEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The current model for the tricarboxylic acid cycle in Dictyostelium discoideum is based on extensive experimental studies of enzyme kinetics in vitro and of metabolite fluxes measured in vivo. In the previous papers (Shiraishi, F., and Savageau, M. A. (1992) J. Biol. Chem. 267, 22912-22918; 22919-22925; 22926-22933; 22934-22943) of this series we have carried out extensive analyses of the current model within the framework of biochemical systems theory with a view toward understanding the behavior of the integrated system. The model was found to be ill determined with respect to at least three of its features. In this paper we propose a minimal modification in the model that is consistent with previous experimental data but also includes recycling of amino acids for protein synthesis, one of the neglected features identified as important in the previous analysis. We again perform an analysis within the framework of biochemical systems theory to determine the systemic consequences of this change. The results show that the robustness of the modified model, as determined by the parameter sensitivities, is improved by 2 orders of magnitude over that of the previous model. Analysis of the dynamics shows that the turnover times for the pools of alanine, glutamate, and aspartate are reduced by 2 orders of magnitude and made more physiologically realistic. The distribution of flux is no longer rigidly fixed, and problems previously centered on the metabolism of pyruvate have been partially alleviated. Continued discrepancies lead us to question the degree to which kinetic data obtained with purified enzymes in vitro faithfully reflect the kinetic behavior of the integrated enzyme system in vivo. We must continue to re-examine the manner in which the kinetics of reactions in vivo are represented and to reassess the physical conditions that prevail in vitro and in vivo. Results in this paper direct our attention toward specific aspects of the system where these efforts should be focused. Thus, a minimal modification of the previous model has led to several improvements that make it more representative of the tricarboxylic acid cycle in D. discoideum, and the analysis in this paper leads to further predictions for improving the model.	UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030054] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-30054] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBE KR, 1992, J BIOL CHEM, V267, P3106; CLEGG JS, 1984, AM J PHYSIOL, V246, pR133, DOI 10.1152/ajpregu.1984.246.2.R133; FRANKE J, 1973, J MOL BIOL, V81, P173, DOI 10.1016/0022-2836(73)90187-3; GREGG JH, 1956, J CELL COMPAR PHYSL, V47, P483, DOI 10.1002/jcp.1030470312; IRVINE DH, 1991, CANONICAL NONLINEAR, P90; KELLY PJ, 1979, BIOCHEM J, V184, P589, DOI 10.1042/bj1840589; KELLY PJ, 1979, BIOCHEM J, V184, P581, DOI 10.1042/bj1840581; LIDDEL GU, 1961, DEV BIOL, V3, P265, DOI 10.1016/0012-1606(61)90047-1; Mahler H. R., 1966, BIOL CHEM; Savageau M. A., 1992, FUNDAMENTALS MED CEL, V3A, P45; SAVAGEAU MA, 1992, J THEOR BIOL, V154, P131, DOI 10.1016/S0022-5193(05)80194-8; SAVAGEAU MA, 1989, J THEOR BIOL, V141, P93, DOI 10.1016/S0022-5193(89)80011-6; Segel I.H., 1975, ENZYME KINETICS; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22912; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22926; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22934; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22919; SORRIBAS A, 1989, MATH BIOSCI, V94, P239, DOI 10.1016/0025-5564(89)90066-7; SRERE PA, 1975, ADV ENZYMOL RAMB, V43, P57; Srere PA, 1989, STRUCTURAL ORG ASPEC; VOIT EO, 1990, USERS GUIDE ESSYNS; WHITE GJ, 1961, BIOCHIM BIOPHYS ACTA, V53, P285, DOI 10.1016/0006-3002(61)90441-3; WRIGHT BE, 1992, J BIOL CHEM, V267, P3101; WRIGHT BE, 1960, BIOCHIM BIOPHYS ACTA, V43, P62, DOI 10.1016/0006-3002(60)90407-8; WRIGHT BE, 1960, BIOCHIM BIOPHYS ACTA, V43, P67, DOI 10.1016/0006-3002(60)90408-X	25	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16917	16928						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349583				2022-12-27	WOS:A1993LQ98800011
J	VIHINEN, T; AUVINEN, P; ALANENKURKI, L; JALKANEN, M				VIHINEN, T; AUVINEN, P; ALANENKURKI, L; JALKANEN, M			STRUCTURAL ORGANIZATION AND GENOMIC SEQUENCE OF MOUSE SYNDECAN-1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; CELL-SURFACE PROTEOGLYCAN; MAMMARY EPITHELIAL-CELLS; INTEGRAL MEMBRANE PROTEOGLYCAN; FIBROBLAST GROWTH-FACTOR; MOLECULAR-CLONING; MESENCHYMAL INTERACTIONS; TRANSIENT EXPRESSION; CORE PROTEINS; TUMOR-CELLS	Syndecan-1 is an integral membrane proteoglycan, which binds several extracellular matrix components and growth factors. Its expression follows morphogenetic rather than histological patterns during embryonic development and is regulated by epithelial-mesenchymal interactions during organogenesis. Malignant transformation has been shown to suppress syndecan-1 expression. In order to understand better the regulation of syndecan-1 expression, we have determined the structural organization of mouse syndecan-1 gene. Several genomic clones were isolated, covering the entire 23-kilobase (kb) syndecan-1 gene. All five exons, four introns, and the 5'- and 3'-flanking regions were sequenced. The first intron was very long (17,582 base pairs (bp)) if compared with the others that were only a few hundred nucleotides in length. The first exon contained only the signal sequence and exons II-IV all the glycosaminoglycan binding sites. The fifth exon resided both transmembrane and cytoplasmic domains, which are known to be conserved among the members of the syndecan family. This genomic structure explains why these members could have heterologous extracellular domains and homologous transmembrane and cytoplasmic domains. Syndecan-1 gene was shown by primer extension analysis to have three transcription initiation sites which were confirmed by polymerase chain reaction. These initiation sites were found to locate -217, -266, and -591 bp from described cDNA (Saunders, S., Jalkanen, M., O'Farrell, S., and Bernfield, M. (1989) J. Cell Biol. 108, 1547-1556). Within the 5'-end of the gene a 2000-bp-long CpG nucleotide-rich sequence resembling a CpG island was found, which started from the transcription initiation sites and ended in the first intron. At the 3'-end of the gene an other polyadenylation signal sequence was revealed 638 bp downstream from the first one. The two mRNAs (2.6 kb and 3.4 kb) were shown to be produced by alternative polyadenylation.	TURKU CTR BIOTECHNOL, TYKISTOKATU 6, BIOCITY, POB 123, SF-20521 TURKU, FINLAND; UNIV TURKU, INST BIOMED, DEPT MED BIOCHEM, SF-20520 TURKU 52, FINLAND	University of Turku; University of Turku			Auvinen, Petri/D-5044-2009; Auvinen, Petri/AAP-8117-2021	Auvinen, Petri/0000-0002-3947-4778; 	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009399] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 09399-01] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALAKAPEE M, 1990, SOMAT CELL MOLEC GEN, V16, P501, DOI 10.1007/BF01233200; BACIU PC, 1992, MOL BIOL CELL, V3, pA64; Battey, 1986, BASIC METHODS MOL BI; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOUTIN EL, 1991, DEV BIOL, V148, P63, DOI 10.1016/0012-1606(91)90317-V; BRAUKER JH, 1991, DEV BIOL, V147, P285, DOI 10.1016/0012-1606(91)90286-C; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIZMECISMITH G, 1992, J BIOL CHEM, V267, P15729; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; ELENIUS K, 1990, J BIOL CHEM, V265, P17837; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; HAYASHI K, 1987, J HISTOCHEM CYTOCHEM, V35, P1079, DOI 10.1177/35.10.2957423; HELLMAN L, 1987, GENE ANAL TECH, V4, P9, DOI 10.1016/0735-0651(87)90007-0; HSIAO KC, 1991, NUCLEIC ACIDS RES, V19, P2787, DOI 10.1093/nar/19.10.2787; INKI P, 1991, AM J PATHOL, V139, P1333; INKI P, 1992, LAB INVEST, V66, P314; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; JALKANEN M, 1993, TRENDS GLYCOSCI GLYC, V5, P107; JALKANEN M, 1991, RECEPTORS EXTRACELLU, P1; JEANNOTTE L, 1987, MOL ENDOCRINOL, V1, P749, DOI 10.1210/mend-1-10-749; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KODA JE, 1985, J BIOL CHEM, V260, P8157; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; LEPPA S, 1991, CELL REGUL, V2, P1; LI WZ, 1991, MOL CELL BIOL, V11, P666, DOI 10.1128/MCB.11.2.666; LU Q, 1992, J MOL BIOL, V225, P985, DOI 10.1016/0022-2836(92)90099-6; MALI M, 1990, J BIOL CHEM, V265, P6884; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; OETTINGER HF, 1991, GENOMICS, V11, P334, DOI 10.1016/0888-7543(91)90140-A; PIERCE A, 1992, J BIOL CHEM, V267, P3894; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAPRAEGER A, 1986, J CELL BIOL, V103, P2683, DOI 10.1083/jcb.103.6.2683; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SALMIVIRTA M, 1992, EXP CELL RES, V200, P444, DOI 10.1016/0014-4827(92)90194-D; SALMIVIRTA M, 1992, J BIOL CHEM, V267, P17606; Sambrook J, 1989, MOL CLONING LABORATO; SANDERSON RD, 1989, CELL REGUL, V1, P27, DOI 10.1091/mbc.1.1.27; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOLURSH M, 1990, DEV BIOL, V140, P83, DOI 10.1016/0012-1606(90)90055-N; SUN XJ, 1989, J BIOL CHEM, V264, P11288; SUTHERLAND AE, 1991, DEVELOPMENT, V113, P339; SVED J, 1990, P NATL ACAD SCI USA, V87, P4692, DOI 10.1073/pnas.87.12.4692; TRAUTMAN MS, 1991, DEVELOPMENT, V111, P213; VAAHTOKARI A, 1991, DEVELOPMENT, V113, P985; VAINIO S, 1992, DEV DYNAM, V194, P105, DOI 10.1002/aja.1001940204; VAINIO S, 1991, DEV BIOL, V147, P322, DOI 10.1016/0012-1606(91)90290-J; VAINIO S, 1992, DEV BIOL, V152, P221, DOI 10.1016/0012-1606(92)90130-9; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; VOGEL A, 1978, P NATL ACAD SCI USA, V75, P2810, DOI 10.1073/pnas.75.6.2810; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEISINGER G, 1992, J BIOL CHEM, V267, P4508; WEITZHANDLER M, 1988, J BIOL CHEM, V263, P6949; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; YASUKAWA K, 1987, EMBO J, V6, P2939, DOI 10.1002/j.1460-2075.1987.tb02598.x	66	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17261	17269						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349612				2022-12-27	WOS:A1993LQ98800059
J	BOISSEL, JP; LEE, WR; PRESNELL, SR; COHEN, FE; BUNN, HF				BOISSEL, JP; LEE, WR; PRESNELL, SR; COHEN, FE; BUNN, HF			ERYTHROPOIETIN STRUCTURE-FUNCTION-RELATIONSHIPS - MUTANT PROTEINS THAT TEST A MODEL OF TERTIARY STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN ERYTHROPOIETIN; COLONY-STIMULATING FACTOR; HAMSTER OVARY CELLS; CYTOKINE RECEPTOR SUPERFAMILY; HUMAN GROWTH-HORMONE; 3-DIMENSIONAL STRUCTURE; HUMAN INTERLEUKIN-4; SECONDARY STRUCTURE; EXTRACELLULAR DOMAIN; GLOBULAR PROTEINS	On the basis of its primary sequence and the location of its disulfide bonds, we propose a structural model of the erythropoietic hormone erythropoietin (Epo) which predicts a four alpha-helical bundle motif, in common with other cytokines. In order to test this model, site-directed mutants were prepared by high level transient expression in Cos7 cells and analyzed by a radioimmuno assay and by bioassays utilizing mouse and human Epo-dependent cell lines. Deletions of 5 to 8 residues within predicted alpha-helices resulted in the failure of export of the mutant protein from the cell. In contrast, deletions at the NH2 terminus (DELTA2-5), the COOH terminus (DELTA163-166), or in predicted interhelical loops (AB: DELTA32-36, DELTA53-57; BC: DELTA78-82; CD: DELTA111-119) resulted in the export of immunologically detectable Epo muteins that were biologically active. The mutein DELTA48-52 could be readily detected by radio-immunoassay but had markedly decreased biological activity. However, replacement of each of these deleted residues by serine resulted in Epo muteins with full biological activity. Replacement of Cys29 and Cys33 by tyrosine residues also resulted in the export of fully active Epo. Therefore, this small disulfide loop is not critical to Epo's stability or function. The properties of the muteins that we tested are consistent with our proposed model of tertiary structure.	UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	BOISSEL, JP (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA.			Lee, W Robert/0000-0002-3545-0170	NHLBI NIH HHS [R01-HL42949] Funding Source: Medline; NIGMS NIH HHS [R01-GM 39900] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039900] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ANDRES DA, 1991, J BIOL CHEM, V266, P14277; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; Carnot P, 1906, CR HEBD ACAD SCI, V143, P432; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COHEN FE, 1986, BIOCHEMISTRY-US, V25, P266, DOI 10.1021/bi00349a037; COHEN FE, 1986, SCIENCE, V234, P349, DOI 10.1126/science.3489989; COHEN FE, 1979, J MOL BIOL, V132, P275, DOI 10.1016/0022-2836(79)90260-2; COHEN FE, 1987, PROTEINS, V2, P162, DOI 10.1002/prot.340020209; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CURTIS BM, 1991, PROTEINS, V11, P111, DOI 10.1002/prot.340110204; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DAVIS JM, 1987, BIOCHEMISTRY-US, V26, P2633, DOI 10.1021/bi00383a034; DELORME E, 1992, BIOCHEMISTRY-US, V31, P9871, DOI 10.1021/bi00156a003; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; DUBE S, 1988, J BIOL CHEM, V263, P17516; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; ERSLEV A, 1953, BLOOD, V8, P349, DOI 10.1182/blood.V8.4.349.349; FAQUIN WC, 1992, BLOOD, V79, P1987; FAQUIN WC, 1993, IN PRESS EXP HEMATOL, V21; FUKUDA MN, 1989, BLOOD, V73, P84; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GERSHONI JM, 1983, ANAL BIOCHEM, V131, P1, DOI 10.1016/0003-2697(83)90128-8; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; HANKINS WD, 1987, BLOOD, V70, pA173; HARRIS KW, 1992, J BIOL CHEM, V267, P15205; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; JACOBSON LO, 1957, NATURE, V179, P633, DOI 10.1038/179633a0; KINGSTON RE, 1991, CURRENT PROTOCOLS MO, V1; KOMATSU N, 1991, CANCER RES, V51, P341; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Krumdieck N, 1943, P SOC EXP BIOL MED, V54, P14, DOI 10.3181/00379727-54-14283; KRYSTAL G, 1983, EXP HEMATOL, V11, P649; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI PH, 1986, J BIOL CHEM, V261, P3116; LEVITT M, 1976, NATURE, V261, P552, DOI 10.1038/261552a0; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; LIN FK, 1987, NATO ASI SER H, V8, P23; MANAVALAN P, 1992, J PROTEIN CHEM, V11, P321, DOI 10.1007/BF01024870; MIYAKE T, 1977, J BIOL CHEM, V252, P5558; NARHI LO, 1991, J BIOL CHEM, V266, P23022; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; Parry D A, 1988, J Mol Recognit, V1, P107, DOI 10.1002/jmr.300010302; POWERS R, 1992, SCIENCE, V256, P1673, DOI 10.1126/science.256.5064.1673; PRESNELL SR, 1992, BIOCHEMISTRY-US, V31, P983, DOI 10.1021/bi00119a006; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; REDFIELD C, 1991, BIOCHEMISTRY-US, V30, P11029, DOI 10.1021/bi00110a004; REISSMANN KR, 1950, BLOOD, V5, P372, DOI 10.1182/blood.V5.4.372.372; RICHMOND TJ, 1978, J MOL BIOL, V119, P537, DOI 10.1016/0022-2836(78)90201-2; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI H, 1987, J BIOL CHEM, V262, P12059; SMITH LJ, 1992, J MOL BIOL, V224, P899, DOI 10.1016/0022-2836(92)90457-U; SPIVAK JL, 1989, BLOOD, V73, P90; STERNBERG MJE, 1982, INT J BIOL MACROMOL, V4, P137, DOI 10.1016/0141-8130(82)90042-3; TAKEUCHI M, 1990, J BIOL CHEM, V265, P12127; TSUDA E, 1990, EUR J BIOCHEM, V188, P405, DOI 10.1111/j.1432-1033.1990.tb15417.x; WANG FF, 1985, ENDOCRINOLOGY, V116, P2286, DOI 10.1210/endo-116-6-2286; WASLEY LC, 1991, BLOOD, V77, P2624; WEN D, 1993, IN PRESS BLOOD; YAMAGUCHI K, 1991, J BIOL CHEM, V266, P20434; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139	69	107	189	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15983	15993						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340419				2022-12-27	WOS:A1993LN30500093
J	CHEN, CS; POENIE, M				CHEN, CS; POENIE, M			NEW FLUORESCENT-PROBES FOR PROTEIN-KINASE-C - SYNTHESIS, CHARACTERIZATION, AND APPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOCYTOCHEMICAL EVIDENCE; MALEIC ANHYDRIDES; RAT FIBROBLASTS; PHORBOL ESTERS; LIVING CELLS; LOCALIZATION; CALCIUM; SELECTIVITY; ACTIVATION; INHIBITORS	Fluorescent derivatives of the bisindolylmaleimide inhibitors of protein kinase C (PKC) were synthesized and tested with respect to their inhibitory potency, specificity, and usefulness as fluorescent cytological stains for PKC. Several of the fluorescent bisindolylmaleimide derivatives (fim-1, fim-2, and rim-1) acted as ATP-competitive catalytic site inhibitors and retained much of the potency and specificity of the parental compound. The R6-C1 and the PKCbeta1-overexpressing R6-PKC3 cell lines were used for testing fim-1 and rim-1 as cytological stains for PKC. Comparisons showed that the R6-PKC3 cells stained much more brightly than R6-C1 cells. When R6-PKC3 cells were treated with the phorbol ester phorbol 12-myristate 13-acetate (PMA) for 30 min, staining with fim-1 or anti-PKCbeta1 revealed a dramatic translocation of PKC to the cell periphery. When R6-PKC3 cells were exposed to PMA for 24 h to down-regulate PKC, cytoplasmic staining was drastically reduced. Staining patterns obtained with an antibody specific for PKCbeta1 and with fim-1 were remarkably similar except for mitochondrial staining, which was only seen with fim-1. A closer examination of the mitochondrial staining showed that mitochondria convert from filamentous to punctate shapes and cluster around the nucleus when cells are treated with PMA. This punctate morphology, perinuclear clustering, and staining with fim-1 persists when PKC is down-regulated. Overall, these results indicate that fim-1 and rim-1 can serve as useful fluorescent probes for PKC. The mitochondrial staining may be due to a PKC isoform resistant to down-regulation.	UNIV TEXAS,DEPT ZOOL,141 PATTERSON LABS,AUSTIN,TX 78712	University of Texas System; University of Texas Austin			Poenie, Martin/A-7428-2009	Poenie, Martin/0000-0003-2524-4039	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040605] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40605] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALAZS M, 1991, J CELL BIOCHEM, V46, P266, DOI 10.1002/jcb.240460311; BORNER C, 1992, J BIOL CHEM, V267, P12892; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cb.04.110188.001103; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; DAVIS PD, 1990, TETRAHEDRON LETT, V31, P2353; DAVIS PD, 1990, TETRAHEDRON LETT, V31, P5201, DOI 10.1016/S0040-4039(00)97842-0; GAPSKI GR, 1975, J MED CHEM, V18, P526, DOI 10.1021/jm00239a020; GARCIABORRON JC, 1990, J PROTEIN CHEM, V9, P683, DOI 10.1007/BF01024763; GIRARD PR, 1987, CANCER RES, V47, P2892; GREGORIO C, 1992, P NATL ACAD SCI USA, V77, P990; GUADAGNO SN, 1992, J BIOL CHEM, V267, P2697; HAGIWARA M, 1988, PHARMACOLOGY, V36, P365, DOI 10.1159/000138324; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HO AK, 1988, J BIOL CHEM, V263, P9292; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HUANG KP, 1986, J BIOL CHEM, V261, P4781; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; ITO T, 1988, J CELL BIOL, V107, P929, DOI 10.1083/jcb.107.3.929; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; JOLY F, 1990, BIOCHEM J, V271, P501, DOI 10.1042/bj2710501; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; LAWSON D, 1978, J CELL BIOL, V79, P394, DOI 10.1083/jcb.79.2.394; LISKAMP RMJ, 1985, BIOCHEM BIOPH RES CO, V131, P920, DOI 10.1016/0006-291X(85)91327-0; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; TRAN PL, 1984, NOUV J CHIM, V8, P751; TRAN PL, 1985, CARCINOGENESIS, V6, P433, DOI 10.1093/carcin/6.3.433; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z; ZIDOVETZKI R, 1992, BIOCHIM BIOPHYS ACTA, V1134, P261, DOI 10.1016/0167-4889(92)90185-E	35	70	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15812	15822						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340406				2022-12-27	WOS:A1993LN30500072
J	DELISSER, HM; YAN, HC; NEWMAN, PJ; MULLER, WA; BUCK, CA; ALBELDA, SM				DELISSER, HM; YAN, HC; NEWMAN, PJ; MULLER, WA; BUCK, CA; ALBELDA, SM			PLATELET ENDOTHELIAL-CELL ADHESION MOLECULE-1 (CD31)-MEDIATED CELLULAR AGGREGATION INVOLVES CELL-SURFACE GLYCOSAMINOGLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; HEPARIN-BINDING; N-CAM; HETEROPHILIC ADHESION; MEDIATED ADHESION; PROTEIN; CD31; IDENTIFICATION; PECAM-1; FIBRONECTIN	Platelet/endothelial cell adhesion molecule-I (PECAM-1, CD31) is a 130-kDa integral membrane glycoprotein expressed on endothelial cells, platelets, and leukocytes. Experiments analyzing the aggregation of mouse L-cells stably transfected with full-length PECAM-1 cDNA have demonstrated that PECAM-1 is capable of mediating calcium-dependent heterophilic aggregation. In this report the ligand interactions involved in the aggregation process were studied. This aggregation was inhibited by heparin and chondroitin sulfate, but not by other glycosaminoglycans. Enzymatic removal of cell surface glycosaminoglycans confirmed a PECAM-1-glycosaminoglycan interaction and suggested that this interaction involved glycosaminoglycans on adjacent cells. PECAM-1 contains a glycosaminoglycan consensus binding sequence in the second immunoglobulin-like domain of the molecule's extracellular domain. A comparable region in the related adhesion protein N-CAM has been shown to mediate the adhesive properties of N-CAM. Cells expressing mutant PECAM-1 protein missing the second domain failed to aggregate. Synthetic peptides mimicking the consensus glycosaminoglycan binding sequence, L-K-R-E-K-N, inhibited aggregation. These results demonstrate that PECAM-1-mediated aggregation is dependent on the binding of PECAM-1 to specific glycosaminoglycans on adjacent cells via a glycosaminoglycan consensus binding sequence in the second immunoglobulin-like homology domain.	UNIV PENN,SCH MED,DEPT MED,DIV PULM,PHILADELPHIA,PA 19104; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; BLOOD CTR SOUTHEASTERN WISCONSIN,INST BLOOD RES,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT CELLULAR BIOL,MILWAUKEE,WI 53207; ROCKEFELLER UNIV,NEW YORK,NY 10021	University of Pennsylvania; The Wistar Institute; Versiti Blood Center of Wisconsin; Medical College of Wisconsin; Rockefeller University			DeLisser, Horace/AFM-1942-2022		NHLBI NIH HHS [HL43002-02, HL-01587, HL-39023] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039023, R01HL043002, K11HL001587] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059; ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BALDWIN HS, 1992, CIRCULATION, V86, P1203; BERMAN ME, 1992, FASEB J, V6, pA1888; BRENAN M, 1986, EUR J IMMUNOL, V16, P423, DOI 10.1002/eji.1830160419; BRONNERFRASER M, 1985, J CELL BIOL, V101, P610, DOI 10.1083/jcb.101.2.610; CABANAS C, 1989, EUR J IMMUNOL, V19, P1373, DOI 10.1002/eji.1830190804; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; COLE GJ, 1986, NATURE, V320, P445, DOI 10.1038/320445a0; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; FAASSEN AE, 1992, J CELL BIOL, V116, P521, DOI 10.1083/jcb.116.2.521; FILBIN MT, 1990, NATURE, V344, P871, DOI 10.1038/344871a0; GENG JG, 1991, J BIOL CHEM, V266, P22313; GILL PJ, 1986, BIOCHEMISTRY-US, V25, P405, DOI 10.1021/bi00350a020; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GRUMET M, 1988, J CELL BIOL, V106, P487, DOI 10.1083/jcb.106.2.487; HAYMAN EG, 1985, J CELL BIOL, V100, P1948, DOI 10.1083/jcb.100.6.1948; HORNE MK, 1989, BLOOD, V74, P238; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; KELTON JG, 1986, HAEMOSTASIS, V16, P173; LEDERMAN S, 1989, J IMMUNOL, V143, P1149; LOW SH, 1991, J BIOL CHEM, V266, P13391; MASSIA SP, 1992, J BIOL CHEM, V267, P10133; MAURO VP, 1992, J CELL BIOL, V119, P191, DOI 10.1083/jcb.119.1.191; MULLER WA, 1992, J EXP MED, V175, P1401, DOI 10.1084/jem.175.5.1401; MULLER WA, 1989, J EXP MED, V170, P399, DOI 10.1084/jem.170.2.399; MUNAIM SI, 1991, DEV BIOL, V143, P297, DOI 10.1016/0012-1606(91)90080-M; MURRAY BA, 1992, J CELL BIOL, V117, P1311, DOI 10.1083/jcb.117.6.1311; NADER HB, 1991, J BIOL CHEM, V266, P10518; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; OHTO H, 1985, BLOOD, V66, P873; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; PARISH CR, 1988, J IMMUNOL, V141, P3498; PROBSTMEIER R, 1989, J NEUROCHEM, V53, P1794, DOI 10.1111/j.1471-4159.1989.tb09245.x; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; REYES AA, 1990, CELL REGUL, V1, P567, DOI 10.1091/mbc.1.8.567; SCHIMMENTI LA, 1992, J CELL PHYSIOL, V153, P417, DOI 10.1002/jcp.1041530222; SIEBER F, 1981, J CELL BIOL, V90, P55, DOI 10.1083/jcb.90.1.55; SIMMONS DL, 1990, J EXP MED, V171, P2147, DOI 10.1084/jem.171.6.2147; STJOHN T, 1990, CELL, V60, P45, DOI 10.1016/0092-8674(90)90714-P; STOCKINGER H, 1990, J IMMUNOL, V145, P3889; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; VANMOURIK JA, 1985, J BIOL CHEM, V260, P1300; YAMADA KM, 1980, J BIOL CHEM, V255, P6055; YAMADA KM, 1987, J CELL PHYSIOL, V130, P21, DOI 10.1002/jcp.1041300105	50	173	175	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					16037	16046						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340425				2022-12-27	WOS:A1993LN30500099
J	STERNEMARR, R; GUREVICH, VV; GOLDSMITH, P; BODINE, RC; SANDERS, C; DONOSO, LA; BENOVIC, JL				STERNEMARR, R; GUREVICH, VV; GOLDSMITH, P; BODINE, RC; SANDERS, C; DONOSO, LA; BENOVIC, JL			POLYPEPTIDE VARIANTS OF BETA-ARRESTIN AND ARRESTIN3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTOR KINASE; GTP-BINDING PROTEIN; S-ANTIGEN; PINEAL-GLAND; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODY; SEQUENCE-ANALYSIS; ADENYLYL CYCLASE; CDNA CLONES; RHODOPSIN	Retinal arrestin (S-antigen) inactivates the photo-transduction cascade by binding to light-activated phosphorylated rhodopsin and thereby ''arresting'' coupling to the G protein transducin. Beta-arrestin (betaarr), a ubiquitous arrestin homolog, acts analogously to desensitize the beta2-adrenergic receptor by disrupting G(s) receptor interaction. In an attempt to identify additional ''arrestins'' which might regulate the multitude of G protein-coupled receptors, we have isolated two bovine brain cDNAs which encode polypeptide variants of an arrestin homolog which we have designated arrestin3 (arr3). The open reading frames of these two cDNAs are identical except that the long form, arr3L, contains an 11-amino-acid insert between residues 361 and 362. Arr3 is more closely related to bovine betaarr (78% identity) than to bovine visual arrestin (56% identity). Polymerase chain reaction amplification of RNA and immunoblotting of lysates with an arr3-specific antibody suggest that the short form, arr3S, is the major form of arr3 in all bovine tissues and that it is most abundant in the spleen. Furthermore, polymerase chain reaction amplification of betaarr mRNA indicates that in several tissues (lung, liver, spleen, and pituitary), the major form of betaarr lacks 8 amino acids which are present in brain betaarr. Immunoblotting with an antibody which recognizes betaarr and arr3 with equal sensitivity demonstrates that betaarr (either the long or the short polypeptide) is the major arrestin in all (non-photoreceptor bearing) tissues examined. These observations suggest that in some tissues, as many as four arrestin homolog variants may play a role in the regulation of G protein-coupled receptors.	JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA; WILLS EYE HOSP & RES INST, DIV RES, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, PHILADELPHIA, PA 19107 USA; NIDDKD, MOLEC PATHOPHYSIOL BRANCH, BETHESDA, MD 20892 USA	Jefferson University; Jefferson University; Jefferson University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NEI NIH HHS [EY5095] Funding Source: Medline; NHLBI NIH HHS [HL45964] Funding Source: Medline; NIGMS NIH HHS [GM44944] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY005095] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BERTRAND P, 1990, J BIOL CHEM, V265, P18576; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BOWNDS D, 1972, NATURE-NEW BIOL, V237, P125, DOI 10.1038/newbio237125a0; BRAY P, 1986, P NATL ACAD SCI USA, V83, P8893, DOI 10.1073/pnas.83.23.8893; BROEKHUYSE RM, 1985, CURR EYE RES, V4, P613, DOI 10.3109/02713688508999993; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; DEGEN JL, 1983, J BIOL CHEM, V258, P2153; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DONOSO LA, 1985, INVEST OPHTH VIS SCI, V26, P561; DUA HS, 1992, CURR EYE RES, V11, P107, DOI 10.3109/02713689208999519; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; KIM CM, 1993, IN PRESS RECEPTOR; KNOPSE V, 1988, CURR EYE RES, V7, P1137; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; KUNAPULI P, 1993, IN PRESS P NATL ACAD; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MAYOR F, 1987, J BIOL CHEM, V262, P6468; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RAPOPORT B, 1992, MOL CELL ENDOCRINOL, V84, pR39, DOI 10.1016/0303-7207(92)90038-8; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEURING U, 1990, FEBS LETT, V276, P192, DOI 10.1016/0014-5793(90)80540-Y; SHINOHARA T, 1987, JPN J OPHTHALMOL, V31, P197; SHINOHARA T, 1989, PROGR RETINAL RES, V8, P51; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; SOMERS RL, 1984, SCIENCE, V226, P182, DOI 10.1126/science.6091271; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; VANTOL HHM, 1992, NATURE, V358, P149; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YAMADA T, 1990, SCIENCE, V248, P483, DOI 10.1126/science.2158671; YAMAKI K, 1987, BIOCHEM BIOPH RES CO, V142, P904, DOI 10.1016/0006-291X(87)91499-9; YAMAKI K, 1990, J BIOL CHEM, V265, P20757; ZOZULYA SA, 1990, PROTEIN ENG, V3, P453, DOI 10.1093/protein/3.5.453	57	136	140	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15640	15648						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340388				2022-12-27	WOS:A1993LN30500049
J	WESTERLUND, JA; WEISGRABER, KH				WESTERLUND, JA; WEISGRABER, KH			DISCRETE CARBOXYL-TERMINAL SEGMENTS OF APOLIPOPROTEIN-E MEDIATE LIPOPROTEIN ASSOCIATION AND PROTEIN OLIGOMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING DOMAIN; SEDIMENTATION EQUILIBRIUM; III HYPERLIPOPROTEINEMIA; DENSITY LIPOPROTEINS; PLASMA-LIPOPROTEINS; AMPHIPATHIC HELIX; AQUEOUS-SOLUTION; LIPID PARTICLE; A-IV; CHOLESTEROL	The carboxyl terminus of apolipoprotein (apo) E is required for lipoprotein association and for tetramer formation. To correlate these roles with specific regions within the carboxyl terminus, a series of apoE3 variants with carboxyl-terminal truncations at residues 266, 244, 223, and 191 were expressed in Escherichia coli. As determined by gel permeation and sedimentation equilibrium centrifugation, the four truncated variants were monomeric in solution. Compared to native apoE3 (299 residues), all had reduced affinity for lipoproteins, as assessed by incubation of I-125-labeled proteins with plasma followed by fractionation of lipoprotein classes by gel filtration. The 266-residue variant associated with very low density lipoproteins and high density lipoproteins, but was partly non-lipoprotein-bound (25% of total). Shorter variants, with 244 or fewer residues, did not associate with very low density lipoproteins and only associated slightly (approximately 20%) with high density lipoproteins, with the major portion non-lipoprotein-bound (65-73%). After these proteins were injected into rabbits, the clearance rate was proportional to the plasma level of non-lipoprotein-bound protein. These results indicate lipoprotein association modulates the clearance of apoE, residues within the segment 267-299 are critical for apoE tetramerization and facilitate lipoprotein association, and residues within the segment 245-266 also contribute to lipoprotein association.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,DEPT PATHOL,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; BELCHER JD, 1991, J LIPID RES, V32, P359; BOTHWELL MA, 1978, J BIOL CHEM, V253, P2073; CHAN L, 1991, CURR OPIN LIPIDOL, V2, P96; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; DAVIS RW, 1991, J LIPID RES, V32, P1013; DAYHOFF MO, 1952, J AM CHEM SOC, V74, P2515, DOI 10.1021/ja01130a018; GIANTURCO SH, 1983, J BIOL CHEM, V258, P4526; HORIE Y, 1992, J BIOL CHEM, V267, P1962; HUSSAIN MM, 1989, J BIOL CHEM, V264, P9571; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; LOHSE P, 1992, J LIPID RES, V33, P1583; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1984, J LIPID RES, V25, P1277; MANTULIN WW, 1980, J BIOL CHEM, V255, P8185; POLLET RJ, 1979, J BIOL CHEM, V254, P30; RALL SC, 1986, METHOD ENZYMOL, V128, P273; REIJNGOUD DJ, 1982, BIOCHEMISTRY-US, V21, P2969, DOI 10.1021/bi00541a026; REYNOLDS JA, 1976, J BIOL CHEM, V251, P6013; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1992, J LIPID RES, V33, P141; Sparrow J T, 1980, Ann N Y Acad Sci, V348, P187, DOI 10.1111/j.1749-6632.1980.tb21300.x; SPARROW JT, 1992, BIOCHEMISTRY-US, V31, P1065, DOI 10.1021/bi00119a015; SVEDBERG T, 1940, ULTRACENTRIFUGE, P55; TAJIMA S, 1983, J BIOL CHEM, V258, P73; TALL AR, 1976, J BIOL CHEM, V251, P3749; VOGEL T, 1985, P NATL ACAD SCI USA, V82, P8696, DOI 10.1073/pnas.82.24.8696; WEINBERG RB, 1985, J BIOL CHEM, V260, P4914; WEINBERG RB, 1985, J BIOL CHEM, V260, P4279; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WU YV, 1962, BIOCHEMISTRY-US, V1, P698, DOI 10.1021/bi00910a025; YOKOYAMA S, 1990, BIOCHIM BIOPHYS ACTA, V1047, P99, DOI 10.1016/0005-2760(90)90266-Z; YOKOYAMA S, 1985, J BIOL CHEM, V260, P6375	37	148	151	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15745	15750						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340399				2022-12-27	WOS:A1993LN30500063
J	RAJAN, AS; AGUILARBRYAN, L; NELSON, DA; NICHOLS, CG; WECHSLER, SW; LECHAGO, J; BRYAN, J				RAJAN, AS; AGUILARBRYAN, L; NELSON, DA; NICHOLS, CG; WECHSLER, SW; LECHAGO, J; BRYAN, J			SULFONYLUREA RECEPTORS AND ATP-SENSITIVE K+ CHANNELS IN CLONAL PANCREATIC ALPHA-CELLS - EVIDENCE FOR 2 HIGH-AFFINITY SULFONYLUREA RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PARATHYROID CELLS; LIGAND-BINDING SYSTEMS; POTASSIUM CHANNELS; H-3 GLIBENCLAMIDE; MEMBRANE PATCHES; SKELETAL-MUSCLE; SECRETION; PROTEIN; PURIFICATION; SOMATOSTATIN	We tested for the presence of sulfonylurea receptors in pancreatic alpha cells. Two high affinity sulfonylurea receptors were identified in clonal pancreatic alpha cells (alphaTC-6): a 140-kDa species observed previously in clonal pancreatic beta cells (HIT) and a second 150-kDa protein. The dissociation constant (K(d)) for both receptors is approximately 3.5 nM for an iodinated glyburide analog, 5-iodo-2-hydroxyglyburide. The estimated number of receptors (B(max)) increases approximately 2-fold, from 3.1 to 6.8 pmol/mg of membrane protein as the pH of the binding buffer is reduced from 7.5 to 6. Consistent with the notion that high affinity sulfonylurea receptors are integral components of the A-P-sensitive K+ channel, we demonstrated the presence of ATP-sensitive K+ channels in inside-out patches of alphaTC-6 cells. Whole cell K+ currents that activated with time showed inward rectification at positive potentials (above 0 mV) and were almost completely suppressed by 5 nM glyburide. Likewise, glyburide blocked Rb-86+ efflux from ATP-depleted alphaTC-6 cells, an effect that was reversed by 400 muM diazoxide. The presence of sulfonylurea receptors provides a mechanism by which sulfonylureas can directly modulate alpha cell function. The properties of the 150-kDa receptor and the role of ATP-sensitive K+ channels in alpha cells remain to be elucidated, but as in beta cells, ATP-sensitive K+ channels may be involved in metabolic regulation of alpha cells by glucose.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Baylor College of Medicine; Baylor College of Medicine; Washington University (WUSTL)	RAJAN, AS (corresponding author), BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030, USA.		Nichols, Colin/D-6336-2012		NCRR NIH HHS [RR-04525] Funding Source: Medline; NHLBI NIH HHS [HL45742] Funding Source: Medline; NIDDK NIH HHS [DK41898] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041898] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1992, J BIOL CHEM, V267, P14934; AGUILARBRYAN L, 1990, J BIOL CHEM, V265, P8218; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; Ashford M. L. J, 1990, POTASSIUM CHANNELS S, P300; BELLES B, 1987, PFLUG ARCH EUR J PHY, V409, P582, DOI 10.1007/BF00584657; BERNARDI H, 1988, P NATL ACAD SCI USA, V85, P9816, DOI 10.1073/pnas.85.24.9816; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER A, 1989, SCIENCE, V243, P943, DOI 10.1126/science.2493160; DAVIES NW, 1990, NATURE, V343, P375, DOI 10.1038/343375a0; DEWEILLE JR, 1989, PFLUEGERS ARCH, V414, P580; EFENDIC S, 1980, ACTA PHYSIOL SCAND, V108, P231, DOI 10.1111/j.1748-1716.1980.tb06527.x; FELDMAN HA, 1972, ANAL BIOCHEM, V48, P317, DOI 10.1016/0003-2697(72)90084-X; FINDLAY I, 1992, J PHARMACOL EXP THER, V262, P71; FOSSET M, 1988, FEBS LETT, V242, P94, DOI 10.1016/0014-5793(88)80992-X; GERICH JE, 1989, NEW ENGL J MED, V321, P1231; GRODSKY GM, 1977, FED PROC, V36, P2714; HAMAGUCHI K, 1990, DIABETES, V39, P415, DOI 10.2337/diabetes.39.4.415; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; KRAMER W, 1988, FEBS LETT, V229, P355, DOI 10.1016/0014-5793(88)81155-4; LEDERER WJ, 1989, J PHYSIOL-LONDON, V419, P193, DOI 10.1113/jphysiol.1989.sp017869; LOUBATIERES A, 1957, ANN NY ACAD SCI, V71, P192, DOI 10.1111/j.1749-6632.1957.tb54591.x; LUYCKX AS, 1983, HDB EXPT PHARM, V66, P175; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NELSON DA, 1992, J BIOL CHEM, V267, P14928; NEMETH EF, 1987, J BIOL CHEM, V262, P5188; OSTENSON CG, 1986, DIABETOLOGIA, V29, P861, DOI 10.1007/BF00870141; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; PETERSSON B, 1962, Z ZELLFORSCH MIK ANA, V57, P559, DOI 10.1007/BF00339882; PETERSSON B, 1966, ACTA ENDOCRINOL-COP, V53, P480, DOI 10.1530/acta.0.0530480; POWERS AC, 1990, DIABETES, V39, P406, DOI 10.2337/diabetes.39.4.406; QIN D, 1988, AM J PHYSIOL, V255, pH980, DOI 10.1152/ajpheart.1988.255.4.H980; RAJAN AS, 1990, DIABETES CARE, V13, P340, DOI 10.2337/diacare.13.3.340; RONNER P, 1991, DIABETES S1, V40, pA155; RORSMAN P, 1988, J GEN PHYSIOL, V91, P223, DOI 10.1085/jgp.91.2.223; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SHOBACK DM, 1984, P NATL ACAD SCI-BIOL, V81, P3113, DOI 10.1073/pnas.81.10.3113; SPRUCE AE, 1987, J PHYSIOL-LONDON, V382, P213, DOI 10.1113/jphysiol.1987.sp016364; STURGESS NC, 1985, LANCET, V2, P474; ZUNKLER BJ, 1989, N-S ARCH PHARMACOL, V340, P328	40	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15221	15228						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325894				2022-12-27	WOS:A1993LL75900098
J	TUKEY, RH; PENDURTHI, UR; NGUYEN, NT; GREEN, MD; TEPHLY, TR				TUKEY, RH; PENDURTHI, UR; NGUYEN, NT; GREEN, MD; TEPHLY, TR			CLONING AND CHARACTERIZATION OF RABBIT LIVER UDP-GLUCURONOSYLTRANSFERASE CDNAS - DEVELOPMENTAL AND INDUCIBLE EXPRESSION OF 4-HYDROXYBIPHENYL UGT2B13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; RAT-LIVER; DIGITOXIGENIN-MONODIGITOXOSIDE; DEPENDENT EXPRESSION; GENE; CYTOCHROME-P-450; INDUCTION; PURIFICATION; SEQUENCE; ACID	A polyclonal antibody generated against rabbit liver p-nitrophenol UDP-glucuronosyltransferase (UGT) was used to screen a rabbit liver cDNA expression library constructed in lambdagt11. A 500-base pair cDNA clone, termed pPNP, generated a fusion protein that was antigenic with the antibody. Clone pPNP encoded the 3' region of a UGT. To identify larger recombinants, clone pPNP was used as a probe to screen a second cDNA library constructed in lambdaZAP. Two different cDNA clones were identified by DNA sequence analysis. Based upon their predicted amino acid sequence analysis, the clones encode transferases belonging to the UGT2 subfamily, and have been identified as UGT2B13 and UGT2B14. The predicted N-terminal sequence of UGT2B13 is identical to that determined for the purified rabbit liver estrone UGT. However, expression of the UGT2B13 cDNA in COS-1 cells displayed no activity in the presence of estrone but efficiently conjugated 4-hydroxybiphenyl. Results of Southern blot analysis using the 5' divergent region of the UGT2B13 cDNA that encodes exon 1 demonstrates that multiple genes share sequence homology to UGT2B13, an observation which indicates that the estrone UGT and UGT2B 1 3 genes are encoded by separate alleles. When the 5' variable. regions of the cDNAs where used in Northern blot analysis, the expression of UGT2B 13 and UGT2B 14 were shown to be expressed primarily in adult rabbits. However, when neonatal rabbits were treated with either dexamethasone or rifampicin, UGT2B13 mRNA levels were induced. The neonatal induction of UGT2B13 mRNA corresponded with similar increases in 4-hydroxybiphenyl UGT activity. The expression and induction of UGT2B13 paralleled that of the developmentally regulated rabbit liver progesterone 6beta-hydroxylase P4503A6.	UNIV CALIF SAN DIEGO,CTR CANC,DEPT MED,LA JOLLA,CA 92093; UNIV IOWA,DEPT PHARMACOL,IOWA CITY,IA 52242	University of California System; University of California San Diego; University of Iowa	TUKEY, RH (corresponding author), UNIV CALIF SAN DIEGO,CTR CANC,DEPT PHARMACOL,LA JOLLA,CA 92093, USA.				NATIONAL CANCER INSTITUTE [R01CA037139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026221] Funding Source: NIH RePORTER; NCI NIH HHS [CA37139] Funding Source: Medline; NIGMS NIH HHS [GM26221, GM36590] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGUSTIN C, 1992, BIOCHEM PHARMACOL, V44, P836, DOI 10.1016/0006-2952(92)90426-J; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BANSAL SK, 1980, ANAL BIOCHEM, V109, P321, DOI 10.1016/0003-2697(80)90655-7; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BURCHELL B, 1991, DNA CELL BIOL, V10, P487, DOI 10.1089/dna.1991.10.487; BURCHELL B, 1989, PHARMACOL THERAPEUT, V43, P261, DOI 10.1016/0163-7258(89)90122-8; CARLSON J, 1984, J BIOTECHNOL, V1, P253, DOI 10.1016/0168-1656(84)90017-8; Cox RA., 1968, METHODS ENZYMOL, V12, P120, DOI 10.1016/0076-6879(67)12123-X; Dutton G.F., 1980, GLUCURONIDATION DRUG; FALANY CN, 1983, DRUG METAB DISPOS, V11, P426; GASSER R, 1989, MOL PHARMACOL, V35, P617; GASSER R, 1988, MOL PHARMACOL, V32, P22; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GOVIND S, 1986, DNA-J MOLEC CELL BIO, V5, P371, DOI 10.1089/dna.1986.5.371; GREEN MD, 1989, ARCH BIOCHEM BIOPHYS, V273, P72, DOI 10.1016/0003-9861(89)90163-X; GREEN MD, 1988, ARCH BIOCHEM BIOPHYS, V262, P367, DOI 10.1016/0003-9861(88)90200-7; HAQUE SJ, 1991, DNA CELL BIOL, V10, P515, DOI 10.1089/dna.1991.10.515; JOHNSON EF, 1987, J BIOL CHEM, V262, P5918; KHANI SC, 1987, P NATL ACAD SCI USA, V84, P638, DOI 10.1073/pnas.84.3.638; LEIGHTON JK, 1984, J BIOL CHEM, V259, P1165; LEIGHTON JK, 1984, BIOCHEMISTRY-US, V23, P204, DOI 10.1021/bi00297a005; MACKENZIE PI, 1990, J BIOL CHEM, V265, P3432; MACKENZIE PI, 1990, J BIOL CHEM, V265, P11328; MCMANUS ME, 1990, CANCER RES, V50, P3367; OKINO ST, 1985, P NATL ACAD SCI USA, V82, P5310, DOI 10.1073/pnas.82.16.5310; PENDURTHI UR, 1990, J BIOL CHEM, V265, P14662; PORTER TD, 1989, MOL PHARMACOL, V36, P61; POTENZA CL, 1989, J BIOL CHEM, V264, P16222; QUATTROCHI LC, 1989, MOL PHARMACOL, V36, P66; RITTER JK, 1992, J BIOL CHEM, V267, P3257; Sambrook J, 1989, MOL CLONING LAB MANU, P83; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHUETZ EG, 1986, J BIOL CHEM, V261, P8270; SCHUETZ EG, 1984, J BIOL CHEM, V259, P2007; STYCZYNSKI P, 1991, MOL PHARMACOL, V40, P80; TEPHLY T, 1988, XENOBIOTICA, V18, P1201, DOI 10.3109/00498258809042244; TEPHLY TR, 1990, CHEM RES TOXICOL, V3, P509, DOI 10.1021/tx00018a004; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TUKEY R H, 1990, P423; TUKEY RH, 1982, DRUG METAB DISPOS, V10, P97; TUKEY RH, 1978, BIOCHEM J, V171, P659, DOI 10.1042/bj1710659; TUKEY RH, 1985, J BIOL CHEM, V260, P3347; TUKEY RH, 1981, ARCH BIOCHEM BIOPHYS, V209, P565, DOI 10.1016/0003-9861(81)90314-3; VONMEYERINCK L, 1985, DRUG METAB DISPOS, V13, P700; WATKINS JB, 1982, TOXICOL APPL PHARM, V64, P439, DOI 10.1016/0041-008X(82)90240-X; WATKINS JB, 1985, DRUG METAB DISPOS, V13, P186; YUAN PM, 1983, P NATL ACAD SCI-BIOL, V80, P1169, DOI 10.1073/pnas.80.5.1169; ZUBER MX, 1986, SCIENCE, V234, P1258, DOI 10.1126/science.3535074	48	33	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15260	15266						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325897				2022-12-27	WOS:A1993LL75900103
J	ARTIGUES, A; FARRANT, H; SCHIRCH, V				ARTIGUES, A; FARRANT, H; SCHIRCH, V			CYTOSOLIC SERINE HYDROXYMETHYLTRANSFERASE - DEAMIDATION OF ASPARAGINYL RESIDUES AND DEGRADATION IN XENOPUS-LAEVIS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CARBOXYL METHYLTRANSFERASE; HUMAN-ERYTHROCYTES; METHYLATION; PEPTIDES; ASPARTYL; ISOASPARTATE; PURIFICATION; SPECIFICITY; MECHANISM; SITE	Rabbit liver cytosolic serine hydroxymethyltransferase exists as a set of subforms which exhibit different isoelectric points. Previous studies have shown that deamidation of an asparagine residue at position 5 of the amino acid sequence accounted for some of the charge heterogeneity (Artigues, A., Birkett, A., and Schirch, V. (1990) J. Biol. Chem. 265, 4853-4858). The present study has also identified asparagine 220 as being partially deamidated. An estimated 25-30% of the purified enzyme contains an isoaspartyl residue at position 220. This suggests that deamidation of asparagine 220 occurs by the beta-aspartyl shift mechanism. Western blot analysis of purified cytosolic serine hydroxymethyltransferase, after isoelectric focusing under reducing and denaturing conditions, showed four subforms of the individual subunits with respect to isoelectric point. Extracts from 3-day- and 3.5-year-old rabbit livers showed the presence of these same four subunit subforms. Purified cytosolic serine hydroxymethyltransferase was found to be degraded in 24 h after mechanical injection into Xenopus laevis oocytes. However, when the first 14 amino acid residues are removed from the enzyme by digestion with chymotrypsin, leaving a fully catalytically active enzyme, the rate and extent of degradation of the truncated enzyme in oocytes were significantly reduced. One of the deamidated asparagine residues is at position 5, suggesting that this deamidation site may be a signal for degradation of the enzyme.	VIRGINIA COMMONWEALTH UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,RICHMOND,VA 23298	Virginia Commonwealth University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028143] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28143] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTIGUES A, 1990, J BIOL CHEM, V265, P4853; ASWAD DW, 1987, TRENDS BIOCHEM SCI, V12, P155, DOI 10.1016/0968-0004(87)90073-9; ASWAD DW, 1984, J BIOL CHEM, V259, P714; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BYRNE PC, 1992, BIOCHEM J, V286, P117, DOI 10.1042/bj2860117; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; DESROSIERS RR, 1990, J BIOL CHEM, V265, P21368; DILIBERTO EJ, 1976, J NEUROCHEM, V26, P1159, DOI 10.1111/j.1471-4159.1976.tb07001.x; GALLETTI P, 1989, INT J PEPT PROT RES, V33, P397; GAVILANES F, 1982, J BIOL CHEM, V257, P1431; GEORGENASCIMENT.C, 1990, BIOCHEMISTRY-US, V29, P9586; GIULIAN GG, 1984, ANAL BIOCHEM, V142, P421, DOI 10.1016/0003-2697(84)90486-X; HITCHCOCK MJM, 1987, METHOD ENZYMOL, V152, P276; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; JOHNSON BA, 1991, ANAL BIOCHEM, V192, P384, DOI 10.1016/0003-2697(91)90553-6; JOHNSON BA, 1989, J BIOL CHEM, V264, P14262; KIM S, 1983, J BIOCHEM BIOPH METH, V8, P9, DOI 10.1016/0165-022X(83)90016-7; LADINO CA, 1990, MECH AGEING DEV, V55, P123, DOI 10.1016/0047-6374(90)90020-G; LOWENSON J, 1988, BLOOD CELLS, V14, P103; LOWENSON JD, 1990, J BIOL CHEM, V265, P3106; LOWENSON JD, 1992, J BIOL CHEM, V267, P5985; LURA R, 1988, BIOCHEMISTRY-US, V27, P7671, DOI 10.1021/bi00420a015; MARTINI F, 1987, J BIOL CHEM, V262, P5499; MURRAY ED, 1984, J BIOL CHEM, V259, P722; OCONNOR CM, 1985, BIOCHEM BIOPH RES CO, V132, P1144, DOI 10.1016/0006-291X(85)91926-6; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Robinson A B, 1974, Curr Top Cell Regul, V8, P247; SCHIRCH L, 1968, J BIOL CHEM, V243, P5651; SCHIRCH L, 1980, J BIOL CHEM, V255, P7801; SCHIRCH LVG, 1963, J BIOL CHEM, V238, P1032; SCHIRCH V, 1986, EUR J BIOCHEM, V161, P45, DOI 10.1111/j.1432-1033.1986.tb10122.x; SCHIRCH V, 1991, J BIOL CHEM, V266, P759; TESHIMA G, 1991, BIOCHEMISTRY-US, V30, P3916, DOI 10.1021/bi00230a016; TYLERCROSS R, 1991, J BIOL CHEM, V266, P22549; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532; YUKSEL KU, 1986, ARCH BIOCHEM BIOPHYS, V248, P452, DOI 10.1016/0003-9861(86)90498-4	37	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13784	13790						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314747				2022-12-27	WOS:A1993LJ82500006
J	CUIF, MH; PORTEU, A; KAHN, A; VAULONT, S				CUIF, MH; PORTEU, A; KAHN, A; VAULONT, S			EXPLORATION OF A LIVER-SPECIFIC, GLUCOSE/INSULIN-RESPONSIVE PROMOTER IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PYRUVATE-KINASE GENE; RAT-LIVER; EXPRESSION; CELLS; TRANSCRIPTION; BINDING	The functional role of the different sites binding transcriptional factors on the tissue-specific, glucose-responsive promoter of the L type pyruvate kinase gene (L-PK) has been investigated in transgenic mice. These sites are able to bind, from 3' to 5', HNF1, NF1, HNF4, and MLTF/USF, respectively. We have compared the level of chloramphenicol acetyltransferase reporter transgene expression when driven by a L-PK promoter fragment of either -96 base pairs (bp) (containing only the HNF1 binding site) or -150 bp (lacking the MLTF/USF binding site) or driven by a -183-bp L-PK promoter fragment with or without the NF1 binding site. Our results demonstrate that: 1) HNF1 alone is not sufficient to promote an efficient L-PK gene transcription in vivo; 2) with only binding sites for HNF1, NF1, and HNF4, though the tissue-specific pattern of expression is respected, the level of the gene transcription is low and the hormonal control is lost; 3) the MLTF/USF binding site is the, target of the hormonal control, required for both positive response to carbohydrates and negative response to glucagon; 4) the role of NF1 in the promoter activity could be to negatively modulate the L-PK gene expression in the different tissues, without interfering with the glucose and hormone responsiveness.	INST COCHIN GENET MOLEC,INSERM,U129,RECH GENET & PATHOL MOLEC LAB,24 RUE FAUBOURG ST JACQUES,F-75014 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Vaulont, Sophie/O-6732-2017					BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BOQUET D, 1992, EUR J BIOCHEM, V207, P13, DOI 10.1111/j.1432-1033.1992.tb17013.x; COGNET M, 1991, J BIOL CHEM, V266, P7368; COLANTUONI V, 1987, EMBO J, V6, P631, DOI 10.1002/j.1460-2075.1987.tb04801.x; CUIF MH, 1992, MOL CELL BIOL, V12, P4852, DOI 10.1128/MCB.12.11.4852; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; IMMAMURA K, 1982, METHOD ENZYMOL, V90, P150; JUMP DB, 1990, J BIOL CHEM, V265, P3474; NOGUCHI T, 1993, FEBS LETT, V318, P269, DOI 10.1016/0014-5793(93)80526-Z; PUZENAT N, 1992, BIOCHEM BIOPH RES CO, V189, P1119, DOI 10.1016/0006-291X(92)92320-W; SHIH HM, 1992, J BIOL CHEM, V267, P13222; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; TREMP GL, 1989, J BIOL CHEM, V264, P19904; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1986, J BIOL CHEM, V261, P7621; VAULONT S, 1989, MOL CELL BIOL, V9, P4409, DOI 10.1128/MCB.9.10.4409; WEBER A, 1984, J BIOL CHEM, V259, P1798	17	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13769	13772						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314745				2022-12-27	WOS:A1993LJ82500002
J	ESCALANTE, R; SASTRE, L				ESCALANTE, R; SASTRE, L			SIMILAR ALTERNATIVE SPLICING EVENTS GENERATE 2 SARCOPLASMIC OR ENDOPLASMIC-RETICULUM CA-ATPASE ISOFORMS IN THE CRUSTACEAN ARTEMIA-FRANCISCANA AND IN VERTEBRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CA-2+-ATPASE GENE; SKELETAL-MUSCLE; CA-2+ ATPASE; SEQUENCES; EXPRESSION; KIDNEY; BRAIN; CDNAS; PUMP	A second isoform of the Artemia franciscana sarcoplasmic or endoplasmic reticulum Ca-ATPase has been identified through the isolation of cDNA clones. This isoform differs from the previously identified one only at the C-terminal end of the protein. The last 6 amino acids of the former isoform change to 30 hydrophobic amino acids in the newly identified isoform that have the potentiality of being an additional transmembrane domain. The two A. franciscana isoforms are highly homologous to the two isoforms coded by the mammalian and bird SERCA2 gene, except that the C-terminal extensions share their hydrophobic character but have no significant amino acid homology. The isolation of genomic clones coding for this region of the gene shows that both isoforms arise from the same gene by alternative splicing. The donor splicing site of the penultimate exon can either be recognized and fused to the last exon, giving rise to the mRNA coding for the shortest protein, or remain unrecognized, in which case a polyadenylation site is recognized before the last exon of the gene and the mRNA coding for the largest protein is originated. The alternative splicing used to originate the two isoforms is similar in Artemia and vertebrates. The conservation of the alternative splicing between species so distant in evolution suggests an important physiological role for the existence of the two isoforms of the protein.	CSIC,INST INVEST BIOMED,CALLE ARTURO DUPERIER 4,E-28029 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Escalante, Ricardo/G-8272-2015	Escalante, Ricardo/0000-0001-8547-531X; Sastre, Leandro/0000-0003-3613-5938				BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURK SE, 1989, J BIOL CHEM, V264, P18561; CAMPBELL AM, 1991, J BIOL CHEM, V266, P16050; CAMPBELL AM, 1992, J BIOL CHEM, V267, P9321; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CRUCES J, 1981, BIOCHEM BIOPH RES CO, V98, P404, DOI 10.1016/0006-291X(81)90854-8; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; LYTTON J, 1988, J BIOL CHEM, V263, P15024; LYTTON J, 1989, J BIOL CHEM, V264, P7059; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MAGYAR A, 1990, BIOCHEM BIOPH RES CO, V173, P872, DOI 10.1016/S0006-291X(05)80867-8; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OSUNA C, 1980, EUR J BIOCHEM, V109, P383, DOI 10.1111/j.1432-1033.1980.tb04805.x; PALMERO I, 1989, J MOL BIOL, V210, P737, DOI 10.1016/0022-2836(89)90106-X; SHERMAN F, 1986, LABORATORY COURSE MA, P143	18	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14090	14095						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314776				2022-12-27	WOS:A1993LJ82500047
J	FOOD, MR; ROTHENBERGER, S; GABATHULER, R; HAIDL, ID; REID, G; JEFFERIES, WA				FOOD, MR; ROTHENBERGER, S; GABATHULER, R; HAIDL, ID; REID, G; JEFFERIES, WA			TRANSPORT AND EXPRESSION IN HUMAN MELANOMAS OF A TRANSFERRIN-LIKE GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEINS; SURFACE PROTEIN; PHOSPHOLIPASE-D; ANTIGEN P97; PHOSPHATIDYLINOSITOL; RECEPTOR; IRON; ANTIBODY; SYSTEM; CELLS	Melanotransferrin, also called p97, is a cell surface glycoprotein which was first described as a marker antigen, for human melanoma cells. Although p97 has a striking structural similarity to human serum transferrin and lactoferrin, its function has not yet between determined. One feature that distinguishes p97 from the other members of the transferrin family is the presence of a stretch of 24 hydrophobic amino acids at the C terminus, previously assumed to form a proteinacious transmembrane domain. In this study, sensitivity to bacterial phosphatidylinositol-specific phospholipase C, biosynthetic labeling with [H-3]ethanolamine, and partitioning in Triton X-114 are used to establish that p97 is expressed at the cell surface as a glycosylphosphatidylinositol-anchored protein. In addition, to gain insight into the intracellular transport of p97, biosynthetic transport studies were performed on a melanoma cell line. These studies resulted in the identification of an additional form of p97 which is found in the medium and which likely does not originate from an alternatively spliced form of the p97 mRNA. These findings, together with our recent observation of the co-localization of p97 and the transferrin receptor in brain capillary endothelium (W. A. Jefferies, M. R. Food, R. Gabathuler, S. Rothenberger, T. Yamada, and P. L. McGeer, manuscript submitted) raise important questions about the function of the two forms of p97 detected and the possible involvement of this protein in a cellular iron uptake mechanism that is independent from the transferrin/transferrin receptor system.	UNIV BRITISH COLUMBIA, BIOTECHNOL LAB,RM 237,WESTBROOK BLDG, 6174 UNIV BLVD, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT MED GENET, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT MICROBIOL & IMMUNOL, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT ZOOL, VANCOUVER V6T 1Z3, BC, CANADA	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia			Reid, Gregor/F-6260-2011	Reid, Gregor/0000-0002-7567-3424; Rothenberger, Sylvia/0000-0001-8633-2994				BAKER EN, 1987, TRENDS BIOCHEM SCI, V12, P350, DOI 10.1016/0968-0004(87)90163-0; BASSET P, 1986, CANCER RES, V46, P1644; BAZIL V, 1991, J IMMUNOL, V147, P1567; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROWN JP, 1982, NATURE, V296, P171, DOI 10.1038/296171a0; BROWN JP, 1981, P NATL ACAD SCI-BIOL, V78, P539, DOI 10.1073/pnas.78.1.539; DOERING TL, 1990, J BIOL CHEM, V265, P611; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; HELLSTROM I, 1983, INT J CANCER, V31, P553, DOI 10.1002/ijc.2910310505; HUIZINGA TWJ, 1988, NATURE, V333, P667, DOI 10.1038/333667a0; KAHN M, 1991, J IMMUNOL, V146, P3235; LIAO SK, 1985, J CELL BIOCHEM, V27, P303, DOI 10.1002/jcb.240270311; LISANTI MP, 1990, J MEMBRANE BIOL, V117, P1, DOI 10.1007/BF01871561; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; LOW MG, 1985, NATURE, V318, P62, DOI 10.1038/318062a0; METZ CN, 1991, J BIOL CHEM, V266, P17733; MORAN P, 1992, J CELL BIOL, V119, P763, DOI 10.1083/jcb.119.4.763; PLOWMAN GD, 1983, NATURE, V303, P70, DOI 10.1038/303070a0; ROSE TM, 1986, P NATL ACAD SCI USA, V83, P1261, DOI 10.1073/pnas.83.5.1261; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SCALLON BJ, 1991, SCIENCE, V252, P446, DOI 10.1126/science.2017684; SHIH YJ, 1990, J BIOL CHEM, V265, P19077; STURROCK A, 1990, J BIOL CHEM, V265, P3139; TAKAMI N, 1992, J BIOL CHEM, V267, P1042; THORSTENSEN K, 1988, J BIOL CHEM, V263, P16837; VONBOXBERG Y, 1990, EUR J BIOCHEM, V190, P249; WOODBURY RG, 1981, INT J CANCER, V27, P145, DOI 10.1002/ijc.2910270204; WOODBURY RG, 1980, P NATL ACAD SCI-BIOL, V77, P2183, DOI 10.1073/pnas.77.4.2183	30	87	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3034	3040						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300636				2022-12-27	WOS:A1994MV43200096
J	LEE, JS; FAVRE, B; HEMMINGS, BA; KIEFER, B; NAGAMINE, Y				LEE, JS; FAVRE, B; HEMMINGS, BA; KIEFER, B; NAGAMINE, Y			OKADAIC ACID-DEPENDENT INDUCTION OF THE UROKINASE-TYPE PLASMINOGEN-ACTIVATOR GENE ASSOCIATED WITH STABILIZATION AND AUTOREGULATION OF C-JUN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ACTIN-BINDING-PROTEIN; DNA-BINDING; MESSENGER-RNA; MOLECULAR-CLONING; CATALYTIC SUBUNIT; PHORBOL-ESTER; KIDNEY-CELLS; V-JUN; PHOSPHORYLATION	We have previously shown that the tumor promoter okadaic acid (OA), an inhibitor of protein phosphatases 1 and 2A, transcriptionally induces the urokinase-type plasminogen activator (uPA) gene in LLC-PK1 cells. This induction occurs independently of the protein kinase C-and cAMP-dependent signaling pathways. Here we show that a sequence located 2.0 kilobases upstream of the uPA gene, which resembles an AP-1-recognition sequence, mediates the action of OA. DNA-protein interaction studies, together with mRNA and protein analyses, indicate that c-Jun, but not c-Fos, is involved in OA-dependent uPA gene induction. The appearance of high levels of uPA mRNA and DNA binding activity of c-Jun to the AP-1-like site correspond to the appearance of c-Jun accumulation, suggesting that c-Jun accumulation is a critical event in OA-dependent uPA gene induction. c-Jun protein levels increase significantly between 100 and 160 min following OA treatment, whereas c-Jun translation increases only slightly in this time frame, suggesting that post-translation mechanisms are also involved in c-Jun accumulation. Pulse-chase analyses shows that OA specifically stabilizes c-Jun. We discuss our results with respect to the possibility that protein phosphatase 2A maintains c-Jun in its down-regulated state in LLC-PK1 cells.	FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANDRUS L, 1988, J BIOL CHEM, V263, P6183; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAICHWAL VR, 1992, GENE DEV, V6, P1493, DOI 10.1101/gad.6.8.1493; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOTTERI FM, 1990, J BIOL CHEM, V265, P13327; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CASSADY AI, 1991, NUCLEIC ACIDS RES, V19, P6839, DOI 10.1093/nar/19.24.6839; CHEN M, 1989, J BIOL CHEM, V264, P14282; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1991, MOL ASPECTS CELLULAR, V6, P295; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEGEN JL, 1985, J BIOL CHEM, V260, P2426; DUFFY MJ, 1990, CANCER RES, V50, P6827; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GOODE N, 1992, J BIOL CHEM, V267, P16878; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KHEWGOODALL Y, 1991, BIOCHEMISTRY-US, V30, P89, DOI 10.1021/bi00215a014; KIM SJ, 1990, CELL REGUL, V1, P269, DOI 10.1091/mbc.1.3.269; LEE JS, 1993, NUCLEIC ACIDS RES, V21, P3365, DOI 10.1093/nar/21.15.3365; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MENOUD PA, 1993, NUCLEIC ACIDS RES, V21, P1845, DOI 10.1093/nar/21.8.1845; MILLMAN G, 1981, SOMAT CELL GENET, V7, P161; NAGAMINE Y, 1983, CELL, V32, P1181, DOI 10.1016/0092-8674(83)90301-X; NAGAMINE Y, 1991, EMBO J, V10, P117, DOI 10.1002/j.1460-2075.1991.tb07927.x; NAGAMINE Y, 1984, NUCLEIC ACIDS RES, V12, P9525, DOI 10.1093/nar/12.24.9525; NAGAMINE Y, 1992, FIBRINOLYSIS, V6, P121; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; PONTREMOLI S, 1987, P NATL ACAD SCI USA, V84, P398, DOI 10.1073/pnas.84.2.398; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SCHONTHAL A, 1992, NEW BIOL, V4, P16; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; THEVENIN C, 1991, J BIOL CHEM, V266, P9363; VONDERAHE D, 1990, NUCLEIC ACIDS RES, V18, P1991, DOI 10.1093/nar/18.8.1991; YU H, 1990, CANCER RES, V50, P7623; ZHANG Z, 1988, BIOCHEM BIOPH RES CO, V151, P355, DOI 10.1016/0006-291X(88)90601-8; ZIEGLER A, 1991, J BIOL CHEM, V266, P21067	66	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2887	2894						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300623				2022-12-27	WOS:A1994MV43200078
J	SIPPEL, CJ; MCCOLLUM, MJ; PERLMUTTER, DH				SIPPEL, CJ; MCCOLLUM, MJ; PERLMUTTER, DH			BILE-ACID TRANSPORT BY THE RAT-LIVER CANALICULAR BILE-ACID TRANSPORT ECTO-ATPASE PROTEIN IS DEPENDENT ON ATP BUT NOT ON ITS OWN ECTO-ATPASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-TRANSLOCATING ATPASE; RESISTANCE P-GLYCOPROTEIN; NUCLEOTIDE-BINDING SITE; CELL-ADHESION MOLECULE; MULTIDRUG-RESISTANCE; CYSTIC-FIBROSIS; TAUROCHOLATE TRANSPORT; MEMBRANE-VESICLES; CHLORIDE CHANNELS; EXPRESSION	We have shown that bile acid efflux and ecto-ATPase activities are two distinct properties of a single rat liver hepatocyte canalicular membrane protein (Sippel, C. J., Suchy, F. J., Ananthanarayanan, M., and Perlmutter, D. H. (1993) J. Biol. Chem. 268, 2083-2091). Bile acid efflux in COS cells transfected with this rat hepatocyte canalicular bile acid transport/ecto-ATPase cDNA is stimulated by ATP and inhibited by nonhydrolyzable ATP analogs. In this study, we depleted transfected COS cells of ATP to examine whether bile acid efflux mediated by this transporter was dependent on ATP or just stimulated by ATP. We also used mutagenesis of an ATPase consensus sequence in the ectoplasmic domain to examine the relationship of ATPase activity to bile acid efflux mediated by the same polypeptide. The results indicate that bile acid transport is abrogated by ATP depletion and reconstituted by exogenous ATP in a concentration-dependent and saturable manner. Introduction of mutations at amino acids Gly97 and Arg98 in the ATPase consensus sequence abrogated ATPase activity but did not affect synthesis or cell surface delivery of the transporter and did not affect its bile acid transport activity. Taken together, the data indicate that bile acid efflux mediated by the rat hepatocyte canalicular bile acid transport/ecto-ATPase protein is dependent on ATP but not on its own ATPase activity. The data, therefore, imply that 1) ATP affects its bile acid transport activity through an entirely distinct mechanism; and 2) if there is any functional relationship between the ecto-ATPase and bile acid transport properties, it is mediated indirectly through regulation of net ATP concentrations in the canalicular space by the ecto-ATPase.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	SIPPEL, CJ (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PEDIAT,400 S KINGSHIGHWAY BLVD,ST LOUIS,MO 63110, USA.				NICHD NIH HHS [K08 HD00954-01, T32 HDO7409] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007409, K08HD000954] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABRAHAM EH, 1992, P NATL ACAD SCI USA, V90, P312; ADACHI Y, 1991, HEPATOLOGY, V14, P655, DOI 10.1016/0270-9139(91)90053-X; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ARIAS IM, 1993, HEPATOLOGY, V17, P318, DOI 10.1002/hep.1840170225; ARISPE N, 1992, P NATL ACAD SCI USA, V89, P1539, DOI 10.1073/pnas.89.5.1539; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLITZER B, 1982, AM J PHYSIOL, V6, pG48; CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; CULIC O, 1992, BIOCHEM J, V285, P47, DOI 10.1042/bj2850047; CULLEN BR, 1987, METHOD ENZYMOL, V152, P562; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KAST C, 1992, HEPATOLOGY, V16, pA148; KAUR P, 1992, J BIOL CHEM, V267, P19272; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; LIN SH, 1989, J BIOL CHEM, V264, P14408; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MULLER M, 1991, J BIOL CHEM, V266, P18920; NATHANSON MH, 1991, HEPATOLOGY, V14, P551, DOI 10.1002/hep.1840140324; NIKAIDO H, 1992, SCIENCE, V258, P936, DOI 10.1126/science.1279804; NISHIDA T, 1992, HEPATOLOGY, V16, pA149; ODIN P, 1986, BIOCHEM J, V236, P559, DOI 10.1042/bj2360559; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; PERLMUTTER DH, 1988, J BIOL CHEM, V263, P16499; RUETZ S, 1987, J BIOL CHEM, V262, P11324; SHNEIDER BL, 1993, J BIOL CHEM, V268, P6985; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; SIPPEL CJ, 1990, AM J PHYSIOL, V258, pG728, DOI 10.1152/ajpgi.1990.258.5.G728; SMITH DJ, 1992, HEPATOLOGY, V15, P969, DOI 10.1002/hep.1840150535; STUTTS MJ, 1992, P NATL ACAD SCI USA, V89, P1621, DOI 10.1073/pnas.89.5.1621; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WINE JJ, 1992, NATURE, V360, P18, DOI 10.1038/360018a0; YIH LH, 1991, CELL BIOL INT REP, V15, P253, DOI 10.1016/0309-1651(91)90157-E; ZIMNIAK P, 1993, HEPATOLOGY, V17, P330, DOI 10.1002/hep.1840170226	42	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2820	2826						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300615				2022-12-27	WOS:A1994MV43200069
J	YURCHENCO, PD; CHENG, YS				YURCHENCO, PD; CHENG, YS			SELF-ASSEMBLY AND CALCIUM-BINDING SITES IN LAMININ - A 3-ARM INTERACTION-MODEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES CELL ATTACHMENT; COLLAGEN TYPE-IV; BASEMENT-MEMBRANE; NIDOGEN COMPLEX; A-CHAIN; MULTIDOMAIN PROTEIN; NEURITE OUTGROWTH; TUMOR LAMININ; LONG-ARM; B-CHAINS	Laminin, a four-arm glycoprotein, polymerizes in vitro into networks similar to those found in basement membranes. We have dissected this calcium-dependent assembly by analyzing proteolytic fragment binding using equilibrium gel filtration, ultracentrifugation, and electron microscopy. The cathepsin G fragment C1-4 (three short arms) was found to aggregate with a critical concentration similar to that for laminin. Like laminin polymerization, this assembly was inhibited by the smaller elastase short arm fragments E4 (B1 domains VI and V) and E1' (A-B2 short arm complex). Fragment E4 bound directly to E1' in a calcium-dependent manner (K(D) = 1.4 muM). In contrast, homologous self-interactions of short arm fragments and all interactions of long arm fragments were considerably weaker or nonexistent. While electron micrographs of E1' or E4 alone contained mostly monomers, those of E1'/E4 mixtures contained dimers and oligomers with E1' dimers connected to each other through their A and B2 arms, often with visible E4 molecules at their junctions. Ca-45(2+) bound principally to fragment E1' with localization to the end of the B2 chain. These data support a model in which polymerization requires the interaction of all three ligands, one from each short arm, with calcium activating assembly by binding to the B2 short arm.			YURCHENCO, PD (corresponding author), ROBERT WOOD JOHNSON MED SCH,DEPT PATHOL,675 HOES LANE,PISCATAWAY,NJ 08854, USA.			Yurchenco, Peter/0000-0003-0387-2317	NIDDK NIH HHS [R01-DK36425] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036425] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUMAILLEY M, 1989, EUR J BIOCHEM, V184, P241, DOI 10.1111/j.1432-1033.1989.tb15013.x; AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BRUCH M, 1989, EUR J BIOCHEM, V185, P271, DOI 10.1111/j.1432-1033.1989.tb15112.x; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P849; CHAKRAVARTI S, 1990, J BIOL CHEM, V265, P10597; DEUTZMANN R, 1988, EUR J BIOCHEM, V177, P35, DOI 10.1111/j.1432-1033.1988.tb14342.x; EDGAR D, 1988, J CELL BIOL, V106, P1299, DOI 10.1083/jcb.106.4.1299; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ENGVALL E, 1992, EXP CELL RES, V198, P115, DOI 10.1016/0014-4827(92)90156-3; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; FUJIWARA S, 1988, BIOCHEM J, V252, P453, DOI 10.1042/bj2520453; FUJIWARA S, 1984, EUR J BIOCHEM, V143, P145, DOI 10.1111/j.1432-1033.1984.tb08353.x; GERL M, 1991, EUR J BIOCHEM, V202, P167, DOI 10.1111/j.1432-1033.1991.tb16358.x; HORWITZ A, 1985, J CELL BIOL, V101, P2134, DOI 10.1083/jcb.101.6.2134; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; KALB E, 1991, J BIOL CHEM, V266, P19047; KALLUNKI P, 1992, J CELL BIOL, V119, P679, DOI 10.1083/jcb.119.3.679; KUSCHEGULLBERG M, 1992, EMBO J, V11, P4519, DOI 10.1002/j.1460-2075.1992.tb05553.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LIM WA, 1991, METHOD ENZYMOL, V208, P196; MANN K, 1988, EUR J BIOCHEM, V178, P71, DOI 10.1111/j.1432-1033.1988.tb14430.x; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; OOSAWA F, 1975, THERMODYNAMICS POLYM, P199; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PALM SL, 1985, BIOCHEMISTRY-US, V24, P7753, DOI 10.1021/bi00347a038; PAULSSON M, 1989, J BIOL CHEM, V264, P18726; PAULSSON M, 1988, EUR J BIOCHEM, V177, P477, DOI 10.1111/j.1432-1033.1988.tb14397.x; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; PAULSSON M, 1988, J BIOL CHEM, V263, P5424; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHITTNY JC, 1990, J CELL BIOL, V110, P825, DOI 10.1083/jcb.110.3.825; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YURCHENCO PD, 1993, J BIOL CHEM, V268, P8356; YURCHENCO PD, 1990, J BIOL CHEM, V265, P3981; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	44	222	226	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17286	17299						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349613				2022-12-27	WOS:A1993LQ98800062
J	CHERNOUSOV, MA; CAREY, DJ				CHERNOUSOV, MA; CAREY, DJ			N-SYNDECAN (SYNDECAN-3) FROM NEONATAL RAT-BRAIN BINDS BASIC FIBROBLAST GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; MAMMARY EPITHELIAL-CELLS; SURFACE PROTEOGLYCAN; ENDOTHELIAL-CELLS; FACTOR RECEPTOR-1; EXPRESSION; FAMILY; BFGF; DIFFERENTIATION; SPECIFICITY	The cell surface proteoglycan N-syndecan (syndecan 3) was isolated from neonatal rat brain. Purified brain N-syndecan had biochemical properties Very similar to N-syndecan previously identified in Schwann cells: it contained mainly, if not exclusively, heparan sulfate glycosaminoglycan chains and had a core protein with an apparent molecular mass of 120 kDa by sodium dodecyl sulfate-gel electrophoresis. We examined the interactions between purified N-syndecan and extracellular ligands using a solid phase binding assay. It was found that among all proteins tested, including a variety growth factors and extracellular matrix molecules, only basic fibroblast growth factor (bFGF) exhibited significant N-syndecan binding. N-syndecan binding to bFGF was saturable and exhibited a K(D) = 0.5 nM. Soluble bFGF effectively competed with immobilized bFGF for binding to N-syndecan, indicating that these two proteins also interact in solution. Heparin and heparan sulfate, but not chondroitin sulfate, inhibited N-syndecan-bFGF binding. Isolated N-syndecan core protein did not exhibit significant binding to bFGF. Thus, the heparan sulfate chains of N-syndecan, rather than its core protein, appear to be responsible for binding to bFGF. Interestingly, acidic fibroblast growth factor, which is structurally similar to bFGF, did not exhibit significant N-syndecan binding. N-syndecan also did not bind to several other heparin-binding proteins used in this study, indicating a high degree of specificity for the N-syndecan-bFGF interaction. Both N-syndecan and bFGF are abundant in neonatal brain, suggesting that N-syndecan may function as a co-receptor for bFGF during nerve tissue development.	SIGFRIED & JANET WEIS CTR RES, GEISINGER CLIN 26-13, DANVILLE, PA 17822 USA						NINDS NIH HHS [NS21925] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021925] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; BERNFIELD M, 1991, ANN NY ACAD SCI, V638, P182, DOI 10.1111/j.1749-6632.1991.tb49029.x; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; ELENIUS K, 1990, J BIOL CHEM, V265, P17837; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; ENGELE J, 1992, DEV BIOL, V152, P363, DOI 10.1016/0012-1606(92)90143-5; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; GIMENEZGALLEGO G, 1985, SCIENCE, V230, P1385, DOI 10.1126/science.4071057; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KODA JE, 1985, J BIOL CHEM, V260, P8157; LORIES V, 1992, J BIOL CHEM, V267, P1116; MERTENS G, 1992, J BIOL CHEM, V267, P20435; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NEUFELD G, 1987, J CELL PHYSIOL, V131, P131, DOI 10.1002/jcp.1041310119; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; RAPRAEGER AC, 1983, J BIOL CHEM, V258, P3632; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SUN XJ, 1989, J BIOL CHEM, V264, P11288; SUTHERLAND AE, 1991, DEVELOPMENT, V113, P339; TIMPL R, 1979, J BIOL CHEM, V254, P9933; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	28	104	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16810	16814						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344959				2022-12-27	WOS:A1993LQ33600102
J	DAVIS, JF; FELDER, MR				DAVIS, JF; FELDER, MR			MOUSE ETHANOL-INDUCIBLE CYTOCHROME-P-450 (P450IIE1) - CHARACTERIZATION OF CDNA CLONES AND TESTOSTERONE INDUCTION IN KIDNEY TISSUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-NITROSODIMETHYLAMINE DEMETHYLASE; RNA STABILITY INVITRO; MESSENGER-RNA; ALCOHOL-DEHYDROGENASE; RIBONUCLEOPROTEIN-PARTICLES; ANDROGEN INDUCTION; LIVER; RAT; EXPRESSION; ACID	A mouse cDNA clone for the ethanol-inducible cytochrome P-450 (P450IIE1) was obtained by screening a liver cDNA library with an oligonucleotide representing a consensus sequence found in the orthologous rat, human, and rabbit sequences. The protein sequence deduced from the cDNA sequence had an identity of 93% to rat, 81% to rabbit, and 76% to human orthologous sequences. The highest levels of P450IIE1 mRNA were found in liver of both sexes, and male kidney. Developmentally, C57BL/6 female liver P450IIE 1 mRNA was detectable 1 day postpartum and reached steady-state levels in animals approximately 16-20 days of age. Kidney and adrenal gland P450IIE1 mRNA was found to be induced 25-50-fold and 4-fold by testosterone treatment, respectively, and the level in both tissues reached maximum levels between 12 h and 2 days after treatment. Nuclear run-on experiments demonstrated that testosterone treatment for 24-48 h resulted in a slight transcriptional activation of the P450IIE1 gene in the kidney. However, the increase in transcription rate was far below the increase in mRNA level, suggesting that much of the induction occurs by posttranscriptional mechanisms. This process requires the androgen receptor since mutant Tfm mice lacking receptor are not inducible.			DAVIS, JF (corresponding author), UNIV S CAROLINA,DEPT BIOL SCI,COLUMBIA,SC 29208, USA.				NIAAA NIH HHS [AA 06608] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006608] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AHIR S, 1989, CANCER RES, V49, P3737; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENSON SA, 1984, BIOTECHNIQUES    MAY, P126; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERGER FG, 1984, J BIOL CHEM, V259, P7941; BERGER FG, 1986, BIOCHEMISTRY-US, V25, P1170, DOI 10.1021/bi00353a034; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CECI JD, 1986, GENE, V41, P217, DOI 10.1016/0378-1119(86)90101-0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DERMAN E, 1981, P NATL ACAD SCI-BIOL, V78, P5425, DOI 10.1073/pnas.78.9.5425; DONG ZG, 1988, ARCH BIOCHEM BIOPHYS, V263, P29, DOI 10.1016/0003-9861(88)90610-8; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; EDWARDS RJ, 1989, BIOCHEMISTRY-US, V28, P3762, DOI 10.1021/bi00435a021; FELDER MR, 1988, J BIOL CHEM, V263, P14531; FORKERT PG, 1991, CARCINOGENESIS, V12, P2259, DOI 10.1093/carcin/12.12.2259; GEHRING U, 1971, NATURE-NEW BIOL, V232, P106, DOI 10.1038/newbio232106a0; GRUBER LN, 1983, AM J CLIN HYPN, V25, P263; HONG JY, 1989, CANCER RES, V49, P2973; HONG JY, 1987, BIOCHEM BIOPH RES CO, V142, P1077, DOI 10.1016/0006-291X(87)91525-7; JOHANSSON I, 1988, BIOCHEMISTRY-US, V27, P1925, DOI 10.1021/bi00406a019; KHANI SC, 1988, J BIOL CHEM, V263, P7170; KHANI SC, 1987, P NATL ACAD SCI USA, V84, P638, DOI 10.1073/pnas.84.3.638; KIM SG, 1990, BIOCHEM BIOPH RES CO, V172, P767, DOI 10.1016/0006-291X(90)90740-E; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KOOP DR, 1982, J BIOL CHEM, V257, P8472; KUBOTA S, 1988, BIOCHEM BIOPH RES CO, V150, P304, DOI 10.1016/0006-291X(88)90520-7; LIEBER CS, 1980, GASTROENTEROLOGY, V79, P373; MANIATIS T, 1982, MOL CLONING LABORATO, P65; OHNISHI K, 1977, J BIOL CHEM, V252, P7124; PALMITER RD, 1981, J BIOL CHEM, V256, P6341; PORT JD, 1992, J BIOL CHEM, V267, P24103; PORTER TD, 1989, MOL PHARMACOL, V36, P61; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; RYAN DE, 1985, J BIOL CHEM, V260, P6385; SONG BJ, 1986, J BIOL CHEM, V261, P6689; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THOMAS PE, 1987, BIOCHEMISTRY-US, V26, P2280, DOI 10.1021/bi00382a031; TUSSEY L, 1989, P NATL ACAD SCI USA, V86, P5903, DOI 10.1073/pnas.86.15.5903; UMENO M, 1988, J BIOL CHEM, V263, P4956; WATSON G, 1985, GENE, V36, P15, DOI 10.1016/0378-1119(85)90065-4; WATSON G, 1988, MOL CELL BIOL, V8, P2117, DOI 10.1128/MCB.8.5.2117; WRIGHTON SA, 1986, BIOCHEMISTRY-US, V25, P6731, DOI 10.1021/bi00370a001; YANG CS, 1985, BIOCHEM BIOPH RES CO, V128, P1007, DOI 10.1016/0006-291X(85)90147-0; YOO JSH, 1987, CANCER RES, V47, P3378; ZHANG YL, 1985, MOL CELL ENDOCRINOL, V43, P151, DOI 10.1016/0303-7207(85)90078-4	46	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16584	16589						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344939				2022-12-27	WOS:A1993LQ33600073
J	SIMAN, R; MISTRETTA, S; DURKIN, JT; SAVAGE, MJ; LOH, T; TRUSKO, S; SCOTT, RW				SIMAN, R; MISTRETTA, S; DURKIN, JT; SAVAGE, MJ; LOH, T; TRUSKO, S; SCOTT, RW			PROCESSING OF THE BETA-AMYLOID PRECURSOR - MULTIPLE PROTEASES GENERATE AND DEGRADE POTENTIALLY AMYLOIDOGENIC FRAGMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PROTEIN-PRECURSOR; CYSTEINE PROTEINASES; CATHEPSIN-L; CULTURED-CELLS; IDENTIFICATION; PEPTIDE; INHIBITORS; FIBRILS; BRAIN	Proteolytic processing of the beta-amyloid precursor proteins (APP) is required for release of the beta/A4 protein and its deposition into the amyloid plaques characteristic of aging and Alzheimer's disease. We have examined the involvement of acidic intracellular compartments in APP processing in cultured human cells. The use of acidotropic agents and inhibitors to a specific class of lysosomal protease, coupled with metabolic labeling and immunoprecipitation, revealed that APP is degraded within an acidic compartment to produce at least 12 COOH-terminal fragments. Nine likely contain the entire beta/A4 domain and, therefore, are potentially amyloidogenic. Treatment with E64 or Z-Phe-Ala-CHN2 irreversibly blocked activities of the lysosomal cysteine proteases cathepsins B and L but did not inhibit the lysosomal aspartic protease cathepsin D and did not alter the production of potentially amyloidogenic fragments. Instead, the inhibitors prevented further degradation of the fragments. Thus, large numbers of potentially amyloidogenic fragments of APP are routinely generated in an acidic compartment by noncysteine proteases and then are eliminated within lysosomes by cysteine proteases. Immunoblot and immunohistochemical analyses confirmed that chronic cysteine protease inhibition leads to accumulation of potentially amyloidogenic APP fragments in lysosomes. The results provide further support for the hypothesis that an acidic compartment may be involved in amyloid formation and begin to define the proteolytic events that may be important for amyloidogenesis.			SIMAN, R (corresponding author), CEPHALON INC,145 BRANDYWINE PKWY,W CHESTER,PA 19380, USA.							ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BENOWITZ LI, 1989, EXP NEUROL, V106, P237, DOI 10.1016/0014-4886(89)90156-8; BURDICK D, 1992, J BIOL CHEM, V267, P546; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CASTANO EM, 1986, BIOCHEM BIOPH RES CO, V141, P782, DOI 10.1016/S0006-291X(86)80241-8; CATALDO AM, 1990, BRAIN RES, V513, P181, DOI 10.1016/0006-8993(90)90456-L; CATALDO AM, 1991, P NATL ACAD SCI USA, V88, P10998, DOI 10.1073/pnas.88.24.10998; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; CRAWFORD C, 1988, BIOCHEM J, V253, P751, DOI 10.1042/bj2530751; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GREEN GDJ, 1981, J BIOL CHEM, V256, P1923; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIRSCHKE H, 1981, BIOCHEM BIOPH RES CO, V101, P454, DOI 10.1016/0006-291X(81)91281-X; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; NEVE RL, 1992, P NATL ACAD SCI USA, V89, P3448, DOI 10.1073/pnas.89.8.3448; NORDSTEDT C, 1991, P NATL ACAD SCI USA, V88, P8910, DOI 10.1073/pnas.88.20.8910; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; RIJNBOUTT S, 1992, J BIOL CHEM, V267, P15665; SAVAGE MJ, 1993, IN PRESS NEUROSCIENC; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMAN R, 1990, J NEUROSCI, V10, P2400; TAKAHASHI T, 1981, METHOD ENZYMOL, V80, P565; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WIEDERANDERS B, 1992, J BIOL CHEM, V267, P13708; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201	43	83	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16602	16609						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344942				2022-12-27	WOS:A1993LQ33600076
J	SKARE, JT; AHMER, BMM; SEACHORD, CL; DARVEAU, RP; POSTLE, K				SKARE, JT; AHMER, BMM; SEACHORD, CL; DARVEAU, RP; POSTLE, K			ENERGY TRANSDUCTION BETWEEN MEMBRANES - TONB, A CYTOPLASMIC MEMBRANE-PROTEIN, CAN BE CHEMICALLY CROSS-LINKED IN-VIVO TO THE OUTER-MEMBRANE RECEPTOR FEPA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; POLYACRYLAMIDE GELS; AMINO TERMINUS; GENE-PRODUCTS; TRANSPORT; VITAMIN-B12; SUPPRESSION; TOPOLOGY; CLEAVAGE	TonB, a cytoplasmic membrane protein, couples cytoplasmic membrane protonmotive force to active transport across the outer membrane of Escherichia coli. In vivo cross-linking studies were initiated to analyze TonB interactions with other cell envelope proteins. Four TonB-specific cross-linked complexes were detected with apparent molecular masses of 195, 77, 59, and 43.5 kDa. The 195-kDa complex was shown to contain both TonB and FepA, the outer membrane receptor for the siderophore enterochelin. The 195-kDa complex is absent in strains missing either TonB or FepA and can be detected by either TonB-specific or FepA-specific monoclonal antibodies. This is the first direct in vivo evidence that TonB can span the periplasmic space to interact physically with outer membrane receptors. Consistent with that observation, the outer membrane protease OmpT was shown to play a role in TonB turnover, both in the presence and absence of ExbB. We had previously shown that the absence of ExbB results in the rapid degradation of TonB. The absence of OmpT could be used to stabilize TonB in an exbB=Tn10 strain such that steady state levels of TonB protein are identical to a wild-type strain. Under those conditions, the absence of ExbB results in greatly reduced TonB activity, indicating that ExbB plays a direct role in energy transduction and probably secondarily protects TonB protein from proteolysis. The 59-kDa complex was absent in an exbB=Tn10 strain, suggesting either that ExbB is in the complex with TonB or that ExbB is required to form the 59-kDa complex. A tolQ nonsense mutation had no effect on the cross-linking profile observed, confirming that its participation in TonB-dependent phenomena is minor and most likely the result of evolutionary cross-talk.	WASHINGTON STATE UNIV,DEPT MICROBIOL,PULLMAN,WA 99164; WASHINGTON STATE UNIV,DEPT GENET & CELL BIOL,PULLMAN,WA 99164; WASHINGTON STATE UNIV,DEPT BIOCHEM & BIOPHYS,PULLMAN,WA 99164; BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,SEATTLE,WA 98121	Washington State University; Washington State University; Washington State University; Bristol-Myers Squibb			Ahmer, Brian M. M./F-2228-2010	Ahmer, Brian M. M./0000-0002-4267-7322; Postle, Kathleen/0000-0001-9451-777X	NIGMS NIH HHS [GM42146] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042146] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL PE, 1990, J BACTERIOL, V172, P3826, DOI 10.1128/jb.172.7.3826-3829.1990; BRADBEER C, 1991, BIOFACTORS, V3, P11; BRAUN V, 1989, J BACTERIOL, V171, P6387, DOI 10.1128/jb.171.11.6387-6390.1989; BRAUN V, 1991, BIOL MET, V4, P14, DOI 10.1007/BF01135552; BREWER S, 1990, J MOL BIOL, V216, P883, DOI 10.1016/S0022-2836(99)80008-4; CODERRE PE, 1984, FEMS MICROBIOL LETT, V25, P111, DOI 10.1111/j.1574-6968.1984.tb01385.x; ELISH ME, 1988, J GEN MICROBIOL, V134, P1355; ENGVALL E, 1977, MED BIOL, V55, P193; FISCHER E, 1989, J BACTERIOL, V171, P5127, DOI 10.1128/jb.171.9.5127-5134.1989; GERSHONI JM, 1983, ANAL BIOCHEM, V131, P1, DOI 10.1016/0003-2697(83)90128-8; HANCOCK REW, 1976, J BACTERIOL, V125, P409, DOI 10.1128/JB.125.2.409-415.1976; HANNAVY K, 1990, J MOL BIOL, V216, P897, DOI 10.1016/S0022-2836(99)80009-6; HELLER KJ, 1988, GENE, V64, P147, DOI 10.1016/0378-1119(88)90488-X; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; Jones R.N., 1985, MANUAL CLIN MICROBIO, P972; KADNER RJ, 1990, MOL MICROBIOL, V4, P2027, DOI 10.1111/j.1365-2958.1990.tb00562.x; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Miller JH, 1972, EXPT MOL GENETICS, P201; MURPHY CK, 1990, J BACTERIOL, V172, P2736, DOI 10.1128/jb.172.5.2736-2746.1990; POSTLE K, 1988, J BIOL CHEM, V263, P11000; POSTLE K, 1990, MOL MICROBIOL, V4, P2019, DOI 10.1111/j.1365-2958.1990.tb00561.x; POSTLE K, 1983, P NATL ACAD SCI-BIOL, V80, P5235, DOI 10.1073/pnas.80.17.5235; PROSSNITZ E, 1988, J BIOL CHEM, V263, P17917; REYNOLDS PR, 1980, J BIOL CHEM, V255, P4313; ROOF SK, 1991, J BACTERIOL, V173, P5554, DOI 10.1128/jb.173.17.5554-5557.1991; SCHOFFLER H, 1989, MOL GEN GENET, V217, P378, DOI 10.1007/BF02464907; SCHWYN B, 1987, ANAL BIOCHEM, V160, P47, DOI 10.1016/0003-2697(87)90612-9; SKARE JT, 1991, MOL MICROBIOL, V5, P2883, DOI 10.1111/j.1365-2958.1991.tb01848.x; SKARE JT, 1989, J BACTERIOL, V171, P4442, DOI 10.1128/JB.171.8.4442-4447.1989; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; TAM MR, 1982, INFECT IMMUN, V36, P1042, DOI 10.1128/IAI.36.3.1042-1053.1982; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUCKMAN M, 1992, J BACTERIOL, V174, P320, DOI 10.1128/jb.174.1.320-323.1992; WEBSTER RE, 1991, MOL MICROBIOL, V5, P1005, DOI 10.1111/j.1365-2958.1991.tb01873.x; WHITE JC, 1973, J BIOL CHEM, V248, P3978	36	195	197	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16302	16308						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344918				2022-12-27	WOS:A1993LQ33600035
J	WHATLEY, RE; STROUD, ED; BUNTING, M; ZIMMERMAN, GA; MCINTYRE, TM; PRESCOTT, SM				WHATLEY, RE; STROUD, ED; BUNTING, M; ZIMMERMAN, GA; MCINTYRE, TM; PRESCOTT, SM			GROWTH-DEPENDENT CHANGES IN ARACHIDONIC-ACID RELEASE FROM ENDOTHELIAL-CELLS ARE MEDIATED BY PROTEIN-KINASE-C AND CHANGES IN DIACYLGLYCEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2; HYDROLYZING PHOSPHOLIPASE-A2; PROSTACYCLIN PRODUCTION; HUMAN-NEUTROPHILS; PHORBOL ESTER; THROMBIN; CALCIUM; PHOSPHATIDYLCHOLINE; STIMULATION	When stimulated, endothelial cells release arachidonic acid from phospholipids and oxidize it to eicosanoids. The rate-limiting step in this pathway is the initial release step, catalyzed by phospholipase(s), a process that exhibits growth-dependent changes. We examined the role of protein kinase C (PKC) as a regulator of this process. Activators and inhibitors of protein kinase C, used at different growth states, demonstrated distinct differences in their effects on arachidonic acid release, consistent with a growth-dependent change in PKC activity (with greater activity in proliferating cells compared with quiescent cells). Although immunoreactive PKC was slightly greater in the proliferating cells, there was a more striking redistribution of PKC activity between cytosol and membrane. To identify the cause, we measured the diacyl-glycerol (DG) content and found that DG concentrations decreased as cells progressed from preconfluence to confluence. Further studies demonstrated increases in DG kinase and DG lipase in confluent compared with preconfluent cells, consistent with the alterations in DG content. These findings suggest that growth-dependent changes in DG lipase and DG kinase activities regulate basal DG levels and PKC activity. The consequent alteration in PKC activity regulates the growth-dependent changes in arachidonic acid release.	UNIV UTAH, VET AFFAIRS MED CTR, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, ECCLES PROGRAM HUMAN MOLEC BIOL & GENET, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, SCH MED, DEPT MED, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, SCH MED, DEPT BIOCHEM, SALT LAKE CITY, UT 84112 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	WHATLEY, RE (corresponding author), UNIV UTAH, NORA ECCLES HARRISON CARDIOVASC RES & TRAINING INS, BLDG 500, SALT LAKE CITY, UT 84112 USA.				NHLBI NIH HHS [HL 43689, HL 34127, F32 HL 07529] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL043689, R01HL034127, F32HL007529] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALHENCGELAS F, 1982, PROSTAG OTH LIPID M, V24, P723, DOI 10.1016/0090-6980(82)90040-5; ALONSO F, 1986, BIOCHIM BIOPHYS ACTA, V878, P273, DOI 10.1016/0005-2760(86)90156-6; AMES BN, 1960, J BIOL CHEM, V235, P769; BELL RM, 1991, J BIOL CHEM, V266, P4661; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DANIEL LW, 1988, BIOCHEM BIOPH RES CO, V151, P291, DOI 10.1016/0006-291X(88)90592-X; EVANS CE, 1984, PROSTA LEUKOTR MED, V14, P255, DOI 10.1016/0262-1746(84)90209-9; FALLMAN M, 1992, J BIOL CHEM, V267, P2656; FARAGO A, 1990, FEBS LETT, V268, P350, DOI 10.1016/0014-5793(90)81284-U; GARCIA MC, 1991, BIOCHIM BIOPHYS ACTA, V1083, P37, DOI 10.1016/0005-2760(91)90122-X; GOLDSMITH JC, 1984, LAB INVEST, V51, P643; HALLDORSSON H, 1988, ARTERIOSCLEROSIS, V8, P147, DOI 10.1161/01.ATV.8.2.147; HALSEY DL, 1987, J BIOL CHEM, V262, P2234; HAMILTON KK, 1987, J CLIN INVEST, V79, P600, DOI 10.1172/JCI112853; HARLOW E, 1988, ANTIBODIES LABORATOR; INGERMANWOJENSKI CM, 1988, PROSTAGLANDINS, V36, P127, DOI 10.1016/0090-6980(88)90300-0; JAFFE EA, 1987, J BIOL CHEM, V262, P8557; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LAMBERT TL, 1986, J BIOL CHEM, V261, P5288; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; MAJERUS PW, 1982, METHOD ENZYMOL, V86, P11; MARTELL RE, 1987, J BIOL CHEM, V262, P5570; MARTIN TW, 1988, BIOCHEM BIOPH RES CO, V157, P1271, DOI 10.1016/S0006-291X(88)81012-X; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PACHTER JA, 1992, J BIOL CHEM, V267, P9826; PREISS J, 1986, J BIOL CHEM, V261, P8597; PRESCOTT SM, 1984, P NATL ACAD SCI-BIOL, V81, P3534, DOI 10.1073/pnas.81.11.3534; RYU SH, 1990, J BIOL CHEM, V265, P17941; SHARP JD, 1991, J BIOL CHEM, V266, P14850; URATSUJI Y, 1988, J CELL PHYSIOL, V136, P431, DOI 10.1002/jcp.1041360306; WHATLEY RE, 1989, J BIOL CHEM, V264, P6325; WHATLEY RE, 1988, ARTERIOSCLEROSIS, V8, P321, DOI 10.1161/01.ATV.8.3.321; WHATLEY RE, 1990, PROG LIPID RES, V29, P45, DOI 10.1016/0163-7827(90)90005-6; WHORTON AR, 1984, LIPIDS, V19, P17, DOI 10.1007/BF02534603; ZAVOICO GB, 1990, J CELL PHYSIOL, V143, P596, DOI 10.1002/jcp.1041430326; ZIMMERMAN GA, 1985, CIRCULATION, V72, P718, DOI 10.1161/01.CIR.72.4.718; ZIMMERMAN GA, 1990, METHOD ENZYMOL, V187, P520	42	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16130	16138						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344898				2022-12-27	WOS:A1993LQ33600013
J	SHEMESH, J; EHRLICH, R				SHEMESH, J; EHRLICH, R			ABERRANT BIOSYNTHESIS AND TRANSPORT OF CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX-MOLECULES IN CELLS TRANSFORMED WITH HIGHLY ONCOGENIC HUMAN ADENOVIRUSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIC LYMPHOCYTES-T; INTRACELLULAR-TRANSPORT; SURFACE EXPRESSION; MONOCLONAL-ANTIBODIES; INTERFERON-GAMMA; MESSENGER-RNA; TRANSLATIONAL REPRESSION; ENDOPLASMIC-RETICULUM; TRANSCRIPTION FACTOR; ANTIGEN RECEPTOR	The expression of class I major histocompatibility complex antigens on the surface of cells transformed by adenovirus 12 (Ad12) is generally very low. The absence of class I antigens correlates with the high oncogenicity of this virus. In primary embryonal fibroblasts from transgenic mice that express both endogenous H-2 genes and a miniature swine class I gene (PD1), Ad12-mediated transformation results in complete suppression of cell surface expression of class I antigens, but only 50% of the cell lines tested demonstrated decreased steady state levels of class I mRNA. The complete absence of cell surface class I antigens is accompanied by decreased levels of newly synthesized class I molecules. Those molecules that are immunoprecipitated by class I-specific antibodies are assembled with beta2-microglobulin, but their transport through the Golgi is inefficient. The biosynthesis of both the endogenous H-2K, H-2D, and the transgene product, PD1, is similarly altered in the transformed cells. The results suggest that Ad12 transformation is associated with both reduced synthesis rate and inefficient transport of class I molecules to the cell surface. This might be a general mechanism by which virus-infected or -transformed cells escape immune surveillance.	TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT CELL RES & IMMUNOL,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University								ACKRILL AM, 1988, ONCOGENE, V3, P483; AHRINGER J, 1991, NATURE, V349, P347; ALLEN H, 1986, P NATL ACAD SCI USA, V83, P7447, DOI 10.1073/pnas.83.19.7447; ANDERSSON M, 1987, J IMMUNOL, V138, P3960; ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BOS JL, 1983, EMBO J, V2, P73, DOI 10.1002/j.1460-2075.1983.tb01383.x; BOUILLOT M, 1989, NATURE, V339, P443; BRAUN RE, 1991, ENZYME, V44, P120; BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9; BURGERT HG, 1987, P NATL ACAD SCI USA, V84, P1356, DOI 10.1073/pnas.84.5.1356; CERUNDOLO V, 1990, NATURE, V345, P349; CHEN C, 1988, J CELL BIOL, V107, P2149, DOI 10.1083/jcb.107.6.2149; CHNG JLC, 1990, SCIENCE, V248, P1003, DOI 10.1126/science.2343304; COPLELAND CS, 1988, CELL, V53, P197; DAVIS WC, 1987, VET IMMUNOL IMMUNOP, V15, P337, DOI 10.1016/0165-2427(87)90005-5; DOHERTY PC, 1984, ADV CANCER RES, V42, P1, DOI 10.1016/S0065-230X(08)60455-8; EAGER KB, 1985, P NATL ACAD SCI USA, V82, P5525, DOI 10.1073/pnas.82.16.5525; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FELLOUS M, 1977, IMMUNOGENETICS, V5, P423, DOI 10.1007/BF01570501; FOHRING B, 1983, VIROLOGY, V131, P463, DOI 10.1016/0042-6822(83)90512-3; FRELS WI, 1985, SCIENCE, V228, P577, DOI 10.1126/science.3885396; FRIEDMAN DJ, 1988, VIROLOGY, V165, P303, DOI 10.1016/0042-6822(88)90689-7; GOODENOW RS, 1985, SCIENCE, V230, P777, DOI 10.1126/science.2997918; GOOSSEN B, 1990, EMBO J, V9, P4127, DOI 10.1002/j.1460-2075.1990.tb07635.x; GRAHAM FL, 1984, ADENOVIRUSES, P339; HAMMERLING GJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P245, DOI 10.1016/0304-419X(87)90008-4; HO MK, 1982, J IMMUNOL, V128, P1221; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; HYMAN R, 1977, IMMUNOGENETICS, V4, P171, DOI 10.1007/BF01575656; JACOBY WB, 1979, METHOD ENZYMOL, V58, P110; JEFFERIES WA, 1988, EMBO J, V7, P3423, DOI 10.1002/j.1460-2075.1988.tb03216.x; JEFFERIES WA, 1990, J EXP MED, V172, P1653, DOI 10.1084/jem.172.6.1653; JUTILA MA, 1988, EUR J IMMUNOL, V18, P1819, DOI 10.1002/eji.1830181125; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KATOH S, 1990, EMBO J, V9, P127, DOI 10.1002/j.1460-2075.1990.tb08088.x; KLAR D, 1989, EMBO J, V8, P475, DOI 10.1002/j.1460-2075.1989.tb03400.x; Kohler G., 1981, IMMUNE SYSTEM, V2, P202; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KOPPELMAN B, 1990, J IMMUNOL, V145, P2730; KRUYS V, 1990, ENZYME, V44, P193, DOI 10.1159/000468757; LALANNE JL, 1983, NUCLEIC ACIDS RES, V11, P1567, DOI 10.1093/nar/11.5.1567; LANCET D, 1979, P NATL ACAD SCI USA, V76, P3844, DOI 10.1073/pnas.76.8.3844; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MAGUIRE K, 1991, ONCOGENE, V6, P1417; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MEIJER I, 1989, J VIROL, V9, P4039; MILLER KG, 1981, CELL, V27, P165, DOI 10.1016/0092-8674(81)90370-6; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; NIELSCH U, 1991, EMBO J, V10, P4169, DOI 10.1002/j.1460-2075.1991.tb04995.x; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; OZATO K, 1981, J IMMUNOL, V126, P317; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROTUNDO RL, 1989, J BIOL CHEM, V264, P3146; Sambrook J., 1989, MOL CLONING LAB MANU; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SHEMESH J, 1991, J VIROL, V65, P5544, DOI 10.1128/JVI.65.10.5544-5548.1991; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; STANDART N, 1990, ENZYME, V44, P106, DOI 10.1159/000468751; TANAKA K, 1985, SCIENCE, V228, P26, DOI 10.1126/science.3975631; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; VASAVADA R, 1986, P NATL ACAD SCI USA, V83, P5257, DOI 10.1073/pnas.83.14.5257; VITELLO A, 1990, SCIENCE, P1423; WHITE BA, 1982, J BIOL CHEM, V257, P8569; WILLIAMS DB, 1985, J CELL BIOL, V101, P725, DOI 10.1083/jcb.101.3.725; WILLIAMS DB, 1988, J BIOL CHEM, V263, P4549; WILLIAMS DB, 1989, J IMMUNOL, V142, P2796; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266; ZHOU DFH, 1989, J IMMUNOL, V143, P3390; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZINKERNAGEL R, 1979, ADV IMMUNOL, V22, P51	78	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15704	15711						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340394				2022-12-27	WOS:A1993LN30500058
J	HISANAGA, S; ISHIGURO, K; UCHIDA, T; OKUMURA, E; OKANO, T; KISHIMOTO, T				HISANAGA, S; ISHIGURO, K; UCHIDA, T; OKUMURA, E; OKANO, T; KISHIMOTO, T			TAU-PROTEIN KINASE-II HAS A SIMILAR CHARACTERISTIC TO CDC2 KINASE FOR PHOSPHORYLATING NEUROFILAMENT PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; SUBUNIT NF-H; NEUROFIBRILLARY TANGLES; POSTTRANSLATIONAL MODIFICATION; RAT; ANTIBODIES; NEURONS; POLYPEPTIDES; DEPHOSPHORYLATION; IDENTIFICATION	Tau protein kinase II purified from a bovine brain tau protein fraction (Ishiguro, K., Takamatsu, M., Tomizawa, K., Omori, A., Takahashi, M., Arioka, M., Uchida, T., and Imahori, K. (1992) J. Biol. Chem. 267, 10897-10901) was shown to have a similar substrate specificity to cdc2 kinase in that both phosphorylate neurofilament (NF) proteins. Tau protein kinase II recognized the dephosphorylated form of the heavy subunit of NF (NF-H) as a predominant substrate. The substrate was phosphorylated to the same extent with tau protein kinase II as with cdc2 kinase. Upon phosphorylation, the electrophoretic mobility of the NF-H on SDS-polyacrylamide gel electrophoresis changed to the position of the phosphorylated form. A synthetic peptide containing a KSPXK sequence was by far a better substrate for tau protein kinase II than that containing a KSPXX sequence, as was also observed with cdc2 kinase. NF-H lost its microtubule-associating ability upon phosphorylation with tau protein kinase II as well as with cdc2 kinase. Although anti-PSTAIR antibody (PSTAIR is an amino acid sequence commonly found in cdc2 and several cdc2-related kinases) failed to react with tau protein kinase II, tau protein kinase II bound to p13suc1-Sepharose beads (p13suc1 is a yeast protein known to bind to cdc2 kinase).	MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN		HISANAGA, S (corresponding author), TOKYO INST TECHNOL,FAC BIOSCI,CELL & DEV BIOL,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN.							ANDERTON BH, 1982, NATURE, V298, P84, DOI 10.1038/298084a0; AUTILIOGAMBETTI L, 1983, BANBURY REPORT, V15, P117; BAILLY E, 1992, J CELL SCI, V101, P529; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BLACK MM, 1988, J NEUROSCI, V8, P3296; BREEN KC, 1988, FEBS LETT, V241, P213, DOI 10.1016/0014-5793(88)81064-0; CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; CHOU YH, 1991, J BIOL CHEM, V266, P7325; CORK LC, 1986, J NEUROPATH EXP NEUR, V45, P56, DOI 10.1097/00005072-198601000-00005; DAUTIGNY A, 1988, BIOCHEM BIOPH RES CO, V154, P1099, DOI 10.1016/0006-291X(88)90254-9; DOSEMECI A, 1990, CELL MOL NEUROBIOL, V10, P369, DOI 10.1007/BF00711181; DRAETTA G, 1988, ONCOGENE, V2, P553; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; GLICKSMAN MA, 1987, J NEUROBIOL, V18, P167, DOI 10.1002/neu.480180205; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; GUAN RJ, 1992, J NEUROCHEM, V58, P1365, DOI 10.1111/j.1471-4159.1992.tb11351.x; HAYES TE, 1991, NEW BIOL, V3, P259; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HISANAGA S, 1990, CELL REGUL, V1, P237, DOI 10.1091/mbc.1.2.237; HISANAGA S, 1988, J MOL BIOL, V202, P297, DOI 10.1016/0022-2836(88)90459-7; HISANAGA S, 1989, J NEUROSCI, V9, P959; HISANAGA S, 1990, J BIOL CHEM, V265, P21852; HISANAGA S, 1991, J BIOL CHEM, V266, P21798; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; ISHIGURO K, 1991, NEUROSCI LETT, V128, P195, DOI 10.1016/0304-3940(91)90259-V; ISHIGURO K, 1988, J BIOCHEM-TOKYO, V104, P319, DOI 10.1093/oxfordjournals.jbchem.a122465; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; JONES SM, 1982, J BIOL CHEM, V257, P9902; JULIEN JP, 1982, J BIOL CHEM, V257, P467; JULIEN JP, 1983, BIOCHIM BIOPHYS ACTA, V755, P25, DOI 10.1016/0304-4165(83)90268-4; KISHIMOTO T, 1988, DEV GROWTH DIFFER, V30, P105; KOSIK KS, 1987, J NEUROSCI, V7, P3142; KSIEZAKREDING H, 1987, P NATL ACAD SCI USA, V84, P3410, DOI 10.1073/pnas.84.10.3410; KUSUBATA M, 1992, J BIOL CHEM, V267, P20937; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPIDOTLIESON Y, 1992, P NATL ACAD SCI USA, V89, P579, DOI 10.1073/pnas.89.2.579; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; LEW J, 1992, J BIOL CHEM, V267, P13383; LIEBERBURG I, 1989, P NATL ACAD SCI USA, V86, P2463, DOI 10.1073/pnas.86.7.2463; MEYERSON M, 1991, COLD SPRING HARB SYM, V56, P177; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NIXON RA, 1987, J NEUROSCI, V7, P1145; NUKINA N, 1987, P NATL ACAD SCI USA, V84, P3415, DOI 10.1073/pnas.84.10.3415; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OOKATA K, 1992, EMBO J, V11, P1763, DOI 10.1002/j.1460-2075.1992.tb05228.x; PANT HC, 1986, J BIOL CHEM, V261, P2968; PAPASOZOMENOS SC, 1987, CELL MOTIL CYTOSKEL, V8, P210, DOI 10.1002/cm.970080303; RODER HM, 1991, J NEUROSCI, V11, P3325; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; TORUDELBAUFFE D, 1986, BIOCHEM J, V235, P283, DOI 10.1042/bj2350283; WIBLE BA, 1989, P NATL ACAD SCI USA, V86, P720, DOI 10.1073/pnas.86.2.720	53	96	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15056	15060						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325881				2022-12-27	WOS:A1993LL75900076
J	PHILIPS, A; CHALBOS, D; ROCHEFORT, H				PHILIPS, A; CHALBOS, D; ROCHEFORT, H			ESTRADIOL INCREASES AND ANTIESTROGENS ANTAGONIZE THE GROWTH FACTOR-INDUCED ACTIVATOR PROTEIN-1 ACTIVITY IN MCF7 BREAST-CANCER CELLS WITHOUT AFFECTING C-FOS AND C-JUN SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RECEPTOR; PROGESTERONE-RECEPTOR; LEUCINE ZIPPER; CDNA SEQUENCES; MESSENGER-RNA; ANTIESTROGENS; STIMULATION; CULTURE; INSULIN; BINDING	In estrogen receptor positive human breast cancer cells, anti-estrogens inhibit the mitogenic effect of growth factors in the absence of estrogens. As activator protein-1 (AP-1) activity is one of the first nuclear events following growth factor receptor activation, we studied the effects of estrogens and anti-estrogens on growth factor-induced AP-1 activity using transient transfection of the AP-1-responsive gene (AP-1)4-TK-CAT into MCF7 cells. The growth factor-induced AP-1 response was increased by estradiol and inhibited by anti-estrogens in conditions where growth factor-induced c-fos and c-jun mRNA levels were unchanged by hormone and anti-hormone treatments. The same regulations were obtained when the AP-1 response was directly induced by co-transfection of c-fos and c-jun expression vectors. Co-transfection of the wild-type estrogen receptor HEGO amplified both effects. Inhibition of AP-1 activity by anti-estrogens was unlikely to be explained by the presence of residual estrogens in MCF7 cells. (i) anti-estrogens inhibited AP-1 activity in conditions where they had no effect on basal ERE-mediated activity levels, whereas estradiol was as efficient in stimulating both activities. (ii) The relative efficacy of the two anti-estrogens, OH-tamoxifen and ICI 164,384 in inhibiting these two activities was different; OH-tamoxifen was more efficient in inhibiting ERE-mediated activity, whereas ICI 164,384 was more efficient in trans-repressing AP-1-mediated activity. We conclude that in conditions where c-fos and c-jun syntheses were not affected, the estrogen receptor cooperated with growth factors to stimulate the AP-1 response when activated by estrogens but inhibited AP-1-mediated transcription when occupied by anti-estrogens.	UNIV MONTPELLIER, 60 RUE NAVACELLES, F-34090 MONTPELLIER, FRANCE; INSERM, U148, HORMONES & CANC UNIT, F-34090 MONTPELLIER, FRANCE	Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier			PHILIPS, Alexandre/AAB-6047-2020					AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BERTHOIS Y, 1989, BIOCHEM BIOPH RES CO, V159, P126, DOI 10.1016/0006-291X(89)92413-3; CAPONY F, 1978, MOL CELL ENDOCRINOL, V11, P181, DOI 10.1016/0303-7207(78)90006-0; CHALBOS D, 1982, J CLIN ENDOCR METAB, V55, P276, DOI 10.1210/jcem-55-2-276; CHALBOS D, 1986, NUCLEIC ACIDS RES, V14, P965, DOI 10.1093/nar/14.2.965; COEZY E, 1982, CANCER RES, V42, P317; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DARBRE P, 1983, CANCER RES, V43, P349; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FREISS G, 1990, J STEROID BIOCHEM, V37, P777, DOI 10.1016/0960-0760(90)90419-L; FURR BJA, 1984, PHARMACOL THERAPEUT, V25, P127, DOI 10.1016/0163-7258(84)90043-3; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; Katzenellenbogen B S, 1979, Recent Prog Horm Res, V35, P259; KATZENELLENBOGEN BS, 1990, ENDOCRINOLOGY, V126, P891, DOI 10.1210/endo-126-2-891; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LIPPMAN M, 1976, CANCER RES, V36, P4595; LIPPMAN ME, 1986, BREAST CANCER RES TR, V7, P59, DOI 10.1007/BF01806790; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; ROCHEFORT H, 1987, TRENDS PHARMACOL SCI, V8, P126, DOI 10.1016/0165-6147(87)90180-5; ROCHEFORT H, 1980, HORMONES CANCER, V14, P21; ROUX P, 1991, ONCOGENE, V6, P2155; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SAMBROOK J, 1989, MOL CLONING LABORATO, P1630; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SIRBASKU DA, 1979, HORMONES CELL CULTUR, V6, P477; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; SUMIDA C, 1989, ENDOCRINOLOGY, V124, P591, DOI 10.1210/endo-124-2-591; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; VANDERBURG B, 1990, MOL ENDOCRINOL, V4, P1720, DOI 10.1210/mend-4-11-1720; VIC P, 1987, BIOCHEM BIOPH RES CO, V146, P1502; VIGNON F, 1986, ENDOCRINOLOGY, V118, P1537, DOI 10.1210/endo-118-4-1537; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	44	148	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14103	14108						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314777				2022-12-27	WOS:A1993LJ82500049
J	CARTER, RS; AVADHANI, NG				CARTER, RS; AVADHANI, NG			COOPERATIVE BINDING OF GA-BINDING PROTEIN TRANSCRIPTION FACTORS TO DUPLICATED TRANSCRIPTION INITIATION REGION REPEATS OF THE CYTOCHROME-C-OXIDASE SUBUNIT-IV GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; AFFINITY DNA-BINDING; TFIID COMPLEX; NUCLEAR FACTOR; LESS PROMOTER; SEQUENCE; ELEMENTS; SITE; TATA; ACTIVATION	Transcriptional activity of the TATA-less cytochrome c oxidase subunit IV (COXIV) gene promoter depends upon two tandemly repeated sequence elements, each mapping immediately downstream of major loci of transcriptional initiation. In this paper, we demonstrate that binding of the GA-binding protein (GABP) to ets sequence motifs within each repeated unit is required for transcriptional activation of the COXIV promoter. High affinity binding of GABP to the COXIV promoter required both the DNA-binding GABP alpha subunit and the non-DNA-binding GABP beta subunit. Binding of the heteromeric GABP complex to sequences containing two GABP binding sites was shown to have a 10-20 fold greater affinity than to DNA sequences with a single site. GABP binding was necessary for promoter function of a 33-base pair fragment of the COXIV initiation region in transfected 3T3 or COS cells. Binding of GABP to the COXIV initiation region was also required for maximal transcriptional stimulation by an upstream Sp1 binding site. The initiation region was demonstrated to direct accurate transcriptional initiation in vitro, and mutations to the GABP binding sites affected not only transcriptional activity but also initiation site selection. These results indicate that the initiation region repeats of the COXIV promoter may function as GABP-dependent initiator motifs that position mRNA start sites in the absence of a TATA box or other promoter elements.	UNIV PENN,SCH VET MED,DEPT ANIM BIOL,BIOCHEM LAB,PHILADELPHIA,PA 19104	University of Pennsylvania					NATIONAL CANCER INSTITUTE [R37CA022762, R01CA022762] Funding Source: NIH RePORTER; NCI NIH HHS [CA-22762] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATCHISON ML, 1989, MOL CELL BIOL, V9, P2067, DOI 10.1128/MCB.9.5.2067; BASU A, 1993, J BIOL CHEM, V268, P4188; BASU A, 1991, J BIOL CHEM, V266, P15450; BEAUPAIN D, 1990, NUCLEIC ACIDS RES, V18, P6509, DOI 10.1093/nar/18.22.6509; BHAT KS, 1989, BIOCHEMISTRY-US, V28, P763, DOI 10.1021/bi00428a052; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1991, ARCH BIOCHEM BIOPHYS, V288, P97, DOI 10.1016/0003-9861(91)90169-J; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DROUIN J, 1992, MOL ENDOCRINOL, V6, P1299, DOI 10.1210/me.6.8.1299; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HARIHARAN N, 1989, GENE DEV, V3, P1789, DOI 10.1101/gad.3.11.1789; HONG D, 1993, EMBO J, V12, P501; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LAMARCO KL, 1989, GENE DEV, V3, P1372, DOI 10.1101/gad.3.9.1372; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAFER B, 1991, J BIOL CHEM, V266, P10989; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THOMPSON CC, 1991, SCIENCE, V253, P789; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; VARBASIUS JV, 1993, GENE DEV, V7, P380; VARBASIUS JV, 1991, MOL CELL BIOL, V11, P5631; VERRIJZER CP, 1992, MOL CELL BIOL, V12, P542, DOI 10.1128/MCB.12.2.542; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATANABE H, 1990, EMBO J, V9, P841, DOI 10.1002/j.1460-2075.1990.tb08181.x; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; YOGANATHAN T, 1992, BIOCHEM J, V287, P349, DOI 10.1042/bj2870349; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	49	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4381	4387						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308008				2022-12-27	WOS:A1994MW98900076
J	HARGROVE, MS; SINGLETON, EW; QUILLIN, ML; ORTIZ, LA; PHILLIPS, GN; OLSON, JS; MATHEWS, AJ				HARGROVE, MS; SINGLETON, EW; QUILLIN, ML; ORTIZ, LA; PHILLIPS, GN; OLSON, JS; MATHEWS, AJ			HIS(64)(E7)-]TYR APOMYOGLOBIN AS A REAGENT FOR MEASURING RATES OF HEMIN DISSOCIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; SITE-DIRECTED MUTAGENESIS; HUMAN HEMOGLOBIN; SYNTHETIC GENE; BINDING; MECHANISM; DISORDER; RESIDUE	To develop an assay for hemin dissociation, His(64)(E7) was replaced by Tyr in sperm whale myoglobin producing a holoprotein with a distinct green color due to an intense absorption band at 600 nm. Val(6)8(E11) was replaced by Phe in the same protein to increase its stability. When excess Tyr(64)-Val(68) apoglobin is mixed with either metmyoglobin or methemoglobin, the solution turns from brown to green, and the absorbance changes can be used to measure complete time courses for hemin dissociation from either holoprotein. This assay has been used to measure rates of hemin dissociation from native metmyoglobin, four myoglobin mutants (Ala(64)(E7), Ala(68)(E11), Phe(68)(E11), and Glu(45)(CD3)), native methemoglobin, valence hybrid hemoglobins, and two mutant hemoglobins ((alpha(Gly-E7)beta(native))(2), and (alpha(native)beta(Gly-E7))(2)). Two kinetic phases were observed for hemin dissociation from native human hemo-globin at pH 7.0 and 37 degrees C. Valence and mutant hybrid hemoglobins were used to assign the faster phase (k = 7.8 +/- 2.0 h(-1)) to hemin dissociation from ferric beta subunits and the slower (k = 0.6 +/- 0.15 h(-1)) to dissociation from (alpha subunits. The corresponding rate for wild-type metmyoglobin 0.007 +/- 0.004 h(-1).	RICE UNIV, WM KECK CTR COMP BIOL, HOUSTON, TX 77251 USA; SOMATOGEN INC, BOULDER, CO 80301 USA	Rice University	HARGROVE, MS (corresponding author), RICE UNIV, DEPT BIOCHEM & CELL BIOL, HOUSTON, TX 77251 USA.		ortiz, luis a/H-9851-2013	ortiz, luis a/0000-0003-4510-7066; Olson, John/0000-0002-0760-5403	NIAMS NIH HHS [AR 40252] Funding Source: Medline; NIGMS NIH HHS [GM-08280, GM-35649] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035649, T32GM008280] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOJULA HS, 1986, BIOCHEM J, V237, P613, DOI 10.1042/bj2370613; Ascoli F, 1981, Methods Enzymol, V76, P72; BANERJEE R, 1962, BIOCHIM BIOPHYS ACTA, V64, P368, DOI 10.1016/0006-3002(62)90746-1; BANERJEE R, 1962, BIOCHIM BIOPHYS ACTA, V64, P385, DOI 10.1016/0006-3002(62)90747-3; BANERJEE R, 1962, BIOCHEM BIOPH RES CO, V8, P114, DOI 10.1016/0006-291X(62)90247-4; BELLELLI A, 1993, J BIOL CHEM, V268, P4742; BELLELLI A, 1990, J BIOL CHEM, V265, P18898; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUNN HF, 1968, J BIOL CHEM, V243, P465; BUNN HF, 1986, HEMOGLOBIN MOL GENET, P634; CARVER TE, 1992, J BIOL CHEM, V267, P14443; COLETTA M, 1985, J BIOL CHEM, V260, P4151; EGEBERG KD, 1990, BIOCHEMISTRY-US, V29, P9783, DOI 10.1021/bi00494a004; EGEBERG KD, 1990, J BIOL CHEM, V265, P11788; GIACOMETTI GM, 1977, J BIOL CHEM, V252, P7447; GIBSON QH, 1963, J BIOL CHEM, V238, P1384; GIBSON QH, 1960, BIOCHEM J, V77, P328, DOI 10.1042/bj0770328; LAMAR GN, 1984, J AM CHEM SOC, V106, P6395, DOI 10.1021/ja00333a050; LIGHT WR, 1987, J BIOL CHEM, V262, P46; LIGHT WR, 1987, THESIS WM RICE U; MATHEWS AJ, 1991, J BIOL CHEM, V266, P21631; MURPHY MRN, 1985, STRUCTURE BEEF LIVER; NAGAI K, 1987, NATURE, V329, P858, DOI 10.1038/329858a0; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; Riggs A., 1981, Methods in Enzymology, V76, P5; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; SMERDON SJ, 1993, BIOCHEMISTRY-US, V32, P5132, DOI 10.1021/bi00070a023; SMITH ML, 1984, FEBS LETT, V169, P147, DOI 10.1016/0014-5793(84)80307-5; SMITH ML, 1991, P NATL ACAD SCI USA, V88, P882, DOI 10.1073/pnas.88.3.882; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; TAME J, 1991, J MOL BIOL, V218, P761, DOI 10.1016/0022-2836(91)90264-7; TOMODA A, 1978, J BIOL CHEM, V253, P7415; Vandegriff K D, 1992, Biotechnol Genet Eng Rev, V10, P403; WINTERBOURN CC, 1977, BIOCHEM J, V165, P141, DOI 10.1042/bj1650141	36	205	209	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4207	4214						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307983				2022-12-27	WOS:A1994MW98900049
J	MORIMOTO, BH; KOSHLAND, DE				MORIMOTO, BH; KOSHLAND, DE			CONDITIONAL ACTIVATION OF CAMP SIGNAL-TRANSDUCTION BY PROTEIN-KINASE-C - THE EFFECT OF PHORBOL ESTERS ON ADENYLYL-CYCLASE IN PERMEABILIZED AND INTACT-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; NEUROSECRETORY POTENTIATION; HUMAN-PLATELETS; CYCLIC-AMP; PHOSPHORYLATION; EXPRESSION; LINE; IDENTIFICATION; STIMULATION; INHIBITION	To understand the convergence of cAMP and protein kinase C signal transduction, adenylyl cyclase isozyme identification and biochemical studies were performed on the HT4 neural cell line. In HT4 cells, basal cAMP production by adenylyl cyclase types I and VI were unaffected by phorbol esters, nor did phorbol esters have any effect on forskolin-induced cAMP production. However, phorbol esters synergistically increased cAMP production when adrenaline receptors were simultaneously activated, indicating a conditional activation of cAMP production by phorbol esters. A permeabilized cell preparation was used to analyze the mechanism by which phorbol esters were affecting cAMP production. This preparation enables G-proteins to be activated directly by GTP gamma S or bacterial toxins. In the permeabilized cell preparation, phorbol esters enhanced cAMP produced by GTP gamma S-activated G-protein, A stimulatory G protein pathway may be involved since phorbol esters synergistically increased cAMP production by cholera toxin, yet had no effect on that produced by pertussis toxin. In this cell culture model, phorbol esters stimulate cAMP production only when some component of the cAMP cascade is simultaneously activated. Moreover, the pattern of modulation suggests that protein kinase C acts on an activated component of the second messenger system, such as the G-protein or the coupling of the G protein with adenylyl cyclase, and not on the resting state of the protein components.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley	MORIMOTO, BH (corresponding author), PURDUE UNIV, DEPT CHEM, W LAFAYETTE, IN 47907 USA.				NIDDK NIH HHS [DK09765] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009765, R37DK009765] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BROOKER G, 1986, J CYCLIC NUCL PROT, V11, P113; BUSHFIELD M, 1990, BIOCHEM J, V268, P449, DOI 10.1042/bj2680449; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOI EJ, 1993, BIOCHEMISTRY-US, V32, P1891, DOI 10.1021/bi00059a001; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FISHMAN PH, 1990, G PROTEINS, P127; GUSOVSKY F, 1991, MOL PHARMACOL, V39, P124; HOUSLAY MD, 1991, EUR J BIOCHEM, V195, P9, DOI 10.1111/j.1432-1033.1991.tb15671.x; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEVITZKI A, 1990, G PROTEINS MEDIATORS, P1; MORIMOTO BH, 1991, P NATL ACAD SCI USA, V88, P10835, DOI 10.1073/pnas.88.23.10835; MORIMOTO BH, 1990, P NATL ACAD SCI USA, V87, P3518, DOI 10.1073/pnas.87.9.3518; MORIMOTO BH, 1990, NEURON, V5, P875, DOI 10.1016/0896-6273(90)90347-I; NAGHSHINEH S, 1986, J BIOL CHEM, V261, P4534; PEPPERS SC, 1986, J BIOL CHEM, V261, P4665; SIMMOTEIT R, 1991, FEBS LETT, V285, P99, DOI 10.1016/0014-5793(91)80734-K; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; UI M, 1990, G PROTEINS, P45; WHITTEMORE SR, 1991, J NEUROSCI RES, V28, P156, DOI 10.1002/jnr.490280203; WIENER E, 1989, J BIOL CHEM, V264, P4324; YATOMI Y, 1992, EUR J BIOCHEM, V205, P1003, DOI 10.1111/j.1432-1033.1992.tb16867.x; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604	32	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4065	4069						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307964				2022-12-27	WOS:A1994MW98900028
J	SPALDING, TA; BIRDSALL, NJM; CURTIS, CAM; HULME, EC				SPALDING, TA; BIRDSALL, NJM; CURTIS, CAM; HULME, EC			ACETYLCHOLINE MUSTARD LABELS THE BINDING-SITE ASPARTATE IN MUSCARINIC ACETYLCHOLINE-RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLETHYLCHOLINE MUSTARD; IRREVERSIBLE BINDING; ANTAGONIST BINDING; GUINEA-PIG; MEMBRANES; CELLS	Acetylcholine mustard (AChM) is an analogue of acetylcholine (ACh) in which the onium headgroup is replaced by a chemically reactive aziridinium moiety. AChM aziridinium has agonist activity, but, having bound, reacts with and blocks the muscarinic receptor (mAChR) binding site. Purified mAChRs from rat forebrain have been specifically labeled with [H-3]AChM. The linkage formed is cleaved by hydroxylamine, is found within cyanogen bromide (CNBr) peptides with molecular masses of approximately 2.4 and 3.9 kDa, and is close to a disulfide bonded cysteine. Edman degradation reveals a site of label attachment 26 residues C-terminal to a CNBr cleavage site. As in the case of the alkylating antagonist analogue [H-3]propylbenzilylcholine mustard, these findings indicate that a conserved aspartic acid residue in transmembrane helix 3 of the mAChRs, corresponding to Asp-105 (m1 sequence), is the site of label attachment.	MRC,NATL INST MED RES,DIV PHYS BIOCHEM,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research								BAKER SP, 1986, MOL PHARMACOL, V30, P411; BARLOW RB, 1964, INTRODUCTION CHEMICA, P185; BOLDEN CP, 1990, J PHARMACOL EXP THER, V254, P136; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; CASSEL D, 1976, BIOCHIM BIOPHYS ACTA, V452, P538, DOI 10.1016/0005-2744(76)90206-0; CURTIS CAM, 1989, J BIOL CHEM, V264, P489; HILF G, 1992, EUR J PHARM-MOLEC PH, V225, P245, DOI 10.1016/0922-4106(92)90026-R; HULME EC, 1990, BIOCHEM SOC T, V18, P440, DOI 10.1042/bst0180440; JACKSON CH, 1972, J MED CHEM, V15, P1183, DOI 10.1021/jm00281a026; KURTENBACH E, 1990, J BIOL CHEM, V265, P13702; LAZARENO S, 1993, LIFE SCI, V52, P449, DOI 10.1016/0024-3205(93)90301-I; MEYER EM, 1987, J NEUROCHEM, V48, P477, DOI 10.1111/j.1471-4159.1987.tb04117.x; Page K. M., 1993, Life Sciences, V52, P560, DOI 10.1016/0024-3205(93)90336-2; ROBINSON DA, 1975, BRIT J PHARMACOL, V53, P363, DOI 10.1111/j.1476-5381.1975.tb07372.x; SPALDING TA, 1993, LIFE SCI, V52, P561; UCHIYAMA H, 1990, J NEUROCHEM, V54, P1870, DOI 10.1111/j.1471-4159.1990.tb04885.x; WHEATLEY M, 1987, CELLULAR MOL BASIS C, P91; WONG SKF, 1988, J BIOL CHEM, V263, P7925	18	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4092	4097						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307968				2022-12-27	WOS:A1994MW98900032
J	KLEINBERGERDORON, N; KANNER, BI				KLEINBERGERDORON, N; KANNER, BI			IDENTIFICATION OF TRYPTOPHAN RESIDUES CRITICAL FOR THE FUNCTION AND TARGETING OF THE GAMMA-AMINOBUTYRIC-ACID TRANSPORTER (SUBTYPE-A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; DOPAMINE TRANSPORTER; GLYCINE TRANSPORTER; GABA TRANSPORTER; MOUSE-BRAIN; NEUROTRANSMITTER TRANSPORTERS; PLASMA-MEMBRANE; XENOPUS OOCYTES; BETA-ALANINE; CLONING	The gamma-aminobutyric acid transporter is localized in nerve terminals. It catalyzes coupled electrogenic translocation of the neurotransmitter with two or three sodium ions and one chloride ion. The transporter contains 599 amino acids and 12 putative membrane spanning alpha-helices. It is the first described member of a neurotransmitter transporter superfamily. Using site-directed mutagenesis we have investigated the role of all 10 tryptophan residues predicted to reside in these helices. All 10 have been changed to serine as well as to leucine residues. Expression of mutant cDNAs in which the tryptophans, located in positions 68, 222, and 230, are replaced by either of these two amino acids reveals that they are severely impaired in gamma-aminobutyric acid transport. Mutants in which a phenylalanine or a tyrosine residue is introduced, at either position 68 or 230, are active. On the other hand, at the 222 position replacement of the tryptophan by the aromatic amino acids results in inactive transport. After prelabeling of the proteins with [S-35]methionine, immunoprecipitation of mutant transporters indicates that their expression levels are similar to those of the wild type. Reconstitution experiments, aimed to reveal the activity of transporter molecules not apparent in the plasma membrane, indicate that the lack of activity of the W230S transporter in intact cells is by and large due to its inefficient targeting to the plasma membrane. Tryptophan residues 68 and 222 appear to be required for the intrinsic activity of the transporter. Based on several observations, including one that tryptophan residue 222 is conserved in all amino acid transporter members of the superfamily, but not in those transporting biogenic amines, we hypothesize that the pi electrons of this tryptophan could be involved in the binding of the amino group of these neurotransmitters.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT BIOCHEM,POB 1172,IL-91010 JERUSALEM,ISRAEL	Hebrew University of Jerusalem					NINDS NIH HHS [NS 16708] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016708] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENNETT JP, 1974, LIFE SCI, V15, P1046; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BORDEN LA, 1992, J BIOL CHEM, V267, P21098; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARK JA, 1992, NEURON, V9, P337, DOI 10.1016/0896-6273(92)90172-A; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; FOLCH J, 1957, J BIOL CHEM, V226, P497; FREMEAU RT, 1992, NEURON, V89, P7189; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; GUIMBAL C, 1993, J BIOL CHEM, V268, P8418; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KANNER BI, 1989, BIOCHEMISTRY-US, V28, P3722, DOI 10.1021/bi00435a015; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU QR, 1993, J BIOL CHEM, V268, P2106; LIU QR, 1992, P NATL ACAD SCI USA, V89, P12145, DOI 10.1073/pnas.89.24.12145; LIU QR, 1992, FEBS LETT, V305, P110, DOI 10.1016/0014-5793(92)80875-H; LOEWENTHAL R, 1992, J MOL BIOL, V224, P759, DOI 10.1016/0022-2836(92)90560-7; LOEWENTHAL R, 1991, BIOCHEMISTRY-US, V30, P6775, DOI 10.1021/bi00241a021; LOPEZCORCUERA B, 1992, J BIOL CHEM, V267, P17491; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; RADIAN R, 1986, J BIOL CHEM, V261, P5437; RADIAN R, 1990, J NEUROSCI, V10, P1319; RADIAN R, 1985, J BIOL CHEM, V260, P1859; SCHLOSS P, 1992, FEBS LETT, V307, P76, DOI 10.1016/0014-5793(92)80905-V; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; USDIN TB, 1991, P NATL ACAD SCI USA, V88, P11168, DOI 10.1073/pnas.88.24.11168; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649	45	73	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3063	3067						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300640				2022-12-27	WOS:A1994MV43200100
J	BAER, ME; SANCAR, GB				BAER, ME; SANCAR, GB			THE ROLE OF CONSERVED AMINO-ACIDS IN SUBSTRATE-BINDING AND DISCRIMINATION BY PHOTOLYASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI DNA PHOTOLYASE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; PYRIMIDINE DIMERS; GEL-ELECTROPHORESIS; ACTION MECHANISM; 2ND CHROMOPHORE; PHR1 PHOTOLYASE; IDENTIFICATION; PROTEINS	DNA photolyases catalyze the light-dependent repair of pyrimidine dimers in DNA. We have utilized chemical modification and site-directed mutagenesis to probe the interactions involved in substrate recognition by the yeast photolyase Phr1. Lys517 was protected from reductive methylation in the presence of substrate, but not in its absence, and the specific and nonspecific association constants for substrate binding by Phr1 (Lys517 --> Ala) were decreased 10-fold. These results establish a role for Lys517 in substrate binding. Mutations at Arg507, Lys463, and Trp387 reduced both the overall affinity for substrate and substrate discrimination. Sites of altered interactions in ES complexes were identified by methylation and ethylation interference techniques. Interaction with the base immediately 3' to the dimer was altered in the Phr1 (Lys517 --> Ala).DNA complex, whereas interactions with the phosphate and base immediately 5' to the dimer were reduced when Phr1 (Arg507 --> Ala) bound substrate. Multiple interactions 5' and 3' to the dimer were perturbed in complexes containing Phr1 (Trp387 --> Ala) or Phr1 (Lys463 --> Ala). In addition the quantum yield for dimer photolysis by Phr1 (Trp387 --> Ala) was reduced 3-fold. The locations of these mutations establish that a portion of the DNA binding domain is comprised of residues in the highly conserved carboxyl-terminal half of the enzyme.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NIGMS NIH HHS [GM35123] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035123] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAER M, 1989, MOL CELL BIOL, V9, P4777, DOI 10.1128/MCB.9.11.4777; CABACUNGAN JC, 1982, ANAL BIOCHEM, V124, P272, DOI 10.1016/0003-2697(82)90038-0; FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P301, DOI 10.1016/0968-0004(87)90146-0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; HARM H, 1968, MUTAT RES, V6, P355, DOI 10.1016/0027-5107(68)90053-5; HASELTINE WA, 1980, NATURE, V285, P634, DOI 10.1038/285634a0; HELENE C, 1981, CRC CR REV BIOCH MOL, V10, P213, DOI 10.3109/10409238109113600; HUSAIN I, 1987, J BIOL CHEM, V262, P13188; JOHNSON JL, 1988, P NATL ACAD SCI USA, V85, P2046, DOI 10.1073/pnas.85.7.2046; JORNS MS, 1984, BIOCHEMISTRY-US, V23, P2673, DOI 10.1021/bi00307a021; KIENER A, 1989, J BIOL CHEM, V264, P13880; KIM ST, 1991, BIOCHEMISTRY-US, V30, P8623, DOI 10.1021/bi00099a019; KIM ST, 1992, P NATL ACAD SCI USA, V89, P900, DOI 10.1073/pnas.89.3.900; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LI YF, 1990, BIOCHEMISTRY-US, V29, P5698, DOI 10.1021/bi00476a009; MALHOTRA K, 1992, J BIOL CHEM, V267, P2909; MYLES GM, 1987, NUCLEIC ACIDS RES, V15, P1227, DOI 10.1093/nar/15.3.1227; PEARLMAN DA, 1985, SCIENCE, V227, P1304, DOI 10.1126/science.3975615; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; RUPERT CS, 1962, J GEN PHYSIOL, V45, P725, DOI 10.1085/jgp.45.4.725; RUPERT CS, 1962, J GEN PHYSIOL, V45, P703, DOI 10.1085/jgp.45.4.703; SANCAR GB, 1987, J BIOL CHEM, V262, P15457; SANCAR GB, 1985, J BACTERIOL, V161, P769, DOI 10.1128/JB.161.2.769-771.1985; SANCAR GB, 1988, GENE, V64, P87, DOI 10.1016/0378-1119(88)90483-0; SANCAR GB, 1985, NUCLEIC ACIDS RES, V13, P8231, DOI 10.1093/nar/13.22.8231; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; SANCAR GB, 1987, J BIOL CHEM, V262, P478; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schulz G. E., 1979, PRINCIPLES PROTEIN S; Segel I.H., 1975, ENZYME KINETICS; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; TAKEDA Y, 1986, J BIOL CHEM, V261, P8606; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P8858, DOI 10.1021/bi00489a049; TERRY BJ, 1983, J BIOL CHEM, V258, P9820; WITMER MR, 1989, J AM CHEM SOC, V111, P9261; YASUHIRA S, 1992, J BIOL CHEM, V267, P25644	40	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16717	16724						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344951				2022-12-27	WOS:A1993LQ33600090
J	CHAWLA, A; LAZAR, MA				CHAWLA, A; LAZAR, MA			INDUCTION OF REV-ERBA-ALPHA, AN ORPHAN RECEPTOR ENCODED ON THE OPPOSITE STRAND OF THE ALPHA-THYROID HORMONE-RECEPTOR GENE, DURING ADIPOCYTE DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER BINDING-PROTEIN; PREADIPOCYTE CELL-LINE; TUMOR-NECROSIS-FACTOR; ADIPOSE CONVERSION; MESSENGER-RNA; RETINOIC ACID; 3T3-L1 CELLS; C-FOS; EXPRESSION; TRANSCRIPTION	Rev-ErbAalpha (Rev-Erb) is a nuclear hormone receptor-related transcriptional activator that is encoded on the noncoding strand of the alpha-thyroid hormone receptor (TR) gene. The similarities between Rev-Erb and receptors for differentiating agents, as well as the abundance of Rev-Erb mRNA in fat, led us to study Rev-Erb gene expression during adipogenesis. Remarkably, Rev-Erb mRNA levels increased dramatically during the differentiation of 3T3-L1 cells into adipocytes. Rev-Erb was similarly induced in the related 3T3-F442A cell line but not in nondifferentiating 3T3-C2 cells. The time course of Rev-Erb induction was similar to that of C/EBPalpha, an important transcriptional regulator in adipocytes, and Rev-Erb mRNA was superinduced by cycloheximide. Nuclear run-on assays indicated that an increased rate of Rev-Erb mRNA synthesis accounted for the increased steady state mRNA levels; the half-life of Rev-Erb mRNA was indistinguishable in preadipocytes and adipocytes. Treatment of preadipocytes with retinoic acid inhibited adipocyte differentiation and also prevented Rev-Erb induction. Thus, there is a correlation between Rev-Erb gene expression and differentiation, and transcriptional regulation by Rev-Erb could play an important role in the generation and/or maintenance of the adipocyte phenotype. Interestingly, and possibly related to the overlap between the Rev-Erb gene and the exon specific for TRalpha2, the induction of Rev-Erb was also associated with a 3-fold increase in the ratio of TRalpha1 to TRalpha2 mRNA levels, indicating that Rev-Erb expression has the potential to modulate adipocyte gene expression by multiple mechanisms.	UNIV PENN,SCH MED,DEPT MED,DIV ENDOCRINOL DIABET & METAB,611 CRB,422 CURIE BLVD,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania			Lazar, Mitchell A/AAF-3738-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045586] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45586] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACHMANN K, 1985, ENDOCRINOLOGY, V117, P1084, DOI 10.1210/endo-117-3-1084; BENBROOK D, 1987, SCIENCE, V238, P788, DOI 10.1126/science.3672126; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; COOK KS, 1985, J CELL BIOL, V100, P514, DOI 10.1083/jcb.100.2.514; CRONRATH CM, 1987, ENDOCRINOLOGY, V120, P43, DOI 10.1210/endo-120-1-43; DAVIS KD, 1992, J BIOL CHEM, V267, P3185; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DISTEL RJ, 1992, J BIOL CHEM, V267, P5937; ELKS ML, 1985, ENDOCRINOLOGY, V117, P947, DOI 10.1210/endo-117-3-947; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; GHARBICHIHI J, 1991, HORM METAB RES, V23, P423, DOI 10.1055/s-2007-1003717; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KURIHARCUCH W, 1982, DIFFERENTIATION, V23, P164, DOI 10.1111/j.1432-0436.1982.tb01279.x; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; LAZAR MA, 1990, J BIOL CHEM, V265, P12859; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; LAZAR MA, 1991, ENDOCRIN METAB CLIN, V20, P681, DOI 10.1016/S0889-8529(18)30239-1; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; MUNROE SH, 1991, J BIOL CHEM, V266, P22083; RON D, 1992, J CLIN INVEST, V89, P223, DOI 10.1172/JCI115566; SATO M, 1980, BIOCHEM BIOPH RES CO, V95, P1839, DOI 10.1016/S0006-291X(80)80113-6; SEAGRAVES WA, 1990, GENE DEV, V4, P204; SESTOFT L, 1980, CLIN ENDOCRINOL, V13, P489, DOI 10.1111/j.1365-2265.1980.tb03415.x; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; STONE RL, 1990, DIFFERENTIATION, V45, P119, DOI 10.1111/j.1432-0436.1990.tb00465.x; TEBOUL M, 1991, J RECEPTOR RES, V11, P865, DOI 10.3109/10799899109064684; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WILLIAMS PM, 1992, MOL ENDOCRINOL, V6, P1135, DOI 10.1210/me.6.7.1135	46	175	181	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16265	16269						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344913				2022-12-27	WOS:A1993LQ33600029
J	DOHERTY, RD; KANE, PM				DOHERTY, RD; KANE, PM			PARTIAL ASSEMBLY OF THE YEAST VACUOLAR H+-ATPASE IN MUTANTS LACKING ONE SUBUNIT OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; VESICLE PROTON PUMP; PRE-GOLGI DEGRADATION; SACCHAROMYCES-CEREVISIAE; ADENOSINE-TRIPHOSPHATASE; TRANSLOCATING ATPASE; MUTATIONAL ANALYSIS; GENE-PRODUCT; COMPLEX; ACIDIFICATION	Partial assembly of the peripheral and integral membrane sectors of the yeast vacuolar H+-ATPase has been detected in mutants lacking one subunit of the enzyme. Assembled complexes of the vacuolar H+-ATPase could be immunoprecipitated from biosynthetically labeled wild-type cells using monoclonal antibodies specific for the 69- and 60-kDa subunits of the enzyme, and assembled membrane (V0) sectors could be immunoprecipitated using a monoclonal antibody against the 100-kDa subunits. Parallel immunoprecipitations from mutant cells lacking one subunit of the vacuolar H+-ATPase revealed different degrees of assembly depending on the subunit that was missing. Partially assembled complexes of the peripheral subunits could also be detected in a soluble, cytoplasmic fraction from wild-type and mutant cells following glycerol gradient fractionation. The results indicate that the peripheral (V1) sector and integral membrane (V0) sectors of the yeast vacuolar H+-ATPase can assemble independently. The 69-, 60-, and 27-kDa subunits all appear to be necessary for any assembly of the V1 sector to occur, but these subunits and the 32-kDa subunit can assemble into a complex in the absence of the 42-kDa peripheral subunit. The implications of the results for the structure and assembly of the yeast vacuolar H+-ATPase are discussed.	SUNY HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,750 E ADAMS ST,SYRACUSE,NY 13210; COLL WILLIAM & MARY,DEPT CHEM,WILLIAMSBURG,VA 23185	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; William & Mary								ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; ADACHI I, 1990, J BIOL CHEM, V265, P967; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ANRAKU Y, 1991, NEW ERA BIOENERGETIC, P131; ARAI H, 1988, J BIOL CHEM, V263, P8796; BAUERLE CM, 1993, IN PRESS J BIOL CHEM; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; FOURY, 1990, J BIOL CHEM, V0265; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HO MN, 1993, J BIOL CHEM, V268, P221; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; NELSON H, 1989, J BIOL CHEM, V264, P5313; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; OHYA Y, 1991, J BIOL CHEM, V266, P13971; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; SABOLIC I, 1992, J CELL BIOL, V119, P111, DOI 10.1083/jcb.119.1.111; Sherman F., 1982, METHODS YEAST GENETI; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; WANG ZQ, 1990, J BIOL CHEM, V265, P21957; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737	37	100	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16845	16851						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344963				2022-12-27	WOS:A1993LQ33600107
J	GUPTA, SD; GAN, K; SCHMID, MB; WU, HC				GUPTA, SD; GAN, K; SCHMID, MB; WU, HC			CHARACTERIZATION OF A TEMPERATURE-SENSITIVE MUTANT OF SALMONELLA-TYPHIMURIUM DEFECTIVE IN APOLIPOPROTEIN N-ACYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE LIPOPROTEIN; ESCHERICHIA-COLI CHROMOSOME; GEOTRICHUM-CANDIDUM LIPASE; CDNA CLONING; TETRACYCLINE RESISTANCE; ENDOPLASMIC-RETICULUM; CYTOPLASMIC MEMBRANE; NUCLEOTIDE-SEQUENCE; MUREIN-LIPOPROTEIN; COPPER RESISTANCE	On screening 440 temperature-sensitive (ts) mutants of Salmonella typhimurium, a mutant strain SE5312 which accumulated apolipoprotein (ALP) at 42-degrees-C was identified. In vitro assay of apolipoprotein N-acyl-transferase activity indicated that the mutant cell envelope contained reduced activity as compared to the wild-type strain. Transduction with a Mud-P22 mapping set placed the ts mutation to 14-17 min region of the S. typhimurium chromosome. P22 transduction using transposon insertions in this region revealed a linkage of the ts mutation to cobD (6%), nag (8%), and corC68 (99%). The ts phenotype was complemented by a 2.3-kilobase EcoRI subclone derived from lambda-phage 170 of Kohara's bank of Escherichia coli. Restriction enzyme analysis of the cloned DNA revealed that this 2.3-kilobase EcoRI fragment included the copper transport (cutE) gene in E. coli. The mutant strain SE5312 was copper-sensitive at 30-degrees-C, and the complementing clone conferred copper resistance and restored the ALP N-acyltransferase activity in the mutant cell. Wild-type strain of S. typhimurium harboring this clone exhibited elevated levels of ALP N-acyltransferase activity. These results suggest that the cloned gene encodes the ALP N-acyltransferase. Upon shift to the non-permissive temperature, the viability of the mutant cells decreased, and the mutant cells assumed anomalous morphology. Temperature-resistant revertants could be readily isolated, and a subset of tr revertants contained no detectable lipoprotein. A lpp=Tn10 derivative of the mutant SE5312 was also temperature-resistant. These observations suggest that ALP N-acyltransferase is essential for the growth and viability of S. typhimurium, and this requirement is decreased in the absence of major outer membrane lipoprotein.	UNIFORMED SERV UNIV HLTH SCI,DEPT MICROBIOL,BETHESDA,MD 20814; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Uniformed Services University of the Health Sciences - USA; Princeton University					NIGMS NIH HHS [GM 28811] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028811] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARPAGAUS M, 1991, J BIOL CHEM, V266, P6966; ASAI Y, 1989, J BACTERIOL, V171, P6867, DOI 10.1128/jb.171.12.6867-6869.1989; BENSON NR, 1992, J BACTERIOL, V174, P1673, DOI 10.1128/jb.174.5.1673-1681.1992; BOCHNER BR, 1980, J BACTERIOL, V143, P926, DOI 10.1128/JB.143.2.926-933.1980; BOUVIER J, 1991, J BACTERIOL, V173, P5523, DOI 10.1128/jb.173.17.5523-5531.1991; BRAUN V, 1975, BIOCHIM BIOPHYS ACTA, V415, P335, DOI 10.1016/0304-4157(75)90013-1; CHA JS, 1991, P NATL ACAD SCI USA, V88, P8915, DOI 10.1073/pnas.88.20.8915; CHAN RK, 1972, VIROLOGY, V50, P883, DOI 10.1016/0042-6822(72)90442-4; COLLET C, 1990, MOL BIOL EVOL, V7, P9; FILIP C, 1973, J BACTERIOL, V115, P717, DOI 10.1128/JB.115.3.717-722.1973; GAN K, 1993, J BIOL CHEM, V268, P16544; GIBSON MM, 1991, MOL MICROBIOL, V5, P2753, DOI 10.1111/j.1365-2958.1991.tb01984.x; GRABAU C, 1992, J BACTERIOL, V174, P2138, DOI 10.1128/JB.174.7.2138-2144.1992; GUPTA SD, 1991, FEMS MICROBIOL LETT, V78, P37; GUPTA SD, 1991, J BIOL CHEM, V266, P9983; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HAYASHI S, 1985, J BACTERIOL, V161, P949, DOI 10.1128/JB.161.3.949-954.1985; HIROTA Y, 1977, P NATL ACAD SCI USA, V74, P1417, DOI 10.1073/pnas.74.4.1417; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; KANEGASAKI S, 1979, EUR J BIOCHEM, V95, P287, DOI 10.1111/j.1432-1033.1979.tb12964.x; KAWAGUCHI Y, 1989, NATURE, V341, P164, DOI 10.1038/341164a0; KISSEL JA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P227, DOI 10.1016/0005-2760(89)90201-4; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAI JS, 1981, J BACTERIOL, V145, P657, DOI 10.1128/JB.145.1.657-660.1981; LAI JS, 1980, J BIOL CHEM, V255, P5384; MARCUS H, 1990, FEMS MICROBIOL LETT, V68, P149, DOI 10.1016/0378-1097(90)90141-C; MATSUSHIMA M, 1991, FEBS LETT, V293, P37, DOI 10.1016/0014-5793(91)81147-Z; MELLANO MA, 1988, J BACTERIOL, V170, P2879, DOI 10.1128/jb.170.6.2879-2883.1988; OVNIC M, 1991, GENOMICS, V11, P956, DOI 10.1016/0888-7543(91)90020-F; RIDDLES PW, 1991, GENE, V108, P289, DOI 10.1016/0378-1119(91)90448-K; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; ROGERS SD, 1991, J BACTERIOL, V173, P6742, DOI 10.1128/jb.173.21.6742-6748.1991; ROTERING H, 1984, FEMS MICROBIOL LETT, V22, P61; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMID MB, 1989, GENETICS, V123, P625; SHANABRUCH WG, 1981, J BACTERIOL, V147, P827, DOI 10.1128/JB.147.3.827-835.1981; SHIMADA Y, 1989, J BIOCHEM-TOKYO, V106, P383, DOI 10.1093/oxfordjournals.jbchem.a122862; SHIMADA Y, 1990, J BIOCHEM-TOKYO, V107, P703, DOI 10.1093/oxfordjournals.jbchem.a123112; TOKUNAGA M, 1982, P NATL ACAD SCI-BIOL, V79, P2255, DOI 10.1073/pnas.79.7.2255; YAMAGATA H, 1982, J BACTERIOL, V152, P1163; YAMAGUCHI K, 1988, J BACTERIOL, V170, P3747, DOI 10.1128/jb.170.8.3747-3749.1988; ZHANG WY, 1992, J BIOL CHEM, V267, P19631; ZSCHUNKE F, 1991, BLOOD, V78, P506	46	62	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16551	16556						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344936				2022-12-27	WOS:A1993LQ33600068
J	ANDERSON, PJ				ANDERSON, PJ			THE MODIFICATION OF HEMOGLOBIN BY CITRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYHEMOGLOBIN-S; ALPHA-CHAINS; IDENTIFICATION; BINDING; SITE	Citrate, when activated by a water-soluble carbodiimide, covalently modifies hemoglobin. At pH values near neutrality, complete modification of the N-terminal valine residues of alpha- and beta-globin chains can be accomplished with a high degree of specificity. These groups react at a much more rapid rate than a slower reacting set of functional groups. Modification of hemoglobin with citrate alters the oxygen affinity of the protein. Although the p50 is not changed, the cooperative nature of oxygen binding is greatly decreased. Hemoglobin S modified with citrate is more soluble than unmodified hemoglobin S. The time taken for deoxygenated hemoglobin S to come out of solution in concentrated phosphate solutions is increased by citrate modification.			ANDERSON, PJ (corresponding author), UNIV OTTAWA,DEPT BIOCHEM,OTTAWA K1H 8M5,ONTARIO,CANADA.							ADACHI K, 1987, J BIOL CHEM, V262, P10470; ADACHI K, 1979, J BIOL CHEM, V254, P7765; ANDERSON PJ, 1970, BIOCHEM J, V117, P292; BENESCH RE, 1988, BIOCHEM BIOPH RES CO, V156, P9, DOI 10.1016/S0006-291X(88)80798-8; BERBERS GAM, 1991, J LAB CLIN MED, V117, P157; Carraway K L, 1972, Methods Enzymol, V25, P616, DOI 10.1016/S0076-6879(72)25060-1; CHATTERJEE R, 1986, J BIOL CHEM, V261, P9929; FANTL WJ, 1987, BIOCHEMISTRY-US, V26, P5755, DOI 10.1021/bi00392a026; FREEDMAN RB, 1968, BIOCHEM J, V108, P383, DOI 10.1042/bj1080383; GILLES MA, 1990, ANAL BIOCHEM, V184, P244, DOI 10.1016/0003-2697(90)90675-Y; HOARE DG, 1967, J BIOL CHEM, V242, P2447; KAVANAUGH MP, 1988, BIOCHEMISTRY-US, V27, P1804, DOI 10.1021/bi00405a062; KLOTZ IM, 1981, SCIENCE, V213, P724, DOI 10.1126/science.7256275; KLOTZ IM, 1985, J BIOL CHEM, V260, P6215; LANG ME, 1990, OXYGEN TRANSPORT TIS, V12, P225; MEJILLANO MR, 1991, J BIOL CHEM, V266, P657; PERUTZ MF, 1980, J MOL BIOL, V138, P649, DOI 10.1016/S0022-2836(80)80022-2; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; SHIMIZU K, 1974, BIOCHEMISTRY-US, V13, P809, DOI 10.1021/bi00701a026; VANDEGRIFF KD, 1991, J BIOL CHEM, V266, P2697; VERBURG JG, 1992, J BIOL CHEM, V267, P3886	21	3	3	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15504	15509						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340379				2022-12-27	WOS:A1993LN30500030
J	POON, D; WEIL, PA				POON, D; WEIL, PA			IMMUNOPURIFICATION OF YEAST TATA-BINDING PROTEIN AND ASSOCIATED FACTORS - PRESENCE OF TRANSCRIPTION FACTOR-IIIB TRANSCRIPTIONAL ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SACCHAROMYCES-CEREVISIAE; POLYMERASE-III; FACTOR-TFIIIB; PURIFICATION; COACTIVATORS; ACTIVATION; ANTIBODIES; HOMOLOGY; ENCODES; COMPLEX	The TATA-binding proteins (TBP) from both human and Drosophila have been shown to exist in various distinct multiprotein complexes that are required, respectively, for transcription by all three RNA polymerases. In contrast, in vitro biochemical analyses have suggested that yeast TBP exists as a monomeric 27-kDa protein free in solution. We have examined the oligomerization state of yeast TBP and report here that yeast TBP, like human and Drosophila TBPs, is also stably associated with other proteins in vitro. Using anti-TBP antibodies we have immunopurified yeast TBP and associated factors (TBP-associated factors or TAFs). When this fraction was analyzed by SDS-polyacrylamide gel electrophoresis, polypeptides of approximate relative molecular size ranging from 170 to 60 kDa are prominently represented. Immunoblot analysis revealed that one of these TAFs, TAF70, corresponds to BRF1/TDS4/PCF4, a subunit of transcription factor (TF) IIIB. Furthermore, this highly purified TAF fraction can reconstitute polymerase III transcription when supplemented with purified RNA polymerase III and TFIIIC. Our data indicate that our TAF fraction contains TFIIIB transcription factor activity and that all the subunits of yeast TFIIIB are stably complexed with TBP.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Vanderbilt University								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COMAI L, 1992, CELL, V69, P685; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; HUET J, 1985, J BIOL CHEM, V260, P5304; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; KLEKAMP MS, 1986, J BIOL CHEM, V261, P2819; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; PARSONS MC, 1990, J BIOL CHEM, V265, P5095; POON D, 1991, MOL CELL BIOL, V11, P4809, DOI 10.1128/MCB.11.10.4809; POON D, 1993, J BIOL CHEM, V268, P5005; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAGGART AKP, 1992, CELL, V71; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	32	86	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15325	15328						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340360				2022-12-27	WOS:A1993LN30500001
J	WASHKO, PW; WANG, YH; LEVINE, M				WASHKO, PW; WANG, YH; LEVINE, M			ASCORBIC-ACID RECYCLING IN HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COULOMETRIC ELECTROCHEMICAL DETECTION; PERFORMANCE LIQUID-CHROMATOGRAPHY; DEHYDROASCORBIC ACID; DIABETES-MELLITUS; HYDROGEN-PEROXIDE; FREE-RADICALS; PLASMA; LEUKOCYTES; PROTECTION; SUPEROXIDE	Ascorbic acid (vitamin C) accumulation in activated human neutrophils is increased as much as 10-fold above the mM concentrations present in normal neutrophils. Internal concentrations as high as 14 mM are achieved when external vitamin is at physiologic concentration. The mechanism is by oxidation of external vitamin to dehydroascorbic acid, preferential transmembrane translocation of dehydroascorbic acid, and intracellular reduction to ascorbic acid within minutes. These data indicate that vitamin C accumulation is enhanced in activated human neutrophils and that human neutrophils utilize and recycle oxidized external vitamin C under physiologic conditions.	NIDDKD,CELL BIOL & BIOCHEM SECT,CELL BIOL & GENET LAB,BLDG 8,RM 415,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BABIOR BM, 1984, BLOOD, V64, P959; BAEHNER RL, 1977, BLOOD, V50, P327; BANERJEE A, 1982, ANN CLIN BIOCHEM, V19, P65, DOI 10.1177/000456328201900201; BERGSTEN P, 1990, J BIOL CHEM, V265, P2584; BIGLEY RH, 1974, J EXP MED, V139, P1084, DOI 10.1084/jem.139.5.1084; BLAKE DR, 1981, CLIN SCI, V61, P483, DOI 10.1042/cs0610483; COX BD, 1975, BIOCHEM MED METAB B, V12, P183, DOI 10.1016/0006-2944(75)90110-6; DHARIWAL KR, 1991, AM J CLIN NUTR, V54, P712, DOI 10.1093/ajcn/54.4.712; DHARIWAL KR, 1990, ANAL BIOCHEM, V189, P18, DOI 10.1016/0003-2697(90)90037-A; DRATH DB, 1974, INFECT IMMUN, V10, P1077, DOI 10.1128/IAI.10.5.1077-1083.1974; FANTONE JC, 1982, AM J PATHOL, V107, P397; HENDRY JM, 1964, CLIN CHIM ACTA, V9, P498, DOI 10.1016/0009-8981(64)90089-0; HORNIG D, 1971, CLIN CHIM ACTA, V32, P33, DOI 10.1016/0009-8981(71)90460-8; IRWIN MI, 1976, J NUTR, V106, P823; JENNINGS PE, 1987, DIABETES RES CLIN EX, V6, P151; KLEBANOFF SJ, 1978, NEUTROPHIL FUNCTION, P438; LIU TZ, 1982, CLIN CHEM, V28, P2225; Lunec J, 1985, Free Radic Res Commun, V1, P31, DOI 10.3109/10715768509056534; MILLER TE, 1969, J BACTERIOL, V98, P949, DOI 10.1128/JB.98.3.949-955.1969; MRTENSSON J, 1991, P NATL ACAD SCI USA, V88, P4656, DOI 10.1073/pnas.88.11.4656; NISHIKIMI M, 1975, BIOCHEM BIOPH RES CO, V63, P463, DOI 10.1016/0006-291X(75)90710-X; OHNO Y, 1985, J BIOL CHEM, V260, P8438; OKAMURA M, 1980, CLIN CHIM ACTA, V103, P259; Ralli EP, 1938, J CLIN INVEST, V17, P765, DOI 10.1172/JCI101006; ROOS D, 1980, AGENTS ACTIONS, V10, P528, DOI 10.1007/BF02024158; SALIN ML, 1975, J CLIN INVEST, V56, P1319, DOI 10.1172/JCI108208; SAUBERLICH HE, 1975, ANN NY ACAD SCI, V258, P438, DOI 10.1111/j.1749-6632.1975.tb29302.x; SHILOTRI PG, 1977, J NUTR, V107, P1513, DOI 10.1093/jn/107.8.1513; SHILOTRI PG, 1977, AM J CLIN NUTR, V30, P1077, DOI 10.1093/ajcn/30.7.1077; SKLAR LA, 1985, J BIOL CHEM, V260, P1461; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STANKOVA L, 1975, INFECT IMMUN, V12, P252, DOI 10.1128/IAI.12.2.252-256.1975; STANKOVA L, 1984, METABOLISM, V33, P347, DOI 10.1016/0026-0495(84)90197-5; STEWART CP, 1953, BIOCHEM J, V53, P254, DOI 10.1042/bj0530254; WASHKO P, 1992, J BIOL CHEM, V267, P23568; WASHKO P, 1989, J BIOL CHEM, V264, P18996; WASHKO PW, 1989, ANAL BIOCHEM, V181, P276, DOI 10.1016/0003-2697(89)90243-1; WASHKO PW, 1992, ANAL BIOCHEM, V204, P1, DOI 10.1016/0003-2697(92)90131-P; WELLS WW, 1990, J BIOL CHEM, V265, P15361; WINTERBOURN CC, 1983, BIOCHIM BIOPHYS ACTA, V763, P175, DOI 10.1016/0167-4889(83)90041-1	40	232	235	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15531	15535						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340380				2022-12-27	WOS:A1993LN30500034
J	LU, WY; ZHANG, WL; MOLLOY, SS; THOMAS, G; RYAN, K; CHIANG, YW; ANDERSON, S; LASKOWSKI, M				LU, WY; ZHANG, WL; MOLLOY, SS; THOMAS, G; RYAN, K; CHIANG, YW; ANDERSON, S; LASKOWSKI, M			ARG(15)-LYS(17)-ARG(18) TURKEY OVOMUCOID 3RD DOMAIN INHIBITS HUMAN FURIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEINASES; SEQUENCES; CLEAVAGE; ENZYMES	Turkey ovomucoid third domain with Leu18 in its reactive site is a potent inhibitor of many serine proteinases: subtilisins, chymotrypsins, and elastases. Previous studies showed that an L18K mutation made it a moderately strong inhibitor of trypsin, while an L18E mutation made it a strong inhibitor of Glu-specific Streptomyces griseus proteinase (GluSGP). For human furin substrates the consensus optimal sequence is RXKR down. Therefore the A15R, T17K, and L18R mutations were made in turkey ovomucoid third domain. The mutant inhibits human furin with a K(a) of 1.1 x 10(7) M-1. As human furin catalyzes an obligatory step in human immunodeficiency virus proliferation, this inhibitor, along with the others already available, deserves further study.	PURDUE UNIV, DEPT CHEM, BROWN CHEM BLDG, W LAFAYETTE, IN 47907 USA; OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA; RUTGERS UNIV, DEPT CHEM, PISCATAWAY, NJ 08854 USA; RUTGERS UNIV, DEPT MOLEC BIOL & BIOCHEM, PISCATAWAY, NJ 08854 USA; RUTGERS UNIV, CTR ADV BIOTECHNOL & MED, PISCATAWAY, NJ 08854 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Oregon Health & Science University; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick			Lu, Wuyuan/J-8452-2017; Lu, Wuyuan/B-2268-2010	Lu, Wuyuan/0000-0003-1318-9968; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG010462] Funding Source: NIH RePORTER; NIA NIH HHS [AG 10462] Funding Source: Medline; NIDDK NIH HHS [DK 44629] Funding Source: Medline; NIGMS NIH HHS [GM 10831] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APOSTOL I, 1993, IN PRESS J PROTEIN C, V12; BRESNAHAN PA, 1993, MECHANISMS INTRACELL, P225; CHAN SJ, 1992, P NATL ACAD SCI USA, V89, P6678, DOI 10.1073/pnas.89.15.6678; CREIGHTON TE, 1989, TRENDS BIOCHEM SCI, V14, P319, DOI 10.1016/0968-0004(89)90159-X; EMPIE MW, 1982, BIOCHEMISTRY-US, V21, P2274, DOI 10.1021/bi00539a002; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HILL RE, 1987, NATURE, V326, P96, DOI 10.1038/326096a0; HIRONO S, 1979, J MOL BIOL, V131, P855, DOI 10.1016/0022-2836(79)90205-5; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; KOMIYAMA T, 1991, J BIOL CHEM, V266, P10727; LASKOWSKI M, 1987, COLD SPRING HARB SYM, V52, P545, DOI 10.1101/SQB.1987.052.01.062; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LASKOWSKI M, 1987, BIOCHEMISTRY-US, V26, P202, DOI 10.1021/bi00375a028; LU W, 1992, 6TH S PROT SOC SAN D, P79; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MOEHRING JM, 1993, J BIOL CHEM, V268, P2590; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; OTLEWSKI J, 1987, BIOL CHEM H-S, V368, P1505; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCOTT MJ, 1987, J BIOL CHEM, V262, P5899; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; WIECZOREK M, 1987, BIOCHEM BIOPH RES CO, V144, P499, DOI 10.1016/S0006-291X(87)80537-5; YOSHIDA N, 1988, J BIOCHEM, V104, P451, DOI 10.1093/oxfordjournals.jbchem.a122488	25	56	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14583	14585						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325837				2022-12-27	WOS:A1993LL75900009
J	HAREL, R; FUTERMAN, AH				HAREL, R; FUTERMAN, AH			INHIBITION OF SPHINGOLIPID SYNTHESIS AFFECTS AXONAL OUTGROWTH IN CULTURED HIPPOCAMPAL-NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI-APPARATUS; CELLS; CERAMIDE	Neuronal growth is regulated by both extracellular and cellular determinants and is believed to proceed by the addition of new membrane material at the growth cone. To determine whether lipid synthesis is necessary to maintain neuronal growth, we have examined the effect of Fumonisin B1, an inhibitor of ceramide synthesis, on the development of cultured hippocampal neurons. Fumonisin B1 inhibits ceramide synthesis in hippocampal neurons both in vivo and in vitro. Ganglioside synthesis and content was reduced after Fumonisin B1 treatment, and ganglioside GD1b was not detectable at the cell surface by immunofluorescence. Inhibition of sphingolipid synthesis by Fumonisin B1 had a significant effect on axonal growth. Between days 2-3 in culture, mean axon length increased from 170 to 240 mum, but in Fumonisin-treated cells, no increase in axon length was observed. Addition of a fluorescent derivative of ceramide together with Fumonisin B1 reversed this effect, confirming that Fumonisin B1 acts via inhibition of ceramide synthase. Further, ceramide by itself caused a significant increase in axon length. We discuss three possible mechanisms by which inhibition of sphingolipid synthesis could disrupt axonal growth, among them the possibility that ongoing sphingolipid synthesis is necessary to provide new membrane material to the growing axon.	WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science				Futerman, Anthony/0000-0003-0013-0115				BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPENOT RB, 1991, J NEUROSCI, V11, P1126; COLLINS RN, 1992, J BIOL CHEM, V267, P24906; Craig A M, 1992, Curr Opin Neurobiol, V2, P602, DOI 10.1016/0959-4388(92)90025-G; DOTTI CG, 1988, J NEUROSCI, V8, P1454; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; FERREIRA A, 1992, J CELL BIOL, V117, P595, DOI 10.1083/jcb.117.3.595; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; FUTERMAN AH, 1993, IN PRESS CURR TOP ME; Goslin K., 1991, CULTURING NERVE CELL, P251; HAKAMORI S, 1990, J BIOL CHEM, V265, P18713; HANADA K, 1992, J BIOL CHEM, V267, P23527; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HARTH S, 1978, ANAL BIOCHEM, V86, P543, DOI 10.1016/0003-2697(78)90781-9; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; LEDEEN RW, 1989, NEUROBIOLOGY GLYCOCO, P43; MANDON EC, 1992, J BIOL CHEM, V267, P11144; NORRED WP, 1992, MYCOPATHOLOGIA, V117, P73, DOI 10.1007/BF00497281; ORTEGA E, 1990, MOL IMMUNOL, V27, P1269, DOI 10.1016/0161-5890(90)90031-T; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PAGANO RE, 1990, BIOCHEM SOC T, V18, P361, DOI 10.1042/bst0180361; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; ROSENWALD AG, 1992, BIOCHEMISTRY-US, V31, P3581, DOI 10.1021/bi00129a005; SAITO M, 1985, BIOCHEM BIOPH RES CO, V127, P1, DOI 10.1016/S0006-291X(85)80117-0; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; TRINCHERA M, 1991, J BIOL CHEM, V266, P9093; UEMURA K, 1991, J BIOCHEM-TOKYO, V110, P96, DOI 10.1093/oxfordjournals.jbchem.a123549; WANG E, 1992, J NUTR, V122, P1706, DOI 10.1093/jn/122.8.1706; WANG E, 1991, J BIOL CHEM, V266, P14486; WU GS, 1991, J NEUROCHEM, V56, P95, DOI 10.1111/j.1471-4159.1991.tb02567.x; YOO HS, 1992, TOXICOL APPL PHARM, V114, P9, DOI 10.1016/0041-008X(92)90090-F	34	173	175	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14476	14481						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314804				2022-12-27	WOS:A1993LJ82500098
J	ROLDAN, ERS; FRAGIO, C				ROLDAN, ERS; FRAGIO, C			PHOSPHOLIPASE-A2 ACTIVATION AND SUBSEQUENT EXOCYTOSIS IN THE CA2+/IONOPHORE-INDUCED ACROSOME REACTION OF RAM SPERMATOZOA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG SPERMATOZOA; PROTEIN-KINASE-C; UNSATURATED FATTY-ACIDS; SEA-URCHIN SPERM; HUMAN-NEUTROPHILS; MAMMALIAN SPERMATOZOA; POSSIBLE INVOLVEMENT; DIFFERENTIAL ACTIONS; 2ND MESSENGERS; CA-2+ INFLUX	In ram spermatozoa treatment with Ca2+ and A23187 or ionomycin stimulated the release of arachidonic acid (20:4) and exocytosis of the acrosome in a time- and concentration-dependent manner. Diacylglycerol did not appear to be the source of 20:4. On the other hand, generation of 20:4 was significantly correlated with breakdown of phosphatidylcholine, phosphatidylserine, and phosphatidylethanolamine under a variety of conditions, thus indicating that 20:4 release was due to phospholipase A2 activity. Generation of 20:4 preceded acrosomal exocytosis. Moreover, it was significantly correlated with exocytosis when spermatozoa were stimulated with Ca2+ and A23187 or ionomycin for different periods of time or with different ionophore concentrations. Treatment with Ro 31-4493, a compound that has been found to inhibit sperm phospholipase A2 activity in vitro, considerably reduced both the release of 20:4 and exocytosis; addition of exogenous 20:4 or lysophosphatidylcholine overcame the inhibitory effect of Ro 31-4493. Spermatozoa preincubated with several unsaturated fatty acids, including 20:4, underwent exocytosis much more rapidly when treated with Ca2+/A23187. Exogenous lysophosphatidylcholine also enhanced acrosomal exocytosis and this effect was mimicked by an alkyl-containing analogue (1-O-alkyl-glycerophosphorylcholine = lyso-platelet activating factor). These results indicate that phospholipase A2 plays a fundamental role in the exocytosis of the acrosome elicited by Ca2+ and ionophore stimulation. Therefore, it is possible that activation of this enzyme constitutes an essential Ca2+-dependent event underlying exocytosis in response to physiological stimuli.			ROLDAN, ERS (corresponding author), AFRC, BABRAHAM INST, DEPT DEV & SIGNALLING, CELL RECOGNIT & SIGNALLING LAB, CAMBRIDGE CB2 4AT, ENGLAND.		Roldan, Eduardo R.S./M-7947-2014	Roldan, Eduardo R.S./0000-0002-7545-4248				ALVAREZ JG, 1989, J ANDROL, V10, pP43; ANDERSON RA, 1990, MOL REPROD DEV, V27, P305, DOI 10.1002/mrd.1080270405; ANTAKI P, 1988, GAMETE RES, V19, P305, DOI 10.1002/mrd.1120190309; BALSINDE J, 1991, J BIOL CHEM, V266, P15638; BASS DA, 1987, J BIOL CHEM, V262, P6643; BAULDRY SA, 1991, BIOCHIM BIOPHYS ACTA, V1084, P178; BAULDRY SA, 1988, J BIOL CHEM, V263, P16787; BENNET PJ, 1987, BIOCHIM BIOPHYS ACTA, V919, P255, DOI 10.1016/0005-2760(87)90265-7; BILLAH MM, 1987, BIOCHEM BIOPH RES CO, V144, P683, DOI 10.1016/S0006-291X(87)80019-0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BURCH RM, 1988, FEBS LETT, V234, P283, DOI 10.1016/0014-5793(88)80099-1; COLLADOESCOBAR D, 1990, J IMMUNOL, V144, P244; CREUTZ CE, 1981, J CELL BIOL, V91, P247, DOI 10.1083/jcb.91.1.247; DAVIS PD, 1988, BIOCHEM SOC T, V16, P816, DOI 10.1042/bst0160816; DEGEORGE JJ, 1987, J BIOL CHEM, V262, P9979; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DOMINO SE, 1989, BIOL REPROD, V41, P133, DOI 10.1095/biolreprod41.1.133; FLEMING AD, 1981, GAMETE RES, V4, P253, DOI 10.1002/mrd.1120040402; FLEMING AD, 1984, J EXP ZOOL, V229, P485, DOI 10.1002/jez.1402290317; GOPPELTSTRUEBE M, 1989, BRIT J PHARMACOL, V98, P1287, DOI 10.1111/j.1476-5381.1989.tb12676.x; GUERETTE P, 1988, GAMETE RES, V19, P203, DOI 10.1002/mrd.1120190210; HARRISON RAP, 1982, J EXP ZOOL, V222, P81, DOI 10.1002/jez.1402220111; HARRISON RAP, 1990, J REPROD FERTIL, P51; HAZEN SL, 1991, J BIOL CHEM, V266, P5629; HENDERSON LM, 1989, BIOCHEM J, V264, P249, DOI 10.1042/bj2640249; HINKOVSKA VT, 1987, INT J BIOCHEM, V19, P569, DOI 10.1016/0020-711X(87)90143-1; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; IMAI A, 1990, COMP BIOCHEM PHYS B, V95, P635, DOI 10.1016/0305-0491(90)90033-P; JONES R, 1976, PROC R SOC SER B-BIO, V193, P317, DOI 10.1098/rspb.1976.0050; JONES R, 1979, FERTIL STERIL, V31, P531; KRAMER RM, 1987, BIOCHEM J, V248, P779, DOI 10.1042/bj2480779; LANGLAIS J, 1992, BIOCHEM BIOPH RES CO, V182, P208, DOI 10.1016/S0006-291X(05)80132-9; LAX Y, 1990, BIOCHIM BIOPHYS ACTA, V1043, P12, DOI 10.1016/0005-2760(90)90104-6; LLANOS MN, 1982, J EXP ZOOL, V221, P107, DOI 10.1002/jez.1402210114; Lucy J.A., 1970, NATURE, V227, P814, DOI 10.1038/227815a0; LUI CW, 1979, J EXP ZOOL, V207, P173, DOI 10.1002/jez.1402070202; MAJERUS PW, 1984, CELL, V37, P701, DOI 10.1016/0092-8674(84)90405-7; MATSUMURA K, 1991, DEV GROWTH DIFFER, V33, P365; MEIZEL S, 1984, J EXP ZOOL, V231, P283, DOI 10.1002/jez.1402310213; MEIZEL S, 1983, FEBS LETT, V161, P315, DOI 10.1016/0014-5793(83)81032-1; MILLS SC, 1969, J REPROD FERTIL, V18, P367, DOI 10.1530/jrf.0.0180367; MITCHELL KT, 1986, ANAL BIOCHEM, V158, P447, DOI 10.1016/0003-2697(86)90574-9; NEILL AR, 1972, BIOCHEM J, V127, P375, DOI 10.1042/bj1270375; NEILL AR, 1973, J REPROD FERTIL, V34, P279, DOI 10.1530/jrf.0.0340279; OHZU E, 1982, J EXP ZOOL, V224, P259, DOI 10.1002/jez.1402240216; ONO K, 1982, DEV GROWTH DIFFER, V24, P305; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; PILTCH A, 1989, BIOCHEM J, V261, P395, DOI 10.1042/bj2610395; POLLARD HB, 1988, J EXP BIOL, V139, P267; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; RIFFO M, 1992, HISTOCHEMISTRY, V97, P25, DOI 10.1007/BF00271278; Roldan E.R.S., 1990, P179; ROLDAN ERS, 1989, BIOCHEM J, V259, P397, DOI 10.1042/bj2590397; ROLDAN ERS, 1992, BIOCHEM J, V281, P767, DOI 10.1042/bj2810767; ROLDAN ERS, 1990, BIOCHEM BIOPH RES CO, V172, P8, DOI 10.1016/S0006-291X(05)80165-2; ROLDAN ERS, 1988, BIOCHEM BIOPH RES CO, V155, P901, DOI 10.1016/S0006-291X(88)80581-3; ROLDAN ERS, 1991, BIOCHEM BIOPH RES CO, V176, P294, DOI 10.1016/0006-291X(91)90923-U; RONKKO S, 1992, INT J BIOCHEM, V24, P869, DOI 10.1016/0020-711X(92)90091-E; Scott T W, 1973, J Reprod Fertil Suppl, V18, P65; SCOTT TW, 1967, BIOCHEM J, V102, P456, DOI 10.1042/bj1020456; SELIVONCHICK DP, 1980, BIOCHIM BIOPHYS ACTA, V618, P242, DOI 10.1016/0005-2760(80)90030-2; SHAMSBORHAN G, 1981, GAMETE RES, V4, P407, DOI 10.1002/mrd.1120040506; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; THAKKAR JK, 1983, BIOCHIM BIOPHYS ACTA, V754, P44, DOI 10.1016/0005-2760(83)90080-2; THAKKAR JK, 1984, BIOL REPROD, V30, P679, DOI 10.1095/biolreprod30.3.679; THOMAS P, 1989, BIOCHEM J, V264, P539, DOI 10.1042/bj2640539; WEINMAN S, 1986, J HISTOCHEM CYTOCHEM, V34, P1171, DOI 10.1177/34.9.2426345; ZANEVELD LJD, 1992, COMP SPERMATOLOGY 20, P277	69	74	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13962	13970						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314762				2022-12-27	WOS:A1993LJ82500031
J	WIKSTROM, L; LODISH, HF				WIKSTROM, L; LODISH, HF			UNFOLDED H2B ASIALOGLYCOPROTEIN RECEPTOR SUBUNIT POLYPEPTIDES ARE SELECTIVELY DEGRADED WITHIN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DEGRADATION; VIRUS GLYCOPROTEIN; SECRETORY PROTEINS; CELL-SURFACE; PRE-GOLGI; TRANSPORT; CALCIUM; RETENTION; THAPSIGARGIN; TRANSFERRIN	When expressed alone in fibroblasts, approximately 80% of newly made H2b subunits of the human asialoglycoprotein receptor are retained and degraded in the endoplasmic reticulum (ER), whereas about 20% reaches the plasma membrane (1). Thapsigargin, an inhibitor of the ER Ca2+ ATPase, blocks ER folding of the H1 (2) as well as of the H2b subunit, prevents maturation of H2b, and accelerates ER degradation of newly made H2b. The secretory pathway is normal in thapsigargin-treated cells, as monitored by maturation of the vesicular stomatitis virus G protein. The protease inhibitors TLCK and TPCK block the first step in ER degradation of H2, an endoproteolytic cleavage just exoplasmic to the membrane-spanning domain. In protease inhibitor-treated cells, the approximately 80% of H2b that would normally be degraded remains in the ER; as judged by migration on nonreducing SDS-polyacrylamide gel electrophoresis this H2b is improperly folded. Thus, incorrectly folded H2b is normally subjected to ER degradation. In the presence of thapsigargin H2b cannot fold properly and is degraded within the ER. The preferential ER degradation of misfolded or unfolded membrane proteins demonstrated here, functions as a step in ER quality control.	WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; LUDWIG INST CANC RES,S-10401 STOCKHOLM,SWEDEN	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Ludwig Institute for Cancer Research					NIGMS NIH HHS [GM 35012] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035012] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BISCHOFF J, 1988, J CELL BIOL, V106, P1067, DOI 10.1083/jcb.106.4.1067; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CHUN KT, 1992, J BIOL CHEM, V267, P4236; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; HENIS YI, 1990, J CELL BIOL, V111, P1409, DOI 10.1083/jcb.111.4.1409; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; INOUE S, 1992, J BIOL CHEM, V267, P9080; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LODISH HF, 1983, VIROLOGY, V125, P335, DOI 10.1016/0042-6822(83)90206-4; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LODISH HF, 1991, TRENDS BIOCHEM SCI, V16, P374, DOI 10.1016/0968-0004(91)90154-N; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; ROOS N, 1988, SCANNING MICROSCOPY, V2, P323; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P158; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; STROUS GJAM, 1983, J CELL BIOL, V97, P1815, DOI 10.1083/jcb.97.6.1815; TANIYAMA Y, 1991, J BIOL CHEM, V266, P6456; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WIKSTROM L, 1992, J BIOL CHEM, V267, P5; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; ZILBERSTEIN A, 1980, CELL, V21, P417, DOI 10.1016/0092-8674(80)90478-X	39	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14412	14416						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314799				2022-12-27	WOS:A1993LJ82500090
J	DOKTER, WHA; DIJKSTRA, AJ; KOOPMANS, SB; STULP, BK; KECK, W; HALIE, MR; VELLENGA, E				DOKTER, WHA; DIJKSTRA, AJ; KOOPMANS, SB; STULP, BK; KECK, W; HALIE, MR; VELLENGA, E			G(ANH)MTETRA, A NATURAL BACTERIAL-CELL WALL BREAKDOWN PRODUCT, INDUCES INTERLEUKIN-1-BETA AND INTERLEUKIN-6 EXPRESSION IN HUMAN MONOCYTES - A STUDY OF THE MOLECULAR MECHANISMS INVOLVED IN INFLAMMATORY CYTOKINE EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCCURRING MURAMYL PEPTIDES; SLOW-WAVE SLEEP; NF-KAPPA-B; ESCHERICHIA-COLI; HUMAN PROINTERLEUKIN-1-BETA; TRANSCRIPTION FACTOR; MUREIN HYDROLASES; GENE-EXPRESSION; HUMAN-URINE; PEPTIDOGLYCAN	It is believed that induction of cytokine expression by bacterial cell wall components plays a role in the development and course of sepsis. However, most attention has been focused on lipopolysaccharide (LPS). We studied the ability of N-acetylglucosaminyl-1,6-anhydro-N-acetylmuramyl-L-alanyl-D-isoglutamyl-m-diaminopimelyl-D-alanine (G(Anh)MTetra), a naturally occurring breakdown product of peptidoglycan that is produced by soluble lytic transglycosylase of Escherichia coli, to induce cytokine expression in human monocytes. G(Anh)MTetra was found to strongly induce interleukin (IL)-1 beta and IL-6 mRNA expression after 2 h and IL-1 beta and IL-6 protein secretion after 48 h of activation. The increase in mRNA accumulation was at least partly due to an increase in the transcription rates of the respective genes and was accompanied by a strong induction of nuclear factor-kappa B and activator protein-1 transcription factor expression. Experiments using inhibitors of protein kinase C, protein kinase A, and tyrosine kinase-dependent pathways revealed that G(Anh)MTetra-induced IL-1 beta and IL-6 mRNA expression involves activation of an H7-inhibitable pathway. By using the protein synthesis inhibitor cycloheximide, it was shown that G(Anh)MTetra-induced IL-6 mRNA expression depends on the synthesis of new protein, whereas G(Anh)MTetra-induced IL-1 beta mRNA accumulation does not. When responses to G(Anh)MTetra were compared with those to LPS and muramyldipeptide (MDP), it was found that the optimal response to G(Anh)MTetra induction was similar to that of LPS but significantly higher than the response to MDP. Furthermore, maximal G(Anh)MTetra-induced IL-1 beta and IL-6 mRNA expression could be enhanced by co stimulation with LPS or MDP, suggesting that different receptors and/or transduction pathways were involved. These results indicate that G(Anh)MTetra induces IL-1 beta and IL-6 expression in human monocytes suggesting a possible role for G(Anh)MTetra in the release of cytokines during sepsis.	UNIV GRONINGEN,DEPT MED,DIV HEMATOL,9713 EZ GRONINGEN,NETHERLANDS; HOFFMAN LA ROCHE LTD,DEPT PHARMA RES,CH-4002 BASEL,SWITZERLAND	University of Groningen; Roche Holding								AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; AZUMA I, 1992, INT J IMMUNOPHARMACO, V14, P487; BAUERLE PA, 1988, CELL, V53, P211; BRACH MA, 1992, EUR J IMMUNOL, V22, P2705, DOI 10.1002/eji.1830221034; BRAKENHOFF JPJ, 1987, J IMMUNOL, V139, P4116; CHAUHAN D, 1993, BLOOD, V81, P1540; CLARK BD, 1986, NUCLEIC ACIDS RES, V14, P7897, DOI 10.1093/nar/14.20.7897; COOKSON BT, 1989, BIOCHEMISTRY-US, V28, P1744, DOI 10.1021/bi00430a048; DEWIT H, 1993, EXP HEMATOL, V21, P785; DINARELLO CA, 1986, FASEB J, V45, P2545; DINARELLO CA, 1991, BLOOD, V77, P1627; DOFFERHOFF ASM, 1993, J ANTIMICROB CHEMOTH, V31, P373, DOI 10.1093/jac/31.3.373; DOKTER WHA, 1993, BLOOD, V81, P35; DOKTERWHA, 1993, BLOOD, V81, P337; DZIARSKI R, 1991, J BIOL CHEM, V266, P4713; DZIARSKI R, 1991, J BIOL CHEM, V266, P4719; ELONZ F, 1974, BIOCHEM BIOPH RES CO, V59, P1317; ENGEL H, 1992, J BACTERIOL, V174, P6394, DOI 10.1128/JB.174.20.6394-6403.1992; ENGEL H, 1992, APPL MICROBIOL BIOT, V37, P772, DOI 10.1007/BF00174845; FENTON MJ, 1988, J IMMUNOL, V140, P2267; FENTON MJ, 1987, J IMMUNOL, V138, P3972; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GOLD MR, 1985, INFECT IMMUN, V49, P731, DOI 10.1128/IAI.49.3.731-741.1985; GRUSS HJ, 1992, BLOOD, V80, P2563; HAEGEMAN G, 1986, EUR J BIOCHEM, V159, P625, DOI 10.1111/j.1432-1033.1986.tb09931.x; HELLE M, 1991, J IMMUNOL METHODS, V138, P47, DOI 10.1016/0022-1759(91)90063-L; HOLTJE JV, 1991, J GEN MICROBIOL, V137, P441, DOI 10.1099/00221287-137-3-441; HOLTJE JV, 1975, J BACTERIOL, V124, P1067; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KOVACS EJ, 1989, J IMMUNOL, V143, P3532; KRUEGER JM, 1984, J BIOL CHEM, V259, P2659; KRUEGER JM, 1987, BRAIN RES, V403, P249, DOI 10.1016/0006-8993(87)90062-X; KRUEGER JM, 1982, J BIOL CHEM, V257, P1664; LECONTEL C, 1993, J IMMUNOL, V150, P4541; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIEBERMANN TA, 1990, MOL CELL BIOL, V10, P2327; MARTIN SA, 1984, J BIOL CHEM, V259, P2652; MARTIN SA, 1987, J BIOL CHEM, V262, P7514; MCCABE WR, 1981, CURRENT CLIN TOPICS, V2, P121; MUNOZ C, 1991, J CLIN INVEST, V88, P1747, DOI 10.1172/JCI115493; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PARRILLO JE, 1990, ANN INTERN MED, V113, P227, DOI 10.7326/0003-4819-113-3-227; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; POLANSKI M, 1989, J IMMUNOL, V143, P2706; RIESENFELDORN I, 1989, INFECT IMMUN, V57, P1890, DOI 10.1128/IAI.57.7.1890-1893.1989; Sambrook J, 1989, MOL CLONING LABORATO; SCHLINDER R, 1990, J BIOL CHEM, V265, P10232; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SINHA RK, 1980, INFECT IMMUN, V29, P914; Tufano M A, 1991, Eur Cytokine Netw, V2, P361; TUOMANEN E, 1985, J INFECT DIS, V151, P535, DOI 10.1093/infdis/151.3.535; TUOMANEN E, 1985, J INFECT DIS, V151, P859, DOI 10.1093/infdis/151.5.859; TUOMANEN E, 1987, AM REV RESPIR DIS, V135, P869, DOI 10.1164/arrd.1987.135.4.869; TURNER M, 1989, J IMMUNOL, V143, P3556; VELLENGA E, 1988, BLOOD, V71, P1529; VERMEULEN MW, 1984, INFECT IMMUN, V46, P476, DOI 10.1128/IAI.46.2.476-483.1984	57	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4201	4206						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307982				2022-12-27	WOS:A1994MW98900048
J	HAZUDA, DJ; WOLFE, AL; HASTINGS, JC; ROBBINS, HL; GRAHAM, PL; LAFEMINA, RL; EMINI, EA				HAZUDA, DJ; WOLFE, AL; HASTINGS, JC; ROBBINS, HL; GRAHAM, PL; LAFEMINA, RL; EMINI, EA			VIRAL LONG TERMINAL REPEAT SUBSTRATE-BINDING CHARACTERISTICS OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INTEGRASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; RETROVIRAL DNA INTEGRATION; PROTEIN INVITRO; SEQUENCES; RECOGNITION; IDENTIFICATION; RECOMBINATION; ENDONUCLEASE; CLEAVAGE; REQUIRES	A DNA binding assay was developed for the human immunodeficiency virus type 1 (HIV-1) integrase. The assay was capable of defining discrete complexes between the enzyme and the viral long terminal repeat (LTR) substrate. DNA binding reflected the sequence requirements previously demonstrated for the enzyme's 3'-end processing activity. Binding exhibited a nonlinear dependence on integrase concentration, suggesting that the enzyme functions as a multimer. The oligomeric state was investigated by UV-photo-cross-linking of integrase-LTR oligonucleotide complexes using DNA substrates substituted with 5-bromo-2'-deoxycytidine within the integrase recognition sequence. In the absence of divalent cation, integrase cross-linked to the LTR oligonucleotide as a single species whose mobility by SDS-polyacrylamide gel electrophoresis was consistent with the formation of tetramers. Using these techniques, analysis of the binding properties of integrase mutants demonstrated that the catalytic and sequence-specific DNA binding activities of the enzyme are distinct, involving residues within the conserved ''DD(35)E'' and zinc finger motifs, respectively.			HAZUDA, DJ (corresponding author), MERCK RES LABS,W POINT,PA 19486, USA.		Graham, Petra/V-8136-2019	Graham, Petra/0000-0003-2890-2447				BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BURKE CJ, 1992, J BIOL CHEM, V267, P9639; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; FAYET O, 1990, MOL MICROBIOL, V4, P1771, DOI 10.1111/j.1365-2958.1990.tb00555.x; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; GOFF SP, 1992, ANNU REV GENET, V26, P527, DOI 10.1146/annurev.ge.26.120192.002523; HANAS JS, 1983, J BIOL CHEM, V258, P4120; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; JONES KS, 1992, J BIOL CHEM, V267, P16037; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KATZMAN M, 1991, P NATL ACAD SCI USA, V88, P4695, DOI 10.1073/pnas.88.11.4695; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KHAN E, 1991, NUCLEIC ACIDS RES, V19, P851, DOI 10.1093/nar/19.4.851; KROGSTAD PA, 1990, J VIROL, V64, P2796, DOI 10.1128/JVI.64.6.2796-2801.1990; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAFEMINA RL, 1992, J VIROL, V66, P7414, DOI 10.1128/JVI.66.12.7414-7419.1992; LAFEMINA RL, 1991, J VIROL, V65, P5624, DOI 10.1128/JVI.65.10.5624-5630.1991; LEAVITT AD, 1992, J VIROL, V66, P2359, DOI 10.1128/JVI.66.4.2359-2368.1992; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; ROTH MJ, 1990, J VIROL, V64, P4709, DOI 10.1128/JVI.64.10.4709-4717.1990; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; SHERMAN PA, 1992, J VIROL, V66, P3593, DOI 10.1128/JVI.66.6.3593-3601.1992; STRUHL K, 1990, PROTEINS FORM FUNCTI; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; VANGENT DC, 1991, NUCLEIC ACIDS RES, V19, P3821, DOI 10.1093/nar/19.14.3821; VINCENT KA, 1993, J VIROL, V67, P425, DOI 10.1128/JVI.67.1.425-437.1993; VINK C, 1991, J VIROL, V65, P4636, DOI 10.1128/JVI.65.9.4636-4644.1991	33	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3999	4004						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307956				2022-12-27	WOS:A1994MW98900018
J	SATO, S; HUGHES, RC				SATO, S; HUGHES, RC			REGULATION OF SECRETION AND SURFACE EXPRESSION OF MAC-2, A GALACTOSIDE-BINDING PROTEIN OF MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRIFFONIA-SIMPLICIFOLIA I-B4; MONOCLONAL-ANTIBODIES; PERITONEAL-MACROPHAGES; MEMBRANE-GLYCOPROTEINS; LECTIN BINDING; CELLS; LAMININ; ACTIVATION; IGE; CHAINS	Mac-2, a 30-35-kDa galactoside-binding protein, is synthesized at similar levels in murine peritoneal exudate macrophages whether recruited in response to an intraperitoneal pathogen Mycobacterium microti, to sterile inflammatory stimuli such as thioglycollate broth, or to concanavalin A. In elicited or activated macrophages up to 30% of Mac-2 is constitutively secreted, and secretion is stimulated markedly by calcium ionophore A23187. Only thioglycollate elicited macrophages express cell surface Mac-2, and binding is mostly (>80%) a result of affinity for cell surface carbohydrate structures. Mac-2 surface expression is markedly reduced upon further activation of thioglycollate elicited macrophages with bacterial lipopolysaccharide in vitro. Polylactosamine structures are present on all macrophage populations examined as determined by binding of Lycopersicon esculentum lectin, whereas alpha-galactosyl residues detected by Griffonia simplicifolia isolectin B4 are expressed only on the thioglycollate elicited macrophages, indicating that these residues are the major determinants responsible for Mac-2 surface expression. Chemical crosslinking experiments have identified binding of endogenous cell-surface Mac-2 to three glycoproteins of molecular masses of 92, 125, and 180 kDa containing alpha-galactosyl and polylactosamine structures on thioglycollate-elicited macrophages. The restricted cell surface distribution of Mac-2 on thioglycollate-elicited peritoneal macrophages, a population of recently recruited monocytes, suggests a role(s) in early events of macrophage infiltration and tissue fixation such as extravasion and cell-matrix interactions.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research								ADAMS DO, 1984, ANNU REV IMMUNOL, V2, P283, DOI 10.1146/annurev.immunol.2.1.283; ARNAOUT MA, 1990, BLOOD, V75, P1037; BAUVOIS B, 1992, J IMMUNOL, V148, P3912; Bayer E A, 1979, Methods Enzymol, V62, P308; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; Colin Hughes R., 1992, CURR OPIN STRUC BIOL, V2, P687, DOI 10.1016/0959-440X(92)90202-I; FLOTTE TJ, 1983, AM J PATHOL, V111, P112; FODDY L, 1990, J CELL SCI, V97, P139; FRIGERI LG, 1992, J IMMUNOL, V148, P861; GALILI U, 1988, J BIOL CHEM, V263, P17755; HAINES KA, 1983, P NATL ACAD SCI-BIOL, V80, P3448, DOI 10.1073/pnas.80.11.3448; HO MK, 1982, J IMMUNOL, V128, P1221; HOLNESS CL, 1993, J BIOL CHEM, V268, P9661; HSU DK, 1992, J BIOL CHEM, V267, P14167; HUGHES RC, 1992, BIOCHEM SOC T, V20, P279, DOI 10.1042/bst0200279; IRIMURA T, 1987, EUR J IMMUNOL, V17, P73, DOI 10.1002/eji.1830170113; KAWASHIMA H, 1990, GLYCOCONJUGATE J, V7, P323, DOI 10.1007/BF01073376; KOTHS K, 1993, J BIOL CHEM, V268, P14245; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; LINSLEY PS, 1986, BIOCHEMISTRY-US, V25, P2978, DOI 10.1021/bi00358a037; MADDOX DE, 1982, CELL IMMUNOL, V71, P202, DOI 10.1016/0008-8749(82)90509-3; MASSA SM, 1993, BIOCHEMISTRY-US, V32, P260, DOI 10.1021/bi00052a033; MERCURIO AM, 1985, J IMMUNOL, V135, P1305; MERCURIO AM, 1988, J CELL BIOL, V107, P1873, DOI 10.1083/jcb.107.5.1873; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; MIZOGUCHI A, 1984, J BIOL CHEM, V259, P1949; MUNRO JM, 1992, AM J PATHOL, V141, P1397; Murphy L A, 1978, Methods Enzymol, V50, P345; NABARRA B, 1988, LAB INVEST, V58, P524; NACHBAR MS, 1982, METHOD ENZYMOL, V83, P363; OCHIENG J, 1993, BIOCHEMISTRY-US, V32, P4455, DOI 10.1021/bi00067a038; PETRYNIAK J, 1992, EUR J BIOCHEM, V206, P197, DOI 10.1111/j.1432-1033.1992.tb16917.x; PETRYNIAK J, 1986, ARCH BIOCHEM BIOPHYS, V244, P57, DOI 10.1016/0003-9861(86)90094-9; RABINOWITZ SS, 1991, J EXP MED, V174, P827, DOI 10.1084/jem.174.4.827; RAZ A, 1988, CANCER RES, V48, P645; RAZ A, 1986, CANCER RES, V46, P3667; RAZ A, 1981, CANCER RES, V41, P3642; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; ROSENBERG I, 1991, J BIOL CHEM, V266, P18731; SATO S, 1992, J BIOL CHEM, V267, P6983; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; SATO S, 1991, J BIOL CHEM, V266, P11485; SAWADA R, 1993, J BIOL CHEM, V268, P12675; SHAW LM, 1993, J BIOL CHEM, V268, P11401; SHAW LM, 1989, J EXP MED, V169, P303, DOI 10.1084/jem.169.1.303; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; SOROKIN SP, 1992, ANAT REC, V232, P520, DOI 10.1002/ar.1092320409; TABOR DR, 1992, J CELL PHYSIOL, V152, P500, DOI 10.1002/jcp.1041520309; TABOR DR, 1989, J LEUKOCYTE BIOL, V45, P452, DOI 10.1002/jlb.45.5.452; TAKACS B, 1987, J IMMUNOL, V138, P1999; WANG JL, 1992, BIOCHEM SOC T, V20, P269, DOI 10.1042/bst0200269; WARFEL AH, 1992, J LEUKOCYTE BIOL, V52, P80, DOI 10.1002/jlb.52.1.80; WARFEL AH, 1991, J CELL PHYSIOL, V147, P265, DOI 10.1002/jcp.1041470211; WOO HJ, 1990, J BIOL CHEM, V265, P7097	55	231	237	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4424	4430						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308013				2022-12-27	WOS:A1994MW98900082
J	YAMASAKI, K; DAIHO, T; KANAZAWA, T				YAMASAKI, K; DAIHO, T; KANAZAWA, T			3'-O-(5-FLUORO-2,4-DINITROPHENYL)-ATP EXCLUSIVELY LABELS LYS-492 AT THE ACTIVE-SITE OF THE SARCOPLASMIC-RETICULUM CA2+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING-SITE; ADENOSINE-TRIPHOSPHATASE; FLUORESCEIN ISOTHIOCYANATE; CA-2+-TRANSPORTING ATPASE; TRIPHOSPHOPYRIDOXAL; IDENTIFICATION; VESICLES; PEPTIDE; CALCIUM; PROTEIN	Sarcoplasmic reticulum vesicles were labeled with 40 mu M 3'-O-(5-fluoro-2,4-dinitrophenyl)-ATP (FDNP-ATP) at 25 degrees C and pH 7.0 for 4 h. The Ca-2+-ATPase was inhibited strongly. The enzyme was almost completely protected either by 20 mM Mg.ATP or by 50 mM acetyl phosphate against this inhibition. P-i gave no protection. There was a linear relationship between the extent of this inhibition and the Mg.ATP-sensitive part of the content of bound FDNP-ATP. Extrapolation showed that the enzyme is completely inhibited by Mg.ATP sensitive binding of 3.6 nmol of FDNP-ATP/mg of the vesicle protein. This value is in good agreement with the content of the phosphorylation site (3.3 nmol/mg of the vesicle protein) in the vesicles used. These findings indicate that binding of 1 mol of FDNP-ATP per mol of the active sites leads to a complete inhibition of the enzyme. The acetylphosphatase activity and phosphorylation with ATP were also strongly inhibited by this labeling, whereas phosphorylation with P-i was not inhibited. The labeled vesicles were solubilized in SDS, and the Ca2+-ATPase was purified by size exclusion high performance liquid chromatography. Mapping the labeled peptides in the tryptic digest by reversed-phase high performance liquid chromatography and sequencing showed that Lys-492 was exclusively labeled with FDNP-ATP These results show that Lys-492 is located in or near the ATP binding site and apart from the phosphorylation site and P-i binding site. Molecular modeling of FDNP-ATP suggests that this Lys-492 residue is situated on the 3'-OH side of the ribose moiety of bound ATP and is close to the alpha-phosphoryl group.	ASAHIKAWA MED COLL,DEPT BIOCHEM,ASAHIKAWA 078,JAPAN	Asahikawa Medical College								AHKOW G, 1980, J ORG CHEM, V45, P4399, DOI 10.1021/jo01310a027; ALLEN G, 1976, FEBS LETT, V63, P188, DOI 10.1016/0014-5793(76)80223-2; AZEGAMI M, 1975, J BIOCHEM-TOKYO, V78, P409, DOI 10.1093/oxfordjournals.jbchem.a130921; AZEGAMI M, 1964, J BIOCHEM-TOKYO, V55, P346, DOI 10.1093/oxfordjournals.jbchem.a127892; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; BASTIDE F, 1973, Journal of Biological Chemistry, V248, P8385; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CHUAN H, 1988, J BIOL CHEM, V263, P13003; DEGANI C, 1973, J BIOL CHEM, V248, P8222; DYALL LK, 1960, J CHEM SOC, P5160, DOI 10.1039/jr9600005160; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; FRAENKEL-CONRAT H, 1955, Methods Biochem Anal, V2, P359, DOI 10.1002/9780470110188.ch12; FRIEDMAN Z, 1970, FEBS LETT, V11, P69, DOI 10.1016/0014-5793(70)80494-X; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; KANAZAWA T, 1971, J BIOCHEM-TOKYO, V70, P95, DOI 10.1093/oxfordjournals.jbchem.a129631; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LACAPERE JJ, 1993, BIOCHEMISTRY-US, V32, P3414, DOI 10.1021/bi00064a027; LIPMANN F, 1945, J BIOL CHEM, V159, P21; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKINOSE M, 1967, PFLUG ARCH GES PHYS, V294, pR82; MAROUX S, 1966, BIOCHIM BIOPHYS ACTA, V122, P147, DOI 10.1016/0926-6593(66)90098-1; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MAYINGER P, 1992, BIOCHEMISTRY-US, V31, P10536, DOI 10.1021/bi00158a017; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; NEIL GL, 1966, NATURE, V210, P903, DOI 10.1038/210903a0; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; PUCELL A, 1971, J BIOL CHEM, V246, P3389; STEFANOVA HI, 1993, BIOCHEMISTRY-US, V32, P356, DOI 10.1021/bi00052a044; WU JC, 1989, BIOCHEMISTRY-US, V28, P8905, DOI 10.1021/bi00448a033; YAMAGATA K, 1993, J BIOL CHEM, V268, P20930; YAMAMOTO H, 1988, J BIOCHEM-TOKYO, V103, P452, DOI 10.1093/oxfordjournals.jbchem.a122291; YAMAMOTO H, 1989, J BIOCHEM-TOKYO, V106, P1121, DOI 10.1093/oxfordjournals.jbchem.a122976; YAMAMOTO T, 1967, J BIOCHEM-TOKYO, V62, P558, DOI 10.1093/oxfordjournals.jbchem.a128706	38	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4129	4134						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307973				2022-12-27	WOS:A1994MW98900038
J	CANTILINA, T; SAGARA, Y; INESI, G; JONES, LR				CANTILINA, T; SAGARA, Y; INESI, G; JONES, LR			COMPARATIVE-STUDIES OF CARDIAC AND SKELETAL SARCOPLASMIC-RETICULUM ATPASES - EFFECT OF A PHOSPHOLAMBAN ANTIBODY ON ENZYME ACTIVATION BY CA2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-CATALYZED PHOSPHORYLATION; CALCIUM ADENOSINE-TRIPHOSPHATASE; BETA-ADRENERGIC STIMULATION; TRANSPORT ATPASE; MONOCLONAL-ANTIBODY; CA2+-DEPENDENT ATPASE; CA-2+ PUMP; CA-2+-ATPASE; BINDING; PROTEIN	Vesicular fragments of skeletal (LSR) and cardiac (CSR) sarcoplasmic reticulum were compared with the aim of defining the effect of a monoclonal phospholamban (Pl) antibody (Ab). The Pl Ab has no effect on LSR, while enhancing the Ca2+ transport rates of CSR at Ca2+ concentrations below saturation. We found no direct effect of the Pl Ab on Ca2+ binding by the ATPase in the absence of ATP. Equilibrium measurements of Ca2+ binding yield positively cooperative isotherms which are best fit with a two-interacting sites equation. LSR and CSR display nearly identical affinities for Ca2+, and no effect of the Pl Ab is observed. Taking advantage of a stable CrATP-enzyme complex, we demonstrated that the stoichiometric ratio of occluded Ca2+ to catalytic sites is 2 in either LSR or CSR and that the addition of Pl Ab does not affect the Ca2+ concentration dependence of Ca2+ occluded after equilibration of the system. Interestingly, the cooperative interaction between the two Ca2+ sites is lost in the occluded state, with only one of the two sites acquiring lumenal exposure. The concentration dependence of Ca2+ inhibition of CSR ATPase phosphorylation with P(i) is also unaffected by the Pl Ab. Contrary to the lack of Pl Ab effect on reactions measured at equilibrium, enhancement of phosphorylated intermediate formation by the Pl Ab is obtained in kinetic experiments in which nonsaturating Ca2+ and ATP are added to CSR preincubated with EGTA. Therefore, Ab binding to Pl reduces specifically the activation energy for a slow transition triggered by Ca2+ binding, with consequent enhancement of overall kinetics under conditions enhancing the rate-limiting contribution of this transition.	UNIV MARYLAND, SCH MED, DEPT BIOL CHEM, 108 N GREENE ST, BALTIMORE, MD 21201 USA; INDIANA UNIV, SCH MED, KRANNERT INST CARDIOL, INDIANAPOLIS, IN 46202 USA	University System of Maryland; University of Maryland Baltimore; Indiana University System; Indiana University-Purdue University Indianapolis								BLINKS JR, 1982, PROG BIOPHYS MOL BIO, V40, P1, DOI 10.1016/0079-6107(82)90011-6; BRIGGS FN, 1992, J BIOL CHEM, V267; CHAMBERLAIN BK, 1983, J BIOL CHEM, V258, P6602; CHEN ZD, 1991, J BIOL CHEM, V266, P12386; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLELAND WW, 1982, METHOD ENZYMOL, V87, P159; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DUPONT Y, 1982, BIOCHIM BIOPHYS ACTA, V688, P75, DOI 10.1016/0005-2736(82)90580-6; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FERNANDEZBELDA F, 1984, J BIOL CHEM, V259, P9687; INESI G, 1990, J MEMBRANE BIOL, V116, P1, DOI 10.1007/BF01871666; INESI G, 1980, J BIOL CHEM, V255, P3025; INESI G, 1988, METHOD ENZYMOL, V157, P154; INESI G, 1992, ADV ENZYMOL RAMB, V65, P185; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; JONES LR, 1978, J BIOL CHEM, V253, P1643; JONES LR, 1988, METHOD ENZYMOL, V157, P360; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; KIMURA Y, 1991, J MOL CELL CARDIOL, V23, P1223, DOI 10.1016/0022-2828(91)90080-6; KIRCHBERGER MA, 1974, J BIOL CHEM, V249, P6166; KIRCHBERGER MA, 1982, J BIOL CHEM, V257, P5685; KRANIAS EG, 1980, BIOCHIM BIOPHYS ACTA, V628, P438; LINDEMANN JP, 1983, J BIOL CHEM, V258, P464; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; MORRIS GL, 1991, J BIOL CHEM, V266, P11270; PETITHORY JR, 1986, BIOCHEMISTRY-US, V25, P4493, DOI 10.1021/bi00364a006; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; SCHWARTZENBACH G, 1957, HELV CHIM ACTA, V40, P1186; SERPERSU EH, 1982, EUR J BIOCHEM, V122, P347, DOI 10.1111/j.1432-1033.1982.tb05887.x; SHAM JSK, 1991, AM J PHYSIOL, V261, pH1344, DOI 10.1152/ajpheart.1991.261.4.H1344; SHIGEKAWA M, 1976, J BIOL CHEM, V251, P6894; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; SUKO J, 1973, J PHYSIOL-LONDON, V228, P563, DOI 10.1113/jphysiol.1973.sp010100; SUMBILLA C, 1991, J BIOL CHEM, V266, P12682; SUMIDA M, 1978, J BIOL CHEM, V253, P8772; SUZUKI T, 1986, J BIOL CHEM, V261, P7018; TADA M, 1982, MOL CELL BIOCHEM, V46, P73; TADA M, 1980, J BIOL CHEM, V255, P1985; TADA M, 1988, METHOD ENZYMOL, V157, P107; TOYOFUKU T, 1992, J BIOL CHEM, V267, P14490; VILSEN B, 1987, BIOCHIM BIOPHYS ACTA, V898, P313, DOI 10.1016/0005-2736(87)90072-1; VILSEN B, 1986, BIOCHIM BIOPHYS ACTA, V855, P429, DOI 10.1016/0005-2736(86)90089-1; WEGENER AD, 1989, J BIOL CHEM, V264, P11468	46	132	134	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17018	17025						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349590				2022-12-27	WOS:A1993LQ98800023
J	HEISTERKAMP, N; KAARTINEN, V; VANSOEST, S; BOKOCH, GM; GROFFEN, J				HEISTERKAMP, N; KAARTINEN, V; VANSOEST, S; BOKOCH, GM; GROFFEN, J			HUMAN ABR ENCODES A PROTEIN WITH GAP(RAC) ACTIVITY AND HOMOLOGY TO THE DBL NUCLEOTIDE EXCHANGE FACTOR DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BCR GENE; REGULATORY DOMAIN; MOLECULAR-CLONING; KINASE-ACTIVITY; VAV; PRODUCT; REGION; RAS; CDC24; CDNAS	We have previously cloned a segment of a gene, ABR, homologous to the BCR gene, which encodes a protein consisting of three distinct functional domains. In the present study, genomic ABR sequences were used to isolate human ABR cDNAs. Surprisingly, the two types of ABR cDNAs identified differed only in their most 5' coding sequences. These are predicted to encode proteins of 93.5 and 92.3 kDa molecular mass. ABR showed a differential expression pattern in various mouse tissues, analogous to that of BCR, and the highest level was found in brain. Similar to BCR, ABR contains a region with homology to DBL, vav, and CDC24, which are likely to or have been shown to encode GTP exchange factors. A domain of ABR with similarity to GAP(rho) was expressed as a fusion protein in Escherichia coli and was shown to have GAP activity toward rac. Although both ABR and BCR have GAP activity, ABR lacks homology to the serine/threonine kinase domain of BCR. Therefore, ABR is likely to have cellular functions overlapping with but also distinct from those of BCR.	CHILDRENS HOSP LOS ANGELES, DEPT PATHOL, MOLEC DIAG SECT, 4650 SUNSET BLVD, LOS ANGELES, CA 90027 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Children's Hospital Los Angeles; Scripps Research Institute; Scripps Research Institute			Heisterkamp, Nora/C-1698-2012; Kaartinen, Vesa/AAU-5396-2021	Heisterkamp, Nora/0000-0003-2769-2273; Kaartinen, Vesa/0000-0002-9432-510X	NATIONAL CANCER INSTITUTE [R01CA047456, R55CA047456] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044428] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47456] Funding Source: Medline; NHLBI NIH HHS [HL48008] Funding Source: Medline; NIGMS NIH HHS [GM44428] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JM, 1992, ONCOGENE, V7, P611; AGNEL M, 1992, MOL CELL BIOL, V12, P5111, DOI 10.1128/MCB.12.11.5111; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHEN LC, 1991, P NATL ACAD SCI USA, V88, P3847, DOI 10.1073/pnas.88.9.3847; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUANG TH, 1993, J BIOL CHEM, V268, P775; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COLLINS S, 1987, MOL CELL BIOL, V7, P2870, DOI 10.1128/MCB.7.8.2870; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DISILVESTRE D, 1990, NUCLEIC ACIDS RES, V18, P5924, DOI 10.1093/nar/18.19.5924; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEISTERKAMP N, 1989, NUCLEIC ACIDS RES, V17, P8821, DOI 10.1093/nar/17.21.8821; HEISTERKAMP N, 1993, CAUSES CONSEQUENCES, P359; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; RON D, 1991, NEW BIOL, V3, P372; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; STAM K, 1985, NEW ENGL J MED, V313, P1429, DOI 10.1056/NEJM198512053132301; ZHU QS, 1990, NUCLEIC ACIDS RES, V18, P7119, DOI 10.1093/nar/18.23.7119	32	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16903	16906						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349582				2022-12-27	WOS:A1993LQ98800009
J	RAMKUMAR, V; STILES, GL; BEAVEN, MA; ALI, H				RAMKUMAR, V; STILES, GL; BEAVEN, MA; ALI, H			THE A(3) ADENOSINE RECEPTOR IS THE UNIQUE ADENOSINE RECEPTOR WHICH FACILITATES RELEASE OF ALLERGIC MEDIATORS IN MAST-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MOLECULAR-CLONING; LIGAND-BINDING; RBL-2H3 CELLS; EXPRESSION; SUBTYPES	Mast cells release the mediators of the immediate hypersensitivity reaction. Adenosine is known to modulate this process, but the receptor responsible for this is not the classical A1 or A2 adenosine receptors. This study was undertaken to determine whether the unique adenosine receptor (AR) previously postulated in a cultured mast cell line (RBL-2H3 cells) is the recently cloned A3AR. The receptors were quantitated by the agonist I-125-labeled APNEA (aminophenylethyladenosine), an A3AR agonist, which yielded B(max) and K(d) values of 826 fmol/mg protein and 34 nM, respectively. A variety of adenosine analogs competed for I-125-APNEA binding sites with the following potency series: (R)-phenylisopropyladenosine = 5'-N-ethylcarboxamide adenosine > (S)-phenylisopropyladenosine. I-125-APNEA binding was relatively insensitive to the xanthine amine congener (XAC, 1 muM), a selective antagonist for the A1AR. Functionally, activation of these A3AR stimulated the production of inositol 1,4,5-triphosphate, leading to an increase in the level of intracellular Ca2+. Furthermore, while activation of these receptors alone produced little secretory response in RBL-2H3 cells, it enhanced antigen-induced secretion by 2-2.5-fold. Northern blotting studies using poly(A+) RNA from RBL-2H3 cells detected two transcripts of 2.0 and 3.5 kilobases, which hybridized to an A3AR cDNA but not to the A1 or A2AR cDNA probes. These data indicate that the unique AR that potentiates the secretory response to antigen in RBL-2H3 cells is exclusively the A3AR.	DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED CARDIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED RHEUMATOL & IMMUNOL,DURHAM,NC 27710; NHLBI,CHEM PHARMACOL LAB,BETHESDA,MD 20892	Duke University; Duke University; Duke University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	RAMKUMAR, V (corresponding author), SO ILLINOIS UNIV,SCH MED,DEPT PHARMACOL,801 N RUTLEDGE ST,SPRINGFIELD,IL 62794, USA.							ALI H, 1991, J PHARMACOL EXP THER, V258, P954; ALI H, 1990, J BIOL CHEM, V265, P745; BARRETT K E, 1984, Agents and Actions, V14, P488, DOI 10.1007/BF01973856; CHURCH MK, 1986, BRIT J PHARMACOL, P233; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; DAVIS GD, 1986, METHODS MOL BIOL; DELEAN A, 1982, MOL PHARMACOL, V21, P5; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; HANCOCK AA, 1979, MOL PHARMACOL, V16, P1; HIDE M, 1991, J BIOL CHEM, V266, P15221; KINET JP, 1990, FC RECEPTORS ACTION, P239; LIBERT F, 1991, EMBO J, V10, P1677, DOI 10.1002/j.1460-2075.1991.tb07691.x; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; MAHAN LC, 1991, MOL PHARMACOL, V40, P1; MEYERHOF W, 1991, FEBS LETT, V284, P155, DOI 10.1016/0014-5793(91)80674-R; OLAH ME, 1992, J BIOL CHEM, V267, P10764; OLAH ME, 1990, ARCH BIOCHEM BIOPHYS, V283, P440, DOI 10.1016/0003-9861(90)90665-L; RAMKUMAR V, 1990, MOL PHARMACOL, V37, P149; RAMKUMAR V, 1991, MOL PHARMACOL, V40, P639; Ramkumar V, 1988, Prog Drug Res, V32, P195; STILES GL, 1986, J NEUROCHEM, V47, P1020; STILES GL, 1986, J BIOL CHEM, V261, P839; STILES GL, 1992, J BIOL CHEM, V267, P6451; VANDERHOEK JY, 1982, J BIOL CHEM, V257, P2191; VANPEL A, 1985, SOMAT CELL MOLEC GEN, V11, P467; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	26	408	429	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16887	16890						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349579				2022-12-27	WOS:A1993LQ98800005
J	FRIEDRICH, T; KROGER, B; BIALOJAN, S; LEMAIRE, HG; HOFFKEN, HW; REUSCHENBACH, P; OTTE, M; DODT, J				FRIEDRICH, T; KROGER, B; BIALOJAN, S; LEMAIRE, HG; HOFFKEN, HW; REUSCHENBACH, P; OTTE, M; DODT, J			A KAZAL-TYPE INHIBITOR WITH THROMBIN SPECIFICITY FROM RHODNIUS-PROLIXUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTICOAGULANT PEPTIDE TAP; RAY CRYSTAL-STRUCTURE; FACTOR-XA; OVOMUCOID INHIBITOR; REACTIVE SITE; 3RD DOMAIN; SALIVARY; PROTEINS; BINDING; TRYPSIN	A thrombin-specific inhibitor with an apparent molecular mass of 11 kDa has been purified from the insect Rhodnius prolixus. Amino-terminal protein sequence analysis allowed the molecular cloning of the corresponding cDNA. The open reading frame codes for a protein of about 103 amino acid residues and displays an internal sequence homology of residues 6-48 with residues 57-101 indicating a two-domain structure. Based on the amino acid sequence the two domains exhibit high homology to protease inhibitors belonging to the Kazal-type family. Model building suggests that the first domain binds to the active site with residue His10 pointing into the specificity pocket. From gel filtration and tight-binding inhibition experiments the inhibitor appears to form 1:1 complexes with thrombin. Periplasma-directed heterologous expression of the rhodniin cDNA in Escherichia coli yields the intact thrombin inhibitor. Natural and recombinant rhodniin both display inhibition constants of about 2 x 10(-13) M.	TH DARMSTADT,INST BIOCHEM,W-6100 DARMSTADT,GERMANY	Technical University of Darmstadt	FRIEDRICH, T (corresponding author), BASF AG,DEPT BIOTECHNOL,BIOTECHNOL ZHB,W-6700 LUDWIGSHAFEN,GERMANY.							ARDELT W, 1985, BIOCHEMISTRY-US, V24, P5313, DOI 10.1021/bi00341a007; Ben Hamouda M.H., 1982, Archives de l'Institut Pasteur de Tunis, V59, P251; BODE W, 1986, EMBO J, V5, P2453, DOI 10.1002/j.1460-2075.1986.tb04521.x; BODE W, 1992, PROTEIN SCI, V1, P426; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDZYNSKI AZ, 1981, P SOC EXP BIOL MED, V168, P266; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DENNIS S, 1990, EUR J BIOCHEM, V188, P61, DOI 10.1111/j.1432-1033.1990.tb15371.x; DUONG LT, 1989, EP0352119A2; ELECTRICWALA A, 1991, BLOOD COAGUL FIBRIN, V2, P83, DOI 10.1097/00001721-199102000-00013; FENTON JW, 1991, BLOOD COAGUL FIBRIN, V2, P69, DOI 10.1097/00001721-199102000-00011; FINK E, 1986, BIOL CHEM H-S, V367, P1235, DOI 10.1515/bchm3.1986.367.2.1235; FRITZ JD, 1991, NUCLEIC ACIDS RES, V19, P3747, DOI 10.1093/nar/19.13.3747; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARDELL SJ, 1989, J BIOL CHEM, V264, P17947; HAWKINS RI, 1966, BRIT J HAEMATOL, V12, P86, DOI 10.1111/j.1365-2141.1966.tb00130.x; HELLMANN K, 1966, BRIT J HAEMATOL, V12, P376, DOI 10.1111/j.1365-2141.1966.tb05647.x; HELLMANN K, 1965, NATURE, V207, P265, DOI 10.1038/207265a0; HELLMANN K, 1964, NATURE, V201, P1008, DOI 10.1038/2011008a0; HOCHSTRASSER K, 1989, Protein Sequences and Data Analysis, V2, P453; HUANG TF, 1989, BIOCHEMISTRY-US, V28, P661, DOI 10.1021/bi00428a037; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LEATHERBARROW RJ, 1980, GRAFIT VERSION 2 0; LI P, 1988, THESIS TEMPLE U PHIL; Maniatis T, 1989, DECONTAMINATION DILU; Mann K G, 1976, Methods Enzymol, V45, P123; MARKWARDT F, 1957, H-S Z PHYSIOL CHEM, V308, P147, DOI 10.1515/bchm2.1957.308.1.147; MARKWARDT F, 1960, NATURWISSENSCHAFTEN, V47, P43, DOI 10.1007/BF00590750; MARKWARDT F, 1963, BLUTGERINNUNGSHEMMEN; MAYWALD F, 1988, GENE, V68, P357, DOI 10.1016/0378-1119(88)90038-8; Morrison J.F., 1985, COMMENTS MOL CELL BI, V2, P347; MUSIL D, 1991, J MOL BIOL, V220, P739, DOI 10.1016/0022-2836(91)90114-L; Reisinger P W, 1988, Protein Seq Data Anal, V1, P259; REISINGER PWM, 1987, BIOL CHEM H-S, V368, P717, DOI 10.1515/bchm3.1987.368.1.717; RIBEIRO JMC, 1981, EXPERIENTIA, V37, P384, DOI 10.1007/BF01959876; RIBEIRO JMC, 1981, J EXP BIOL, V94, P219; RIBEIRO JMC, 1980, J INSECT PHYSIOL, V26, P303, DOI 10.1016/0022-1910(80)90138-9; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMITZ T, 1991, EUR J BIOCHEM, V195, P251, DOI 10.1111/j.1432-1033.1991.tb15701.x; SZARDENINGS M, 1989, THESIS TU BERLIN GER; VLASUK GP, 1991, THROMB HAEMOSTASIS, V65, P257; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510; Williams J W, 1979, Methods Enzymol, V63, P437; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	46	169	177	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16216	16222						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344906				2022-12-27	WOS:A1993LQ33600022
J	KAST, R; FURSTENBERGER, G; MARKS, F				KAST, R; FURSTENBERGER, G; MARKS, F			ACTIVATION OF CYTOSOLIC PHOSPHOLIPASE-A2 BY TRANSFORMING GROWTH-FACTOR-ALPHA IN HEL-30 KERATINOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ARACHIDONIC-ACID METABOLISM; GLOMERULAR MESANGIAL CELLS; SIGNAL TRANSDUCTION; PHOSPHOINOSITIDE TURNOVER; TYROSINE PHOSPHORYLATION; EPIDERMAL-CELLS; FACTOR RECEPTOR; TUMOR PROMOTER; PHORBOL ESTERS	In the mouse keratinocyte line HEL-30 the epidermal mitogen transforming growth factor-alpha (TGF-alpha) stimulated the rapid release of arachidonic acid in a dose- and time-dependent manner. The liberation of arachidonic acid was due to the activation of a Ca2+-dependent cytosolic phospholipase A2 (cPLA2). The activation mechanism critically depended on a functionally active epidermal growth factor receptor tyrosine kinase and occurred independently of phospholipase C-mediated increases in cellular diacylglycerol and inositol 1,4,5-trisphosphate concentrations and protein kinase C activation. The activation included an increase in cytosolic PLA2 (cPLA2) activity and an association of the enzyme with the membrane fraction. Both activation steps apparently occurred in the presence of basal cytoplasmic Ca2+ concentrations. Moreover, cPLA2 or a closely associated protein was found to be phosphorylated on tyrosine upon TGF-alpha challenge of the cells. The data suggest that tyrosine phosphorylation is involved in the TGF-alpha-induced activation of cPLA2.	GERMAN CANC RES CTR, RES PROGRAM TUMOR CELL REGULAT, IM NEUENHEIMER FELD 280, W-6900 HEIDELBERG 1, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)								AXELROD J, 1990, BIOCHEM SOC T, V18, P503, DOI 10.1042/bst0180503; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BJIERE KS, 1974, ANAL BIOCHEM, V58, P238; BLACKWELL GJ, 1977, BRIT J PHARMACOL, V59, P353, DOI 10.1111/j.1476-5381.1977.tb07500.x; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; CHANG J, 1987, BIOCHEM PHARMACOL, V36, P2429, DOI 10.1016/0006-2952(87)90512-0; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DVIR A, 1991, J CELL BIOL, V113, P857, DOI 10.1083/jcb.113.4.857; ELDER JT, 1989, SCIENCE, V243, P811, DOI 10.1126/science.2916128; FISCHER SM, 1991, CANCER RES, V51, P850; FISHER GJ, 1989, BIOCHEM BIOPH RES CO, V163, P1344, DOI 10.1016/0006-291X(89)91126-1; Fursin G. I., 1990, Engineering Information in Data Bases and Knowledge Based Systems. Techno-Data '90. Proceedings of the International Conference Techno-Data '90, P107; FURSTENBERGER G, 1981, CANCER LETT, V11, P191, DOI 10.1016/0304-3835(81)90107-5; FURSTENBERGER G, 1987, J CANCER RES CLIN, V113, P310, DOI 10.1007/BF00397714; GALEY CI, 1985, J INVEST DERMATOL, V85, P319, DOI 10.1111/1523-1747.ep12276908; GANSS M, 1982, FEBS LETT, V142, P54, DOI 10.1016/0014-5793(82)80218-4; Glaser K B, 1990, Adv Exp Med Biol, V275, P1; GOLDBERG HJ, 1990, BIOCHEM J, V267, P461, DOI 10.1042/bj2670461; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; GOTTLIEB AB, 1988, J EXP MED, V167, P670, DOI 10.1084/jem.167.2.670; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; HAMMARSTROM S, 1979, J INVEST DERMATOL, V73, P180, DOI 10.1111/1523-1747.ep12581645; IMAMOTO A, 1991, MOL CARCINOGEN, V4, P52, DOI 10.1002/mc.2940040109; KAST R, 1991, EUR J BIOCHEM, V202, P941, DOI 10.1111/j.1432-1033.1991.tb16454.x; KAST R, 1993, IN PRESS FEBS LETT; KLEIN SB, 1992, J CELL PHYSIOL, V151, P326, DOI 10.1002/jcp.1041510214; KRAMER RM, 1988, BIOCHIM BIOPHYS ACTA, V959, P269, DOI 10.1016/0005-2760(88)90200-7; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KVEDAR J, 1987, J INVEST DERMATOL, V88, P124, DOI 10.1111/1523-1747.ep12525270; LEIBERSPERGER H, 1991, J BIOL CHEM, V266, P14778; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS BL, 1988, BIOCHEM J, V256, P469, DOI 10.1042/bj2560469; MARGOLIS BL, 1988, BIOCHEM J, V249, P587, DOI 10.1042/bj2490587; MOOLENAAR WH, 1986, J BIOL CHEM, V261, P279; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; MOSCAT J, 1988, MOL ENDOCRINOL, V2, P799, DOI 10.1210/mend-2-9-799; MUKHERJEE AB, 1992, DNA CELL BIOL, V11, P233, DOI 10.1089/dna.1992.11.233; MURRAY AW, 1979, CANCER LETT, V7, P71, DOI 10.1016/S0304-3835(79)80098-1; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; PARKER J, 1987, J BIOL CHEM, V262, P5385; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; PRUZANSKI W, 1991, IMMUNOL TODAY, V12, P143, DOI 10.1016/0167-5699(91)90077-7; SCHLAEPFER DD, 1987, J BIOL CHEM, V262, P6931; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; SPAARGAREN M, 1992, BIOCHEM J, V287, P37, DOI 10.1042/bj2870037; TAKUWA N, 1991, J BIOL CHEM, V266, P14237; TALWAR HS, 1990, J INVEST DERMATOL, V95, P705, DOI 10.1111/1523-1747.ep12514507; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; VELU TJ, 1990, MOL CELL ENDOCRINOL, V70, P205, DOI 10.1016/0303-7207(90)90211-P; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WEISS BA, 1991, J BIOL CHEM, V266, P2126; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x	59	71	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16795	16802						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344957				2022-12-27	WOS:A1993LQ33600100
J	KWON, YG; SRINIVASAN, J; MENDELOW, M; PLUSKEY, S; LAWRENCE, DS				KWON, YG; SRINIVASAN, J; MENDELOW, M; PLUSKEY, S; LAWRENCE, DS			STEREOCHEMISTRY SPECIFIES THE REGIOCHEMISTRY OF PHOSPHORYLATION IN 2 CAMP-DEPENDENT PROTEIN-KINASE SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMER-BOUND OXIME; BOVINE CARDIAC-MUSCLE; APOLIPOPROTEIN-A-I; CATALYTIC SUBUNIT; PEPTIDE MODEL; SEQUENCE; SEGMENTS	The substrate specificity of the cAMP-dependent protein kinase has been assessed with peptides bearing threoninol diastereomers. The threoninol residue contains both a primary alcohol and a secondary alcohol, either of which may serve as a site of phosphorylation. The enzyme-catalyzed phosphorylation of Gly-Arg-Thr-Gly-Arg-Arg-Asn-(2R,3R)-threoninol furnishes a K(m) of 498 +/- 39 muM and a V(max) of 7.8 +/- 0.2 mumol/min-mg, whereas the phosphorylation of Gly-Arg-Thr-Gly-Arg-Arg-Asn-(2S,3S)-threoninol provides a K(m) of 16.3 +/- 0.8 muM and a V(max) of 16.0 +/- 0.4 mumol/min-mg. Mass spectral analysis of the phosphopeptide reaction products revealed that each species is phosphorylated only once. H-1-coupled P-31 NMR experiments unequivocally demonstrated that the (2R,3R)-isomer is specifically phosphorylated at the secondary alcohol, whereas the (2S,3S)-isomer is exclusively phosphorylated at the primary alcohol. This regiospecificity appears to be a consequence of the stereochemistry at C-2 in the threoninol residues. The structural attributes of the protein kinase that appear to be responsible for the observed differentiation between the C-2 stereoisomers is discussed.	SUNY Buffalo, DEPT CHEM, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NIGMS NIH HHS [GM45989] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045989] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG RN, 1978, BIOCHEMISTRY-US, V17, P2840, DOI 10.1021/bi00607a022; DEGRADO WF, 1982, J ORG CHEM, V47, P3258, DOI 10.1021/jo00138a011; DEGRADO WF, 1980, J ORG CHEM, V45, P1295, DOI 10.1021/jo01295a026; FERAMISCO JR, 1979, J BIOL CHEM, V254, P6987; HO C, 1969, BIOCHEMISTRY-US, V8, P2074, DOI 10.1021/bi00833a044; KAISER ET, 1989, ACCOUNTS CHEM RES, V22, P47, DOI 10.1021/ar00158a001; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KREBS EG, 1985, BIOCHEM SOC T, V13, P813, DOI 10.1042/bst0130813; KWON YG, 1993, J BIOL CHEM, V268, P10713; NAKAGAWA SH, 1983, J ORG CHEM, V48, P678, DOI 10.1021/jo00153a012; NAKAGAWA SH, 1985, J AM CHEM SOC, V107, P7087, DOI 10.1021/ja00310a055; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PROROK M, 1989, J BIOCHEM BIOPH METH, V18, P167, DOI 10.1016/0165-022X(89)90001-8; PROROK M, 1989, J BIOL CHEM, V264, P17727; SHOJI S, 1983, BIOCHEMISTRY-US, V22, P3702, DOI 10.1021/bi00284a025; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	19	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16725	16729						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344952				2022-12-27	WOS:A1993LQ33600091
J	WOO, SB; SHENOY, BC; WOOD, HG; MAGNER, WJ; KUMAR, GK; BEEGEN, H; SAMOLS, D				WOO, SB; SHENOY, BC; WOOD, HG; MAGNER, WJ; KUMAR, GK; BEEGEN, H; SAMOLS, D			EFFECT OF DELETION FROM THE CARBOXYL-TERMINUS OF THE 12 S-SUBUNIT ON ACTIVITY OF TRANSCARBOXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOTIN ENZYMES; MUTAGENESIS	Transcarboxylase from Propionibacterium shermanii is a biotin-containing enzyme which catalyzes the reversible transfer of a carboxyl group from methylmalonyl-CoA to pyruvate. The central hexameric 12 S subunit of the enzyme associates with six 6 S subunits in the complete enzyme complex. We have constructed a series of cloned genes which encode COOH-terminal truncations of the 12 S subunit. Five of these subunits, which remained soluble following expression in Escherichia coli and were missing from 39 to 97 COOH-terminal amino acids, were purified and compared to the full-length subunit after enzyme complexes were assembled in vitro. All of the truncated subunits were 90% as active in the transcarboxylase reaction as wild type except the reaction containing the shortest complex, TC-12 S (1-507), which had 54% of the wild type activity (TC-12 S-WT). The reduced activity was not due to a lack of CoA ester binding sites or the K(m) for substrate. However, TC-12 S (1-507) was slower to form than TC-12 S-WT and had more incomplete complexes as judged by high performance liquid chromatrography gel filtration profiles and electron microscopy. Isolated TC-12 S (1-507) was 70-80% as active as TC-12 S-WT. We also noted that the truncated form was heat-labile compared to wild type. We conclude that the COOH-terminal region of the 12 S subunit plays a role in assembly and stability of the hexamer and also affects the binding of 6 S subunits to form enzyme complexes. Once complexes do form, the catalytic capacity of TC-12 S (1-507) is almost the same as TC-12 S-WT.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,10900 EUCLID AVE,CLEVELAND,OH 44106	Case Western Reserve University			Magner, William/A-4573-2019	Magner, William/0000-0001-5314-9536	NIGMS NIH HHS [GM 40786] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040786] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAHLER C, 1981, BIOCHEM INT, V3, P349; BERGER M, 1976, J BIOL CHEM, V251, P7021; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUANG M, 1975, BIOCHEMISTRY-US, V4, P1161; HENNESSEY JP, 1982, BIOCHEMISTRY-US, V21, P642, DOI 10.1021/bi00533a007; KRAUS JP, 1986, P NATL ACAD SCI USA, V83, P8040; KUMAR GK, 1982, J BIOL CHEM, V257, P13828; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MURTIF VL, 1985, P NATL ACAD SCI USA, V82, P5617, DOI 10.1073/pnas.82.17.5617; MURTIF VL, 1987, J BIOL CHEM, V262, P11813; NORTHROP DB, 1969, J BIOL CHEM, V244, P5808; PHILLIPS NFB, 1986, BIOCHEMISTRY-US, V25, P1644, DOI 10.1021/bi00355a030; POTO EM, 1978, J BIOL CHEM, V253, P2979; RYLATT DB, 1977, ARCH BIOCHEM BIOPHYS, V183, P113, DOI 10.1016/0003-9861(77)90425-8; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; SHENOY BC, 1992, J BIOL CHEM, V267, P18407; TAKAI T, 1988, J BIOL CHEM, V263, P2651; WARBURG O, 1941, BIOCHEM Z, V310, P394; Wood H G, 1976, CRC Crit Rev Biochem, V4, P47, DOI 10.3109/10409237609102558; WOOD HG, 1977, ANNU REV BIOCHEM, V46, P385, DOI 10.1146/annurev.bi.46.070177.002125; WRIGLEY NG, 1977, J BIOL CHEM, V252, P1500	22	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16413	16419						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344927				2022-12-27	WOS:A1993LQ33600050
J	YOU, JC; MCHENRY, CS				YOU, JC; MCHENRY, CS			HIV NUCLEOCAPSID PROTEIN - EXPRESSION IN ESCHERICHIA-COLI, PURIFICATION, AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; ROUS-SARCOMA VIRUS; AVIAN RETROVIRUS PARTICLES; DNA-BINDING PROTEINS; NUCLEIC-ACIDS; MYELOBLASTOSIS VIRUS; STRUCTURAL PROTEINS; VIRAL INFECTIVITY; GAG POLYPROTEIN; RNA	The single-stranded nucleocapsid protein that coats the RNA genome of human immunodeficiency virus within the virion core has been produced in Escherichia coli and purified to homogeneity. The mature 55-amino acid protein, normally generated from the gag polyprotein precursor by HIV protease-catalyzed processing of both its amino and carboxyl termini, was produced in E. coli with authentic termini directly, without the need for processing. The protein was purified 30-fold to apparent homogeneity, as determined by both amino acid analysis and SDS-polyacrylamide gel electrophoresis. Sequencing of each terminus of the purified protein indicated that no proteolytic degradation occurred. A molar extinction coefficient (epsilon280 = 8350 cm-1 M-1) was, determined. The purified nucleocapsid protein binds tightly to single-stranded RNA as judged by a nitrocellulose filter binding assay. A binding constant (K(w)) of 1 x 10(8) M-1 was calculated. Using fluorescence quenching of nucleocapsid protein upon RNA binding as an assay, a binding site size of seven nucleotides was determined. These results contrast to a larger 15-nucleotide site measured by others for a larger form of nucleocapsid protein-containing sequences from its immature precursor. The possible relevance of these findings are discussed.			YOU, JC (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026600] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI26600] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ambler R P, 1972, Methods Enzymol, V25, P262, DOI 10.1016/S0076-6879(72)25023-6; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BENZ EW, 1979, P NATL ACAD SCI USA, V76, P3294, DOI 10.1073/pnas.76.7.3294; BESS JW, 1992, J VIROL, V66, P840, DOI 10.1128/JVI.66.2.840-847.1992; BOLOGNESI DP, 1978, SCIENCE, V199, P183, DOI 10.1126/science.202022; BOONE LR, 1981, J VIROL, V37, P109, DOI 10.1128/JVI.37.1.109-116.1981; BOONE LR, 1980, P NATL ACAD SCI-BIOL, V77, P847, DOI 10.1073/pnas.77.2.847; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN MJ, 1980, P NATL ACAD SCI-BIOL, V77, P1296, DOI 10.1073/pnas.77.3.1296; COVEY SN, 1986, NUCLEIC ACIDS RES, V14, P623, DOI 10.1093/nar/14.2.623; CRAWFORD S, 1985, J VIROL, V53, P899, DOI 10.1128/JVI.53.3.899-907.1985; DAVIS J, 1976, J VIROL, V18, P709, DOI 10.1128/JVI.18.2.709-718.1976; DAVIS NL, 1972, J VIROL, V10, P1010, DOI 10.1128/JVI.10.5.1010-1020.1972; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; FITZGERALD DW, 1991, BIOCHEMISTRY-US, V30, P5195, DOI 10.1021/bi00235a012; FLEISSNER E, 1973, J VIROL, V12, P1612, DOI 10.1128/JVI.12.6.1612-1615.1973; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8; GILBOA E, 1979, CELL, V16, P863, DOI 10.1016/0092-8674(79)90101-6; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195; GRIEP MA, 1992, J BIOL CHEM, V267, P3052; HAGERMAN PJ, 1985, BIOCHEMISTRY-US, V24, P7032; HENDERSON LE, 1981, J BIOL CHEM, V256, P8400; HENDERSON LE, 1988, UCLA S MOL CELL BIOL, V71, P135; HIEMSTRA H, 1986, J BACTERIOL, V168, P140, DOI 10.1128/jb.168.1.140-151.1986; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; KARPEL RL, 1987, J BIOL CHEM, V262, P4961; KELLY RC, 1976, J BIOL CHEM, V251, P7240; KHAN R, 1992, J BIOL CHEM, V267, P6689; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPSON GP, 1965, ANAL BIOCHEM, V11, P374, DOI 10.1016/0003-2697(65)90026-6; LEIS J, 1983, J VIROL, V48, P361, DOI 10.1128/JVI.48.2.361-369.1983; LEVIN JG, 1974, J VIROL, V14, P152, DOI 10.1128/JVI.14.1.152-161.1974; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0; LOHMAN TM, 1986, J MOL BIOL, V187, P603, DOI 10.1016/0022-2836(86)90338-4; LONG CW, 1980, VIROLOGY, V104, P491, DOI 10.1016/0042-6822(80)90352-9; LU AH, 1979, VIROLOGY, V93, P269, DOI 10.1016/0042-6822(79)90297-6; Maniatis T., 1982, MOL CLONING; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486; MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; OERTLE S, 1990, J VIROL, V64, P5757, DOI 10.1128/JVI.64.12.5757-5763.1990; OROSZLAN S, 1976, VIROLOGY, V72, P523, DOI 10.1016/0042-6822(76)90182-3; PENG C, 1989, J VIROL, V63, P2550, DOI 10.1128/JVI.63.6.2550-2556.1989; ROSS EK, 1991, AIDS RES HUM RETROV, V7, P475, DOI 10.1089/aid.1991.7.475; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULEIN M, 1978, J VIROL, V26, P54, DOI 10.1128/JVI.26.1.54-60.1978; SHIELDS A, 1978, CELL, V14, P601, DOI 10.1016/0092-8674(78)90245-3; SHIODA T, 1990, VIROLOGY, V175, P139, DOI 10.1016/0042-6822(90)90194-V; SMITH BJ, 1979, NUCLEIC ACIDS RES, V7, P2055; SOUTH TL, 1990, BIOCHEMISTRY-US, V29, P7786, DOI 10.1021/bi00486a002; STOLTZFUS CM, 1975, J VIROL, V16, P1161, DOI 10.1128/JVI.16.5.1161-1170.1975; SYKORA KW, 1981, J GEN VIROL, V55, P379, DOI 10.1099/0022-1317-55-2-379; TRITCH RJ, 1991, J VIROL, V65, P922, DOI 10.1128/JVI.65.2.922-930.1991; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; VARMUS H, 1984, RNA TUMOR VIRUSES, V1; VERONESE FD, 1987, AIDS RES HUM RETROV, V3, P253, DOI 10.1089/aid.1987.3.253; VOYNOW SL, 1985, J VIROL, V55, P79, DOI 10.1128/JVI.55.1.79-85.1985; WILLIAMS KR, 1983, J BIOL CHEM, V258, P3346	67	88	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16519	16527						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344933				2022-12-27	WOS:A1993LQ33600064
J	BUTTERS, CA; WILLADSEN, KA; TOBACMAN, LS				BUTTERS, CA; WILLADSEN, KA; TOBACMAN, LS			COOPERATIVE INTERACTIONS BETWEEN ADJACENT TROPONIN-TROPOMYOSIN COMPLEXES MAY BE TRANSMITTED THROUGH THE ACTIN FILAMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; RABBIT SKELETAL-MUSCLE; CARDIAC THIN FILAMENT; F-ACTIN; STRIATED-MUSCLE; NONPOLYMERIZABLE TROPOMYOSIN; MYOSIN SUBFRAGMENT-1; ALPHA-TROPOMYOSIN; BINDING; CONTRACTION	Recent analyses of the assembly of thin filaments containing altered forms of troponin (or no troponin) suggested that the strongly cooperative nature of troponin-tropomyosin binding to actin might be primarily caused by indirect interactions involving the actin lattice, rather than by direct contacts between neighboring troponin-tropomyosin molecules. To test this hypothesis, thin filament assembly was examined using either cardiac tropomyosin digested with carboxypeptidase A (cbpTm) or a tropomyosin with defective function at both amino and carboxyl termini (unacetylated cbpTm). Compared to intact troponin-tropomyosin, both troponin-cbpTm and troponin-unacetylated cbpTm had much weaker binding to actin; however, cooperative interactions were only slightly reduced. These data support the implication that the primary source of the cooperativity involves troponin-tropomyosin-promoted conformational changes within the actin polymer. Surprisingly, the effects of tropomyosin amino- and carboxyl-terminal structural defects on troponin-tropomyosin binding to actin were not additive. In the presence of troponin, tropomyosin molecules with either defect had the same diminution in actin affinity as molecules with both defects. Finally, the Ca2+ sensitivity of troponin-tropomyosin binding to actin was increased by alteration of either end of tropomyosin.	UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa; University of Iowa					NHLBI NIH HHS [HL38834] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038834, R01HL038834] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRANDT PW, 1987, J MOL BIOL, V195, P885, DOI 10.1016/0022-2836(87)90492-X; CHO YJ, 1990, J BIOL CHEM, V265, P538; COLLINS JH, 1977, J BIOL CHEM, V252, P6356; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; GRAND RJA, 1976, BIOCHEM J, V159, P633, DOI 10.1042/bj1590633; GREASER ML, 1973, J BIOL CHEM, V248, P2125; HEALD RW, 1988, J BIOL CHEM, V263, P5254; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; HILL LE, 1992, J BIOL CHEM, V267, P16106; Hill T. L., 1985, COOPERATIVITY THEORY; HILL TL, 1980, P NATL ACAD SCI-BIOL, V77, P3186, DOI 10.1073/pnas.77.6.3186; HITCHCOCK SE, 1973, J MOL BIOL, V80, P825, DOI 10.1016/0022-2836(73)90212-X; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; INGRAHAM RH, 1984, J BIOL CHEM, V259, P9544; INGRAHAM RH, 1985, BIOCHEMISTRY-US, V24, P5221, DOI 10.1021/bi00340a040; ISHII Y, 1991, J BIOL CHEM, V266, P6894; ISHII Y, 1987, BIOCHEMISTRY-US, V26, P4922, DOI 10.1021/bi00390a005; IZAKOV VY, 1991, CIRC RES, V69, P1171; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7035, DOI 10.1021/bi00396a027; LEWIS WG, 1980, J BIOL CHEM, V255, P6854; MAK AS, 1983, J BIOL CHEM, V258, P4330; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; MAK AS, 1981, BIOCHEM BIOPH RES CO, V101, P208, DOI 10.1016/S0006-291X(81)80032-0; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MEHEGAN JP, 1991, J BIOL CHEM, V266, P966; METZGER JM, 1991, J GEN PHYSIOL, V98, P233, DOI 10.1085/jgp.98.2.233; MOSS RL, 1992, CIRC RES, V70, P865, DOI 10.1161/01.RES.70.5.865; MOSS RL, 1985, J GEN PHYSIOL, V86, P585, DOI 10.1085/jgp.86.4.585; PAN BS, 1989, J BIOL CHEM, V264, P8495; PEARLSTONE JR, 1976, P NATL ACAD SCI USA, V73, P1902, DOI 10.1073/pnas.73.6.1902; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; POTTER JD, 1974, ARCH BIOCHEM BIOPHYS, V162, P436, DOI 10.1016/0003-9861(74)90202-1; SODEK J, 1978, J BIOL CHEM, V253, P1129; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWENSON CA, 1992, BIOCHEMISTRY-US, V31, P3420, DOI 10.1021/bi00128a017; SZCZESNA D, 1989, BIOL CHEM H-S, V370, P399, DOI 10.1515/bchm3.1989.370.1.399; TOBACMAN LS, 1990, J BIOL CHEM, V265, P931; TOBACMAN LS, 1987, J BIOL CHEM, V263, P2668; VANEERD JP, 1975, BIOCHEM BIOPH RES CO, V64, P122, DOI 10.1016/0006-291X(75)90227-2; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; WALSH TP, 1984, J MOL BIOL, V182, P265; WEGNER A, 1979, J MOL BIOL, V131, P839, DOI 10.1016/0022-2836(79)90204-3; WEGNER A, 1981, BIOCHEMISTRY-US, V20, P5633, DOI 10.1021/bi00522a043; WILKINSON JM, 1978, NATURE, V271, P31, DOI 10.1038/271031a0; WILLADSEN KA, 1992, J BIOL CHEM, V267, P23746; WILLIAMS DL, 1988, BIOCHEMISTRY-US, V27, P6987, DOI 10.1021/bi00418a048; ZASEDATELEV AS, 1971, MOL BIOL, V131, P839; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	52	69	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15565	15570						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340383				2022-12-27	WOS:A1993LN30500039
J	FREIJE, JP; BALBIN, M; ABRAHAMSON, M; VELASCO, G; DALBOGE, H; GRUBB, A; LOPEZOTIN, C				FREIJE, JP; BALBIN, M; ABRAHAMSON, M; VELASCO, G; DALBOGE, H; GRUBB, A; LOPEZOTIN, C			HUMAN CYSTATIN-D - CDNA CLONING, CHARACTERIZATION OF THE ESCHERICHIA-COLI EXPRESSED INHIBITOR, AND IDENTIFICATION OF THE NATIVE PROTEIN IN SALIVA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN WHOLE SALIVA; C AMYLOID ANGIOPATHY; AMINO-ACID-SEQUENCE; CATHEPSIN-B; CYSTEINE PROTEINASES; BIOLOGICAL-FLUIDS; GAMMA-TRACE; GENE FAMILY; 3 MEMBERS; PURIFICATION	A cDNA coding for cystatin D, a human member of the cystatin protein family, has been cloned after specific amplification of reverse-transcribed parotid gland RNA. After replacing the segment encoding the putative 20-residue signal peptide with one encoding the Escherichia coli OmpA leader sequence, the cDNA was expressed in E. coli. The isolated recombinant protein exhibited K(i) values of 1.2 nM and >1 muM for papain and cathepsin B, respectively. An antiserum raised against recombinant cystatin D recognized a protein in human saliva with electrophoretical mobility identical to that of the recombinant protein. Immunoenzymatic analysis revealed that this cysteine proteinase inhibitor is present in human saliva and tears at concentrations of 3.8 and 0.5 mg/liter, respectively, while it was not detected in seminal plasma, blood plasma, milk, or cerebrospinal fluid. Cystatin D purified from human saliva by immunosorption displayed a heterogeneous N-terminal end, with sequences starting at residues 5, 7, 9, and 11 of the predicted N-terminal portion of the mature protein. On the basis of structural and functional properties, cystatin D represents a novel cysteine proteinase inhibitor possibly playing a protective role against proteinases present in the oral cavity.	UNIV OVIEDO,DEPT BIOL FUNC,E-33006 OVIEDO,SPAIN; UNIV LUND HOSP,DEPT CLIN CHEM,S-22185 LUND,SWEDEN; NOVO NORDISK AS,GENEEXPRESS,DK-2100 COPENHAGEN,DENMARK	University of Oviedo; Lund University; Skane University Hospital; Novo Nordisk			Abrahamson, Magnus/CAG-9507-2022; Velasco, Gloria/AAS-5842-2021; Freije, José M.P./A-6535-2008; Balbín, Milagros/I-4206-2015; Lopez-Otin, Carlos/AAB-2106-2020	Velasco, Gloria/0000-0001-8032-5056; Freije, José M.P./0000-0002-4688-8266; Balbín, Milagros/0000-0001-5325-0407; Lopez-Otin, Carlos/0000-0001-6964-1904; Grubb, Anders/0000-0002-0125-3662				ABRAHAMSON M, 1988, FEBS LETT, V236, P14, DOI 10.1016/0014-5793(88)80276-X; ABRAHAMSON M, 1990, BIOCHEM J, V268, P287, DOI 10.1042/bj2680287; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; ABRAHAMSON M, 1992, HUM GENET, V89, P377; ABRAHAMSON M, 1989, INTRACELLULAR PROTEO, P305; ADAM A, 1985, CLIN CHEM, V31, P423; ALHASHIMI I, 1988, J BIOL CHEM, V263, P9381; BALBIN M, 1993, HUM GENET, V90, P668; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BARRETT AJ, 1987, TRENDS BIOCHEM SCI, V12, P193, DOI 10.1016/0968-0004(87)90092-2; BARRETT AJ, 1986, BIOCHEM J, V236, P312, DOI 10.1042/bj2360312; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BJORCK L, 1989, NATURE, V337, P385, DOI 10.1038/337385a0; BJORCK L, 1990, J VIROL, V64, P941; BUTTLE DJ, 1990, SCAND J CLIN LAB INV, V50, P509, DOI 10.3109/00365519009089165; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALBOGE H, 1989, GENE, V79, P325, DOI 10.1016/0378-1119(89)90214-X; FREIJE JP, 1991, J BIOL CHEM, V266, P20538; HALL A, 1992, J ENZYM INHIB, V6, P113, DOI 10.3109/14756369209040742; HAWKE DH, 1987, BIOCHEM BIOPH RES CO, V145, P1248, DOI 10.1016/0006-291X(87)91571-3; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; ISEMURA S, 1987, J BIOCHEM-TOKYO, V102, P693, DOI 10.1093/oxfordjournals.jbchem.a122107; ISEMURA S, 1991, J BIOCHEM, V110, P648, DOI 10.1093/oxfordjournals.jbchem.a123634; ISEMURA S, 1986, FEBS LETT, V198, P145, DOI 10.1016/0014-5793(86)81201-7; ISEMURA S, 1984, J BIOCHEM-TOKYO, V96, P489, DOI 10.1093/oxfordjournals.jbchem.a134861; JEPPSSON JO, 1979, CLIN CHEM, V25, P629; KIRSCHKE H, 1987, LYSOSOMES THEIR ROLE, P193; KRIEGER TJ, 1991, J BIOL CHEM, V266, P8376; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY E, 1989, J EXP MED, V169, P1771, DOI 10.1084/jem.169.5.1771; LINDAHL P, 1992, BIOCHEM J, V281, P49, DOI 10.1042/bj2810049; LOFBERG H, 1979, SCAND J CLIN LAB INV, V39, P619, DOI 10.3109/00365517909108866; LOFBERG H, 1987, STROKE, V18, P431, DOI 10.1161/01.STR.18.2.431; Maniatis T., 1982, MOL CLONING; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORT JS, 1984, ARTHRITIS RHEUM, V27, P509, DOI 10.1002/art.1780270505; MULLERESTERL W, 1986, TRENDS BIOCHEM SCI, V11, P336, DOI 10.1016/0968-0004(86)90293-8; NICKLIN MJH, 1984, BIOCHEM J, V223, P245, DOI 10.1042/bj2230245; OLAFSSON I, 1990, SCAND J CLIN LAB INV, V50, P85, DOI 10.3109/00365519009091569; OPPENHEIM FG, 1988, J BIOL CHEM, V263, P7472; ORLOWSKI M, 1983, MOL CELL BIOCHEM, V52, P49; PALSDOTTIR A, 1988, LANCET, V2, P603; RAMASUBBU N, 1991, BIOCHEM J, V280, P341, DOI 10.1042/bj2800341; RAWLINGS ND, 1990, J MOL EVOL, V30, P60, DOI 10.1007/BF02102453; RAWLINGS ND, 1990, COMPUT APPL BIOSCI, V6, P118; SABATINI LM, 1989, J DENT RES, V68, P1138, DOI 10.1177/00220345890680070101; SAITOH E, 1988, BIOL CHEM H-S, V369, P191; SAITOH E, 1991, BIOMED BIOCHIM ACTA, V50, P599; SAITOH E, 1987, GENE, V61, P329, DOI 10.1016/0378-1119(87)90196-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIDEGGER JJ, 1955, INT ARCH ALLER A IMM, V7, P103, DOI 10.1159/000228215; Sloane B F, 1990, Semin Cancer Biol, V1, P137; TAUGNER R, 1985, HISTOCHEMISTRY, V83, P103, DOI 10.1007/BF00495138; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	56	66	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15737	15744						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340398				2022-12-27	WOS:A1993LN30500062
J	FUJII, M; HORI, H; MIYAZAKI, G; MORIMOTO, H; YONETANI, T				FUJII, M; HORI, H; MIYAZAKI, G; MORIMOTO, H; YONETANI, T			THE PORPHYRIN-IRON HYBRID HEMOGLOBINS - ABSENCE OF THE FE-HIS BONDS IN ONE TYPE OF SUBUNITS FAVORS A DEOXY-LIKE STRUCTURE WITH LOW-OXYGEN AFFINITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; PARTIALLY LIGANDED HEMOGLOBIN; PROTOPORPHYRIN-IX; QUATERNARY STRUCTURES; COBALT MYOGLOBINS; ADULT HEMOGLOBIN; CARBON-DIOXIDE; BETA-CHAINS; EQUILIBRIUM; BINDING	Protoporphyrin-protoheme hybrid hemoglobins (Hb), in which the protohemes (Fe) in either the alpha- or beta-subunits were substituted with protoporphyrins IX (PP) alpha(PP)2beta(Fe)2 and alpha(Fe)2beta(PP)2 have been prepared. The structural and functional properties of these hybrid Hbs were investigated by measuring oxygen equilibrium curves and proton nuclear magnetic resonance spectra. The equilibrium constants of the first ligand, K1, observed for alpha(PP)2beta(Fe)2 were much smaller than K1 values of HbA. The effects of pH and inositol hexaphosphate on K1 were substantially diminished. On the other hand, K1 values of alpha(Fe)2beta(PP)2 were similar to those of HbA, including the pH and inositol hexaphosphate effects. The deoxy forms of alpha(PP)2beta(Fe)2 and alpha(Fe)2beta(PP)2 showed exchangeable proton resonances at 11 and 14 parts/million arising from the hydrogen bonds at the alpha1beta2 contact in a deoxy-like structure. In the liganded form, these signals were dependent upon solution conditions. As K1 became larger, the reduction in the intensity of these signals was observed for both liganded forms. The resonance position of E11 Val originating from the beta subunits of alpha(PP)2beta(Fe-CO)2 also varied in accordance with K1. We compare properties of PP-Fe hybrids with those of Co-Fe and Ni-Fe hybrids and conclude that the first oxygen binding to the beta heme may be linked to the metal-proximal His interaction in the a subunits. However, the first oxygen binding to the a heme is linked minimally to the metal-proximal His interaction in the beta subunits but may be correlated instead to the position of E11 Val relative to the porphyrin plane in the beta subunits.	UNIV PENN,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; OSAKA UNIV,FAC ENGN SCI,DEPT BIOPHYS ENGN,TOYONAKA,OSAKA 560,JAPAN	University of Pennsylvania; Osaka University					NHLBI NIH HHS [HL 14508] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL014508, R37HL014508] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANERJEE R, 1969, J MOL BIOL, V42, P351, DOI 10.1016/0022-2836(69)90048-5; CASSOLY R, 1971, EUR J BIOCHEM, V19, P514, DOI 10.1111/j.1432-1033.1971.tb01343.x; COLE SJ, 1971, J AM CHEM SOC, V93, P2153, DOI 10.1021/ja00738a011; DALVIT C, 1985, BIOCHEMISTRY-US, V24, P3398, DOI 10.1021/bi00335a003; ELLFOLK N, 1966, J CHROMATOGR, V25, P373, DOI 10.1016/S0021-9673(01)98255-X; FANELLI AR, 1958, BIOCHIM BIOPHYS ACTA, V30, P608, DOI 10.1016/0006-3002(58)90108-2; FERMI G, 1975, J MOL BIOL, V97, P237, DOI 10.1016/S0022-2836(75)80037-4; FUNG LWM, 1975, BIOCHEMISTRY-US, V14, P2526, DOI 10.1021/bi00682a036; HAYASHI A, 1973, BIOCHIM BIOPHYS ACTA, V310, P309, DOI 10.1016/0005-2795(73)90110-4; HAYASHI N, 1966, J BIOL CHEM, V241, P79; IKEDASAITO M, 1977, J BIOL CHEM, V252, P620; IMAI K, 1970, Biochimica et Biophysica Acta, V200, P189, DOI 10.1016/0005-2795(70)90163-7; IMAI K, 1980, J MOL BIOL, V138, P635, DOI 10.1016/S0022-2836(80)80021-0; Imai K., 1982, ALLOSTERIC EFFECTS H; INUBUSHI T, 1986, J AM CHEM SOC, V108, P3799, DOI 10.1021/ja00273a040; ISHIMORI K, 1988, BIOCHEMISTRY-US, V27, P4060, DOI 10.1021/bi00411a023; ISHIMORI K, 1992, BIOCHEMISTRY-US, V31, P3256, DOI 10.1021/bi00127a030; ISHIMORI K, 1989, BIOCHEMISTRY-US, V28, P8603, DOI 10.1021/bi00447a050; KIKUCHI G, 1964, BIOCHIM BIOPHYS ACTA, V90, P199, DOI 10.1016/0304-4165(64)90142-4; KILMARTIN JV, 1973, J BIOL CHEM, V248, P7039; KILMARTIN JV, 1971, BIOCHEM J, V124, P31, DOI 10.1042/bj1240031; LAMAR GN, 1979, PORPHYRINS, V4, P129; LEONARD JJ, 1974, BIOCHEMISTRY-US, V13, P1460, DOI 10.1021/bi00704a022; LINDSTROMTR, 1972, BIOCHEMISTRY-US, V11, P1677; LINDSTROMTR, 1973, BIOCHEMISTRY-US, V12, P134; LUISI B, 1990, J MOL BIOL, V214, P7, DOI 10.1016/0022-2836(90)90139-D; LYNCH RE, 1976, J BIOL CHEM, V251, P1015; MAEDA T, 1972, BIOCHEMISTRY-US, V11, P3685, DOI 10.1021/bi00770a004; MATSUKAWA S, 1979, J BIOL CHEM, V254, P2358; MAYER A, 1973, J MOL BIOL, V81, P187, DOI 10.1016/0022-2836(73)90188-5; MIURA S, 1984, BIOCHEMISTRY-US, V23, P2492, DOI 10.1021/bi00306a027; MIURA S, 1982, BIOCHEMISTRY-US, V21, P6280, DOI 10.1021/bi00267a037; NAGAI K, 1977, J MOL BIOL, V111, P41, DOI 10.1016/S0022-2836(77)80130-7; NAGAI K, 1980, P NATL ACAD SCI-BIOL, V77, P2033, DOI 10.1073/pnas.77.4.2033; NAGAI K, 1982, BIOCHEMISTRY-US, V21, P842, DOI 10.1021/bi00534a005; OGAWA S, 1972, BIOCHEM BIOPH RES CO, V49, P1485, DOI 10.1016/0006-291X(72)90507-4; PARKHURST LJ, 1970, J BIOL CHEM, V245, P4131; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; PERUTZ MF, 1976, BIOCHEMISTRY-US, V15, P378, DOI 10.1021/bi00647a022; PULSINELLI PD, 1973, P NATL ACAD SCI USA, V270, P3800; RUSSU IM, 1987, BIOCHIM BIOPHYS ACTA, V914, P40, DOI 10.1016/0167-4838(87)90159-2; SHIBAYAMA N, 1986, J MOL BIOL, V192, P331, DOI 10.1016/0022-2836(86)90368-2; SHIBAYAMA N, 1986, J MOL BIOL, V192, P323, DOI 10.1016/0022-2836(86)90367-0; SHIBAYAMA N, 1987, BIOCHEMISTRY-US, V26, P2194, DOI 10.1021/bi00382a019; SIMOLO K, 1985, J AM CHEM SOC, V107, P2865, DOI 10.1021/ja00296a006; STYNES DV, 1973, J AM CHEM SOC, V95, P1796, DOI 10.1021/ja00787a018; SUGITA Y, 1975, J BIOL CHEM, V250, P1251; SUZUKI T, 1965, BIOCHEM BIOPH RES CO, V19, P691, DOI 10.1016/0006-291X(65)90312-8; TREFFRY A, 1974, BIOCHEM J, V137, P319, DOI 10.1042/bj1370319; TSUBAKI M, 1979, J BIOCHEM-TOKYO, V86, P1029, DOI 10.1093/oxfordjournals.jbchem.a132596; VIGGIANO G, 1979, P NATL ACAD SCI USA, V76, P3673, DOI 10.1073/pnas.76.8.3673; VIGGIANO G, 1978, BIOCHEMISTRY-US, V17, P795, DOI 10.1021/bi00598a007; WATERMAN MR, 1970, J BIOL CHEM, V245, P5847; WINTERBOURN CC, 1976, BIOCHEM J, V155, P493, DOI 10.1042/bj1550493; WINTERHA.KH, 1966, NATURE, V211, P932, DOI 10.1038/211932a0	56	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15386	15393						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340369				2022-12-27	WOS:A1993LN30500014
J	CHAN, D; TAYLOR, TKF; COLE, WG				CHAN, D; TAYLOR, TKF; COLE, WG			CHARACTERIZATION OF AN ARGININE-789 TO CYSTEINE SUBSTITUTION IN ALPHA-1(II) COLLAGEN CHAINS OF A PATIENT WITH SPONDYLOEPIPHYSEAL DYSPLASIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOGEN-BROMIDE PEPTIDES; GENE COL2A1; MILD CHONDRODYSPLASIA; SERINE SUBSTITUTION; GEL-ELECTROPHORESIS; II PROCOLLAGEN; ALPHA-CHAINS; MUTATION; CELLS; IDENTIFICATION	A child with spondyloepiphyseal dysplasia congenita was shown to be heterozygous for a mutation of the COL2A1 gene that encodes the alpha1(II) chain of type II collagen. The alpha1(II) chains extracted from cartilage contained disulfide-bonded dimeric and trimeric alpha1(II) chains. Carboxymethylation confirmed that some of the type II collagen chains contained cysteine residues that are not normally present in alpha1(II) chains. Cyanogen bromide peptide mapping showed that the abnormal cysteine residue was located in the alpha1(II) CB10.5 peptide. Amplification products of the corresponding region of alpha1(II) cDNA prepared from cultured dermal fibroblasts were shown by chemical cleavage and single strand conformation polymorphism analyses to contain a sequence anomaly. DNA sequencing showed a transition of C2913T in exon 41 of one allele of the COL2A1 gene resulting in the substitution of arginine 789 by cysteine in the alpha1(II) chain. The mutation resulted in the loss of a MaeII cleavage site that was used to confirm that the proband was heterozygous for the mutation and that neither parent showed evidence of the mutation. The type II collagen extracted from cartilage and from chondrocytes cultured in alginate beads showed similar characteristics. Approximately a third of the type II collagen chains were mutant, and the secretion of molecules containing mutant chains was impaired. The thermal stability of the collagen extracted from cartilage was normal. This study confirmed the importance of dominant negative mutations of the COL2A1 gene in producing the spondyloepiphyseal dysplasia congenita phenotype.	UNIV MELBOURNE,ROYAL CHILDRENS HOSP,DEPT PEDIAT,PARKVILLE,VIC 3052,AUSTRALIA; ROYAL N SHORE HOSP,DEPT ORTHOPAED & TRAUMAT SURG,ST LEONARDS,NSW 2065,AUSTRALIA	Royal Children's Hospital Melbourne; University of Melbourne; Royal North Shore Hospital			Chan, Danny/C-4203-2009	Chan, Danny/0000-0003-3824-5778				AHMAD NN, 1991, P NATL ACAD SCI USA, V88, P6624, DOI 10.1073/pnas.88.15.6624; ALAKOKKO L, 1990, P NATL ACAD SCI USA, V87, P6565, DOI 10.1073/pnas.87.17.6565; BALDWIN CT, 1989, BIOCHEM J, V262, P521, DOI 10.1042/bj2620521; BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; BYERS PH, 1991, J MED GENET, V28, P433, DOI 10.1136/jmg.28.7.433; CHAN D, 1984, ANAL BIOCHEM, V139, P322, DOI 10.1016/0003-2697(84)90012-5; CHAN D, 1991, J BIOL CHEM, V266, P12487; CHEAH KSE, 1985, P NATL ACAD SCI USA, V82, P2555, DOI 10.1073/pnas.82.9.2555; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; COLE WG, 1981, BIOCHEM J, V197, P377, DOI 10.1042/bj1970377; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; EYRE DR, 1991, J CLIN INVEST, V87, P357, DOI 10.1172/JCI114994; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; GUO JF, 1989, CONNECT TISSUE RES, V19, P277, DOI 10.3109/03008208909043901; Higuchi R, 1989, PCR TECHNOLOGY PRINC, P31; HORTON WA, 1992, P NATL ACAD SCI USA, V89, P4583, DOI 10.1073/pnas.89.10.4583; JIMINEZ SA, 1992, ARTICULAR CARTILAGE, P167; LACHMAN RS, 1992, EUR J RADIOL, V14, P1, DOI 10.1016/0720-048X(92)90052-B; LEE B, 1989, SCIENCE, V244, P978, DOI 10.1126/science.2543071; MILLER EJ, 1973, BIOCHEMISTRY-US, V12, P3153, DOI 10.1021/bi00741a003; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; SPRANGER J, 1988, PATHOL IMMUNOPATH R, V7, P76, DOI 10.1159/000157098; TILLER GE, 1990, P NATL ACAD SCI USA, V87, P3889, DOI 10.1073/pnas.87.10.3889; VISSING H, 1989, J BIOL CHEM, V264, P18265	27	93	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15238	15245						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325895				2022-12-27	WOS:A1993LL75900100
J	FLINT, DH; EMPTAGE, MH; FINNEGAN, MG; FU, WG; JOHNSON, MK				FLINT, DH; EMPTAGE, MH; FINNEGAN, MG; FU, WG; JOHNSON, MK			THE ROLE AND PROPERTIES OF THE IRON-SULFUR CLUSTER IN ESCHERICHIA-COLI DIHYDROXY-ACID DEHYDRATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC CIRCULAR-DICHROISM; ELECTRON-PARAMAGNETIC-RES; COMPLETE NUCLEOTIDE-SEQUENCE; SPECTROSCOPIC CHARACTERIZATION; AZOTOBACTER-VINELANDII; ACTIVATED ACONITASE; SYNTHETIC ANALOGS; 4FE-4S CLUSTER; PROTEIN; FERREDOXIN	Dihydroxy-acid dehydratase has been purified from Escherichia coli and characterized as a homodimer with a subunit molecular weight of 66,000. The combination of UV visible absorption, EPR, magnetic circular dichroism, and resonance Raman spectroscopies indicates that the native enzyme contains a [4Fe-4S]2+,+ cluster, in contrast to spinach dihydroxy-acid dehydratase which contains a [2Fe-2S]2+,+ cluster (Flint, D. H., and Emptage, M. H. (1988) J. Biol. Chem. 263, 3558-3564). In frozen solution, the reduced [4Fe-4S]+ cluster has a S = 3/2 ground state with minor contributions from forms with S = 1/2 and possibly S = 5/2 ground states. Resonance Raman studies of the [4Fe-4S]2+ cluster in E. coli dihydroxy-acid dehydratase indicate non-cysteinyl coordination of a specific iron, which suggests that it is likely to be directly involved in catalysis as is the case with aconitase (Emptage, M. H., Kent, T. A., Kennedy, M. C., Beinert, H., and Munck, E. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 4674-4678). Dihydroxy-acid dehydratase from E. coli is inactivated by O2 in vitro and in vivo as a result of oxidative degradation of the [4Fe-4S] cluster. Compared to aconitase, the oxidized cluster of E. coli dihydroxy-acid dehydratase appears to be less stable as either a cubic or linear [3Fe-4S] cluster or a [2Fe-2S] cluster. Oxidative degradation appears to lead to a complete breakdown of the Fe-S cluster, and the resulting protein cannot be reactivated with Fe2+ and thiol reducing agents.	UNIV GEORGIA,CTR MET ENZYME STUDIES,ATHENS,GA 30602; UNIV GEORGIA,DEPT CHEM,ATHENS,GA 30602	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	FLINT, DH (corresponding author), DUPONT CO INC,DEPT CENT RES & DEV,WILMINGTON,DE 19880, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033806] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33806] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ABELES RH, 1976, ACCOUNTS CHEM RES, V9, P114, DOI 10.1021/ar50099a006; ARFIN SM, 1969, J BIOL CHEM, V244, P2250; ARMSTRONG FA, 1989, BIOCHEM J, V264, P265, DOI 10.1042/bj2640265; BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Beinert H, 1978, Methods Enzymol, V54, P435; BOEHME DE, 1976, NATURE, V262, P418, DOI 10.1038/262418a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN OR, 1978, BIOCHEM BIOPH RES CO, V85, P1219, DOI 10.1016/0006-291X(78)90672-1; BRUSCHI M, 1988, FEMS MICROBIOL LETT, V54, P155, DOI 10.1111/j.1574-6968.1988.tb02741.x; CARNEY MJ, 1988, J AM CHEM SOC, V110, P6084, DOI 10.1021/ja00226a025; CARNEY MJ, 1989, INORG CHEM, V28, P1497, DOI 10.1021/ic00307a015; CIOFFI EA, 1980, ANAL BIOCHEM, V104, P485, DOI 10.1016/0003-2697(80)90104-9; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; COX JL, 1987, GENE, V56, P185, DOI 10.1016/0378-1119(87)90136-3; CZERNUSZEWICZ RS, 1987, J AM CHEM SOC, V109, P7178, DOI 10.1021/ja00257a045; DREYER JL, 1985, EUR J BIOCHEM, V150, P145, DOI 10.1111/j.1432-1033.1985.tb09000.x; EMPTAGE M H, 1990, P315; EMPTAGE MH, 1983, J BIOL CHEM, V258, P1106; EMPTAGE MH, 1988, ACS SYM SER, V372, P343; EMPTAGE MH, 1983, P NATL ACAD SCI-BIOL, V80, P4674, DOI 10.1073/pnas.80.15.4674; FEE JA, 1980, BIOCHEM INT, V1, P304; FLINT DH, 1992, BIOCHEMISTRY-US, V31, P10331, DOI 10.1021/bi00157a022; FLINT DH, 1988, J BIOL CHEM, V263, P3558; FU WG, 1992, J BIOL CHEM, V267, P16135; FUJ W, 1992, J BIOL CHEM, V267, P15502; GRABOWSKI R, 1991, EUR J BIOCHEM, V199, P89, DOI 10.1111/j.1432-1033.1991.tb16095.x; GRAY JE, 1981, MOL GEN GENET, V183, P428, DOI 10.1007/BF00268761; HAMILTON CL, 1989, J BIOL CHEM, V264, P11605; Hill R. L., 1971, ENZYMES, V5, P539; HILL RK, 1973, J AM CHEM SOC, V95, P7857, DOI 10.1021/ja00804a048; JOHNSON MK, 1988, ACS SYM SER, V372, P326; JOHNSON MK, 1982, IRON SULFUR PROTEINS, P267; KELLY JM, 1986, FEBS LETT, V202, P274, DOI 10.1016/0014-5793(86)80700-1; KENNEDY MC, 1988, J BIOL CHEM, V263, P8194; KENNEDY MC, 1984, J BIOL CHEM, V259, P4463; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KENT TA, 1982, P NATL ACAD SCI-BIOL, V79, P1096, DOI 10.1073/pnas.79.4.1096; Kiritani K., 1970, METHOD ENZYMOL, V17, P755; KUCHTA RD, 1986, BIOCHEMISTRY-US, V25, P7301, DOI 10.1021/bi00371a009; KUO CF, 1987, J BIOL CHEM, V262, P4724; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; LAWTHER RP, 1987, NUCLEIC ACIDS RES, V15, P2137, DOI 10.1093/nar/15.5.2137; LINDAHL PA, 1987, J BIOL CHEM, V262, P14945; LINDAHL PA, 1987, INORG CHEM, V26, P3912, DOI 10.1021/ic00270a018; LOPES JM, 1986, NUCLEIC ACIDS RES, V14, P2779, DOI 10.1093/nar/14.6.2779; MADDEN JF, 1989, BIOCHEMISTRY-US, V28, P5474; MATSUBARA H, 1983, PROTEIN NUCLEIC ACID, P168; MELOCHE HP, 1964, J BIOL CHEM, V239, P3505; MEYER J, 1986, BIOCHEMISTRY-US, V25, P6054, DOI 10.1021/bi00368a033; MYERS JW, 1961, J BIOL CHEM, V236, P1414; ONATE YA, 1989, J BIOL CHEM, V264, P18386; ONATE YA, 1993, IN PRESS BIOCH BIOPH; RICHARDS AJM, 1990, SPECTROCHIM ACTA A, V46, P987, DOI 10.1016/0584-8539(90)80015-Q; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; SCHWEIGER G, 1987, EUR J BIOCHEM, V169, P441, DOI 10.1111/j.1432-1033.1987.tb13631.x; SCOPES RK, 1984, ANAL BIOCHEM, V136, P530, DOI 10.1016/0003-2697(84)90257-4; TELSER J, 1986, J BIOL CHEM, V261, P4840; UZAN M, 1981, MOL GEN GENET, V182, P462, DOI 10.1007/BF00293936	60	127	169	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14732	14742						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325851				2022-12-27	WOS:A1993LL75900033
J	TAKEDA, J; GIDHJAIN, M; XU, LZ; FROGUEL, P; VELHO, G; VAXILLAIRE, M; COHEN, D; SHIMADA, F; MAKINO, H; NISHI, S; STOFFEL, M; VIONNET, N; STCHARLES, R; HARRISON, RW; WEBER, IT; BELL, GI; PILKIS, SJ				TAKEDA, J; GIDHJAIN, M; XU, LZ; FROGUEL, P; VELHO, G; VAXILLAIRE, M; COHEN, D; SHIMADA, F; MAKINO, H; NISHI, S; STOFFEL, M; VIONNET, N; STCHARLES, R; HARRISON, RW; WEBER, IT; BELL, GI; PILKIS, SJ			STRUCTURE-FUNCTION STUDIES OF HUMAN BETA-CELL GLUCOKINASE - ENZYMATIC-PROPERTIES OF A SEQUENCE POLYMORPHISM, MUTATIONS ASSOCIATED WITH DIABETES, AND OTHER SITE-DIRECTED MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEXOKINASE-B; CONFORMATION; EXPRESSION; LIVER	Glucokinase plays a key role in the regulation of glucose metabolism in insulin-secreting pancreatic beta-cells and in the liver. Recent studies have shown that mutations in this enzyme can lead to the development of a form of non-insulin-dependent diabetes mellitus that is characterized by an autosomal dominant mode of inheritance and onset during childhood. Here, we report the catalytic properties of five additional missense mutations associated with diabetes (Glu70 --> Lys, Ser131 --> Pro, Ala188 --> Thr, Trp257 --> Arg and Lys414 --> Glu), one polymorphism present in both normal and diabetic subjects (Asp4 --> Asn), and three site-directed mutations (Glu177 --> Lys, Glu256 --> Ala, and Lys414 --> Ala). The Trp257 --> Arg mutation generated an enzyme that had an activity that was less than 0.5% of that for native human beta-cell glucokinase. By contrast, the Glu70 --> Lys, Ser131 --> Pro, Ala188 --> Thr, and Lys414 --> Glu mutations had a V(max) that was 20-100% of normal but a K(m) for glucose that was 8-14-fold greater than the native enzyme. There was no effect of the Asp4 --> Asn polymorphism or the Glu177 --> Lys substitution on glucokinase activity. The Lys414 --> Ala substitution had no effect on V(max) but increased the K(m) for glucose 2-fold and the Glu256 --> Ala substitution caused a approximately 200-fold decrease in V(max). These studies have led to the identification of additional residues involved in glucokinase catalysis and substrate binding.	SUNY, HLTH SCI CTR,DEPT PHYSIOL & BIOPHYS,LEVEL 6,RM 140, STONY BROOK, NY 11794 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT BIOCHEM & MOLEC BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA; CTR ETUD POLYMORPHISM HUMAIN, F-75010 PARIS, FRANCE; CHIBA UNIV, SCH MED, DEPT INTERNAL MED 2, CHIBA 260, JAPAN; HAMAMATSU UNIV SCH MED, DIV INTERNAL MED 2, HAMAMATSU, SHIZUOKA 43132, JAPAN; THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College; Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; Chiba University; Hamamatsu University School of Medicine; Jefferson University			Velho, Gilberto/Q-6724-2017; FROGUEL, Philippe/O-6799-2017; Vionnet, Nathalie/N-6302-2017	Velho, Gilberto/0000-0001-8811-363X; FROGUEL, Philippe/0000-0003-2972-0784; Harrison, Robert/0000-0003-2449-1214	NIDDK NIH HHS [DK-44840, DK-20595, DK-38354] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK038354, P60DK020595, R01DK038354, P01DK044840] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON CM, 1979, SCIENCE, V204, P375, DOI 10.1126/science.220706; ANDERSON CM, 1978, J MOL BIOL, V123, P1, DOI 10.1016/0022-2836(78)90373-X; ANDREONE TL, 1989, J BIOL CHEM, V264, P363; BARK P, 1992, P NATL ACAD SCI USA, V89, P7290; BENNETT WS, 1980, J MOL BIOL, V140, P211, DOI 10.1016/0022-2836(80)90103-5; CHEIN CT, 1989, BIOCHEM BIOPH RES CO, V165, P817; FLATHERTY KM, 1990, NATURE, V346, P623; FLATHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; GIDHJAIN M, 1993, P NATL ACAD SCI USA, V90, P1932, DOI 10.1073/pnas.90.5.1932; GRANNER DK, 1990, J BIOL CHEM, V265, P16012; HARRISON RW, 1985, THESIS YALE U NEW HA; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KATAGIRI H, 1992, LANCET, V340, P1316, DOI 10.1016/0140-6736(92)92494-Z; LANGE AJ, 1991, BIOCHEM J, V277, P159, DOI 10.1042/bj2770159; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; NISHI S, 1992, DIABETOLOGIA, V35, P743; SAKURA H, 1992, J CLIN ENDOCR METAB, V75, P1571, DOI 10.1210/jc.75.6.1571; SHIMADA F, 1993, IN PRESS DIABETOLOGI, V36; STOFFEL M, 1992, NAT GENET, V2, P153, DOI 10.1038/ng1092-153; STOFFEL M, 1992, P NATL ACAD SCI USA, V89, P7698, DOI 10.1073/pnas.89.16.7698; STOFFEL M, 1993, IN PRESS DIABETES; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VANSCHAFTINGEN E, 1992, ADV ENZYME REGUL, V32, P133; VELHO G, 1992, LANCET, V340, P444, DOI 10.1016/0140-6736(92)91768-4; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; WEINHOUSE S, 1976, CURR TOP CELL REGUL, V11, P1	27	57	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15200	15204						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325892				2022-12-27	WOS:A1993LL75900095
J	WENG, ZG; TAYLOR, JA; TURNER, CE; BRUGGE, JS; SEIDELDUGAN, C				WENG, ZG; TAYLOR, JA; TURNER, CE; BRUGGE, JS; SEIDELDUGAN, C			DETECTION OF SRC HOMOLOGY 3-BINDING PROTEINS, INCLUDING PAXILLIN, IN NORMAL AND V-SRC-TRANSFORMED BALB/C 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; ABL TYROSINE KINASE; SIGNAL TRANSDUCTION; BINDING PROTEIN; C-SRC; CATALYTIC DOMAINS; CELLULAR PROTEINS; FOCAL ADHESIONS; SH3 DOMAINS; PP60C-SRC	The Src homology 3 (SH3) domain, located in the amino-terminal, noncatalytic half of pp60src, is highly conserved among members of the Src family of tyrosine kinases. SH3 domains have also been identified in a variety of proteins otherwise unrelated to protein-tyrosine kinases. The presence of SH3 domains in proteins with diverse functions suggests this domain may be important for directing protein-protein interactions necessary for protein function or cellular localization. To explore possible interactions between the SH3 domain and cellular proteins, we have established conditions for the isolation of proteins that bind in solution to the Src SH3 domain. A 67-amino acid fragment of c-Src containing either the entire glutathione S-transferase-SH3 domain (GST-SH3) or the SH3 domain from the neuronal form of c-Src (GST-SH3+) was expressed as a glutathione S-transferase fusion protein. The GST fusion proteins were incubated with lysates from [S-35]methionine-labeled Balb/c 3T3 cells or v-Src-transformed Balb/c 3T3 cells. We found that GSTSH3, but not wild-type GST, specifically interacted with multiple cellular proteins, whereas GST-SH3+ only weakly associated with a small subset of these proteins. The majority of the SH3-binding proteins were found in particulate and detergent-insoluble cell fractions. Anti-phosphotyrosine immunoblots of the SH3-binding proteins revealed that several of the SH3-binding proteins are phosphorylated on tyrosine in v-Src-transformed cells. In addition, a number of the SH3-binding proteins were phosphorylated on serine and/or threonine in in vitro kinase assays, suggesting that one or more of the SH3-binding proteins has kinase activity. We identified paxillin, a vinculin-binding protein, as one of the Src SH3-binding proteins. This finding strongly supports the hypothesis that SH3 domains may be involved in subcellular localization of proteins to cytoskeleton and/or cellular membranes.	ARIAD PHARMACEUT,26 LANDSDOWNE ST,CAMBRIDGE,MA 02139; UNIV PENN,SCH MED,HOWARD HUGHES MED INST,DEPT MICROBIOL,PHILADELPHIA,PA 19104; SUNY HLTH SCI CTR,DEPT ANAT & CELL BIOL,SYRACUSE,NY 13210	Takeda Pharmaceutical Company Ltd; Takeda Oncology; Howard Hughes Medical Institute; University of Pennsylvania; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NATIONAL CANCER INSTITUTE [R01CA027951, R37CA027951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047607, R01GM047607] Funding Source: NIH RePORTER; NCI NIH HHS [CA27951] Funding Source: Medline; NIGMS NIH HHS [R01 GM047607, GM47607] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BRUGGE JS, 1984, J BIOL CHEM, V259, P4550; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1981, MOL CELL BIOL, V1, P394, DOI 10.1128/MCB.1.5.394; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI H, 1990, GENE DEV, V4, P2342, DOI 10.1101/gad.4.12b.2342; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LEVINSON AD, 1981, P NATL ACAD SCI-BIOL, V78, P1624, DOI 10.1073/pnas.78.3.1624; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; PAWSON T, 1988, ONCOGENE, V3, P491; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Potts W M, 1988, Oncogene Res, V3, P343; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MK, 1990, J BIOL CHEM, V265, P1837; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	61	229	234	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14956	14963						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325872				2022-12-27	WOS:A1993LL75900064
J	LILLEY, RM; RIESEN, H; ANDREWS, TJ				LILLEY, RM; RIESEN, H; ANDREWS, TJ			THE SOURCE AND CHARACTERISTICS OF CHEMILUMINESCENCE ASSOCIATED WITH THE OXYGENASE REACTION CATALYZED BY MN2+-RIBULOSEBISPHOSPHATE CARBOXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; RIBULOSEBISPHOSPHATE CARBOXYLASE; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; BINDING	We confirm the observation of Mogel and McFadden (Mogel, S. N., and McFadden, B. A. (1990) Biochemistry 29, 8333-8337) that ribulosebisphosphate carboxylase/oxygenase (rubisco) exhibits chemiluminescence while catalyzing its oxygenase reaction in the presence of Mn2+. However, our results with the spinach and Rhodospirillum rubrum enzymes differ markedly in the following respects. 1) Chemiluminescence intensity was directly proportional to enzyme concentration and behaved as if representing the rate of oxygenase catalysis. 2) The wavelength spectrum peaked at about 770 nm and extended beyond 810 nm. This seems inconsistent with chemiluminescence generated by simultaneous decay of pairs of singlet O2 molecules. It is consistent with manganese(II) luminescence and we discuss its possible sources. The time course of chemiluminescence (resolution, 0.25 s) was distinctively different for spinach and R. rubrum enzymes during the initial 5 s of catalysis, with the bacterial enzyme exhibiting a pronounced initial ''burst.'' Chemiluminescence by the spinach enzyme responded to substrate concentrations in a manner consistent with known oxygenase properties, exhibiting Michaelis-Menten kinetics with ribulose-1,5-bisphosphate (K(m) 400 nM). Chemiluminescence required carbamylated enzyme with Mn2+ bound at the active site (activation energy, -57.1 KJ . mol-1). As an indicator of oxygenase activity, chemiluminescence represents an improvement over oxygen electrode measurements in response time and sensitivity by factors of at least 100.	AUSTRALIAN NATL UNIV,RES SCH CHEM,CANBERRA,ACT 2601,AUSTRALIA; AUSTRALIAN NATL UNIV,RES SCH BIOL SCI,CANBERRA,ACT 2601,AUSTRALIA	Australian National University; Australian National University	LILLEY, RM (corresponding author), UNIV WOLLONGONG,DEPT BIOL SCI,NORTHFIELDS AVE,WOLLONGONG,NSW 2522,AUSTRALIA.		Lilley, Ross/B-8127-2008	Lilley, Ross/0000-0002-4292-4629				Andrews T.J., 1987, BIOCH PLANTS, P131, DOI 10.1016/B978-0-12-675410-0.50009-9; BADGER MR, 1980, J BIOL CHEM, V255, P7870; Badger MR, 1978, CARNEGIE I WASHINGTO, P355; DRAGO RS, 1983, COORDINATION CHEM ME, P247; EDMONDSON DL, 1990, FEBS LETT, V260, P62, DOI 10.1016/0014-5793(90)80066-R; EDMONDSON DL, 1990, PLANT PHYSIOL, V93, P1376, DOI 10.1104/pp.93.4.1376; Englman R, 1979, NONRADIATIVE DECAY I; GUNDERMANN KD, 1987, CHEMILUMINESCENCE OR; Horecker B. L., 1958, BIOCHEM PREP, V6, P83; JORDAN DB, 1983, J BIOL CHEM, V258, P3752; JORDAN DB, 1983, BIOCHEMISTRY-US, V22, P3410, DOI 10.1021/bi00283a017; JORDAN DB, 1981, PLANT PHYSIOL, V67, P237, DOI 10.1104/pp.67.2.237; KHAN AU, 1970, J AM CHEM SOC, V92, P3293, DOI 10.1021/ja00714a010; Lever A.B.P., 1985, INORGANIC ELECT SPEC, V2nd; MARTIN MN, 1981, FEBS LETT, V129, P39, DOI 10.1016/0014-5793(81)80750-8; MOGEL SN, 1990, BIOCHEMISTRY-US, V29, P8333, DOI 10.1021/bi00488a019; MORELL MK, 1990, FEBS LETT, V265, P41, DOI 10.1016/0014-5793(90)80879-N; MORELL MK, 1992, AUST J BOT, V40, P431, DOI 10.1071/BT9920431; PAUL K, 1991, BIOCHEMISTRY-US, V30, P10019, DOI 10.1021/bi00105a029	19	7	7	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13877	13884						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314755				2022-12-27	WOS:A1993LJ82500019
J	SMITH, RL; BANKS, JL; SNAVELY, MD; MAGUIRE, ME				SMITH, RL; BANKS, JL; SNAVELY, MD; MAGUIRE, ME			SEQUENCE AND TOPOLOGY OF THE CORA MAGNESIUM TRANSPORT-SYSTEMS OF SALMONELLA-TYPHIMURIUM AND ESCHERICHIA-COLI - IDENTIFICATION OF A NEW CLASS OF TRANSPORT PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYTOPIC MEMBRANE-PROTEIN; DNA-BINDING PROTEINS; UVRD GENE; NUCLEOTIDE-SEQUENCE; EXPRESSION; CLONING; EXPORT; HELICES; FUSIONS; SUBUNIT	The CorA Mg2+ transport systems of Salmonella typhimurium and Escherichia coli mediate both influx and efflux of Mg2+. The product of the CorA locus is sufficient for mediation of me, influx while product(s) of the unlinked CorBCD loci allow CorA to mediate efflux in addition to influx. The nucleotide sequences of the S. typhimurium and E. coli CorA loci have been determined. The locus in each species consists of a single gene expressing a protein with gel molecular masses of 42 kDa (S. typhimurium) and 39 kDa (E. coli). The predicted amino acid sequences of these proteins are each 316 amino acids in length, are 98% identical, and lack homology to any known protein. Although CorA is an integral membrane protein by biochemical criteria, its predicted amino acid sequence contains 28% charged amino acid. Membrane localization of CorA was shown to be dependent on the Sec pathway in E. coli. Hydropathy analysis predicts two C-terminal hydrophobic sequences of sufficient length to span the membrane bilayer. The membrane topology of CorA was determined by constructing deletion derivatives of CorA and genetically fusing them to BlaM or LacZ cassettes. The enzymatic activities of these hybrid proteins indicate that the N-terminal 235 amino acid residues of the CorA protein are located within the periplasmic space, comprising a single periplasmic domain. The C-terminal region of CorA is composed of three membrane-spanning segments rather than the two suggested by hydropathy plots, thus depositing the C terminus within the cytoplasm. This topology suggests that CorA functions as an oligomer since three membrane loops are most likely insufficient for any sort of membrane pore or channel. Its lack of homology to known proteins and its topology indicate that the CorA Mg2+ transporter represents a new class of membrane transport system.			SMITH, RL (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHARMACOL, CLEVELAND, OH 44106 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007319] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039447] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32-DK07319] Funding Source: Medline; NIGMS NIH HHS [GM39447] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBANO M, 1989, J BACTERIOL, V171, P5386, DOI 10.1128/jb.171.10.5386-5404.1989; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BASSFORD P, 1991, CELL, V65, P367, DOI 10.1016/0092-8674(91)90453-6; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BROOMESMITH JK, 1990, MOL MICROBIOL, V4, P1637, DOI 10.1111/j.1365-2958.1990.tb00540.x; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; Creighton TE, 1983, PROTEINS STRUCTURES; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; DIMRI GP, 1992, J BACTERIOL, V174, P4583, DOI 10.1128/JB.174.14.4583-4593.1992; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FINCH PW, 1984, NUCLEIC ACIDS RES, V12, P5789, DOI 10.1093/nar/12.14.5789; Gennis R.B., 1989, BIOMEMBRANES; GIBSON MM, 1991, MOL MICROBIOL, V5, P2753, DOI 10.1111/j.1365-2958.1991.tb01984.x; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIGGINS CF, 1988, GENE, V72, P3, DOI 10.1016/0378-1119(88)90122-9; HILLE B, 1992, IONIC CHANNELS EXCIT, P1; HMIEL SP, 1989, J BACTERIOL, V171, P4742, DOI 10.1128/jb.171.9.4742-4751.1989; HMIEL SP, 1986, J BACTERIOL, V168, P1444, DOI 10.1128/jb.168.3.1444-1450.1986; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEAR JD, 1988, SCIENCE, V240, P1177, DOI 10.1126/science.2453923; LEE JI, 1992, J BIOL CHEM, V267, P938; LEWIS MJ, 1990, J BIOL CHEM, V265, P10541; LODISH HF, 1988, TRENDS BIOCHEM SCI, V13, P332, DOI 10.1016/0968-0004(88)90101-6; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; MANOIL C, 1988, TRENDS GENET, V4, P223, DOI 10.1016/0168-9525(88)90154-0; MANOIL C, 1990, J BACTERIOL, V172, P1035, DOI 10.1128/jb.172.2.1035-1042.1990; MCKNIGHT SL, 1988, CURR TOP MICROBIOL, V141, P186; Miller JH., 1972, EXPT BACTERIAL GENET; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; OEDA K, 1981, MOL GEN GENET, V184, P191, DOI 10.1007/BF00272904; PARK MH, 1976, J BACTERIOL, V126, P1096, DOI 10.1128/JB.126.3.1096-1103.1976; Quiocho FA, 1991, CURR OPIN STRUC BIOL, V1, P922, DOI 10.1016/0959-440X(91)90087-A; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; RICHARDSON JS, 1989, TRENDS BIOCHEM SCI, V14, P304, DOI 10.1016/0968-0004(89)90070-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SILVER S, 1992, MICROBIOL REV, V56, P195, DOI 10.1128/MMBR.56.1.195-228.1992; Silver S., 1987, ION TRANSPORT PROKAR, P165; SNAVELY MD, 1989, J BACTERIOL, V171, P4761, DOI 10.1128/jb.171.9.4761-4766.1989; SNAVELY MD, 1991, J BIOL CHEM, V266, P824; SNAVELY MD, 1989, J BACTERIOL, V171, P4752, DOI 10.1128/jb.171.9.4752-4760.1989; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; TENG Q, 1991, J MOL BIOL, V218, P607, DOI 10.1016/0022-2836(91)90705-B; TRAXLER B, 1992, J BIOL CHEM, V267, P5339; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1990, PROTEIN ENG, V4, P109, DOI 10.1093/protein/4.2.109; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WU JH, 1992, J BIOL CHEM, V267, P12570; YAMAMOTO Y, 1986, J BIOCHEM-TOKYO, V99, P1579, DOI 10.1093/oxfordjournals.jbchem.a135631; YUN CH, 1991, J BIOL CHEM, V266, P10967	54	105	114	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14071	14080						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314774				2022-12-27	WOS:A1993LJ82500045
J	FERREIRA, GC				FERREIRA, GC			MAMMALIAN FERROCHELATASE - OVEREXPRESSION IN ESCHERICHIA-COLI AS A SOLUBLE-PROTEIN, PURIFICATION AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROPOIETIC PROTOPORPHYRIA; MOLECULAR-CLONING; GENE; EXPRESSION; SEQUENCE; DEFECT; MUTANT; DNA	Ferrochelatase (protoheme ferrolyase, EC 4.99.1.1), a membrane bound protein, catalyzes the terminal step of the heme biosynthesis in all living systems. A cDNA encoding the murine ferrochelatase (Taketani, S., Nakahashi, Y., Osumi, T, and Tokunaga, R. (1990) J. Biol. Chem. 265, 19377-19380) has been expressed in Escherichia coli, using the alkaline phosphatase promoter. Ferrochelatase was not only overexpressed in an active form, but more importantly, was produced as a ''soluble protein'' (i.e. associated with the soluble bacterial protein fraction). A simple purification from the ferrochelatase overproducing bacterial strain yielded similar to 50 mg of protein/2-3 liters of bacterial culture. Recombinant ferrochelatase exhibited identical physical and catalytic properties to those of mammalian ferrochelatases. Specifically, the recombinant ferrochelatase has iron and porphyrin as substrates, and N-methylprotoporphyrin and metal ions (e.g. Hg2+ and Mn2+), as strong inhibitors of its enzyme activity. The K-m values are 112.5 mu m for iron and 95 mu m for deuteroporphyrin IX which are in the same range of the K-m values determined for the ferrochelatases isolated from natural sources. This report describes the overexpression of a mammalian ferrochelatase in E. coli, as a soluble protein, and its purification from an overproducing strain. The production of a functional and ''soluble'' ferrochelatase has significance for the pursuit of structural and functional studies of this enzyme.			FERREIRA, GC (corresponding author), UNIV S FLORIDA,COLL MED,H LEE MOFFITT CANC CTR,INST BIOMOLEC SCI,DEPT BIOCHEM & MOLEC BIOL,TAMPA,FL 33682, USA.		Ferreira, Gloria C/A-4709-2012	Ferreira, Gloria C/0000-0001-9279-2217				Akhtar M., 1991, BIOSYNTHESIS TETRAPY, P67; BOULECHFAR S, 1993, GENOMICS, V16, P645, DOI 10.1006/geno.1993.1242; BRENNER DA, 1991, P NATL ACAD SCI USA, V88, P849, DOI 10.1073/pnas.88.3.849; BRENNER DA, 1992, AM J HUM GENET, V50, P1203; CHAN RYY, 1993, BIOCHEM J, V292, P343, DOI 10.1042/bj2920343; CORNISHBOWDEN A, 1981, FUUNDAMENTALS ENZYME, P99; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; DAILEY HA, 1983, J BIOL CHEM, V258, P1453; DAILEY HA, 1986, METHOD ENZYMOL, V123, P401; DAILEY HA, 1982, J BIOL CHEM, V257, P4714; ELDRIDGE MG, 1992, PROTEIN SCI, V1, P271; FALK JE, 1964, PORPHYRINS METALLOPO; FERREIRA GC, 1993, J BIOL CHEM, V268, P584; FRUSTACI JM, 1993, J BACTERIOL, V175, P2154, DOI 10.1128/JB.175.7.2154-2156.1993; FRUSTACI JM, 1992, J BACTERIOL, V174, P4223, DOI 10.1128/JB.174.13.4223-4229.1992; GARBOCZI DN, 1988, J BIOL CHEM, V263, P15694; JORDAN PM, 1991, BIOSYNTHESIS TETRAPY, P257; KAPPAS A, 1989, METABOLIC BASIS INHE, P1305; KENDALL DA, 1988, J BIOL CHEM, V263, P7261; LABBEBOIS R, 1990, J BIOL CHEM, V265, P7278; LABBEBOIS R, 1993, IN PRESS METAL IONS; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMORIL J, 1991, BIOCHEM BIOPH RES CO, V181, P594, DOI 10.1016/0006-291X(91)91231-Z; MIYAMOTO K, 1991, J MOL BIOL, V219, P393, DOI 10.1016/0022-2836(91)90180-E; NAKAHASHI Y, 1990, BIOCHIM BIOPHYS ACTA, V1037, P321, DOI 10.1016/0167-4838(90)90032-B; NAKAHASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P748, DOI 10.1016/S0006-291X(05)80099-3; NAKAHASHI Y, 1992, P NATL ACAD SCI USA, V89, P281, DOI 10.1073/pnas.89.1.281; NAKAHIGASHI K, 1991, P NATL ACAD SCI USA, V88, P10520, DOI 10.1073/pnas.88.23.10520; NORDMANN Y, 1990, BIOSYNTHESIS HEME CH, P491; PORRA R, 1963, BIOCHEM J, V87, P1181; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRAKA JG, 1991, J BIOL CHEM, V266, P24637; TAKETANI S, 1990, J BIOL CHEM, V265, P19377; TAKETANI S, 1981, J BIOL CHEM, V256, P2748; WANG XH, 1993, BIOCHIM BIOPHYS ACTA, V1181, P198, DOI 10.1016/0925-4439(93)90112-E; WHITCOMBE DM, 1991, GENOMICS, V11, P1152, DOI 10.1016/0888-7543(91)90044-F	38	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4396	4400						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308010				2022-12-27	WOS:A1994MW98900078
J	OH, BH; KANG, CH; DEBONDT, H; KIM, SH; NIKAIDO, K; JOSHI, AK; AMES, GFL				OH, BH; KANG, CH; DEBONDT, H; KIM, SH; NIKAIDO, K; JOSHI, AK; AMES, GFL			THE BACTERIAL PERIPLASMIC HISTIDINE-BINDING PROTEIN - STRUCTURE/FUNCTION ANALYSIS OF THE LIGAND-BINDING SITE AND COMPARISON WITH RELATED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; TRANSPORT-SYSTEMS; ACTIVE-TRANSPORT; RESOLUTION STRUCTURE; AGROBACTERIUM-TUMEFACIENS; MALTOSE TRANSPORT; ARGININE-BINDING; LYSINE-BINDING; X-RAY	Bacterial periplasmic binding proteins are initial receptors in the process of active transport across cell membranes and/or chemotaxis. Among them, the histidine-binding protein (HisJ) has been extensively studied from the biochemical, physiological, and genetic points of view. The three dimensional crystal structure of the histidine binding protein complexed with histidine has been determined at 2.5-Angstrom resolution by the molecular replacement method using as a probe structure the previously solved lysine liganded structure of the lysine-, arginine-, ornithine binding protein (LAG), which shares 70% sequence identity with HisJ. The structure is bi-lobate; the two lobes, one bigger than the other, are connected by two short strands and are in contact with each other (closed) enclosing the histidine. Charged, polar, and non-polar side chains, as well as the peptide backbone, are involved in tight binding of the histidine. The bound histidine is involved in eight direct hydrogen bonds, six with the bigger lobe and two with the smaller lobe, in one potential water-mediated hydrogen bond with the bigger lobe, as well as in ionic interactions. The HisJ residues surrounding the ligand are the same as the LAO residues interacting with lysine, except for residue 52 which is leucine in HisJ and phenylalanine in LAG. The Leu-52 in HisJ makes a hydrophobic interaction with the imidazole ring of histidine. Of seven mutations affecting the ligand-binding site, five are located in the ligand-binding site, one in a con strand, and one at the domains interface. Based on comparisons among related binding proteins, the specific interactions between the ligands and the respective binding protein residues are predicted for the glutamine-binding protein and the opines-binding protein	LAWRENCE BERKELEY LAB, DEPT CHEM, BERKELEY, CA 94720 USA; LAWRENCE BERKELEY LAB, DIV STRUCT BIOL, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley			Oh, Byung-Ha/C-2061-2011		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030725] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043747] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30725] Funding Source: Medline; NIDDK NIH HHS [DK43747] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS MD, 1989, J BIOL CHEM, V264, P15739; ADAMS MD, 1991, J BIOL CHEM, V266, P6209; AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; AMES GFL, 1970, P NATL ACAD SCI USA, V66, P1096, DOI 10.1073/pnas.66.4.1096; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; AMES GFL, 1974, J BIOL CHEM, V249, P634; AMES GFL, 1977, J BACTERIOL, V129, P1289, DOI 10.1128/JB.129.3.1289-1297.1977; AMES GFL, 1990, BACTERIAL ENERGETICS, P225; BENNETT WS, 1984, CRIT REV BIOCH, V15, P290; BINNS AN, 1988, ANNU REV MICROBIOL, V42, P5750; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1991, X PLOR; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; DEAN DA, 1990, RES MICROBIOL, V141, P348, DOI 10.1016/0923-2508(90)90010-N; FUGINAGA M, 1987, J APPL CRYSTALLOGR, V21, P273; GOKCEN S, 1992, THESIS U CALIFORNIA; GUYON P, 1980, P NATL ACAD SCI-BIOL, V77, P2693, DOI 10.1073/pnas.77.5.2693; HIGGINS CF, 1981, P NATL ACAD SCI-BIOL, V78, P6038, DOI 10.1073/pnas.78.10.6038; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; HUBER R, 1985, MOL REPLACEMENT, P58; JOSHI AK, 1991, BIOTECHNIQUES, V10, P42; KANG CH, 1991, J BIOL CHEM, V266, P23893; KANG CH, 1989, J MOL BIOL, V207, P643, DOI 10.1016/0022-2836(89)90475-0; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; KERPPOLA RE, 1990, THESIS U CALIFORNIA; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUSTU SG, 1979, J BACTERIOL, V138, P218, DOI 10.1128/JB.138.1.218-234.1979; LEVER JE, 1972, J BIOL CHEM, V247, P4317; LUKAT GS, 1993, J CELL BIOCHEM, V51, P41, DOI 10.1002/jcb.240510109; MILLER DM, 1983, J BIOL CHEM, V258, P3665; MIMMACK ML, 1989, P NATL ACAD SCI USA, V86, P8257, DOI 10.1073/pnas.86.21.8257; MIMURA CS, 1990, J BIOL CHEM, V265, P19535; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; Mowbray S L, 1990, Receptor, V1, P41; NIKAIDO K, 1992, J BIOL CHEM, V267, P20706; NOHNO T, 1986, MOL GEN GENET, V205, P260, DOI 10.1007/BF00430437; OH BH, 1993, J BIOL CHEM, V268, P11348; PFLUGRATH JW, 1988, J MOL BIOL, V200, P163, DOI 10.1016/0022-2836(88)90341-5; POWELL MJD, 1977, MATH PROGRAM, V12, P273; PROSSNITZ E, 1989, THESIS U CALIFORNIA; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; QUIOCHO FA, 1977, J BIOL CHEM, V252, P5142; QUIOCHO FA, 1984, NATURE, V310, P381, DOI 10.1038/310381a0; RAO SN, 1980, ACTA CRYSTALLOGR A, V36, P878, DOI 10.1107/S0567739480001854; Rossmann M. G., 1972, MOL REPLACEMENT METH; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P225, DOI 10.1107/S0021889879012218; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SACK JS, 1989, J MOL BIOL, V206, P193, DOI 10.1016/0022-2836(89)90532-9; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SHEN QC, 1989, J MOL BIOL, V210, P849, DOI 10.1016/0022-2836(89)90112-5; SHIFRIN S, 1966, J BIOL CHEM, V241, P3424; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; THOMPSON J, 1992, ANNU REV BIOCHEM, V61, P517; TJANDRA N, 1992, J BIOMOL NMR, V2, P149, DOI 10.1007/BF01875526; VALDIVIA RH, 1991, J BACTERIOL, V173, P6398, DOI 10.1128/jb.173.20.6398-6405.1991; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; ZANKER H, 1992, J BACTERIOL, V174, P841, DOI 10.1128/jb.174.3.841-849.1992	59	90	91	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4135	4143						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307974				2022-12-27	WOS:A1994MW98900039
J	PARSELL, DA; KOWAL, AS; LINDQUIST, S				PARSELL, DA; KOWAL, AS; LINDQUIST, S			SACCHAROMYCES-CEREVISIAE HSP104 PROTEIN - PURIFICATION AND CHARACTERIZATION OF ATP-INDUCED STRUCTURAL-CHANGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BINDING; COMPLEX; RING; HYDROLYSIS; MUTATIONS; PARTICLE; SUBUNIT; MEMBER; FAMILY	Heat-shock proteins (hsps) function in a variety of ways to help cells and organisms cope with environmental changes. One class of hsps, the Hsp100 proteins, is especially important for tolerance to a variety of extremely stressful conditions (e.g. high temperatures or high concentrations of ethanol). To begin to characterize the mechanism of action of Hsp100 proteins, we have initiated an in vitro analysis of the Saccharomyces cerevisiae Hsp104 protein. Here, we report the purification and initial structural characterization of the wild-type protein and three variants carrying mutations in the two ATP-binding site consensus elements. As demonstrated by both gel filtration chromatography and by cross-linking studies with glutaraldehyde, Hsp104 forms a homohexameric particle. By electron microscopy, these particles are ring-shaped and reminiscent of proteins in the Hsp60 and TF55/TCP families. In contrast to these other proteins, Hsp104 forms single rings, each containing only six subunits. More strikingly, the assembly and maintenance of Hsp104 particles are dependent upon the presence of adenine nucleotides. Oligomerization appears to primarily depend upon the second of the two ATP-binding sites in the protein.	UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA	University of Chicago; Howard Hughes Medical Institute; University of Chicago					NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001777] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01777] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BANEYX F, 1992, J BIOL CHEM, V267, P11637; BRIDGER WA, 1983, CELL ATP, V5; CRAIG EA, 1985, MOL CELL BIOL, V5, P3517, DOI 10.1128/MCB.5.12.3517; Creighton T. E., 1984, PROTEINS STRUCTURES, V2nd; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HECHT MH, 1983, P NATL ACAD SCI-BIOL, V80, P2676, DOI 10.1073/pnas.80.9.2676; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LIU QY, 1988, VIROLOGY, V163, P638, DOI 10.1016/0042-6822(88)90308-X; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MIAN IS, 1993, TRENDS BIOCHEM SCI, V18, P125; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; PARSELL DA, 1993, PHILOS T R SOC B, V339, P279, DOI 10.1098/rstb.1993.0026; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; ROZEN F, 1989, MOL CELL BIOL, V9, P4061, DOI 10.1128/MCB.9.9.4061; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SANCHEZ Y, 1993, IN PRESS J BACTERIOL; SCHENA M, 1991, P389; SPIESS E, 1987, ELECT MICROSCOPY MOL, P147; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; WALL JS, 1986, ANNU REV BIOPHYS BIO, V15, P355; WOO KM, 1992, J BIOL CHEM, V267, P20429; XIA ZG, 1990, J BIOL CHEM, V265, P6517	40	165	171	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4480	4487						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308017				2022-12-27	WOS:A1994MW98900089
J	LONG, JJ; WANG, JL; BERRY, JO				LONG, JJ; WANG, JL; BERRY, JO			CLONING AND ANALYSIS OF THE C4-PHOTOSYNTHETIC NAD-DEPENDENT MALIC ENZYME OF AMARANTH MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; KINETIC-PROPERTIES; MESSENGER-RNA; PLANTS; PHOTOSYNTHESIS; METABOLISM; SEQUENCE; PYRUVATE; BINDING; LEAVES	In some C4 plant species, a mitochondrial NAD-dependent malic enzyme (EC 1.1.1.39) (NAD-ME) catalyzes the decarboxylation of 4 carbon malate in the bundle sheath cells, releasing CO2 for the Calvin cycle of photosynthesis. In amaranth, a dicotyledonous NAD-ME-type C4 plant, the photosynthetic NAD-ME purified as two subunits of 65 and 60 kDa, designated alpha and beta, respectively. Antiserum raised against the a subunit reacted only with the 65-kDa protein in immunoblot analysis. Immunogold electron microscopy using the alpha subunit antiserum demonstrated that this protein was localized specifically to the mitochondrial matrix of bundle sheath cells. The complete nucleotide sequence of a 2300-base pair alpha subunit cDNA clone showed that this gene encodes a protein that contains all of the motifs required for a complete and functional malic enzyme. The alpha subunit has significant similarity along its entire length to other known NAD- and NADP-dependent malic enzymes from plants, animals, and bacteria. The findings presented here provide new insights about the C4 photosynthetic NAD-ME and its evolutionary relationship to other forms of malic enzyme present in eukaryotic and prokaryotic organisms.	SUNY BUFFALO,DEPT BIOL SCI,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								AOYAGI K, 1984, PLANT PHYSIOL, V75, P393, DOI 10.1104/pp.75.2.393; ARTUS NN, 1985, FEBS LETT, V182, P225, DOI 10.1016/0014-5793(85)80305-7; BAGCHI S, 1987, J BIOL CHEM, V262, P1558; BERRY JO, 1985, MOL CELL BIOL, V5, P2238, DOI 10.1128/MCB.5.9.2238; BERRYMAN MA, 1990, J HISTOCHEM CYTOCHEM, V38, P159, DOI 10.1177/38.2.1688894; CUSHMAN JC, 1992, EUR J BIOCHEM, V208, P259, DOI 10.1111/j.1432-1033.1992.tb17181.x; DAVIES DD, 1979, ANNU REV PLANT PHYS, V30, P131, DOI 10.1146/annurev.pp.30.060179.001023; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Edwards GE., 1981, BIOCH PLANTS, P237, DOI [10.1016/B978- 0- 12-675408- 7.50012-4, DOI 10.1016/B978-0-12-675408-7.50012-4]; GROVER SD, 1981, ARCH BIOCHEM BIOPHYS, V209, P396, DOI 10.1016/0003-9861(81)90297-6; GUTIERRE.M, 1974, PLANTA, V119, P279, DOI 10.1007/BF00388331; HATCH M D, 1974, Australian Journal of Plant Physiology, V1, P357; HATCH MD, 1974, ARCH BIOCHEM BIOPHYS, V165, P188, DOI 10.1016/0003-9861(74)90155-6; HATCH MD, 1987, BIOCHIM BIOPHYS ACTA, V895, P81, DOI 10.1016/S0304-4173(87)80009-5; HATCH MD, 1970, PROGR PHYTOCHEMISTRY, P35; KOBAYASHI K, 1989, J BIOL CHEM, V264, P3200; LAETSCH WM, 1968, AM J BOT, V55, P875, DOI 10.2307/2440550; LOEBER G, 1991, J BIOL CHEM, V266, P3016; MAGNUSON MA, 1986, J BIOL CHEM, V261, P1183; POULOSE AJ, 1983, ARCH BIOCHEM BIOPHYS, V220, P652, DOI 10.1016/0003-9861(83)90459-9; PRY TA, 1980, BIOCHEMISTRY-US, V19, P951, DOI 10.1021/bi00546a020; ROTHERMEL BA, 1989, J BIOL CHEM, V264, P19587; SHEEN J, 1991, PLANT CELL, V3, P225, DOI 10.1105/tpc.3.3.225; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; VONHEJNE G, 1987, EUR J BIOCHEM, V180, P535; WANG JL, 1992, PLANT CELL, V4, P173, DOI 10.1105/tpc.4.2.173; WEDDING RT, 1983, PLANT PHYSIOL, V72, P1021, DOI 10.1104/pp.72.4.1021; WEDDING RT, 1989, PLANT PHYSIOL, V90, P367, DOI 10.1104/pp.90.2.367; WILLEFORD KO, 1987, J BIOL CHEM, V262, P8423	29	75	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2827	2833						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300616				2022-12-27	WOS:A1994MV43200070
J	LIN, XH; GUO, C; GU, LJ; DEUEL, TF				LIN, XH; GUO, C; GU, LJ; DEUEL, TF			SITE-SPECIFIC METHYLATION INHIBITS TRANSCRIPTIONAL ACTIVITY OF PLATELET-DERIVED GROWTH FACTOR-A-CHAIN PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG BINDING-PROTEIN; DNA METHYLATION; GENE-EXPRESSION; CYTOSINE METHYLATION; CELL-GROWTH; REGION; INACTIVATION; INVOLVEMENT; BETA	Expression of the platelet-derived growth factor (PDGF) A-chain gene is temporally and spatially restricted in development and highly regulated in selected normal and tumor cell lines. Because DNA methylation appears to be important in regulating tissue specific gene expression, we tested the influence of in vitro methylation of the human PDGF A-chain promoter on its activity in vivo in transient transfection assays. We now report that PDGF A-chain promoter activity is strongly repressed by DNA methylation in a DNA sequence-specific manner and that the repression of promoter activity by methylation requires a methyl CpG-binding protein(s). We also report that incubation of HeLa cells with 5-azacytidine sharply increases levels of endogenous PDGF A-chain gene transcripts. These results indicate that the promoter activity of the PDGF A-chain gene is sharply and selectively reduced by in vitro DNA methylation and that DNA methylation in vivo also may reduce its function in selected cell lines.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,216 S KINGSHIGHWAY BLVD,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)					NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL031102, P50HL014147, R01HL031102] Funding Source: NIH RePORTER; NCI NIH HHS [CA49712] Funding Source: Medline; NHLBI NIH HHS [HL14147, HL31102] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEDNARIK DP, 1991, NEW BIOL, V3, P969; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; CHOI YC, 1991, J BIOL CHEM, V266, P20504; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chomet PS, 1991, CURR OPIN CELL BIOL, V3, P438, DOI 10.1016/0955-0674(91)90071-6; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; DYNAN WS, 1989, TRENDS GENET, V5, P35, DOI 10.1016/0168-9525(89)90016-4; GAY CG, 1990, J BIOL CHEM, V265, P3284; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; LEVINE A, 1991, P NATL ACAD SCI USA, V88, P6515, DOI 10.1073/pnas.88.15.6515; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIN XH, 1992, J BIOL CHEM, V267, P25614; MAJACK RA, 1990, J CELL BIOL, V111, P239, DOI 10.1083/jcb.111.1.239; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095; NISTER M, 1988, CANCER RES, V48, P3910; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; THOMPSON JP, 1991, J BIOL CHEM, V266, P2549; TONG BD, 1987, NATURE, V328, P619, DOI 10.1038/328619a0; VENOLIA L, 1982, P NATL ACAD SCI-BIOL, V79, P2352, DOI 10.1073/pnas.79.7.2352; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; YEH HJ, 1991, CELL, V64, P209, DOI 10.1016/0092-8674(91)90222-K; YISRAELI J, 1988, P NATL ACAD SCI USA, V85, P4638, DOI 10.1073/pnas.85.13.4638	34	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17334	17340						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349616				2022-12-27	WOS:A1993LQ98800067
J	PHOENIX, DA; KUSTERS, R; HIKITA, C; MIZUSHIMA, S; DEKRUIJFF, B				PHOENIX, DA; KUSTERS, R; HIKITA, C; MIZUSHIMA, S; DEKRUIJFF, B			OMPF-LPP SIGNAL SEQUENCE MUTANTS WITH VARYING CHARGE HYDROPHOBICITY RATIOS PROVIDE EVIDENCE FOR A PHOSPHATIDYLGLYCEROL-SIGNAL SEQUENCE INTERACTION DURING PROTEIN TRANSLOCATION ACROSS THE ESCHERICHIA-COLI INNER MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL REGION; POSITIVE CHARGE; PLASMA-MEMBRANE; CYTOPLASMIC MEMBRANE; SECA PROTEIN; ENDOPLASMIC-RETICULUM; ACIDIC PHOSPHOLIPIDS; PRECURSOR PROTEINS; LIPID INTERACTIONS; MODEL MEMBRANES	Using inverted Escherichia coli inner membrane vesicles we have analyzed the phosphatidylglycerol dependence of translocation of an OmpF-Lpp fusion protein carrying a signal sequence with varying positive charge at the N terminus and a hydrophobic core of varying length. It is shown that there is a direct relationship between the phosphatidylglycerol requirement of translocation and the requirement within the translocation process for positive charges on the signal sequence. This provides further evidence that the negative head group of the lipid is required for functional interaction with the positively charged N terminus of the signal sequence.	UNIV TOKYO, INST MOLEC & CELLULAR BIOSCI, TOKYO 113, JAPAN; UNIV UTRECHT, CTR BIOMEMBRANES & LIPID ENZYMOL, UTRECHT, NETHERLANDS	University of Tokyo; Utrecht University			Phoenix, David A/F-8719-2011	Phoenix, David A/0000-0003-4865-6132				AKITA M, 1990, J BIOL CHEM, V265, P8164; BATENBURG AM, 1988, BIOCHEMISTRY-US, V27, P5678, DOI 10.1021/bi00415a043; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORCHERT TV, 1991, J BACTERIOL, V173, P276, DOI 10.1128/jb.173.1.276-282.1991; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; BRIGGS MS, 1985, SCIENCE, V228, P1096, DOI 10.1126/science.3158076; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CAMMACK KA, 1965, BIOCHEM J, V96, P671, DOI 10.1042/bj0960671; DEMEL RA, 1990, BIOCHIM BIOPHYS ACTA, V1027, P155, DOI 10.1016/0005-2736(90)90079-4; DEVRIJE GJ, 1990, MOL MICROBIOL, V4, P143; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; DIRIENZO JM, 1979, CELL, V17, P155, DOI 10.1016/0092-8674(79)90303-9; ENGELMAN DM, 1982, J LIPID RES, V23, P660; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; HIKITA C, 1992, J BIOL CHEM, V267, P12375; HOYT DW, 1991, BIOCHEMISTRY-US, V30, P10155, DOI 10.1021/bi00106a012; IINO T, 1987, J BIOL CHEM, V262, P7412; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; INOUYE S, 1982, P NATL ACAD SCI-BIOL, V79, P3438, DOI 10.1073/pnas.79.11.3438; KELLER RCA, 1992, BIOCHEMISTRY-US, V31, P1672, DOI 10.1021/bi00121a014; KILLIAN JA, 1990, EMBO J, V9, P815, DOI 10.1002/j.1460-2075.1990.tb08178.x; KUSTERS R, 1991, J BIOL CHEM, V266, P8659; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; PAGES JM, 1978, EUR J BIOCHEM, V86, P589, DOI 10.1111/j.1432-1033.1978.tb12343.x; POORTHUIS BJHM, 1983, METHOD ENZYMOL, V98, P592; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SASAKI S, 1990, J BIOL CHEM, V265, P4358; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIMON SM, 1989, P NATL ACAD SCI USA, V86, P6176, DOI 10.1073/pnas.86.16.6176; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; VANDEENEN LLM, 1964, ADV LIPID RES, V2, P167; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P1895, DOI 10.1073/pnas.86.6.1895; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; YAMANE K, 1987, J BIOL CHEM, V262, P2358	42	53	71	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17069	17073						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349595				2022-12-27	WOS:A1993LQ98800031
J	BLASCO, MA; LAZARO, JM; BLANCO, L; SALAS, M				BLASCO, MA; LAZARO, JM; BLANCO, L; SALAS, M			PHI-29 DNA-POLYMERASE ACTIVE-SITE - THE CONSERVED AMINO-ACID MOTIF KX3NSXYG IS INVOLVED IN TEMPLATE-PRIMER BINDING AND DNTP SELECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL PROTEIN; DIRECTED MUTAGENESIS; APHIDICOLIN RESISTANCE; EXONUCLEASE ACTIVITY; SECONDARY-STRUCTURE; ESCHERICHIA-COLI; ALPHA; REPLICATION; INITIATION; NUCLEOTIDE	Phi29 DNA polymerase shares with other alpha-like DNA polymerases several regions of amino acid similarity. Among them, the conserved region characterized by the amino acid motif ''Kx3NSxYG'' has been proposed to form part of the polymerization active site of alpha-like DNA polymerases. Mutants in phi29 DNA polymerase residue Tyr390 of this conserved motif had been previously described to be affected in DNA-dependent dNTP binding. In this paper, the functional significance of this conserved motif is further studied by the analysis of mutants in conserved residues Asn387, Ser388, and Gly391. Residue Phe393 of phi29 DNA polymerase has also been selected as target for site-directed mutagenesis because of its conservation within the group of alpha-like DNA polymerases from genomes that replicate by a protein-priming mechanism. Mutant N387Y was shown to be affected both in initiation and polymerization reactions, showing 3-fold higher K(m) value for dATP and more than 11-fold lower V(max) value than the wild-type enzyme in the initiation reaction; moreover, it was affected in enzyme-DNA translocation. Mutant S388G retained initiation and polymerization activities; interestingly, this mutation significantly increased the efficiency of dNTP incorporation in non-templated reactions. Mutation Gly391 to Asp abolished template-primer binding as shown by gel retardation assays; this mutant was drastically affected in template-dependent dNTP incorporation both in initiation and polymerization reactions, but the efficiency of the non-templated phi29 terminal protein-deoxynucleotidylation was higher than with the wild-type protein. Mutation Phe393 to Tyr severely decreased initial binding to template-primer DNA molecules, resulting in a reduced activity in DNA primer-dependent polymerization reactions but not in phi29 terminal protein-dependent ones.	UAM,CSIC,CTR BIOL MOLEC SEVERO OCHOA,CANTO BLANCO,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Salas, Margarita/J-9873-2014; Blanco, Luis/I-1848-2015; Blasco, Maria A./M-1694-2014	Salas, Margarita/0000-0001-5939-3441; Blasco, Maria A./0000-0002-4211-233X	NIGMS NIH HHS [5R01 GM27242-13] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1987, J MOL BIOL, V197, P331, DOI 10.1016/0022-2836(87)90127-6; BERNAD A, 1990, GENE, V94, P45, DOI 10.1016/0378-1119(90)90466-5; BERNAD A, 1987, EMBO J, V6, P4219, DOI 10.1002/j.1460-2075.1987.tb02770.x; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BERNAD A, 1990, P NATL ACAD SCI USA, V87, P4610, DOI 10.1073/pnas.87.12.4610; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLANCO L, 1985, NUCLEIC ACIDS RES, V13, P1239, DOI 10.1093/nar/13.4.1239; BLANCO L, 1985, P NATL ACAD SCI USA, V82, P6404, DOI 10.1073/pnas.82.19.6404; BLANCO L, 1989, J BIOL CHEM, V264, P8935; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BLANCO L, 1986, VIROLOGY, V153, P179, DOI 10.1016/0042-6822(86)90021-8; BLANCO L, 1984, P NATL ACAD SCI-BIOL, V81, P5325, DOI 10.1073/pnas.81.17.5325; BLANCO L, 1992, J BIOL CHEM, V267, P1225; BLASCO MA, 1992, J BIOL CHEM, V267, P19427; BLASCO MA, 1991, J BIOL CHEM, V266, P7904; BLASCO MA, 1990, NUCLEIC ACIDS RES, V18, P4763; BLASCO MA, 1992, CHROMOSOMA, V102, P32; BORK P, 1991, BIOCHEM BIOPH RES CO, V180, P666, DOI 10.1016/S0006-291X(05)81117-9; BUTLER MM, 1990, NUCLEIC ACIDS RES, V18, P7381, DOI 10.1093/nar/18.24.7381; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; DEFILIPPES FM, 1989, J VIROL, V63, P4060, DOI 10.1128/JVI.63.9.4060-4063.1989; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; ESTEBAN JA, 1992, BIOCHEMISTRY-US, V31, P350, DOI 10.1021/bi00117a006; GARMENDIA C, 1992, J BIOL CHEM, V267, P2594; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIBBS JS, 1988, P NATL ACAD SCI USA, V85, P6672, DOI 10.1073/pnas.85.18.6672; GRABHERR R, 1992, VIROLOGY, V188, P721, DOI 10.1016/0042-6822(92)90527-V; HALL JD, 1989, NUCLEIC ACIDS RES, V17, P9231, DOI 10.1093/nar/17.22.9231; INCIARTE MR, 1976, VIROLOGY, V74, P314, DOI 10.1016/0042-6822(76)90338-X; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; KHAN NN, 1991, NUCLEIC ACIDS RES, V19, P1627, DOI 10.1093/nar/19.7.1627; KHAN NN, 1984, NUCLEIC ACIDS RES, V12, P3695, DOI 10.1093/nar/12.8.3695; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LARDER BA, 1987, EMBO J, V6, P169, DOI 10.1002/j.1460-2075.1987.tb04735.x; MATSUMOTO K, 1989, GENE, V84, P247; MATTHEWS JT, 1989, J VIROL, V63, P4913, DOI 10.1128/JVI.63.11.4913-4918.1989; MENDEZ J, 1992, P NATL ACAD SCI USA, V89, P9579, DOI 10.1073/pnas.89.20.9579; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PENALVA MA, 1982, P NATL ACAD SCI-BIOL, V79, P5522, DOI 10.1073/pnas.79.18.5522; PREISSNER R, 1991, BIOCHEM BIOPH RES CO, V180, P660, DOI 10.1016/S0006-291X(05)81116-7; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRAUSS EC, 1986, ANAL BIOCHEM, V154, P353, DOI 10.1016/0003-2697(86)90536-1; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WATABE K, 1984, BIOCHEM BIOPH RES CO, V123, P1019, DOI 10.1016/S0006-291X(84)80235-1; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; ZABALLOS A, 1989, GENE, V83, P187, DOI 10.1016/0378-1119(89)90104-2	51	49	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16763	16770						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344956				2022-12-27	WOS:A1993LQ33600096
J	MOESTRUP, SK; NIELSEN, S; ANDREASEN, P; JORGENSEN, KE; NYKJAER, A; ROIGAARD, H; GLIEMANN, J; CHRISTENSEN, EI				MOESTRUP, SK; NIELSEN, S; ANDREASEN, P; JORGENSEN, KE; NYKJAER, A; ROIGAARD, H; GLIEMANN, J; CHRISTENSEN, EI			EPITHELIAL GLYCOPROTEIN-330 MEDIATES ENDOCYTOSIS OF PLASMINOGEN ACTIVATOR-PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; HUMAN ALPHA-2-MACROGLOBULIN RECEPTOR; RENAL PROXIMAL TUBULE; NECROSIS-FACTOR-ALPHA; HEYMANN NEPHRITIS; MONOCLONAL-ANTIBODIES; LIGAND RECOGNITION; MESSENGER-RNA; HIGH-AFFINITY; BRUSH-BORDER	Epithelial glycoprotein 330 (gp330) is structurally similar to the multifunctional alpha2-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha2MR/LRP). gp330 and alpha2MR/LRP bind Ca2+ with high affinity, and both receptors bind and mediate endocytosis Of alpha2MR-associated protein (RAP). In the present report, we describe that affinity-purified gp330 from rabbit renal cortex binds plasminogen activator inhibitor type-1 (PAI-1) complexed with urokinase-type plasminogen activator (uPA). Alpha2M-methylamine, which binds with high affinity to alpha2MR/LRP, did not bind to gp330. The apparent K(d) for binding of uPA.PAI-1 complexes was about 0.8 nM at 4-degrees-C. The binding was calcium-dependent and inhibited by recombinant RAP (rRAP) and tissue type plasminogen activator-PAI-1 complexes. Thin sections of rabbit renal proximal tubules bound I-125-labeled uPA.PAI-1 and rRAP in the apical part of proximal tubules corresponding to the localization of gp330. The binding of I-125-uPA.PAI-1 complexes in tubules was abolished by excess unlabeled rRAP, and a rRAP-inhibitable endocytosis and degradation of labeled uPA.PAI-1 complexes was demonstrated by perfusion of isolated rabbit proximal tubules. The results establish an endocytotic function of gp330 and suggest that gp330 is an important component of the fibrinolytic system in gp330-containing epithelia as found in, for example, kidney and lung.	AARHUS UNIV, INST ANAT, DEPT CELL BIOL, DK-8000 AARHUS, DENMARK; AARHUS UNIV, INST MOLEC BIOL, DK-8000 AARHUS, DENMARK	Aarhus University; Aarhus University	MOESTRUP, SK (corresponding author), AARHUS UNIV, INST MED BIOCHEM, DK-8000 AARHUS, DENMARK.		Moestrup, Søren Kragh/AAD-1735-2019; Moestrup, Søren Kragh/A-1403-2014	Moestrup, Søren Kragh/0000-0003-3862-2107; Nykjaer, Anders/0000-0001-6422-6736				BERTOZZI P, 1990, NEW ENGL J MED, V322, P890, DOI 10.1056/NEJM199003293221304; CHATELET F, 1986, AM J PATHOL, V122, P512; CHRISTENSEN EI, 1992, J HISTOCHEM CYTOCHEM, V40, P1481, DOI 10.1177/40.10.1382088; CHRISTENSEN EI, 1979, KIDNEY INT, V16, P301, DOI 10.1038/ki.1979.132; DOXSEY S, 1983, J CELL BIOL, V97, pA178; FURUKAWA T, 1990, J BIOCHEM-TOKYO, V108, P297, DOI 10.1093/oxfordjournals.jbchem.a123197; GEBBINK RK, 1993, IN PRESS J BIOCH; GROSS TJ, 1991, AM J PHYSIOL, V260, pL286, DOI 10.1152/ajplung.1991.260.4.L286; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1991, J BIOL CHEM, V266, P21232; IDELL S, 1989, J CLIN INVEST, V84, P181, DOI 10.1172/JCI114139; IWAMOTO T, 1990, KIDNEY INT, V37, P1466, DOI 10.1038/ki.1990.137; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; KERJASCHKI D, 1982, P NATL ACAD SCI-BIOL, V79, P5557, DOI 10.1073/pnas.79.18.5557; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KRISTENSEN P, 1991, J HISTOCHEM CYTOCHEM, V39, P341, DOI 10.1177/39.3.1899685; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LARSSON LI, 1984, J CELL BIOL, V98, P894, DOI 10.1083/jcb.98.3.894; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; MARSHALL BC, 1992, J BIOL CHEM, V267, P11462; MOESTRUP SK, 1990, EXP CELL RES, V190, P195, DOI 10.1016/0014-4827(90)90185-D; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MOESTRUP SK, 1990, J BIOL CHEM, V265, P12623; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; Moll S., 1992, Journal of the American Society of Nephrology, V3, P605; MUNCH M, 1991, FEBS LETT, V295, P102, DOI 10.1016/0014-5793(91)81395-O; Nakamura Tsukasa, 1992, Journal of the American Society of Nephrology, V3, P607; NIELSEN JT, 1986, AM J PHYSIOL, V251, pF822, DOI 10.1152/ajprenal.1986.251.5.F822; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; NYKJAER A, 1990, BIOCHIM BIOPHYS ACTA, V1052, P399, DOI 10.1016/0167-4889(90)90149-8; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PIETROMONACO S, 1990, P NATL ACAD SCI USA, V87, P1811, DOI 10.1073/pnas.87.5.1811; QUAX PHA, 1990, J BIOL CHEM, V265, P15560; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; SAPPINO AP, 1991, J CLIN INVEST, V87, P962, DOI 10.1172/JCI115104; SAWDEY MS, 1991, J CLIN INVEST, V88, P1346, DOI 10.1172/JCI115440; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035	39	176	178	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16564	16570						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344937				2022-12-27	WOS:A1993LQ33600070
J	OLAH, GA; TRAKHANOV, S; TREWHELLA, J; QUIOCHO, FA				OLAH, GA; TRAKHANOV, S; TREWHELLA, J; QUIOCHO, FA			LEUCINE ISOLEUCINE VALINE-BINDING PROTEIN CONTRACTS UPON BINDING OF LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-SCATTERING; RESOLUTION STRUCTURE; NEUTRON-SCATTERING; ACTIVE-TRANSPORT; SALMONELLA-TYPHIMURIUM; CONFORMATIONAL CHANGE; BACTERIAL TRANSPORT; YEAST HEXOKINASE; ESCHERICHIA-COLI; HYDROGEN-BONDS	Small-angle x-ray scattering and computer modeling have been used to study the effects of ligand binding to the leucine/isoleucine/valine-binding protein, an initial component of the high-affinity active transport system for branched-chain aliphatic amino acids in Escherichia coli. Measurements were made with no ligand present and with either L-leucine or L-valine present. Upon binding of either leucine or valine, there is a decrease in the radius of gyration, from 23.2 +/- 0.2 to 22.2 +/- 0.2 angstrom and in the maximum particle dimension, from 82 +/- 3 to 73 +/- 3 angstrom. The x-ray structure of the unbound form has been determined and gives a radius of gyration and a maximum dimension consistent with the values found for the solution structure in this study (Sack, J. S., Saper, M. A., and Quiocho, F. A. (1989) J. Mol. Biol. 206,171-191). The reduction in the radius of gyration and maximum dimension upon ligand binding can be accounted for by a substrate-induced cleft closure in a combined ''hinge-twist'' motion. Modeling of the substrate-bound state was done by comparison of this protein with another periplasmic binding protein (L-arabinose-binding protein), which possesses a similar two-lobe structure and for which the x-ray structure is known in its ligand-bound form.	HOWARD HUGHES MED INST,HOUSTON,TX 77030	Howard Hughes Medical Institute	OLAH, GA (corresponding author), LOS ALAMOS NATL LAB,DIV ISOTOPE & NUCL CHEM,LOS ALAMOS,NM 87545, USA.			Trewhella, Jill/0000-0002-8555-6766				ADLER J, 1975, ANNU REV BIOCHEM, V44, P341, DOI 10.1146/annurev.bi.44.070175.002013; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; ANTONOV VK, 1973, BIOKHIMIYA, V39, P1294; BENNETT WS, 1978, P NATL ACAD SCI USA, V75, P4848, DOI 10.1073/pnas.75.10.4848; BENNETT WS, 1984, CRC CR REV BIOCH MOL, V15, P291, DOI 10.3109/10409238409117796; BLECHNER SL, 1992, BIOCHEMISTRY-US, V31, P11326, DOI 10.1021/bi00161a010; CHEN SH, 1986, METHOD ENZYMOL, V130, P79; FURLONG CE, 1987, ESCHERICHIA COLI SAL, P768; Guinier A., 1939, ANN PHYS-NEW YORK, V11, P161, DOI DOI 10.1051/ANPHYS/193911120161; HARRISON SC, 1978, NATURE, V276, P368, DOI 10.1038/276368a0; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; JACROT B, 1981, BIOPOLYMERS, V20, P2413, DOI 10.1002/bip.1981.360201110; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KRIGBAUM WR, 1970, BIOCHEMISTRY-US, V9, P1216, DOI 10.1021/bi00807a024; LUCK LA, 1991, BIOCHEMISTRY-US, V30, P4248, DOI 10.1021/bi00231a021; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; Macnab R. M., 1987, ESCHERICHIA COLI SAL, V1, P732; MCDONALD RC, 1979, BIOCHEMISTRY-US, V18, P338, DOI 10.1021/bi00569a017; MILLER DM, 1983, J BIOL CHEM, V258, P3665; MOORE PB, 1980, J APPL CRYSTALLOGR, V13, P168, DOI 10.1107/S002188988001179X; NEWCOMER ME, 1981, J BIOL CHEM, V256, P3218; OLAH GA, 1993, BIOCHEMISTRY-US, V32, P3649, DOI 10.1021/bi00065a018; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PFLUGRATH JW, 1988, J MOL BIOL, V200, P163, DOI 10.1016/0022-2836(88)90341-5; PFLUGRATH JW, 1985, NATURE, V314, P257, DOI 10.1038/314257a0; PILZ I, 1982, SMALL ANGLE XRAY SCA, P244; QUIOCHO FA, 1977, J BIOL CHEM, V252, P5142; QUIOCHO FA, 1984, NATURE, V310, P381, DOI 10.1038/310381a0; Quiocho FA, 1991, CURR OPIN STRUC BIOL, V1, P922, DOI 10.1016/0959-440X(91)90087-A; Sack J. S., 1988, J MOL GRAPHICS, V6, P244; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SOSNICK TR, 1992, BIOCHEMISTRY-US, V31, P1779, DOI 10.1021/bi00121a028; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; TRAKHANOV S, 1985, THESIS MOSKOW I BIOO; VOROTYNTSEVA TI, 1981, BIOORG KHIM+, V7, P45; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; VYAS NK, 1987, NATURE, V327, P635, DOI 10.1038/327635a0; WILSON DB, 1978, BACTERIAL TRANSPORT, P495	39	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16241	16247						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344909				2022-12-27	WOS:A1993LQ33600025
J	REN, JM; MARSHALL, BA; GULVE, EA; GAO, JP; JOHNSON, DW; HOLLOSZY, JO; MUECKLER, M				REN, JM; MARSHALL, BA; GULVE, EA; GAO, JP; JOHNSON, DW; HOLLOSZY, JO; MUECKLER, M			EVIDENCE FROM TRANSGENIC MICE THAT GLUCOSE-TRANSPORT IS RATE-LIMITING FOR GLYCOGEN DEPOSITION AND GLYCOLYSIS IN SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INSULIN	A line of transgenic mice was constructed in which the human Glut1 glucose transporter is overexpressed in skeletal muscle. Overexpression of Glut1 protein was evident in epitrochlearis, extensor digitorum longus (EDL), and quadriceps muscles, and resulted in 6.6-7.4-fold elevations in basal glucose transport activity as measured in isolated muscles in vitro. The elevated glucose transporter activity in the skeletal muscles of transgenic mice was associated with a 10-fold increase in glycogen concentration in EDL and quadriceps muscles that was not due to an increase in muscle glycogen synthase activity or a decrease in glycogen phosphorylase activity. The increased glucose transport activity also resulted in a 2-fold increase in muscle lactate concentration, with no increase in muscle glucose 6-phosphate. Despite a slight (10%) increase in muscle hexokinase activity, there was a 4-fold increase in total muscle free glucose in transgenic mice, indicating that hexokinase becomes rate-limiting for glucose uptake when the rate of glucose transport is very high. These results demonstrate that the muscle glycogen content can be dramatically elevated by increasing the muscle Glut1 protein level and that glucose transport is a rate-limiting step for muscle glucose disposal in normal, resting mice.	WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)			Mueckler, Mike M/F-6115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018986, R01DK038495] Funding Source: NIH RePORTER; NIA NIH HHS [AG00078] Funding Source: Medline; NIDDK NIH HHS [DK18986, DK38495] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARON AD, 1988, AM J PHYSIOL, V255, pE769, DOI 10.1152/ajpendo.1988.255.6.E769; BURANT CF, 1991, RECENT PROG HORM RES, V47, P349; CARTEE GD, 1989, AM J PHYSIOL, V256, pE494, DOI 10.1152/ajpendo.1989.256.4.E494; DEVASKAR SU, 1992, PEDIATR RES, V31, P1, DOI 10.1203/00006450-199201000-00001; GULVE EA, 1993, AM J PHYSIOL, V264, pE319, DOI 10.1152/ajpendo.1993.264.3.E319; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; KORNFELD R, 1962, J BIOL CHEM, V237, P1772; Krebs HA, 1932, H-S Z PHYSIOL CHEM, V210, P33, DOI 10.1515/bchm2.1932.210.1-2.33; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; PASSONNEAU JV, 1974, ANAL BIOCHEM, V60, P405, DOI 10.1016/0003-2697(74)90248-6; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; UYEDA K, 1965, J BIOL CHEM, V240, P4682; YOUNG DA, 1985, AM J PHYSIOL, V248, pC406, DOI 10.1152/ajpcell.1985.248.5.C406; YOUNG DA, 1986, J BIOL CHEM, V261, P6049; ZIEL FH, 1988, DIABETES, V37, P885, DOI 10.2337/diabetes.37.7.885	16	238	246	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16113	16115						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344895				2022-12-27	WOS:A1993LQ33600009
J	WEN, DY; LAURSEN, RA				WEN, DY; LAURSEN, RA			STRUCTURE-FUNCTION-RELATIONSHIPS IN AN ANTIFREEZE POLYPEPTIDE - THE ROLE OF CHARGED AMINO-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX DIPOLE MODEL; ALPHA-HELICES; PEPTIDES; STABILIZATION; PROTEINS; ICE	Several analogs of an alanine-rich alpha-helical antifreeze polypeptide were synthesized and studied to evaluate the role of charged amino acids on structure and activity. Alpha-helix content and thermal stability were assessed by circular dichroism spectrometry and antifreeze activity by freezing point depression (thermal hysteresis) and ice crystal growth rate measurements. Rearrangement, deletion and replacement of charged amino acids resulted in reduced helicity and antifreeze activity in some cases, but the effects were not dramatic. We conclude that the i+4 ion pair Lys18/Glu22 helps to stabilize the alpha-helix but is not absolutely essential for activity. NH2-terminal Asp1 does not contribute significantly to helix stability or activity, but the COOH terminus is sensitive to modification, since replacement of Arg37 can lead to reduced helix content and activity. In general, factors which reduce alpha-helix content also reduce antifreeze activity.	BOSTON UNIV,DEPT CHEM,590 COMMONWEALTH AVE,BOSTON,MA 02215	Boston University								Ananthanarayanan VS, 1989, LIFE CHEM REPORTS, V7, P1; ARGOS P, 1982, INT J PEPT PROT RES, V19, P380; CHAKRABARTTY A, 1991, EUR J BIOCHEM, V202, P1057, DOI 10.1111/j.1432-1033.1991.tb16470.x; CHAKRABARTTY A, 1989, J BIOL CHEM, V264, P11313; CHAKRABARTTY A, 1989, J BIOL CHEM, V264, P11307; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; DEVRIES AL, 1984, PHILOS T R SOC B, V304, P575; FAIRMAN R, 1989, PROTEINS, V5, P1, DOI 10.1002/prot.340050102; Feeney R E, 1978, Adv Protein Chem, V32, P191, DOI 10.1016/S0065-3233(08)60576-8; GREENFIELD N, 1969, ANNU REV BIOPHYS BIO, V15, P59; HEW CL, 1992, EUR J BIOCHEM, V203, P33, DOI 10.1111/j.1432-1033.1992.tb19824.x; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; KNIGHT CA, 1991, BIOPHYS J, V59, P409, DOI 10.1016/S0006-3495(91)82234-2; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MERUTKA G, 1991, BIOCHEMISTRY-US, V30, P4245, DOI 10.1021/bi00231a020; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; WEN DY, 1992, BIOPHYS J, V63, P1659, DOI 10.1016/S0006-3495(92)81750-2; WEN DY, 1993, J BIOL CHEM, V268, P16401; WEN DY, 1992, J BIOL CHEM, V267, P14102; YANG DSC, 1988, NATURE, V333, P232, DOI 10.1038/333232a0	23	20	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16396	16400						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344924				2022-12-27	WOS:A1993LQ33600047
J	SHAFQAT, S; TAMARAPPOO, BK; KILBERG, MS; PURANAM, RS; MCNAMARA, JO; GUADANOFERRAZ, A; FREMEAU, RT				SHAFQAT, S; TAMARAPPOO, BK; KILBERG, MS; PURANAM, RS; MCNAMARA, JO; GUADANOFERRAZ, A; FREMEAU, RT			CLONING AND EXPRESSION OF A NOVEL NA+-DEPENDENT NEUTRAL AMINO-ACID TRANSPORTER STRUCTURALLY RELATED TO MAMMALIAN NA+ GLUTAMATE COTRANSPORTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; SYSTEM-ASC; GLYCINE TRANSPORTER; GABA TRANSPORTER; SEQUENCE; HEPATOCYTES; KIDNEY; CDNA; IDENTIFICATION; MECHANISMS	A cDNA has been isolated from human hippocampus that appears to encode a novel Na+-dependent, Cl--independent, neutral amino acid transporter. The putative protein, designated SATT, is 529 amino acids long and exhibits significant amino acid sequence identity (39-44%) with mammalian L-glutamate transporters. Expression of SATT cDNA in HeLa cells induced stereospecific uptake Of L-serine, L-alanine, and L-threonine that was not inhibited by excess (3 mM) 2-(methylamino)-isobutyric acid, a specific substrate for the System A amino acid transporter. SATT expression in HeLa cells did not induce the transport of radiolabeled L-cysteine, L-glutamate, or related dicarboxylates. Northern blot hybridization revealed high levels of SATT mRNA in human skeletal muscle, pancreas, and brain, intermediate levels in heart, and low levels in liver, placenta, lung, and kidney. SATT transport characteristics are similar to the Na+-dependent neutral amino acid transport activity designated System ASC, but important differences are noted. These include: 1) SATT's apparent low expression in ASC-containing tissues such as liver or placenta; 2) the lack of mutual inhibition between serine and cysteine; and 3) the lack of trans-stimulation. SATT may represent one of multiple activities that exhibit System ASC-like transport characteristics in diverse tissues and cell lines.	DUKE UNIV, MED CTR,DEPT PHARMACOL,BOX 3813, 436 NANALINE H DUKE BLDG,RES DR, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT NEUROBIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED NEUROL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, VET AFFAIRS MED CTR, DURHAM, NC 27710 USA; UNIV FLORIDA, COLL MED, DEPT BIOCHEM & MOLEC BIOL, GAINESVILLE, FL 32610 USA	Duke University; Duke University; Duke University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); State University System of Florida; University of Florida			Guadaño-Ferraz, Ana/J-7870-2013	Guadaño-Ferraz, Ana/0000-0002-0666-935X; PURANAM, RAM/0000-0003-4383-3849	NIDDK NIH HHS [DK-31580, DK-28374] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028374, R01DK031580] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; BARKER GA, 1990, EXP PHYSIOL, V75, P3, DOI 10.1113/expphysiol.1990.sp003382; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BORDEN LA, 1992, J BIOL CHEM, V267, P21098; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CLARK JA, 1992, NEURON, V9, P337, DOI 10.1016/0896-6273(92)90172-A; COLLARINI EJ, 1987, ANNU REV NUTR, V7, P75, DOI 10.1146/annurev.nu.07.070187.000451; DEGUCHI Y, 1990, J BIOL CHEM, V265, P21704; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAZZOLA GC, 1981, J BIOL CHEM, V256, P6054; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HANDLOGTEN ME, 1981, J BIOL CHEM, V256, P7905; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HUNDAL HS, 1989, J PHYSIOL-LONDON, V408, P93, DOI 10.1113/jphysiol.1989.sp017449; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KILBERG MS, 1979, BIOCHEM BIOPH RES CO, V88, P744, DOI 10.1016/0006-291X(79)92110-7; KILBERG MS, 1989, METHOD ENZYMOL, V173, P564; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KONG CT, 1993, J BIOL CHEM, V268, P1509; LIU QR, 1993, J BIOL CHEM, V268, P2106; MANN GE, 1986, BIOCHIM BIOPHYS ACTA, V858, P263, DOI 10.1016/0005-2736(86)90331-7; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; VADGAMA JV, 1984, J BIOL CHEM, V259, P3648; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALLACE B, 1990, J BACTERIOL, V172, P3214, DOI 10.1128/jb.172.6.3214-3220.1990; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596	34	195	200	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15351	15355						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340364				2022-12-27	WOS:A1993LN30500008
J	HUGHES, SD; QUAADE, C; JOHNSON, JH; FERBER, S; NEWGARD, CB				HUGHES, SD; QUAADE, C; JOHNSON, JH; FERBER, S; NEWGARD, CB			TRANSFECTION OF ATT-20(INS) CELLS WITH GLUT-2 BUT NOT GLUT-1 CONFERS GLUCOSE-STIMULATED INSULIN-SECRETION - RELATIONSHIP TO GLUCOSE-METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; RAT PANCREAS; K+ CHANNELS; B-CELLS; EXPRESSION; TRANSPORTER; ISLETS; GLUCOKINASE; SEQUENCE; LIVER	Glucose is thought to stimulate insulin release from islet beta-cells through generation of metabolic signals. In the current study we have introduced the genes encoding the facilitated glucose transporters known as GLUT-1 and GLUT-2 into AtT-20ins cells to assess their impact on glucose-stimulated insulin release and glucose metabolism. We find that transfection of AtT-20ins cells with GLUT-2, but not GLUT-1, confers glucose-stimulated insulin release in both static incubation and perifusion studies. Cells transfected with GLUT-1 have a K(m) for 3-O-methyl glucose uptake of 4 mM and a V(max) of 5-6 mmol/min/liter cell space. These values are increased compared to untransfected AtT-20ins cells (K(m) = 2 mM; V(max) = 0.5 mmol/min/liter cell space), but are less than observed in GLUT-2-transfected lines (K(m) = 16-17 mM; V(max) = 17-25 mmol/min/liter cell space). Despite these dramatic differences in glucose transport affinity and capacity, the rates of [5-H-3]glucose usage are not different in the control and transfected lines over a range of glucose concentrations from 10 muM to 20 mM. We conclude that the specific effect of GLUT-2 on glucose-stimulated insulin release in AtT-20ins cells is not related to changes in the overall rate of glucose metabolism and may instead involve physical coupling of GLUT-2 with cellular proteins and/or structures involved in glucose signaling.	UNIV TEXAS, SW MED CTR, GIFFORD LABS DIABET RES, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Ferber, Sarah/0000-0003-2764-2786	NIDDK NIH HHS [P01-DK42582] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042582] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; AXELROD JD, 1983, BIOCHEMISTRY-US, V22, P2222, DOI 10.1021/bi00278a025; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; CHEN L, 1990, P NATL ACAD SCI USA, V87, P4088, DOI 10.1073/pnas.87.11.4088; CLARK SA, 1990, ENDOCRINOLOGY, V127, P2779, DOI 10.1210/endo-127-6-2779; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; FERBER S, 1991, MOL ENDOCRINOL, V5, P319, DOI 10.1210/mend-5-3-319; FLEISCHER N, 1992, DIABETES, V41, pA5; GERMAN MS, 1991, DIABETES S1, V40, pA163; GHOSH A, 1991, J BIOL CHEM, V266, P22887; GIORDANO E, 1991, J CLIN INVEST, V87, P2178, DOI 10.1172/JCI115251; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; HUGHES SD, 1992, P NATL ACAD SCI USA, V89, P688, DOI 10.1073/pnas.89.2.688; HUGHES SD, 1991, J BIOL CHEM, V266, P4521; JETTON TL, 1992, P NATL ACAD SCI USA, V89, P2619, DOI 10.1073/pnas.89.7.2619; JOHNSON JH, 1990, J BIOL CHEM, V265, P6548; JOHNSON JH, 1990, SCIENCE, V250, P546, DOI 10.1126/science.2237405; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KNUDSEN P, 1983, AM J PHYSIOL, V245, pE338, DOI 10.1152/ajpendo.1983.245.4.E338; LIANG Y, 1990, J BIOL CHEM, V265, P16863; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MALAISSE WJ, 1991, INT J BIOCHEM, V23, P1471, DOI 10.1016/0020-711X(91)90290-4; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NEWGARD CB, 1992, BIO-TECHNOL, V10, P1112, DOI 10.1038/nbt1092-1112; NEWGARD CB, 1990, BIOCHEM SOC T, V18, P851, DOI 10.1042/bst0180851; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; TAL M, 1992, J BIOL CHEM, V267, P17241; TAL M, 1992, MOL CELL BIOL, V12, P422, DOI 10.1128/MCB.12.1.422; THORENS B, 1990, DIABETES CARE, V13, P209, DOI 10.2337/diacare.13.3.209; TRUS MD, 1981, DIABETES, V30, P911, DOI 10.2337/diabetes.30.11.911; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; VANSCHRAVENDIJK CFH, 1992, J BIOL CHEM, V267, P21344; WEISS JN, 1987, SCIENCE, V238, P67, DOI 10.1126/science.2443972; WHEELER TJ, 1981, J BIOL CHEM, V252, P5456; WILSON JE, 1984, REGULATION CARBOHYDR, P45; YIN L, 1992, DIABETES, V41, P792	39	149	157	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15205	15212						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325893				2022-12-27	WOS:A1993LL75900096
J	KNIBBS, RN; AGRWAL, N; WANG, JL; GOLDSTEIN, IJ				KNIBBS, RN; AGRWAL, N; WANG, JL; GOLDSTEIN, IJ			CARBOHYDRATE-BINDING PROTEIN-35 .2. ANALYSIS OF THE INTERACTION OF THE RECOMBINANT POLYPEPTIDE WITH SACCHARIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERTEBRATE LECTINS; ENDOGENOUS LECTINS; CULTURED-CELLS; MAC-2 ANTIGEN; IGE; LAMININ; MOUSE; IDENTIFICATION; RECOGNITION; SPECIFICITY	The carbohydrate binding specificity of recombinant carbohydrate-binding protein 35 (rCBP35) has been investigated by quantitative precipitation using a series of glycoproteins and carbohydrate-protein conjugates and by inhibition of precipitation using well defined carbohydrate haptens. Synthetic glycoconjugates and glycoproteins containing terminal nonreducing galactosyl units in beta-linkage were capable of forming a precipitate with rCBP35. If the glycoprotein or glycoconjugate contained terminal Neu5Ac, or galactose in alpha-linkage, precipitate formation was not observed. We also found that murine laminin, which contains polylactosamine structures, reacted more strongly than did bovine fetuin. Using carbohydrate-bovine serum albumin (BSA) glycoconjugates, we found that the tetrasaccharide Galbeta1,4GlcNAcbeta1,3Galbeta1,4-GlcNAc-BSA reacted more strongly than the disaccharide Galbeta1,4GlcNAc-BSA conjugate, suggesting that the binding site accommodates carbohydrate ligands greater in size than a disaccharide. Equilibrium dialysis experiments using [H-3]lactose showed that rCBP35 binds 1 mol (n = 0.84) of lactose/30, 000 g atoms of protein, with an affinity constant of 2.07 x 10(4) M-1. The binding site on the polypeptide appears to contain four subsites that recognize the sequence Galbeta1,4GlcNAcbeta1,Galbeta1,X-. All disaccharides tested that contain a nonreducing beta-galactosyl unit behaved as inhibitors of precipitation at approximately the same concentration, suggesting that the reducing position of the tetrasaccharide does not play an important role in the specific binding to the fourth subsite. The reducing sugar may serve to hold the saccharide in a tunnel like binding pocket since methyl-beta-D-galactoside itself is an extremely poor inhibitor.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University	KNIBBS, RN (corresponding author), UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109, USA.				NATIONAL CANCER INSTITUTE [R01CA020424] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029470] Funding Source: NIH RePORTER; NCI NIH HHS [CA-20424] Funding Source: Medline; NIGMS NIH HHS [GM-38740, GM-29470] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRWAL N, 1992, J BIOL CHEM, V268, P14932; ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; ANDERSON RL, 1992, TRENDS GLYCOSCI GLYC, V4, P43; ARUMUGHAM RG, 1986, BIOCHIM BIOPHYS ACTA, V883, P112, DOI 10.1016/0304-4165(86)90142-X; BARONDES S, 1988, TRENDS BIOCHEM SCI, V3, P480; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; COWLES EA, 1990, J BIOL CHEM, V265, P17706; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FODDY L, 1990, J CELL SCI, V97, P139; FRIGERI LG, 1990, J BIOL CHEM, V265, P20763; FUJIWARA S, 1988, BIOCHEM J, V252, P453, DOI 10.1042/bj2520453; HARRISON FL, 1991, J CELL SCI, V100, P9; HAYES CE, 1975, J BIOL CHEM, V250, P6837; HSU DK, 1992, J BIOL CHEM, V267, P14167; KNIBBS RN, 1991, J BIOL CHEM, V266, P83; KNIBBS RN, 1989, BIOCHEMISTRY-US, V28, P6379, DOI 10.1021/bi00441a034; LAING JG, 1989, J BIOL CHEM, V264, P1907; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOUTSATSOS IK, 1986, J CELL BIOL, V102, P477, DOI 10.1083/jcb.102.2.477; ODA Y, 1991, GENE, V99, P279; RAZ A, 1989, CANCER RES, V49, P3489; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; ROFF CF, 1983, J BIOL CHEM, V258, P657; ROFF CF, 1983, BIOCHEM J, V211, P625, DOI 10.1042/bj2110625; SATO S, 1992, J BIOL CHEM, V267, P6983; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; WANG J L, 1991, Glycobiology, V1, P243, DOI 10.1093/glycob/1.3.243; WOO HJ, 1990, J BIOL CHEM, V265, P7097	31	87	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14940	14947						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325871				2022-12-27	WOS:A1993LL75900062
J	TURNER, GE; BORKOVICH, KA				TURNER, GE; BORKOVICH, KA			IDENTIFICATION OF A G-PROTEIN ALPHA-SUBUNIT FROM NEUROSPORA-CRASSA THAT IS A MEMBER OF THE G(I) FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DICTYOSTELIUM-DISCOIDEUM MEMBRANES; BLUE-LIGHT; SIGNAL TRANSDUCTION; PLASMA-MEMBRANES; ADP-RIBOSYLATION; GENE; DIVERSITY; PERTUSSIS; MUTANTS; MOUSE	Heterotrimeric G proteins, consisting of alpha, beta, and gamma subunits, are implicated in major signal transduction pathways controlling a diversity of functions in eukaryotic organisms. In the filamentous fungus Neurospora crassa, G proteins are implicated in the regulation of several environmental responses. As a first step in studying the role of G proteins in these processes, we have cloned the genes for two alpha subunits, gna-1 and gna-2, from Neurospora. The genes are located on different chromosomes and are differentially regulated during asexual development. The encoded proteins (Gna-1 and Gna-2) are the same size as members of the G(i)-alpha family (approximately 40 kDa). The Gna-1 protein sequence is 55% identical overall to members of the G(i) family and contains the consensus sequences for ADP-ribosylation by pertussis toxin and incorporation of myristic acid, which are found in this group. These properties make Gna-1 the first identified microbial alpha subunit to be a member of any class. Furthermore, incubation of a N. crassa plasma membrane fraction with pertussis toxin results in ADP-ribosylation of a protein substrate which is the approximate size of Gna-1. The predicted Gna-2 protein sequence does not share a high degree of sequence identity with the G(i) class. However, the coding region contains at least one intron in a position conserved in the G(i) family. We propose that the G(i) family of alpha subunits is ancient and during evolution may have first appeared in filamentous fungi.	UNIV TEXAS, HLTH SCI CTR, DEPT MICROBIOL & MOLEC GENET, HOUSTON, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston								Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BORKOVICH KA, 1991, METHOD ENZYMOL, V200, P205; BOWMAN EJ, 1988, METHOD ENZYMOL, V157, P562; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Davis R.H., 1970, METHODS ENZYMOL, V17, P79, DOI [10.1016/0076-6879(71)17168-6, DOI 10.1016/0076-6879(71)17168-6]; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DICKER JW, 1990, J GEN MICROBIOL, V136, P1413, DOI 10.1099/00221287-136-7-1413; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; ERICKSON JW, 1987, GENE DEV, V1, P419, DOI 10.1101/gad.1.5.419; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; HARDING RW, 1983, PLANT PHYSIOL, V72, P996, DOI 10.1104/pp.72.4.996; INNOCENTI FD, 1983, PHOTOCHEM PHOTOBIOL, V37, P49, DOI 10.1111/j.1751-1097.1983.tb04432.x; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KHACHATRIAN L, 1987, BIOCHEM BIOPH RES CO, V149, P975, DOI 10.1016/0006-291X(87)90504-3; KOZAK KR, 1991, BIOCHEM BIOPH RES CO, V179, P1225, DOI 10.1016/0006-291X(91)91703-F; KRITSKY MS, 1982, ARCH MICROBIOL, V133, P206, DOI 10.1007/BF00415002; LOCHRIE MA, 1991, CELL REGUL, V2, P135, DOI 10.1091/mbc.2.2.135; Metzenberg R, 1989, FUNGAL GENET NEWSL, V36, P51; METZENBERG RL, 1985, P NATL ACAD SCI USA, V82, P2067, DOI 10.1073/pnas.82.7.2067; NAKAFUKU M, 1988, P NATL ACAD SCI USA, V85, P1374, DOI 10.1073/pnas.85.5.1374; NAWRATH C, 1990, J PHOTOCH PHOTOBIO B, V4, P261, DOI 10.1016/1011-1344(90)85032-R; OKAICHI K, 1992, MOL BIOL CELL, V3, P735, DOI 10.1091/mbc.3.7.735; ORBACH MJ, 1986, MOL CELL BIOL, V6, P2452, DOI 10.1128/MCB.6.7.2452; ORBACH MJ, 1990, J BIOL CHEM, V265, P10981; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PUPILLO M, 1992, MOL BIOL CELL, V3, P1229, DOI 10.1091/mbc.3.11.1229; RAPORT CJ, 1989, J BIOL CHEM, V264, P7122; SADHU C, 1992, MOL CELL BIOL, V12, P1977, DOI 10.1128/MCB.12.5.1977; Sambrook J, 1989, MOL CLONING LABORATO; SARGENT ML, 1967, PLANT PHYSIOL, V42, P1504, DOI 10.1104/pp.42.11.1504; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPIEGEL AM, 1991, TRENDS BIOCHEM SCI, V16, P338, DOI 10.1016/0968-0004(91)90139-M; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; UI M, 1980, ADP RIBOSYLATING TOX, P45; VANHAASTERT PJM, 1987, EUR J BIOCHEM, V162, P251; WARPEHA KMF, 1991, P NATL ACAD SCI USA, V88, P8925, DOI 10.1073/pnas.88.20.8925; WEST RE, 1985, J BIOL CHEM, V260, P4428; WILKIE T M, 1991, Methods (Orlando), V2, P32, DOI 10.1016/S1046-2023(05)80123-9; WU LJ, 1991, BIOCHEM BIOPH RES CO, V179, P1141, DOI 10.1016/0006-291X(91)91690-E	45	97	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14805	14811						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325859				2022-12-27	WOS:A1993LL75900044
J	KAUSHAL, GP; ZENG, YC; ELBEIN, AD				KAUSHAL, GP; ZENG, YC; ELBEIN, AD			BIOSYNTHESIS OF GLUCOSIDASE-II IN SUSPENSION-CULTURED SOYBEAN CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; MUNG BEAN SEEDLINGS; ENDOPLASMIC-RETICULUM; GLYCOPROTEIN-BIOSYNTHESIS; MEMBRANE-PROTEINS; PRE-GOLGI; PURIFICATION; REDUCTASE; DEGRADATION; CLEAVAGE	Since antibody against homogeneous mung bean glucosidase II cross-reacted with a 110-kDa protein from cultured soybean cells and also precipitated this activity from extracts of soybean cells, we used this antibody to examine the biosynthesis, turnover, and cellular localization of glucosidase II in soybean cells. Time course studies of [S-35]methionine incorporation into glucosidase II (as well as pulse-chase studies) showed that this enzyme is synthesized as a 110-kDa protein that does not change in size from very early labeling times to those as late as 60 h, indicating the absence of a cleavable signal sequence or extensive modification of the carbohydrate. Furthermore, glucosidase II remained susceptible to digestion by endo-beta-N-acetylglucosaminidase H throughout this time period, and the major oligosaccharide structure was a Man9(GlcNAc)2 with small amounts of Glc1Man9(GlcNAc)2. The half-life of the biosynthesized glucosidase II was about 36 h, and no secretion of this protein occurred. Membranes of gently disrupted cells were separated by sucrose-density gradient centrifugation, and fractions were tested for glucosidase II activity as well as for marker enzymes. The bulk of the glucosidase II activity fractionated with endoplasmic reticulum membranes. Detergent solubility studies with Triton X-114 suggested that glucosidase II did not have a hydrophobic domain and is probably a luminal endoplasmic reticulum protein.			KAUSHAL, GP (corresponding author), UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021800] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-21800] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BARNUN S, 1980, P NATL ACAD SCI-BIOL, V77, P965, DOI 10.1073/pnas.77.2.965; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRADA D, 1990, J CELL BIOL, V110, P309, DOI 10.1083/jcb.110.2.309; BRADA D, 1984, EUR J BIOCHEM, V141, P149, DOI 10.1111/j.1432-1033.1984.tb08169.x; BRISKIN DP, 1987, METHOD ENZYMOL, V148, P542; BROWN DA, 1984, P NATL ACAD SCI-BIOL, V81, P1674, DOI 10.1073/pnas.81.6.1674; BURNS DM, 1982, J BIOL CHEM, V257, P9991; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CHRISPEELS MJ, 1991, ANNU REV PLANT PHYS, V42, P21, DOI 10.1146/annurev.pp.42.060191.000321; Dixon R. A., 1985, PLANT CELL CULTURE P, P1; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; GRINNA LS, 1979, J BIOL CHEM, V254, P8814; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HINO Y, 1985, BIOCHEMISTRY-US, V24, P800, DOI 10.1021/bi00324a040; HOHENSCHUTZ LD, 1981, PHYTOCHEMISTRY, V20, P811, DOI 10.1016/0031-9422(81)85181-3; HUBBARD SC, 1979, J BIOL CHEM, V254, P4568; KAUSHAL GP, 1990, J BIOL CHEM, V265, P16271; KEDERSHA NL, 1985, BIOCHEMISTRY-US, V24, P5960, DOI 10.1021/bi00342a041; Kobata A., 1984, BIOL CARBOHYDRATES, V2, P87; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS MJ, 1992, J MOL BIOL, V226, P913, DOI 10.1016/0022-2836(92)91039-R; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LISCUM L, 1983, P NATL ACAD SCI-BIOL, V80, P7165, DOI 10.1073/pnas.80.23.7165; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; LUCOCQ JM, 1986, J CELL BIOL, V102, P2137, DOI 10.1083/jcb.102.6.2137; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MICHAEL JM, 1980, ARCH BIOCHEM BIOPHYS, V199, P249, DOI 10.1016/0003-9861(80)90278-7; MOREMEN KW, 1986, J BIOL CHEM, V261, P945; OKADA Y, 1982, EUR J BIOCHEM, V122, P393, DOI 10.1111/j.1432-1033.1982.tb05894.x; PAN YT, 1983, BIOCHEMISTRY-US, V22, P3975, DOI 10.1021/bi00285a038; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; POTRYKUS I, 1988, METHODS PLANT MOL BI, P381; ROSENFELD MG, 1984, J CELL BIOL, V99, P1076, DOI 10.1083/jcb.99.3.1076; SAXENA S, 1987, BIOCHEM J, V247, P563, DOI 10.1042/bj2470563; STROUS GJ, 1987, J BIOL CHEM, V262, P3620; STRUCK DK, 1980, BIOCH GLYCOPROTEINS, P35; STURM A, 1987, PLANT PHYSIOL, V85, P741, DOI 10.1104/pp.85.3.741; SZUMILO T, 1985, ANAL BIOCHEM, V151, P32, DOI 10.1016/0003-2697(85)90049-1; SZUMILO T, 1986, ARCH BIOCHEM BIOPHYS, V247, P261, DOI 10.1016/0003-9861(86)90583-7	43	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14536	14542						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314807				2022-12-27	WOS:A1993LJ82500106
J	ROGHANI, M; MANSUKHANI, A; DELLERA, P; BELLOSTA, P; BASILICO, C; RIFKIN, DB; MOSCATELLI, D				ROGHANI, M; MANSUKHANI, A; DELLERA, P; BELLOSTA, P; BASILICO, C; RIFKIN, DB; MOSCATELLI, D			HEPARIN INCREASES THE AFFINITY OF BASIC FIBROBLAST GROWTH-FACTOR FOR ITS RECEPTOR BUT IS NOT REQUIRED FOR BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR PRODUCTION; CAPILLARY ENDOTHELIAL-CELLS; FACTOR FGF RECEPTOR; SULFATE PROTEOGLYCAN; EXTRACELLULAR-MATRIX; PROTEOLYTIC DEGRADATION; 3-DIMENSIONAL STRUCTURE; PHOSPHOLIPASE-C; ACIDIC FGF; EXPRESSION	The role of heparin or heparan sulfates in the interaction of basic fibroblast growth factor (bFGF) with its high affinity receptor were investigated using purified extracellular ligand-binding region of FGF receptor-1 (FGFR-1) and intact receptors expressed in a myeloid cell line (32D) that does not express detectable levels of heparan sulfate proteoglycans or in Chinese hamster ovary (CHO) cell mutants defective in heparan sulfate synthesis. The purified extracellular domain of FGFR-1 formed complexes with I-125-bFGF both in the presence or absence of heparin. Intact FGFR-1 expressed in 32D cells also bound the same amount of I-125-bFGF in the presence or absence of heparin when saturating concentrations of bFGF were used. Varying the concentration of I-125-bFGF showed that heparin increased the amount of I-125-bFGF bound at low bFGF concentrations and increased the affinity of bFGF for its receptor by about 3-fold. To eliminate the possibility of alteration of bFGF properties through the chemical modification reactions, bFGF was labeled biosynthetically. The binding of biosynthetically labeled bFGF to FGFR-1 also did not require heparin. When FGFR-1 or FGFR-2 were expressed in mutant CHO cells deficient in heparan sulfate synthesis, the cells also bound I-125-bFGF in the absence of heparin, and the addition of heparin increased the affinity of bFGF for its receptors 2-3-fold. Thus, heparin or heparan sulfate is not required for the binding of bFGF to its receptors but increases the binding affinity to a moderate degree. Finally, the requirement for heparin in signal transduction through the receptor was investigated. Expression of c-fos mRNA was induced by bFGF in 32D cells expressing FGFR-1 to the same extent in the presence or absence of heparin.	NYU MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016; NYU MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016; NYU MED CTR,KAPLAN COMPREHENS CANC CTR,NEW YORK,NY 10016; RAYMOND & BEVERLY SACKLER LABS,NEW YORK,NY 10016	New York University; New York University; New York University			Dell'Era, Patrizia/ABD-5848-2020; Dell'Era, Patrizia/N-6964-2019; Dell'Era, Patrizia/G-5294-2010; Bellosta, Paola/AAA-3413-2020	Dell'Era, Patrizia/0000-0001-6682-6321; Bellosta, Paola/0000-0003-1913-5661; Moscatelli, David/0000-0002-4627-4213; Mansukhani, Alka/0000-0003-1020-3242	NATIONAL CANCER INSTITUTE [R01CA042229] Funding Source: NIH RePORTER; NCI NIH HHS [CA34289, CA42229] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRESJL, 1992, J BIOL CHEM, V267, P5927; ARMSTRONG E, 1992, CANCER RES, V52, P2004; BASHKIN P, 1992, J CELL PHYSIOL, V151, P126, DOI 10.1002/jcp.1041510117; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; BRUNNER G, 1991, J CELL BIOL, V114, P1275, DOI 10.1083/jcb.114.6.1275; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DAMON DH, 1989, J CELL PHYSIOL, V138, P221, DOI 10.1002/jcp.1041380202; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GIMENEZGALLEGO G, 1986, BIOCHEM BIOPH RES CO, V135, P541, DOI 10.1016/0006-291X(86)90028-8; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; JAYE M, 1987, J BIOL CHEM, V262, P16612; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KAPLOW JM, 1990, BIOCHEM BIOPH RES CO, V172, P107, DOI 10.1016/S0006-291X(05)80179-2; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; Kiefer M C, 1991, Growth Factors, V5, P115, DOI 10.3109/08977199109000276; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; Linemeyer DL, 1990, GROWTH FACTORS, V3, P287, DOI 10.3109/08977199009003671; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MUELLER SN, 1989, J CELL PHYSIOL, V140, P439, DOI 10.1002/jcp.1041400306; NEUFELD G, 1985, J BIOL CHEM, V260, P3860; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PRESTA M, 1989, J CELL PHYSIOL, V140, P68, DOI 10.1002/jcp.1041400109; PRESTA M, 1992, BIOCHEM BIOPH RES CO, V185, P1098, DOI 10.1016/0006-291X(92)91739-D; PRESTRELSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V293, P314, DOI 10.1016/0003-9861(92)90401-H; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROSENGART TK, 1988, BIOCHEM BIOPH RES CO, V152, P432, DOI 10.1016/S0006-291X(88)80732-0; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; Savona C, 1991, GROWTH FACTORS, V5, DOI 10.3109/08977199109000291; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; SOMMER A, 1987, BIOCHEM BIOPH RES CO, V144, P543, DOI 10.1016/S0006-291X(87)80001-3; SQUIRES CH, 1988, J BIOL CHEM, V263, P16297; UHLRICH S, 1986, BIOCHEM BIOPH RES CO, V137, P1205, DOI 10.1016/0006-291X(86)90353-0; VIGNY M, 1988, J CELL PHYSIOL, V137, P321, DOI 10.1002/jcp.1041370216; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	61	232	240	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3976	3984						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307953				2022-12-27	WOS:A1994MW98900015
J	FERRARA, J; MCCUAIG, K; HENDY, GN; USKOKOVIC, M; WHITE, JH				FERRARA, J; MCCUAIG, K; HENDY, GN; USKOKOVIC, M; WHITE, JH			HIGHLY POTENT TRANSCRIPTIONAL ACTIVATION BY 16-ENE DERIVATIVES OF 1,25-DIHYDROXYVITAMIN-D3 - LACK OF MODULATION BY 9-CIS-RETINOIC ACID OF RESPONSE TO 1,25-DIHYDROXYVITAMIN-D3 OR ITS DERIVATIVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGEN-RECEPTOR; 9-CIS RETINOIC ACID; MYELOID-LEUKEMIA CELLS; RAT OSTEOCALCIN GENE; THYROID-HORMONE; NUCLEAR-PROTEIN; DIRECT REPEAT; X-RECEPTOR; ELEMENTS; BINDING	Although several studies have been performed on the biological activities of analogs of 1,25-dihydroxyvitamin D3 (1,25-(OH)2 D3) at the whole animal and cellular levels, little work has been done to analyze their transcriptional activation properties. A highly inducible 1,25-(OH)2 D3-responsive promoter composed of three copies of the mouse osteopontin vitamin D3 response element (VDRE3) inserted upstream of a herpes simplex virus thymidine kinase promoter has been constructed, and its transcriptional properties have been analyzed by transient transfection into the monkey kidney cell line COS-7 and the rat osteoblast-like osteosarcoma line ROS 17/2.8. We have studied systematically transcriptional activation by a number of 1,25-(OH)2 D3 analogs, particularly those substituted at positions 16, 23, 26, and 27, sites that are targets for metabolism. Strikingly, except for derivatives that bind the 1,25-(OH)2 D3 receptor (VDR) very weakly, we find no parallel between the potency of action of a derivative as a transcriptional inducer and its affinity for the VDR. Derivatives substituted by multiple bonds at positions 16 and/or 23, although having varying affinities for the VDR, all stimulate transcription more potently than D3, in some cases at 100-fold lower concentrations. The peak transcriptional activity observed varies by only approximately 20% among different active analogs, indicating little difference in the activity of the VDR once bound to ligand. Gel retardation assays with ROS 17/2.8 nuclear extracts suggest that the VDR binds to the mouse osteopontin VDRE predominantly as a heterodimer with retinoid X receptor(s) (RXR(s)). We find that 9-cis-retinoic acid, the cognate ligand for RXRs, does not have a significant effect on the response of the VDRE3 promoter to 1,25-(OH)2 D3 or a number of its derivatives in ROS 17/2.8 or in COS-7 cells, under conditions in which promoters containing retinoid X response elements are activated. This suggests that 9-cis-retinoic acid may not act on the response to 1,25-(OH)2 D3 or its derivatives by directly influencing the transcriptional activity of VDR/RXR heterodimers. This promoter/reporter system should be useful for analyzing the tissue-specific transcriptional activity of 1,25-(OH)2 D3 and its derivatives in any cell type amenable to transient transfection.	MCGILL UNIV,DEPT PHYSIOL,MCINTYRE MED SCI BLDG,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA; MCGILL UNIV,ROYAL VICTORIA HOSP,CALCIUM RES LAB,MONTREAL H3A 1A1,QUEBEC,CANADA; HOFFMANN LA ROCHE INC,NUTLEY,NJ 07110	McGill University; McGill University; Royal Victoria Hospital; Roche Holding			white, john h/N-9782-2013	white, john h/0000-0002-4785-2687				ABE E, 1981, P NATL ACAD SCI-BIOL, V78, P4990, DOI 10.1073/pnas.78.8.4990; ABE J, 1991, ENDOCRINOLOGY, V129, P832, DOI 10.1210/endo-129-2-832; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BARSHAVIT Z, 1983, P NATL ACAD SCI-BIOL, V80, P5907, DOI 10.1073/pnas.80.19.5907; BOUILLON R, 1992, J BIOL CHEM, V267, P3044; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CLEMENS TL, 1990, PRINCIPLES PRACTICE, P417; COLSTON K, 1981, ENDOCRINOLOGY, V108, P1083, DOI 10.1210/endo-108-3-1083; DEMAY MB, 1992, MOL ENDOCRINOL, V6, P557, DOI 10.1210/me.6.4.557; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DIGMAN JD, 1983, NUCLEIC ACIDS RES, V11, P1475; EISMAN JA, 1986, CELL BIOCHEM FUNCT, V4, P115, DOI 10.1002/cbf.290040207; FREAKE HC, 1981, BIOCHEM BIOPH RES CO, V101, P1131, DOI 10.1016/0006-291X(81)91565-5; GILL HS, 1984, J MED CHEM, V33, P480; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAQ M, 1993, J CLIN INVEST, V91, P2416, DOI 10.1172/JCI116475; HAUSSLER MR, 1977, NEW ENGL J MED, V297, P974, DOI 10.1056/NEJM197711032971804; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOLICK MF, 1971, BIOCHEMISTRY-US, V10, P2799; HOLICK MF, 1981, J INVEST DERMATOL, V76, P51; HOSOMI J, 1983, ENDOCRINOLOGY, V113, P1950, DOI 10.1210/endo-113-6-1950; IKEKAWA N, 1983, J STEROID BIOCHEM, V19, P907; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LAWSON DEM, 1971, NATURE, V230, P228, DOI 10.1038/230228a0; LAWSON DEM, 1979, VITAMIN D, P167; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIAN J, 1989, P NATL ACAD SCI USA, V86, P1143, DOI 10.1073/pnas.86.4.1143; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; MADER S, 1993, J BIOL CHEM, V268, P591; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARTINEZ E, 1989, EMBO J, V8, P3781, DOI 10.1002/j.1460-2075.1989.tb08555.x; MCCUAIG K, 1992, CELL GROWTH DIFFER, V3, P165; MIYAURA C, 1981, BIOCHEM BIOPH RES CO, V102, P937, DOI 10.1016/0006-291X(81)91628-4; MORRISON NA, 1991, J BONE MINER RES, V6, P893; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; MUNDY GR, 1989, CALCIUM HOMEOSTASIS; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; NORMAN AW, 1971, SCIENCE, V173, P51, DOI 10.1126/science.173.3991.51; PONCHON G, 1969, J CLIN INVEST, V48, P2032, DOI 10.1172/JCI106168; ROODMAN GD, 1985, P NATL ACAD SCI USA, V82, P8213, DOI 10.1073/pnas.82.23.8213; ROSS TK, 1992, P NATL ACAD SCI USA, V89, P256, DOI 10.1073/pnas.89.1.256; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SONE T, 1991, MOL ENDOCRINOL, V5, P1578, DOI 10.1210/mend-5-11-1578; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANAKA Y, 1984, ARCH BIOCHEM BIOPHYS, V229, P348, DOI 10.1016/0003-9861(84)90161-9; TERPENING CM, 1991, MOL ENDOCRINOL, V5, P373, DOI 10.1210/mend-5-3-373; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; USKOKOVIC MR, 1991, VITAMIN D, P139; Wasserman R H, 1974, Vitam Horm, V32, P299; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZHOU JY, 1991, BLOOD, V78, P75; ZHOU JY, 1990, P NATL ACAD SCI USA, V87, P3929, DOI 10.1073/pnas.87.10.3929	64	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2971	2981						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300629				2022-12-27	WOS:A1994MV43200088
J	SHUMAN, B; DIX, TA				SHUMAN, B; DIX, TA			CLONING, NUCLEOTIDE-SEQUENCE, AND EXPRESSION OF A PARA-HYDROXYBENZOATE HYDROXYLASE ISOZYME GENE FROM PSEUDOMONAS-FLUORESCENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVIN-CONTAINING MONOOXYGENASES; AMINO-ACID-SEQUENCE; TERTIARY STRUCTURE; TYROSINE RESIDUES; CRYSTAL-STRUCTURE; CNBR PEPTIDES; PURIFICATION; AERUGINOSA; PROTEIN; OXYGEN	A gene encoding for a putative isozyme of p-hydroxybenzoate hydroxylase (PHBH) has been isolated from Pseudomonas fluorescens (ATCC 13525). A comparison of the translated amino acid sequence with that of the known PHBH from P. fluorescens revealed that the new enzyme contains 3 additional amino acids and has 73% absolute homology to the previously known enzyme; conservation of secondary and active-site structures implied that the isozyme and known enzyme share the same general tertiary structure. Subsequent expression of the isozyme in Escherichia coli produced an enzyme with a specific activity about half that of the previously characterized PHBHs from P. fluorescens and Pseudomonas aeruginosa; in addition, somewhat weaker binding affinities for both NADPH and p-hydroxybenzoate were observed. Speculations are made on the reason for the existence of the isozyme, which does not appear to be expressed routinely in P. fluorescens.	UNIV CALIF IRVINE, DEPT BIOCHEM, IRVINE, CA 92717 USA; UNIV CALIF IRVINE, DEPT BIOL CHEM, IRVINE, CA 92717 USA	University of California System; University of California Irvine; University of California System; University of California Irvine								BENESI HA, 1949, J AM CHEM SOC, V71, P2703, DOI 10.1021/ja01176a030; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BOHME HJ, 1972, J CHROMATOGR, V69, P209, DOI 10.1016/S0021-9673(00)83103-9; DAVIS LG, 1986, BASIC METHODS MOL BI, P44; DERETIC V, 1989, BIO-TECHNOL, V7, P1250; DERETIC V, 1987, BIO-TECHNOL, V5, P469, DOI 10.1038/nbt0587-469; ENTSCH B, 1991, J BIOL CHEM, V266, P17341; ENTSCH B, 1990, METHOD ENZYMOL, V188, P138; ENTSCH B, 1989, BIOCHIM BIOPHYS ACTA, V999, P313, DOI 10.1016/0167-4838(89)90014-9; ENTSCH B, 1976, J BIOL CHEM, V251, P2550; ENTSCH B, 1988, GENE, V71, P279, DOI 10.1016/0378-1119(88)90044-3; ENTSCH B, 1990, FLAVINS FLAVOPROTEIN, P219; FLASHNER MS, 1974, MOL MECHANISMS OXYGE, P245; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; HOFSTEENGE J, 1980, EUR J BIOCHEM, V113, P141; HOWELL LG, 1972, J BIOL CHEM, V247, P4340; Husain M, 1978, Methods Enzymol, V53, P543; HUSAIN M, 1979, J BIOL CHEM, V254, P6657; Kirschke H., 1979, PROTEIN DEGRADATION, V75, P15; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDOW SE, 1989, SCIENCE, V244, P1300, DOI 10.1126/science.2660261; LODGE J, 1990, FEMS MICROBIOL LETT, V67, P221, DOI 10.1016/0378-1097(90)90199-Z; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTHEWS BW, 1981, J MOL BIOL, V147, P545, DOI 10.1016/0022-2836(81)90399-5; MULLER F, 1979, EUR J BIOCHEM, V101, P235, DOI 10.1111/j.1432-1033.1979.tb04236.x; RICHMOND MH, 1975, GENETICS BIOCH PSEUD, P341; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREUDER HA, 1989, J MOL BIOL, V208, P679, DOI 10.1016/0022-2836(89)90158-7; SCHREUDER HA, 1988, J MOL BIOL, V199, P637, DOI 10.1016/0022-2836(88)90307-5; SPECTOR T, 1972, J BIOL CHEM, V247, P7123; SPECTOR T, 1972, J BIOL CHEM, V247, P4679; ULMER KM, 1983, SCIENCE, V219, P666, DOI 10.1126/science.6572017; VANBERKEL WJH, 1987, EUR J BIOCHEM, V167, P35; VANDERLAAN JM, 1989, EUR J BIOCHEM, V179, P715, DOI 10.1111/j.1432-1033.1989.tb14605.x; VEREIJKEN JM, 1980, EUR J BIOCHEM, V113, P151; WALSH C, 1980, ACCOUNTS CHEM RES, V13, P148, DOI 10.1021/ar50149a004; WEIJER WJ, 1982, BIOCHIM BIOPHYS ACTA, V704, P385, DOI 10.1016/0167-4838(82)90170-4; WEIJER WJ, 1983, EUR J BIOCHEM, V133, P109, DOI 10.1111/j.1432-1033.1983.tb07435.x; WESTPHAL AH, 1990, FLAVINS FLAVOPROTEIN, P231; WIJNANDS RA, 1986, BIOCHEMISTRY-US, V25, P4211, DOI 10.1021/bi00363a007; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; ZIEGLER DM, 1988, DRUG METAB REV, V19, P1, DOI 10.3109/03602538809049617; ZIEGLER DM, 1990, TRENDS PHARMACOL SCI, V11, P321, DOI 10.1016/0165-6147(90)90235-Z	44	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17057	17062						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349594				2022-12-27	WOS:A1993LQ98800029
J	TUMA, PL; STACHNIAK, MC; COLLINS, CA				TUMA, PL; STACHNIAK, MC; COLLINS, CA			ACTIVATION OF DYNAMIN GTPASE BY ACIDIC PHOSPHOLIPIDS AND ENDOGENOUS RAT-BRAIN VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TEMPERATURE-SENSITIVE MUTANT; MICROTUBULE-ASSOCIATED PROTEINS; SEA-URCHIN EGGS; MYOSIN-I; MECHANOCHEMICAL ENZYME; CYTOPLASMIC DYNEIN; BINDING; ENDOCYTOSIS; PURIFICATION	Dynamin is a GTPase thought to play a role in endocytosis based on genetic analysis of its homolog in Drosophila melanogaster shibire. Previous studies have stressed an in vitro association with microtubules, though additional evidence suggests that dynamin associates with membranous organelles. In an analysis of the enzymatic and membrane binding properties of dynamin, we have found that the acidic phospholipids, phosphatidylserine, phosphatidylglycerol, and phosphatidylinositol, are able to stimulate GTP hydrolysis in a manner similar to activation previously shown with microtubules. A neutral phospholipid, phosphatidylcholine, had no effect on dynamin GTPase. Activation of dynamin was biphasic, with a decrease in activity back to basal levels with increased concentrations of either microtubules or liposomes. A comparison between GTPase stimulation induced by microtubules and that by phospholipids suggests that ionic interactions between the basic C-terminal domain of dynamin and the negatively charged microtubule or phospholipid head group are important. In support of this, GTPase stimulation by these agents in combination was not additive. A salt-extracted membrane fraction from brain tissue also activated dynamin GTPase, though to a lower extent than pure phospholipids. These results suggest that membrane components could be responsible for some aspects of the regulation of dynamin function in vivo.	NORTHWESTERN UNIV, SCH MED, DEPT CELL MOLEC & STRUCT BIOL, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA	Northwestern University								ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; BAZZI MD, 1992, BIOCHEMISTRY-US, V31, P1125, DOI 10.1021/bi00119a022; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7961, DOI 10.1021/bi00246a013; BOGGS JM, 1982, LIPID PROTEIN INTERA, V2, P1; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; Collins C A, 1991, Trends Cell Biol, V1, P57, DOI 10.1016/0962-8924(91)90090-V; COLLINS CA, 1986, P NATL ACAD SCI USA, V83, P4799, DOI 10.1073/pnas.83.13.4799; COLLINS CA, 1989, CELL MOTIL CYTOSKEL, V14, P491, DOI 10.1002/cm.970140407; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DOBERSTEIN SK, 1992, J CELL BIOL, V117, P1241, DOI 10.1083/jcb.117.6.1241; FERRARESE C, 1987, J NEUROCHEM, V48, P1093, DOI 10.1111/j.1471-4159.1987.tb05632.x; GRAHAM JM, 1992, CELL BIOL LABFAX, P77; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HAYDEN SM, 1990, J CELL BIOL, V111, P443, DOI 10.1083/jcb.111.2.443; HERSKOVITS J S, 1991, Journal of Cell Biology, V115, p34A; KESSELL I, 1989, P NATL ACAD SCI USA, V86, P4968, DOI 10.1073/pnas.86.13.4968; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; MASUR SK, 1990, J NEUROGENET, V6, P191, DOI 10.3109/01677069009107110; MIYATA H, 1989, J CELL BIOL, V109, P1519, DOI 10.1083/jcb.109.4.1519; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; ORR JW, 1992, J BIOL CHEM, V267, P15263; SCAIFE R, 1990, J CELL BIOL, V111, P3023, DOI 10.1083/jcb.111.6.3023; SCHROEDER C C, 1991, Journal of Cell Biology, V115, p34A; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1991, METHOD ENZYMOL, V196, P192; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; SHPETNER HS, 1992, MOL BIOL CELL, V3, pA4; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STACHNIAK M C, 1990, Journal of Cell Biology, V111, p291A; URIU T, 1991, J NEUROCHEM, V56, P1548, DOI 10.1111/j.1471-4159.1991.tb02050.x; VALLEE RB, 1986, METHOD ENZYMOL, V134, P89; VALLEE RB, 1986, METHOD ENZYMOL, V134, P116; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	36	150	152	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17240	17246						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349610				2022-12-27	WOS:A1993LQ98800056
J	JUPP, R; FLORES, O; NELSON, JA; GHAZAL, P				JUPP, R; FLORES, O; NELSON, JA; GHAZAL, P			THE DNA-BINDING SUBUNIT OF HUMAN TRANSCRIPTION FACTOR-IID CAN INTERACT WITH THE TATA BOX AS A MULTIMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RNA POLYMERASE-II; PREINITIATION COMPLEX; PROTEIN; INITIATION; ACTIVATION; PROMOTER	Transcription initiation from eukaryotic protein-coding genes is a complex process that minimally requires RNA polymerase (pol) II (B) and at least seven general transcription factors. The 38-kDa subunit (TBP) of the human general transcription factor TFIID recognizes the TATA sequence element and initiates the assembly of the other general transcription factors and RNA pol II. It is believed, based on experiments with yeast recombinant protein, that TBP binds as a monomer to DNA. Using purified recombinant human TBP protein we find that TBP interacts with the TATA element as both a monomer and a dimer. The multimeric binding of TBP to DNA revealed by this study has important implications for the role of TBP in transcription initiation and suggests novel mechanisms whereby other transcription factors may interact with a RNA pol II preinitiation complex.	Scripps Res Inst, DEPT IMMUNOL, DIV VIROL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; SALK INST BIOL STUDIES, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Salk Institute								BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1992, J BIOL CHEM, V267, P2786; GHAZAL P, 1991, J VIROL, V65, P2299, DOI 10.1128/JVI.65.5.2299-2307.1991; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; LEUTHARDT A, 1988, GENE, V68, P35, DOI 10.1016/0378-1119(88)90596-3; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PTASHNE M, 1990, NATURE, V346, P346; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495	21	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16105	16108						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344893				2022-12-27	WOS:A1993LQ33600007
J	LEE, CG; HURWITZ, J				LEE, CG; HURWITZ, J			HUMAN RNA HELICASE-A IS HOMOLOGOUS TO THE MALELESS PROTEIN OF DROSOPHILA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-CHROMOSOME INACTIVATION; MESSENGER-RNA; DOSAGE COMPENSATION; NUCLEOTIDE-SEQUENCE; POLYMERASE-II; XIST GENE; MELANOGASTER; REGION; MUTANT; DNA	RNA helicase A is an abundant nuclear enzyme of HeLa cells that unwinds double-stranded RNA in a 3' to 5' direction (Lee, C. G., and Hurwitz, J. (1992) J. Biol. Chem. 267, 4398-4407). A complementary DNA (cDNA) clone expressing RNA helicase A was isolated by screening a human cDNA library with polyclonal antibodies produced against the purified protein. The deduced amino acid sequence from this clone showed that RNA helicase A is a member of the DEAH family of proteins thought to be helicases. Sequence comparison among all known proteins of the DEAH family revealed that the highest homology was between RNA helicase A and the maleless protein (MLE) of Drosophila. There was 49% identity and 85% similarity throughout the overall primary sequences of both proteins, suggesting that RNA helicase A is the human counterpart of Drosophila MLE. Polyclonal antibodies against Drosophila MLE recognized RNA helicase A in crude nuclear extracts of HeLa cells as well as the purified protein. A recombinant RNA helicase A containing 6 histidine residues at the NH2 terminus was expressed in Sf9 cells using a baculovirus vector. The protein isolated from insect cells and the enzyme purified from HeLa cells exhibited identical RNA helicase and RNA-dependent ATPase activities.			LEE, CG (corresponding author), MEM SLOAN KETTERING CANC CTR, SLOAN KETTERING INST, GRAD PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA.							BARR ML, 1962, ACTA CYTOL, V6, P34; BELOTE JM, 1980, GENETICS, V96, P165; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; CHEN JH, 1990, NUCLEIC ACIDS RES, V18, P6447, DOI 10.1093/nar/18.21.6447; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; DALY RF, 1977, AM J HUM GENET, V29, P83; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORER DR, 1990, NUCLEIC ACIDS RES, V18, P5489, DOI 10.1093/nar/18.18.5489; DORVAL BC, 1991, NATURE, V349, P1823; ERICKSON JW, 1991, SCIENCE, V251, P1071, DOI 10.1126/science.1900130; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; FRIEDMANN T, 1979, CELL, V17, P715, DOI 10.1016/0092-8674(79)90278-2; FUKUNAGA A, 1975, GENETICS, V81, P135; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GURURAJAN R, 1991, NATURE, V349, P717, DOI 10.1038/349717a0; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; IGGO RD, 1991, MOL CELL BIOL, V11, P1326, DOI 10.1128/MCB.11.3.1326; JAMIESON DJ, 1991, NATURE, V349, P715, DOI 10.1038/349715a0; KERNAN MJ, 1991, CELL, V66, P949, DOI 10.1016/0092-8674(91)90440-A; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KIM SH, 1992, EMBO J, V11, P2319, DOI 10.1002/j.1460-2075.1992.tb05291.x; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; LAIN S, 1990, NUCLEIC ACIDS RES, V18, P7003, DOI 10.1093/nar/18.23.7003; LEE CG, 1992, J BIOL CHEM, V267, P4398; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LUCCHESI J C, 1982, Genetics, V100, pS42; LUCCHESI JC, 1977, CHROMOSOMA, V65, P1, DOI 10.1007/BF00293126; LUCCHESI JC, 1987, ADV GENET, V24, P371, DOI 10.1016/S0065-2660(08)60013-9; LYON MF, 1988, AM J HUM GENET, V42, P8; MARONI G, 1973, CHROMOSOMA, V40, P361, DOI 10.1007/BF00399428; MUKHERJEE AS, 1965, NATURE, V207, P785, DOI 10.1038/207785a0; MUNROE SH, 1988, EMBO J, V7, P2523, DOI 10.1002/j.1460-2075.1988.tb03100.x; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PINKHAM JL, 1983, NUCLEIC ACIDS RES, V11, P3531, DOI 10.1093/nar/11.11.3531; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; Sambrook J, 1989, MOL CLONING LABORATO; SCHWER B, 1992, EMBO J, V11, P5033, DOI 10.1002/j.1460-2075.1992.tb05610.x; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SPENA A, 1985, EMBO J, V4, P2153, DOI 10.1002/j.1460-2075.1985.tb03909.x; STRAUSS EJ, 1991, GENE DEV, V5, P629, DOI 10.1101/gad.5.4.629; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIDA S, 1981, JPN J GENET, V56, P523, DOI 10.1266/jjg.56.523; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359	52	156	160	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16822	16830						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344961				2022-12-27	WOS:A1993LQ33600104
J	ALAM, T; AN, MR; MIFFLIN, RC; HSIEH, CC; GE X; PAPACONSTANTINOU, J				ALAM, T; AN, MR; MIFFLIN, RC; HSIEH, CC; GE, X; PAPACONSTANTINOU, J			TRANSACTIVATION OF THE ALPHA-1-ACID GLYCOPROTEIN GENE ACUTE-PHASE RESPONSIVE ELEMENT BY MULTIPLE ISOFORMS OF C/EBP AND GLUCOCORTICOID RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-PROTEIN; ENRICHED TRANSCRIPTIONAL ACTIVATOR; MOUSE ALBUMIN PROMOTER; DNA-BINDING; NUCLEAR-PROTEIN; 3T3-L1 PREADIPOCYTES; GEL-ELECTROPHORESIS; FACTORS INTERACT; LEUCINE ZIPPER; EXPRESSION	Alpha1-acid glycoprotein (AGP) is a major acute phase protein synthesized primarily by the liver. The AGP gene is transcriptionally activated in hepatocytes during the acute phase response to bacterial lipopolysaccharide. In this study, we analyzed an acute phase responsive element (APRE) located between nucleotide residues -127 to -104 relative to the transcription initiation site of the mouse AGP gene. Binding studies show that several trans-acting factors interact with the APRE. Using monospecific antibodies we demonstrate that three isoforms of the CCAAT/enhancer-binding protein (C/EBP) family, namely C/EBPalpha, C/EBPbeta, and C/EBPdelta, bind to the APRE. Furthermore, with liver nuclear protein from control animals, C/EBPalpha is the predominant form that binds to the APRE, whereas with nuclear proteins from acute phase-induced animals, C/EBPalpha is replaced by C/EBPbeta. The mechanism of activation of the AGP gene during the acute phase response appears to involve an exchange of C/EBPalpha by C/EBPbeta. C/EBPdelta does not play a role in this reaction. Interestingly, the C/EBP binding site of the APRE partially overlaps a functional glucocorticoid responsive element. We present evidence that both purified C/EBPalpha and glucocorticoid receptor bind strongly to the APRE. By site-specific mutation, we have identified the C/EBP and glucocorticoid receptor binding sites in the APRE. These mutants were used in expression vectors to demonstrate that both C/EBP and glucocorticoid receptor are essential for maximal response to interleukin-6 and dexamethasone. These results demonstrate that the APRE is a composite binding site for multiple factors that are responsible for the transcriptional control of the mouse AGP. Finally, functional analyses indicate that C/EBPalpha, C/EBPbeta, and C/EBPdelta are strong transcriptional trans-activators of the AGP APRE in hepatoma cells. These data suggest that the regulatory activity of the C/EBP with the APRE in the liver may require interactions with adjacent proteins.	UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOL CHEM & GENET, GALVESTON, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston			Papaconstantinou, John/E-3312-2010					AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, BIOCHEMISTRY-US, V31, P1928, DOI 10.1021/bi00122a005; ALAM T, 1992, J BIOL CHEM, V267, P5021; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1989, GENETICS BIOCH PHYSL; BENNETT M, 1980, P NATL ACAD SCI-BIOL, V77, P6109, DOI 10.1073/pnas.77.10.6109; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARTER KC, 1989, J BIOL CHEM, V264, P4112; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; COOPER R, 1987, BIOCHEMISTRY-US, V26, P5244, DOI 10.1021/bi00391a006; COOPER R, 1986, J BIOL CHEM, V261, P1849; DENTE L, 1987, EMBO J, V6, P2289, DOI 10.1002/j.1460-2075.1987.tb02503.x; DENTE L, 1988, GENE DEV, V2, P259, DOI 10.1101/gad.2.2.259; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FEY GH, 1987, MOL BIOL MED, V4, P323; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; FRIEDMAN MJ, 1983, P NATL ACAD SCI-BIOL, V80, P5421, DOI 10.1073/pnas.80.17.5421; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; IZBAN MG, 1989, J BIOL CHEM, V264, P9171; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KLEIN ES, 1988, MOL ENDOCRINOL, V2, P1343, DOI 10.1210/mend-2-12-1343; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KUSHNER I, 1989, ANN NY ACAD SCI, V557, P19; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEE YM, 1993, MOL CELL BIOL, V13, P432, DOI 10.1128/MCB.13.1.432; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; MUELLER CR, 1991, CELL, V65, P915; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; PEI DQ, 1990, J VIROL, V64, P1517, DOI 10.1128/JVI.64.4.1517-1522.1990; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; REINKE R, 1985, J BIOL CHEM, V260, P4397; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RON D, 1990, MOL CELL BIOL, V10, P4389, DOI 10.1128/MCB.10.8.4389; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SNYERS L, 1990, P NATL ACAD SCI USA, V87, P2838, DOI 10.1073/pnas.87.7.2838; SRINIVASAN G, 1990, MOL ENDOCRINOL, V4, P209, DOI 10.1210/mend-4-2-209; TSAI SY, 1990, J BIOL CHEM, V265, P17055; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; YIANGOU M, 1991, BIOCHEMISTRY-US, V30, P3798; ZHANG DE, 1990, J BIOL CHEM, V265, P3382	62	98	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15681	15688						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340393				2022-12-27	WOS:A1993LN30500055
J	MCCONVILLE, MJ; COLLIDGE, TAC; FERGUSON, MAJ; SCHNEIDER, P				MCCONVILLE, MJ; COLLIDGE, TAC; FERGUSON, MAJ; SCHNEIDER, P			THE GLYCOINOSITOL PHOSPHOLIPIDS OF LEISHMANIA-MEXICANA PROMASTIGOTES - EVIDENCE FOR THE PRESENCE OF 3 DISTINCT PATHWAYS OF GLYCOLIPID BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; HUMAN MONONUCLEAR PHAGOCYTES; MAJOR PROMASTIGOTES; GLYCOSYLATED-PHOSPHATIDYLINOSITOLS; STRUCTURAL CHARACTERIZATION; DONOVANI LIPOPHOSPHOGLYCAN; SURFACE GLYCOPROTEIN; VIRULENCE FACTORS; STAGE; IDENTIFICATION	Most macromolecules at the cell surface of parasitic protozoa of the genus Leishmania, including the major surface glycoproteins and a complex lipophosphoglycan (LPG), are attached to the plasma membrane via glycosyl-phosphatidylinositol (GPI) anchors. Free glycoinositol phospholipids (GIPLs) which are not linked to protein or phosphoglycan have also been found. In this study, we show that L. mexicana promastigotes synthesize two distinct GIPL lineages, comprising at least 10 glycolipid species. These structures were characterized using a combination of gas-liquid chromatography-mass spectrometry, methylation linkage analysis, and chemical and exoglycosidase sequencing. The major lineage contains GIPLs with the glycan structures Manalpha1-3Manalpha1-4GlcN (iM2), Manalpha1-6(Manalpha1-3)Manalpha1-4GlcN (iM3), and Manalpha1-2Manalpha1-6(Manalpha1-3)Manalpha1-4GlcN (iM4), which are linked to alkylacyl-PI containing predominantly C16:0 and C18:0 fatty acids and C18:0 alkyl chains (referred to as the hybrid type GIPLs). A proportion of the iM3 and iM4 species (32 and 4%, respectively) are substituted with an ethanolamine-phosphate residue. The location of this residue on the core glucosamine residue was inferred from the results of methylation analyses and alpha-mannosidase digestion. The minor GIPL lineage contains GIPLs with the same glycan sequences as the glycolipid anchor of LPG (referred to as the type-2 GIPLs). The alkylacyl-PI or lyso-alkyl-PI lipid moieties of these GIPLs differ from those of the hybrid type GIPLs and from the main pool of alkylacyl-PI in containing significant levels of C24:0 and C26:0 alkyl chains. The most polar of these GIPLs, LPGp, has the properties expected of a biosynthetic precursor to the LPG, having the structure, [GRAPHICS] Finally, the GPI anchors of the major promastigote proteins were found to contain the glycan sequence Manalpha1-2Manalpha1-6Manalpha1-4GlcN, and an alkylacyl-PI lipid moiety which was highly enriched for C24:0 or C26:0 alkyl chains. These data suggest that L. mexicana promastigotes contain three distinct pathways of GPI biosynthesis. The possibility that the distinct alkyl chain compositions of the different GPI glycolipids reflects the subcellular compartmentalization of different GPI biosynthetic pathways is discussed.			MCCONVILLE, MJ (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND.		Ferguson, Michael A. J./F-7829-2010	Ferguson, Michael A. J./0000-0003-1321-8714; Schneider, Pascal/0000-0003-0677-9409	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AVILA JL, 1991, J CLIN MICROBIOL, V29, P2305, DOI 10.1128/JCM.29.10.2305-2312.1991; BAHR V, 1993, MOL BIOCHEM PARASIT, V58, P107, DOI 10.1016/0166-6851(93)90095-F; BLACKWELL JM, 1985, J EXP MED, V162, P324, DOI 10.1084/jem.162.1.324; BOUVIER J, 1989, MOL BIOCHEM PARASIT, V37, P235, DOI 10.1016/0166-6851(89)90155-2; BOUVIER J, 1985, J BIOL CHEM, V260, P5504; BUTIKOFER P, 1992, EUR J BIOCHEM, V208, P677, DOI 10.1111/j.1432-1033.1992.tb17234.x; CARVER MA, 1991, J BIOL CHEM, V266, P10974; CHAN J, 1989, P NATL ACAD SCI USA, V86, P2453, DOI 10.1073/pnas.86.7.2453; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DASILVA RP, 1989, J IMMUNOL, V143, P617; DEEG MA, 1992, J BIOL CHEM, V267, P18573; DESCOTEAUX A, 1992, J IMMUNOL, V149, P3008; DOERING TL, 1989, J BIOL CHEM, V264, P11168; FIELD MC, 1991, MOL BIOCHEM PARASIT, V48, P227, DOI 10.1016/0166-6851(91)90118-P; GLASER TA, 1991, MOL BIOCHEM PARASIT, V45, P337, DOI 10.1016/0166-6851(91)90102-C; HIROSE S, 1992, J BIOL CHEM, V267, P16968; ILLG T, 1992, J BIOL CHEM, V267, P6834; KELLEHER M, 1992, P NATL ACAD SCI USA, V89, P6, DOI 10.1073/pnas.89.1.6; LEDERKREMER RM, 1991, J BIOL CHEM, V266, P23670; LOHMAN KL, 1990, P NATL ACAD SCI USA, V87, P8393, DOI 10.1073/pnas.87.21.8393; MCCONVILLE MJ, 1992, J BIOL CHEM, V267, P5855; MCCONVILLE MJ, 1987, P NATL ACAD SCI USA, V84, P8941, DOI 10.1073/pnas.84.24.8941; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; MCCONVILLE MJ, 1991, J BIOL CHEM, V266, P15170; MCCONVILLE MJ, 1992, EMBO J, V11, P3593, DOI 10.1002/j.1460-2075.1992.tb05443.x; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCCONVILLE MJ, 1991, CELL BIOL INT REP, V15, P779, DOI 10.1016/0309-1651(91)90033-F; MCCONVILLE MJ, 1989, J BIOL CHEM, V264, P757; MCCONVILLE MJ, 1990, MOL BIOCHEM PARASIT, V38, P57, DOI 10.1016/0166-6851(90)90205-Z; MCNEELY TB, 1990, J IMMUNOL, V144, P2745; MEDINAACOSTA E, 1989, MOL BIOCHEM PARASIT, V37, P263, DOI 10.1016/0166-6851(89)90158-8; MENON AK, 1990, J BIOL CHEM, V265, P9033; MURRAY PJ, 1989, J IMMUNOL, V143, P4221; PIMENTA PFP, 1992, SCIENCE, V256, P1812, DOI 10.1126/science.1615326; PIMENTA PFP, 1991, EXP PARASITOL, V72, P191, DOI 10.1016/0014-4894(91)90137-L; PREVIATO JO, 1990, J BIOL CHEM, V265, P2518; PREVIATO JO, 1992, J BIOL CHEM, V267, P24279; PUENTES SM, 1990, J IMMUNOL, V145, P4311; ROSEN G, 1988, MOL BIOCHEM PARASIT, V27, P93, DOI 10.1016/0166-6851(88)90028-X; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SCHNEIDER P, 1993, ANAL BIOCHEM, V210, P106, DOI 10.1006/abio.1993.1158; SCHNEIDER P, 1992, EXP PARASITOL, V75, P196, DOI 10.1016/0014-4894(92)90179-E; SCHNEIDER P, 1993, IN PRESS BIOCH J; SINGH BN, 1988, BIOCHEM BIOPH RES CO, V157, P1239, DOI 10.1016/S0006-291X(88)81007-6; THOMAS JR, 1992, J BIOL CHEM, V267, P6829; TURCO SJ, 1991, MOL BIOCHEM PARASIT, V45, P91, DOI 10.1016/0166-6851(91)90030-A; TURCO SJ, 1989, J BIOL CHEM, V264, P6711; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; WASSEF MK, 1985, LIPIDS, V20, P108, DOI 10.1007/BF02534216; WILSON ME, 1986, J IMMUNOL, V136, P4681; WILSON ME, 1988, INFECT IMMUN, V56, P363, DOI 10.1128/IAI.56.2.363-369.1988	51	112	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15595	15604						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340385				2022-12-27	WOS:A1993LN30500043
J	SAITO, K; CROWLEY, JS; MARKEY, SP; HEYES, MP				SAITO, K; CROWLEY, JS; MARKEY, SP; HEYES, MP			A MECHANISM FOR INCREASED QUINOLINIC ACID FORMATION FOLLOWING ACUTE SYSTEMIC IMMUNE STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBROSPINAL-FLUID; KYNURENIC ACID; INDOLEAMINE 2,3-DIOXYGENASE; L-TRYPTOPHAN; RAT-BRAIN; 3-HYDROXYANTHRANILIC ACID; NEUROACTIVE KYNURENINES; IMMUNODEFICIENCY VIRUS; INDOLEAMINE-2,3-DIOXYGENASE; QUANTIFICATION	Mechanisms for increased levels of quinolinic acid (QUIN) following systemic immune stimulation were investigated. In gerbils, systemic administration of pokeweed mitogen (PWM) increased plasma and cerebrospinal fluid QUIN levels, while plasma kynurenic acid levels were decreased and cerebrospinal fluid kynurenic acid levels were unchanged. PWM also increased the QUIN concentrations of brain and systemic tissues. In slices of spleen, lung, liver, duodenum, and kidney, PWM caused marked increases in [C-13(6)]QUIN formation from L-[C-13(6)]tryptophan (but not from [C-13(6)anthranilic acid). PWM also increased QUIN excretion in the urine and enhanced the formation and excretion of [C-13(6)]QUIN following an intraperitoneal injection Of L-[C-13(6)]tryptophan. Indoleamine-2,3-dioxygenase activity was increased in the brain, kidney, lung, spleen, and duodenum while hepatic L-tryptophan-2,3-dioxygenase activity was reduced, data consistent with in vitro L-kynurenine formation from L-tryptophan. Kynurenine-3-hydroxylase activity was increased in the duodenum, lung, and spleen, but not in the brain, kidney, or liver. Kynureninase activity was increased in the brain, lung, and duodenum, but not in the spleen, kidney, or liver. 3-Hydroxyanthranilate-3,4-dioxygenase activity was unchanged in the brain, lung, and liver. No change in kynurenine aminotransferase activity was observed in the brain or lung, while liver kynurenine aminotransferase activity was reduced. We conclude that increased activities of kynurenine pathway enzymes in various tissues following systemic immune stimulation, in conjunction with macrophage infiltration of the affected tissue, provide a mechanism to account for increased concentrations of QUIN.			SAITO, K (corresponding author), NIMH, ANALYT BIOCHEM SECT, CLIN SCI LAB, BETHESDA, MD 20892 USA.							ABALLI AJ, 1978, PEDIATR RES, V12, P646, DOI 10.1203/00006450-197805000-00006; BARAN H, 1990, J NEUROCHEM, V55, P738, DOI 10.1111/j.1471-4159.1990.tb04553.x; BENDER DA, 1983, MOL ASPECTS MED, V6, P101, DOI 10.1016/0098-2997(83)90005-5; BESKID M, 1991, EXP PATHOL-JENA, V41, P110, DOI 10.1016/S0232-1513(11)80007-1; CARLIN JM, 1989, EXPERIENTIA, V45, P535, DOI 10.1007/BF01990503; DANGELI F, 1955, J BIOL CHEM, V214, P281; FOSTER AC, 1986, J NEUROCHEM, V47, P23; FUKUI S, 1991, J NEUROCHEM, V56, P2007, DOI 10.1111/j.1471-4159.1991.tb03460.x; HAYCOCK KA, 1992, STATVIEW, P466; HEYES MP, 1992, J NEUROIMMUNOL, V40, P71, DOI 10.1016/0165-5728(92)90214-6; HEYES MP, 1990, J CHROMATOGR-BIOMED, V530, P108, DOI 10.1016/S0378-4347(00)82308-7; HEYES MP, 1991, ANN NEUROL, V29, P202, DOI 10.1002/ana.410290215; HEYES MP, 1992, BRAIN, V115, P1249, DOI 10.1093/brain/115.5.1249; HEYES MP, 1992, BRAIN RES, V570, P237, DOI 10.1016/0006-8993(92)90587-Y; HEYES MP, 1988, ANAL BIOCHEM, V174, P349, DOI 10.1016/0003-2697(88)90556-8; HEYES MP, 1992, FASEB J, V6, P2977, DOI 10.1096/fasebj.6.11.1322853; HEYES MP, 1992, BIOCHEM J, V283, P633, DOI 10.1042/bj2830633; HEYES MP, 1989, ANN NEUROL, V26, P275; HEYES MP, 1988, BIOMED ENVIRON MASS, V15, P291, DOI 10.1002/bms.1200150509; HEYES MP, 1988, J NEUROCHEM, V51, P1446, DOI 10.1111/j.1471-4159.1988.tb01183.x; HEYES MP, 1988, J CHROMATOGR-BIOMED, V428, P340, DOI 10.1016/S0378-4347(00)83925-0; HEYES MP, 1990, J NEUROCHEM, V55, P338, DOI 10.1111/j.1471-4159.1990.tb08857.x; HIRATA F, 1971, J BIOL CHEM, V246, P7825; KAWAI J, 1988, ENZYME, V39, P181, DOI 10.1159/000469117; LAPIN IP, 1978, J NEURAL TRANSM, V42, P37, DOI 10.1007/BF01262727; LARDY H, 1980, BIOCH MED ASPECTS TR, P199; MARTIN A, 1992, J NEUROPSYCH CLIN N, V4, P270; OKUNO E, 1987, J NEUROCHEM, V49, P771, DOI 10.1111/j.1471-4159.1987.tb00960.x; PERKINS MN, 1983, J PHARMACOL EXP THER, V226, P551; RIOS C, 1991, NEUROCHEM RES, V16, P1139, DOI 10.1007/BF00966592; SAITO K, 1993, BIOCHEM J, V291, P11, DOI 10.1042/bj2910011; SAITO K, 1990, BIOCHEM INT, V20, P71; SAITO K, 1992, NEUROSCIENCE, V51, P25, DOI 10.1016/0306-4522(92)90467-G; SAITO K, 1993, J NEUROCHEM, V60, P180, DOI 10.1111/j.1471-4159.1993.tb05836.x; SAITO K, 1991, LIFE SCI, V49, P527, DOI 10.1016/0024-3205(91)90070-R; SAITO K, 1991, BRAIN RES, V546, P151, DOI 10.1016/0006-8993(91)91171-V; SAITO K, 1991, BRAIN RES, V540, P353, DOI 10.1016/0006-8993(91)90536-5; SCHWARCZ R, 1983, SCIENCE, V219, P316, DOI 10.1126/science.6849138; SPECIALE C, 1989, NEUROSCI LETT, V104, P345, DOI 10.1016/0304-3940(89)90601-0; STONE TW, 1984, NEUROSCI LETT, V52, P335, DOI 10.1016/0304-3940(84)90184-8; TAKIKAWA O, 1986, J BIOL CHEM, V261, P3648; TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934; UEDA T, 1978, J BIOCHEM-TOKYO, V84, P687, DOI 10.1093/oxfordjournals.jbchem.a132174; VECSEI L, 1990, BRAIN RES BULL, V25, P623, DOI 10.1016/0361-9230(90)90123-H; WERNER ER, 1988, BIOL CHEM H-S, V369, P337, DOI 10.1515/bchm3.1988.369.1.337; YOSHIDA R, 1986, ARCH BIOCHEM BIOPHYS, V249, P596, DOI 10.1016/0003-9861(86)90038-X	46	167	168	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15496	15503						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340378				2022-12-27	WOS:A1993LN30500029
J	WOODLOCK, TJ; YOUNG, DA; BOAL, TR; LICHTMAN, MA; SEGEL, GB				WOODLOCK, TJ; YOUNG, DA; BOAL, TR; LICHTMAN, MA; SEGEL, GB			PHORBOL ESTER-INDUCED MEMBRANE-PROTEINS IN CHRONIC LEUKEMIC B-LYMPHOCYTES - CANDIDATE PROTEINS FOR THE L-SYSTEM AMINO-ACID TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAIRY-CELL LEUKEMIA; SACCHAROMYCES-CEREVISIAE; MULTICOMPONENT ANALYSIS; TRIPHOSPHATASE-ACTIVITY; NUCLEOTIDE-SEQUENCE; KINETIC-PARAMETERS; DIFFERENTIATION; NA+; 5'-NUCLEOTIDASE; ELECTROPHORESIS	Chronic lymphocytic leukemia (CLL) B-lymphocytes have markedly diminished membrane L-system amino acid transport as compared with normal mature B- and T-lymphocytes. L-system functional recovery is induced in CLL B-cells by the maturational agent, 12-O-tetradecanoylphorbol-13-acetate ( TPA). The studies reported here extend the analysis of CLL B-cell maturation by comparing membrane protein expression in untreated and TPA-treated CLL B-cells, with the identification of candidate proteins for the L-system transporter. Cell membrane proteins of resting and TPA-treated CLL B-lymphocytes were studied using ultra-high resolution giant two-dimensional gel electrophoresis. Cellular proteins were metabolically labeled with [S-35]methionine, and, in separate experiments, membrane proteins were photoaffinity labeled with [I-125] iodoazidophenylalanine, an amino acid transported by the L-system and which binds at or near the L-system transport carrier. In a partially purified membrane preparation, approximately 1400 proteins were identified by metabolic labeling. Following TPA treatment for 17 h, 14 new metabolically labeled membrane proteins were identified, and five of these also were labeled by the L-system photoprobe. Photolabeling of four of these proteins was inhibited by an excess of the L-system prototype amino acid, 2-aminobicyclo(2.2.1)heptane-2-carboxylic acid. Given these labeling characteristics, one or more of these four proteins may be related to the L-system amino acid transport carrier.	UNIV ROCHESTER,SCH MED,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED,DEPT PEDIAT,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED,DEPT BIOPHYS,ROCHESTER,NY 14642; UNIV ROCHESTER,ST MARYS HOSP,CTR CANC,SCH MED,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester; University of Rochester					NATIONAL CANCER INSTITUTE [R01CA034691] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016177] Funding Source: NIH RePORTER; NCI NIH HHS [CA34691] Funding Source: Medline; NHLBI NIH HHS [HL07152-17] Funding Source: Medline; NIDDK NIH HHS [DK16177] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAMPBELL GS, 1992, J BIOL CHEM, V267, P12496; CARLSSON M, 1989, LEUKEMIA, V3, P593; CHRISTENSEN HN, 1969, J BIOL CHEM, V244, P1510; FRANCO A, 1989, EUR J IMMUNOL, V19, P1171, DOI 10.1002/eji.1830190703; GALE RP, 1985, ANN INTERN MED, V103, P101, DOI 10.7326/0003-4819-103-1-101; GORDON J, 1984, J IMMUNOL, V132, P541; GRATECOS D, 1982, BIOCHIM BIOPHYS ACTA, V705, P218, DOI 10.1016/0167-4838(82)90181-9; GUY K, 1983, EUR J IMMUNOL, V13, P156, DOI 10.1002/eji.1830130212; HARLOW E, 1988, ANTIBODIES LABORATOR; HO AD, 1986, CANCER, V58, P96, DOI 10.1002/1097-0142(19860701)58:1<96::AID-CNCR2820580117>3.0.CO;2-3; JAUNIAUX JC, 1990, EUR J BIOCHEM, V190, P39, DOI 10.1111/j.1432-1033.1990.tb15542.x; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V694, P27, DOI 10.1016/0304-4157(82)90013-2; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KORNFELD R, 1974, J BIOL CHEM, V249, P1295; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMANTIA K, 1977, BLOOD, V50, P683; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LOPES J, 1973, J CLIN INVEST, V52, P1297, DOI 10.1172/JCI107298; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARIQUE D, 1973, CANCER RES, V33, P2761; MITSUI H, 1991, IMMUNOL LETT, V27, P105, DOI 10.1016/0165-2478(91)90136-X; NOREN O, 1983, EUR J BIOCHEM, V134, P71, DOI 10.1111/j.1432-1033.1983.tb07532.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OSTLUND L, 1986, BLOOD, V67, P152; PARKS DR, 1979, P NATL ACAD SCI USA, V76, P1962, DOI 10.1073/pnas.76.4.1962; RABILLOUD T, 1991, P NATL ACAD SCI USA, V88, P1830, DOI 10.1073/pnas.88.5.1830; RUOHO AE, 1984, MEMBRANES DETERGENTS, P119; SAMUELS BL, 1987, LEUKEMIA, V1, P365; SEGEL GB, 1979, J CELL PHYSIOL, V100, P109, DOI 10.1002/jcp.1041000111; SEGEL GB, 1983, J CELL PHYSIOL, V116, P372, DOI 10.1002/jcp.1041160315; SEGEL GB, 1989, J BIOL CHEM, V264, P16399; SEGEL GB, 1985, J CELL PHYSIOL, V124, P424, DOI 10.1002/jcp.1041240310; SEGEL GB, 1984, J CLIN INVEST, V74, P17, DOI 10.1172/JCI111398; STAROS JV, 1978, BIOCHEMISTRY-US, V17, P3321, DOI 10.1021/bi00609a023; TERNYNCK T, 1974, BLOOD, V43, P789, DOI 10.1182/blood.V43.6.789.789; TOTTERMAN TH, 1980, NATURE, V288, P176, DOI 10.1038/288176a0; VANDENBOL M, 1989, GENE, V83, P153, DOI 10.1016/0378-1119(89)90413-7; VANWINKLE LJ, 1985, J BIOL CHEM, V260, P2118; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WILLARDGALLO KE, 1984, CLIN CHEM, V30, P2069; WOODLOCK TJ, 1990, J CELL PHYSIOL, V145, P217, DOI 10.1002/jcp.1041450205; WOODLOCK TJ, 1988, J CLIN INVEST, V81, P32, DOI 10.1172/JCI113306; YOUNG DA, 1983, METHOD ENZYMOL, V91, P190	45	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					16020	16027						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340423				2022-12-27	WOS:A1993LN30500097
J	YANAGISAWA, S; IZUI, K				YANAGISAWA, S; IZUI, K			MOLECULAR-CLONING OF 2 DNA-BINDING PROTEINS OF MAIZE THAT ARE STRUCTURALLY DIFFERENT BUT INTERACT WITH THE SAME SEQUENCE MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYLASE GENE; NUCLEAR FACTORS INTERACT; TRANSCRIPTION FACTOR; PLANT GENES; TRANSGENIC PLANTS; CDNA CLONE; PROMOTER; EXPRESSION; ENHANCER; ELEMENT	Nuclear extracts from maize leaves have been shown previously to contain a factor, MNF1, that interacts with both the cauliflower mosaic virus 35S promoter and the promoter of the maize gene for phosphoenol-pyruvate carboxylase, which is involved in C4 photosynthesis. We have isolated two cDNA clones encoding proteins (MNB1a and MNB1b), that bind to an MNF1-binding site in a sequence-specific manner, by screening of a maize cDNA expression library with synthetic oligonucleotides. Using various mutated oligonucleotides, we showed that both proteins recognize an AAGG motif at the MNF1-binding site as important bases for binding, as does MNF1 in maize nuclear extracts. However, the binding specificities of MNB1a and MNB1b are similar but not identical to that of MNF1. The deduced amino acid sequences of these proteins are completely different from each other. The basic region of MNB1b exhibits homology to the high mobility group (HMG) box of the vertebrate HMG1 family, whereas MNB1a exhibits no homology to any known proteins. Southern blot analysis of genomic DNA revealed that the cDNA for MNB1a is derived from a multigene family whose members have highly homologous N-terminal basic domain, whereas the gene for MNB1b exhibits only limited homology to a few other genes. These results suggest that the MNF1-binding site on the 35S promoter is a target of multiple DNA-binding proteins.	OSAKA CITY UNIV,FAC SCI,DEPT BIOL,SUMIYOSHI KU,OSAKA 558,JAPAN; KYOTO UNIV,FAC SCI,DEPT CHEM,SAKYO KU,KYOTO 60601,JAPAN	Osaka Metropolitan University; Kyoto University								ALLEN RD, 1989, PLANT CELL, V1, P623, DOI 10.1105/tpc.1.6.623; BENFEY PN, 1989, SCIENCE, V244, P174, DOI 10.1126/science.244.4901.174; BENFEY PN, 1989, EMBO J, V8, P2195, DOI 10.1002/j.1460-2075.1989.tb08342.x; BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; BRUNNER B, 1992, THESIS SWISS FEDERAL; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; DEHESH K, 1992, EMBO J, V11, P4131, DOI 10.1002/j.1460-2075.1992.tb05506.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FANG RX, 1989, PLANT CELL, V1, P141, DOI 10.1105/tpc.1.1.141; FROMM H, 1989, PLANT CELL, V1, P977, DOI 10.1105/tpc.1.10.977; GRASSER KD, 1991, NUCLEIC ACIDS RES, V19, P2573, DOI 10.1093/nar/19.10.2573; GRASSER KD, 1990, J BIOL CHEM, V265, P4185; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; KATAGIRI F, 1989, NATURE, V340, P727, DOI 10.1038/340727a0; KAWAMURA T, 1990, J BIOCHEM-TOKYO, V107, P165, DOI 10.1093/oxfordjournals.jbchem.a123002; KAY R, 1987, SCIENCE, V236, P1299, DOI 10.1126/science.236.4806.1299; LAM E, 1990, PLANT CELL, V2, P857, DOI 10.1105/tpc.2.9.857; LESSARD PA, 1991, PLANT MOL BIOL, V16, P397, DOI 10.1007/BF00023991; MATSUOKA M, 1991, MOL GEN GENET, V225, P411, DOI 10.1007/BF00261681; MIKAMI K, 1989, NUCLEIC ACIDS RES, V17, P9707, DOI 10.1093/nar/17.23.9707; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; OEDA K, 1991, EMBO J, V10, P1793, DOI 10.1002/j.1460-2075.1991.tb07704.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHARF KD, 1990, EMBO J, V9, P4495, DOI 10.1002/j.1460-2075.1990.tb07900.x; SCHELL JS, 1987, SCIENCE, V237, P1176; SCHINDLER U, 1992, EMBO J, V11, P1275, DOI 10.1002/j.1460-2075.1992.tb05171.x; SCHINDLER U, 1990, EMBO J, V9, P3415, DOI 10.1002/j.1460-2075.1990.tb07549.x; SCHINDLER U, 1992, EMBO J, V11, P1261, DOI 10.1002/j.1460-2075.1992.tb05170.x; SIMS TL, 1981, J BIOL CHEM, V256, P8252; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SINGH J, 1990, BIOCHEMISTRY-US, V29, P6295, DOI 10.1021/bi00478a026; SINGH K, 1990, PLANT CELL, V2, P891, DOI 10.1105/tpc.2.9.891; TABATA T, 1989, SCIENCE, V245, P965, DOI 10.1126/science.2772648; TAKATSUJI H, 1992, EMBO J, V11, P241, DOI 10.1002/j.1460-2075.1992.tb05047.x; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WATT F, 1988, NUCLEIC ACIDS RES, V16, P1471, DOI 10.1093/nar/16.4.1471; WEISSHAAR B, 1991, EMBO J, V10, P1777, DOI 10.1002/j.1460-2075.1991.tb07702.x; WEN L, 1989, NUCLEIC ACIDS RES, V17, P1197, DOI 10.1093/nar/17.3.1197; WILLIAMS ME, 1992, PLANT CELL, V4, P485, DOI 10.1105/tpc.4.4.485; YANAGISAWA S, 1989, J BIOCHEM-TOKYO, V106, P982, DOI 10.1093/oxfordjournals.jbchem.a122986; YANAGISAWA S, 1990, MOL GEN GENET, V224, P325, DOI 10.1007/BF00262425; YANAGISAWA S, 1992, PLANT MOL BIOL, V19, P545, DOI 10.1007/BF00026781	43	124	172	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					16028	16036						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340424				2022-12-27	WOS:A1993LN30500098
J	COLLINS, MJ; ARCIERO, DM; HOOPER, AB				COLLINS, MJ; ARCIERO, DM; HOOPER, AB			OPTICAL SPECTROPOTENTIOMETRIC RESOLUTION OF THE HEMES OF HYDROXYLAMINE OXIDOREDUCTASE - HEME QUANTITATION AND PH-DEPENDENCE OF E(M)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROSOMONAS-EUROPAEA; REDOX POTENTIOMETRY; RESONANCE SPECTROSCOPY; CYTOCHROME-C; REDUCTION; P-460; P460; SITE	The hemes of hydroxylamine oxidoreductase (HAO) have been analyzed optically by potentiometric titrations using a low volume optically transparent thin layer electrochemical cell. The electrochemical behavior of the HAO monomeric unit has been interpreted by modeling the spectroelectrochemical data at several wavelengths to eight one-electron Nernst sites: seven c-type hemes and one P460 heme. Of the seven c-hemes, six show alpha-bands with absorption maxima at or near 553 nm. One c-heme has an alpha-band absorption maximum at 559 nm. The six c-553 hemes have midpoint potentials at pH 7.0 of +288, -10, -162, -192, -265 and -412 mV versus the normal hydrogen electrode (NHE). The c-559 heme has a midpoint potential (E(m)') at pH 7.0 of +11 mV versus NHE. The midpoint potential of the P460 heme is at -260 mV versus NHE at pH 7.0. In contrast, the midpoint potential for the P460 heme in another protein, cytochrome P460, from the same organism is -402 mV versus NHE at pH 7.0. Midpoint potentials of the c-hemes show little, if any, pH dependence over the range of pH 6-8. In contrast, E(m)' for the P460 heme changes with a slope of -60 mV/pH unit over the same range. Electrochemical isolation of the P460 heme at pH 8.0 led to the discovery of a broad spectroscopic feature centered near 740 nm that was assigned to the oxidized P460 heme. Changes in the spectroelectrochemical behavior of HAO after inactivation by H2O2 was almost exclusively restricted to the P460 heme of HAO. Both the 464-nm absorption band of the reduced P460 heme and the 740-nm band of the oxidized heme were no longer present. For the c-hemes, the only effect seems to be a slight shift in E(m)' for a single c-553 heme from -162 to -135 mV.	UNIV MINNESOTA,DEPT GENET & CELL BIOL,ST PAUL,MN 55108; VITERBO COLL,DEPT CHEM,LA CROSSE,WI 54601	University of Minnesota System; University of Minnesota Twin Cities								ANDERSON CW, 1979, ANAL BIOCHEM, V93, P366, DOI 10.1016/S0003-2697(79)80164-5; ANDERSSON KK, 1991, BIOCHEM BIOPH RES CO, V174, P358, DOI 10.1016/0006-291X(91)90528-F; ANDERSSON KK, 1984, J BIOL CHEM, V259, P6833; ARCIERO DM, 1991, BIOCHEMISTRY-US, V30, P11466, DOI 10.1021/bi00112a014; ARCIERO DM, 1991, BIOCHEMISTRY-US, V30, P11459, DOI 10.1021/bi00112a013; ARCIERO DM, 1993, J BIOL CHEM, V266, P14645; COLETTA M, 1991, EUR J BIOCHEM, V202, P1101, DOI 10.1111/j.1432-1033.1991.tb16476.x; ELLIS WR, 1986, BIOCHEMISTRY-US, V25, P161, DOI 10.1021/bi00349a023; ERICKSON RH, 1972, BIOCHIM BIOPHYS ACTA, V275, P231, DOI 10.1016/0005-2728(72)90044-8; HOOPER AB, 1977, BIOCHEMISTRY-US, V16, P455, DOI 10.1021/bi00622a018; HOOPER AB, 1978, BIOCHEMISTRY-US, V17, P2984, DOI 10.1021/bi00608a007; HOOPER AB, 1984, EUR J BIOCHEM, V141, P565, DOI 10.1111/j.1432-1033.1984.tb08230.x; HOOPER AB, 1965, J BIOL CHEM, V240, P4044; LIPSCOMB JD, 1982, BIOCHEMISTRY-US, V21, P3965, DOI 10.1021/bi00260a010; LIPSCOMB JD, 1982, BIOCHEMISTRY-US, V21, P3973, DOI 10.1021/bi00260a011; LOGAN MSP, 1991, THESIS U MINNESOTA S; MILLER DJ, 1984, J GEN MICROBIOL, V130, P3049; NASRI H, 1987, J AM CHEM SOC, V109, P2549, DOI 10.1021/ja00242a069; NUMATA M, 1990, J BIOCHEM, V108, P1016, DOI 10.1093/oxfordjournals.jbchem.a123300; PRINCE RC, 1987, BIOCHEMISTRY-US, V26, P970, DOI 10.1021/bi00377a043; PRINCE RC, 1983, FEBS LETT, V163, P25, DOI 10.1016/0014-5793(83)81154-5; SCHAPPACHER M, 1983, INORG CHIM A-BIOINOR, V78, pL9, DOI 10.1016/S0020-1693(00)86461-0; TERRY KR, 1981, BIOCHEMISTRY-US, V20, P7026, DOI 10.1021/bi00527a039; YAMANAKA T, 1979, J BIOCHEM, V86, P1101, DOI 10.1093/oxfordjournals.jbchem.a132604	24	41	42	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14655	14662						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325842				2022-12-27	WOS:A1993LL75900022
J	DEANGELIS, PL; PAPACONSTANTINOU, J; WEIGEL, PH				DEANGELIS, PL; PAPACONSTANTINOU, J; WEIGEL, PH			ISOLATION OF A STREPTOCOCCUS-PYOGENES GENE LOCUS THAT DIRECTS HYALURONAN BIOSYNTHESIS IN ACAPSULAR MUTANTS AND IN HETEROLOGOUS BACTERIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GRAM-POSITIVE BACTERIA; ESCHERICHIA-COLI; RHEUMATIC-FEVER; CLONING; DNA; INFECTIONS; MINICELLS; PLASMIDS; SYNTHASE; CAPSULE	A contiguous 3-kilobase pair region of DNA was isolated from Group A Streptococcus pyogenes (GAS) that can direct hyaluronic acid (HA) capsule biosynthesis in acapsular mutants as well as heterologous bacteria. The DNA was identified by transposon 916 insertional mutagenesis and subcloned into a plasmid shuttle vector. Mutant acapsular GAS or Enterococcus faecalis containing this plasmid, but not vector alone, displayed a mucoid phenotype on agar plates, possessed a capsule as seen by light microscopy, and produced HA in quantities comparable with wild-type GAS. The polysaccharide was shown to be authentic HA based on its recognition by a specific proteoglycan and its degradation by Streptomyces hyaluronate lyase. Escherichia coli with the complementing plasmid also produced HA but at only 10% of the level made by the above cells. E. coli minicell analysis showed that two proteins, 42 and 45 kDa, are expressed by the functional DNA insert. Deletion analysis of the insert in the minicells revealed that the 42-kDa protein is essential for HA production. This is the first demonstration of reconstitution of HA capsule biosynthesis in vivo.	UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOL CHEM & GENET, GALVESTON, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston			Papaconstantinou, John/E-3312-2010		NIGMS NIH HHS [GM35978] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BISNO AL, 1991, NEW ENGL J MED, V325, P783, DOI 10.1056/NEJM199109123251106; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; CAPARON MG, 1991, METHOD ENZYMOL, V204, P556; CLEWELL DB, 1988, J BACTERIOL, V170, P3046, DOI 10.1128/jb.170.7.3046-3052.1988; COLLINS CH, 1976, MICROBIOLOGICAL METH, P110; Dochez AR, 1919, J EXP MED, V30, P179, DOI 10.1084/jem.30.3.179; DOUGHERTY BA, 1992, J EXP MED, V175, P1291, DOI 10.1084/jem.175.5.1291; DUNNY GM, 1991, APPL ENVIRON MICROB, V57, P1194, DOI 10.1128/AEM.57.4.1194-1201.1991; EHTESHAM NZ, 1991, BIOTECHNIQUES, V11, P718; GAWRONBURKE C, 1984, J BACTERIOL, V159, P214, DOI 10.1128/JB.159.1.214-221.1984; HAKANSSON S, 1986, ACTA PATH MICRO IM B, V94, P139; KAPLAN EL, 1989, J INFECT DIS, V159, P101, DOI 10.1093/infdis/159.1.101; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANSING M, 1993, BIOCHEM J, V289, P179, DOI 10.1042/bj2890179; MATSUMURA P, 1977, J BACTERIOL, V132, P996, DOI 10.1128/JB.132.3.996-1002.1977; MEAGHER RB, 1977, CELL, V10, P521, DOI 10.1016/0092-8674(77)90039-3; MIN H, 1986, ANAL BIOCHEM, V155, P275, DOI 10.1016/0003-2697(86)90437-9; OCONNOR SP, 1987, J INFECT DIS, V156, P495, DOI 10.1093/infdis/156.3.495; PREHM P, 1983, BIOCHEM J, V211, P181, DOI 10.1042/bj2110181; PREHM P, 1986, BIOCHEM J, V235, P887, DOI 10.1042/bj2350887; QUINN RW, 1957, BIOCHEM J, V95, P290; ROBERTS IS, 1989, BIOCHEM SOC T, V17, P462, DOI 10.1042/bst0170462; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARTZ B, 1990, LANCET, V336, P1167, DOI 10.1016/0140-6736(90)92777-F; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; TENGBLAD A, 1980, BIOCHEM J, V185, P101, DOI 10.1042/bj1850101; TRIEUCUOT P, 1991, GENE, V102, P99, DOI 10.1016/0378-1119(91)90546-N; TRISCOTT MX, 1986, J BIOL CHEM, V261, P6004; VANDERIJN I, 1992, J BIOL CHEM, V267, P24302; WESSELS MR, 1991, P NATL ACAD SCI USA, V88, P8317, DOI 10.1073/pnas.88.19.8317	30	109	127	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14568	14571						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325836				2022-12-27	WOS:A1993LL75900005
J	MARGULIES, L; SEHGAL, PB				MARGULIES, L; SEHGAL, PB			MODULATION OF THE HUMAN INTERLEUKIN-6 PROMOTER (IL-6) AND TRANSCRIPTION FACTOR-C/EBP BETA (NF-IL6) ACTIVITY BY P53 SPECIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE ELEMENT; BREAST-CARCINOMA; BINDING-PROTEIN; NUCLEAR FACTOR; DNA-BINDING; WILD-TYPE; GENE; EXPRESSION; ENHANCER; ACTIVATION	Constitutive up-regulation of interleukin-6 (IL-6) gene expression is observed in many neoplastic cell lines. The contribution of mutations in p53 to the up-regulation of the IL-6 promoter was evaluated in transient transfection experiments. In HeLa cells, wild-type (wt) human or murine p53 preferentially repressed the IL-6 promoter. The p53 mutants Val-135 and Phe-132 up-regulated IL-6 promoter activity in these cells at both 32.5 and 37-degrees-C. The temperature-sensitive Val-135 mutant was not only not inhibitory or ''wt-like'' at the lower temperature, but had gained a transcriptional activator phenotype which was temperature-independent in HeLa cells. The functional DNA target for transcriptional modulation of the IL-6 promoter by p53 species included the multiple cytokine- and second messenger-response element (-173 to -145); point mutations in the transcription factor C/EBPbeta-binding site within the second messenger-response element largely blocked the ability of p53 mutants Val-135 and Phe-132 to up-regulate this promoter. The up-regulation of IL-6 promoter constructs by co-transfection into HeLa cells of a C/EBPbeta constitutive expression vector was blocked in a dominant negative manner by wt p53. In contrast, the p53 mutants Val-135 and Phe-132 further enhanced C/EBPbeta-mediated up-regulation of IL-6 promoter constructs. The modulation of C/EBPbeta function by p53 species provides a basis for the involvement of p53 not only in the regulation of cytokine synthesis but also in the altered responsiveness of tumor cells to cytokines.	NEW YORK MED COLL, DEPT MED, VALHALLA, NY 10595 USA	New York Medical College	MARGULIES, L (corresponding author), NEW YORK MED COLL, DEPT MICROBIOL & IMMUNOL, VALHALLA, NY 10595 USA.				NIAID NIH HHS [AI-16262] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016262] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIRA S, 1992, CIBA F SYMP, V167, P47; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHEN L, 1988, P NATL ACAD SCI USA, V85, P8037, DOI 10.1073/pnas.85.21.8037; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HIRANO T, 1992, CLIN IMMUNOL IMMUNOP, V62, pS60, DOI 10.1016/0090-1229(92)90042-M; ISSHIKI H, 1991, NEW BIOL, V3, P63; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NATSUKA S, 1992, BLOOD, V79, P460; NATSUKA S, 1991, FEBS LETT, V291, P58, DOI 10.1016/0014-5793(91)81103-F; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAY A, 1989, ANN NY ACAD SCI, V557, P353; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; RAY A, 1991, P NATL ACAD SCI USA, V88, P7086, DOI 10.1073/pnas.88.16.7086; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SEHGAL PB, 1990, P SOC EXP BIOL MED, V195, P183; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TABIBZADEH SS, 1989, AM J PATHOL, V135, P427; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TAMM I, 1989, J EXP MED, V170, P1649, DOI 10.1084/jem.170.5.1649; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WIETZERBIN J, 1989, ANN NY ACAD SCI, V557, P162; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	55	113	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15096	15100						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325885				2022-12-27	WOS:A1993LL75900081
J	MCLAREN, RS; ROSS, J				MCLAREN, RS; ROSS, J			INDIVIDUAL PURIFIED CORE AND LINKER HISTONES INDUCE HISTONE-H4 MESSENGER-RNA DESTABILIZATION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; GENE-EXPRESSION; DNA-REPLICATION; 3' END; STABILITY; TRANSCRIPTION; ACCUMULATION; DEGRADATION; SEQUENCES; KINETICS	The replication-dependent histone genes encode mRNAs that are expressed during S phase. When DNA synthesis ceases, histone mRNAs are rapidly degraded via the activation of a specific mRNA destabilization process. It has been proposed that this process is autoregulated by histone proteins and is triggered by an increase in the abundance of cytoplasmic histones that accompanies the cessation of DNA synthesis. Consistent with this proposal, all four core histones, in conjunction with cytosol, specifically trigger a 3-4-fold destabilization of polysome-associated histone mRNA in cell-free extracts. Here, we show that each individual purified core histone or purified linker histone H1 can autoregulate (destabilize) histone mRNA in vitro. Three basic polypeptides, protamines, poly-L-lysine, and poly-L-arginine, accelerate an early step in the decay pathway but do not fully autoregulate the mRNA. These data suggest that histones function by overcoming a holdup point at an early step in histone mRNA degradation and that unique properties of histones, aside from their basic domains, are necessary to trigger autoregulation.	UNIV WISCONSIN,MCARDLE LAB CANC RES,1400 UNIV AVE,MADISON,WI 53706; UNIV WISCONSIN,DEPT PATHOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NCI NIH HHS [CA23076, CA07175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023076, P30CA007175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAN J, 1986, J MOL BIOL, V187, P591, DOI 10.1016/0022-2836(86)90337-2; ALTERMAN RBM, 1984, MOL CELL BIOL, V4, P2364; BAUMBACH LL, 1987, BIOCHEMISTRY-US, V26, P6178, DOI 10.1021/bi00393a034; BAUMBACH LL, 1984, BIOCHEMISTRY-US, V23, P1618, DOI 10.1021/bi00303a006; BONNER WM, 1988, BIOCHEMISTRY-US, V27, P6542, DOI 10.1021/bi00417a052; BUTLER WB, 1973, BIOCHIM BIOPHYS ACTA, V294, P481, DOI 10.1016/0005-2787(73)90104-4; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; CROSS SL, 1988, MOL CELL BIOL, V8, P945, DOI 10.1128/MCB.8.2.945; DELISLE AJ, 1983, MOL CELL BIOL, V3, P1920, DOI 10.1128/MCB.3.11.1920; ECKNER R, 1991, EMBO J, V10, P3513, DOI 10.1002/j.1460-2075.1991.tb04915.x; GALLWITZ D, 1969, SCIENCE, V163, P1351, DOI 10.1126/science.163.3873.1351; GRUNSTEIN M, 1992, SCI AM, V267, P68, DOI 10.1038/scientificamerican1092-68; HARRIS ME, 1991, MOL CELL BIOL, V11, P2416, DOI 10.1128/MCB.11.5.2416; HEINTZ N, 1991, BIOCHIM BIOPHYS ACTA, V1088, P327, DOI 10.1016/0167-4781(91)90122-3; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; ISENBERG I, 1979, ANNU REV BIOCHEM, V48, P159, DOI 10.1146/annurev.bi.48.070179.001111; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE BJ, 1987, P NATL ACAD SCI USA, V84, P6189, DOI 10.1073/pnas.84.17.6189; LIU TJ, 1989, MOL CELL BIOL, V9, P3499, DOI 10.1128/MCB.9.8.3499; LUSCHER B, 1985, P NATL ACAD SCI USA, V82, P4389, DOI 10.1073/pnas.82.13.4389; LUSCHER B, 1987, EMBO J, V6, P1721, DOI 10.1002/j.1460-2075.1987.tb02423.x; MARZLUFF WF, 1988, TRENDS BIOCHEM SCI, V13, P49, DOI 10.1016/0968-0004(88)90027-8; MEEKSWAGNER D, 1986, CELL, V44, P43, DOI 10.1016/0092-8674(86)90483-6; MORRIS TD, 1991, MOL CELL BIOL, V11, P544, DOI 10.1128/MCB.11.1.544; OLIVER D, 1974, BIOCHEMISTRY-US, V13, P746, DOI 10.1021/bi00701a017; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; PANDEY NB, 1987, MOL CELL BIOL, V7, P4557, DOI 10.1128/MCB.7.12.4557; PELTZ SW, 1987, MOL CELL BIOL, V7, P4345, DOI 10.1128/MCB.7.12.4345; ROSS J, 1986, J MOL BIOL, V188, P579, DOI 10.1016/S0022-2836(86)80008-0; ROSS J, 1986, MOL CELL BIOL, V6, P4362, DOI 10.1128/MCB.6.12.4362; ROSS J, 1987, J BIOL CHEM, V262, P9374; SARBIAN E, 1985, MOL CELL BIOL, V5, P1279; SCHUMPERLI D, 1986, CELL, V45, P471, DOI 10.1016/0092-8674(86)90277-1; SCHUMPERLI D, 1988, TRENDS GENET, V4, P187, DOI 10.1016/0168-9525(88)90074-1; SENSHU T, 1980, J BIOCHEM-TOKYO, V87, P1659, DOI 10.1093/oxfordjournals.jbchem.a132910; SENSHU T, 1979, J BIOCHEM, V86, P1259, DOI 10.1093/oxfordjournals.jbchem.a132641; SITTMAN DB, 1983, P NATL ACAD SCI-BIOL, V80, P1849, DOI 10.1073/pnas.80.7.1849; Smith MM, 1991, CURR OPIN CELL BIOL, V3, P429, DOI 10.1016/0955-0674(91)90070-F; SMITH MM, 1988, J CELL BIOL, V106, P557, DOI 10.1083/jcb.106.3.557; STAUBER C, 1986, EMBO J, V5, P3297, DOI 10.1002/j.1460-2075.1986.tb04643.x; STAUBER C, 1988, NUCLEIC ACIDS RES, V16, P9399, DOI 10.1093/nar/16.20.9399; STEIN GS, 1984, MOL CELL BIOCHEM, V64, P105; ZHONG R, 1983, NUCLEIC ACIDS RES, V11, P7409, DOI 10.1093/nar/11.21.7409	43	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14637	14644						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325840				2022-12-27	WOS:A1993LL75900020
J	BOWES, AE; SAMAD, AH; JIANG, P; WEAVER, B; MELLORS, A				BOWES, AE; SAMAD, AH; JIANG, P; WEAVER, B; MELLORS, A			THE ACQUISITION OF LYSOPHOSPHATIDYLCHOLINE BY AFRICAN TRYPANOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; PHOSPHATIDYLINOSITOL MEMBRANE ANCHORS; BLOOD-STREAM FORMS; ERYTHROCYTE-MEMBRANES; FATTY-ACIDS; BRUCEI; BIOSYNTHESIS; PHOSPHATIDYLCHOLINE; PRECURSORS; IDENTIFICATION	Bloodstream forms of the African trypanosome, Trypanosoma brucei, can acquire substantial amounts of exogenous lysophospholipid. Lysophosphatidylcholine uptake is through a pathway consisting of three enzymes, phospholipase A1, acyl-CoA ligase, and lysophosphatidylcholine: acyl-CoA acyltransferase. The pathway enables the organism to acquire fatty acids and phospholipid head groups such as choline. Radio-labeling and C-13 NMR studies show that two molecules of lysophosphatidylcholine are used to generate one molecule of cellular phosphatidylcholine. The three enzymes are associated with the trypanosomal plasma membrane and are accessible to exogenous substrates. The first enzyme, phospholipase A1, generates free fatty acid from exogenous lysophospholipid, which the second enzyme, a ligase, uses to form acyl-CoA. The fatty acyl-CoA formed by this route is in a separate pool from that derived from exogenous free fatty acid and is used by the third enzyme, acyltransferase, to acylate a second molecule of exogenous lysophospholipid. Acyltransferase is accessible to exogenous and endogenous acyl-CoA. The high activity of this pathway in bloodstream forms, compared with procyclic culture form trypanosomes, suggests that it may play a role in the acquisition of fatty acids for synthesis of the membrane form of the variant surface glycoprotein. Extracellular myristoyllysophosphatidylcholine can be used by trypanosomes as a source of myristate in remodeling the lipid anchor of the variant surface glycoprotein.	UNIV GUELPH,GUELPH WATERLOO CTR GRAD WORK CHEM,DEPT CHEM & BIOCHEM,GUELPH N1G 2W1,ONTARIO,CANADA	University of Guelph; University of Waterloo; Guelph-Waterloo Centre for Graduate Work in Chemistry & Biochemistry								BARANY M, 1987, BIOCHIM BIOPHYS ACTA, V923, P339, DOI 10.1016/0304-4165(87)90041-9; BARTANA J, 1971, BIOCHEM J, V122, P353, DOI 10.1042/bj1220353; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; COLARD O, 1980, BIOCHIM BIOPHYS ACTA, V618, P88, DOI 10.1016/0005-2760(80)90056-9; CONDREA E, 1967, BIOCHIM BIOPHYS ACTA, V135, P669, DOI 10.1016/0005-2736(67)90097-1; COPPENS I, 1988, P NATL ACAD SCI USA, V85, P6753, DOI 10.1073/pnas.85.18.6753; CZICHOS J, 1986, EXP PARASITOL, V62, P283, DOI 10.1016/0014-4894(86)90033-0; DISE CA, 1980, J LIPID RES, V21, P292; DIXON H, 1972, COMP BIOCHEM PHYSIOL, V41, P1, DOI 10.1016/0305-0491(72)90002-8; DIXON H, 1970, COMP BIOCHEM PHYSIOL, V33, P111, DOI 10.1016/0010-406X(70)90487-1; DIXON H, 1971, COMP BIOCHEM PHYSIOL, V39, P247, DOI 10.1016/0305-0491(71)90168-4; DOERING TL, 1990, J BIOL CHEM, V265, P611; DOERING TL, 1991, SCIENCE, V252, P1851, DOI 10.1126/science.1829548; DOLE VP, 1956, J CLIN INVEST, V35, P150, DOI 10.1172/JCI103259; ERBLAND JF, 1965, BIOCHIM BIOPHYS ACTA, V106, P139, DOI 10.1016/0005-2760(65)90102-5; ESKO JD, 1982, P NATL ACAD SCI-BIOL, V79, P1698, DOI 10.1073/pnas.79.6.1698; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4963; GALLO RL, 1984, ARCH BIOCHEM BIOPHYS, V235, P544, DOI 10.1016/0003-9861(84)90228-5; GODFREY D. G., 1958, EXPTL PARASITOL, V7, P255, DOI 10.1016/0014-4894(58)90022-5; Groot P H, 1976, Adv Lipid Res, V14, P75; HAJDUK SL, 1989, J BIOL CHEM, V264, P5210; HAMBREY PN, 1981, MOL BIOCHEM PARASIT, V2, P177, DOI 10.1016/0166-6851(81)90098-0; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1991, J CELL BIOL, V114, P61, DOI 10.1083/jcb.114.1.61; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MELLORS A, 1989, PARASITOL TODAY, V5, P239, DOI 10.1016/0169-4758(89)90255-X; MENON AK, 1990, J BIOL CHEM, V265, P9033; MOLYNEUX DH, 1983, BIOL TRYPANOSOMA LEI, P13; MORAND O, 1985, BIOCHIM BIOPHYS ACTA, V835, P68, DOI 10.1016/0005-2760(85)90031-1; NYE WH, 1961, J CLIN INVEST, V40, P1194, DOI 10.1172/JCI104349; OLIVEIRA MM, 1964, J LIPID RES, V5, P156; OPPERDOES FR, 1982, MOL BIOCHEM PARASIT, V5, P309, DOI 10.1016/0166-6851(82)90038-X; PAIGE LA, 1989, J MED CHEM, V32, P1665, DOI 10.1021/jm00128a001; PORTMAN OW, 1973, BIOCHIM BIOPHYS ACTA, V326, P34, DOI 10.1016/0005-2760(73)90025-8; RENOOIJ W, 1974, BIOCHIM BIOPHYS ACTA, V363, P287, DOI 10.1016/0005-2736(74)90069-8; RENOOIJ W, 1976, EUR J BIOCHEM, V61, P53, DOI 10.1111/j.1432-1033.1976.tb09996.x; RIFKIN MR, 1985, MOL BIOCHEM PARASIT, V15, P245, DOI 10.1016/0166-6851(85)90088-X; ROBERTS MF, 1990, METHOD ENZYMOL, V197, P31; SAGE L, 1981, TROPENMED PARASITOL, V32, P215; SAMAD A, 1988, MOL BIOCHEM PARASIT, V29, P159, DOI 10.1016/0166-6851(88)90071-0; SAVARD JD, 1982, BIOCHIM BIOPHYS ACTA, V711, P40, DOI 10.1016/0005-2760(82)90007-8; SCHMIDT CF, 1977, BIOCHEMISTRY-US, V16, P3948, DOI 10.1021/bi00637a002; SHAPIRO SZ, 1986, EXP PARASITOL, V61, P432, DOI 10.1016/0014-4894(86)90199-2; Shohet S. B, 1970, Biochim. biophys. Acta, V202, P202, DOI 10.1016/0005-2760(70)90237-7; STEIN O, 1967, BIOCHIM BIOPHYS ACTA, V137, P232, DOI 10.1016/0005-2760(67)90099-9; STEIN Y, 1966, BIOCHIM BIOPHYS ACTA, V116, P95, DOI 10.1016/0005-2760(66)90095-6; STOFFEL W, 1971, H-S Z PHYSIOL CHEM, V352, P1058, DOI 10.1515/bchm2.1971.352.2.1058; TAMURA A, 1985, J BIOCHEM-TOKYO, V97, P353, DOI 10.1093/oxfordjournals.jbchem.a135060; TETLEY L, 1987, J CELL SCI, V87, P363; VIAL HJ, 1982, J PARASITOL, V68, P379, DOI 10.2307/3280946; VOORHEIS HP, 1980, MOL BIOCHEM PARASIT, V1, P177, DOI 10.1016/0166-6851(80)90016-X; WEBSTER P, 1989, EUR J CELL BIOL, V49, P295; ZEISEL SH, 1981, ANNU REV NUTR, V1, P95, DOI 10.1146/annurev.nu.01.070181.000523	59	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13885	13892						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314756				2022-12-27	WOS:A1993LJ82500020
J	SCHWELBERGER, HG; KANG, HA; HERSHEY, JWB				SCHWELBERGER, HG; KANG, HA; HERSHEY, JWB			TRANSLATION INITIATION FACTOR-EIF-5A EXPRESSED FROM EITHER OF 2 YEAST GENES OR FROM HUMAN CDNA - FUNCTIONAL IDENTITY UNDER AEROBIC AND ANAEROBIC CONDITIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPUSINE-CONTAINING PROTEIN; SACCHAROMYCES-CEREVISIAE; FACTOR EIF-4D; SEQUENCES; DNA; ELECTROPHORESIS; FRAGMENTS; PROMOTER; CLONING	Translation initiation factor eIF-5A (previously named eIF-4D) is an essential and highly conserved protein in eukaryotic cells that promotes formation of the first peptide bond. One of its lysine residues is posttranslationally modified by spermidine to form hypusine, a unique residue required for eIF-5A activity. In Saccharomyces cerevisiae eIF-5A is encoded by two highly homologous genes, TIF51A and TIF51B. The two genes are regulated reciprocally by oxygen, where under aerobic conditions TIF51A is expressed and TIF51B is repressed, and under anaerobic conditions the opposite occurs. In order to study the products of the two genes individually, yeast strains were constructed that express either TIF51A or TIF51B under control of a galactose promoter. Each gene gives rise to two isoelectric variants, eIF-5Aa (more acidic) and eIF-5Ab (more basic), both of which carry the hypusine modification. Expression of either TIF51A or TIF51B promotes growth under both aerobic and anaerobic conditions, indicating that the two gene products function indistinguishably. The human cDNA encoding eIF-5A also was expressed in yeast, and the plasmid shuffle technique was used to demonstrate that the human protein can substitute for the homologous yeast protein in vivo. These results indicate that human and yeast eIF-5A are not only conserved at the sequence level but are functionally interchangeable in vivo.			SCHWELBERGER, HG (corresponding author), UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616, USA.				NIGMS NIH HHS [GM22135] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN M, 1989, J BIOL CHEM, V264, P12145; BENNE R, 1978, J BIOL CHEM, V253, P3070; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; COOPER HL, 1983, P NATL ACAD SCI-BIOL, V80, P1854, DOI 10.1073/pnas.80.7.1854; ELION EA, 1984, CELL, V39, P663, DOI 10.1016/0092-8674(84)90473-2; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GORDON ED, 1987, J BIOL CHEM, V262, P16585; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOLM C, 1986, GENE, V42, P169, DOI 10.1016/0378-1119(86)90293-3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KANG HA, 1992, MOL GEN GENET, V233, P487, DOI 10.1007/BF00265449; LOWRY CV, 1983, P NATL ACAD SCI-BIOL, V80, P151, DOI 10.1073/pnas.80.1.151; LOWRY CV, 1986, MOL CELL BIOL, V6, P4145, DOI 10.1128/MCB.6.12.4145; Maniatis T., 1982, MOL CLONING; MEHTA KD, 1990, J BIOL CHEM, V265, P8802; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARK MH, 1984, J BIOL CHEM, V259, P2123; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; SCHWELBERGER HG, 1989, EUR J BIOCHEM, V180, P301, DOI 10.1111/j.1432-1033.1989.tb14648.x; Sherman F., 1986, METHODS YEAST GENETI; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P18527; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P1578; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035	27	65	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14018	14025						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314769				2022-12-27	WOS:A1993LJ82500038
J	SINGERKRUGER, B; FRANK, R; CRAUSAZ, F; RIEZMAN, H				SINGERKRUGER, B; FRANK, R; CRAUSAZ, F; RIEZMAN, H			PARTIAL-PURIFICATION AND CHARACTERIZATION OF EARLY AND LATE ENDOSOMES FROM YEAST - IDENTIFICATION OF 4 NOVEL PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FACTOR PHEROMONE; RECEPTOR-MEDIATED ENDOCYTOSIS; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; PLASMA-MEMBRANE; KEX2 PROTEASE; GOLGI STACK; STE2 GENE; TRANSPORT; FUSION	Previously (Singer, B., and Riezman, H. (1990) J. Cell Biol. 110, 1911-1922), we provided evidence for the existence of an endocytic intermediate(s) from the yeast Saccharomyces cerevisiae that is responsible for the transport of the pheromone alpha-factor from the plasma membrane to the vacuole. Here we show by kinetic analysis that the endocytic apparatus of yeast is composed of early and late endosomes, similar to what has been found in animal cells. We have developed a three-step isolation procedure to purify early and late endosomes, consisting of differential centrifugation, flotation on a Nycodenz density gradient, and sedimentation density gradient centrifugation on sucrose/D2O. Using internalized S-35-alpha-factor as a marker, the endosomal fractions were substantially enriched over other membranes, except for Golgi elements and a compartment containing binding protein. These contaminants could not be removed by other standard purification methods. We have analyzed the protein composition of our most pure early and late endosome fractions. By two-dimensional gel analysis we identified more than 20 protein spots that are highly enriched in the early/late endosomal fractions. N-terminal protein sequencing resulted in the identification of four novel proteins.	UNIV BASEL, BIOCTR, KLINGELBERGSTR 70, CH-4056 BASEL, SWITZERLAND; ZENTRUM MOLEK BIOL HEIDELBERG, W-6900 HEIDELBERG, GERMANY	University of Basel; Ruprecht Karls University Heidelberg				Riezman, Howard/0000-0003-4680-9422				ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; BEAUMELLE BD, 1990, J CELL BIOL, V111, P1811, DOI 10.1083/jcb.111.5.1811; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BLUMER KJ, 1988, J BIOL CHEM, V263, P10836; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; CHVATCHKO Y, 1986, CELL, V46, P355, DOI 10.1016/0092-8674(86)90656-2; COURTOY PJ, 1984, J CELL BIOL, V98, P870, DOI 10.1083/jcb.98.3.870; CUNNINGHAM KW, 1989, YEAST, V5, P25, DOI 10.1002/yea.320050105; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; DULIC V, 1991, METHOD ENZYMOL, V194, P697; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; GAUSEPOHL H, 1986, ADV METHODS PROTEIN, P149; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GRUENBERG JE, 1986, EMBO J, V5, P3091, DOI 10.1002/j.1460-2075.1986.tb04615.x; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1991, EUR J CELL BIOL, V56, P8; Hubbard AL, 1989, CURR OPIN CELL BIOL, V1, P675, DOI 10.1016/0955-0674(89)90033-1; JENNESS DD, 1983, CELL, V35, P521, DOI 10.1016/0092-8674(83)90186-1; JENNESS DD, 1986, MOL CELL BIOL, V6, P318, DOI 10.1128/MCB.6.1.318; JENNESS DD, 1986, CELL, V46, P345, DOI 10.1016/0092-8674(86)90655-0; KREIBICH G, 1973, J CELL BIOL, V58, P436, DOI 10.1083/jcb.58.2.436; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBEL D, 1978, ANAL BIOCHEM, V85, P86, DOI 10.1016/0003-2697(78)90277-4; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; RIEZMAN H, 1985, CELL, V40, P1001, DOI 10.1016/0092-8674(85)90360-5; RIEZMAN H, 1992, NATO ASI SERIES H, V62, P467; Rodman JS, 1990, CURR OPIN CELL BIOL, V2, P664, DOI 10.1016/0955-0674(90)90108-Q; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SINGER B, 1990, J CELL BIOL, V110, P1911, DOI 10.1083/jcb.110.6.1911; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANTUINEN E, 1987, J HISTOCHEM CYTOCHEM, V35, P327, DOI 10.1177/35.3.3546482; WALL DA, 1985, J CELL BIOL, V101, P2104, DOI 10.1083/jcb.101.6.2104	46	98	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14376	14386						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314797				2022-12-27	WOS:A1993LJ82500085
J	BRIGLE, KE; SEITHER, RL; WESTIN, EH; GOLDMAN, ID				BRIGLE, KE; SEITHER, RL; WESTIN, EH; GOLDMAN, ID			INCREASED EXPRESSION AND GENOMIC ORGANIZATION OF A FOLATE-BINDING PROTEIN HOMOLOGOUS TO THE HUMAN PLACENTAL ISOFORM IN L1210 MURINE LEUKEMIA-CELL LINES WITH A DEFECTIVE REDUCED FOLATE CARRIER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT CARRIER; KB CELLS; MEMBRANE; METHOTREXATE; RECEPTOR; SEQUENCE; CLONING; CDNA; GENE; DNA	This laboratory previously described an L1210 leukemia cell line (MTX(r)A) selected for resistance to methotrexate by virtue of impaired transport. In this line, the reduced folate carrier had unchanged affinity for methotrexate, was present at the cell surface in usual quantity, but did not deliver drug into the cell, indicative of a functional defect in the translocation process. In this study, we further characterize this cell line along with a subline (F2-MTX(r)A) selected for growth in low levels of folic acid. This subline demonstrates continued high resistance to methotrexate and very low influx of [H-3]methotrexate and 5-[H-3]formyltetrahydrofolate, indicating the persistence of the defect in the reduced folate carrier. Both MTX(r)A and F2-MTX(r)A are shown to overexpresses FBP2, the murine homolog of a folate-binding protein initially isolated from human placenta. Compared with parent L1210 cells, Northern analysis revealed FBP2 expression to be elevated 40 fold in the MTX(r)A line and 500-fold in F2-MTX(r)A. The large increase in FBP2 expression in the F2-MTX(r)A line correlates with a 10-fold increase in [H-3]folic acid membrane surface binding and a 1000-fold decrease in the folic acid growth requirement compared with parental L1210 cells. Also, there are 20- and 500-fold decreases in the 5-formyltetrahydrofolate growth requirement compared with parent L1210 and MTX(r)A cells, respectively. Finally, the genomic organization of the FBP2 locus is presented. The results of Northern analyses using probes specific to FBP2 5'-untranslated sequences or to a splice junction within this region suggest that the up-regulated FBP2-specific message in F2- MTX(r)A utilizes 5'-noncoding se quences distinct from those used in the message encoded in L1210 cell lines with low level FBP2 expression. The MTX(r)A cells provide an example of a line selected for primary resistance to methotrexate that also exhibits concomitant increased expression of a folate-binding protein. Further overexpression of this folate binding protein (which has homology to that initially identified in placenta) provides cells with the ability to meet cellular folate needs in a folate deprived environment.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,MASSEY CANC CTR,RICHMOND,VA 23298	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University					NATIONAL CANCER INSTITUTE [R35CA039807] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09340, CA-39807] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRIGLE KE, 1992, J BIOL CHEM, V267, P22351; BRIGLE KE, 1991, J BIOL CHEM, V266, P17243; BRIGLE KE, 1994, IN PRESS BIOCH PHARM; CAMPBELL IG, 1991, CANCER RES, V51, P5329; CAVALCANTI F, 1992, CELL BIOCHEM FUNCT, V10, P1, DOI 10.1002/cbf.290100102; CONEY LR, 1991, CANCER RES, V51, P6125; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; FRY DW, 1979, J MEMBRANE BIOL, V50, P123, DOI 10.1007/BF01868944; FRY DW, 1982, J MEMBRANE BIOL, V66, P87, DOI 10.1007/BF01868485; GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163-7258(85)90083-X; GOLDMAN ID, 1971, ANN NY ACAD SCI, V186, P400; HENDERSON GB, 1988, J MEMBRANE BIOL, V101, P247, DOI 10.1007/BF01872839; HENDERSON GB, 1980, ARCH BIOCHEM BIOPHYS, V202, P144, DOI 10.1016/0003-9861(80)90416-6; JANSEN G, 1989, CANCER RES, V49, P1959; JANSEN G, 1989, CANCER RES, V49, P2455; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAMEN BA, 1991, J CLIN INVEST, V87, P1442, DOI 10.1172/JCI115150; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LICHTENSTEIN NS, 1969, BIOCHIM BIOPHYS ACTA, V193, P456, DOI 10.1016/0005-2736(69)90204-1; MATHERLY LH, 1987, J BIOL CHEM, V262, P710; PAIN ST, 1993, J MOL BIOL, V229, P1175; RATNAM M, 1989, BIOCHEMISTRY-US, V28, P8249, DOI 10.1021/bi00446a042; SADASIVAN E, 1989, J BIOL CHEM, V264, P5806; SADASIVAN E, 1992, BIOCHIM BIOPHYS ACTA, V1131, P91, DOI 10.1016/0167-4781(92)90103-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; SCHUETZ JD, 1989, J BIOL CHEM, V264, P16261; SIROTNAK FM, 1980, PHARMACOL THERAPEUT, V8, P71, DOI 10.1016/0163-7258(80)90060-1; WANG X, 1992, BIOCHEM PHARMACOL, V44, P1898	31	23	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4267	4272						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307991				2022-12-27	WOS:A1994MW98900058
J	MCCARTHY, SA; BICKNELL, R				MCCARTHY, SA; BICKNELL, R			ACTIVIN-A BINDS TO A HETEROTRIMERIC RECEPTOR COMPLEX ON THE VASCULAR ENDOTHELIAL-CELL SURFACE - EVIDENCE FOR A TYPE-3 ACTIVIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ERYTHROID-DIFFERENTIATION FACTOR; SERINE THREONINE KINASE; MONOCLONAL-ANTIBODIES; EXPRESSION CLONING; BETA; IDENTIFICATION; LEUKEMIA; INHIBIN; SYSTEM	The effect of transfection of the type 2 activin receptor, ACTR2, on binding of I-125-activin-A to the surface of bovine aortic endothelial cells (BAEC) was investigated. BAEC transfected either with full-length ACTR2 or with a truncated form of ACTR2 lacking the intracellular kinase domain (ACTR2T) displayed two classes of I-125-activin-A binding sites, one of high affinity (K-d = 250-254 pM) and one of low affinity (K-d = 6.5-16 nM). Affinity labeling of ACTR2-transfected BAEC with I-125-activin-A revealed labeled species of 55, 95, 100, and 160 kDa, all four of which were immunoprecipitated by an anti-ACTR2 monoclonal antibody. Only the 95- and 100-kDa species, however, were immunoprecipitated following denaturation of the affinity-labeled cell lysate with SDS. BAEC transfected with an epitope-tagged form of ACTR2T (ACTR2TMyc) displayed intense 55- and 70-kDa affinity-labeled forms of the truncated receptor, together with a 160-kDa species. As with the full-length receptor, the 160-kDa species associated non-covalently with ACTR2TMyc. These data indicate that, in vascular endothelial cells, ACTR2 forms a high affinity heterotrimeric receptor complex with activin binding proteins characteristic of type 1 and type 3 activin receptors, and that formation of the complex does not require the kinase domain of ACTR2.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND LABS,MOLEC ANGIOGENESIS GR,OXFORD OX3 9DU,ENGLAND	Cancer Research UK; University of Oxford			McCarthy, Sarah/HCI-8963-2022	Bicknell, Roy/0000-0002-0941-8919				ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, pCH15; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CAMPEN CA, 1988, BIOCHEM BIOPH RES CO, V157, P844, DOI 10.1016/S0006-291X(88)80326-7; CENTRELLA M, 1991, MOL CELL BIOL, V11, P250, DOI 10.1128/MCB.11.1.250; CHIEFETZ S, 1992, J BIOL CHEM, V267, P19027; CHIEFETZ S, 1987, CELL, V48, P409; DEJONG FH, 1988, PHYSIOL REV, V68, P555, DOI 10.1152/physrev.1988.68.2.555; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GROOME N, 1991, HYBRIDOMA, V10, P309, DOI 10.1089/hyb.1991.10.309; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HINO M, 1989, J BIOL CHEM, V264, P10309; KONDO S, 1989, BIOCHEM BIOPH RES CO, V161, P1267, DOI 10.1016/0006-291X(89)91379-X; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATHEWS LS, 1993, J BIOL CHEM, V268, P19013; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MCCARTHY SA, 1993, J BIOL CHEM, V268, P23066; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; SHAO LE, 1992, BLOOD, V79, P773; SUGINO H, 1988, J BIOL CHEM, V263, P15249; VALE W, 1990, PEPTIDE GROWTH FACTO, P211; WANG XF, 1991, CELL, V67, P796; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	34	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3909	3912						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307945				2022-12-27	WOS:A1994MW98900002
J	PAROLA, AL; KOBILKA, BK				PAROLA, AL; KOBILKA, BK			THE PEPTIDE PRODUCT OF A 5' LEADER CISTRON IN THE BETA(2) ADRENERGIC-RECEPTOR MESSENGER-RNA INHIBITS RECEPTOR SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTORS; GCN4 MESSENGER-RNA; TRANSLATIONAL CONTROL; AMINO-ACID; ALPHA-2-ADRENERGIC RECEPTOR; EUKARYOTIC RIBOSOMES; EXPRESSION; GENE; RECOGNITION; CLONING	The 5' leader region of mammalian beta(2) adrenergic receptor messenger RNAs (mRNA) have a short open reading frame (sORF) preceding the receptor cistron. Mutational inactivation of the sORF start codon increased beta(2) receptor expression and translation 1.9 fold from beta(2) receptor genes transfected into COS-7 cells. sORF inactivation also increased receptor synthesis 2.4-fold in a cell-free expression system that synthesizes functional beta(2) receptor in vitro. Translational initiation at the sORF was demonstrated both in vitro and in transfected COS-7 cells using an epitope-tagged fusion protein. Using the fusion protein as a reporter for initiation at the sORF shows that 5' leader mutations which increase translation of the sORF decrease receptor translation. Mutation analysis of the 5' leader region and peptide coding sequences suggests the peptide itself inhibits beta(2) receptor expression. Consistent with this hypothesis, a synthetic peptide corresponding to the peptide encoded by the beta(2) receptor sORF potently inhibits translation in vitro. Our results suggest that a nonoverlapping cistron in the beta(2) receptor mRNA 5' leader region is translated and the resulting peptide inhibits receptor translation.	STANFORD UNIV,SCH MED,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT MED CARDIOL,STANFORD,CA 94305	Stanford University; Howard Hughes Medical Institute; Stanford University; Stanford University				Kobilka, Brian/0000-0001-5958-3990				ALLEN JM, 1988, EMBO J, V7, P133, DOI 10.1002/j.1460-2075.1988.tb02792.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKLAND PR, 1990, NUCLEIC ACIDS RES, V18, P682, DOI 10.1093/nar/18.3.682; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HACKETT PB, 1986, J MOL BIOL, V190, P45, DOI 10.1016/0022-2836(86)90074-4; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HINNEBUSCH AG, 1988, P NATL ACAD SCI USA, V85, P7279, DOI 10.1073/pnas.85.19.7279; HUNT T, 1985, NATURE, V316, P580, DOI 10.1038/316580a0; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; KOBILKA BK, 1987, J BIOL CHEM, V262, P15796; KOBILKA BK, 1990, J BIOL CHEM, V265, P7610; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINK R, 1992, MOL PHARMACOL, V42, P16; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; SARKAR G, 1992, NUCLEIC ACIDS RES, V20, P871, DOI 10.1093/nar/20.4.871; STEWART V, 1985, J BACTERIOL, V164, P731, DOI 10.1128/JB.164.2.731-740.1985; SURYANARAYANA S, 1992, METHODS, V3, P193; TZAMARIAS D, 1986, P NATL ACAD SCI USA, V83, P4849, DOI 10.1073/pnas.83.13.4849; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0	30	182	188	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4497	4505						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308019				2022-12-27	WOS:A1994MW98900091
J	YU, L; GOLDBERG, IH; DEDON, PC				YU, L; GOLDBERG, IH; DEDON, PC			ENEDIYNE-MEDIATED DNA-DAMAGE IN NUCLEI IS MODULATED AT THE LEVEL OF THE NUCLEOSOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE PARTICLE; DEOXYRIBONUCLEIC-ACID; ANTITUMOR ANTIBIOTICS; NEOCARZINOSTATIN CHROMOPHORE; CALICHEAMICIN GAMMA-1(I); AFLATOXIN-B1 ADDUCTION; CHROMATIN STRUCTURE; ETHIDIUM-BROMIDE; MINOR-GROOVE; CLEAVAGE	DNA damage in HeLa nuclei and isolated nucleosome core particles has been examined for several members of the enediyne family of antitumor antibiotics: calicheamicin gamma(1)(I) (CAL), esperamicin A(1) (ESP A1), esperamicin C (ESP C), and neocarzinostatin (NCS). In nuclei, both NCS and ESP A1 produced DNA damage limited to the linker region of the nucleosome, while CAL and ESP C, an analog of ESP A1 missing the deoxyfucose-anthranilate moiety, damaged both the core and linker DNA. DNA fragments produced by CAL and ESP C in the nucleosome core occurred with a 10-11-nucleotide periodicity similar to that produced by DNase I, while damage produced by NCS and ESP A1 appeared to be limited to the terminal portions of the core DNA The damage in nuclei is shown to be caused directly by the drugs with little contribution from endogenous factors, such as nucleases and topoisomerases. Features of drug structure that may limit damage to the nucleosome core include the presence of substituents on both sides of the CAL/ESP-type core, and the presence of an intercalating moiety, such as the naphthoate of NCS and possibly the anthranilate of ESP A1.	MIT,DIV TOXICOL,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School				Dedon, Peter/0000-0003-0011-3067	NCI NIH HHS [CA44257, CA57633] Funding Source: Medline; NIEHS NIH HHS [ES02190] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044257, R01CA057633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002190] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ausubel FM, 1988, MOL REPROD DEV; BECKMANN RP, 1987, BIOCHEMISTRY-US, V26, P5409, DOI 10.1021/bi00391a029; BEERMAN TA, 1983, MOL PHARMACOL, V23, P493; BENNETT RAO, 1993, BIOCHEMISTRY-US, V32, P3188, DOI 10.1021/bi00063a034; CARTWRIGHT IL, 1983, P NATL ACAD SCI-BIOL, V80, P3213, DOI 10.1073/pnas.80.11.3213; CARTWRIGHT IL, 1982, NUCLEIC ACIDS RES, V10, P5835, DOI 10.1093/nar/10.19.5835; CECH T, 1977, CELL, V11, P631, DOI 10.1016/0092-8674(77)90080-0; CHAIRES JB, 1983, BIOCHEMISTRY-US, V22, P284, DOI 10.1021/bi00271a009; CHIN DH, 1986, BIOCHEMISTRY-US, V25, P1009, DOI 10.1021/bi00353a009; CHRISTNER DF, 1992, J AM CHEM SOC, V114, P8763, DOI 10.1021/ja00049a002; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; DASGUPTA D, 1985, BIOCHEMISTRY-US, V24, P7049, DOI 10.1021/bi00346a004; DEDON PC, 1992, CHEM RES TOXICOL, V5, P311, DOI 10.1021/tx00027a001; DEDON PC, 1990, J BIOL CHEM, V265, P14713; DEDON PC, 1992, BIOCHEMISTRY-US, V31, P1917, DOI 10.1021/bi00122a004; DEDON PC, 1992, NUCLEIC ACID TARGETE, P475; DING WD, 1991, J AM CHEM SOC, V113, P6617, DOI 10.1021/ja00017a038; DRAK J, 1991, P NATL ACAD SCI USA, V88, P7464, DOI 10.1073/pnas.88.17.7464; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; Elgin SCR, 1990, CURR OPIN CELL BIOL, V2, P437, DOI 10.1016/0955-0674(90)90125-X; FEIGON J, 1979, NUCLEIC ACIDS RES, V6, P2327, DOI 10.1093/nar/6.6.2327; GOLDBERG IH, 1991, ACCOUNTS CHEM RES, V24, P191, DOI 10.1021/ar00007a001; GOPALAKRISHNAN S, 1989, BIOCHEMISTRY-US, V28, P726, DOI 10.1021/bi00428a047; HATAYAMA T, 1979, BIOCHIM BIOPHYS ACTA, V563, P59, DOI 10.1016/0005-2787(79)90007-8; HATAYAMA T, 1982, BIOCHEM BIOPH RES CO, V104, P889, DOI 10.1016/0006-291X(82)91332-8; HAWLEY RC, 1989, P NATL ACAD SCI USA, V86, P1105, DOI 10.1073/pnas.86.4.1105; HAYES JJ, 1991, BIOCHEMISTRY-US, V30, P8434, DOI 10.1021/bi00098a022; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HEARST JE, 1989, CHEM RES TOXICOL, V2, P69, DOI 10.1021/tx00008a001; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HURLEY I, 1982, BIOCHEMISTRY-US, V21, P4999, DOI 10.1021/bi00263a025; IRVIN TR, 1984, P NATL ACAD SCI-BIOL, V81, P664, DOI 10.1073/pnas.81.3.664; KAPPEN LS, 1993, SCIENCE, V261, P1319, DOI 10.1126/science.8362243; KAPPEN LS, 1987, BIOCHEMISTRY-US, V26, P384, DOI 10.1021/bi00376a008; KAPPEN LS, 1992, P NATL ACAD SCI USA, V89, P6706, DOI 10.1073/pnas.89.15.6706; KAPPEN LS, 1992, BIOCHEMISTRY-US, V31, P9081, DOI 10.1021/bi00152a052; KUO MT, 1978, NATURE, V271, P83, DOI 10.1038/271083a0; KUO MT, 1978, BIOCHIM BIOPHYS ACTA, V518, P186, DOI 10.1016/0005-2787(78)90129-6; LEE MD, 1991, ACCOUNTS CHEM RES, V24, P235, DOI 10.1021/ar00008a003; LEET JE, 1992, J AM CHEM SOC, V114, P7946, DOI 10.1021/ja00046a071; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3618, DOI 10.1021/bi00769a019; LIU LF, 1990, DNA TOPOLOGY ITS BIO, P371; LONG BH, 1989, P NATL ACAD SCI USA, V86, P2, DOI 10.1073/pnas.86.1.2; LUTTER LC, 1978, J MOL BIOL, V124, P391, DOI 10.1016/0022-2836(78)90306-6; MCHUGH MM, 1982, BIOCHIM BIOPHYS ACTA, V696, P7, DOI 10.1016/0167-4781(82)90003-3; MCMURRAY CT, 1991, BIOCHEMISTRY-US, V30, P5631, DOI 10.1021/bi00237a001; MCMURRAY CT, 1991, BIOCHEMISTRY-US, V30, P5644, DOI 10.1021/bi00237a002; MCMURRAY CT, 1986, P NATL ACAD SCI USA, V83, P8472, DOI 10.1073/pnas.83.22.8472; MCMURRAY CT, 1985, BIOCHEMISTRY-US, V24, P7037, DOI 10.1021/bi00346a002; MOORE CW, 1988, CANCER RES, V48, P6837; MOYER R, 1989, J BIOL CHEM, V264, P12226; NOLL M, 1974, NATURE, V251, P249, DOI 10.1038/251249a0; PAOLETTI J, 1977, BIOCHEMISTRY-US, V16, P351, DOI 10.1021/bi00622a002; POVIRK LF, 1985, P NATL ACAD SCI USA, V82, P3182, DOI 10.1073/pnas.82.10.3182; POVIRK LF, 1980, BIOCHEMISTRY-US, V19, P4773, DOI 10.1021/bi00562a009; POVIRK LF, 1979, BIOCHEMISTRY-US, V18, P96, DOI 10.1021/bi00568a015; POVIRK LF, 1988, BIOCHEMISTRY-US, V27, P3850, DOI 10.1021/bi00410a049; POVIRK LF, 1981, BIOCHEMISTRY-US, V20, P4007, DOI 10.1021/bi00517a009; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; Sambrook J, 1989, MOL CLONING LABORATO; SUGIURA Y, 1989, P NATL ACAD SCI USA, V86, P7672, DOI 10.1073/pnas.86.20.7672; SUGIURA Y, 1990, P NATL ACAD SCI USA, V87, P3831, DOI 10.1073/pnas.87.10.3831; TRAVERS AA, 1987, TRENDS BIOCHEM SCI, V12, P108, DOI 10.1016/0968-0004(87)90050-8; UESUGI M, 1993, BIOCHEMISTRY-US, V32, P4622, DOI 10.1021/bi00068a020; van Holde KE., 1989, SPRINGER SERIES MOL; WALKER S, 1992, P NATL ACAD SCI USA, V89, P4608, DOI 10.1073/pnas.89.10.4608; WALKER S, 1993, J AM CHEM SOC, V115, P7954, DOI 10.1021/ja00071a004; WILLIAMS LD, 1988, BIOCHEMISTRY-US, V27, P3004, DOI 10.1021/bi00408a051; WILLIAMS LD, 1988, NUCLEIC ACIDS RES, V16, P11607, DOI 10.1093/nar/16.24.11607; WOLFFE A, 1992, CHROMATIN STRUCTURE; YAGER TD, 1984, J BIOL CHEM, V259, P4212; YAO J, 1991, BIOCHEMISTRY-US, V30, P8408, DOI 10.1021/bi00098a019; ZEIN N, 1989, SCIENCE, V244, P697, DOI 10.1126/science.2717946; ZEIN N, 1988, SCIENCE, V240, P1198, DOI 10.1126/science.3240341; ZHAO B, 1990, CANCER LETT, V50, P141, DOI 10.1016/0304-3835(90)90244-R	76	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4144	4151						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307975				2022-12-27	WOS:A1994MW98900040
J	GIBSON, QH; REGAN, R; OLSON, JS; CARVER, TE; DIXON, B; POHAJDAK, B; SHARMA, PK; VINOGRADOV, SN				GIBSON, QH; REGAN, R; OLSON, JS; CARVER, TE; DIXON, B; POHAJDAK, B; SHARMA, PK; VINOGRADOV, SN			KINETICS OF LIGAND-BINDING TO PSEUDOTERRANOVA-DECIPIENS AND ASCARIS-SUUM HEMOGLOBINS AND TO LEU-29-]TYR SPERM WHALE MYOGLOBIN MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PECTINATA BACTERIA SYMBIOSIS; AMINO-ACID-SEQUENCES; HEME-PROTEINS; RECOMBINATION; RESONANCE; AFFINITY; DYNAMICS	The kinetics of binding of O2, CO, and NO to the octameric, two-domain hemoglobins of the parasitic nematodes Pseudoterranova decipiens and Ascaris suum were determined on nanosecond and picosecond time scales using flash photolysis. The two nematode hemoglobins have very similar kinetic properties. On the picosecond time scale, they exhibit an unusual behavior in showing a geminate reaction with oxygen that is biphasic and dependent on the flash intensity. The geminate reaction with NO is also faster and more complete than for sperm whale myoglobin; however, in contrast to the O2 reaction, it is homogeneous. In addition, the oxygen dissociation rate of P. decipiens hemoglobin, 0.0035 s-1, is as low as that of A. suum hemoglobin, 0.004 s-1 (Gibson, Q. H., and Smith, M. H. (1965) Proc. R. Soc. Lond. B Biol. Sci. 163, 206-214). A mutant of sperm whale myoglobin suggested by sequence alignment of the nematode hemoglobins, Leu-29 --> Tyr, did not have kinetic properties similar to them.	CORNELL UNIV,DEPT MOLEC & CELL BIOL,ITHACA,NY 14853; RICE UNIV,WM KECK CTR COMPUTAT BIOL,HOUSTON,TX 77251; RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251; DALHOUSIE UNIV,DEPT BIOL SCI,HALIFAX B3H 4H2,NS,CANADA; WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM,DETROIT,MI 48201	Cornell University; Rice University; Rice University; Dalhousie University; Wayne State University	GIBSON, QH (corresponding author), CORNELL UNIV,DEPT BIOCHEM,227 BIOTECHNOL BLDG,ITHACA,NY 14853, USA.		Dixon, Brian/B-7655-2011	Olson, John/0000-0002-0760-5403; Dixon, Brian/0000-0003-4213-5483	NHLBI NIH HHS [HL-47020] Funding Source: Medline; NIGMS NIH HHS [GM-14276, GM-35649] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM014276, R01GM035649] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; CARVER TE, 1992, J BIOL CHEM, V267, P14443; CARVER TE, 1990, J BIOL CHEM, V265, P20007; COLETTA M, 1986, BIOCHIM BIOPHYS ACTA, V870, P169, DOI 10.1016/0167-4838(86)90021-X; DARAWSHE S, 1987, BIOCHEM J, V242, P689, DOI 10.1042/bj2420689; DARAWSHE S, 1991, EUR J BIOCHEM, V201, P169, DOI 10.1111/j.1432-1033.1991.tb16270.x; DAVENPORT HE, 1949, PROC R SOC SER B-BIO, V136, P255, DOI 10.1098/rspb.1949.0024; DEBAERE I, 1992, P NATL ACAD SCI USA, V89, P4638, DOI 10.1073/pnas.89.10.4638; DIXON B, 1991, P NATL ACAD SCI USA, V88, P5655, DOI 10.1073/pnas.88.13.5655; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; GIBSON QH, 1986, J BIOL CHEM, V261, P228; GIBSON QH, 1989, J BIOL CHEM, V264, P100; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P206, DOI 10.1098/rspb.1965.0067; KRAUS DW, 1990, J BIOL CHEM, V265, P16043; KRAUS DW, 1990, J BIOL CHEM, V265, P16054; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECOMTE JTJ, 1987, J MOL BIOL, V209, P235; LESK AM, 1980, J MOL BIOL, V136, P225, DOI 10.1016/0022-2836(80)90373-3; MIMS MP, 1983, J BIOL CHEM, V258, P6125; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; ROHLFS RJ, 1988, J BIOL CHEM, V263, P1803; SHERMAN DR, 1992, SCIENCE, V258, P1930, DOI 10.1126/science.1470914; SHERMAN DR, 1992, P NATL ACAD SCI USA, V89, P11696, DOI 10.1073/pnas.89.24.11696; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; VINOGRADOV SN, 1993, IN PRESS COMP BIOCH	27	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16993	16998						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349589				2022-12-27	WOS:A1993LQ98800020
J	ZHENG, S; BROWN, MC; TAFFET, SM				ZHENG, S; BROWN, MC; TAFFET, SM			LIPOPOLYSACCHARIDE STIMULATES BOTH NUCLEAR-LOCALIZATION OF THE NUCLEAR FACTOR-KAPPA-B 50-KDA SUBUNIT AND LOSS OF THE 105-KDA PRECURSOR IN RAW264 MACROPHAGE-LIKE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DNA-BINDING SUBUNIT; PROTEIN-KINASE-C; TRANSCRIPTION FACTOR; ACTIVATION; REL; INHIBITOR; P50; ENHANCERS; FAMILY	Nuclear factor kappaB (NF-kappaB) is an important regulator of gene expression in cells of the immune system. One such gene, tumor necrosis factor, is induced by bacterial lipopolysaccharide (LPS) in macrophages, and this induction has been shown to be mediated in part by NF-kappaB activation in murine macrophages. In this study, immunochemical analysis was used to follow LPS activation of the NF-kappaB 50-kDa subunit in the RAW264 macrophage-like cell line. The recombinant NF-kappaB 50-kDa subunit was used as an immunogen to produce a rabbit antiserum, which was then affinity-purified using a portion of the NF-kappaB 50-kDa subunit that does not have homology to other members of the c-rel gene family. Untreated macrophages had little NF-kappaB in the nucleus as detected by Western immunoblotting. The protein was predominantly localized in the cytoplasmic fraction. Interestingly, NF-kappaB was found as the 50-kDa mature protein and 105-kDa precursor. After LPS treatment, there was a rapid nuclear translocation of NF-kappaB as detected by immunoblot analysis. There was also a rapid decrease in the amount of the cytoplasmic 105-kDa protein. This may indicate that the 105-kDa protein is a reservoir for the 50-kDa protein and that one of the actions of LPS is to increase the rate of 105-kDa precursor processing.	SUNY HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,750 E ADAMS ST,SYRACUSE,NY 13210; SUNY HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,SYRACUSE,NY 13210; SUNY HLTH SCI CTR,PROGRAM CELL & MOLEC BIOL,SYRACUSE,NY 13210	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center								BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BEUSCHER HU, 1990, J IMMUNOL, V144, P2178; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; CURY JD, 1988, J IMMUNOL, V141, P4306; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OSTROWSKI J, 1991, J BIOL CHEM, V266, P12722; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; RIVIERE Y, 1991, NATURE, V350, P625, DOI 10.1038/350625a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUKAHARA T, 1897, J BIOCHEM-TOKYO, V101, P1447; VINCENTI MP, 1992, J CELL PHYSIOL, V150, P204, DOI 10.1002/jcp.1041500127; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	39	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17233	17239						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349609				2022-12-27	WOS:A1993LQ98800055
J	DASILVA, AJ; RUDD, CE				DASILVA, AJ; RUDD, CE			A 72-KILODALTON FYN-RELATED POLYPEPTIDE (P72FYN-R) BINDS TO THE ANTIGEN-RECEPTOR/CD3 (TCR/CD3) COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; CELL ANTIGEN RECEPTOR; AMINO-TERMINAL DOMAIN; MIDDLE-T ANTIGEN; SIGNAL TRANSDUCTION; CROSS-LINKING; CD4 RECEPTOR; LYMPHOCYTE-T; ZETA-CHAIN; P56LCK	Protein-tyrosine kinases play crucial roles in the activation and transformation of T lymphocytes. In this study, we have identified a variant of the fyn kinase at 70-72 kDa (termed p72fyn-R) that can preferentially associate with the TcR/CD3 complex in certain T cells. Phosphoamine acid analysis revealed that the CD3-associated p72fyn-R is labeled on both tyrosine and serine/threonine residues. TcR/CD3-associated p72fyn-R could be specifically reprecipitated using anti-fyn antisera to both the N and C terminus of p59fyn. In addition, two-dimensional phosphotryptic peptide map patterns of TcR/CD3-associated p72fyn and anti-fyn-precipitable p72 were identical. By contrast, a comparison of p72fyn-R and p62fyn showed similarities and differences. p72fyn-R possesses a peptide corresponding to the autophosphorylation site that migrates in the same position as found for p59/62fyn. However, p72fyn-R possessed at least four novel phosphorylated sites labeled on serine and threonine residues that are absent in the p62fyn pattern. Phosphatase digestion experiments indicated that p72fyn-R is more resistant to dephosphorylation than p59/62fyn. Two-dimensional phosphotryptic analysis indicated that the novel serine/threonine phosphorylation sites were responsible for the resistance to phosphatase digestion. Although the exact nature of the relationship between p72fyn-R and p59/62fyn remains undetermined, these data indicate that TcR/CD3 may utilize novel variants of src-related kinases in the generation of signals which regulate T-cell growth.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	DASILVA, AJ (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR IMMUNOL, BOSTON, MA 02115 USA.		Rudd, Christopher E/GOH-2021-2022; Rudd, Christopher E/ABF-7259-2021	Rudd, Christopher E/0000-0001-5295-9019; 	PHS HHS [R01 12069] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BURGESS KE, 1992, P NATL ACAD SCI USA, V89, P9311, DOI 10.1073/pnas.89.19.9311; BURGESS KE, 1991, EUR J IMMUNOL, V21, P1663, DOI 10.1002/eji.1830210712; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHENG SH, 1991, J VIROL, V65, P170, DOI 10.1128/JVI.65.1.170-179.1991; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DASILVA AJ, 1992, MOL IMMUNOL, V29, P1417, DOI 10.1016/0161-5890(92)90215-J; ESPINO PC, 1992, ONCOGENE, V7, P317; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PRASAD KVS, 1992, MOL CELL BIOL, V12, P5260, DOI 10.1128/MCB.12.11.5260; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; SWARUP G, 1983, J BIOL CHEM, V258, P341; TELFER JC, 1991, SCIENCE, V254, P439, DOI 10.1126/science.1925604; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	39	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16537	16543						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344934				2022-12-27	WOS:A1993LQ33600066
J	PURI, KD; KHAN, MI; GUPTA, D; SUROLIA, A				PURI, KD; KHAN, MI; GUPTA, D; SUROLIA, A			THERMODYNAMIC AND KINETIC-STUDIES ON THE MECHANISM OF BINDING OF METHYLUMBELLIFERYL GALACTOSIDES TO THE BASIC AGGLUTININ FROM WINGED BEAN (PSOPHOCARPUS-TETRAGONOLOBUS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; ALPHA-D-MANNOPYRANOSIDE; DIMERIC CONCANAVALIN-A; CARBOHYDRATE-BINDING; PEANUT AGGLUTININ; LECTIN; FLUORESCENCE; SPECIFICITY; MOLECULES; METHYL	The binding of winged bean basic agglutinin (WBA I) to 4-methylumbelliferyl (MeUmb) galactosides was examined by extrinsic fluorescence titration and stopped-flow spectrofluorimetry. Upon binding to WBA I, MeUmb alpha-galactosides show quenching in fluorescence intensity, decrease in UV absorbance with a concomitant blue shift, and decrease in fluorescence excited-state lifetimes. However, their beta-analogues show enhancement in fluorescence intensity, increase in UV absorbance with a red shift, and an increase in fluorescence excited-state lifetimes. This implies that the umbelliferyl groups of alpha- and beta-galactosides experience non-polar and polar microenvironments, respectively, upon binding to WBA I. Replacement of the anomeric hydroxyl group of galactose by 4-methylumbelliferyl moiety increases the affinity of resulting saccharides. Substitution of C-2 hydroxyl of galactose by an acetamido group leads to increased affinity due to a favorable entropy change. This suggests that acetamido group of MeUmb-alpha/beta-GalNAc binds to a relatively non-polar subsite of WBA I. Most interestingly, this substitution also reduces the association rate constants dramatically. Inspection of the activation parameters reveals that the enthalpy of activation is the limiting factor for the differences in the forward rate constants for these saccharides and the entropic contribution to the activation energy is small.	INDIAN INST SCI,MOLEC BIOPHYS UNIT,BANGALORE 560012,KARNATAKA,INDIA; NATL CHEM LAB,DIV PEDIAT ENDOCRINOL,POONA 411008,MAHARASHTRA,INDIA	Indian Institute of Science (IISC) - Bangalore; Council of Scientific & Industrial Research (CSIR) - India; CSIR - National Chemical Laboratory (NCL)			SUROLIA, AVADESHA/C-5442-2009					ACHARYA S, 1990, J BIOL CHEM, V265, P11586; APPUKUTTAN PS, 1981, ANAL BIOCHEM, V113, P253, DOI 10.1016/0003-2697(81)90074-9; BESSLER W, 1974, J BIOL CHEM, V249, P2819; BREWER CF, 1973, BIOCHEMISTRY-US, V12, P4448, DOI 10.1021/bi00746a023; CHIPMAN DM, 1967, J BIOL CHEM, V242, P4388; CLEGG RM, 1977, BIOCHEMISTRY-US, V16, P167, DOI 10.1021/bi00621a002; DEAN BR, 1973, BIOCHIM BIOPHYS ACTA, V322, P141, DOI 10.1016/0005-2795(73)90184-0; DECASTEL M, 1982, BIOCHEM BIOPH RES CO, V106, P638, DOI 10.1016/0006-291X(82)91158-5; DECASTEL M, 1984, ARCH BIOCHEM BIOPHYS, V232, P640, DOI 10.1016/0003-9861(84)90584-8; FARINA RD, 1980, BIOCHIM BIOPHYS ACTA, V631, P428, DOI 10.1016/0304-4165(80)90019-7; Goldstein I., 1986, LECTINS, DOI DOI 10.1016/B978-0-12-449945-4.50007-5; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; GRAY RD, 1973, J BIOL CHEM, V248, P7547; GUPTA D, 1992, J BIOL CHEM, V267, P8909; HAMMES GG, 1982, ENZYME CATALYSIS REG, P179; KHAN MI, 1986, J BIOL CHEM, V261, P3013; KORTT AA, 1985, ARCH BIOCHEM BIOPHYS, V236, P544, DOI 10.1016/0003-9861(85)90657-5; LANDSCHOOT AV, 1980, EUR J BIOCHEM, V103, P307; Landshcoot A., 1978, EUR J BIOCHEM, V83, P277, DOI [10.1111/j.1432-1033.1978.tb12092.x, DOI 10.1111/J.1432-1033.1978.TB12092.X]; LEWIS SD, 1976, ARCH BIOCHEM BIOPHYS, V172, P689, DOI 10.1016/0003-9861(76)90125-9; LIN WY, 1988, BIOCHEMISTRY-US, V27, P5068, DOI 10.1021/bi00414a018; LIS H, 1986, ANNU REV BIOCHEM, V55, P35, DOI 10.1146/annurev.bi.55.070186.000343; LOONTIENS FG, 1977, BIOCHEMISTRY-US, V16, P159, DOI 10.1021/bi00621a001; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDA T, 1989, MOL IMMUNOL, V26, P189, DOI 10.1016/0161-5890(89)90101-6; NEUROHR KJ, 1981, BIOCHEMISTRY-US, V20, P3499, DOI 10.1021/bi00515a030; PODDER SK, 1978, FEBS LETT, V85, P313, DOI 10.1016/0014-5793(78)80481-5; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Sharon N., 1989, LECTINS, P66; SWAMY MJ, 1986, BIOCHEM J, V234, P515, DOI 10.1042/bj2340515	30	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16378	16387						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344923				2022-12-27	WOS:A1993LQ33600045
J	SUGINO, K; KUROSAWA, N; NAKAMURA, T; TAKIO, K; SHIMASAKI, S; LING, N; TITANI, K; SUGINO, H				SUGINO, K; KUROSAWA, N; NAKAMURA, T; TAKIO, K; SHIMASAKI, S; LING, N; TITANI, K; SUGINO, H			MOLECULAR HETEROGENEITY OF FOLLISTATIN, AN ACTIVIN-BINDING PROTEIN - HIGHER AFFINITY OF THE CARBOXYL-TERMINAL TRUNCATED FORMS FOR HEPARAN-SULFATE PROTEOGLYCANS ON THE OVARIAN GRANULOSA-CELL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-DIFFERENTIATION FACTOR; FOLLICLE-STIMULATING-HORMONE; FSH-RELEASING PROTEIN; PORCINE FOLLISTATIN; XENOPUS-LAEVIS; 2 FORMS; INHIBIN; BETA; EXPRESSION; PITUITARY	Follistatin (FS), an activin-binding protein, is a monomer derived from two polypeptide core sequences of 315 (FS-315) and 288 (FS-288) amino acids originated from alternatively spliced mRNA. To define the structural heterogeneity of native FS, we purified six molecular forms of FS from porcine ovaries. Protein chemical analysis revealed that the structural differences among the six isoforms were caused by truncation of the carboxyl-terminal region and/or the presence of carbohydrate chains, resulting in the formation of FS-315, FS-288, and FS composed of 303 amino acids (FS-303) in various forms of glycosylation on the two potential Asn-linked glycosylation sites. The majority of FS isolated from porcine ovaries was FS-303, which may have been derived from FS-315 by proteolytic cleavage of the 12 COOH-terminal amino acids. All six molecular species have almost the same activin binding activity (K(d) = 540-680 pM). By contrast, the COOH-terminal truncated form, FS-288, showed much higher affinity for the rat granulosa cell surface than FS-303, whereas FS-315 had no affinity. FS-288 bound to heparan sulfate-Sepharose CL-4B, but FS-315 did not, suggesting that the truncated forms of FS bind to heparan sulfate proteoglycans on the cell. COS cells transfected with the FS-288 DNA expressed the FS-288 protein, which adhered to the cell surface, but cells transfected with the FS-315 DNA secreted the expressed protein into the medium, which did not bind to the cell surface. In rat anterior pituitary culture, FS-288 (ED50 = 2 ng/ml) was more potent in suppressing follicle-stimulating hormone release than FS-303 (ED50 = 10 ng/ml) and FS-315 (ED50 = 20 ng/ml). These results suggest that cell-associated FS traps activin more tightly in the matrix, thereby more effectively blocking the activity of activin on heparan sulfate proteoglycans of the cell surface and that cell-associated FS plays an important role in controlling the various actions of activin in a paracrine or autocrine manner.	UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN; INST PHYS & CHEM RES,FRONTIER RES PROGRAM,WAKO,SAITAMA 35101,JAPAN; WHITTIER INST DIABET & ENDOCRINOL,DEPT MOLEC ENDOCRINOL,LA JOLLA,CA 92037; FUJITA HLTH UNIV,SCH MED,TOYOAKE,AICHI 47011,JAPAN	Tokushima University; RIKEN; Fujita Health University				Kurosawa, Nobuyuki/0000-0002-1548-4541	NICHD NIH HHS [P01-HD-09696] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; BILLESTRUP N, 1990, MOL ENDOCRINOL, V4, P356, DOI 10.1210/mend-4-2-356; BROXMEYER HE, 1988, P NATL ACAD SCI USA, V85, P9052, DOI 10.1073/pnas.85.23.9052; ESCH FS, 1987, MOL ENDOCRINOL, V1, P849, DOI 10.1210/mend-1-11-849; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; HASEGAWA Y, 1986, ENDOCRINOL JAPON, V33, P645; HASHIMOTO M, 1990, BIOCHEM BIOPH RES CO, V173, P193, DOI 10.1016/S0006-291X(05)81040-X; HSUEH AJW, 1987, P NATL ACAD SCI USA, V84, P5082, DOI 10.1073/pnas.84.14.5082; HUTCHINSON LA, 1987, BIOCHEM BIOPH RES CO, V146, P1405, DOI 10.1016/0006-291X(87)90806-0; INOUYE S, 1991, BIOCHEM BIOPH RES CO, V179, P352, DOI 10.1016/0006-291X(91)91377-O; INOUYE S, 1991, ENDOCRINOLOGY, V129, P815, DOI 10.1210/endo-129-2-815; KITAOKA M, 1988, BIOCHEM BIOPH RES CO, V157, P48, DOI 10.1016/S0006-291X(88)80009-3; KOGAWA K, 1991, ENDOCRINOLOGY, V128, P1434, DOI 10.1210/endo-128-3-1434; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; LING N, 1985, P NATL ACAD SCI USA, V82, P7217, DOI 10.1073/pnas.82.21.7217; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MURATA M, 1988, P NATL ACAD SCI USA, V85, P2434, DOI 10.1073/pnas.85.8.2434; MURATA M, 1988, BIOCHEM BIOPH RES CO, V151, P230, DOI 10.1016/0006-291X(88)90583-9; NAKAMURA T, 1992, BIOCHIM BIOPHYS ACTA, V1135, P103, DOI 10.1016/0167-4889(92)90173-9; NAKAMURA T, 1991, J BIOL CHEM, V266, P19432; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; NAKAMURA T, 1985, J BIOCHEM, V97, P1561, DOI 10.1093/oxfordjournals.jbchem.a135213; ROBERTSON DM, 1987, BIOCHEM BIOPH RES CO, V149, P744, DOI 10.1016/0006-291X(87)90430-X; SAITO S, 1991, BIOCHEM BIOPH RES CO, V176, P413, DOI 10.1016/0006-291X(91)90940-9; SAITO S, 1991, ENDOCRINOL JAPON, V38, P377; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; SHIMASAKI S, 1988, BIOCHEM BIOPH RES CO, V152, P717, DOI 10.1016/S0006-291X(88)80097-4; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; SHIOZAKI M, 1992, P NATL ACAD SCI USA, V89, P1553, DOI 10.1073/pnas.89.5.1553; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SUGINO H, 1988, BIOCHEM BIOPH RES CO, V153, P281, DOI 10.1016/S0006-291X(88)81219-1; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; UENO N, 1987, P NATL ACAD SCI USA, V84, P8282, DOI 10.1073/pnas.84.23.8282; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; Vale W., 1990, HDB EXPT PHARM, P211; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; XIAO S, 1991, MOL CELL ENDOCRINOL, V79, P99, DOI 10.1016/0303-7207(91)90100-7; YING SY, 1988, ENDOCR REV, V9, P267, DOI 10.1210/edrv-9-2-267; YU J, 1987, NATURE, V330, P765, DOI 10.1038/330765a0	44	208	226	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15579	15587						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340384				2022-12-27	WOS:A1993LN30500041
J	CAO, YJ; MAHRENHOLZ, AM; DEPAOLIROACH, AA; ROACH, PJ				CAO, YJ; MAHRENHOLZ, AM; DEPAOLIROACH, AA; ROACH, PJ			CHARACTERIZATION OF RABBIT SKELETAL-MUSCLE GLYCOGENIN - TYROSINE-194 IS ESSENTIAL FOR FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; BIOSYNTHESIS; BIOGENESIS; PRIMER; ANTIBODIES; SYNTHASE; LINKAGE	The biogenesis of glycogen involves a specific initiation event mediated by the initiator protein, glycogenin, which undergoes self-glucosylation to generate an oligosaccharide primer from which the glycogen molecule grows. Rabbit muscle glycogenin was expressed at high levels in Escherichia coli and purified close to homogeneity in a procedure that involved binding to a UDP-agarose affinity column. The resulting protein had subunit molecular weight of 38,000 as judged by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate. Analysis of peptide fragments by mass spectroscopy indicated that the recombinant glycogenin was already glucosylated at Tyr-194 and contained from 1 to 8 glucose residues attached. The enzyme was active as a glucosyl transferase and could incorporate a further approximately 5 mol of glucose/mol. The apparent K(m) for the glucosyl donor UDP-glucose was 4.5 muM, and the pH optimum was pH 8. Of a number of nucleotides and related compounds surveyed, UDP and UTP were the most effective inhibitors. There was also a correlation between inhibition and the presence of a pyrophosphate group. Of several oligosaccharides of glucose, only maltose caused significant inhibition. The glucosylation reaction was first order with respect to glycogenin suggesting that it was intramolecular. The efficacy of the purified glycogenin as a substrate for the elongation reaction catalyzed by glycogen synthase was significantly enhanced if glycogenin was first allowed to undergo self-glucosylation. The length of the priming oligosaccharide is thus important for glycogen synthase action. A mutant of glycogenin, in which Tyr-194 was changed to Phe, behaved identically to the wild-type through purification and in particular bound to the UDP-agarose affinity matrix. Despite these indications of the protein's overall structural integrity, it was unable to self-glucosylate. This result indicates that Tyr-194 is necessary for glycogenin function and is consistent with Tyr-194 being the sole site of glucosylation.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202; CITY HOPE NATL MED CTR,BECKMAN RES INT,DIV IMMUNOL,DUARTE,CA 91010	Indiana University System; Indiana University-Purdue University Indianapolis; City of Hope; Beckman Research Institute of City of Hope					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027221, R01DK027221] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK27221] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAMPBELL DG, 1989, EUR J BIOCHEM, V185, P119, DOI 10.1111/j.1432-1033.1989.tb15090.x; Kennedy L., 1985, MEMBRANES MUSCLE, P65; KRISMAN CR, 1975, EUR J BIOCHEM, V52, P117, DOI 10.1111/j.1432-1033.1975.tb03979.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMAKO J, 1990, BIOCHEM INT, V21, P251; LOMAKO J, 1990, FEBS LETT, V264, P13, DOI 10.1016/0014-5793(90)80752-5; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; LOMAKO J, 1990, FEBS LETT, V268, P8, DOI 10.1016/0014-5793(90)80959-M; LOMAKO J, 1992, CARBOHYD RES, V227, P331, DOI 10.1016/0008-6215(92)85082-B; PITCHER J, 1988, EUR J BIOCHEM, V176, P391, DOI 10.1111/j.1432-1033.1988.tb14294.x; PITCHER J, 1987, EUR J BIOCHEM, V169, P497, DOI 10.1111/j.1432-1033.1987.tb13637.x; RODRIGUEZ IR, 1985, BIOCHEM BIOPH RES CO, V132, P829, DOI 10.1016/0006-291X(85)91206-9; RODRIGUEZ IR, 1988, ARCH BIOCHEM BIOPHYS, V260, P628, DOI 10.1016/0003-9861(88)90491-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMYTHE C, 1989, EUR J BIOCHEM, V183, P205, DOI 10.1111/j.1432-1033.1989.tb14914.x; SMYTHE C, 1991, EUR J BIOCHEM, V200, P625, DOI 10.1111/j.1432-1033.1991.tb16225.x; SMYTHE C, 1990, EUR J BIOCHEM, V189, P199, DOI 10.1111/j.1432-1033.1990.tb15477.x; SMYTHE C, 1988, EMBO J, V7, P2681, DOI 10.1002/j.1460-2075.1988.tb03121.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAMURA T, 1983, CELL, V34, P587, DOI 10.1016/0092-8674(83)90391-4; VISKUPIC E, 1992, J BIOL CHEM, V267, P25759	21	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14687	14693						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325847				2022-12-27	WOS:A1993LL75900027
J	HEIDENREICH, KA; ZEPPELIN, T; ROBINSON, LJ				HEIDENREICH, KA; ZEPPELIN, T; ROBINSON, LJ			INSULIN AND INSULIN-LIKE GROWTH FACTOR-I INDUCE C-FOS EXPRESSION IN POSTMITOTIC NEURONS BY A PROTEIN KINASE-C-DEPENDENT PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL NERVOUS-SYSTEM; FETAL CHICK NEURONS; NEURITE FORMATION; MESSENGER-RNA; RAT-BRAIN; ONCOGENE EXPRESSION; RIBONUCLEIC-ACID; HEPATOMA-CELLS; 3T3 CELLS; MOUSE	Recent studies indicate that insulin and insulin-like growth factors regulate development of the nervous system. The signal transduction pathways that mediate the neurotrophic responses to these peptides are largely unknown. The aims of this study were to examine the regulation of c-fos mRNA expression by insulin and insulin-like growth factor I (IGF-I) in postmitotic neurons derived from fetal chick forebrain and to investigate the role of protein kinase C (PKC) in c-fos induction by these growth factors. Cultured neurons were treated with growth factors or other known activators of c-fos gene expression, and then total cellular RNA was isolated and analyzed by Northern analysis using a full-length mouse c-fos cDNA probe. Fetal calf serum, insulin, IGF-I, 12-O-tetradecanoylphorbol (TPA), and cycloheximide induced a 2.2-kilo-base c-fos transcript in neurons. Increased levels of c-fos mRNA were apparent as early as 15 min after the addition of insulin. Levels peaked after 60 min and then remained high up to 180 min. The onset of c-fos induction by IGF-I was similar to insulin; however, the response was more transient. Analyses of dose-response curves indicate that insulin and IGF-I stimulate c-fos expression by interacting with their own receptor type. The decay rate of c-fos mRNA was unaltered by insulin or IGF-I. Pretreatment of neurons with actinomycin D (2 muM) for 5 min prior to the addition of insulin completely blocked the induction of c-fos mRNA. TPA increased c-fos mRNA levels with similar kinetics to that of insulin and IGF-I; however, the attenuation phase more closely paralleled that of insulin. Two inhibitors of PKC, sphingosine and staurosporine, completely blocked the induction of c-fos mRNA by insulin, IGF-I, and TPA. These data indicate that insulin and IGF-I stimulate transcription of the c-fos gene in neurons by a PKC-mediated pathway. Increased AP-1 activity may mediate some of the neurotrophic responses to insulin and IGF-I.	VET AFFAIRS MED CTR, RES SERV, DENVER, CO 80220 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	HEIDENREICH, KA (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL, C-236, 4200 E 9TH AVE, DENVER, CO 80262 USA.							AIZENMAN Y, 1986, P NATL ACAD SCI USA, V83, P2263, DOI 10.1073/pnas.83.7.2263; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; DICICCOBLOOM E, 1988, P NATL ACAD SCI USA, V85, P4066, DOI 10.1073/pnas.85.11.4066; GOLDSTEIN ME, 1982, J NEUROIMMUNOL, V3, P203, DOI 10.1016/0165-5728(82)90023-6; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANNUN YA, 1991, METHOD ENZYMOL, V201, P316; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HASELBACHER GK, 1985, P NATL ACAD SCI USA, V82, P2153, DOI 10.1073/pnas.82.7.2153; HAUGUELDEMOUZON S, 1991, MOL ENDOCRINOL, V5, P51, DOI 10.1210/mend-5-1-51; HAVRANKOVA J, 1978, NATURE, V272, P827, DOI 10.1038/272827a0; HAVRANKOVA J, 1978, P NATL ACAD SCI USA, V75, P5737, DOI 10.1073/pnas.75.11.5737; HEIDENREICH KA, 1990, J BIOL CHEM, V265, P15076; HEIDENREICH KA, 1989, ENDOCRINOLOGY, V125, P1451, DOI 10.1210/endo-125-3-1451; HEIDENREICH KA, 1988, J NEUROCHEM, V51, P878, DOI 10.1111/j.1471-4159.1988.tb01824.x; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; ISHIZUKA T, 1992, END SOC ABSTR, P177; KAPPY M, 1984, J NEUROCHEM, V42, P198, DOI 10.1111/j.1471-4159.1984.tb09717.x; KENNER KA, 1991, ENDOCRINOLOGY, V129, P301, DOI 10.1210/endo-129-1-301; KRUIJER W, 1986, J BIOL CHEM, V261, P7929; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LESNIAK MA, 1988, ENDOCRINOLOGY, V123, P2089, DOI 10.1210/endo-123-4-2089; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MATSUI M, 1990, ONCOGENE, V5, P249; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; MILL JF, 1985, P NATL ACAD SCI USA, V82, P7126, DOI 10.1073/pnas.82.20.7126; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; ONG J, 1987, ENDOCRINOLOGY, V120, P353, DOI 10.1210/endo-120-1-353; PURO DG, 1984, SCIENCE, V225, P1170, DOI 10.1126/science.6089343; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RECIOPINTO E, 1984, P NATL ACAD SCI-BIOL, V81, P2562, DOI 10.1073/pnas.81.8.2562; RECIOPINTO E, 1986, J NEUROSCI, V6, P1211; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; SARA VR, 1982, ACTA PHYSIOL SCAND, V115, P467, DOI 10.1111/j.1748-1716.1982.tb07105.x; STRULOVICI B, 1991, J BIOL CHEM, V266, P168; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; TAUB R, 1987, J BIOL CHEM, V262, P10893; THOENEN H, 1985, SCIENCE, V229, P238, DOI 10.1126/science.2409599; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON MJ, 1992, DIABETES S1, V44, pA6; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VARON S, 1984, J NEUROSCI, V4, P654; VERMA IM, 1987, ADV CANCER RES, V49, P29, DOI 10.1016/S0065-230X(08)60793-9; XUE ZG, 1988, CELL DIFFER DEV, V25, P1	51	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14663	14670						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325843				2022-12-27	WOS:A1993LL75900023
J	VILE, GF; TYRRELL, RM				VILE, GF; TYRRELL, RM			OXIDATIVE STRESS RESULTING FROM ULTRAVIOLET-A IRRADIATION OF HUMAN SKIN FIBROBLASTS LEADS TO A HEME OXYGENASE-DEPENDENT INCREASE IN FERRITIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; OXIDANT STRESS; HEAT-SHOCK; PROTEIN; LIVER; IRON; CELLS; SUPEROXIDE; INDUCTION; RADICALS	Heme oxygenase-1 mRNA levels increase following exposure of many mammalian cell lines to oxidative stress such as ultraviolet A (UVA) irradiation. Here we demonstrate a 4-fold increase in microsomal heme oxygenase activity and a 40% decrease in microsomal heme content 14 h after treatment of human skin fibroblasts (FEK4) with 250 kJ m-2 of UVA radiation. Paralleling this was a 2-fold increase in ferritin levels that was sustained for at least 46 h after UVA irradiation. Treatment of fibroblasts with the iron chelating agent desferrioxamine, after the UVA-dependent induction of heme oxygenase, prevented the increase in ferritin levels. Treatment of fibroblasts with Sn-protoporphyrin IX (an inhibitor of heme oxygenase) also prevented the effect of UVA radiation on ferritin levels. Thus we conclude that the effect of UVA radiation on ferritin levels is via the heme oxygenase-dependent release of iron from endogenous heme sources. We propose that the increase in ferritin that follows UVA irradiation would decrease intracellular free iron such that iron-catalyzed free radical reactions would be restricted during periods of subsequent oxidative stress.			VILE, GF (corresponding author), SWISS INST EXPTL CANC RES,CH BOVERESSES 155,CH-1066 EPALINGES,SWITZERLAND.							APPLEGATE LA, 1991, CANCER RES, V51, P974; AUBAILLY M, 1991, PHOTOCHEM PHOTOBIOL, V54, P769, DOI 10.1111/j.1751-1097.1991.tb02088.x; AUST S D, 1985, Journal of Free Radicals in Biology and Medicine, V1, P3, DOI 10.1016/0748-5514(85)90025-X; BAKER MS, 1986, ARCH BIOCHEM BIOPHYS, V246, P581, DOI 10.1016/0003-9861(86)90313-9; BALLA G, 1992, J BIOL CHEM, V267, P18148; Battey, 1986, BASIC METHODS MOL BI; BLACK HS, 1987, PHOTOCHEM PHOTOBIOL, V46, P213, DOI 10.1111/j.1751-1097.1987.tb04759.x; BOLANN BJ, 1990, EUR J BIOCHEM, V193, P899, DOI 10.1111/j.1432-1033.1990.tb19415.x; BORG DC, 1984, ISR J CHEM, V24, P38; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; COCCIA EM, 1992, MOL CELL BIOL, V12, P3015, DOI 10.1128/MCB.12.7.3015; CUNNINGHAM ML, 1985, PHOTOCHEM PHOTOBIOL, V42, P125, DOI 10.1111/j.1751-1097.1985.tb01549.x; CZOCHRALSKA B, 1984, BIOCHIM BIOPHYS ACTA, V801, P403, DOI 10.1016/0304-4165(84)90145-4; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; ESTABROOK RW, 1967, METHOD ENZYMOL, V10, P212; GRANICK S, 1975, J BIOL CHEM, V250, P9215; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HARRISON PM, 1973, INORGANIC BIOCH, P253; HIWASA T, 1986, CANCER RES, V46, P2474; KEYSE SM, 1990, MOL CELL BIOL, V10, P4967, DOI 10.1128/MCB.10.9.4967; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KEYSE SM, 1987, J BIOL CHEM, V262, P14821; KEYSE SM, 1989, CARCINOGENESIS, V11, P787; KUROSS SA, 1988, BLOOD, V71, P876; KUTTY RK, 1988, ARCH BIOCHEM BIOPHYS, V260, P638, DOI 10.1016/0003-9861(88)90492-4; LIN JJ, 1990, SCIENCE, V247, P74, DOI 10.1126/science.2294594; MAINES MD, 1975, J BIOL CHEM, V250, P4171; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MAINES MD, 1986, J BIOL CHEM, V261, P411; MCCORMICK JP, 1976, SCIENCE, V191, P468; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; SHIBAHARA S, 1978, ARCH BIOCHEM BIOPHYS, V188, P243, DOI 10.1016/S0003-9861(78)80006-X; STERRENBERG L, 1984, TOXICOL LETT, V22, P153, DOI 10.1016/0378-4274(84)90059-6; STOCKER R, 1990, FREE RADICAL RES COM, V9, P101, DOI 10.3109/10715769009148577; TAKETANI S, 1989, FEBS LETT, V245, P173, DOI 10.1016/0014-5793(89)80215-7; TENHUNEN R, 1970, BIOCHEMISTRY-US, V9, P298, DOI 10.1021/bi00804a016; TRAKSHEL GM, 1986, J BIOL CHEM, V261, P1131; WALLING C, 1975, ACCOUNTS CHEM RES, V8, P125, DOI 10.1021/ar50088a003	41	350	356	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14678	14681						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325845				2022-12-27	WOS:A1993LL75900025
J	DEBINSKI, W; PURI, RK; KREITMAN, RJ; PASTAN, I				DEBINSKI, W; PURI, RK; KREITMAN, RJ; PASTAN, I			A WIDE-RANGE OF HUMAN CANCERS EXPRESS INTERLEUKIN-4 (IL4) RECEPTORS THAT CAN BE TARGETED WITH CHIMERIC TOXIN COMPOSED OF IL4 AND PSEUDOMONAS EXOTOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSION PROTEIN; RECOMBINANT IMMUNOTOXIN; ESCHERICHIA-COLI; ANIMAL TOXICITY; TUMOR-CELLS; CYTOTOXICITY; AERUGINOSA; SEQUENCES; CARCINOMA; DOMAINS	A chimeric toxin has been constructed by fusion of a gene encoding human interleukin 4 (hIL4) to a gene encoding a mutant form of Pseudomonas exotoxin A (PE) which cannot bind to its receptors (PE4E). The chimeric gene was expressed in Escherichia coli where large amounts of the chimeric toxin, hIL4-PE4E, was produced. Purified hIL4-PE4E was very cytotoxic to cancer cell lines of both hematopoietic and solid tumor origin. In the HUT 102 T cell leukemia and Daudi B cell lymphoma cell lines, protein synthesis was inhibited by 50% (ID50) at a hIL4-PE4E concentration of 2 and 7 ng/ml (25 and 86 pM, respectively). hIL4-PE4E was also very cytotoxic to cell lines derived from carcinomas of the colon, breast, stomach, liver, adrenals, and prostate, as well as melanoma and epidermoid carcinoma, indicating that hIL4 receptors are widely expressed on human malignancies. We also found that human phytohemagglutinin- activated peripheral blood lymphocytes were extremely sensitive to hIL4-PE4E with an ID50 of 0.2 ng/ml (2.5 pM). The cytotoxic action of hIL4-PE4E was specific because it was blocked by an excess of hIL4 and not of human interleukin 2. In addition, hIL4-PE4ED553, an enzymatically inactive form of the chimeric toxin, was not cytotoxic. These results suggest that the hIL4 receptor may be a target for therapy in malignant and immunologic disorders using hIL4 chimeric toxin.	NCI,DIV CANC BIOL DIAG & CTR,MOLEC BIOL LAB,9000 ROCKVILLE PIKE,BETHESDA,MD 20892; US FDA,CTR BIOL EVALUAT & RES,DIV CELLULAR & GENE THERAPIES,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA)			pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BATRA JK, 1989, P NATL ACAD SCI USA, V86, P845; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; CHAUDHARY VK, 1990, J BIOL CHEM, V265, P16306; DEBINSKI W, 1991, MOL CELL BIOL, V11, P1751, DOI 10.1128/MCB.11.3.1751; DEBINSKI W, 1992, J CLIN INVEST, V90, P405, DOI 10.1172/JCI115875; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; GRAY GL, 1984, P NATL ACAD SCI-BIOL, V81, P2645, DOI 10.1073/pnas.81.9.2645; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; JINNO Y, 1988, J BIOL CHEM, V263, P13203; KREITMAN RJ, 1992, BIOCONJUGATE CHEM, V3, P58, DOI 10.1021/bc00013a009; KREITMAN RJ, 1990, P NATL ACAD SCI USA, V87, P8291, DOI 10.1073/pnas.87.21.8291; KREITMAN RJ, 1992, BLOOD, V79, P1775; LAKKIS F, 1991, EUR J IMMUNOL, V21, P2253, DOI 10.1002/eji.1830210937; LORBERBOUMGALSKI H, 1988, J BIOL CHEM, V263, P18650; LORBERBOUMGALSKI H, 1990, J BIOL CHEM, V265, P16311; MORRISON BW, 1992, J BIOL CHEM, V267, P11957; OBIRI NI, 1993, J CLIN INVEST, V91, P88, DOI 10.1172/JCI116205; OGATA M, 1989, P NATL ACAD SCI USA, V86, P4215, DOI 10.1073/pnas.86.11.4215; PASTAN I, 1991, SCIENCE, V254, P1173, DOI 10.1126/science.1683495; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; PURI RK, 1991, CANCER RES, V51, P3011; PURI RK, 1993, IN PRESS CANCER INVE; SIEGALL CB, 1989, FASEB J, V3, P2647, DOI 10.1096/fasebj.3.14.2556314; SIEGALL CB, 1990, J BIOL CHEM, V265, P16318; SIEGALL CB, 1991, CANCER RES, V51, P2831; SIEGALL CB, 1990, CANCER RES, V50, P7786; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; TUNGEKAR MF, 1991, CANCER RES, V51, P261; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; YOKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894, DOI 10.1073/pnas.83.16.5894	32	71	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14065	14070						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314773				2022-12-27	WOS:A1993LJ82500044
J	KIRSCH, GE; DREWE, JA; DEBIASI, M; HARTMANN, HA; BROWN, AM				KIRSCH, GE; DREWE, JA; DEBIASI, M; HARTMANN, HA; BROWN, AM			FUNCTIONAL INTERACTIONS BETWEEN K+ PORE RESIDUES LOCATED IN DIFFERENT SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; RAT-BRAIN; BLOCKADE; REGION; AXONS	The aqueous pore (P-region) of homotetrameric voltage-gated K+ channels has been modeled as a radially symmetrical eight-stranded antiparallel beta-barrel to which each of the four subunits contributes equally. This model has hydrogen bonding between residues located on adjacent subunits and predicts that subunit interactions might have functional consequences. Previously we have used point mutations and an electrophysiological assay to detect functional interactions between a pair of residues at positions 369 and 374 in the P-region, but we could not distinguish between intra- and intersubunit interactions. In the present paper, we present evidence for interaction across subunit boundaries after co-injecting two cRNAs encoding subunits differing from each other at either position 369 or 374. Comparison of the phenotypes of homo- and heterotetrameric channels suggests that pore residues residing in adjacent subunits form a closely packed structure which determines both ion conductance and stability of the open state of the channel. Our results are consistent with a structure in which pore residues 369 and 374 are located in close proximity on adjacent antiparallel strands to allow both intra- and intersubunit interactions.	BAYLOR COLL MED,DEPT MOLEC PHYSIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine	KIRSCH, GE (corresponding author), BAYLOR COLL MED,DEPT ANESTHESIOL,HOUSTON,TX 77030, USA.		De Biasi, Mariella/M-7646-2017	De Biasi, Mariella/0000-0002-0687-8872	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023877, R01NS029473] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37044] Funding Source: Medline; NINDS NIH HHS [NS23877, NS29473] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; BEZANILLA F, 1972, J GEN PHYSIOL, V60, P588, DOI 10.1085/jgp.60.5.588; BOGUSZ S, 1992, PROTEIN ENG, V5, P285, DOI 10.1093/protein/5.4.285; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; DEBIASI M, 1993, PFLUG ARCH EUR J PHY, V422, P354, DOI 10.1007/BF00374291; DREWE JA, 1993, IN PRESS METHODS NEU; DURRELL SR, 1992, BIOPHYS J, V62, P238; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HILLE B, 1973, J GEN PHYSIOL, V61, P669, DOI 10.1085/jgp.61.6.669; HURST RS, 1992, J BIOL CHEM, V267, P23742; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KIRSCH GE, 1991, AM J PHYSIOL, V261, pC583, DOI 10.1152/ajpcell.1991.261.4.C583; KIRSCH GE, 1992, NEURON, V8, P499, DOI 10.1016/0896-6273(92)90278-L; KIRSCH GE, 1991, FEBS LETT, V278, P55, DOI 10.1016/0014-5793(91)80082-E; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; Sambrook J, 1989, MOL CLONING LABORATO; TAGLIALATELA M, 1991, MOL PHARMACOL, V40, P299; TYTGAT J, 1992, NATURE, V359, P420, DOI 10.1038/359420a0; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YELLEN G, 1984, J GEN PHYSIOL, V84, P157, DOI 10.1085/jgp.84.2.157; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	28	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13799	13804						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314749				2022-12-27	WOS:A1993LJ82500008
J	GOESSLING, LS; MASCOTTI, DP; BHATTACHARYYAPAKRASI, M; GANG, H; THACH, RE				GOESSLING, LS; MASCOTTI, DP; BHATTACHARYYAPAKRASI, M; GANG, H; THACH, RE			IRREVERSIBLE STEPS IN THE FERRITIN SYNTHESIS INDUCTION PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT BINDING-PROTEIN; IRON-SULFUR CLUSTER; RNA-BINDING; MESSENGER-RNAS; RABBIT LIVER; PURIFICATION; INVITRO; ACONITASE	The ability of cells to re-repress ferritin synthesis after removal of an inducing agent (iron or heme) was investigated. Re-repression was found to be a slow process, requiring approximately 4 (after iron removal) to 10 h (after heme removal) for completion. Desferrioxamine mesylate (Desferal) had only a slight effect on the rate of re-repression, whereas cycloheximide was strongly inhibitory, indicating that new protein synthesis is re quired for re-repression. Re-repression occurred at a slow but significant rate in the presence of both Desferal and cycloheximide. These results indicate that, in the absence of an iron chelator, the induction of ferritin synthesis is essentially irreversible. The kinetics of the previously reported covalent modification of IRE-binding protein (IRE-BP) were then examined, to see whether this phenomenon might account (at least in part) for the irreversibility of induction. It was found that the heme- or iron dependent disappearance of 98-kDa IRE-BP occurred rapidly (within 1 h), and was equally rapidly reversed upon removal of heme after a 1-h exposure. By contrast, after a 4-h exposure to heme, little 98-kDa IRE-BP could be regenerated after heme removal. These results suggest that the slow, irreversible covalent modification of IRE-BP correlates closely over time with the induction of ferritin synthe sis. The covalent modification of IRE-BP depends on cell growth rate, and is most readily detected in rapidly growing cells.	WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63130	Washington University (WUSTL)			Mascotti, David/G-3594-2012	Mascotti, David/0000-0003-1184-6784	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020484] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 20484] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BROWN PH, 1989, J BIOL CHEM, V264, P13383; CONSTABLE A, 1992, P NATL ACAD SCI USA, V89, P4554, DOI 10.1073/pnas.89.10.4554; DANIELSMCQUEEN S, 1992, GENE, V122, P271, DOI 10.1016/0378-1119(92)90215-B; EISENSTEIN RS, 1990, ENZYME, V44, P42, DOI 10.1159/000468746; GOESSLINGLS, 1992, SCIENCE, V256, P670; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KLAUSNER RD, 1993, CELL, V72, P119; KUHN LC, 1991, BRIT J HAEMATOL, V79, P1, DOI 10.1111/j.1365-2141.1991.tb07998.x; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LIN JJ, 1990, ENZYME, V44, P59, DOI 10.1159/000468747; MELEFORS O, 1993, BIOESSAYS, V15, P85, DOI 10.1002/bies.950150203; ROGERS JT, 1992, IRON HUMAN DISEASE, P77; ROUAULT TA, 1989, P NATL ACAD SCI USA, V86, P5768, DOI 10.1073/pnas.86.15.5768; TANG CK, 1992, J BIOL CHEM, V267, P24466; THEIL EC, 1990, J BIOL CHEM, V265, P4771; WALDEN WE, 1989, J BIOL CHEM, V264, P13765	19	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4343	4348						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308003				2022-12-27	WOS:A1994MW98900070
J	POSNER, BI; FAURE, R; BURGESS, JW; BEVAN, AP; LACHANCE, D; ZHANGSUN, GY; FANTUS, IG; NG, JB; HALL, DA; LUM, BS; SHAVER, A				POSNER, BI; FAURE, R; BURGESS, JW; BEVAN, AP; LACHANCE, D; ZHANGSUN, GY; FANTUS, IG; NG, JB; HALL, DA; LUM, BS; SHAVER, A			PEROXOVANADIUM COMPOUNDS - A NEW CLASS OF POTENT PHOSPHOTYROSINE PHOSPHATASE INHIBITORS WHICH ARE INSULIN MIMETICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; RECEPTOR TYROSINE KINASE; RAT ADIPOCYTES; CRYSTAL-STRUCTURE; DIABETIC RATS; VANADATE TREATMENT; BLOOD-GLUCOSE; V-51; PHOSPHORYLATION; STIMULATION	Twelve peroxovanadium (pV) compounds, each containing an oxo ligand, one or two peroxo anions, and an ancillary ligand in the inner coordination sphere of V, were synthesized, crystallized, and characterized by V-51 NMR as >95% pure. These compounds activated the insulin receptor kinase (IRK) of cultured hepatoma cells, stimulated lipogenesis in adipocytes, and inhibited the in situ dephosphorylation of autophosphorylated IRs and epidermal growth factor receptors of rat liver endosomes. The phosphotyrosine phosphatase inhibitory and IRK activating potencies of these compounds were linearly correlated (r = 0.74; p < 0.003), decayed in parallel in solution, and varied considerably with the ancillary ligands within these compounds. In vivo administration activated rat liver IRK in parallel with its tyrosine phosphorylation. Co-administration of insulin plus pV was markedly synergistic in both respects. pV administration significantly decreased circulating insulin and plasma glucose concentrations; the latter to levels seen after a dose of insulin yielding greater than or equal to 50% occupancy of IRs in vivo. Two compounds (mpV(pic) and mpV(2,6-pdc)) displayed relative specificity as phosphotyrosine phosphatase inhibitors by inhibiting IR dephosphorylation to a significantly greater degree than epidermal growth factor receptor dephosphorylation. Thus, pV compounds are the most potent phosphotyrosine phosphatase inhibitors described to date. Their capacity to activate IRK appears to derive from their phosphotyrosine phosphatase inhibitory activity. Their hypoglycemic action is due to a direct tissue effect.	MCGILL UNIV,DEPT MED,MONTREAL H3A 1A1,PQ,CANADA; MCGILL UNIV,DEPT CHEM,MONTREAL H3A 1A1,PQ,CANADA	McGill University; McGill University	POSNER, BI (corresponding author), ROYAL VICTORIA HOSP,POLYPEPTIDE HORMONE LAB,687 PINE AVE W,ROOM H5 45,MONTREAL H3A 1A1,PQ,CANADA.		Posner, Barry/B-6733-2008	Bevan, Paul/0000-0002-0656-9164				BEGIN D, 1975, INORG CHEM, V14, P1785, DOI 10.1021/ic50150a009; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BLONDEL O, 1989, DIABETOLOGIA, V32, P185, DOI 10.1007/BF00265092; BRICHARD SM, 1988, ENDOCRINOLOGY, V123, P2048, DOI 10.1210/endo-123-4-2048; BURGESS JW, 1992, J BIOL CHEM, V267, P10077; BUTLER A, 1989, J AM CHEM SOC, V111, P2802, DOI 10.1021/ja00190a010; CLARK AS, 1985, BIOCHEM J, V232, P273, DOI 10.1042/bj2320273; CRANS DC, 1990, J AM CHEM SOC, V112, P2901, DOI 10.1021/ja00164a009; DREW RE, 1972, INORG CHEM, V11, P1079, DOI 10.1021/ic50111a033; DREW RE, 1973, INORG CHEM, V12, P829, DOI 10.1021/ic50122a025; DUBYAK GR, 1980, J BIOL CHEM, V255, P5306; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FAURE R, 1992, J BIOL CHEM, V267, P11215; GIL J, 1988, J BIOL CHEM, V263, P1868; HARRISON AT, 1985, J CHEM SOC DALTON, P1173, DOI 10.1039/dt9850001173; HARTKAMP H, 1959, ANGEW CHEM INT EDIT, V71, P553, DOI 10.1002/ange.19590711708; HEATH E, 1981, J CHEM SOC DALTON, P1105, DOI 10.1039/dt9810001105; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HEYLIGER CE, 1985, SCIENCE, V227, P1474, DOI 10.1126/science.3156405; HILL G, 1987, BONE MARROW TRANSPL, V2, P315; HOWARTH OW, 1979, J CHEM SOC DALTON, P1388, DOI 10.1039/dt9790001388; KADOTA S, 1987, J BIOL CHEM, V262, P8252; KADOTA S, 1986, BIOCHEM BIOPH RES CO, V138, P174, DOI 10.1016/0006-291X(86)90262-7; KADOTA S, 1987, BIOCHEM BIOPH RES CO, V147, P259, DOI 10.1016/S0006-291X(87)80115-8; KHAN MN, 1989, J BIOL CHEM, V264, P12931; MEYEROVITCH J, 1987, J BIOL CHEM, V262, P6658; MIMOUN H, 1983, NOUV J CHIM, V7, P467; MIMOUN H, 1983, J AM CHEM SOC, V105, P3101, DOI 10.1021/ja00348a025; QUILITZSCH U, 1979, INORG CHEM, V18, P869, DOI 10.1021/ic50193a069; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SALAPALA J, 1971, J CHEM SOC A, P1132, DOI 10.1039/j19710001132; SHAVER A, 1993, INORG CHEM, V32, P3109, DOI 10.1021/ic00066a024; SHECHTER Y, 1980, NATURE, V284, P556, DOI 10.1038/284556a0; STOMBERG R, 1986, ACTA CHEM SCAND A, V40, P168, DOI 10.3891/acta.chem.scand.40a-0168; STROUT HV, 1989, ENDOCRINOLOGY, V124, P1918, DOI 10.1210/endo-124-4-1918; SVENSSON IB, 1971, ACTA CHEM SCAND, V25, P898, DOI 10.3891/acta.chem.scand.25-0898; TAMURA S, 1984, J BIOL CHEM, V259, P6650; TOLMAN EL, 1979, LIFE SCI, V25, P1159, DOI 10.1016/0024-3205(79)90138-3; TRACEY AS, 1992, J AM CHEM SOC, V114, P3835, DOI 10.1021/ja00036a035; VULETIC N, 1973, J CHEM SOC DALTON, P1137, DOI 10.1039/dt9730001137	40	518	533	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4596	4604						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308031				2022-12-27	WOS:A1994MW98900103
J	SKELLY, PJ; KIM, JW; CUNNINGHAM, J; SHOEMAKER, CB				SKELLY, PJ; KIM, JW; CUNNINGHAM, J; SHOEMAKER, CB			CLONING, CHARACTERIZATION, AND FUNCTIONAL EXPRESSION OF CDNAS ENCODING GLUCOSE-TRANSPORTER PROTEINS FROM THE HUMAN PARASITE SCHISTOSOMA-MANSONI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; ESCHERICHIA-COLI; GAMMA-SUBUNIT; PROKARYOTES; EUKARYOTES; TRANSITION; METABOLISM; CERCARIAE; RECEPTOR; INVITRO	The blood-dwelling adult form of the parasitic worm, Schistosoma mansoni, consumes prodigious quantities of host glucose following its transport across the tegument. Immunologic or pharmacologic targeting of the relevant transporter proteins might form the basis of a schistosome control strategy. Here we report the isolation and characterization of three different full-length cDNAs whose predicted protein sequences show a high degree of sequence and structural similarity to the facilitated diffusion transporter proteins of other animals, plants, and bacteria. Functional expression of two cDNAs has been achieved by injection of Xenopus oocytes with in vitro derived sense strand RNA. Injected oocytes have a significantly increased ability to take up radiolabelled glucose analogues over controls. S. mansoni glucose transporters expressed in oocytes exhibit stereospecificity for D-glucose, have relaxed specificity for different hexoses, exhibit sodium independence, and are markedly inhibited by phloretin and cytochalasin B. These two transporters, expressed in oocytes, have a K-m for 3-O-methylglucose of 1.3 and 2 mM. A third glucose transporter homologue cDNA appears to derive from a recent pseudogene. Both of the functional S. mansoni glucose transporter genes are expressed in larval and adult male and female schistosomes.	BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	SKELLY, PJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT TROP PUBL HLTH,BOSTON,MA 02115, USA.				NIAID NIH HHS [5R01AI28499-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028499] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALDWIN SA, 1989, ANNU REV PHYSIOL, V51, P459, DOI 10.1146/annurev.physiol.51.1.459; BUEDING E, 1950, J GEN PHYSIOL, V33, P475, DOI 10.1085/jgp.33.5.475; CORNFORD EM, 1988, J PARASITOL, V74, P116, DOI 10.2307/3282487; CORNFORD EM, 1979, J PARASITOL, V65, P357, DOI 10.2307/3280273; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; FRIPP PJ, 1967, COMP BIOCHEM PHYSIOL, V23, P893, DOI 10.1016/0010-406X(67)90349-0; GESTELAND RF, 1992, SCIENCE, V257, P1640, DOI 10.1126/science.1529352; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HENDERSON PJF, 1990, PHILOS T ROY SOC B, V326, P391, DOI 10.1098/rstb.1990.0020; HOREMANS AMC, 1991, PARASITOLOGY, V102, P259, DOI 10.1017/S0031182000062570; ISSEROFF H, 1972, COMP BIOCHEM PHYSIOL, V43, P849, DOI 10.1016/0300-9629(72)90157-0; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; KELLER K, 1989, J BIOL CHEM, V264, P18884; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; MCCORMACK K, 1989, NATURE, V340, P103, DOI 10.1038/340103a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; ROGERS SH, 1975, INT J PARASITOL, V5, P369, DOI 10.1016/0020-7519(75)90086-7; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHOEMAKER CB, 1992, MOL BIOCHEM PARASIT, V53, P17, DOI 10.1016/0166-6851(92)90003-3; SKELLY PJ, 1993, MOL BIOCHEM PARASIT, V60, P93, DOI 10.1016/0166-6851(93)90032-S; STEIN LD, 1986, MOL BIOCHEM PARASIT, V20, P253, DOI 10.1016/0166-6851(86)90106-4; THOMPSON DP, 1984, MOL BIOCHEM PARASIT, V13, P59; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; UGLEM GL, 1975, J PARASITOL, V61, P390, DOI 10.2307/3279309; VANOORDT BEP, 1985, MOL BIOCHEM PARASIT, V16, P117, DOI 10.1016/0166-6851(85)90080-5; VANOORDT BEP, 1989, PARASITOLOGY, V98, P409, DOI 10.1017/S0031182000061497; WHITE MK, 1989, NATURE, V340, P103, DOI 10.1038/340103b0	31	74	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4247	4253						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307988				2022-12-27	WOS:A1994MW98900055
J	HERBERT, JM; LAMARCHE, I; PRABONNAUD, V; DOL, F; GAUTHIER, T				HERBERT, JM; LAMARCHE, I; PRABONNAUD, V; DOL, F; GAUTHIER, T			TISSUE-TYPE PLASMINOGEN-ACTIVATOR IS A POTENT MITOGEN FOR HUMAN AORTIC SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL-CELLS; PROTEIN KINASE-C; FIBROBLAST GROWTH-FACTOR; RAT CAROTID-ARTERY; GENE-EXPRESSION; EXTRACELLULAR-MATRIX; SIGNAL TRANSDUCTION; THROMBIN RECEPTOR; PROLIFERATION; UROKINASE	Tissue-type plasminogen activator (t-PA) is a potent and efficacious mitogen for growth-arrested cultured human aortic smooth muscle cells, stimulating an increase in cell number at 0.3-30 nM concentration. Double-chain t-PA is as efficient as single-chain t-PA in stimulating smooth muscle cell mitogenesis, whereas single-chain urokinase-type plasminogen activator (u-PA) or u-PA and plasmin or plasminogen are ineffective. Plasminogen activator inhibitor-1, Pefabloc-TPA, diisopropyl fluorophosphate or alpha1-anti-trypsin inhibit the mitogenic effect of t-PA for smooth muscle cells in a dose-dependent manner, showing that it is dependent on the enzymatic activity. t-PA activated phosphoinositide turnover in smooth muscle cells through a pertussis toxin-insensitive pathway and stimulated proto-oncogene c-fos and c-jun mRNA levels. These findings indicate that t-PA stimulates vascular human smooth muscle cell proliferation and suggest for the first time that it may contribute to intimal smooth muscle cell proliferation after vascular injury as a result of angioplasty or vascular compromise during atherogenesis.			HERBERT, JM (corresponding author), SANOFI RECH,HEMOBIOL RES DEPT,195 ROUTE ESPAGNE,F-31036 TOULOUSE,FRANCE.							AU YPT, 1992, J BIOL CHEM, V267, P3438; BARON-VAN EVERCOOREN A, 1987, DEV BRAIN RES, V36, P101, DOI 10.1016/0165-3806(87)90068-X; BERK BC, 1991, BIOCHEM J, V274, P799, DOI 10.1042/bj2740799; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; Binder B R, 1990, Blood Coagul Fibrinolysis, V1, P717; BJORKERUD S, 1988, CIRC RES, V62, P1011, DOI 10.1161/01.RES.62.5.1011; CARNEY DH, 1985, CELL, V42, P479, DOI 10.1016/0092-8674(85)90105-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOWES AW, 1992, CIRC RES, V70, P1128, DOI 10.1161/01.RES.70.6.1128; CLOWES AW, 1990, CIRC RES, V67, P61, DOI 10.1161/01.RES.67.1.61; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DEUEL TF, 1984, J CLIN INVEST, V74, P669, DOI 10.1172/JCI111482; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GELEHRTER TD, 1986, J CLIN INVEST, V77, P165, DOI 10.1172/JCI112271; GOLDSMITH GH, 1981, EXP MOL PATHOL, V35, P257, DOI 10.1016/0014-4800(81)90065-4; GRIMALDI G, 1986, EMBO J, V5, P855, DOI 10.1002/j.1460-2075.1986.tb04295.x; HERBERT JM, 1992, FEBS LETT, V301, P155, DOI 10.1016/0014-5793(92)81237-G; KAIBUCHI K, 1986, J BIOL CHEM, V261, P1187; KANTHOU C, 1992, FEBS LETT, V314, P143, DOI 10.1016/0014-5793(92)80961-F; KIRCHHEIMER JC, 1987, FASEB J, V1, P125, DOI 10.1096/fasebj.1.2.3038646; KIRCHHEIMER JC, 1987, THROMB RES, V48, P291, DOI 10.1016/0049-3848(87)90441-5; KNUDSEN BS, 1987, J CLIN INVEST, V80, P1082, DOI 10.1172/JCI113164; KORNER G, 1993, J CELL PHYSIOL, V154, P456, DOI 10.1002/jcp.1041540303; LAMPUGNANI MG, 1990, BLOOD, V76, P1173; LEVIN EG, 1978, THROMB RES, V15, P869; LIBBY P, 1988, NEW ENGL J MED, V318, P1493, DOI 10.1056/NEJM198806093182303; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LIOTTA LA, 1981, CANCER RES, V41, P4629; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; MIMURO J, 1987, BLOOD, V70, P721; MOONEN G, 1985, DEV BRAIN RES, V20, P41, DOI 10.1016/0165-3806(85)90085-9; MOORE JP, 1986, J BIOL CHEM, V261, P8158; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PARANJPE M, 1980, LIFE SCI, V26, P1223, DOI 10.1016/0024-3205(80)90067-3; PAUL R, 1987, THROMB RES, V46, P793, DOI 10.1016/0049-3848(87)90071-5; RANBY M, 1982, THROMB RES, V7, P175; REILLY CF, 1991, J BIOL CHEM, V266, P9419; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SCHLEEF RR, 1990, J CELL BIOL, V110, P155, DOI 10.1083/jcb.110.1.155; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEISS RH, 1993, J BIOL CHEM, V268, P5724	48	72	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3076	3080						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300642				2022-12-27	WOS:A1994MV43200102
J	MARKOVICH, D; BISSIG, M; SORRIBAS, V; HAGENBUCH, B; MEIER, PJ; MURER, H				MARKOVICH, D; BISSIG, M; SORRIBAS, V; HAGENBUCH, B; MEIER, PJ; MURER, H			EXPRESSION OF RAT RENAL SULFATE TRANSPORT-SYSTEMS IN XENOPUS-LAEVIS OOCYTES - FUNCTIONAL-CHARACTERIZATION AND MOLECULAR-IDENTIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOLATERAL MEMBRANE-VESICLES; AMINO-ACID-TRANSPORT; RABBIT KIDNEY CORTEX; PROXIMAL TUBULE; BRUSH-BORDER; ANION-EXCHANGE; SPECIFICITY; NA+; CLONING; CDNA	Renal proximal tubular sulfate reabsorption is mediated by brush border membrane Na+/sulfate-cotransport and basolateral Na+-independent sulfate transport. Injection of rat kidney cortex mRNA into Xenopus laevis oocytes induced Na+-dependent as well as Na+-independent sulfate transport. The inhibition pattern of Na+-dependent uptake coincided with that known for the brush border membrane; the inhibition pattern of Na+-independent uptake suggested that this activity could be related to the basolateral cell surface. By Northern blot hybridization of size-fractionated mRNA, we provide evidence that the Na+-dependent uptake is induced by an mRNA species related to a recently cloned cDNA encoding rat renal cortex Na+/SO4 Cotransport (NaSi-1; Markovich, D., Forgo, J., Stange, G., Biber, J., and Murer, H. (1993) Proc. Natl. Acad. Sci. U. S. A. 90,8073-8077); the Na+-independent sulfate transport activity seems to be related to an mRNA species encoding a rat liver Na+-independent sulfate transporter (Bissig, M., Hagenbuch, B., Stieger, B., Koller, T., and Meier, P. J. (1994) J. Biol. Chem. 269,3017-3021). Hybrid depletion experiments using antisense oligonucleotides provided further evidence for the association of the expressed transport activities to NaSi-1 and sat-1, respectively.	UNIV ZURICH,INST PHYSIOL,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND; UNIV HOSP ZURICH,DEPT MED,DIV CLIN PHARMACOL & TOXICOL,CH-8091 ZURICH,SWITZERLAND	University of Zurich; University of Zurich; University Zurich Hospital			Markovich, Daniel/F-7884-2012; Hagenbuch, Bruno/M-5294-2016	Hagenbuch, Bruno/0000-0002-2938-8630; Sorribas, Victor/0000-0003-3457-323X				AHEARN GA, 1984, J MEMBRANE BIOL, V78, P177, DOI 10.1007/BF01925966; BAESTLEIN C, 1986, AM J PHYSIOL, V250, pF226; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; BERTRAN J, 1992, BIOCHEM J, V281, P717, DOI 10.1042/bj2810717; BISSIG M, 1994, J BIOL CHEM, V269, P3017; BRAZY PC, 1981, AM J PHYSIOL, V241, pF300, DOI 10.1152/ajprenal.1981.241.3.F300; DAVID C, 1992, PFLUG ARCH EUR J PHY, V421, P455, DOI 10.1007/BF00370256; GRINSTEIN S, 1980, AM J PHYSIOL, V238, pF452, DOI 10.1152/ajprenal.1980.238.6.F452; HAGENBUCH B, 1985, PFLUG ARCH EUR J PHY, V405, P202, DOI 10.1007/BF00582561; HIERHOLZER K, 1960, AM J PHYSIOL, V198, P833, DOI 10.1152/ajplegacy.1960.198.4.833; KARNISKI LP, 1987, AM J PHYSIOL, V253, pF513, DOI 10.1152/ajprenal.1987.253.3.F513; KUO SM, 1988, J BIOL CHEM, V263, P9710; LOW I, 1984, AM J PHYSIOL, V246, pF334, DOI 10.1152/ajprenal.1984.246.3.F334; LUECKE H, 1979, Biochemical Journal, V182, P223; MAGAGNIN S, 1992, J BIOL CHEM, V267, P15384; MAGAGNIN S, 1993, P NATL ACAD SCI USA, V90, P5979, DOI 10.1073/pnas.90.13.5979; MARKOVICH D, 1993, P NATL ACAD SCI USA, V90, P8073, DOI 10.1073/pnas.90.17.8073; MARKOVICH D, 1993, J BIOL CHEM, V268, P1362; MURER H, 1992, HDB PHYSL 8, V2, P2165; PRITCHARD JB, 1983, P NATL ACAD SCI-BIOL, V80, P2603, DOI 10.1073/pnas.80.9.2603; PRITCHARD JB, 1987, AM J PHYSIOL, V252, pF346, DOI 10.1152/ajprenal.1987.252.2.F346; SCHNEIDER EG, 1984, J BIOL CHEM, V259, P4591; TALOR Z, 1987, EUR J BIOCHEM, V164, P695, DOI 10.1111/j.1432-1033.1987.tb11182.x; TURNER RJ, 1984, AM J PHYSIOL, V247, pF793, DOI 10.1152/ajprenal.1984.247.5.F793; ULLRICH KJ, 1988, AM J PHYSIOL, V254, pF453, DOI 10.1152/ajprenal.1988.254.4.F453; ULLRICH KJ, 1982, PHILOS T ROY SOC B, V299, P549, DOI 10.1098/rstb.1982.0151; ULLRICH KJ, 1985, PFLUG ARCH EUR J PHY, V404, P311, DOI 10.1007/BF00585341; ULLRICH KJ, 1985, PFLUG ARCH EUR J PHY, V404, P300, DOI 10.1007/BF00585339; ULLRICH KJ, 1985, PFLUG ARCH EUR J PHY, V404, P307, DOI 10.1007/BF00585340; ULLRICH KJ, 1984, PFLUG ARCH EUR J PHY, V402, P264, DOI 10.1007/BF00585509; ULLRICH KJ, 1985, PFLUG ARCH EUR J PHY, V404, P293, DOI 10.1007/BF00585338; ULLRICH KJ, 1980, PFLUG ARCH EUR J PHY, V387, P127, DOI 10.1007/BF00584263; WERNER A, 1990, J BIOL CHEM, V265, P12331; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608	35	69	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3022	3026						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300634				2022-12-27	WOS:A1994MV43200094
J	LOKKER, NA; GODOWSKI, PJ				LOKKER, NA; GODOWSKI, PJ			GENERATION AND CHARACTERIZATION OF A COMPETITIVE ANTAGONIST OF HUMAN HEPATOCYTE GROWTH-FACTOR, HGF/NK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; PLASMINOGEN-ACTIVATOR; KRINGLE-2 DOMAIN; ESCHERICHIA-COLI; LIGAND-BINDING; FACTOR RECEPTOR; C-MET; EXTRACELLULAR DOMAIN; MOLECULAR-CLONING; HUMAN-FIBROBLASTS	Our previous studies have suggested that a derivative of hepatocyte growth factor (HGF), HGF/NK2, containing the coding sequences for the N-terminal hairpin and first two kringle domains, is sufficient to mediate high affinity binding to the HGF receptor. Here, we wished to test directly whether HGF/NK1 (N-terminal hairpin and first kringle domains) could bind the receptor and/or mediate receptor signaling. HGF/NK1 was expressed in Escherichia coli and purified to homogeneity using heparin-affinity and fast protein liquid cation-exchange chromatography. Biological characterization of HGF/NK1 showed that it can compete for binding to the HGF receptor on human lung carcinoma A549 cells and to a soluble form of the HGF receptor. HGF/NK1 is inefficient at promoting autophosphorylation of the HGF receptor, although some activity was detected at very high concentrations. HGF/NK1 fails to exhibit mitogenic properties even at very high concentrations. However, HGF/NK1 can act as a potent competitive antagonist in this assay. Our data demonstrate directly that a receptor binding determinant of HGF is located within the N-terminal 32-212 residues of HGF. HGF/NK1 will serve as a powerful tool for (i) generating neutralizing antibodies, (ii) in determining x-ray crystallographic and nuclear magnetic resonance structures, and (iii) for in vivo studies as an HGF antagonist.	GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech								BENNETT WF, 1991, J BIOL CHEM, V266, P5191; BOTTARO DP, 1991, SCIENCE, V254, P1382; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; BYEON IJL, 1991, EUR J BIOCHEM, V197, P155, DOI 10.1111/j.1432-1033.1991.tb15894.x; CANALS F, 1992, BIOCHEMISTRY-US, V31, P4493, DOI 10.1021/bi00133a016; CARTER P, 1992, BIO-TECHNOL, V10, P163, DOI 10.1038/nbt0292-163; CASTELLINO FJ, 1981, J BIOL CHEM, V256, P4778; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; CHANG CN, 1987, GENE, V55, P189, DOI 10.1016/0378-1119(87)90279-4; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CLEARY S, 1989, BIOCHEMISTRY-US, V28, P1884, DOI 10.1021/bi00430a068; CONTI P, 1992, SCAND J IMMUNOL, V36, P27, DOI 10.1111/j.1365-3083.1992.tb02937.x; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIRENZO MF, 1991, ONCOGENE, V6, P1997; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HENZEL WJ, 1987, J CHROMATOGR, V404, P41, DOI 10.1016/S0021-9673(01)86835-7; HENZEL WJ, 1990, ANAL BIOCHEM, V187, P228, DOI 10.1016/0003-2697(90)90448-I; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; LAX I, 1991, J BIOL CHEM, V266, P13828; LIU C, 1992, ONCOGENE, V7, P181; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MARK MR, 1992, J BIOL CHEM, V267, P26166; MATSUMOTO K, 1991, J GASTROEN HEPATOL, V6, P509, DOI 10.1111/j.1440-1746.1991.tb00897.x; MEHNHART N, 1991, BIOCHEMISTRY-US, V30, P1948; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MOTTA A, 1987, BIOCHEMISTRY-US, V26, P3827, DOI 10.1021/bi00387a014; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NALDINI L, 1991, ONCOGENE, V6, P501; OKADA S, 1992, ENDOCRINOLOGY, V130, P2284, DOI 10.1210/en.130.4.2284; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PETROS AM, 1988, ARCH BIOCHEM BIOPHYS, V264, P192, DOI 10.1016/0003-9861(88)90585-1; PICKEN RN, 1983, INFECT IMMUN, V42, P269, DOI 10.1128/IAI.42.1.269-275.1983; Sambrook J, 1989, MOL CLONING LABORATO; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHOLTISSEK S, 1987, NUCLEIC ACIDS RES, V15, P318; SHIMA N, 1991, BIOCHEM BIOPH RES CO, V180, P1151, DOI 10.1016/S0006-291X(05)81187-8; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; THORSEN S, 1981, BIOCHIM BIOPHYS ACTA, V668, P377, DOI 10.1016/0005-2795(81)90171-9; THORSEN S, 1975, BIOCHIM BIOPHYS ACTA, V393, P55, DOI 10.1016/0005-2795(75)90216-0; TREXLER M, 1983, P NATL ACAD SCI-BIOL, V80, P2457, DOI 10.1073/pnas.80.9.2457; TULINSKY A, 1991, THROMB HAEMOSTASIS, V66, P16; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANZONNEVELD AJ, 1986, J BIOL CHEM, V261, P14214; VERHEIJEN JH, 1986, EMBO J, V5, P3525, DOI 10.1002/j.1460-2075.1986.tb04678.x; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; YOSHIYAMA Y, 1991, BIOCHEM BIOPH RES CO, V175, P660, DOI 10.1016/0006-291X(91)91616-K; ZARNEGAR R, 1989, CANCER RES, V49, P3314; ZHIGAO L, 1992, PROTEIN EXPRESSION P, V3, P212; ZURAWSKI SM, 1992, EMBO J, V11, P3905, DOI 10.1002/j.1460-2075.1992.tb05483.x	58	90	111	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17145	17150						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349603				2022-12-27	WOS:A1993LQ98800042
J	MORIKAMI, A; EHARA, G; YUUKI, K; NAKAMURA, K				MORIKAMI, A; EHARA, G; YUUKI, K; NAKAMURA, K			MOLECULAR-CLONING AND CHARACTERIZATION OF CDNAS FOR THE GAMMA-SUBUNIT AND EPSILON-SUBUNIT OF MITOCHONDRIAL F1F0 ATP SYNTHASE FROM THE SWEET-POTATO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTARY-DNA SEQUENCE; NUCLEOTIDE-SEQUENCE; ALPHA-SUBUNIT; ANTIGENIC CHARACTERIZATION; BOVINE MITOCHONDRIA; DELTA-SUBUNIT; F1-ATPASE; F1ATPASE; PURIFICATION; GENE	Mitochondrial F1F0 ATP synthases purified from dicotyledonous plants contain six different subunits named alpha, beta, gamma, delta, delta', and epsilon. Our previous N-terminal amino acid sequence analyses indicated that the gamma- and epsilon-subunits of the sweet potato mitochondrial F1 correspond to the gamma- and epsilon-subunits of animal mitochondrial F1, respectively (Kimura, T., Nakamura, K., Kajiura, H., Hattori, H., Nelson, N., and Asahi, T. (1989) J. Biol. Chem. 264, 3183-3186). A cDNA clone for the gamma-subunit of the sweet potato mitochondrial F1 was identified by oligonucleotide hybridization selection of a cDNA library, and a cDNA clone for the epsilon-subunit was isolated by reverse polymerase chain reaction and hybridization selection of a cDNA library by the polymerase chain reaction product. The 1.4-kilobase long cDNA for the gamma-subunit contained a 978-base pair open reading frame coding for a precursor for the gamma-subunit. The mature gamma-subunit is composed of 281 amino acids, and its sequence showed significantly higher similarities with the gamma-subunit of animal mitochondrial F1 and bacterial F1 compared with the gamma-subunit of chloroplast CF1 from plants. The precursor for the gamma-subunit contained N-terminal presequence of 45 amino acid residues. By contrast, the 0.46-kilobase long cDNA for the epsilon-subunit contained a coding sequence of 207-base pairs for the mature epsilon-subunit of 69 amino acid residues that is preceded by an ATG codon suggesting that the epsilon-subunit is synthesized without the cleavable presequence for mitochondrial import. The amino acid sequence of the epsilon-subunit of sweet potato mitochondrial F1 showed similarities of 25 and 36% amino acid positional identity with the epsilon-subunits of mitochondrial F1 from yeast and bovine, respectively.	NAGOYA UNIV,SCH AGR,BIOCHEM LAB,CHIKUSA KU,NAGOYA 46401,JAPAN	Nagoya University								ARENDS H, 1984, EMBO J, V3, P377, DOI 10.1002/j.1460-2075.1984.tb01815.x; ARSELIN G, 1991, J BIOL CHEM, V266, P723; BOUTRY M, 1983, J BIOL CHEM, V258, P8524; BOUTRY M, 1985, EMBO J, V7, P649; BRAUN CJ, 1985, PLANT PHYSIOL, V79, P571, DOI 10.1104/pp.79.2.571; DUNN PPJ, 1985, BIOCHEM J, V225, P821, DOI 10.1042/bj2250821; DYER MR, 1989, BIOCHEMISTRY-US, V28, P3670, DOI 10.1021/bi00435a008; HACK E, 1983, EMBO J, V2, P1783, DOI 10.1002/j.1460-2075.1983.tb01658.x; HAMASUR B, 1992, EUR J BIOCHEM, V205, P409, DOI 10.1111/j.1432-1033.1992.tb16794.x; HORAK A, 1985, BIOCHIM BIOPHYS ACTA, V810, P310, DOI 10.1016/0005-2728(85)90215-4; HORAK A, 1990, FEBS LETT, V274, P9, DOI 10.1016/0014-5793(90)81316-G; INOHARA N, 1991, J BIOL CHEM, V266, P7333; ISSAC PG, 1985, CURR GENET, V10, P321; ITOH A, 1993, BIOSCI BIOTECH BIOCH, V57, P152, DOI 10.1271/bbb.57.152; IWASAKI Y, 1985, PLANT MOL BIOL, V5, P339, DOI 10.1007/BF00037554; IWASAKI Y, 1983, ARCH BIOCHEM BIOPHYS, V227, P164, DOI 10.1016/0003-9861(83)90359-4; KANAZAWA H, 1981, BIOCHEM BIOPH RES CO, V103, P604, DOI 10.1016/0006-291X(81)90494-0; KIMURA T, 1989, J BIOL CHEM, V264, P3183; KIMURA T, 1993, PLANT CELL PHYSIOL, V34, P345; KIMURA T, 1990, J BIOL CHEM, V265, P6079; KOBAYASHI K, 1986, FEBS LETT, V203, P144, DOI 10.1016/0014-5793(86)80731-1; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MASON JG, 1990, PLANT MOL BIOL, V14, P1007, DOI 10.1007/BF00019397; MORIKAMI A, 1987, J BIOCHEM-TOKYO, V101, P967, DOI 10.1093/oxfordjournals.jbchem.a121966; MORIKAMI A, 1992, J BIOL CHEM, V267, P72; NAKAGAWA T, 1990, EUR J BIOCHEM, V191, P557, DOI 10.1111/j.1432-1033.1990.tb19157.x; OUAZZANI C, 1991, PLANT SCI, V74, P53, DOI 10.1016/0168-9452(91)90255-7; RANDALL SK, 1985, PLANT PHYSIOL, V79, P957, DOI 10.1104/pp.79.4.957; SPITSBERG VL, 1985, PLANT PHYSIOL, V77, P339, DOI 10.1104/pp.77.2.339; TYBULEWICZ VLJ, 1984, J MOL BIOL, V179, P185, DOI 10.1016/0022-2836(84)90465-0; VINAS O, 1990, BIOCHEM J, V265, P321, DOI 10.1042/bj2650321; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WALKER JE, 1987, J MOL BIOL, V197, P89, DOI 10.1016/0022-2836(87)90611-5	33	16	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17205	17210						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349605				2022-12-27	WOS:A1993LQ98800051
J	BUSH, AI; MULTHAUP, G; MOIR, RD; WILLIAMSON, TG; SMALL, DH; RUMBLE, B; POLLWEIN, P; BEYREUTHER, K; MASTERS, CL				BUSH, AI; MULTHAUP, G; MOIR, RD; WILLIAMSON, TG; SMALL, DH; RUMBLE, B; POLLWEIN, P; BEYREUTHER, K; MASTERS, CL			A NOVEL ZINC(II) BINDING-SITE MODULATES THE FUNCTION OF THE BETA-A4 AMYLOID PROTEIN-PRECURSOR OF ALZHEIMERS-DISEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN PLATELETS; DOWNS-SYNDROME; CELL; PURIFICATION; BRAIN; METALLOTHIONEIN; EXPRESSION; DEMENTIA; NEURONS	Abnormalities of zinc metabolism occur in Alzheimer's disease (AD), a condition where pathological catabolism of the amyloid protein precursor (APP) causes cerebral betaA4 amyloidosis. An association between zinc and ApP metabolism was sought by studying the binding of Zn-65(2+) to APP. Zn-65(2+) bound in a rapid, saturable, and specific manner (K(D) = 764 nM). A novel zinc binding motif, strongly conserved between members of the APP family, was located between the cysteine-rich and negatively charged domains of the protein. Zinc increased binding of ''P to heparin and has been shown to potentiate the inhibition of coagulation factor XIa by an APP isoform containing a Kunitz-type inhibitory domain (Komiyama, Y., Murakami, T., Egawa, H., Okubo, S., Yasunaga, K., and Murata, K. (1992) Thromb. Res. 66,397-408) situated near the zinc binding region. Zinc is a factor that modulates the functional properties of the substrate for betaA4 amyloidogenesis.	UNIV MELBOURNE, DEPT PATHOL, PARKVILLE, VIC 3052, AUSTRALIA; MENTAL HLTH RES INST VICTORIA, NEUROPATHOL LAB, PARKVILLE, VIC 3052, AUSTRALIA; UNIV HEIDELBERG, CTR MOLEC BIOL, W-6900 HEIDELBERG, GERMANY	University of Melbourne; Ruprecht Karls University Heidelberg			Bush, Ashley I/A-1186-2007; Bush, Ashley/Y-2457-2019; Moir, Robert D./M-7612-2017	Bush, Ashley I/0000-0001-8259-9069; Bush, Ashley/0000-0001-8259-9069; Moir, Robert D./0000-0001-5431-3553				BAKER RJ, 1978, THROMB HAEMOSTASIS, V39, P360; BUSH AI, 1992, ANN NEUROL, V32, P57, DOI 10.1002/ana.410320110; BUSH AI, 1990, J BIOL CHEM, V265, P15977; CHANG CD, 1978, INT J PEPT PROT RES, V11, P246; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; CONSTANTINIDIS J, 1990, Encephale, V16, P231; CUNNINGHAM BC, 1991, SCIENCE, V253, P545, DOI 10.1126/science.1907025; DUNCAN MW, 1992, J NEUROSCI, V12, P1523, DOI 10.1523/jneurosci.12-04-01523.1992; EMDIN SO, 1980, DIABETOLOGIA, V19, P174, DOI 10.1007/BF00275265; FRANCESCHI C, 1988, J MENT DEFIC RES, V32, P169; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GUIROY DC, 1987, P NATL ACAD SCI USA, V84, P2073, DOI 10.1073/pnas.84.7.2073; HERSHEY CO, 1983, NEUROLOGY, V33, P1350, DOI 10.1212/WNL.33.10.1350; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOMIYAMA Y, 1992, THROMB RES, V66, P397, DOI 10.1016/0049-3848(92)90289-M; LUI E, 1990, J AM GERIATR SOC, V38, P633, DOI 10.1111/j.1532-5415.1990.tb01421.x; LUO LQ, 1990, J NEUROSCI, V10, P3849, DOI 10.1523/JNEUROSCI.10-12-03849.1990; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MOIR RD, 1992, J NEUROCHEM, V59, P1490, DOI 10.1111/j.1471-4159.1992.tb08465.x; OCTAVE JN, 1989, BRAIN RES, V486, P369, DOI 10.1016/0006-8993(89)90525-8; PARRISH RF, 1981, BIOCHEM J, V193, P407, DOI 10.1042/bj1930407; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; ROSEN DR, 1989, P NATL ACAD SCI USA, V86, P2478, DOI 10.1073/pnas.86.7.2478; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHUBERT W, 1991, BRAIN RES, V563, P184, DOI 10.1016/0006-8993(91)91532-6; SMALL DH, 1984, P NATL ACAD SCI-BIOL, V81, P959, DOI 10.1073/pnas.81.3.959; SNOW AD, 1987, LAB INVEST, V57, P687; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TRUDELLE Y, 1975, INT J PEPT PROT RES, V7, P403; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; VEBER DF, 1972, J AM CHEM SOC, V94, P5456, DOI 10.1021/ja00770a600; WASCO W, 1993, GENOMICS, V15, P237, DOI 10.1006/geno.1993.1047; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WASCO W, 1993, IN PRESS NATURE GENE; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WEIDEMANN A, 1989, CELL, V89, P57; WENSTRUP D, 1990, BRAIN RES, V533, P125, DOI 10.1016/0006-8993(90)91804-P	41	259	269	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16109	16112						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344894				2022-12-27	WOS:A1993LQ33600008
J	ITO, K; OKADA, Y; ISHIDA, K; MINAMIURA, N				ITO, K; OKADA, Y; ISHIDA, K; MINAMIURA, N			HUMAN SALIVARY ENDO-BETA-N-ACETYLGLUCOSAMINIDASE HS SPECIFIC FOR COMPLEX TYPE SUGAR CHAINS OF GLYCOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSAMINIDASE ACTIVITY; PAROTID ALPHA-AMYLASE; RAT-LIVER; FLAVOBACTERIUM-MENINGOSEPTICUM; SUBSTRATE SPECIFICITIES; DIPLOCOCCUS-PNEUMONIAE; CARBOHYDRATE MOIETIES; STREPTOMYCES-GRISEUS; CYTOSOLIC LOCATION; GLYCOSIDASE-F	The enzyme that catalyzed the conversion of human salivary alpha-amylase family A (HSA-A) to family B (HSA-B) was identified. It was partially purified from the precipitate obtained by centrifugation of human saliva at 105,000 x g for 60 min by solubilization with 3[(3-cholamidopropyl)dimethylammonio]-1-propane sulfonate and column chromatographies with Sephacryl S-300-HR and hydroxylapatite. The enzyme preparation was practically free from contaminating exoglycosidases and proteases. The enzyme cleaved the N,N'-diacetylchitobiose moiety of the sugar chain of HSA-A, as shown by the isolation of the protein moiety which contained 1 GlcNAc and 1 Fuc residue and the sugar chain (Gal)2(Fuc)1(GlcNAc)2(Man)3(GlcNAc). This enzyme also cleaved the N,N'-diacetylchitobiose moiety of the sugar chain of human transferrin tetraglycopeptide Asn-Tyr-Asn(GlcNAc)2(Man)3(GlcNAc)2-(Gal)2-Lys to yield equimolar amounts of peptide Asn-Tyr-Asn(GlcNAc)Lys and sugar chain (Gal)2(GlcNAc)2-(Man)3(GlcNAc). The enzyme was identified as an endo-beta-N-acetylglucosaminidase. The enzyme acted on HSA-A with desialylated and defucosylated outer chain moieties of the sugar chains at a similar rate as that of native HSA-A. The enzyme activity was reduced to 13 and 5% using HSA-A with the sugar chains whose outer chain moieties lacked Gal and GlcNAc, respectively, from the nonreducing end. The enzyme also acted on human transferrin, calf fetuin, and asparagine oligosaccharides of transferrin and fetuin. On the other hand, the enzyme did not act on ovalbumin, RNase B, Taka-amylase, yeast invertase, and ovalbumin asparagine oligosaccharides. These results indicate that human salivary endo-beta-N-acetylglucosaminidase is specific for complex type sugar chains and can release the sugar chains from native glycoproteins and glycopeptides regardless of the existence of a Fuc residue on the proximal GlcNAc of the N,N'-diacetylchitobiose core of their sugar chains. The source of the enzyme was epithelial cells peeling from the oral cavity epithelium into saliva. The enzyme was thought to be integrated on the surface of the epithelial cell membrane. This enzyme was named endo-beta-N-acetylglucosaminidase HS. Thus, these studies indicate that the properties of the enzyme are distinct from those of known endo-beta-N-acetylglucosaminidase and endo-beta-N-acetylglucosaminidase HS is a novel endo-beta-N-acetylglucosaminidase.			ITO, K (corresponding author), OSAKA CITY UNIV, FAC SCI, DEPT BIOL, 3-3-138 SUGIMOTO, SUMIYOSHI KU, OSAKA 558, JAPAN.							BAENZIGER JU, 1979, J BIOL CHEM, V254, P9795; BAUSSANT T, 1986, EUR J BIOCHEM, V159, P381, DOI 10.1111/j.1432-1033.1986.tb09879.x; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; Hodge JE, 1962, METHODS CARBOHYDRATE, DOI DOI 10.1371/JOURNAL.PONE.0065418; HOLMES EW, 1979, ANAL BIOCHEM, V93, P167, DOI 10.1016/S0003-2697(79)80060-3; HUANG CC, 1970, CARBOHYD RES, V13, P127, DOI 10.1016/S0008-6215(00)84902-2; IIJIMA Y, 1971, ARCH BIOCHEM BIOPHYS, V145, P50, DOI 10.1016/0003-9861(71)90008-7; ITO K, 1985, J BIOCHEM, V97, P1357, DOI 10.1093/oxfordjournals.jbchem.a135188; ITO K, 1992, J BIOCHEM, V112, P88, DOI 10.1093/oxfordjournals.jbchem.a123871; ITO S, 1975, ARCH BIOCHEM BIOPHYS, V171, P78, DOI 10.1016/0003-9861(75)90009-0; ITO S, 1975, BIOCHEM BIOPH RES CO, V63, P938, DOI 10.1016/0006-291X(75)90659-2; KADOWAKI S, 1991, J BIOCHEM-TOKYO, V110, P17, DOI 10.1093/oxfordjournals.jbchem.a123536; KADOWAKI S, 1990, AGR BIOL CHEM TOKYO, V54, P97, DOI 10.1080/00021369.1990.10869923; KAUFFMAN DL, 1970, ARCH BIOCHEM BIOPHYS, V137, P325, DOI 10.1016/0003-9861(70)90446-7; KELLER PJ, 1971, BIOCHEMISTRY-US, V10, P4867, DOI 10.1021/bi00802a006; KIYOHARA T, 1976, J BIOCHEM, V80, P9, DOI 10.1093/oxfordjournals.jbchem.a131263; KOIDE N, 1974, J BIOL CHEM, V249, P4897; KORNFELD R, 1976, ANNU REV BIOCHEM, V45, P217, DOI 10.1146/annurev.bi.45.070176.001245; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; LIANG CJ, 1980, J BIOCHEM-TOKYO, V88, P51; MAKINO M, 1966, BIOCHEM BIOPH RES CO, V24, P961, DOI 10.1016/0006-291X(66)90344-5; MURAMATS.T, 1971, J BIOL CHEM, V246, P5534; MURAMATSU T, 1978, J BIOCHEM, V83, P363, DOI 10.1093/oxfordjournals.jbchem.a131922; NEUMANN NP, 1967, BIOCHEMISTRY-US, V6, P468, DOI 10.1021/bi00854a015; PIERCE RJ, 1980, BIOCHEM J, V185, P261, DOI 10.1042/bj1850261; PIERCE RJ, 1979, BIOCHEM J, V180, P673, DOI 10.1042/bj1800673; PLUMMER T H JR, 1991, Glycobiology, V1, P257, DOI 10.1093/glycob/1.3.257; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; PORETZ RD, 1970, BIOCHEMISTRY-US, V9, P2890, DOI 10.1021/bi00816a021; TACHIBANA Y, 1982, ARCH BIOCHEM BIOPHYS, V214, P199, DOI 10.1016/0003-9861(82)90023-6; TACHIBANA Y, 1981, J BIOCHEM-TOKYO, V90, P1291, DOI 10.1093/oxfordjournals.jbchem.a133594; TAI T, 1977, J BIOL CHEM, V252, P6687; TAI T, 1975, J BIOL CHEM, V250, P8569; TAI T, 1977, BIOCHEM BIOPH RES CO, V78, P434, DOI 10.1016/0006-291X(77)91273-6; TAKAHASHI N, 1981, BIOCHIM BIOPHYS ACTA, V657, P457, DOI 10.1016/0005-2744(81)90331-4; TAKAHASHI N, 1977, BIOCHEM BIOPH RES CO, V76, P1194, DOI 10.1016/0006-291X(77)90982-2; TARENTINO AL, 1992, J BIOL CHEM, V267, P3868; TARENTINO AL, 1974, J BIOL CHEM, V249, P818; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TARENTINO AL, 1976, J BIOL CHEM, V251, P6537; TARENTINO AL, 1972, J BIOL CHEM, V247, P2629; TARENTINO AL, 1975, BIOCHEM BIOPH RES CO, V67, P455, DOI 10.1016/0006-291X(75)90337-X; TRIBLE RB, 1991, J BIOL CHEM, V266, P1646; UCHIDA Y, 1974, BIOCHIM BIOPHYS ACTA, V350, P425, DOI 10.1016/0005-2744(74)90517-8; WRIGHT DE, 1964, ARCH ORAL BIOL, V9, P321, DOI 10.1016/0003-9969(64)90064-0; YAMAGUCHI H, 1971, J BIOCHEM, V70, P587, DOI 10.1093/oxfordjournals.jbchem.a129675; YAMAMOTO M, 1991, ARCH BIOCHEM BIOPHYS, V289, P76, DOI 10.1016/0003-9861(91)90444-N; YAMASHITA K, 1980, J BIOL CHEM, V255, P5635; YAMASHITA K, 1978, J BIOL CHEM, V253, P3862; YANG FM, 1984, P NATL ACAD SCI-BIOL, V81, P2752, DOI 10.1073/pnas.81.9.2752	53	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					16074	16081						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340428				2022-12-27	WOS:A1993LN30500104
J	SUN, Q; HAMPSON, RK; ROTTMAN, FM				SUN, Q; HAMPSON, RK; ROTTMAN, FM			IN-VITRO ANALYSIS OF BOVINE GROWTH-HORMONE PREMESSENGER RNA ALTERNATIVE SPLICING - INVOLVEMENT OF EXON SEQUENCES AND TRANS-ACTING FACTOR(S)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; SITE SELECTION; BINDING PROTEINS; INFLUENZA-VIRUS; EXPRESSION; COMPLEXES; GENE; REGULATORS; FACTOR-SF2; PRECURSORS	Bovine growth hormone (bGH) pre-mRNA is alternatively spliced, resulting in retention of the last intron (intron D) in a fraction of the cytosolic bGH mRNA. To study the mechanism of this alternative splicing event, we examined the splicing of bGH pre-mRNA in vitro. The splicing of bGH intron D in vitro required a 115-base pair segment of exon 5, reflecting the positive influence of exon sequences observed in transfected cells. No detectable spliceosome complex formation was observed using bGH pre-mRNA containing the 115-base pair deletion in exon 5. The in vitro splicing of the wild type bGH pre-mRNA was inhibited by the addition of RNA containing the 115-nucleotide exon sequence, but not by nonspecific RNAs. UV irradiation of the in vitro splicing reaction resulted in specific cross-linking of a 35-kDa protein(s) to the 115-nucleotide bGH exon sequence. These results suggest that terminal exon sequences are required at an early step of spliceosome complex formation and are consistent with a mechanism in which saturable, trans-acting factor(s) bind to these exon sequences to activate spliceosome complex formation and splicing of bGH intron D.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, CLEVELAND, OH 44106 USA	Case Western Reserve University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032770] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-32770] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRIS CH, 1989, MOL CELL BIOL, V9, P259, DOI 10.1128/MCB.9.1.259; ALONSOCAPLEN FV, 1991, MOL CELL BIOL, V11, P1092, DOI 10.1128/MCB.11.2.1092; BENNETT M, 1992, MOL CELL BIOL, V12, P3165, DOI 10.1128/MCB.12.7.3165; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; COOKE NE, 1988, J BIOL CHEM, V263, P9001; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; ESTES PA, 1992, J BIOL CHEM, V267, P14902; FREYER GA, 1987, J BIOL CHEM, V262, P4267; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; FURDON PJ, 1988, MOL CELL BIOL, V8, P860, DOI 10.1128/MCB.8.2.860; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GORDON DF, 1983, MOL CELL ENDOCRINOL, V33, P81, DOI 10.1016/0303-7207(83)90058-8; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HAMPSON RK, 1987, P NATL ACAD SCI USA, V84, P2673, DOI 10.1073/pnas.84.9.2673; KONARSKA MM, 1989, METHOD ENZYMOL, V180, P442; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; LAMB RA, 1980, CELL, V21, P475, DOI 10.1016/0092-8674(80)90484-5; LUHRMANN R, 1987, STRUCTURE FUNCTION M, P71; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; McKeown M, 1990, Genet Eng (N Y), V12, P139; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; NIWA M, 1991, GENE DEV, V5, P2086, DOI 10.1101/gad.5.11.2086; OHNO M, 1987, P NATL ACAD SCI USA, V84, P5187, DOI 10.1073/pnas.84.15.5187; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; WOYCHIK RP, 1984, P NATL ACAD SCI-BIOL, V81, P3944, DOI 10.1073/pnas.81.13.3944; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769	36	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15659	15666						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340391				2022-12-27	WOS:A1993LN30500052
J	HORIGOME, K; PRYOR, JC; BULLOCK, ED; JOHNSON, EM				HORIGOME, K; PRYOR, JC; BULLOCK, ED; JOHNSON, EM			MEDIATOR RELEASE FROM MAST-CELLS BY NERVE GROWTH-FACTOR - NEUROTROPHIN SPECIFICITY AND RECEPTOR MEDIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PROTEIN-KINASE; TRK PROTOONCOGENE PRODUCT; BIOCHEMICAL-CHARACTERIZATION; BIOLOGICAL-ACTIVITY; MOLECULAR-CLONING; MONONUCLEAR-CELLS; FACTOR FAMILY; NGF RECEPTOR; PC12 CELLS; RAT	Nerve growth factor causes mediator release from rat peritoneal mast cells in the presence of lysophosphatidylserine. We have investigated the neurotrophin and receptor specificity involved in this response. Nerve growth factor produced a dose-dependent release of [C-14]serotonin in the presence of lysophosphatidylserine with an EC50 of approximately 1 nM. Incubation with brain-derived neurotrophic factor and neurotrophin-3 did not produce a response. Northern blot analysis with probes for low affinity nerve growth factor receptor (p75), trkA, trkB, and trkC demonstrated a detectable signal for trkA only. Western blots of trkA immunoprecipitates from mast cell culture lysates, probed with anti-phosphotyrosine antibodies, demonstrated expression of functional TrkA protein. To determine whether p75, trkB, or trkC mRNA was present in amounts below the limit of detection for Northern analysis, a sensitive reverse transcriptase polymerase chain reaction protocol was used; again rat peritoneal mast cells demonstrated only trkA. The predominant form of trkA message expressed in rat peritoneal mast cells was smaller than the neuronal form. An 18-nucleotide exon (coding for 6 amino acids in the extracellular domain) in the neuronal message was not found in the predominant mast cell trkA message. PC12 cells, a rat pheochromocytoma cell line, and dissociated rat sympathetic neurons showed both trkA and p75, but not trkB or trkC. Anterior pituitary expressed both trkB and trkC, but not trkA. To confirm the lack of expression of p75 on mast cells, I-125-nerve growth factor was chemically cross-linked to mast cells or PC12 cells and then immunoprecipitated with a monoclonal antibody specific for p75, 192-IgG; no p75 was detected. Thus, mediator release from rat peritoneal mast cells by nerve growth factor was specific and not a general property of neurotrophins, and the response was modulated through the trkA proto-oncogene. To our knowledge, this is the first description of a bone marrow-derived cell type that expresses trkA at both the mRNA and protein levels. These data provide further evidence that p75 is not necessary for nerve growth factor signal transduction.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,660 S EUCLID AVE,BOX 8103,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT NEUROL SURG,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024679] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24679] Funding Source: Medline; DS NIH HHS [DS 5 T32 NF07205-10] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); DS NIH HHS		ALOE L, 1977, BRAIN RES, V133, P358, DOI 10.1016/0006-8993(77)90772-7; ALOE L, 1988, J NEUROIMMUNOL, V18, P1, DOI 10.1016/0165-5728(88)90129-4; BARKER PA, 1992, 4011 SOC NEUR WASH, V18, P948; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BRUNI A, 1982, FEBS LETT, V138, P190, DOI 10.1016/0014-5793(82)80438-9; CARROLL SL, 1992, NEURON, V9, P779, DOI 10.1016/0896-6273(92)90040-K; CATTANEO A, 1986, MOL ASPECTS NEUROBIO, P3136; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; GEE AP, 1983, P NATL ACAD SCI-BIOL, V80, P7215, DOI 10.1073/pnas.80.23.7215; HALBOOK F, 1991, NEURON, V6, P845; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOSANG M, 1985, J BIOL CHEM, V260, P655; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON MI, 1983, METHOD ENZYMOL, V103, P334; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P229; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MEAKIN SO, 1992, P NATL ACAD SCI USA, V89, P2374, DOI 10.1073/pnas.89.6.2374; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MORGAN B, 1989, J NEUROSCI RES, V23, P41, DOI 10.1002/jnr.490230106; MORRISON DC, 1974, J IMMUNOL, V12, P573; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; OTTEN U, 1985, EUR J PHARMACOL, V106, P199; PRYOR JC, 1992, 40117 SOC NEUR WASH, V18, P950; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; SULLIVAN TJ, 1975, J IMMUNOL, V114, P1473; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P1950, DOI 10.1073/pnas.83.6.1950; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; THORPE LW, 1987, J NEUROSCI RES, V17, P128, DOI 10.1002/jnr.490170206; THORPE LW, 1987, J NEUROSCI RES, V18, P134, DOI 10.1002/jnr.490180120; TOMIOKA M, 1988, J ALLERGY CLIN IMMUN, V82, P599, DOI 10.1016/0091-6749(88)90971-2; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; YAN Q, 1987, DEV BIOL, V121, P139, DOI 10.1016/0012-1606(87)90147-3; YAN Q, 1991, CLIN SCI, V80, P565, DOI 10.1042/cs0800565; YAN Q, 1990, J NEUROCYTOL, V19, P302, DOI 10.1007/BF01188400	54	205	214	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14881	14887						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325866				2022-12-27	WOS:A1993LL75900054
J	KEYOMARSI, K; SAMET, J; MOLNAR, G; PARDEE, AB				KEYOMARSI, K; SAMET, J; MOLNAR, G; PARDEE, AB			THE THYMIDYLATE SYNTHASE INHIBITOR, ICI-D1694, OVERCOMES TRANSLATIONAL DETAINMENT OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-10-PROPARGYL-5,8-DIDEAZAFOLIC ACID; MESSENGER-RNA; COLON-CARCINOMA; BREAST-CANCER; CELL-LINE; CB 3717; ANTIFOLATE; TUMOR; SYNTHETASE; INVIVO	We have investigated the mechanism of inactivation of thymidylate synthase (TS) by ICI D1694 (a folate-based quinazoline) in normal versus tumor-derived human mammary epithelial cells. ICI D1694 is a very potent cytotoxic agent against these cells with IC50 values of 1-2 nM. Its growth inhibitory activity was completely reversed by the addition of thymidine, confirming that TS is its sole target in these cells. Remarkably, TS protein levels rose by 10-40-fold following treatment with ICI D1694, depending on cell type, while TS mRNA levels remained constant. The mechanism appears to be a release of ''detainment'' of TS translation, since addition of cycloheximide, a translational inhibitor, blocked the TS protein levels from rising. But coadministration of 5,6-dichlorobenzimidazole, a transcriptional inhibitor, did not overcome protein accumulation, nor did thymidine which overcomes growth inhibition by ICI D1694. 5,10-Methylenetetrahydrofolate (via folinic acid), however, did block the effects of ICI D1694, showing that the drug has its effect upon both detainment and enzyme inhibition by binding to the folate substrate site of TS. In addition, in the presence of ICI D1694, TS protein was no longer cell cycle-regulated as evident by its constitutive expression in synchronized cells. This accumulation and constitutive expression of TS induced by D1694 should increase drug resistance under a clinical setting. We suggest that an ideal inhibitor of TS would target the TS allosteric site that binds to TS mRNA, responsible for specific translation of the protein, thereby complimenting inactivation of the enzyme.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	KEYOMARSI, K (corresponding author), HARVARD UNIV, SCH MED,DANA FARBER CANC INST, DIV CELL GROWTH & REGULAT,44 BINNEY ST, RM D810B, BOSTON, MA 02115 USA.		Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849	NCI NIH HHS [CA08949-02, CA 22427] Funding Source: Medline; NCRR NIH HHS [S07RR05526-29] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA008949, P01CA022427] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005526] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALISON DL, 1985, CANCER CHEMOTH PHARM, V14, P265; ARBUCK SG, 1989, CANCER, V63, P1036, DOI 10.1002/1097-0142(19890315)63:6+<1036::AID-CNCR2820631309>3.0.CO;2-K; BAND V, 1990, CANCER RES, V50, P7351; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALVERT AH, 1986, J CLIN ONCOL, V4, P1245, DOI 10.1200/JCO.1986.4.8.1245; CANTWELL BMJ, 1988, EUR J CANCER CLIN ON, V24, P733, DOI 10.1016/0277-5379(88)90307-0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU E, 1990, CANCER RES, V50, P5834; CHU E, 1993, P NATL ACAD SCI USA, V90, P517, DOI 10.1073/pnas.90.2.517; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; CISNEROS R J, 1988, Drugs of the Future, V13, P859; CLARKE S, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P406; CRISSMAN HA, 1974, SCIENCE, V184, P1297, DOI 10.1126/science.184.4143.1297; DAVISSON VJ, 1989, J BIOL CHEM, V264, P9145; EINHORN LH, 1989, J CLIN ONCOL, V7, P1377, DOI 10.1200/JCO.1989.7.10.1377; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRY DW, 1978, ANAL BIOCHEM, V90, P809, DOI 10.1016/0003-2697(78)90172-0; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; HARRAP KR, 1989, ADV ENZYME REGUL, V29, P161, DOI 10.1016/0065-2571(89)90099-X; HEIDELBERGER C, 1983, ADV ENZYMOL RAMB, V54, P57; JACKMAN A L, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P342; JACKMAN AL, 1991, ADV ENZYME REGUL, V31, P13, DOI 10.1016/0065-2571(91)90006-8; JACKMAN AL, 1990, CANCER RES, V50, P5212; JACKMAN AL, 1991, CANCER RES, V51, P5579; JONES TR, 1981, EUR J CANCER, V17, P11, DOI 10.1016/0014-2964(81)90206-1; KAMB A, 1992, BIOCHEMISTRY-US, V31, P9883, DOI 10.1021/bi00156a005; KAMB A, 1992, BIOCHEMISTRY-US, V31, P12876, DOI 10.1021/bi00166a024; KEYOMARSI K, 1988, J BIOL CHEM, V263, P14402; KEYOMARSI K, 1990, J BIOL CHEM, V265, P19163; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KEYOMARSI K, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P330; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MATTHEWS DA, 1990, J MOL BIOL, V214, P937, DOI 10.1016/0022-2836(90)90347-O; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; MONTFORT WR, 1990, BIOCHEMISTRY-US, V29, P6964, DOI 10.1021/bi00482a004; NEWELL DR, 1982, P AM ASSOC CANC RES, V23, P181; PINTER K, 1988, DNA-J MOLEC CELL BIO, V7, P235, DOI 10.1089/dna.1988.7.235; POON MA, 1989, J CLIN ONCOL, V7, P1407, DOI 10.1200/JCO.1989.7.10.1407; REDDY GPV, 1980, P NATL ACAD SCI-BIOL, V77, P3312; ROBERTS D, 1966, BIOCHEMISTRY-US, V5, P3546, DOI 10.1021/bi00875a022; RODE W, 1980, J BIOL CHEM, V255, P1305; SPEARS CP, 1982, CANCER RES, V42, P450; STEPHENS T C, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P342; TOMICH PK, 1974, J BIOL CHEM, V249, P7613; VANDERWILT CL, 1992, CANCER RES, V52, P4922; WASHTIEN WL, 1984, MOL PHARMACOL, V25, P171; YIN MB, 1992, CANCER RES, V52, P5900	51	88	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15142	15149						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325888				2022-12-27	WOS:A1993LL75900087
J	HOU, XY; JOHNSON, AC; ROSNER, MR				HOU, XY; JOHNSON, AC; ROSNER, MR			IDENTIFICATION OF AN EPIDERMAL GROWTH-FACTOR RECEPTOR TRANSCRIPTIONAL REPRESSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-BINDING-SITES; DNA-BINDING; STIMULATES TRANSCRIPTION; ENHANCED EXPRESSION; GENE AMPLIFICATION; CARCINOMA-CELLS; PROMOTER; PURIFICATION; ONCOGENE; SEQUENCE	Identification of the factors controlling transcription of the epidermal growth factor (EGF) receptor gene is essential for understanding regulation of the EGF receptor and its overexpression in human carcinomas. In this study, we have identified a 60-base pair (bp) region (-919 to -860) relative to the AUG translation initiation codon in the EGF receptor 5' promoter that functions as a cis-acting EGF receptor transcriptional repressor (ETR). This fragment also acted as a repressor when linked to the thymidine kinase promoter. Gel mobility shift assays demonstrated that trans-acting factors bind to 60- and 19 bp fragments. Competition and chloramphenicol acetyltransferase assays with oligonucleotides containing mutations and deletions in this region indicate that the TTCGAGGG sequence (-877 to -870) is required for binding as well as repressor activity. While the ETR-protected region contains consensus sequences for the E2F binding site, no competition was observed with an E2F binding fragment. However, DNA-protein blot analysis indicates that both the 60- and 19-bp fragments specifically bind a 128-kDa polypeptide in extracts from HeLa or A431 human epidermoid carcinoma cells. These results suggest that a novel transcription factor(s) negatively regulates EGF receptor gene expression through binding to the ETR element.	UNIV CHICAGO, BEN MAY INST, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; NATL CANC INST, MOLEC BIOL LAB, BETHESDA, MD 20892 USA	University of Chicago; University of Chicago; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NCI NIH HHS [CA 35541] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035541] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; Cowley GO, 1984, CANCER CELL, V1, P5; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HUDSON LG, 1990, P NATL ACAD SCI USA, V87, P7536, DOI 10.1073/pnas.87.19.7536; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KAGEYAMA R, 1988, P NATL ACAD SCI USA, V85, P5016, DOI 10.1073/pnas.85.14.5016; KAGEYAMA R, 1988, J BIOL CHEM, V263, P6329; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; LAIMINS LA, 1982, P NATL ACAD SCI-BIOL, V79, P6453, DOI 10.1073/pnas.79.21.6453; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LIN CR, 1984, SCIENCE, V224, P843, DOI 10.1126/science.6326261; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAEKAWA T, 1989, J BIOL CHEM, V264, P5488; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; MERLINO GT, 1985, J CLIN INVEST, V75, P1077, DOI 10.1172/JCI111770; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; ROBIDOUX S, 1992, MOL CELL BIOL, V12, P3796, DOI 10.1128/MCB.12.9.3796; ROY RJ, 1991, BIOTECHNIQUES, V11, P770; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; XU YH, 1984, P NATL ACAD SCI-BIOL, V81, P7308, DOI 10.1073/pnas.81.23.7308; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; YAMAMOTO T, 1986, CANCER RES, V46, P414; YAN DH, 1991, MOL CELL BIOL, V11, P1875, DOI 10.1128/MCB.11.4.1875; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; ZHAO XY, 1992, MOL CELL BIOL, V12, P2739, DOI 10.1128/MCB.12.6.2739	45	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4307	4312						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307997				2022-12-27	WOS:A1994MW98900064
J	TOUGU, K; PENG, H; MARIANS, KJ				TOUGU, K; PENG, H; MARIANS, KJ			IDENTIFICATION OF A DOMAIN OF ESCHERICHIA-COLI PRIMASE REQUIRED FOR FUNCTIONAL INTERACTION WITH THE DNAB HELICASE AT THE REPLICATION FORK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COORDINATED LEADING-STRAND; OKAZAKI FRAGMENT SIZE; PRIMER SYNTHESIS; PROTEIN ACTION; GENE PRODUCT; PBR322 DNA; T4-61-PROTEIN; T4-41-PROTEIN; MECHANISM; PRIMOSOME	Primase plays a key role in governing the sequence of events required on the lagging strand during a cycle of Okazaki fragment synthesis. To begin to probe the protein-protein interactions necessary for primase function at the replication fork, we have used limited trypsinolysis to separate primase into two functional domains, an N-terminal domain of 49 kDa (p49) and a carboxyl-terminal domain of 16 kDa (p16). p49 retained primase activity in replication assays that utilized bacteriophage M13 DNA carrying the bacteriophage G4 origin of DNA replication as the template, but was inactive during general priming or the conversion of phi X174 single-stranded circular (ss(c))-DNA to the replicative form (RF) and could not support lagging strand DNA synthesis at replication forks reconstituted with the phi X-type primosomal proteins and the DNA polymerase m holoenzyme. On the other hand, p16 inhibited those replication reactions that included the replication fork helicase, DnaB (general priming, phi X174 ss(c) --> RF, and at the replication fork), but had no effect on those that did not (M13Gori ss(c) --> RF). These results demonstrate that p49 defines a domain of primase required for catalytic activity, that p16 defines a domain of primase required for functional interaction with DnaB, and that it is a protein-protein interaction with DnaB that attracts primase to the replication fork.	CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Cornell University	TOUGU, K (corresponding author), MEM SLOAN KETTERING CANC CTR,MOLEC BIOL PROGRAM,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034557, R01GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1979, P NATL ACAD SCI USA, V76, P4308, DOI 10.1073/pnas.76.9.4308; ARAI K, 1981, J BIOL CHEM, V256, P5253; ARAI KI, 1981, P NATL ACAD SCI-BIOL, V78, P707, DOI 10.1073/pnas.78.2.707; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P398; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; GROMPE M, 1991, J BACTERIOL, V173, P1268, DOI 10.1128/jb.173.3.1268-1278.1991; HINTON DM, 1987, J BIOL CHEM, V262, P10873; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; KAGUNI J, 1979, J MOL BIOL, V135, P863, DOI 10.1016/0022-2836(79)90516-3; Kornberg A., 1992, DNA REPLICATION, P182; LARK KG, 1972, NATURE-NEW BIOL, V240, P237, DOI 10.1038/newbio240237a0; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE MS, 1989, J BIOL CHEM, V264, P14531; LIU CC, 1981, J BIOL CHEM, V256, P2821; MARIANS KJ, 1984, CRC CR REV BIOCH MOL, V17, P153, DOI 10.3109/10409238409113604; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MOK M, 1987, J BIOL CHEM, V262, P16644; MURAKAMI Y, 1985, J BACTERIOL, V162, P830, DOI 10.1128/JB.162.2.830-832.1985; NORRIS V, 1986, J BACTERIOL, V168, P494, DOI 10.1128/jb.168.2.494-504.1986; NOSSAL NG, 1987, J BIOL CHEM, V262, P10879; ROWEN L, 1978, J BIOL CHEM, V253, P758; SCHERZINGER E, 1977, EUR J BIOCHEM, V72, P543, DOI 10.1111/j.1432-1033.1977.tb11278.x; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; SUAN W, 1993, J BIOL CHEM, V268, P8026; SWART JR, 1993, J BIOL CHEM, V268, P12970; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WICKNER S, 1973, P NATL ACAD SCI USA, V70, P1613, DOI 10.1073/pnas.70.5.1613; WRIGHT M, 1973, P NATL ACAD SCI USA, V70, P3120, DOI 10.1073/pnas.70.11.3120; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4074; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	36	131	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4675	4682						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308039				2022-12-27	WOS:A1994MW98900114
J	WANG, S; VIK, SB				WANG, S; VIK, SB			SINGLE AMINO-ACID INSERTIONS PROBE THE ALPHA-SUBUNIT OF THE ESCHERICHIA-COLI F(1)F(0)-ATP SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F1F0 ATP SYNTHASE; H+-ATPASE; A-SUBUNIT; PROTON TRANSLOCATION; TRANSMEMBRANE TOPOLOGY; PROTEOLIPID SUBUNIT; MEMBRANE-PROTEINS; MUTATIONS; F0F1-ATPASE; F1F0-ATPASE	Single amino acid insertions of alanine or aspartate have been introduced into the a subunit of the F1F0-ATP synthase at seven different sites, after residues 187, 193, 198, 202, 212, 217, and 222. These sites span a highly conserved region of the a subunit, parts of which are thought to be located in transmembrane spanning regions. Alanine insertions have little or no effect on function after positions 187, 193, 198, and 202, indicating that the region spanned by these residues is not essential for function. Alanine insertions after residues 212 and 217 disrupt ATP synthase function without grossly affecting the assembly of the enzyme, while the alanine insertion after residue 222 disrupts both ATP synthase function and assembly. All of the aspartate insertions are deleterious to ATP synthase function, except after residue 198. At the other six sites, aspartate insertions prevent growth on succinate minimal medium, indicating an inability to synthesize ATP. Aspartate insertions after residues 187 and 193 result in a subunits that do not fractionate with membranes, as indicated by immunoblotting. These results support a model of the a subunit in which residues 187-193 and residues 212-222 are part of distinct transmembrane spans, separated by a short extramembrane loop. The results are consistent with an important interaction between residues 212-222 of the a subunit and b or c subunits. General aspects of ''insertion scanning mutagenesis'' are also discussed.	SO METHODIST UNIV,DEPT BIOL SCI,DALLAS,TX 75275	Southern Methodist University				Vik, Steven/0000-0002-5285-015X	NIGMS NIH HHS [R01 GM040508, GM40508] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040508] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BJORBAEK C, 1990, FEBS LETT, V260, P31, DOI 10.1016/0014-5793(90)80058-Q; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAIN BD, 1986, J BIOL CHEM, V261, P43; CAIN BD, 1989, J BIOL CHEM, V264, P3292; CARUTHERS MH, 1987, METHOD ENZYMOL, V154, P287; COX GB, 1986, BIOCHIM BIOPHYS ACTA, V849, P62, DOI 10.1016/0005-2728(86)90096-4; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; HARTZOG PE, 1993, J BACTERIOL, V175, P1337, DOI 10.1128/JB.175.5.1337-1343.1993; HENNIG J, 1986, MOL GEN GENET, V8, P543; HERMOLIN J, 1989, J BIOL CHEM, V264, P3896; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; HOPPE J, 1983, EMBO J, V2, P105, DOI 10.1002/j.1460-2075.1983.tb01389.x; HOPPE J, 1984, BIOCHIM BIOPHYS ACTA, V768, P1, DOI 10.1016/0304-4173(84)90005-3; HOWITT SM, 1990, BIOCHIM BIOPHYS ACTA, V1015, P264, DOI 10.1016/0005-2728(90)90030-8; HUMBERT R, 1983, J BACTERIOL, V153, P416, DOI 10.1128/JB.153.1.416-422.1983; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS MJ, 1990, J BIOL CHEM, V265, P10541; LIGHTOWLERS RN, 1988, BIOCHIM BIOPHYS ACTA, V933, P241, DOI 10.1016/0005-2728(88)90031-X; LIGHTOWLERS RN, 1987, BIOCHIM BIOPHYS ACTA, V894, P399, DOI 10.1016/0005-2728(87)90118-6; MARTI T, 1992, P NATL ACAD SCI USA, V89, P1219, DOI 10.1073/pnas.89.4.1219; Miller J. H., 1972, EXPT MOL GENETICS, P431; NIEUWENHUIS FJ, 1973, BIOCHIM BIOPHYS ACTA, V325, P62, DOI 10.1016/0005-2728(73)90151-5; PAULE CR, 1989, ARCH BIOCHEM BIOPHYS, V274, P270, DOI 10.1016/0003-9861(89)90439-6; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; SCHNEIDER E, 1987, MICROBIOL REV, V51, P477, DOI 10.1128/MMBR.51.4.477-497.1987; SEBALD W, 1980, P NATL ACAD SCI-BIOL, V77, P785, DOI 10.1073/pnas.77.2.785; SENIOR AE, 1983, BIOCHIM BIOPHYS ACTA, V726, P81, DOI 10.1016/0304-4173(83)90001-0; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SONDEK J, 1990, PROTEINS, V7, P299, DOI 10.1002/prot.340070402; VIK SB, 1992, BIOCHIM BIOPHYS ACTA, V1140, P199, DOI 10.1016/0005-2728(92)90009-Q; VIK SB, 1988, J BIOL CHEM, V263, P6599; VIK SB, 1990, ARCH BIOCHEM BIOPHYS, V282, P125, DOI 10.1016/0003-9861(90)90095-G; VIK SB, 1991, J BACTERIOL, V173, P4544, DOI 10.1128/JB.173.14.4544-4548.1991; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; ZAGURSKY RJ, 1985, GENE ANAL TECH, V2, P89, DOI 10.1016/0735-0651(85)90011-1	38	16	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3095	3099						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300644				2022-12-27	WOS:A1994MV43200105
J	DHARMESH, SM; SKELTON, TP; BAENZIGER, JU				DHARMESH, SM; SKELTON, TP; BAENZIGER, JU			COORDINATE AND RESTRICTED EXPRESSION OF THE PROXAAARG/LYS-SPECIFIC GALNAC-TRANSFERASE AND THE GALNAC-BETA-1,4GLCNAC-BETA-1,2MAN-ALPHA-4-SULFOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; N-ACETYLGALACTOSAMINE-TRANSFERASE; PITUITARY GLYCOPROTEIN HORMONES; INDIVIDUAL GLYCOSYLATION SITES; HAMSTER OVARY CELLS; SIALYLATED OLIGOSACCHARIDES; LUTROPIN OLIGOSACCHARIDES; CARBOHYDRATE STRUCTURES; BOVINE LUTROPIN; TISSUE FACTOR	Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAcbeta1,4GlcNAcbeta1,2Manalpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor. The peptide motif ProXaaArg/Lys (PXR/K), which is recognized by a PXR/K-specific GalNAc-transferase, is present in each of these glycoproteins 6-9 residues NH2-terminal to an Asn glycosylation site. Both the PXR/K-specific GalNAc-transferase and a GalNAcbeta1,4GlcNAcbeta1,2Manalpha (GGnM)-4-sulfotransferase are required for synthesis of the S4GGnM sequence. Glycoproteins which do not contain the PXR/K motif but bear Asn-linked oligosaccharides terminating with GGnM or sialic acidalpha2,3/6GGnM have also been described, suggesting a distinct GalNAc-transferase may be responsible for their synthesis. We have examined a number of tissues and cultured cell lines for the transfer of sulfate to the trisaccharide acceptor GGnM and transfer of GalNAc to oligosaccharide acceptors on protein which do, human chorionic gonadotropin (hCG), and do not, transferrin (Trf), contain the PXR/K motif. The PXR/K-specific GalNAc-transferase and the GGnM-4-sulfotransferase are expressed in salivary gland, pituitary, lacrimal gland, kidney, and brain, and in the cell lines AtT-20, 293, SHSY5Y, and alphaT3. In contrast Bowes, EL-4, and B16L6 cell extracts transferred GalNAc to oligosaccharides acceptors on Trf but not on hCG. A number of tissues and cell lines displayed transfer of GalNAc to both hCG and to Trf suggesting that two distinct GalNAc-transferases were present. The GGnM-4-sulfotransferase was expressed in tissues and cell lines which expressed the PXR/K-specific GalNAc-transferase but not in cell lines expressing exclusively the Trf-specific GalNAc-transferase. Thus, the PXR/K-specific GalNAc-transferase and the GGnM-4-sulfotransferase are coordinately expressed in a number of tissues other than pituitary. The Trf-specific GalNAc-transferase may account for the presence of beta1,4-linked GalNAc on glycoproteins which do not contain the PXR/K motif.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Baenziger, Jacques U/E-9430-2012		NIDDK NIH HHS [R01-DK41738] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P1312; CHAN A L, 1991, Glycobiology, V1, P173, DOI 10.1093/glycob/1.2.173; COLBURN P, 1988, IN VITRO CELL DEV B, V24, P1133; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; GREEN ED, 1985, P NATL ACAD SCI USA, V82, P7850, DOI 10.1073/pnas.82.23.7850; GREEN ED, 1984, P NATL ACAD SCI-BIOL, V81, P5320, DOI 10.1073/pnas.81.17.5320; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; HIYAMA J, 1992, GLYCOBIOLOGY, V2, P401, DOI 10.1093/glycob/2.5.401; HOOPER LV, 1993, IN PRESS ANAL BIOCH; MENGELING BJ, 1991, ANAL BIOCHEM, V199, P286, DOI 10.1016/0003-2697(91)90103-Z; NEMANSKY M, 1992, BIOCHEM J, V287, P311, DOI 10.1042/bj2870311; NIMTZ M, 1990, FEBS LETT, V271, P14, DOI 10.1016/0014-5793(90)80361-L; PALCIC M M, 1991, Glycobiology, V1, P205, DOI 10.1093/glycob/1.2.205; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; SKELTON TP, 1991, J BIOL CHEM, V266, P17142; SKELTON TP, 1992, J BIOL CHEM, V267, P12998; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SMITH PL, 1992, J BIOL CHEM, V267, P19140; SMITH PL, 1993, J BIOL CHEM, V268, P795; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SMITH PL, 1990, P NATL ACAD SCI USA, V87, P7275, DOI 10.1073/pnas.87.18.7275; SPELLMAN MW, 1989, J BIOL CHEM, V264, P14100; TANAKA N, 1992, J BIOCHEM-TOKYO, V112, P68, DOI 10.1093/oxfordjournals.jbchem.a123867; TOMIYA N, 1993, J BIOL CHEM, V268, P113; UJIHARA M, 1992, GLYCOBIOLOGY, V2, P225, DOI 10.1093/glycob/2.3.225; WARNCRAMER BJ, 1991, THROMB RES, V61, P515, DOI 10.1016/0049-3848(91)90159-T; WEISSHAAR G, 1991, EUR J BIOCHEM, V195, P257, DOI 10.1111/j.1432-1033.1991.tb15702.x; WEISSHAAR G, 1990, EUR J BIOCHEM, V192, P741, DOI 10.1111/j.1432-1033.1990.tb19285.x	32	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17096	17102						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349598				2022-12-27	WOS:A1993LQ98800034
J	APT, KE; HOFFMAN, NE; GROSSMAN, AR				APT, KE; HOFFMAN, NE; GROSSMAN, AR			THE GAMMA-SUBUNIT OF R-PHYCOERYTHRIN AND ITS POSSIBLE MODE OF TRANSPORT INTO THE PLASTID OF RED ALGAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORPHYRIDIUM-CRUENTUM; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; ENDOPLASMIC-RETICULUM; B-PHYCOERYTHRIN; PROTEINS; POLYPEPTIDES; ORGANIZATION; SEQUENCE; CYANOBACTERIUM; CALLITHAMNION	R-phycoerythrin is the major light-harvesting pigment protein of most red algal phycobilisomes. It is composed of three pigmented polypeptide subunits, the alpha, beta, and gamma. While alpha and beta phycoerythrin subunits are each unique in the red alga Aglaothamnion neglectum, there are two different gamma subunits with distinct molecular masses. Both gamma subunits are pigmented by virtue of covalently attached linear tetrapyrroles. The amino acid sequence of one of the gamma subunits, as deduced from the nucleotide sequence of a cDNA clone, has no significant similarity to any known sequence in the data bases. This result is surprising, since the gamma subunit of phycoerythrin is thought to have a function that is similar to cyanobacterial linker polypeptides. The A. neglectum gamma subunit is synthesized as a 36-kDa precursor protein that is processed at the amino terminus to yield a 33-kDa mature protein. The amino-terminal extension was able to direct the pea small subunit of Rubisco into isolated pea chloroplasts. This result suggests that red algae transport proteins into the plastid by a mechanism similar to that of higher plants. There are significant changes in levels of mRNA encoding the gamma33 subunit when A. neglectum is grown under different conditions of illumination and in nitrogen-deficient medium. These changes parallel those previously observed for transcripts encoding the alpha and beta phycoerythrin subunits. Hence, there may be coordinated expression of nuclear and plastid-encoded phycoerythrin subunit genes.			APT, KE (corresponding author), CARNEGIE INST WASHINGTON, DEPT PLANT BIOL, 290 PANAMA ST, STANFORD, CA 94305 USA.							ADAM Z, 1993, PLANT PHYSIOL, V102, P35, DOI 10.1104/pp.102.1.35; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; APT KE, 1993, PLANT MOL BIOL, V21, P27, DOI 10.1007/BF00039615; APT KE, 1993, PHOTOSYNTH RES, V35, P235, DOI 10.1007/BF00016555; APT KE, 1992, PLANT PHYSIOL, V99, P1732, DOI 10.1104/pp.99.4.1732; BERNARD C, 1992, P NATL ACAD SCI USA, V89, P9564, DOI 10.1073/pnas.89.20.9564; BHAYA D, 1991, MOL GEN GENET, V229, P400, DOI 10.1007/BF00267462; Bryant D.A., 1991, CELL CULTURE SOMATIC, V1st ed., P255; CAVALIERSMITH T, 1982, BIOL J LINN SOC, V17, P289, DOI 10.1111/j.1095-8312.1982.tb02023.x; CAVALIERSMITH T, 1980, ENDOCYTOBIOLOGY ENDO, P893; CHUA NH, 1978, P NATL ACAD SCI USA, V75, P6110, DOI 10.1073/pnas.75.12.6110; CHUA NH, 1979, J CELL BIOL, V81, P461, DOI 10.1083/jcb.81.3.461; CHUA NH, 1979, J BIOL CHEM, V254, P215; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DOUGLAS SE, 1991, NATURE, V350, P148, DOI 10.1038/350148a0; EGELHOFF T, 1983, P NATL ACAD SCI-BIOL, V80, P3339, DOI 10.1073/pnas.80.11.3339; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; Esau K., 1977, ANATOMY SEED PLANTS; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GANTT E, 1966, J CELL BIOL, V29, P423, DOI 10.1083/jcb.29.3.423; GIBBS SP, 1981, INT REV CYTOL, V72, P49, DOI DOI 10.1016/S0074-7696(08)61194-8; GLAUSER M, 1992, EUR J BIOCHEM, V205, P927, DOI 10.1111/j.1432-1033.1992.tb16859.x; Glazer A.N., 1987, CYANOBACTERIA, P69; GLAZER AN, 1977, J BIOL CHEM, V252, P32; GLAZER AN, 1989, J BIOL CHEM, V264, P1; GROSSMAN A, 1990, MOL GEN GENET, V224, P91, DOI 10.1007/BF00259455; HAND JM, 1989, EMBO J, V8, P3195, DOI 10.1002/j.1460-2075.1989.tb08478.x; HOVANESSIAN AG, 1988, IMMUNOL TODAY, V9, P161, DOI 10.1016/0167-5699(88)91288-1; INNIS MA, 1990, PCR PROTOCOLS, P54; KLOTZ AV, 1985, J BIOL CHEM, V260, P4856; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAUX PG, 1985, EMBO J, V4, P1911, DOI 10.1002/j.1460-2075.1985.tb03870.x; MacColl R., 1987, PHYCOBILIPROTEINS; MAGRUDER WH, 1984, J PHYCOL, V20, P436, DOI 10.1111/j.0022-3646.1984.00436.x; Maniatis T., 1982, MOL CLONING; MARTIN W, 1992, J MOL EVOL, V35, P385, DOI 10.1007/BF00171817; MORSCHEL E, 1982, PLANTA, V154, P251, DOI 10.1007/BF00387871; MORSCHEL E, 1991, PHOTOSYNTHETICA, V25, P137; ONG LJ, 1984, SCIENCE, V224, P80, DOI 10.1126/science.224.4644.80; Pueschel C.M., 1990, BIOL RED ALGAE, P7; REDLINGER T, 1981, PLANT PHYSIOL, V68, P1375, DOI 10.1104/pp.68.6.1375; ROELL MK, 1993, PLANT MOL BIOL, V21, P47, DOI 10.1007/BF00039617; ROSEN KM, 1990, BIOTECHNIQUES, V8, P398; Saiki R. K., 1990, PCR PROTOCOLS GUIDE, P13; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIRMER T, 1986, J MOL BIOL, V188, P651, DOI 10.1016/S0022-2836(86)80013-4; SHIVJI MS, 1991, CURR GENET, V19, P49, DOI 10.1007/BF00362087; SIDLER W, 1989, BIOL CHEM H-S, V370, P115, DOI 10.1515/bchm3.1989.370.1.115; STADNICHUK IN, 1984, MOL BIOL+, V18, P272; SUGITA M, 1987, MOL GEN GENET, V209, P247, DOI 10.1007/BF00329650; SWANSON RV, 1990, ANAL BIOCHEM, V188, P295, DOI 10.1016/0003-2697(90)90609-D; TALARICO L, 1990, PHYCOLOGIA, V29, P292, DOI 10.2216/i0031-8884-29-3-292.1; Timko MP, 1985, MOL BIOL PHOTOSYNTHE, P381; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WHERMEYER W, 1990, EXPT PHYCOLOGY, V1, P158; WILBANKS SM, 1993, J BIOL CHEM, V268, P1236; YU MH, 1981, PLANT PHYSIOL, V68, P482, DOI 10.1104/pp.68.2.482; ZUBER H, 1987, LIGHT REACTIONS, P157	59	74	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16208	16215						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344905				2022-12-27	WOS:A1993LQ33600021
J	CUI, Z; VANCE, JE; CHEN, MH; VOELKER, DR; VANCE, DE				CUI, Z; VANCE, JE; CHEN, MH; VOELKER, DR; VANCE, DE			CLONING AND EXPRESSION OF A NOVEL PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE - A SPECIFIC BIOCHEMICAL AND CYTOLOGICAL MARKER FOR A UNIQUE MEMBRANE-FRACTION IN RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID BIOSYNTHESIS; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; METHYLATION PATHWAY; DNA; MITOCHONDRIA; PROTEIN; GOLGI; PHOSPHATIDYLSERINE; SEQUENCE	Phosphatidylethanolamine N-methyltransferase catalyzes the synthesis of phosphatidylcholine from phosphatidylethanolamine and is most active in liver. A cDNA for this enzyme from a rat liver cDNA library has been cloned, sequenced, and expressed in COS-1 cells, McArdle-RH7777 rat hepatoma cells, and Sf9 insect cells. The expressed protein was capable of converting phosphatidylethanolamine into phosphatidyl-choline in intact COS-1 cells, which normally have very low methyltransferase activity. The calculated molecular mass of the methyltransferase protein is 22.3 kDa, which is equivalent to that of the pure protein isolated from rat liver. Comparison of the sequence of the cloned rat liver methyltransferase with the yeast phosphatidylethanolamine methyltransferase PEM2 gene product revealed 44% identical amino acids and 68% similarity in the two predicted protein sequences. A polyclonal antibody was raised against a synthetic peptide corresponding to the carboxyl-terminal region of the enzyme and was affinity purified. The antibody recognized a single protein with a molecular mass of approximately 20 kDa when either rat liver proteins or proteins derived from the transfected COS-1 cells were electrophoresed on polyacrylamide gels containing sodium dodecyl sulfate. Surprisingly, the antibody exhibited no reactivity with endoplasmic reticulum proteins, even though the major phosphatidylethanolamine methyltransferase activity resides on this subcellular organelle. Instead, the antibody specifically recognized a protein in a unique subcellular membrane fraction purified from a crude mitochondrial preparation on a Percoll gradient. Immunocytochemical examination by electron microscopy showed positive labeling only in unique regions of the hepatocytes. The data suggest that this phosphatidylethanolamine methyltransferase is a specific marker for this unique membrane fraction.	UNIV ALBERTA, LIPID & LIPOPROT RES GRP, 320 HERITAGE MED RES CTR, EDMONTON T6G 2S2, AB, CANADA; NATL JEWISH HOSP, DEPT MED, DENVER, CO 80206 USA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON T6G 2S2, AB, CANADA; UNIV ALBERTA, DEPT MED, EDMONTON T6G 2S2, AB, CANADA; UNIV ALBERTA, SURG MED RES INST, EDMONTON T6G 2S2, AB, CANADA	University of Alberta; National Jewish Health; University of Alberta; University of Alberta; University of Alberta					NIGMS NIH HHS [GM 32453] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032453, R01GM032453] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHMAN CR, 1985, SOMAT CELL MOLEC GEN, V11, P499, DOI 10.1007/BF01534844; AUDUBERT F, 1983, J BIOL CHEM, V258, P695; BAUDHUIN P, 1964, BIOCHEM J, V92, P179, DOI 10.1042/bj0920179; BERGERON JJ, 1973, J CELL BIOL, V59, P73, DOI 10.1083/jcb.59.1.73; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CARMAN GM, 1989, PHOSPHATIDYLCHOLINE, P165; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CROZE EM, 1984, J CELL PHYSIOL, V119, P46, DOI 10.1002/jcp.1041190109; DENNIS EA, 1972, J LIPID RES, V13, P263; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EXTON JH, 1990, J BIOL CHEM, V265, P1; FOLCH J, 1957, J BIOL CHEM, V226, P497; GAYNOR PM, 1990, BIOCHIM BIOPHYS ACTA, V1045, P156, DOI 10.1016/0005-2760(90)90145-N; Harlow E., 1988, ANTIBODIES LAB MANUA, P55; HARRISON B, 1986, ANAL BIOCHEM, V158, P307, DOI 10.1016/0003-2697(86)90555-5; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KODAKI T, 1987, J BIOL CHEM, V262, P15428; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LAUSTER R, 1989, J MOL BIOL, V206, P313, DOI 10.1016/0022-2836(89)90481-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARUYAMA T, 1986, NUCLEIC ACIDS RES, V14, pR151, DOI 10.1093/nar/14.suppl.r151; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P107; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RIDGWAY ND, 1992, METHOD ENZYMOL, V209, P366; RIDGWAY ND, 1987, J BIOL CHEM, V262, P17231; RIDGWAY ND, 1988, THESIS U BRIT COLUMB; RIDGWAY ND, 1989, PHOSPHATIDYLCHOLINE, P103; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANCE DE, 1989, PHOSPHATIDYLCHOLINE; VANCE JE, 1988, J BIOL CHEM, V263, P5898; VANCE JE, 1991, J BIOL CHEM, V266, P89; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VOELKER DR, 1989, J BIOL CHEM, V264, P8019; VOELKER DR, 1989, P NATL ACAD SCI USA, V86, P9921, DOI 10.1073/pnas.86.24.9921; VOLKL A, 1985, EUR J BIOCHEM, V149, P257, DOI 10.1111/j.1432-1033.1985.tb08920.x; Wharton DC., 1967, METHOD ENZYMOL, P245; YAMASHITA S, 1982, EUR J BIOCHEM, V128, P589	47	212	218	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16655	16663						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344945				2022-12-27	WOS:A1993LQ33600082
J	METZGER, S; HALAAS, JL; BRESLOW, JL; SLADEK, FM				METZGER, S; HALAAS, JL; BRESLOW, JL; SLADEK, FM			ORPHAN RECEPTOR HNF-4 AND BZIP PROTEIN C/EBP-ALPHA BIND TO OVERLAPPING REGIONS OF THE APOLIPOPROTEIN-B GENE PROMOTER AND SYNERGISTICALLY ACTIVATE TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; STEROID-HORMONE RECEPTORS; HUMAN APOB GENE; A-I GENE; GLUCOCORTICOID RECEPTOR; RESPONSE ELEMENT; RETINOIC ACID; FOS-JUN; NEGATIVE REGULATION; OSTEOCALCIN GENE	As the sole protein component of low density lipoproteins, apolipoprotein B (apoB) plays an important role in cholesterol metabolism. Previously, we found that the proximal promoter region of apoB (-81 to -52 relative to the start site) played a critical role in hepatocyte-specific gene expression and that that region contained overlapping binding sites for nuclear factors AF-1 (-81 to -62) and C/EBP (-69 to -52) (Metzger, S., Leff, T., and Breslow, J. L. (1990) J. Biol. Chem. 265, 9978-9983). In this study, we show that HNF-4, a member of the steroid hormone receptor superfamily, binds the AF-1 site on the apoB promoter and through it activates transcription in transient transfection assays in both liver and non-liver cell lines, HepG2 and HeLa, respectively. Mutational analysis of the AF-1/HNF-4 binding site indicated a correlation of HNF-4 binding and transcriptional activity. In addition, transient co-transfection experiments with HNF-4 and C/EBPalpha expression vectors showed that the two factors can synergistically activate transcription to levels more than 3-fold above the sum of either factor alone. Finally, using gel retardation analysis we show that purified HNF-4 and C/EBP proteins can concurrently occupy their overlapping binding sites on the apoB promoter in vitro. However, since the same system showed a lack of cooperative binding, we argue that an alternative mechanism is responsible for the synergistic effect of HNF-4 and C/EBPalpha on apoB gene transcription.	ROCKEFELLER UNIV,BIOCHEM GENET & METAB LAB,1230 YORK AVE,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOLEC CELL BIOL LAB,NEW YORK,NY 10021	Rockefeller University; Rockefeller University			Breslow, Jan L/B-7544-2008					ALLAN GF, 1991, BIOESSAYS, V13, P73, DOI 10.1002/bies.950130205; BERK AJ, 1990, GENE DEV, V4, P151; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BRESLOW JL, 1988, PHYSIOL REV, V68, P85, DOI 10.1152/physrev.1988.68.1.85; BROOKS AR, 1992, MOL CELL BIOL, V12, P1134, DOI 10.1128/MCB.12.3.1134; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BRUNZELL JD, 1984, ARTERIOSCLEROSIS, V4, P79, DOI 10.1161/01.ATV.4.2.79; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARLSSON P, 1990, GENE, V94, P295, DOI 10.1016/0378-1119(90)90401-C; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DAS HK, 1988, J BIOL CHEM, V263, P11452; DAVIDSON NO, 1988, J LIPID RES, V29, P1511; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FISHER EA, 1988, ARTERIOSCLEROSIS, V8, P797, DOI 10.1161/01.ATV.8.6.797; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HATA S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P211, DOI 10.1016/0167-4781(92)90080-J; HAVEL RJ, 1989, METABOLIC BASIS INHE, P1129; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HUANG LS, 1986, P NATL ACAD SCI USA, V83, P644, DOI 10.1073/pnas.83.3.644; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KARDASSIS D, 1990, J BIOL CHEM, V265, P21733; KARDASSIS D, 1992, J BIOL CHEM, V267, P2622; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEFF T, 1989, J BIOL CHEM, V264, P16132; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; LI WH, 1988, J LIPID RES, V29, P245; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; METZGER S, 1990, J BIOL CHEM, V265, P9978; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; Miller J.H., 1972, EXPT MOL GENETICS; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OLIPHANT AR, 1986, GENE, V44, P177, DOI 10.1016/0378-1119(86)90180-0; OLIVIERO S, 1991, P NATL ACAD SCI USA, V88, P224, DOI 10.1073/pnas.88.1.224; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAMJI DP, 1991, NUCLEIC ACIDS RES, V19, P1139, DOI 10.1093/nar/19.5.1139; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROSS RS, 1991, BIOCHEM BIOPH RES CO, V176, P1116, DOI 10.1016/0006-291X(91)90400-2; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEISHIMA M, 1991, J LIPID RES, V32, P941; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SNIDERMAN A, 1980, P NATL ACAD SCI-BIOL, V77, P604, DOI 10.1073/pnas.77.1.604; SORCITHOMAS M, 1989, J BIOL CHEM, V264, P9039; SRIVASTAVA RAK, 1991, BIOCHIM BIOPHYS ACTA, V1086, P29, DOI 10.1016/0005-2760(91)90151-7; STEINBERG D, 1979, J CLIN INVEST, V64, P292, DOI 10.1172/JCI109451; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; VOZ ML, 1992, MOL CELL BIOL, V12, P3991, DOI 10.1128/MCB.12.9.3991; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WRIGHT APH, 1991, P NATL ACAD SCI USA, V88, P8283, DOI 10.1073/pnas.88.19.8283; WU AL, 1979, J BIOL CHEM, V254, P7316; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	75	100	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16831	16838						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344962				2022-12-27	WOS:A1993LQ33600105
J	WEBSTER, KA; DISCHER, DJ; BISHOPRIC, NH				WEBSTER, KA; DISCHER, DJ; BISHOPRIC, NH			INDUCTION AND NUCLEAR ACCUMULATION OF FOS AND JUN PROTOONCOGENES IN HYPOXIC CARDIAC MYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C ACTIVATION; ALPHA-ACTIN GENE; TRANSCRIPTION FACTOR; PROTOONCOGENE EXPRESSION; ADENOSINE-TRIPHOSPHATE; MEMBRANE PHOSPHOLIPIDS; MOLECULAR MECHANISM; OXIDATION-REDUCTION; CEREBRAL-ISCHEMIA; CELL HYPERTROPHY	Hypoxic and ischemic stresses cause a series of well documented changes in myocardial cells and tissues, including increased anaerobic glycolysis, loss of contractility, changes in lipid and fatty acid metabolism, and eventual irreversible membrane damage and cell death. In this article we describe changes in the expression and regulation of the proto-oncogenes fos and jun in cardiac myocytes exposed to severe hypoxia. The mRNAs encoding c-Fos, c-Jun, Jun-D, and Jun-B were induced within 1 h of exposure to hypoxia, increased 5-10-fold between 1 and 4 h and then declined. These inductions coincided with loss in myocyte contractility but occurred before there was irreversible cell damage or significant ATP loss. Immunostaining with anti-Fos and anti-Jun antibodies revealed the accumulation of these proteins in hypoxic cell nuclei. Pre-treatment of cells with protein kinase inhibitors significantly repressed the response at the mRNA level. We propose that hypoxic stress in these cells activates signal transduction pathways, possibly involving protein kinases, that result in the inductions of fos and jun gene families. Therefore AP1 may regulate myocardial adaptive responses to hypoxia in advance of energy depletion, cell damage, or reoxygenation.	UNIV CALIF SAN FRANSISCO,VET ADM MED CTR,DEPT MED,SAN FRANCISCO,CA 94025	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	WEBSTER, KA (corresponding author), SRI INT,DEPT CELL & MOLEC BIOL,DIV LIFE SCI,MENLO PK,CA 94025, USA.			Webster, Keith A/0000-0002-6431-3642	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044578, R29HL044578] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44578] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALLEN DG, 1987, CIRC RES, V60, P153, DOI 10.1161/01.RES.60.2.153; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BENJAMIN IJ, 1992, J CLIN INVEST, V89, P1685, DOI 10.1172/JCI115768; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P25535; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P20932; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BRAND T, 1992, CIRC RES, V71, P1351, DOI 10.1161/01.RES.71.6.1351; CHIEN KR, 1985, J CLIN INVEST, V75, P1770, DOI 10.1172/JCI111889; CHIEN KR, 1984, CIRC RES, V54, P313, DOI 10.1161/01.RES.54.3.313; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COSTACASNELLIE MR, 1985, BIOCHEM BIOPH RES CO, V133, P1139, DOI 10.1016/0006-291X(85)91255-0; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1991, MOL CELL BIOL, V5, P961; DIAZGUERRA MJM, 1991, J BIOL CHEM, V266, P23568; DOWNING SE, 1990, CIRC RES, V66, P763, DOI 10.1161/01.RES.66.3.763; FERL RJ, 1987, J BIOL CHEM, V262, P7947; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; GUNN AJ, 1990, BRAIN RES, V531, P105, DOI 10.1016/0006-8993(90)90763-2; GUNNING P, 1987, MOL CELL BIOL, V7, P4100, DOI 10.1128/MCB.7.11.4100; HAJJAR RJ, 1991, CARDIOVASC DRUG THER, V5, P961, DOI 10.1007/BF00143520; HALSEY DL, 1987, J BIOL CHEM, V262, P2234; HEACOCK CS, 1990, BRIT J CANCER, V62, P217, DOI 10.1038/bjc.1990.264; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HOH E, 1990, CIRCULATION, V82, P351; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; KARIN M, 1990, MOL ASPECTS CELLULAR, V6, P143; KINDY MS, 1991, J MOL NEUROSCI, V2, P217; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KOMURO I, 1991, J BIOL CHEM, V266, P1265; Larsson L.-I., 1988, IMMUNOCYTOCHEMISTRY; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LOUIS JC, 1988, J BIOL CHEM, V263, P19282; MARTERRE WF, 1991, SURGERY, V110, P184; MATTHEWS PM, 1986, CARDIOVASC RES, V20, P13, DOI 10.1093/cvr/20.1.13; MURPHY BJ, 1991, BRIT J CANCER, V64, P69, DOI 10.1038/bjc.1991.241; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OLAH Z, 1991, EXP BRAIN RES, V84, P403; OLAH Z, 1990, NEUROCHEM RES, V15, P515, DOI 10.1007/BF00966209; OULETTE AJ, 1990, J CLIN INVEST, V85, P766; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PENNEY DG, 1984, GROWTH HEART HLTH DI, P337; PRINZEN FW, 1984, AM J PHYSIOL, V247, pH254; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; ROSENBERG ME, 1991, KIDNEY INT, V39, P1156, DOI 10.1038/ki.1991.146; SAFIRSTEIN R, 1990, KIDNEY INT, V37, P1515, DOI 10.1038/ki.1990.143; SCHIAFFONATI L, 1990, J CELL PHYSIOL, V143, P79, DOI 10.1002/jcp.1041430110; SCHUNKERT H, 1991, P NATL ACAD SCI USA, V88, P11480, DOI 10.1073/pnas.88.24.11480; SEMSNZA GL, 1992, MOL CELL BIOL, V12, P5447; SEN L, 1990, CIRC RES, V67, P599, DOI 10.1161/01.RES.67.3.599; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHUBEITA HE, 1990, CIRCULATION, V82, P687; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; STERN MS, 1988, P NATL ACAD SCI USA, V85, P6964; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TRILIVAS I, 1991, J BIOL CHEM, V266, P8431; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; VILGRAIN I, 1984, J BIOL CHEM, V259, P3403; WEBSTER KA, 1990, MOL CELL BIOL, V10, P2402, DOI 10.1128/MCB.10.5.2402; WEBSTER KA, 1990, J CELL PHYSIOL, V142, P566, DOI 10.1002/jcp.1041420316; WEBSTER KA, 1992, J MOL CELL CARDIOL, V24, P741, DOI 10.1016/0022-2828(92)93388-Z; WEBSTER KA, 1993, J CELL BIOCHEM, V17, P237; WERNS SW, 1990, TRENDS PHARMACOL SCI, V11, P161, DOI 10.1016/0165-6147(90)90068-J	69	196	220	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16852	16858						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344964				2022-12-27	WOS:A1993LQ33600108
J	BOARD, P; SMITH, S; GREEN, J; COGGAN, M; SUZUKI, T				BOARD, P; SMITH, S; GREEN, J; COGGAN, M; SUZUKI, T			EVIDENCE AGAINST A RELATIONSHIP BETWEEN FATTY-ACID ETHYL-ESTER SYNTHASE AND THE PI-CLASS GLUTATHIONE-S-TRANSFERASE IN HUMANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONOXIDATIVE ETHANOL-METABOLISM; GENETIC-HETEROGENEITY; ESCHERICHIA-COLI; HUMAN-PLACENTA; EXPRESSION; CDNA; IDENTIFICATION; RESOLUTION; MYOCARDIUM; PROTEINS	Recently, Bora et al. (Bora, P. S., Bora, N. S., Wu, X., and Lange, L. G. (1991) J. Biol. Chem. 266,16774-16777) reported the cloning and expression of a human fatty acid ethyl ester synthase III (FAEES-III) cDNA that has only four amino acid substitutions compared with human glutathione S-transferase (GST) GSTP1-1, and, when expressed in MCF-7 cells, the protein has both FAEES and GST activities. By site-directed mutagenesis of a GSTP1 cDNA, we have constructed a clone that encodes the FAEES-III protein described by Bora et al. (1991). The recombinant FAEES-III protein was expressed in Escherichia coli and has been shown to be devoid of FAEES and GST activities. The recombinant FAEES-III protein does not bind to a glutathione agarose affinity matrix, presumably because two of the substituted amino acids, Trp-39 --> Cys and Gln-52 --> Glu, are thought to contribute to the GST glutathione binding site. One of the base substitutions in the FAEES-III cDNA encodes an extra SacI site not found in the GSTPI cDNA. Polymerase chain reaction amplification of human genomic DNA has identified the GSTPI gene, but no DNA from the proposed FAEES gene with a diagnostic SacI site has been detected. Evaluation of the hybridization pattern of HindIII genomic restriction fragments has identified fragments that contain the GSTPI gene and a pseudogene (Board et al. 1992), and there do not appear to be any hybridizing fragments that could contain the FAEEs-III gene. Our results do not provide any evidence in support of a relationship between FAEES-III and GST, and the cDNA reported by Bora et al. (1991) may have resulted from a cloning artifact.			BOARD, P (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,MOLEC GENET GRP,GPO BOX 334,CANBERRA,ACT 2601,AUSTRALIA.							AHMAD H, 1990, ARCH BIOCHEM BIOPHYS, V278, P398, DOI 10.1016/0003-9861(90)90277-6; ANDERSSON SGE, 1990, MICROBIOL REV, V54, P198, DOI 10.1128/MMBR.54.2.198-210.1990; BOARD P, 1990, PHARMACOL THERAPEUT, V48, P357, DOI 10.1016/0163-7258(90)90054-6; BOARD PG, 1981, AM J HUM GENET, V33, P36; BOARD PG, 1984, ANN HUM GENET, V48, P223, DOI 10.1111/j.1469-1809.1984.tb01018.x; BOARD PG, 1989, ANN HUM GENET, V53, P205, DOI 10.1111/j.1469-1809.1989.tb01786.x; BOARD PG, 1992, GENOMICS, V14, P470, DOI 10.1016/S0888-7543(05)80243-5; BOARD PG, 1987, BIOCHEM J, V248, P937, DOI 10.1042/bj2480937; BORA PS, 1989, J CLIN INVEST, V84, P1942, DOI 10.1172/JCI114382; BORA PS, 1989, P NATL ACAD SCI USA, V86, P4470, DOI 10.1073/pnas.86.12.4470; BORA PS, 1991, J BIOL CHEM, V266, P16774; BORA PS, 1992, BIOCHEM BIOPH RES CO, V184, P706, DOI 10.1016/0006-291X(92)90647-4; COWELL IG, 1988, BIOCHEM J, V255, P79, DOI 10.1042/bj2550079; GUTHENBERG C, 1981, BIOCHIM BIOPHYS ACTA, V661, P255, DOI 10.1016/0005-2744(81)90012-7; Habig W H, 1981, Methods Enzymol, V77, P398; ISENBERG KE, 1992, BIOCHEM BIOPH RES CO, V185, P938, DOI 10.1016/0006-291X(92)91717-5; KANO T, 1987, CANCER RES, V47, P5626; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MOGELSON S, 1984, BIOCHEMISTRY-US, V23, P4075, DOI 10.1021/bi00313a010; MOSCOW JA, 1988, P NATL ACAD SCI USA, V85, P6518, DOI 10.1073/pnas.85.17.6518; NISHIHIRA J, 1992, BIOCHEM BIOPH RES CO, V185, P1069, DOI 10.1016/0006-291X(92)91735-9; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARMA R, 1991, BIOCHEM J, V275, P507, DOI 10.1042/bj2750507; SIMMONS PC, 1977, ANAL BIOCHEM, V82, P334; SMITH DB, 1988, MOL BIOCHEM PARASIT, V27, P249, DOI 10.1016/0166-6851(88)90044-8; SUZUKI T, 1990, FEBS LETT, V275, P58, DOI 10.1016/0014-5793(90)81438-T; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	33	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15655	15658						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340390				2022-12-27	WOS:A1993LN30500051
J	LANIER, SM; IVKOVIC, B; SINGH, I; NEUMEYER, JL; BAKTHAVACHALAM, V				LANIER, SM; IVKOVIC, B; SINGH, I; NEUMEYER, JL; BAKTHAVACHALAM, V			VISUALIZATION OF MULTIPLE IMIDAZOLINE GUANIDINIUM-RECEPTIVE SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; CLONIDINE-DISPLACING SUBSTANCE; MITOCHONDRIAL OUTER-MEMBRANE; PROTEIN-COUPLED RECEPTORS; ALPHA-2-ADRENERGIC RECEPTOR; BINDING-SITES; VENTROLATERAL MEDULLA; BASOLATERAL MEMBRANES; SIGNAL TRANSDUCTION; RABBIT KIDNEY	Compounds with an imidazoline or guanidinium moiety elicit a variety of stimulatory and inhibitory cell responses in both central and peripheral tissues. Many of these effects are mediated by interaction with alpha-adrenergic receptors, but these molecules also selectively recognize other membrane-bound proteins with high affinity. We used a functionalized derivative of the imidazoline molecule cirazoline to visualize the imidazoline/guanidinium-receptive site (IGRS). 2-[3-Aminophenoxy]methyl imidazoline was radioiodinated and subsequently converted to the arylazide to generate the photoaffinity adduct 2-[3-azido-4-[I-125]iodophenoxy]methyl imidazoline ([I-125]AZIPI). Both 2-[3-amino-4-[I-125]iodophenoxy]methyl imidazoline and [I-125]AZIPI exhibited saturable high affinity binding in rat liver membrane preparations (K(i) = 2-5 nM). In rat liver mitochondrial membranes, [I-125]AZIPI photoincorporates into two peptides with apparent molecular weights of approximately 55,000 and approximately 61,000 as determined by SDS-polyacrylamide gel electrophoresis. The labeling of these two species is blocked by various competing ligands (10 muM) with a potency order expected for an IGRS. The photolabeling of both peptides is blocked by the imidazolines cirazoline and idazoxan or by the guanidinium guanabenz, but it is not altered the alpha2-adrenergic receptor antagonist rauwolscine or by the adrenergic receptor agonist epinephrine. Photoincorporation of [I-125]AZIPI is minimally inhibited by the imidazoline clonidine or by the alpha1-adrenergic receptor antagonist prazosin. However, the guanidinium ligand amiloride exhibits higher affinity for the M(r) = 61,000 peptide as compared with the M(r) = 55,000 peptide, suggesting that the two labeled species differ in their ligand recognition properties. An additional IGRS was identified by photolabeling in membranes prepared from PC-12 pheochromocytoma cells. In PC-12 membranes, [I-125]AZIPI photolabels a major M(r) = approximately 61,000 peptide; the photoincorporation is blocked by cirazoline, guanabenz, and amiloride but not by idazoxan (competing ligands = 10 muM). These data indicate the existence of at least three subtypes of IGRS that differ in their ligand recognition properties, their apparent molecular weight, and their tissue distribution.	MED UNIV S CAROLINA,DEPT PEDIAT,CHARLESTON,SC 29425; RES BIOCHEM INT,NATICK,MA 01760	Medical University of South Carolina	LANIER, SM (corresponding author), MED UNIV S CAROLINA,DEPT PHARMACOL,171 ASHLEY AVE,CHARLESTON,SC 29425, USA.			Lanier, Stephen/0000-0002-2740-7607; Neumeyer, John/0000-0003-2287-9864	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R43GM046605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821] Funding Source: NIH RePORTER; NIGMS NIH HHS [R43 GM-46605] Funding Source: Medline; NINDS NIH HHS [R01 NS-24821] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; ATLAS D, 1984, EUR J BIOCHEM, V144, P287, DOI 10.1111/j.1432-1033.1984.tb08462.x; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BIDET M, 1990, BIOCHIM BIOPHYS ACTA, V1024, P173, DOI 10.1016/0005-2736(90)90221-9; BOURRE JM, 1982, J NEUROCHEM, V38, P643, DOI 10.1111/j.1471-4159.1982.tb08679.x; BOUSQUET P, 1984, J PHARMACOL EXP THER, V230, P232; BOUSQUET P, 1986, EUR J PHARMACOL, V124, P167, DOI 10.1016/0014-2999(86)90138-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTIELLO HF, 1989, J BIOL CHEM, V264, P16000; COOPERSTEINE SJ, 1951, J CELL BIOL, V189, P655; COUPRY I, 1987, BIOCHEM BIOPH RES CO, V147, P1055, DOI 10.1016/S0006-291X(87)80177-8; COUPRY I, 1989, J PHARMACOL EXP THER, V252, P293; DHAUNSI GS, 1992, J BIOL CHEM, V267, P6870; DUZIC E, 1992, J BIOL CHEM, V267, P9844; DUZIC E, 1992, J BIOL CHEM, V267, P24045; ERNSBERGER P, 1990, J PHARMACOL EXP THER, V253, P408; ERNSBERGER P, 1987, EUR J PHARMACOL, V134, P1, DOI 10.1016/0014-2999(87)90125-7; FERRIS CD, 1992, J NEUROSCI, V12, P1567; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; LACHAUDPETTITI V, 1991, EUR J PHARM-MOLEC PH, V206, P23, DOI 10.1016/0922-4106(91)90142-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGIN D, 1990, MOL PHARMACOL, V37, P876; LANIER SM, 1986, P NATL ACAD SCI USA, V83, P9358, DOI 10.1073/pnas.83.24.9358; LAZO O, 1991, MOL CELL BIOCHEM, V100, P159; LIMON I, 1992, J BIOL CHEM, V267, P21645; MACKINNON AC, 1989, BRIT J PHARMACOL, V98, P1143, DOI 10.1111/j.1476-5381.1989.tb12658.x; MEELEY MP, 1986, LIFE SCI, V38, P1119, DOI 10.1016/0024-3205(86)90248-1; MICHEL MC, 1989, TRENDS PHARMACOL SCI, V10, P342, DOI 10.1016/0165-6147(89)90002-3; PAPADOPOULOS V, 1991, ENDOCRINOLOGY, V129, P1481, DOI 10.1210/endo-129-3-1481; PARINI A, 1989, J BIOL CHEM, V264, P11874; PLANT TD, 1991, BRIT J PHARMACOL, V104, P385, DOI 10.1111/j.1476-5381.1991.tb12440.x; REGUNATHAN S, 1991, BIOCHEM PHARMACOL, V42, P2011, DOI 10.1016/0006-2952(91)90602-2; REGUNATHAN S, 1991, MOL PHARMACOL, V40, P884; RUFFOLO RR, 1988, ALPHA 2 ADRENERGIC R, P115; SHULZ A, 1989, N-S ARCH PHARMACOL, V340, P712; TESSON F, 1991, J BIOL CHEM, V266, P155; TIBIRICA E, 1991, J PHARMACOL EXP THER, V256, P606; WANG H, 1992, MOL PHARMACOL, V42, P792; WIKBERG JES, 1990, J NEUROCHEM, V55, P192, DOI 10.1111/j.1471-4159.1990.tb08838.x	41	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					16047	16051						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340426				2022-12-27	WOS:A1993LN30500100
J	MURRAY, NR; BAUMGARDNER, GP; BURNS, DJ; FIELDS, AP				MURRAY, NR; BAUMGARDNER, GP; BURNS, DJ; FIELDS, AP			PROTEIN-KINASE-C ISOTYPES IN HUMAN ERYTHROLEUKEMIA (K562) CELL-PROLIFERATION AND DIFFERENTIATION - EVIDENCE THAT BETA-II PROTEIN-KINASE-C IS REQUIRED FOR PROLIFERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOGENIC RESPONSE; PHORBOL ESTERS; GROWTH-FACTOR; LAMIN-C; ALPHA; ACTIVATION; EXPRESSION; ISOZYMES; PKC; PHOSPHORYLATION	The human erythroleukemia (K562) cell line undergoes megakaryocytic differentiation and cessation of proliferation when treated with phorbol myristate acetate (PMA). To investigate the role of individual protein kinase C (PKC) isotypes in these events, we have assessed PKC isotype expression during leukemic proliferation and PMA-induced differentiation. Immunoblot analysis using isotype-specific antibodies demonstrates that proliferating K562 cells express the alpha, beta(II), and zeta PKC isotypes. PMA-induced differentiation and cytostasis lead to a decrease in beta(II) PKC and increases in alpha and zeta PKC levels. The role of the alpha and beta(II), PKC isotypes was further assessed in cells overexpressing these isotypes. K562 cells overexpressing human alpha PKC grew more slowly and were more sensitive to the cytostatic effects of PMA than control cells, whereas cells overexpressing beta(II) PKC were less sensitive to PMA. PMA-induced cytostasis is reversed upon removal of PMA. Resumption of proliferation is accompanied by reexpression of beta(II) PKC to near control levels, whereas alpha and zeta PKC levels remain elevated for several days after removal of PMA. Proliferation of PMA-withdrawn cells can be partially inhibited by antisense beta(II), PKC oligodeoxyribonucleotide. Growth inhibition is dose-dependent, specific for beta(II) PKC-directed antisense oligonucleotide, and associated with significant inhibition of beta(II) PKC levels indicating that beta(II) PKC is essential for K562 cell proliferation. Sodium butyrate, which unlike PMA induces megakaryocytic differentiation without cytostasis, causes increases in both alpha and beta(II) PKC levels. These data demonstrate that beta(II) PKC is required for K562 cell proliferation, whereas alpha PKC is involved in megakaryocytic differentiation.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHARMACOL, 2119 ABINGTON RD, CLEVELAND, OH 44106 USA; SPHINX PHARMACEUT INC, DURHAM, NC 27717 USA	Case Western Reserve University					NATIONAL CANCER INSTITUTE [R01CA056869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043186] Funding Source: NIH RePORTER; NCI NIH HHS [CA-56869] Funding Source: Medline; NIGMS NIH HHS [GM-43186] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BALAZOVICH KJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P247, DOI 10.1016/0167-4889(87)90141-8; BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; BARR LF, 1991, CANCER RES, V51, P5514; BECKMAN BS, 1992, EXP HEMATOL, V20, P324; BERKOW RL, 1985, BIOCHEM BIOPH RES CO, V131, P1109, DOI 10.1016/0006-291X(85)90205-0; BERRY N, 1990, EUR J BIOCHEM, V189, P205, DOI 10.1111/j.1432-1033.1990.tb15478.x; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHIARUGI V, 1990, BIOCHEM BIOPH RES CO, V173, P528, DOI 10.1016/S0006-291X(05)80066-X; CLEMENS MJ, 1992, J CELL SCI, V103, P881; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; FIELDS AP, 1990, J CELL SCI, V96, P107; FRIEDMAN DL, 1988, J BIOL CHEM, V263, P1103; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOCEVAR BA, 1992, J CELL SCI, V101, P671; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1992, J BIOL CHEM, V267, P21816; MASONGARCIA M, 1990, BIOCHEM BIOPH RES CO, V168, P490, DOI 10.1016/0006-291X(90)92348-4; MCBAIN JA, 1988, CARCINOGENESIS, V9, P123, DOI 10.1093/carcin/9.1.123; MELLONI E, 1987, P NATL ACAD SCI USA, V84, P5282, DOI 10.1073/pnas.84.15.5282; MELLONI E, 1989, J BIOL CHEM, V264, P18414; MINANA MD, 1991, FEBS LETT, V284, P60, DOI 10.1016/0014-5793(91)80761-Q; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; SPANGLER R, 1992, BLOOD, V79, P52; TABILIO A, 1983, CANCER RES, V43, P4569; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0	43	208	217	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15847	15853						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340409				2022-12-27	WOS:A1993LN30500076
J	NAGAYA, T; JAMESON, JL				NAGAYA, T; JAMESON, JL			THYROID-HORMONE RECEPTOR DIMERIZATION IS REQUIRED FOR DOMINANT-NEGATIVE INHIBITION BY MUTATIONS THAT CAUSE THYROID-HORMONE RESISTANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; LIGAND-BINDING DOMAIN; RAT GROWTH-HORMONE; GENERALIZED RESISTANCE; RESPONSE ELEMENTS; AUXILIARY PROTEIN; BETA GENE; TRANSCRIPTIONAL ACTIVITY; MAMMALIAN-CELLS; DNA-BINDING	The syndrome of thyroid hormone resistance (THR) is caused by multiple distinct mutations of the ligand-binding domain of the thyroid hormone beta receptor. Although the mutant receptors are transcriptionally inactive, they inhibit normal receptor function in a dominant negative manner to cause hormone resistance. Because most of the naturally occurring mutations are clustered within two areas that lie on either side of a putative dimerization region, we hypothesized that receptor dimerization was important for dominant negative inhibition. In gel mobility shift assays, two THR mutants (G345R and P453H) formed homodimers as well as heterodimers with the the retinoic acid X receptor alpha. In contrast, an artificial mutation (L428R) in one of the hydrophobic heptad repeats of the putative receptor dimerization domain impaired heterodimerization with retoinoic acid X receptor alpha without altering the formation of homodimers. Double mutants containing either of the THR mutations along with the dimerization mutation formed homodimers but not heterodimers, reflecting the properties of the dimerization mutant alone. In transient expression assays using positively (TRETKLuc) or negatively (TSHalphaLuc) regulated reporter genes, the dominant negative activity of the THR mutants was eliminated by the addition of the dimerization mutation. These results support a mechanism for dominant negative activity by THR mutants in which functionally inactive heterodimers bind to DNA to inhibit access by normal receptors.	MASSACHUSETTS GEN HOSP,THYROID UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Jameson, James/0000-0001-9538-4059	NICHD NIH HHS [HD 28138] Funding Source: Medline; NIDDK NIH HHS [DK 42144] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042144] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS M, 1992, CLIN ENDOCRINOL, V36, P281, DOI 10.1111/j.1365-2265.1992.tb01444.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEEBE JS, 1991, MOL ENDOCRINOL, V5, P85, DOI 10.1210/mend-5-1-85; BIGLER J, 1992, MOL CELL BIOL, V12, P2406, DOI 10.1128/MCB.12.5.2406; BRENT GA, 1992, MOL ENDOCRINOL, V6, P502, DOI 10.1210/me.6.4.502; BRENT GA, 1989, J BIOL CHEM, V264, P178; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CHATTERJEE VKK, 1991, J CLIN INVEST, V87, P1977; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; KATZ D, 1992, MOL ENDOCRINOL, V6, P805, DOI 10.1210/me.6.5.805; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LAZAR MA, 1990, J CLIN INVEST, V86, P1777, DOI 10.1172/JCI114906; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MAGNER JA, 1986, J ENDOCRINOL INVEST, V9, P459, DOI 10.1007/BF03346968; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MCPHAUL MJ, 1991, FASEB J, V5, P2910, DOI 10.1096/fasebj.5.14.1752359; MEIER CA, 1992, MOL ENDOCRINOL, V6, P248, DOI 10.1210/me.6.2.248; MIXSON AJ, 1992, J CLIN ENDOCR METAB, V75, P1039, DOI 10.1210/jc.75.4.1039; NAGAYA T, 1992, J BIOL CHEM, V267, P13014; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; REFETOFF S, 1967, J CLIN ENDOCR METAB, V27, P279, DOI 10.1210/jcem-27-2-279; REFETOFF S, 1982, AM J PHYSIOL, V243, P88; REFETOFF S, 1992, ENDOCRINOLOGIST, V2, P261; SAKURAI A, 1990, MOL ENDOCRINOL, V4, P1988, DOI 10.1210/mend-4-12-1988; SAKURAI A, 1989, P NATL ACAD SCI USA, V86, P8977, DOI 10.1073/pnas.86.22.8977; SASAKI S, 1992, MOL CELL ENDOCRINOL, V84, P159, DOI 10.1016/0303-7207(92)90026-3; SELMI S, 1991, J BIOL CHEM, V266, P11589; TAKEDA K, 1992, J CLIN ENDOCR METAB, V74, P712, DOI 10.1210/jc.74.4.712; TAKEDA K, 1992, J CLIN ENDOCR METAB, V74, P49, DOI 10.1210/jc.74.1.49; USALA SJ, 1990, J CLIN INVEST, V85, P93, DOI 10.1172/JCI114438; USALA SJ, 1991, TRENDS ENDOCRIN MET, V2, P140, DOI 10.1016/1043-2760(91)90004-7; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; WEISS RE, 1992, ANNU REV MED, V43, P363, DOI 10.1146/annurev.med.43.1.363; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YEN PM, 1992, J BIOL CHEM, V267, P3565; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	48	129	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15766	15771						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340402				2022-12-27	WOS:A1993LN30500066
J	TAKAGI, J; FUJISAWA, T; USUI, T; AOYAMA, T; SAITO, Y				TAKAGI, J; FUJISAWA, T; USUI, T; AOYAMA, T; SAITO, Y			A SINGLE-CHAIN 19-KDA FRAGMENT FROM BOVINE THROMBOSPONDIN BINDS TO TYPE-V COLLAGEN AND HEPARIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR; PLATELET THROMBOSPONDIN; CELL ATTACHMENT; MATRIX PROTEINS; I REPEATS; PROPOLYPEPTIDE; ADHESION; GLYCOPROTEIN; PROPERDIN; DOMAIN	Location of the type V collagen-binding domain within bovine thrombospondin (TSP) was investigated by using fragments of reduced and alkylated TSP. A fragment of relative molecular mass (19 kDa) was isolated, which inhibited binding of I-125-TSP to type V collagen in a solid-phase binding assay. A direct binding assay using the I-125-labeled fragment confirmed that the fragment actually bound to collagen. The fragment retained specificity for the native structure of type V collagen like the intact TSP molecule. Its binding to the collagen, however, was not inhibited by Ca2+ in contrast to intact TSP. Amino acid sequence analysis of the 19-kDa fragment suggested that this fragment corresponded to Val333-Lys412, a part of the stalklike region in the human TSP primary structure. It was found that the fragment also bound well to heparin in a specific and saturable manner and, furthermore, binding to type V collagen was inhibited by soluble heparin. Removal of the N-linked sugar chain from this fragment resulted in a 14-kDa fragment. The deglycosylated fragment retained the ability to bind to type V collagen as well as heparin. These results suggest that a type V collagen-binding site is present in the 80-residue portion of bovine TSP (Val333-Lys412) and is likely to be identical or lie very close to a heparin-binding site, which exists in the type I repeat structure.	TOKYO INST TECHNOL, FAC BIOSCI & BIOTECHNOL,DEPT BIOL SCI,OOKAYAMA, MEGURO KU, TOKYO 152, JAPAN	Tokyo Institute of Technology								BACONBAGULEY T, 1987, J BIOL CHEM, V262, P1927; BAENZIGE.NL, 1971, P NATL ACAD SCI USA, V68, P240, DOI 10.1073/pnas.68.1.240; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; DIXIT VM, 1984, J BIOL CHEM, V259, P100; DIXIT VM, 1985, P NATL ACAD SCI USA, V82, P3472, DOI 10.1073/pnas.82.10.3472; FESSLER JH, 1987, STRUCTURE FUNCTION C, P81; FUJISAWA T, 1991, EUR J BIOCHEM, V196, P673, DOI 10.1111/j.1432-1033.1991.tb15864.x; FUNAHASHI M, 1982, ANAL BIOCHEM, V126, P414, DOI 10.1016/0003-2697(82)90537-1; GALVIN NJ, 1987, J CELL BIOL, V104, P1413, DOI 10.1083/jcb.104.5.1413; GAY S, 1985, J IMMUNOL, V135, P1097; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; KAESBERG PR, 1989, J CLIN INVEST, V83, P994, DOI 10.1172/JCI113986; KOSFELD MD, 1992, J BIOL CHEM, V267, P16230; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHAV J, 1984, EUR J BIOCHEM, V145, P151, DOI 10.1111/j.1432-1033.1984.tb08534.x; LAWLER J, 1986, ANN NY ACAD SCI, V485, P273, DOI 10.1111/j.1749-6632.1986.tb34589.x; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LAWLER J, 1986, BLOOD, V67, P1197; LEBARON RG, 1989, J BIOL CHEM, V264, P7950; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MAJACK RA, 1987, CELL MEMBRANES METHO, V3, P55; MANSFIELD PJ, 1990, J CELL BIOL, V111, P3077, DOI 10.1083/jcb.111.6.3077; MARGOSSIAN SS, 1981, J BIOL CHEM, V256, P7495; MUMBY SM, 1984, J CELL BIOL, V98, P646, DOI 10.1083/jcb.98.2.646; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; SILVERSTEIN RL, 1984, J CLIN INVEST, V74, P1625, DOI 10.1172/JCI111578; SOTTILE J, 1991, BIOCHEMISTRY-US, V30, P6556, DOI 10.1021/bi00240a028; TAKAGI J, 1989, J BIOL CHEM, V264, P10425; TAKAGI J, 1992, BIOCHEMISTRY-US, V31, P8530, DOI 10.1021/bi00151a021; TAKAGI J, 1991, J BIOL CHEM, V266, P5575; TAKAGI J, 1989, J BIOL CHEM, V264, P6017; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; TARABOLETTI G, 1987, J CELL BIOL, V105, P2409, DOI 10.1083/jcb.105.5.2409; TUSZYNSKI GP, 1987, SCIENCE, V236, P1570, DOI 10.1126/science.2438772; TUSZYNSKI GP, 1992, J CELL BIOL, V116, P209, DOI 10.1083/jcb.116.1.209; USUI T, 1992, EUR J BIOCHEM, V205, P363, DOI 10.1111/j.1432-1033.1992.tb16788.x; YAOI Y, 1991, EXP CELL RES, V194, P180, DOI 10.1016/0014-4827(91)90351-T; YAOI Y, 1990, BIOCHIM BIOPHYS ACTA, V1035, P139, DOI 10.1016/0304-4165(90)90108-9	45	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15544	15549						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340381				2022-12-27	WOS:A1993LN30500036
J	HILLARP, A; PARDOMANUEL, F; RUIZ, RR; DECORDOBA, SR; DAHLBACK, B				HILLARP, A; PARDOMANUEL, F; RUIZ, RR; DECORDOBA, SR; DAHLBACK, B			THE HUMAN C4B-BINDING PROTEIN BETA-CHAIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECAY-ACCELERATING FACTOR; HUMAN C4-BINDING PROTEIN; COMPLEMENT FACTOR-H; CLASSICAL PATHWAY; C3B INACTIVATOR; ALPHA-CHAIN; COMPONENT; PLASMA; C4B; ACTIVATION	Human complement component C4b-binding protein (C4BP) is composed of seven alpha-chains and one beta-chain. The alpha- and beta-chains are homologous and both contain multiple copies of short consensus repeats (SCR) and in addition carboxyl-terminal non-repeat regions. Each of the alpha-chains contains a binding site for C4b, whereas the beta-chain binds protein S, a vitamin K-dependent protein involved in the regulation of blood coagulation. The alpha- and beta-chain genes are closely linked in the regulators of complement activation gene cluster on the long arm of human chromosome 1, band 1q32. The human beta-chain gene which has now been characterized was found to span more than 10 kilobases of DNA. The presence of at least two different beta-chain gene transcripts was suggested by the isolation of two new cDNA clones which contained different sequences in their extended 5'-untranslated regions. Northern blot analysis demonstrated that the two clones represented distinct beta-chain mRNAs with different 5' end sequences. One class of beta-chain mRNA (denoted A19) was found to be encoded by six exons and primer extension, and Sl nuclease protection assays revealed multiple closely spaced transcription start sites for this mRNA class. Its 5'-untranslated region and signal peptide was encoded by the first exon. The second class of mRNA (denoted A12) had a different transcription start site and its 5'-untranslated region was derived from at least three exons out of which the last one was formed by utilization of an acceptor splice site within the first A19 exon. Exons encoding the mature beta-chain and the 3'-untranslated region were common to both classes of mRNA. The beta-chain contains three SCRs, out of which the first and second are encoded by individual exons, whereas two exons encode the third SCR. The exon encoding the carboxyl-terminal part of the third SCR also encodes 14 amino acids of the non-repeat region. The last exon encodes the remaining 46 carboxyl-terminal amino acids and the entire 3'-untranslated region. The elucidation of the organization of the beta-chain gene provides insight into the sophisticated molecular structure of C4BP and a basis for future structural and functional studies.	LUND UNIV,MALMO GEN HOSP,DEPT CLIN CHEM,S-21401 MALMO,SWEDEN; CTR INVEST BIOL,UNIDAD INMUNOL,E-28006 MADRID,SPAIN	Lund University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)			de Cordoba, Santiago Rodriguez/K-6727-2014; ramos-ruiz, ricardo/Q-2237-2016	de Cordoba, Santiago Rodriguez/0000-0001-6401-1874; ramos-ruiz, ricardo/0000-0002-6331-9786; Dahlback, Bjorn/0000-0003-1546-0328				ANDERSSON A, 1990, SOMAT CELL MOLEC GEN, V16, P493, DOI 10.1007/BF01233199; Ausubel FM, 1988, MOL REPROD DEV; BARNUM SR, 1989, BIOCHEMISTRY-US, V28, P8312, DOI 10.1021/bi00447a008; BARNUM SR, 1990, COMPLEMENT INFLAMMAT, V7, P71, DOI 10.1159/000463131; BERTINA RM, 1985, THROMB HAEMOSTASIS, V53, P268; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BORA NS, 1989, J EXP MED, V169, P597, DOI 10.1084/jem.169.2.597; BRAATEN DC, 1988, NUCLEIC ACIDS RES, V16, P865, DOI 10.1093/nar/16.3.865; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG LP, 1985, BIOCHEM J, V230, P133, DOI 10.1042/bj2300133; COMP PC, 1986, BLOOD, V67, P504; DAHLBACK B, 1983, BIOCHEM J, V209, P857, DOI 10.1042/bj2090857; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DAHLBACK B, 1986, J BIOL CHEM, V261, P2022; DAHLBACK B, 1983, P NATL ACAD SCI-BIOL, V80, P3461, DOI 10.1073/pnas.80.11.3461; DAHLBACK B, 1981, P NATL ACAD SCI-BIOL, V78, P2512, DOI 10.1073/pnas.78.4.2512; DECORDOBA SR, 1991, J EXP MED, V173, P1073, DOI 10.1084/jem.173.5.1073; DECORDOBA SR, 1985, J EXP MED, V161, P1189, DOI 10.1084/jem.161.5.1189; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJISAKU A, 1989, J BIOL CHEM, V264, P2118; FUJITA T, 1979, J EXP MED, V150, P267, DOI 10.1084/jem.150.2.267; FUJITA T, 1978, J EXP MED, V148, P1044, DOI 10.1084/jem.148.4.1044; GIGLI I, 1979, P NATL ACAD SCI USA, V76, P6596, DOI 10.1073/pnas.76.12.6596; HILLARP A, 1989, FEBS LETT, V259, P53, DOI 10.1016/0014-5793(89)81492-9; HILLARP A, 1990, P NATL ACAD SCI USA, V87, P1183, DOI 10.1073/pnas.87.3.1183; JANATOVA J, 1989, BIOCHEMISTRY-US, V28, P4754, DOI 10.1021/bi00437a036; Maniatis T, 1989, DECONTAMINATION DILU; NAGASAWA S, 1980, J IMMUNOL, V125, P578; PARDOMANUEL F, 1990, P NATL ACAD SCI USA, V87, P4529, DOI 10.1073/pnas.87.12.4529; PERLINO E, 1987, EMBO J, V6, P2767, DOI 10.1002/j.1460-2075.1987.tb02571.x; POST T W, 1989, FASEB Journal, V3, pA368; POST TW, 1990, J IMMUNOL, V144, P740; REYCAMPOS J, 1990, GENOMICS, V7, P644, DOI 10.1016/0888-7543(90)90213-E; REYCAMPOS J, 1988, J EXP MED, V167, P664, DOI 10.1084/jem.167.2.664; REYCAMPOS J, 1987, J EXP MED, V166, P246, DOI 10.1084/jem.166.1.246; SCHARFSTEIN J, 1978, J EXP MED, V148, P207, DOI 10.1084/jem.148.1.207; SCHWALBE R, 1990, J BIOL CHEM, V265, P16074; SCHWALBE RA, 1990, J BIOL CHEM, V265, P21749; VELASCO E, 1992, HUM MOL GENET, V1, P552, DOI 10.1093/hmg/1.7.552-a; VIK DP, 1988, J BIOL CHEM, V263, P16720; WALKER FJ, 1984, J BIOL CHEM, V259, P335; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; WONG WW, 1989, J EXP MED, V169, P847, DOI 10.1084/jem.169.3.847	45	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15017	15023						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325877				2022-12-27	WOS:A1993LL75900071
J	KOTULA, L; DESILVA, TM; SPEICHER, DW; CURTIS, PJ				KOTULA, L; DESILVA, TM; SPEICHER, DW; CURTIS, PJ			FUNCTIONAL-CHARACTERIZATION OF RECOMBINANT HUMAN RED-CELL ALPHA-SPECTRIN POLYPEPTIDES CONTAINING THE TETRAMER BINDING-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE SPECTRIN; BETA-SPECTRIN; HEREDITARY ELLIPTOCYTOSIS; MOLECULAR DEFECT; SELF-ASSOCIATION; MUTATION; DOMAIN; CHAIN; PYROPOIKILOCYTOSIS; SKELETON	Spectrin, a heterodimer composed of alpha and beta subunits, interacts with itself head-to-head to form tetramers in the erythrocyte membrane cytoskeleton. The NH2-terminal region of alpha-spectrin, encompassing the alphaI 80-kDa domain, was expressed in Escherichia coli. In addition to the correctly initiated polypeptide, four smaller polypeptides were produced by initiation at internal codons. Only the full-length polypeptide was able to bind to spectrin dimers, beta monomers, and to a recombinant polypeptide containing the COOH terminus of beta-spectrin. The head-to-head interaction with beta-spectrin was also retained by a recombinant polypeptide containing the NH2-terminal 158 amino acids of the alpha subunit. Deletion of the first 27 or 49 NH2-terminal amino acids abolished binding of this polypeptide to the beta monomer. The phasing used to design these recombinant polypeptides was based on a conformational model recently refined by Speicher et al. (Speicher, D. W., DeSilva, T. M., Speicher, K. D., Ursitti, J. A., Hembach, P., and Weglarz, L. (1993) J. Biol. Chem. 268, 4227-4235), where the structural unit begins and terminates around residue 30 of the repeat unit. The binding properties, mobility on gel filtration, and circular dichroism data of the recombinant polypeptides indicated that most polypeptides were able to assume their native conformation.	WISTAR INST ANAT & BIOL,3601 SPRUCE ST,PHILADELPHIA,PA 19104	The Wistar Institute				Kotula, Leszek/0000-0002-7977-7124	NATIONAL CANCER INSTITUTE [P30CA010815] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033884, R01HL038794] Funding Source: NIH RePORTER; NCI NIH HHS [CA 10815] Funding Source: Medline; NHLBI NIH HHS [HL 38794, HL 33884] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT V, 1991, J CLIN INVEST, V87, P1483, DOI 10.1172/JCI115157; DESILVA TM, 1992, BIOCHEMISTRY-US, V31, P10872, DOI 10.1021/bi00159a030; EBER SW, 1988, J CLIN INVEST, V81, P523, DOI 10.1172/JCI113350; GALLAGHER PG, 1991, J BIOL CHEM, V266, P15154; HARLOW E, 1988, ANTIBODIES LABORATOR; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KENNEDY SP, 1991, J CELL BIOL, V115, P267, DOI 10.1083/jcb.115.1.267; KNOWLES WJ, 1983, J CLIN INVEST, V71, P1867, DOI 10.1172/JCI110942; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWLER J, 1982, J CLIN INVEST, V70, P1019, DOI 10.1172/JCI110689; Maniatis T., 1982, MOL CLONING; MORROW JS, 1980, P NATL ACAD SCI-BIOL, V77, P6592, DOI 10.1073/pnas.77.11.6592; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; PALEK J, 1990, SEMIN HEMATOL, V27, P290; POTHIER B, 1990, BLOOD, V75, P2061; SAHR KE, 1990, J BIOL CHEM, V265, P4434; SPEICHER DW, 1983, J BIOL CHEM, V258, P4938; SPEICHER DW, 1992, J BIOL CHEM, V267, P14775; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; SPEICHER DW, 1993, J BIOL CHEM, V268, P4227; SPEICHER DW, 1982, J BIOL CHEM, V257, P9093; TSE WT, 1990, J CLIN INVEST, V86, P909, DOI 10.1172/JCI114792; TSE WT, 1991, BLOOD, V78, P517; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788; YOON SH, 1991, J BIOL CHEM, V266, P8490; YURCHENCO PD, 1982, J BIOL CHEM, V257, P9102	27	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14788	14793						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325856				2022-12-27	WOS:A1993LL75900041
J	CLAUSMEYER, S; KLOSGEN, RB; HERRMANN, RG				CLAUSMEYER, S; KLOSGEN, RB; HERRMANN, RG			PROTEIN IMPORT INTO CHLOROPLASTS - THE HYDROPHILIC LUMENAL PROTEINS EXHIBIT UNEXPECTED IMPORT AND SORTING SPECIFICITIES IN SPITE OF STRUCTURALLY CONSERVED TRANSIT PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; CHLOROPHYLL A/B-PROTEIN; OUTER ENVELOPE MEMBRANE; THYLAKOID MEMBRANE; SMALL SUBUNIT; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; NUCLEOTIDE-SEQUENCE; PRECURSOR PROTEINS; PEA-CHLOROPLASTS; FOREIGN PROTEIN	Plastocyanin and the 16-, 23-, and 33-kDa polypeptides of the oxygen-evolving complex associated with photosystem II are hydrophilic, nuclear encoded components of the photosynthetic machinery that are all located in the lumen of thylakoid membranes. All four proteins are therefore imported into chloroplasts and, in addition, translocated across the thylakoid membrane. They share functionally equivalent, bipartite transit peptides, which are removed in two steps during or after import into the organelle and translocation across the thylakoid membrane, respectively. The transit peptides lack any homology at the sequence level but possess remarkably similar predicted secondary structures. We have studied the targeting potential of the authentic precursor molecules and all possible chimeric combinations generated by a specific, commonly applicable cassette system, which facilitates codon-correct reciprocal exchanges of transit peptides and mature parts. An unexpected specificity of import and sorting processes was found. All constructs can be imported into the organelle, though with greatly differing efficiency. On the other hand, the lumen-targeting parts are essential but not in all cases sufficient for correct intraorganellar routing. This implies that translocation across the thylakoid membrane appears not to depend merely on simple interactions of charged or hydrophobic regions between protein and membrane but requires an additional quality of information that includes the functional co-evolution of a transit peptide with its mature protein. Signaling and sorting appear to be essential at almost every step of the entire process for proper traffic regulation since distinct steps can be impaired (rate-limiting or arrested) in the individual combinations: the transfer across the envelope membranes (e.g. 16/PC) and the interaction with (e.g. 16/33) or the translocation across the thylakoid membrane (e.g. 33/23).	UNIV MUNICH,INST BOT,MENZINGER STR 67,W-8000 MUNICH 19,GERMANY	University of Munich								ANDERSSON B, 1984, BIOCHIM BIOPHYS ACTA, V766, P21, DOI 10.1016/0005-2728(84)90212-3; BARTLETT SG, 1982, METHODS CHLOROPLAST, P1081; BARTLING D, 1990, BOT MAG TOKYO, V2, P119; CAI D, 1993, PLANT J, V3, P383, DOI 10.1046/j.1365-313X.1993.t01-21-00999.x; CHITNIS PR, 1987, PLANT MOL BIOL, V10, P3, DOI 10.1007/BF00014181; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHUA NH, 1977, J CELL BIOL, V74, P441, DOI 10.1083/jcb.74.2.441; CLINE K, 1985, J BIOL CHEM, V260, P3691; CLINE K, 1992, J BIOL CHEM, V267, P2688; COHEN Y, 1992, EMBO J, V11, P79, DOI 10.1002/j.1460-2075.1992.tb05030.x; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DEBOER D, 1991, EMBO J, V10, P2765, DOI 10.1002/j.1460-2075.1991.tb07825.x; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; HAEHNEL W, 1986, ENCY PLANT PHYSL, P547; HAGEMAN J, 1990, PLANT CELL, V2, P479, DOI 10.1105/tpc.2.5.479; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; HAND JM, 1989, EMBO J, V8, P3195, DOI 10.1002/j.1460-2075.1989.tb08478.x; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; Herrmann R. G., 1991, Plant molecular biology 2. Proceedings of a NATO Advanced Study Institute, 14-23 May 1990, Elmau, Germany., P411; JAMES HE, 1989, J BIOL CHEM, V264, P19573; JANSEN T, 1987, FEBS LETT, V216, P234, DOI 10.1016/0014-5793(87)80696-8; JANSEN T, 1988, CURR GENET, V13, P517, DOI 10.1007/BF02427758; KARLINNEUMANN GA, 1986, EMBO J, V5, P9, DOI 10.1002/j.1460-2075.1986.tb04170.x; KEEGSTR AK, 1992, CELL ORGANELLES, P353; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KIRWIN PM, 1988, J BIOL CHEM, V263, P18123; KLOSGEN RB, 1992, PLANT MOL BIOL, V18, P1031, DOI 10.1007/BF00019226; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; KOTELCHU.D, 1968, P NATL ACAD SCI USA, V61, P1163, DOI 10.1073/pnas.61.4.1163; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; MEADOWS JW, 1989, FEBS LETT, V253, P244, DOI 10.1016/0014-5793(89)80968-8; MOULD RM, 1991, J BIOL CHEM, V266, P17286; MOULD RM, 1991, J BIOL CHEM, V266, P12189; MURAKAMI K, 1990, EMBO J, V9, P3201, DOI 10.1002/j.1460-2075.1990.tb07518.x; MUSGROVE JE, 1989, PLANT PHYSIOL, V90, P1616, DOI 10.1104/pp.90.4.1616; NAGANO K, 1973, J MOL BIOL, V75, P401, DOI 10.1016/0022-2836(73)90030-2; NEWMAN BJ, 1988, PLANT MOL BIOL, V10, P511, DOI 10.1007/BF00033606; OSTREM JA, 1989, J BIOL CHEM, V264, P3662; REISS B, 1987, MOL GEN GENET, V209, P116, DOI 10.1007/BF00329845; ROBSON B, 1971, J MOL BIOL, V58, P237, DOI 10.1016/0022-2836(71)90243-9; ROTHER C, 1986, CURR GENET, V11, P171, DOI 10.1007/BF00420603; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEIDLER A, 1990, EMBO J, V9, P1743, DOI 10.1002/j.1460-2075.1990.tb08298.x; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMEEKENS S, 1989, MOL GEN GENET, V216, P178, DOI 10.1007/BF00332249; THEG SM, 1989, J BIOL CHEM, V264, P6730; TYAGI A, 1987, MOL GEN GENET, V207, P288, DOI 10.1007/BF00331591; VALENTIN K, 1993, MOL GEN GENET, V236, P245, DOI 10.1007/BF00277119; VANDENBROECK G, 1985, NATURE, V313, P358, DOI 10.1038/313358a0; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1991, PLANT MOL BIOL REP, V9, P104; WASMANN CC, 1988, J BIOL CHEM, V263, P617; WASMANN CC, 1986, MOL GEN GENET, V205, P446, DOI 10.1007/BF00338081; WEDEL N, 1992, FEBS LETT, V314, P61, DOI 10.1016/0014-5793(92)81462-U; WESTHOFF P, 1985, PLANT MOL BIOL, V4, P137, DOI 10.1007/BF02418761	63	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13869	13876						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314754				2022-12-27	WOS:A1993LJ82500018
J	THISSEN, JA; CASEY, PJ				THISSEN, JA; CASEY, PJ			MICROSOMAL-MEMBRANES CONTAIN A HIGH-AFFINITY BINDING-SITE FOR PRENYLATED PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BOVINE BRAIN; ALPHA-SUBUNITS; BETA-GAMMA; PROTEINS	Prenylation and subsequent processing of many proteins involved in cellular signaling serves to direct and/or anchor these proteins to specific membranes in the cell. One major class of prenylated proteins contains the so-called CAAX motif, such proteins contain a cysteine residue fourth from the COOH terminus. After addition of the isoprenoid to this cysteine residue by specific cytosolic protein prenyltransferases, the proteins are subject to further processing by enzymes associated with microsomal membranes. This suggests that newly prenylated proteins are initially directed to a microsomal membrane compartment for completion of their processing. Using a radiolabeled, prenylated peptide as a ligand, we have identified a specific, high affinity binding site or receptor on microsomal membranes. This receptor is both protease- and heat-sensitive and exhibits saturable binding of the prenylated peptide with a K(D) of 30 nM. Competition analysis indicates that both geranylgeranylated and farnesylated, but not myristoylated, peptides bind to this receptor. A fully processed prenylated protein also does not compete, indicating a role for the three terminal residues of the prenylated peptide in receptor recognition. This receptor may serve to direct newly prenylated proteins to a microsomal compartment for completion of processing prior to trafficking to their final destination in the cell.	DUKE UNIV,MED CTR,CELL GROWTH REGULAT & ONCOGENESIS SECT,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University				Casey, Patrick/0000-0002-7366-9309				ASHBY MN, 1992, P NATL ACAD SCI USA, V89, P4613, DOI 10.1073/pnas.89.10.4613; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CASEY PJ, 1992, J LIPID RES, V33, P1731; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; ENTENMAN C, 1957, METHOD ENZYMOL, V3, P299, DOI 10.1016/S0076-6879(57)03395-9; Fleischer S, 1974, Methods Enzymol, V31, P6; GODDARD C, 1989, J BIOL CHEM, V264, P15173; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; LIMBIRD LE, 1986, CELL SURFACE RECEPTO; MA YT, 1992, BIOCHEMISTRY-US, V31, P11772, DOI 10.1021/bi00162a014; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; PEREZSALA D, 1992, BIOCHEM J, V284, P835, DOI 10.1042/bj2840835; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; VOLKER C, 1991, FEBS LETT, V295, P189, DOI 10.1016/0014-5793(91)81415-5; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	21	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13780	13783						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314746				2022-12-27	WOS:A1993LJ82500005
J	WADA, N; CHOU, JY				WADA, N; CHOU, JY			CHARACTERIZATION OF UPSTREAM ACTIVATION ELEMENTS ESSENTIAL FOR THE EXPRESSION OF GERM-CELL ALKALINE-PHOSPHATASE IN HUMAN CHORIOCARCINOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; GENE-EXPRESSION; BINDING-FACTOR; DNA-BINDING; CACCC-BOX; SEQUENCE; PROMOTER; SP1; PHOSPHATIDYLINOSITOL; TRANSFECTION	Expression of the germ cell alkaline phosphatase is a highly regulated process tied to malignant transformation of the human placenta. Human choriocarcinoma cells (malignant trophoblasts) express primarily the germ cell alkaline phosphatase gene and only low or nondetectable levels of the placental alkaline phosphatase normally found in the human placenta. Here, we show that nucleotides -156 to -1 region relative to the gene transcription start site (+1) contain cis-acting DNA elements that direct germ cell alkaline phosphatase expression in choriocarcinoma cells. Within the minimal activator region, at least three nuclear protein-binding sites, I (-63/-44), II (-87/-67), and III (-136/-103), were identified by DNase I footprinting analysis. All three sites are GC-rich. Sites I and II contain a sequence known to bind the transcription factor AP-2; the AP-2 site in site II overlaps a consensus motif for the transcription factor Sp1. Gel retardation experiments showed that similar nuclear protein factor(s) in JEG-3 choriocarcinoma cells bind to all three sites, with highest affinity to sites I and II. Site-directed mutagenesis that prevents binding of nuclear proteins to either site I or II, or both sites I and II, resulted in the loss of factor binding and reduced activator activity. The germ cell alkaline phosphatase promoter that contains an intact binding site III but altered sites I and II had little activator activity, suggesting that protein-protein interaction is important for germ cell alkaline phosphatase gene activation.	NICHHD,HUMAN GENET BRANCH,BLDG 10,RM 9S242,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								CHANG CH, 1980, CANCER RES, V40, P1506; CHU G, 1981, GENE, V13, P197, DOI 10.1016/0378-1119(81)90008-1; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DENG G, 1992, CANCER RES, V52, P3378; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOELLGAST GJ, 1982, HUMAN ALKALINE PHOSP, P25; FISHMAN L, 1976, CANCER RES, V36, P2268; FISHMAN WH, 1987, ADV CANCER RES, V48, P1, DOI 10.1016/S0065-230X(08)60689-2; FISHMAN WH, 1968, CANCER RES, V28, P150; FORDIS CM, 1986, METHOD ENZYMOL, V151, P382; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GOLDSTEIN DJ, 1982, CLIN CHIM ACTA, V125, P63, DOI 10.1016/0009-8981(82)90046-8; GUMUCIO DL, 1991, BLOOD, V78, P1853; HARRIS H, 1981, HARVEY LECT, V76, P95; HENTHORN PS, 1988, J BIOL CHEM, V263, P12011; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KNOLL BJ, 1988, J BIOL CHEM, V263, P12020; KNOLL BJ, 1987, GENE, V60, P267, DOI 10.1016/0378-1119(87)90235-6; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; LANGE PH, 1982, CANCER RES, V42, P3244; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MANTOVANI R, 1988, NUCLEIC ACIDS RES, V16, P4299, DOI 10.1093/nar/16.10.4299; MARTIN D, 1987, ANN HUM GENET, V51, P145, DOI 10.1111/j.1469-1809.1987.tb01056.x; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MICANOVIC R, 1988, P NATL ACAD SCI USA, V85, P1398, DOI 10.1073/pnas.85.5.1398; MILLAN JL, 1988, P NATL ACAD SCI USA, V85, P3024, DOI 10.1073/pnas.85.9.3024; NAKAYAMA T, 1970, CLIN CHIM ACTA, V30, P543; NOVAK ER, 1979, GYNECOLOGIC OBSTETRI, P476; OGATA S, 1988, J BIOL CHEM, V263, P10489; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; PATTILLO RA, 1968, CANCER RES, V28, P1231; POVINELLI CM, 1991, PLACENTA, V12, P663, DOI 10.1016/0143-4004(91)90500-F; SAKIYAMA T, 1978, ARCH BIOCHEM BIOPHYS, V191, P782, DOI 10.1016/0003-9861(78)90420-4; SAKIYAMA T, 1979, J BIOL CHEM, V254, P935; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; STIGBRAND T, 1982, ISOZYMES-CURR T BIOL, V6, P93; WAHREN B, 1979, INT J CANCER, V24, P749, DOI 10.1002/ijc.2910240608; WATANABE S, 1989, J BIOL CHEM, V264, P12611; WATANABE T, 1991, J BIOL CHEM, V266, P21174; WEISS MJ, 1988, J BIOL CHEM, V263, P12002; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670	49	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14003	14010						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314767				2022-12-27	WOS:A1993LJ82500036
J	GERBER, NC; SLIGAR, SG				GERBER, NC; SLIGAR, SG			A ROLE FOR ASP-251 IN CYTOCHROME P-450CAM OXYGEN ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PUTIDA CYTOCHROME-P-450; SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; REDUCED PUTIDAREDOXIN; SINGLE TURNOVER; BINDING; SUBSTRATE; COMPLEX; HYDROXYLATION; PEROXIDASES	We have mutated Asp-251, Thr-252, and Lys-178 in cytochrome P-450cam and studied their effect on steady-state P-450cam catalysis. The mutation of Asp-251 to Asn, which dramatically slows the reaction rate, affects a pH-dependent step in the reaction cycle. By examining the individual steps in the reaction cycle, we have determined that the effect of the D251N mutation occurs after dioxygen binding. Furthermore, our results suggest that the rate-limiting step of the D251N reaction cycle is the O-O bond scission event and that this residue also plays a crucial role in O-O bond scission in wild-type P-450cam. Based on homology with other P-450 enzymes and previous mutagenesis investigations, this role may be common to other P-450 systems, and we suggest a mechanism that is consistent with the effects of these mutations on enzyme activity.	UNIV ILLINOIS, DEPT CHEM, URBANA, IL 61801 USA; UNIV ILLINOIS, DEPT BIOCHEM, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031756, R01GM033775, R37GM031756] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31756, GM33775] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINS WM, 1987, J AM CHEM SOC, V109, P3754, DOI 10.1021/ja00246a038; ATKINS WM, 1988, BIOCHEMISTRY-US, V27, P1610, DOI 10.1021/bi00405a033; BOWRY VW, 1991, J AM CHEM SOC, V113, P5699, DOI 10.1021/ja00015a025; BREWER CB, 1988, J BIOL CHEM, V263, P791; BREWER CB, 1986, ARCH BIOCHEM BIOPHYS, V249, P515, DOI 10.1016/0003-9861(86)90029-9; DAVIES MD, 1992, BIOCHEMISTRY-US, V31, P11383, DOI 10.1021/bi00161a016; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; DUNFORD HB, 1982, ADV INORG BIOCHEM, V4, P41; EISENSTEIN L, 1977, BIOCHEM BIOPH RES CO, V77, P1377, DOI 10.1016/S0006-291X(77)80131-9; GERBER NC, 1992, J AM CHEM SOC, V114, P8742, DOI 10.1021/ja00048a081; GROVES JT, 1976, J AM CHEM SOC, V98, P859, DOI 10.1021/ja00419a049; GROVES JT, 1985, J CHEM EDUC, V62, P928, DOI 10.1021/ed062p928; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; Gunsalus I C, 1978, Methods Enzymol, V52, P166; GUNSALUS IC, 1973, IRON SULFUR PROTEINS, P151; HEDEGAARD J, 1965, J BIOL CHEM, V240, P4038; HINTZ MJ, 1981, J BIOL CHEM, V256, P6721; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; ISHIGOOKA M, 1992, BIOCHEMISTRY-US, V31, P1528, DOI 10.1021/bi00120a033; KATAGIRI M, 1968, J BIOL CHEM, V243, P3543; LOEW GH, 1980, J AM CHEM SOC, V102, P3655, DOI 10.1021/ja00530a073; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; MEYER E, 1992, PROTEIN SCI, V1, P1543, DOI 10.1002/pro.5560011203; NELSON DR, 1987, MOL BIOL EVOL, V4, P572; Ortiz de Montellano P.R., 2015, CYTOCHROME P450 STRU, P912; PEDERSON TC, 1977, MICROSOMES DRUG OXID, P275; PETERSON JA, 1972, ARCH BIOCHEM BIOPHYS, V149, P197, DOI 10.1016/0003-9861(72)90315-3; PETERSON JA, 1971, ARCH BIOCHEM BIOPHYS, V144, P678, DOI 10.1016/0003-9861(71)90375-4; POULOS TL, 1987, BIOCHEMISTRY-US, V26, P8165, DOI 10.1021/bi00399a022; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; RAAG R, 1989, BIOCHEMISTRY-US, V28, P7586, DOI 10.1021/bi00445a013; RAAG R, 1991, BIOCHEMISTRY-US, V30, P11420, DOI 10.1021/bi00112a008; RODGERS KK, 1991, J MOL BIOL, V221, P1453, DOI 10.1016/0022-2836(91)90945-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ CE, 1984, BIOCHEMISTRY-US, V23, P4743, DOI 10.1021/bi00315a033; SHIMADA H, 1990, INT S OXYGENASES OXY; SHIMADA H, 1993, 2ND INT S CYT P450 M; SLIGAR SG, 1976, BIOCHEMISTRY-US, V15, P5399, DOI 10.1021/bi00669a029; STAYTON PS, 1990, BIOCHEMISTRY-US, V29, P7381, DOI 10.1021/bi00484a005; TSAI R, 1970, P NATL ACAD SCI USA, V66, P1157, DOI 10.1073/pnas.66.4.1157; TSUBAKI M, 1989, BIOCHEMISTRY-US, V28, P9777, DOI 10.1021/bi00451a035; WAGNER GC, 1983, FEBS LETT, V156, P244, DOI 10.1016/0014-5793(83)80505-5; YONETANI T, 1966, J BIOL CHEM, V241, P3240; YU CA, 1974, J BIOL CHEM, V249, P102; ZHOU D, 1992, J BIOL CHEM, V267, P762	46	171	171	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4260	4266						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307990				2022-12-27	WOS:A1994MW98900057
J	HALLAK, H; BRASS, LF; MANNING, DR				HALLAK, H; BRASS, LF; MANNING, DR			FAILURE TO MYRISTOYLATE THE ALPHA-SUBUNIT OF G(Z) IS CORRELATED WITH AN INHIBITION OF PALMITOYLATION AND MEMBRANE ATTACHMENT, BUT HAS NO AFFECT ON PHOSPHORYLATION BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; PERTUSSIS TOXIN; PLASMA-MEMBRANE; HUMAN-PLATELETS; RAS PROTEINS; CELLS; ASSOCIATION; GZ; SUBSTRATE; SITE	The alpha subunit of the GTP-binding regulatory protein G(z) has been shown to be a substrate for N-myristoylation, palmitoylation, and protein kinase C-catalyzed phosphorylation. In the present study, we used an NH2-terminal Gly --> Ala mutation to examine the relevance of myristoylation to phosphorylation and anchorage. 293 cells were transfected with cDNA encoding the normal or mutant form of alpha(z). Normal alpha(z) was myristoylated and stably anchored, as assessed by biosynthetic labeling and sedimentation with membrane following cell lysis. The mutant form of alpha(z) was not myristoylated and was found predominantly (70-90%) in the cytosol. These distributions were corroborated by immunofluorescence microscopy. Thus, the NH2-terminal glycine of alpha(z) appears critical for both myristoylation and anchorage. The effects of the Gly --> Ala mutation, however, were not confined to these two events. Significantly, the mutation also prevented palmitoylation, which presumably occurs at Cys(3) in the normal subunit. Therefore, it cannot be concluded that myristoylation alone is sufficient for anchorage. The protein kinase C-catalyzed phosphorylation of alpha(z) was demonstrated previously to occur near to the NH2 terminus, raising the possibility of an effect of phosphorylation on anchorage or, conversely, an effect of myristoylation and/or palmitoylation on phosphorylation. The phosphorylation induced in 293 cells with phorbol 12-myristate 13-acetate, however, had little impact on anchorage. Moreover, the mutant (and thus cytosolic) form of alpha(z) was as good a substrate for phosphorylation as the normal subunit. The fact that myristoylation occurs in cells containing alpha(z) normally, as well as the fact that phosphorylation does not influence anchorage, was confirmed with mouse anterior pituitary AtT-20 and rat basophilic RBL-2H3 cells. These results demonstrate: 1) that mutagenesis of the glycine needed for myristoylation of alpha(z) also inhibits palmitoylation, 2) that the resultant lack of myristoylation and/or palmitoylation does not support anchorage, and 3) that neither myristoylation, palmitoylation, nor anchorage is required for phosphorylation.	UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania					NHLBI NIH HHS [HL45181] Funding Source: Medline; NIGMS NIH HHS [GM34781] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM034781] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; BERGER M, 1985, FEBS LETT, V187, P289, DOI 10.1016/0014-5793(85)81261-8; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CASNELLIE JE, 1986, J BIOL CHEM, V261, P4921; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HIDE M, 1991, MOL PHARMACOL, V40, P473; HINTON DR, 1990, J NEUROSCI, V10, P2763; HOLTZ D, 1989, CELL, V59, P969, DOI 10.1016/0092-8674(89)90753-8; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; LEWIS JM, 1991, CELL REGUL, V2, P1097, DOI 10.1091/mbc.2.12.1097; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; MAGEE AI, 1985, EMBO J, V4, P1137, DOI 10.1002/j.1460-2075.1985.tb03751.x; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; PARKER EM, 1991, J BIOL CHEM, V266, P519; ROCQUE WJ, 1993, J BIOL CHEM, V268, P9964; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; WILLIAMS AG, 1990, BLOOD, V76, P721; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957	40	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4571	4576						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308028				2022-12-27	WOS:A1994MW98900100
J	LEGOFF, P; MONTANO, MR; SCHODIN, DJ; KATZENELLENBOGEN, BS				LEGOFF, P; MONTANO, MR; SCHODIN, DJ; KATZENELLENBOGEN, BS			PHOSPHORYLATION OF THE HUMAN ESTROGEN-RECEPTOR - IDENTIFICATION OF HORMONE-REGULATED SITES AND EXAMINATION OF THEIR INFLUENCE ON TRANSCRIPTIONAL ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; DEPENDENT PROTEIN-KINASE; GROWTH FACTOR-I; PROGESTERONE-RECEPTOR; GLUCOCORTICOID RECEPTORS; RESPONSIVE ELEMENT; DOWN-REGULATION; DNA-BINDING; ACTIVATION; ANTIESTROGEN	We have used a transient transfection system with a cytomegalovirus-based vector expressing high levels of biologically active human estrogen receptor (ER) in COS-1 cells to study the phosphorylation of human ER and to identify major hormone-regulated phosphorylation sites. The features of phosphorylation of the wildtype ER were very similar to those previously observed for the endogenous ER in uterine cells: The ER exhibited a basal level of phosphorylation which was increased similar to 3-4-fold by estrogen (estradiol) and by antiestrogens (hydroxytamoxifen and ICI164,384), and phosphorylation was increased to an almost similar extent by activation of either protein kinase A or C signal transduction pathways with cholera toxin plus isobutyl methylxanthine (CT+IBMX) or phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), respectively. Phosphoamino acid analysis revealed that the phosphorylation occurred exclusively on serine residues in all cases. Tryptic phosphopeptide analysis of ER, using a two-dimensional peptide mapping procedure, revealed similar patterns for ER in cells treated with estradiol, antiestrogens or TPA; with CT+IBMX treatment, the same phosphopeptides were seen, but the relative phosphorylation of the different ER phosphotryptic peptides differed. In ER deleted of the NH2-terminal A and B (A/B) domains, estrogen and antiestrogen-stimulated phosphorylations were abolished, while the phosphorylation induced by CT+IBMX was maintained. This suggests that sites of phosphorylation enhanced by estradiol and antiestrogen, but not those induced by CT+IBMX, are located in the A/B domain. These results were further confirmed by comparing the tryptic phosphopeptide patterns of wild-type and A/B-deleted receptor upon estradiol and CT+IBMX treatments, and then by site directed mutagenesis, by substituting alanines for the serine residues in the AIS domain (Ser(104), Ser(106), Ser(118), Ser(154), and Ser(167)) involved in known protein kinase consensus sequences. Comparison of the tryptic phosphopeptide patterns of wild-type ER and these mutant ERs allowed us to identify serine 104 and/or serine 106 and serine 118, all three being part of a serine-proline moth, the preferred substrate of proline-directed protein kinase, as major ER phosphorylation sites. When tested with two estrogen responsive reporter gene constructs in several cell types, the mutant S104A, S106A, S118A showed a similar to 40% reduction in transactivation activity in response to E(2), while the mutants S118A and S104A, S106A alone showed a similar to 15% decrease in transactivation. Our studies identify several serines in the NH2-terminal portion of the human ER as being major hormone-regulated phosphorylation sites. The location of these sites in one of the two transactivation domains of the ER is consistent with their modulatory effects on transcriptional activity of the human ER.	UNIV ILLINOIS, DEPT PHYSIOL & BIOPHYS, URBANA, IL 61801 USA; UNIV ILLINOIS, COLL MED, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign			LE GOFF, PASCALE/K-1842-2015	LE GOFF, PASCALE/0000-0002-3931-2197	NCI NIH HHS [CA18119, CA51482] Funding Source: Medline; NICHD NIH HHS [T32 HD7028] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007028] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R37CA018119, R01CA051482, R01CA018119] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ARONICA SM, 1991, ENDOCRINOLOGY, V128, P2045, DOI 10.1210/endo-128-4-2045; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; AURICCHIO F, 1989, J STEROID BIOCHEM, V32, P613, DOI 10.1016/0022-4731(89)90397-X; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHAUCHEREAU A, 1991, J BIOL CHEM, V266, P18280; CHO H, 1993, MOL ENDOCRINOL, V7, P441, DOI 10.1210/me.7.3.441; CHRISTENSEN K, 1991, MOL ENDOCRINOL, V5, P1755, DOI 10.1210/mend-5-11-1755; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DENTON RR, 1992, J BIOL CHEM, V267, P7263; ECKERT RL, 1984, ENDOCRINOLOGY, V114, P629, DOI 10.1210/endo-114-2-629; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HALL FL, 1991, J BIOL CHEM, V266, P17430; Ham J, 1989, CURR OPIN CELL BIOL, V1, P503, DOI 10.1016/0955-0674(89)90012-4; HOECK W, 1989, J BIOL CHEM, V264, P14396; IMAKADO S, 1991, J BIOCHEM-TOKYO, V109, P684, DOI 10.1093/oxfordjournals.jbchem.a123441; KATZENELLENBOGE.BS, 1983, J STEROID BIOCHEM, V18, P59; KATZENELLENBOGEN BS, 1985, BREAST CANCER RES TR, V5, P231, DOI 10.1007/BF01806018; KATZENELLENBOGEN BS, 1990, ENDOCRINOLOGY, V126, P891, DOI 10.1210/endo-126-2-891; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEGOFF P, 1992, ENDOCRINOLOGY S, V130; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MONSMA FJ, 1984, ENDOCRINOLOGY, V115, P143, DOI 10.1210/endo-115-1-143; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; ORTI E, 1989, J BIOL CHEM, V264, P9728; PAKDEL F, 1992, J BIOL CHEM, V267, P3429; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; REESE JC, 1991, NUCLEIC ACIDS RES, V19, P6595, DOI 10.1093/nar/19.23.6595; REESE JC, 1991, J BIOL CHEM, V266, P10880; SHERIDAN PL, 1988, MOL ENDOCRINOL, V2, P1329, DOI 10.1210/mend-2-12-1329; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WASHBURN T, 1991, MOL ENDOCRINOL, V5, P235, DOI 10.1210/mend-5-2-235; WILKINSON JM, 1986, PRACTICAL PROTEIN CH, P122; WRENN CK, 1990, MOL ENDOCRINOL, V4, P1647, DOI 10.1210/mend-4-11-1647	42	375	381	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4458	4466						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308015				2022-12-27	WOS:A1994MW98900086
J	LUTSENKO, S; KAPLAN, JH				LUTSENKO, S; KAPLAN, JH			MOLECULAR EVENTS IN CLOSE PROXIMITY TO THE MEMBRANE-ASSOCIATED WITH THE BINDING OF LIGANDS TO THE NA,K-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; OUTER MEDULLA; (NA,K)-ATPASE; OCCLUSION; PROTEINS; KIDNEY; NA+,K+-ATPASE; DIGESTION; CLEAVAGE; SEQUENCE	The membrane-bound fraction of purified Na,K-ATPase was characterized following extensive proteolytic digestion in the presence of various physiological ligands which stabilize different conformational states of the sodium pump. There are distinctive conformational changes of the protein which are revealed by amino-terminal amino acid sequence analysis of the digests following sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The changes in cleavage patterns result from alterations in domain-domain interactions of the protein. We provide evidence in the alpha-subunit for (i) tight interaction between part of the cytoplasmic ATP binding domain and the membrane-bound portion of the protein; (ii) involvement of the cytoplasmic loop between M2 and M3 in structural rearrangements upon phosphorylation or ion binding; (iii) generation of the same digested products when either ouabain or potassium (rubidium) is present. Similarly, evidence is provided for conformational sensitivity of the extracellular domain of the beta-subunit. The position of the tryptic cleavage point in the beta-subunit is altered depending on whether the alpha-subunit is phosphorylated or whether rubidium ions are occluded. Based upon the conformationally dependent patterns of exposure and protection of different tryptic cleavage sites in the alpha- and beta-subunits we propose a model for intraprotein interactions within the alpha-subunit and between alpha- and beta-subunits following the binding of physiological ligands to the Na,K-ATPase.	UNIV PENN, DEPT PHYSIOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania				Kaplan, Jack/0000-0002-7048-6574	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039500] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39500] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGUELLO JM, 1991, J BIOL CHEM, V266, P14627; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; BROTHERUS JR, 1981, BIOCHEM BIOPH RES CO, V100, P146, DOI 10.1016/S0006-291X(81)80075-7; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; DZHANDZHUGAZYAN KN, 1988, NAPLUS KPLUS PUMP, V268, P181; ELLISDAVIES GCR, 1993, J BIOL CHEM, V268, P11622; FORBUSH B, 1982, J BIOL CHEM, V257, P2678; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JORGENSEN PL, 1986, BIOCHIM BIOPHYS ACTA, V860, P570, DOI 10.1016/0005-2736(86)90555-9; JORGENSEN PL, 1975, BIOCHIM BIOPHYS ACTA, V401, P399, DOI 10.1016/0005-2736(75)90239-4; KAPLAN JH, 1985, ANNU REV PHYSIOL, V47, P535, DOI 10.1146/annurev.ph.47.030185.002535; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KIRLEY TL, 1991, J BIOL CHEM, V266, P19953; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; LUTSENKO S, 1992, ANN NY ACAD SCI, V671, P147, DOI 10.1111/j.1749-6632.1992.tb43792.x; LUTSENKO S, 1993, BIOPHYS J, V64, pA331; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MODYANOV NN, 1990, SODIUM PUMP, P99; NICHOLAS RA, 1984, BIOCHEMISTRY-US, V23, P888, DOI 10.1021/bi00300a015; OHTA T, 1986, FEBS LETT, V204, P297, DOI 10.1016/0014-5793(86)80832-8; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P269, DOI 10.1016/0014-5793(87)80676-2; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHANI M, 1987, BIOCHIM BIOPHYS ACTA, V904, P13, DOI 10.1016/0005-2736(87)90081-2; TANIGUCHI K, 1993, J BIOL CHEM, V268, P15588; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x	32	72	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4555	4564						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308026				2022-12-27	WOS:A1994MW98900098
J	RAGONE, R; COLONNA, G				RAGONE, R; COLONNA, G			ENTHALPY-ENTROPY BALANCE AND CONVERGENCE TEMPERATURES IN PROTEIN UNFOLDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLAR HEAT-CAPACITY; HYDROPHOBIC INTERACTION; GLOBULAR-PROTEINS; HYDRATION; THERMODYNAMICS; STABILITY; WATER	We find that isoenthalpic and isoentropic temperatures characterizing the unfolding of small globular proteins are linked by a simple relationship, which takes into account the occurrence of common values of specific unfolding enthalpy and entropy changes. The difference between these temperatures implies that the hydration effect favors protein folding over a quite large range of temperatures.			RAGONE, R (corresponding author), UNIV NAPLES 2, DEPT BIOCHEM & BIOPHYS, VIA COSTANTINOPOLI 16, I-80138 NAPLES, ITALY.		Colonna, Giovanni/AAY-3568-2021	Colonna, Giovanni/0000-0002-0473-1455				BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; BALDWIN RL, 1992, P NATL ACAD SCI USA, V89, P7110, DOI 10.1073/pnas.89.15.7110; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; Creighton TE, 1991, CURR OPIN STRUC BIOL, V1, P5, DOI 10.1016/0959-440X(91)90004-D; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DOIG AJ, 1992, BIOCHEMISTRY-US, V31, P9371, DOI 10.1021/bi00154a007; FU L, 1992, P NATL ACAD SCI USA, V89, P9335, DOI 10.1073/pnas.89.19.9335; GILL SJ, 1985, J PHYS CHEM-US, V89, P3758, DOI 10.1021/j100263a034; LEE B, 1991, P NATL ACAD SCI USA, V88, P5154, DOI 10.1073/pnas.88.12.5154; MAKHATADZE GI, 1990, J MOL BIOL, V213, P375, DOI 10.1016/S0022-2836(05)80197-4; MULLER N, 1992, TRENDS BIOCHEM SCI, V17, P459, DOI 10.1016/0968-0004(92)90488-U; MULLER N, 1990, ACCOUNTS CHEM RES, V23, P23, DOI 10.1021/ar00169a005; MURPHY KP, 1990, SCIENCE, V247, P559, DOI 10.1126/science.2300815; MURPHY KP, 1992, J MOL BIOL, V227, P293, DOI 10.1016/0022-2836(92)90699-K; MURPHY KP, 1991, J MOL BIOL, V222, P699, DOI 10.1016/0022-2836(91)90506-2; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; PRIVALOV PL, 1990, SCIENCE, V250, P298; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; PRIVALOV PL, 1992, J MOL BIOL, V224, P715, DOI 10.1016/0022-2836(92)90555-X; PRIVALOV PL, 1990, J MOL BIOL, V213, P385, DOI 10.1016/S0022-2836(05)80198-6; RAGONE R, 1993, STUD ORG CHEM, V47, P451; SPOLAR RS, 1992, BIOCHEMISTRY-US, V31, P3947, DOI 10.1021/bi00131a009	22	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4047	4049						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307961				2022-12-27	WOS:A1994MW98900025
J	WELLS, GB; MUSTAFI, D; MAKINEN, MW				WELLS, GB; MUSTAFI, D; MAKINEN, MW			STRUCTURE AT THE ACTIVE-SITE OF AN ACYLENZYME OF ALPHA-CHYMOTRYPSIN AND IMPLICATIONS FOR THE CATALYTIC MECHANISM - AN ELECTRON-NUCLEAR DOUBLE-RESONANCE STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATE KINETIC-PARAMETERS; LABELED AMINO-ACIDS; FROZEN-SOLUTIONS; STEREOELECTRONIC CONTROL; CARBOXYPEPTIDASE-A; SUBZERO TEMPERATURES; COMPUTER-GRAPHICS; SERINE PROTEASES; SPIN-LABELS; HYDROLYSIS	The structure of the acylenzyme intermediate in the hydrolysis of the specific spin-label ester substrate methyl N-(2,2,5,5-tetramethyl-1-oxypyrrolinyl-3-carbon-yl)-L-tryptophanate and its fluoro analogs catalyzed by alpha-chymotrypsin (EC 3.4.21.1) has been determined by electron nuclear double resonance (ENDOR) and molecular modeling methods. By a combination of kinetic and cryoenzymology methods, we have established conditions to stabilize the spin-labeled acylenzyme reaction intermediate. Proton ENDOR features specific for the substrate were assigned on the basis of specific deuteration. From the observed ENDOR shifts for pro tons and fluorines that correspond to principal hyperfine coupling components, the dipolar hyperfine coupling contributions were calculated to estimate electron-nucleus distances. With these dipolar separations as constraints, conformations of the substrate both free in solution and in the active site of alpha-chymotrypsin were determined by molecular graphics analysis. Comparison of the conformation of the bound substrate to that of the free substrate showed that formation of the acylenzyme requires significant torsional alteration in substrate structure. The structural relationships between active site residues and the substrate in its ENDOR-assigned conformation are examined with respect to the requirements of stereoelectronic rules for formation and breakdown of the acylenzyme species.	UNIV CHICAGO,CUMMINGS LIFE SCI CTR,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	University of Chicago			Wells, Gregg/AAU-7798-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007281, R01GM021900] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 07281, GM 21900] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BENDER M L, 1973, Critical Reviews in Biochemistry, V1, P149, DOI 10.3109/10409237309102546; BENDER ML, 1965, ANNU REV BIOCHEM, V34, P49, DOI 10.1146/annurev.bi.34.070165.000405; BENDER ML, 1964, J AM CHEM SOC, V86, P3697, DOI 10.1021/ja01072a019; BIRKTOFT JJ, 1972, J MOL BIOL, V68, P187, DOI 10.1016/0022-2836(72)90210-0; BIZZOZERO SA, 1981, BIOORG CHEM, V10, P46, DOI 10.1016/0045-2068(81)90042-0; BIZZOZERO SA, 1975, FEBS LETT, V59, P105, DOI 10.1016/0014-5793(75)80351-6; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; BLOW DM, 1976, ACCOUNTS CHEM RES, V9, P145, DOI 10.1021/ar50100a004; BRANDT KG, 1967, J BIOL CHEM, V242, P3973; CARTWRIGHT SJ, 1981, CRC CRIT REV BIOCH, V11, P145; CHURG AK, 1978, REV SCI INSTRUM, V49, P212, DOI 10.1063/1.1135368; COTRAIT PM, 1974, ACTA CRYSTALLOGR B, V30, P510; DAYRINGER HE, 1986, J MOL GRAPHICS, V4, P82; DESLONGCHAMPS P, 1975, TETRAHEDRON, V31, P2463, DOI 10.1016/0040-4020(75)80257-2; Deslongchamps P, 1983, STEREOELECTRONIC EFF, P54; DIXON M, 1953, BIOCHEM J, V55, P161, DOI 10.1042/bj0550161; DOUZOU P, 1977, CRYOBIOCHEMISTRY, P286; FINK AL, 1973, BIOCHEMISTRY-US, V12, P1736, DOI 10.1021/bi00733a012; FINK AL, 1979, BIOCHEM J, V181, P733, DOI 10.1042/bj1810733; FINK AL, 1973, ARCH BIOCHEM BIOPHYS, V155, P473, DOI 10.1016/0003-9861(73)90139-2; FRIEDEN C, 1993, TRENDS BIOCHEM SCI, V18, P56; GORENSTEIN DG, 1984, BIOPHYS J, V46, P749, DOI 10.1016/S0006-3495(84)84073-4; GREENSTEIN JP, 1984, CHEM AMINO ACIDS, V3, P2344; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HENDERSON R, 1970, Journal of Molecular Biology, V54, P341, DOI 10.1016/0022-2836(70)90434-1; IIJIMA H, 1987, PROTEINS, V2, P330, DOI 10.1002/prot.340020408; INGLES DW, 1968, BIOCHEM J, V108, P561, DOI 10.1042/bj1080561; JOELA H, 1991, J PHYS CHEM-US, V95, P9135, DOI 10.1021/j100176a021; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KUNUGI S, 1979, J AM CHEM SOC, V101, P3640, DOI 10.1021/ja00507a034; KUNUGI S, 1978, ARCH BIOCHEM BIOPHYS, V189, P298, DOI 10.1016/0003-9861(78)90216-3; KUO LC, 1983, J MOL BIOL, V163, P63, DOI 10.1016/0022-2836(83)90030-X; Lambert J. B., 1971, TOP STEREOCHEM, P19; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEHN JM, 1980, J AM CHEM SOC, V102, P1347, DOI 10.1021/ja00524a019; LIENHARD GE, 1971, COLD SPRING HARB SYM, V36, P45, DOI 10.1101/SQB.1972.036.01.009; LUMRY R, 1971, J PHYS CHEM-US, V75, P1387, DOI 10.1021/j100680a007; MAKINEN MW, 1989, J MOL BIOL, V207, P201, DOI 10.1016/0022-2836(89)90451-8; MAKINEN MW, 1977, ANNU REV BIOPHYS BIO, V6, P301, DOI 10.1146/annurev.bb.06.060177.001505; MARET W, 1991, J BIOL CHEM, V266, P20636; MATTHEWS BW, 1967, NATURE, V214, P652, DOI 10.1038/214652a0; MCCONN J, 1971, J BIOL CHEM, V246, P2918; MUSTAFI D, 1990, J AM CHEM SOC, V112, P2558, DOI 10.1021/ja00163a012; MUSTAFI D, 1990, BIOPOLYMERS, V29, P45, DOI 10.1002/bip.360290108; MUSTAFI D, 1991, J MAGN RESON, V91, P497, DOI 10.1016/0022-2364(91)90376-5; MUSTAFI D, 1994, J BIOL CHEM, V269, P4587; MUSTAFI D, 1993, J AM CHEM SOC, V115, P3674, DOI 10.1021/ja00062a037; MUSTAFI D, 1990, FREE RADICAL RES COM, V10, P95, DOI 10.3109/10715769009145938; MUSTAFI D, 1988, INORG CHEM, V27, P3360, DOI 10.1021/ic00292a020; NARUTO S, 1985, J AM CHEM SOC, V107, P5262, DOI 10.1021/ja00304a037; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; PETKOV D, 1978, BIOCHIM BIOPHYS ACTA, V527, P131, DOI 10.1016/0005-2744(78)90262-0; PHILLIPS DC, 1966, SCI AM, V215, P78, DOI 10.1038/scientificamerican1166-78; Rozantsev E.G., 1970, FREE NITROXYL RADICA, P203; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHONBAUM G, 1961, J BIOL CHEM, V236, P2930; SEGAL DM, 1971, COLD SPRING HARB SYM, V36, P85, DOI 10.1101/SQB.1972.036.01.014; SEGAL DM, 1971, BIOCHEMISTRY-US, V10, P3728; STEITZ TA, 1969, J MOL BIOL, V46, P337, DOI 10.1016/0022-2836(69)90426-4; Tipton K F, 1979, Methods Enzymol, V63, P183; TSUKADA H, 1985, J MOL BIOL, V184, P703, DOI 10.1016/0022-2836(85)90314-6; TURLEY JW, 1972, ACTA CRYSTALL B-STRU, VB 28, P1641, DOI 10.1107/S0567740872004765; VALLEE BL, 1968, P NATL ACAD SCI USA, V59, P498, DOI 10.1073/pnas.59.2.498; WARSHEL A, 1976, J MOL BIOL, V103, P227, DOI 10.1016/0022-2836(76)90311-9; WARSHEL A, 1978, P NATL ACAD SCI USA, V75, P5250, DOI 10.1073/pnas.75.11.5250; WELLS GB, 1988, J AM CHEM SOC, V110, P6343, DOI 10.1021/ja00227a012; WELLS GB, 1990, J AM CHEM SOC, V112, P2566, DOI 10.1021/ja00163a013; WELLS GB, 1987, THESIS U CHICAGO; WILLIAMS RJP, 1971, COLD SPRING HARB SYM, V36, P53, DOI 10.1101/SQB.1972.036.01.010; YIM MB, 1986, J MAGN RESON, V70, P89, DOI 10.1016/0022-2364(86)90365-3; ZERNER B, 1964, J AM CHEM SOC, V86, P3674, DOI 10.1021/ja01072a016	72	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4577	4586						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308029				2022-12-27	WOS:A1994MW98900101
J	LODGE, JK; JOHNSON, RL; WEINBERG, RA; GORDON, JI				LODGE, JK; JOHNSON, RL; WEINBERG, RA; GORDON, JI			COMPARISON OF MYRISTOYL-COA PROTEIN N-MYRISTOYLTRANSFERASES FROM 3 PATHOGENIC FUNGI - CRYPTOCOCCUS-NEOFORMANS, HISTOPLASMA-CAPSULATUM, AND CANDIDA-ALBICANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; FATTY-ACID SYNTHETASE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SUBSTRATE SPECIFICITIES; COENZYME-A; FACTOR ARF; YEAST; GENE; SEQUENCES	Myristoyl-CoA:protein N-myristoyltransferase (Nmt) transfers myristate from CoA to the N-terminal Gly residue of cellular proteins in an ordered reaction mechanism that first involves binding of myristoyl-CoA to the apoenzyme. The gene encoding Saccharomyces cerevisiae Nmt1p (NMT1) is essential for vegetative growth. Candida albicans, Cryptococcus neoformans var. neoformans, and Histoplasma capsulatum are the principal causes of systemic fungal infections in immunocompromised humans. Metabolic labeling studies indicate that they synthesize a small set of cellular N-myristoylproteins during exponential growth on rich media, the most prominent of which co-migrate with two essential functionally interchangeable S. cerevisiae N-myristoylproteins, ADP ribosylation factor-1 (Arf1p) and Arf2p. NMT and ARF genes have been recovered from C. neoformans and H. capsulatum using the polymerase chain reaction. They are single copy genes, interrupted by multiple introns. C. neoformans and H. capsulatum Nmts have approximately 50% amino acid sequence identity with the orthologous S. cerevisiae, C. albicans, and Homo sapiens N-myristoyltransferases, whereas C. neoformans and H. capsulatum Arfs are approximately 80% identical with C. albicans Arf and S. cerevisiae Arf1p and Arf2p. Functional studies of C. neoformans and C. albicans Nmts conducted in Escherichia coli reveal that (i) both efficiently acylate S. cerevisiae Arf2p; (ii) C. neoformans Arf is a substrate for C. neoformans Nmt; and (iii) substitution of an Asp for a Gly located 5 residues from the C terminus of these two enzymes causes marked temperature-dependent reductions in their catalytic efficiency, just as it does with S. cerevisiae and H. sapiens Nmts. Wild type C. neoformans, C. albicans, and H. sapiens NMTs can fully complement the lethal phenotype of a S. cerevisiae nmt1 null allele at 24 and 37-degrees-C when the GAL1-10 promoter controlling their expression is induced by galactose. Only the C. albicans enzyme is able to do so when the promoter is repressed with glucose. This complementation profile likely arises, at least in part, from differences in the protein substrate specificities of the orthologous Nmts. A Gly --> Asp mutation in S. cerevisiae, C. neoformans, C. albicans, and H. sapiens Nmts produces temperature-sensitive growth arrest in isogenic S. cerevisiae strains with a nmt1 null allele. Growth of strains producing the mutant C. albicans or H. sapiens, but not the C. neoformans, enzyme can be rescued by myristate at the nonpermissive temperature (37-degrees-C) even in the presence of cerulenin, an inhibitor of fatty acid synthetase. These latter observations suggest that C. neoformans nmt487D's requirements for, or ability to access to, myristoyl-CoA in S. cerevisiae may differ from those of the Candida or human enzymes. Together, these results emphasize that S. cerevisiae provides an attractive surrogate environment for evaluating functional similarities and differences among orthologous Nmts and for identifying mutant alleles of fungal NMTs that can be used to determine whether protein N-myristoylation is required to maintain the viabilty of these organisms.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,BOX 8103,660 S EUCLID AVE,ST LOUIS,MO 63110; MONSANTO CO,CORP RES LABS,CHESTERFIELD,MO 63198	Washington University (WUSTL); Monsanto				Lodge, Jennifer/0000-0002-2526-1210	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027179, U01AI030188] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30188, AI27179] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALCH WE, 1992, J BIOL CHEM, V267, P13053; DENICH KT, 1992, GENE, V110, P123, DOI 10.1016/0378-1119(92)90455-X; DISMUKES WE, 1988, J INFECT DIS, V157, P624, DOI 10.1093/infdis/157.4.624; DUPONT B, 1992, J MED VET MYCOL, V30, P19; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; DURONIO RJ, 1992, J CELL BIOL, V117, P515, DOI 10.1083/jcb.117.3.515; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; DURONIO RJ, 1991, J CELL BIOL, V113, P1313, DOI 10.1083/jcb.113.6.1313; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; DURONIO RJ, 1991, J BIOL CHEM, V266, P10498; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; EDMAN JC, 1990, MOL CELL BIOL, V10, P4538, DOI 10.1128/MCB.10.9.4538; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FOLZ RJ, 1987, BIOCHEM BIOPH RES CO, V146, P870, DOI 10.1016/0006-291X(87)90611-5; FUNABASHI H, 1989, J BIOCHEM-TOKYO, V105, P751, DOI 10.1093/oxfordjournals.jbchem.a122739; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HERMAN PK, 1991, EMBO J, V10, P4049, DOI 10.1002/j.1460-2075.1991.tb04981.x; HEUCKEROTH RO, 1988, J BIOL CHEM, V263, P2127; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HORI T, 1987, J BIOCHEM-TOKYO, V101, P949, DOI 10.1093/oxfordjournals.jbchem.a121964; JOHNSON DR, 1993, J BIOL CHEM, V268, P483; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KNOLL LJ, 1993, J BIOL CHEM, V268, P4281; KNOLL LJ, 1992, J BIOL CHEM, V267, P5366; KURTZ MB, 1989, MOL GEN GENET, V217, P47, DOI 10.1007/BF00330941; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGNER CA, 1992, J BIOL CHEM, V267, P17159; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; MCILHINNEY RAJ, 1993, BIOCHEM J, V290, P405, DOI 10.1042/bj2900405; MCPHERSON MJ, 1992, PCR PRACTICAL APPROA, P171; OSE TM, 1992, P NATL ACAD SCI USA, V89, P11287; PAIGE LA, 1989, J MED CHEM, V32, P1667; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PALTAUF F, 1992, MOL CELLULAR BIOL YE, V2, P415; PERFECT JR, 1992, GENE, V122, P213, DOI 10.1016/0378-1119(92)90053-R; PERFECT JR, 1991, M INT SOC HUMAN ANIM; ROCQUE WJ, 1993, J BIOL CHEM, V268, P9964; RUDNICK DA, 1992, J BIOL CHEM, V267, P23852; RUDNICK DA, 1993, ADV ENZYMOL RAMB, V67, P375; RUDNICK DA, 1993, P NATL ACAD SCI USA, V90, P1087, DOI 10.1073/pnas.90.3.1087; RUDNICK DA, 1990, J BIOL CHEM, V265, P13370; RUDNICK DA, 1992, P NATL ACAD SCI USA, V89, P10507, DOI 10.1073/pnas.89.21.10507; RUDNICK DA, 1991, J BIOL CHEM, V266, P9732; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERER S, 1990, MICROBIOL REV, V54, P226, DOI 10.1128/MMBR.54.3.226-241.1990; SCHWEIZER E, 1978, MOL CELL BIOCHEM, V21, P95; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGH N, 1985, BIOCHEMISTRY-US, V24, P6598, DOI 10.1021/bi00344a044; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STONE DE, 1991, GENE DEV, V5, P1969, DOI 10.1101/gad.5.11.1969; TOFFALETTI DL, 1993, J BACTERIOL, V175, P1405, DOI 10.1128/JB.175.5.1405-1411.1993; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; VARMA A, 1992, INFECT IMMUN, V60, P1101, DOI 10.1128/IAI.60.3.1101-1108.1992; VARMA A, 1991, J CLIN MICROBIOL, V29, P810, DOI 10.1128/JCM.29.4.810-812.1991; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Wheat L J, 1988, Infect Dis Clin North Am, V2, P841; WIEGAND RC, 1992, J BIOL CHEM, V267, P8591; WOOD DC, 1993, J BIOL CHEM, V268, P4889; WOODS JP, 1992, MOL MICROBIOL, V6, P3603, DOI 10.1111/j.1365-2958.1992.tb01796.x; WORSHAM PL, 1988, J MED VET MYCOL, V26, P137; WORSHAM PL, 1990, MOL GEN GENET, V221, P358, DOI 10.1007/BF00259400	68	105	113	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2996	3009						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300631				2022-12-27	WOS:A1994MV43200091
J	ROOF, WD; HORNE, SM; YOUNG, KD; YOUNG, R				ROOF, WD; HORNE, SM; YOUNG, KD; YOUNG, R			SLYD, A HOST GENE REQUIRED FOR PHI-X174 LYSIS, IS RELATED TO THE FK506-BINDING PROTEIN FAMILY OF PEPTIDYL-PROLYL CIS-TRANS-ISOMERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; NUCLEOTIDE-SEQUENCE; BACTERIOPHAGE; CLONING; REGION; MICROCOMPUTER; EXPRESSION; ALIGNMENT; MUTANTS	Recessive mutations in the slyD gene were isolated by selecting for survival after induction of the cloned lysis gene E of bacteriophage phiX174 (Maratea, D., Young, K., and Young, R. (1985) Gene (Amst.) 40, 39-46). The slyD1 mutation, transduced into the normal phiX174 host, Escherichia coli C, confers an absolute block on the plaque-forming ability of the wild-type phage, indicating that slyD is required for E function rather than for expression from the plasmid vector. The cloning, sequencing, and deletion analysis of a 1-kilobase pair genomic fragment containing the slyD locus, mapping at 73.5', is reported. Three reading frames, orf72, orf159, and orf196, are contained within this fragment, with the latter two reading frames occupying the same DNA on opposite strands. Deletion analysis shows that the complementing activity is restricted to the orf159/orf196 DNA. Complementation of the SlyD phenotype was observed irrespective of the orientation of the orf159/orf196 DNA with respect to a vector promoter, indicating that a cryptic promoter serves slyD on this fragment. Using site-directed mutagenesis, nonsense mutations were created in each reading frame which were silent in the opposing frame. Both orf196 nonsense alleles failed to complement slyD1, whereas both ort159 nonsense alleles retained complementation, demonstrating rigorously that or/796 is slyD. A segment corresponding to the first 150 residues of the predicted SlyD protein has significant similarity throughout its length to the FKBP family of peptidyl-prolyl cis-trans-isomerases or rotamases. The COOH-terminal 46 codons of SlyD encode a remarkable histidine-rich peptide sequence which is at least partly dispensable for slyD function in E-mediated lysis. Overexpression of slyD in E. coli is toxic. These findings are discussed in terms of a model for SlyD involvement in E function and in terms of the general biological role of the ubiquitous FKBP rotamases.	TEXAS A&M UNIV,DEPT BIOCHEM & BIOPHYS,COLL STN,TX 77843; UNIV N DAKOTA,SCH MED,DEPT MICROBIOL & IMMUNOL,GRAND FORKS,ND 58202	Texas A&M University System; Texas A&M University College Station; University of North Dakota Grand Forks			Young, Kevin/A-7954-2013	Young, Kevin/0000-0003-1760-281X; Young, Ry/0000-0001-8001-2914	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027099, R01GM027099] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM027099, GM27099] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARRELL BG, 1976, NATURE, V264, P34, DOI 10.1038/264034a0; BLASI U, 1985, J GEN VIROL, V66, P1209, DOI 10.1099/0022-1317-66-6-1209; BLASI U, 1989, J BIOL CHEM, V264, P4552; BLASI U, 1989, EMBO J, V8, P3501, DOI 10.1002/j.1460-2075.1989.tb08515.x; BLASI U, 1985, J GEN MICROBIOL, V131, P1107; BOUVIER J, 1991, NUCLEIC ACIDS RES, V19, P180, DOI 10.1093/nar/19.1.180; BRADLEY DE, 1969, J GEN VIROL, V5, P113, DOI 10.1099/0022-1317-5-1-113; BUCKLEY KJ, 1986, MOL GEN GENET, V204, P120, DOI 10.1007/BF00330198; CHEN CM, 1990, J BIOL CHEM, V265, P4461; DENHARDT DT, 1965, J MOL BIOL, V12, P641, DOI 10.1016/S0022-2836(65)80318-7; DENHARDT DT, 1965, J MOL BIOL, V12, P647, DOI 10.1016/S0022-2836(65)80319-9; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GODSON GN, 1978, SINGLE STRANDED DNA, P51; GOOSEN N, 1987, PHAGE MU, P41; GROISMAN EA, 1986, J BACTERIOL, V168, P357, DOI 10.1128/jb.168.1.357-364.1986; HAYANO T, 1991, BIOCHEMISTRY-US, V30, P3041, DOI 10.1021/bi00226a009; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HOCHULI E, 1988, J CHROMATOGR, V444, P293, DOI 10.1016/S0021-9673(01)94032-4; HUTCHISON CA, 1966, J MOL BIOL, V18, P429, DOI 10.1016/S0022-2836(66)80035-9; IPPEN K, 1971, J BACTERIOL, V108, P5, DOI 10.1128/JB.108.1.5-9.1971; ISAKI L, 1990, J BACTERIOL, V172, P6512, DOI 10.1128/jb.172.11.6512-6517.1990; ITO K, 1983, CELL, V32, P789, DOI 10.1016/0092-8674(83)90065-X; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; MAKINO K, 1991, J BACTERIOL, V173, P2665, DOI 10.1128/jb.173.8.2665-2672.1991; MARATEA D, 1985, GENE, V40, P39, DOI 10.1016/0378-1119(85)90022-8; Miller J.H., 1972, EXPT MOL GENETICS; NADEAU K, 1993, J BIOL CHEM, V268, P1479; ROOF WD, 1993, J BACTERIOL, V175, P3909, DOI 10.1128/JB.175.12.3909-3912.1993; Sambrook J, 1989, MOL CLONING LABORATO; SHADEL GS, 1992, J BIOL CHEM, V267, P7696; SHPAKOVSKI GV, 1988, NUCLEIC ACIDS RES, V16, P1019; SUNSHINE MG, 1971, VIROLOGY, V46, P691, DOI 10.1016/0042-6822(71)90071-7; TAYLOR DP, 1977, J BACTERIOL, V132, P986, DOI 10.1128/JB.132.3.986-995.1977; TRANDINH CC, 1992, FASEB J, V6, P3410, DOI 10.1096/fasebj.6.15.1464374; VANGIJSEGEM F, 1987, PHAGE MU, P215; WITTE A, 1990, J BACTERIOL, V172, P4109, DOI 10.1128/jb.172.7.4109-4114.1990; WULFING C, 1994, J BIOL CHEM, V269, P2895; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; YOUNG KD, 1982, J VIROL, V44, P993, DOI 10.1128/JVI.44.3.993-1002.1982; YOUNG RY, 1992, MICROBIOL REV, V56, P430, DOI 10.1128/MMBR.56.3.430-481.1992	43	113	119	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2902	2910						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300625				2022-12-27	WOS:A1994MV43200080
J	WALKER, P; MUNOZ, M; MARTINEZ, R; PEITSCH, MC				WALKER, P; MUNOZ, M; MARTINEZ, R; PEITSCH, MC			ACIDIC RESIDUES IN EXTRACELLULAR LOOPS OF THE HUMAN-Y1 NEUROPEPTIDE-Y RECEPTOR ARE ESSENTIAL FOR LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; PANCREATIC-POLYPEPTIDE; PEPTIDE-YY; G-PROTEIN; AGONIST; IDENTIFICATION; MUTAGENESIS; DYNAMICS; CLONING; BRAIN	To investigate whether negatively charged residues of the human Y1 neuropeptide Y (NPY) receptor are required for ligand binding, a series of mutants were constructed in which aspartic acid and glutamic acid residues present in putative extracellular domains of the Y1 receptor were systematically replaced by alanines. The mutant cDNAs were transiently expressed in HeLa cells using a vaccinia virus-derived expression system, and their ability to bind NPY was evaluated. The level of expression of mutants unable to bind NPY was also tested immunologically. In addition, the ability of the mutant proteins to be recruited to the cell surface was assessed by confocal microscopy. Substitution of aspartic acids and glutamic acids of the N-terminal first extracellular domain had no effect on binding. On the other hand, substitution of acidic residues present in the second, third, and fourth extracellular loops resulted in proteins unable to bind I-125-NPY. These results demonstrate that the extracellular loops of the human Y1 NPY receptor are essential portions of its ligand binding domain.	UNIV LAUSANNE,INST BIOCHEM,CH-1066 EPALINGES,SWITZERLAND	University of Lausanne	WALKER, P (corresponding author), CHU VAUDOIS,DIV HYPERTENS,CH-1011 LAUSANNE,SWITZERLAND.		Peitsch, Manuel/J-7416-2017	Peitsch, Manuel/0000-0001-5324-359X				ALLEN J, 1987, P NATL ACAD SCI USA, V84, P2532, DOI 10.1073/pnas.84.8.2532; BALASUBRAMANIAM A, 1990, PEPTIDES, V11, P545, DOI 10.1016/0196-9781(90)90057-C; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BECK A, 1989, FEBS LETT, V244, P119, DOI 10.1016/0014-5793(89)81175-5; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; BLUNDELL TL, 1981, P NATL ACAD SCI-BIOL, V78, P4175, DOI 10.1073/pnas.78.7.4175; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DAHL SG, 1991, P NATL ACAD SCI USA, V88, P8111, DOI 10.1073/pnas.88.18.8111; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FUHLENDORFF J, 1990, P NATL ACAD SCI USA, V87, P182, DOI 10.1073/pnas.87.1.182; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; HACKENTHAL E, 1987, AM J PHYSIOL, V252, pF543, DOI 10.1152/ajprenal.1987.252.3.F543; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; HILBERT MF, 1993, TRENDS PHARMACOL SCI, V14, P7; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; KASSIS S, 1987, J BIOL CHEM, V262, P3429; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KIRBY DA, 1993, J MED CHEM, V36, P385, DOI 10.1021/jm00055a010; KRAUSE J, 1992, MOL PHARMACOL, V41, P817; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LEHMANN J, 1990, DRUG DEVELOP RES, V19, P329, DOI 10.1002/ddr.430190402; MACKERELL AD, 1988, J COMPUT AID MOL DES, V2, P55, DOI 10.1007/BF01532053; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEITSCH MC, 1993, INT IMMUNOL, V5, P233, DOI 10.1093/intimm/5.2.233; PETTERSSON M, 1987, CELL TISSUE RES, V248, P43, DOI 10.1007/BF01239960; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; STANLEY BG, 1986, PEPTIDES, V7, P1189; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; UNDEN A, 1984, EUR J BIOCHEM, V145, P525, DOI 10.1111/j.1432-1033.1984.tb08588.x; WAEBER B, 1988, AM J HYPERTENS, V1, P193, DOI 10.1093/ajh/1.2.193; WAHLESTEDT C, 1986, REGUL PEPTIDES, V13, P307, DOI 10.1016/0167-0115(86)90048-0; WALKER P, 1991, TRENDS PHARMACOL SCI, V12, P111, DOI 10.1016/0165-6147(91)90518-W; WALKER P, 1992, MOL CELL ENDOCRINOL, V91, P107	42	93	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2863	2869						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300621				2022-12-27	WOS:A1994MV43200075
J	CAO, XM; MAHENDRAN, R; GUY, GR; TAN, YH				CAO, XM; MAHENDRAN, R; GUY, GR; TAN, YH			DETECTION AND CHARACTERIZATION OF CELLULAR EGR-1 BINDING TO ITS RECOGNITION SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILMS-TUMOR GENE; GROWTH-FACTOR; C-FOS; TRANSCRIPTION FACTORS; INDUCIBLE GENES; PROTO-ONCOGENE; PROMOTER; EXPRESSION; CELLS; REPRESSION	Most of what is known of the Egr-1 DNA binding site GCGGGGGCG was originally identified by experiments using DNA sequences and bacterially expressed or in vitro translated EGR-1 protein. Here we report the binding of cellular EGR-1 protein derived from HeLa, mouse and human fibroblasts to its consensus sequence. Binding is strongly but transiently stimulated in these cells by serum, phorbol ester, or by okadaic acid, an inhibitor of protein serine/threonine phosphatases 1 and 2A, suggesting the regulation of this gene expression and its DNA binding activity to be under the control of protein kinase(s) and phosphatase(s). When EGR-1 synthesis is stimulated under the above conditions, binding of the transcription factor Spl to its recognition site in the Egr-1 promoter is reduced with a concomitant appearance of EGR-1 DNA binding. This is likely a result of competition between Sp1 and the newly synthesized EGR-1, since there is a partial overlap in the binding sequences recognized by these proteins. In cotransfection experiments EGR-1 activated transcription through multiple copies of GCGGGGGCG 5' to a minimum promoter of c-fos. Interestingly, EGR-1 is shown to down-regulate the transcription of its own gene expression, whereas Sp1 activated Egr-1 gene expression. The detection of cellular EGR-1 binding to the Egr-1 consensus sequence in the different cell types provides a model for studying the mechanism by which an immediate-early gene is regulated by various ligands.			CAO, XM (corresponding author), NATL UNIV SINGAPORE, SIGNAL TRANSDUCT LAB INST MOLEC & CELL BIOL, 10 KENT RIDGE CRESCENT, SINGAPORE 0511, SINGAPORE.		Mahendran, Ratha/B-3827-2012					ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAO XM, 1992, J BIOL CHEM, V267, P1345; CAO XM, 1992, J BIOL CHEM, V267, P12991; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LIM RW, 1989, MOL CELL BIOL, V9, P1790, DOI 10.1128/MCB.9.4.1790; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUNAGA E, 1981, HUM GENET, V57, P231; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SUGGS SV, 1990, NUCLEIC ACIDS RES, V18, P4283, DOI 10.1093/nar/18.14.4283; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAN SH, 1992, NUCLEIC ACIDS RES, V20, P251, DOI 10.1093/nar/20.2.251; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WANG ZY, 1992, J BIOL CHEM, V267, P21999	42	171	184	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16949	16957						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349585				2022-12-27	WOS:A1993LQ98800014
J	CHOU, KC				CHOU, KC			A VECTORIZED SEQUENCE-COUPLING MODEL FOR PREDICTING HIV PROTEASE CLEAVAGE SITES IN PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RETROVIRAL PROTEASES; INHIBITOR; SUBSTRATE; MATURATION; INFECTION; AIDS	What kind of peptide sequences can be cleaved by HIV protease, and what kind cannot be? This is a crucially important problem in designing effective inhibitors against HIV protease as potential drugs for AIDS therapy. To tackle this problem, a sequence-coupling and vectorized model is proposed for predicting the cleavability of oligopeptides by proteases with multiple and extended specificity subsites. In comparison with existing methods, the new method has proved to be an improvement in both the accuracy of the model and the rationality of the statistical treatment. Meanwhile, the Monte Carlo sampling procedure introduced here has also proved to be very useful in dealing with the situation when the experimental data are insufficiently sampled for complete statistics. Owing to its very high rate of correct prediction, it is expected that the new method can be a useful technique for helping to find effective inhibitors of HIV protease, which is one of the targets in designing potential drugs against AIDS. The principle of the new method can also be applied to analyzing the specificity of any multi-subsite enzyme.			CHOU, KC (corresponding author), UPJOHN CO, DEPT COMPUTAT CHEM, KALAMAZOO, MI 49001 USA.		Chou, Kuo-Chen/A-8340-2009					ASHORN P, 1990, P NATL ACAD SCI USA, V87, P7472, DOI 10.1073/pnas.87.19.7472; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BHAT UN, 1984, ELEMENTS APPLIED STO, pCH3; CHOU KC, 1992, EUR J BIOCHEM, V207, P429, DOI 10.1111/j.1432-1033.1992.tb17067.x; CHOU KC, 1981, CHEM SCRIPTA, V18, P126; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GRIFFITHS JT, 1992, BIOCHEMISTRY-US, V31, P5193, DOI 10.1021/bi00137a015; HELLEN CUT, 1989, BIOCHEMISTRY-US, V28, P9881, DOI 10.1021/bi00452a001; HENDERSON LE, 1988, J VIROL, V62, P2587, DOI 10.1128/JVI.62.8.2587-2595.1988; KABSCH W, 1983, FEBS LETT, V155, P179, DOI 10.1016/0014-5793(82)80597-8; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; MARTEL P, 1992, PROG BIOPHYS MOL BIO, V57, P129, DOI 10.1016/0079-6107(92)90023-Y; MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486; MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; PARTIN K, 1990, J VIROL, V64, P3938, DOI 10.1128/JVI.64.8.3938-3947.1990; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; POORMAN RA, 1991, J BIOL CHEM, V266, P14554; PUTNEY S, 1992, TRENDS BIOCHEM SCI, V17, P191, DOI 10.1016/0968-0004(92)90265-B; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; TOH H, 1985, NATURE, V315, P691, DOI 10.1038/315691a0; TOMASSELLI AG, 1991, ADV EXP MED BIOL, V306, P469; TOZSER J, 1992, BIOCHEMISTRY-US, V31, P4793, DOI 10.1021/bi00135a008; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; ZHANG CT, 1992, BIOPHYS J, V63, P1523, DOI 10.1016/S0006-3495(92)81728-9	27	291	293	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16938	16948						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349584				2022-12-27	WOS:A1993LQ98800013
J	HEMER, F; KORNER, C; BRAULKE, T				HEMER, F; KORNER, C; BRAULKE, T			PHOSPHORYLATION OF THE HUMAN 46-KDA MANNOSE 6-PHOSPHATE RECEPTOR IN THE CYTOPLASMIC DOMAIN AT SERINE-56	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II RECEPTOR; CELL-SURFACE; PROTEIN PHOSPHATASES; LYSOSOMAL-ENZYMES; ENDOCYTOSIS; SIGNALS; INTERNALIZATION; REDISTRIBUTION; BIOSYNTHESIS; SPECIFICITY	The human 46-kDa mannose 6-phosphate receptor (MPR46) is phosphorylated in its cytoplasmic domain at serine residues. Substitution of cytoplasmic serines (at positions 35 and 56) with alanine, expression of mutant receptors in baby hamster kidney cells, and phosphopeptide mapping revealed that serine 56 is phosphorylated. Mutant MPR46 and wild-type MPR46 were found to be similarly distributed between the cell surface and intracellular membranes. Phosphate incorporation in the presence of cycloheximide indicates that phosphorylation occurred on pre-existing MPR46. Similar half-lives for the wild-type and mutant receptor proteins (approximately 43 h) and the receptor-associated phosphate (1.4 h) were found. The mutant receptors were internalized at the same rate as the wild-type receptors. Expression of mutant MPR46 and wild-type MPR46 in mouse L-cells deficient in 300-kDa mannose 6-phosphate receptors did not affect the sorting of newly synthesized cathepsin D to lysosomes. Phosphorylation of cytoplasmic serine 56 is therefore essential neither for stability nor for cell-surface expression and transport activities of MPR46.	UNIV GOTTINGEN, INST BIOCHEM 2, GOSSLERSTR 12D, W-3400 GOTTINGEN, GERMANY	University of Gottingen			Braulke, Thomas/AAV-9121-2020	Braulke, Thomas/0000-0002-2336-8532				BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRAULKE T, 1992, BIOCHIM BIOPHYS ACTA, V1138, P334, DOI 10.1016/0925-4439(92)90012-C; BRAULKE T, 1992, J BIOL CHEM, V267, P17347; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COOPER PC, 1982, ANAL BIOCHEM, V126, P301, DOI 10.1016/0003-2697(82)90519-X; CORVERA S, 1985, P NATL ACAD SCI USA, V82, P7314, DOI 10.1073/pnas.82.21.7314; CORVERA S, 1988, P NATL ACAD SCI USA, V85, P7567, DOI 10.1073/pnas.85.20.7567; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAMKE H, 1991, J BIOL CHEM, V266, P24829; GEFFEN I, 1991, P NATL ACAD SCI USA, V88, P8425, DOI 10.1073/pnas.88.19.8425; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HILDEBRANDT E, 1989, ANAL BIOCHEM, V177, P407, DOI 10.1016/0003-2697(89)90075-4; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; MERESSE S, 1990, J BIOL CHEM, V265, P18833; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POHLMANN R, 1987, P NATL ACAD SCI USA, V84, P5575, DOI 10.1073/pnas.84.16.5575; ROSORIUS O, 1993, BIOCHEM J, V292, P833, DOI 10.1042/bj2920833; ROTHENBERGER S, 1987, CELL, V49, P423, DOI 10.1016/0092-8674(87)90295-9; SAYERS JR, 1989, PROTEIN FUNCTION PRA, P279; STEIN M, 1987, BIOL CHEM H-S, V368, P927, DOI 10.1515/bchm3.1987.368.2.927; STEIN M, 1987, BIOL CHEM H-S, V368, P937, DOI 10.1515/bchm3.1987.368.2.937; WAHEED A, 1990, EUR J BIOCHEM, V193, P47, DOI 10.1111/j.1432-1033.1990.tb19302.x; WATANABE H, 1990, P NATL ACAD SCI USA, V87, P8036, DOI 10.1073/pnas.87.20.8036; WENDLAND M, 1991, J BIOL CHEM, V266, P2917; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X	37	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17108	17113						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349600				2022-12-27	WOS:A1993LQ98800036
J	WINDSOR, LJ; GRENETT, H; BIRKEDALHANSEN, B; BODDEN, MK; ENGLER, JA; BIRKEDALHANSEN, H				WINDSOR, LJ; GRENETT, H; BIRKEDALHANSEN, B; BODDEN, MK; ENGLER, JA; BIRKEDALHANSEN, H			CELL-TYPE-SPECIFIC REGULATION OF SL-1 AND SL-2 GENES - INDUCTION OF THE SL-2 GENE BUT NOT THE SL-1 GENE BY HUMAN KERATINOCYTES IN RESPONSE TO CYTOKINES AND PHORBOLESTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; CULTURED HUMAN KERATINOCYTES; HUMAN FIBROBLAST COLLAGENASE; FACTOR-ALPHA; TISSUE INHIBITOR; SYNOVIAL FIBROBLASTS; IV COLLAGENASE; METALLOPROTEINASE INHIBITOR; DIFFERENTIAL EXPRESSION; MONOCLONAL-ANTIBODY	The stromelysin-2 (SL-2) gene is transcriptionally active in normal human keratinocytes and encodes a secreted, catalytically competent but latent matrix metalloproteinase. Phorbolester induction resulted in the emergence of SL-2 (but not SL-1 transcripts), whereas the opposite was true for human mucosal fibroblasts. Expression of keratinocyte SL-2 was also induced by the two keratinocyte growth factors, transforming growth factor-alpha and epidermal growth factor, by the proinflammatory cytokine, tumor necrosis factor-alpha, but, somewhat surprisingly, not by interleukin-1beta. The latent SL-2 proenzyme was isolated from 12-O-tetradecanoylphorbol-13-acetate-induced keratinocytes by immunoaffinity chromatography using a cross-reactive antibody raised against human SL-1. This procedure led to the recovery of a single M(r) 54,000 molecular species at a level of almost-equal-to 0.2 mug/ml of culture medium. Amino-terminal sequencing identified the protein as SL-2 and verified the predicted signal sequence cleavage site. Conformational activation of latent SL-2 precursor by SDS gave rise to a full-length, uncleaved (M(r) 54,000) active form and at the same time exposed a cryptic thiol group. By contrast, organomercurial activation resulted in autolytic truncation of the molecule with loss of M(r) almost-equal-to 10,000 propeptide. SL-2 shared with (human fibroblast) SL-1 the ability to cleave casein, to ''superactivate'' fibroblast type procollagenase, and to form apparently binary, SDS-resistant complexes with tissue inhibitor of metalloproteinases-1.	UNIV ALABAMA, SCH DENT, DEPT ORAL BIOL, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH DENT, ORAL BIOL RES CTR, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH DENT, DEPT DIAGNOST SCI, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT BIOCHEM, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NIDCR NIH HHS [DE08228, DE06028, DE10631] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010631, R01DE006028, P50DE008228] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALTSCHUH D, 1992, BIOCHEMISTRY-US, V31, P6298, DOI 10.1021/bi00142a019; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BAUER EA, 1988, ANN NY ACAD SCI, V548, P174, DOI 10.1111/j.1749-6632.1988.tb18804.x; BAUER EA, 1977, J INVEST DERMATOL, V69, P363, DOI 10.1111/1523-1747.ep12510240; Birkedal-Hansen H, 1992, Matrix Suppl, V1, P368; BIRKEDALHANSEN B, 1988, BIOCHEMISTRY-US, V27, P6751, DOI 10.1021/bi00418a016; BIRKEDALHANSEN H, 1982, BIOCHEM BIOPH RES CO, V107, P1173, DOI 10.1016/S0006-291X(82)80120-4; BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BIRKEDALHANSEN H, 1992, MATRIX SPECIAL S, V1; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; CHIN JR, 1985, J BIOL CHEM, V260, P2367; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; GREEN MR, 1983, DEV BIOL, V100, P506, DOI 10.1016/0012-1606(83)90243-9; GRENETT HE, 1991, GENE, V101, P267, DOI 10.1016/0378-1119(91)90422-8; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; JOHNSONMULLER B, 1978, P NATL ACAD SCI USA, V75, P4417, DOI 10.1073/pnas.75.9.4417; JOHNSONWINT B, 1985, J BIOL CHEM, V260, P2080; JOHNSONWINT B, 1984, J CELL BIOL, V98, P90, DOI 10.1083/jcb.98.1.90; JOHNSONWINT B, 1980, P NATL ACAD SCI-BIOL, V77, P5331, DOI 10.1073/pnas.77.9.5331; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KLEINER DE, 1992, BIOCHEMISTRY-US, V31, P1665, DOI 10.1021/bi00121a013; LEGENDRE N, 1990, Biotechniques, V9, P788; LIN HY, 1987, J BIOL CHEM, V262, P6823; LYONS JG, 1991, BIOCHEMISTRY-US, V30, P1449, DOI 10.1021/bi00220a001; LYONS JG, 1991, PERIODONTAL DISEASE, P291; LYONS JG, 1993, IN PRESS J BIOL CHEM; MACNAUL KL, 1990, J BIOL CHEM, V265, P17238; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; Nagase H, 1992, Matrix Suppl, V1, P421; NICHOLSON R, 1989, BIOCHEMISTRY-US, V28, P5195, DOI 10.1021/bi00438a042; NORDLUND L, 1991, J PERIODONTAL RES, V26, P333, DOI 10.1111/j.1600-0765.1991.tb02071.x; PETERSEN MJ, 1987, J BIOL CHEM, V262, P835; SALO T, 1991, J BIOL CHEM, V266, P11436; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scherrer K., 1969, FUNDAMENTAL TECHNIQU, P413; SCHULTZ GS, 1987, SCIENCE, V235, P350, DOI 10.1126/science.3492044; SIRUM KL, 1989, BIOCHEMISTRY-US, V28, P8691, DOI 10.1021/bi00448a004; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; TURKSEN K, 1991, CELL REGUL, V2, P613, DOI 10.1091/mbc.2.8.613; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILLE JI, 1984, J CELL PHYSL, V121, P835; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	59	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17341	17347						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349617				2022-12-27	WOS:A1993LQ98800068
J	FONTAINE, T; DHULST, C; MADDELEIN, ML; ROUTIER, F; PEPIN, TM; DECQ, A; WIERUSZESKI, JM; DELRUE, B; VANDENKOORNHUYSE, N; BOSSU, JP; FOURNET, B; BALL, S				FONTAINE, T; DHULST, C; MADDELEIN, ML; ROUTIER, F; PEPIN, TM; DECQ, A; WIERUSZESKI, JM; DELRUE, B; VANDENKOORNHUYSE, N; BOSSU, JP; FOURNET, B; BALL, S			TOWARD AN UNDERSTANDING OF THE BIOGENESIS OF THE STARCH GRANULE - EVIDENCE THAT CHLAMYDOMONAS SOLUBLE STARCH SYNTHASE-II CONTROLS THE SYNTHESIS OF INTERMEDIATE SIZE GLUCANS OF AMYLOPECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLANUM-TUBEROSUM-L; ZEA-MAYS-L; GLYCOGEN-SYNTHASE; SACCHAROMYCES-CEREVISIAE; BRANCHING ENZYME; STRUCTURAL GENE; WAXY LOCUS; MAIZE; PURIFICATION; REINHARDTII	Low starch mutants of Chlamydomonas reinhardtii were isolated after x-ray mutagenesis of wild-type strain 137C. The mutants accumulated 20-40% of the normal amount and displayed a 2-fold decrease of the total glycogen-primed soluble starch synthase activity. Three different mutant alleles of the st-3 gene were isolated that were characterized by similar defects and displayed a net increase in amylose content. Amylose-primed synthesis of glucan in native gels revealed a complete wipe out of one of the soluble starch synthases. Zymograms and kinetic analyses performed both in the mutant and in partially purified wild type extracts reveal at least two distinct activities that are partly analogous to higher plant soluble starch synthases I and II (SSI and II). The st-3 mutants were defective for SSII. Methylation and debranching of the purified amylopectin fraction clearly show a decrease in the number of intermediate size glucans (dp8 to 50) and an absolute and relative increase of very short glucans (dp2 to 7). These results suggest that a soluble starch synthase may be necessary for the synthesis or maintenance of intermediate size glucans that are the main component of the branched clusters of amylopectin.	UNIV LILLE 01, CHIM BIOL LAB, CNRS, UNITE MIXTE RECH 111, F-59655 VILLENEUVE DASCQ, FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille			MADDELEIN, Marie-Lise/G-5395-2010; Fontaine, Thierry/F-8227-2011; Fontaine, thierry/Q-2201-2018; Routier, Francoise/O-1611-2019; D'Hulst, Christophe/AAX-2809-2020; D'HULST, Christophe/B-2072-2012	Fontaine, thierry/0000-0002-8184-789X; D'Hulst, Christophe/0000-0002-5556-9099; D'HULST, Christophe/0000-0002-5556-9099; Routier, Francoise/0000-0002-7163-0590; Ball, Steven/0000-0003-1629-1650				BABA T, 1987, STARCH-STARKE, V39, P52, DOI 10.1002/star.19870390207; BALL S, 1991, PLANTA, V185, P17, DOI 10.1007/BF00194509; BALL SG, 1990, PLANT SCI, V66, P1, DOI 10.1016/0168-9452(90)90162-H; BHATTACHARYYA MK, 1990, CELL, V60, P115, DOI 10.1016/0092-8674(90)90721-P; BOYER CD, 1981, PLANT PHYSIOL, V67, P1141, DOI 10.1104/pp.67.6.1141; BOYER CD, 1978, CARBOHYD RES, V61, P321, DOI 10.1016/S0008-6215(00)84492-4; BOYER CD, 1980, STARKE, V32, P217, DOI 10.1002/star.19800320702; COLONNA P, 1984, CARBOHYD RES, V126, P233, DOI 10.1016/0008-6215(84)85381-1; CREECH RG, 1965, GENETICS, V52, P1175; DAIS P, 1982, CARBOHYD RES, V100, P103, DOI 10.1016/S0008-6215(00)81029-0; DELRUE B, 1992, J BACTERIOL, V174, P3612, DOI 10.1128/JB.174.11.3612-3620.1992; ECHT CS, 1981, GENETICS, V99, P275; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FARKAS I, 1990, J BIOL CHEM, V265, P20879; GIDLEY MJ, 1985, CARBOHYD RES, V139, P85; Harris EH, 1989, CHLAMYDOMONAS SOURCE, P25, DOI [DOI 10.1016/B978-0-12-326880-8.50007-9, DOI 10.1126/SCIENCE.246.4936.1503-A]; HEDMAN KD, 1982, BIOCHEM GENET, V20, P483, DOI 10.1007/BF00484699; HOVENKAMPHERMELINK JHM, 1987, THEOR APPL GENET, V75, P217, DOI 10.1007/BF00249167; INOUCHI N, 1987, STARCH-STARKE, V39, P259, DOI 10.1002/star.19870390802; KONISHI Y, 1985, AGR BIOL CHEM TOKYO, V49, P1965, DOI 10.1080/00021369.1985.10867018; KOSSMANN J, 1991, MOL GEN GENET, V230, P39, DOI 10.1007/BF00290648; LELOIR LF, 1961, J BIOL CHEM, V236, P636; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD FD, 1985, PLANT PHYSIOL, V78, P849, DOI 10.1104/pp.78.4.849; MANNERS DJ, 1989, CARBOHYD POLYM, V11, P87, DOI 10.1016/0144-8617(89)90018-0; OZBUN JL, 1971, PLANT PHYSIOL, V48, P765, DOI 10.1104/pp.48.6.765; PARENTE JP, 1985, CARBOHYD RES, V141, P41, DOI 10.1016/S0008-6215(00)90753-5; PENG ZY, 1990, J BIOL CHEM, V265, P13871; Preiss J., 1980, The biochemistry of plants. A comprehensive treatise. Volume 3. Carbohydrates: structure and function., P371; PREISS J, 1967, ARCH BIOCHEM BIOPHYS, V118, P702, DOI 10.1016/0003-9861(67)90407-9; Preiss J., 1980, MECHANISMS SACCHARID, P161; Preiss J, 1991, OXFORD SURVEYS PLANT, V7, P59; Shannon J., 1984, STARCH CHEM TECHNOLO, P25, DOI 10.1016/B978-0-12-746270-7.50009-4; SHURE M, 1983, CELL, V35, P225, DOI 10.1016/0092-8674(83)90225-8; SINGH BK, 1985, PLANT PHYSIOL, V79, P34, DOI 10.1104/pp.79.1.34; TAKEDA Y, 1993, CARBOHYD RES, V240, P253, DOI 10.1016/0008-6215(93)84188-C; TAKEDA Y, 1993, CARBOHYD RES, V240, P265, DOI 10.1016/0008-6215(93)84189-D; TAKEDA Y, 1986, CARBOHYD RES, V148, P299, DOI 10.1016/S0008-6215(00)90397-5; THORN W, 1990, STARCH-STARKE, V42, P455, DOI 10.1002/star.19900421202; VANDERLEIJ FR, 1991, MOL GEN GENET, V228, P240, DOI 10.1007/BF00282472; Weatherwax P, 1922, GENETICS, V7, P568; YEH JY, 1981, STARKE, V33, P222, DOI 10.1002/star.19810330703	42	108	117	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16223	16230						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344907				2022-12-27	WOS:A1993LQ33600023
J	GAUSE, KC; HOMMA, MK; LICCIARDI, KA; SEGER, R; AHN, NG; PETERSON, MJ; KREBS, EG; MEIER, KE				GAUSE, KC; HOMMA, MK; LICCIARDI, KA; SEGER, R; AHN, NG; PETERSON, MJ; KREBS, EG; MEIER, KE			EFFECTS OF PHORBOL ESTER ON MITOGEN-ACTIVATED PROTEIN-KINASE KINASE-ACTIVITY IN WILD-TYPE AND PHORBOL ESTER-RESISTANT EL4 THYMOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; NUCLEAR-LOCALIZATION; SIGNAL TRANSDUCTION; PHOSPHORYLATION; CASCADE; RAS; IDENTIFICATION; INVITRO; RAF-1; RSK	Phorbol ester-sensitive and -resistant EL4 thymoma cell lines differ in their ability to activate mitogen-activated protein kinase (MAPK) in response to phorbol ester. Treatment of wild-type EL4 cells with phorbol ester results in the rapid activations of MAPK and pp90rsk kinase, a substrate for MAPK, while neither kinase is activated in response to phorbol ester in variant EL4 cells. This study examines the activation of MAPK kinase (MAPKK), an activator of MAPK, in wild-type and variant EL4 cells. Phosphorylation of a 40-kDa substrate, identified as MAPK, was observed following in vitro phosphorylation reactions using cytosolic extracts or Mono Q column fractions prepared from phorbol ester-treated wild-type EL4 cells. MAPKK activity coeluted with a portion of the inactive MAPK upon Mono Q anion-exchange chromatography, permitting detection of the MAPKK activity in fractions containing both kinases. This MAPKK activity was present in phorbol ester-treated wild-type cells, but not in phorbol ester-treated variant cells or in untreated wild-type or variant cells. The MAPKK from wild-type cells was able to activate MAPK prepared from either wild-type or variant cells. MAPKK activity could he stimulated in both wild-type and variant EL4 cells in response to treatment of cells with okadaic acid. These results indicate that the failure of variant EL4 cells to activate MAP kinase in response to phorbol ester is due to a failure to activate MAPKK. Therefore, the step that confers phorbol ester resistance to variant EL4 cells lies between the activation of protein kinase C and the activation of MAPKK.	MED UNIV S CAROLINA,DEPT CELL & MOLEC PHARMACOL,171 ASHLEY AVE,CHARLESTON,SC 29425; MED UNIV S CAROLINA,DEPT EXPTL THERAPEUT,CHARLESTON,SC 29425; UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	Medical University of South Carolina; Medical University of South Carolina; University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01 GM 42508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS PD, 1992, J BIOL CHEM, V267, P13135; ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11495; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HOMAN EC, 1991, J BIOL CHEM, V266, P5676; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; MEIER KE, 1991, J BIOL CHEM, V266, P1914; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SANDO JJ, 1982, CANCER RES, V42, P1676; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1992, J BIOL CHEM, V267, P14373; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VALENTINE MA, 1989, J BIOL CHEM, V264, P11282; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173	31	64	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16124	16129						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344897				2022-12-27	WOS:A1993LQ33600012
J	KAWAGUCHI, S; HEMLER, ME				KAWAGUCHI, S; HEMLER, ME			ROLE OF THE ALPHA-SUBUNIT CYTOPLASMIC DOMAIN IN REGULATION OF ADHESIVE ACTIVITY MEDIATED BY THE INTEGRIN VLA-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; MONOCLONAL-ANTIBODY; CELL-ADHESION; GPIIB-IIIA; T-CELLS; EXTRACELLULAR-MATRIX; BETA-SUBUNIT; COMPLEMENT RECEPTORS; FIBRONECTIN RECEPTOR; PLATELET ACTIVATION	To investigate the role of the alpha subunit cytoplasmic domain in the regulation of VLA-2 functional activity, we expressed several chimeric and deleted forms of the alpha2 subunit in two different human cell lines, K562 and RD. Each mutant construct formed surface VLA-2 heterodimers as efficiently as wild type alpha2 subunit, except for a construct (X2CO1127) truncated just before the consensus GFFKR cytoplasmic domain motif, that was not expressed at the cell surface. Truncation of the alpha2 cytoplasmic domain just after the GFFKR motif resulted in a complete loss of constitutive activity of VLA-2 in RD cells. If the integrin was already constitutively inactive, as in K562 cells, the cytoplasmic domain deletion had no effect. In both K562 and RD cells, cytoplasmic tail deletion eliminated up-regulation of adhesion in response to the phorbol ester, phorbol 12-myristate 13-acetate (PMA). In comparison, exchange of the alpha2 cytoplasmic domain with the alpha4 or alpha5 cytoplasmic domains had no effect on constitutive activity (in RD cells), or on constitutive inactivity (in K562 cells) and did not eliminate PMA-stimulated activity (in K562 or RD cells). These results clearly demonstrate that the cytoplasmic domain of an alpha chain (not necessarily from alpha2 itself) is required to maintain VLA-2 constitutive activity and to allow a responsiveness to PMA stimulation. In cases where VLA-2 was either constitutively inactive (as in K562 cells) or inactive due to cytoplasmic domain deletion (e.g. in RD cells), agents such as Mn2+ or the anti-beta1 monoclonal antibody TS2/16 caused a marked increase in adhesive function, thus proving that the integrins were not irreversibly inactive, and that cellular regulatory constraints could be bypassed by extracellular stimuli.	HARVARD UNIV, SCH MED,DANA FARBER CANC INST,RM M613,44 BINNEY ST, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046526] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46526] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALTIERI DC, 1988, J IMMUNOL, V141, P2656; ALTIERI DC, 1991, J IMMUNOL, V147, P1891; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BERGELSON JM, 1993, IN PRESS J CLIN INVE; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; CHAN BMC, 1991, J IMMUNOL, V147, P398; CHEN FA, 1991, J EXP MED, V173, P1111, DOI 10.1084/jem.173.5.1111; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; DETMERS PA, 1987, J CELL BIOL, V105, P1137, DOI 10.1083/jcb.105.3.1137; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; GRZESIAK JJ, 1992, J CELL BIOL, V117, P1109, DOI 10.1083/jcb.117.5.1109; GULINO D, 1990, J BIOL CHEM, V265, P9575; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HELMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545; HEMLER ME, 1990, IMMUNOL REV, V114, P45, DOI 10.1111/j.1600-065X.1990.tb00561.x; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HEMLER ME, 1983, J IMMUNOL, V131, P334; HEMLER ME, 1982, J IMMUNOL, V129, P2734; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KASSNER PD, 1993, IN PRESS J EXP MED; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LARSON RS, 1990, CELL REGUL, V1, P359, DOI 10.1091/mbc.1.4.359; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LEMKE H, 1978, NATURE, V271, P249, DOI 10.1038/271249a0; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MATSUYAMA J, 1992, J IMMUNOL, V148, P1367; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; PATARROYO M, 1985, SCAND J IMMUNOL, V22, P171, DOI 10.1111/j.1365-3083.1985.tb01869.x; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PISCHEL KD, 1987, J IMMUNOL, V138, P226; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; WILKINS JA, 1991, EUR J IMMUNOL, V21, P517, DOI 10.1002/eji.1830210239; WRIGHT SD, 1986, J IMMUNOL, V136, P1759; YAMADA KM, 1990, CANCER RES, V50, P4485; ZYLSTRA S, 1986, CANCER RES, V46, P6446	62	88	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16279	16285						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344915				2022-12-27	WOS:A1993LQ33600031
J	MAHAJAN, PB; THOMPSON, EA				MAHAJAN, PB; THOMPSON, EA			CYCLOSPORINE-A INHIBITS THE ACTIVITY OF A TATA BOX-BINDING PROTEIN THAT IS REQUIRED FOR TRANSCRIPTION FROM THE ADENOVIRUS MAJOR LATE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; INVITRO TRANSCRIPTION; GENE-TRANSCRIPTION; INITIATION; PURIFICATION; SPECIFICITY; EXPRESSION; COMPONENTS; UPSTREAM; EXTRACT	Nuclear extracts from P1798 lymphoma cells support transcription from the adenovirus major late promotor (AdMLP) and the human histone H4 promoter. Nuclear extracts prepared from P1798 cells treated with 1 mug/ml cyclosporine A for 24 h fail to support transcription from AdMLP, whereas transcription from the histone H4 promoter is unimpaired. Both control and cyclosporine-treated extracts contain proteins that interact with synthetic deoxyoligonucleotides that correspond to the CAAT box, TATA box, and upstream stimulatory element of AdMLP. Cyclosporine had no discernible qualitative or quantitative effect upon such DNA-protein interactions, as observed by gel mobility shift assays. Analysis of 5' deletion mutants of AdMLP indicates that deletion of sequences upstream of the TATA box reduces AdMLP transcription by only 50%. This observation suggests that cyclosporine A, which inhibits AdMLP transcription by >90%, is unlikely to act through changes in the amount or activity of upstream activators such as upstream stimulatory factor- or CAAT box-binding proteins. On the other hand, deletion of TATA box sequences between -50 and -11 base pairs virtually eliminates transcription from AdMLP in vitro. A partially purified TFIID fraction was obtained from control P1798 nuclear extracts. The TFIID fraction reconstitutes transcription from AdMLP when added to extracts from cyclosporine A-treated cells. Recombinant TATA box-binding protein also reconstitutes transcription from AdMLP in cyclosporine A-treated extracts. These results are consistent with the hypothesis that cyclosporine A regulates the activity of a subset of general transcription factors which are required for initiation from some promoters (such as AdMLP) but not from others (such as histone H4).	UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston					NCI NIH HHS [R37-CA24347] Funding Source: Medline; NCRR NIH HHS [2507-RR-07205-08] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA024347] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007205] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BOREL JF, 1977, IMMUNOLOGY, V32, P1017; BOREL JF, 1976, AGENTS ACTIONS, V6, P468, DOI 10.1007/BF01973261; BOREL JF, 1986, ANN NY ACAD SCI, V475, P307, DOI 10.1111/j.1749-6632.1986.tb20879.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUEDING E, 1981, AGENTS ACTIONS, V11, P380, DOI 10.1007/BF01982474; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GARG LC, 1989, J BIOL CHEM, V264, P2134; GRANELLIPIPERNO A, 1986, J EXP MED, V163, P922, DOI 10.1084/jem.163.4.922; GRAU GE, 1987, IMMUNOLOGY, V61, P521; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; GUNTER KC, 1989, J IMMUNOL, V142, P3286; HEINTZ N, 1984, P NATL ACAD SCI-BIOL, V81, P2713, DOI 10.1073/pnas.81.9.2713; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; HOHMAN R J, 1990, New Biologist, V2, P663; KELOSKE A, 1992, CELL, V69, P883; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MAHAJAN PB, 1990, MOL ENDOCRINOL, V4, P1515, DOI 10.1210/mend-4-10-1515; MAHAJAN PB, 1987, J BIOL CHEM, V262, P16150; MAHAJAN PB, 1990, J BIOL CHEM, V265, P16225; MAHAJAN PB, 1991, INT J IMMUNOPHARMACO, V13, P803; Maniatis T., 1982, MOL CLONING LABORATO, P86; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; Mason J, 1990, Pharmacol Rev, V41, P423; MCKEON F, 1991, CELL, V66, P823, DOI 10.1016/0092-8674(91)90426-Y; MEISTEREINST M, 1992, CELL, V67, P557; MERMELSTEIN FH, 1989, BIOCHIM BIOPHYS ACTA, V1009, P1, DOI 10.1016/0167-4781(89)90071-7; MITCHELL MT, 1992, J BIOL CHEM, V267, P1995; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NUSSENBLATT RB, 1986, PROG ALLERGY, V38, P159; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PUGH BF, 1992, J BIOL CHEM, V267, P679; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SHEVACH EM, 1985, ANNU REV IMMUNOL, V3, P397; SIERRA F, 1983, NUCLEIC ACIDS RES, V11, P7069, DOI 10.1093/nar/11.20.7069; THANGUE NBL, 1988, TRANSCRIPTION SPLICI, P1; THOMMENSCOTT K, 1981, AGENTS ACTIONS, V11, P770, DOI 10.1007/BF01978803; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WOOD KM, 1984, MOL CELL ENDOCRINOL, V37, P169, DOI 10.1016/0303-7207(84)90049-2	49	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16693	16698						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344948				2022-12-27	WOS:A1993LQ33600087
J	MATHUPALA, SP; LOWE, SE; PODKOVYROV, SM; ZEIKUS, JG				MATHUPALA, SP; LOWE, SE; PODKOVYROV, SM; ZEIKUS, JG			SEQUENCING OF THE AMYLOPULLULANASE (APU) GENE OF THERMOANAEROBACTER-ETHANOLICUS 39E, AND IDENTIFICATION OF THE ACTIVE-SITE BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPHOBIC CLUSTER-ANALYSIS; ALPHA-AMYLASE; CLOSTRIDIUM-THERMOHYDROSULFURICUM; THERMOSTABLE PULLULANASE; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; TAKA-AMYLASE; PURIFICATION; RESIDUES; ENZYME	The complete nucleotide sequence of the gene encoding the dual active amylopullulanase of Thermoanaerobacter ethanolicus 39E (formerly Clostridium thermohydrosulfuricum) was determined. The structural gene (apu) contained a single open reading frame 4443 base pairs in length, corresponding to 1481 amino acids, with an estimated molecular weight of 162,780. Analysis of the deduced sequence of apu with sequences of alpha-amylases and alpha-1,6 debranching enzymes enabled the identification of four conserved regions putatively involved in substrate binding and in catalysis. The conserved regions were localized within a 2.9-kilobase pair gene fragment, which encoded a M(r) 100,000 protein that maintained the dual activities and thermostability of the native enzyme. The catalytic residues of amylopullulanase were tentatively identified by using hydrophobic cluster analysis for comparison of amino acid sequences of amylopullulanase and other amylolytic enzymes. Asp597, Glu626, and Asp703 were individually modified to their respective amide form, or the alternate acid form, and in all cases both alpha-amylase and pullulanase activities were lost, suggesting the possible involvement of 3 residues in a catalytic triad, and the presence of a putative single catalytic site within the enzyme. These findings substantiate amylopullulanase as a new type of amylosaccharidase.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, DEPT MICROBIOL & PUBL HLTH, E LANSING, MI 48824 USA	Michigan State University; Michigan State University								AUSUBEL FM, 1988, CURRENT PROTOCOLS MO, V2; Ausubel FM, 1988, CURRENT PROTOCOLS MO, V1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUISSON G, 1987, EMBO J, V6, P3909, DOI 10.1002/j.1460-2075.1987.tb02731.x; CHAUVAUX S, 1992, J BIOL CHEM, V267, P4472; CLEWELL DB, 1969, P NATL ACAD SCI USA, V62, P1159, DOI 10.1073/pnas.62.4.1159; COLEMAN RD, 1987, J BACTERIOL, V169, P4302, DOI 10.1128/jb.169.9.4302-4307.1987; CROMBRUGGHE B, 1984, SCIENCE, V224, P831; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HOLM L, 1990, PROTEIN ENG, V3, P181, DOI 10.1093/protein/3.3.181; HYUN HH, 1985, APPL ENVIRON MICROB, V49, P1168, DOI 10.1128/AEM.49.5.1168-1173.1985; KLEIN C, 1991, J MOL BIOL, V217, P737, DOI 10.1016/0022-2836(91)90530-J; KURIKI T, 1991, J BACTERIOL, V173, P6147, DOI 10.1128/jb.173.19.6147-6152.1991; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YE, 1993, INT J SYST BACTERIOL, V43, P41, DOI 10.1099/00207713-43-1-41; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; MATHUPALA S, 1990, BIOCHEM BIOPH RES CO, V166, P126, DOI 10.1016/0006-291X(90)91920-N; MATHUPALA SP, 1993, IN PRESS APPL MICROB; MATSUURA Y, 1984, J BIOCHEM-TOKYO, V95, P697, DOI 10.1093/oxfordjournals.jbchem.a134659; MCCONNELL DJ, 1986, BIOCH ENG, V4; MELASNIEMI H, 1990, J GEN MICROBIOL, V136, P447, DOI 10.1099/00221287-136-3-447; MELASNIEMI H, 1988, BIOCHEM J, V250, P813, DOI 10.1042/bj2500813; Miles E W, 1977, Methods Enzymol, V47, P431; MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NAKAMURA A, 1992, FEBS LETT, V296, P37, DOI 10.1016/0014-5793(92)80398-Z; Perbal B., 1988, PRACTICAL GUIDE MOL; PLANT AR, 1987, APPL MICROBIOL BIOT, V26, P427; PODKOVYROV SM, 1993, FEBS LETT, V317, P259, DOI 10.1016/0014-5793(93)81288-B; Rodriguez R.L., 1983, RECOMBINANT DNA TECH; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; SAHA BC, 1988, BIOCHEM J, V252, P343, DOI 10.1042/bj2520343; SAKANO Y, 1982, AGR BIOL CHEM TOKYO, V46, P1121, DOI 10.1080/00021369.1982.10865223; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATA H, 1989, BIOCHIM BIOPHYS ACTA, V991, P388, DOI 10.1016/0304-4165(89)90062-7; SPREINAT A, 1990, APPL MICROBIOL BIOT, V33, P511; TADA S, 1991, AGR BIOL CHEM TOKYO, V55, P1939, DOI 10.1080/00021369.1991.10870884; TAKASAKI Y, 1987, AGR BIOL CHEM TOKYO, V51, P9, DOI 10.1080/00021369.1987.10867996; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220	42	77	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16332	16344						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344920				2022-12-27	WOS:A1993LQ33600040
J	TVERBERG, LA; RUSSO, AF				TVERBERG, LA; RUSSO, AF			REGULATION OF THE CALCITONIN CALCITONIN-GENE-RELATED PEPTIDE GENE BY CELL-SPECIFIC SYNERGY BETWEEN HELIX-LOOP-HELIX AND OCTAMER-BINDING TRANSCRIPTION FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDULLARY-THYROID CARCINOMA; IMMUNOGLOBULIN GENES; NUCLEAR FACTOR; DNA-SEQUENCE; FACTOR OTF-1; E-BOX; ENHANCER; EXPRESSION; PROTEIN; ACTIVATION	The calcitonin/calcitonin gene-related peptide (CGRP) gene is transcribed in thyroid C-cells and a subset of neurons. We have localized sequences required for cell-specific enhancement of calcitonin/CGRP transcription in rat thyroid C-cell lines. An 18-base pair element approximately 1 kilobase pair up-stream of the transcriptional start site stimulated expression of a luciferase reporter gene 50-fold in 44-2C C-cells. There was less than 2-fold stimulation in HeLa and Rat-1 cells, which do not express the endogenous calcitonin/CGRP gene. The enhancer contains potential binding sites for helix-loop-helix (HLH) and octamer transcription factors based on sequence homologies. The functional significance of these sites was shown by point mutations in the HLH and octamer motifs and by separation of the two motifs, all of which decreased enhancer activity greater than 10-fold. The involvement of HLH proteins was further shown by co-expression of the mammalian achaete-scute homologue-1 HLH protein, which activated the enhancer severalfold in HeLa cells. Electrophoretic mobility shift analyses revealed several DNA-protein complexes containing HLH and octamer-binding proteins. One octamer-binding complex (OB1) most likely contains the ubiquitous Oct-1 protein, whereas a second complex (OB2) was cell-specific. In contrast to OB1, OB2 had lower affinity for a consensus octamer motif, and its DNA binding was not affected by addition of antiserum that recognizes Oct-1 and Oct-2 proteins. In addition, we observed a large complex that appears to contain both an HLH protein and OB2. These results demonstrate that calcitonin/CGRP enhancer activity is controlled by a cell-specific synergistic activation involving HLH and octamer-binding factors.	UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	University of Iowa				Russo, Andrew/0000-0002-8156-5649	NICHD NIH HHS [HD25969] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALL DW, 1992, NUCLEIC ACIDS RES, V20, P117, DOI 10.1093/nar/20.1.117; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; DEBUSTROS A, 1986, J BIOL CHEM, V261, P8036; DENT CL, 1991, NUCLEIC ACIDS RES, V19, P4531, DOI 10.1093/nar/19.16.4531; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; ELSHOLTZ HP, 1990, GENE DEV, V4, P43, DOI 10.1101/gad.4.1.43; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GHYSEN A, 1988, GENE DEV, V2, P495, DOI 10.1101/gad.2.5.495; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; JOHNSON JE, 1992, DEVELOPMENT, V114, P75; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; KEMLER I, 1990, FASEB J, V4, P1444, DOI 10.1096/fasebj.4.5.2407588; KEMLER I, 1991, NUCLEIC ACIDS RES, V19, P237, DOI 10.1093/nar/19.2.237; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; MUSZYNSKI M, 1983, J BIOL CHEM, V258, P1678; NAVEHMANY T, 1988, J CLIN INVEST, V81, P270, DOI 10.1172/JCI113305; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; PELEG S, 1990, MOL ENDOCRINOL, V4, P1750, DOI 10.1210/mend-4-11-1750; PETTERSSON M, 1990, J MOL BIOL, V214, P373, DOI 10.1016/0022-2836(90)90187-Q; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; ROEBUCK KA, 1990, MOL CELL BIOL, V10, P341, DOI 10.1128/MCB.10.1.341; RUSSO AF, 1992, MOL ENDOCRINOL, V6, P207, DOI 10.1210/me.6.2.207; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHAFFNER W, 1989, TRENDS GENET, V5, P37, DOI 10.1016/0168-9525(89)90017-6; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHREIBER E, 1990, NUCLEIC ACIDS RES, V18, P5495, DOI 10.1093/nar/18.18.5495; SCHREIBER E, 1993, NUCLEIC ACIDS RES, V21, P253, DOI 10.1093/nar/21.2.253; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STOLARSKYFREDMAN L, 1990, MOL ENDOCRINOL, V4, P497, DOI 10.1210/mend-4-3-497; TVERBERG LA, 1992, J BIOL CHEM, V267, P17567; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8; ZELEZNIKLE NJ, 1992, J BIOL CHEM, V267, P7677	47	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15965	15973						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340417				2022-12-27	WOS:A1993LN30500091
J	ZHAO, GP; SOMERVILLE, RL				ZHAO, GP; SOMERVILLE, RL			A SINGLE AMINO-ACID SWITCH WITHIN THE HINGE REGION OF THE TRYPTOPHAN SYNTHASE BETA-SUBUNIT OF ESCHERICHIA-COLI THAT LEADS TO DIMINISHED ASSOCIATION WITH ALPHA-SUBUNIT AND ARRESTED CONVERSION OF ESII TO PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; L-SERINE; SYNTHETASE; MECHANISM; COMPLEX; BINDING; INDOLE; INACTIVATION; REPLICATION; PROTEIN	The trpB8 mutation of Escherichia coli causes a major conformational change within the beta subunit of tryptophan synthase. The basis of this effect is a replacement of glycine 281 by arginine within a structurally important ''hinge'' region. The mutant subunit, beta(B8), is catalytically active only under certain conditions, both in vivo and in vitro. Physiologically, the availability of wild type alpha subunit is the most important determinant of catalytic proficiency (Zhao, G.-P., and Somerville, R. L. (1992) J. Biol. Chem. 267, 526-541; Zhao, G.-P., and Somerville, R. L. (1993) J. Biol. Chem. 268, 14912-14920). Through enzyme activity titration experiments it was shown that the alpha subunit of tryptophan synthase dramatically stimulates catalysis by the beta2(B8) mutant enzyme. However, by size exclusion high performance liquid chromatography, the stability of the alpha.beta2(B8) complex was markedly reduced in comparison with wild type. The alpha-mediated stimulation of catalysis by the beta2(B8) mutant enzyme was enhanced by polyethylene glycol, a volume excluder. By absorption spectroscopy, it was shown that catalysis by the beta(B8) mutant protein is blocked in at least one step after the formation of a particular Schiff base intermediate (ESII). Either the alpha subunit or ammonium ion was able to overcome this block. The microenvironment of the ESII catalytic intermediate was examined by fluorescence spectroscopy. The data are consistent with a less hydrophobic environment for ESII in the beta2(B8) mutant protein than in the wild type protein. These lines of evidence not only support a conformational switch model of open versus closed states within the beta subunit during the catalytic cycle but also suggest a functional role for the hinge region in the process of conformational switching.	PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NIGMS NIH HHS [GM22131] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022131] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI O, 1974, J BIOL CHEM, V249, P7756; AHMED SA, 1991, J BIOL CHEM, V266, P21548; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BARTHOLMES P, 1976, BIOCHEMISTRY-US, V15, P4712, DOI 10.1021/bi00666a027; BARTHOLMES P, 1979, EUR J BIOCHEM, V95, P323, DOI 10.1111/j.1432-1033.1979.tb12968.x; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P1180, DOI 10.1021/bi00119a030; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; CRAWFORD IP, 1964, P NATL ACAD SCI USA, V51, P390, DOI 10.1073/pnas.51.3.390; CREIGHTO.TE, 1970, EUR J BIOCHEM, V13, P1, DOI 10.1111/j.1432-1033.1970.tb00892.x; CREIGHTON TE, 1966, J BIOL CHEM, V241, P980; CREIGHTON TE, 1970, METHODS ENZYMOLOGY A, V17, P365, DOI DOI 10.1021/ACS.BIOCHEM.8B00167; DREWE WF, 1985, BIOCHEMISTRY-US, V24, P3977, DOI 10.1021/bi00336a027; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8598, DOI 10.1021/bi00489a015; FAEDER EJ, 1971, BIOCHEMISTRY-US, V10, P1041; Friedrich P., 1984, SUPRAMOLECULAR ENZYM; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; GOLDBERG ME, 1968, BIOCHEMISTRY-US, V7, P3662, DOI 10.1021/bi00850a045; GOLDBERG ME, 1967, BIOCHEMISTRY-US, V6, P2113, DOI 10.1021/bi00859a032; HATANAKA M, 1962, ARCH BIOCHEM BIOPHYS, V97, P596, DOI 10.1016/0003-9861(62)90129-7; HENNING U, 1962, J BIOL CHEM, V237, P1523; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JACKSON DA, 1969, J BIOL CHEM, V244, P4526; JARVIS TC, 1990, J BIOL CHEM, V265, P15160; LANE AN, 1981, EUR J BIOCHEM, V120, P379, DOI 10.1111/j.1432-1033.1981.tb05715.x; LANE AN, 1984, DYNAMICS BIOCH SYSTE, P115; MATCHETT WH, 1974, J BIOL CHEM, V249, P4041; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1970, J BIOL CHEM, V245, P6016; MILES EW, 1968, BIOCHEMISTRY-US, V7, P2742, DOI 10.1021/bi00848a008; MILES EW, 1985, PYRIDOXAL PHOSPHATE, P253; MURRYBRELIER A, 1990, J BIOL CHEM, V265, P7987; OGASAHARA K, 1992, J BIOL CHEM, V267, P5222; REGNIER FE, 1983, METHOD ENZYMOL, V91, P137; Swift S, 1991, Biotechnol Genet Eng Rev, V9, P229; WILSON DA, 1965, J BIOL CHEM, V240, P4801; YANG XJ, 1992, J BIOL CHEM, V267, P7520; YANOFSKY C, 1989, BIOCHIM BIOPHYS ACTA, V1000, P133, DOI 10.1016/S0006-3002(89)80013-7; YANOFSKY C, 1987, BIOESSAYS, V6, P133, DOI 10.1002/bies.950060309; YANOFSKY C, 1960, BACTERIOL REV, V24, P221, DOI 10.1128/MMBR.24.2.221-245.1960; YORK SS, 1972, BIOCHEMISTRY-US, V11, P2733, DOI 10.1021/bi00764a029; ZHAO GP, 1993, J BIOL CHEM, V268, P14912; ZHAO GP, 1992, J BIOL CHEM, V267, P526; ZHAO GP, 1987, FASEB J, V46, P1938	45	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14921	14931						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325869				2022-12-27	WOS:A1993LL75900060
J	CARTER, ME; GULICK, T; RAISHER, BD; CAIRA, T; LADIAS, JAA; MOORE, DD; KELLY, DP				CARTER, ME; GULICK, T; RAISHER, BD; CAIRA, T; LADIAS, JAA; MOORE, DD; KELLY, DP			HEPATOCYTE NUCLEAR FACTOR-IV ACTIVATES MEDIUM-CHAIN ACYL-COA DEHYDROGENASE GENE-TRANSCRIPTION BY INTERACTING WITH A COMPLEX REGULATORY ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR SUPERFAMILY; MOLECULAR-CLONING; TISSUE; DEFICIENCY; EXPRESSION; MEMBER; ALPHA-1-ANTITRYPSIN; TRANSTHYRETIN; EFFICIENCY; PROTEINS	We have recently identified a complex transcriptional regulatory element in the medium chain acyl-CoA dehydrogenase (MCAD) gene promoter region that confers response to retinoids through interaction with receptors for all-trans-retinoic acid (RARs) and 9-cis-retinoic acid (RXRs) (Raisher, B. D., Gulick, T., Zhang, Z., Strauss, A. W., Moore, D. D., and Kelly, D. P. (1992) J. Biol. Chem. 267, 20264-20269). We examined the interaction of this element (RARE(MCAD)) with hepatocyte nuclear factor-4 (HNF-4), an orphan receptor with a tissue expression pattern similar to that of MCAD. Electrophoretic mobility shift assays and cotransfection experiments showed that HNF-4 binds with high affinity to RARE(MCAD) to activate transcription by an RXR-independent mechanism. Mutational analysis revealed that the MCAD HNF-4 response element consists of an imperfect direct repeat homologous to the consensus sequence for binding to the thyroid receptor/RAR/RXR subgroup of receptors and that distinct sequence requirements dictate HNF-4 binding and transactivation. Mobility shift assays with anti-HNF-4 antiserum demonstrated that the MCAD HNF-4 response element binds endogenous rat liver HNF-4 supporting its role in the regulation of MCAD gene expression in vivo. Thus, HNF-4 activates MCAD gene transcription via a complex regulatory element, the architecture of which carries important implications for the structure of HNF-4 response elements in general.	WASHINGTON UNIV, DEPT MED, ST LOUIS, MO 63130 USA; WASHINGTON UNIV, DEPT PEDIAT, ST LOUIS, MO 63130 USA; HARVARD UNIV, NEW ENGLAND DEACONESS HOSP, SCH MED, DEPT MED, BOSTON, MA 02215 USA; MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02114 USA	Washington University (WUSTL); Washington University (WUSTL); Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Kelly, Daniel/ABG-2056-2021		NIDDK NIH HHS [DK45416] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045416, R29DK045416] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; AUSIBEL FM, 1992, CURRENT PROTOCOLS MO, V2; Beinert H., 1963, ENZYMES, P447; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; CROSSLEY M, 1992, SCIENCE, V257, P377, DOI 10.1126/science.1631558; DURAN M, 1986, PEDIATRICS, V78, P1052; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KELLY DP, 1990, P NATL ACAD SCI USA, V87, P9236, DOI 10.1073/pnas.87.23.9236; KELLY DP, 1987, P NATL ACAD SCI USA, V84, P4068, DOI 10.1073/pnas.84.12.4068; KELLY DP, 1989, J BIOL CHEM, V264, P18921; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; RAISHER BD, 1992, J BIOL CHEM, V267, P20264; REIJNEN MJ, 1992, P NATL ACAD SCI USA, V89, P6300, DOI 10.1073/pnas.89.14.6300; REVZIN A, 1989, BIOTECHNIQUES, V7, P346; ROY RJ, 1991, BIOTECHNIQUES, V11, P770; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STANLEY CA, 1990, PROG CLIN BIOL RES, V321, P291; STANLEY CA, 1983, PEDIATR RES, V17, P872; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TREEM WR, 1986, HEPATOLOGY, V6, P1270, DOI 10.1002/hep.1840060608; UEMSONO K, 1991, CELL, V65, P1; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VENEPALLY P, 1992, J BIOL CHEM, V267, P17333; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZHANG ZF, 1992, BIOCHEMISTRY-US, V31, P81, DOI 10.1021/bi00116a013	40	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13805	13810						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314750				2022-12-27	WOS:A1993LJ82500009
J	LARNER, JM; PAHUJA, SL; SHACKLETON, CH; MCMURRAY, WJ; GIORDANO, G; HOCHBERG, RB				LARNER, JM; PAHUJA, SL; SHACKLETON, CH; MCMURRAY, WJ; GIORDANO, G; HOCHBERG, RB			THE ISOLATION AND CHARACTERIZATION OF ESTRADIOL-FATTY ACID-ESTERS IN HUMAN OVARIAN FOLLICULAR-FLUID - IDENTIFICATION OF AN ENDOGENOUS LONG-LIVED AND POTENT FAMILY OF ESTROGENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOIDAL DERIVATIVES; HUMAN-PLASMA; PREGNENOLONE; BIOSYNTHESIS; RAT; CORTICOSTERONE; METABOLISM; ESTRIOL; TISSUES	The estradiol-fatty acid esters are highly potent and long-lived estrogens that were first isolated and identified from in vitro biosynthetic experiments (Mellon-Nussbaum S., Ponticorvo, L., Schatz, F., and Hochberg, R. B. (1982) J. Biol. Chem. 257, 5678-5684). Other studies have indicated that these esters exist endogenously, but the evidence is indirect, resting solely on the presence of a nonpolar saponifiable metabolite. Although there are similar reports of other naturally occurring fatty acid esters of biologically active steroid hormones, likewise, none has been isolated and characterized. In this study we have found that follicular fluid from the ovaries of women stimulated with gonadotrophins contains relatively large amounts of a nonpolar saponifiable derivative of estradiol (approximately 10(-7) M), which we presumed to be fatty acid esters. Using a combination of chromatographic techniques we isolated these estradiol metabolites and identified them by mass spectral analysis. They are a mixture of five different estradiol-17 fatty acid esters, The amount of each present was determined by separating the esters by reversed phase high performance liquid chromatography and then quantifying each peak by radioimmunoassay and UV absorption. The esters of estradiol are predominantly unsaturated, with linoleate the most abundant comprising 43% of the total. The other esters are: palmitate (20%), arachidonate (19%), oleate (14%), and stearate (4%). Thus these studies conclusively demonstrate the existence of these unusually powerful estrogens.	YALE UNIV,SCH MED,DEPT OBSTET & GYNECOL,MASS SPECT FACIL,333 CEDAR ST,NEW HAVEN,CT 06510; CHILDRENS HOSP OAKLAND RES INST,OAKLAND,CA 94609; YALE UNIV,SCH MED,CTR COMPREHENS CANC,NEW HAVEN,CT 06510	Yale University; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Yale University					NCI NIH HHS [CA-29591] Funding Source: Medline; NCRR NIH HHS [RR06515] Funding Source: Medline; NIDDK NIH HHS [DK-34400] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034400] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADDO S B, 1989, Steroids, V54, P257, DOI 10.1016/0039-128X(89)90001-9; ADDO SB, 1990, STEROIDS, V55, P492; ALBERT DH, 1980, J BIOL CHEM, V255, P618; BISCHOF P, 1974, EXPERIENTIA, V30, P1101, DOI 10.1007/BF01939032; COUTURE J, 1990, J STEROID BIOCH S, V36, P134; HOCHBERG R, 1979, J STEROID BIOCHEM, V11, P1333, DOI 10.1016/0022-4731(79)90103-1; HOCHBERG RB, 1977, P NATL ACAD SCI USA, V74, P941, DOI 10.1073/pnas.74.3.941; HOCHBERG RB, 1991, NEW BIOL STEROID HOR, P31; JANOCKO L, 1983, SCIENCE, V222, P1334, DOI 10.1126/science.6419346; JONES DL, 1985, J STEROID BIOCHEM, V22, P243, DOI 10.1016/0022-4731(85)90119-0; LARNER JM, 1992, J CLIN ENDOCR METAB, V75, P195, DOI 10.1210/jc.75.1.195; LARNER JM, 1985, ENDOCRINOLOGY, V117, P1209, DOI 10.1210/endo-117-3-1209; LARNER JM, 1985, J STEROID BIOCHEM, V22, P407, DOI 10.1016/0022-4731(85)90446-7; LARNER JM, 1992, STEROIDS, V57, P475; LESZCZYNSKI DE, 1989, BIOCHIM BIOPHYS ACTA, V1014, P90, DOI 10.1016/0167-4889(89)90245-0; MACLUSKY NJ, 1989, ENDOCRINOLOGY, V124, P318, DOI 10.1210/endo-124-1-318; MARGRAF HARRY W., 1963, STEROIDS, V2, P155, DOI 10.1016/S0039-128X(63)80020-3; MELLONNUSSBAUM S, 1980, J BIOL CHEM, V255, P5566; MELLONNUSSBAUM S, 1979, J BIOL CHEM, V254, P2500; MELLONNUSSBAUM SH, 1982, J BIOL CHEM, V257, P5678; PAHUJA SL, 1991, J BIOL CHEM, V266, P7410; PAHUJA SL, 1989, J BIOL CHEM, V264, P3216; PARIS A, 1989, J CHROMATOGR-BIOMED, V493, P367, DOI 10.1016/S0378-4347(00)82743-7; PARIS A, 1989, J STEROID BIOCHEM, V33, P465, DOI 10.1016/0022-4731(89)90338-5; PEARLMAN WH, 1985, J BIOL CHEM, V260, P5296; RAJU U, 1985, J CLIN ENDOCR METAB, V60, P940, DOI 10.1210/jcem-60-5-940; ROY R, 1989, Steroids, V54, P385, DOI 10.1016/0039-128X(89)90052-4; ROY R, 1989, J STEROID BIOCHEM, V33, P257, DOI 10.1016/0022-4731(89)90302-6; ROY R, 1991, BIOCHEM BIOPH RES CO, V179, P1576, DOI 10.1016/0006-291X(91)91753-Y; SCHATZ F, 1981, ENDOCRINOLOGY, V109, P697; WEICHSELBAUM TE, 1960, J CLIN ENDOCR METAB, V20, P1341, DOI 10.1210/jcem-20-10-1341; WEINBAUER GF, 1990, ACTA ENDOCRINOL-COP, V4, P432; ZIELINSKI JE, 1991, J STEROID BIOCHEM, V38, P399, DOI 10.1016/0960-0760(91)90327-2	33	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13893	13899						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314757				2022-12-27	WOS:A1993LJ82500021
J	SAKATA, SF; SHELLY, LL; RUPPERT, S; SCHUTZ, G; CHOU, JY				SAKATA, SF; SHELLY, LL; RUPPERT, S; SCHUTZ, G; CHOU, JY			CLONING AND EXPRESSION OF MURINE S-ADENOSYLMETHIONINE SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE AMINOTRANSFERASE GENE; DNA-BINDING; CYCLIC-AMP; RAT-LIVER; ARABIDOPSIS-THALIANA; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; STRUCTURAL GENE; MESSENGER-RNA; TRANSCRIPTION	Mice homozygous for chromosomal deletions at or around the albino locus on chromosome 7 express reduced levels of a group of liver genes. Here, we report the isolation and characterization of cDNA and genomic clones encoding one of the affected genes, the mouse adult liver S-adenosylmethionine (AdoMet) synthetase. This enzyme catalyzes the synthesis of AdoMet, which functions in transmethylation and transsulfuration. Mouse AdoMet synthetase cDNA is 3232 base pairs (bp) in length and contains an open reading frame that encodes an enzymatically active polypeptide of 396 amino acids. The mouse AdoMet synthetase shares 98 and 96% amino acid sequence identity with the adult liver enzyme in the rat and human, respectively. AdoMet synthetases possess the consensus ATP-binding motif Gly-X-Gly-X-X-Gly and a putative ATP-binding Lys residue at conserved locations. As an initial step toward understanding the control of AdoMet synthetase gene expression, we characterized the complete transcription unit of this gene. The AdoMet synthetase gene spans approximately 18 kilobases and consists of nine exons ranging from 78 to 1920 bp. The transcription initiation site was demonstrated by rapid amplification of cDNA ends and confirmed by primer extension studies. A putative TATA box is located at -28 to -23 bp upstream of the transcription start site. The cis-acting DNA elements in the 5'-flanking region of the AdoMet synthetase gene that drive chloramphenicol acetyltransferase gene expression in mouse hepatocytes were identified by transient expression assays. The -365 to -2-bp DNA region upstream of the transcription start site of the AdoMet synthetase gene contains promoter elements, and the -518 to -366-bp DNA region might be involved in negative gene regulation.	NICHHD, HUMAN GENET BRANCH, BLDG 10, RM 95242, BETHESDA, MD 20892 USA; GERMAN CANC RES CTR, INST CELL & TUMOR BIOL, W-6900 HEIDELBERG, GERMANY	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Helmholtz Association; German Cancer Research Center (DKFZ)								ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ALVAREZ L, 1991, FEBS LETT, V290, P142, DOI 10.1016/0014-5793(91)81245-4; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BOSHART M, 1990, CELL, V61, P905, DOI 10.1016/0092-8674(90)90201-O; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CANTONI GL, 1953, J BIOL CHEM, V204, P403; CHAWLA RK, 1990, DRUGS, V40, P98, DOI 10.2165/00003495-199000403-00010; CHOU JY, 1991, J BIOL CHEM, V266, P5716; CHU G, 1981, GENE, V13, P197, DOI 10.1016/0378-1119(81)90008-1; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DAS HK, 1988, J BIOL CHEM, V263, P11452; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FORDIS M, 1986, METHOD ENZYMOL, V151, P382; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GLUECKSOHNWAELSCH S, 1979, CELL, V16, P225, DOI 10.1016/0092-8674(79)90001-1; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HEBST RS, 1989, P NATL ACAD SCI USA, V86, P1553; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HORIKAWA S, 1989, EUR J BIOCHEM, V184, P497, DOI 10.1111/j.1432-1033.1989.tb15042.x; HORIKAWA S, 1990, J BIOL CHEM, V265, P13683; HORIKAWA S, 1991, BIOCHEM INT, V25, P81; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEBIG ML, 1992, P NATL ACAD SCI USA, V89, P1363, DOI 10.1073/pnas.89.4.1363; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOTB M, 1985, J BIOL CHEM, V260, P3923; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LOOSE DS, 1986, P NATL ACAD SCI USA, V83, P5184, DOI 10.1073/pnas.83.14.5184; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MARKHAM GD, 1984, J BIOL CHEM, V259, P4505; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MATO JM, 1990, DRUGS, V40, P58, DOI 10.2165/00003495-199000403-00006; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MITSUI KI, 1988, J BIOL CHEM, V263, P11211; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MUGLIA L, 1986, P NATL ACAD SCI USA, V83, P7653, DOI 10.1073/pnas.83.20.7653; OKADA G, 1981, BIOCHEMISTRY-US, V20, P934, DOI 10.1021/bi00507a045; PELEMAN J, 1989, PLANT CELL, V1, P81, DOI 10.1105/tpc.1.1.81; PELEMAN J, 1989, GENE, V84, P359, DOI 10.1016/0378-1119(89)90510-6; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; REUE K, 1988, J BIOL CHEM, V263, P6857; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RUPPERT S, 1992, GENE DEV, V6, P1430, DOI 10.1101/gad.6.8.1430; RUPPERT S, 1990, CELL, V61, P895, DOI 10.1016/0092-8674(90)90200-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID W, 1985, P NATL ACAD SCI USA, V82, P2866, DOI 10.1073/pnas.82.9.2866; STRUCK DK, 1980, BIOCH GLYCOPROTEINS, P38; SUMA Y, 1986, J BIOCHEM, V100, P67, DOI 10.1093/oxfordjournals.jbchem.a121707; THOMAS D, 1987, J BIOL CHEM, V262, P16704; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VONDERAHE D, 1985, NATURE, V313, P706, DOI 10.1038/313706a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670	59	66	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13978	13986						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314764				2022-12-27	WOS:A1993LJ82500033
J	YASEEN, NR; MAIZEL, AL; WANG, F; SHARMA, S				YASEEN, NR; MAIZEL, AL; WANG, F; SHARMA, S			COMPARATIVE-ANALYSIS OF NFAT (NUCLEAR FACTOR OF ACTIVATED T-CELLS) COMPLEX IN HUMAN T-LYMPHOCYTE AND B-LYMPHOCYTE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOSPORINE-A; TRANSCRIPTION FACTORS; INTERLEUKIN-2 ENHANCER; ANTIGEN RECEPTOR; EXPRESSION; BINDING; DNA; REQUIREMENTS; MODULATION; ELEMENTS	Nuclear factor of activated T cells (NFAT) is a transcriptional activator that binds to sequences in the interleukin-2 (IL-2) promoter and is thought to be largely responsible for the T cell-specific inducibility of IL-2 expression. Electrophoretic mobility shift assays (EMSA) showed that specific NFAT binding activity could also be induced in human B cells. The B cell NFAT complex, however, was not functional, since it failed to activate transcription from an NFAT-driven chloramphenicol acetyltransferase (CAT) construct. Competition with an AP-1 motif or with anti-Jun and anti-Fos antibodies abolished binding to the NFAT motif in both T and B cells, indicating that Jun and Fos are critical for NFAT complex formation in both cell types. Purified recombinant Jun and Fos proteins failed to bind directly to the NFAT motif. However, when combined with unstimulated B or T cell extracts, full-length, but not truncated, Jun/Fos heterodimers were able to form an NFAT complex, indicating the presence of a constitutively expressed nuclear factor(s) in B and T cells necessary for the formation of the NFAT complex in both cell types. An NFAT oligonucleotide carrying mutations in the 5' purine-rich part of the NFAT sequence failed to form a complex and to compete with the wild type motif for NFAT complex formation in both T and B cells. We therefore propose a model whereby a core NFAT complex consisting of Jun, Fos, and a constitutive nuclear factor is formed in both T and B cells, but an additional factor and/or post-translational modification of a factor, missing in B cells, might be required for transactivation by NFAT.	BROWN UNIV,ROGER WILLIAMS MED CTR,DEPT PATHOL,EXPTL PATHOL SECT,PROVIDENCE,RI 02908; BROWN UNIV,ROGER WILLIAMS CANC CTR,DEPT PATHOL,EXPTL PATHOL SECT,PROVIDENCE,RI 02908; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115	Brown University; Roger Williams Medical Center; Brown University; Roger Williams Medical Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School				Yaseen, Nabeel/0000-0001-6902-5116	NATIONAL CANCER INSTITUTE [U10CA045418, R01CA054763, R01CA055910] Funding Source: NIH RePORTER; NCI NIH HHS [CA45418, CA54763, CA55910] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; CALENDER A, 1990, INT J CANCER, V46, P658, DOI 10.1002/ijc.2910460418; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GRANELLIPIPERNO A, 1991, J IMMUNOL, V147, P2734; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORGAN J, 1989, J VIROL, V63, P3190, DOI 10.1128/JVI.63.7.3190-3194.1989; PETTERSSON M, 1987, GENE DEV, V1, P962, DOI 10.1101/gad.1.9.962; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; WALDMANN TA, 1984, J EXP MED, V160, P1450, DOI 10.1084/jem.160.5.1450; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0	31	77	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14285	14293						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314792				2022-12-27	WOS:A1993LJ82500074
J	BERMEJO, B; REMACHA, M; ORTIZREYES, B; SANTOS, C; BALLESTA, JPG				BERMEJO, B; REMACHA, M; ORTIZREYES, B; SANTOS, C; BALLESTA, JPG			EFFECT OF ACIDIC RIBOSOMAL PHOSPHOPROTEIN MESSENGER-RNA 5'-UNTRANSLATED REGION ON GENE-EXPRESSION AND PROTEIN ACCUMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; EXCESS PROTEIN; YEAST; PROMOTER; CDNA; PHOSPHORYLATION; TRANSFORMATION; DEPLETION	Constructions were made from genes encoding ribosomal acidic phosphoproteins YP1 beta(L44') and YP2 beta(L45) from Saccharomyces cerevisiae in which different parts of the 5'-untransiated regions were included. The constructs were inserted into centromeric plasmids under the control of the GAL1 promoter and expressed in yeast strains in which the genes coding for each acidic protein family, P1 and P2, had been disrupted. Deletions in the 5' region of the two genes have been found to oppositely affect their expression. Deletion of most of this region strongly stimulates the expression of YP2 beta(L45), increasing the translation efficiency of the mRNA, and generating a 6-fold excess of protein in the cell. A similar deletion in the rpYP1 beta gene represses the expression of the protein, reducing drastically the amount of the mRNA in the cell. The overexpression of rpYP2 beta affects the cell growth by inhibiting protein synthesis at the level of initiation. Reduction of the YP2 beta(L45) overproduction by growing in controlled concentrations of glucose abolishes the inhibitory effect. The excess protein, probably as a high molecular weight complex, apparently interferes with the joining of the 60 S subunit to the initiation complex generating the accumulation of polysome half-mers. In addition, the results indicate the existence of a regulatory mechanism by which each one of the two acidic proteins controls the expression of the other polypeptide. YP1 beta(L44') represses the expression of YP2 beta(L45), while this protein stimulates the expression of YP1 beta(L44').	CSIC,CTR BIOL MOLEC SEVERO OCHOA,E-28049 MADRID,SPAIN; UNIV AUTONOMA MADRID,E-28049 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid			Remacha, Miguel/G-1250-2016; Santos, Cruz/ABG-3054-2020	Santos, Cruz/0000-0001-5164-5050				ABOVICH N, 1984, MOL CELL BIOL, V4, P1871, DOI 10.1128/MCB.4.9.1871; BALLESTA JPG, 1993, PROTEIN SYNTHESIS TA, P67; BOZZONI I, 1984, J MOL BIOL, V180, P987, DOI 10.1016/0022-2836(84)90267-5; BROT N, 1972, BIOCHEM BIOPH RES CO, V49, P673, DOI 10.1016/0006-291X(72)90464-0; BURGERS PMJ, 1987, ANAL BIOCHEM, V163, P391, DOI 10.1016/0003-2697(87)90240-5; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; CITRON BA, 1984, J BACTERIOL, V158, P269, DOI 10.1128/JB.158.1.269-278.1984; DABEVA MD, 1986, P NATL ACAD SCI USA, V83, P5854, DOI 10.1073/pnas.83.16.5854; ELBARADI TTAL, 1986, CURR GENET, V10, P733, DOI 10.1007/BF00405095; ELKON K, 1986, P NATL ACAD SCI USA, V83, P7419, DOI 10.1073/pnas.83.19.7419; FRIED HM, 1985, MOL CELL BIOL, V5, P99, DOI 10.1128/MCB.5.1.99; HAMILTON R, 1987, NUCLEIC ACIDS RES, V15, P3581, DOI 10.1093/nar/15.8.3581; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; ISONO S, 1981, MOL GEN GENET, V183, P473, DOI 10.1007/BF00268767; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JUANVIDALES F, 1984, BIOCHEMISTRY-US, V23, P390; KIM CH, 1983, J MOL BIOL, V165, P79, DOI 10.1016/S0022-2836(83)80243-5; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRAAKMAN LS, 1991, BIOCHIM BIOPHYS ACTA, V1090, P204, DOI 10.1016/0167-4781(91)90102-R; KRUISWIJK T, 1978, EUR J BIOCHEM, V83, P245, DOI 10.1111/j.1432-1033.1978.tb12089.x; LUCIOLI A, 1988, MOL CELL BIOL, V8, P4792, DOI 10.1128/MCB.8.11.4792; MAGER WH, 1991, MOL CELL BIOCHEM, V104, P181; MAICAS E, 1988, MOL CELL BIOL, V8, P169, DOI 10.1128/MCB.8.1.169; MITSUI K, 1988, J BIOCHEM-TOKYO, V104, P908, DOI 10.1093/oxfordjournals.jbchem.a122581; Moller W., 1986, STRUCTURE FUNCTION G, P309; MORRISSEY JJ, 1975, BIOCHEM BIOPH RES CO, V65, P293, DOI 10.1016/S0006-291X(75)80092-1; NAM HG, 1986, MOL CELL BIOL, V6, P1535, DOI 10.1128/MCB.6.5.1535; NARANDA T, 1993, J BIOL CHEM, V268, P2451; NARANDA T, 1991, P NATL ACAD SCI USA, V88, P10563, DOI 10.1073/pnas.88.23.10563; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; RAMAGOPAL S, 1976, EUR J BIOCHEM, V69, P289, DOI 10.1111/j.1432-1033.1976.tb10885.x; REMACHA M, 1990, MOL CELL BIOL, V10, P2182, DOI 10.1128/MCB.10.5.2182; REMACHA M, 1992, J BIOL CHEM, V267, P12061; REMACHA M, 1988, J BIOL CHEM, V263, P9094; ROTENBERG MO, 1988, GENE DEV, V2, P160, DOI 10.1101/gad.2.2.160; SAENZROBLES MT, 1990, BIOCHIM BIOPHYS ACTA, V1050, P51, DOI 10.1016/0167-4781(90)90140-W; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZMADRID F, 1979, EUR J BIOCHEM, V98, P409, DOI 10.1111/j.1432-1033.1979.tb13200.x; SANCHEZMADRID F, 1981, EUR J BIOCHEM, V114, P609, DOI 10.1111/j.1432-1033.1981.tb05187.x; SANDERMANN J, 1979, FEBS LETT, V107, P343, DOI 10.1016/0014-5793(79)80404-4; SANTOS C, 1993, BIOCHEMISTRY-US, V32, P4231, DOI 10.1021/bi00067a010; SCHIJMAN AG, 1992, NUCLEIC ACIDS RES, V20, P2894, DOI 10.1093/nar/20.11.2894; SCHIJMAN AG, 1990, NUCLEIC ACIDS RES, V18, P3399, DOI 10.1093/nar/18.11.3399; Sherman F., 1983, METHODS YEAST GENETI; SHIMMIN LC, 1989, J MOL EVOL, V29, P448, DOI 10.1007/BF02602915; SUBRAMANIAN AR, 1975, J MOL BIOL, V95, P1, DOI 10.1016/0022-2836(75)90330-7; TSAY YF, 1988, GENE DEV, V2, P664, DOI 10.1101/gad.2.6.664; VANAGTHOVEN A, 1978, EUR J BIOCHEM, V91, P553; VAZQUEZ MP, 1992, NUCLEIC ACIDS RES, V20, P2893, DOI 10.1093/nar/20.11.2893; VAZQUEZ MP, 1992, NUCLEIC ACIDS RES, V20, P2894; VILELLA MD, 1991, EUR J BIOCHEM, V196, P407, DOI 10.1111/j.1432-1033.1991.tb15831.x; WARNER JR, 1985, MOL CELL BIOL, V5, P1512, DOI 10.1128/MCB.5.6.1512; WARNER JR, 1977, CELL, V11, P201, DOI 10.1016/0092-8674(77)90331-2; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; WOOL IG, 1991, BIOCHIMIE, V73, P861, DOI 10.1016/0300-9084(91)90127-M	56	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3968	3975						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307952				2022-12-27	WOS:A1994MW98900014
J	COPPEE, JY; BRASSEUR, G; BRIVETCHEVILLOTTE, P; COLSON, AM				COPPEE, JY; BRASSEUR, G; BRIVETCHEVILLOTTE, P; COLSON, AM			NONNATIVE INTRAGENIC REVERSIONS SELECTED FROM SACCHAROMYCES-CEREVISIAE CYTOCHROME B-DEFICIENT MUTANTS - STRUCTURAL AND FUNCTIONAL FEATURES OF THE CATALYTIC CENTER N-DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOCYTOCHROME-B; MITOCHONDRIAL MUTANTS; FRAMESHIFT MUTATIONS; YEAST MITOCHONDRIA; COMPLEX-III; WILD-TYPE; GENE; REVERTANTS; ANTIMYCIN; SUPPRESSORS	A total of 110 revertants have been isolated from two well characterized cytochrome b deficient (mit(-)) mutants. The mit(-) mutations are located in an extramembranous loop linking the transmembrane alpha-helices IV and V of cytochrome b which has been postulated to be part of the catalytic center Q(N) and therefore is assumed to be essential for the functioning of the bc(1) complex. The molecular bases of the reversions were identified by sequencing the cytochrome b mRNAs. This allowed us to identify seven new structures of cytochrome b which are more or less compatible with its catalytic activity. The secondary mutations occurred either at the level of the original site mutation or at adjacent positions (region 204-208 of the polypeptide chain), or even at a distance of more than 150 amino acids (position 30) suggesting topological interaction between these two areas. All the revertants recovered cytochrome contents and phosphorylation efficiencies similar to the wild type ones, albeit differences appeared in their specific growth rates and NADH respirations. The failure in bc(1) complex functioning induced by the mutation S206L and its restoration by non native reversions are tentatively explained.	UNIV CATHOLIQUE LOUVAIN,DEPT BIOL,GENET MICROBIENNE LAB,UNITE GENET,B-1348 LOUVAIN,BELGIUM; LAB CHIM BACTERIENNE,UNITE METAB ENERGET,F-13275 MARSEILLE 9,FRANCE	Universite Catholique Louvain; UDICE-French Research Universities; Aix-Marseille Universite								BRASSEUR G, 1993, BIOCHEM SOC T, V22, pS60; BRIQUET M, 1981, EUR J BIOCHEM, V117, P333, DOI 10.1111/j.1432-1033.1981.tb06342.x; BRIVETCHEVILLOTTE P, 1989, FEBS LETT, V255, P5, DOI 10.1016/0014-5793(89)81050-6; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; CHEVILLOTTEBRIVET P, 1983, EUR J BIOCHEM, V129, P653; CHEVILLOTTEBRIVET P, 1987, BIOCHIMIE, V69, P25, DOI 10.1016/0300-9084(87)90268-9; CHEVILLOTTEBRIVET P, 1980, EUR J BIOCHEM, V111, P161; COLSON AM, 1993, J BIOENERG BIOMEMBR, V25, P211, DOI 10.1007/BF00762583; COLSON AM, 1992, BIOCHIM BIOPHYS ACTA, V1101, P157; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; DIRAGO JP, 1990, J BIOL CHEM, V265, P15750; DIRAGO JP, 1990, J BIOL CHEM, V265, P3332; FOX TD, 1980, NATURE, V288, P60, DOI 10.1038/288060a0; HACKER B, 1993, BIOCHEMISTRY-US, V32, P4403, DOI 10.1021/bi00067a033; HAID A, 1979, EUR J BIOCHEM, V94, P451, DOI 10.1111/j.1432-1033.1979.tb12913.x; JACQ C, 1980, ORG EXPRESSION MITOC, P139; KOTYLAK Z, 1977, GENETICS BIOGENESIS, P83; KRUSZEWSKA A, 1984, CURR GENET, V9, P1, DOI 10.1007/BF00396198; LAZOWSKA J, 1989, J MOL BIOL, V205, P275, DOI 10.1016/0022-2836(89)90341-0; LAZOWSKA J, 1980, CELL, V22, P333, DOI 10.1016/0092-8674(80)90344-X; LEMESLEMEUNIER D, 1993, J BIOL CHEM, V268, P15626; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; MEUNIERLEMESLE D, 1980, EUR J BIOCHEM, V111, P151; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; PRATJE E, 1977, MOL GEN GENET, V152, P167, DOI 10.1007/BF00268814; RICH PR, 1991, BIOSCIENCE REP, V11, P539, DOI 10.1007/BF01130217; TRON T, 1990, CURR GENET, V18, P413, DOI 10.1007/BF00309910; TRON T, 1991, FEBS LETT, V278, P26, DOI 10.1016/0014-5793(91)80075-E; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990	30	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4221	4226						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307985				2022-12-27	WOS:A1994MW98900051
J	KANAYA, E; ANAGUCHI, H; KIKUCHI, M				KANAYA, E; ANAGUCHI, H; KIKUCHI, M			INVOLVEMENT OF 2 SULFUR-ATOMS OF PROTEIN DISULFIDE-ISOMERASE AND ONE SULFUR ATOM OF THE DSBA/PPFA PROTEIN IN THE OXIDATION OF MUTANT HUMAN LYSOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; ACTIVE-SITE; THIOREDOXIN; IDENTIFICATION; ISOMERIZATION; RIBONUCLEASE; REACTIVITY; RESOLUTION; CATALYSIS	Protein disulfide isomerase (PDI) and the DsbA/PpfA protein catalyze the oxidation of mutant human lysozyme, L79CC81A, which has two native disulfide bonds, Cys(6)-Cys(128) and Cys(30)-Cys(116), a non-native Cys(79)-Cys(95), and 2 free cysteine residues at positions 65 and 77. Oxidation of L79CC81A (R-form) yielded two isomers, L79CC81A-a (A-form) with tandem-linked Cys(65)-Cys(77) and Cys(79)-Cys(95), and L79CC81A-b (B-form) with crosslinked Cys(65)-Cys(79) and Cys(77)-Cys(95) (Kanaya, E., Ishihara, It., Tsunasawa, S., Nokihara, K., and Kikuchi, M. (1993) Biochem. J. 292, 469-476). PDI mainly enhanced the formation of the A- form in the absence of oxidized glutathione (GSSG); however, as the concentration of GSSG increased, it markedly accelerated the formation of the B-form. In contrast, the DspA/PpfA protein mainly enhanced the formation of the A-form, regardless of the presence or absence of GSSG. These results and the presumed spatial locations of Cys(65), Cys(77), and Cys(79)-Cys(95) in the R-form suggest that 1 of the half-cystine residues in the active site of PDI and the DsbA/PpfA protein can react with 1 of the 2 free Cys residues of the R-form. The dependence on GSSG of the B-form formation with PDI can be explained by the formation of two transient in termolecular disulfide bonds between PDI and the R-form and the attack of GSSG by the resultant thiolate anion of Cys(79) or Cys(95). The independence of the reac tion with the DsbA/PpfA protein from GSSG can be explained by the formation of one transient intermolecular disulfide bond. The possible formation of the two transient intermolecular disulfide bonds involving two sulfur atoms of PDI and 2 cysteine or half cystine residues of the substrate could explain the high isomerase activity of PDI.	PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN									AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; ARTYMIUK PJ, 1981, J MOL BIOL, V152, P737, DOI 10.1016/0022-2836(81)90125-X; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; HAWKINS HC, 1991, BIOCHEM J, V275, P349, DOI 10.1042/bj2750349; HAWKINS HC, 1991, BIOCHEM J, V275, P335, DOI 10.1042/bj2750335; HAYANO T, 1993, FEBS LETT, V328, P203, DOI 10.1016/0014-5793(93)80993-5; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KALLIS GB, 1980, J BIOL CHEM, V255, P261; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KANAYA E, 1993, BIOCHEM J, V292, P469, DOI 10.1042/bj2920469; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KIKUCHI M, 1988, P NATL ACAD SCI USA, V85, P9411, DOI 10.1073/pnas.85.24.9411; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LUNDSTROM J, 1992, J BIOL CHEM, V267, P9047; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; PIGIET VP, 1986, P NATL ACAD SCI USA, V83, P7643, DOI 10.1073/pnas.83.20.7643; VUORI K, 1992, J BIOL CHEM, V267, P7211	29	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4273	4278						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307992				2022-12-27	WOS:A1994MW98900059
J	KIM, S; BURGESS, BK				KIM, S; BURGESS, BK			PURIFICATION AND CHARACTERIZATION OF NITROGENASE FROM A DELTA-NIFW STRAIN OF AZOTOBACTER-VINELANDII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-MOLYBDENUM COFACTOR; AZORHIZOBIUM-CAULINODANS ORS571; GENE-CLUSTER; KLEBSIELLA-PNEUMONIAE; NUCLEOTIDE-SEQUENCE; DEFINED DELETIONS; FIXATION GENE; FIXABC REGION; IDENTIFICATION; MUTANT	Deletion of the nifW gene in Azotobacter vinelandii yields a strain (DJ224) that grows poorly under N-2 fixing conditions (Jacobson, M. R., Cash, V. L., Weiss, M. C., Laird, N. F., Newton, W. E., and Dean, D. R. (1989) Mol. and Gen. Genet. 219, 49-57). Here we report the purification of nitrogenase from DJ224. The purified Fe protein was indistinguishable from wild-type. The MoFe protein was indistinguishable from the wild-type MoFe protein by the criteria of sodium dodecyl sulfate-polyacrylamide gel electrophoresis, native gel electrophoresis, two-dimensional gel electrophoresis, metal analysis, UV/visible and EPR spectroscopies. It was different by the criteria of CD spectroscopy and specific activities. At a 5:1 molar ratio of Fe protein to MoFe protein, H-2 evolution under argon was identical to wild-type, C2H2 reduction was inhibited by 27%, N-2 reduction was inhibited by 38%, and CO inhibited H-2 evolution by 17%. The above data show that the nifW gene product is not required for: 1) detectable alteration of the polypeptide; 2) the synthesis of the metal portion of FeMo cofactor; or 3) FeMo cofactor insertion. The MoFe protein synthesized in the absence of NifW appears to have an alteration near the FeMo cofactor site, possibly at homocitrate, which causes differential inhibition of different substrates.	UNIV CALIF IRVINE, DEPT MOLEC BIOL & BIOCHEM, IRVINE, CA 92717 USA	University of California System; University of California Irvine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043144] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM43144] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIGONI F, 1991, MOL GEN GENET, V225, P514, DOI 10.1007/BF00261695; ARNOLD W, 1988, J MOL BIOL, V203, P715, DOI 10.1016/0022-2836(88)90205-7; BEYNON J, 1988, NUCLEIC ACIDS RES, V16, P9860, DOI 10.1093/nar/16.20.9860; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; BURGESS BK, 1993, MOLYBDENUM ENZYMES C; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; CLARK LJ, 1955, ANAL CHEM, V27, P2000, DOI 10.1021/ac60108a046; CORBIN JL, 1984, APPL ENVIRON MICROB, V47, P1027, DOI 10.1128/AEM.47.5.1027-1030.1984; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Dean D.R., 1992, BIOL NITROGEN FIXATI, P763; EVANS DJ, 1991, J BACTERIOL, V173, P5457, DOI 10.1128/jb.173.17.5457-5469.1991; GAVINI N, 1992, J BIOL CHEM, V267, P21179; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; GOTTSCHALK G, 1986, BACTERIAL METABOLISM, P137; HASELKORN R, 1992, BIOL NITROGEN FIXATI, P116; HOOVER TR, 1987, NATURE, V329, P855, DOI 10.1038/329855a0; HWANG JC, 1973, BIOCHIM BIOPHYS ACTA, V292, P256, DOI 10.1016/0005-2728(73)90270-3; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; KAMINSKI PA, 1988, MOL GEN GENET, V214, P496, DOI 10.1007/BF00330486; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; LI JG, 1990, J BACTERIOL, V172, P5884, DOI 10.1128/jb.172.10.5884-5891.1990; LIANG JH, 1990, BIOCHEMISTRY-US, V29, P8577, DOI 10.1021/bi00489a011; MASEPOHL B, 1993, MOL GEN GENET, V238, P369, DOI 10.1007/BF00291996; MAY HD, 1991, BIOCHEM J, V277, P457, DOI 10.1042/bj2770457; MCLEAN PA, 1981, NATURE, V292, P655, DOI 10.1038/292655a0; MEIJER WG, 1992, J BACTERIOL, V174, P3855, DOI 10.1128/jb.174.12.3855-3866.1992; MILCAMPS A, 1993, BIOCHIM BIOPHYS ACTA, V1173, P237, DOI 10.1016/0167-4781(93)90188-J; Newton WE, 1992, BIOL NITROGEN FIXATI, P877; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PAGE WJ, 1992, FEMS MICROBIOL LETT, V103, P149, DOI 10.1111/j.1574-6968.1992.tb05832.x; PAUL W, 1989, EUR J BIOCHEM, V178, P675, DOI 10.1111/j.1432-1033.1989.tb14497.x; RAWLINGS J, 1978, J BIOL CHEM, V253, P1001; ROBINSON AC, 1986, J BACTERIOL, V166, P180, DOI 10.1128/jb.166.1.180-186.1986; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; SCOTT DJ, 1992, J BIOL CHEM, V267, P20002; Smith B. E., 1985, Nitrogen fixation research progress, P597; SMITH BE, 1992, EUR J BIOCHEM, V205, P1, DOI 10.1111/j.1432-1033.1992.tb16746.x; STRANDBERG GW, 1968, CAN J MICROBIOL, V14, P25, DOI 10.1139/m68-005; THORNELEY RNF, 1985, MOLYBDENUM ENZYMES, P222; VANDEBOGART M, 1967, ANAL BIOCHEM, V20, P325, DOI 10.1016/0003-2697(67)90038-3; VAUGHN SA, 1989, BIOCHEMISTRY-US, V28, P419, DOI 10.1021/bi00428a002; Yates M. G., 1992, BIOL NITROGEN FIXATI, P685	45	7	7	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4215	4220						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307984				2022-12-27	WOS:A1994MW98900050
J	KURUMIZAKA, H; IKAWA, S; IKEYA, T; OGAWA, T; SHIBATA, T				KURUMIZAKA, H; IKAWA, S; IKEYA, T; OGAWA, T; SHIBATA, T			A CHIMERIC RECA PROTEIN EXHIBITS ALTERED DOUBLE-STRANDED DNA-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSED CIRCULAR DNA; ESCHERICHIA-COLI; GENETIC-RECOMBINATION; DUPLEX DNA; BRANCH MIGRATION; COMPLEX; EXCHANGE; MOLECULES; RENATURATION; INHIBITION	RecAc38 protein, a chimeric RecA protein of Escherichia coli and Pseudomonas aeruginosa, is proficient in the renaturation from complementary single strands. However, RecAc38 protein showed a significant deficiency in promoting homologous pairing of single-stranded DNA and double-stranded DNA. RecAc38 protein was able to remove the secondary structure of single-stranded DNA, the first step of homologous pairing, at a slightly reduced rate. RecAc38 protein-single-stranded DNA-complex (presynaptic complex) was found to be deficient in the sequence-independent binding to double-stranded DNA which is a step in the search for the homology. On the other hand, once unwinding was initiated, RecAc38 protein was able to propagate the unwinding of the double helix at the same extent as wild-type Rec-A protein. These defects and the proficiency of RecAc38 protein are explained by a model showing that RecA protein has three distinct DNA strand-binding sites (a site for the primary binding to single-stranded DNA, a site for the binding to a strand of second single- or double-stranded DNA, and a site required for the binding to the other strand of the double-stranded DNA) and that RecAc38 protein has a defect in the third site.	INST PHYS & CHEM RES, CELLULAR & MOLEC BIOL LAB, WAKO, SAITAMA 35101, JAPAN; OSAKA UNIV, FAC SCI, DEPT BIOL, TOYONAKA, OSAKA 560, JAPAN; SAITAMA UNIV, GRAD SCH SCI & ENGN, URAWA, SAITAMA 338, JAPAN	RIKEN; Osaka University; Saitama University				Kurumizaka, Hitoshi/0000-0001-7412-3722				ARAI N, 1992, NUCLEIC ACIDS RES, V20, P3679, DOI 10.1093/nar/20.14.3679; BIANCHI M, 1983, CELL, V34, P931, DOI 10.1016/0092-8674(83)90550-0; BRYANT FR, 1985, P NATL ACAD SCI USA, V82, P297, DOI 10.1073/pnas.82.2.297; CAZENAVE C, 1983, EMBO J, V2, P2247, DOI 10.1002/j.1460-2075.1983.tb01730.x; CHOW SA, 1985, P NATL ACAD SCI USA, V82, P5646, DOI 10.1073/pnas.82.17.5646; CHOW SA, 1988, J BIOL CHEM, V263, P200; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; CUNNINGHAM RP, 1979, NATURE, V281, P191, DOI 10.1038/281191a0; CUNNINGHAM RP, 1979, NATURE, V282, P426, DOI 10.1038/282426a0; DICAPUA E, 1987, EMBO J, V6, P2493, DOI 10.1002/j.1460-2075.1987.tb02531.x; ENGLUND PT, 1969, J BIOL CHEM, V244, P3038; FLORY J, 1984, P NATL ACAD SCI-BIOL, V81, P7026, DOI 10.1073/pnas.81.22.7026; GONDA DK, 1983, CELL, V34, P647, DOI 10.1016/0092-8674(83)90397-5; HORII T, 1991, BIOCHIMIE, V73, P177, DOI 10.1016/0300-9084(91)90200-K; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; IKAWA S, 1989, J BIOL CHEM, V264, P21167; IWABUCHI MA, 1983, J BIOL CHEM, V258, P2394; KAHN R, 1984, J BIOL CHEM, V259, P7495; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KOWALCZYKOWSKI SC, 1989, J MOL BIOL, V207, P719, DOI 10.1016/0022-2836(89)90239-8; KOWALCZYKOWSKI SC, 1987, P NATL ACAD SCI USA, V84, P3127, DOI 10.1073/pnas.84.10.3127; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; MENETSKI JP, 1990, J MOL BIOL, V211, P845, DOI 10.1016/0022-2836(90)90078-Z; NORDEN B, 1990, J MOL BIOL, V216, P223, DOI 10.1016/S0022-2836(05)80311-0; OGAWA T, 1979, COLD SPRING HARB SYM, V43, P909, DOI 10.1101/SQB.1979.043.01.099; OGAWA T, 1992, J MOL BIOL, V226, P651, DOI 10.1016/0022-2836(92)90622-Q; OHTANI T, 1982, NATURE, V299, P86, DOI 10.1038/299086a0; PUGH BF, 1987, J BIOL CHEM, V262, P1326; PUGH BF, 1987, J BIOL CHEM, V262, P1337; RADDING CM, 1982, COLD SPRING HARB SYM, V47, P821, DOI 10.1101/SQB.1983.047.01.094; ROBERTS JW, 1979, COLD SPRING HARB SYM, V43, P917, DOI 10.1101/SQB.1979.043.01.100; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SHIBATA T, 1984, COLD SPRING HARB SYM, V49, P541, DOI 10.1101/SQB.1984.049.01.061; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P5100, DOI 10.1073/pnas.76.10.5100; SHIBATA T, 1981, J BIOL CHEM, V256, P7557; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; SHIBATA T, 1982, J BIOL CHEM, V257, P3981; SHIBATA T, 1981, J BIOL CHEM, V256, P7565; SHIBATA T, 1982, J BIOL CHEM, V257, P370; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TAKAHASHI M, 1989, EUR J BIOCHEM, V183, P617, DOI 10.1111/j.1432-1033.1989.tb21091.x; TSANG SS, 1985, BIOCHEMISTRY-US, V24, P3226, DOI 10.1021/bi00334a023; TSANG SS, 1985, J MOL BIOL, V185, P295, DOI 10.1016/0022-2836(85)90405-X; WABIKO H, 1983, EUR J BIOCHEM, V137, P263, DOI 10.1111/j.1432-1033.1983.tb07824.x; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8829; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WU AM, 1983, P NATL ACAD SCI-BIOL, V80, P1256, DOI 10.1073/pnas.80.5.1256	51	15	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3068	3075						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300641				2022-12-27	WOS:A1994MV43200101
J	MORI, M; EKI, T; TAKAHASHIKUDO, M; HANAOKA, F; UI, M; ENOMOTO, T				MORI, M; EKI, T; TAKAHASHIKUDO, M; HANAOKA, F; UI, M; ENOMOTO, T			CHARACTERIZATION OF DNA-SYNTHESIS AT A RESTRICTIVE TEMPERATURE IN THE TEMPERATURE-SENSITIVE MUTANTS, TSFT5 CELLS, THAT BELONG TO THE COMPLEMENTATION GROUP OF TS85 CELLS CONTAINING A THERMOLABILE UBIQUITIN-ACTIVATING ENZYME E1 - INVOLVEMENT OF THE UBIQUITIN-CONJUGATING SYSTEM IN DNA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE FM3A CELLS; CHROMOSOME CONDENSATION; HEAT-LABILE; POLYMERASE-ALPHA; PROTEIN LIGASE; X-CHROMOSOME; G2 PHASE; PHOSPHORYLATION; DISAPPEARANCE; PURIFICATION	A temperature-sensitive mutant defective in DNA replication, tsFT5, has been isolated from the mouse mammary carcinoma cell line FM3A. DNA synthesis in tsFT5 cells at a restrictive temperature (39-degrees-C) has been characterized in detail. Incorporation of [H-3]-thymidine decreased rapidly after an increase in temperature to 39-degrees-C and the incorporation was less than 20% and 10% of the initial level after 4 and 8 h, respectively. Analysis by DNA fiber autoradiography revealed that the initiation of DNA replication at the origin of the replicons was impaired in tsFT5 cells but that the DNA chain elongation rate of the mutant cells did not decrease at the nonpermissive temperature. tsFT5 cells were confirmed to belong to the complementation group which includes ts85 cells arrested mainly in the G2 phase at the nonpermissive temperature. It has been observed that the amount of ubiquitin-conjugated histone H2A (uH2A) in ts85 cells decreases at the nonpermissive temperature (Marunouchi, T., Yasuda, H., Matsumoto, Y., and Yamada, M. (1980) Biochem. Biophys. Res. Commun. 95, 126-131). The amount of uH2A in tsFT5 cells also decreased rapidly at 39-degrees-C. This decrease occurred at the same time as or slightly preceding to reduction in DNA synthesis, and the reappearance of uH2A was followed by the restoration of DNA synthesis after the temperature was reduced. A similar temporal relationship between decrease in the amount of uH2A and reduction in DNA synthesis was observed in ts85 cells cultured at 39-degrees-C. However, the rates of the decrease of uH2A and of the reduction in DNA synthesis in ts85 cells were slower than those observed in tsFT5 cells. A comparison of the thermolability of purified ubiquitin-activating enzyme E1s revealed that the E1 from ts85 cells had a thermolability intermediate between those of the E1 from tsFT5 cells and of the wild-type cells. A reduction in the phosphorylation of histone H1 was observed in tsFT5 cells cultured at 39-degrees-C, but the reduction occurred several hours after the decrease in uH2A and the reduction in DNA synthesis.	UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo				Takahashi, Mami/0000-0001-5062-811X				AYUSAWA D, 1992, CELL STRUCT FUNCT, V17, P113, DOI 10.1247/csf.17.113; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; EKI T, 1986, J BIOL CHEM, V261, P8888; EKI T, 1990, J BIOL CHEM, V265, P26; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HUBERMAN JA, 1968, J MOL BIOL, V32, P327, DOI 10.1016/0022-2836(68)90013-2; KUDO M, 1991, EXP CELL RES, V192, P110, DOI 10.1016/0014-4827(91)90164-P; KULKA RG, 1988, J BIOL CHEM, V263, P15726; LEE PL, 1986, BIOCHEMISTRY-US, V25, P3134, DOI 10.1021/bi00359a010; MATSUI SI, 1979, P NATL ACAD SCI USA, V76, P6386, DOI 10.1073/pnas.76.12.6386; MATSUMOTO YI, 1980, NATURE, V284, P181, DOI 10.1038/284181a0; MAYER A, 1989, J BIOL CHEM, V264, P2060; MINEO C, 1986, EXP CELL RES, V167, P53, DOI 10.1016/0014-4827(86)90203-X; MITA S, 1980, EXP CELL RES, V126, P407, DOI 10.1016/0014-4827(80)90280-3; MUELLER RD, 1985, J BIOL CHEM, V260, P5147; MURAKAMI Y, 1985, P NATL ACAD SCI USA, V82, P1761, DOI 10.1073/pnas.82.6.1761; NAKANO N, 1966, TOHOKU J EXP MED, V88, P69, DOI 10.1620/tjem.88.69; NURSE P, 1985, TRENDS GENET, V1, P51, DOI 10.1016/0168-9525(85)90023-X; OHTSUBO M, 1988, BIOCHEM BIOPH RES CO, V153, P1173, DOI 10.1016/S0006-291X(88)81351-2; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; TAKADATAKAYAMA R, 1991, J BIOL CHEM, V266, P15716; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; WEST MHP, 1980, BIOCHEMISTRY-US, V19, P3238, DOI 10.1021/bi00555a022; WEST MHP, 1980, NUCLEIC ACIDS RES, V8, P4671, DOI 10.1093/nar/8.20.4671; YASUDA H, 1981, BIOCHEMISTRY-US, V20, P4414, DOI 10.1021/bi00518a028; YASUDA H, 1991, CELL STRUCT FUNCT, V16, P105, DOI 10.1247/csf.16.105; YASUMITSU H, 1985, CELL STRUCT FUNCT, V10, P79, DOI 10.1247/csf.10.79; ZACKSENHAUS E, 1990, EMBO J, V9, P2923, DOI 10.1002/j.1460-2075.1990.tb07483.x	34	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16803	16809						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344958				2022-12-27	WOS:A1993LQ33600101
J	NESBITT, S; NESBIT, A; HELFRICH, M; HORTON, M				NESBITT, S; NESBIT, A; HELFRICH, M; HORTON, M			BIOCHEMICAL-CHARACTERIZATION OF HUMAN OSTEOCLAST INTEGRINS - OSTEOCLASTS EXPRESS ALPHA-V-BETA-3, ALPHA-2-BETA-1, AND ALPHA-V-BETA-1 INTEGRINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; EXTRACELLULAR-MATRIX RECEPTORS; CELL-SURFACE GLYCOPROTEIN; VITRONECTIN RECEPTOR; FIBRONECTIN RECEPTOR; MONOCLONAL-ANTIBODY; ADHESION RECEPTORS; ALPHA-SUBUNIT; BETA-SUBUNIT; LAMININ RECEPTOR	The study of osteoclast integrins has been previously hampered by the lack of a source of large numbers of purified osteoclasts. Osteoclastoma, a human giant cell tumor of bone, supplied a rich source of osteoclasts within a tissue containing many diverse cell types. Osteoclastoma integrin immunostaining confirmed the presence of the integrin alphavbeta3 complex and the alpha2 and beta1 integrin subunits on osteoclasts. However, weak integrin expression, for example with alphavbeta5, was difficult to interpret. Purification with magnetic beads coated with vitronectin receptor monoclonal antibody (13C2) enabled osteoclast membranes to be isolated with high purity and yield (57%) from osteoclastoma tissue. Positively (osteoclast-enriched) selected membranes were biochemically assessed for integrin expression by immunoprecipitation and visualization by non-radioactive enhanced chemiluminescence. Alpha1, alpha4, alpha6, alpha8, alphaM, alphaX, gpIIb, beta4, beta6, and beta8 integrin chains were undetectable at a sensitivity of 1 ng. Alpha3, alpha5, alphaL, beta2, and alphavbeta5 were found in the negatively selected osteoclastoma tissue but not in the positively purified osteoclast membranes. The presence of alphavbeta1 and alpha2beta1 dimers was demonstrated biochemically on the immunoisolated osteoclast membranes. Osteoclast alphavbeta3 isolation by Arg-Gly-Asp (RGD) affinity chromatography for NH2-terminal amino acid sequencing confirmed that the osteoclast vitronectin receptor was identical to that previously characterized on other cell types. In situ hybridization using human alphav riboprobes in osteoclasts from human and rodent bone further demonstrated the high level and specificity of expression of alphav vitronectin receptor in osteoclasts.			NESBITT, S (corresponding author), ST BARTHOLOMEWS HOSP, IMPERIAL CANC RES FUND, HAEMOPOIESIS RES GRP, DOMINION HOUSE, LONDON EC1A 7BE, ENGLAND.							AMIOT M, 1986, SCAND J IMMUNOL, V23, P109, DOI 10.1111/j.1365-3083.1986.tb01948.x; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BODARY SC, 1990, J BIOL CHEM, V265, P5938; BOSSY B, 1991, EMBO J, V10, P2375, DOI 10.1002/j.1460-2075.1991.tb07776.x; CAIXIA S, 1991, CELL IMMUNOL, V138, P216, DOI 10.1016/0008-8749(91)90146-3; CHAMBERS TJ, 1985, J PATHOL, V145, P297, DOI 10.1002/path.1711450403; CLOVER J, 1992, J CELL SCI, V103, P267; COLLINOSDOBY P, 1991, J BONE MINER RES, V6, P1353; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; DEDHAR S, 1990, J CELL BIOL, V110, P2185, DOI 10.1083/jcb.110.6.2185; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; FALCIONI R, 1988, CANCER RES, V48, P816; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; FRADET Y, 1984, P NATL ACAD SCI-BIOL, V81, P224, DOI 10.1073/pnas.81.1.224; FREED E, 1989, EMBO J, V8, P2955, DOI 10.1002/j.1460-2075.1989.tb08445.x; GEHLSEN KR, 1988, SCIENCE, V241, P1228, DOI 10.1126/science.2970671; HELFRICH MH, 1992, J BONE MINER RES, V7, P335; HELFRICH MH, 1992, J BONE MINER RES, V7, P345; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HILDRETH JEK, 1983, EUR J IMMUNOL, V13, P202, DOI 10.1002/eji.1830130305; HOGAN B, 1986, MANIPULATING MOUSE E, P228; HOGG N, 1986, EUR J IMMUNOL, V16, P240, DOI 10.1002/eji.1830160306; HOGG N, 1985, CELL IMMUNOL, V48, P549; HORTON M, 1990, INT J EXP PATHOL, V71, P741; HORTON MA, 1989, J BONE MINER RES, V4, P803; HORTON MA, 1985, CANCER RES, V45, P5663; HORTON MA, 1984, J PATHOL, V144, P281, DOI 10.1002/path.1711440410; HORTON MA, 1991, EXP CELL RES, V195, P368, DOI 10.1016/0014-4827(91)90386-9; HORWITZ A, 1985, J CELL BIOL, V101, P2134, DOI 10.1083/jcb.101.6.2134; HUGHES DE, 1993, J BONE MINER RES, V8, P527; HYNES RO, 1982, CELL, V69, P11; Jaffe HL, 1940, ARCH PATHOL, V30, P993; KAJIJI S, 1989, EMBO J, V8, P673, DOI 10.1002/j.1460-2075.1989.tb03425.x; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KRISSANSEN GW, 1990, J BIOL CHEM, V265, P823; LAKKAKORPI PT, 1991, J CELL BIOL, V115, P1179, DOI 10.1083/jcb.115.4.1179; MACDONALD BR, 1986, J BONE MINER RES, V1, P227; MARSHALL JF, 1991, INT J CANCER, V49, P924, DOI 10.1002/ijc.2910490621; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MESSNER DJ, 1989, J CELL BIOL, V108, P2149, DOI 10.1083/jcb.108.6.2149; MODDERMAN PW, 1988, THROMB HAEMOSTASIS, V60, P68; MOYLE M, 1991, J BIOL CHEM, V266, P19650; NESBITT SA, 1992, ANAL BIOCHEM, V206, P267, DOI 10.1016/0003-2697(92)90365-E; OURSLER MJ, 1991, J BONE MINER RES, V6, P375; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SHARPE PT, 1988, METHODS CELL SEPARAT, P208; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; SONNENBERG A, 1987, J BIOL CHEM, V262, P10376; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; ZAMBONINZALLONE A, 1989, EXP CELL RES, V182, P645, DOI 10.1016/0014-4827(89)90266-8	62	137	140	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16737	16745						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344953				2022-12-27	WOS:A1993LQ33600093
J	SCHIEVEN, GL; KIRIHARA, JM; BURG, DL; GEAHLEN, RL; LEDBETTER, JA				SCHIEVEN, GL; KIRIHARA, JM; BURG, DL; GEAHLEN, RL; LEDBETTER, JA			P72SYK TYROSINE KINASE IS ACTIVATED BY OXIDIZING CONDITIONS THAT INDUCE LYMPHOCYTE TYROSINE PHOSPHORYLATION AND CA2+ SIGNALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN-KINASES; ZETA-CHAIN; IGD ANTIBODIES; B-CELLS; TRANSDUCTION; STIMULATION; INHIBITION; MYELOPEROXIDASE; PHOSPHOTYROSINE	We have used H2O2 as a pharmacologic agent to examine the effects of oxidizing conditions on lymphocyte signal pathways. Treatment of Ramos cells with 5-10 mM H2O2 gave rapid and strong tyrosine phosphorylation of multiple cellular proteins and activation of p72syk to levels equal to or greater than that observed upon surface Ig cross-linking. Strong Ca2+ signals that could be blocked by the tyrosine kinase inhibitor herbimycin A were also observed under these conditions. However, there was no increase in activity for the Src family kinases p56lck, p59fyn, or p56/p53lyn. Our findings that the p72syk tyrosine kinase responds to H2O2 treatment of cells suggest that this kinase is likely to contribute to cellular tyrosine phosphorylation and calcium signaling induced by oxidizing conditions. Furthermore, H2O2 may be useful as a pharmacologic agent to distinguish the effects of p72syk-related kinases from those of Src family kinases.	PURDUE UNIV, DEPT MED CHEM & PHARMACOGNOSY, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	SCHIEVEN, GL (corresponding author), BRISTOL MYERS SQUIBB, PHARMACEUT RES INST, 3005 1ST AVE, SEATTLE, WA 98121 USA.			Geahlen, Robert/0000-0001-8400-2924	NATIONAL CANCER INSTITUTE [R01CA037372] Funding Source: NIH RePORTER; NCI NIH HHS [CA37372] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLACK HS, 1987, PHOTOCHEM PHOTOBIOL, V46, P213, DOI 10.1111/j.1751-1097.1987.tb04759.x; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; CAMBIER J, 1988, P NATL ACAD SCI USA, V85, P6493, DOI 10.1073/pnas.85.17.6493; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DUNCAN DD, 1989, TOXICOL APPL PHARM, V100, P485, DOI 10.1016/0041-008X(89)90296-2; ELHAG A, 1986, J IMMUNOL, V136, P3420; ELHAG A, 1987, J IMMUNOL, V139, P2406; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAMPS MP, 1988, ONCOGENE, V2, P305; KIM KM, 1991, J IMMUNOL, V146, P819; KIM KM, 1992, J IMMUNOL, V148, P29; KLEBANOFF SJ, 1986, J IMMUNOL, V136, P4220; LANE PJL, 1991, J IMMUNOL, V146, P715; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; SCHIEVEN GL, 1992, J IMMUNOL, V149, P1676; SCHIEVEN GL, 1993, MOL BIOL CELL, V4, P523, DOI 10.1091/mbc.4.5.523; SCHIEVEN GL, 1992, MOL BIOL CELL, V3, pA148; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; WANGE RL, 1992, J BIOL CHEM, V267, P11685; ZIONCHECK TF, 1988, J BIOL CHEM, V263, P19195	32	168	171	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16688	16692						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344947				2022-12-27	WOS:A1993LQ33600086
J	SAKAMAKI, K; WANG, HM; MIYAJIMA, I; KITAMURA, T; TODOKORO, K; HARADA, N; MIYAJIMA, A				SAKAMAKI, K; WANG, HM; MIYAJIMA, I; KITAMURA, T; TODOKORO, K; HARADA, N; MIYAJIMA, A			LIGAND-DEPENDENT ACTIVATION OF CHIMERIC RECEPTORS WITH THE CYTOPLASMIC DOMAIN OF THE INTERLEUKIN-3 RECEPTOR BETA-SUBUNIT (BETA-IL3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; PROTEIN TYROSINE PHOSPHORYLATION; GROWTH SIGNAL TRANSDUCTION; MURINE ERYTHROPOIETIN RECEPTOR; HUMAN IL-2 RECEPTOR; T-CELL LINE; GM-CSF; EXPRESSION CLONING; HORMONE RECEPTOR; ESSENTIAL REGION	Beta(IL3) (formerly known as AIC2A), a beta subunit of the murine interleukin-3 receptor (IL-3R), is not only required for formation of the high affinity receptor but is also important for signal transduction. To examine the function of beta(IL3) in signal transduction, we constructed several chimeric receptors consisting of the intracellular portion of beta(IL3) and the extracellular portion of other members of the cytokine receptor super-family, i.e. the human interleukin-2 receptor beta chain (hIL-2Rbeta), the human interleukin-4 receptor (hIL-4R), and the murine erythropoietin receptor (mEpoR). These chimeric receptors and normal cytokine receptors were expressed in an IL-3-dependent murine proB cell line, Ba/F3, and an IL-2-dependent murine T cell line, CTLL2. Regardless of the origin of the extracellular domain, these chimeric receptors were functional in Ba/F3 cells; they stimulated proliferation and induced tyrosine phosphorylation in response to the cytokine corresponding to the extracellular domain. However, the response of transfectants expressing chimeric receptors was similar to, but not identical with, the response of Ba/F3 cells to mIL-3. We present evidence that the IL-4R and EpoR probably have an additional component which is involved in signal transduction.	DNAX RES INST MOLEC & CELLULAR BIOL INC, MOLEC & CELLULAR BIOL RES INST, DEPT MOLEC BIOL, PALO ALTO, CA 94304 USA; DNAX RES INST MOLEC & CELLULAR BIOL INC, MOLEC & CELLULAR BIOL RES INST, DEPT IMMUNOL, PALO ALTO, CA 94304 USA; RIKEN TSUKUBA LIFE SCI CTR, KOHYADAI, TSUKUBA, JAPAN	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; RIKEN			Kitamura, Toshio/AAA-2071-2021	Sakamaki, Kazuhiro/0000-0002-7072-9628				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; ARIMA N, 1992, J IMMUNOL, V149, P83; ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; AUGUSTINE JA, 1990, BIOCHIM BIOPHYS ACTA, V1052, P313, DOI 10.1016/0167-4889(90)90227-5; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CHIBA T, 1992, BIOCHEM BIOPH RES CO, V186, P1236, DOI 10.1016/S0006-291X(05)81538-4; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DURONIO V, 1992, J BIOL CHEM, V267, P21856; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HARADA N, 1992, J BIOL CHEM, V267, P22752; HARADA N, 1990, P NATL ACAD SCI USA, V87, P857, DOI 10.1073/pnas.87.3.857; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HULI J, 1989, J IMMUNOL, V142, P800; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; JUBINSKY PT, 1993, BLOOD, V81, P587; KANAKURA Y, 1991, BLOOD, V77, P243; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KITAMURA T, 1992, BLOOD, V80, P84; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MAYEUX P, 1991, J BIOL CHEM, V266, P23380; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MIYAJIMA A, 1992, INT J CELL CLONING, V10, P126, DOI 10.1002/stem.5530100302; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MURATA Y, 1990, BIOCHEM BIOPH RES CO, V173, P1102, DOI 10.1016/S0006-291X(05)80899-X; OTANI H, 1992, P NATL ACAD SCI USA, V89, P2789, DOI 10.1073/pnas.89.7.2789; PARK LS, 1992, P NATL ACAD SCI USA, V89, P4295, DOI 10.1073/pnas.89.10.4295; SABE H, 1991, INT IMMUNOL, V3, P1137, DOI 10.1093/intimm/3.11.1137; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATOH T, 1992, J BIOL CHEM, V267, P25423; SATOH T, 1992, J BIOL CHEM, V267, P24149; SEEDORF K, 1991, J BIOL CHEM, V266, P12424; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SHOWERS MO, 1992, BLOOD, V80, P3070; TAKAKI S, 1991, EMBO J, V10, P2833, DOI 10.1002/j.1460-2075.1991.tb07832.x; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WATSON J, 1979, J EXP MED, V150, P1510, DOI 10.1084/jem.150.6.1510; YAMAMURA Y, 1992, EMBO J, V11, P4909, DOI 10.1002/j.1460-2075.1992.tb05597.x; ZON LI, 1992, MOL CELL BIOL, V12, P2949, DOI 10.1128/MCB.12.7.2949	54	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15833	15839						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340408				2022-12-27	WOS:A1993LN30500074
J	SUGIURA, N; SAKURAI, K; HORI, Y; KARASAWA, K; SUZUKI, S; KIMATA, K				SUGIURA, N; SAKURAI, K; HORI, Y; KARASAWA, K; SUZUKI, S; KIMATA, K			PREPARATION OF LIPID-DERIVATIZED GLYCOSAMINOGLYCANS TO PROBE A REGULATORY FUNCTION OF THE CARBOHYDRATE MOIETIES OF PROTEOGLYCANS IN CELL-MATRIX INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRONECTIN-MEDIATED ADHESION; CHONDROITIN-SULFATE; MONOCLONAL-ANTIBODY; COLLAGEN SUBSTRATA; FIBROBLASTS; ATTACHMENT; CARTILAGE; CHAINS; SUGARS	We have shown previously that chondroitin sulfate, but not heparan sulfate/heparin, linked to either natural core proteins or serum albumin interferes with cell-to-substrate adhesion, provided that the external proteoglycans are topologically immobilized on plastic plates. In order to study the roles of glycosaminoglycan chains (GAGs) as recognition structure, a new assay system is now developed which involves the conversion of free GAGs to reactive lactone derivatives selectively modified at the reducing end. The modified GAGs can be coupled to the amino group of phosphatidylethanolamine (PE) for use as probes on either plastic plates or cell surfaces. Incubation of GAG-PE solutions in polystyrene plates results in a time- and dose-dependent increase of the density of the GAG chains noncovalently immobilized onto the plates. No immobilization is detected with any of the GAG-PE samples that have been treated with phospholipase D. A M(r) 30,000 chondroitin sulfate conjugate to PE (CS-PE), when immobilized onto a fibronectin-coated well for 2 h at an initial concentration of 0.06 mug/100 mul/well, inhibits the adhesion of baby hamster kidney (BHK) cells to the substratum by approximately 50%, whereas heparin-, heparan sulfate-, hyaluronic acid-, and dermatan sulfate-PE do not. The effect of CS-PE is abolished by treating the CS-PE-coated plates with chondroitinase ABC. A similar level of inhibition by CS-PE is found when the RGD-containing 120-kDa fragment of fibronectin is used in place of fibronectin. CS-PE in soluble form, once exposed to BHK cells in suspension, can be associated with the cell surfaces, thereby exerting some inhibitory effects on cell-to-substrate adhesion. On a per mol basis, however, the activity of cell-associated CS-PE is far lower than that of substrate-associated CS-PE. Together the results indicate that our GAG-PEs offer useful tools for probing regulatory function of the GAG moieties of proteoglycans and further support the hypothesis that the inhibitory regulation of cell-to-matrix adhesion by large chondroitin sulfate proteoglycans is caused by an interaction between the cell surface and the chondroitin sulfate chains topologically immobilized on extracellular matrices.	AICHI MED UNIV,INST MOLEC SCI MED,NAGAKUTE,AICHI 48011,JAPAN; SEIKAGAKU CORP,TOKYO RES INST,TOKYO 207,JAPAN	Aichi Medical University; Seikagaku Corporation								AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; AVNUR Z, 1984, CELL, V38, P811, DOI 10.1016/0092-8674(84)90276-9; BIDANSET DJ, 1992, J CELL BIOL, V118, P1523, DOI 10.1083/jcb.118.6.1523; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BOREL E, 1952, HELV CHIM ACTA, V35, P115, DOI 10.1002/hlca.19520350116; BRENNAN MJ, 1983, CANCER RES, V43, P4302; HAYASHI K, 1992, J CELL BIOL, V119, P945, DOI 10.1083/jcb.119.4.945; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; Humphries M.J., 1991, RECEPTORS EXTRACELLU, P195; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; JALKANEN M, 1991, RECEPTORS EXTRACELLU, P1; KATO M, 1987, J BIOL CHEM, V262, P7180; LEE YC, 1992, TRENDS GLYCOSCI GLYC, V4, P251; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; OGAMO A, 1982, CARBOHYD RES, V105, P69, DOI 10.1016/S0008-6215(00)81855-8; PIERSCHBACHER MD, 1981, CELL, V26, P259, DOI 10.1016/0092-8674(81)90308-1; RICH AM, 1981, NATURE, V293, P224, DOI 10.1038/293224a0; ROLLINS BJ, 1979, BIOCHEMISTRY-US, V18, P441; ROSEMAN S, 1991, TRENDS GLYCOSCI GLYC, V3, P438; ROSENBERG LC, 1986, CIBA F SYMP, V124, P47; RUOSLAHTI E, 1982, METHOD ENZYMOL, V82, P803; RUOSLAHTI E, 1991, CELL BIOL EXTRACELLU; RYU EK, 1979, J LIPID RES, V20, P561; SANANTONIO JD, 1992, J CELL PHYSIOL, V150, P8; SHIOZAWA S, 1992, ANN RHEUM DIS, V51, P869, DOI 10.1136/ard.51.7.869; STOLL MS, 1988, BIOCHEM J, V256, P661, DOI 10.1042/bj2560661; Sugiura Nobuo, 1992, Cell Structure and Function, V17, P510; SUZUKI S, 1991, PURE APPL CHEM, V63, P545, DOI 10.1351/pac199163040545; TAKAGAKI K, 1990, J BIOCHEM BIOPH METH, V21, P209, DOI 10.1016/0165-022X(90)90014-4; TAKEMOTO H, 1985, ANAL BIOCHEM, V145, P245, DOI 10.1016/0003-2697(85)90357-4; TANG PW, 1985, BIOCHEM BIOPH RES CO, V132, P474, DOI 10.1016/0006-291X(85)91158-1; UENO Y, 1988, CHEM PHARM BULL, V36, P4971; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10; YAMADA KM, 1981, IMMUNOCHEMISTRY EXTR, P111; YAMAGATA M, 1987, J BIOL CHEM, V262, P4146; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012	36	76	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15779	15787						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340404				2022-12-27	WOS:A1993LN30500068
J	WILSON, AL; MALTESE, WA				WILSON, AL; MALTESE, WA			ISOPRENYLATION OF RAB1B IS IMPAIRED BY MUTATIONS IN ITS EFFECTOR DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING-PROTEINS; VESICULAR TRANSPORT; MOLECULAR-CLONING; SMG P25A; FARNESYLTRANSFERASE; SEQUENCE; GERANYLGERANYLTRANSFERASE; CYSTEINE; SUBUNIT; FAMILY	Low molecular mass GTP-binding proteins encoded by the Rab gene family are posttranslationally modified by a specific geranylgeranyltransferase (GGTase II), which catalyzes the thioether linkage of geranylgeranyl isoprenoids to cysteines within one of the following carboxyl-terminal sequence motifs: GGCC, CXC, CCSN. Short peptides containing these sequences are poor substrates for isoprenylation in vitro, suggesting that structural domains remote from the carboxyl terminus are required for interactions between Rab proteins and GGTase II. To begin to define these domains, deletions and point mutations were created within the Rab1B gene, and the ability of the mutant translation products to undergo isoprenylation was evaluated in reticulocyte lysates. Deletion of amino acids 2-9 diminished but did not eliminate isoprenylation of Rab1B, suggesting that the extreme amino-terminal region is not absolutely required for interaction with GGTase II. Longer deletions in the amino-terminal region, which probably disrupt the overall conformation of Rab1B, completely prevented isoprenylation. Site-directed mutations predicted to lie in the amino-terminal variable region (Y5N), the beta3 strand (Q60E), and Loop 7 (A110D) of the Rab1B structure did not reduce isoprenylation. However, two mutations (I41N, D44N) in the effector domain, which appears to mediate interactions with proteins that stimulate GTP hydrolysis or GDP dissociation, essentially abolished the ability of Rab1B to undergo isoprenylation. These findings imply that the effector domain plays a key role in the isoprenylation of Rab proteins, either by serving as a prenyltransferase binding site or by facilitating interactions with accessory proteins that allow Rab1B to assume a specific guanine nucleotide-dependent conformation that is recognized by GGTase II.	WEIS CTR RES,GEISINGER CLIN,100 N ACAD AVE,DANVILLE,PA 17822						NCI NIH HHS [CA34569] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034569] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BECKER J, 1991, EMBO J, V10, P785, DOI 10.1002/j.1460-2075.1991.tb08010.x; BUCCI C, 1991, BIOTECH CELL REG, V4, P103; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; CHAVRIER P, 1992, GENE, V112, P261, DOI 10.1016/0378-1119(92)90387-5; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; Higuchi R., 1989, PCR TECHNOLOGY, P61; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KHOSRAVIFAR R, 1992, J BIOL CHEM, V267, P24363; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; OVERMEYER JH, 1992, J BIOL CHEM, V267, P22686; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VIELH E, 1989, NUCLEIC ACIDS RES, V17, P1770, DOI 10.1093/nar/17.4.1770; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	38	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14561	14564						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325834				2022-12-27	WOS:A1993LL75900003
J	CAMEJO, G; FAGER, G; ROSENGREN, B; HURTCAMEJO, E; BONDJERS, G				CAMEJO, G; FAGER, G; ROSENGREN, B; HURTCAMEJO, E; BONDJERS, G			BINDING OF LOW-DENSITY LIPOPROTEINS BY PROTEOGLYCANS SYNTHESIZED BY PROLIFERATING AND QUIESCENT HUMAN ARTERIAL SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE; GROWTH-FACTOR; ATHEROSCLEROSIS; ACCUMULATION; TISSUE; ATHEROGENESIS; MACROPHAGES; APO-B-100; CULTURE; HEPARIN	Chondroitin sulfate-rich proteoglycans secreted by arterial intima smooth muscle cells appear involved in low density lipoprotein entrapment and modification. Hypothetically, such a process may contribute to atherogenesis. We compared composition and size of those proteoglycans synthesized by proliferating and resting human arterial smooth muscle cells for which low density lipoprotein had affinity. Lipoprotein-binding proteoglycans secreted by proliferating cells were larger than those of resting cells (M(r) = 1.1 x 10(6) versus 0.8 x 10(6)). This was primarily caused by increased M(r) of the chondroitin sulfate chains (6 x 10(4) versus 3.5 x 10(4)). The glycosaminoglycan chains of the proteoglycans from both cells were made of more than 90% chondroitin 6-sulfate and chondroitin 4-sulfate in a 6:4 ratio. Affinity chromatography indicated that low density lipoprotein had a higher affinity with the proteoglycans synthesized by proliferating cells than those from resting cells. Measured with gel mobility shift assay, the apparent affinity constant of low density lipoproteins for proteoglycans from proliferating cells was 3-fold higher than that for proteoglycans from resting cells. This increased affinity appeared related to the higher relative proportion of proteoglycans with longer glycosaminoglycan chains secreted by the proliferating cells than those secreted by the resting cells.	GOTHENBURG UNIV,SAHLGRENS HOSP,DEPT HEART & LUNG DIS,WALLENBERG LAB,S-41345 GOTHENBURG,SWEDEN	Sahlgrenska University Hospital; University of Gothenburg	CAMEJO, G (corresponding author), ASTRA HASSLE,PRECLIN RES LABS,DEPT BIOCHEM,S-43183 MOLNDAL,SWEDEN.							ALAVI MZ, 1992, ATHEROSCLEROSIS, V95, P59, DOI 10.1016/0021-9150(92)90176-H; ALVES CS, 1988, ATHEROSCLEROSIS, V73, P113, DOI 10.1016/0021-9150(88)90032-9; BERENSON GS, 1984, EXP MOL PATHOL, V41, P267, DOI 10.1016/0014-4800(84)90043-1; BIHARIVARGA M, 1964, J ATHEROSCLER RES, V4, P106, DOI 10.1016/S0368-1319(64)80020-X; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; CAMEJO G, 1988, ARTERIOSCLEROSIS, V8, P368, DOI 10.1161/01.ATV.8.4.368; CAMEJO G, 1982, ADV LIPID RES, V19, P1; CHEN JK, 1991, IN VITRO CELL DEV B, V27, P6; EDWARDS IJ, 1988, J BIOL CHEM, V263, P9612; FABER M, 1949, ARCH PATHOL, V48, P342; FAGER G, 1992, IN VITRO CELL DEV-AN, V28A, P176; FAGER G, 1992, IN VITRO CELL DEV-AN, V28A, P168; FAGER G, 1988, EXP CELL RES, V176, P319, DOI 10.1016/0014-4827(88)90334-5; GOLDBERG RL, 1990, CONNECT TISSUE RES, V24, P265, DOI 10.3109/03008209009152154; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; HOFF HF, 1983, ARTERY, V12, P104; HOFF HF, 1986, ATHEROSCLEROSIS, V61, P231, DOI 10.1016/0021-9150(86)90143-7; HOLLANDER W, 1976, EXP MOL PATHOL, V25, P106, DOI 10.1016/0014-4800(76)90021-6; HOLLMANN J, 1986, EXP CELL RES, V167, P484, DOI 10.1016/0014-4827(86)90188-6; HURTCAMEJO E, 1992, ARTERIOSCLER THROMB, V12, P569, DOI 10.1161/01.ATV.12.5.569; HURTCAMEJO E, 1990, J LIPID RES, V31, P1387; HURTCAMEJO E, 1990, J LIPID RES, V31, P43; LINDAHL U, 1973, J BIOL CHEM, V248, P7234; NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795; OLSSON U, 1991, BIOCHIM BIOPHYS ACTA, V1097, P37, DOI 10.1016/0925-4439(91)90021-Z; REZVIN A, 1989, BIOTECHNIQUES, V7, P346; ROSENFELD ME, 1992, ARTERIOSCLER THROMB, V12, P985, DOI 10.1161/01.ATV.12.8.985; ROSS R, 1991, TRENDS CARDIOVAS MED, V1, P277, DOI 10.1016/1050-1738(91)90043-E; SCHMIDT A, 1990, EUR J CELL BIOL, V52, P229; SCHONHERR E, 1991, J BIOL CHEM, V266, P1740; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SRINIVASAN SR, 1989, BIOCHIM BIOPHYS ACTA, V1006, P159, DOI 10.1016/0005-2760(89)90190-2; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; VIJAYAGOPAL P, 1992, BIOCHIM BIOPHYS ACTA, V1135, P129, DOI 10.1016/0167-4889(92)90128-X; WAGNER WD, 1988, ARTERIOSCLEROSIS, V6, P407; WIGHT TN, 1986, CIBA F SYMP, V124, P241; WIGHT TN, 1989, ARTERIOSCLEROSIS, V9, P1, DOI 10.1161/01.ATV.9.1.1; YLAHERTTUALA S, 1991, ANN MED, V23, P561, DOI 10.3109/07853899109150518	38	137	138	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14131	14137						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314779				2022-12-27	WOS:A1993LJ82500053
J	CHEN, JW; YANG, SH; JAYARAM, M				CHEN, JW; YANG, SH; JAYARAM, M			TESTS FOR THE FRACTIONAL ACTIVE-SITE MODEL IN FLP SITE-SPECIFIC RECOMBINATION - ASSEMBLY OF A FUNCTIONAL RECOMBINATION COMPLEX IN HALF-SITE AND FULL-SITE STRAND TRANSFER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGIONAL SIMILARITIES; SUBSTRATE RECOGNITION; CIRCLE PLASMID; MUTANTS; DNA; PROTEIN; MECHANISM; MUTATIONS; TARGET; BENDS	The Arg191-His305-Arg308 (the RHR triad) and Tyr343 of Flp site-specific recombinase correspond to the invariant tetrad residues of the integrase family of proteins. Flp mutants altered at these positions are blocked at the strand cleavage or the strand exchange step of recombination. Hybrid half-site-recombinase complexes formed by step-arrest mutants of Flp have revealed that an Flp monomer occupying a half-site does not cleave that half-site but rather cleaves a half-site occupied by a second Flp monomer. This trans-DNA cleavage is neatly accommodated by a model in which an Flp active site is assembled by contribution of amino acid residues from at least two protein monomers. Using a combination of wild type Flp, single, double, and triple step-arrest Flp mutants, critical predictions of the fractional active-site model have been verified. First, a wild type monomer paired with an RHR triad Tyr343 double mutant is a catalytically inactive combination. Second, each pairwise combination of a single, double, or triple RHR mutant with Flp(Y343F) yields approximately equivalent levels of catalytic complementation. Half-site to half-site and half-site to full-site crosses suggest that execution of a strand transfer event within a half-site and between a half-site and a full site requires dimeric and tetrameric Flp configurations, respectively.	UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712	University of Texas System; University of Texas Austin								AMIN A, 1991, MOL CELL BIOL, V11, P4497, DOI 10.1128/MCB.11.9.4497; ANDREWS BJ, 1986, MOL CELL BIOL, V11, P4497; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; CHEN JW, 1991, J MOL BIOL, V218, P107, DOI 10.1016/0022-2836(91)90877-9; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CHEN JW, 1992, J MOL BIOL, V69, P647; EVANS BR, 1990, J BIOL CHEM, V265, P18504; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; Maniatis T., 1982, MOL CLONING; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; PARSONS RL, 1990, J BIOL CHEM, V265, P4527; PRASAD PV, 1987, P NATL ACAD SCI USA, V84, P2189, DOI 10.1073/pnas.84.8.2189; PRASAD PV, 1986, MOL CELL BIOL, V6, P4329, DOI 10.1128/MCB.6.12.4329; QIAN XH, 1990, J BIOL CHEM, V265, P21779; QIAN XH, 1992, J BIOL CHEM, V267, P7794; SCHWARTZ CJE, 1989, J MOL BIOL, V205, P647, DOI 10.1016/0022-2836(89)90310-0; SCHWARTZ CJE, 1990, J MOL BIOL, V216, P289, DOI 10.1016/S0022-2836(05)80320-1; SERRE MC, 1992, J MOL BIOL, V225, P643, DOI 10.1016/0022-2836(92)90391-V; SERRE MC, 1992, J MOL BIOL, V225, P621, DOI 10.1016/0022-2836(92)90390-6; UTATSU I, 1987, J BACTERIOL, V169, P5537, DOI 10.1128/jb.169.12.5537-5545.1987; WENTE SR, 1987, P NATL ACAD SCI USA, V84, P31, DOI 10.1073/pnas.84.1.31	23	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14417	14425						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314800				2022-12-27	WOS:A1993LJ82500091
J	MACFARLANE, DE; MANZEL, L				MACFARLANE, DE; MANZEL, L			ACTIVATION OF BETA-ISOZYME OF PROTEIN-KINASE-C (PKC-BETA) IS NECESSARY AND SUFFICIENT FOR PHORBOL ESTER-INDUCED DIFFERENTIATION OF HL-60 PROMYELOCYTES - STUDIES WITH PKC-BETA-DEFECTIVE PET MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DIFFERENTIATION; GENE-EXPRESSION; LEUKEMIA-CELLS; RETINOIC ACID; HETEROGENEITY; INDUCTION; RESISTANT; MULTIPLE; DIESTER; FAMILY	12-O-Tetradecanoylphorbol-13-acetate (TPA) induces growth arrest and differentiation of a number of leukemia cell lines including HL-60 human promyelocytic leukemia. We investigated the involvement of protein kinase C (PKC) isotypes in phorbol ester-induced differentiation using the phorbol ester tolerant PET mutant of HL-60 cells, which (in contrast to the parent phorbol ester-sensitive (wild-type) S variant of HL-60 cells) does not growth-arrest, become adherent, or undergo apoptosis when exposed to TPA (Macfarlane, D. E., Gailani, D., and Vann, K. (1988) Br. J. Haematol. 68, 291-302). In comparison to S cells, we found that proliferating PET cells markedly underexpress mRNA for PKC beta, but do express PKC alpha and PKC delta. The PKC beta-selective activator 12-deoxyphorbol 13-phenylacetate 20-acetate induces growth arrest, adherence, surface expression of CD11a, and apoptosis in S cells, but not in PET cells. Expression of PKC beta in PET cells can be restored by exposing them to dihydroxyvitamin D-3, and this treatment restores the ability of subsequently added 12-deoxyphorbol 13-phenylacetate 20-acetate or TPA to induce immediate cell adherence and growth arrest of PET cells. These data led us to conclude that activation of PKC beta is both necessary and sufficient for phorbol ester-induced growth arrest and adherence in these myeloid cells.	UNIV IOWA,IOWA CITY,IA 52242	University of Iowa	MACFARLANE, DE (corresponding author), VET ADM MED CTR,DEPT MED,IOWA CITY,IA 52242, USA.			Macfarlane, Donald/0000-0001-8785-5690				AIHARA H, 1991, P NATL ACAD SCI USA, V88, P11062, DOI 10.1073/pnas.88.24.11062; CHOMCZYNSKI PA, 1991, CURRENT PROTOCOLS S, V14; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; GAILANI D, 1989, CANCER RES, V49, P5329; GALLAGHER R, 1979, BLOOD, V54, P713; HOOPER WC, 1989, BIOCHIM BIOPHYS ACTA, V1013, P47, DOI 10.1016/0167-4889(89)90126-2; HUBERMAN E, 1979, P NATL ACAD SCI USA, V76, P293; KELLEHER D, 1992, FEBS LETT, V301, P310, DOI 10.1016/0014-5793(92)80264-H; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KORETZKY GA, 1989, J IMMUNOL, V143, P1692; KUBO K, 1987, FEBS LETT, V223, P138, DOI 10.1016/0014-5793(87)80524-0; MACFARLANE DE, 1988, BRIT J HAEMATOL, V68, P291, DOI 10.1111/j.1365-2141.1988.tb04205.x; MACFARLANE DE, 1994, IN PRESS LEUKEMIA BA; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MCSWINEKENNICK RL, 1991, J BIOL CHEM, V266, P15135; MILLS GB, 1988, CELL, V55, P91, DOI 10.1016/0092-8674(88)90012-8; NISHIKAWA M, 1990, CANCER RES, V50, P621; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBEID LM, 1990, J BIOL CHEM, V265, P2370; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1988, BIOCHEMISTRY-US, V27, P2083, DOI 10.1021/bi00406a040; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1988, J BIOL CHEM, V263, P6927; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; SPIVAK JL, 1990, MOL BIOL HAEMATOPOIE, P420; TANAKA Y, 1992, J BIOCHEM-TOKYO, V111, P265, DOI 10.1093/oxfordjournals.jbchem.a123747; TONETTI DA, 1992, CELL GROWTH DIFFER, V3, P739; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121	31	146	149	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4327	4331						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308000				2022-12-27	WOS:A1994MW98900067
J	XU, B; KRUDY, GA; ROSEVEAR, PR				XU, B; KRUDY, GA; ROSEVEAR, PR			IDENTIFICATION OF THE METAL LIGANDS AND CHARACTERIZATION OF A PUTATIVE ZINC-FINGER IN METHIONYL-TRANSFER-RNA SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; DNA-BINDING DOMAIN; ESCHERICHIA-COLI; GLUCOCORTICOID RECEPTOR; 3-DIMENSIONAL STRUCTURE; CD-113 NMR; SITE; PROTEINS; RECOGNITION; RESOLUTION	A truncated form of the methionyl-tRNA synthetase (DELTAMTS), which has been cloned, overproduced, and characterized, was used in an attempt to better understand the role of the enzyme-bound zinc in the amino-acylation process. Apo-, Zn2+-, Co2+-, and Cd-113(2+)-substituted DELTAMTS proteins were prepared in vivo and purified to homogeneity. Apo-DELTAMTS was devoid of enzymatic activity in the aminoacylation of tRNA(fMet) and in the methionine-dependent ATP-pyrophosphate exchange reactions. Kinetic constants in both the aminoacylation and ATP-pyrophosphate exchange reactions for the Co2+- and Cd-113(2+)-substituted DELTAMTS proteins were found to be identical with those of the native Zn2+ protein. The low energy absorption spectrum of Co2+-substituted DELTAMTS resembles the d-d transition bands characteristic of tetrahedrally coordinated Co2+- substituted proteins. A strong S --> Co2+ charge transfer absorption at 350 nm was clearly evident having a molar absorptivity consistent with four thiolate ligands. The environment of the metal center was further probed by measuring the Cd-113 chemical shift of Cd-113(2+)-substituted DELTAMTS. A single resonance at 759.6 ppm was observed. This chemical shift is consistent with Cd2+, coordinated to four thiolate ligands. The Escherichia coli methionyl-tRNA synthetase contains a potential metal binding sequence Cys-X2-Cys-X9-Cys-X2-Cys in a connecting polypeptide within the nucleotide fold. Titration of a 21-amino acid peptide corresponding to this putative metal binding site, Cys145-Cys161, was shown to bind Co2+ with a K(d) of 120 +/- 11 muM. These results demonstrate that the isolated zinc finger binding domain is capable of specifically forming a stoichiometric complex with the divalent cation. Taken together, our studies identify the 4 cysteine residues in the zinc finger-like domain as the metal binding ligands in the E. coli methionyl-tRNA synthetase. The role of the enzyme-bound metal appears to be structural and not directly involved in catalysis.	UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77225	University of Texas System					NIGMS NIH HHS [GM 41232] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041232] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMITAGE IM, 1982, BIOL MAGN RESON, V4, P79; BARKER DG, 1982, EUR J BIOCHEM, V127, P449; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BOBSEIN BR, 1981, J BIOL CHEM, V256, P5313; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; BRUNIE S, 1987, J MOL GRAPHICS, V5, P16; BURBAUM JJ, 1990, PROTEINS, V7, P99, DOI 10.1002/prot.340070202; BURBAUM JJ, 1991, BIOCHEMISTRY-US, V30, P319, DOI 10.1021/bi00216a002; CASSIO D, 1971, EUR J BIOCHEM, V20, P283, DOI 10.1111/j.1432-1033.1971.tb01393.x; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; CURDEL A, 1968, Febs Letters, V1, P133, DOI 10.1016/0014-5793(68)80040-7; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; GHOSH G, 1990, BIOCHEMISTRY-US, V29, P2220, DOI 10.1021/bi00461a003; KELLENBACH E, 1991, FEBS LETT, V291, P367, DOI 10.1016/0014-5793(91)81322-Y; KISSELEV LL, 1981, EUR J BIOCHEM, V120, P511, DOI 10.1111/j.1432-1033.1981.tb05729.x; LANE RW, 1977, J AM CHEM SOC, V99, P84, DOI 10.1021/ja00443a017; MAY SW, 1978, BIOCHEMISTRY-US, V17, P3333, DOI 10.1021/bi00609a025; MAYAUX JF, 1982, EUR J BIOCHEM, V128, P41; MAYAUX JF, 1981, BIOCHEMISTRY-US, V20, P4647, DOI 10.1021/bi00519a020; MILLER WT, 1991, BIOCHEMISTRY-US, V30, P6970, DOI 10.1021/bi00242a023; MILLER WT, 1992, P NATL ACAD SCI USA, V89, P2032, DOI 10.1073/pnas.89.6.2032; MOORE WT, 1991, TECHNIQUES PROTEIN C, V2, P511; NUREKI O, 1991, J BIOL CHEM, V266, P3268; OMBURO GA, 1992, J BIOL CHEM, V267, P13278; PAN T, 1990, BIOCHEMISTRY-US, V29, P9218, DOI 10.1021/bi00491a016; POSORSKE LH, 1979, BIOCHIM BIOPHYS ACTA, V576, P128, DOI 10.1016/0005-2795(79)90491-4; ROSEVEAR PR, 1988, BIOCHEMISTRY-US, V27, P7931, DOI 10.1021/bi00420a052; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; SERPERSU EH, 1986, BIOCHEMISTRY-US, V25, P68, DOI 10.1021/bi00349a011; South T L, 1990, Adv Inorg Biochem, V8, P199; SPECKHARD DC, 1977, BIOCHEMISTRY-US, V16, P5228, DOI 10.1021/bi00643a011; STARZYK RM, 1989, BIOCHEMISTRY-US, V28, P8479, DOI 10.1021/bi00447a031; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; VALLEE BL, 1984, ADV ENZYMOL RAMB, V56, P283; VASAK M, 1981, BIOCHEMISTRY-US, V20, P6659, DOI 10.1021/bi00526a021; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679; WILLIAMS JS, 1991, BIOCHEMISTRY-US, V30, P6412, DOI 10.1021/bi00240a010	43	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16259	16264						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344912				2022-12-27	WOS:A1993LQ33600028
J	DINIZ, MRV; PAINE, MJI; DINIZ, CR; THEAKSTON, RDG; CRAMPTON, JM				DINIZ, MRV; PAINE, MJI; DINIZ, CR; THEAKSTON, RDG; CRAMPTON, JM			SEQUENCE OF THE CDNA CODING FOR THE LETHAL NEUROTOXIN TX1 FROM THE BRAZILIAN ARMED SPIDER PHONEUTRIA-NIGRIVENTER PREDICTS THE SYNTHESIS AND PROCESSING OF A PREPROTOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FUNNEL-WEB SPIDER; AGELENOPSIS-APERTA; VENOM; PURIFICATION; ACID; PRECURSORS; PEPTIDES	A cDNA library was constructed from the venom glands of the Brazilian ''armed'' spider, Phoneutria nigriventer, and a clone coding for Tx1, a lethal toxin, was identified and sequenced. The sequence data derived from this cDNA clone combined with the previously determined amino acid sequence predict that Tx1 is initially synthesized as a preprotoxin. Four segments (comprising the signal sequence, a short, 15-amino acid, glutamate-rich sequence, the functional toxin, and 2 glycine residues) can be distinguished. The structure of the preprotoxin and the proposed processing steps required to form the mature Tx1 toxin show similarities with the synthesis and processing of omega-agatoxin IA.	CTR PESQUISA & DESENVOLVIMENTO,FDN EZEQUIEL DIAS,BR-30510-10 BELO HORIZON,MG,BRAZIL		DINIZ, MRV (corresponding author), UNIV LIVERPOOL,LIVERPOOL SCH TROP MED,WOLFSON UNIT MOLEC GENET,PEMBROKE PL,LIVERPOOL L3 5QA,ENGLAND.		Paine, Mark John Ingraham/O-7450-2019	Paine, Mark John Ingraham/0000-0003-2061-7713	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS ME, 1990, J BIOL CHEM, V265, P861; BARRIO AVALINO, 1955, ACTA PHYSIOL LATINOAMER, V5, P132; BOUCHIER C, 1991, BIOCHIM BIOPHYS ACTA, V1088, P401, DOI 10.1016/0167-4781(91)90132-6; BOUGIS PE, 1989, J BIOL CHEM, V264, P19259; BRAZIL V, 1925, MEM I BUTANTAN, V2, P1; CAMMUE BPA, 1992, J BIOL CHEM, V267, P2228; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORDEIRO MD, 1993, TOXICON, V31, P35, DOI 10.1016/0041-0101(93)90354-L; CORDEIRO MD, 1992, FEBS LETT, V310, P153, DOI 10.1016/0014-5793(92)81318-G; DINIZ CARLOS R., 1963, AN ACAD BRASIL CIENC, V35, P283; DINIZ CR, 1990, FEBS LETT, V263, P251, DOI 10.1016/0014-5793(90)81386-3; ENTWISTLE ID, 1982, TOXICON, V20, P1059, DOI 10.1016/0041-0101(82)90108-8; FAINZILBER M, 1991, EUR J BIOCHEM, V202, P589, DOI 10.1111/j.1432-1033.1991.tb16412.x; FAZZAL A, 1989, FEBS LETT, V257, P260; FONTANA MD, 1985, BRAZ J MED BIOL RES, V18, P557; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; Kreil G, 1980, Ann N Y Acad Sci, V343, P338, DOI 10.1111/j.1749-6632.1980.tb47262.x; LUCAS S, 1988, TOXICON, V26, P759, DOI 10.1016/0041-0101(88)90317-0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELLHAM HRB, 1976, EUR J BIOCHEM, V67, P247; RESENDE C, 1991, TOXICON, V29, P1225; RICHTER K, 1990, P NATL ACAD SCI USA, V87, P4836, DOI 10.1073/pnas.87.12.4836; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS AD, 1992, J BIOL CHEM, V267, P20701; SCHEMBERG S, 1971, VENOMOUS ANIMALS THE, P217; SKINNER WS, 1989, J BIOL CHEM, V264, P2150; STAPLETON A, 1990, J BIOL CHEM, V265, P2054	29	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15340	15342						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340362				2022-12-27	WOS:A1993LN30500005
J	SAXENA, U; FERGUSON, E; BISGAIER, CL				SAXENA, U; FERGUSON, E; BISGAIER, CL			APOLIPOPROTEIN-E MODULATES LOW-DENSITY-LIPOPROTEIN RETENTION BY LIPOPROTEIN-LIPASE ANCHORED TO THE SUBENDOTHELIAL MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER PROTEIN-DEFICIENCY; CHOLESTEROL-FED RABBITS; ESTER TRANSFER ACTIVITY; SMOOTH-MUSCLE CELLS; PLASMA-LIPOPROTEINS; ATHEROSCLEROTIC LESIONS; A-I; PHOSPHOLIPID LIPOSOMES; COLLAGEN COMPLEXES; MOUSE MACROPHAGES	Lipoprotein lipase (lipase), a key enzyme in lipoprotein triglyceride metabolism, has been shown to markedly increase low density lipoprotein (LDL) retention by subendothelial matrix. In the present study we assessed the role that lipoprotein and matrix components play in retention of LDL by lipase anchored to the subendothelial matrix. Lipase addition to subendothelial matrix increased LDL retention by 66-fold. Scatchard analysis of LDL binding to lipase-containing matrix yielded an association constant of 12 nm. Exogenous addition of the matrix components, heparan sulfate and dermatan sulfate (i.e. chondroitin sulfate B), reduced LDL retention by greater than 90%. These glycosaminoglycans (GAGs) also reduced lipolytic activity associated with the matrix, suggesting that lipase was released from its binding sites on the matrix. In contrast, other matrix components (collagen, fibronectin, vitronectin, and chondroitin sulfate A) neither affected LDL release nor matrix lipolytic activity. Thus, heparan sulfate and dermatan sulfate function to anchor lipase to the subendothelial cell matrix. The effects of apolipoprotein E (apoE) and apoA-I were also examined. Preincubation of the subendothelial matrix with apoE, followed by washing, did not affect subsequent lipase binding to the matrix nor its ability to retain LDL. However, the direct addition of apoE alone or in combination with phospholipid liposomes decreased lipase-mediated LDL retention in a concentration-dependent fashion. Addition of apoA-I had no effect. Thus, in these studies apoE functions to displace LDL bound to lipase, but not lipase anchored to the matrix. To further examine the physiologic implications of this process, we assessed the ability of human apoE-rich and apoE-poor high density lipoproteins (HDL) to displace LDL from matrix-anchored lipase. ApoE-rich HDL reduced LDL retention dramatically (86% at 2.5 mug/ml). In contrast, apoE-poor HDL, at the highest concentration evaluated (400 mug/ml), decreased LDL retention by only 32%. Overall, these data suggest apoE and specifically apoE-containing HDL reduce the lipase-mediated retention of LDL by subendothelial matrix. This observation, in part could explain the protective effects of apoE and apoE-containing HDL against atherosclerosis.			SAXENA, U (corresponding author), WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES DIV, DEPT PHARMACOL, ANN ARBOR, MI 48105 USA.							BADIMON JJ, 1990, J CLIN INVEST, V85, P1234, DOI 10.1172/JCI114558; BARTER PJ, 1978, BIOCHIM BIOPHYS ACTA, V531, P233, DOI 10.1016/0005-2760(78)90147-9; BASU SK, 1981, P NATL ACAD SCI-BIOL, V78, P7545, DOI 10.1073/pnas.78.12.7545; BASU SK, 1983, SCIENCE, V219, P871, DOI 10.1126/science.6823554; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BISGAIER CL, 1991, J LIPID RES, V32, P21; BISGAIER CL, 1989, J BIOL CHEM, V264, P862; BOCAN TMA, 1988, ARTERIOSCLEROSIS, V8, P499, DOI 10.1161/01.ATV.8.5.499; BOSNER MS, 1988, P NATL ACAD SCI USA, V85, P7438, DOI 10.1073/pnas.85.20.7438; CAMEJO G, 1982, ADV LIPID RES, V19, P1; CAMEJO G, 1985, BIOMED BIOCHIM ACTA, V44, P389; CHAJEKSHAUL T, 1990, BIOCHIM BIOPHYS ACTA, V1042, P168, DOI 10.1016/0005-2760(90)90003-G; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CLARK AB, 1985, J BIOL CHEM, V260, P4778; DIPERSIO LP, 1990, J BIOL CHEM, V265, P16801; DORY L, 1991, J LIPID RES, V32, P783; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; EDWARDS IJ, 1990, AM J PATHOL, V136, P609; FALCONE DJ, 1988, ARTERIOSCLEROSIS, V8, P263, DOI 10.1161/01.ATV.8.3.263; FALCONE DJ, 1984, J CELL BIOL, V99, P1266, DOI 10.1083/jcb.99.4.1266; FOGELMAN AM, 1988, J CELL SCI, P135; GLOMSET JA, 1968, J LIPID RES, V9, P155; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GUYTON JR, 1992, AM J PATHOL, V141, P925; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOFF HF, 1975, CIRC RES, V37, P72, DOI 10.1161/01.RES.37.1.72; HOUGH GP, 1990, EUR HEART J, V11, P62, DOI 10.1093/eurheartj/11.suppl_E.62; HURTCAMEJO E, 1990, ARTERIOSCLEROSIS, V10, pA783; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; IVERIUS PH, 1972, J BIOL CHEM, V247, P2607; JACKSON RL, 1985, FEBS LETT, V190, P297, DOI 10.1016/0014-5793(85)81304-1; JOHANSSON J, 1991, ARTERIOSCLER THROMB, V11, P174, DOI 10.1161/01.ATV.11.1.174; KOIZUMI J, 1985, ATHEROSCLEROSIS, V58, P175, DOI 10.1016/0021-9150(85)90064-4; KOIZUMI J, 1991, ATHEROSCLEROSIS, V90, P189, DOI 10.1016/0021-9150(91)90114-I; KUROSAKA D, 1991, ATHEROSCLEROSIS, V88, P15, DOI 10.1016/0021-9150(91)90252-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1979, BIOCHIM BIOPHYS ACTA, V575, P81, DOI 10.1016/0005-2760(79)90133-4; MAHLEY RW, 1977, J LIPID RES, V18, P314; MAHLEY RW, 1984, J LIPID RES, V25, P1277; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; OBRIEN KD, 1992, J CLIN INVEST, V89, P1544, DOI 10.1172/JCI115747; OSCHRY Y, 1982, J LIPID RES, V23, P1099; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RADHAKRISHNAMUR.B, 1982, GLYCOCONJUGATES, V4, P265; RADHAKRISHNAMURTHY B, 1990, EUR HEART J, V11, P148, DOI 10.1093/eurheartj/11.suppl_E.148; RIFICI VA, 1984, J BIOL CHEM, V259, P3814; SAXENA U, 1991, J BIOL CHEM, V266, P17516; SAXENA U, 1989, J BIOL CHEM, V264, P4349; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; SCANU AM, 1971, ANAL BIOCHEM, V44, P576, DOI 10.1016/0003-2697(71)90247-8; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHONFELD G, 1974, J CLIN INVEST, V54, P236, DOI 10.1172/JCI107758; SCHWENKE DC, 1989, ARTERIOSCLEROSIS, V9, P895, DOI 10.1161/01.ATV.9.6.895; SCHWENKE DC, 1989, ARTERIOSCLEROSIS, V9, P908, DOI 10.1161/01.ATV.9.6.908; SRINIVAS.SR, 1972, ATHEROSCLEROSIS, V16, P95, DOI 10.1016/0021-9150(72)90012-3; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; WILLIAMS KJ, 1987, J CLIN INVEST, V79, P1466, DOI 10.1172/JCI112975; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WISSLER RW, 1954, AMA ARCH PATHOL, V57, P333; YAMADA N, 1992, J CLIN INVEST, V89, P706, DOI 10.1172/JCI115639; YAMASHITA S, 1990, J CLIN INVEST, V86, P688, DOI 10.1172/JCI114764; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P10143, DOI 10.1073/pnas.88.22.10143; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	66	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14812	14819						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325860				2022-12-27	WOS:A1993LL75900045
J	SHINOMURA, T; NISHIDA, Y; ITO, K; KIMATA, K				SHINOMURA, T; NISHIDA, Y; ITO, K; KIMATA, K			CDNA CLONING OF PG-M, A LARGE CHONDROITIN SULFATE PROTEOGLYCAN EXPRESSED DURING CHONDROGENESIS IN CHICK LIMB BUDS - ALTERNATIVE SPLICED MULTIFORMS OF PG-M AND THEIR RELATIONSHIPS TO VERSICAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARTILAGE PROTEOGLYCAN; EMBRYO CARTILAGE; FIBRONECTIN; SEQUENCES; PROTEINS; GLYCOSAMINOGLYCANS; NITROCELLULOSE; CONDENSATION; ATTACHMENT; FRAGMENTS	We have isolated cDNA clones encoding the core protein of PG-M, a large chondroitin sulfate proteoglycan that has been shown to be expressed in the prechondrogenic condensation area of the developing chick limb buds (Shinomura T., Jensen, K. L., Yamagata, M., Kimata, K., and Solursh, M. (1990) Anat. Embryol. 181, 227-233). The amino acid sequence deduced from the cDNA analysis revealed the presence of a hyaluronic acid binding domain at the amino-terminal side and two epidermal growth factor-like domains, a lectin-like domain, and a complement regulatory protein-like domain at the carboxyl-terminal side. These domains show an extremely high homology to corresponding domains of a human fibroblast large chondroitin sulfate proteoglycan, versican. Such evolutionally conserved structures in the PG-M core protein might be involved in important biological functions of this molecule. On the other hand, the chondroitin sulfate attachment domain at the middle region of the PG-M core protein shows no significant amino acid sequence homology to the corresponding domain of the versican core protein. Further, the chondroitin sulfate attachment domain of PG-M core protein is about 100 kDa larger than that of versican core protein. The finding of alternatively spliced forms of the PG-M core protein suggests that versican might be one of the multiple forms of PG-M.	AICHI MED UNIV,INST MOLEC SCI MED,NAGAKUTE,AICHI 48011,JAPAN	Aichi Medical University			Nishida, Yoshihiro/I-7354-2014					BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; CHANDRASEKARAN L, 1992, BIOCHEM J, V288, P903, DOI 10.1042/bj2880903; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HALBERG DF, 1988, J BIOL CHEM, V263, P9486; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HUBER S, 1988, J BIOL CHEM, V263, P752; KIMATA K, 1986, J BIOL CHEM, V261, P3517; KIMURA JH, 1987, METHOD ENZYMOL, V144, P372; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; ROSEN SD, 1992, TRENDS GLYCOSCI GLYC, V4, P1; SANANTONIO JD, 1987, DEV BIOL, V123, P17; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINOMURA T, 1983, J BIOL CHEM, V258, P9314; SHINOMURA T, 1992, J BIOL CHEM, V267, P1265; SHINOMURA T, 1990, ANAT EMBRYOL, V181, P227; SHINOMURA T, 1990, DEV GROWTH DIFFER, V32, P243; SOLURSH M, 1991, DEV PATTERNING VERTE, P171; SWALLA BJ, 1984, DIFFERENTIATION, V26, P42, DOI 10.1111/j.1432-0436.1984.tb01371.x; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOROGOOD PV, 1975, J EMBRYOL EXP MORPH, V33, P581; TOOLE BP, 1991, DEV PATTERNING VERTE, P215; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012; YAMAGATA M, 1986, J BIOL CHEM, V261, P3526; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	32	165	167	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14461	14469						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314802				2022-12-27	WOS:A1993LJ82500096
J	WANG, Y; VONHIPPEL, PH				WANG, Y; VONHIPPEL, PH			ESCHERICHIA-COLI TRANSCRIPTION TERMINATION FACTOR-RHO .2. BINDING OF OLIGONUCLEOTIDE COFACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMBDA-PR PROMOTER; MESSENGER-RNA; DEPENDENT TERMINATION; GEL-ELECTROPHORESIS; KINETICS; ATP; SEQUENCE; HELICASE; DOMAINS; PATHWAY	The relative binding affinities for rho of the oligonucleotide rho ATPase cofactors studied in the accompanying paper (Wang, Y., and von Hippel, P. H. (1993) J. Biol. Chem. 268, 13940-13946) have been determined by gel mobility shift and ultrafiltration binding analyses. We find that each rho hexamer carries three strong and three weak RNA-binding sites that differ approximately 10-fold in their affinities for oligonucleotide cofactors. Furthermore, in contrast to the sequence dependence of ATPase activation, we find that the binding affinities of these oligonucleotide cofactors for rho depend only on their cytosine content. In addition, we show that changes in the positions of rU residues in the oligo(rU,rC) cofactors (which significantly modulate the ATPase activity of rho) have no effect on binding affinities and that the addition of ATP, ADP, or the nonhydrolyzable ATP analog adenosine 5'-(beta,gamma-methylene) triphosphate also does not change the binding affinities of the oligonucleotide cofactors for rho. Considered in the context of the coupling of the rho ATPase and RNA binding and release cycles, these results suggest that rC residues are required for the formation of stable rho-RNA complexes, whereas rU residues at the 5' termini of cofactors bound to rho initiate or facilitate the release of the RNA from the individual cofactor site as a consequence of ATP hydrolysis. Thus, both the tightness of the binding of RNA segments to the individual RNA-binding sites of rho and the rate of release of these segments from these sites are critical in controlling the ATPase rate of rho and probably also in modulating the function of this protein in transcript termination.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; University of Oregon				von Hippel, Peter H./0000-0003-2512-8097	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015792, R37GM015792, R01GM029158] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29158, GM-15792] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAR D G, 1991, Journal of Cellular Biochemistry Supplement, P239; BEAR DG, 1985, P NATL ACAD SCI USA, V82, P1911, DOI 10.1073/pnas.82.7.1911; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BRENNAN CA, 1991, J BIOL CHEM, V266, P17296; DOLAN JW, 1990, J BIOL CHEM, V265, P5747; DOMBROSKI AJ, 1988, P NATL ACAD SCI USA, V85, P2538, DOI 10.1073/pnas.85.8.2538; ENGEL D, 1984, NUCLEIC ACIDS RES, V12, P7389, DOI 10.1093/nar/12.19.7389; FAUS I, 1989, BIOCHEMISTRY-US, V28, P3510, DOI 10.1021/bi00434a054; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALLUPPI G, 1980, J MOL BIOL, V138, P5513; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P121, DOI 10.1021/bi00116a018; GEISELMANN J, 1992, PROTEIN SCI, V1, P861, DOI 10.1002/pro.5560010704; GEISELMANN J, 1992, PROTEIN SCI, V1, P850, DOI 10.1002/pro.5560010703; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P111, DOI 10.1021/bi00116a017; GEISELMANN J, 1993, IN PRESS P NATL ACAD, V90; HART CM, 1991, J BIOL CHEM, V266, P24140; JOHNSON KA, 1983, J BIOL CHEM, V258, P3825; JOHNSON KA, 1985, ANNU REV BIOPHYS BIO, V14, P161, DOI 10.1146/annurev.bb.14.060185.001113; KLOTZ IM, 1971, BIOCHEMISTRY-US, V10, P3065, DOI 10.1021/bi00792a013; KLOTZ IM, 1985, Q REV BIOPHYS, V18, P227, DOI 10.1017/S0033583500000354; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; MCSWIGGEN JA, 1985, THESIS U OREGON EUGE; MORGAN WD, 1984, J BIOL CHEM, V259, P8664; MORGAN WD, 1985, NUCLEIC ACIDS RES, V13, P3739, DOI 10.1093/nar/13.10.3739; MORGAN WD, 1983, J BIOL CHEM, V258, P9565; MORGAN WD, 1983, J BIOL CHEM, V258, P9553; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5767; SEIFRIED SE, 1992, P NATL ACAD SCI USA, V89, P10454, DOI 10.1073/pnas.89.21.10454; WANG Y, 1993, J BIOL CHEM, V268, P13940	30	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13947	13955						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314761				2022-12-27	WOS:A1993LJ82500029
J	VANTILBEURGH, H; ROUSSEL, A; LALOUEL, JM; CAMBILLAU, C				VANTILBEURGH, H; ROUSSEL, A; LALOUEL, JM; CAMBILLAU, C			LIPOPROTEIN-LIPASE - MOLECULAR-MODEL BASED ON THE PANCREATIC LIPASE X-RAY STRUCTURE - CONSEQUENCES FOR HEPARIN-BINDING AND CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPHOBIC CLUSTER-ANALYSIS; LOW-DENSITY LIPOPROTEINS; HEPATIC LIPASE; APOLIPOPROTEIN-C; HUMAN-PLASMA; COMPLEX; PROTEIN; ENZYME; SITE; TRIACYLGLYCEROL	Lipoprotein lipase and pancreatic lipase have about 30% sequence identity, suggesting a similar tertiary fold. Three-dimensional models of lipoprotein lipase were constructed, based upon two recently determined x-ray crystal structures of pancreatic lipase, in which the active site was in an open and closed conformation, respectively. These models allow us to propose a few hypotheses on the structural determinants of lipoprotein lipase which are responsible for heparin binding, dimer formation, and phospholipase activity. The folding of the protein assembles a number of positive charge clusters at the back of the molecule, opposite the active site. These clusters probably form the heparin binding site, as confirmed by recent site directed mutagenesis experiments. The active sites of lipoprotein lipase and pancreatic lipase look very similar, except for the lid (a surface loop covering the catalytic serine in the inactive state). A different open (active) conformation of the lid in both enzymes may be responsible for their differing substrate specificities. Predictions of the nature of the lipoprotein lipase dimer remain elusive, although our model enabled us to propose a few possibilities.	FAC MED NORD, CNRS, CRISTALLISAT & MACROMOLEC BIOL LAB, F-13916 MARSEILLE 20, FRANCE; UNIV UTAH, HLTH SCI CTR, HOWARD HUGHES MED INST, SALT LAKE CITY, UT 84132 USA; FAC PHARM MONTPELLIER, CTR BIOCHIM STRUCT, F-34060 MONTPELLIER, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Universite de Montpellier								ATKINS EDT, 1976, HEPARIN CHEM CLIN US; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BERRYMAN DE, 1993, J BIOL CHEM, V268, P3272; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BRUIN T, 1992, EUR J BIOCHEM, V208, P267, DOI 10.1111/j.1432-1033.1992.tb17182.x; BRUNGER AT, 1990, XPLOR VERSION 2 1 MA; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CARDIN AD, 1988, EICOSANOIDS APOLIPRO, P157; CLARKE AR, 1985, BIOCHIM BIOPHYS ACTA, V827, P358, DOI 10.1016/0167-4838(85)90220-1; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; DECKELBAUM RJ, 1992, BIOCHEMISTRY-US, V31, P8544, DOI 10.1021/bi00151a023; DEREWENDA ZS, 1991, J BIOL CHEM, V266, P23112; DUGI KA, 1992, J BIOL CHEM, V267, P25086; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; EMMERICH J, 1992, J BIOL CHEM, V267, P4161; FAUSTINELLA F, 1992, BIOCHEMISTRY-US, V31, P7219, DOI 10.1021/bi00147a002; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P9481; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; GARFINKEL AS, 1987, PLASMA LIPOPROTEINS; GETZOFF ED, 1983, NATURE, V306, P287, DOI 10.1038/306287a0; HATA A, 1993, J BIOL CHEM, V268, P8447; HJORTH A, 1993, BIOCHEMISTRY-US, V32, P4702, DOI 10.1021/bi00069a003; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JACKSON RL, 1977, P NATL ACAD SCI USA, V74, P1942, DOI 10.1073/pnas.74.5.1942; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; LIU GQ, 1992, BIOCHEM J, V285, P731, DOI 10.1042/bj2850731; LOOKENE A, 1993, EUR J BIOCHEM, V213, P185, DOI 10.1111/j.1432-1033.1993.tb17747.x; LOWE ME, 1992, J BIOL CHEM, V267, P17069; MARTINEZ C, 1992, NATURE, V356, P615, DOI 10.1038/356615a0; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; OLIVECRONA T, 1987, LIPOPROTEIN LIPASE; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; PERSSON B, 1991, FEBS LETT, V288, P33, DOI 10.1016/0014-5793(91)80997-H; ROBERTS VA, 1991, J BIOL CHEM, V266, P13431; ROUSSEL A, 1991, SILICON GRAPHICS DIR; SCHRAG JD, 1992, J BIOL CHEM, V267, P4300; SEMENKOVICH CF, 1990, J BIOL CHEM, V265, P5429; SHIMADA K, 1981, J CLIN INVEST, V68, P995, DOI 10.1172/JCI110354; SHIRAI K, 1983, J LIPID RES, V24, P721; STUCKEY JA, 1992, PROTEINS, V14, P277, DOI 10.1002/prot.340140213; TEGONI M, 1993, PROTEINS, V16, P408, DOI 10.1002/prot.340160409; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WONG H, 1991, P NATL ACAD SCI USA, V88, P11290, DOI 10.1073/pnas.88.24.11290; WOODCOCK S, 1992, PROTEIN ENG, V5, P629, DOI 10.1093/protein/5.7.629; [No title captured]	50	151	159	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4626	4633						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308035				2022-12-27	WOS:A1994MW98900107
J	YANG, BH; LEJOHN, HB				YANG, BH; LEJOHN, HB			NADP(+)-ACTIVABLE, NAB(+)-SPECIFIC GLUTAMATE-DEHYDROGENASE - PURIFICATION AND IMMUNOLOGICAL ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE GELS; IMMUNODETECTION; MECHANISM; PROTEINS	An NAD(+)-specific glutamate dehydrogenase (NAD-GDH) that is inducible by L-glutamine was isolated from Achlya klebsiana and purified to electrophoretic homogeneity. The enzyme is only partially active in vitro unless NADP(+) (an activator) is present in both its oxidative deamination and reductive amination reactions. This type of enzyme was reported (LeJohn, H. B. (1971) Nature 231, 164-168) to be widespread among the amorphous group of algae-related fungi classified as Oomycota. The enzyme retained its dependence on NADP(+) at all stages of its purification. NADP(+) decreased the K-m of substrates 3-fold and increased the V-max 4-fold. M(r) of the undenatured enzyme was 480,000, and, denatured, only a single subunit of M(r), 120,000 was seen. A polyclonal antibody raised in rabbit against purified enzyme subunit excised from SDS-polyacrylamide gel electrophoresis gels immunoprecipitated the M(r) 120,000 polypeptide, the undenatured enzyme, and a physically distinct polypeptide of M(r), 74,000. The antibody, purified against the M(r) 120,000 enzyme subunit as anchored antigen on Sepharose, still immunoprecipitated the M(r) 74,000 polypeptide. The M(r) 74,000 polypeptide was found to be a subunit of a M(r) 220,000 native protein.	UNIV MANITOBA, DEPT MICROBIOL, WINNIPEG R3T 2N2, MB, CANADA; MANITOBA INST CELL BIOL, WINNIPEG R3E 0V9, MB, CANADA; UNIV MANITOBA, FAC MED, DEPT HUMAN GENET, WINNIPEG R3E 0W3, MB, CANADA	University of Manitoba; University of Manitoba								AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAZIN H, 1906, METHOD ENZYMOL, V121, P638; CAMERON LE, 1972, J BIOL CHEM, V247, P4729; CHOMCZYNSKI P, 1977, ANAL BIOCHEM, V132, P156; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P188; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P173, DOI 10.1016/0926-6569(63)90226-8; Dewald B, 1974, Methods Enzymol, V32, P82; DEWET JR, 1984, DNA-J MOLEC CELL BIO, V3, P437, DOI 10.1089/dna.1.1984.3.437; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; KAPOOR M, 1993, BIOCHEM CELL BIOL, V71, P205, DOI 10.1139/o93-032; LEJOHN HB, 1971, NATURE, V231, P164, DOI 10.1038/231164a0; LEJOHN HB, 1994, J BIOL CHEM, V269, P4523; LEJOHN HB, 1994, J BIOL CHEM, V269, P4513; LEJOHN HB, 1970, J BIOL CHEM, V245, P3890; LEJOHN HB, 1975, EVOL BIOL, V7, P79; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER SM, 1990, J BACTERIOL, V172, P4927, DOI 10.1128/jb.172.9.4927-4935.1990; PALMITER RD, 1971, J BIOL CHEM, V246, P724; Smith E.L., 1975, ENZYMES, P293, DOI DOI 10.1016/S1874-6047(08)60213-9; STEVENSON RM, 1971, J BIOL CHEM, V246, P2127; TIMMONS TM, 1990, METHOD ENZYMOL, V182, P679; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANCUROVA I, 1989, J GEN MICROBIOL, V135, P3311; WEBER K, 1969, J BIOL CHEM, V244, P4406; YANG B, 1992, THESIS U MANITOBA	27	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4506	4512						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308020				2022-12-27	WOS:A1994MW98900092
J	ISHIHARA, H; ASANO, T; TSUKUDA, K; KATAGIRI, H; INUKAI, K; ANAI, M; KIKUCHI, M; YAZAKI, Y; MIYAZAKI, J; OKA, Y				ISHIHARA, H; ASANO, T; TSUKUDA, K; KATAGIRI, H; INUKAI, K; ANAI, M; KIKUCHI, M; YAZAKI, Y; MIYAZAKI, J; OKA, Y			OVEREXPRESSION OF HEXOKINASE-I BUT NOT GLUT1 GLUCOSE-TRANSPORTER ALTERS CONCENTRATION-DEPENDENCE OF GLUCOSE-STIMULATED INSULIN-SECRETION IN PANCREATIC BETA-CELL LINE MIN6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIABETIC HYPERGLYCEMIA; NONSENSE MUTATION; GLUCOKINASE GENE; TRANSGENIC MICE; RAT-BRAIN; EXPRESSION; METABOLISM; ISLETS; MOUSE; LIVER	The recently established pancreatic beta-cell line MIN6 retains the ability to secrete insulin in response to physiological glucose concentrations. To investigate the role of glucose transport and phosphorylation in glucose-stimulated insulin secretion by beta-cells, MIN6 cells were stably transfected with a rabbit GLUT1 glucose transporter cDNA or a rat hexokinase I cDNA cloned in an expression vector. Overexpression of GLUT1 increased 3-O-methylglucose uptake, but did not alter either glucose utilization or glucose-stimulated insulin secretion. In contrast, clones overexpressing hexokinase I exhibited enhanced glucose-stimulated insulin secretion at glucose concentrations below 10 mM with a concomitant increase in glucose utilization. Maximal insulin secretion as well as the maximal rate of glucose utilization were not altered in these clones. Insulin secretion stimulated by 2-ketoisocaproate, a non-glucose secretagogue, was not affected by hexokinase I expression. These results strongly suggest that the glucose phosphorylating step, but not glucose transport step, regulates glucose-stimulated insulin secretion by modulating the glycolytic rate in the beta-cell.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT DIS RELATED GENE REGULAT RES SANDOZ,BUNKYO KU,TOKYO 113,JAPAN; ASAHI LIFE FDN,INST ADULT DIS,SHINJUKU KU,TOKYO 160,JAPAN	University of Tokyo; Novartis; Sandoz; University of Tokyo; Asahi Life Foundation			Miyazaki, Jun-ichi/N-1976-2015	Miyazaki, Jun-ichi/0000-0003-2475-589X				ARORA KK, 1990, J BIOL CHEM, V265, P6481; ASHCROFT SJ, 1972, BIOCHEM J, V126, P525, DOI 10.1042/bj1260525; ASHCROFT SJH, 1980, DIABETOLOGIA, V18, P5, DOI 10.1007/BF01228295; CALDERHEAD DM, 1988, J BIOL CHEM, V263, P12171; CLARK SA, 1990, ENDOCRINOLOGY, V127, P2779, DOI 10.1210/endo-127-6-2779; EPSTEIN PN, 1992, P NATL ACAD SCI USA, V89, P12038, DOI 10.1073/pnas.89.24.12038; GRIFFIN LD, 1992, BIOCHIM BIOPHYS ACTA, V1129, P309, DOI 10.1016/0167-4781(92)90508-W; HAMAGUCHI K, 1991, DIABETES, V40, P842, DOI 10.2337/diabetes.40.7.842; ISHIHARA H, 1993, DIABETOLOGIA, V36, P1139, DOI 10.1007/BF00401058; JOHNSON JH, 1990, J BIOL CHEM, V265, P6548; JOHNSON JH, 1990, SCIENCE, V250, P546, DOI 10.1126/science.2237405; KATAGIRI H, 1992, LANCET, V340, P1316, DOI 10.1016/0140-6736(92)92494-Z; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MEGLASSON MD, 1984, AM J PHYSIOL, V246, pE1, DOI 10.1152/ajpendo.1984.246.1.E1; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MORITA Y, 1992, BIOCHEM BIOPH RES CO, V188, P8, DOI 10.1016/0006-291X(92)92342-U; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; OKA Y, 1988, J BIOL CHEM, V263, P13432; ORCI L, 1990, J CLIN INVEST, V86, P1615, DOI 10.1172/JCI114883; ORCI L, 1990, P NATL ACAD SCI USA, V87, P9953, DOI 10.1073/pnas.87.24.9953; SALAS J, 1965, J BIOL CHEM, V240, P1014; SCHWAB DA, 1989, P NATL ACAD SCI USA, V86, P2563, DOI 10.1073/pnas.86.8.2563; TAL M, 1992, P NATL ACAD SCI USA, V89, P5744, DOI 10.1073/pnas.89.13.5744; THORENS B, 1990, DIABETES CARE, V13, P209, DOI 10.2337/diacare.13.3.209; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; THORENS B, 1990, P NATL ACAD SCI USA, V87, P6492, DOI 10.1073/pnas.87.17.6492; TRUS MD, 1981, DIABETES, V30, P911, DOI 10.2337/diabetes.30.11.911; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; WHITESELL RR, 1991, BIOCHEMISTRY-US, V30, P11560, DOI 10.1021/bi00113a011; ZHANG HJ, 1989, DIABETES, V38, P44, DOI 10.2337/diabetes.38.1.44	32	63	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3081	3087						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300643				2022-12-27	WOS:A1994MV43200103
J	LIU, J; MATHIAS, S; YANG, ZH; KOLESNICK, RN				LIU, J; MATHIAS, S; YANG, ZH; KOLESNICK, RN			RENATURATION AND TUMOR-NECROSIS-FACTOR-ALPHA STIMULATION OF A 97-KDA CERAMIDE-ACTIVATED PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SENSITIVE METHOD; CELLS; SPHINGOMYELINASE; PHOSPHORYLATION; DIFFERENTIATION; SPHINGOSINE; MECHANISM; PATHWAY	Recent investigations identified a new signal transduction pathway, termed the sphingomyelin pathway, which may mediate the action of tumor necrosis factor (TNF)alpha and interleukin-1beta (Mathias, S., Younes, A., Kan, C., Orlow, I., Joseph, C., and Kolesnick, R. N. (1993) Science 259, 519-522). This pathway is initiated by hydrolysis of sphingomyelin to ceramide by a neutral sphingomyelinase and stimulation of a ceramide-activated Ser/Thr protein kinase. Recent investigations demonstrated that kinase activity is proline-directed, recognizing substrates in which the phosphoacceptor site is followed by a proline residue. Until now, the kinase has been defined only as a membrane-bound activity capable of phosphorylating a peptide derived from the sequence surrounding Thr669 of the epidermal growth factor receptor. In the present studies, the kinase was quantitatively extracted from membrane with detergent and separated from protein kinase C by anion-exchange chromatography and isoelectric focusing. Ceramide-activated protein kinase was resolved as an exclusively membrane-bound, 97-kDa protein with a pI of 7.05. Kinase activity toward the epidermal growth factor receptor peptide co-purified with activity toward a generic proline-directed substrate, myelin basic protein. Kinase activity was reconstituted by a denaturation-renaturation procedure and demonstrated activity toward self (autophosphorylation) and exogenous substrate (myelin basic protein). Autophosphorylation occurred exclusively on serine residues. These activities were enhanced to 7-fold of control by ceramide and TNFalpha. These investigations provide additional evidence for a role for ceramide-activated protein kinase in signal transduction for TNFalpha.	MEM SLOAN KETTERING CANC CTR, SIGNAL TRANSDUCT LAB, 1275 YORK AVE, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center					NCI NIH HHS [CA-42385] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042385] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIM MY, 1991, J BIOL CHEM, V266, P484; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; KOLESNICK RN, 1989, J BIOL CHEM, V264, P7617; KOLESNICK RN, 1988, J BIOL CHEM, V263, P6534; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; RAINES MA, 1993, J BIOL CHEM, V268, P14572; Trautschold I., 1963, METHODS ENZYMATIC AN, P543; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997	24	205	213	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3047	3052						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300638				2022-12-27	WOS:A1994MV43200098
J	CHAE, HZ; KIM, IH; KIM, K; RHEE, SG				CHAE, HZ; KIM, IH; KIM, K; RHEE, SG			CLONING, SEQUENCING, AND MUTATION OF THIOL-SPECIFIC ANTIOXIDANT GENE OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE-SUPEROXIDE-DISMUTASE; GLUTATHIONE-PEROXIDASE; HYDROGEN-PEROXIDE; NUCLEOTIDE-SEQUENCE; FREE-RADICALS; NUCLEAR GENE; OXIDATION; YEAST; PROTEIN; INACTIVATION	We have previously shown that the yeast Saccharomyces cerevisiae contains an antioxidant enzyme that can provide protection against a thiol-containing oxidation system but not against an oxidation system without thiol. This 25-kDa enzyme was thus named thiol-specific antioxidant (TSA). We have now isolated and sequenced a yeast genomic DNA fragment that encodes TSA. Comparison of the predicted amino acid sequence of TSA with those of conventional antioxidant enzymes, including catalases, peroxidases, and superoxide dismutases, revealed no sequence homology. The 195-amino acid TSA sequence contains 2 cysteine residues. Southern blot analysis of petite yeast DNA, studies with protein synthesis inhibitors, and protein immunoblot analyses of cytosolic and mitochondrial proteins suggest that TSA is a cytosolic protein encoded by nuclear DNA (chromosome XIII). The yeast TSA gene was selectively disrupted by homologous recombination. The haploid tsa mutant was viable under air, suggesting that TSA is not essential for cell viability. The growth rates of the tsa mutant and wild-type strains were identical under anaerobic conditions. However, under aerobic conditions, especially in the presence of methyl viologen or a peroxide (t-butyl hydroperoxide or H2O2), the growth rate of the mutant was significantly less than that of wild-type cells. This result suggests that TSA is a physiologically important antioxidant.	NHLBI,BIOCHEM LAB,BLDG 3,RM 122,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Kim, Il-Han/W-1401-2019					Barton J.P., 1970, INT J RADIAT PHYS CH, V2, P159; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BERMINGHAMMCDONOGH O, 1988, P NATL ACAD SCI USA, V85, P4789, DOI 10.1073/pnas.85.13.4789; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; BOVERIS A, 1982, SUPEROXIDE DISMUTASE, V2, P15; BUETTNER GR, 1984, FEBS LETT, V177, P295, DOI 10.1016/0014-5793(84)81303-4; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; CHANG EC, 1991, J BIOL CHEM, V266, P4417; COHEN G, 1988, EUR J BIOCHEM, V176, P159; COSTA M, 1977, BIOCHEM BIOPH RES CO, V78, P596, DOI 10.1016/0006-291X(77)90221-2; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; GOLRING ES, 1970, J MOL BIOL, V52, P323; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; GRALLA EB, 1992, ADV GENET, V30, P252; HARMAN LS, 1986, J BIOL CHEM, V261, P1642; HARMAN LS, 1984, J BIOL CHEM, V259, P5606; HEINECKE JW, 1987, J BIOL CHEM, V262, P10098; HOROWITZ PM, 1987, J BIOL CHEM, V262, P8728; KAPUT J, 1982, J BIOL CHEM, V257, P5054; Karmann W., 1969, INT J RADIAT PHYS CH, V1, P395; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIM K, 1985, J BIOL CHEM, V260, P5394; KIM KW, 1988, J BIOL CHEM, V263, P4704; LEVINE RL, 1983, J BIOL CHEM, V258, P1823; MARRES CAM, 1985, EUR J BIOCHEM, V147, P153, DOI 10.1111/j.1432-1033.1985.tb08731.x; MASON RP, 1990, METHOD ENZYMOL, V186, P318; MISRA HP, 1974, J BIOL CHEM, V249, P2151; MONTE DD, 1986, BIOCHEM BIOPH RES CO, V137, P303; MOTTLEY C, 1987, MOL PHARMACOL, V31, P417; OHTAKI S, 1982, J BIOL CHEM, V257, P761; PERMAN PS, 1970, ARCH BIOCHEM BIOPHYS, V136, P245; PUNEKAR NS, 1987, J BIOL CHEM, V262, P6714; REYNOLDS CH, 1980, BIOCHEM J, V185, P451, DOI 10.1042/bj1850451; ROSS D, 1985, J BIOL CHEM, V260, P5028; ROSS D, 1984, BIOCHEM BIOPH RES CO, V125, P109, DOI 10.1016/S0006-291X(84)80341-1; ROSS D, 1988, PHARMACOL THERAPEUT, V37, P231, DOI 10.1016/0163-7258(88)90027-7; SAEZ G, 1982, BIOCHIM BIOPHYS ACTA, V719, P24, DOI 10.1016/0304-4165(82)90302-6; SCHREIBER J, 1989, J BIOL CHEM, V264, P7936; SCHUCKELT R, 1991, FREE RADICAL RES COM, V14, P343, DOI 10.3109/10715769109093424; SHORTLE D, 1982, SCIENCE, V217, P371, DOI 10.1126/science.7046050; SIMIC M, 1970, J AM CHEM SOC, V92, P6096, DOI 10.1021/ja00723a067; SPEVAK W, 1986, MOL GEN GENET, V203, P73, DOI 10.1007/BF00330386; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; SVENSSON BE, 1988, BIOCHEM J, V249, P521, DOI 10.1042/bj2490521; SVENSSON BE, 1988, BIOCHEM J, V253, P441, DOI 10.1042/bj2530441; TROTTA PP, 1974, J BIOL CHEM, V249, P1915; VANLOON APGM, 1986, P NATL ACAD SCI USA, V83, P3820; Wardman P, 1988, GLUTATHIONE CONJUGAT, P43	49	283	299	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16815	16821						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344960				2022-12-27	WOS:A1993LQ33600103
J	BETZEL, C; SINGH, TP; VISANJI, M; PETERS, K; FITTKAU, S; SAENGER, W; WILSON, KS				BETZEL, C; SINGH, TP; VISANJI, M; PETERS, K; FITTKAU, S; SAENGER, W; WILSON, KS			STRUCTURE OF THE COMPLEX OF PROTEINASE-K WITH A SUBSTRATE-ANALOG HEXAPEPTIDE INHIBITOR AT 2.2-ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY; 3-DIMENSIONAL STRUCTURE; CHLOROMETHYL KETONE; ACTIVE-SITE; SUBTILISIN; TRYPSIN; REFINEMENT; MECHANISM; GEOMETRY	The crystal structure of a transition state/product complex formed by the interaction between proteinase K and the substrate analogue N-Ac-L-Pro-L-Ala-L-Pro-L-Phe-D-Ala-L-Ala-NH2 has been determined at a resolution of 2.2 angstrom and refined to an R-factor of 0.165 for 12,725 reflections. The inhibitor forms a stable complex through a series of hydrogen bonds with protein atoms and water molecules. The inhibitor is hydrolyzed between Phe4I and D-Ala5I (I indicates inhibitor). The two fragments are separated by a distance of 3.07 angstrom between the carbonyl carbon and the main chain nitrogen. Both fragments remain bound to the protein. The N-terminal fragment occupies subsites S5 to S1, whereas the C-terminal part is bound in S1' and S2', the first time that electron density for a substrate analogue has been observed in the P1' and P2' sites of a subtilisin-like enzyme. The flexible segments of the substrate recognition sites Gly100-Tyr104 and Ser132-Gly136 move appreciably to accommodate the inhibitor. Biochemical results indicate an inhibition by this specifically designed peptide of 95%.	ALL INDIA INST MED SCI,DEPT BIOPHYS,NEW DELHI 110029,INDIA; MARTIN LUTHER UNIV HALLE WITTENBERG,INST PHYSIOL CHEM,O-4020 HALLE,GERMANY; FREE UNIV BERLIN,INST KRISTALLOG,W-1000 BERLIN 33,GERMANY	All India Institute of Medical Sciences (AIIMS) New Delhi; Martin Luther University Halle Wittenberg; Free University of Berlin	BETZEL, C (corresponding author), DESY,EUROPEAN MOLEC BIOL LAB,NOTKESTR 85,W-2000 HAMBURG 52,GERMANY.		Betzel, Christian/G-8105-2018	Betzel, Christian/0000-0002-3879-5019; Wilson, Keith/0000-0002-3581-2194				ARGAWAL RC, 1978, ACTA CRYSTALLOGR A, V34, P791; BAUER CA, 1976, BIOCHIM BIOPHYS ACTA, V438, P495, DOI 10.1016/0005-2744(76)90265-5; BETZEL C, 1988, EUR J BIOCHEM, V178, P155, DOI 10.1111/j.1432-1033.1988.tb14440.x; BETZEL C, 1986, FEBS LETT, V197, P105, DOI 10.1016/0014-5793(86)80307-6; BETZEL C, 1988, PROTEINS, V4, P157, DOI 10.1002/prot.340040302; BLOW DM, 1976, ACCOUNTS CHEM RES, V9, P145, DOI 10.1021/ar50100a004; BODE W, 1987, EUR J BIOCHEM, V166, P673, DOI 10.1111/j.1432-1033.1987.tb13566.x; BROMME D, 1986, ARCH BIOCHEM BIOPHYS, V244, P439, DOI 10.1016/0003-9861(86)90611-9; DRENTH J, 1972, EUR J BIOCHEM, V26, P177, DOI 10.1111/j.1432-1033.1972.tb01754.x; HENDRICKSON WA, 1981, INT S BIOMOLECULAR S, P43; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; HUBER R, 1974, J MOL BIOL, V89, P73, DOI 10.1016/0022-2836(74)90163-6; JONES TA, 1983, COMPUTATIONAL CRYSTA, P303; KOSSIAKOFF AA, 1980, NATURE, V288, P414, DOI 10.1038/288414a0; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; MACHIN PA, 1983, DARESBURY LABORATORY, V10, P3; MOULT J, 1985, J MOL BIOL, V182, P555, DOI 10.1016/0022-2836(85)90241-4; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; SCHLECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157; THOMPSON RC, 1973, BIOCHEMISTRY-US, V12, P57, DOI 10.1021/bi00725a011; WOLF WM, 1991, J BIOL CHEM, V266, P17695; WRIGHT CS, 1969, NATURE, V221, P235, DOI 10.1038/221235a0	23	44	44	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15854	15858						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340410				2022-12-27	WOS:A1993LN30500077
J	HOCKENSMITH, JW; KUBASEK, WL; VORACHEK, WR; VONHIPPEL, PH				HOCKENSMITH, JW; KUBASEK, WL; VORACHEK, WR; VONHIPPEL, PH			LASER CROSS-LINKING OF PROTEINS TO NUCLEIC-ACIDS .1. EXAMINING PHYSICAL PARAMETERS OF PROTEIN-NUCLEIC ACID COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINATION FACTOR-RHO; BACTERIOPHAGE T4-GENE 32-PROTEIN; DNA-REPLICATION SYSTEM; GENE 32 PROTEIN; PHOTOCHEMICAL ADDITION; AMINO-ACIDS; DEOXYRIBONUCLEIC-ACID; MELTING PROTEINS; BINDING-PROTEIN; TRANSCRIPTION	Pulsed laser cross-linking results in efficient and rapid formation of covalent bonds between proteins and the nucleic acids to which they are bound, creating a ''snapshot'' of the protein-nucleic acid equilibrium existing at the moment of irradiation. The ''frozen'' equilibrium allows the determination of protein-nucleic acid binding constants, confirming both theoretical predictions and experimental determinations by standard physical chemical methods. Laser cross-linking results accurately reflect the alteration of protein-nucleic acid interactions induced by traditional methods such as increasing the salt concentration or by the addition of a nucleic acid that competes for binding of the protein. Thus this technique is very useful for the study of the association of proteins and protein complexes with nucleic acids under environmental conditions at which the reactions are not amenable to study by traditional physical chemical methods. In this paper we continue our calibration of the method, focusing primarily on interactions with single-stranded DNA-binding proteins and describe techniques for measuring quantitative interactions between nucleic acid constructs and single-protein or multiprotein complexes. Laser cross-linking can also provide direct evidence that binding correlates with functional activity.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403; UNIV OREGON,DEPT BIOL,EUGENE,OR 97403	University of Oregon; University of Oregon; University of Oregon	HOCKENSMITH, JW (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,BOX 440,CHARLOTTESVILLE,VA 22908, USA.			von Hippel, Peter H./0000-0003-2512-8097	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015792, T32GM007759, R01GM029158, R01GM015792] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29158, GM-15792, GM-07759] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BITTNER M, 1979, J BIOL CHEM, V254, P9565; CARROLL RB, 1975, J MOL BIOL, V91, P275, DOI 10.1016/0022-2836(75)90380-0; DIZDAROGLU M, 1985, INT J RADIAT BIOL, V47, P63, DOI 10.1080/09553008514550091; DOLEJSI MK, 1988, THESIS U OREGON; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; FLORY J, 1982, CELL, V28, P747, DOI 10.1016/0092-8674(82)90054-X; FODOR SPA, 1986, J RAMAN SPECTROSC, V17, P471, DOI 10.1002/jrs.1250170609; HOCKENSMITH JW, 1991, METHOD ENZYMOL, V208, P211; HOCKENSMITH JW, 1986, J BIOL CHEM, V261, P3512; HOCKENSMITH JW, 1993, J BIOL CHEM, V268, P15721; HUANG WM, 1972, J BIOL CHEM, V247, P3139; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; JENSEN DE, 1976, J BIOL CHEM, V251, P7215; KELLY RC, 1976, J BIOL CHEM, V251, P7240; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; KRAUSS G, 1981, BIOCHEMISTRY-US, V20, P5346, DOI 10.1021/bi00521a040; KUBASEK WL, 1993, IN PRESS PHOTOCHEM P; Maxam A M, 1980, Methods Enzymol, V65, P499; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; MESNER LD, 1992, P NATL ACAD SCI USA, V89, P2521, DOI 10.1073/pnas.89.7.2521; MOROWITZ HJ, 1950, SCIENCE, V111, P229; MORRIS CF, 1979, J BIOL CHEM, V254, P6787; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NIKOGOSYAN DN, 1990, INT J RADIAT BIOL, V57, P233, DOI 10.1080/09553009014552411; NOSSAL NG, 1974, J BIOL CHEM, V249, P5668; REEVE AE, 1980, PHOTOCHEM PHOTOBIOL, V31, P297, DOI 10.1111/j.1751-1097.1980.tb02544.x; REEVE AE, 1980, PHOTOCHEM PHOTOBIOL, V31, P413, DOI 10.1111/j.1751-1097.1980.tb02561.x; SCHOTT HN, 1974, BIOCHEM BIOPH RES CO, V59, P1112, DOI 10.1016/S0006-291X(74)80093-8; SEIFRIED SE, 1992, P NATL ACAD SCI USA, V89, P10454, DOI 10.1073/pnas.89.21.10454; SETLOW P, 1972, J BIOL CHEM, V247, P232; SHETLAR MD, 1984, PHOTOCHEM PHOTOBIOL, V39, P135, DOI 10.1111/j.1751-1097.1984.tb03418.x; SHETLAR MD, 1984, PHOTOCHEM PHOTOBIOL, V39, P125, DOI 10.1111/j.1751-1097.1984.tb03417.x; SHETLAR MD, 1984, PHOTOCHEM PHOTOBIOL, V39, P141, DOI 10.1111/j.1751-1097.1984.tb03419.x; SMITH KC, 1969, BIOCHEM BIOPH RES CO, V34, P354, DOI 10.1016/0006-291X(69)90840-7; SMITH KC, 1968, BIOCHEMISTRY-US, V7, P1033, DOI 10.1021/bi00843a023; WAHL AF, 1983, J BACTERIOL, V155, P922, DOI 10.1128/JB.155.2.922-925.1983	38	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15712	15720						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340395				2022-12-27	WOS:A1993LN30500059
J	AGRWAL, N; SUN, Q; WANG, SY; WANG, JL				AGRWAL, N; SUN, Q; WANG, SY; WANG, JL			CARBOHYDRATE-BINDING PROTEIN-35 .1. PROPERTIES OF THE RECOMBINANT POLYPEPTIDE AND THE INDIVIDUALITY OF THE DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ENDOGENOUS LECTINS; CULTURED-CELLS; MOLECULAR-CLONING; 3T3 FIBROBLASTS; MAC-2 ANTIGEN; IGE; GALACTOSE; IDENTIFICATION; LOCALIZATION	The cDNA clone for carbohydrate-binding protein 35 (CBP35) was engineered into the bacterial expression vector pIN III ompA2, which directs the secretion of the expressed protein into the periplasmic space. Recombinant CBP35 was purified from this system, at a level of approximately 50 mg/liter of bacterial culture. Digestion of recombinant CBP35 with collagenase D, followed by purification using saccharide-specific affinity chromatography yielded a M(r) approximately 16,000 polypeptide, corresponding to the COOH-terminal domain (residues 118-264) of the CBP35 polypeptide. This indicates that the COOH-terminal half of CBP35 contains the carbohydrate recognition domain, consistent with its sequence homology to other S-type lectins. The NH2-terminal domain (residues 1-137) was derived by site-directed mutagenesis of the cDNA, in which stop codons are inserted in place of Gly138 and Gly139, and expression of the mutant cDNA in the same pIN III ompA2 system. The purified NH2-terminal domain failed to bind to saccharide-specific affinity resins. Differential scanning calorimetry of rCBP35 and its individual domains yielded transition temperatures of approximately 39 and approximately 56-degrees-C for the NH2- and COOH-terminal domains, respectively. Lactose binding by the COOH-terminal domain shifted the transition temperature to 65-degrees-C, whereas sucrose failed to yield the same effect. These results suggest that the individual domains of the CBP35 polypeptide are folded independently.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University					NIGMS NIH HHS [GM-38740, GM-27203] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027203] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRWAL N, 1989, J BIOL CHEM, V264, P17236; BARONDES SH, 1988, TRENDS BIOCHEM SCI, V13, P480, DOI 10.1016/0968-0004(88)90235-6; BERG RA, 1973, BIOCHEM BIOPH RES CO, V52, P115, DOI 10.1016/0006-291X(73)90961-3; Bjerrum O. J., 1986, ANAL ELECTROPHORESIS; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; CRITTENDEN SL, 1984, MOL CELL BIOL, V4, P1252, DOI 10.1128/MCB.4.7.1252; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; EDGE V, 1985, BIOCHEMISTRY-US, V24, P5899, DOI 10.1021/bi00342a032; FRIGERI LG, 1990, J BIOL CHEM, V265, P20763; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; HO MK, 1982, J IMMUNOL, V128, P1221; HSU DK, 1992, J BIOL CHEM, V267, P14167; JIA SH, 1988, J BIOL CHEM, V263, P6009; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAING JG, 1989, J BIOL CHEM, V264, P1907; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; MANLY SP, 1985, BIOCHEMISTRY-US, V24, P3842, DOI 10.1021/bi00336a004; MILLER EJ, 1971, BIOCHEMISTRY-US, V10, P1652, DOI 10.1021/bi00785a024; MOUTSATSOS IK, 1986, J CELL BIOL, V102, P477, DOI 10.1083/jcb.102.2.477; MOUTSATSOS IK, 1987, P NATL ACAD SCI USA, V84, P6452, DOI 10.1073/pnas.84.18.6452; ODA Y, 1991, GENE, V99, P279; RAZ A, 1991, CANCER RES, V51, P2173; RAZ A, 1989, CANCER RES, V49, P3489; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; ROFF CF, 1983, J BIOL CHEM, V258, P657; Sambrook J, 1989, MOL CLONING LABORATO; SCHEIN CH, 1988, BIO-TECHNOL, V6, P291, DOI 10.1038/nbt0388-291; TAKAGI H, 1988, BIO-TECHNOL, V6, P948, DOI 10.1038/nbt0888-948; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VILLAR E, 1985, J BIOL CHEM, V260, P2245; WANG J L, 1991, Glycobiology, V1, P243, DOI 10.1093/glycob/1.3.243; WHITE TK, 1990, ARCH BIOCHEM BIOPHYS, V276, P510, DOI 10.1016/0003-9861(90)90752-K; WRAY W, 1981, ANAL BIOCHEM, V48, P617	37	106	108	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14932	14939						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325870				2022-12-27	WOS:A1993LL75900061
J	DAVIS, RJ				DAVIS, RJ			THE MITOGEN-ACTIVATED PROTEIN-KINASE SIGNAL-TRANSDUCTION PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GROWTH-FACTOR RECEPTOR; C-JUN; PHOSPHORYLATION SITE; SKELETAL-MUSCLE; MAP KINASE; SUBSTRATE; IDENTIFICATION; MYC		UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,PROGRAM MOLEC MED,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester	DAVIS, RJ (corresponding author), UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,WORCESTER,MA 01605, USA.				NATIONAL CANCER INSTITUTE [R01CA058396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037845] Funding Source: NIH RePORTER; NCI NIH HHS [CA58396] Funding Source: Medline; NIGMS NIH HHS [GM37845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALDER V, 1992, J BIOL CHEM, V267, P17001; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; CHOU SY, 1992, MOL BIOL CELL, V3, P1117, DOI 10.1091/mbc.3.10.1117; CLARK LI, 1991, J BIOL CHEM, V266, P15180; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4193; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; KYRIAKIS JM, 1993, IN PRESS FRONTIERS M; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; LEE RM, 1992, J BIOL CHEM, V267, P1088; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SAKSELA K, 1992, ONCOGENE, V7, P347; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SETH A, 1991, J BIOL CHEM, V266, P23521; SETH A, 1992, J BIOL CHEM, V267, P24796; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; Treisman R, 1990, Semin Cancer Biol, V1, P47; UEDA K, 1990, J NEUROSCI, V10, P3295; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	55	2064	2112	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14553	14556						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325833				2022-12-27	WOS:A1993LL75900001
J	RADOMINSKA, A; LITTLE, J; PYREK, JS; DRAKE, RR; IGARI, Y; FOURNELGIGLEUX, S; MAGDALOU, J; BURCHELL, B; ELBEIN, AD; SIEST, G; LESTER, R				RADOMINSKA, A; LITTLE, J; PYREK, JS; DRAKE, RR; IGARI, Y; FOURNELGIGLEUX, S; MAGDALOU, J; BURCHELL, B; ELBEIN, AD; SIEST, G; LESTER, R			A NOVEL UDP-GLC-SPECIFIC GLUCOSYLTRANSFERASE CATALYZING THE BIOSYNTHESIS OF 6-O-GLUCOSIDES OF BILE-ACIDS IN HUMAN LIVER-MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN LENGTH; RAT-LIVER; HYODEOXYCHOLIC-ACID; DOLICHYL PHOSPHOGLUCOSE; GLUCURONOSYLTRANSFERASE; GLUCURONIDATION; BILIRUBIN; GLUCURONYLTRANSFERASE; EXPRESSION; PURIFICATION	Two active site-directed photoaffinity analogs, 5-[beta-P-32]azido-UDP-glucuronic acid and 5-[beta-P-32]azido-UDP-glucose, were used for the characterization of UDP-sugar-utilizing enzymes in human liver microsomes. Both compounds were recognized by human microsomal proteins: major photolabeled bands of 50-56 kDa were detected. Both photoincorporations were competitively decreased by increasing concentrations of either UDP-Glc or UDP-GlcUA, indicating a high affinity for both nucleotides. The patterns of photoaffinity labeling in the 50-56-kDa range by the two probes were significantly different, indicating the presence of different UDP-GlcUA- and UDP-Glc-specific enzymes of similar molecular mass. The presence of a UDP-Glc-dependent transferase was confirmed by the identification of an enzymatic activity catalyzing the formation of glucosides of the 6alpha-hydroxylated bile acid hyodeoxycholic acid (3alpha,6alpha-diOH (HDCA)) in the presence of UDP-Glc. The specific activity of 1.5-3.2 nmol/min/mg of protein was similar to that of 6alpha-glucuronidation of HDCA. The apparent K(m) for UDP-Glc estimated with HDCA was 280 muM, and the formation of HDCA glucosides was strongly inhibited by UDP-GlcUA (apparent K(i) = 7 muM). Evidence is presented that HDCA-specific UDP-glucuronosyltransferase clone UGT2B4) expressed in V79 cells is not involved in glucosidation of HDCA and is not photolabeled with 5-[beta-P-32]azido-UDP-Glc. Rigorous structure identification of the biosynthetic product proved that HDCA was glucosidated at the 6-position. Thus, this UDP-Glc-dependent activity catalyzing the biosynthesis of 6-O-glucosides of 6alpha-hydroxylated bile acids represents a new pathway in the metabolism of these bile acids.	UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205; UNIV KENTUCKY,COLL PHARM,LEXINGTON,KY 40536; CTR MED,F-54000 NANCY,FRANCE; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT BIOCHEM MED,DUNDEE DD1 9SY,SCOTLAND	University of Arkansas System; University of Arkansas Medical Sciences; University of Kentucky; University of Dundee	RADOMINSKA, A (corresponding author), UNIV ARKANSAS MED SCI HOSP,DEPT INTERNAL MED,DIV GASTROENTEROL,4301 W MARKHAM,SLOT 567-1,LITTLE ROCK,AR 72205, USA.			SIEST, Gerard/0000-0002-3001-760X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD014198] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038678] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-08238] Funding Source: Medline; NICHD NIH HHS [HD-14198] Funding Source: Medline; NIDDK NIH HHS [DK-38678] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACK P, 1976, H-S Z PHYSIOL CHEM, V357, P213, DOI 10.1515/bchm2.1976.357.1.213; BANERJEE DK, 1989, J BIOL CHEM, V264, P2024; BANERJEE DK, 1981, BIOCHEMISTRY-US, V20, P1561, DOI 10.1021/bi00509a024; BARNES S, 1989, J LIPID RES, V30, P529; BURCHELL B, 1984, BIOCHEM J, V223, P461, DOI 10.1042/bj2230461; COUGHTRIE MWH, 1988, MOL PHARMACOL, V34, P729; DRAKE RR, 1992, J BIOL CHEM, V267, P11360; DRAKE RR, 1991, J BIOL CHEM, V266, P23257; DRAKE RR, 1989, J BIOL CHEM, V264, P11928; DRAKE RR, 1992, GLYCOBIOLOGY, V2, P279, DOI 10.1093/glycob/2.4.279; Dutton G.F., 1980, GLUCURONIDATION DRUG; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FEVERY J, 1971, BIOCHEM J, V125, P803, DOI 10.1042/bj1250803; FOURNELGIGLEUX S, 1991, MOL PHARMACOL, V39, P177; FOURNELGIGLEUX S, 1989, FEBS LETT, V243, P119, DOI 10.1016/0014-5793(89)80111-5; GESSNER T, 1973, BIOCHEM J, V132, P249, DOI 10.1042/bj1320249; IRSHAID YM, 1987, MOL PHARMACOL, V31, P27; JACKSON MR, 1987, BIOCHEM J, V242, P581, DOI 10.1042/bj2420581; JOHNSON MR, 1991, J BIOL CHEM, V266, P10227; KIRKPATRICK RB, 1984, J BIOL CHEM, V259, P6179; LABOW RS, 1972, BIOCHEM J, V128, P491, DOI 10.1042/bj1280491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MAGDALOU J, 1982, J BIOL CHEM, V257, P13624; MARSCHALL HU, 1987, BIOCHIM BIOPHYS ACTA, V921, P392, DOI 10.1016/0005-2760(87)90041-5; MARSCHALL HU, 1987, FEBS LETT, V213, P411, DOI 10.1016/0014-5793(87)81532-6; MATERN H, 1989, BIOCHIM BIOPHYS ACTA, V1004, P67, DOI 10.1016/0005-2760(89)90214-2; MATERN H, 1987, BIOCHIM BIOPHYS ACTA, V921, P1, DOI 10.1016/0005-2760(87)90163-9; MATERN H, 1991, EUR J BIOCHEM, V200, P393, DOI 10.1111/j.1432-1033.1991.tb16197.x; MATERN H, 1984, P NATL ACAD SCI-BIOL, V81, P7036, DOI 10.1073/pnas.81.22.7036; MATERN H, 1982, J BIOL CHEM, V257, P7422; PALMER RH, 1967, P NATL ACAD SCI USA, V58, P1047, DOI 10.1073/pnas.58.3.1047; PARQUET M, 1988, EUR J BIOCHEM, V171, P329, DOI 10.1111/j.1432-1033.1988.tb13794.x; RADOMINSKA A, 1988, J LIPID RES, V29, P501; RADOMINSKA A, 1990, BIOCHEM J, V272, P597, DOI 10.1042/bj2720597; RADOMINSKAPYREK A, 1987, J CLIN INVEST, V80, P234, DOI 10.1172/JCI113053; RADOMINSKAPYREK A, 1986, J LIPID RES, V27, P89; RADOMINSKAPYREK A, 1986, J LIPID RES, V27, P102; RITTER JK, 1990, J BIOL CHEM, V265, P7900; Rothstein A, 1980, Ann N Y Acad Sci, V358, P1, DOI 10.1111/j.1749-6632.1980.tb15381.x; SPIRO MJ, 1985, J BIOL CHEM, V260, P5808; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANSTAPEL F, 1988, ARCH BIOCHEM BIOPHYS, V263, P216, DOI 10.1016/0003-9861(88)90630-3; VANSTAPEL F, 1987, J BIOL CHEM, V262, P4616; WONG KP, 1971, BIOCHEM J, V125, P929, DOI 10.1042/bj1250929a; ZIMNIAK P, 1988, J LIPID RES, V29, P183; ZOCCOLI MA, 1982, J BIOL CHEM, V257, P3919	47	49	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15127	15135						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325887				2022-12-27	WOS:A1993LL75900085
J	SALVUCCI, ME; RAJAGOPALAN, K; SIEVERT, G; HALEY, BE; WATT, DS				SALVUCCI, ME; RAJAGOPALAN, K; SIEVERT, G; HALEY, BE; WATT, DS			PHOTOAFFINITY-LABELING OF RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE OXYGENASE ACTIVASE WITH ATP GAMMA-BENZOPHENONE - IDENTIFICATION OF THE ATP GAMMA-PHOSPHATE BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; RUBISCO ACTIVASE; ADENYLATE KINASE; ESCHERICHIA-COLI; SITES; 1,5-BISPHOSPHATE; 5'-TRIPHOSPHATE; HYDROLYSIS; EXPRESSION; F1-ATPASE	The phosphate-binding domain of the ATP-binding site of tobacco Rubisco (ribulose-1,5-bisphosphate carboxylase/oxygenase) activase was elucidated by photoaffinity labeling with a monoanhydride of ADP with N-(4-(benzoyl)phenylmethyl)phosphoramide ([gamma-P-32] ATPgammaBP). Covalent incorporation of [gamma-P-32]ATPgammaBP into the 42-kDa Rubisco activase subunit was dependent upon irradiation with ultraviolet light. Photolabeling of Rubisco activase with ATPgammaBP exhibited saturation kinetics; the apparent K(d) for photolabeling was 5 muM. Two lines of evidence showed that ATPgammaBP modified Rubisco activase at the ATP-binding domain. First, physiological concentrations of ATP and ADP afforded complete protection against photolabeling of Rubisco activase by ATPgammaBP. Second, photolysis of Rubisco activase in the presence of ATPgammaBP decreased both the ATPase and the Rubisco activating activities. Inactivation of enzyme activity was dependent on ATPgammaBP concentration and could be prevented by including ADP during photolabeling. The region of Rubisco activase that was modified by ATPgammaBP was identified by isolating photolabeled peptides. Sequence analysis showed that ATPgammaBP modified Rubisco activase in two distinct regions; one region, S117-A136, is adjacent to the P-loop and the other region, V223-T234, exhibits homology to a region of adenylate kinase that ligates the essential metal ion. Photolabeling of these two regions of Rubisco activase was consistent with modification of the ATP gamma-phosphate-binding domain of Rubisco activase with ATPgammaBP.	UNIV KENTUCKY,DEPT CHEM,LEXINGTON,KY 40546; UNIV KENTUCKY,DEPT MED CHEM,LEXINGTON,KY 40546; UNIV KENTUCKY,DEPT AGRON,LEXINGTON,KY 40546	University of Kentucky; University of Kentucky; University of Kentucky	SALVUCCI, ME (corresponding author), UNIV KENTUCKY,USDA ARS,107-A ANIM PATHOL BLDG,LEXINGTON,KY 40546, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035766] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35766] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON L, 1986, ANAL BIOCHEM, V154, P250, DOI 10.1016/0003-2697(86)90523-3; BAR-ZVI D, 1992, Journal of Biological Chemistry, V267, P11029; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUAN H, 1988, J BIOL CHEM, V263, P13003; COLMAN RF, 1990, ENZYMES, V19, P283; CRAFTSBRANDNER SJ, 1991, PLANTA, V183, P300, DOI 10.1007/BF00197802; DOUKAS MA, 1992, BIOCONJUGATE CHEM, V3, P484, DOI 10.1021/bc00018a004; EDMONDSON DL, 1990, FEBS LETT, V260, P62, DOI 10.1016/0014-5793(90)80066-R; GALARDY RE, 1974, J BIOL CHEM, V249, P3510; GUTTERIDGE S, 1986, NATURE, V324, P274, DOI 10.1038/324274a0; JORDAN DB, 1983, J BIOL CHEM, V258, P3752; KORANGY F, 1992, J BIOL CHEM, V267, P1727; LILLEY RM, 1990, PLANT PHYSIOL, V94, P245, DOI 10.1104/pp.94.1.245; MAHMOOD R, 1987, J BIOL CHEM, V262, P14479; MIZIORKO HM, 1990, J BIOL CHEM, V265, P3642; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PERCHOROWICZ JT, 1981, P NATL ACAD SCI-BIOL, V78, P2985, DOI 10.1073/pnas.78.5.2985; POTTER MD, 1992, J BIOL CHEM, V267, P2023; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; RAJAGOPALAN K, 1993, J BIOL CHEM, V268, P14230; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7451, DOI 10.1021/bi00484a014; ROBINSON SP, 1989, ARCH BIOCHEM BIOPHYS, V268, P93, DOI 10.1016/0003-9861(89)90568-7; ROBINSON SP, 1988, PLANT PHYSIOL, V88, P1008, DOI 10.1104/pp.88.4.1008; SALVUCCI ME, 1992, ARCH BIOCHEM BIOPHYS, V298, P688, DOI 10.1016/0003-9861(92)90467-B; SALVUCCI ME, 1992, BIOCHEMISTRY-US, V31, P4479, DOI 10.1021/bi00133a014; SALVUCCI ME, 1985, PHOTOSYNTH RES, V7, P197; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHEN JB, 1991, J BIOL CHEM, V266, P8963; TAGAYA M, 1987, J BIOL CHEM, V262, P8257; TAGAYA M, 1988, FEBS LETT, V233, P347, DOI 10.1016/0014-5793(88)80457-5; Turro NJ., 1965, MODERN MOL PHOTOCHEM; WANG ZY, 1991, BIOCHIM BIOPHYS ACTA, V1079, P263, DOI 10.1016/0167-4838(91)90067-A; WANG ZY, 1992, PLANT PHYSIOL, V100, P1858, DOI 10.1104/pp.100.4.1858; WERNEKE JM, 1988, P NATL ACAD SCI USA, V85, P787, DOI 10.1073/pnas.85.3.787; WILLIAMS N, 1982, J BIOL CHEM, V257, P2834; YAN HG, 1991, BIOCHEMISTRY-US, V30, P5539, DOI 10.1021/bi00236a029; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5; ZHU GH, 1991, PLANT PHYSIOL, V97, P1354, DOI 10.1104/pp.97.4.1354	39	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14239	14244						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314787				2022-12-27	WOS:A1993LJ82500067
J	SINNETTSMITH, J; ZACHARY, I; VALVERDE, AM; ROZENGURT, E				SINNETTSMITH, J; ZACHARY, I; VALVERDE, AM; ROZENGURT, E			BOMBESIN STIMULATION OF P125 FOCAL ADHESION KINASE TYROSINE PHOSPHORYLATION - ROLE OF PROTEIN-KINASE-C, CA2+ MOBILIZATION, AND THE ACTIN CYTOSKELETON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; HETEROLOGOUS MITOGENIC DESENSITIZATION; RAPIDLY STIMULATE; SIGNAL TRANSDUCTION; ENDOTHELIN RECEPTOR; PHOSPHOLIPASE-C; PHORBOL ESTERS; GROWTH-FACTOR; EARLY EVENTS; VASOPRESSIN	Activation of protein kinase C (PKC) in quiescent Swiss 3T3 cells using either the tumor promoter phorbol 12,13-dibutyrate (PDB) or diacylglycerols increased the tyrosine phosphorylation of p125 focal adhesion kinase (p125FAK) by 3.8-fold. PDB stimulation of p125FAK tyrosine phosphorylation was detected within 1 min and reached a maximum within 5 min, considerably slower than PDB stimulation of 80K/MARCKS phosphorylation which was maximal within 1 min. In sharp contrast, bombesin-induced tyrosine phosphorylation of p125FAK reached a maximum (8-fold stimulation) within 1 min after addition of the peptide and occurred with a half-maximal effect of 0.08 nM, 6-fold lower than the half-maximal effect of bombesin on 80K/MARCKS phosphorylation. Down-regulation of PKC by prolonged treatment with PDB blocked the effect of PDB on p125FAK tyrosine phosphorylation but had no effect on the response to bombesin. A selective inhibitor of PKC, GF 109203X, markedly inhibited the stimulation of p125FAK tyrosine phosphorylation by PDB but had little effect on the response to bombesin, vasopressin, and endothelin. Bombesin stimulation of tyrosine phosphorylation could also be dissociated from mobilization of Ca2+ from intracellular stores. Depletion of the intracellular Ca2+ pool by treatment with the tumor promoter thapsigargin completely blocked the ability of bombesin to transiently increase the cytosolic Ca2+ concentration but had no effect on bombesin stimulation of p125FAK tyrosine phosphorylation. In contrast, cytochalasin D, an agent which selectively disrupts the network of actin microfilaments, completely inhibited bombesin- and PDB-induced p125FAK tyrosine phosphorylation. Within the same concentration range (0.3-2 muM), the drug had no effect on other early events stimulated by bombesin, including Ca2+ mobilization and activation of PKC. These findings demonstrate that neither the PKC nor Ca2+ pathways are responsible for the rapid stimulation of p125FAK tyrosine phosphorylation by neuropeptide growth factors. Furthermore, the integrity of the actin cytoskeleton is essential for the effects of both PDB and bombesin.	IMPERIAL CANC RES FUND,POB 123,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND	Cancer Research UK								ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BROOKS SF, 1992, J BIOL CHEM, V267, P14212; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANN REV CELL BIOL, V7, P337; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COFFER A, 1990, FEBS LETT, V263, P80, DOI 10.1016/0014-5793(90)80710-Z; COLLINS MKL, 1984, J CELL PHYSIOL, V118, P133, DOI 10.1002/jcp.1041180205; COLLINS MKL, 1983, P NATL ACAD SCI-BIOL, V80, P1924, DOI 10.1073/pnas.80.7.1924; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; ERUSALIMSKY JD, 1989, J CELL PHYSIOL, V141, P253, DOI 10.1002/jcp.1041410204; FORCE T, 1991, J BIOL CHEM, V266, P6650; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MILLAR JBA, 1990, J BIOL CHEM, V265, P19973; MIURA Y, 1993, J BIOL CHEM, V268, P510; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; PELLETIER AJ, 1992, MOL BIOL CELL, V3, P989, DOI 10.1091/mbc.3.9.989; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZPENA A, 1986, J CELL PHYSIOL, V129, P124, DOI 10.1002/jcp.1041290117; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1990, PHILOS T ROY SOC B, V327, P209, DOI 10.1098/rstb.1990.0055; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SECKL M, 1993, J BIOL CHEM, V268, P9548; SINNETTSMITH J, 1988, J CELL BIOCHEM, V38, P237, DOI 10.1002/jcb.240380403; SINNETTSMITH J, 1990, BIOCHEM J, V265, P485, DOI 10.1042/bj2650485; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THASTRUP O, 1987, BIOCHIM BIOPHYS ACTA, V927, P65, DOI 10.1016/0167-4889(87)90066-8; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WU DQ, 1992, J BIOL CHEM, V267, P1811; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	56	280	281	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14261	14268						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314789				2022-12-27	WOS:A1993LJ82500071
J	TENG, H; SEGURA, E; GRUBMEYER, C				TENG, H; SEGURA, E; GRUBMEYER, C			CONSERVED CYSTEINE RESIDUES OF HISTIDINOL DEHYDROGENASE ARE NOT INVOLVED IN CATALYSIS - NOVEL CHEMISTRY REQUIRED FOR ENZYMATIC ALDEHYDE OXIDATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE; PURIFICATION; MUTAGENESIS; INHIBITORS; BINDING	The 4-electron oxidoreductase L-histidinol dehydrogenase (HDH, EC 1.1.1.23) oxidizes the amino alcohol histidinol to histidine via an aldehyde-level intermediate at a single active site. The enzyme contains two Zn2+ per dimer, and treatment with metal chelators causes a metal-reversible inactivation. NAD-linked aldehyde oxidations, for which glyceraldehyde-3-phosphate dehydrogenase has served as the major paradigm, are thought to proceed via cysteine-based thiohemiacetals. Sequenced forms of HDH contain two conserved cysteine residues, Cys-116 and Cys-153 in the Salmonella typhimurium enzyme, and in previous work we have shown that HDH is inactivated by active site modification of Cys-116 by the reagent 4-nitro-7-chlorobenzadioxazole. Thus, Cys-116 is an excellent candidate for the active site nucleophile in HDH. In the current studies we show that treatment of HDH with the Zn2+ chelator 1,10-phenanthroline exposes Cys-116 to specific modification by iodoacetate, resulting in irreversible loss of activity. Site-specific mutagenesis was used to explore the roles of the conserved cysteine residues. The mutant enzymes C116S, C153S, C116A, and C153A and the double mutant C116,153A were each overproduced and purified to homogeneity. All mutant enzymes showed normal k(cat) and K(m) values for catalysis. The double mutant protein was unstable, and the single mutants also lose significant activities over a 3-h period during which wild-type enzyme retains full activity. The C116S mutant, and to a lesser extent the C116A mutant, were sensitive to the presence of EDTA in the assay medium, but the other mutants or wild-type enzyme were not, suggesting that Cys-116 may be near, but probably not liganded to, the bound metal ion. The results clearly indicate that HDH does not use a cysteine-based thiohemiacetal as a catalytic intermediate, requiring a new paradigm for NAD-linked aldehyde oxidation. Some models for the reaction are presented and discussed.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,3400 N BROAD ST,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; NYU,DEPT BIOL,NEW YORK,NY 10003	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; New York University								ADAMS E, 1954, J BIOL CHEM, V209, P829; ADAMS E, 1955, J BIOL CHEM, V217, P325; ALIFANO P, 1991, CELL, V64, P553; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BLATTER EE, 1990, BIOCHEM J, V272, P351, DOI 10.1042/bj2720351; BURGER E, 1981, EUR J BIOCHEM, V118, P125, DOI 10.1111/j.1432-1033.1981.tb05494.x; CARLOMAGNO MS, 1988, J MOL BIOL, V203, P585, DOI 10.1016/0022-2836(88)90194-5; CORBIER C, 1992, BIOCHEMISTRY-US, V31, P12532, DOI 10.1021/bi00164a033; ECCLESTON ED, 1979, J BIOL CHEM, V254, P1399; EISSES KT, 1989, BIOORG CHEM, V17, P268, DOI 10.1016/0045-2068(89)90028-X; GRUBMEYER C, 1989, ARCH BIOCHEM BIOPHYS, V272, P311, DOI 10.1016/0003-9861(89)90224-5; GRUBMEYER CT, 1986, BIOCHEMISTRY-US, V25, P4778, DOI 10.1021/bi00365a009; GRUBMEYER CT, 1990, J AM CHEM SOC, V112, P5906, DOI 10.1021/ja00172a002; HARRIS JI, 1976, ENZYMES, V13, P1; JONES JB, 1985, ENZYMES ORGANIC SYNT, P3; JORDANSTARCK TC, 1989, J BIOL CHEM, V264, P17919; KISHORE GM, 1988, ANNU REV BIOCHEM, V57, P627, DOI 10.1146/annurev.bi.57.070188.003211; KOHNO T, 1981, J MOL BIOL, V147, P451, DOI 10.1016/0022-2836(81)90495-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SY, 1987, J BACTERIOL, V169, P3938, DOI 10.1128/jb.169.9.3938-3944.1987; LOOMES KM, 1990, BIOCHEMISTRY-US, V29, P2070, DOI 10.1021/bi00460a015; LOPER JC, 1968, J BIOL CHEM, V243, P3264; MCCANN J, 1975, P NATL ACAD SCI USA, V72, P979, DOI 10.1073/pnas.72.3.979; NAGAI A, 1991, ARCH BIOCHEM BIOPHYS, V284, P127, DOI 10.1016/0003-9861(91)90274-M; NAGAI A, 1991, P NATL ACAD SCI USA, V88, P4133, DOI 10.1073/pnas.88.10.4133; ORDMAN AB, 1977, J BIOL CHEM, V252, P1320; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WARREN WA, 1970, J BIOL CHEM, V245, P1675; WEINER H, 1991, ENZYMOLOGY MOL BIOL, V3, P1; YOURNO J, 1968, J BIOL CHEM, V243, P3273	34	35	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14182	14188						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314784				2022-12-27	WOS:A1993LJ82500060
J	HEMRIC, ME; TRACY, PB; HAEBERLE, JR				HEMRIC, ME; TRACY, PB; HAEBERLE, JR			CALDESMON ENHANCES THE BINDING OF MYOSIN TO THE CYTOSKELETON DURING PLATELET ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; PROTEIN-KINASE-C; LIGHT CHAIN KINASE; NONMUSCLE CALDESMON; ATPASE ACTIVITY; HEAVY-MEROMYOSIN; BLOOD-PLATELETS; SHAPE CHANGE; F-ACTIN; PHOSPHORYLATION	Activation of platelets with physiological agents results in distinct cellular events such as shape change, cell aggregation, granule secretion, and clot retraction. Translocation of soluble cytoplasmic myosin to the actin cytoskeleton occurs during activation and may be involved in some of these physiological responses. Phosphorylation of the 20,000-dalton myosin light chain occurs in parallel with myosin translocation; however, exceptions to this correlation have been reported. The present study tests the hypothesis that the actin- and myosin-binding protein, caldesmon, is required for this enhanced binding of myosin to the actin cytoskeleton. Caldesmon, a putative regulatory protein found in nonmuscle and smooth muscle cells, binds actin and myosin simultaneously to form an actin-caldesmon myosin complex and ''tethers'' myosin to actin in a manner that promotes, rather than inhibits, translocation of actin filaments relative to myosin. In this study, we demonstrated that a purified myosin-binding fragment of caldesmon competitively blocks caldesmon dependent tethering in an in vitro motility assay and that this effect is prevented by phosphorylating the fragment. More importantly, we demonstrated that the unphosphorylated, but not the phosphorylated, fragment displaces myosin from the cytoskeleton of activated platelets; this suggests that caldesmon enhances the binding of myosin to the cytoskeleton during platelet activation.	UNIV VERMONT, COLL MED, DEPT MOLEC PHYSIOL & BIOPHYS, BURLINGTON, VT 05405 USA; UNIV VERMONT, COLL MED, DEPT BIOCHEM, BURLINGTON, VT 05405 USA	University of Vermont; University of Vermont					NHLBI NIH HHS [HL28001] Funding Source: Medline; NIAMS NIH HHS [AR08164, AR40259] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040259, F32AR008164] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAM LP, 1989, J BIOL CHEM, V264, P7698; ADAM LP, 1993, BIOPHYS J, V64, pA122; BRASS LF, 1985, J BIOL CHEM, V260, P5172; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BRYAN J, 1991, J MUSCLE RES CELL M, V12, P372, DOI 10.1007/BF01738592; BURGOYNE RD, 1986, NATURE, V319, P68, DOI 10.1038/319068a0; COX AC, 1984, J CELL BIOL, V98, P8, DOI 10.1083/jcb.98.1.8; CROSBIE R, 1991, J BIOL CHEM, V266, P20001; DANIEL JL, 1984, J BIOL CHEM, V259, P9826; FOX JEB, 1982, J BIOL CHEM, V257, P4120; HAEBERLE JR, 1992, J BIOL CHEM, V267, P23001; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HEMRIC ME, 1993, J BIOL CHEM, V268, P15305; HEMRIC ME, 1990, J BIOL CHEM, V265, P19672; HETTASCH JM, 1991, J BIOL CHEM, V266, P11876; HIGASHIHARA M, 1991, BLOOD, V78, P3224; HOLMSEN H, 1979, ANNU REV MED, V30, P119, DOI 10.1146/annurev.me.30.020179.001003; IKEBE M, 1990, BIOCHEMISTRY-US, V29, P11242, DOI 10.1021/bi00503a013; JENNINGS LK, 1981, J BIOL CHEM, V256, P6927; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU FWM, 1993, BIOPHYS J, V64, pA29; MUSTARD JF, 1989, METHOD ENZYMOL, V169, P3; NACHMIAS VT, 1987, J CELL BIOL, V105, P1761, DOI 10.1083/jcb.105.4.1761; NGAI PK, 1985, BIOCHEM BIOPH RES CO, V127, P533, DOI 10.1016/S0006-291X(85)80192-3; NGAI PK, 1987, BIOCHEM J, V244, P417, DOI 10.1042/bj2440417; NOVY RE, 1991, J BIOL CHEM, V266, P16917; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; PERSECHINI A, 1981, SCIENCE, V213, P1383, DOI 10.1126/science.6455737; PHO DB, 1986, FEBS LETT, V202, P117, DOI 10.1016/0014-5793(86)80660-3; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; SELLERS JR, 1982, J BIOL CHEM, V257, P3880; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SUTHERLAND C, 1989, J BIOL CHEM, V264, P578; TANAKA T, 1990, EUR J BIOCHEM, V188, P495, DOI 10.1111/j.1432-1033.1990.tb15427.x; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; VELAZ L, 1990, J BIOL CHEM, V265, P2929; VELAZ L, 1989, J BIOL CHEM, V264, P9602; WALKER G, 1989, J BIOL CHEM, V264, P496; WALSH MP, 1983, METHOD ENZYMOL, V99, P279; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0; YAZAWA M, 1980, J BIOCHEM, V87, P1313, DOI 10.1093/oxfordjournals.jbchem.a132869	45	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4125	4128						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307972				2022-12-27	WOS:A1994MW98900037
J	MIKI, J; KUSUKI, H; TSUGUMI, S; KANAZAWA, H				MIKI, J; KUSUKI, H; TSUGUMI, S; KANAZAWA, H			AMINO-ACID REPLACEMENTS AT BINDING-SITES OF MONOCLONAL-ANTIBODY IN THE F1-ATPASE BETA-SUBUNIT FROM ESCHERICHIA-COLI CAUSED ALTERED SUBUNIT INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; ADENOSINE-TRIPHOSPHATASE; NUCLEOTIDE-SEQUENCE; H+-ATPASE; SYNTHASE; TRANSFORMATION; F1-ATPASE; CLONING; F0F1; DNA	The monoclonal antibodies (mAb), beta 12 and beta 31, against the beta subunit of Escherichia coli F-1-ATPase (Miki, J., Matsuda, T., Kariya, H., Ohmori, H., Tsuchiya, T, Futai, M., and Kanazawa, H. (1992) Arch, Biochem. Biophys. 294, 373-381) recognize the amino-terminal portion of the maximal 104 residues, that are not exposed to the surface of the F-1-ATPase. To identify the epitope residues within these 104 residues, we introduced random mutations in the region, and clones without binding activity to the mAb, beta 12 and beta 31, were screened. beta subunits defective in binding with mAb beta 12 or beta 31 had amino acid replacements at residues 26, 40, 52, 71, and 74 or at residues 40, 41, 43, 44, 46, and 52, respectively. These residues could be part of the epitope and are possibly located close together. We tested the effects of the mutations on oxidative phosphorylation-dependent growth by introducing expression plasmids of the beta subunit gene with the point mutations into the beta-less mutant, JP17. The alpha and beta subunits were missing from the JP17 membranes, and both subunits were assembled functionally after expression of the beta subunit was induced by introducing the expression plasmid. The replacement of Leu-40 by Pro caused the amounts of the a and p subunits on the membranes to be reduced less than 20% of the amounts in wild type. The replacement of Glu-41 by Lys caused a loss of the alpha subunit on the membranes, without any decrease in the beta subunit. These results indicated that the mutation of Leu-40 to Pro affects the essential role of the beta subunit in the assembly of the alpha and beta subunits on the membranes and that the mutation of Glu-41 to Lys partly affects it. The amino-terminal region of the beta subunit, in particular its ternary structure, including residues 40 and 41, plays an important role in the molecular assembly of the alpha and beta subunits on the membranes.	OKAYAMA UNIV,FAC ENGN SCI,DEPT BIOTECHNOL,OKAYAMA,JAPAN	Okayama University								BERUS KI, 1965, J MOL BIOL, V11, P476; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; FUTAI M, 1983, MICROBIOL REV, V47, P285, DOI 10.1128/MMBR.47.3.285-312.1983; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; KANAZAWA H, 1980, J BIOCHEM-TOKYO, V88, P695, DOI 10.1093/oxfordjournals.jbchem.a133022; KANAZAWA H, 1982, BIOCHEM BIOPH RES CO, V105, P1257, DOI 10.1016/0006-291X(82)90922-6; KANAZAWA H, 1980, P NATL ACAD SCI-BIOL, V77, P7005, DOI 10.1073/pnas.77.12.7005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RSF, 1991, BIOCHEMISTRY-US, V30, P6842, DOI 10.1021/bi00242a006; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MIKI J, 1992, ARCH BIOCHEM BIOPHYS, V294, P373, DOI 10.1016/0003-9861(92)90698-V; NOUMI T, 1986, J BIOL CHEM, V261, P7070; NOUMI T, 1987, J BIOL CHEM, V262, P14978; OHTA S, 1986, J BIOCHEM-TOKYO, V99, P135, DOI 10.1093/oxfordjournals.jbchem.a135452; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X	22	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4227	4232						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307986				2022-12-27	WOS:A1994MW98900052
J	MONTERO, M; GARCIASANCHO, J; ALVAREZ, J				MONTERO, M; GARCIASANCHO, J; ALVAREZ, J			PHOSPHORYLATION DOWN-REGULATES THE STORE-OPERATED CA2+ ENTRY PATHWAY OF HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; PROTEIN-PHOSPHORYLATION; RESPIRATORY-BURST; NADPH OXIDASE; OKADAIC ACID; INTRACELLULAR CALCIUM; ACTIVATION; PHOSPHATASES; PHOSPHOPROTEIN; TRANSLOCATION	We have reported previously that the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine (fMLP) inhibits transiently Ca2+ entry through the plasma membrane Ca2+ pathway activated by emptying the intracellular Ca2+ stores (Montero, M., Garcia-Sancho, J., and Alvarez, J. (1993) J. Biol. Chem. 268, 13055-13061). We show here that calyculin A and okadaic acid, inhibitors of protein phosphatases 1 and 2A, prevent the spontaneous reversion of the fMLP-induced inhibition of the entry of Ca2+ and Mn2+ (used as a Ca2+ surrogate), leading to a permanently inhibited Ca2+ entry pathway. At high concentrations or long incubation times the phosphatase inhibitors were even able to inhibit the store-operated Ca2+ entry pathway (SOCP) in the absence of fMLP. Inhibition of SOCP by phorbol dibutyrate, which is not reversible, was not modified by phosphatase inhibitors. These results provide additional support for the view that fMLP inhibits SOCP through phosphorylation of either the SOCP protein or a regulatory protein and indicate that dephosphorylation mediated by protein phosphatases 1 and/or 2A restores the activity of SOCP after inhibition by fMLP. The time course of the inhibition of SOCP by fMLP was similar to the one reported previously for the transient fMLP-induced phosphorylation of a 47-kDa protein involved in the generation of respiratory burst, which was similarly affected by the phosphatase inhibitors.	UNIV VALLADOLID,FAC MED,DEPT BIOQUIM & BIOL MOLEC & FISIOL,E-47005 VALLADOLID,SPAIN	Universidad de Valladolid			Montero, Mayte/K-8212-2014; Alvarez, Javier/K-8210-2014; Garcia-Sancho, Javier/K-2975-2014	Montero, Mayte/0000-0001-7702-6653; Alvarez, Javier/0000-0003-0636-5521; Garcia-Sancho, Javier/0000-0003-4573-7930				BABIOR BM, 1988, ARCH BIOCHEM BIOPHYS, V264, P361, DOI 10.1016/0003-9861(88)90300-1; BERLIN RD, 1993, CELL CALCIUM, V14, P379, DOI 10.1016/0143-4160(93)90042-5; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; DING JB, 1992, J BIOL CHEM, V267, P6442; DUSI S, 1993, BIOCHEM J, V290, P173, DOI 10.1042/bj2900173; FODER B, 1989, CELL CALCIUM, V10, P477, DOI 10.1016/0143-4160(89)90025-0; GARCIA RC, 1992, BIOCHEM J, V286, P687, DOI 10.1042/bj2860687; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEYWORTH PG, 1986, BIOCHEM J, V239, P723, DOI 10.1042/bj2390723; HEYWORTH PG, 1989, BIOCHEM J, V260, P243, DOI 10.1042/bj2600243; ISHIHARA H, 1989, J PHARMACOL EXP THER, V250, P388; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LU DJ, 1992, AM J PHYSIOL, V262, pC39, DOI 10.1152/ajpcell.1992.262.1.C39; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MONTERO M, 1991, BIOCHEM J, V277, P73, DOI 10.1042/bj2770073; MONTERO M, 1992, BIOCHEM J, V288, P519, DOI 10.1042/bj2880519; MONTERO M, 1993, J BIOL CHEM, V268, P13055; OHTSUKA T, 1990, J BIOL CHEM, V265, P15418; REIBMAN J, 1988, J BIOL CHEM, V263, P6322; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318	23	58	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3963	3967						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307951				2022-12-27	WOS:A1994MW98900013
J	MCLEOD, RS; ZHAO, Y; SELBY, SL; WESTERLUND, J; YAO, ZM				MCLEOD, RS; ZHAO, Y; SELBY, SL; WESTERLUND, J; YAO, ZM			CARBOXYL-TERMINAL TRUNCATION IMPAIRS LIPID RECRUITMENT BY APOLIPOPROTEIN-B100 BUT DOES NOT AFFECT SECRETION OF THE TRUNCATED APOLIPOPROTEIN-B-CONTAINING LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; HEP G2 CELLS; MESSENGER-RNA; RAT-LIVER; FAMILIAL HYPOBETALIPOPROTEINEMIA; TRIGLYCERIDE-RICH; STOP CODON; EXPRESSION; IDENTIFICATION; INTESTINE	Human apolipoprotein (apo) B plays an obligatory role in the assembly and secretion of hepatic triglycerde-rich lipoproteins. Investigation of the truncated human apoB variants associated with hypobetalipoproteinemia has suggested that both size and secretion of apoB-containing lipoproteins may be reduced by carboxyl-terminal truncation. To examine the role of the carboxyl terminus of apoB in the assembly and secretion of hepatic lipoproteins, we have generated rat hepatoma McA-RH7777 cells that synthesize and secrete the full-length human apoB100 and the truncated forms B94, B88, B80, B72, and B60. In the resulting lipoproteins, particle density was inversely related to the logarithm of apoB length, ranging from 1.019 g/ml for apoB100 to 1.06 g/ml for B60. Furthermore, particle diameter (as determined by non-denaturing gel electrophoresis) was directly correlated with apoB length, ranging from 21.4 nm for apoB100 to 17.7 nm for B60. The relationship between apoB length and particle geometry was best defined by a linear correlation between length and core volume; a 10% decrease in apoB length resulted in an approximately 13% decrease in core volume. These observations, which are in agreement with the observations of aberrant lipoproteins in hypobetalipoproteinemia, suggest that lipid recruitment by apoB is progressively reduced by carboxyl-terminal truncation. However, pulse-chase studies indicated that carboxyl-terminal truncation did not impair apoB secretion. The recombinant human apoB forms were secreted as efficiently as endogenous rat apoB100; approximately 20% of total newly synthesized apoB72, B80, or B100 was secreted at the end of the chase. Intracellular degradation of newly synthesized apoB was observed for both the truncated human and the endogenous rat proteins. These data suggest that the low apoB levels in hypobetalipoproteinemia might not be caused by impaired secretion of the truncated apoB proteins.	UNIV ALBERTA,HERITAGE MED RES CTR 328,LIPID & LIPOPROT RES GRP,EDMONTON TG2 2S2,AB,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T22 2S2,AB,CANADA	University of Alberta; University of Alberta			McLeod, Roger/F-8014-2015	McLeod, Roger/0000-0002-6740-5569				ANDERSON DW, 1977, BIOCHIM BIOPHYS ACTA, V493, P55, DOI 10.1016/0005-2795(77)90259-8; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BLACKHART BD, 1990, J BIOL CHEM, V265, P8358; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; BOSTROM K, 1990, J BIOL CHEM, V265, P22446; CATTANEO R, 1991, ANNU REV GENET, V25, P71, DOI 10.1146/annurev.ge.25.120191.000443; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHATTERTON JE, 1991, J BIOL CHEM, V266, P5955; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; DAVIDSON NO, 1988, J BIOL CHEM, V263, P13482; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1993, J LIPID RES, V34, P167; ELOVSON J, 1992, CIRCULATION, V86, P692; FARESE RV, 1992, J LIPID RES, V33, P569; FAZIO S, 1992, J BIOL CHEM, V267, P6941; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; KRAUSS RM, 1982, J LIPID RES, V23, P97; KRUEL ES, 1992, J LIPID RES, V33, P1037; LINTON MF, 1993, J LIPID RES, V34, P521; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; MARCEL YL, 1987, ARTERIOSCLEROSIS, V7, P166, DOI 10.1161/01.ATV.7.2.166; PARHOFER KG, 1990, J LIPID RES, V31, P2001; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; PULLINGER CR, 1992, J LIPID RES, V33, P699; SPARKS JD, 1990, J BIOL CHEM, V265, P8854; SPRING DJ, 1992, J LIPID RES, V33, P233; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; TENNYSON GE, 1989, P NATL ACAD SCI USA, V86, P500, DOI 10.1073/pnas.86.2.500; WELTY FK, 1991, J CLIN INVEST, V87, P1748, DOI 10.1172/JCI115193; YAO ZM, 1993, ARTERIOSCLER THROMB, V13, P1476, DOI 10.1161/01.ATV.13.10.1476; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YAO ZM, 1992, J BIOL CHEM, V267, P1175; YOUNG SG, 1987, J BIOL CHEM, V262, P16604; YOUNG SG, 1990, J CLIN INVEST, V85, P933, DOI 10.1172/JCI114522; YOUNG SG, 1990, CIRCULATION, V80, P219	39	80	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2852	2862						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300620				2022-12-27	WOS:A1994MV43200074
J	QUEST, AFG; BARDES, ESG; BELL, RM				QUEST, AFG; BARDES, ESG; BELL, RM			A PHORBOL ESTER BINDING DOMAIN OF PROTEIN KINASE-C-GAMMA - DELETION ANALYSIS OF THE CYS2 DOMAIN DEFINES A MINIMAL 43-AMINO ACID PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY DOMAIN; DILUTE-SOLUTION; ACTIVATION; EXPRESSION; FAMILY; ZINC; PURIFICATION; RECEPTOR; PHOSPHATIDYLSERINE; DIACYLGLYCEROL	Cysteine-rich regions of protein kinase C (PKC) are critical for the lipid-dependent regulation of activity and are implicated in the coordination of zinc. A glutathione S-transferase fusion protein containing the second cysteine-rich region, Cys2, of PKCgamma with bound zinc with a stoichiometry of 1.8 +/- 0.1 mol of zinc/mol of protein. Deletion analysis within this cysteine-rich region defined amino acids essential for zinc coordination. An NH2-terminal histidine (His102) and a COOH-terminal cysteine (Cys151) were both critical for the coordination of distinct zinc atoms. Both represent the ultimate residues of a 50-amino acid consensus motif with six conserved cysteines and two conserved histidines present in the cysteine-rich regions of all PKC isoforms. Removal of histidine His102 abolished phorbol ester binding, while deletion of cysteine Cys151 did not. Deletion of valine (Val147) greatly diminished phorbol ester binding, which was completely lost only when valine (Val144) was also deleted. No significant further reduction in zinc stoichiometry below one resulted even when three COOH-terminal conserved cysteines (Cys151, Cys143, and Cys135) and a conserved histidine (His140) were deleted. These results are consistent with a model in which two zinc atoms are tetracoordinated per cysteine-rich region in two independent coordination spheres that are not functionally equivalent. These analyses determine a minimal peptide (residues 102-144) of 43 amino acids capable of [H-3]PDBu binding.	DUKE UNIV,MED CTR,CELL GROWTH REGULAT & ONCOGENESIS SECT,POB 3711,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038737] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38737] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; AKITA Y, 1990, J BIOL CHEM, V265, P354; BELL RM, 1991, J BIOL CHEM, V266, P4661; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; BURNS DJ, 1992, PROTEIN KINASE C CUR, P25; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; EBLING JG, 1985, P NATL ACAD SCI USA, V82, P815; GANONG BR, 1986, P NATL ACAD SCI USA, V83, P1184, DOI 10.1073/pnas.83.5.1184; HANNUN YA, 1986, J BIOL CHEM, V261, P9341; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUBBARD SR, 1991, SCIENCE, V254, P1776; JEFFREY AM, 1986, P NATL ACAD SCI USA, V83, P241, DOI 10.1073/pnas.83.2.241; KAIBUCHI K, 1981, J BIOL CHEM, V256, P7146; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKOWSKE M, 1989, J BIOL CHEM, V264, P16155; MURUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ONO Y, 1988, J BIOL CHEM, V263, P6927; ORR JW, 1992, J BIOL CHEM, V267, P15263; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; RANDO RR, 1988, FASEB J, V2, P2348, DOI 10.1096/fasebj.2.8.3282960; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; TABUSE Y, 1989, SCIENCE, V243, P1713, DOI 10.1126/science.2538925; TAKAI Y, 1979, J BIOCHEM-TOKYO, V86, P575, DOI 10.1093/oxfordjournals.jbchem.a132557; TAKAI Y, 1979, J BIOL CHEM, V254, P3962; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WENDER PA, 1986, P NATL ACAD SCI USA, V83, P4214, DOI 10.1073/pnas.83.12.4214; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WILLOTT E, 1992, AM J PHYSIOL, V262, pC1119, DOI 10.1152/ajpcell.1992.262.5.C1119	43	118	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2961	2970						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300628				2022-12-27	WOS:A1994MV43200087
J	SUZUKI, C; NIKKUNI, S				SUZUKI, C; NIKKUNI, S			THE PRIMARY AND SUBUNIT STRUCTURE OF A NOVEL TYPE KILLER TOXIN PRODUCED BY A HALOTOLERANT YEAST, PICHIA-FARINOSA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL RECEPTOR; SACCHAROMYCES-CEREVISIAE; GENE ENCODES; KLUYVEROMYCES-LACTIS; FUNCTIONAL DOMAINS; USTILAGO-MAYDIS; ALPHA-FACTOR; CHARACTER; PROTEIN; PREPROTOXIN	A halotolerant yeast, Pichia farinosa KK1 strain, produces a unique killer toxin termed SMK toxin (salt-mediated killer toxin) which shows its maximum killer activity in the presence of 2 M NaCl. The toxin consists of two distinct subunits, alpha and beta, which are tightly linked without a disulfide bond under acidic conditions, even in the presence of 6 M urea. Under neutral conditions, however, the alpha subunit precipitates, resulting in the dissociation of the subunits and the loss of killer activity. The nucleotide sequence of the SMK1 gene predicts a 222 amino acid preprotoxin with a typical signal sequence, the hydrophobic alpha, an interstitial gamma polypeptide with a putative glycosylation site, and the hydrophilic beta. Amino acid sequence analyses of peptide fragments including the carboxyl-terminal peptides from each subunit suggest that the alpha and beta subunits consist of amino acid residues 19-81 and 146-222 of the preprotoxin, respectively, and the molecular weight of the mature alphabeta dimer is 14,214. The KEX2-like endopeptidase and KEX1-like carboxypeptidase may be involved in the stepwise processing of the SMK preprotoxin. The maturation process and the functions of the SMK toxin are compared with the K1 toxin of Saccharomyces cerevisiae.			SUZUKI, C (corresponding author), MINIST AGR FORESTRY & FISHERIES, NATL FOOD RES INST, 2-1-2 KANNON DAI, TSUKUBA, IBARAKI 305, JAPAN.		SUZUKI, Chise/AAR-1986-2020	SUZUKI, Chise/0000-0001-7148-8101				BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BOONE C, 1990, J CELL BIOL, V110, P1833, DOI 10.1083/jcb.110.5.1833; BOONE C, 1986, CELL, V46, P105, DOI 10.1016/0092-8674(86)90864-0; BOSTIAN KA, 1983, CELL, V32, P169, DOI 10.1016/0092-8674(83)90507-X; BOSTIAN KA, 1984, CELL, V36, P741, DOI 10.1016/0092-8674(84)90354-4; BOSTIAN KA, 1980, CELL, V19, P403, DOI 10.1016/0092-8674(80)90514-0; BUSSEY H, 1979, J BACTERIOL, V140, P888, DOI 10.1128/JB.140.3.888-892.1979; COOPER A, 1989, MOL CELL BIOL, V9, P2706, DOI 10.1128/MCB.9.6.2706; Cryer D R, 1975, Methods Cell Biol, V12, P39; DELAPENA P, 1981, J BIOL CHEM, V256, P420; DIGNARD D, 1991, MOL GEN GENET, V227, P127, DOI 10.1007/BF00260717; DMOCHOWSKA A, 1987, CELL, V50, P573, DOI 10.1016/0092-8674(87)90030-4; FINK GR, 1972, P NATL ACAD SCI USA, V69, P2846, DOI 10.1073/pnas.69.10.2846; GUNGE N, 1981, J BACTERIOL, V145, P382, DOI 10.1128/JB.145.1.382-390.1981; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; HUTCHINS K, 1983, J BACTERIOL, V154, P161, DOI 10.1128/JB.154.1.161-169.1983; INGLIS AS, 1983, METHOD ENZYMOL, V91, P324; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KAGIYAMA S, 1988, AGR BIOL CHEM TOKYO, V52, P1; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEIBOWITZ MJ, 1976, P NATL ACAD SCI USA, V73, P2061, DOI 10.1073/pnas.73.6.2061; LI WZ, 1991, MOL CELL BIOL, V11, P666, DOI 10.1128/MCB.11.2.666; MARTINAC B, 1990, P NATL ACAD SCI USA, V87, P6228, DOI 10.1073/pnas.87.16.6228; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MEADEN P, 1990, MOL CELL BIOL, V10, P3013, DOI 10.1128/MCB.10.6.3013; MIWA A, 1988, MISO SCI TECHNOLOGY, V36, P25; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; NAUMOV G, 1991, CURR GENET, V20, P269, DOI 10.1007/BF00318514; PALFREE RGE, 1979, EUR J BIOCHEM, V93, P487, DOI 10.1111/j.1432-1033.1979.tb12847.x; PEERY T, 1987, MOL CELL BIOL, V7, P470, DOI 10.1128/MCB.7.1.470; PHILLISKIRK G, 1975, A VAN LEEUW J MICROB, V41, P147, DOI 10.1007/BF02565046; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Southern E, 1979, Methods Enzymol, V68, P152; STARK MJR, 1986, EMBO J, V5, P1995, DOI 10.1002/j.1460-2075.1986.tb04455.x; STURLEY SL, 1986, EMBO J, V5, P3381, DOI 10.1002/j.1460-2075.1986.tb04654.x; SUZUKI C, 1989, AGR BIOL CHEM TOKYO, V53, P2593, DOI 10.1080/00021369.1989.10869744; SUZUKI C, 1989, AGR BIOL CHEM TOKYO, V53, P2599, DOI 10.1080/00021369.1989.10869745; TAKAYAMA S, 1987, NATURE, V326, P102, DOI 10.1038/326102a0; TAO JS, 1990, MOL CELL BIOL, V10, P1373, DOI 10.1128/MCB.10.4.1373; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TIPPER DJ, 1991, MOL MICROBIOL, V5, P2331, DOI 10.1111/j.1365-2958.1991.tb02078.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WICKNER RB, 1974, J BACTERIOL, V117, P1356, DOI 10.1128/JB.117.3.1356-1357.1974; WICKNER RB, 1991, MOL BIOL YEAST SACCH, V1, P263; YOUNG TW, 1978, A VAN LEEUW J MICROB, V44, P59, DOI 10.1007/BF00400077; Young TW, 1987, YEASTS, V2, P131; ZHU H, 1991, MOL CELL BIOL, V11, P175, DOI 10.1128/MCB.11.1.175; ZHU H, 1987, J BIOL CHEM, V262, P10728; ZHU YS, 1992, MOL MICROBIOL, V6, P511, DOI 10.1111/j.1365-2958.1992.tb01496.x	52	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3041	3046						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300637				2022-12-27	WOS:A1994MV43200097
J	TYAGI, SC; SIMON, SR				TYAGI, SC; SIMON, SR			REGULATION OF NEUTROPHIL ELASTASE ACTIVITY BY ELASTIN-DERIVED PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE ELASTASE; PORCINE PANCREATIC ELASTASE; CATHEPSIN-G; INHIBITORS; PURIFICATION; DEGRADATION; EMPHYSEMA; PLASMA	To understand the interaction between elastin and elastase, elastin from human aorta was incubated with human leukocyte elastase under conditions favoring proteolysis. Low molecular weight species were separated from the protein fraction by a small centrifuged gel filtration column. The only product of the elastin digest detected on acid polyacrylamide gel electrophoresis was a single band of slower cathodal mobility than human leukocyte elastase alone. This band cross-reacts with antibody to human elastase, indicating that the slow migrating band contains elastase. The putative human leukocyte elastase-elastin-derived peptide complex was treated with hydroxylamine to cleave any possible acyl-enzyme complexes and was then measured for amidolytic activity. Analysis of the amino acid composition of elastin-derived peptide indicates the presence of alanine, glycine, and richness in hydrophobic residues, suggesting that these residues are involved in elastase interaction(s). Incubation of the elastase-elastin-derived peptide with alpha1-protease inhibitor causes dissociation of the complex and formation of an elastase-alpha1-protease inhibitor complex. Our results suggest that, locally at the site of proteolysis, elastase activity may be regulated by elastin-derived peptide(s) during elastinolysis.	UNIV MISSOURI,DEPT BIOCHEM,DIV CARDIOL,COLUMBIA,MO 65212; UNIV MISSOURI,DALTON RES CTR,COLUMBIA,MO 65212; SUNY,DEPT PATHOL,STONY BROOK,NY 11794; SUNY,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College	TYAGI, SC (corresponding author), UNIV MISSOURI,DEPT MED,DIV CARDIOL,COLUMBIA,MO 65212, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL014262, R01HL014262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048595] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-14262] Funding Source: Medline; NIGMS NIH HHS [GM-48595] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUGH RJ, 1976, BIOCHEMISTRY-US, V15, P836, DOI 10.1021/bi00649a017; BIETH JG, 1986, BIOL EXTRACELLULAR M, P217; BOUDIER C, 1981, J BIOL CHEM, V256, P256; CAMPBELL EJ, 1982, P NATL ACAD SCI-BIOL, V79, P6941, DOI 10.1073/pnas.79.22.6941; CHAPMAN HA, 1984, BIOCHEM J, V222, P721, DOI 10.1042/bj2220721; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1342; EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/annurev.bi.53.070184.003441; JANOFF A, 1985, ANNU REV MED, V36, P207; JANOFF A, 1985, AM REV RESPIR DIS, V132, P417; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURELL CB, 1975, EUR J BIOCHEM, V57, P107, DOI 10.1111/j.1432-1033.1975.tb02281.x; MANTHORPE M, 1983, J CELL BIOL, V97, P1882, DOI 10.1083/jcb.97.6.1882; MORRISON HM, 1990, AM J RESP CELL MOL, V2, P263, DOI 10.1165/ajrcmb/2.3.263; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; NIEWOEHNER DE, 1988, J LAB CLIN MED, V111, P15; PADRINES M, 1991, AM J RESP CELL MOL, V4, P187, DOI 10.1165/ajrcmb/4.2.187; REILLY CF, 1980, BIOCHIM BIOPHYS ACTA, V621, P147, DOI 10.1016/0005-2795(80)90070-7; REVERA G, 1978, ANAL BIOCHEM, V85, P506; Rosenbloom Joel, 1993, P167; RUCKER RB, 1984, ENVIRON HEALTH PERSP, V55, P179, DOI 10.2307/3429702; SANDBERG LB, 1981, NEW ENGL J MED, V304, P566, DOI 10.1056/NEJM198103053041004; SENIOR RM, 1976, BIOCHEM BIOPH RES CO, V72, P1327, DOI 10.1016/S0006-291X(76)80160-X; STARCHER BC, 1976, ANAL BIOCHEM, V74, P441, DOI 10.1016/0003-2697(76)90224-4; THOMAS J, 1963, NATURE, V200, P651, DOI 10.1038/200651a0; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TYAGI SC, 1990, BIOCHEMISTRY-US, V29, P9970, DOI 10.1021/bi00494a030; URRY DW, 1983, ULTRASTRUCT PATHOL, V4, P227, DOI 10.3109/01913128309140793; WHITE R, 1982, AM REV RESPIR DIS, V125, P779; YASUTAKE A, 1981, BIOCHEMISTRY-US, V20, P3675, DOI 10.1021/bi00516a002	29	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16513	16518						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344932				2022-12-27	WOS:A1993LQ33600063
J	NUREKI, O; KOHNO, T; SAKAMOTO, K; MIYAZAWA, T; YOKOYAMA, S				NUREKI, O; KOHNO, T; SAKAMOTO, K; MIYAZAWA, T; YOKOYAMA, S			CHEMICAL MODIFICATION AND MUTAGENESIS STUDIES ON ZINC-BINDING OF AMINOACYL-TRANSFER RNA-SYNTHETASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMUS-THERMOPHILUS HB8; ISOLEUCYL-TRANSFER-RNA; TRANSCRIPTION FACTOR-IIIA; ASPARTYL-TRANSFER RNA; VALYL-TRANSFER-RNA; ESCHERICHIA-COLI; EXTREME THERMOPHILE; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE	Thermus thermophilus methionyl-tRNA synthetase consists of two identical subunits with a potential Zn2+-binding sequence of Cys-X2-Cys-X13-Cys-X2-His (Nureki, O., Muramatsu, T., Suzuki, K., Kohda, D., Matsuzawa, H., Ohta, T. Miyazawa, T., and Yokoyama, S. (1991) J. Biol. Chem. 266, 3268-3277). Upon chemical modification of the 3 Cys residues of T. thermophilus MetRS with sodium p-(hydroxymercuri)phenylsulfonate, one Zn2+ ion was released from one subunit of the molecule, as monitored with 4-(2-pyridylazo)resorcinol. Site-directed mutagenesis of Cys and His residues in the Zn2+-binding sequence reduced the aminoacylation activity; the k(cat) value was markedly decreased, and the K(m) values for L-methionine and tRNA(f)Met were increased. Similarly, Cys modification released two Zn2+ ions from T. thermophilus and Escherichia coli isoleucyl-tRNA synthetases and E. coli threonyl-tRNA synthetase, which have Zn2+-binding motifs, and impaired their activities. By contrast, three other aminoacyl-tRNA synthetases that lack Zn2+-binding motif neither released Zn2+ ion nor lost their activities upon Cys modification. These results indicate that the Zn2+-binding sequences are important for catalysis and recognition in the aminoacylation reactions of a subgroup of aminoacyl-tRNA synthetases.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN; PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN	University of Tokyo			Sakamoto, Kensaku/N-7496-2015; Yokoyama, Shigeyuki/N-6911-2015	Sakamoto, Kensaku/0000-0003-2866-5031; Yokoyama, Shigeyuki/0000-0003-3133-7338				AVALOS J, 1991, FEBS LETT, V286, P176, DOI 10.1016/0014-5793(91)80968-9; BARSTOW DA, 1986, GENE, V46, P37, DOI 10.1016/0378-1119(86)90164-2; BERG JM, 1990, J BIOL CHEM, V265, P6513; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BRETON R, 1986, J BIOL CHEM, V261, P610; BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; CHANG PK, 1990, J BIOL CHEM, V265, P20898; CRUZEN ME, 1991, J BIOL CHEM, V266, P9919; CSANK C, 1992, J BIOL CHEM, V267, P4592; DARDEL F, 1984, J BACTERIOL, V160, P1115, DOI 10.1128/JB.160.3.1115-1122.1984; ERIANI G, 1990, NUCLEIC ACIDS RES, V18, P7109, DOI 10.1093/nar/18.23.7109; ERIANI G, 1989, NUCLEIC ACIDS RES, V17, P5725, DOI 10.1093/nar/17.14.5725; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FASIOLO F, 1985, J BIOL CHEM, V260, P5571; FETT R, 1991, J BIOL CHEM, V266, P1448; GAMPEL A, 1989, P NATL ACAD SCI USA, V86, P6023, DOI 10.1073/pnas.86.16.6023; GIEDROC DP, 1986, BIOCHEMISTRY-US, V25, P4969, DOI 10.1021/bi00365a037; HALL CV, 1982, J BIOL CHEM, V257, P6132; HERBERT CJ, 1988, EMBO J, V7, P473, DOI 10.1002/j.1460-2075.1988.tb02835.x; HERBERT CJ, 1988, MOL GEN GENET, V213, P297, DOI 10.1007/BF00339595; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; HOUNTONDJI C, 1990, BIOCHEMISTRY-US, V29, P8190, DOI 10.1021/bi00487a029; HSIEH SL, 1991, BIOCHEM J, V278, P809, DOI 10.1042/bj2780809; HUNT JB, 1984, J BIOL CHEM, V259, P4793; HUNT JB, 1986, ANAL BIOCHEM, V146, P150; JACOBSON GR, 1973, ENZYMES, V9, P225; KAWAKAMI M, 1985, FEBS LETT, V185, P162, DOI 10.1016/0014-5793(85)80762-6; KISSELEV LL, 1981, EUR J BIOCHEM, V120, P511, DOI 10.1111/j.1432-1033.1981.tb05729.x; KOHDA D, 1987, J BIOL CHEM, V262, P558; KOHDA D, 1984, FEBS LETT, V174, P20, DOI 10.1016/0014-5793(84)81069-8; LIU J, 1992, ANN ASS CAN FR AV SC, V60, P26; LUDMERER SW, 1987, J BIOL CHEM, V262, P10801; MAYAUX JF, 1982, EUR J BIOCHEM, V128, P41; MAYAUX JF, 1981, BIOCHEMISTRY-US, V20, P4647, DOI 10.1021/bi00519a020; MAYAUX JF, 1983, P NATL ACAD SCI-BIOL, V80, P6152, DOI 10.1073/pnas.80.20.6152; MECHULAM Y, 1985, J BACTERIOL, V163, P787, DOI 10.1128/JB.163.2.787-791.1985; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MILLER WT, 1991, BIOCHEMISTRY-US, V30, P2635, DOI 10.1021/bi00224a011; MILLER WT, 1991, BIOCHEMISTRY-US, V30, P6970, DOI 10.1021/bi00242a023; MILLER WT, 1992, P NATL ACAD SCI USA, V89, P2032, DOI 10.1073/pnas.89.6.2032; NUREKI O, 1992, EUR J BIOCHEM, V204, P465, DOI 10.1111/j.1432-1033.1992.tb16656.x; NUREKI O, 1991, J BIOL CHEM, V266, P3268; PAPE LK, 1985, NUCLEIC ACIDS RES, V13, P6171, DOI 10.1093/nar/13.17.6171; PLUMBRIDGE JA, 1982, J BACTERIOL, V152, P650; POSORSKE LH, 1979, BIOCHIM BIOPHYS ACTA, V576, P128, DOI 10.1016/0005-2795(79)90491-4; PUTNEY SD, 1981, SCIENCE, V213, P1497, DOI 10.1126/science.7025207; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SHANG ZG, 1989, BIOCHEMISTRY-US, V28, P9790, DOI 10.1021/bi00451a037; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; SPRINGER M, 1989, EMBO J, V8, P2417, DOI 10.1002/j.1460-2075.1989.tb08372.x; STARZYK RM, 1989, BIOCHEMISTRY-US, V28, P8479, DOI 10.1021/bi00447a031; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; TZAGOLOFF A, 1988, J BIOL CHEM, V263, P850; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WALTER P, 1983, P NATL ACAD SCI-BIOL, V80, P2437, DOI 10.1073/pnas.80.9.2437; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679	58	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15368	15373						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340367				2022-12-27	WOS:A1993LN30500011
J	STEINBECK, MJ; KHAN, AU; KARNOVSKY, MJ				STEINBECK, MJ; KHAN, AU; KARNOVSKY, MJ			EXTRACELLULAR PRODUCTION OF SINGLET OXYGEN BY STIMULATED MACROPHAGES QUANTIFIED USING 9,10-DIPHENYLANTHRACENE AND PERYLENE IN A POLYSTYRENE FILM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-GENERATING SYSTEM; MOLECULAR-OXYGEN; HYDROGEN-PEROXIDE; XANTHINE-OXIDASE; BACTERICIDAL ACTIVITY; LIPID PEROXIDATION; MOUSE MACROPHAGES; HUMAN-NEUTROPHILS; PLASMA-MEMBRANE; H+-ATPASE	The extracellular production of singlet oxygen (O2(1DELTA(g)) by stimulated macrophages was measured using a modification of our quantitative method initially developed to measure the intracellular production of O2(1DELTA(g)) by neutrophils (Steinbeck, M. J., Khan, A. U., and Karnovsky, M. J. (1992) J. Biol. Chem. 267, 13425-13433). Glass coverslips were coated with the specific chemical trap for O2(1DELTA(g)), 9,10-diphenylanthracene (DPA) and perylene, which is an internal standard, in a methylene chloride solution containing 0.3 mg/ml polystyrene. On evaporation, the polystyrene formed an even coating of DPA and perylene over the surface of a glass coverslip (PDP film). Unstimulated macrophages or macrophages stimulated with 4beta-phorbol 12-myristate 13-acetate (PMA) or formyl-methionyl-leucyl-phenylalanine (fMLP) were then added to the PDP film in a darkened room and incubated at 37-degrees-C for 30 min in a humidified 5% CO2 atmosphere. Both unstimulated and stimulated cells adhered to the PDP film in approximately equivalent numbers. Only stimulated cells produced measurable amounts of O2(1DELTA(g)) in a dose-dependent response to either PMA or fMLP. The production of O2(1DELTA(g)) by macrophages stimulated with PMA was maximal in response to 25 ng, 17.8 +/- 1.3 nmol Of O2(1DELTA(g))/approximately 1.00 x 10(6) cells. The maximal response for fMLP was at a concentration of 1 muM, 18.4 +/- 1.0 nmol Of O2(1DELTA(g))/approximately 1.00 x 10(6) cells. The specific detection of O2(1DELTA(g)) by this method was confirmed by thermally releasing O2(1DELTA(g)) from the DPA-O2(1DELTA(g)) reaction product, DPA-endoperoxide, regenerating the original DPA compound. Production of O2(1DELTA(g)) by the stimulated cells was inhibited 80-89% by the addition of 60-120 mug of superoxide dismutase, an enzyme that converts superoxide to hydrogen peroxide and ground state molecular oxygen or 79-84% with the addition of 2 mM histidine, an avid quencher Of O2(1DELTA(g)). Neither of these additions interfered with adhesion of the cells to the PDP film. The ability of superoxide dismutase to inhibit the production of O2(1DELTA(g)) suggested that O2(1DELTA(g)) was produced via a superoxide-dependent route. The ability of an oxidase to produce O2(1DELTA(g)) secondary to superoxide production was substantiated further using a xanthine oxidase-acetaldehyde system. Purified xanthine oxidase produced both superoxide and O2(1DELTA(g)), and their production was inhibited by the addition of superoxide dismutase. The production Of O2(1DELTA(g)) by this system was also verified by thermally reversing the reaction. With the use of the PDP film, we have modified our original method for the intracellular detection Of O2(1DELTA(g)) and have demonstrated that extracellular production of O2(1DELTA(g)) by stimulated macrophages can be quantified and appears to be generated via a superoxide-dependent pathway.			STEINBECK, MJ (corresponding author), HARVARD UNIV,SCH MED,DEPT PATHOL,BLDG D2,RM 442,200 LONGWOOD AVE,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008507] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-08507] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALLEN RC, 1972, BIOCHEM BIOPH RES CO, V47, P679, DOI 10.1016/0006-291X(72)90545-1; ARNESON RM, 1970, ARCH BIOCHEM BIOPHYS, V136, P352, DOI 10.1016/0003-9861(70)90205-5; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BABIOR GL, 1981, J CLIN INVEST, V67, P1724, DOI 10.1172/JCI110210; BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BADWEY JA, 1983, J CELL PHYSIOL, V115, P208, DOI 10.1002/jcp.1041150216; BIELSKI BHJ, 1977, J PHYS CHEM-US, V81, P1048, DOI 10.1021/j100526a005; BROWNE RJ, 1965, CAN J CHEMISTRY, V43, P2915, DOI 10.1139/v65-402; CLARK RA, 1987, J BIOL CHEM, V262, P4065; COHEN HJ, 1978, J CLIN INVEST, V61, P1081, DOI 10.1172/JCI109007; COREY EJ, 1987, BIOCHEM BIOPH RES CO, V145, P842, DOI 10.1016/0006-291X(87)91041-2; COREY EJ, 1964, J AM CHEM SOC, V86, P3881, DOI 10.1021/ja01072a062; FOOTE CS, 1964, J AM CHEM SOC, V86, P3879, DOI 10.1021/ja01072a060; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; FRIMER AA, 1985, SINGLET O2, V1; GOLDSTEIN IM, 1977, J CLIN INVEST, V59, P249, DOI 10.1172/JCI108635; GREEN TR, 1980, BIOCHEM BIOPH RES CO, V94, P262, DOI 10.1016/S0006-291X(80)80215-4; GREENWALD RA, 1991, SEMIN ARTHRITIS RHEU, V20, P219, DOI 10.1016/0049-0172(91)90018-U; GUIRAUD HJ, 1906, J AM CHEM SOC, V98, P1984; HELD AM, 1978, J AM CHEM SOC, V100, P5732, DOI 10.1021/ja00486a025; HODGSON EK, 1976, ARCH BIOCHEM BIOPHYS, V172, P202, DOI 10.1016/0003-9861(76)90067-9; IYER GYN, 1963, CAN J BIOCHEM PHYS, V41, P427; JOHNSTON RB, 1978, J EXP MED, V148, P115; KANOFSKY JR, 1988, J BIOL CHEM, V263, P9692; KELLOGG EW, 1975, J BIOL CHEM, V250, P8812; KELLOGG EW, 1977, J BIOL CHEM, V252, P6721; KHAN AU, 1976, J PHYS CHEM-US, V80, P2219, DOI 10.1021/j100561a018; KHAN AU, 1981, J AM CHEM SOC, V103, P6516, DOI 10.1021/ja00411a051; KHAN AU, 1977, J AM CHEM SOC, V99, P370, DOI 10.1021/ja00444a010; KHAN AU, 1963, J CHEM PHYS, V39, P2105, DOI 10.1063/1.1734588; KHAN AU, 1970, J AM CHEM SOC, V92, P3293, DOI 10.1021/ja00714a010; KHAN AU, 1970, SCIENCE, V168, P476, DOI 10.1126/science.168.3930.476; KING MM, 1975, J BIOL CHEM, V250, P6496; KRINSKY NI, 1974, SCIENCE, V186, P363, DOI 10.1126/science.186.4161.363; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MERKEL PB, 1972, J AM CHEM SOC, V94, P7244, DOI 10.1021/ja00776a003; MURRAY HW, 1980, J EXP MED, V152, P1596, DOI 10.1084/jem.152.6.1596; NAGANO T, 1985, PHOTOCHEM PHOTOBIOL, V41, P31; NATHAN CF, 1977, J EXP MED, V146, P1648, DOI 10.1084/jem.146.6.1648; PAUL B, 1968, BIOCHIM BIOPHYS ACTA, V156, P168, DOI 10.1016/0304-4165(68)90116-5; ROSEN H, 1977, J BIOL CHEM, V252, P4803; ROSEN H, 1979, J EXP MED, V149, P27, DOI 10.1084/jem.149.1.27; ROSEN H, 1978, CLIN RES, V26, P404; ROSENTHAL I, 1975, ISRAEL J CHEM, V13, P86; ROSSI F, 1964, EXPERIENTIA, V20, P21, DOI 10.1007/BF02146019; SINGH A, 1978, PHOTOCHEM PHOTOBIOL, V28, P4; SINGH A, 1978, PHOTOCHEM PHOTOBIOL, V28, P5; SOBERMAN RJ, 1981, LYMPHOKINES, V3, P11; STEINBECK MJ, 1992, J BIOL CHEM, V267, P13425; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; TAKAYAMA K, 1977, BIOCHEM BIOPH RES CO, V75, P1052, DOI 10.1016/0006-291X(77)91488-7; TAPPER H, 1992, BIOCHEM J, V281, P245, DOI 10.1042/bj2810245; TAUBER AI, 1977, J CLIN INVEST, V60, P374, DOI 10.1172/JCI108786; TOMITA M, 1969, BIOCHEMISTRY-US, V8, P5149, DOI 10.1021/bi00840a069; TURRO NJ, 1981, J AM CHEM SOC, V103, P7218, DOI 10.1021/ja00414a029; WASSERMA.HH, 1972, J AM CHEM SOC, V94, P4991, DOI 10.1021/ja00769a034; Wilson T, 1970, Photophysiology, V5, P49	59	123	131	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15649	15654						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340389				2022-12-27	WOS:A1993LN30500050
J	STROM, MS; BERGMAN, P; LORY, S				STROM, MS; BERGMAN, P; LORY, S			IDENTIFICATION OF ACTIVE-SITE CYSTEINES IN THE CONSERVED DOMAIN OF PILD, THE BIFUNCTIONAL TYPE-IV PILIN LEADER PEPTIDASE N-METHYLTRANSFERASE OF PSEUDOMONAS-AERUGINOSA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR PROTEIN SECRETION; ESCHERICHIA-COLI; CHER METHYLTRANSFERASE; PULLULANASE SECRETION; KLEBSIELLA-OXYTOCA; PREPILIN PEPTIDASE; MOLECULAR-CLONING; BINDING-SITE; SEQUENCE; GENE	PilD is a bifunctional enzyme responsible for cleavage of the leader peptides from the precursors of the type IV pilin and four proteins with type IV pilin-like amino termini that are required for extracellular protein secretion in Pseudomonas aeruginosa. Following cleavage, PilD also catalyzes the second major post-translational modification of these proteins, namely the N-methylation of the amino-terminal phenylalanine residues of the mature polypeptides. In this report, we demonstrate that the enzymatic activities of PilD involve cysteine residues that lie within a cytoplasmic domain that shows a high degree of similarity to other proteins postulated to perform the same function in other bacterial species. Both activities are reduced in the presence of sulfhydryl-reactive reagents such as N-ethylmaleimide and p-chloromercuribenzoate. Mutagenesis of pilD resulting in specific amino acid substitutions in all of the Cys residues in PilD show that the 4 conserved cysteines in the cytoplasmic domain are required for full peptidase activity in vivo and for complete peptidase and methyltransferase activities in vitro. Conversely, substitution for a Cys residue in a membrane spanning domain had no effect on PilD activities in vivo or in vitro. Evidence suggests that the peptidase and methyltransferase sites of PilD are adjacent, with the Cys residues in the cytoplasmic domain important for methyl donor binding, as prior reaction of PilD with the S-adenosyl-L-methionine analogue sinefungin afforded complete protection of peptidase activity from inactivation with N-ethylmaleimide.							NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021451, R37AI021451] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21451] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLY M, 1992, MOL MICROBIOL, V6, P1121, DOI 10.1111/j.1365-2958.1992.tb01550.x; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; DUFOUR E, 1988, BIOCHIMIE, V70, P1335, DOI 10.1016/0300-9084(88)90004-1; DUPUY B, 1991, J BACTERIOL, V173, P7589, DOI 10.1128/jb.173.23.7589-7598.1991; DUPUY B, 1992, MOL MICROBIOL, V6, P1887, DOI 10.1111/j.1365-2958.1992.tb01361.x; FAHEY RC, 1978, J BACTERIOL, V133, P1126, DOI 10.1128/JB.133.3.1126-1129.1978; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GREENE PJ, 1981, J BIOL CHEM, V256, P2143; ISHIMOTO KS, 1992, J BACTERIOL, V174, P3514, DOI 10.1128/JB.174.11.3514-3521.1992; KAUFMAN MR, 1991, GENE DEV, V5, P1834, DOI 10.1101/gad.5.10.1834; KOGA T, 1993, INFECT IMMUN, V61, P1371, DOI 10.1128/IAI.61.4.1371-1377.1993; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAUER P, 1993, MOL MICROBIOL, V8, P357, DOI 10.1111/j.1365-2958.1993.tb01579.x; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1990, J BACTERIOL, V172, P1035, DOI 10.1128/jb.172.2.1035-1042.1990; MARRS CF, 1985, J BACTERIOL, V163, P132, DOI 10.1128/JB.163.1.132-139.1985; MCKERN NM, 1983, FEBS LETT, V164, P149, DOI 10.1016/0014-5793(83)80039-8; MEYER TF, 1984, P NATL ACAD SCI-BIOL, V81, P6110, DOI 10.1073/pnas.81.19.6110; Miller J. H, 1972, EXPT MOL GENETICS; MOHAN S, 1989, J BACTERIOL, V171, P6043, DOI 10.1128/jb.171.11.6043-6051.1989; NUNN D, 1990, J BACTERIOL, V172, P2911, DOI 10.1128/jb.172.6.2911-2919.1990; NUNN DN, 1991, P NATL ACAD SCI USA, V88, P3281, DOI 10.1073/pnas.88.8.3281; NUNN DN, 1992, P NATL ACAD SCI USA, V89, P47, DOI 10.1073/pnas.89.1.47; PAN T, 1989, P NATL ACAD SCI USA, V86, P3145, DOI 10.1073/pnas.86.9.3145; PASLOSKE BL, 1988, MOL MICROBIOL, V2, P489, DOI 10.1111/j.1365-2958.1988.tb00055.x; PUGSLEY AP, 1992, MOL MICROBIOL, V6, P751, DOI 10.1111/j.1365-2958.1992.tb01525.x; PUGSLEY AP, 1990, MOL MICROBIOL, V4, P365, DOI 10.1111/j.1365-2958.1990.tb00604.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SHAW CE, 1990, INFECT IMMUN, V58, P3042, DOI 10.1128/IAI.58.9.3042-3049.1990; SOM S, 1987, NUCLEIC ACIDS RES, V15, P313, DOI 10.1093/nar/15.1.313; Stock A, 1988, Adv Exp Med Biol, V231, P387; STROM MS, 1992, J BACTERIOL, V174, P7345, DOI 10.1128/jb.174.22.7345-7351.1992; STROM MS, 1991, J BIOL CHEM, V266, P1656; STROM MS, 1991, J BACTERIOL, V173, P1175, DOI 10.1128/jb.173.3.1175-1180.1991; STROM MS, 1987, J BACTERIOL, V169, P3181, DOI 10.1128/jb.169.7.3181-3188.1987; STROM MS, 1993, P NATL ACAD SCI USA, V90, P2404, DOI 10.1073/pnas.90.6.2404; SUBBARAMAIAH K, 1991, J BIOL CHEM, V266, P19023; SUBBARAMAIAH K, 1992, J BIOL CHEM, V267, P8636; TONJUM T, 1991, J GEN MICROBIOL, V137, P2483, DOI 10.1099/00221287-137-10-2483; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	44	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15788	15794						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340405				2022-12-27	WOS:A1993LN30500069
J	DMITRIEV, O; DECKERSHEBESTREIT, G; ALTENDORF, K				DMITRIEV, O; DECKERSHEBESTREIT, G; ALTENDORF, K			ATP SYNTHESIS ENERGIZED BY DELTA-PNA AND DELTA-PHI IN PROTEOLIPOSOMES CONTAINING THE F(0)F(1)-ATPASE FROM PROPIONIGENIUM-MODESTUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE-REDUCING BACTERIA; DECOMPOSE FATTY-ACIDS; ESCHERICHIA-COLI; ADENOSINE-TRIPHOSPHATASE; BETA-SUBUNIT; GEN-NOV; SYNTHASE; ENZYME; ION; RECONSTITUTION	After incorporation of the purified Na+-translocating F0F1-ATPase from Propionigenium modestum into preformed phospholipid vesicles the synthesis of ATP from ADP and inorganic phosphate could be observed under conditions where a valinomycin-mediated K+ diffusion potential (DELTAphi) and/or a Na+ concentration gradient (DELTApNa) were imposed. This reaction was not inhibited by the protonophore carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP). Furthermore, the DELTApNa-driven ATP synthesis was stimulated by FCCP. In contrast, the addition of the Na+/H+ antiporter monensin or of the F0F1 inhibitors N,N-dicyclohexylcarbodiimide and venturicidin abolished the synthesis of ATP completely. Finally, DELTApNa alone was able to elicit ATP synthesis, when a Na+ concentration gradient of sufficient magnitude was applied. In this case ATP synthesis occurred above a threshold level of approximately 120 mV and, furthermore, DELTAphi and DELTApNa appear to be equivalent as driving forces for this process. Therefore, the data provide firm evidence for the concept that DELTAmu''Na+ is the primary driving force for the synthesis of ATP in P. modestum.	UNIV OSNABRUCK,FACHBEREICH BIOL CHEM,ARBEITSGRP MIKROBIOL,BARBARASTR 11,W-4500 OSNABRUCK,GERMANY	University Osnabruck			Dmitriev, Oleg/AAB-7830-2019					ARNOLD A, 1976, ANAL BIOCHEM, V71, P209, DOI 10.1016/0003-2697(76)90029-4; BOKRANZ M, 1985, BIOCHIM BIOPHYS ACTA, V810, P332, DOI 10.1016/0005-2728(85)90218-X; DECKERSHEBESTREIT G, 1992, J BIOL CHEM, V267, P12364; DIMROTH P, 1992, BIOCHIM BIOPHYS ACTA, V1101, P236, DOI 10.1016/S0005-2728(05)80029-5; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FRIEDL P, 1979, EUR J BIOCHEM, V100, P175, DOI 10.1111/j.1432-1033.1979.tb02046.x; HEISE R, 1992, EUR J BIOCHEM, V206, P553, DOI 10.1111/j.1432-1033.1992.tb16959.x; HILPERT W, 1984, EMBO J, V3, P1665, DOI 10.1002/j.1460-2075.1984.tb02030.x; IWAMOTO A, 1991, J BIOL CHEM, V266, P16350; JUNESCH U, 1985, BIOCHIM BIOPHYS ACTA, V809, P429, DOI 10.1016/0005-2728(85)90194-X; JUNESCH U, 1987, BIOCHIM BIOPHYS ACTA, V893, P275, DOI 10.1016/0005-2728(87)90049-1; JUNESCH U, 1991, FEBS LETT, V294, P275, DOI 10.1016/0014-5793(91)81447-G; KIMMICH GA, 1975, ANAL BIOCHEM, V69, P187, DOI 10.1016/0003-2697(75)90580-1; KLUGE C, 1992, BIOCHEMISTRY-US, V31, P12665, DOI 10.1021/bi00165a017; LAUBINGER W, 1987, EUR J BIOCHEM, V168, P475, DOI 10.1111/j.1432-1033.1987.tb13441.x; LAUBINGER W, 1990, BIOCHEMISTRY-US, V29, P5458, DOI 10.1021/bi00475a008; LAUBINGER W, 1988, BIOCHEMISTRY-US, V27, P7531, DOI 10.1021/bi00419a053; LAUBINGER W, 1989, BIOCHEMISTRY-US, V28, P7194, DOI 10.1021/bi00444a010; Linnett P E, 1979, Methods Enzymol, V55, P472; MATSUNOYAGI A, 1993, J BIOL CHEM, V268, P1539; SCHMIDT G, 1987, BIOCHIM BIOPHYS ACTA, V890, P392, DOI 10.1016/0005-2728(87)90168-X; SENIOR AE, 1984, ARCH BIOCHEM BIOPHYS, V228, P49, DOI 10.1016/0003-9861(84)90045-6; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SLOOTEN L, 1989, BIOCHIM BIOPHYS ACTA, V975, P148, DOI 10.1016/S0005-2728(89)80213-0; SONE N, 1977, J BIOCHEM-TOKYO, V82, P1751, DOI 10.1093/oxfordjournals.jbchem.a131873; SONE N, 1977, J BIOL CHEM, V252, P2956; TAKEDA K, 1985, J BIOCHEM-TOKYO, V97, P1401, DOI 10.1093/oxfordjournals.jbchem.a135194; WIDDEL F, 1983, ARCH MICROBIOL, V134, P286, DOI 10.1007/BF00407804; WIDDEL F, 1981, ARCH MICROBIOL, V129, P395, DOI 10.1007/BF00406470; WIDDEL F, 1980, THESIS U GOTTINGEN G	31	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14776	14780						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325855				2022-12-27	WOS:A1993LL75900039
J	HARRIS, DE; WARSHAW, DM				HARRIS, DE; WARSHAW, DM			SMOOTH AND SKELETAL-MUSCLE MYOSIN BOTH EXHIBIT LOW DUTY CYCLES AT ZERO LOAD IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE KINESIN MOLECULES; ACTIN-FILAMENTS; SLIDING MOVEMENT; VELOCITY; MICROTUBULES; TROPOMYOSIN; TRANSPORT; MOTION	Smooth muscle's stress equals that of skeletal muscle with less myosin. Thus, under isometric conditions, smooth muscle myosin may spend a greater fraction of its cycle time attached to actin in a high force state (i.e. higher duty cycle). If so, then smooth muscle myosin may also have a higher duty cycle under unloaded conditions. To test this, we used an in vitro motility assay in which fluorescently labeled actin filaments move freely over a sparsely coated (5-100 mug/ml) myosin surface. Actin filament velocity (V) was a function of the number of cross-bridges capable of interacting with an actin filament (N) and the duty cycle (f), V = (a x V(max)) x (1 - (1 - f)N) (Uyeda et al., 1990; Harada et al., 1990). N was estimated from the myosin density on the motility surface and the actin filament length. Data for V versus N were fit to the above equation to predict f. The duty cycle of smooth muscle myosin (4.0 +/- 0.7%) was not significantly different from that of skeletal muscle myosin (3.8 +/- 0.5%) in agreement with values estimated by Uyeda et al. (1990) for skeletal muscle myosin under unloaded conditions. The duty cycles of smooth and skeletal muscle myosin may still differ under isometric conditions.			HARRIS, DE (corresponding author), UNIV VERMONT, DEPT MOLEC PHYSIOL & BIOPHYS, BURLINGTON, VT 05405 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045161] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR034872] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45161] Funding Source: Medline; NIAMS NIH HHS [AR34872] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; EISENBERG E, 1980, BIOPHYS J, V29, P195, DOI 10.1016/S0006-3495(80)85126-5; FINER J, 1992, PHYSIOLOGIST, V35, P87; GOLDMAN YE, 1977, J PHYSIOL-LONDON, V269, pP55; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HARADA Y, 1987, NATURE, V326, P805, DOI 10.1038/326805a0; HARRINGTON WF, 1984, ANNU REV BIOCHEM, V53, P35, DOI 10.1146/annurev.bi.53.070184.000343; HARRIS DE, 1990, J GEN PHYSIOL, V96, P581, DOI 10.1085/jgp.96.3.581; HIGUCHI H, 1991, NATURE, V352, P353; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; KIEHART DP, 1990, CELL, V60, P347, DOI 10.1016/0092-8674(90)90583-Z; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; MILLER RH, 1985, J CELL BIOL, V101, P2181, DOI 10.1083/jcb.101.6.2181; MURPHY RA, 1974, J GEN PHYSIOL, V64, P691, DOI 10.1085/jgp.64.6.691; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; ROSENFELD SS, 1984, J BIOL CHEM, V259, P1908; SCHROER TA, 1991, ANNU REV PHYSIOL, V53, P629, DOI 10.1146/annurev.ph.53.030191.003213; SELLERS JR, 1990, SCIENCE, V249, P406, DOI 10.1126/science.2377894; SHEETZ MP, 1983, NATURE, V303, P31, DOI 10.1038/303031a0; SPUDICH JA, 1990, NATURE, V348, P284, DOI 10.1038/348284a0; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TOYOSHIMA YY, 1989, NATURE, V341, P154, DOI 10.1038/341154a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; VALE RD, 1987, ANNU REV CELL BIOL, V3, P347, DOI 10.1146/annurev.cb.03.110187.002023; VANBUREN P, 1993, BIOPHYS J, V64, pA230; WAKABAYASHI T, 1975, J MOL BIOL, V93, P477, DOI 10.1016/0022-2836(75)90241-7; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WORK SS, 1992, ANAL BIOCHEM, V202, P275, DOI 10.1016/0003-2697(92)90106-H; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0	35	138	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14764	14768						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325853				2022-12-27	WOS:A1993LL75900037
J	IWATA, M; WIGHT, TN; CARLSON, SS				IWATA, M; WIGHT, TN; CARLSON, SS			A BRAIN EXTRACELLULAR-MATRIX PROTEOGLYCAN FORMS AGGREGATES WITH HYALURONAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; SMOOTH-MUSCLE CELLS; ELECTRON-MICROSCOPIC CHARACTERIZATION; CARTILAGE PROTEOGLYCANS; PROTEINS; VERSICAN; BINDING; NERVE; CORE	Unlike many tissues, the adult central nervous system extracellular matrix (ECM) has few known components. Previously, we characterized a large chondroitin sulfate proteoglycan, pgT1, from adult rat brain which has the properties of a general brain ECM component and is immunologically distinct from aggrecan and versican (Iwata, M., and Carlson, S. S. (1993) J. Neurosci. 13, 195-207). In this study we demonstrate that pgT1 binds hyaluronan with relatively high affinity. The pgT1 preparation isolated from rat brain aggregates in non-denaturing conditions. This aggregation is abolished by incubation of pgT1 with Streptomyces hyaluronidase. Examination of these aggregates by electron microscope reveals a structure in which an average of 18 subunits arise laterally from opposite sides of an elongated 350-nm filament. These pgT1 aggregates resemble the proteoglycan aggregates in cartilage which are composed of aggrecan and hyaluronan. Using affinity coelectrophoresis, we measure a dissociation constant (K(d)) of 0.9 +/- 0.2 nM for the interaction of pgT1 and hyaluronan. These new findings, combined with the general distribution of pgT1 in brain, suggest that pgT1/hyaluronan aggregates are an extended general structure of the brain extracellular matrix network.	UNIV WASHINGTON,DEPT PHYSIOL & BIOPHYS,SJ-40,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL 18645] Funding Source: Medline; NINDS NIH HHS [NS22367] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022367] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AQUINO DA, 1984, J CELL BIOL, V99, P1117, DOI 10.1083/jcb.99.3.1117; ATKINS EDT, 1974, POLYMER, V15, P263, DOI 10.1016/0032-3861(74)90122-0; AXELSSON I, 1983, J BIOL CHEM, V238, P8915; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BUCKWALTER JA, 1983, J BONE JOINT SURG AM, V65, P958, DOI 10.2106/00004623-198365070-00011; BUCKWALTER JA, 1982, J BIOL CHEM, V257, P9830; BURNETTE WN, 1981, ANAL BIOCHEM, V122, P364; CARLSON SS, 1987, J CELL BIOL, V105, P3075, DOI 10.1083/jcb.105.6.3075; CHANG Y, 1983, J BIOL CHEM, V258, P5679; CLELAND RL, 1977, J BIOL CHEM, V252, P420; FALTZ LL, 1979, J BIOL CHEM, V254, P1375; FRYER HJL, 1992, J BIOL CHEM, V267, P9874; GORDON CN, 1968, BIOCHIM BIOPHYS ACTA, V155, P305, DOI 10.1016/0005-2787(68)90363-8; HAMAI A, 1989, AGR BIOL CHEM TOKYO, V53, P2163, DOI 10.1080/00021369.1989.10869625; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HARDINGHAM TE, 1976, BIOCHEM J, V157, P127, DOI 10.1042/bj1570127; HASCALL GK, 1980, J ULTRA MOL STRUCT R, V70, P369, DOI 10.1016/S0022-5320(80)80019-0; HASCALL VC, 1988, ISI ATLAS-BIOCHEM, V1, P189; HEINEGARD D, 1978, BIOCHEM J, V175, P913, DOI 10.1042/bj1750913; HEINEGARD D, 1987, METHOD ENZYMOL, V144, P319; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; IOZZO R V, 1982, Journal of Biological Chemistry, V257, P11135; IWATA M, 1993, J NEUROSCI, V13, P195; IWATA M, 1991, J BIOL CHEM, V266, P323; KIMURA JH, 1978, J BIOL CHEM, V253, P4721; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; MARGOLIS RU, 1967, BIOCHIM BIOPHYS ACTA, V141, P91, DOI 10.1016/0304-4165(67)90248-6; PAULSSON M, 1987, COLLAGEN REL RES, V7, P443; PECHAK DG, 1985, J CELL BIOL, V100, P1767, DOI 10.1083/jcb.100.5.1767; PERIDES G, 1992, J BIOL CHEM, V267, P23883; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RAUCH U, 1991, J BIOL CHEM, V266, P14785; ROSENBERG L, 1975, J BIOL CHEM, V250, P1877; ROSENBERG L, 1970, J BIOL CHEM, V245, P4123; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; SCHONHERR E, 1991, J BIOL CHEM, V266, P17640; THYBERG J, 1975, BIOCHEM J, V151, P157, DOI 10.1042/bj1510157; UNDERHILL CB, 1989, CIBA FDN S, V143, P87; VOGEL H, 1992, J NEUROCYTOL, V21, P363, DOI 10.1007/BF01191704; WETLAUFER DB, 1973, ANNU REV BIOCHEM, V42, P135, DOI 10.1146/annurev.bi.42.070173.001031; Wight T. N., 1991, CELL BIOL EXTRACELLU; WIGHT TN, 1983, J CELL BIOL, V96, P167, DOI 10.1083/jcb.96.1.167; ZAREMBA S, 1989, NEURON, V2, P1207, DOI 10.1016/0896-6273(89)90305-X; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	46	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15061	15069						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325882				2022-12-27	WOS:A1993LL75900077
J	HWANG, CS; KOLATTUKUDY, PE				HWANG, CS; KOLATTUKUDY, PE			MOLECULAR-CLONING AND SEQUENCING OF THIOESTERASE-B CDNA AND STIMULATION OF EXPRESSION OF THE THIOESTERASE-B GENE ASSOCIATED WITH HORMONAL INDUCTION OF PEROXISOME PROLIFERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN ACYL-COA; FATTY-ACID SYNTHASE; RAT MAMMARY-GLAND; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; UROPYGIAL GLANDS; PRODUCT SPECIFICITY; NUCLEOTIDE-SEQUENCE; HYDROLASE ACTIVITY; TARGETING SIGNAL	The primary structure deduced from the cDNA of a medium-chain fatty acyl-CoA hydrolase designated thioesterase B from the uropygial gland of mallard duck was determined. A near full-length thioesterase B cDNA was isolated from a duck uropygial gland cDNA library using a 120-base pair polymerase chain reaction probe generated from first strand of cDNA and primers synthesized on the basis of two segments of the enzyme. The nucleotide sequence of this cDNA showed an open reading frame encoding a polypeptide of 557 amino acids including a 25-amino acid leader sequence. It showed little homology to the thioesterase domain of fatty acid synthase and S-acyl fatty acid synthase thioesterase, but showed homology to some esterases such as carboxylesterases. Northern blot showed one major transcript at 2.4 kilobases. The highest level of this transcript was in the uropygial gland, much less in the liver and kidney, and not detectable in other organs. Elevation of thioesterase B transcript level was associated with peroxisome proliferation occurring in the mating season and the increase in transcript level correlated with peroxisome proliferation and synthesis of 3-hydroxyfatty acid diester pheromones resulting from estradiol treatment. This thioesterase may be associated with peroxisome proliferation or peroxisomal metabolism.	OHIO STATE UNIV, OHIO STATE BIOTECHNOL CTR, 206 RIGHTMIRE HALL, 1060 CARMACK RD, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, BIOCHEM PROGRAM, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			kolattukudy, pappachan e/A-1350-2012		NCI NIH HHS [CA58035] Funding Source: Medline; NIGMS NIH HHS [GM-18278] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018278] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXSON SEH, 1988, J BIOL CHEM, V263, P13564; ARPAGAUS M, 1990, BIOCHEMISTRY-US, V29, P124, DOI 10.1021/bi00453a015; ASIEDU D, 1992, LIPIDS, V27, P241, DOI 10.1007/BF02536469; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BERGE RK, 1985, BIOCHIM BIOPHYS ACTA, V837, P141, DOI 10.1016/0005-2760(85)90237-1; BERGE RK, 1984, INT J BIOCHEM, V16, P403, DOI 10.1016/0020-711X(84)90139-3; BERGE RK, 1981, BIOCHEM J, V199, P639, DOI 10.1042/bj1990639; BERGE RK, 1984, EUR J BIOCHEM, V141, P637, DOI 10.1111/j.1432-1033.1984.tb08239.x; BOHNET S, 1991, J BIOL CHEM, V266, P9795; BONNER WM, 1972, J BIOL CHEM, V247, P3123; CHEESBROUGH TM, 1985, ARCH BIOCHEM BIOPHYS, V237, P208, DOI 10.1016/0003-9861(85)90271-1; DAYHOFF MO, 1972, ATLAS PROTEIN SEQUEN, V5, P53; DERENOBALES M, 1980, ARCH BIOCHEM BIOPHYS, V205, P464, DOI 10.1016/0003-9861(80)90129-0; EVERS ME, 1991, FEMS MICROBIOL LETT, V90, P73, DOI 10.1016/0378-1097(91)90649-U; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GRIMALDI PA, 1992, P NATL ACAD SCI USA, V89, P10930, DOI 10.1073/pnas.89.22.10930; HENRY MF, 1992, CELL, V70, P671, DOI 10.1016/0092-8674(92)90435-F; HEYMANN E, 1982, METABOLIC BASIS DETO, P229; HIREMATH LS, 1992, EUR J BIOCHEM, V203, P449, DOI 10.1111/j.1432-1033.1992.tb16569.x; KATOH H, 1984, BIOCHEM PHARMACOL, V33, P1081, DOI 10.1016/0006-2952(84)90517-3; KAUER TE, 1978, BIOCHEM J, V179, P515; KAWASHIMA Y, 1983, BIOCHIM BIOPHYS ACTA, V750, P365, DOI 10.1016/0005-2760(83)90041-3; KNUDSEN J, 1976, BIOCHEM J, V160, P683, DOI 10.1042/bj1600683; KOLATTUKUDY PE, 1987, J LIPID RES, V28, P582; KORZA G, 1988, J BIOL CHEM, V263, P3486; LEE KY, 1979, J BIOL CHEM, V254, P4516; LIBERTINI LJ, 1978, J BIOL CHEM, V253, P1393; MANIATIS T, 1982, MOL CLONING LABORATO, P326; MATSUNAGA T, 1985, EUR J BIOCHEM, V152, P331, DOI 10.1111/j.1432-1033.1985.tb09202.x; MENTLEIN R, 1984, ARCH BIOCHEM BIOPHYS, V228, P230, DOI 10.1016/0003-9861(84)90064-X; MENTLEIN R, 1984, BIOCHEM PHARMACOL, V33, P1243, DOI 10.1016/0006-2952(84)90176-X; MENTLEIN R, 1985, BIOCHEM J, V232, P479, DOI 10.1042/bj2320479; MENTLEIN R, 1985, ARCH BIOCHEM BIOPHYS, V240, P801, DOI 10.1016/0003-9861(85)90089-X; MENTLEIN R, 1986, J BIOL CHEM, V261, P7816; NAGGERT J, 1991, J BIOL CHEM, V266, P11044; NUTTLEY WM, 1990, J CELL SCI, V95, P463; OHLROGGE JB, 1978, ARCH BIOCHEM BIOPHYS, V189, P382, DOI 10.1016/0003-9861(78)90225-4; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; POULOSE AJ, 1985, J BIOL CHEM, V260, P5953; RANDHAWA ZI, 1987, BIOCHEMISTRY-US, V26, P1365, DOI 10.1021/bi00379a024; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; ROBBI M, 1991, J BIOL CHEM, V266, P20498; ROGERS L, 1982, J BIOL CHEM, V257, P880; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SIKORAV JL, 1987, EMBO J, V6, P1865, DOI 10.1002/j.1460-2075.1987.tb02445.x; SPENCER AK, 1978, J BIOL CHEM, V253, P5922; SULTER GJ, 1990, ARCH MICROBIOL, V153, P485, DOI 10.1007/BF00248431; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; TAKAGI Y, 1988, J BIOCHEM-TOKYO, V104, P801, DOI 10.1093/oxfordjournals.jbchem.a122553; TSUJITA T, 1992, J BIOL CHEM, V267, P23489; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; YABUSAKI KK, 1979, J BIOL CHEM, V254, P2314; YANG CY, 1988, BIOCHEMISTRY-US, V27, P7773, DOI 10.1021/bi00420a028	57	23	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14278	14284						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314791				2022-12-27	WOS:A1993LJ82500073
J	TRANGUCH, AJ; ENGELKE, DR				TRANGUCH, AJ; ENGELKE, DR			COMPARATIVE STRUCTURAL-ANALYSIS OF NUCLEAR RNASE-P RNAS FROM YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYLOGENETIC COMPARATIVE-ANALYSIS; RIBONUCLEASE-P; SECONDARY STRUCTURE; ESCHERICHIA-COLI; M1 RNA; CATALYTIC SUBUNIT; SEQUENCE-ANALYSIS; SACCHAROMYCES; COMPONENT; GENE	Secondary structure models for yeast nuclear RNase P RNAs were derived by phylogenetic comparative analysis. RNase P RNA genes from six Saccharomyces species were characterized and compared with the published gene sequences of Saccharomyces cerevisiae (RPR1), Schizosaccharomyces pombe, and Schizosaccharomyces octosporus. The general organization of the Saccharomyces genes were similar: all were present in single copy and contained RNA polymerase III-specific regulatory elements, including tRNA gene-like A- and B-box promoters located within 5' leader regions and poly(T) terminators following the mature RNA domain. As observed previously, two RNase P RNAs were present in each of the species: a shorter RNA corresponding to the mature domain and a longer possible precursor RNA that includes the 5' leader sequences. The mature RNA domains of three of these genes were sufficiently divergent from the S. cerevisiae RNA such that compensatory base changes in paired elements were readily identified, yet homologous regions could be aligned. A striking common core of primary and secondary structure emerged for the Saccharomyces RNase P RNAs. Furthermore, the Schizosaccharomyces homologs conformed in large part to the Saccharomyces conserved core and shared with it a distinctive structural domain that has so far only been observed in the yeast nuclear RNase P RNAs. Comparison of the yeast core to a previously published eubacterial conserved core and to the RNA homologs from vertebrates revealed a number of similarities, suggesting that RNase P RNA from diverse sources may share a core of structurally conserved elements.	UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					NCI NIH HHS [P30CA46592] Funding Source: Medline; NCRR NIH HHS [M01 RR00042] Funding Source: Medline; NIGMS NIH HHS [GM 34869] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034869] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN S, 1989, ADV ENZYMOL RAMB, V62, P1; BARNS SM, 1991, J BACTERIOL, V173, P2250, DOI 10.1128/JB.173.7.2250-2255.1991; BARTKIEWICZ M, 1989, GENE DEV, V3, P488, DOI 10.1101/gad.3.4.488; BICKNELL JN, 1970, J BACTERIOL, V101, P505, DOI 10.1128/JB.101.2.505-512.1970; Boeke J.D., 1991, MOL CELLULAR BIOL YE, V1, P193; BROWN JW, 1990, CELL, V62, P407, DOI 10.1016/0092-8674(90)90003-W; BROWN JW, 1991, COMPUT APPL BIOSCI, V7, P391; BROWN JW, 1991, BIOCHIMIE, V73, P689, DOI 10.1016/0300-9084(91)90049-7; BURGIN AB, 1990, EMBO J, V9, P4111, DOI 10.1002/j.1460-2075.1990.tb07633.x; CHASTAIN M, 1991, PROG NUCLEIC ACID RE, V41, P131; CULBERTSON MR, 1989, YEAST, V5, P405, DOI 10.1002/yea.320050602; DARR SC, 1990, J BIOL CHEM, V265, P12927; DARR SC, 1992, TRENDS BIOCHEM SCI, V17, P178, DOI 10.1016/0968-0004(92)90262-8; DARR SC, 1992, BIOCHEMISTRY-US, V31, P328, DOI 10.1021/bi00117a003; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DORIA M, 1991, NUCLEIC ACIDS RES, V19, P2315, DOI 10.1093/nar/19.9.2315; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FOX GE, 1975, NATURE, V256, P505, DOI 10.1038/256505a0; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GUERRIERTAKADA C, 1984, BIOCHEMISTRY-US, V23, P6327, DOI 10.1021/bi00321a006; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HAAS ES, 1991, SCIENCE, V254, P853, DOI 10.1126/science.1719634; HOLLINGSWORTH MJ, 1986, MOL CELL BIOL, V6, P1058, DOI 10.1128/MCB.6.4.1058; JAMES BD, 1989, METHOD ENZYMOL, V180, P227; JAMES BD, 1988, CELL, V52, P19, DOI 10.1016/0092-8674(88)90527-2; JAYANTHI GP, 1992, ARCH BIOCHEM BIOPHYS, V296, P264, DOI 10.1016/0003-9861(92)90571-D; KIM SH, 1978, TRANSFER RNA, P248; KRUPP G, 1986, EMBO J, V5, P1697, DOI 10.1002/j.1460-2075.1986.tb04413.x; KURTZMAN CP, 1991, YEAST, V7, P61, DOI 10.1002/yea.320070107; LAWRENCE NP, 1986, J MOL BIOL, V191, P163, DOI 10.1016/0022-2836(86)90253-6; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6986, DOI 10.1073/pnas.88.16.6986; LEE JY, 1989, MOL CELL BIOL, V9, P2536, DOI 10.1128/MCB.9.6.2536; LEE JY, 1991, MOL CELL BIOL, V11, P721, DOI 10.1128/MCB.11.2.721; LEVITT M, 1969, NATURE, V224, P759, DOI 10.1038/224759a0; LUMELSKY N, 1988, J MOL BIOL, V202, P443, DOI 10.1016/0022-2836(88)90277-X; MILLER DL, 1983, CELL, V34, P911, DOI 10.1016/0092-8674(83)90548-2; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NIEUWLANDT DT, 1991, J BIOL CHEM, V266, P5689; NOLLER HF, 1981, SCIENCE, V212, P403, DOI 10.1126/science.6163215; PACE NR, 1990, J BIOL CHEM, V265, P3587; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REED RE, 1982, CELL, V30, P627, DOI 10.1016/0092-8674(82)90259-8; REICH C, 1986, J BIOL CHEM, V261, P7888; Sambrook J, 1989, MOL CLONING LABORATO; SANDMEYER SB, 1990, ANNU REV GENET, V24, P491; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHU HH, 1991, MOL CELL BIOL, V11, P1662, DOI 10.1128/MCB.11.3.1662; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TABOR S, 1987, J BIOL CHEM, V262, P16212; WAUGH DS, 1993, FASEB J, V7, P188, DOI 10.1096/fasebj.7.1.7678561; ZIMMERLY S, 1990, FEBS LETT, V271, P189, DOI 10.1016/0014-5793(90)80403-6; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	54	71	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14045	14053						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314772				2022-12-27	WOS:A1993LJ82500042
J	WANG, Y; VONHIPPEL, PH				WANG, Y; VONHIPPEL, PH			ESCHERICHIA-COLI TRANSCRIPTION TERMINATION FACTOR-RHO .1. ATPASE ACTIVATION BY OLIGONUCLEOTIDE COFACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMBDA-PR PROMOTER; CRO MESSENGER-RNA; DEPENDENT TERMINATION; SECONDARY STRUCTURE; GENE-EXPRESSION; PROTEIN; SITES; SPECIFICITY; POLYMERASE; HYDROLYSIS	Rho protein is required to bring about RNA release from Escherichia coli transcription complexes paused at specific (rho-dependent) termination sites. Rho functions in termination as a hexamer of identical subunits arranged in D3 symmetry, with each rho subunit carrying an RNA- and an ATP-binding site. The detailed mechanism of rho-catalyzed transcript release remains to be determined, but it is clear that the RNA-dependent ATPase activity that is stimulated by interaction with the nascent transcript is essential to the termination function of rho. In this study, we have used short (8-10 nucleotide residues) synthetic ribo-oligonucleotides to model the interaction of segments of the RNA cofactor with rho. A poly(dC) enhancement procedure was used to permit the measurement of steady state ATPase parameters. We show that (i) ATPase activation is cofactor composition- and sequence-dependent; (ii) at least 60% of the residues of these short RNA cofactors must be cytosine to produce maximal rho ATPase activation; (iii) oligo(rU,rC) co: factors with the rU residues located at the 5' termini of the oligomer are much better ATPase cofactors than oligomers containing rC residues only; (iv) this enhanced stimulation is not observed if the rU residues are replaced by rA residues; (v) this cofactor activity relative to oligo(rC) is reversed if the rU residues are placed at the 3' terminus of RNA oligomer; and (vi) these nucleotide sequence and composition effects do not appear to be functions of K+ or Mg2+ concentration. These ATPase activation results are correlated with the binding to rho of oligonucleotide cofactors in the accompanying paper (Wang, Y., and von Hippel, P. H. (1993) J. Biol. Chem. 268,13947-13955).	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; University of Oregon				von Hippel, Peter H./0000-0003-2512-8097	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015792, R01GM029158, R01GM015792] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-15792, GM-29158] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1979, P NATL ACAD SCI USA, V76, P1613, DOI 10.1073/pnas.76.4.1613; ALIFANO P, 1991, CELL, V64, P553; ANDRUS A, 1988, ABI USER B, V47, P1; BEAR D G, 1991, Journal of Cellular Biochemistry Supplement, P239; BEAR DG, 1988, TRENDS BIOCHEM SCI, V13, P343, DOI 10.1016/0968-0004(88)90104-1; BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BRENNAN CA, 1990, J BIOL CHEM, V265, P5440; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; CANTOR CR, 1965, J MOL BIOL, V13, P65, DOI 10.1016/S0022-2836(65)80080-8; CANTOR CR, 1970, BIOPOLYMERS, V9, P1059, DOI 10.1002/bip.1970.360090909; CASHEL M, 1969, J CHROMATOGR, V40, P103, DOI 10.1016/S0021-9673(01)96624-5; CERUZZI MAF, 1985, J BIOL CHEM, V260, P9412; CHEN CYA, 1986, CELL, V46, P1023, DOI 10.1016/0092-8674(86)90701-4; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; Fasman G. D., 1975, HDB BIOCH MOL BIOL, V1; FAUS I, 1989, BIOCHEMISTRY-US, V28, P3510, DOI 10.1021/bi00434a054; GALLUPPI G, 1976, RNA POLYMERASE, P657; GALLUPPI G, 1980, J MOL BIOL, V138, P5513; GEISELMANN J, 1992, PROTEIN SCI, V1, P861, DOI 10.1002/pro.5560010704; GEISELMANN J, 1992, PROTEIN SCI, V1, P850, DOI 10.1002/pro.5560010703; HART CM, 1991, J BIOL CHEM, V266, P24140; HOWARD BH, 1976, J BIOL CHEM, V251, P2520; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; LAU LF, 1982, P NATL ACAD SCI-BIOL, V79, P6171, DOI 10.1073/pnas.79.20.6171; LOWERY C, 1977, J BIOL CHEM, V252, P1375; LOWERY C, 1977, J BIOL CHEM, V252, P1381; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; MCSWIGGEN JA, 1985, THESIS U OREGON EUGE; MORGAN WD, 1984, J BIOL CHEM, V259, P8664; MORGAN WD, 1985, NUCLEIC ACIDS RES, V13, P3739, DOI 10.1093/nar/13.10.3739; MORGAN WD, 1983, J BIOL CHEM, V258, P9565; MORGAN WD, 1983, J BIOL CHEM, V258, P9553; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P88, DOI 10.1073/pnas.82.1.88; NEHRKE KW, 1992, NUCLEIC ACIDS RES, V20, P6107, DOI 10.1093/nar/20.22.6107; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; PLATT T, 1992, TRANSCRIPTIONAL REGU, P365; REISBIG RR, 1981, BIOCHEMISTRY-US, V20, P1907, DOI 10.1021/bi00510a029; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; RICHARDSON JP, 1980, BIOCHEMISTRY-US, V19, P4293, DOI 10.1021/bi00559a022; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; SEIFRIED SE, 1992, P NATL ACAD SCI USA, V89, P10454, DOI 10.1073/pnas.89.21.10454; SHARP JA, 1984, J BIOL CHEM, V259, P2268; VONHIPPEL PH, 1991, P NATL ACAD SCI USA, V88, P2307, DOI 10.1073/pnas.88.6.2307; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; WANG Y, 1993, J BIOL CHEM, V268, P13947; WARSHAW MM, 1965, J MOL BIOL, V13, P54, DOI 10.1016/S0022-2836(65)80079-1; WU AM, 1981, P NATL ACAD SCI-BIOL, V78, P2913, DOI 10.1073/pnas.78.5.2913; YAGER TD, 1987, MOL CELL BIOL E COLI, P1241; ZALATAN F, 1992, J BIOL CHEM, V267, P19082	49	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13940	13946						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314760				2022-12-27	WOS:A1993LJ82500028
J	WU, WI; LIN, YP; WANG, E; MERRILL, AH; CARMAN, GM				WU, WI; LIN, YP; WANG, E; MERRILL, AH; CARMAN, GM			REGULATION OF PHOSPHATIDATE PHOSPHATASE-ACTIVITY FROM THE YEAST SACCHAROMYCES-CEREVISIAE BY SPHINGOID BASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOLIPID BIOSYNTHESIS; MIXED MICELLES; HUMAN-PLATELETS; INOSITOL; INHIBITION; CELLS; PHOSPHOHYDROLASE; SPHINGOLIPIDS; METABOLISM	The regulation of Saccharomyces cerevisiae membrane-associated phosphatidate phosphatase (3-sn-phosphatidate phosphohydrolase, EC 3.1.3.4) activity by sphingoid bases was examined using Triton X-100/lipid-mixed micelles. Sphingosine, phytosphingosine, and sphinganine inhibited purified preparations of the 104- and 45-kDa forms of phosphatidate phosphatase in a dose-dependent manner. The structural requirements for the sphingoid base inhibition of phosphatidate phosphatase activity were a free amino group and a long chain hydrocarbon. A detailed kinetic analysis was performed to determine the mechanism of phosphatidate phosphatase inhibition by sphingoid bases. The phosphatidate phosphatase dependence on phosphatidate was cooperative (Hill numbers of approximately 2) in the absence and presence of sphingoid bases. Sphingosine, phytosphingosine, and sphinganine were parabolic competitive inhibitors of phosphatidate phosphatase activity. This indicated that more than one inhibitor molecule contributed to the exclusion of phosphatidate from the enzyme. The aK(i) values (inhibitor constants) for sphingosine, phytosphingosine, and sphinganine were 1.5, 0.4, and 0.2 mol %, respectively, and the K(m) value for phosphatidate was 2.2 mol %. The cellular concentrations of free phytosphingosine and sphinganine were 0.16 and 0.53 mol %, respectively, relative to the total phospholipids in S. cerevisiae. The cellular concentrations of phytosphingosine and sphinganine were in the range of the aK(i) values for these sphingoid bases. These results raised the suggestion that phosphatidate phosphatase activity may be regulated in vivo by sphingoid bases.	RUTGERS UNIV,COOK COLL,NEW JERSEY AGR EXPT STN,DEPT FOOD SCI,NEW BRUNSWICK,NJ 08903; EMORY UNIV,SCH MED,ROLLINS RES CTR,DEPT BIOCHEM,ATLANTA,GA 30322	Rutgers State University New Brunswick; Emory University				Merrill, Alfred/0000-0002-6673-968X	NIGMS NIH HHS [GM-28140, GM-33369] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028140, R01GM033369] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGUS WW, 1972, ARCH BIOCHEM BIOPHYS, V151, P483, DOI 10.1016/0003-9861(72)90525-5; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINDLEY DN, 1984, PROG LIPID RES, V23, P115, DOI 10.1016/0163-7827(84)90001-8; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CULBERTSON MR, 1975, GENETICS, V80, P23; EXTON JH, 1990, J BIOL CHEM, V265, P1; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1987, J BIOL CHEM, V262, P13620; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HANSON BA, 1980, J LIPID RES, V21, P309; HENRY SA, 1977, J BACTERIOL, V130, P472, DOI 10.1128/JB.130.1.472-484.1977; HOSAKA K, 1984, BIOCHIM BIOPHYS ACTA, V796, P110; Kates M., 1986, TECHNIQUES LIPIDOLOG, P186; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; Kennedy E. P., 1986, LIPIDS MEMBRANES PRE, P171; KISS Z, 1990, J BIOL CHEM, V265, P7345; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; LAVIE Y, 1990, FEBS LETT, V277, P7, DOI 10.1016/0014-5793(90)80796-L; LICHTENBERG D, 1983, BIOCHIM BIOPHYS ACTA, V737, P285, DOI 10.1016/0304-4157(83)90004-7; LIN YP, 1989, J BIOL CHEM, V264, P8641; LIN YP, 1990, J BIOL CHEM, V265, P166; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; MOORE TS, 1982, ANNU REV PLANT PHYS, V33, P235, DOI 10.1146/annurev.pp.33.060182.001315; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; OGITA K, 1990, P NATL ACAD SCI USA, V87, P5011, DOI 10.1073/pnas.87.13.5011; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; PINTO WJ, 1992, J BACTERIOL, V174, P2575, DOI 10.1128/jb.174.8.2575-2581.1992; QUINLAN JJ, 1992, J BIOL CHEM, V267, P18013; ROBSON RJ, 1983, ACCOUNTS CHEM RES, V16, P251, DOI 10.1021/ar00091a003; Segel IH., 1975, ENZYME KINETICS, P1, DOI 10.1016/0014-5793(75)80457-1; SMITH SW, 1957, J BIOL CHEM, V228, P915; SMITH SW, 1974, J BIOL CHEM, V249, P3395; STEINER MR, 1972, BIOCHIM BIOPHYS ACTA, V260, P222, DOI 10.1016/0005-2760(72)90035-5; STEVENS VL, 1990, BIOCHIM BIOPHYS ACTA, V1051, P37, DOI 10.1016/0167-4889(90)90171-9; TAYLOR FR, 1979, BIOCHIM BIOPHYS ACTA, V575, P204, DOI 10.1016/0005-2760(79)90022-5; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WANG E, 1991, J BIOL CHEM, V266, P14486; WELLS GB, 1983, J BIOL CHEM, V258, P200; ZWEERINK MM, 1992, J BIOL CHEM, V267, P25032	48	82	84	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13830	13837						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314751				2022-12-27	WOS:A1993LJ82500013
J	CRAXTON, A; ERNEUX, C; SHEARS, SB				CRAXTON, A; ERNEUX, C; SHEARS, SB			INOSITOL 1,4,5,6-TETRAKISPHOSPHATE IS PHOSPHORYLATED IN RAT-LIVER BY A 3-KINASE THAT IS DISTINCT FROM INOSITOL 1,4,5-TRISPHOSPHATE 3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOINOSITOL 1,3,4,5,6-PENTAKISPHOSPHATE; CELLS; METABOLISM; PHOSPHATES; TETRAKISPHOSPHATES; 3,4,5,6-TETRAKISPHOSPHATE; PENTAKISPHOSPHATE; EXPRESSION; RECEPTOR; ENZYMES	Liver homogenates phosphorylated inositol 1,4,5,6-tetrakisphosphate exclusively to inositol 1,3,4,5,6-pentakisphosphate. Approximately 30% of this phosphorylating activity was associated with the particulate fraction of the cell, in contrast to the inositol 3,4,5,6 tetrakisphosphate 1-kinase, which was 90% soluble. This soluble 1-kinase activity was resolved from the soluble activity that phosphorylated inositol 1,4,5,6 tetrakisphosphate by an-ion-exchange chromatography. The two phosphorylating activities were also found to be differentially inhibited by inositol 1,3,4-trisphosphate (IC50 for 3-kinase > 100 mu m; IC50 for 1-kinase < 1 mu M). Thus, we have demonstrated that inositol 1,4,5,6-tetrakisphosphate is phos phorylated directly by a 3-kinase, -and inositol 3,4,5,6 tetrakisphosphate is not an obligatory intermediate, in contrast to one previous model (Oliver, K. G., Putney, J. W., Jr., Obie, J. F., and Shears, S. B. (1992) J. Biol, Chem. 267, 21528-21534). Inositol 1,4,5,6-tetrakisphosphate 3-kinase was inhibited by inositol 1,3,4,6-tetrakisphosphate (IC50, 1 mu M). Soluble inositol 1,4,5,6-tetrakisphosphate 3-kinase and inositol 1,4,5-trisphosphate 3-kinase were resolved by anion exchange chromatography. Furthermore, cDNA clones of two isozymes of inositol 1,4,5-trisphosphate 3-kinase from rat and human brain did not phosphorylate inositol 1,4,5,6-tetrakisphosphate. Thus, these two 3-kinase activities are performed by distinct enzymes.	FREE UNIV BRUSSELS,SCH MED,INST INTERDISCIPLINARY RES,B-1070 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel	CRAXTON, A (corresponding author), NIEHS,CELLULAR & MOLEC PHARMACOL LAB,INOSITOL LIPID SECT,RES TRIANGLE PK,NC 27709, USA.		Shears, Stephen B/C-6335-2019	Shears, Stephen B/0000-0001-7309-8916				ALI N, 1993, J BIOL CHEM, V268, P6161; BALLA T, 1989, J BIOL CHEM, V264, P9386; BARKER CJ, 1992, BIOCHEM J, V286, P469, DOI 10.1042/bj2860469; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; ERNEUX C, 1991, TRENDS PHARMACOL SCI, V12, P174, DOI 10.1016/0165-6147(91)90539-5; IRVINE RF, 1992, BIOCHEM J, V281, P261, DOI 10.1042/bj2810261; Kirk CJ., 1990, PEPTIDE HORMONE ACTI, P151; MATTINGLY RR, 1991, J BIOL CHEM, V266, P15144; MCCONNELL FM, 1991, BIOCHEM J, V280, P323, DOI 10.1042/bj2800323; MENNITI FS, 1993, TRENDS BIOCHEM SCI, V18, P53, DOI 10.1016/0968-0004(93)90053-P; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; NOGIMORI K, 1991, J BIOL CHEM, V266, P16499; OLIVER KG, 1992, J BIOL CHEM, V267, P21528; POLOKOFF MA, 1988, J BIOL CHEM, V263, P11922; SAFRANY ST, 1991, FEBS LETT, V278, P252, DOI 10.1016/0014-5793(91)80128-P; Shears Stephen B., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P63; STEPHENS L, 1988, BIOCHEM J, V249, P271, DOI 10.1042/bj2490271; STEPHENS LR, 1988, BIOCHEM J, V253, P721, DOI 10.1042/bj2530721; STEPHENS LR, 1991, BIOCHEM J, V275, P485, DOI 10.1042/bj2750485; STEPHENS LR, 1990, BIOCHEM J, V265, P435, DOI 10.1042/bj2650435; TAKAZAWA K, 1990, BIOCHEM J, V272, P107, DOI 10.1042/bj2720107; TAKAZAWA K, 1991, BIOCHEM J, V278, P883, DOI 10.1042/bj2780883; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018	24	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4337	4342						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308002				2022-12-27	WOS:A1994MW98900069
J	DEBEER, MC; KINDY, MS; LANE, WS; DEBEER, FC				DEBEER, MC; KINDY, MS; LANE, WS; DEBEER, FC			MOUSE SERUM AMYLOID-A PROTEIN (SAA(5)) STRUCTURE AND EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; A GENE FAMILY; TRANSCRIPTIONAL REGULATION; GEL-ELECTROPHORESIS; CDNA SEQUENCES; MESSENGER-RNA; IDENTIFICATION; APOPROTEIN; APOLIPOPROTEIN; NITROCELLULOSE	A novel member of the mouse serum amyloid A protein family, SAA(5), has been identified as a normal apolipoprotein component of non-acute-phase high density lipoprotein (HDL). The structure of SAA(5) was derived from a clone isolated from a normal Balb/c liver cDNA library. The clone predicts a pre-SAA(5) molecule of 130 residues from which an 18-residue leader peptide is cleaved. The mature molecule has an octapeptide insert spanning from position 70 to 77. Similar inserts are found in human C-SAA and, paradoxically, in acute-phase SAA molecules of a number of other species. There is 48% amino acid identity between apo-SAA(5) and the other mouse SAA proteins and 57% identity between the human C-SAA and apo-SAA(5). The SAA, mRNA is three times larger than previously identified SAA mRNAs. Although SAA(5) is constitutively expressed in the liver, it has a rapid albeit muted response to inflammatory stimuli. The increase of SAA(5) mRNA is due to increased transcription rather than mRNA stabilization. Plasma SAA(5) levels during the acute phase are biphasic, either because of translational control or displacement from HDL and rapid clearance. We propose that constitutive SAAs (SAA(5)) on normal HDL contribute to its normal physiological role, whereas the dramatically inducible family members (SAA(1), SAA(2), SAA(3)) equip this particle for an altered functional role during inflammation.	UNIV KENTUCKY,MED CTR,DEPT MED,LEXINGTON,KY 40536; UNIV KENTUCKY,MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536; VET AFFAIRS MED CTR,LEXINGTON,KY 40511; HARVARD UNIV,MICROCHEM FACIL,CAMBRIDGE,MA 02138	University of Kentucky; University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center; Harvard University					NIAMS NIH HHS [AR 40379] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040379] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BENDITT EP, 1979, P NATL ACAD SCI USA, V76, P4092, DOI 10.1073/pnas.76.8.4092; BENSON MD, 1989, J LAB CLIN MED, V113, P67; BRISSETTE L, 1989, J BIOL CHEM, V264, P19327; COETZEE GA, 1986, J BIOL CHEM, V261, P9644; DEBEER MC, 1991, BIOCHEM J, V280, P45, DOI 10.1042/bj2800045; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; EISENBERG S, 1984, J LIPID RES, V25, P1017; ERIKSEN N, 1980, P NATL ACAD SCI-BIOL, V77, P6860, DOI 10.1073/pnas.77.11.6860; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FOLCH J, 1957, J BIOL CHEM, V226, P497; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HOFFMAN JS, 1983, J CLIN INVEST, V71, P926, DOI 10.1172/JCI110847; HOFFMAN JS, 1982, J BIOL CHEM, V257, P510; KINDY MS, 1986, J BIOL CHEM, V261, P2865; KISILEVSKY R, 1992, LAB INVEST, V66, P778; KLUVEBECKERMAN B, 1989, COMP BIOCHEM PHYS B, V94, P175, DOI 10.1016/0305-0491(89)90030-8; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LOWELL CA, 1986, J BIOL CHEM, V261, P8442; LOWELL CA, 1986, J BIOL CHEM, V261, P8453; MARHAUG G, 1990, J BIOL CHEM, V265, P10049; MCADAM KPWJ, 1976, J EXP MED, V144, P1121, DOI 10.1084/jem.144.4.1121; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MEEK RL, 1986, J EXP MED, V164, P2006, DOI 10.1084/jem.164.6.2006; MEEK RL, 1992, P NATL ACAD SCI USA, V89, P7949, DOI 10.1073/pnas.89.17.7949; MERCER JFB, 1985, NUCLEIC ACIDS RES, V13, P7929, DOI 10.1093/nar/13.22.7929; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELLAR GC, 1991, J BIOL CHEM, V266, P3505; SLETTEN K, 1989, SCAND J IMMUNOL, V30, P117, DOI 10.1111/j.1365-3083.1989.tb01195.x; STEARMAN RS, 1986, NUCLEIC ACIDS RES, V14, P797, DOI 10.1093/nar/14.2.797; STEEL DM, 1993, BIOCHEM J, V291, P701, DOI 10.1042/bj2910701; STRACHAN AF, 1988, BIOCHEM J, V250, P203, DOI 10.1042/bj2500203; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VORNDAM AV, 1986, ANAL BIOCHEM, V152, P221, DOI 10.1016/0003-2697(86)90401-X; WATSON G, 1992, SCAND J IMMUNOL, V36, P703, DOI 10.1111/j.1365-3083.1992.tb03131.x; WHITEHEAD AS, 1992, J BIOL CHEM, V267, P3862; YAMAMOTO K, 1985, P NATL ACAD SCI USA, V82, P2915, DOI 10.1073/pnas.82.9.2915	42	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4661	4667						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308037				2022-12-27	WOS:A1994MW98900112
J	GOLDBERG, MA; SCHNEIDER, TJ				GOLDBERG, MA; SCHNEIDER, TJ			SIMILARITIES BETWEEN THE OXYGEN-SENSING MECHANISMS REGULATING THE EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR AND ERYTHROPOIETIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL MITOGEN; PERMEABILITY FACTOR; MESSENGER-RNA; FACTOR FAMILY; GENE; HYPOXIA; PROTEIN; ENHANCER; CHEMORECEPTORS; ACCUMULATION	The ability to adapt successfully to periods of relative hypoxia is crucial to the survival of all higher life forms. Several genes have previously been identified which are up-regulated in response to hypoxia; these include the genes encoding erythropoietin (Epo), platelet derived growth factor B chain, endothelin, interleukin-1 alpha, ornithine decarboxylase, and vascular endothelial growth factor (VEGF). However, the molecular mechanisms by which hypoxia is sensed remain enigmatic. In addition, it is unknown whether the genes mentioned share a common oxygen-sensing signal transduction pathway. In this report we demonstrate multiple similarities between the oxygen-sensing mechanisms regulating the expression of VEGF and Epo. The expression of both mRNAs is significantly up-regulated by hypoxia and cobalt chloride (CoCl2), and the half-life of both mRNAs is markedly prolonged by cycloheximide. In addition, hypoxic induction of both Epo and VEGF is inhibited by carbon monoxide. As part of our investigation into the signal transduction pathway responsible for the hypoxia and cobalt induction of these genes, we discovered that the expression of members of the jun and fos protooncogene families is also up-regulated early after exposure to either of these stimuli. These findings provide support for the hypothesis that the mechanism(s) by which hypoxia is sensed at a molecular level may be highly conserved and tightly regulated.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	GOLDBERG, MA (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV HEMATOL ONCOL, 221 LONGWOOD AVE, LMRC 222, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045098] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45098] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKER H, 1989, ANNU REV PHYSIOL, V51, P835, DOI 10.1146/annurev.physiol.51.1.835; ADAIR TH, 1990, AM J PHYSIOL, V259, pR393, DOI 10.1152/ajpregu.1990.259.3.R393; BECK I, 1993, BLOOD, V82, P704; BECK I, 1991, J BIOL CHEM, V266, P15563; BERU N, 1986, MOL CELL BIOL, V6, P2571, DOI 10.1128/MCB.6.7.2571; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BONDURANT MC, 1986, MOL CELL BIOL, V6, P2731, DOI 10.1128/MCB.6.7.2731; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; COBURN RF, 1979, PREV MED, V8, P310, DOI 10.1016/0091-7435(79)90008-2; CONN G, 1990, P NATL ACAD SCI USA, V87, P1323, DOI 10.1073/pnas.87.4.1323; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; DIGIULIO C, 1990, J APPL PHYSIOL, V68, P1844, DOI 10.1152/jappl.1990.68.5.1844; ERSLEV AJ, 1987, J LAB CLIN MED, V109, P429; FAQUIN WC, 1993, EXP HEMATOL, V21, P420; FAQUIN WC, 1992, BLOOD, V79, P1987; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; GOLDBERG MA, 1991, BLOOD, V77, P271; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GOLDWASSER E, 1958, BLOOD, V13, P55, DOI 10.1182/blood.V13.1.55.55; HEISTAD DD, 1980, CIRCULATION, V61, P463, DOI 10.1161/01.CIR.61.3.463; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; JACOBSON LO, 1957, NATURE, V179, P633, DOI 10.1038/179633a0; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KNIGHTON DR, 1983, SCIENCE, V221, P1283, DOI 10.1126/science.6612342; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; KRANTZ SB, 1991, BLOOD, V77, P419; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy AP, 1989, GROWTH FACTORS, V2, P9, DOI 10.3109/08977198909069077; LONGO LD, 1993, P NATL ACAD SCI USA, V90, P692, DOI 10.1073/pnas.90.2.692; MADAN A, 1993, P NATL ACAD SCI USA, V90, P3928, DOI 10.1073/pnas.90.9.3928; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; Sambrook J, 1989, MOL CLONING LABORATO; SCHUSTER SJ, 1989, BLOOD, V73, P13; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHREENIWAS R, 1992, J CLIN INVEST, V90, P2333, DOI 10.1172/JCI116122; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STRYER L, 1988, BIOCHEMISTRY-US, P313; SUNDERMAN FW, 1982, YALE J BIOL MED, V55, P123; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VOELKEL NF, 1986, AM REV RESPIR DIS, V133, P1186; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; YOUNGSON C, 1993, NATURE, V365, P153, DOI 10.1038/365153a0; ZANJANI ED, 1977, J LAB CLIN MED, V89, P640	53	554	581	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4355	4359						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308005				2022-12-27	WOS:A1994MW98900072
J	LI, YY; INOUYE, M				LI, YY; INOUYE, M			AUTOPROCESSING OF PROTHIOLSUBTILISIN-E IN WHICH ACTIVE-SITE SERINE-221 IS ALTERED TO CYSTEINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PRO-SEQUENCE; SUBTILISIN-E; INTRAMOLECULAR CHAPERONE; DENATURED SUBTILISIN; PROTEASE; PEPTIDE; POLYMERASE; EXPRESSION; INVITRO	Subtilisin, an extracellular serine protease from Bacillus subtilis, requires the amino-terminal propeptide of 77 amino acid residues for the formation of the active enzyme. The propeptide is cleaved upon completion of folding. Serine 221 at the active center was substituted with cysteine, and the mutant enzyme (prothiolsubtilisin) was expressed in Escherichia coli under the control of a T7 promoter. Prothiolsubtilisin, which was produced as inclusion bodies, was dissolved in 6 M guanidine HC1 and purified to near homogeneity in the presence of 5 M urea. The purified protein was renatured by stepwise dialysis. In spite of the mutation at the active center, the propeptide was found to be autoprocessed with similar to-60-80% efficiency. However, protease activity could not be detected in the final product by the spectrophotometric assay. Moreover, the cleaved propeptide remained tightly bound to thiolsubtilisin without being digested, as evident by SDS polyacrylamide gel electrophoresis. The amino terminal sequence of the processed thiolsubtilisin was determined and proved that the propeptide was cleaved at a site identical to that of wildtype prosubtilisin. The processed thiolsubtilisin was also found to contain one free SH group/molecule. These results unambiguously demonstrate that the processing of prosubtilisin occurs by an intramolecular autoprocessing mechanism.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center								ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BOYER HW, 1968, ARCH BIOCHEM BIOPHYS, V128, P442, DOI 10.1016/0003-9861(68)90050-7; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; INOUYE M, 1991, ENZYME, V45, P314, DOI 10.1159/000468904; KOBAYASHI T, 1992, J MOL BIOL, V226, P931, DOI 10.1016/0022-2836(92)91042-N; LERNER CG, 1990, J BIOL CHEM, V265, P20085; LERNER CG, 1990, NUCLEIC ACIDS RES, V18, P4631, DOI 10.1093/nar/18.15.4631; Maniatis T., 1982, MOL CLONING; NAKAMURA K, 1982, Journal of Molecular and Applied Genetics, V1, P289; NECT KE, 1966, P NATL ACAD SCI USA, V56, P1606; OHTA Y, 1991, MOL MICROBIOL, V5, P1507, DOI 10.1111/j.1365-2958.1991.tb00797.x; OHTA Y, 1990, MOL MICROBIOL, V4, P295, DOI 10.1111/j.1365-2958.1990.tb00596.x; PHILIPP M, 1983, MOL CELL BIOCHEM, V51, P5, DOI 10.1007/BF00215583; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHINDE U, 1993, P NATL ACAD SCI USA, V90, P6924, DOI 10.1073/pnas.90.15.6924; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; STRAUSBERG S, 1993, BIOCHEMISTRY-US, V32, P8112, DOI 10.1021/bi00083a009; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WITHER JR, 1991, P NATL ACAD SCI USA, V88, P9330; WONG SL, 1986, J BIOL CHEM, V261, P176; ZHU X, 1992, LIFE SCI ADV, V11, P35; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	29	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4169	4174						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307978				2022-12-27	WOS:A1994MW98900043
J	OKAZAKI, T; BIELAWSKA, A; DOMAE, N; BELL, RM; HANNUN, YA				OKAZAKI, T; BIELAWSKA, A; DOMAE, N; BELL, RM; HANNUN, YA			CHARACTERISTICS AND PARTIAL-PURIFICATION OF A NOVEL CYTOSOLIC, MAGNESIUM-INDEPENDENT, NEUTRAL SPHINGOMYELINASE ACTIVATED IN THE EARLY SIGNAL-TRANSDUCTION OF 1-ALPHA,25-DIHYDROXYVITAMIN D-3-INDUCED HL-60 CELL-DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE-C; INHIBITION; MECHANISM; TURNOVER	Treatment of HL-60 cells with 1 alpha,25-dihydroxyvitamin D-3 induces activation of a neutral sphingomyelinase (SMase), resulting in a decrease in sphingomyelin (SM) levels and an increase in ceramide levels in a proposed ''sphingomyelin cycle'' of cell regulation (Okazaki, T, Bell, R., and Hannun, Y. (1989) J. Biol. Chem 264, 19076-19080). Cell-permeable synthetic ceramides induce HL-60 cell differentiation toward a monocytic lineage without conversion to sphingosine, suggesting that ceramide is a lipid mediator of cell differentiation (Okazaki, T., Bielawska, A., Bell, R., and Hannun, Y. (1990) J. Biol. Chem. 265, 15823-15831). In this study, we investigated a novel SMase that was activated 2-2.5 h after treatment of cells with 1 alpha,25-dihydroxyvitamin D-3. The activated SMase was localized to the cytosolic fraction. It was inhibited by copper, ferric iron, and zinc and showed optimal activity at pH 7.5. A mixed micellar assay was developed for the enzyme, with optimal activity achieved at 12 mol % SM in Triton X-100 mixed micelles and at 20 mol % SM in deoxycholate micelles. The activity was modestly enhanced by phosphatidic acid, phosphatidylserine, or phosphatidylinositol, but not by other major phospholipids. Purification was performed by chromatography on DEAE anion-exchange, Q-Sepharose Fast Flow, hydroxylapatite, sphingosylphosphocholine affinity, and Superose 12 gel filtration columns. Two peaks of activity with molecular masses of 45 and 95 kDa were resolved by gel filtration chromatography on Superose 12. The specific activities of the purified 45- and 95-kDa enzymes were 2780 and 2790 nmol/mg/h, respectively. These data identify a novel cytosolic, magnesium-independent, neutral SMase(s) that is activated during cell differentiation.	DUKE UNIV,DEPT MED,DURHAM,NC 27710; DUKE UNIV,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University	OKAZAKI, T (corresponding author), OSAKA DENT UNIV,DEPT MED,CYUOU KU,1-5-17 OTEMAE,OSAKA,OSAKA 540,JAPAN.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020205, R37DK020205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-20205] Funding Source: Medline; NIGMS NIH HHS [GM-43825] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNHOLZ Y, 1966, J BIOL CHEM, V241, P3731; Brady R. O., 1983, METABOLIC BASIS INHE, P831; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HIRSHFELD D, 1975, ARCH BIOCHEM BIOPHYS, V167, P186, DOI 10.1016/0003-9861(75)90455-5; JONES CS, 1981, BIOCHEM J, V195, P373, DOI 10.1042/bj1950373; KIM MY, 1991, J BIOL CHEM, V266, P484; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEHLHORN IE, 1988, BIOCHIM BIOPHYS ACTA, V939, P151, DOI 10.1016/0005-2736(88)90056-9; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; NILSSON A, 1969, BIOCHIM BIOPHYS ACTA, V176, P339, DOI 10.1016/0005-2760(69)90192-1; NOJIRI H, 1991, J BIOL CHEM, V266, P4531; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15822; RAO BG, 1976, J LIPID RES, V17, P506; SPENCE MW, 1989, J BIOL CHEM, V264, P5358; STOFFEL W, 1971, H-S Z PHYSIOL CHEM, V352, P1058, DOI 10.1515/bchm2.1971.352.2.1058; WONG P, 1991, J BIOL CHEM, V266, P14877; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	27	191	205	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4070	4077						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307965				2022-12-27	WOS:A1994MW98900029
J	SAVAGE, TJ; HATCH, MW; CROTEAU, R				SAVAGE, TJ; HATCH, MW; CROTEAU, R			MONOTERPENE SYNTHASES OF PINUS-CONTORTA AND RELATED CONIFERS - A NEW CLASS OF TERPENOID CYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SAGE SALVIA-OFFICINALIS; ESSENTIAL HISTIDINE RESIDUE; SODIUM DODECYL-SULFATE; MENTHA-X-PIPERITA; GERANYL PYROPHOSPHATE; PARTIAL-PURIFICATION; SESQUITERPENE CYCLASE; GLANDULAR TRICHOMES; NERYL PYROPHOSPHATE; 4S-LIMONENE SYNTHASE	A cell-free extract from the xylem of lodgepole pine (Pinus contorta) catalyzes the conversion of [1-H-3(1)]geranyl pyrophosphate to a variety of moneterpene olefins found in lodgepole pine oleoresin. This monoterpene synthase activity is similar to previously described terpenoid cyclases from grand fir (Abies grandis) and other higher plants in molecular mass (67 +/- 2 kDa as estimated by size exclusion chromatography), K-m for geranyl pyrophosphate (7.8 +/- 1.9 mu M), and isoelectric point (4.75 +/- 0.2 as determined by isoelectric focusing), but the cyclases from both lodgepole pine and grand fir are unlike previously characterized terpenoid cyclases from angiosperms and fungi, in that they have an alkaline pH optimum (pH 7.8), are activated by K+, Rb+, Cs+, or NH4+ (Li+ and Na+ are not effective), require either Mn2+ or Fe2+ as divalent metal ion cofactors (Mg2+ is not effective), and are not protected by the substratemetal ion complex against inhibition by the histidine-directed reagent diethyl pyrocarbonate. Chromatography of the pine xylem extracts on a quaternary amino anion-exchange resin results in the separation of four similar, but distinct, multiple product monoterpene synthases that produce sabinene, beta-phellandrene, 3-carene, and beta-pinene as the principal components, respectively. The major cyclase (phellandrene synthase) was subsequently purified by hydroxyapatite chromatography and electrophoresis. V8 proteolysis provided a peptide map significantly different from that obtained with limonene synthase from spearmint (Mentha spicata), and limited NH2-terminal sequencing of the phellandrene synthase fragments revealed no significant similarity to the deduced amino acid sequence of the angiosperm limonene synthase, the only monoterpene cyclase to be cloned and sequenced thus far. Furthermore, polyclonal antibodies raised against the angiosperm limonene synthase did not detectably cross react with any proteins in extracts from either lodgepole pine or grand fir by immunoblotting analysis. In addition to these structural differences between cyclases from conifers and herbaceous angiosperms, the unusual pH optimum, mono- and divalent metal ion requirement, and reactivity toward histidine carbethoxylation indicate that monoterpene cyclases isolated from conifers may also have a different complement of active-site amino acid residues involved in substrate binding and catalysis than those of terpenoid cyclases previously isolated from angiosperms.	WASHINGTON STATE UNIV,INST BIOL CHEM,PULLMAN,WA 99164	Washington State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031354, R01GM031354] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-31354] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO WR, 1991, ARCH BIOCHEM BIOPHYS, V286, P511, DOI 10.1016/0003-9861(91)90073-R; ALONSO WR, 1993, ARCH BIOCHEM BIOPHYS, V301, P58, DOI 10.1006/abbi.1993.1114; ALONSO WR, 1992, J BIOL CHEM, V267, P7582; BERNARDDAGAN C, 1982, PHYSIOL VEG, V20, P775; Bienfait H. F., 1983, Metals and micronutrients: uptake and utilization by plants, P111; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BURSTEIN Y, 1974, BIOCHEMISTRY-US, V13, P205, DOI 10.1021/bi00698a030; CANE DE, 1990, CHEM REV, V90, P1089, DOI 10.1021/cr00105a002; CANE DE, 1987, ARCH BIOCHEM BIOPHYS, V254, P421, DOI 10.1016/0003-9861(87)90120-2; Capozzi G., 1974, CHEM THIOL GROUP 2; CHAYET L, 1977, ARCH BIOCHEM BIOPHYS, V180, P318, DOI 10.1016/0003-9861(77)90044-3; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLBY SM, 1993, J BIOL CHEM, V268, P23016; CROTEAU R, 1989, J BIOL CHEM, V264, P15309; CROTEAU R, 1977, PLANT PHYSIOL, V59, P519, DOI 10.1104/pp.59.3.519; CROTEAU R, 1987, CHEM REV, V87, P929, DOI 10.1021/cr00081a004; CROTEAU R, 1981, PLANT PHYSIOL, V67, P820, DOI 10.1104/pp.67.4.820; CROTEAU R, 1976, ARCH BIOCHEM BIOPHYS, V176, P734, DOI 10.1016/0003-9861(76)90217-4; CROTEAU R, 1989, J BIOL CHEM, V264, P2075; CROTEAU R, 1988, J BIOL CHEM, V263, P10063; CROTEAU R, 1979, ARCH BIOCHEM BIOPHYS, V198, P512, DOI 10.1016/0003-9861(79)90526-5; CROTEAU R, 1977, ARCH BIOCHEM BIOPHYS, V179, P257, DOI 10.1016/0003-9861(77)90110-2; CROTEAU R, 1990, ARCH BIOCHEM BIOPHYS, V277, P374, DOI 10.1016/0003-9861(90)90593-N; CROTEAU R, 1980, ARCH BIOCHEM BIOPHYS, V200, P534, DOI 10.1016/0003-9861(80)90385-9; CROTEAU R, 1985, METHOD ENZYMOL, V110, P383; CROTEAU RB, 1990, J CHROMATOGR, V500, P349, DOI 10.1016/S0021-9673(00)96076-X; CROTEAU RB, 1987, BIOCHEMISTRY-US, V26, P5383, DOI 10.1021/bi00391a025; DEHAL SS, 1988, ARCH BIOCHEM BIOPHYS, V261, P346, DOI 10.1016/0003-9861(88)90350-5; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUEBER MT, 1978, PLANT PHYSIOL, V62, P598, DOI 10.1104/pp.62.4.598; FAHN A, 1979, SECRETORY TISSUES PL, P176; FERSHT A, 1985, ENZYME STRUCTURE MEC, P405; FROST RG, 1977, PLANT PHYSIOL, V59, P22, DOI 10.1104/pp.59.1.22; GAMBLIEL H, 1984, J BIOL CHEM, V259, P740; GAMBLIEL H, 1982, J BIOL CHEM, V257, P2335; GERSHENZON J, 1991, RECENT ADV PHYTOCHEM, V25, P347; Gershenzon J., 1992, HERBIVORES THEIR INT, VVolume 1, P165; GIJZEN M, 1992, ARCH BIOCHEM BIOPHYS, V294, P670, DOI 10.1016/0003-9861(92)90740-N; HALLAHAN TW, 1988, ARCH BIOCHEM BIOPHYS, V264, P618, DOI 10.1016/0003-9861(88)90328-1; HOHN TM, 1986, ARCH BIOCHEM BIOPHYS, V251, P756, DOI 10.1016/0003-9861(86)90386-3; HOHN TM, 1989, ARCH BIOCHEM BIOPHYS, V272, P137, DOI 10.1016/0003-9861(89)90204-X; JOVIN TM, 1973, ANN NY ACAD SCI, V209, P477, DOI 10.1111/j.1749-6632.1973.tb47551.x; KING HL, 1977, BIOCHEMISTRY-US, V16, P3815, DOI 10.1021/bi00636a015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWINSOHN E, 1991, PLANT PHYSIOL, V96, P38, DOI 10.1104/pp.96.1.38; LEWINSOHN E, 1992, ARCH BIOCHEM BIOPHYS, V293, P167, DOI 10.1016/0003-9861(92)90380-F; MCCASKILL D, 1992, PLANTA, V187, P445, DOI 10.1007/BF00199962; MUNCK SL, 1990, ARCH BIOCHEM BIOPHYS, V282, P58, DOI 10.1016/0003-9861(90)90086-E; Penhallow D.P, 1907, MANUAL N AM GYMNOSPE MANUAL N AM GYMNOSPE; POULOSE AJ, 1978, ARCH BIOCHEM BIOPHYS, V191, P400, DOI 10.1016/0003-9861(78)90104-2; RAJAONARIVONY JIM, 1992, ARCH BIOCHEM BIOPHYS, V296, P49, DOI 10.1016/0003-9861(92)90543-6; RAJAONARIVONY JIM, 1992, ARCH BIOCHEM BIOPHYS, V299, P77, DOI 10.1016/0003-9861(92)90246-S; ROBARDS AW, 1968, PLANTA, V82, P179, DOI 10.1007/BF01305721; ROBINSON DR, 1970, BIOCHEMISTRY-US, V9, P80, DOI 10.1021/bi00803a011; ROJAS MC, 1983, ARCH BIOCHEM BIOPHYS, V222, P389, DOI 10.1016/0003-9861(83)90535-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SECKBACH J, 1972, J ULTRA MOL STRUCT R, V39, P65, DOI 10.1016/S0022-5320(72)80007-8; Suelter C., 1974, METAL IONS BIOL SYST, V3, P201; SUELTER CH, 1970, SCIENCE, V168, P789, DOI 10.1126/science.168.3933.789; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VINCENT JB, 1992, TRENDS BIOCHEM SCI, V17, P105, DOI 10.1016/0968-0004(92)90246-6; VOGELI U, 1990, PLANT PHYSIOL, V93, P182, DOI 10.1104/pp.93.1.182; WAGSCHAL K, 1991, TETRAHEDRON, V47, P5933, DOI 10.1016/S0040-4020(01)86486-3; WERKER E, 1969, Botanical Journal of the Linnean Society, V62, P379, DOI 10.1111/j.1095-8339.1969.tb01974.x; WERKER E, 1968, NATURE, V218, P388, DOI 10.1038/218388a0; WHITE EE, 1983, PHYTOCHEMISTRY, V22, P1399, DOI 10.1016/S0031-9422(00)84022-4; WOODING FBP, 1965, J ULTRA MOL STRUCT R, V13, P233, DOI 10.1016/S0022-5320(65)80072-7; ZAVARIN E, 1970, PHYTOCHEMISTRY, V9, P1049, DOI 10.1016/S0031-9422(00)85225-5	68	62	68	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4012	4020						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307957				2022-12-27	WOS:A1994MW98900020
J	SONTAG, JM; FYKSE, EM; USHKARYOV, Y; LIU, JP; ROBINSON, PJ; SUDHOF, TC				SONTAG, JM; FYKSE, EM; USHKARYOV, Y; LIU, JP; ROBINSON, PJ; SUDHOF, TC			DIFFERENTIAL EXPRESSION AND REGULATION OF MULTIPLE DYNAMINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTANT; DROSOPHILA-MELANOGASTER; MECHANOCHEMICAL ENZYME; PROTEIN; ENDOCYTOSIS; SHIBIRE; MICROTUBULES; GTPASE; DEPHOSPHORYLATION; SYNAPTOPHYSIN	Dynamin is a GTP-, microtubule, and phospholipid-binding protein that is expressed primarily in brain. In Drosophila, the shibire gene encodes a homologue of dynamin; mutations in this gene result in a defect in endocytosis, suggesting a function for dynamin in endocytic membrane traffic. In the present study we show that there are at least two distinct dynamin genes in mammals whose products are referred to as dynamins I and II. The two dynamins are similar to each other (79% identity) and are both equally homologous to the Drosophila shibire gene product (66% identity). The highest degree of identity between dynamins is observed in their N-terminal halves, whereas their C termini exhibit little homology. Transcripts of both dynamin genes are subject to at least two alternative splicing events, the first of which is identically found in both dynamins, whereas the second site of alternative splicing is different between the two types of dynamins. The first alternatively spliced sequence of the dynamins consists of an interior region that is present in two distinct but homologous forms in both dynamins, suggesting alternative use of exons in both genes at identical positions. The second site of alternative splicing results in the generation of different C termini in dynamin I and in the inclusion or exclusion of an interior four amino acid sequence in dynamin II. The two dynamins exhibit remarkable differences in their tissue distribution and regulation. Dynamin I is almost exclusively expressed in the central nervous system Conversely, dynamin II is expressed ubiquitously in all tissues tested. Previous studies revealed that the GTPase activity of dynamin I is regulated by phosphorylation by protein kinase C in nerve terminals. Expression of dynamins I and II by transfection in COS cells demonstrates that only dynamin I but not dynamin II is a substrate for protein kinase C. Our data suggest a specialization in the endocytic functions and the regulation of dynamins between neural and non-neural tissues in mammals.	UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; JOHN HUNTER HOSP, ENDOCRINE UNIT, NEWCASTLE, NSW 2310, AUSTRALIA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; John Hunter Hospital			Ushkaryov, Yuri/AAQ-2985-2020; Robinson, Phillip J/G-4008-2011	Ushkaryov, Yuri/0000-0002-5712-8297; Robinson, Phillip J/0000-0002-7878-0313; Liu, Jun-Ping/0000-0001-7442-2116				CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; FAIRE K, 1992, P NATL ACAD SCI USA, V89, P8376, DOI 10.1073/pnas.89.17.8376; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; JONES BA, 1992, GENE DEV, V6, P380, DOI 10.1101/gad.6.3.380; KESSELL I, 1989, P NATL ACAD SCI USA, V86, P4968, DOI 10.1073/pnas.86.13.4968; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; MASUR SK, 1990, J NEUROGENET, V6, P191, DOI 10.3109/01677069009107110; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; NAKATA T, 1991, NEURON, V7, P461, DOI 10.1016/0896-6273(91)90298-E; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OBAR RA, 1991, J CELL SCI, P143; POODRY CA, 1979, J CELL BIOL, V81, P520, DOI 10.1083/jcb.81.3.520; ROBINSON PJ, 1987, J NEUROCHEM, V48, P187, DOI 10.1111/j.1471-4159.1987.tb13146.x; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; Sambrook J, 1989, MOL CLONING LABORATO; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; SIHRA TS, 1992, J BIOL CHEM, V267, P1983; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TUMA PL, 1993, J BIOL CHEM, V268, P17240; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; VALLEE RB, 1992, J MUSCLE RES CELL M, V13, P493, DOI 10.1007/BF01737991; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VATER CA, 1992, J CELL BIOL, V119, P773, DOI 10.1083/jcb.119.4.773; YEH E, 1991, NATURE, V349, P713, DOI 10.1038/349713a0	35	167	168	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4547	4554						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308025				2022-12-27	WOS:A1994MW98900097
J	STOLL, LL; DENNING, GM; KASNER, NA; HUNNINGHAKE, GW				STOLL, LL; DENNING, GM; KASNER, NA; HUNNINGHAKE, GW			PLATELET-ACTIVATING-FACTOR MAY STIMULATE BOTH RECEPTOR-DEPENDENT AND RECEPTOR-INDEPENDENT INCREASES IN [CA2+] IN HUMAN AIRWAY EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SMOOTH-MUSCLE CELLS; FUTURE CLINICAL IMPLICATIONS; CYTOSOLIC FREE CALCIUM; SIGNAL TRANSDUCTION; FACTOR PAF; LINKED DIGLYCERIDES; ANTAGONISTS; PATHWAYS; ASTHMA	Platelet-activating factor (PAF) is a potent mediator which produces a wide range of biological responses by binding to specific, high affinity receptors on the target cell surface. In addition, we and others have observed cellular responses to PAF which are not receptor-mediated. We report here that in HBE-16 human bronchial epithelial cells, PAF produces a biphasic increase in [Ca2+](i) consisting of a rapid initial increase due to release from intracellular stores followed by a gradual, sustained phase caused by influx of extracellular Ca2+. Under certain conditions, the PAF receptor antagonist L-659,989 completely blocks the release of Ca2+ from intracellular stores, suggesting a complete block of the receptor-mediated response. Under these same conditions, a residual influx of extracellular Ca2+ is observed, suggesting a possible receptor-independent response. HBE-16 cells partially metabolize PAF to 1-O-alkyl-2 acetyl-sn-glycerol (AAG), a bioactive diacylglycerol analog. Moreover, AAG stimulates Ca2+ influx in these cells; the response to AAG is at least 100-fold more potent than that to PAF. Taken together, these results suggest that PAF may stimulate Ca2+ influx in HBE-16 cells through a receptor-independent pathway mediated by AAG. Thus these studies suggest a previ ously unrecognized dual-pathway regulatory mechanism for PAF in the airway.	UNIV IOWA, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA	University of Iowa	STOLL, LL (corresponding author), UNIV IOWA, DEPT ANESTHESIA, 2-317 BSB, IOWA CITY, IA 52242 USA.							BARNES PJ, 1991, ANN NY ACAD SCI, V629, P193; BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P9317, DOI 10.1021/bi00450a011; BERDEL WE, 1987, ANTICANCER RES, V7, P1181; BLANK ML, 1984, BIOCHEM BIOPH RES CO, V118, P344, DOI 10.1016/0006-291X(84)91107-0; BROCK TA, 1986, AM J PHYSIOL, V250, P1086, DOI 10.1152/ajpheart.1986.250.6.H1086; BUCKLEY TL, 1989, EUR J PHARMACOL, V163, P275, DOI 10.1016/0014-2999(89)90196-9; DANIEL LW, 1988, BIOCHEM BIOPH RES CO, V151, P291, DOI 10.1016/0006-291X(88)90592-X; DEMPSEY EC, 1990, J CELL PHYSIOL, V144, P159, DOI 10.1002/jcp.1041440121; DUBOURDIEU DJ, 1990, BIOCHIM BIOPHYS ACTA, V1054, P326, DOI 10.1016/0167-4889(90)90104-L; FORD DA, 1989, J BIOL CHEM, V264, P13818; GANDHI CR, 1990, J BIOL CHEM, V265, P18234; GRUENERT DC, 1988, P NATL ACAD SCI USA, V85, P5951, DOI 10.1073/pnas.85.16.5951; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIRAFUJI M, 1992, JPN J PHARMACOL, V58, P231, DOI 10.1254/jjp.58.231; HOSFORD D, 1990, CRIT REV THER DRUG, V7, P261; HWANG SB, 1988, J PHARMACOL EXP THER, V246, P534; KESTER M, 1987, FASEB J, V1, P215, DOI 10.1096/fasebj.1.3.2442057; KOLTAI M, 1991, DRUGS, V42, P174, DOI 10.2165/00003495-199142020-00002; KOLTAI M, 1991, DRUGS, V42, P9, DOI 10.2165/00003495-199142010-00002; MCCANN JD, 1989, AM J PHYSIOL, V257, pL116, DOI 10.1152/ajplung.1989.257.2.L116; MULDOON LL, 1990, CELL REGUL, V1, P379, DOI 10.1091/mbc.1.4.379; PAGE CP, 1988, J ALLERGY CLIN IMMUN, V81, P144, DOI 10.1016/0091-6749(88)90233-3; PALMER S, 1986, BIOCHEM J, V238, P491, DOI 10.1042/bj2380491; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; REDONDO JM, 1988, J BIOL CHEM, V263, P17467; SHUKLA SD, 1992, FASEB J, V6, P2296, DOI 10.1096/fasebj.6.6.1312046; SMITH IL, 1992, BLOOD COAGUL FIBRIN, V3, P759, DOI 10.1097/00001721-199212000-00009; SMITH LJ, 1991, AM REV RESPIR DIS, V143, pS100, DOI 10.1164/ajrccm/143.5_Pt_2.S100; SNYDER F, 1990, AM J PHYSIOL, V259, pC697, DOI 10.1152/ajpcell.1990.259.5.C697; STOLL LL, 1989, J CELL PHYSIOL, V139, P253, DOI 10.1002/jcp.1041390206; STOLL LL, 1989, CELL REGUL, V1, P13, DOI 10.1091/mbc.1.1.13; STOLL LL, 1987, J CELL PHYSIOL, V133, P103, DOI 10.1002/jcp.1041330113; STOLL LL, 1991, J CELL SCI, V100, P145; TAN WC, 1992, AM REV RESPIR DIS, V146, P916, DOI 10.1164/ajrccm/146.4.916; VOELKEL NF, 1986, PROSTAGLANDINS, V32, P359, DOI 10.1016/0090-6980(86)90005-5; WANG DJ, 1991, J CELL PHYSIOL, V146, P473, DOI 10.1002/jcp.1041460319	36	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4254	4259						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307989				2022-12-27	WOS:A1994MW98900056
J	DAHL, NK; GUTHEIL, WG; LISCUM, L				DAHL, NK; GUTHEIL, WG; LISCUM, L			ABNORMAL REGULATION OF LOW-DENSITY LIPOPROTEIN-SENSITIVE EVENTS IN A CHOLESTEROL TRANSPORT MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; HAMSTER OVARY CELLS; MEVALONATE-DERIVED PRODUCT; NIEMANN-PICK DISEASE; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; ENDOPLASMIC-RETICULUM; UT-1 CELLS; INTRACELLULAR-TRANSPORT; C FIBROBLASTS; MESSENGER-RNA	We have isolated and characterized Chinese hamster ovary cell mutants defective in the intracellular transport of low density lipoprotein (LDL)-derived cholesterol (Dahl, N. K., Reed, K. L., Daunais, M. A., Faust, J. R., and Liscum, L. (1992) J. Biol. Chem. 267, 4889-4896). Mutant 2-2, which exhibits a cholesterol transport defect indistinguishable from the Niemann-Pick C phenotype, shows impaired but not absent LDL-mediated suppression of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase activity. In parental cells, LDL suppression of HMG-CoA reductase is modulated by two mechanisms, decreased gene transcription and accelerated protein turnover. Using the chimeric protein HMGal as a reporter protein for LDL-mediated turnover and Northern blot analysis to monitor HMG-CoA reductase mRNA levels, we have dissected the contributions of these two regulatory responses to LDL-mediated suppression of HMG-CoA reductase activity. Kinetic modeling using the kinlsq program showed the following. Mutant 2-2 exhibits normal LDL-mediated acceleration of HMGal degradation, coupled with relatively abnormal regulation of mRNA. This suggests that the LDL-cholesterol signaling pathway to the nucleus is defective relative to the signal that results in HMG-CoA reductase turnover. In addition, LDL-mediated acceleration of HMGal turnover occurs well before LDL stimulation of cholesterol esterification in mutant 2-2, whereas these events occur synchronously in the parental cell line. This suggests that more than one pathway or mechanism exists for LDL-cholesterol signaling to the endoplasmic reticulum.	TUFTS UNIV,SCH MED,DEPT PHYSIOL,136 HARRISON AVE,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	Tufts University; Tufts University			Dahl, Neera/AAI-7380-2021; Dahl, Neera/AAV-4856-2021	Gutheil, William/0000-0001-7491-4591	NIAID NIH HHS [AI 31866] Funding Source: Medline; NIDDK NIH HHS [DK 07542] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007542] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAHL NK, 1992, J BIOL CHEM, V267, P4889; DAWSON PA, 1991, J BIOL CHEM, V266, P9128; DOOLITTLE GM, 1982, BIOCHIM BIOPHYS ACTA, V713, P529, DOI 10.1016/0005-2760(82)90313-7; FAUST J, 1987, J BIOL CHEM, V262, P1996; FAUST JR, 1982, P NATL ACAD SCI-BIOL, V79, P5205, DOI 10.1073/pnas.79.17.5205; GIL G, 1986, J BIOL CHEM, V261, P3710; GIL G, 1986, J BIOL CHEM, V261, P3717; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1987, J BIOL CHEM, V262, P17002; LISCUM L, 1992, J LIPID RES, V33, P1239; LISCUM L, 1991, J BIOL CHEM, V266, P16599; LISCUM L, 1989, J BIOL CHEM, V264, P11796; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSKEY KL, 1985, J BIOL CHEM, V260, P271; LUSKEY KL, 1982, P NATL ACAD SCI-BIOL, V79, P6210, DOI 10.1073/pnas.79.20.6210; LUSKEY KL, 1983, J BIOL CHEM, V258, P8462; MA PTS, 1986, P NATL ACAD SCI USA, V83, P8370, DOI 10.1073/pnas.83.21.8370; Maniatis T., 1982, MOL CLONING; MANNERVIK B, 1983, CONT ENZYME KINETICS, P75; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; PEFFLEY D, 1985, J BIOL CHEM, V260, P9949; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; RICE JA, 1988, MATH STATISTICS DATA, P561; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; SMITH JR, 1988, J BIOL CHEM, V263, P18480; XU XX, 1991, J BIOL CHEM, V266, P17040	40	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16979	16986						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349588				2022-12-27	WOS:A1993LQ98800018
J	DING, JB; BADWEY, JA				DING, JB; BADWEY, JA			STIMULATION OF NEUTROPHILS WITH A CHEMOATTRACTANT ACTIVATES SEVERAL NOVEL PROTEIN-KINASES THAT CAN CATALYZE THE PHOSPHORYLATION OF PEPTIDES DERIVED FROM THE 47-KDA PROTEIN-COMPONENT OF THE PHAGOCYTE OXIDASE AND MYRISTOYLATED ALANINE-RICH C-KINASE SUBSTRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; SODIUM DODECYL-SULFATE; PHOSPHOLIPASE-D ACTIVATION; GTP-BINDING PROTEIN; CELL-FREE SYSTEM; NADPH-OXIDASE; SUPEROXIDE PRODUCTION; CALCIUM MOBILIZATION; CHEMOTACTIC FACTORS; POLYACRYLAMIDE-GEL	Novel protein kinases that may participate in the signal transduction pathways of neutrophils were sought by a procedure based on the ability of these enzymes to undergo renaturation and catalyze the phosphorylation of a peptide substrate fixed in a gel. We report that neutrophils contain four uncharacterized protein kinases with molecular masses of about 69, 63, 49, and 40 kDa, which are rapidly activated upon stimulation of these cells with the chemoattractant fMet-Leu-Phe. These kinases can catalyze the phosphorylation of a peptide that corresponds to residues 297-331 of the 47-kDa subunit of the NADPH oxidase system (p47-phox). A peptide that corresponds to residues 153-178 of the human myristolyated alanine-rich C kinase substrate (MARCKS) protein was also a substrate for the 69- and 63-kDa kinases. The time course for the activation of these enzymes was similar to the phosphorylation of p47-phox and MARCKS in intact neutrophils. In contrast, stimulation of these cells with 4beta-phorbol 12-myristate 13-acetate, the calcium ionophore A23187, or the combination of these agonists did not activate these enzymes. Activation of the 63- and 40-kDa protein kinases was blocked by pertussis toxin, calyculin A, and staurosporine. Several other unidentified protein kinases were also active with these peptides but did not exhibit enhanced activity after cell stimulation with this method.	BOSTON BIOMED RES INST,20 STANIFORD ST,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Boston Biomedical Research Institute; Harvard University; Harvard Medical School					NIAID NIH HHS [AI23323, AI28342] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028342, R01AI023323] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; Badwey J A, 1986, Methods Enzymol, V132, P365; BADWEY JA, 1989, BIOCHEM BIOPH RES CO, V158, P1029, DOI 10.1016/0006-291X(89)92825-8; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BOKOCH GM, 1984, CELL, V39, P301, DOI 10.1016/0092-8674(84)90008-4; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; DEWALD B, 1988, J BIOL CHEM, V263, P16179; DING JB, 1993, J BIOL CHEM, V268, P5234; DING JB, 1992, J BIOL CHEM, V267, P6442; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; GEAHLEN RL, 1986, ANAL BIOCHEM, V153, P151, DOI 10.1016/0003-2697(86)90074-6; GOMEZCAMBRONERO J, 1992, P NATL ACAD SCI USA, V89, P7551, DOI 10.1073/pnas.89.16.7551; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HEYWORTH PG, 1990, J BIOENERG BIOMEMBR, V22, P1, DOI 10.1007/BF00762842; HEYWORTH PG, 1989, BIOCHEM J, V260, P243, DOI 10.1042/bj2600243; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HUANG CK, 1988, J BIOL CHEM, V263, P13144; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KAIBUCHI K, 1983, J BIOL CHEM, V258, P6701; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KORCHAK HM, 1988, J BIOL CHEM, V263, P11098; KRAMER IM, 1988, BIOCHIM BIOPHYS ACTA, V971, P189; KRAMER IM, 1989, J BIOL CHEM, V264, P5876; LACKS SA, 1980, J BIOL CHEM, V255, P7467; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MOLSKI TFP, 1984, BIOCHEM BIOPH RES CO, V124, P644, DOI 10.1016/0006-291X(84)91603-6; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; PARK JW, 1992, J BIOL CHEM, V267, P17327; PELECH SL, 1987, BIOCHEMISTRY-US, V26, P7960, DOI 10.1021/bi00398a062; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PILLOUDDAGHER MC, 1992, BIOCHEM BIOPH RES CO, V186, P731, DOI 10.1016/0006-291X(92)90807-W; PRICE DJ, 1991, J BIOL CHEM, V266, P16281; ROBINSON JM, 1990, BIOCHIM BIOPHYS ACTA, V1055, P55, DOI 10.1016/0167-4889(90)90090-Z; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; Rubin C S, 1974, Methods Enzymol, V38, P308; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SHAAFI RI, 1988, J LEUKOCYTE BIOL, V43, P18, DOI 10.1002/jlb.43.1.18; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; SNYDERMAN R, 1984, ANNU REV IMMUNOL, V2, P257, DOI 10.1146/annurev.immunol.2.1.257; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TYAGI SR, 1991, J BIOL CHEM, V266, P3498; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P9563; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WHITE JR, 1984, J BIOL CHEM, V259, P8605; WISE BC, 1982, J BIOL CHEM, V257, P8489	59	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17326	17333						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349615				2022-12-27	WOS:A1993LQ98800066
J	PENG, HM; DING, XX; COON, MJ				PENG, HM; DING, XX; COON, MJ			ISOLATION AND HETEROLOGOUS EXPRESSION OF CLONED CDNAS FOR 2 RABBIT NASAL MICROSOMAL PROTEINS, CYP2A10 AND CYP2A11, THAT ARE RELATED TO NASAL MICROSOMAL CYTOCHROME-P450 FORM A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLFACTORY-SPECIFIC CYTOCHROME-P-450; UDP-GLUCURONOSYL TRANSFERASE; AMINO-ACID-SEQUENCE; CATALYTIC ACTIVITY; ESCHERICHIA-COLI; LIVER-MICROSOMES; MESSENGER-RNA; INDUCTION; PURIFICATION; CLONING	Nasal microsomal P450 form a (NMa), a major cytochrome P450 isozyme in rabbit olfactory and respiratory nasal mucosa with high activity toward a variety of odorants and environmental toxicants, was previously purified to electrophoretic homogeneity from rabbit nasal microsomes. In the present study, a cDNA library constructed from poly(A)+ RNA from rabbit respiratory nasal mucosa was screened with antibodies to P450 NMa, and five immunopositive clones were isolated and characterized. Sequence analysis indicated that the clones encode two highly similar P450s that contain 494 amino acid residues, with the first 20 corresponding to P450 NMa, and differ from each other in only 8 residues scattered throughout the polypeptide chains. On the basis of structural homology the two proteins are designated as CYP2A10 and CYP2A11 and are the first members of the P450 2A subfamily to be identified in nasal tissue. Genomic blot analysis indicated that 2A10 and 2A11 are apparently not allelic variants. Both genes are expressed in liver and lung as well as in nasal tissues, as judged by RNA blot analysis, but the relative levels of the two mRNAs differ. Both enzymes were partially purified after expression of the cDNAs in Escherichia coli and shown to catalyze the oxygenation of a variety of substrates, including ethanol and procarcinogens such as N-nitrosodiethylamine and phenacetin. P450 2A10 is generally more active than P450 2A11 and strikingly so in the conversion of testosterone to androstenedione.	UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, 1301 CATHERINE RD, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK010339, R37DK010339] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-10339] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AOYAMA T, 1989, J BIOL CHEM, V264, P21327; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BURKHART BA, 1985, J BIOL CHEM, V260, P5357; CHEN Y, 1992, NEUROREPORT, V3, P749, DOI 10.1097/00001756-199209000-00007; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAHL AR, 1991, CRIT REV TOXICOL, V21, P345, DOI 10.3109/10408449109019571; DING X, 1988, BIOCHEMISTRY-US, V27, P8330, DOI 10.1021/bi00422a007; DING X, 1992, HDB EXPT PHARM, V105, P351; DING XX, 1991, METHOD ENZYMOL, V206, P603; DING XX, 1990, MOL PHARMACOL, V37, P489; DING XX, 1990, DRUG METAB DISPOS, V18, P742; DING XX, 1992, MOL PHARMACOL, V42, P1027; DING XX, 1991, ARCH BIOCHEM BIOPHYS, V285, P120, DOI 10.1016/0003-9861(91)90337-I; DING XX, 1992, DRUG METAB DISPOS, V20, P792; DING XX, 1986, MOL PHARMACOL, V30, P370; FRENCH JS, 1979, ARCH BIOCHEM BIOPHYS, V195, P565, DOI 10.1016/0003-9861(79)90383-7; GETCHELL ML, 1993, ANN OTO RHINOL LARYN, V102, P368, DOI 10.1177/000348949310200509; GONZALEZ FJ, 1992, TRENDS PHARMACOL SCI, V13, P346, DOI 10.1016/0165-6147(92)90107-H; GOTOH O, 1992, J BIOL CHEM, V267, P83; GREENLEE WF, 1978, J PHARMACOL EXP THER, V205, P596; HONG JY, 1992, CARCINOGENESIS, V13, P2141, DOI 10.1093/carcin/13.11.2141; KIMURA S, 1989, BIOCHEMISTRY-US, V28, P3798, DOI 10.1021/bi00435a026; KOOP DR, 1981, J BIOL CHEM, V256, P704; KOOP DR, 1984, ARCH BIOCHEM BIOPHYS, V235, P228, DOI 10.1016/0003-9861(84)90272-8; KRONBACH T, 1991, J BIOL CHEM, V266, P6215; LAI TS, 1990, ARCH BIOCHEM BIOPHYS, V283, P429, DOI 10.1016/0003-9861(90)90664-K; LARSON JR, 1991, J BIOL CHEM, V266, P7321; LAZARD D, 1990, BIOCHEMISTRY-US, V29, P7433, DOI 10.1021/bi00484a012; LAZARD D, 1991, NATURE, V349, P790, DOI 10.1038/349790a0; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; MANIATIS T, 1982, MOL CLONING LABORATO, P200; MATSUNAGA T, 1988, J BIOL CHEM, V263, P17995; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; NEF P, 1989, J BIOL CHEM, V264, P6780, DOI 10.1016/S0021-9258(18)83497-4; NEF P, 1990, J BIOL CHEM, V265, P2903; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OSAWA Y, 1987, ANAL BIOCHEM, V164, P355, DOI 10.1016/0003-2697(87)90504-5; PERNECKY SJ, 1993, P NATL ACAD SCI USA, V90, P2651, DOI 10.1073/pnas.90.7.2651; PORTER TD, 1991, METHOD ENZYMOL, V206, P108; POULOS TL, 1985, J BIOL CHEM, V260, P6122; PUTT D, 1992, FASEB J, V6, pA1569; REED CJ, 1986, BIOCHEM J, V240, P585, DOI 10.1042/bj2400585; SQUIRES EJ, 1988, J BIOL CHEM, V263, P4166; TARTOF KD, 1987, FOCUS, V9, P12; WALTERS E, 1992, J NEUROSCI RES, V33, P103, DOI 10.1002/jnr.490330113; YAMANO S, 1990, BIOCHEMISTRY-US, V29, P1322, DOI 10.1021/bi00457a031; ZUPKO K, 1991, EUR J BIOCHEM, V196, P51, DOI 10.1111/j.1432-1033.1991.tb15784.x	47	42	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17253	17260						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349611				2022-12-27	WOS:A1993LQ98800058
J	YUAN, CS; YEH, J; LIU, SM; BORCHARDT, RT				YUAN, CS; YEH, J; LIU, SM; BORCHARDT, RT			MECHANISM OF INACTIVATION OF S-ADENOSYLHOMOCYSTEINE HYDROLASE BY (Z)-4',5'-DIDEHYDRO-5'-DEOXY-5'-FLUOROADENOSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-HOMOCYSTEINE HYDROLASE; NEPLANOCIN-A; INHIBITORS; NUCLEOSIDES; BINDING; ENZYME	S-Adenosyl-L-homocysteine (AdoHcy) hydrolase, an enzyme important in the regulation of biological methylation reactions, was shown by McCarthy et al. (McCarthy, J. R., Jarvi, E. T., Matthews, D. P., Edwards, M. L., Prakash, N. J., Bowlin, T. L., Mehdi, S., and Bey, P. (1989) J. Am. Chem. Soc. 111, 1127-1128) to be inactivated by (Z)-4',5'-didehydro-5'deoxy-5'-fluoroadenosine (ZDDFA). In this study we have shown that the mechanism of this inactivation of AdoHcy hydrolase (NAD+ form) includes a rapid addition of water to the 5'-position of ZDDFA and elimination of fluoride ion, resulting in the formation of the 5'-carboxaldehydes 3 and 4. The 5'-carboxaldehydes 3 and 4 are then oxidized in a slower step to the 3'-keto-5'-carboxaldehydes 5 and 6 by reduction of the enzyme-bound NAD+ to NADH. Evidence in support of this mechanism includes the observation that the first step in this mechanism (i.e. elimination of fluoride ion and formation of the 5'-carboxaldehydes 3 and 4) can be catalyzed by apo-AdoHcy hydrolase and the NADH form of AdoHcy hydrolase. Incubation of ZDDFA with either the apo or NADH form of AdoHcy hydrolase resulted in rapid release of fluoride ion (determined by F-19 NMR) and formation of the 5'-carboxaldehydes 3 and 4 (determined by high performance liquid chromatography). The carboxaldehydes 3 and 4 were synthesized independently and were shown to be potent inhibitors of the NAD+ form of the enzyme. When the relative first-order rates of fluoride ion release (determined by F-19 NMR) from ZDDFA, NAD+ reduction to NADH, and inactivation of the NAD+ form of the enzyme were compared, the release of fluoride ion was found to be approximately 20 times faster than NAD+ reduction or enzyme inactivation. Incubation of ZDDFA with the NAD+ form of AdoHcy hydrolase was shown to afford the 3'-keto-5'-carboxaldehydes 5 and 6, which were also formed upon incubation of the enzyme with the 5'-carboxaldehydes 3 and 4. The 3'-keto-5'-carboxaldehydes 5 and 6 were shown to be tightly (but not covalently) bound to the enzyme, since these products could be released by treatment of the ZDDFA-inactivated enzyme with HClO4 or other denaturing agents.	UNIV KANSAS, DEPT BIOCHEM, LAWRENCE, KS 66045 USA; UNIV KANSAS, DEPT MED CHEM, LAWRENCE, KS 66045 USA	University of Kansas; University of Kansas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029332] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29332] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELES RH, 1982, BIOCHEMISTRY-US, V21, P5557, DOI 10.1021/bi00265a027; BORCHARDT RT, 1979, TRANSMETHYLATION, P197; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cantoni GL., 1980, NATURAL SULFUR COMPO, P67; CHIANG PK, 1979, BIOCHEM PHARMACOL, V28, P1897, DOI 10.1016/0006-2952(79)90642-7; DECLERCQ E, 1987, BIOCHEM PHARMACOL, V36, P2567, DOI 10.1016/0006-2952(87)90533-8; DELAHABA G, 1959, J BIOL CHEM, V234, P603; GOMI T, 1989, BIOCHIM BIOPHYS ACTA, V994, P172, DOI 10.1016/0167-4838(89)90157-X; GOMI T, 1989, J BIOL CHEM, V264, P16138; HASOBE M, 1989, ANTIMICROB AGENTS CH, V33, P828, DOI 10.1128/AAC.33.6.828; HOHMAN RJ, 1985, P NATL ACAD SCI USA, V82, P4578, DOI 10.1073/pnas.82.14.4578; JARVI ET, 1991, J MED CHEM, V34, P647, DOI 10.1021/jm00106a028; Keller B. T., 1988, ANTIVIRAL DRUG DEV M, P123; KITZ R, 1962, J BIOL CHEM, V237, P3245; LIU SM, 1993, J MED CHEM, V36, P883, DOI 10.1021/jm00059a013; LIU SM, 1992, BIOORG MED CHEM LETT, V2, P1741, DOI 10.1016/S0960-894X(00)80467-9; LUI S, 1992, ANTIVIR RES, V19, P247; MADHAVAN GVB, 1988, J MED CHEM, V31, P1798, DOI 10.1021/jm00117a021; MARTIN SF, 1978, TETRAHEDRON LETT, P1943; MATUSZEWSKA B, 1987, J BIOL CHEM, V262, P265; MCCARTHY JR, 1989, J AM CHEM SOC, V111, P1127, DOI 10.1021/ja00185a052; Mehdi S, 1990, J Enzyme Inhib, V4, P1, DOI 10.3109/14756369009030383; PALMER JL, 1979, J BIOL CHEM, V254, P1217; PARRY RJ, 1991, BIOCHEMISTRY-US, V30, P9988, DOI 10.1021/bi00105a025; PUGH CSG, 1978, J BIOL CHEM, V253, P4075; RANSOHOFF RM, 1987, ANTIVIR RES, V7, P317, DOI 10.1016/0166-3542(87)90014-3; RICHARDS HH, 1978, J BIOL CHEM, V253, P4476; WOLFE MS, 1991, J MED CHEM, V34, P1521, DOI 10.1021/jm00109a001	29	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17030	17037						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349591				2022-12-27	WOS:A1993LQ98800025
J	FERRARI, S; PEARSON, RB; SIEGMANN, M; KOZMA, SC; THOMAS, G				FERRARI, S; PEARSON, RB; SIEGMANN, M; KOZMA, SC; THOMAS, G			THE IMMUNOSUPPRESSANT RAPAMYCIN INDUCES INACTIVATION OF P70(S6K) THROUGH DEPHOSPHORYLATION OF A NOVEL SET OF SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							P70 S6 KINASE; SIGNAL TRANSDUCTION; TYROSINE KINASE; PROTEIN-KINASES; NEGATIVE CHARGE; PHOSPHORYLATION; ACTIVATION; STIMULATION; MUTAGENESIS; PHOSPHATE	The immunosuppressant rapamycin selectively abolishes phosphorylation and activation of p70s6k/p85s6k at concentrations that either block or suppress cell growth. The four sites of phosphorylation associated with p70s6k/p85s6k activation all display Ser/Thr-Pro motifs and are closely clustered within a putative autoinhibitory domain of the enzyme. To produce a constitutively active, rapamycin-resistant form of the kinase, these four sites were converted to either Asp or Glu. When overexpressed in human 293 cells, the activity of the mutant is similar to that of the parent enzyme, under conditions where the parent is phosphorylated and active. Unexpectedly, however, the mutant remains sensitive to rapamycin and is inactivated in vitro by protein phosphatase 2A. Peptide maps reveal that rapamycin abolishes the activity of the overexpressed p70s6k through the dephosphorylation of a novel set of sites distinct from those associated with mitogenic activation.	FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research			Pearson, Richard Bruce/I-1451-2013; Ferrari, Stefano/I-7357-2016	Pearson, Richard Bruce/0000-0001-5919-5090; Ferrari, Stefano/0000-0002-6607-215X				AOSTINIS P, 1992, EUR J BIOCHEM, V205, P241; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HERBST R, 1991, J BIOL CHEM, V266, P19908; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KOZMA SC, 1993, J BIOL CHEM, V268, P7134; KOZMA SC, 1992, REV PHYSIOL BIOCH P, V119, P123; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1992, EMBO J, V11, P1743, DOI 10.1002/j.1460-2075.1992.tb05226.x; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; MARCUS F, 1988, J BIOL CHEM, V263, P6058; MORLEY SJ, 1991, PHARMACOL THERAPEUT, V50, P291, DOI 10.1016/0163-7258(91)90047-P; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	28	113	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16091	16094						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344891				2022-12-27	WOS:A1993LQ33600003
J	SHIRINSKY, VP; VOROTNIKOV, AV; BIRUKOV, KG; NANAEV, AK; COLLINGE, M; LUKAS, TJ; SELLERS, JR; WATTERSON, DM				SHIRINSKY, VP; VOROTNIKOV, AV; BIRUKOV, KG; NANAEV, AK; COLLINGE, M; LUKAS, TJ; SELLERS, JR; WATTERSON, DM			A KINASE-RELATED PROTEIN STABILIZES UNPHOSPHORYLATED SMOOTH-MUSCLE MYOSIN MINIFILAMENTS IN THE PRESENCE OF ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; HEAVY-MEROMYOSIN; CHICKEN GIZZARD; SKELETAL-MUSCLE; CALMODULIN; BINDING; PHOSPHORYLATION; FILAMENTS; ACTIN; PURIFICATION	An apparent paradox in smooth muscle biology is the ability of unphosphorylated myosin to maintain a filamentous structure in the presence of ATP in vivo, whereas unphosphorylated myosin filaments are depolymerized in vitro in the presence of ATP. This suggests that additional uncharacterized factors are required for the stabilization of myosin filaments in the presence of ATP. We report here that an abundant smooth muscle protein forms sedimentable complexes with unphosphorylated smooth muscle myosin, partially reverses the depolymerizing effect of ATP on unphosphorylated myosin, and promotes the assembly of minifilaments as revealed by electron microscopy. This protein is called kinase-related protein (KRP) because it is derived from a gene within the gene for myosin light chain kinase (MLCK) and has an amino acid sequence identical to the carboxyl-terminal domain of MLCK. Consistent with the results with purified KRP, deletion of the KRP domain within MLCK results in a diminished ability of MLCK to interact with unphosphorylated myosin. KRP binds to the heavy meromyosin fragment of myosin but not to myosin rod or fragments lacking the hinge region and light chains. Altogether, these results suggest that KRP may play a critical role in stabilizing unphosphorylated myosin filaments and that the KRP domain of MLCK may be important for subcellular targeting to filaments.	NHLBI,MOLEC CARDIOL LAB,BETHESDA,MD 20892; RUSSIAN ACAD MED SCI,CARDIOL RES CTR,MOLEC ENDOCRINOL LAB,MOSCOW 121552,RUSSIA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Medical Research Center of Cardiology; Russian Academy of Medical Sciences	SHIRINSKY, VP (corresponding author), VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232, USA.		Shirinsky, Vladimir/AAN-3938-2020; Vorotnikov, Alexander/A-8392-2014; Vorotnikov, Alexander/AAN-3080-2020; Birukov, Konstantin/FJB-5755-2022	Vorotnikov, Alexander/0000-0002-1460-971X; Vorotnikov, Alexander/0000-0002-1460-971X; Watterson, Daniel/0000-0001-7605-5866	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030861] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47070] Funding Source: Medline; NIGMS NIH HHS [GM30861] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELSTEIN RS, 1982, METHOD ENZYMOL, V85, P298; BELKIN AM, 1988, J BIOL CHEM, V263, P6631; COLLINGE M, 1992, MOL CELL BIOL, V12, P2359, DOI 10.1128/MCB.12.5.2359; CRAIG R, 1983, NATURE, V302, P436, DOI 10.1038/302436a0; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; FASOLO M, 1991, BIOCHEM BIOPH RES CO, V175, P277, DOI 10.1016/S0006-291X(05)81231-8; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; GILLIS JM, 1988, J MUSCLE RES CELL M, V9, P18, DOI 10.1007/BF01682145; HAIECH J, 1991, J BIOL CHEM, V266, P3427; HOMSHER E, 1992, AM J PHYSIOL, V262, pC714, DOI 10.1152/ajpcell.1992.262.3.C714; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; ITO M, 1989, J BIOL CHEM, V264, P13971; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MURPHY RA, 1989, ANNU REV PHYSIOL, V51, P275, DOI 10.1146/annurev.ph.51.030189.001423; NGAI PK, 1985, BIOCHEM J, V230, P695, DOI 10.1042/bj2300695; ONISHI H, 1982, J BIOCHEM-TOKYO, V92, P871, DOI 10.1093/oxfordjournals.jbchem.a134001; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; RUEGG JC, 1986, CALCIUM MUSCLE ACTIV, P201; SCHAEFER WH, 1987, J BIOL CHEM, V262, P1025; SELLERS JR, 1984, J BIOL CHEM, V259, P4203; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; SELLERS JR, 1985, J BIOL CHEM, V260, P5815; SELLERS JR, 1984, J BIOL CHEM, V259, P7740; SHATTUCK RL, 1988, J CELL BIOL, V107, P747; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; SMALL JV, 1977, BIOCH SMOOTH MUSCLE, P413; SOBIESZEK A, 1972, COLD SPRING HARB SYM, V37, P109; SOMLYO AV, 1981, NATURE, V294, P567, DOI 10.1038/294567a0; SUZUKI H, 1978, J BIOCHEM, V84, P1529, DOI 10.1093/oxfordjournals.jbchem.a132278; TRYBUS KM, 1987, J CELL BIOL, V105, P3007, DOI 10.1083/jcb.105.6.3007; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; VANELDIK LJ, 1984, BIOCHEM BIOPH RES CO, V124, P752, DOI 10.1016/0006-291X(84)91022-2; VANELDIK LJ, 1979, J BIOL CHEM, V254, P250	36	109	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16578	16583						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344938				2022-12-27	WOS:A1993LQ33600072
J	DICKINSON, CJ; DAUGHERTY, D; GUO, YJ; STADLER, B; FINNISS, S; YAMADA, T				DICKINSON, CJ; DAUGHERTY, D; GUO, YJ; STADLER, B; FINNISS, S; YAMADA, T			SUBSTRATE-SPECIFICITY OF THE GASTRIN-AMIDATING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-HYDROXYGLYCINE INTERMEDIATE; N-C LYASE; HUMAN GALANIN; D-ALANINE; HYDROXYLATING MONOOXYGENASE; PORCINE PITUITARY; MOLECULAR-CLONING; PEPTIDE AMIDES; MESSENGER-RNA; 2 ENZYMES	As is the case with many other peptide hormones of the brain and gut, gastrin requires a carboxyl-terminal amide moiety for optimal biological activity. In the structure of progastrin, the carboxyl-terminal Phe of gastrin is followed by the sequence Gly93-Arg94-Arg95, which must be processed sequentially by an endoprotease, a carboxypeptidase, and an amidating enzyme to produce amidated bioactive gastrin. To examine the molecular determinants of peptide amidation in vivo, we mutated the wild-type Gly93 residue of progastrin to Ala93 and Ser93 and expressed the three progastrin DNAs in GH3 and MTC 6-23 endocrine cell lines. Although substantial quantities of amidated gastrin were seen in cells expressing wild-type progastrin, replacement of Gly93 With Ala93 completely abolished production of amidated gastrin when the cells were incubated in standard medium containing only L-alanine. In a similar fashion, cells expressing [Ser93]progastrin also demonstrated no production of amidated gastrin. When cells expressing [Ala93]- or [Ser93]progastrin were incubated in the presence of 1 mg/ml D-alanine or D-serine, respectively, a small but consistent amount of amidated gastrin production was detected (< 1% of wild type). These data lead us to conclude that the amidating enzyme has a rigid substrate specificity for a glycine-extended precursor. Furthermore, this in vivo substrate specificity confirms the importance of the pro-S-alpha-hydrogen of the carboxyl-terminal glycine for enzyme-substrate recognition.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	DICKINSON, CJ (corresponding author), UNIV MICHIGAN,MED CTR,DEPT PEDIAT,C6105 MIB,ANN ARBOR,MI 48109, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK001903, P30DK034933, R01DK034306] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK-34306, K08-DK-01903, P30-DK-34933] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERSANI M, 1991, FEBS LETT, V283, P189, DOI 10.1016/0014-5793(91)80585-Q; BOEL E, 1983, P NATL ACAD SCI-BIOL, V80, P2866, DOI 10.1073/pnas.80.10.2866; BRADBURY AF, 1983, BIOCHEM BIOPH RES CO, V112, P372, DOI 10.1016/0006-291X(83)91473-0; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAUGHERTY D, 1989, PHYSIOL REV, V69, P482, DOI 10.1152/physrev.1989.69.2.482; DAUGHERTY DF, 1991, AM J PHYSIOL, V260, pG783, DOI 10.1152/ajpgi.1991.260.5.G783; DICKINSON C, 1989, HDB PHYSL NEUROENDOC, P63; DICKINSON CJ, 1991, J BIOL CHEM, V266, P334; EIPPER BA, 1992, J BIOL CHEM, V267, P4008; EIPPER BA, 1991, J BIOL CHEM, V266, P7827; EVANS HF, 1991, ENDOCRINOLOGY, V129, P1682, DOI 10.1210/endo-129-3-1682; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREGORY H, 1964, NATURE, V204, P931, DOI 10.1038/204931a0; HUSTEN EJ, 1991, J BIOL CHEM, V266, P17004; INNIS MA, 1990, PCR PROTOCOLS GUIDE, P306; IWASAKI Y, 1991, EUR J BIOCHEM, V201, P551, DOI 10.1111/j.1432-1033.1991.tb16314.x; KATO I, 1990, BIOCHEM BIOPH RES CO, V172, P197, DOI 10.1016/S0006-291X(05)80193-7; KATOPODIS AG, 1991, BIOCHEMISTRY-US, V30, P6189, DOI 10.1021/bi00239a016; KAWAHARA T, 1992, J CHEM SOC CHEM COMM, P625, DOI 10.1039/c39920000625; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LACEY JC, 1988, P NATL ACAD SCI USA, V85, P4996, DOI 10.1073/pnas.85.14.4996; LANDYMORELIM AEN, 1983, BIOCHEM BIOPH RES CO, V117, P289, DOI 10.1016/0006-291X(83)91573-5; MARINO LR, 1991, J BIOL CHEM, V266, P6133; MATSUMOTO M, 1987, AM J PHYSIOL, V252, pG315, DOI 10.1152/ajpgi.1987.252.3.G315; MCKNIGHT GL, 1992, DIABETES, V41, P82, DOI 10.2337/diabetes.41.1.82; MERKLER DJ, 1991, ARCH BIOCHEM BIOPHYS, V289, P192, DOI 10.1016/0003-9861(91)90461-Q; MOR A, 1991, J BIOL CHEM, V266, P6264; MOR A, 1990, BIOCHEM BIOPH RES CO, V170, P30, DOI 10.1016/0006-291X(90)91236-L; RAMER SE, 1988, J AM CHEM SOC, V110, P8526, DOI 10.1021/ja00233a032; RICHTER K, 1987, SCIENCE, V238, P200, DOI 10.1126/science.3659910; ROKAEUS A, 1986, P NATL ACAD SCI USA, V83, P6287, DOI 10.1073/pnas.83.17.6287; ROSENQUIST GL, 1980, GASTROINTESTINAL HOR, P769; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT WE, 1991, P NATL ACAD SCI USA, V88, P11435, DOI 10.1073/pnas.88.24.11435; STOLLER TJ, 1988, J CELL BIOL, V107, P2087, DOI 10.1083/jcb.107.6.2087; SUZUKI K, 1990, EMBO J, V9, P4259, DOI 10.1002/j.1460-2075.1990.tb07874.x; TAJIMA M, 1990, J BIOL CHEM, V265, P9602; TAKAHASHI K, 1990, BIOCHEM BIOPH RES CO, V169, P524, DOI 10.1016/0006-291X(90)90362-Q; TAKEUCHI T, 1991, J BIOL CHEM, V266, P17409; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; VRONTAKIS ME, 1987, J BIOL CHEM, V262, P16755; YAMANE T, 1981, BIOCHEMISTRY-US, V20, P7059, DOI 10.1021/bi00528a001; YOUNG SD, 1989, J AM CHEM SOC, V111, P1933, DOI 10.1021/ja00187a088; ZEYTINOGLU FN, 1980, ENDOCRINOLOGY, V107, P509, DOI 10.1210/endo-107-2-509	46	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15929	15934						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340416				2022-12-27	WOS:A1993LN30500086
J	LOMAS, DA; FINCH, JT; SEYAMA, K; NUKIWA, T; CARRELL, RW				LOMAS, DA; FINCH, JT; SEYAMA, K; NUKIWA, T; CARRELL, RW			ALPHA-1-ANTITRYPSIN S(IIYAMA) (SER(53)-]PHE) - FURTHER EVIDENCE FOR INTRACELLULAR LOOP-SHEET POLYMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN ALPHA-1-PROTEINASE INHIBITOR; DEFICIENCY ALLELE; LIVER; VARIANT; MMALTON; PROTEINS; DISEASE	Antitrypsin S(iiyama) is a rare example of the deficiency variants of antitrypsin that accumulate in the endoplasmic reticulum of the hepatocyte. The common example is Z antitrypsin, which has a mutation (Glu342 --> Lys) at the junction of the head of the fifth strand of the A sheet and the base of the reactive center loop. It was previously shown that Z antitrypsin spontaneously polymerizes due to the insertion of the reactive center loop of one molecule into the A sheet of a second. The mutation in antitrypsin S(iiyama)(Ser53 --> Phe) affects a residue that provides a ridge for the sliding movement that opens the A sheet, and it had been predicted that this would result in the same type of loop-sheet polymerization observed with the Z variant. We confirm this here and show that virtually all the plasma antitrypsin in a homozygote for the S(iiyama) variant was polymerized due to non-covalent bonding with a loss of accessibility of the reactive center loop. The common basis of the polymerization of Z and S(iiyama) antitrypsin is supported by identical findings on electron microscopy. Taken together these results confirm that loop-sheet polymerization is a general mechanism and as such is likely to be responsible for the intracellular inclusions associated with liver pathology.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; JUNTENDO UNIV,SCH MED,DEPT RESP MED,BUNKYO KU,TOKYO 113,JAPAN	MRC Laboratory Molecular Biology; Juntendo University	LOMAS, DA (corresponding author), UNIV CAMBRIDGE,DEPT HAEMATOL,CAMBRIDGE,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CURIEL DT, 1989, J BIOL CHEM, V264, P13938; ERIKSSON S, 1975, NEW ENGL J MED, V292, P176, DOI 10.1056/NEJM197501232920403; FABBRETTI G, 1992, LIVER, V12, P296; FRAIZER GC, 1989, AM J HUM GENET, V44, P894; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; GRAHAM A, 1989, HUM GENET, V84, P55, DOI 10.1007/BF00210671; JEPPSSON JO, 1976, FEBS LETT, V65, P195, DOI 10.1016/0014-5793(76)80478-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; LOMAS DA, 1993, J BIOL CHEM, V268, P516; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; MATSUNAGA E, 1990, AM J HUM GENET, V46, P602; ROBERTS EA, 1984, AM J CLIN PATHOL, V82, P424, DOI 10.1093/ajcp/82.4.424; SEYAMA K, 1991, J BIOL CHEM, V266, P12627; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAVIS J, 1981, METHOD ENZYMOL, V80, P754; YOSHIDA A, 1976, P NATL ACAD SCI USA, V73, P1324, DOI 10.1073/pnas.73.4.1324	19	184	190	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15333	15335						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340361				2022-12-27	WOS:A1993LN30500003
J	MOON, C; PRESTON, GM; GRIFFIN, CA; JABS, EW; AGRE, P				MOON, C; PRESTON, GM; GRIFFIN, CA; JABS, EW; AGRE, P			THE HUMAN AQUAPORIN-CHIP GENE - STRUCTURE, ORGANIZATION, AND CHROMOSOMAL LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR INTRINSIC PROTEIN; TRANSMEMBRANE CHANNEL PROTEINS; INTEGRAL MEMBRANE-PROTEIN; LENS FIBER MEMBRANE; ESCHERICHIA-COLI; GLYCEROL FACILITATOR; INSITU HYBRIDIZATION; NUCLEOTIDE-SEQUENCE; SOYBEAN NODULIN-26; WATER CHANNELS	Aquaporin-CHIP is the first known molecular water channel. Originally identified in red cells and renal tubules, transcripts and proteins related to AQP-CHIP are also expressed in diverse epithelia with distinct developmental patterns. Northern analyses of RNA from several tissues revealed transcripts of 3.1 kilobases and other sizes. The nucleotide sequences of human kidney AQP-CHIP cDNAs are identical to the human bone marrow AQP-CHIP cDNA. The 17-kilobase human AQP-CHIP structural gene was isolated, and restriction maps were constructed and partially sequenced. The TATA consensus sequence is located 87 bp 5' to the translation initiation site, and sequences surrounding the polyadenylation consensus were determined. Four exons were identified corresponding to amino acids 1-128, 129-183, 184-2 10, and 211-269, separated by introns of 9.6, 0.43, and 0.80 kilobases. Genomic Southern analyses indicated the existence of a single AQP-CHIP gene which was located at human chromosome 7p14 by in situ hybridization. Sequence comparisons of AQP-CHIP and cDNAs of similar proteins from diverse species suggested a common evolutionary origin. At least three of these proteins are now known to function as membrane water pores and are referred to as the ''Aquaporins.'' These genomic AQP-CHIP DNA sequences should permit molecular characterization of the complex patterns of AQP-CHIP expression.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED & CELL BIOL ANAT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT ONCOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT & MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, CTR MED GENET, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University				Jabs, Ethylin/0000-0001-8983-5466	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033991, R01HL048268, R37HL048268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R03AA009012] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48268, HL33991] Funding Source: Medline; NIAAA NIH HHS [AA09012] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AGRE P, 1993, IN PRESS AM J PHYSL; BAKER ME, 1990, CELL, V60, P185, DOI 10.1016/0092-8674(90)90731-S; BHATT B, 1988, NUCLEIC ACIDS RES, V16, P3951, DOI 10.1093/nar/16.9.3951; BONDY C, 1993, P NATL ACAD SCI USA, V90, P4500, DOI 10.1073/pnas.90.10.4500; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEEN PMT, 1992, BIOCHEM BIOPH RES CO, V188, P1267, DOI 10.1016/0006-291X(92)91368-Z; DENKER BM, 1988, J BIOL CHEM, V263, P15634; EHRING GR, 1990, J GEN PHYSIOL, V96, P631, DOI 10.1085/jgp.96.3.631; FENG DF, 1990, METHOD ENZYMOL, V183, P375; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; GUERRERO FD, 1990, PLANT MOL BIOL, V15, P11, DOI 10.1007/BF00017720; HELLER KB, 1980, J BACTERIOL, V144, P274, DOI 10.1128/JB.144.1.274-278.1980; HOFTE H, 1992, PLANT PHYSIOL, V99, P561, DOI 10.1104/pp.99.2.561; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; MAUREL C, 1993, IN PRESS EMBO J; MURAMATSU S, 1989, NUCLEIC ACIDS RES, V17, P4378; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; NIELSEN S, 1993, IN PRESS P NATL ACAD; PAO GM, 1991, MOL MICROBIOL, V5, P33, DOI 10.1111/j.1365-2958.1991.tb01823.x; PISANO MM, 1991, GENOMICS, V11, P981; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; RAO Y, 1990, NATURE, V345, P163, DOI 10.1038/345163a0; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; Sambrook J, 1989, MOL CLONING LABORATO; SANDAL NN, 1988, NUCLEIC ACIDS RES, V16, P9347, DOI 10.1093/nar/16.19.9347; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH BL, 1991, J BIOL CHEM, V266, P6407; VANAELST L, 1991, EMBO J, V10, P2095, DOI 10.1002/j.1460-2075.1991.tb07742.x; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; WISTOW GJ, 1991, TRENDS BIOCHEM SCI, V16, P170, DOI 10.1016/0968-0004(91)90065-4; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZHANG RB, 1993, J CELL BIOL, V120, P359, DOI 10.1083/jcb.120.2.359	36	104	112	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15772	15778						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340403				2022-12-27	WOS:A1993LN30500067
J	BEDALE, WA; INMAN, RB; COX, MM				BEDALE, WA; INMAN, RB; COX, MM			A REVERSE DNA STRAND EXCHANGE MEDIATED BY RECA PROTEIN AND EXONUCLEASE-I - THE GENERATION OF APPARENT DNA STRAND BREAKS BY RECA PROTEIN IS EXPLAINED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENETIC-RECOMBINATION; DEOXYRIBONUCLEIC-ACID; UNWINDING PROTEIN; BRANCH MIGRATION; BINDING-PROTEIN; 3-STRANDED DNA; M13 VECTORS; PURIFICATION; COMPLEXES	The combined action of exonuclease I and recA protein leads to a kind of reverse DNA strand exchange in which joint molecules formed on the ''wrong'' or distal end of a linear duplex in the presence of ATP are stabilized by exonuclease I degradation of the displaced (+) strand. Continued pairing and degradation of the displaced strand leads to strand exchange that appears to progress with a polarity opposite that of the normal recA protein promoted reaction (i. e. 3'-5' with respect to the (+) strand). However, in contrast to the normal 5'-3' strand exchange, the displaced strand is completely degraded in the process. When the linear duplex DNA substrate has a heterologous region at the 5' (proximal) end, the major product (described in a previous study (Bedale, W. A., Inman, R. B., and Cox, M. M. (1991) J. Biol. Chem. 266, 6499-6510)) is a circular duplex DNA molecule with a double-stranded tail whose length corresponds closely to the heterologous segment of the substrate. The origin of this product is here shown to be the result of the exonuclease activity of exonuclease I (either added exogenously or present as a trace contaminant of recA protein or SSB protein preparations), as opposed to endonucleolytic or mechanical breakage. The levels of exonuclease I required to generate these products are sufficiently low that they are undetected by assays for exonuclease contamination in recA protein preparations. These results demonstrate that the interplay of recA protein with other enzymes can have a profound effect on both the mechanism and outcome of recA protein-promoted DNA strand exchange. They also demonstrate that the (+) strand of the duplex DNA substrate is at least transiently displaced in recA protein-mediated pairing even when joint molecules are limited to the distal end.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Bedale, Wendy/0000-0002-0122-4255	NIGMS NIH HHS [GM32335, T32-GM07215, GM14711] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032335, U01GM032335, R01GM014711, T32GM007215] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZUMA K, 1992, GENE DEV, V6, P1679, DOI 10.1101/gad.6.9.1679; BEDALE WA, 1991, J BIOL CHEM, V266, P6499; BIANCHI ME, 1983, CELL, V35, P511, DOI 10.1016/0092-8674(83)90185-X; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CHASE JW, 1974, J BIOL CHEM, V249, P4545; CHASE JW, 1981, GENE AMPLIFICATION A, P147; Cox M M, 1983, Cold Spring Harb Symp Quant Biol, V47 Pt 2, P803; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1982, J BIOL CHEM, V257, P8523; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; COX MM, 1987, DNA REPLICATION RECO, P597; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Davis R., 1980, ADV BACTERIAL GENETI; EICHLER DC, 1977, J BIOL CHEM, V252, P499; FREITAG N, 1988, J BIOL CHEM, V263, P19525; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; HSIEH P, 1990, GENE DEV, V4, P1951, DOI 10.1101/gad.4.11.1951; JAIN SK, 1992, J BIOL CHEM, V267, P4215; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; JWANG BR, 1992, P NATL ACAD SCI USA, V89, P7596, DOI 10.1073/pnas.89.16.7596; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KIM JI, 1992, J BIOL CHEM, V267, P16444; KIM JI, 1992, J BIOL CHEM, V267, P16438; KONFORTI BB, 1992, J MOL BIOL, V227, P38, DOI 10.1016/0022-2836(92)90680-I; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KUSHNER SR, 1971, P NATL ACAD SCI USA, V68, P824, DOI 10.1073/pnas.68.4.824; LEHMAN IR, 1964, J BIOL CHEM, V239, P2628; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MOLINEUX IJ, 1975, J MOL BIOL, V98, P811, DOI 10.1016/S0022-2836(75)80012-X; MOLINEUX IJ, 1974, J BIOL CHEM, V249, P6090; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; PHILLIPS GJ, 1988, J BACTERIOL, V170, P2089, DOI 10.1128/jb.170.5.2089-2094.1988; PRASHER DC, 1983, J BIOL CHEM, V258, P6340; RADDING CM, 1989, BIOCHIM BIOPHYS ACTA, V1008, P131, DOI 10.1016/0167-4781(80)90001-9; RAO BJ, 1991, P NATL ACAD SCI USA, V88, P2984, DOI 10.1073/pnas.88.8.2984; RAO BJ, 1991, BIOCHIMIE, V73, P363, DOI 10.1016/0300-9084(91)90102-7; RAO BJ, 1993, IN PRESS J MOL BIOL; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; ROSSELLI W, 1991, EMBO J, V10, P4391, DOI 10.1002/j.1460-2075.1991.tb05017.x; Sambrook J, 1989, MOL CLONING LABORATO; SHIBATA T, 1981, J BIOL CHEM, V256, P7557; STASIAK A, 1992, MOL MICROBIOL, V6, P3267, DOI 10.1111/j.1365-2958.1992.tb02194.x; VALES LD, 1982, J BIOL CHEM, V257, P8799; WALCZAK CE, 1993, CELL MOTIL CYTOSKEL, V24, P17, DOI 10.1002/cm.970240103; WEISS B, 1981, ENZYMES, V14, P203; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P6149, DOI 10.1073/pnas.78.10.6149	50	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15004	15016						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325876				2022-12-27	WOS:A1993LL75900070
J	BOCKHOLT, SM; BURRIDGE, K				BOCKHOLT, SM; BURRIDGE, K			CELL SPREADING ON EXTRACELLULAR-MATRIX PROTEINS INDUCES TYROSINE PHOSPHORYLATION OF TENSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ROUS-SARCOMA VIRUS; FOCAL ADHESIONS; TRANSFORMING PROTEIN; VINCULIN; TALIN; PAXILLIN	A small number of proteins becomes tyrosine-phosphorylated in response to integrin-mediated cell adhesion to extracellular matrix proteins. Previous work has identified two of these tyrosine-phosphorylated proteins as the focal adhesion kinase and paxillin. Here we identify a third focal adhesion protein, tensin, that becomes tyrosine-phosphorylated during cell adhesion to extracellular matrix proteins. The tyrosine phosphorylation of tensin does not occur when cells adhere to plastic or polylysine and is blocked when microfilament assembly and cell spreading are inhibited with cytochalasin D. In addition, we show that other focal adhesion proteins such as talin and vinculin do not become tyrosine-phosphorylated under the same conditions of cell spreading on extracellular matrix proteins.			BOCKHOLT, SM (corresponding author), UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CB 7090,214 TAYLOR HALL,CHAPEL HILL,NC 27599, USA.							BOCKHOLT SM, 1992, EXP CELL RES, V203, P39, DOI 10.1016/0014-4827(92)90037-9; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; DECLUE JE, 1987, MOL CELL BIOL, V7, P371, DOI 10.1128/MCB.7.1.371; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; OTEY C, 1990, HYBRIDOMA, V9, P57, DOI 10.1089/hyb.1990.9.57; PASQUALE EB, 1986, P NATL ACAD SCI USA, V83, P5507, DOI 10.1073/pnas.83.15.5507; PELLETIER AJ, 1992, MOL BIOL CELL, V3, P989, DOI 10.1091/mbc.3.9.989; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; WILKINS JA, 1986, J CELL BIOL, V103, P1483, DOI 10.1083/jcb.103.4.1483; WILKINS JA, 1987, J CELL BIOL, V105, pA103	24	250	250	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14565	14567						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325835				2022-12-27	WOS:A1993LL75900004
J	SKURAT, AV; CAO, YJ; ROACH, PJ				SKURAT, AV; CAO, YJ; ROACH, PJ			GLUCOSE CONTROL OF RABBIT SKELETAL-MUSCLE GLYCOGENIN EXPRESSED IN COS CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PHOSPHORYLATION; SYNTHASE; BIOGENESIS; PRIMER; DNA; BIOSYNTHESIS; INITIATION; ANTIBODIES; SEQUENCE; CLONING	Glycogenin is a self-glucosylating protein involved in the initiation of glycogen synthesis. Rabbit skeletal muscle glycogenin, transiently expressed in COS cells, was found exclusively in the low speed supernatant fraction, with M(r) 37-38,000. The protein was capable of self-glucosylation and was, if suitably primed, an effective substrate for glycogen synthase. Rabbit muscle glycogen synthase was similarly expressed, to a level 7-10-fold over the endogenous activity. Most of the expressed protein was found in the low speed pellet fraction. However, when co-expressed with glycogenin, a significant increase in the proportion of glycogen synthase in the soluble fraction was observed. Therefore, glycogenin interacts with glycogen synthase in the cell and redistributes the synthase to the soluble fraction. Co-expression of an inactive form of glycogenin did not affect glycogen synthase localization. The expressed glycogenin could be detected as two distinguishable species, differing slightly in electrophoretic mobility, depending on the glucose concentration of the cell culture medium. At 25 mM glucose, a form of M(r) 38,000 was observed; however, upon transfer to 5 mM glucose, it converted to a species of slightly lower M(r). The M(r) of the 38,000-dalton species could be also be reduced by treatment of the cell extract with a-amylase. It was additionally found that the 38,000-dalton glycogenin was a much more effective glycogen synthase substrate than the lower M(r) species. These results, therefore, raise the possibility of a novel mechanism for the control of glycogen metabolism in which glucose levels would regulate the glucosylation state of glycogenin, which in turn would determine glycogenin's efficacy as a substrate for elongation by glycogen synthase.			SKURAT, AV (corresponding author), INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202, USA.				NIDDK NIH HHS [DK27221] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027221, R37DK027221] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD Z, 1986, ARCH BIOCHEM BIOPHYS, V250, P329, DOI 10.1016/0003-9861(86)90734-4; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARMSTRONG DJ, 1989, ARCH BIOCHEM BIOPHYS, V275, P16, DOI 10.1016/0003-9861(89)90344-5; BAI G, 1990, J BIOL CHEM, V265, P7843; BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BROWN NE, 1971, BIOCHIM BIOPHYS ACTA, V242, P69, DOI 10.1016/0005-2744(71)90088-X; BROWNER MF, 1989, P NATL ACAD SCI USA, V86, P1443, DOI 10.1073/pnas.86.5.1443; CAMPBELL DG, 1989, EUR J BIOCHEM, V185, P119, DOI 10.1111/j.1432-1033.1989.tb15090.x; COHEN P, 1982, NATURE, V296, P613, DOI 10.1038/296613a0; Cohen P., 1986, ENZYMES, VXVII, P461; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FARKAS I, 1990, J BIOL CHEM, V265, P20879; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V281, P443, DOI 10.1042/bj2810443; FRIEDMAN DL, 1963, BIOCHEMISTRY-US, V2, P669, DOI 10.1021/bi00904a009; Kennedy L., 1985, MEMBRANES MUSCLE, P65; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE RD, 1989, BIOCHEM INT, V18, P961; LOMAKO J, 1990, BIOCHEM INT, V21, P251; LOMAKO J, 1990, FEBS LETT, V264, P13, DOI 10.1016/0014-5793(90)80752-5; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; LOMAKO J, 1990, FEBS LETT, V268, P8, DOI 10.1016/0014-5793(90)80959-M; LOMAKO J, 1992, CARBOHYD RES, V227, P331, DOI 10.1016/0008-6215(92)85082-B; Maniatis T., 1982, MOL CLONING; NIMMO HG, 1976, EUR J BIOCHEM, V68, P21, DOI 10.1111/j.1432-1033.1976.tb10761.x; PITCHER J, 1988, EUR J BIOCHEM, V176, P391, DOI 10.1111/j.1432-1033.1988.tb14294.x; PITCHER J, 1987, EUR J BIOCHEM, V169, P487; Roach P. J., 1986, ENZYMES, VXVII, P499; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; RODRIGUEZ IR, 1988, ARCH BIOCHEM BIOPHYS, V260, P628, DOI 10.1016/0003-9861(88)90491-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMYTHE C, 1991, EUR J BIOCHEM, V200, P625, DOI 10.1111/j.1432-1033.1991.tb16225.x; SMYTHE C, 1990, EUR J BIOCHEM, V189, P199, DOI 10.1111/j.1432-1033.1990.tb15477.x; SMYTHE C, 1988, EMBO J, V7, P2681, DOI 10.1002/j.1460-2075.1988.tb03121.x; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VISKUPIC E, 1992, J BIOL CHEM, V267, P25759; WHELAN WJ, 1986, BIOESSAYS, V5, P136, DOI 10.1002/bies.950050312; ZHANG WM, 1989, FASEB J, V3, P2532, DOI 10.1096/fasebj.3.13.2509275	40	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14701	14707						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325849				2022-12-27	WOS:A1993LL75900029
J	PASTORINO, JG; SNYDER, JW; SERRONI, A; HOEK, JB; FARBER, JL				PASTORINO, JG; SNYDER, JW; SERRONI, A; HOEK, JB; FARBER, JL			CYCLOSPORINE AND CARNITINE PREVENT THE ANOXIC DEATH OF CULTURED-HEPATOCYTES BY INHIBITING THE MITOCHONDRIAL PERMEABILITY TRANSITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER MEMBRANE-PERMEABILITY; LIVER-MITOCHONDRIA; INORGANIC-PHOSPHATE; HEART-MITOCHONDRIA; OXIDATIVE STRESS; DYSFUNCTION; MECHANISMS; NUCLEOTIDES; REVERSAL; CALCIUM	Cyclosporin A (CyA) and L-carnitine (LC) prevented the killing of cultured hepatocytes by anoxia and rotenone but not by cyanide. Neither CyA nor LC affected the rate or extent of the loss of the mitochondrial membrane potential or the rate or extent of the depletion of ATP. Atractyloside blocked the ability of both CyA and LC to protect, and D-carnitine antagonized the effect of LC but not that of CyA. Cell killing by cyanide was prevented when the phospholipase A2 inhibitor butacaine was added together with CyA. Butacaine by itself had no effect on cell killing. In a swelling assay with isolated rat liver mitochondria having a low calcium content, phenylarsine oxide or palmitoyl-CoA induced the inner membrane permeability transition when electron transport was inhibited by rotenone or cyanide. CyA prevented the permeability transition with rotenone but not with cyanide, and atractyloside reversed the effect of CyA. LC prevented the permeability transition occurring with palmitoyl-CoA plus rotenone but not with palmitoyl-CoA plus cyanide. Atractyloside and D-carnitine antagonized the protective effect of LC. Inhibition of the cyanide-dependent permeability transition in isolated liver mitochondria required the presence of both CyA and butacaine. These data document the close correlation between the effect of CyA and LC on the response of cultured hepatocytes to inhibition of mitochondrial electron transport and their ability to prevent the permeability transition in isolated mitochondria. It is concluded that the ability of CyA and LC to protect cultured hepatocytes is a consequence of their ability to prevent the mitochondrial permeability transition, indicating that this event is likely to be causally linked to the genesis of irreversible injury. Thus, cell death with anoxia or inhibitors of electron transport is related to a mitochondrial alteration by a mechanism that is independent of the maintenance of a membrane potential or cellular stores of ATP.	THOMAS JEFFERSON UNIV,DEPT PATHOL & CELL BIOL,RM 251,JEFFERSON ALUMNI HALL,PHILADELPHIA,PA 19107	Jefferson University				Hoek, Jan/0000-0001-7127-4218	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA07186] Funding Source: Medline; NIDDK NIH HHS [DK38305] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATRICE MC, 1984, J BIOL CHEM, V259, P1279; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; BROEKEMEIER KM, 1989, BIOCHEM BIOPH RES CO, V163, P561, DOI 10.1016/0006-291X(89)92174-8; CROMPTON M, 1988, EUR J BIOCHEM, V178, P489, DOI 10.1111/j.1432-1033.1988.tb14475.x; CROMPTON M, 1988, BIOCHEM J, V255, P357; FARBER JL, 1981, ARCH BIOCHEM BIOPHYS, V211, P312, DOI 10.1016/0003-9861(81)90459-8; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HAWORTH RA, 1980, J MEMBRANE BIOL, V54, P231, DOI 10.1007/BF01870239; HOEK JB, 1980, J BIOL CHEM, V255, P1458; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; IBRAVBOA UC, 1989, BIOCHEM BIOPH RES CO, V161, P619; KANE AB, 1985, AM J PHYSIOL, V249, pC256, DOI 10.1152/ajpcell.1985.249.3.C256; LEQUOC K, 1988, ARCH BIOCHEM BIOPHYS, V265, P249, DOI 10.1016/0003-9861(88)90125-7; MASAKI N, 1989, ARCH BIOCHEM BIOPHYS, V270, P672, DOI 10.1016/0003-9861(89)90550-X; MITTNACHT S, 1981, J BIOL CHEM, V256, P3199; MITTNACHT S, 1979, J BIOL CHEM, V254, P9871; NOVGORODOV SA, 1992, J BIOL CHEM, V267, P16274; PFEIFFER DR, 1979, J BIOL CHEM, V254, P1485; SAKAIDA I, 1992, AM J PHYSIOL, V263, pC684, DOI 10.1152/ajpcell.1992.263.3.C684; SCHMID PC, 1981, J LIPID RES, V22, P882; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SNYDER JW, 1990, ARCH BIOCHEM BIOPHYS, V276, P132, DOI 10.1016/0003-9861(90)90019-U; SNYDER JW, 1993, AM J PHYSIOL, V264, pC709, DOI 10.1152/ajpcell.1993.264.3.C709; THOMSON AW, 1990, IMMUNOL TODAY, V11, P35; TONINELLO A, 1983, BIOCHEM BIOPH RES CO, V111, P792, DOI 10.1016/0006-291X(83)91368-2; WALAJTYSRHODE E, 1992, J BIOL CHEM, V267, P370	28	301	303	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13791	13798						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314748				2022-12-27	WOS:A1993LJ82500007
J	KANG, HA; HERSHEY, JWB				KANG, HA; HERSHEY, JWB			EFFECT OF INITIATION-FACTOR EIF-5A DEPLETION ON PROTEIN-SYNTHESIS AND PROLIFERATION OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPUSINE-CONTAINING PROTEIN; FACTOR 4D; TRANSLATION; PURIFICATION; YEAST; REPRESSION; MUTATIONS	Eukaryotic translation initiation factor eIF-5A (formerly eIF-4D) is thought to function in protein synthesis by promoting synthesis of the first peptide bond because it stimulates methionyl-puromycin formation in vitro. eIF-5A is encoded by two genes (TIF51A and TIF51B) in Saccharomyces cerevisiae; the protein and its hypusine modification are essential for cell viability. To analyze the factor's function in vivo, we expressed from the repressible GAL promoter a functional but unstable eIF-5A fusion protein (R-eIF-5A) with an NH2-terminal arginine which is subject to rapid turnover through the NH2-terminal end rule proteolytic pathway. When the conditional mutant strain is shifted from galactose to glucose medium, the rapid disappearance of R-eIF-5A protein occurs within one generation, causing an immediate inhibition of cell growth. However, eIF-5A-depleted cells synthesize protein at about 70% of the wild type rate and exhibit only a slight change in polysome profiles reflecting a subtle defect in a late step of translation initiation. These results suggest that the activity of eIF-5A may not be absolutely essential for general protein synthesis. Rather, eIF-5A may be selectively required for translation of certain mRNAs and/or may be involved in some other aspect of cell metabolism.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616	University of California System; University of California Davis					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BENNE R, 1978, J BIOL CHEM, V253, P3070; BLUM S, 1989, P NATL ACAD SCI USA, V86, P6043, DOI 10.1073/pnas.86.16.6043; COOPER HL, 1983, P NATL ACAD SCI-BIOL, V80, P1854, DOI 10.1073/pnas.80.7.1854; DUNCAN RF, 1986, J BIOL CHEM, V261, P2903; GORDON ED, 1987, J BIOL CHEM, V262, P16590; GORDON ED, 1987, J BIOL CHEM, V262, P16585; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HERSHEY JWB, 1990, BIOCHIM BIOPHYS ACTA, V1050, P160, DOI 10.1016/0167-4781(90)90159-Y; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KANG HA, 1992, MOL GEN GENET, V233, P487, DOI 10.1007/BF00265449; KANG HA, 1993, J BIOL CHEM, V268, P14750; KEMPER WM, 1976, J BIOL CHEM, V251, P5551; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY CV, 1988, MOL CELL BIOL, V8, P4651, DOI 10.1128/MCB.8.11.4651; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; METHA KD, 1990, J BIOL CHEM, V265, P8802; PARK EC, 1992, P NATL ACAD SCI USA, V89, P1249, DOI 10.1073/pnas.89.4.1249; PARK MH, 1984, J BIOL CHEM, V259, P2123; PARK MH, 1989, J BIOL CHEM, V264, P18531; PARK MH, 1993, BIOFACTORS, V4, P95; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; SCHWELBERGER HG, 1993, J BIOL CHEM, V268, P14018; Sherman F., 1986, METHODS YEAST GENETI; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P18527; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P1578; STRUHL K, 1979, PNATL ACAD SCI US, V76, P503; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; THOMAS A, 1979, EUR J BIOCHEM, V98, P329, DOI 10.1111/j.1432-1033.1979.tb13192.x; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WATSON PA, 1991, CYTOMETRY, V12, P242, DOI 10.1002/cyto.990120306; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819	36	264	290	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3934	3940						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307948				2022-12-27	WOS:A1994MW98900008
J	LIU, YH; MICHALOPOULOS, GK; ZARNEGAR, R				LIU, YH; MICHALOPOULOS, GK; ZARNEGAR, R			STRUCTURAL AND FUNCTIONAL-CHARACTERIZATION OF THE MOUSE HEPATOCYTE GROWTH-FACTOR GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR HEPATOPOIETIN-A; HUMAN SKIN FIBROBLASTS; FACTOR MESSENGER-RNA; FAT-STORING CELLS; TRANSCRIPTION FACTOR; RAT-LIVER; PARTIAL-HEPATECTOMY; NEGATIVE REGULATION; MOLECULAR-CLONING; ESTROGEN-RECEPTOR	To understand the molecular mechanisms underlying the regulation of hepatocyte growth factor (HGF) gene expression and to define the DNA sequences essential for its cell-type specific and inducible expression, we have isolated and characterized the 5'-flanking region of the HGF gene. A genomic clone containing 2.8 kilobases of the 5'-flanking region of the HGF gene has been isolated from a mouse liver genomic library. Sequence analysis showed that the promoter region of the mouse HGF gene contains a noncanonical TATA box (ATAAA). Further analysis of the 5'- flanking region revealed a number of putative regulatory elements, such as four interleukin-6 response elements (IL-6 RE), two potential binding sites for NF-IL6, a TGF-beta inhibitory element (TIE), a cAMP response element (CRE), two estrogen response elements (ERE) including one located in the first intron, a potential vitamin D response element (VDRE) which overlaps a chicken ovalbumin upstream promoter (COUP) transcription factor binding element, two liver-specific transcription factor (C/EBP) binding sites, and a B cell- and macrophage-specific transcriptional factor binding site (PU.1/ETS). To determine the location of sites that may be critical for the function of the HGF promoter, we constructed a series of chimeric genes containing variable regions of the 5'-flanking sequence of HGF gene and the coding region for chloramphenicol acetyltransferase (CAT). Transient transfection of chimeric plasmids demonstrated that the mouse HGF gene promoter containing 70 base pairs of the 5'-flanking sequences was active in mouse fibroblast NIH 3T3 cells and in human endometrial carcinoma RL95-2 cells. This basal transcription activity of the HGF promoter was modulated;in NM 3T3 and RL95-2 cells by multiple upstream elements. Three positive elements were identified at positions -2848 to -2674, -1386 to -1231, and -699 to -274, and three negative candidate elements were mapped to positions -1652 to -1386, -964 to -699, and -274 to -70, respectively. By the combination of a series of 5'-end deletion and internal deletion, a cell type specific negative regulatory element in RL95-2 cells was localized to the nucleotide position -964 to -699. Moreover, the reporter plasmid containing interleukin 6 (IL-6) response element was responsive to IL 6 stimulation in stably transfected NIH 3T3 cells. Our findings revealed a complex pattern of transcriptional regulation of the mouse HGF gene expression.	UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh				Liu, Youhua/0000-0002-4740-805X	NCI NIH HHS [CA 35373] Funding Source: Medline; NIEHS NIH HHS [R01ES06109-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006109] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CONNOR AM, 1989, BIOCHIM BIOPHYS ACTA, V1009, P75, DOI 10.1016/0167-4781(89)90081-X; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; DEFRANCES MC, 1992, DEVELOPMENT, V116, P388; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; GOHDA E, 1992, FEBS LETT, V301, P107, DOI 10.1016/0014-5793(92)80220-B; GUERIN SL, 1990, J BIOL CHEM, V265, P22035; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; JAKOWLEW SB, 1992, MOL ENDOCRINOL, V6, P1285, DOI 10.1210/me.6.8.1285; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P367; KONO S, 1992, BIOCHEM BIOPH RES CO, V186, P991, DOI 10.1016/0006-291X(92)90844-B; LINDROOS PM, 1991, HEPATOLOGY, V13, P743, DOI 10.1002/hep.1840130422; LIU YH, 1993, MOL CELL BIOL, V13, P1836, DOI 10.1128/MCB.13.3.1836; LIU YH, 1991, J BIOL CHEM, V266, P21880; LIU YH, 1992, MOL ENDOCRINOL, V6, P355, DOI 10.1210/me.6.3.355; LIU YH, 1993, IN PRESS BIOCH BIOPH; LOCKER J, 1993, EUKARYOTIC GENE TRAN, P321; MAHER JJ, 1993, J CLIN INVEST, V91, P2244, DOI 10.1172/JCI116451; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; MATSUMOTO K, 1992, BIOCHEM BIOPH RES CO, V188, P235, DOI 10.1016/0006-291X(92)92375-8; MATSUMOTO K, 1992, J BIOL CHEM, V267, P24917; MICHALOPOULOS GK, 1992, HEPATOLOGY, V15, P149, DOI 10.1002/hep.1840150125; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIYAZAWA K, 1991, BIOCHEMISTRY-US, V30, P9170, DOI 10.1021/bi00102a007; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NISHINO T, 1991, BIOCHEM BIOPH RES CO, V181, P323, DOI 10.1016/S0006-291X(05)81421-4; OKAJIMA A, 1990, EUR J BIOCHEM, V193, P375, DOI 10.1111/j.1432-1033.1990.tb19349.x; OKAJIMA A, 1993, EUR J BIOCHEM, V213, P113, DOI 10.1111/j.1432-1033.1993.tb17740.x; PETIT C, 1986, P NATL ACAD SCI USA, V83, P2561, DOI 10.1073/pnas.83.8.2561; RAMADORI G, 1992, BIOCHEM BIOPH RES CO, V183, P739, DOI 10.1016/0006-291X(92)90545-V; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIRMACHER P, 1992, HEPATOLOGY, V15, P5, DOI 10.1002/hep.1840150103; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SIMONE VD, 1992, BIOCHIM BIOPHYS ACTA, V1132, P119; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAJIMA H, 1991, FEBS LETT, V291, P229, DOI 10.1016/0014-5793(91)81291-F; TAMURA M, 1993, J BIOL CHEM, V268, P8140; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; UEHARA Y, 1992, J CELL BIOL, V117, P889, DOI 10.1083/jcb.117.4.889; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WOLF HK, 1991, AM J PATHOL, V138, P1035; ZARNEGAR R, 1989, BIOCHEM BIOPH RES CO, V163, P1370, DOI 10.1016/0006-291X(89)91130-3; ZARNEGAR R, 1990, P NATL ACAD SCI USA, V87, P1252, DOI 10.1073/pnas.87.3.1252; ZARNEGAR R, 1991, BIOCHEM BIOPH RES CO, V177, P559, DOI 10.1016/0006-291X(91)92020-K; ZARNEGAR R, 1989, CANCER RES, V49, P3314	58	145	147	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4152	4160						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307976				2022-12-27	WOS:A1994MW98900041
J	ROBERTS, SB; RIPELLINO, JA; INGALLS, KM; ROBAKIS, NK; FELSENSTEIN, KM				ROBERTS, SB; RIPELLINO, JA; INGALLS, KM; ROBAKIS, NK; FELSENSTEIN, KM			NON-AMYLOIDOGENIC CLEAVAGE OF THE BETA-AMYLOID PRECURSOR PROTEIN BY AN INTEGRAL MEMBRANE METALLOENDOPEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; CULTURED-CELLS; APP-SECRETASE; GENE; MUTATION; PEPTIDE; IDENTIFICATION; PHOSPHORYLATION; SEQUENCE; ENZYME	The beta-amyloid precursor protein (beta-APP) is a membrane spanning glycoprotein. The small beta-protein domain within the precursor is presumed to be the source of amyloid found in plaques characteristic of Alzheimer's disease. The amino terminus of beta-APP is released from cells by cleavages that produce both potentially amyloidogenic and nonamyloidogenic fragments of the carboxyl terminus. We developed a cell free system that imposes specificity and co-localization to characterize the proteolytic activity that cleaves the precursor within the beta-protein domain. A reporter protein containing the carboxyl-terminal 105 amino acids of beta-APP provided a specific substrate for cleavage at Lys16 of the beta-protein. The protease inhibitor profile and solubility characteristics of the activity demonstrate the cleavage is produced by an integral membrane metalloendopeptidase.	CUNY MT SINAI SCH MED,DEPT PSYCHIAT,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,FISHBERG RES CTR NEUROBIOL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	ROBERTS, SB (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,CNS DRUG DISCOVERY,DEPT BIOPHYS & MOLEC BIOL,5 RES PKWY,WALLINGFORD,CT 06492, USA.		Robakis, Nikolaos/AAA-1838-2021					ALLSOP D, 1991, BRAIN RES, V551, P1, DOI 10.1016/0006-8993(91)90905-B; ANDERSON JP, 1992, J NEUROCHEM, V59, P2328; ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FERNANDEZMADRID I, 1991, ANN NEUROL, V30, P730, DOI 10.1002/ana.410300516; GILLESPIE SL, 1992, BIOCHEM BIOPH RES CO, V187, P1285, DOI 10.1016/0006-291X(92)90442-N; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1992, SCIENCE, V255, P690; GOLDGABER D, 1987, SCIENCE, V235, P8778; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KOJIMA S, 1992, FEBS LETT, V304, P57, DOI 10.1016/0014-5793(92)80588-8; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V179, P1670, DOI 10.1016/0006-291X(91)91767-7; MCDERMOTT JR, 1991, BIOCHEM BIOPH RES CO, V179, P1148, DOI 10.1016/0006-291X(91)91691-5; MIYAZAKI K, 1993, NATURE, V362, P839, DOI 10.1038/362839a0; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; POWERS JC, 1986, RES MONOGRAPHS CELL, V12, P219; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMALL DH, 1991, BIOCHEMISTRY-US, V30, P10795, DOI 10.1021/bi00108a027; TAGAWA K, 1991, BIOCHEM BIOPH RES CO, V177, P377, DOI 10.1016/0006-291X(91)91994-N; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	31	93	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3111	3116						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300647				2022-12-27	WOS:A1994MV43200108
J	TAMORI, Y; HASHIRAMOTO, M; CLARK, AE; MORI, H; MURAOKA, A; KADOWAKI, T; HOLMAN, GD; KASUGA, M				TAMORI, Y; HASHIRAMOTO, M; CLARK, AE; MORI, H; MURAOKA, A; KADOWAKI, T; HOLMAN, GD; KASUGA, M			SUBSTITUTION AT PRO(385) OF GLUT1 PERTURBS THE GLUCOSE-TRANSPORT FUNCTION BY REDUCING CONFORMATIONAL FLEXIBILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE; PROTEOLYTIC DISSECTION; PROLINE RESIDUES; PROTEIN; BINDING; MUTAGENESIS; RESOLUTION; KINETICS; CARRIER; HELICES	The mammalian glucose transporter, GLUT1, is capable of alternating between two conformations which expose either an outward- or inward-facing ligand binding site. The possibility that these conformational changes are related to the presence of prolines and glycines in transmembrane region 10 was investigated by site-directed mutagenesis. Chinese hamster ovary clones which were transfected with Pro385 --> Ile and Pro385 --> glycine mutations of GLUT1 were shown, by Western blotting and cell surface carbohydrate labeling, to have expression levels which were comparable with the wild type. The transport activity was markedly reduced as a result of the Pro385 --> isoleucine but not in the Pro385 --> glycine mutation. The loss of transport activity in the Pro385 --> isoleucine clone was associated with loss of labeling by the exofacial photoaffinity ligand, 2-N-4-(1-azi-2,2,2-trifluoroethyl)benzoyl-1,3-bis(D-mannos-4-yloxy)-2-propylamine (ATB-BMPA), but there was no loss in labeling by the inside site-directed ligand cytochalasin B. These results suggest that the transporter cannot adopt the outward-directed conformation in the Pro385 --> isoleucine clone. By contrast, the glycine substitution for proline at this position resulted in a retention of the ligand binding properties at both inside and outside sites. We suggest a putative mode of operation of the transporter which involves conformational flexibility about the prolines in transmembrane segment 10 such that helices 11 and 12 can alternately either pack against the outside (ATB-BMPA binding) site in helices 7, 8, and 9 or against the inner (cytochalasin B binding) site at the base of transmembrane segment 10.	KOBE UNIV, SCH MED,DEPT INTERNAL MED 3,7-5-1 KUSUNOKI CHO, CHUO KU, KOBE 650, JAPAN; UNIV BATH, DEPT BIOCHEM, BATH BA2 7AY, AVON, ENGLAND; UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN	Kobe University; University of Bath; University of Tokyo				Holman, Geoffrey/0000-0001-7045-1358				ALVAREZ J, 1987, J BIOL CHEM, V262, P3502; APPLEMAN JR, 1985, J BIOL CHEM, V260, P4575; BARNETT JEG, 1973, BIOCHEM J, V131, P211, DOI 10.1042/bj1310211; BARNETT JEG, 1975, BIOCHEM J, V145, P417, DOI 10.1042/bj1450417a; BLANDL CY, 1986, P NATL ACAD SCI USA, V83, P917; CAIRNS MT, 1987, BIOCHIM BIOPHYS ACTA, V905, P295, DOI 10.1016/0005-2736(87)90458-5; CARRUTHERS A, 1986, J BIOL CHEM, V261, P1028; CELENZA JL, 1988, P NATL ACAD SCI USA, V85, P2130, DOI 10.1073/pnas.85.7.2130; CHIN JJ, 1987, P NATL ACAD SCI USA, V84, P4113, DOI 10.1073/pnas.84.12.4113; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLARK AE, 1990, BIOCHEM J, V269, P615, DOI 10.1042/bj2690615; CONSLER TG, 1991, BIOCHEMISTRY-US, V30, P1291, DOI 10.1021/bi00219a019; DAVIDSEN AF, 1992, MORIOND AST, P125; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; GIBBS AF, 1988, BIOCHEM J, V256, P421, DOI 10.1042/bj2560421; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; HEBERT DN, 1992, J BIOL CHEM, V267, P23829; HOLMAN GD, 1987, BIOCHIM BIOPHYS ACTA, V897, P395, DOI 10.1016/0005-2736(87)90437-8; KAWAKAMI T, 1988, J BIOL CHEM, V263, P14276; KING APJ, 1991, BIOCHEMISTRY-US, V30, P11546, DOI 10.1021/bi00113a009; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAY JM, 1989, J MEMBRANE BIOL, V106, P227; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; OKA Y, 1990, NATURE, V345, P227; PAWAGI AB, 1990, BIOCHEMISTRY-US, V29, P950, DOI 10.1021/bi00456a015; VILSEN B, 1989, J BIOL CHEM, V264, P21024; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; WALMSLEY AR, 1987, BIOCHIM BIOPHYS ACTA, V901, P229, DOI 10.1016/0005-2736(87)90119-2; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001	32	50	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2982	2986						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300630				2022-12-27	WOS:A1994MV43200089
J	ROY, RP; NAGEL, RL; ACHARYA, AS				ROY, RP; NAGEL, RL; ACHARYA, AS			MOLECULAR-BASIS OF THE INHIBITION OF BETA-S-CHAIN-DEPENDENT POLYMERIZATION BY MOUSE ALPHA-CHAIN - SEMISYNTHESIS OF CHIMERAS OF HUMAN AND MOUSE ALPHA-CHAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SICKLE-CELL HEMOGLOBIN; NUCLEATION-CONTROLLED AGGREGATION; TRANSGENIC MICE; DEOXYHEMOGLOBIN-S; ESCHERICHIA-COLI; HIGH EXPRESSION; FIBERS; STRANDS; GLOBINS	The transgenic mouse models expressing beta(S)-globin genes do not fully exhibit the sickling phenotype, primarily as a result of the inhibition of beta(S)-chain-dependent polymerization by the mouse alpha-chains. The mouse alpha-chain differs from the human alpha-chain at 19 sequence locations. Of these, only alpha78 and alpha116 are the known hemoglobin (Hb) S polymer contact sites. To define whether the inhibition of polymerization by the mouse alpha-chain is solely a consequence of the differences at these two sites or additional sites of sequence differences are also involved, we have constructed chimeric alpha-chains by employing the alpha-globin semisynthetic reaction (Sahni, G., Cho, Y. J., Iyer, K. S., Khan, S. A., Seetharam, R., and Acharya, A. S. (1989) Biochemistry 28, 5456-5461). Mouse alpha1-30 Was spliced with human alpha31-141 using endoproteinase Glu-C to generate a chimeric alpha-globin (alpha(MH)) containing eight of the 19 sequence differences of mouse alpha-globin. Similarly, human alpha1-30 was spliced with mouse alpha31-141 to generate another chimeric alpha-globin (alpha(HM)) containing 11 sequence differences. The respective chimeric globins were purified, reconstituted with heme and beta(S)-chain into tetrameric hemoglobin, and the tetramers were purified by ion-exchange chromatography. The inhibitory potential of the chimeric alpha(MH)-chain on the polymerization is 10-fold lower than that of the mouse alpha-chain. The absence of the alpha31-141 region of the mouse alpha-chain relieves only a portion of the inhibition. The inhibitory potential of alpha(MH) contributed by the mouse alpha1-30 segment is significant although none of the sequence differences in this segment are located at any of the implicated polymer contact sites. The chimeric alpha(HM)-chain also inhibits the polymerization, but the extent of inhibition is again lower (4-fold) than that of the full-length mouse alpha-chain. The results demonstrate that the inhibitory potential of mouse alpha-chains involves the sequence differences from both the alpha1-30 and alpha31-141 regions. Besides, since the sum of the inhibitory potential of either of these chimeric alpha-chains is lower than that of the intact mouse alpha-chains, we speculate that conformational changes that require the copresence of sequence differences in both portions of the mouse alpha-chain also contribute to the inhibitory propensity of the mouse alpha-chain.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,DIV HEMATOL,1300 MORRIS PK AVE,ULLMANN 924,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NHLBI NIH HHS [HL38655] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038655] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1980, J BIOL CHEM, V255, P3092; ADACHI K, 1991, HEMOGLOBIN, V15, P417, DOI 10.3109/03630269108998861; ADACHI K, 1979, J BIOL CHEM, V254, P7765; BAUDINCHICH V, 1990, P NATL ACAD SCI USA, V87, P1845, DOI 10.1073/pnas.87.5.1845; BEHRINGER RR, 1989, SCIENCE, V245, P971, DOI 10.1126/science.2772649; BENESCH RE, 1977, NATURE, V269, P772, DOI 10.1038/269772a0; BENESCH RE, 1979, J BIOL CHEM, V254, P8169; BIHOREAU MT, 1992, PROTEIN SCI, V1, P145; Bucci E, 1981, Methods Enzymol, V76, P97; CARRAGHER B, 1988, J MOL BIOL, V199, P315, DOI 10.1016/0022-2836(88)90316-6; CLEGG JB, 1966, J MOL BIOL, V19, P91, DOI 10.1016/S0022-2836(66)80052-9; CONSTANTINI F, 1986, SCIENCE, V233, P1192; DYKES GW, 1979, J MOL BIOL, V130, P451, DOI 10.1016/0022-2836(79)90434-0; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; FABRY ME, 1992, P NATL ACAD SCI USA, V89, P12150, DOI 10.1073/pnas.89.24.12150; FABRY ME, 1992, P NATL ACAD SCI USA, V89, P12155, DOI 10.1073/pnas.89.24.12155; FRONTICELLI C, 1991, J PROTEIN CHEM, V10, P495, DOI 10.1007/BF01025477; LUISI BF, 1986, NATURE, V320, P555, DOI 10.1038/320555a0; NAGEL RL, 1979, P NATL ACAD SCI USA, V76, P670, DOI 10.1073/pnas.76.2.670; NAGEL RL, 1980, NATURE, V283, P832, DOI 10.1038/283832a0; NAGEL RL, BIOL CLIN ASPECTS HE, P195; RHODA MD, 1984, BIOCHIM BIOPHYS ACTA, V786, P62, DOI 10.1016/0167-4838(84)90154-7; RHODA MD, 1988, BIOCHIM BIOPHYS ACTA, V952, P208, DOI 10.1016/0167-4838(88)90117-3; RODGERS DW, 1987, P NATL ACAD SCI USA, V84, P6157, DOI 10.1073/pnas.84.17.6157; RYAN TM, 1990, SCIENCE, V247, P566, DOI 10.1126/science.2154033; SAHNI G, 1989, BIOCHEMISTRY-US, V28, P5456, DOI 10.1021/bi00439a021; WATOWICH SJ, 1989, J MOL BIOL, V209, P821, DOI 10.1016/0022-2836(89)90610-4; WELLEMS TE, 1981, J MOL BIOL, V153, P1011, DOI 10.1016/0022-2836(81)90464-2; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2; YIP YK, 1977, P NATL ACAD SCI USA, V74, P64, DOI 10.1073/pnas.74.1.64	30	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16406	16412						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344926				2022-12-27	WOS:A1993LQ33600049
J	STREHLOW, I; SEEGERT, D; FRICK, C; BANGE, FC; SCHINDLER, C; BOTTGER, EC; DECKER, T				STREHLOW, I; SEEGERT, D; FRICK, C; BANGE, FC; SCHINDLER, C; BOTTGER, EC; DECKER, T			THE GENE ENCODING IFP 53/TRYPTOPHANYL-TRANSFER-RNA SYNTHETASE IS REGULATED BY THE GAMMA-INTERFERON ACTIVATION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA-SYNTHETASE; CHAIN RELEASE FACTOR; GUANYLATE-BINDING PROTEIN; TRANSCRIPTIONAL INDUCTION; RESPONSE ELEMENT; CYTOPLASMIC ACTIVATION; GEL-ELECTROPHORESIS; ALPHA; PROMOTER; ISGF3	We have obtained genomic DNA encoding the interferon-gamma (IFN-gamma)-inducible IFP 53/tryptophanyl-tRNA synthetase. Comparison with several different IFP 53 cDNA clones revealed a complex pattern of alternatively spliced 5'-untranslated regions. The interferon-responsive region within the IFP 53 promoter was found to contain a gamma-interferon activation site (GAS) but not the interferon-stimulated response element and to bind the gamma-interferon activation factor (GAF). GAF.GAS complexes contained the IFN-regulated 91-kDa protein. Competition experiments defined the GAS boundaries and showed that GAF binding to the IFP 53 GAS could be prevented by an excess of the IFN-gamma response regions of several other IFN-gamma-inducible genes. We thus provide evidence for a central role of GAS.GAF in gene transcription mediated by IFN-gamma and suggest a consensus sequence defining more precisely the requirements for GAF binding to DNA.	FRAUNHOFER INST TOXICOL & MOLEC BIOL,NIKOLAI FUCHSSTR 1,W-3000 HANNOVER 61,GERMANY; MED SCH HANNOVER,INST MED MICROBIOL,W-3000 HANNOVER 61,GERMANY; COLUMBIA UNIV COLL PHYS & SURG,NEW YORK,NY 10032	Fraunhofer Gesellschaft; Hannover Medical School; Columbia University			Böttger, Erik C./F-6175-2011					ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BANGE FC, 1992, FEBS LETT, V300, P162, DOI 10.1016/0014-5793(92)80187-L; BUWITT U, 1992, EMBO J, V11, P489, DOI 10.1002/j.1460-2075.1992.tb05079.x; CHENG YSE, 1991, MOL CELL BIOL, V11, P4717, DOI 10.1128/MCB.11.9.4717; COSTA RH, 1988, MOL CELL BIOL, V8, P81, DOI 10.1128/MCB.8.1.81; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; Demaeyer E., 1988, INTERFERONS OTHER RE; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FINN PW, 1990, P NATL ACAD SCI USA, V87, P914, DOI 10.1073/pnas.87.3.914; FLECKNER J, 1991, P NATL ACAD SCI USA, V88, P11520, DOI 10.1073/pnas.88.24.11520; FLOHR T, 1992, INFECT IMMUN, V60, P4418, DOI 10.1128/IAI.60.10.4418-4421.1992; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FROLOVA LY, 1991, GENE, V109, P291, DOI 10.1016/0378-1119(91)90624-K; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; KARA CJ, 1991, CURR OPIN IMMUNOL, V3, P16, DOI 10.1016/0952-7915(91)90070-H; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KHAN KD, 1990, MOL CELL BIOL, V10, P5150, DOI 10.1128/MCB.10.10.5150; LEE CC, 1990, P NATL ACAD SCI USA, V87, P3508, DOI 10.1073/pnas.87.9.3508; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; RUBIN BY, 1991, J BIOL CHEM, V266, P24245; Sambrook J, 1989, MOL CLONING LABORATO; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STARK GR, 1992, J INTERFERON RES, V12, P147, DOI 10.1089/jir.1992.12.147; STREHLOW I, 1992, NUCLEIC ACIDS RES, V20, P3865, DOI 10.1093/nar/20.15.3865; TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934; WILLIAMS BRG, 1991, EUR J BIOCHEM, V200, P1, DOI 10.1111/j.1432-1033.1991.tb21041.x	42	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16590	16595						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344940				2022-12-27	WOS:A1993LQ33600074
J	YAMAMOTOHONDA, R; KADOWAKI, T; MOMOMURA, K; TOBE, K; TAMORI, Y; SHIBASAKI, Y; MORI, Y; KABURAGI, Y; KOSHIO, O; AKANUMA, Y; YAZAKI, Y; KASUGA, M				YAMAMOTOHONDA, R; KADOWAKI, T; MOMOMURA, K; TOBE, K; TAMORI, Y; SHIBASAKI, Y; MORI, Y; KABURAGI, Y; KOSHIO, O; AKANUMA, Y; YAZAKI, Y; KASUGA, M			NORMAL INSULIN-RECEPTOR SUBSTRATE-1 PHOSPHORYLATION IN AUTOPHOSPHORYLATION-DEFECTIVE TRUNCATED INSULIN-RECEPTOR - EVIDENCE THAT PHOSPHORYLATION OF SUBSTRATES MIGHT BE SUFFICIENT FOR CERTAIN BIOLOGICAL EFFECTS EVOKED BY INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; EPIDERMAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; PROTEIN-KINASE; SIGNAL TRANSDUCTION; DOMAIN AUTOPHOSPHORYLATION; CONFORMATIONAL CHANGE; BETA-SUBUNIT; INTACT CELL; C-TERMINUS	A mutant human insulin receptor that lacked the 82 amino acids of the COOH terminus of the beta-subunit (del82) was studied. Both the wild type insulin receptor (HIR) and the mutant receptor were expressed in Chinese hamster ovary (CHO) cells by stable transfection. Autophosphorylation and tyrosine kinase activities toward exogenous substrates of solubilized and partially purified del82 were severely impaired. When CHO cells transfected with del82 (CHO-del82) were stimulated with insulin, autophosphorylation was decreased to a great extent compared with cells expressing HIR (CHO-HIR). Nevertheless, tyrosine phosphorylation of an endogenous substrate, pp185, and insulin receptor substrate-1 (IRS-1) in CHO-del82 was comparable with that in CHO-HIR. Insulin-stimulated activation of phosphatidylinositol 3-kinase activity in CHO-del82 was also equivalent to that in CHO-HIR. Moreover, CHO-del82 exhibited the same insulin sensitivity as CHO-HIR with respect to 2-deoxyglucose uptake and thymidine incorporation into DNA. Insulin-induced internalization in CHO-del82 was decreased by 46% as compared with that in CHO-HIR. These data suggest that: 1) the COOH-terminal domain of the insulin receptor may play an inhibitory role in the phosphorylation of pp185 and IRS-1; and 2) phosphorylation of substrates such as pp185 and IRS-1, rather than autophosphorylation of the receptor per se, correlates better with certain biological effects that were mediated by insulin, suggesting that phosphorylation of the substrates might be sufficient for transducing signals downstream.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN; ASAHI LIFE FDN,INST DIABET CARE & RES,CHIYODA KU,TOKYO 100,JAPAN; KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE 650,JAPAN	University of Tokyo; Asahi Life Foundation; Kobe University								ANDO A, 1992, J BIOL CHEM, V267, P12788; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BARON V, 1990, BIOCHEMISTRY-US, V29, P4634, DOI 10.1021/bi00471a019; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHOU CK, 1987, J BIOL CHEM, V262, P1842; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARI J, 1987, J BIOL CHEM, V262, P15341; HAWLEY DM, 1989, J BIOL CHEM, V264, P2438; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KADOWAKI T, 1990, J BIOL CHEM, V265, P19143; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; KASUGA M, 1983, P NATL ACAD SCI-BIOL, V80, P2137, DOI 10.1073/pnas.80.8.2137; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KASUGA M, 1982, J BIOL CHEM, V257, P392; KOSHIO O, 1989, FEBS LETT, V254, P22, DOI 10.1016/0014-5793(89)81001-4; KULL FC, 1982, BIOCHEM BIOPH RES CO, V106, P1019, DOI 10.1016/0006-291X(82)91813-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE BA, 1991, J BIOL CHEM, V266, P13405; LEWIS RE, 1990, J BIOL CHEM, V265, P947; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; MADDUX BA, 1991, J BIOL CHEM, V266, P6731; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; MYERS MG, 1991, J BIOL CHEM, V266, P10616; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; RAPUANO M, 1991, J BIOL CHEM, V266, P12902; ROTH RA, 1983, SCIENCE, V219, P299, DOI 10.1126/science.6849137; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; RUSSELLDS, 1987, J BIOL CHEM, V262, P11833; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TASHIROHASHIMOTO Y, 1989, J BIOL CHEM, V264, P6879; THIES RS, 1989, J BIOL CHEM, V264, P12820; TOBE K, 1990, DIABETES, V39, P528, DOI 10.2337/diabetes.39.5.528; TOBE K, 1993, J BIOL CHEM, V268, P11167; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; YAMAMOTOHONDA R, 1990, J BIOL CHEM, V265, P14777; YONEZAWA K, 1992, J BIOL CHEM, V267, P440; YONEZAWA K, 1991, MOL ENDOCRINOL, V5, P194, DOI 10.1210/mend-5-2-194; ZANG B, 1991, J BIOL CHEM, V266, P990	59	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16859	16865						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344965				2022-12-27	WOS:A1993LQ33600109
J	ZHENG, CF; GUAN, KL				ZHENG, CF; GUAN, KL			DEPHOSPHORYLATION AND INACTIVATION OF THE MITOGEN-ACTIVATED PROTEIN-KINASE BY A MITOGEN-INDUCED THR TYR PROTEIN PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SIGNAL-REGULATED KINASES; TYROSINE PHOSPHATASE; VACCINIA VIRUS; PHOSPHORYLATION; THREONINE; GENE; IDENTIFICATION; EXPRESSION; SITES; PURIFICATION	The activation of extracellular signal-regulated kinase (ERK) or mitogen-activated protein kinase (MAPK) by a dual specific kinase, MEK (MAPK or ERK kinase), is a critical event in the mitogenic signal transduction pathway. However, little is known about the mechanism of ERK inactivation, which occurs after stimulation. In this report, we demonstrated that a dual specific protein phosphatase, HVH1 (human VH1 phosphatase homolog) whose expression is induced by mitogenic growth factors, specifically inactivates ERK. When several phosphoproteins were tested for recombinant HVH1, only MEK-activated ERK1 was dephosphorylated. HVH1 selectively dephosphorylated threonine and tyrosine residues but not serine residues of the activated ERK1. Inactivation of ERK1 by HVH1 could be reversed by MEK, suggesting that HVH1 dephosphorylates the same residues that are recognized and phosphorylated by MEK. Our results suggest that mitogenic growth factors transiently activate ERK (peak at 5 min followed by a rapid decline) by temporally activating MEK (the on signal) and inducing the expression of HVH phosphatase (the off signal).	UNIV MICHIGAN,INST GERONTOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG008808, P30AG008808] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00042] Funding Source: Medline; NIA NIH HHS [AG-08808] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHN NG, 1990, J BIOL CHEM, V265, P11487; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHARLES CH, 1992, ONCOGENE, V7, P187; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GUAN K, 1992, P NATL ACAD SCI USA, V89, P12175, DOI 10.1073/pnas.89.24.12175; GUAN K, 1991, J BIOL CHEM, V266, P12964; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; JESSUS C, 1992, CELL, V68, P323, DOI 10.1016/0092-8674(92)90473-P; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SEGER R, 1992, J BIOL CHEM, V267, P14373; SETH A, 1991, J BIOL CHEM, V266, P23521; SHENG ZQ, 1993, J BIOL CHEM, V268, P4728; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	27	156	168	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16116	16119						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344896				2022-12-27	WOS:A1993LQ33600010
J	ARONDEL, V; BENNING, C; SOMERVILLE, CR				ARONDEL, V; BENNING, C; SOMERVILLE, CR			ISOLATION AND FUNCTIONAL EXPRESSION IN ESCHERICHIA-COLI OF A GENE ENCODING PHOSPHATIDYLETHANOLAMINE METHYLTRANSFERASE (EC-2.1.1.17) FROM RHODOBACTER-SPHAEROIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID BIOSYNTHESIS; RAT-LIVER; PURIFICATION; YEAST; METHYLATION; PATHWAY; CLONING; PROTEIN	Phosphatidylcholine is a major component of membranes in most eukaryotes, but it is found only in a small number of bacteria, where it is synthesized by N-methylation of phosphatidylethanolamine. In yeast and other fungi the methylation of phosphatidylethanolamine to phosphatidylcholine proceeds in two steps: the methylation of phosphatidylethanolamine by phosphatidylethanolamine methyltransferase followed by the methylation of monomethylphosphatidylethanolamine by phospholipid methyltransferase. Here we describe the isolation of two allelic phosphatidylcholine-deficient mutants of Rhodobacter sphaeroides which are unable to methylate phosphatidylethanolamine, monomethylphosphatidylethanolamine, or dimethylphosphatidylethanolamine. A DNA fragment containing a gene designated pmtA, which encodes a 22.9-kDa protein, was found to complement both mutants. Expression of this gene in Escherichia coli, which normally lacks phosphatidylcholine or methylated derivatives of phosphatidylethanolamine, resulted in the formation of phosphatidylcholine. A protein extract derived from the E. coli strain expressing the pmtA gene was able to convert phosphatidylethanolamine, mono- and dimethylphosphatidylethanolamine into phosphatidylcholine. Based on these data we conclude that the product of the pmtA gene catalyzes a sequence of three chemically distinct, methylation reactions beginning with phosphatidylethanolamine and leading to the formation of phosphatidylcholine in R. sphaeroides.			ARONDEL, V (corresponding author), MICHIGAN STATE UNIV,DEPT ENERGY,PLANT RES LAB,E LANSING,MI 48824, USA.		Benning, Christoph/Y-2528-2019; Somerville, Christopher R/A-4048-2009	Benning, Christoph/0000-0001-8585-3667; Somerville, Christopher R/0000-0003-4647-0094				Ausubel FM, 1988, MOL REPROD DEV; BENNING C, 1992, J BACTERIOL, V174, P6479, DOI 10.1128/JB.174.20.6479-6487.1992; BENNING C, 1992, J BACTERIOL, V174, P2352, DOI 10.1128/JB.174.7.2352-2360.1992; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAIN BD, 1984, J BIOL CHEM, V259, P942; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CRONAN JE, 1972, BIOCHIM BIOPHYS ACTA, V265, P25, DOI 10.1016/0304-4157(72)90018-4; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; GUREVITZ M, 1985, P NATL ACAD SCI USA, V82, P6546, DOI 10.1073/pnas.82.19.6546; JENSEN NJ, 1988, MASS SPECTROM REV, V7, P41, DOI 10.1002/mas.1280070103; JOHNSTON NC, 1983, J GEN MICROBIOL, V129, P1075; KANESHIRO T, 1964, J BIOL CHEM, V239, P1705; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KODAKI T, 1987, J BIOL CHEM, V262, P15428; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, V2, P1190; NIKOLOFF DM, 1991, ANNU REV GENET, V25, P559; OGAWA H, 1983, ARCH BIOCHEM BIOPHYS, V226, P265, DOI 10.1016/0003-9861(83)90293-X; PIERCE JW, 1982, METHOD ENZYMOL, V89, P47; RIDGWAY ND, 1987, J BIOL CHEM, V262, P17231; Sambrook J, 1989, MOL CLONING LABORATO; SCARBOROUGH GA, 1967, J BIOL CHEM, V242, P238; SILVER BL, 1985, PHYSICAL CHEM MEMBRA, P57; SISTROM WR, 1962, J GEN MICROBIOL, V28, P607, DOI 10.1099/00221287-28-4-607; SISTROM WR, 1960, J GEN MICROBIOL, V22, P778, DOI 10.1099/00221287-22-3-778; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAHARA Y, 1986, AGR BIOL CHEM TOKYO, V50, P257, DOI 10.1080/00021369.1986.10867372; van Niel CB, 1944, BACTERIOL REV, V8, P1; Vance D E, 1981, Methods Enzymol, V71 Pt C, P581; VANCE DE, 1988, PROG LIPID RES, V27, P61, DOI 10.1016/0163-7827(88)90005-7; Wilkinson S., 1988, MICROBIAL LIPIDS; YAZDI MA, 1990, J GEN MICROBIOL, V136, P1335, DOI 10.1099/00221287-136-7-1335	34	68	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					16002	16008						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340421				2022-12-27	WOS:A1993LN30500095
J	PASCHAL, BM; HOLZBAUR, ELF; PFISTER, KK; CLARK, S; MEYER, DI; VALLEE, RB				PASCHAL, BM; HOLZBAUR, ELF; PFISTER, KK; CLARK, S; MEYER, DI; VALLEE, RB			CHARACTERIZATION OF A 50-KDA POLYPEPTIDE IN CYTOPLASMIC DYNEIN PREPARATIONS REVEALS A COMPLEX WITH P150(GLUED) AND A NOVEL ACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; IDENTIFICATION; TRANSPORT; INVITRO; BRAIN; GENE; 1C	Earlier work identified a series of accessory polypeptides of 150, 74, 59, 57, 55, 53, 50, and 45 kDa copurifying with cytoplasmic dynein. In the present study immunoprecipitation of the 50-kDa polypeptide from bovine brain cytosol with a specific monoclonal antibody revealed coprecipitating components of 150, 135, 62, and 45 kDa, which were completely distinct from the polypeptides immunoprecipated using an antibody to the well established 74-kDa cytoplasmic dynein subunit. The 150- and 135-kDa polypeptides reacted with an antibody to p150Glued, the mammalian homologue of the Drosophila Glued gene. N-terminal microsequencing of tryptic peptides of the major 45-kDa component of the complex revealed it to be the alpha-isoform of centractin, a novel form of actin. Immunoblotting of sucrose gradient-fractionated brain cytosol revealed p150Glued, p50, and centractin to cosediment exclusively at 20 S. Immunofluorescence microscopy using antibody to p150Glued revealed centrosomal staining, which was abolished by microtubule depolymerization. Together these results reveal the 50-kDa polypeptide to be part of a cytosolic complex distinct from cytoplasmic dynein. However, the immunolocalization data indicate an association with microtubule minus ends, suggesting a possible interaction with cytoplasmic dynein in the cell.	WORCESTER FDN EXPTL BIOL INC, CELL BIOL GRP, SHREWSBURY, MA 01545 USA; UNIV PENN, SCH VET MED, DEPT ANIM BIOL, PHILADELPHIA, PA 19104 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT ANAT & CELL BIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	Worcester Foundation for Biomedical Research; University of Pennsylvania; University of Virginia; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM047434, R01GM047434, R01GM026701] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47434, GM26701] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD R, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P71; CLARK SW, 1992, NATURE, V359, P246, DOI 10.1038/359246a0; COLLINS CA, 1989, CELL MOTIL CYTOSKEL, V14, P491, DOI 10.1002/cm.970140407; GAREN SH, 1983, DEV BIOL, V96, P445, DOI 10.1016/0012-1606(83)90182-3; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; HOLZBAUR ELF, 1989, J CELL BIOL, V109, P157; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER JP, 1992, NATURE, V359, P244, DOI 10.1038/359244a0; LEESMILLER JP, 1992, P NATL ACAD SCI USA, V89, P80, DOI 10.1073/pnas.89.1.80; LIN SXH, 1992, J CELL SCI, V101, P125; MEYYEROWITZ EM, 1983, DEV BIOL, V62, P112; MITCHELL DR, 1991, J CELL BIOL, V113, P835, DOI 10.1083/jcb.113.4.835; NEELY MD, 1988, J CELL BIOL, V107, P1767, DOI 10.1083/jcb.107.5.1767; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PASCHAL BM, 1992, J CELL BIOL, V118, P1133, DOI 10.1083/jcb.118.5.1133; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; PORTER ME, 1989, ANNU REV CELL BIOL, V5, P119; RICKARD JE, 1990, J CELL BIOL, V110, P1623, DOI 10.1083/jcb.110.5.1623; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SCHWOB E, 1992, NATURE, V355, P179, DOI 10.1038/355179a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vallee R, 1991, Trends Cell Biol, V1, P25, DOI 10.1016/0962-8924(91)90066-I; VALLEE RB, 1988, NATURE, V332, P561, DOI 10.1038/332561a0; [No title captured]	27	120	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15318	15323						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325901				2022-12-27	WOS:A1993LL75900111
J	MASSON, P; ADKINS, S; GOUET, P; LOCKRIDGE, O				MASSON, P; ADKINS, S; GOUET, P; LOCKRIDGE, O			RECOMBINANT HUMAN BUTYRYLCHOLINESTERASE G390V, THE FLUORIDE-2 VARIANT, EXPRESSED IN CHINESE-HAMSTER OVARY CELLS, IS A LOW-AFFINITY VARIANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SERUM-CHOLINESTERASE; HORSE PLASMA CHOLINESTERASE; ACTIVE-SITES; GENETIC-VARIANTS; ACETYLCHOLINESTERASE; LOCALIZATION; REFINEMENT; REACTIVITY; KINETICS	Kinetics of recombinant fluoride-2 variant of human butyrylcholinesterase (Gly390 Val) secreted by Chinese hamster ovary cells were compared to recombinant usual and to usual butyrylcholinesterase purified from human plasma. The usual and fluoride-2 variant were indistinguishable with regard to hydrolysis of benzoylcholine (K(m) = 5 muM), neutral esters, and at high concentrations of acetylthiocholine, propionylthiocholine, and butyrylthiocholine. However, at low substrate concentrations K(m) values for acetylthiocholine and succinyldithiocholine were 2-6-fold higher for the fluoride-2 variant. pH rate profiles revealed small differences in pK(a) that could be attributed to changes in the active site histidine environment. On the other hand, Arrhenius plot analysis of o-nitrophenylbutyrate hydrolysis at pH 7.5 showed no difference in activation energy between fluoride-2 and usual butyrylcholinesterases. Both exhibited an anomalous temperature dependence with a wavelike change in activation energy around 18-degrees-C. Affinity of the fluoride-2 variant for sodium fluoride, tacrine, dibucaine, amodiaquin, and succinyldioholine was lower than for usual enzyme. Apparent K(i) for succinyldicholine was 125 muM for the fluoride-2 variant and 20 muM for the usual enzyme. Organophosphate inhibition showed equivalent reactivity, indicating that the point mutation altered only the binding properties of the variant. Thus, K(m) and K(i) changes explain the succinyldicholine sensitivity of people carrying the fluoride-2 variant.	UNIV NEBRASKA,MED CTR,EPPLEY INST,600 S 42ND ST,OMAHA,NE 68198; SERV SANTE ARMEES,CTR RECH,UNITE BIOCHIM,F-38702 LA TRONCHE,FRANCE; UNIV MICHIGAN,SCH MED,DEPT TOXICOL,ANN ARBOR,MI 48109; INST BIOL STRUCT,CRISTALLOG MACROMOLEC LAB,F-38027 GRENOBLE,FRANCE	University of Nebraska System; University of Nebraska Medical Center; University of Michigan System; University of Michigan; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)			Adkins, Stephen W/G-2050-2014; Masson, Patrick/AAA-7213-2019; Masson, Patrick YM/J-3964-2013	Masson, Patrick/0000-0002-7837-3662; Masson, Patrick YM/0000-0002-7837-3662; gouet, patrice/0000-0001-9485-6157	NCI NIH HHS [P30 CA 36727] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDRIDGE WN, 1953, BIOCHEM J, V53, P62, DOI 10.1042/bj0530062; ALLDERDICE PW, 1991, GENOMICS, V11, P452, DOI 10.1016/0888-7543(91)90154-7; ALLEN FH, 1983, ACCOUNTS CHEM RES, V16, P146, DOI 10.1021/ar00089a001; ALLEN FH, 1979, ACTA CRYSTALLOGR B, V35, P2331, DOI 10.1107/S0567740879009249; ARPAGAUS M, 1990, BIOCHEMISTRY-US, V29, P124, DOI 10.1021/bi00453a015; BAMFORD KF, 1964, ANN HUM GENET, V27, P417; BERMAN HA, 1990, BIOCHEMISTRY-US, V29, P10640, DOI 10.1021/bi00499a010; BRESTKIN A P, 1968, Biokhimiya, V33, P817; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAUET G, 1987, BIOCHEM CELL BIOL, V65, P529, DOI 10.1139/o87-068; CAUET G, 1987, BIOCHIM BIOPHYS ACTA, V912, P338, DOI 10.1016/0167-4838(87)90037-9; CHRISTIA.ST, 1968, J PHARM SCI, V57, P1025, DOI 10.1002/jps.2600570624; CLERY C, 1992, BIOCHIM BIOPHYS ACTA, V1159, P295, DOI 10.1016/0167-4838(92)90059-M; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DIETZ AA, 1972, AM J HUM GENET, V24, P58; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; ERIKSSON H, 1979, BIOCHIM BIOPHYS ACTA, V567, P161, DOI 10.1016/0005-2744(79)90183-9; FERRO A, 1987, BIOCHIM BIOPHYS ACTA, V916, P193, DOI 10.1016/0167-4838(87)90108-7; GAAL J, 1983, EUR J BIOCHEM, V135, P157, DOI 10.1111/j.1432-1033.1983.tb07631.x; GATLEY SJ, 1991, BIOCHEM PHARMACOL, V41, P1249, DOI 10.1016/0006-2952(91)90665-R; GAUGHAN G, 1991, GENOMICS, V11, P455, DOI 10.1016/0888-7543(91)90155-8; GIBNEY G, 1990, P NATL ACAD SCI USA, V87, P7546, DOI 10.1073/pnas.87.19.7546; GUTTORMSON R, 1979, ACTA CRYSTALLOGR B, V28, P2702; HAREL M, 1992, P NATL ACAD SCI USA, V89, P10827, DOI 10.1073/pnas.89.22.10827; HARRIS H, 1961, NATURE, V191, P496, DOI 10.1038/191496a0; HAYWARD BS, 1977, J CRYST MOL STRUCT, V7, P275, DOI 10.1007/BF01351374; HEILBRONN E, 1961, ACTA CHEM SCAND, V15, P1386, DOI 10.3891/acta.chem.scand.15-1386; HEILBRONN H, 1965, ACTA CHEM SCAND, V19, P1333; HERSH LB, 1974, J PHARMACOL EXP THER, V189, P544; JENSEN B, 1976, ACTA CHEM SCAND B, V30, P1002, DOI 10.3891/acta.chem.scand.30b-1002; KALOW W, 1955, CAN J BIOCHEM PHYS, V33, P568; KALOW W, 1964, CAN J PHYSIOL PHARM, V42, P161, DOI 10.1139/y64-020; KALOW W, 1959, ANESTHESIOLOGY, V20, P505, DOI 10.1097/00000542-195907000-00008; KALOW W, 1958, BIOCHEM PHARMACOL, V1, P183; KITZ R, 1962, J BIOL CHEM, V237, P3245; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LADU BN, 1991, CELL MOL NEUROBIOL, V11, P79, DOI 10.1007/BF00712801; Lehmann H, 1963, Br Med J, V1, P1116; LIDDELL J, 1963, ACTA GENET STAT MED, V13, P95; LOCKRIDGE O, 1990, PHARMACOL THERAPEUT, V47, P35, DOI 10.1016/0163-7258(90)90044-3; LOCKRIDGE O, 1987, J BIOL CHEM, V262, P549; LOCKRIDGE O, 1978, J BIOL CHEM, V253, P361; MAIN AR, 1969, J BIOL CHEM, V244, P829; MAIN AR, 1961, BIOCHEM J, V79, P246, DOI 10.1042/bj0790246; MASSON P, 1988, BIOCHIM BIOPHYS ACTA, V954, P208, DOI 10.1016/0167-4838(88)90073-8; MCCOMB R B, 1965, Clin Chem, V11, P645; MCGUIRE MC, 1989, P NATL ACAD SCI USA, V86, P953, DOI 10.1073/pnas.86.3.953; MCTIERNAN C, 1987, P NATL ACAD SCI USA, V84, P6682, DOI 10.1073/pnas.84.19.6682; NARAYANAN R, 1981, INT J PEPT PROT RES, V17, P170; NOGUEIRA CP, 1992, AM J HUM GENET, V51, P821; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; OZER N, 1987, ARCH BIOCHEM BIOPHYS, V255, P89, DOI 10.1016/0003-9861(87)90297-9; PAGE JD, 1985, MOL PHARMACOL, V27, P437; POWELL JS, 1986, P NATL ACAD SCI USA, V83, P6465, DOI 10.1073/pnas.83.17.6465; PRYOR AN, 1992, J AM CHEM SOC, V114, P3896, DOI 10.1021/ja00036a043; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; SOYLEMEZ Z, 1985, COMP BIOCHEM PHYS C, V81, P433, DOI 10.1016/0742-8413(85)90033-7; SOYLEMEZ Z, 1984, ARCH BIOCHEM BIOPHYS, V235, P650, DOI 10.1016/0003-9861(84)90240-6; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; Sussman JL, 1992, CURR OPIN STRUC BIOL, V2, P721; URLAUB G, 1986, SOMAT CELL MOLEC GEN, V12, P555, DOI 10.1007/BF01671941; VALENTINO RJ, 1981, BIOCHEM PHARMACOL, V30, P1643, DOI 10.1016/0006-2952(81)90392-0; WETHERELL JR, 1986, BIOCHEM PHARMACOL, V35, P939, DOI 10.1016/0006-2952(86)90080-8; WHITTAKE.M, 1964, ACTA GENET STAT MED, V14, P281; Whittaker M., 1986, CHOLINESTERASE; ZAPF PW, 1973, CLIN CHIM ACTA, V44, P237, DOI 10.1016/0009-8981(73)90386-0	68	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14329	14341						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314794				2022-12-27	WOS:A1993LJ82500080
J	AKSAMIT, RR; BACKLUND, PS; MOOS, M; CARYK, T; GOMI, T; OGAWA, H; FUJIOKA, M; CANTONI, GL				AKSAMIT, RR; BACKLUND, PS; MOOS, M; CARYK, T; GOMI, T; OGAWA, H; FUJIOKA, M; CANTONI, GL			THE ROLE OF CYSTEINE-78 IN FLUOROSULFONYLBENZOYLADENOSINE INACTIVATION OF RAT-LIVER S-ADENOSYLHOMOCYSTEINE HYDROLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-HOMOCYSTEINE HYDROLASE; AMINO-ACID SEQUENCE; SITE-DIRECTED MUTAGENESIS; DICTYOSTELIUM-DISCOIDEUM; COENZYME BINDING; CDNA SEQUENCE; PROTEINS; PURIFICATION; RESIDUES; ENZYME	Inactivation of rat liver S-adenosylhomocysteine hydrolase by the site-directed reagent 5'-p-fluorosulfonyl-benzoyladenosine (FSBA) is associated with the formation of a disulfide bond between Cys-78 and Cys-112 (Takata, Y., and Fujioka, M. (1984) Biochemistry 23, 4357-4362; Gomi, T., Ogawa,H., and Fujioka, M. (1986) J. Biol. Chem. 261, 13422-13425). To characterize the inactivation mechanism more precisely, the properties of four hydrolase proteins mutated at Cys-78 or Cys-112 were compared to those of the wild-type enzyme. When Cys-78 was mutated to either a serine or an alanine, proteins with greatly reduced enzymatic activity were obtained, large effects on kinetic constants were observed, and enzymatic activity was not affected by incubation with FSBA. When Cys-112 was mutated to either a serine or an alanine, the activity was similar to the wild-type protein, only small changes in the kinetic constants were observed, and the enzyme was inactivated more rapidly upon incubation with FSBA. FSBA inactivation of the C112A mutant protein was accompanied by the formation of a disulfide between Cys-78 and Cys-52. The data indicate that FSBA initially reacts with Cys-78 and that Cys-78 has an important role in the structure of the enzyme.	US FDA, CTR BIOL EVALUAT & RES, DEV BIOL LAB, BETHESDA, MD 20892 USA; TOYAMA MED & PHARMACEUT UNIV, FAC MED, DEPT BIOCHEM, SUGITANI, TOYAMA 93001, JAPAN	US Food & Drug Administration (FDA); University of Toyama	AKSAMIT, RR (corresponding author), NIMH, GEN & COMPARAT BIOCHEM LAB, BLDG 36, RM 3D06, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.		Moos, Malcolm C/F-3673-2011	Moos, Malcolm C/0000-0002-9575-9938				ANNAMALAI AE, 1981, J BIOL CHEM, V256, P276; Borchardt R. T., 1986, BIOL METHYLATION DRU, P227; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLMAN RF, 1983, ANNU REV BIOCHEM, V52, P67, DOI 10.1146/annurev.bi.52.070183.000435; COULL J M, 1990, Journal of Protein Chemistry, V9, P259; COULTERKARIS DE, 1989, ANN HUM GENET, V53, P169, DOI 10.1111/j.1469-1809.1989.tb01781.x; DELAHABA G, 1959, J BIOL CHEM, V234, P603; DELAHABA G, 1986, BIOCHEMISTRY-US, V25, P8337, DOI 10.1021/bi00373a031; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOSKELAND SO, 1982, BIOCHIM BIOPHYS ACTA, V708, P185, DOI 10.1016/0167-4838(82)90219-9; FUJIOKA M, 1981, J BIOL CHEM, V256, P1631; GOMI T, 1986, J BIOL CHEM, V261, P3422; GOMI T, 1989, BIOCHIM BIOPHYS ACTA, V994, P172, DOI 10.1016/0167-4838(89)90157-X; GOMI T, 1989, J BIOL CHEM, V264, P16138; GOMI T, 1990, J BIOL CHEM, V265, P16102; GURANOWSKI A, 1977, EUR J BIOCHEM, V80, P517, DOI 10.1111/j.1432-1033.1977.tb11907.x; HENDERSON DM, 1992, MOL BIOCHEM PARASIT, V53, P169, DOI 10.1016/0166-6851(92)90019-G; HOHMAN RJ, 1984, ARCH BIOCHEM BIOPHYS, V233, P785, DOI 10.1016/0003-9861(84)90507-1; KASIR J, 1988, BIOCHEM BIOPH RES CO, V153, P359, DOI 10.1016/S0006-291X(88)81231-2; KAWALLECK P, 1992, P NATL ACAD SCI USA, V89, P4713, DOI 10.1073/pnas.89.10.4713; KIM IK, 1983, ARCH BIOCHEM BIOPHYS, V226, P65, DOI 10.1016/0003-9861(83)90271-0; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOOS M, 1988, J BIOL CHEM, V263, P6005; OGAWA H, 1987, P NATL ACAD SCI USA, V84, P719, DOI 10.1073/pnas.84.3.719; PALMER JL, 1979, J BIOL CHEM, V254, P1217; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; POTTER MD, 1992, J BIOL CHEM, V267, P2023; PRASAD SS, 1993, GENOME, V36, P57, DOI 10.1139/g93-008; RICHARDS HH, 1978, J BIOL CHEM, V253, P4476; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEBESTOVA L, 1984, COLLECT CZECH CHEM C, V49, P1543, DOI 10.1135/cccc19841543; SGANGA MW, 1992, P NATL ACAD SCI USA, V89, P6328, DOI 10.1073/pnas.89.14.6328; SHIMIZU S, 1984, EUR J BIOCHEM, V141, P385, DOI 10.1111/j.1432-1033.1984.tb08203.x; Speicher D.W., 1989, TECHNIQUES PROTEIN C, P24; TAKATA Y, 1984, BIOCHEMISTRY-US, V23, P4357, DOI 10.1021/bi00314a017; TAKATA Y, 1991, BIOCHEM J, V277, P399, DOI 10.1042/bj2770399; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2	43	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4084	4091						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307967				2022-12-27	WOS:A1994MW98900031
J	MORROW, JD; MINTON, TA; MUKUNDAN, CR; CAMPBELL, MD; ZACKERT, WE; DANIEL, VC; BADR, KF; BLAIR, IA; ROBERTS, LJ				MORROW, JD; MINTON, TA; MUKUNDAN, CR; CAMPBELL, MD; ZACKERT, WE; DANIEL, VC; BADR, KF; BLAIR, IA; ROBERTS, LJ			FREE RADICAL-INDUCED GENERATION OF ISOPROSTANES IN-VIVO - EVIDENCE FOR THE FORMATION OF D-RING AND E-RING ISOPROSTANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; FAST-ATOM-BOMBARDMENT; MASS-SPECTROMETRY; PROSTAGLANDINS; PHOSPHOLIPIDS; SERIES; NONCYCLOOXYGENASE; INVIVO; RATS	We recently reported the discovery that a series of novel prostaglandin (PG)F-2-like compounds (F-2-isoprostanes) are produced in vivo independent of the cyclooxygenase as products of free radical-catalyzed lipid peroxidation. F-2-isoprostanes are initially formed in situ from arachidonic acid esterified to phospholipids and then released preformed. We have now investigated whether PGD(2)/E(2)-like isoprostanes are also produced by rearrangement of the PGG(2)-like intermediates involved in isoprostane formation. Using a variety of approaches utilizing mass spectrometry, compelling evidence was obtained for the presence of D-2/E(2)-isoprostane-containing phosphospholipids in the liver (85 +/- 33 ng/g of liver) and free D-2/E(2)-isoprostanes in the circulation (215 +/- 90 pg/ml) of rats treated with CCl4 to induce lipid peroxidation. In untreated rats, levels of D-2/E(2)-isoprostanes esterified in liver phospholipids were much lower (0.90 +/- 0.10 ng/g), and free compounds could not be detected in the circulation (<5 pg/ml). Interestingly, one of the E(2)-isoprostanes that would be expected to be formed in abundance, 8-epi-PGE(2), was found to be a potent renal vasoconstrictor, and these effects could be abrogated by SQ29548, a thromboxane receptor antagonist. Further understanding of the biological consequences of the for mation of these novel compounds and factors that influence their formation may provide valuable insights into the pathophysiology of oxidant injury.	VANDERBILT UNIV, SCH MED, DEPT PHARMACOL, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA; EMORY UNIV, DEPT MED, DIV NEPHROL, ATLANTA, GA 30033 USA; VET AFFAIRS MED CTR, ATLANTA, GA 30033 USA	Vanderbilt University; Vanderbilt University; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System			Blair, Ian A/B-3320-2010		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042056, R37GM042056] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39261] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NIGMS NIH HHS [GM42056] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; AWAD JA, 1993, J BIOL CHEM, V268, P4161; BRASH AR, 1987, BIOCHEMISTRY-US, V26, P5465, DOI 10.1021/bi00391a038; BURK RF, 1979, TOXICOL APPL PHARM, V50, P467, DOI 10.1016/0041-008X(79)90400-9; DUNN MJ, 1977, AM J PHYSIOL, V233, pF169, DOI 10.1152/ajprenal.1977.233.3.F169; ELLINGSON JS, 1987, J LIPID RES, V28, P1016; FUKUNAGA M, 1993, AM J PHYSIOL, V264, pC1619, DOI 10.1152/ajpcell.1993.264.6.C1619; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HAMBERG M, 1973, P NATL ACAD SCI USA, V70, P899, DOI 10.1073/pnas.70.3.899; HANRAS C, 1991, J AM OIL CHEM SOC, V68, P804, DOI 10.1007/BF02660591; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HUGHES H, 1983, ANAL BIOCHEM, V130, P431, DOI 10.1016/0003-2697(83)90612-7; JACKSON EK, 1989, J PHARMACOL EXP THER, V250, P9; JENSEN NJ, 1986, LIPIDS, V21, P580, DOI 10.1007/BF02534056; KAYGANICHHARRISON KA, 1993, J LIPID RES, V34, P1229; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; MORROW JD, 1993, IN PRESS BIOCH BIOPH; OCONNOR DE, 1981, J AM CHEM SOC, V103, P223, DOI 10.1021/ja00391a056; PACEASCIAK C, 1971, J CHROMATOGR, V56, P129, DOI 10.1016/S0021-9673(00)97786-0; PACEASCIAK CR, 1989, ADV PROSTAGLANDIN TH, V18, P251; PARSONS WG, 1988, J IMMUNOL, V141, P2413; RADIN NS, 1969, METHOD ENZYMOL, V14, P245; ROBERTS LJ, 1987, CRC HDB EICOSANOIDS, V1, P233; SOUTHORN PA, 1988, MAYO CLIN PROC, V63, P390, DOI 10.1016/S0025-6196(12)64862-9; TABER DF, 1992, J ORG CHEM, V57, P441, DOI 10.1021/jo00028a012; TAKAHASHI K, 1992, J CLIN INVEST, V90, P136, DOI 10.1172/JCI115826; WENDELBORN DF, 1990, METHOD ENZYMOL, V187, P51; ZIRROLLI JA, 1990, J AM SOC MASS SPECTR, V1, P325, DOI 10.1016/1044-0305(90)85009-B	31	285	288	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4317	4326						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307999				2022-12-27	WOS:A1994MW98900066
J	KRAMARCY, NR; VIDAL, A; FROEHNER, SC; SEALOCK, R				KRAMARCY, NR; VIDAL, A; FROEHNER, SC; SEALOCK, R			ASSOCIATION OF UTROPHIN AND MULTIPLE DYSTROPHIN SHORT FORMS WITH THE MAMMALIAN-M(R) 58,000 DYSTROPHIN-ASSOCIATED PROTEIN (SYNTROPHIN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; CULTURED XENOPUS MUSCLE; SKELETAL-MUSCLE; NEUROMUSCULAR-JUNCTIONS; GLYCOPROTEIN COMPLEX; NONMUSCLE TISSUES; ELECTRIC TISSUE; CYSTEINE-RICH; 58K PROTEIN; LOCALIZATION	Electric tissue syntrophin, originally described as an M(r) 58,000 postsynaptic protein having homologs in mammalian muscle, was previously shown to associate with dystrophin in Triton extracts of Torpedo postsynaptic membranes. It also associates with the Torpedo M(r) 87,000 postsynaptic protein (87K), the core of which is a superdomain homologous to the cysteine-rich (CR) and COOH-terminal (CT) domains of human dystrophin. Using immunoaffinity purifications from various rat tissues and immunoblotting, we find that syntrophin associates with dystrophin, utrophin (the chromosome 6-encoded dystrophin homolog formerly known as dystrophin-related protein), multiple proteins which are cross-reactive with 87K, and two subfamilies of 71K-like proteins (CRCT-containing proteins encoded by the dystrophin gene under the control of an alternative promoter in intron 62). One 71K subfamily retains the dystrophin COOH-terminal sequence; the other has an alternative COOH-terminal sequence caused by deletion of the penultimate exon by alternative splicing. The relative masses of the members of the subfamilies suggest they arise by alternative splicing at other previously described sites within CT. These results establish that syntrophin is a general ligand for the CRCT domain in mammalian dystrophin and its homologs. They also reveal a greater diversity in 71K proteins than has previously been apparent.			KRAMARCY, NR (corresponding author), UNIV N CAROLINA,DEPT PHYSIOL,CHAPEL HILL,NC 27599, USA.		Vidal, Adriana/AAG-8944-2021		FIC NIH HHS [1-F05-TW04733] Funding Source: Medline; NINDS NIH HHS [NS14871, NS15293] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015293, R01NS014871] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; BEWICK GS, 1992, NEUROREPORT, V3, P857, DOI 10.1097/00001756-199210000-00009; BIES RD, 1992, NUCLEIC ACIDS RES, V20, P1725, DOI 10.1093/nar/20.7.1725; Blake Derek J., 1992, Human Molecular Genetics, V1, P103, DOI 10.1093/hmg/1.2.103; BLOCH RJ, 1991, J CELL BIOL, V115, P435, DOI 10.1083/jcb.115.2.435; BUTLER MH, 1992, J BIOL CHEM, V267, P6213; BYERS TJ, 1991, J CELL BIOL, V115, P411, DOI 10.1083/jcb.115.2.411; CARR C, 1989, J CELL BIOL, V109, P1753, DOI 10.1083/jcb.109.4.1753; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CHEN Q, 1990, J CELL BIOL, V110, P2061, DOI 10.1083/jcb.110.6.2061; COX GA, 1993, NAT GENET, V4, P87, DOI 10.1038/ng0593-87; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FARDEAU M, 1990, CR ACAD SCI III-VIE, V311, P197; FEENER CA, 1989, NATURE, V338, P509, DOI 10.1038/338509a0; FROEHNER SC, 1987, J CELL BIOL, V104, P1633, DOI 10.1083/jcb.104.6.1633; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P347, DOI 10.1146/annurev.ne.16.030193.002023; FUJIWARA K, 1976, J CELL BIOL, V71, P848, DOI 10.1083/jcb.71.3.848; HELLIWELL TR, 1992, AM J HUM GENET, V50, P508; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1991, ANN NEUROL, V30, P605, DOI 10.1002/ana.410300414; HUGNOT JP, 1992, P NATL ACAD SCI USA, V89, P7506, DOI 10.1073/pnas.89.16.7506; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KHURANA TS, 1990, J BIOL CHEM, V265, P16717; KIM TW, 1992, P NATL ACAD SCI USA, V89, P11642, DOI 10.1073/pnas.89.23.11642; KOENIG M, 1990, J BIOL CHEM, V265, P4560; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KRAMARCY NR, 1990, FEBS LETT, V274, P171, DOI 10.1016/0014-5793(90)81356-S; LANSMAN JB, 1991, J MUSCLE RES CELL M, V12, P409, DOI 10.1007/BF01738325; LEDERFEIN D, 1992, P NATL ACAD SCI USA, V89, P5346, DOI 10.1073/pnas.89.12.5346; LEMAIRE C, 1988, EMBO J, V7, P4157, DOI 10.1002/j.1460-2075.1988.tb03311.x; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; LIDOV HGW, 1993, NEUROSCIENCE, V54, P167, DOI 10.1016/0306-4522(93)90392-S; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; LOVE DR, 1991, P NATL ACAD SCI USA, V88, P3243, DOI 10.1073/pnas.88.8.3243; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MILNER RE, 1992, BIOCHEM J, V288, P1037, DOI 10.1042/bj2881037; NGUYEN TM, 1992, BIOCHEM J, V288, P663, DOI 10.1042/bj2880663; NICHOLSON LVB, 1990, ACTA NEUROPATHOL, V80, P239, DOI 10.1007/BF00294640; NICHOLSON LVB, 1992, ACTA NEUROL SCAND, V86, P8, DOI 10.1111/j.1600-0404.1992.tb08046.x; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; OHLENDIECK K, 1993, NEUROLOGY, V43, P795, DOI 10.1212/WNL.43.4.795; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PENG HB, 1992, J CELL SCI, V103, P551; RAPAPORT D, 1992, DIFFERENTIATION, V49, P187, DOI 10.1111/j.1432-0436.1992.tb00666.x; RECAN D, 1992, J CLIN INVEST, V89, P712, DOI 10.1172/JCI115640; SATO O, 1992, J BIOCHEM-TOKYO, V112, P631, DOI 10.1093/oxfordjournals.jbchem.a123951; SEALOCK R, 1991, J CELL BIOL, V113, P1133, DOI 10.1083/jcb.113.5.1133; SHIMIZU T, 1989, BIOMED RES-TOKYO, V10, P405, DOI 10.2220/biomedres.10.405; SUZUKI A, 1992, FEBS LETT, V308, P154, DOI 10.1016/0014-5793(92)81265-N; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R; WAGNER KR, 1993, IN PRESS J NEUROCHEM; YEADON JE, 1991, J CELL BIOL, V115, P1069, DOI 10.1083/jcb.115.4.1069; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	58	155	158	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2870	2876						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300622				2022-12-27	WOS:A1994MV43200076
J	PORTEU, F; HIEBLOT, C				PORTEU, F; HIEBLOT, C			TUMOR-NECROSIS-FACTOR INDUCES A SELECTIVE SHEDDING OF ITS P75-RECEPTOR FROM HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR TNF RECEPTOR; NF-KAPPA-B; FACTOR-BINDING-PROTEIN; CELL-SURFACE; MOLECULAR-CLONING; SOLUBLE FORM; MONOCLONAL-ANTIBODIES; LIGAND-BINDING; I TNF; EXPRESSION	The effect of tumor necrosis factor alpha (TNF) on the expression of its specific receptors (p55 TNF-R and p75 TNF-R) on the surface of human neutrophils (PMN) and mononuclear cells (MNC) was investigated and compared to the effect of various agonists. PMN and-MNC express both p55 and p75 TNF-R on their membranes. Within minutes of incubation with chemotactic factors or calcium ionophore A23187, both types of TNF-R were down-regulated from the surface on both cell populations. At the same time, soluble forms of these TNF-R appeared in supernatants, in amounts proportional to the extent of down-regulation induced by each stimulus, suggesting that shedding is the major mechanism leading to loss of p55 and p75 TNF-R upon activation with these agonists. Likewise, TNF induced 60-80% and 73-90% decreases in PMN surface p55 TNF-R and p75 TNF-R, respectively. However, modulation of the two types of TNF-R by TNF proceeded through different mechanisms. TNF induced a selective shedding of the p75 TNF-R since, by both enzyme-linked immunosorbent assay and Western blot analysis, only the p75 TNF-R was detected in supernatants of cells stimulated with TNF. Down-modulation of surface p55 TNF-R most probably resulted from TNF-induced receptor internalization, since I-125-TNF bound to PMN p55 TNF-R was rapidly internalized with a t1/2 = 5 min and preincubation of PMN with TNF inhibited by 68 +/- 6% the release of p55 TNF-R triggered upon subsequent treatment with A23187. The apparently unique property of TNF to induce a differential modulation of the two types of TNF-R at the surface of PMN and MNC might play an important role in the control of peripheral blood cell responses to TNF.			PORTEU, F (corresponding author), HOP NECKER ENFANTS MALAD,INSERM,U90,161 RUE SEVRES,F-75743 PARIS 15,FRANCE.		PORTEU, Françoise/I-8445-2016	PORTEU, Françoise/0000-0002-2403-4163				ADERKA D, 1992, J EXP MED, V175, P323, DOI 10.1084/jem.175.2.323; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; BROUCKAERT P, 1992, LYMPHOKINE CYTOK RES, V11, P193; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; GAMBLE JR, 1985, P NATL ACAD SCI USA, V82, P8667, DOI 10.1073/pnas.82.24.8667; GEHR G, 1992, J IMMUNOL, V149, P911; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GULLBERG U, 1992, EUR J CELL BIOL, V58, P307; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KALTHOFF H, 1993, J BIOL CHEM, V268, P2762; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; KRUPPA G, 1992, J IMMUNOL, V148, P3152; KULL FC, 1981, CANCER RES, V41, P4885; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANTZ M, 1990, J CLIN INVEST, V86, P1396, DOI 10.1172/JCI114853; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1990, J BIOL CHEM, V265, P20131; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; MOSSALAYI MD, 1990, J EXP MED, V171, P959, DOI 10.1084/jem.171.3.959; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; NAUME B, 1991, J IMMUNOL, V146, P3045; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; PEETRE C, 1988, EUR J HAEMATOL, V41, P414; PENNICA D, 1993, BIOCHEMISTRY-US, V32, P3131, DOI 10.1021/bi00063a027; PENNICA D, 1992, J BIOL CHEM, V267, P21172; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; PORTEU F, 1992, J LEUKOCYTE BIOL, V52, P122, DOI 10.1002/jlb.52.1.122; PORTEU F, 1991, J BIOL CHEM, V266, P18846; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; RICHTER J, 1990, P NATL ACAD SCI USA, V87, P9472, DOI 10.1073/pnas.87.23.9472; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHALABY MR, 1985, J IMMUNOL, V135, P2069; SHALABY MR, 1990, J EXP MED, V172, P1517, DOI 10.1084/jem.172.5.1517; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SPINAS GA, 1992, J CLIN INVEST, V90, P533, DOI 10.1172/JCI115891; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; TSUJIMOTO M, 1987, J BIOCHEM-TOKYO, V102, P1571, DOI 10.1093/oxfordjournals.jbchem.a122206; VANDENABEELE P, 1992, J EXP MED, V176, P1015, DOI 10.1084/jem.176.4.1015; VANOSTADE X, 1993, NATURE, V361, P266; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WATANABE N, 1989, CANCER IMMUNOL IMMUN, V28, P157; WINZEN R, 1993, J IMMUNOL, V150, P4346; WINZEN R, 1992, J IMMUNOL, V148, P3454; WONG GHW, 1992, J IMMUNOL, V149, P3350; YOSHIE O, 1986, J BIOCHEM-TOKYO, V100, P531, DOI 10.1093/oxfordjournals.jbchem.a121744	61	98	100	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2834	2840						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300617				2022-12-27	WOS:A1994MV43200071
J	QUINET, E; YANG, TP; MARINOS, C; TALL, A				QUINET, E; YANG, TP; MARINOS, C; TALL, A			INHIBITION OF THE CELLULAR SECRETION OF CHOLESTERYL ESTER TRANSFER PROTEIN BY A VARIANT PROTEIN FORMED BY ALTERNATIVE SPLICING OF MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LIPID TRANSFER PROTEIN; HIGH-DENSITY-LIPOPROTEIN; CORONARY HEART-DISEASE; GENE; BINDING	Alternative splicing of mRNA is often used as a regulatory switch, determining whether a functional protein is made or not. The plasma cholesteryl ester transfer protein (CETP) mediates the transfer of cholesteryl esters from high density lipoproteins to other lipoproteins. In addition to the mRNA encoding plasma CETP, human tissues contain an alternatively spliced variant in which exon 9-derived sequences are omitted. To determine a possible regulatory role of alternative splicing, COS cells were co-transfected with full-length and exon 9-deleted cDNAs. The exon 9-deleted protein was poorly secreted and inhibited the secretion of full-length CETP, due to formation of an intracellular heteromeric complex between full-length and exon 9-deleted proteins. The findings suggest a novel use of alternative splicing to generate a poorly secreted protein variant, which complexes with the active form and prevents its secretion by cells.			QUINET, E (corresponding author), COLUMBIA UNIV,DEPT MED,DIV MOLEC MED,NEW YORK,NY 10032, USA.		Tall, Alan/AAT-8528-2021		NHLBI NIH HHS [HL43165, HL21006] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043165, P50HL021006] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGELLON LB, 1990, BIOCHEMISTRY-US, V29, P1372, DOI 10.1021/bi00458a004; AGELLON LB, 1992, J BIOL CHEM, V267, P22336; BROWN ML, 1989, NATURE, V342, P448, DOI 10.1038/342448a0; DRAYNA D, 1987, NATURE, V327, P632, DOI 10.1038/327632a0; FAUST RA, 1990, BIOCHIM BIOPHYS ACTA, V1042, P404, DOI 10.1016/0005-2760(90)90171-S; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HESLER CB, 1987, J BIOL CHEM, V262, P2275; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; INAZU A, 1991, BIOCHEMISTRY-US, V31, P2352; JIANG XC, 1992, J CLIN INVEST, V90, P1290, DOI 10.1172/JCI115993; JIANG XC, 1991, J BIOL CHEM, V266, P4631; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MATTOX W, 1992, J BIOL CHEM, V267, P19023; QUINET E, 1991, J CLIN INVEST, V87, P1559, DOI 10.1172/JCI115169; QUINET EM, 1993, J LIPID RES, V34, P845; QUINET EM, 1990, J CLIN INVEST, V85, P357, DOI 10.1172/JCI114446; RHOADS GG, 1976, NEW ENGL J MED, V294, P293, DOI 10.1056/NEJM197602052940601; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; STEVENSON SC, 1993, BIOCHEMISTRY-US, V32, P5121, DOI 10.1021/bi00070a021; WANG S, 1992, J BIOL CHEM, V267, P17487	22	35	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16891	16894						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349580				2022-12-27	WOS:A1993LQ98800006
J	TAKAHASHI, Y; REDDY, GR; UEDA, N; YAMAMOTO, S; ARASE, S				TAKAHASHI, Y; REDDY, GR; UEDA, N; YAMAMOTO, S; ARASE, S			ARACHIDONATE 12-LIPOXYGENASE OF PLATELET-TYPE IN HUMAN EPIDERMAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE LEUKOCYTES; MAMMALIAN LIPOXYGENASES; MOLECULAR-CLONING; PSORIATIC SKIN; ACID; TRANSFORMATIONS; KERATINOCYTES; LOCALIZATION; EXPRESSION; DISTINCT	A homogenate of epidermal cells isolated from human skin converted arachidonic acid to 12S-hydroxy-5,8,10,14-eicosatetraenoic acid and 15-hydroxy-5,8,11,13-eicosatetraenoic acid as the main lipoxygenase products. The production of these hydroxy acids was not stimulated by the addition of 1 mM NADPH required for cytochrome P-450 reaction, but inhibited by 65-75% with 40 muM nordihydroguaiaretic acid, a nonspecific lipoxygenase inhibitor. In addition to these lipoxygenase products, the epidermal cell homogenate converted arachidonic acid to prostaglandin E2 together with minor amounts of prostaglandins D2 and F2a and 12-hydroxy-5,8,10-heptadecatrienoic acid. Thromboxane B2 was not detected. This finding rules out the possible contamination of platelet 12-lipoxygenase in the epidermal cells. After subcellular fractionation of the epidermal cell homogenate, the 12-lipoxygenase activity was found in the 164,000 x g supernatant, the 164,000 x g pellet, and the 10,000 x g pellet. The cytosolic enzyme and the enzymes solubilized from the two pellets produced 12S-hydroperoxy-5,8,10,14-eicosatetraenoic acid as the primary product in contrast to cytochrome P-450 which produces primarily hydroxy acids. The 12-lipoxygenase in the 164,000 x g supernatant and the solubilized enzymes from the 164,000 x g pellet and 10,000 x g pellet were precipitable by antibodies raised against human platelet 12-lipoxygenase, but not by antibodies against porcine leukocyte 12-lipoxygenase. The immunoprecipitated 12-lipoxygenase from each fraction was almost inactive with linoleic acid as substrate, characteristic of 12-lipoxygenase of platelet-type. Furthermore, 12-lipoxygenase mRNA in the epidermal cells could be reverse-transcribed and amplified by polymerase chain reaction with the primers specific for human platelet 12-lipoxygenase cDNA, but not with those for porcine leukocyte 12-lipoxygenase cDNA. Thus, the 12-lipoxygenase of human epidermal cells is similar to human platelet 12-lipoxygenase in terms of immunogenicity, catalytic property, and primary structure, and distinct from leukocyte 12-lipoxygenase.	UNIV TOKUSHIMA, SCH MED, DEPT BIOCHEM, TOKUSHIMA 770, JAPAN; UNIV TOKUSHIMA, SCH MED, DEPT DERMATOL, TOKUSHIMA 770, JAPAN	Tokushima University; Tokushima University								CHANG WC, 1992, J BIOL CHEM, V267, P3657; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HAMMARSTROM S, 1979, J INVEST DERMATOL, V73, P180, DOI 10.1111/1523-1747.ep12581645; HAMMARSTROM S, 1975, P NATL ACAD SCI USA, V72, P5130, DOI 10.1073/pnas.72.12.5130; HANSBROUGH JR, 1990, J BIOL CHEM, V265, P1771; HOLTZMAN MJ, 1989, J CLIN INVEST, V84, P1446, DOI 10.1172/JCI114319; IZUMI T, 1990, P NATL ACAD SCI USA, V87, P7477, DOI 10.1073/pnas.87.19.7477; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHMUD I, 1993, BIOCHIM BIOPHYS ACTA, V1166, P211, DOI 10.1016/0005-2760(93)90099-U; MATSUDA S, 1993, BIOCHIM BIOPHYS ACTA, V1180, P243, DOI 10.1016/0925-4439(93)90045-3; NADLER JL, 1992, 8TH INT C PROST REL, P165; NEWMAN PJ, 1988, J CLIN INVEST, V82, P739, DOI 10.1172/JCI113656; NISHIYAMA M, 1992, J NEUROCHEM, V58, P1395, DOI 10.1111/j.1471-4159.1992.tb11355.x; NUGTEREN DH, 1987, BIOCHIM BIOPHYS ACTA, V921, P135, DOI 10.1016/0005-2760(87)90179-2; NUGTEREN DH, 1975, BIOCHIM BIOPHYS ACTA, V380, P299, DOI 10.1016/0005-2760(75)90016-8; OKADA N, 1983, ARCH DERMATOL RES, V275, P130, DOI 10.1007/BF00412889; OPAS EE, 1989, BRIT J DERMATOL, V120, P49, DOI 10.1111/j.1365-2133.1989.tb07765.x; ROSENBACH T, 1990, J INVEST DERMATOL, V95, P104, DOI 10.1111/1523-1747.ep12874064; RUZICKA T, 1983, BIOCHIM BIOPHYS ACTA, V751, P369, DOI 10.1016/0005-2760(83)90295-3; SHINJO F, 1986, J BIOL CHEM, V261, P3377; TAKAHASHI Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P613, DOI 10.1016/0003-9861(88)90294-9; UEDA N, 1988, J BIOL CHEM, V263, P1937; UEDA N, 1990, J BIOL CHEM, V265, P2311; VANOS CPA, 1981, BIOCHIM BIOPHYS ACTA, V663, P177, DOI 10.1016/0005-2760(81)90204-6; WALSTRA P, 1987, BIOCHIM BIOPHYS ACTA, V921, P312, DOI 10.1016/0005-2760(87)90032-4; WOOLLARD PM, 1986, BIOCHEM BIOPH RES CO, V136, P169, DOI 10.1016/0006-291X(86)90891-0; YAMAMOTO S, 1991, FREE RADICAL BIO MED, V10, P149, DOI 10.1016/0891-5849(91)90008-Q; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; YAMAMOTO S, 1993, DEV ONCOL, V71, P7; YOKOYAMA C, 1986, J BIOL CHEM, V261, P6714; YOSHIMOTO T, 1990, P NATL ACAD SCI USA, V87, P2142, DOI 10.1073/pnas.87.6.2142; YOSHIMOTO T, 1982, BIOCHIM BIOPHYS ACTA, V713, P638; YOSHIMOTO T, 1990, BIOCHEM BIOPH RES CO, V172, P1230, DOI 10.1016/0006-291X(90)91580-L; ZIBOH VA, 1984, J INVEST DERMATOL, V83, P248, DOI 10.1111/1523-1747.ep12340250	37	77	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16443	16448						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344930				2022-12-27	WOS:A1993LQ33600054
J	TAN, FL; MORRIS, PW; SKIDGEL, RA; ERDOS, EG				TAN, FL; MORRIS, PW; SKIDGEL, RA; ERDOS, EG			SEQUENCING AND CLONING OF HUMAN PROLYLCARBOXYPEPTIDASE (ANGIOTENSINASE-C) - SIMILARITY TO BOTH SERINE CARBOXYPEPTIDASE AND PROLYLENDOPEPTIDASE FAMILIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL PROTECTIVE PROTEIN; BRAIN PROLYL ENDOPEPTIDASE; DIPEPTIDYL PEPTIDASE-IV; ACTIVE-SITE RESIDUES; BETA-GALACTOSIDASE; ENZYME; IDENTIFICATION; INACTIVATION; OLIGOPEPTIDASE; NEURAMINIDASE	Prolylcarboxypeptidase, a lysosomal serine carboxypeptidase, cleaves COOH-terminal amino acids linked to proline, as in angiotensin II and III and [des-Arg9] bradykinin. About 25% of the enzyme protein was sequenced, and the complete sequence was deduced from its human kidney cDNA. The cDNA insert contained an open reading frame of 1488 base pairs coding for a protein of 496 residues. The authentic NH2-terminal sequence matched the deduced protein sequence starting with residue 46, suggesting the presence of both a signal and propeptide. The mature enzyme (451 residues) has a calculated M(r) = 51,043, whereas the M(r) of the purified glycoprotein is 58,000, indicating 12% carbohydrate. The overall sequence identity with serine peptidases is low (10-18%), but sequences around residues of the putative catalytic triad (Ser134, Asp333, His411) are similar (30-67%) to both the serine carboxypeptidases (e.g. deamidase or lysosomal protective protein, yeast carboxypeptidase Y, and KEX1 gene product) and the prolylendopeptidase family. Thus, prolylcarboxypeptidase links these two families, suggesting an evolutionary relationship. It is inhibited (K(i) = 2.6 x 10(-7) M) by benzyloxycarbonyl-Pro-prolinal, a specific inhibitor of prolylendopeptidase, another angiotensin metabolizing enzyme. Prolylcarboxypeptidase contains serine or threonine residues repeated as the 26th residue 7 out of 9 times, with identical or similar amino acids in other positions in the repeats. The KEX1 gene product contains a similar motif, with serine or threonine as every 27th residue. The importance of prolylcarboxypeptidase is strongly suggested by its presence in various organs and cells and by the substrates it cleaves.	UNIV ILLINOIS,COLL MED,DEPT ANESTHESIOL,CHICAGO,IL 60612; UNIV ILLINOIS,COLL MED,DEPT BIOCHEM,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	TAN, FL (corresponding author), UNIV ILLINOIS,COLL MED,DEPT PHARMACOL,CHICAGO,IL 60612, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036082, R01HL036473, R01HL036081, R37HL036473] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36082, HL36081, HL36473] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETT AJ, 1992, BIOL CHEM H-S, V373, P353, DOI 10.1515/bchm3.1992.373.2.353; BECH LM, 1989, CARLSBERG RES COMMUN, V54, P165, DOI 10.1007/BF02904470; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BOWEN DM, 1973, BIOCHEM J, V131, P417, DOI 10.1042/bj1310417; BREDDAM K, 1986, CARLSBERG RES COMMUN, V51, P83, DOI 10.1007/BF02907561; DAZZO A, 1982, P NATL ACAD SCI-BIOL, V79, P4535, DOI 10.1073/pnas.79.15.4535; DMOCHOWSKA A, 1987, CELL, V50, P573, DOI 10.1016/0092-8674(87)90030-4; FERRARIO CM, 1990, HYPERTENSION S1, V15, P13; FROHMAN LA, 1989, J CLIN INVEST, V83, P1533, DOI 10.1172/JCI114049; GALJART NJ, 1988, CELL, V54, P755, DOI 10.1016/S0092-8674(88)90999-3; GALJART NJ, 1991, J BIOL CHEM, V266, P14754; HAYASHI R, 1973, J BIOL CHEM, V248, P8366; JACKMAN HL, 1992, J BIOL CHEM, V267, P2872; JACKMAN HL, 1990, J BIOL CHEM, V265, P11265; KOHARA K, 1991, HYPERTENSION, V17, P131, DOI 10.1161/01.HYP.17.2.131; KUMAMOTO K, 1981, J CLIN INVEST, V67, P210, DOI 10.1172/JCI110015; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAWRENCE AC, 1992, NEUROENDOCRINOLOGY, V55, P105, DOI 10.1159/000126103; LIAO DI, 1990, J BIOL CHEM, V265, P6528; LIAO DI, 1992, BIOCHEMISTRY-US, V31, P9796, DOI 10.1021/bi00155a037; MATSUNAGA M, 1969, JPN CIRC J, V33, P541; MCCALDON P, 1988, PROTEINS, V4, P99, DOI 10.1002/prot.340040204; MISUMI Y, 1992, BIOCHIM BIOPHYS ACTA, V1131, P333, DOI 10.1016/0167-4781(92)90036-Y; MITTA M, 1989, J BIOCHEM-TOKYO, V106, P548, DOI 10.1093/oxfordjournals.jbchem.a122891; MORREAU H, 1992, J BIOL CHEM, V267, P17949; MORRIS PW, 1992, 6TH ANN S PROT SOC, pS85; ODYA C, 1981, METHOD ENZYMOL, V81, P460; ODYA CE, 1978, J BIOL CHEM, V253, P5927; OGATA S, 1992, BIOCHEMISTRY-US, V31, P2582, DOI 10.1021/bi00124a019; POLGAR L, 1992, FEBS LETT, V311, P281, DOI 10.1016/0014-5793(92)81120-B; RAWLINGS ND, 1991, BIOCHEM J, V279, P907, DOI 10.1042/bj2790907; RENNEX D, 1991, BIOCHEMISTRY-US, V30, P2195, DOI 10.1021/bi00222a025; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; Ruegg U T, 1977, Methods Enzymol, V47, P111; Sambrook J, 1989, MOL CLONING LABORATO; SCALONI A, 1992, J BIOL CHEM, V267, P3811; SKIDGEL RA, 1981, ANAL BIOCHEM, V118, P113, DOI 10.1016/0003-2697(81)90165-2; SKIDGEL RA, 1989, J BIOL CHEM, V264, P2236; SORENSEN SB, 1987, CARLSBERG RES COMMUN, V52, P285, DOI 10.1007/BF02907171; Sorrells K., 1972, FUNDAMENTAL MECHANIS, P393; STONE SR, 1991, BIOCHEM J, V276, P837, DOI 10.1042/bj2760837; TAN FL, 1990, J BIOL CHEM, V265, P13; VONHEIJNE G, 1987, SEQUENCE ANAL MOL BI, P112; WILK S, 1983, J NEUROCHEM, V41, P69, DOI 10.1111/j.1471-4159.1983.tb11815.x; WILK S, 1983, LIFE SCI, V33, P2149, DOI 10.1016/0024-3205(83)90285-0; YANG HYT, 1967, NATURE, V215, P1402, DOI 10.1038/2151402a0; YANG HYT, 1970, BIOCHEM PHARMACOL, V19, P1201, DOI 10.1016/0006-2952(70)90380-1; YOSHIMOTO T, 1991, J BIOCHEM-TOKYO, V110, P873, DOI 10.1093/oxfordjournals.jbchem.a123682; ZHOU XY, 1991, EMBO J, V10, P4041, DOI 10.1002/j.1460-2075.1991.tb04980.x	49	99	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16631	16638						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344943				2022-12-27	WOS:A1993LQ33600079
J	KARRAN, P; MACPHERSON, P; CECCOTTI, S; DOGLIOTTI, E; GRIFFIN, S; BIGNAMI, M				KARRAN, P; MACPHERSON, P; CECCOTTI, S; DOGLIOTTI, E; GRIFFIN, S; BIGNAMI, M			O(6)-METHYLGUANINE RESIDUES ELICIT DNA-REPAIR SYNTHESIS BY HUMAN CELL-EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; ESCHERICHIA-COLI; O6-METHYLGUANINE-DNA METHYLTRANSFERASE; EXCISION REPAIR; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; 3-METHYLADENINE-DNA GLYCOSYLASE; REPLICATION INVITRO; ALKYLATING-AGENTS; INITIATION; DEFICIENT	We have investigated the processing of O6-methylguanine (O6-MeGua) in plasmid DNA by extracts of human cells defective in O6-MeGua-DNA methyltransferase. Cell extracts of HeLaMR cells performed viral T antigen-independent DNA synthesis on plasmids that had been treated with low concentrations of methylating agents. The in vitro DNA synthesis was non-semiconservative and depended on the presence of O6-MeGua in the substrate. The involvement of DNA polymerase delta or epsilon and proliferating cell nuclear antigen but not single-strand binding protein was indicated by partial fractionation, inhibitor, and antibody studies. Processing of O6-MeGua is not via the UV nucleotide excision repair pathway since additional component(s) are apparently required to perform repair synthesis on the methylated substrate. This is the first direct demonstration of DNA repair synthesis provoked by O6-MeGua in DNA. Since O6-MeGua is not excised from DNA by Mex- cells, it represents a novel type of processing of the methylated base that may be involved in its cytotoxicity.	IST SUPER SANITA,COMPARAT TOXICOL & ECOTOXICOL LAB,I-00161 ROME,ITALY	Istituto Superiore di Sanita (ISS)	KARRAN, P (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,ENGLAND.							ALADJEM MI, 1992, MUTAT RES, V276, P339, DOI 10.1016/0165-1110(92)90020-A; AU KG, 1992, J BIOL CHEM, V267, P12142; BASU AK, 1988, CHEM RES TOXICOL, V1, P1, DOI 10.1021/tx00001a001; BIGGERSTAFF M, 1992, J BIOL CHEM, V267, P6879; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; CARTY MP, 1993, MOL CELL BIOL, V13, P533, DOI 10.1128/MCB.13.1.533; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; DAY RS, 1980, NATURE, V288, P724, DOI 10.1038/288724a0; DAY RS, 1987, J CELL SCI S, V6, P333; DECKER RS, 1986, MOL CELL BIOL, V6, P3815, DOI 10.1128/MCB.6.11.3815; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; FRANKLIN WA, 1988, EMBO J, V7, P3617, DOI 10.1002/j.1460-2075.1988.tb03240.x; GALLAGHER PE, 1982, BIOCHEMISTRY-US, V21, P6404, DOI 10.1021/bi00268a013; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; HARRIS AL, 1983, CANCER RES, V43, P3247; KAINA B, 1991, CARCINOGENESIS, V12, P1857; KALAMEGHAM R, 1988, CARCINOGENESIS, V9, P1749, DOI 10.1093/carcin/9.10.1749; KARRAN P, 1980, J MOL BIOL, V140, P101, DOI 10.1016/0022-2836(80)90358-7; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; KARRAN P, 1982, NATURE, V296, P868, DOI 10.1038/296868a0; LARSON K, 1985, MUTAT RES, V150, P77, DOI 10.1016/0027-5107(85)90103-4; LAWLEY PD, 1984, ACS MONOGR SER, V182, P25; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; Lindahl T, 1975, MOL MECHANISMS REPAI, P31; LJUNGQUIST S, 1977, J BIOL CHEM, V252, P2808; MAGEE TR, 1992, EMBO J, V11, P4219, DOI 10.1002/j.1460-2075.1992.tb05516.x; MATTERN MR, 1981, CARCINOGENESIS, V2, P1215, DOI 10.1093/carcin/2.11.1215; PEGG AE, 1990, CANCER RES, V50, P6119; ROSA S, 1991, NUCLEIC ACIDS RES, V19, P5569, DOI 10.1093/nar/19.20.5569; SASSANFAR M, 1991, J BIOL CHEM, V266, P2767; SCUDIERO DA, 1984, CANCER RES, V44, P961; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; Singer B., 1983, MOL BIOL MUTAGENS CA; SKLAR R, 1981, NATURE, V289, P417, DOI 10.1038/289417a0; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; ULLAH S, 1992, BIOCHEMISTRY-US, V31, P7998; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; WU ZN, 1992, CANCER RES, V52, P32; ZHUKOVSKAYA N, 1992, NUCLEIC ACIDS RES, V20, P6081, DOI 10.1093/nar/20.22.6081	47	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15878	15886						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340413				2022-12-27	WOS:A1993LN30500080
J	WILSON, ME; PAETZ, KE; RAMAMOORTHY, R; DONELSON, JE				WILSON, ME; PAETZ, KE; RAMAMOORTHY, R; DONELSON, JE			THE EFFECT OF ONGOING PROTEIN-SYNTHESIS ON THE STEADY-STATE LEVELS OF GP63 RNAS IN LEISHMANIA-CHAGASI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE MESSENGER-RNA; 3' UNTRANSLATED REGION; AU-RICH SEQUENCES; C-MYC; SURFACE GLYCOPROTEIN; TRYPANOSOMA-BRUCEI; STABILITY INVITRO; TUBULIN GENES; DONOVANI; PROMASTIGOTES	G63, the major surface glycoprotein of Leishmania chagasi promastigotes, increases 11-fold in amount as promastigotes grow from logarithmic to stationary phase. Transcripts from three different classes of gp63 genes are differentially expressed during this development (Ramamoorthy, R., Donelson, J. E., Paetz, K. E., Maybodi, M., Roberts, S. P., and Wilson, M. E. (1992) J. Biol. Chem. 267, 1888-1895). We studied the effect of protein synthesis inhibitors on gp63 mRNAs. The steady state level of log class gp63 RNA, expressed primarily in logarithmic phase promastigotes, increased 16.5-fold after incubation in cycloheximide. A similar increase in log gp63 RNAs was caused by inhibitors that block different steps in translation. In contrast, the levels of stationary class gp63 RNA, expressed in stationary phase parasites, and constitutive class gp63 RNA, expressed throughout promastigote growth, increased only 2.3- and 1.5-fold, respectively. The latter was not statistically significant. Nuclear run-on assays showed that the cycloheximide effect was not due to an increased rate of transcription. However, the t1/2 Of log RNAs was prolonged 6.5-fold after incubation in cycloheximide, in contrast to a 1.7-fold increase in the t1/2 of ATPase RNA, suggesting that cycloheximide specifically stabilizes log gp63 mRNAs. Thus, a highly labile negative regulatory protein, such as an RNase, may specifically target log gp63 RNAs for degradation.	UNIV IOWA,DEPT MED,IOWA CITY,IA 52242; UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; VET ADM MED CTR,IOWA CITY,IA 52240; HOWARD HUGHES MED INST,IOWA CITY,IA 52242	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Howard Hughes Medical Institute			Donelson, John E/F-5795-2010	Wilson, Mary/0000-0001-8680-7275	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032135, R29AI030126] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI32135, R29 AI30126] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ALTUS MS, 1991, J BIOL CHEM, V266, P21190; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CHANG CS, 1986, P NATL ACAD SCI USA, V83, P100, DOI 10.1073/pnas.83.1.100; CHAUDHURI G, 1989, J BIOL CHEM, V264, P7483; COX GS, 1990, J BIOL CHEM, V265, P13190; DELISLE AJ, 1983, MOL CELL BIOL, V3, P1920, DOI 10.1128/MCB.3.11.1920; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; DORN PL, 1991, MOL BIOCHEM PARASIT, V44, P133, DOI 10.1016/0166-6851(91)90229-Y; ENGLUND PT, 1982, ANNU REV BIOCHEM, V51, P695, DOI 10.1146/annurev.bi.51.070182.003403; GAY DA, 1989, P NATL ACAD SCI USA, V86, P5763, DOI 10.1073/pnas.86.15.5763; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HARRIS ME, 1991, MOL CELL BIOL, V11, P2416, DOI 10.1128/MCB.11.5.2416; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KIMMEL BE, 1985, GENE, V35, P237, DOI 10.1016/0378-1119(85)90002-2; KOOTER JM, 1984, NUCLEIC ACIDS RES, V12, P9457, DOI 10.1093/nar/12.24.9457; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MEADE JC, 1989, MOL BIOCHEM PARASIT, V33, P81, DOI 10.1016/0166-6851(89)90045-5; MEDINAACOSTA E, 1989, MOL BIOCHEM PARASIT, V37, P263, DOI 10.1016/0166-6851(89)90158-8; PACHTER JS, 1987, CELL, V51, P283, DOI 10.1016/0092-8674(87)90155-3; PEARSON RD, 1980, J IMMUNOL, V125, P2195; PELTZ SW, 1987, MOL CELL BIOL, V7, P4345, DOI 10.1128/MCB.7.12.4345; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; RAMAMOORTHY R, 1992, J BIOL CHEM, V267, P1888; RINGOLD GM, 1984, P NATL ACAD SCI-BIOL, V81, P3964, DOI 10.1073/pnas.81.13.3964; RUSSELL DG, 1986, J IMMUNOL, V136, P2613; SACKS DL, 1984, SCIENCE, V223, P1417, DOI 10.1126/science.6701528; Sambrook J, 1989, MOL CLONING LABORATO; SHAPIRO SZ, 1982, ANAL BIOCHEM, V127, P112, DOI 10.1016/0003-2697(82)90152-X; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPITHILL TW, 1987, MOL BIOCHEM PARASIT, V24, P23, DOI 10.1016/0166-6851(87)90112-5; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; VAZQUEZ D, 1979, RIBOSOMES STRUCTURE, P847; WILSON ME, 1984, INFECT IMMUN, V46, P128, DOI 10.1128/IAI.46.1.128-134.1984; WILSON ME, 1988, J IMMUNOL, V141, P265; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YEN TJ, 1988, MOL CELL BIOL, V8, P1224, DOI 10.1128/MCB.8.3.1224; ZARLEY JH, 1991, J CLIN INVEST, V88, P1511, DOI 10.1172/JCI115461	43	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15731	15736						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340397				2022-12-27	WOS:A1993LN30500061
J	VYAS, K; RAJARATHNAM, K; YU, LP; EMERSON, SD; LAMAR, GN; KRISHNAMOORTHI, R; MIZUKAMI, H				VYAS, K; RAJARATHNAM, K; YU, LP; EMERSON, SD; LAMAR, GN; KRISHNAMOORTHI, R; MIZUKAMI, H			H-1-NMR INVESTIGATION OF THE HEME CAVITY OF ELEPHANT (E7 GLN) MET-CYANO-MYOGLOBIN - EVIDENCE FOR A B-HELIX PHENYLALANINE INTERACTION WITH BOUND LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; NUCLEAR MAGNETIC-RESONANCE; DISTAL SIDE; ELECTRONIC-STRUCTURE; 2-DIMENSIONAL NMR; CARBON-MONOXIDE; MODEL COMPOUNDS; ASSIGNMENT; PROTEINS; BINDING	A combination of one- and two-dimensional NMR experiments has been used to identify and spatially locate the heme pocket residues in the paramagnetic, low spin, met-cyano complex of elephant myoglobin. In addition to assigning resonances of the conserved residues, we have also assigned Gln64(E7) and an aromatic ring designated Phe(A) whose side chain is inserted into the heme pocket, as found earlier for elephant carbonmonoxy-myoglobin and oxy-myoglobin (Yu, L. P., La Mar, G. N., and Mizukami, H. (1990) Biochemistry 29, 2578-2585). The assigned conserved proximal side residues (Leu89(F4), Ala90(F5), His93(F8), His97(FG3), Ile99(FG5), Leu104(G5), Phe138(H15), and Tyr146(H23)) and conserved distal side residues (Phe43(CD1), Thr67(E10), Val68(E11), and Ala71(E14)) in elephant met-cyano-myoglobin are found to have orientations similar to those in sperm whale met-cyano-myoglobin. The observed dipolar connectivities and dipolar shift pattern for the substituted Gln64(E7) place the Gln in the heme pocket oriented toward the iron, as found for His64(E7). The conserved structural elements demand that the inserted Phe(A) originate from the B-helix (i.e. Phe27 or Phe33). Dipolar contacts between the inserted Phe(A) and the conserved residues Phe43(CD1), Val68(E11), Ile107(G8), and Gln64(E7), place Phe(A) in the position occupied by the B10 residue in sperm whale myoglobin (Mb), with the larger size of the Phe(A) side chain as compared to the replaced Leu being accommodated by the vacancy that occurs in sperm whale Mb. The paramagnetic induced relaxation places Phe(A) in van der Waals contact with the bound ligand. Hence we conclude that the B10 position of elephant Mb is occupied by a Phe, and this substitution relative to sperm whale Mb is responsible for the low autoxidation rate and low reduction potential of elephant Mb. A reduced autoxidation rate has been reported for a sperm whale synthetic point mutant Leu29(B10) --> Phe (Carver, T. E., Brantley, R. E., Jr., Singleton, E. W., Arduini, R. M., Quillin, M. L., Phillips, G. N., and Olson, J. S. (1992) J. Biol. Chem. 267, 14443-14450). The published sequence of elephant Mb places B-helix Phe residues at position 27(B8) and 33(B14), but a Phe at neither of these positions can account for the observed NMR properties. Since a large proportion of the substitutions in elephant relative to sperm whale Mb, and some of the least conservative, occur in the B-helix, neither a structurally perturbed B-helix nor an error in the sequence can be discounted.	UNIV CALIF DAVIS,DEPT CHEM,DAVIS,CA 95616; WAYNE STATE UNIV,DEPT BIOL SCI,DETROIT,MI 48202	University of California System; University of California Davis; Wayne State University				Yu, Liping/0000-0003-3536-6427	NHLBI NIH HHS [HL 16087] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016087, R37HL016087] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BARTNICKI DE, 1983, J BIOL CHEM, V258, P1599; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BELLELLI A, 1990, J BIOL CHEM, V265, P18898; BRAUNSTEIN D, 1988, P NATL ACAD SCI USA, V85, P8497, DOI 10.1073/pnas.85.22.8497; BRUNORI M, 1992, J BIOL CHEM, V267, P2258; CARVER TE, 1992, J BIOL CHEM, V267, P14443; CASE DA, 1979, J MOL BIOL, V132, P343, DOI 10.1016/0022-2836(79)90265-1; COOKE RM, 1987, EUR J BIOCHEM, V166, P399, DOI 10.1111/j.1432-1033.1987.tb13529.x; CUTNELL JD, 1981, J AM CHEM SOC, V103, P3567, DOI 10.1021/ja00402a053; DALVIT C, 1987, J MOL BIOL, V194, P313, DOI 10.1016/0022-2836(87)90378-0; DAYHOFF MO, 1972, ATLAS PROTEIN SEQUEN, V5, P235; DENE H, 1980, PROC R SOC SER B-BIO, V207, P111, DOI 10.1098/rspb.1980.0016; EMERSON SD, 1988, J AM CHEM SOC, V110, P4176, DOI 10.1021/ja00221a013; EMERSON SD, 1990, BIOCHEMISTRY-US, V29, P1545, DOI 10.1021/bi00458a028; EMERSON SD, 1990, BIOCHEMISTRY-US, V29, P1556, DOI 10.1021/bi00458a029; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; HANSON JC, 1981, J MOL BIOL, V153, P117, DOI 10.1016/0022-2836(81)90530-1; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KERR EA, 1985, J BIOL CHEM, V260, P8360; KRISHNAMOORTHI R, 1984, J BIOL CHEM, V259, P8826; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LAMAR GN, 1986, J AM CHEM SOC, V108, P5568, DOI 10.1021/ja00278a033; LECOMTE JTJ, 1986, EUR BIOPHYS J BIOPHY, V13, P373, DOI 10.1007/BF00265673; LECOMTE JTJ, 1987, J AM CHEM SOC, V109, P7219, DOI 10.1021/ja00257a068; MAGDE D, 1985, P SOC PHOTO-OPT INST, V533, P2, DOI 10.1117/12.946532; MAYER A, 1974, J MOL BIOL, V86, P749, DOI 10.1016/0022-2836(74)90351-9; OLSON JS, 1988, NATURE, V336, P265, DOI 10.1038/336265a0; QIN J, 1992, J BIOMOL NMR, V2, P597, DOI 10.1007/BF02192849; QIN J, 1992, J MOL BIOL, V224, P891, DOI 10.1016/0022-2836(92)90456-T; RAJARATHNAM K, 1992, J AM CHEM SOC, V114, P9048, DOI 10.1021/ja00049a042; RAJARATHNAM K, 1993, IN PRESS BIOCHEMISTR, V32; RAJARATHNAM K, 1992, THESIS U CALIFORNIA; RANCE M, 1987, J MAGN RESON, V74, P557, DOI 10.1016/0022-2364(87)90277-0; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; ROMEROHERRERA AE, 1981, J MOL EVOL, V17, P140, DOI 10.1007/BF01733907; SHARMA VS, 1987, BIOCHEMISTRY-US, V26, P3837, DOI 10.1021/bi00387a015; SHULMAN RG, 1971, J MOL BIOL, V57, P93, DOI 10.1016/0022-2836(71)90121-5; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SUZUKI T, 1987, BIOCHIM BIOPHYS ACTA, V914, P170, DOI 10.1016/0167-4838(87)90060-4; SUZUKI T, 1988, ZOOL SCI, V5, P69; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; VAINSHTEIN BK, 1977, DOKL AKAD NAUK SSSR, V223, P238; WALLACE WJ, 1982, J BIOL CHEM, V257, P4966; YU LP, 1990, BIOCHEMISTRY-US, V29, P2578, DOI 10.1021/bi00462a021; YU LPP, 1990, J AM CHEM SOC, V112, P9527, DOI 10.1021/ja00182a012; [No title captured]	49	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14826	14835						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325862				2022-12-27	WOS:A1993LL75900047
J	LANGE, Y; STREBEL, F; STECK, TL				LANGE, Y; STREBEL, F; STECK, TL			ROLE OF THE PLASMA-MEMBRANE IN CHOLESTEROL ESTERIFICATION IN RAT HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COENZYME-A; CULTURED HUMAN-FIBROBLASTS; LEYDIG TUMOR-CELLS; ACYLTRANSFERASE; METABOLISM; COA; MACROPHAGES; ZYMOSTEROL; TRANSPORT; MOVEMENT	The source of the cholesterol used for ester synthesis by cultured rat hepatoma cells was examined. The activities synthesizing and esterifying cholesterol codistributed with RNA at a high buoyant density, presumably in the rough endoplasmic reticulum (RER). Cholesterol mass was undetectable in the RER, and the transfer of cholesterol synthesized in the RER to the cell surface was more than 100 times greater than was its esterification. Similarly, essentially all of the cholesterol liberated from ingested intracellular lipoproteins was recovered at the cell surface. The plasma membranes, which contained approximately 87% of cell cholesterol, provided >100 times more cholesterol for esterification in the RER than did nascent cholesterol. The supply of cholesterol was rate-limiting for esterification in cell homogenates. Prior oxidation of plasma membrane cholesterol in intact cells reduced the acyl-CoA:chlosterol acyltransferase activity in isolates proportionately. Finally, cholesterol in hepatoma plasma membranes was a far better substrate for in vitro esterification than was that in fibroblast plasma membranes, red blood cell ghosts, or liposomes. We conclude that the level of saturation of acyl-CoA:cholesterol acyltransferase, controlled principally through the bidirectional movement of the substrate between plasma membranes and RER, plays a major role in the regulation of cholesterol esterification.	RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT BIOCHEM,CHICAGO,IL 60612; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	Rush University; University of Chicago	LANGE, Y (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT PATHOL,1653 W CONGRESS PKWY,CHICAGO,IL 60612, USA.		Lange, Yvonne/A-7794-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028448, R55HL028448] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 28448] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BILLHEIMER JT, 1981, ANAL BIOCHEM, V111, P331, DOI 10.1016/0003-2697(81)90570-4; BRAESAMLE DL, 1990, J LIPID RES, V31, P103; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1976, J BIOL CHEM, V251, P3277; DOOLITTLE GM, 1982, BIOCHIM BIOPHYS ACTA, V713, P529, DOI 10.1016/0005-2760(82)90313-7; ECHEVARRIA F, 1990, J BIOL CHEM, V265, P8484; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; KAPLAN MR, 1985, J CELL BIOL, V101, P466; LANGE Y, 1983, J BIOL CHEM, V258, P5130; LANGE Y, 1992, J LIPID RES, V33, P315; LANGE Y, 1984, J BIOL CHEM, V259, P4624; LANGE Y, 1985, J BIOL CHEM, V260, P5592; LANGE Y, 1991, J BIOL CHEM, V266, P21439; LANGE Y, 1991, J LIPID RES, V32, P329; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; NAGY L, 1990, ENDOCRINOLOGY, V126, P2267, DOI 10.1210/endo-126-5-2267; NAGY L, 1990, BIOCHEM J, V271, P809, DOI 10.1042/bj2710809; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; REINHART MP, 1987, J BIOL CHEM, V262, P9649; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROTHBLAT GH, 1974, LIPIDS, V9, P526, DOI 10.1007/BF02532500; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STECK TL, 1988, J BIOL CHEM, V263, P13023; SUCKLING KE, 1985, J LIPID RES, V26, P647; TABAS I, 1988, J BIOL CHEM, V263, P1266; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284; WIRTZ KWA, 1990, EXPERIENTIA, V46, P592, DOI 10.1007/BF01939698; XU XX, 1991, J BIOL CHEM, V266, P17040	30	94	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13838	13843						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314752				2022-12-27	WOS:A1993LJ82500014
J	BARKALOW, FJ; SCHWARZBAUER, JE				BARKALOW, FJ; SCHWARZBAUER, JE			INTERACTIONS BETWEEN FIBRONECTIN AND CHONDROITIN SULFATE ARE MODULATED BY MOLECULAR CONTEXT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING DOMAIN; CELL-SUBSTRATE ADHESION; PLASMA FIBRONECTIN; PROTEOLYTIC FRAGMENTS; III MODULE; PROTEOGLYCAN; MATRIX; GLYCOSAMINOGLYCANS; IDENTIFICATION; LOCALIZATION	Interactions between fibronectin (FN) and glycosaminoglycans are essential for extracellular matrix morphology and cell adhesion. One of the most abundant glycosaminoglycans is chondroitin sulfate, and here we show that recombinant FNs (deminectins (DN)) containing the carboxyl-terminal cell, heparin, and fibrin domains bind specifically to chondroitin sulfate in affinity chromatography assays. Using a panel of mutant DNs, important determinants for chondroitin sulfate binding have been localized to repeats III13 and III14 within the heparin domain. In particular, mutation of an arginine pair in repeat III13 to neutral residues ablated binding to chondroitin sulfate as we previously reported for heparin (Barkalow, F.J.B., and Schwarzbauer, J.E. (1991) J. Biol. Chen. 266, 7812-7818). These results, in combination with the ability of heparin and chondroitin sulfate to compete for binding to DNs, demonstrate that these two glycosaminoglycans interact with similar or overlapping sites in FN. One important difference between FN interactions with heparin and chondroitin sulfate is that, while FN and DNs bound equally to heparin, FN bound less efficiently than DNs to chondroitin sulfate. Reduced binding to chondroitin sulfate was also observed with a larger recombinant FN lacking internal repeats III1-7 indicating that the amino-terminal region acts to limit binding to the carboxyl-terminal domain. Our results demonstrate that interactions between FN and chondroitin sulfate are modulated by molecular context.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University				Schwarzbauer, Jean/0000-0003-1012-7593	NCI NIH HHS [CA-09253, CA-44627] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA009253, R01CA044627] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; BARON M, 1992, BIOCHEMISTRY-US, V31, P2068, DOI 10.1021/bi00122a025; BELLOSTA P, 1993, J CELL BIOL, V121, P705, DOI 10.1083/jcb.121.3.705; BENECKY MJ, 1988, BIOCHEMISTRY-US, V27, P7565, DOI 10.1021/bi00419a058; BIDANSET DJ, 1992, J CELL BIOL, V118, P1523, DOI 10.1083/jcb.118.6.1523; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BRENNAN MJ, 1983, CANCER RES, V43, P4302; DANISHEFSKY I, 1976, THROMB RES, V8, P131, DOI 10.1016/0049-3848(76)90256-5; GOLD LI, 1983, BIOCHEMISTRY-US, V22, P4113, DOI 10.1021/bi00286a019; HAYASHI M, 1980, J BIOL CHEM, V255, P17; Hynes RO, 1990, FIBRONECTINS; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; INGHAM KC, 1990, BIOCHEM J, V272, P605, DOI 10.1042/bj2720605; IZZARD CS, 1986, EXP CELL RES, V165, P320, DOI 10.1016/0014-4827(86)90586-0; JALKANEN M, 1991, RECEPTORS EXTRACELLU, P1; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; KORNBLIHTT AR, 1984, EMBO J, V3, P221, DOI 10.1002/j.1460-2075.1984.tb01787.x; LAM LH, 1976, BIOCHEM BIOPH RES CO, V69, P570, DOI 10.1016/0006-291X(76)90558-1; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MCCARTHY JB, 1988, BIOCHEMISTRY-US, V27, P1380, DOI 10.1021/bi00404a044; MCCARTHY JB, 1990, J CELL BIOL, V110, P777, DOI 10.1083/jcb.110.3.777; MINGUELL JJ, 1992, EXP CELL RES, V201, P200, DOI 10.1016/0014-4827(92)90364-E; MOORADIAN DL, 1993, INVEST OPHTH VIS SCI, V34, P153; NOVOKHATNY V, 1992, J MOL BIOL, V227, P1182, DOI 10.1016/0022-2836(92)90530-W; PERKINS ME, 1979, CELL, V16, P944; PERRIS R, 1987, J CELL BIOL, V105, P2511, DOI 10.1083/jcb.105.6.2511; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SCHWARZBAUER JE, 1989, J CELL BIOL, V109, P3445, DOI 10.1083/jcb.109.6.3445; SCHWARZBAUER JE, 1987, EMBO J, V6, P2573, DOI 10.1002/j.1460-2075.1987.tb02547.x; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; SEKIGUCHI K, 1983, J BIOL CHEM, V258, P4359; SEKIGUCHI K, 1980, P NATL ACAD SCI-BIOL, V77, P2661, DOI 10.1073/pnas.77.5.2661; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WOODS A, 1992, J CELL SCI, V101, P277; YAMADA KM, 1980, J BIOL CHEM, V255, P6055; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012	41	56	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3957	3962						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307950				2022-12-27	WOS:A1994MW98900012
J	GUICHERIT, OM; COOPER, BF; RUDOLPH, FB; KELLEMS, RE				GUICHERIT, OM; COOPER, BF; RUDOLPH, FB; KELLEMS, RE			AMPLIFICATION OF AN ADENYLOSUCCINATE SYNTHETASE GENE IN ALANOSINE-RESISTANT MURINE T-LYMPHOMA CELLS - MOLECULAR-CLONING OF A CDNA-ENCODING THE NONMUSCLE ISOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURINE NUCLEOTIDE CYCLE; CONSENSUS SEQUENCE; MAMMALIAN-CELLS; RAT-LIVER; BINDING; BIOSYNTHESIS; MECHANISM; DEAMINASE; PROTEINS; DENOVO	Adenylosuccinate synthetase (EC 6.3.4.4) catalyzes the initial step in the conversion of IMP to AMP. Two isoforms of this enzyme have been observed in vertebrates. A muscle isozyme is highly abundant in cardiac and skeletal muscle tissue and is thought to play a role in muscle energy metabolism. The non-muscle isozyme, which is present at low levels in most tissues, likely functions in de novo AMP biosynthesis. The analysis of the non-muscle isozyme has been hampered by its low abundance and instability during purification. In this study a genetic selection scheme was used to generate a murine T lymphoma cell line which was at least 100-fold enriched for the non-muscle isozyme, as a result of amplification of the non-muscle synthetase gene. This cell line made possible the purification of the non-muscle isozyme, and the subsequent isolation of isozyme-specific peptides. Based on peptide sequence information a degenerate oligonucleotide probe was designed and used to screen a mouse kidney cDNA library. A 1.5-kilobase cDNA encoding the non-muscle isozyme was cloned and found to contain an open reading frame of 1368 base pairs encoding 456 amino acids. Gene transfer experiments showed that the cDNA encoded a 50-kDa protein, the size expected for mammalian synthetases, that correlated with the presence of high levels of synthetase activity. The deduced amino acid sequence of the mouse non-muscle synthetase is similar to 75% identical to the previously reported mouse muscle synthetase. Southern blot analysis of mouse genomic DNA with the isozyme specific cDNA probes revealed that the synthetase isozymes are encoded by separate genes. The non-muscle gene is expressed in most tissues but is virtually undetectable in striated muscle tissues. Three different transcripts (1.7, 2.8, and 3.4 kilobases) are detected for the nonmuscle isozyme which show a similar tissue distribution. The availability of a cDNA for the non-muscle isozyme of adenylosuccinate synthetase will facilitate further comparative analyses with the previously cloned muscle isozyme.	BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; RICE UNIV,INST BIOSCI BIOENGN,HOUSTON,TX 77005; RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77005	Baylor College of Medicine; Baylor College of Medicine; Rice University; Rice University					NCI NIH HHS [CA14030] Funding Source: Medline; NICHD NIH HHS [2 P30 HD24064] Funding Source: Medline; NIGMS NIH HHS [GM42436] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA014030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042436] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOGUSKY RT, 1976, J CLIN INVEST, V58, P326, DOI 10.1172/JCI108476; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COOPE BF, 1985, THESIS RICE U; COOPER FB, 1982, FED PROC, V41, P2756; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; EIN JM, 1990, INT J SPORTS MED, V11, pS36; GUICHERIT OM, 1991, J BIOL CHEM, V266; Kellems RE, 1993, GENE AMPLIFICATION M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI LW, 1991, GENOMICS, V9, P322, DOI 10.1016/0888-7543(91)90260-L; LIU F, 1992, J BIOL CHEM, V267, P2388; LOWE CR, 1984, METHOD ENZYMOL, V104, P97; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MAHNKEZIZELMAN DK, 1992, J BIOL CHEM, V267; MANFREDI JP, 1989, AM J PHYSIOL, V257, pC29, DOI 10.1152/ajpcell.1989.257.1.C29; MATSUDA Y, 1977, BIOCHEM BIOPH RES CO, V78, P766, DOI 10.1016/0006-291X(77)90245-5; MORISAKI T, 1990, J BIOL CHEM, V265, P11482; MOSS KM, 1975, BIOCHEM J, V150, P275, DOI 10.1042/bj1500275; POWELL SM, 1992, FEBS LETT, V303, P4, DOI 10.1016/0014-5793(92)80465-S; SABINA RL, 1990, J BIOL CHEM, V265, P9423; SABINA RL, 1989, METABOLIC BASIS INHE, V1, P1077; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTZ V, 1976, J BIOL CHEM, V251, P485; SHEEHAN TG, 1977, BIOCHEM SOC T, V5, P1753, DOI 10.1042/bst0051753; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; TYAGI AK, 1984, ADV PHARMACOL CHEMOT, V20, P69, DOI 10.1016/S1054-3589(08)60265-3; VANDENBERGHE G, 1992, PROG NEUROBIOL, V39, P547, DOI 10.1016/0301-0082(92)90006-Z; VANWAARDE A, 1988, BIOL REV, V63, P259; WIESMULLER L, 1991, J BIOL CHEM, V266, P2480; WOLFE SA, 1988, J BIOL CHEM, V263, P19147	33	16	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4488	4496						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308018				2022-12-27	WOS:A1994MW98900090
J	VANDERBEND, RL; DEWIDT, J; HILKMANN, H; VANBLITTERSWIJK, WJ				VANDERBEND, RL; DEWIDT, J; HILKMANN, H; VANBLITTERSWIJK, WJ			DIACYLGLYCEROL KINASE IN RECEPTOR-STIMULATED CELLS CONVERTS ITS SUBSTRATE IN A TOPOLOGICALLY RESTRICTED MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SIGNAL TRANSDUCTION; PHOSPHATIDIC-ACID; PHOSPHATIDYLCHOLINE BREAKDOWN; PHOSPHOLIPID-METABOLISM; INDUCED TRANSLOCATION; HUMAN FIBROBLASTS; HUMAN-PLATELETS; RAT-BRAIN; PHOSPHORYLATION	The regulation of diacylglycerol (DG) kinase activity was studied in fibroblasts and Jurkat T cells. We questioned whether enzyme activity only depends on substrate availability or whether it requires receptor stimulation. To this end, we raised DG levels up to 15-fold by treatment of cells with bacterial phosphatidylinositol-specific phospholipase C (PLC). In detergent cell lysates, DG kinase was readily capable of converting this surplus of DG to phosphatidic acid (PA), but in intact cells the enzyme remained inactive. Stimulation of fibroblasts with bradykinin or endothelin and Jurkat cells with anti CDS resulted in DG kinase-mediated formation of PA, but its level was unaffected by PLC pretreatment. Likewise, in streptolysin O-permeabilized fibroblasts, where bradykinin stimulation in the presence of [gamma-P-32]ATP and guanosine 5'-O-(thiotriphosphate) generates [P-32]PA exclusively via DG kinase, PLC pretreatment did not affect the amount of [P-32]PA formed. We conclude that DG kinase acts on DG generated by receptor stimulation, but not on DG generated by exogenous PLC. We propose a model in which DG kinase physically associates with endogenous PLC. Within this complex, receptor-induced DG would then be transmitted (''channeled'') from endogenous PLC to the active site of DG kinase, whereas excess DG generated randomly in the plasma membrane by bacterial PLC is inaccessible to this catalytic site.	NETHERLANDS CANC INST, DIV CELLULAR BIOCHEM, 1066 CX AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute								ALLAN D, 1978, NATURE, V276, P289, DOI 10.1038/276289a0; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P9378, DOI 10.1073/pnas.83.24.9378; BISHOP WR, 1986, J BIOL CHEM, V261, P2513; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; COCKROFT S, 1987, J CELL BIOL, V105, P339; DAS S, 1986, BIOCHEMISTRY-US, V25, P2882, DOI 10.1021/bi00358a022; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; GRIFFITH OH, 1991, METHOD ENZYMOL, V197, P493; HAMILTON JG, 1988, LIPIDS, V23, P1146, DOI 10.1007/BF02535281; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KATO M, 1990, J BIOL CHEM, V265, P794; LEMAITRE RN, 1990, BIOCHEM J, V266, P291, DOI 10.1042/bj2660291; MACDONALD ML, 1988, J BIOL CHEM, V263, P1584; MACDONALD ML, 1988, J BIOL CHEM, V263, P1575; MARONEY AC, 1989, J BIOL CHEM, V264, P2537; MAY WS, 1986, P NATL ACAD SCI USA, V83, P1281, DOI 10.1073/pnas.83.5.1281; MUIR JG, 1986, BIOCHIM BIOPHYS ACTA, V885, P176, DOI 10.1016/0167-4889(86)90086-8; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAGANO RE, 1985, J BIOL CHEM, V260, P1909; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; SAKANE F, 1991, J BIOL CHEM, V266, P7096; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SCHAAP D, 1993, BIOCHEM J, V289, P875, DOI 10.1042/bj2890875; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; SOLING HD, 1989, J BIOL CHEM, V264, P10643; STRATHOPOULOS VM, 1990, BIOCHEM J, V272, P569; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANBLITTERSWIJK WJ, 1993, EMBO J, V12, P2655, DOI 10.1002/j.1460-2075.1993.tb05926.x; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10344; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10337; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; VANLIER RAW, 1987, EUR J IMMUNOL, V17, P1599, DOI 10.1002/eji.1830171112; YADA Y, 1990, J BIOL CHEM, V265, P19237	36	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4098	4102						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307969				2022-12-27	WOS:A1994MW98900033
J	WIENTZEK, M; KAY, CM; OIKAWA, K; RYAN, RO				WIENTZEK, M; KAY, CM; OIKAWA, K; RYAN, RO			BINDING OF INSECT APOLIPOPHORIN-III TO DIMYRISTOYLPHOSPHATIDYLCHOLINE VESICLES - EVIDENCE FOR A CONFORMATIONAL CHANGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; MANDUCA-SEXTA; SECONDARY STRUCTURE; LIPID TRANSPORT; PURIFICATION; PHOSPHATIDYLCHOLINE; INTERCONVERSIONS; RECOMBINANTS; COMPLEXES	Apolipophorin-III (apoLp-III), a hemolymph protein of Manduca sexta, can reversibly associate with the surface of lipoprotein particles. In order to examine the lipid-associated form of apoLp-III, the present studies investigate the structure and properties of apoLp-III complexes with dimyristoylphosphatidylcholine (DMPC). Association of apoLp-III with DMPC vesicles results in the formation of uniform discs with an average diameter and width of 18.5 +/- 2.0 nm and 4.8 +/- 0.8 nm, respectively, as determined by electron microscopy. ApoLp-III.DMPC complexes analyzed by pore limiting native gradient PAGE demonstrated that a single major species of complex was formed within a wide range of lipid to protein molar ratios (DMPC:apoLp-III; 13:1 to 360:1). Flotation equilibrium experiments, conducted in an analytical ultracentrifuge, confirmed that only one species of apoLp-III DMPC complex was formed at an initial lipid to protein molar ratio of 67:1, with an apparent molecular mass of 642,000. Complexes cross-linked with dimethyl suberimidate indicate that there are a maximum of 6 apoLp-III molecules per disc. Circular dichroism experiments revealed that apoLp-III becomes essentially completely a-helical on formation of apoLp-III DMPC complexes. Compared to apoLp-III in the lipid-free state, apoLp-III DMPC complexes were relatively resistant to denaturation by guanidine HCl, displaying denaturation transitions with midpoints at 2.2 and 3.7 M guanidine HCl, respectively. The fluorescence excitation and emission spectra of apoLp-III DMPC complexes demonstrate a large enhancement of tyrosine fluorescence as compared to the lipid-free state, suggesting that a conformational change occurs when apoLp-III associates with a lipid surface. Denaturation of apoLp-III in the complex by guanidine HCl resulted in a tyrosine fluorescence level similar to that of lipid-free apoLp-III in the presence of guanidine HCl. The tyrosine-induced fluorescence of the complex was quenched with both Cs+ (K-q = 0.573 M(-1)) and KI (K-q = 0.376 M(-1)). The results presented in this study indicate that the conformation of apoLp-III is stabilized when complexed with phospholipids and suggest that tyrosine fluorescence provides a sensitive method to detect M. sexta apoLp-III interaction with lipid surfaces. Based on the data obtained, together with the length of ru-helices derived from the x-ray crystal structure of Locusta migratoria apoLp-III, we propose a model for the interaction of apoLp-III with phospholipid.	UNIV ALBERTA,DEPT BIOCHEM,LIPID & LIPOPROT RES GRP,EDMONTON T6G 2S2,AB,CANADA; UNIV ALBERTA,DEPT BIOCHEM,PROT STRUCTURE & FUNCT GRP,MED RES COUNCIL,EDMONTON T6G 2S2,AB,CANADA	University of Alberta; University of Alberta								Atkinson D, 1980, Ann N Y Acad Sci, V348, P284, DOI 10.1111/j.1749-6632.1980.tb21308.x; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; BROUILLETTE CG, 1984, BIOCHEMISTRY-US, V23, P359, DOI 10.1021/bi00297a027; CHERVENKA CH, 1969, MANUAL ANAL ULTRACEN; COLE KD, 1987, J BIOL CHEM, V262, P11794; DEMEL RA, 1992, BIOCHIM BIOPHYS ACTA, V1124, P151, DOI 10.1016/0005-2760(92)90091-9; EISINGER J, 1969, BIOCHEMISTRY-US, V8, P3902, DOI 10.1021/bi00838a004; FORTE T, 1974, BIOCHIM BIOPHYS ACTA, V337, P169, DOI 10.1016/0005-2760(74)90199-4; FORTE TM, 1971, BIOCHIM BIOPHYS ACTA, V248, P381, DOI 10.1016/0005-2760(71)90026-9; GWYNNE J, 1975, J BIOL CHEM, V250, P2269; HAMILTON RL, 1976, J CLIN INVEST, V58, P667, DOI 10.1172/JCI108513; HOLDEN HM, 1988, J BIOL CHEM, V263, P3960; HOMER RB, 1976, BIOCHIM BIOPHYS ACTA, V434, P297, DOI 10.1016/0005-2795(76)90222-1; JONAS A, 1993, J BIOL CHEM, V268, P1596; JONAS A, 1989, J BIOL CHEM, V264, P4818; Jonas A., 1992, STRUCTURE FUNCTION A, P217; Kahlon T S, 1986, Methods Enzymol, V129, P26; KAWOOYA JK, 1986, J BIOL CHEM, V261, P3588; KAWOOYA JK, 1984, J BIOL CHEM, V259, P733; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINS L, 1992, STRUCTURE FUNCTION A, P251; NELSON CA, 1974, ANAL BIOCHEM, V59, P69, DOI 10.1016/0003-2697(74)90010-4; Pownall H. J., 1987, PLASMA LIPOPROTEINS, P95; PRASAD SV, 1986, J BIOL CHEM, V261, P558; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; REIJNGOUD DJ, 1982, BIOCHEMISTRY-US, V21, P2969, DOI 10.1021/bi00541a026; RIFICI VA, 1985, BIOCHIM BIOPHYS ACTA, V834, P205, DOI 10.1016/0005-2760(85)90157-2; RYAN RO, 1985, J BIOL CHEM, V260, P782; RYAN RO, 1990, J LIPID RES, V31, P1725; RYAN RO, 1993, J BIOL CHEM, V268, P1525; RYAN RO, 1986, J BIOL CHEM, V261, P563; SEGREST JP, 1977, CHEM PHYS LIPIDS, V18, P7, DOI 10.1016/0009-3084(77)90023-8; SEGREST JP, 1992, J LIPID RES, V33, P141; SHAPIRO JP, 1988, ANNU REV ENTOMOL, V33, P297, DOI 10.1146/annurev.en.33.010188.001501; SHAPIRO JP, 1983, BIOCHEM BIOPH RES CO, V115, P924, DOI 10.1016/S0006-291X(83)80023-0; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; SWANEY JB, 1978, J BIOL CHEM, V253, P7069; SWANEY JB, 1980, J BIOL CHEM, V255, P877; TAJIMA S, 1982, J BIOCHEM-TOKYO, V91, P1273, DOI 10.1093/oxfordjournals.jbchem.a133812; TALL AR, 1977, J BIOL CHEM, V252, P4701; VANDERHORST DJ, 1988, J BIOL CHEM, V263, P2027; VANDERHORST DJ, 1990, BIOCHIM BIOPHYS ACTA, V1047, P195, DOI 10.1016/0005-2760(90)90518-3; WEINBERG RB, 1990, J BIOL CHEM, V265, P8081; WELLS MA, 1987, J BIOL CHEM, V262, P4172; WELLS MA, 1985, INSECT BIOCHEM, V15, P565, DOI 10.1016/0020-1790(85)90116-7; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WLODAWER A, 1979, FEBS LETT, V104, P231, DOI 10.1016/0014-5793(79)80821-2; ZHANG YP, 1993, BIOCHEMISTRY-US, V32, P3942, DOI 10.1021/bi00066a014	49	96	97	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4605	4612						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308032				2022-12-27	WOS:A1994MW98900104
J	ZIEGLER, M; XIAO, R; PENEFSKY, HS				ZIEGLER, M; XIAO, R; PENEFSKY, HS			CLOSE PROXIMITY OF CYS(64) AND CYS(140) IN THE DELTA-SUBUNIT OF ESCHERICHIA-COLI F1-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; ADENOSINE-TRIPHOSPHATASE; NUCLEOTIDE-SEQUENCE; EXCIMER FLUORESCENCE; SPECTRAL PROPERTIES; SYNTHASE; F1; PROTEINS; COMPLEX; OPERON	The delta subunit of the F-1-ATPase from Escherichia coli contains 2 cysteine residues, one at position 64 and the second at position 140 of the amino acid sequence. These residues were specifically labeled with sulfhydryl reagents in this study without labeling other -SH groups in the enzyme. Modification of Cys(140) by maleimides such as N-ethylmaleimide or fluorescein maleimide resulted in a reconstitutively active enzyme that was indistinguishable from the native protein. Labeling of Cys(64) with Or without concomitant labeling of Cys(140) resulted in a reconstitutively inactive enzyme. The ATPase activity of either form of the labeled enzyme was unaffected. However, labeling of Cys(64) was accompanied by dissociation of the delta subunit from the enzyme. These observations suggest a role for the microenvironment of Cys(64) in interactions of the delta subunit with other subunits in the enzyme. Two types of evidence support the conclusion that the 2 cysteine residues of the delta subunit are in close proximity. First, incorporation of pyrene maleimide into both delta cysteines led to excimer formation. Second, incubation of F-1 with 5,5'-dithiobis(2-nitrobenzoic acid) resulted in quantitative formation of a disulfide bond between Cys(64) and Cys(140), presumably via disulfide interchange. The enzyme containing the internally cross-linked delta subunit exhibited an undiminished ability to support proton pumping when reconstituted into F-1-depleted membrane vesicles. The presence of 2 closely apposed cysteinyl residues in the delta subunit of the native enzyme places constraints on the type of structure that may be proposed for the subunit.	SUNY HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, SYRACUSE, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center				Ziegler, Mathias/0000-0001-6961-2396	NIGMS NIH HHS [GM21737] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021737] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BETCHERLANGE SL, 1978, J BIOL CHEM, V253, P3757; BRAGG PD, 1973, ARCH BIOCHEM BIOPHYS, V159, P664, DOI 10.1016/0003-9861(73)90505-5; BRAGG PD, 1986, BIOCHIM BIOPHYS ACTA, V851, P385, DOI 10.1016/0005-2728(86)90075-7; COX GB, 1970, BIOCHEM J, V117, P551, DOI 10.1042/bj1170551; DUSZYNSKI J, 1988, BIOCHEMISTRY-US, V27, P6288, DOI 10.1021/bi00417a014; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ENGELBRECHT S, 1990, BIOCHIM BIOPHYS ACTA, V1015, P379, DOI 10.1016/0005-2728(90)90072-C; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; GAY NJ, 1981, NUCLEIC ACIDS RES, V9, P3919, DOI 10.1093/nar/9.16.3919; ISSARTEL JP, 1992, EXPERIENTIA, V48, P351, DOI 10.1007/BF01923429; KINNUNEN PKJ, 1993, FLUORESCENCE SPECTRO, P159; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRER SS, 1975, P NATL ACAD SCI USA, V72, P3377, DOI 10.1073/pnas.72.9.3377; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUMPER L., 1965, ADVANCE ENZYMOL, V27, P199; MABUCHI K, 1981, BIOCHEM BIOPH RES CO, V102, P172, DOI 10.1016/0006-291X(81)91504-7; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; NIELSEN J, 1981, MOL GEN GENET, V184, P33, DOI 10.1007/BF00271191; PENEFSKY H, 1991, ADV ENZYMOL REL AREA, V64, P173; Penefsky H S, 1979, Methods Enzymol, V56, P527; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; SEN AC, 1990, J BIOL CHEM, V265, P14277; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; STERNWEIS PC, 1977, BIOCHEMISTRY-US, V16, P4020, DOI 10.1021/bi00637a013; TOZER RG, 1986, EUR J BIOCHEM, V161, P513, DOI 10.1111/j.1432-1033.1986.tb10472.x; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WISE JG, 1990, J BIOL CHEM, V265, P10403	33	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4233	4239						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307987				2022-12-27	WOS:A1994MW98900053
J	PALMGREN, MG; CHRISTENSEN, G				PALMGREN, MG; CHRISTENSEN, G			FUNCTIONAL COMPARISONS BETWEEN PLANT PLASMA-MEMBRANE H+-ATPASE ISOFORMS EXPRESSED IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; ARABIDOPSIS-THALIANA; MOLECULAR-CLONING; ENDOPLASMIC-RETICULUM; NA+/K+-ATPASE; CELLS; GENE; FAMILY; ROOTS; NA,K-ATPASE	To examine the functional properties of the three major isoforms of plasma membrane H+-ATPase expressed in Arabidopsis thaliana (AHA1, AHA2, and AHA3), we employed a system for the heterologous expression of functional plant plasma membrane H+-ATPase in yeast (Villalba, J. M., Palmgren, M. G., Berberian. G. E., Ferguson, C., and Serrano, R. (1992) J. Biol. Chem. 267,12341-12349). Each isoform was expressed efficiently but appeared to be retained in the endoplasmic reticulum of yeast. All isoforms displayed qualitatively similar enzymatic properties, but quantitative differences were found. When compared with AHA3, AHA1 and AHA2 had an apparent higher turnover rate for ATP hydrolysis, exhibited a 10-fold higher apparent affinity for ATP, and a 3-fold higher sensitivity toward vanadate. In addition, AHA2 had a slightly lower apparent affinity for H+ and seemed to be more susceptible to activation by lysophosphatidylcholine than did AHA1 and AHA3. This study represents the first comparison of the functional properties of isoforms of the plant plasma membrane H+-ATPase.	UNIV COPENHAGEN, AUGUST KROGH INST, DK-2100 COPENHAGEN, DENMARK	University of Copenhagen	PALMGREN, MG (corresponding author), ROYAL VET & AGR UNIV, DEPT PLANT BIOL, THORVALDSENSVEJ 40, DK-1871 FREDERIKSBERG C, DENMARK.		Palmgren, Michael/A-9808-2013	Palmgren, Michael/0000-0002-9982-6114				BAGINSKI ES, 1967, CLIN CHEM, V13, P326; BLANCO G, 1993, P NATL ACAD SCI USA, V90, P1824, DOI 10.1073/pnas.90.5.1824; BOUTRY M, 1989, BIOCHEM BIOPH RES CO, V162, P567, DOI 10.1016/0006-291X(89)92348-6; BOWMAN BJ, 1986, J MEMBRANE BIOL, V94, P83, DOI 10.1007/BF01871190; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISKIN DP, 1990, BIOCHIM BIOPHYS ACTA, V1019, P95, DOI 10.1016/0005-2728(90)90129-R; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CAPIEAUX E, 1989, J BIOL CHEM, V264, P7437; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; DEWITT ND, 1991, PLANT J, V1, P121, DOI 10.1111/j.1365-313X.1991.00121.x; DUPONT FM, 1988, PLANT PHYSIOL, V86, P717, DOI 10.1104/pp.86.3.717; ERASO P, 1987, FEBS LETT, V224, P193, DOI 10.1016/0014-5793(87)80446-5; EWING NN, 1990, PLANT PHYSIOL, V94, P1874, DOI 10.1104/pp.94.4.1874; GALLAGHER SR, 1987, PLANT PHYSIOL, V83, P265, DOI 10.1104/pp.83.2.265; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GROUZIS JP, 1990, PLANT PHYSIOL, V93, P1175, DOI 10.1104/pp.93.3.1175; HAGER A, 1991, PLANTA, V185, P527, DOI 10.1007/BF00202963; HARPER JF, 1990, J BIOL CHEM, V265, P13601; HARPER JF, 1989, P NATL ACAD SCI USA, V86, P1234, DOI 10.1073/pnas.86.4.1234; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; LINGREL JB, 1992, J BIOENERG BIOMEMBR, V24, P263; LYTTON J, 1992, J BIOL CHEM, V267, P14483; MORIAU L, 1993, PLANT MOL BIOL, V21, P955, DOI 10.1007/BF00023594; OLIVARI C, 1993, BOT ACTA, V106, P13, DOI 10.1111/j.1438-8677.1993.tb00332.x; PALMGREN MG, 1991, PHYSIOL PLANTARUM, V83, P314, DOI 10.1111/j.1399-3054.1991.tb02159.x; PALMGREN MG, 1993, FEBS LETT, V317, P216, DOI 10.1016/0014-5793(93)81279-9; PALMGREN MG, 1991, J BIOL CHEM, V266, P20470; PALMGREN MG, 1990, J BIOL CHEM, V265, P13423; PARDO JM, 1989, J BIOL CHEM, V264, P8557; PARDO JM, 1989, PLANT MEMBRANE TRANS, P499; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PEREZ C, 1992, J BIOL CHEM, V267, P1204; SCHALLER GE, 1988, PLANTA, V173, P509, DOI 10.1007/BF00958964; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SERRANO R, 1991, BIOCHIM BIOPHYS ACTA, V1062, P157, DOI 10.1016/0005-2736(91)90387-N; SERRANO R, 1989, ANNU REV PLANT PHYS, V40, P61; SUSSMAN MR, 1989, PLANT CELL, V1, P953, DOI 10.1105/tpc.1.10.953; SUSSMAN MR, 1992, TRANSPORT AND RECEPTOR PROTEINS OF PLANT MEMBRANES, P5; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; SWEADNER KJ, 1990, BIOCHIM BIOPHYS ACTA, V1029, P13, DOI 10.1016/0005-2736(90)90431-M; VARA F, 1982, J BIOL CHEM, V257, P2826; VERBOOMEN H, 1992, BIOCHEM J, V286, P591, DOI 10.1042/bj2860591; VILLALBA JM, 1991, PLANTA, V185, P458, DOI 10.1007/BF00202953; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341	46	112	116	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3027	3033						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300635				2022-12-27	WOS:A1994MV43200095
J	REN, HZ; STILES, GL				REN, HZ; STILES, GL			CHARACTERIZATION OF THE HUMAN A(1)-ADENOSINE RECEPTOR GENE - EVIDENCE FOR ALTERNATIVE SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A1 ADENOSINE RECEPTOR; AMINO-ACID DECARBOXYLASE; BETA-2-ADRENERGIC RECEPTOR; MOLECULAR-CLONING; MESSENGER-RNAS; EXPRESSION; BRAIN; ORGANIZATION; PROMOTER; ISOFORMS	To approach transcriptional and translational regulation of adenosine receptors, we have isolated cDNA and genomic clones of the human A1 adenosine receptor (A1AR). The cDNA, when inserted into the pCMV5 expression vector and transfected into COS-7 or CHO cells, leads to the expression of a functional A1AR that displayed all the appropriate pharmacologic properties. The human A1AR gene consists of at least six exons and five introns. A single intron interrupts the coding sequence, while the remaining introns are within the 5'-untranslated region. Comparison of our cDNA with one by Libert et al. (Libert, F., Van Sande, J., Lefort, A., Czernilofsky, A., Dumont, J. E., Vasart, G., Ensinger, H. A., and Mendla, K. D. (1992) Biochem. Biophys. Res. Commun. 187, 919-926) reveals that exon 4 in the 5'-untranslated region was completely missing from their sequence. Study of mRNAs from a range of human tissues by reverse transcription-polymerase chain reaction using a variety of primers revealed clear evidence for alternative splicing. Transcripts containing exons 4, 5, and 6 were found in all tissues expressing A1AR, while a separate transcript with exons 3, 5, and 6 was seen only in selected tissues. No transcript contains both exons 3 and 4. No evidence for expression of exons 1 and 2 could be discerned. Exon 4 contains two AUG initiation codons with reasonable Kozak consensus, suggesting the possibility of translational regulation. Exon 3 contains no AUG initiation codons.	DUKE UNIV,MED CTR,DEPT MED,BOX 3444,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	Duke University; Duke University					NHLBI NIH HHS [R01-HL-35134, P50HL17670] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035134, P50HL017670] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AATSINKI JT, 1992, MOL CELL ENDOCRINOL, V84, P127, DOI 10.1016/0303-7207(92)90079-L; ALBERT VR, 1992, P NATL ACAD SCI USA, V89, P12053, DOI 10.1073/pnas.89.24.12053; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; CHASE PB, 1993, AM J RESP CELL MOL, V8, P240, DOI 10.1165/ajrcmb/8.3.240; CHEN K, 1992, MOL BRAIN RES, V14, P20, DOI 10.1016/0169-328X(92)90005-V; CHIN JH, 1989, ANN NEUROL, V26, P695, DOI 10.1002/ana.410260602; COLLINS S, 1993, BIOCHIM BIOPHYS ACTA, V1172, P171, DOI 10.1016/0167-4781(93)90287-N; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; DELL KR, 1992, J BIOL CHEM, V267, P21225; EMORINE LJ, 1987, P NATL ACAD SCI USA, V84, P6995, DOI 10.1073/pnas.84.20.6995; FERKANY JW, 1986, DRUG DEVELOP RES, V9, P85, DOI 10.1002/ddr.430090202; GANDELMAN KY, 1991, J NEUROCHEM, V56, P1024, DOI 10.1111/j.1471-4159.1991.tb02024.x; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; HERSHEY AD, 1991, J BIOL CHEM, V266, P4366; ICHINOSE H, 1992, BIOCHEMISTRY-US, V31, P11546, DOI 10.1021/bi00161a036; IKUYAMA S, 1992, MOL ENDOCRINOL, V6, P793, DOI 10.1210/me.6.5.793; JIN JP, 1992, J MOL BIOL, V227, P1269, DOI 10.1016/0022-2836(92)90540-Z; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LATCHMAN D S, 1990, New Biologist, V2, P297; LIBERT F, 1991, EMBO J, V10, P1677, DOI 10.1002/j.1460-2075.1991.tb07691.x; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; LIBERT F, 1992, BIOCHEM BIOPH RES CO, V187, P919, DOI 10.1016/0006-291X(92)91285-X; MAHAN LC, 1991, MOL PHARMACOL, V40, P1; MONSMA FJ, 1989, NATURE, V342, P926, DOI 10.1038/342926a0; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; OLAH ME, 1992, J BIOL CHEM, V267, P10764; OLAH ME, 1992, ANNU REV PHYSIOL, V54, P211, DOI 10.1146/annurev.physiol.54.1.211; OMALLEY KL, 1990, BIOCHEMISTRY-US, V29, P1367, DOI 10.1021/bi00458a003; REPPERT SM, 1991, MOL ENDOCRINOL, V5, P1037, DOI 10.1210/mend-5-8-1037; REYNOLDS GA, 1985, J BIOL CHEM, V260, P369; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; Sambrook J, 1989, MOL CLONING LABORATO; SEYFRIED CE, 1992, GENOMICS, V13, P832, DOI 10.1016/0888-7543(92)90162-L; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STILES GL, 1990, CLIN RES, V38, P10; STILES GL, 1992, J BIOL CHEM, V267, P6451; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; TOWNSENDNICHOLSON A, 1992, MOL BRAIN RES, V16, P365, DOI 10.1016/0169-328X(92)90248-A; TSANG SS, 1993, BIOTECHNIQUES, V14, P380; TUCKER AL, 1992, FEBS LETT, V297, P107, DOI 10.1016/0014-5793(92)80338-H; WANG HY, 1992, MOL ENDOCRINOL, V6, P320, DOI 10.1210/me.6.3.320; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	45	70	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3104	3110						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300646				2022-12-27	WOS:A1994MV43200107
J	VENDELAND, SC; BEILSTEIN, MA; CHEN, CL; JENSEN, ON; BAROFSKY, E; WHANGER, PD				VENDELAND, SC; BEILSTEIN, MA; CHEN, CL; JENSEN, ON; BAROFSKY, E; WHANGER, PD			PURIFICATION AND PROPERTIES OF SELENOPROTEIN-W FROM RAT MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-PEROXIDASE; LASER DESORPTION; IODOTHYRONINE 5'-DEIODINASE; MASS-SPECTROMETRY; SELENIUM; SELENOCYSTEINE; PROTEINS; MATRIX; IDENTIFICATION; SELENOENZYME	Following injection with [Se-75]selenite, a low molecular weight Se-75-selenocysteine containing protein was purified from rat muscle. The purification procedure involved ammonium sulfate fractionation, Sephadex G-50 gel filtration, cation exchange chromatography on CM-Sephadex, and reverse phase high pressure liquid chromatography using a C-18 Vydac column. Four forms of the protein were separated by the cation exchange and reverse phase chromatography steps. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry of the four proteins revealed masses of 9550 +/- 1, 9596 +/- 1.2, 9858 +/- 1.3, and 9898 +/- 1.1 daltons. Glutamate, glycine, lysine, leucine, and valine are the major amino acids in this protein. About 0.92 g atoms of selenium was found per g mol of protein, and this selenium was present as selenocysteine. Thus, this appears to be a new selenoprotein, and we have named it selenoprotein W.	OREGON STATE UNIV,DEPT AGR CHEM,CORVALLIS,OR 97331	Oregon State University			Jensen, Ole N/J-1763-2012	Jensen, Ole N/0000-0003-1862-8528	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038306] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38306] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARTHUR JR, 1990, BIOCHEM J, V272, P537, DOI 10.1042/bj2720537; BEAVIS RC, 1992, ORG MASS SPECTROM, V27, P156, DOI 10.1002/oms.1210270217; BEHNE D, 1990, BIOCHEM BIOPH RES CO, V173, P1143, DOI 10.1016/S0006-291X(05)80905-2; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; BEILSTEIN MA, 1981, J INORG BIOCHEM, V15, P339, DOI 10.1016/S0162-0134(00)80237-8; BEILSTEIN MA, 1993, FASEB J, V7, pA289; BIRNBAUMER L, 1990, FASEB J, V4, P3178, DOI 10.1096/fasebj.4.14.2172060; BLACK RS, 1978, BIOINORG CHEM, V8, P161, DOI 10.1016/S0006-3061(00)80241-0; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; FLOHE L, 1973, FEBS LETT, V32, P132, DOI 10.1016/0014-5793(73)80755-0; HAWKES WC, 1985, J INORG BIOCHEM, V23, P77, DOI 10.1016/0162-0134(85)83011-7; HILL KE, 1991, J BIOL CHEM, V266, P10050; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; KARAS M, 1987, INT J MASS SPECTROM, V78, P53, DOI 10.1016/0168-1176(87)87041-6; KRAUS RJ, 1983, BIOCHEMISTRY-US, V22, P5853, DOI 10.1021/bi00294a026; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOORE S, 1963, METHOD ENZYMOL, V6, P819, DOI 10.1016/0076-6879(63)06257-1; MUTH OH, 1958, SCIENCE, V128, P1090, DOI 10.1126/science.128.3331.1090; MUTH OH, 1963, J AM VET MED ASSOC, V142, P272; OH SH, 1974, BIOCHEMISTRY-US, V13, P1825, DOI 10.1021/bi00706a008; PEDERSEN ND, 1972, BIOINORG CHEM, V2, P33; PEDERSEN ND, 1969, PAC SLOP BIOCH C, P49; READ R, 1990, J BIOL CHEM, V265, P17899; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; TRIPP MJ, 1993, IN PRESS J TRACE ELE; WHANGER PD, 1992, 5TH INT S SEL BIOL M, P17; WHANGER PD, 1987, SELENIUM BIOL MED A, P133	27	132	140	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17103	17107						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349599				2022-12-27	WOS:A1993LQ98800035
J	DORMANN, P; BORCHERS, T; KORF, U; HOJRUP, P; ROEPSTORFF, P; SPENER, F				DORMANN, P; BORCHERS, T; KORF, U; HOJRUP, P; ROEPSTORFF, P; SPENER, F			AMINO-ACID EXCHANGE AND COVALENT MODIFICATION BY CYSTEINE AND GLUTATHIONE EXPLAIN ISOFORMS OF FATTY-ACID-BINDING PROTEIN OCCURRING IN BOVINE LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; CYTOSOL; DEAMIDATION; SEQUENCE; PURIFICATION; ASPARAGINYL; RESIDUES; PEPTIDE	A unique property of the liver-type member of the family of fatty acid-binding proteins is the heterogeneic pattern observed upon isolation, which can only partly be ascribed to the state of lipidation. Here we unraveled the structural basis of the heterogeneity of delipidated liver-type fatty acid-binding protein (L-FABP). Charge fractions of L-FABP focusing at pH 6.0 and at pH 7.0/7.1 were first isolated from bovine liver. Upon reduction, however, two distinct isoforms, namely pI 6.0 L-FABP and pI 7.0 L-FABP, were observed. From these isoforms peptides were generated enzymically and chemically by four independent methods. Peptides were separated by reverse phase high performance liquid chromatography and analyzed by Edman degradation and plasma desorption mass spectrometry. The complete amino acid sequences of the isoforms were established; they consist of 127 amino acids and each is N-terminally blocked with an acetyl group. The difference between pI 6.0 L-FABP and pI 7.0 L-FABP was attributed to an asparagine-aspartate exchange at position 105. When tryptic peptides of the pH 7.0/7.1 fraction were analyzed, discrepancies between sequence and mass data of the peptides containing at position 69 the sole cysteine of L-FABP led to the disclosure of a cysteinylation occurring at this position and giving rise to the slightly more basic pH 7.1 species. Moreover, chemical modification studies revealed that a part of the pH 6.0 fraction was pl 7.0 L-FABP that was glutathionylated at Cys69. Neither modification, however, prevented the binding of fatty acids. Together amino acid exchange and covalent modification of cysteine entirely explain the heterogeneity of L-FABP from bovine liver.	UNIV MUNSTER, DEPT BIOCHEM, WILHELM KLEMM STR 2, D-48149 MUNSTER, GERMANY; ODENSE UNIV, DEPT MOLEC BIOL, DK-5230 ODENSE, DENMARK	University of Munster; University of Southern Denmark			Højrup, Peter/ABG-8477-2020; Korf, Ulrike/G-2795-2013	Hojrup, Peter/0000-0002-7838-6180				Allen G., 1981, SEQUENCING PROTEINS; BANSAL MP, 1989, J BIOL CHEM, V264, P13780; BORCHERS T, 1990, MOL CELL BIOCHEM, V98, P127; BORDEWICK U, 1989, BIOL CHEM H-S, V370, P229, DOI 10.1515/bchm3.1989.370.1.229; Bornstein P, 1977, Methods Enzymol, V47, P132; CHAN L, 1985, J BIOL CHEM, V260, P2629; COX DJ, 1971, ANAL BIOCHEM, V41, P138, DOI 10.1016/0003-2697(71)90199-0; GEIGER T, 1987, J BIOL CHEM, V262, P785; GORDON JI, 1983, J BIOL CHEM, V258, P3356; HAUNERLAND N, 1984, H-S Z PHYSIOL CHEM, V365, P365, DOI 10.1515/bchm2.1984.365.1.365; HITOMI M, 1990, EUR J BIOCHEM, V187, P713, DOI 10.1111/j.1432-1033.1990.tb15358.x; JAGSCHIES G, 1985, EUR J BIOCHEM, V152, P537, DOI 10.1111/j.1432-1033.1985.tb09229.x; KAMISAKA K, 1981, HEPATOLOGY, V1, P221, DOI 10.1002/hep.1840010305; MCKERROW JH, 1971, ANAL BIOCHEM, V42, P565, DOI 10.1016/0003-2697(71)90074-1; MIDELFORT CF, 1972, P NATL ACAD SCI USA, V69, P1816, DOI 10.1073/pnas.69.7.1816; MIKKELSEN J, 1987, BIOCHEM J, V248, P709, DOI 10.1042/bj2480709; OCKNER RK, 1982, J BIOL CHEM, V257, P7872; ODANI S, 1988, ANAL BIOCHEM, V171, P305, DOI 10.1016/0003-2697(88)90491-5; RASMUSSEN JT, 1990, BIOCHEM J, V265, P849, DOI 10.1042/bj2650849; ROEPSTORFF P, 1988, BIOMED ENVIRON MASS, V16, P9, DOI 10.1002/bms.1200160103; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHULENBERGSCHELL H, 1988, EUR J BIOCHEM, V170, P565, DOI 10.1111/j.1432-1033.1988.tb13735.x; SPENER F, 1992, BIOCHEM SOC T, V20, P806, DOI 10.1042/bst0200806; SPENER F, 1989, FEBS LETT, V244, P1, DOI 10.1016/0014-5793(89)81149-4; TAKAHASHI K, 1982, FEBS LETT, V140, P63, DOI 10.1016/0014-5793(82)80521-8; TRULZSCH D, 1981, ARCH BIOCHEM BIOPHYS, V209, P433, DOI 10.1016/0003-9861(81)90300-3; UNTERBERG C, 1990, J BIOL CHEM, V265, P16255; VEERKAMP JH, 1991, BIOCHIM BIOPHYS ACTA, V1081, P1, DOI 10.1016/0005-2760(91)90244-C; VONECKARDSTEIN A, 1991, J LIPID RES, V32, P1465; WILTON DC, 1989, BIOCHEM J, V261, P273, DOI 10.1042/bj2610273	30	46	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16286	16292						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344916				2022-12-27	WOS:A1993LQ33600032
J	NISHIDA, HI; ARAI, H; NISHIDA, T				NISHIDA, HI; ARAI, H; NISHIDA, T			CHOLESTEROL ESTER TRANSFER MEDIATED BY LIPID TRANSFER PROTEIN AS INFLUENCED BY CHANGES IN THE CHARGE CHARACTERISTICS OF PLASMA-LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY LIPOPROTEINS; EXCHANGE PROTEIN; DEXTRAN SULFATE; NEUTRAL LIPIDS; ACYLTRANSFERASE; LECITHIN; APOLIPOPROTEIN; STABILITY; PARTICLES; VESICLES	The relationship between the cholesterol ester (CE) transfer activity of lipid transfer protein (LTP) and its affinity with lipid and lipoprotein particles was investigated. The study of the effects of chemical modification of low density lipoprotein (LDL) amino groups and carboxyl groups on the CE transfer activity showed that the maximal activity is obtained upon succinylation or acetylation of approximately 7% of LDL amino groups. Further increases in the extent of modification progressively reduced the transfer activity. The treatment of LDL with fatty acids gave results comparable to the chemical modification of LDL amino groups. The addition of low concentrations of fatty acids was stimulatory, while that of high concentrations was inhibitory. Although increases in the positive charges of LDL by the carboxyl group modification did not appreciably influence the CE transfer, the addition of cationic detergents gave a profound effect on the CE transfer. A maximal CE transfer activity was obtained upon addition of very small amounts of the detergents, with the higher concentrations sharply reducing the transfer activity. We also studied the effects of the concentrations of phosphate buffer and various salts on the CE transfer as well as the affinity of LTP for very low density lipoproteins, low density lipoproteins, high density lipoproteins 3, and high density lipoproteins 2. It appeared that the affinity of LTP for various lipoproteins is governed by a delicate balance of electrostatic and hydrophobic interactions. Optimal degrees of the interaction of LTP with both donor and acceptor particles seem to be required for the maximal degree of CE transfer.	UNIV ILLINOIS,DEPT FOOD SCI,BURNSIDES RES LAB,1208 W PENN AVE,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign					NHLBI NIH HHS [HL-17597] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL017597, R01HL017597, F31HL117597] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANGHAM AD, 1974, METHODS MEMBRANE BIO, V1, P1; BARTER PJ, 1990, BIOCHIM BIOPHYS ACTA, V1045, P81, DOI 10.1016/0005-2760(90)90206-D; BATZRI S, 1973, BIOCHIM BIOPHYS ACTA, V298, P1015, DOI 10.1016/0005-2736(73)90408-2; COGAN U, 1969, BIOCHIM BIOPHYS ACTA, V187, P444, DOI 10.1016/0005-2760(69)90020-4; HELENIUS A, 1971, BIOCHEMISTRY-US, V10, P2542; IHM J, 1980, BIOCHEM BIOPH RES CO, V93, P1114, DOI 10.1016/0006-291X(80)90604-X; JACKSON RL, 1973, J BIOL CHEM, V248, P2639; JANADO M, 1986, J SOLUTION CHEM, V15, P839, DOI 10.1007/BF00646091; JONAS A, 1986, BIOCHIM BIOPHYS ACTA, V876, P474, DOI 10.1016/0005-2760(86)90034-2; KATO H, 1989, J BIOL CHEM, V264, P4082; KIM YC, 1979, J BIOL CHEM, V254, P9621; LAGROST L, 1992, BIOCHIM BIOPHYS ACTA, V1124, P159, DOI 10.1016/0005-2760(92)90092-A; LEVY RS, 1967, J LIPID RES, V8, P463; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUX SE, 1972, J BIOL CHEM, V247, P7510; MORTON RE, 1985, J BIOL CHEM, V260, P2593; MORTON RE, 1990, J LIPID RES, V31, P1559; MUESING RA, 1971, BIOCHEMISTRY-US, V10, P2952; NISHIDA HI, 1986, J BIOL CHEM, V261, P2028; NISHIDA HI, 1990, J BIOL CHEM, V265, P4876; NISHIDA T, 1968, J LIPID RES, V9, P627; NISHIDA T, 1970, J BIOL CHEM, V245, P4689; PATTNAIK NM, 1978, BIOCHIM BIOPHYS ACTA, V530, P428, DOI 10.1016/0005-2760(78)90163-7; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; SAMMETT D, 1985, J BIOL CHEM, V260, P6687; SHORE V, 1967, BIOCHEMISTRY-US, V6, P1962, DOI 10.1021/bi00859a012; SINGLETON WS, 1965, J AM OIL CHEM SOC, V42, P53, DOI 10.1007/BF02558256; SWENSON TL, 1988, J BIOL CHEM, V263, P5150; TALL AR, 1986, J LIPID RES, V27, P361; TALL AR, 1984, J BIOL CHEM, V259, P9587; WASHABAUGH MW, 1986, J BIOL CHEM, V261, P2477; YAMAZAKI S, 1983, J BIOL CHEM, V258, P5847; YOKOYAMA S, 1980, J BIOL CHEM, V255, P7333	33	77	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16352	16360						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344921				2022-12-27	WOS:A1993LQ33600042
J	SAHASRABUDHE, SR; BROWN, AM; HULMES, JD; JACOBSEN, JS; VITEK, MP; BLUME, AJ; SONNENBERG, JL				SAHASRABUDHE, SR; BROWN, AM; HULMES, JD; JACOBSEN, JS; VITEK, MP; BLUME, AJ; SONNENBERG, JL			ENZYMATIC GENERATION OF THE AMINO-TERMINUS OF THE BETA-AMYLOID PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; CULTURED-CELLS; MAMMALIAN-CELLS; CATHEPSIN-G; CLEAVAGE; BRAIN; ALPHA-1-ANTICHYMOTRYPSIN; IDENTIFICATION; DERIVATIVES	The major pathological change in Alzheimer's disease is the deposition of 39-42-amino acid beta-amyloid peptide (BAP) in the brain. Since BAP begins at the aspartate residue (Asp1, or codon 672 of the amyloid precursor protein (APP)770 transcript), the ability of several proteases to cleave the peptide bond methionine-Asp1 (M/D) was evaluated by using peptides and recombinant APP molecules as substrates. Cathepsin G and chymotrypsin cleave the synthetic peptide HSEVKMDAEF at M/D under acidic conditions, whereas cleavage at lysine-methionine (K/M) predominates when the pH is alkaline. Trypsin and cathepsins B, D, and L are unable to cleave the synthetic peptide at M/D. Peptide SEVNLDAEF, representing the mutation found in early onset Alzheimer's disease families from Sweden, is cleaved by cathepsin G and chymotrypsin at leucine-aspartate (L/D). Incubation of cathepsin G with soluble protease nexin-2 obtained from recombinant APP (APP-REP) derivatives resulted in proteolytic cleavage at or near the amino terminus of BAP. Cathepsin G-mediated cleavage was also observed in the domain representing the amino terminus of BAP when mature plasma membrane-associated APP-REP molecules were used as substrates. Our results strongly suggest the involvement of a chymotrypsin-like serine protease in the generation of the amino terminus of BAP beginning at Asp1.	AMER CYANAMID CO,LEDERLE LABS,CENT NERVOUS SYST BIOL RES DEPT,200-3610,PEARL RIVER,NY 10965; AMER CYANAMID CO,LEDERLE LABS,DEPT PROT CHEM,DIV MED RES,PEARL RIVER,NY 10965				brown, abraham/R-8823-2019	Vitek, Michael/0000-0001-8140-8048				ABRAHAM CR, 1991, BIOCHEM BIOPH RES CO, V174, P790, DOI 10.1016/0006-291X(91)91487-W; ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P561; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; Dixon M, 1964, ENZYMES, P54; DONNELLY RJ, 1988, NEUROBIOL AGING, V9, P333, DOI 10.1016/S0197-4580(88)80078-2; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; ISHIURA S, 1989, FEBS LETT, V257, P388, DOI 10.1016/0014-5793(89)81579-0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MORI H, 1992, J BIOL CHEM, V267, P17082; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; NELSON RB, 1990, J BIOL CHEM, V265, P3836; OLTERSDORF T, 1989, NATURE, V341, P141; SAHASRABUDHE SR, 1992, J BIOL CHEM, V267, P25602; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMALL DH, 1991, BIOCHEMISTRY-US, V30, P10795, DOI 10.1021/bi00108a027; TANAKA T, 1985, BIOCHEMISTRY-US, V24, P2040, DOI 10.1021/bi00329a036; TRONG HL, 1987, BIOCHEMISTRY-US, V26, P6988; Vitek M.P., 1988, BRAIN RES, V464, P121; WANG R, 1991, J BIOL CHEM, V266, P16960; WIEDEMANN A, 1989, CELL, V57, P115	33	34	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16699	16705						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344949				2022-12-27	WOS:A1993LQ33600088
J	MAENZ, DD; CHENU, C; BERTELOOT, A				MAENZ, DD; CHENU, C; BERTELOOT, A			HETEROTROPIC EFFECTS OF DIPOLAR AMINO-ACIDS ON THE ACTIVITY OF THE ANIONIC AMINO-ACID-TRANSPORT SYSTEM-X(AG)(-) IN RABBIT JEJUNAL BRUSH-BORDER MEMBRANE-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPID FILTRATION APPARATUS; SMALL-INTESTINE; COTRANSPORT; GLUTAMATE; NUTRITION; SYSTEM; K+	D-Aspartic acid was used as a specific substrate to evaluate the effects of dipolar amino acids on the high affinity anionic amino acid transport system X(AG)- in rabbit jejunal brush-border membrane vesicles. At pH 6, increasing L-phenylalanine concentrations caused a saturable activation of 0.05 mM D-aspartic acid uptake (K(a) = 2.4 mM), and a saturating concentration of effector increased the V(max) of transport (2.6-fold) without any significant effect on the K(m). At pH 8, however, a complex activation/inhibition curve was obtained with increasing L-phenylalanine concentrations, and a saturating concentration of effector increased both the V(max) (1.5-fold) and K(m) (2.1-fold) for transport. Increasing concentrations of L-valine, L-isoleucine, L-methionine, and L-threonine also showed complex activation/inhibition curves of D-aspartic acid uptake at both pH 6 and 8. The maximum level of activation, the plateau reached at saturating concentrations, and the concentration of effector producing either maximum activation or inhibition were, however, different at these two pH values. By using an optimum concentratiOn of 10 mM L-valine at pH 6, the absence of trans-activation and of further activation by a cis-gradient of effector could be demonstrated. These results suggest that two allosteric sites directly accessible from the external medium are responsible for the heterotropic activation of intestinal system X(AG)- by dipolar amino acids and that, under physiological conditions, such effects might compensate for the lack of specificity of the neutral brush-border system.	UNIV MONTREAL,FAC MED,DEPT PHYSIOL,MEMBRANE TRANSPORT RES GRP,CP 6128,SUCCURSALE A,MONTREAL H3C 3J7,QUEBEC,CANADA	Universite de Montreal								ADIBI SA, 1973, J CLIN INVEST, V52, P1586, DOI 10.1172/JCI107335; BELIVEAU R, 1990, BIOCHEM J, V268, P195, DOI 10.1042/bj2680195; BERTELOOT A, 1986, BIOCHIM BIOPHYS ACTA, V861, P447, DOI 10.1016/0005-2736(86)90453-0; BERTELOOT A, 1984, BIOCHIM BIOPHYS ACTA, V775, P129, DOI 10.1016/0005-2736(84)90163-9; BERTELOOT A, 1990, METHOD ENZYMOL, V192, P409; BERTELOOT A, 1991, J MEMBRANE BIOL, V122, P111, DOI 10.1007/BF01872635; BERTELOOT A, 1990, COMP PHYSL, V7, P130; BOTTS DJ, 1958, FARADAY T SOC, V54, P593; CHENU C, 1993, J MEMBRANE BIOL, V132, P95; CHRISTENSEN HN, 1984, BIOCHIM BIOPHYS ACTA, V779, P255, DOI 10.1016/0304-4157(84)90012-1; CHRISTENSEN HN, 1982, PHYSIOL REV, V62, P1193, DOI 10.1152/physrev.1982.62.4.1193; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CORCELLI A, 1983, BIOCHIM BIOPHYS ACTA, V732, P24, DOI 10.1016/0005-2736(83)90182-7; CORCELLI A, 1982, BIOCHIM BIOPHYS ACTA, V689, P97, DOI 10.1016/0005-2736(82)90193-6; HARIG JM, 1987, BIOCHIM BIOPHYS ACTA, V903, P358, DOI 10.1016/0005-2736(87)90226-4; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; LAWLESS K, 1987, AM J PHYSIOL, V253, pG637, DOI 10.1152/ajpgi.1987.253.5.G637; MAENZ DD, 1992, J BIOL CHEM, V267, P1510; MAENZ DD, 1991, BIOCHIM BIOPHYS ACTA, V1069, P250, DOI 10.1016/0005-2736(91)90132-R; MAKOWSKE M, 1982, J BIOL CHEM, V257, P4635; MAKOWSKE M, 1982, J BIOL CHEM, V257, P5663; MALO C, 1991, J MEMBRANE BIOL, V122, P127, DOI 10.1007/BF01872636; MUNCK BG, 1980, J MEMBRANE BIOL, V53, P45, DOI 10.1007/BF01871171; RAJENDRAN VM, 1987, AM J PHYSIOL, V252, pG33, DOI 10.1152/ajpgi.1987.252.1.G33; ROBINSON J. W. L., 1964, GASTROENTEROLOGIA [BASEL], V101, P330; STEVENS BR, 1982, J MEMBRANE BIOL, V66, P213, DOI 10.1007/BF01868496; STEVENS BR, 1984, ANNU REV PHYSIOL, V46, P417; WINGROVE TG, 1987, AM J PHYSIOL, V252, pC105, DOI 10.1152/ajpcell.1987.252.1.C105	28	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15361	15367						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340366				2022-12-27	WOS:A1993LN30500010
J	MERRILL, GA; BUTLER, M; HOROWITZ, PM				MERRILL, GA; BUTLER, M; HOROWITZ, PM			LIMITED TRYPTIC DIGESTION NEAR THE AMINO-TERMINUS OF BOVINE LIVER RHODANESE PRODUCES ACTIVE ELECTROPHORETIC VARIANTS WITH ALTERED REFOLDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMS; PROTEINS; ENZYME	When the enzyme rhodanese was partially digested by immobilized trypsin, it retained greater than 50% of its original activity although less than 10% of the undigested enzyme remained. The predominant daughter species were two 31-kDa polypeptides whose amino termini corresponded to either residue 44 or 45 of the enzyme's sequence. Following digestion, charged species were isolated by ion exchange chromatography. Denaturing electrophoresis revealed that a 4-kDa peptide remained associated with the 31-kDa fragment. This 4-kDa peptide appears to correspond to the amino-terminal 45 residues of rhodanese. Further proteolysis gave a 2.5-kDa peptide that dissociated under non-denaturing conditions without apparent change in migration of the 31-kDa fragment on SDS gels. Refolding of undigested, urea-denatured rhodanese restored much of its activity. Similar treatment of rhodanese following limited tryptic digestion resulted in no regain of activity. Refolding of a mixture of intact and digested rhodanese resulted in regain of activity appropriate for the amount of intact rhodanese in the sample, indicating that clipped rhodanese does not inhibit refolding of intact rhodanese. It is concluded that portions of the amino terminus of rhodanese are important in the enzyme's folding, but are not essential for the enzyme's sulfurtransferase activity.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,CTR DEV & APPLICAT BIOANALYT METHODS,SAN ANTONIO,TX 78284; BROOKE ARMY MED CTR,DEPT CLIN INVEST,FT SAM HOUSTON,TX 78234	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; San Antonio Military Medical Center; United States Department of Defense; United States Army					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIRD BA, 1988, BIOCHIM BIOPHYS ACTA, V956, P30, DOI 10.1016/0167-4838(88)90294-4; ALEXANDER K, 1986, J BIOL CHEM, V262, P6595; BLUMENTHAL KM, 1971, J BIOL CHEM, V246, P2430; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; CANNELLA C, 1981, EUR J BIOCHEM, V119, P491, DOI 10.1111/j.1432-1033.1981.tb05634.x; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; HOROWITZ P, 1983, J BIOL CHEM, V258, P1614; HOROWITZ PM, 1987, J BIOL CHEM, V262, P14544; HOROWITZ PM, 1987, J BIOL CHEM, V262, P8728; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; KRATZIN HD, 1989, ANAL BIOCHEM, V183, P1, DOI 10.1016/0003-2697(89)90161-9; Kurzban G P, 1991, Protein Expr Purif, V2, P379, DOI 10.1016/1046-5928(91)90097-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1993, J PROTEIN CHEM, V12, P65, DOI 10.1007/BF01024916; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; MERRILL GA, 1992, J PROTEIN CHEM, V11, P193, DOI 10.1007/BF01025225; MILLER D, 1990, J BIOL CHEM, V266, P4686; OGATA K, 1989, J BIOL CHEM, V264, P2718; PLOEGMAN JH, 1978, J MOL BIOL, V123, P557, DOI 10.1016/0022-2836(78)90207-3; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; STEVEN PF, 1986, ANAL BIOCHEM, V155, P83; TANDON S, 1986, J BIOL CHEM, V261, P5615; TRUMPOWER BL, 1974, BIOCHEM BIOPH RES CO, V57, P532, DOI 10.1016/0006-291X(74)90965-6	26	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15611	15620						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340386				2022-12-27	WOS:A1993LN30500045
J	SINGHAL, RK; WILSON, SH				SINGHAL, RK; WILSON, SH			SHORT GAP-FILLING SYNTHESIS BY DNA POLYMERASE-BETA IS PROCESSIVE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC ACID POLYMERASE; PERMEABLE HUMAN-FIBROBLASTS; REPAIR SYNTHESIS; ESCHERICHIA-COLI; EXCISION REPAIR; HUMAN-CELLS; IDENTIFICATION; ALPHA; INHIBITORS; EXPRESSION	Mammalian DNA polymerase beta (beta-pol) is considered to be part of the DNA repair machinery. However, there have been conceptual problems with this idea because beta-pol does not completely fill some gapped substrates, and unlike other DNA polymerases, beta-pol adds just one dNMP for each cycle of binding to the DNA substrate, incorporation, and product release (distributive synthesis). To examine the questions of complete gap filling and gap recognition by beta-pol, we designed template-primer substrates with a range of gap sizes from 1 to 53 template residues between the 3'-OH primer and a downstream polynucleotide. M13mp18(+) single-stranded DNA was used as template, and synthetic deoxyoligonucleotides were used as primers and downstream polynucleotides. We find that beta-pol can completely fill gaps and that the gap-filling activity on substrates with gaps of up to 6 nucleotides is highly processive rather than distributive; processive synthesis to fill a gap strictly required 5'-phosphate on the 5'-moiety of the gap. Similar specificity for filling short gaps was not observed with other DNA polymerases. These results on substrate specificity and the mechanism of beta-pol suggest distinct requirements for the role of beta-pol in vivo.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293				ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; BARIL EF, 1971, BIOCHEMISTRY-US, V10, P1981, DOI 10.1021/bi00787a004; CHANG LMS, 1975, J MOL BIOL, V93, P219, DOI 10.1016/0022-2836(75)90129-1; CHANG LMS, 1973, J BIOL CHEM, V248, P3789; CHANG LMS, 1972, BIOCHEMISTRY-US, V11, P1264, DOI 10.1021/bi00757a023; DATE T, 1988, BIOCHEMISTRY-US, V27, P2983, DOI 10.1021/bi00408a048; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIGIUSEPPE JA, 1989, BIOCHEMISTRY-US, V28, P9515, DOI 10.1021/bi00450a040; DRESLER SL, 1983, J BIOL CHEM, V258, P9990; FRY M, 1986, ANIMAL CELL DNA POLY, P135; HAMMOND RA, 1990, BIOCHEMISTRY-US, V29, P286, DOI 10.1021/bi00453a039; JENKINS TM, 1992, SCIENCE, V258, P475, DOI 10.1126/science.1411545; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; MATSUKAGE A, 1974, P NATL ACAD SCI USA, V71, P578, DOI 10.1073/pnas.71.2.578; MATSUMOTO Y, 1989, MOL CELL BIOL, V9, P3750, DOI 10.1128/MCB.9.9.3750; MILLER MR, 1982, J BIOL CHEM, V257, P204; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; RANDAHL H, 1988, J BIOL CHEM, V263, P12228; SIEDLECKI JA, 1980, NUCLEIC ACIDS RES, V8, P361, DOI 10.1093/nar/8.2.361; SMITH CA, 1984, BIOCHEMISTRY-US, V23, P1383, DOI 10.1021/bi00302a008; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; TANABE K, 1979, BIOCHEMISTRY-US, V18, P3407; WANG TSF, 1980, BIOCHEMISTRY-US, V19, P1782, DOI 10.1021/bi00550a009; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199	26	221	225	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15906	15911						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340415				2022-12-27	WOS:A1993LN30500083
J	KOHRI, K; NOMURA, S; KITAMURA, Y; NAGATA, T; YOSHIOKA, K; IGUCHI, M; YAMATE, T; UMEKAWA, T; SUZUKI, Y; SINOHARA, H; KURITA, T				KOHRI, K; NOMURA, S; KITAMURA, Y; NAGATA, T; YOSHIOKA, K; IGUCHI, M; YAMATE, T; UMEKAWA, T; SUZUKI, Y; SINOHARA, H; KURITA, T			STRUCTURE AND EXPRESSION OF THE MESSENGER-RNA ENCODING URINARY STONE PROTEIN (OSTEOPONTIN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETED PHOSPHOPROTEIN-I; MINERALIZED-TISSUE FORMATION; BONE SIALOPROTEIN; RAT BONE; NEOPLASTIC TRANSFORMATION; DEVELOPMENTAL EXPRESSION; FIBROBLAST ATTACHMENT; KIDNEY; MATRIX; CELLS	The chemical nature of urinary stone protein is poorly understood. We have sequenced a cDNA of urinary calcium oxalate stone protein extracted with EDTA. cDNA sequences showed complete identity between urinary stone protein and human osteopontin. Osteopontin protein was detected by staining with Stains-All, which specifically stains phosphoproteins, and by digestion with the highly specific protease thrombin, demonstrating that urinary calcium oxalate stones consist of osteopontin protein. We used a technique of in situ hybridization to detect osteopontin mRNA in the kidney. In control rats, distal tubular cells were sporadically positive, and proximal tubular cells and glomeruli were negative for osteopontin mRNA. A rat model of stone formation was induced with glyoxylic acid. In stone-forming rats, staining of distal tubular cells was remarkably increased, but proximal tubular cells and glomeruli were still negative. Immunostaining for the osteopontin protein also revealed that epithelial cells of distal tubules were weakly positive in control rats and significantly increased in stone-forming rats, although proximal tubular cells and glomeruli were negative. Northern blot analysis showed a significant increase of osteopontin mRNA in stone-forming rats in proportion to the dosage and the duration of the stone-inducing drugs. These results show that osteopontin in the kidney is presumably involved in urinary stone formation as the stone matrix.	KINKI UNIV, SCH MED, DEPT BIOCHEM, SAYAMA, OSAKA 589, JAPAN; KINKI UNIV, SCH MED, DEPT PEDIAT, SAYAMA, OSAKA 589, JAPAN; OSAKA UNIV, SCH MED, DEPT PATHOL, SUITA, OSAKA 565, JAPAN; UNIV TOKUSHIMA, SCH DENT, DEPT PERIODONTOL & ENDODONTOL, TOKUSHIMA 770, JAPAN	Kindai University (Kinki University); Kindai University (Kinki University); Osaka University; Tokushima University	KOHRI, K (corresponding author), KINKI UNIV, SCH MED, DEPT UROL, SAYAMA, OSAKA 589, JAPAN.							BOYCE WH, 1968, AM J MED, V45, P673, DOI 10.1016/0002-9343(68)90203-9; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; CHANG PL, 1991, CANCER RES, V51, P2144; DOMENICUCCI C, 1988, BIOCHEM J, V253, P139, DOI 10.1042/bj2530139; FRANZEN A, 1985, BIOCHEM J, V232, P715, DOI 10.1042/bj2320715; GIACHELLI C, 1991, BIOCHEM BIOPH RES CO, V177, P867, DOI 10.1016/0006-291X(91)91870-I; GOLDBERG HA, 1988, COLLAGEN REL RES, V8, P187; HIENZSCH E, 1979, UROL RES, V7, P223; KEUTEL H. J., 1964, INVEST UROL, V2, P115; KIEFER MC, 1989, NUCLEIC ACIDS RES, V17, P3306, DOI 10.1093/nar/17.8.3306; KING JS, 1957, P SOC EXP BIOL MED, V95, P183, DOI 10.3181/00379727-95-23161; KING JS, 1959, ARCH BIOCHEM BIOPHYS, V82, P455, DOI 10.1016/0003-9861(59)90142-0; KOHRI K, 1992, BIOCHEM BIOPH RES CO, V184, P859, DOI 10.1016/0006-291X(92)90669-C; KRUMLAUF R, 1987, DEVELOPMENT, V99, P603; KUBOTA T, 1989, BIOCHEM BIOPH RES CO, V162, P1453, DOI 10.1016/0006-291X(89)90837-1; LIAN JB, 1977, J CLIN INVEST, V59, P1151, DOI 10.1172/JCI108739; MARK MP, 1987, J HISTOCHEM CYTOCHEM, V35, P707, DOI 10.1177/35.7.3295029; MARK MP, 1988, CELL TISSUE RES, V251, P23, DOI 10.1007/BF00215443; MOORE S, 1975, BRIT J UROL, V47, P489, DOI 10.1111/j.1464-410X.1975.tb06244.x; NAGATA T, 1991, BIOCHEM J, V274, P513, DOI 10.1042/bj2740513; NAGATA T, 1989, BIOCHEM BIOPH RES CO, V165, P234, DOI 10.1016/0006-291X(89)91059-0; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; SENGER DR, 1989, BIOCHIM BIOPHYS ACTA, V996, P43, DOI 10.1016/0167-4838(89)90092-7; SENGER DR, 1988, CANCER RES, V48, P5770; SENGER DR, 1989, ANTICANCER RES, V9, P1291; SHIRAGA H, 1992, P NATL ACAD SCI USA, V89, P426, DOI 10.1073/pnas.89.1.426; SINGH K, 1990, J BIOL CHEM, V265, P18696; SOMERMAN MJ, 1987, J BONE MINER RES, V2, P259; SOMERMAN MJ, 1988, CALCIFIED TISSUE INT, V43, P50, DOI 10.1007/BF02555169; SPECTOR AR, 1976, INVEST UROL, V13, P387; SWANSON GJ, 1989, HEARING RES, V41, P169, DOI 10.1016/0378-5955(89)90008-7; VERMEULEN CW, 1968, AM J MED, V45, P684, DOI 10.1016/0002-9343(68)90204-0; YOON K, 1987, BIOCHEM BIOPH RES CO, V148, P1129, DOI 10.1016/S0006-291X(87)80250-4; YOSHIDA O, 1990, UROL INT, V45, P104, DOI 10.1159/000281680; YOSHIOKA K, 1985, AM J PATHOL, V121, P156; ZHANG R, 1990, J BIOL CHEM, V265, P15375	39	227	230	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15180	15184						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325891				2022-12-27	WOS:A1993LL75900092
J	TAMURA, K; TANIMOTO, K; ISHII, M; MURAKAMI, K; FUKAMIZU, A				TAMURA, K; TANIMOTO, K; ISHII, M; MURAKAMI, K; FUKAMIZU, A			PROXIMAL AND CORE DNA ELEMENTS ARE REQUIRED FOR EFFICIENT ANGIOTENSINOGEN PROMOTER ACTIVATION DURING ADIPOGENIC DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER BINDING-PROTEIN; BLOOD-PRESSURE REGULATION; 3T3-L1 PREADIPOCYTES; GENE-EXPRESSION; MOLECULAR-BIOLOGY; MESSENGER-RNA; ADIPOCYTE DIFFERENTIATION; TRANSCRIPTION; CELLS; C/EBP	Angiotensinogen is abundantly expressed in adipose tissue as well as in liver where it is mainly produced. To address the mechanism of this adipogenic expression, promoter regions of the mouse angiotensinogen gene are fused to the chloramphenicol acetyltransferase reporter gene and stably transfected into 3T3-L1 preadipocytes. Promoter activity correlates well with an increase of mRNA levels during adipogenic differentiation, thereby demonstrating that the induction is primarily due to transcriptional activation. Deletion analysis indicates that the proximal promoter region from -96 to +22 is able to mediate the chloramphenicol acetyltransferase induction and identifies two transcriptionally active regions: AGE1 (position -399 to -139) and AGE2 (position -96 to -52). Heterologous promoter assay reveals that AGE1 behaves with a constitutive enhancer-like property and that AGE2 functions as a differentiation-inducible activator. Gel shift experiments show that AGE2 specifically binds a novel factor (AGF2), which is induced upon differentiation. Furthermore, a constitutive factor (AGF3) binds to the core promoter region including the exon 1 (from -6 to +22, AGE3). Mutations within either AGE2 or AGE3 that disrupt nuclear factors binding in vitro dramatically reduced the chloramphenicol acetyltransferase activation in the native promoter context. These results suggest that both AGE2 and AGE3 are necessary for mediating efficient activation of the mouse angiotensinogen promoter during adipogenic differentiation.	UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN; YOKOHAMA CITY UNIV,SCH MED,DEPT INTERNAL MED,KANAGAWA 236,JAPAN	University of Tsukuba; Yokohama City University			fukamizu, akiyoshi/J-5350-2012; Tanimoto, Keiji/B-2600-2014	fukamizu, akiyoshi/0000-0002-8786-6020; Tanimoto, Keiji/0000-0003-1971-6546				BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; CAMPBELL DJ, 1987, J CLIN INVEST, V79, P1, DOI 10.1172/JCI112768; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHENEVAL D, 1991, P NATL ACAD SCI USA, V88, P8465, DOI 10.1073/pnas.88.19.8465; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; CLOUSTON W M, 1988, Genomics, V2, P240, DOI 10.1016/0888-7543(88)90008-0; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; DANESCH U, 1992, J BIOL CHEM, V267, P7185; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FERRARIO CM, 1990, J CARDIOVASC PHARM, V15, pS1, DOI 10.1097/00005344-199000153-00001; FREDERICH RC, 1992, HYPERTENSION, V19, P339, DOI 10.1161/01.HYP.19.4.339; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FUKAMIZU A, 1991, BIOMED BIOCHIM ACTA, V50, P659; GOMEZ RA, 1988, ENDOCRINOLOGY, V123, P2298, DOI 10.1210/endo-123-5-2298; GOMEZ RA, 1990, PEDIATR NEPHROL, V4, P421, DOI 10.1007/BF00862529; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KALINYAK JE, 1991, J ENDOCRINOL INVEST, V14, P647, DOI 10.1007/BF03347886; KIMURA S, 1992, EMBO J, V11, P821, DOI 10.1002/j.1460-2075.1992.tb05119.x; KRIEGER JE, 1991, HYPERTENSION, V18, P3; KUIPERS OP, 1991, NUCLEIC ACIDS RES, V19, P4558, DOI 10.1093/nar/19.16.4558; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; LYNCH KR, 1991, HYPERTENSION, V17, P263, DOI 10.1161/01.HYP.17.3.263; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; ROCCHINI AP, 1991, HYPERTENSION, V17, P837, DOI 10.1161/01.HYP.17.6.837; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RON D, 1992, J CLIN INVEST, V89, P223, DOI 10.1172/JCI115566; SADOWSKI HB, 1992, J BIOL CHEM, V267, P4722; SAMUELSSON L, 1991, EMBO J, V10, P3787, DOI 10.1002/j.1460-2075.1991.tb04948.x; SAYE J, 1990, HYPERTENSION, V15, P867, DOI 10.1161/01.HYP.15.6.867; SAYE JA, 1989, AM J PHYSIOL, V256, pC448, DOI 10.1152/ajpcell.1989.256.2.C448; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEPHENS JM, 1992, J BIOL CHEM, V267, P13580; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P7895, DOI 10.1073/pnas.89.17.7895; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; TAMURA K, 1992, JPN HEART J, V33, P113; TAMURA K, 1992, NUCLEIC ACIDS RES, V20, P3617, DOI 10.1093/nar/20.14.3617; TEWKSBURY DA, 1990, HYPERTENSION PATHOPH, V1, P1197; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WILLIAMS PM, 1992, MOL ENDOCRINOL, V6, P1135, DOI 10.1210/me.6.7.1135; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879	58	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15024	15032						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325878				2022-12-27	WOS:A1993LL75900072
J	SU, K; STOLLER, T; ROCCO, J; ZEMSKY, J; GREEN, R				SU, K; STOLLER, T; ROCCO, J; ZEMSKY, J; GREEN, R			PRE-GOLGI DEGRADATION OF YEAST PREPRO-ALPHA-FACTOR EXPRESSED IN A MAMMALIAN-CELL - INFLUENCE OF CELL-TYPE-SPECIFIC OLIGOSACCHARIDE PROCESSING ON INTRACELLULAR FATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; ANTIGEN RECEPTOR CHAINS; SACCHAROMYCES-CEREVISIAE; BREFELDIN-A; PROTEIN-DEGRADATION; SECRETORY GLYCOPROTEINS; FOREIGN PROTEINS; FACTOR PRECURSOR; GLYCOSYLATION; COMPLEX	We demonstrate that expression of yeast prepro-alpha-factor in GH3 rat pituitary cells results in its degradation in an endoplasmic reticulum (ER) or early Golgi compartment, suggesting that this wild-type prohormone is recognized as abnormal or misfolded in the context of a mammalian ER. In GH3 cells, as in yeast, the nascent polypeptide is efficiently targeted to the ER, where it undergoes cleavage of its amino-terminal signal peptide and core glycosylation to form glycosylated pro-alpha-factor (gpalphaf). Subsequently, however, this species disappears from cells with a half-time of 25-30 min (including a 10-20-min lag), and no alpha-factor-or proregion-derived products can be detected. Localization of the degradative process to the ER is suggested by its occurrence in the presence of brefeldin A or chloroquine and by the endoglycosidase H susceptibility of the substrate. We present evidence that Asn-linked oligosaccharide processing, which differs in extent between yeast and mammalian cells, may be an important factor in determining degradation in this heterologous circumstance. When GH3 cells are treated with deoxymannojirimycin, an inhibitor of ER alpha-mannosidases, gpalphaf is essentially stable, suggesting that trimming of core oligosaccharides below Man8 (a process that does not occur in yeast) strongly promotes proteolysis. Inhibition of ER glucosidase activity by treatment with deoxynojirimycin, by contrast, considerably accelerates the disappearance of gpalphaf (t1/2 = 8-10 min). These data indicate that cell type-specific post-translational modifications of a secretory glycoprotein can substantially modify its recognition by the mammalian ER degradative apparatus.	CUNY MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10029; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV BIOL & CANC,BRONX,NY 10461	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Yeshiva University; Albert Einstein College of Medicine								AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; ATKINSON PH, 1984, J CELL BIOL, V98, P2245, DOI 10.1083/jcb.98.6.2245; BAUSE E, 1986, BIOSCIENCE REP, V6, P827, DOI 10.1007/BF01117106; BERGH MLE, 1987, P NATL ACAD SCI USA, V84, P3570, DOI 10.1073/pnas.84.11.3570; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; BISCHOFF J, 1986, J BIOL CHEM, V261, P4758; BISCHOFF J, 1986, J BIOL CHEM, V261, P4768; BITTER GA, 1984, P NATL ACAD SCI-BIOL, V81, P5330, DOI 10.1073/pnas.81.17.5330; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BRAKE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P4642, DOI 10.1073/pnas.81.15.4642; BYRD JC, 1982, J BIOL CHEM, V257, P4657; CAPLAN S, 1991, J BACTERIOL, V173, P627, DOI 10.1128/jb.173.2.627-635.1991; CHEN C, 1988, J CELL BIOL, V107, P2149, DOI 10.1083/jcb.107.6.2149; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GIL G, 1985, CELL, V41, P241; GREEN R, 1986, J BIOL CHEM, V261, P7558; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PEYRIERAS N, 1983, EMBO J, V2, P823, DOI 10.1002/j.1460-2075.1983.tb01509.x; RIZZOLO LJ, 1988, J BIOL CHEM, V263, P9520; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; STOCKERT RJ, 1983, HEPATOLOGY, V3, P750; STOLLER TJ, 1988, J CELL BIOL, V107, P2087, DOI 10.1083/jcb.107.6.2087; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; TRIMBLE RJ, 1992, GUIDEBOOK SECRETORY; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WATERS MG, 1988, J BIOL CHEM, V263, P6209; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973	48	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14301	14309						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314793				2022-12-27	WOS:A1993LJ82500076
J	BIERHUIZEN, MFA; MAEMURA, K; FUKUDA, M				BIERHUIZEN, MFA; MAEMURA, K; FUKUDA, M			EXPRESSION OF A DIFFERENTIATION ANTIGEN AND POLY-N-ACETYLLACTOSAMINYL O-GLYCANS DIRECTED BY A CLONED CORE 2 BETA-1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH SYNDROME; HAMSTER-KIDNEY CELLS; MAJOR SIALOGLYCOPROTEIN; LINKED OLIGOSACCHARIDES; SIALYL-LEX; SURFACE SIALOGLYCOPROTEIN; MONOCLONAL-ANTIBODY; HUMAN LEUKOSIALIN; SIALOPHORIN CD43; LEUKEMIA-CELLS	Chinese hamster ovary (CHO) cells do not contain detectable amounts of core 2 beta-1,6-N-acetylglucosaminyl-transferase, C2GnT, and thus lack various modifications in their branched O-linked oligosaccharides. In the pre-sent study, the O-linked oligosaccharides and the occurrence of a differentiation antigen were analyzed in CHO cells stably transfected with cDNA encoding human leukosialin alone (CHO-leu) or with cDNAs encoding both leukosialin and C2GnT (CHO-leu.C2GnT). The analysis of O-glycans, released from [H-3]glucosamine labeled cells, revealed that CHO-leu cells synthesize O-glycans with a Gal beta 1-->3GalNAc backbone, whereas CHO-leu C2GnT cells synthesize in addition O-glycans with a Gal beta 1-->3(Gal beta 1-->4GlcNAc beta 1-->6)GalNAc backbone. Moreover, CHO-leu C2GnT cells express poly-N-acetyllactosaminyl extensions from the GlcNAc beta 1-->6 branch in O-glycans, while CHO-leu cells express no detectable amount of poly-N-acetyllactosaminyl O-glycans. It was also demonstrated that leukosialin in CHO-leu C2GnT cells is recognized by the T305 monoclonal antibody, while the same antibody did not react at all with CHO-leu cells. In addition, the transient expression cloning scheme using the T305 monoclonal antibody as a selectin marker and COS-1 cells, which endogenously express C2GnT as recipient cells, resulted in the isolation of cDNA encoding leukosialin. These results indicate that C2GnT determines the expression of poly-N-acetyllactosamines in O-glycans and together with leukosialin, an onco-differentiation antigen recognized by the T305 antibody.	LA JOLLA CANC RES FDN,CANC RES CTR,GLYOCBIOL PROGRAM,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [CA33000, CA33895] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA033000, R01CA033000, R01CA033895] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARDMAN B, 1992, P NATL ACAD SCI USA, V89, P5001, DOI 10.1073/pnas.89.11.5001; BAZIL V, 1993, P NATL ACAD SCI USA, V90, P3792, DOI 10.1073/pnas.90.9.3792; BERG EL, 1991, J BIOL CHEM, V266; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CARLSSON SR, 1986, J BIOL CHEM, V261, P2787; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; DYER MJS, 1981, J EXP MED, V154, P1164, DOI 10.1084/jem.154.4.1164; FEINBERG AP, 1983, ANAL BIOCHEM, V12, P6; FOX RI, 1983, J IMMUNOL, V131, P762; FUKUDA M, 1991, Glycobiology, V1, P347, DOI 10.1093/glycob/1.4.347; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; FUKUDA M, 1993, SEMIN HEMATOL, V30, P138; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA MN, 1981, J BIOL CHEM, V256, P3900; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GULLEY ML, 1988, J IMMUNOL, V140, P3751; HESSION C, 1989, P NATL ACAD SCI USA, V87, P3743; HIGGINS EA, 1991, J BIOL CHEM, V266, P6280; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KUDO S, 1991, J BIOL CHEM, V266, P8483; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; NATHAN C, 1993, J CELL BIOL, V122, P243, DOI 10.1083/jcb.122.1.243; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; NONG YH, 1989, J EXP MED, V170, P259, DOI 10.1084/jem.170.1.259; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; PARK JK, 1991, NATURE, V350, P706, DOI 10.1038/350706a0; PAULSON JC, 1982, J BIOL CHEM, V257; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PIERCE M, 1986, J BIOL CHEM, V261, P772; PILLER F, 1991, J EXP MED, V173, P1501, DOI 10.1084/jem.173.6.1501; PILLER F, 1988, J BIOL CHEM, V263, P15146; PILLER V, 1989, J BIOL CHEM, V264, P18824; PILLER V, 1990, J BIOL CHEM, V265, P9264; REMOLD-O'DONNELL E, 1990, Immunodeficiency Reviews, V2, P151; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SADLER JE, 1979, J BIOL CHEM, V254, P2112; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITOH O, 1991, BLOOD, V77, P1491; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI H, 1987, J BIOL CHEM, V262, P12059; SAWADA R, 1993, J BIOL CHEM, V268, P12675; SAWADA R, 1994, J BIOL CHEM, V269, P1425; SCHMID K, 1992, P NATL ACAD SCI USA, V89, P663, DOI 10.1073/pnas.89.2.663; SHELLEY CS, 1989, P NATL ACAD SCI USA, V86, P2819, DOI 10.1073/pnas.86.8.2819; SMITH DF, 1990, J BIOL CHEM, V265, P6225; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; YAMASHITA K, 1984, J BIOL CHEM, V259, P834; YOKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894, DOI 10.1073/pnas.83.16.5894; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	59	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4473	4479						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308016				2022-12-27	WOS:A1994MW98900088
J	LEE, NH; EARLEHUGHES, J; FRASER, CM				LEE, NH; EARLEHUGHES, J; FRASER, CM			AGONIST-MEDIATED DESTABILIZATION OF M1 MUSCARINIC ACETYLCHOLINE-RECEPTOR MESSENGER-RNA - ELEMENTS INVOLVED IN MESSENGER-RNA STABILITY ARE LOCALIZED IN THE 3'-UNTRANSLATED REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; PROTEIN-KINASE-C; SITE-DIRECTED MUTAGENESIS; MESSENGER-RNA LEVEL; INDUCED DOWN-REGULATION; PITUITARY GH3 CELLS; BETA-2-ADRENERGIC RECEPTOR; COUPLED RECEPTORS; LIGAND-BINDING; HORMONE TRH	The effects of chronic agonist exposure on receptor number (down-regulation) have been shown, in part, to be due to effects on mRNA levels. Agonist-mediated effects on muscarinic acetylcholine receptor (mAChR) mRNA were investigated in Chinese hamster ovary (CHO) cells stably transfected with mi mAChR gene constructs containing the open reading frame and a series of deletions of the flanking 3'-untranslated region (3'-UTR). Carbachol (CBC) down-regulated m1 mAChRs encoded by the construct m1C1, an mi mAChR transcript containing the entire flanking 3'UTR (nucleotides 1526-2622), in a time dependent fashion with maximal decreases occurring by 12 h. Steady-state levels of m1C1 mRNA declined in a parallel fashion beginning 6 h after CBC pretreatment. Similar findings were obtained with m1C2, a construct which is missing all but 261 bases of flanking 3'-UTR (nucleotides (nt) 1526-1786). Since the rate of mRNA degradation represents an important potential regulatory mechanism to control the level of gene expression, we investigated the effects of CBC treatment on m1C1 and m1C2 mRNA stability. The half-life of either transcript in untreated cells was approximately 14 h, whereas m1C1 and m1C2 transcript half-lives decreased to similar to 3 h in cells treated with CBC. Agonist-induced destabilization of m1C2 mRNA could be mimicked by phorbol esters in a concentration-dependent manner and blocked by the protein kinase inhibitor, H-7. In contrast, mi mAChR mRNA constructs missing nt 1526-1786 of the 3'-UTR (m1C3 and m1C4) did not undergo agonist or phorbol ester-induced destabilization. In the neuroblastoma cell line IMR-32, endogenous mi mAChR mRNA was down-regulated and destabilized following CBC treatment. These results demonstrate that agonist-induced mRNA destabilization is a potential mechanism for regulating mi mAChR levels. Furthermore, deletion studies identify a 261 base region of the 3'-UTR having the potential to form stable stem-loop structures which likely harbors element(s) responsible for message destabilization.	NIAAA,NEUROGENET LAB,ROCKVILLE,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	LEE, NH (corresponding author), INST GENOM RES,DEPT MOLEC & CELLULAR BIOL,GAITHERSBURG,MD 20878, USA.			Fraser, Claire/0000-0003-1462-2428				ATWATER JA, 1990, ANNU REV GENET, V24, P519; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P152; CHUNG FZ, 1988, J BIOL CHEM, V263, P4052; CLEVELAND D W, 1989, New Biologist, V1, P121; COLLINS S, 1992, TRENDS BIOCHEM SCI, V17, P37, DOI 10.1016/0968-0004(92)90425-9; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOSS RC, 1981, J BIOL CHEM, V256, P2281; DURET L, 1993, NUCLEIC ACIDS RES, V21, P2315, DOI 10.1093/nar/21.10.2315; FRASER CM, 1989, J BIOL CHEM, V264, P9266; FUJIMOTO J, 1991, MOL ENDOCRINOL, V5, P1527, DOI 10.1210/mend-5-10-1527; FUJIMOTO J, 1992, ENDOCRINOLOGY, V130, P1879, DOI 10.1210/en.130.4.1879; FUKAMAUCHI F, 1991, J NEUROCHEM, V56, P716, DOI 10.1111/j.1471-4159.1991.tb08210.x; HABECKER BA, 1992, P NATL ACAD SCI USA, V89, P5035, DOI 10.1073/pnas.89.11.5035; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOUGH C, 1990, BIOCHEM BIOPH RES CO, V170, P46, DOI 10.1016/0006-291X(90)91238-N; IZZO NJ, 1990, P NATL ACAD SCI USA, V87, P6268, DOI 10.1073/pnas.87.16.6268; KLEIN WL, 1979, BIOCHEM BIOPH RES CO, V90, P506, DOI 10.1016/0006-291X(79)91264-6; KOMAN A, 1993, NEUROSCI LETT, V149, P79, DOI 10.1016/0304-3940(93)90352-L; KUKKONEN J, 1992, J PHARMACOL EXP THER, V263, P1487; LEE NH, 1993, J BIOL CHEM, V268, P7949; LILES WC, 1986, J BIOL CHEM, V261, P5307; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NARAYANAN CS, 1992, J BIOL CHEM, V267, P17296; NATHANSON NM, 1989, MUSCARINIC RECEPTORS, P419; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PORT JD, 1992, J BIOL CHEM, V267, P24103; Sambrook J, 1989, MOL CLONING LABORATO; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SAVARESE TM, 1992, J BIOL CHEM, V267, P11439; STEEL MC, 1993, MOL PHARMACOL, V43, P694; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VANDUUREN BL, 1979, CANCER RES, V39, P2644; WANG H, 1991, J BIOL CHEM, V266, P780; WANG SZ, 1990, FEBS LETT, V276, P185, DOI 10.1016/0014-5793(90)80538-T; ZUCKER M, 1981, NUCLEIC ACIDS RES, V9, P133	43	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4291	4298						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307995				2022-12-27	WOS:A1994MW98900062
J	ZHU, GH; SPREITZER, RJ				ZHU, GH; SPREITZER, RJ			DIRECTED MUTAGENESIS OF CHLOROPLAST RIBULOSEBISPHOSPHATE CARBOXYLASE/OXYGENASE - SUBSTITUTIONS AT LARGE SUBUNIT ASPARAGINE-123 AND SERINE-379 DECREASE CO2/O-2 SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; RHODOSPIRILLUM-RUBRUM; CHLAMYDOMONAS-REINHARDII; ACTIVE-SITE; 1,5-DIPHOSPHATE CARBOXYLASE; OXYGENASE; MUTANT; DNA; 1,5-BISPHOSPHATE	Chloroplast-encoded large subunits of ribulose-1,5-bisphosphate carboxylase/oxygenase (EC 4.1.1.39) are insoluble when separated from the holoenzyme or expressed in Escherichia coli, limiting directed mutagenesis to prokaryotic enzymes. In the present study, we performed directed mutagenesis and chloroplast transformation with the large subunit gene of Chlamydomonas reinhardtii. Two separate mutations were created that are known to influence the CO2/O-2 specificity of prokaryotic enzymes. The asparagine 123 to glycine and serine 379 to alanine substitutions gave rise to photosynthesis-deficient mutants that synthesize normal levels of holoenzyme. The V-max for carboxylation was reduced more than 95% and the K-m(CO2) was increased more than 3-fold for both mutant enzymes. K-m(O-2) was slightly reduced for the glycine 123 enzyme, but increased more than 5-fold for the alanine 379 enzyme. CO2/O-2 specificity factors for both enzymes are decreased by more than 70%. K-m values for ribulose 1,5-bisphosphate are not significantly affected, but binding affinities for the transition-state analog 2-carboxy-D-arabinitol 1,5 bisphosphate are reduced. The changes brought about by these substitutions in the eukaryotic large subunit are different from the changes observed in prokaryotic enzymes.			ZHU, GH (corresponding author), UNIV NEBRASKA,DEPT BIOCHEM,LINCOLN,NE 68583, USA.							ANDREWS TJ, 1988, J BIOL CHEM, V263, P12213; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; BOYNTONJE, 1993, METHOD ENZYMOL, V217, P510; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN Z, 1988, P NATL ACAD SCI USA, V85, P4696, DOI 10.1073/pnas.85.13.4696; CHEN Z, 1991, PLANTA, V83, P597; CHEN ZX, 1992, PHOTOSYNTH RES, V31, P157, DOI 10.1007/BF00028792; CHEN ZX, 1991, BIOCHEMISTRY-US, V30, P8846, DOI 10.1021/bi00100a017; CHEN ZX, 1989, J BIOL CHEM, V264, P3051; CHENE P, 1992, J MOL BIOL, V225, P891, DOI 10.1016/0022-2836(92)90408-C; CURMI PMG, 1992, J BIOL CHEM, V267, P16980; DAY AG, 1993, BIOCHEMISTRY-US, V32, P1940, DOI 10.1021/bi00059a009; DRON M, 1982, J MOL BIOL, V162, P775, DOI 10.1016/0022-2836(82)90547-2; FINER JJ, 1992, PLANT CELL REP, V11, P323, DOI 10.1007/BF00233358; GATENBY AA, 1984, EUR J BIOCHEM, V144, P361, DOI 10.1111/j.1432-1033.1984.tb08472.x; GUTTERIDGE S, 1993, J BIOL CHEM, V268, P7818; HARPEL MR, 1992, J BIOL CHEM, V267, P6475; HARPEL MR, 1991, J BIOL CHEM, V266, P24734; JORDAN DB, 1981, PLANT PHYSIOL, V67, P237, DOI 10.1104/pp.67.2.237; KINDLE KL, 1991, P NATL ACAD SCI USA, V88, P1721, DOI 10.1073/pnas.88.5.1721; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; KUEHN GD, 1978, BIOCHEM J, V175, P909, DOI 10.1042/bj1750909; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAING WA, 1974, PLANT PHYSIOL, V54, P678, DOI 10.1104/pp.54.5.678; LARIMER FW, 1987, J BIOL CHEM, V262, P15327; LEE GJ, 1992, BIOCHEMISTRY-US, V31, P2304, DOI 10.1021/bi00123a014; NEWMAN SM, 1991, MOL GEN GENET, V230, P65, DOI 10.1007/BF00290652; NEWMAN SM, 1990, GENETICS, V126, P875; OGREN WL, 1984, ANNU REV PLANT PHYS, V35, P415, DOI 10.1146/annurev.pp.35.060184.002215; PARRY MAJ, 1992, PLANTA, V187, P109, DOI 10.1007/BF00201631; PIERCE J, 1980, BIOCHEMISTRY-US, V19, P934, DOI 10.1021/bi00546a018; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER G, 1990, J MOL BIOL, V211, P989, DOI 10.1016/0022-2836(90)90088-4; SOPER TS, 1992, J BIOL CHEM, V267, P8452; SPREITZER RJ, 1981, PLANT PHYSIOL, V67, P565, DOI 10.1104/pp.67.3.565; SPREITZER RJ, 1982, FEBS LETT, V148, P117, DOI 10.1016/0014-5793(82)81255-6; SPREITZER RJ, 1987, CURR GENET, V11, P611, DOI 10.1007/BF00393924; SPREITZER RJ, 1993, ANNU REV PLANT PHYS, V44, P411, DOI 10.1146/annurev.pp.44.060193.002211; TABITA FR, 1974, J BIOL CHEM, V249, P3459; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; WURTZ EA, 1979, MOL GEN GENET, V170, P235, DOI 10.1007/BF00267056; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YU WZ, 1992, P NATL ACAD SCI USA, V89, P3904, DOI 10.1073/pnas.89.9.3904; ZHU GH, 1990, PLANT PHYSIOL, V93, P244, DOI 10.1104/pp.93.1.244	46	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3952	3956						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307949				2022-12-27	WOS:A1994MW98900011
J	BANKI, K; HALLADAY, D; PERL, A				BANKI, K; HALLADAY, D; PERL, A			CLONING AND EXPRESSION OF THE HUMAN GENE FOR TRANSALDOLASE - A NOVEL HIGHLY REPETITIVE ELEMENT CONSTITUTES AN INTEGRAL-PART OF THE CODING SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOME; VIRUS; DNA; RNA	A novel highly repetitive retrotransposable element was cloned based on a limited sequence homology to the human T-cell leukemia virus and a related endogenous retroviral sequence, HRES-1. This repetitive element was found to constitute an integral part of the coding sequence of the human gene for transaldolase. In comparison with the intronless yeast gene, structural analysis of the human transaldolase genomic locus revealed that the human gene is comprised of five exons, second and third of which uniquely developed by insertion of a retrotransposable element. The 1329-base pair full-length cDNA, clone 4/2-4/1, contains an open reading frame coding for a protein of 336 amino acids with a predicted molecular mass of 38 kDa. This protein shows a 58% overall sequence homology with the 37-kDa yeast transaldolase. Antibodies raised against a 22-kDa recombinant polypeptide expressed from a 474-base pair 5' fragment of clone 4/2-4/1, containing repetitive exons 2 and 3, cross-reacted with yeast transaldolase and recognized the 38-kDa native human protein. Detection of a retrotransposon in the coding sequence of the human transaldolase gene demonstrates the importance of these repetitive elements in evolution of the eukaryotic genome.	SUNY HLTH SCI CTR,COLL MED,DEPT MED,750 E ADAMS ST,SYRACUSE,NY 13210; SUNY HLTH SCI CTR,COLL MED,DEPT MICROBIOL & IMMUNOL,SYRACUSE,NY 13210; SUNY HLTH SCI CTR,COLL MED,DEPT PATHOL,SYRACUSE,NY 13210	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center				Perl, Andras/0000-0002-5017-1348	NCRR NIH HHS [SO7 RR-05648-23] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005648] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BANKI K, 1992, P NATL ACAD SCI USA, V89, P1939, DOI 10.1073/pnas.89.5.1939; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROWL R, 1985, GENE, V38, P31, DOI 10.1016/0378-1119(85)90200-8; FANNING TG, 1987, BIOCHIM BIOPHYS ACTA, V910, P203, DOI 10.1016/0167-4781(87)90112-6; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HORECKER BL, 1953, J AM CHEM SOC, V75, P2021, DOI 10.1021/ja01104a532; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mayes P., 1993, HARPERS BIOCH, P201; PERL A, 1989, NUCLEIC ACIDS RES, V17, P6841, DOI 10.1093/nar/17.17.6841; Perl A, 1993, Trends Microbiol, V1, P153, DOI 10.1016/0966-842X(93)90131-A; PONTREMOLI S, 1961, P NATL ACAD SCI USA, V47, P1942, DOI 10.1073/pnas.47.12.1942; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; SAMBROOK J, 1987, MOL CLONING LABORATO; SCHAAFF I, 1990, EUR J BIOCHEM, V188, P597, DOI 10.1111/j.1432-1033.1990.tb15440.x; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; TEMIN HM, 1985, MOL BIOL EVOL, V2, P455; TSOLAS O, 1970, ARCH BIOCHEM BIOPHYS, V136, P287, DOI 10.1016/0003-9861(70)90353-X; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; [No title captured]	22	63	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2847	2851						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300619				2022-12-27	WOS:A1994MV43200073
J	JACKOWSKI, S; JACKSON, PD; ROCK, CO				JACKOWSKI, S; JACKSON, PD; ROCK, CO			SEQUENCE AND FUNCTION OF THE AAS GENE IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; DIAMINOPIMELATE DECARBOXYLASE SYNTHESIS; MEMBRANE-DERIVED OLIGOSACCHARIDES; COENZYME-A SYNTHETASE; NUCLEOTIDE-SEQUENCE; COA SYNTHETASE; FATTY-ACIDS; MOLECULAR CHARACTERIZATION; 2-ACYL LYSOPHOSPHOLIPIDS; TETRACYCLINE RESISTANCE	2-Acylglycerophosphoethanolamine (2-acyl-GPE) acyltransferase and acyl-acyl carrier protein (acyl-ACP) synthase activities are encoded by the aas gene in Escherichia coli. The aas gene was cloned, and the DNA sequence of the aas gene and the region between aas and galR established the clockwise gene order in the 61.2 min of the E. coli chromosome as aas-orf-galR-lysA-lysR-orf-araE. The aas gene consists of a single open reading frame of 2,157 base pairs predicted to encode a protein of 80.6 kDa. Strains harboring multiple copies of the aas gene overproduced both 2-acyl-GPE acyltransferase and acyl-ACP synthetase activities in vitro and had higher specific activities for the incorporation of exogenous fatty acids and lysophospholipids into the membrane in vivo. Specific expression of the aas gene yielded a protein with an apparent molecular mass of 81 kDa. Comparison of the predicted amino acid sequence of the aas gene with mammalian, yeast, and bacterial long chain acyl-coenzyme A synthetases revealed three domains of high similarity which are postulated to form the acyl-AMP binding pocket. These data verify that 2-acyl-GPE acyltransferase and acyl-ACP synthetase are reactions carried out by the same gene product, verify the role of 2-acyl-GPE acyltransferase/acyl-ACP synthetase in the acylation of endogenous 2-acyl-GPE, and establish the product of the aas gene as the rate-limiting enzyme in the uptake and incorporation of exogenous 2-acyllysophospholipids.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, 332 N LAUDERDALE ST, POB 318, MEMPHIS, TN 38101 USA; UNIV TENNESSEE CTR HLTH SCI, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center			Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NCI NIH HHS [CA21765] Funding Source: Medline; NIGMS NIH HHS [GM34496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBRIGHT FR, 1973, J BIOL CHEM, V248, P3968; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BLACK PN, 1992, J BIOL CHEM, V267, P25513; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCHNER BR, 1980, J BACTERIOL, V143, P926, DOI 10.1128/JB.143.2.926-933.1980; BOOTH BR, 1980, BIOCHEM BIOPH RES CO, V94, P1029, DOI 10.1016/0006-291X(80)90522-7; BOWIE LJ, 1978, METHOD ENZYMOL, V57, P15; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATTOPADHYAY PK, 1977, P NATL ACAD SCI USA, V74, P5318, DOI 10.1073/pnas.74.12.5318; COEN DMV, 1990, CURRENT PROTOCOLS MO; CONNERTON IF, 1990, MOL MICROBIOL, V4, P451, DOI 10.1111/j.1365-2958.1990.tb00611.x; COOPER CL, 1989, J BIOL CHEM, V264, P7384; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIRUSSO CC, 1985, J BACTERIOL, V161, P583, DOI 10.1128/JB.161.2.583-588.1985; DOI O, 1975, J BIOL CHEM, V250, P5208; DURONIO RJ, 1992, J CELL BIOL, V117, P515, DOI 10.1083/jcb.117.3.515; EGGEN RIL, 1991, J BACTERIOL, V173, P6383, DOI 10.1128/jb.173.20.6383-6389.1991; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; HEATON MP, 1992, J BACTERIOL, V174, P4707, DOI 10.1128/JB.174.14.4707-4717.1992; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOMMA H, 1981, BIOCHIM BIOPHYS ACTA, V663, P1, DOI 10.1016/0005-2760(81)90189-2; HOMMA H, 1982, J BIOCHEM, V91, P1103, DOI 10.1093/oxfordjournals.jbchem.a133792; HORI K, 1991, J BIOCHEM-TOKYO, V110, P111, DOI 10.1093/oxfordjournals.jbchem.a123528; HSU L, 1991, J BIOL CHEM, V266, P13783; HSU L, 1989, J BACTERIOL, V171, P1203, DOI 10.1128/jb.171.2.1203-1205.1989; JACKOWSKI S, 1986, J BIOL CHEM, V261, P1328; JENKINS LS, 1987, J BACTERIOL, V169, P42, DOI 10.1128/jb.169.1.42-52.1987; KARASAWA K, 1985, J BIOCHEM, V98, P1117, DOI 10.1093/oxfordjournals.jbchem.a135360; KOBAYASHI T, 1984, J BIOCHEM, V96, P137, DOI 10.1093/oxfordjournals.jbchem.a134805; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOLODRUBETZ D, 1981, J BACTERIOL, V148, P472, DOI 10.1128/JB.148.2.472-479.1981; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LOZOYA E, 1988, EUR J BIOCHEM, V176, P661, DOI 10.1111/j.1432-1033.1988.tb14328.x; MACCABE AP, 1991, J BIOL CHEM, V266, P12646; MAIDEN MCJ, 1988, J BIOL CHEM, V263, P8003; MALOY SR, 1981, J BACTERIOL, V145, P1110, DOI 10.1128/JB.145.2.1110-1111.1981; Maniatis T., 1982, MOL CLONING; MASUDA T, 1989, GENE, V77, P265; RAETZ CRH, 1979, J BACTERIOL, V137, P860, DOI 10.1128/JB.137.2.860-868.1979; ROCK CO, 1980, ANAL BIOCHEM, V102, P362, DOI 10.1016/0003-2697(80)90168-2; ROCK CO, 1984, J BIOL CHEM, V259, P6188; ROCK CO, 1979, J BIOL CHEM, V254, P7116; ROCK CO, 1985, J BIOL CHEM, V260, P2720; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHULMAN H, 1977, J BIOL CHEM, V252, P4250; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; STRAGIER P, 1983, J MOL BIOL, V168, P333, DOI 10.1016/S0022-2836(83)80022-9; STRAGIER P, 1983, J MOL BIOL, V168, P321, DOI 10.1016/S0022-2836(83)80021-7; STRAGIER P, 1983, J MOL BIOL, V168, P307, DOI 10.1016/S0022-2836(83)80020-5; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TABOR S, 1990, CURRENT PROTOCOLS MO; VONWILCKENBERGMANN B, 1982, P NATL ACAD SCI-BIOL, V79, P2427	52	58	62	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2921	2928						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300626				2022-12-27	WOS:A1994MV43200082
J	WULFING, C; LOMBARDERO, J; PLUCKTHUN, A				WULFING, C; LOMBARDERO, J; PLUCKTHUN, A			AN ESCHERICHIA-COLI PROTEIN CONSISTING OF A DOMAIN HOMOLOGOUS TO FK506-BINDING PROTEINS (FKBP) AND A NEW METAL-BINDING MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; CIS-TRANS-ISOMERASE; NUCLEOTIDE-SEQUENCE; CYCLOSPORINE-A; DNA FRAGMENTS; CYCLOPHILIN; OPERON; NICKEL; HYDROGENASE; AMPLIFICATION	Initially detected as a persistent contaminant in immobilized metal affinity chromatography of recombinant proteins in Escherichia coli, a 196-amino acid protein was isolated, cloned, overexpressed, and characterized. It consists of two domains, of which the first (146 amino acids) shows some homology to the FK506-binding proteins. The second domain (50 amino acids) is extremely rich in potentially metal-binding amino acids, such as histidine, cysteine, and acidic amino acids. The protein binds Ni2+ and Zn2+ tightly with 1:1 stoichiometry, Cu2+ and Co2+ with lower affinity, and Mn2+, Fe2+, Fe3+, Mg2+, and Ca2+ hardly at all.	MAX PLANCK INST BIOCHEM, PROT ENGN GRP, W-8033 MARTINSRIED, GERMANY	Max Planck Society			Plückthun, Andreas/C-2746-2009	Plückthun, Andreas/0000-0003-4191-5306				ARNOLD FH, 1991, BIO-TECHNOL, V9, P151, DOI 10.1038/nbt0291-151; BEVERIDGE TJ, 1989, METAL IONS BACTERIA, P1; BOHM R, 1990, MOL MICROBIOL, V4, P231, DOI 10.1111/j.1365-2958.1990.tb00590.x; BRENDEL V, 1984, NUCLEIC ACIDS RES, V12, P4411, DOI 10.1093/nar/12.10.4411; BRENT R, 1981, P NATL ACAD SCI-BIOL, V78, P4204, DOI 10.1073/pnas.78.7.4204; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; CONOVER RC, 1990, J AM CHEM SOC, V112, P4562, DOI 10.1021/ja00167a074; DIXON NE, 1975, J AM CHEM SOC, V97, P4131, DOI 10.1021/ja00847a045; EVANS HJ, 1987, ANNU REV MICROBIOL, V41, P335; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; GEBEYEHU G, 1987, NUCLEIC ACIDS RES, V15, P4513, DOI 10.1093/nar/15.11.4513; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HAUSINGER RP, 1987, MICROBIOL REV, V51, P22, DOI 10.1128/MMBR.51.1.22-42.1987; HAYANO T, 1991, BIOCHEMISTRY-US, V30, P3041, DOI 10.1021/bi00226a009; HIDALGO E, 1992, J BACTERIOL, V174, P4130, DOI 10.1128/jb.174.12.4130-4139.1992; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; ISHII SI, 1983, METHOD ENZYMOL, V91, P378; KAINZ P, 1992, ANAL BIOCHEM, V202, P46, DOI 10.1016/0003-2697(92)90203-J; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lindner Peter, 1992, Methods (Orlando), V4, P41, DOI 10.1016/1046-2023(92)90055-D; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; LUTZ S, 1991, MOL MICROBIOL, V5, P123, DOI 10.1111/j.1365-2958.1991.tb01833.x; MENON NK, 1990, J BACTERIOL, V172, P1969, DOI 10.1128/jb.172.4.1969-1977.1990; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERRY ACF, 1988, J BACTERIOL, V170, P1691, DOI 10.1128/jb.170.4.1691-1697.1988; PONCE MR, 1992, NUCLEIC ACIDS RES, V20, P623, DOI 10.1093/nar/20.3.623; PORATH J, 1987, BIOTECHNOL PROGR, V3, P14, DOI 10.1002/btpr.5420030104; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; PRZYBYLA AE, 1992, FEMS MICROBIOL LETT, V88, P109, DOI 10.1016/0378-1097(92)90687-J; ROOF WD, 1994, J BIOL CHEM, V269, P2902; Sambrook J, 1989, MOL CLONING LABORATO; SCHERER GFE, 1980, NUCLEIC ACIDS RES, V8, P3895, DOI 10.1093/nar/8.17.3895; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; Silver J., 1991, PCR PRACTICAL APPROA, P137; STORMO GD, 1982, NUCLEIC ACIDS RES, V10, P2971, DOI 10.1093/nar/10.9.2971; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; ZIMMER M, 1990, J AM CHEM SOC, V112, P1062, DOI 10.1021/ja00159a027; [No title captured]	44	127	132	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2895	2901						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300624				2022-12-27	WOS:A1994MV43200079
J	CHANDLER, P; PENNINGTON, M; MACCECCHINI, ML; NASHED, NT; SKOLNICK, P				CHANDLER, P; PENNINGTON, M; MACCECCHINI, ML; NASHED, NT; SKOLNICK, P			POLYAMINE-LIKE ACTIONS OF PEPTIDES DERIVED FROM CONANTOKIN-G, AN N-METHYL-D-ASPARTATE (NMDA) ANTAGONIST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR IONOPHORE COMPLEX; GAMMA-CARBOXYGLUTAMATE; PROTEIN CONFORMATION; RECOGNITION SITE; MODULATORY SITE; CHANNEL COMPLEX; MK-801 BINDING; GLYCINE SITE; ION CHANNEL; L-GLUTAMATE	Conantokins-T and -G are highly conserved polypeptides derived from Conus venoms. The N-methyl-D-aspartate (NMDA) antagonist properties of these compounds have been attributed to a potent noncompetitive inhibition of polyamine responses. Substitution of the highly conserved gamma-carboxyglutamate residues as well as modification of the N and C termini of conantokin-G abolished the inhibition of polyamine responses at the NMDA receptor complex. However, several of these modified polypeptides closely mimicked the neurochemical profile of polyamines at the NMDA receptor complex. One of these derivatives, Tyr0-conantokin-G, was found to be the most potent compound exhibiting polyamine-like actions at the NMDA receptor complex described to date, approximately 7-fold more potent than spermine. Circular dichroism studies demonstrate a significant alpha-helical content in conantokin-G (27% in aqueous medium). However, this alpha-helicity is not sufficient for the NMDA antagonist action of the parent peptide and is neither necessary nor sufficient for the polyamine-like behavior of several conantokin-G analogs. The modified conantokin-G derivatives described in this report should be useful probes for examining the role of both polyamines and the polyamine recognition site in the operation of the NMDA receptor complex.	NIDDK,NEUROSCI LAB,BLDG 8,RM 111,BETHESDA,MD 20892; NIDDK,BIOORGAN LAB,BETHESDA,MD 20892; BACHEM BIOSCI,PHILADELPHIA,PA 19104	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				pennington, michael/0000-0001-5446-3447				CARTER CJ, 1990, J PHARMACOL EXP THER, V253, P475; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; FINK J, 1989, INT J PEPT PROT RES, V33, P412; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HAACK JA, 1990, J BIOL CHEM, V265, P6025; HERNANDEZ JF, 1990, J CELL BIOL C, V14, P242; HOOD WF, 1989, NEUROSCI LETT, V98, P91, DOI 10.1016/0304-3940(89)90379-0; HORI T, 1991, SYNAPSE, V8, P13, DOI 10.1002/syn.890080103; JOHNSON KM, 1989, DRUG DEVELOP RES, V17, P281, DOI 10.1002/ddr.430170405; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KEMP JA, 1988, P NATL ACAD SCI USA, V85, P6547, DOI 10.1073/pnas.85.17.6547; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; LONDON ED, 1991, NMDA RECEPTOR RELATED AGENTS : BIOCHEMISTRY, PHARMACOLOGY AND BEHAVIOR, P71; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; MENA EE, 1990, NEUROSCI LETT, V118, P241, DOI 10.1016/0304-3940(90)90637-O; MYERS RA, 1990, J TOXICOL-TOXIN REV, V9, P179, DOI 10.3109/15569549009033113; NUSSENZVEIG IZ, 1991, BRAIN RES, V561, P285, DOI 10.1016/0006-8993(91)91606-2; OLIVERA BM, 1991, J BIOL CHEM, V266, P22067; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PULLAN LM, 1992, J NEUROCHEM, V59, P2087; RANSOM RW, 1988, J NEUROCHEM, V51, P830, DOI 10.1111/j.1471-4159.1988.tb01818.x; REYNOLDS IJ, 1990, EUR J PHARMACOL, V177, P215, DOI 10.1016/0014-2999(90)90274-A; REYNOLDS IJ, 1987, P NATL ACAD SCI USA, V84, P7744, DOI 10.1073/pnas.84.21.7744; REYNOLDS IJ, 1989, MOL PHARMACOL, V36, P758; REYNOLDS IJ, 1990, J PHARMACOL EXP THER, V255, P1001; RIVIER J, 1987, BIOCHEMISTRY-US, V26, P8508, DOI 10.1021/bi00400a002; ROCK DM, 1992, MOL PHARMACOL, V41, P83; ROMANO C, 1992, MOL PHARMACOL, V41, P785; SACAAN AI, 1990, MOL PHARMACOL, V37, P572; SACAAN AI, 1990, MOL PHARMACOL, V38, P705; SACAAN AI, 1991, NEUROSCI LETT, V121, P219, DOI 10.1016/0304-3940(91)90689-Q; SAKAKIBARA S, 1967, B CHEM SOC JPN, V40, P2164, DOI 10.1246/bcsj.40.2164; SIRCAR R, 1991, BRAIN RES, V556, P280, DOI 10.1016/0006-8993(91)90316-N; SKOLNICK P, 1992, J NEUROCHEM, V59, P1516, DOI 10.1111/j.1471-4159.1992.tb08468.x; WATSON GB, 1990, NEUROPHARMACOLOGY, V29, P727, DOI 10.1016/0028-3908(90)90125-B; WILLIAMS K, 1990, NEURON, V5, P199, DOI 10.1016/0896-6273(90)90309-4; WILLIAMS K, 1991, LIFE SCI, V48, P469, DOI 10.1016/0024-3205(91)90463-L; WONG EHF, 1988, J NEUROCHEM, V50, P274, DOI 10.1111/j.1471-4159.1988.tb13260.x; YANG JT, 1986, METHOD ENZYMOL, V130, P208	39	48	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17173	17178						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349604				2022-12-27	WOS:A1993LQ98800046
J	DELANEROLLE, P; GORGAS, G; LI, XQ; SCHLUNS, K				DELANEROLLE, P; GORGAS, G; LI, XQ; SCHLUNS, K			MYOSIN LIGHT-CHAIN PHOSPHORYLATION DOES NOT INCREASE DURING YEAST PHAGOCYTOSIS BY MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RECEPTOR MEDIATED PHAGOCYTOSIS; ACTIN-BINDING PROTEIN; SMOOTH-MUSCLE; CELL MOTILITY; F-ACTIN; POLYMERIZATION; CONFORMATION; LOCOMOTION; INHIBITOR; KINASE	We have studied the role of myosin II light chain phosphorylation in yeast phagocytosis by J774 cells. J774 cells, which are mouse cells of monocyte/macrophage lineage, ingest opsonized yeast particles, and the rate of internalization is linear for 60 min at 37-degrees-C. Immunoprecipitation of myosin II from cells labeled with P-32, using an affinity-purified antibody to myosin II purified from J774 cells, demonstrated phosphorylation of both the myosin heavy chain and the 20-kDa light chain (PMLC) prior to the addition of the opsonized yeast. However, the levels of heavy chain and PMLC phosphorylation did not change during the linear phase of yeast uptake by J774 cells. Other experiments demonstrated that the amount of myosin II associated with the cytoskeleton did not change during phagocytosis, further supporting the observation that PMLC phosphorylation does not increase during phagocytosis. In contrast, F-actin increased by 1.6-fold during the linear phase of phagocytosis. Two additional approaches were used to analyze in greater detail the role of myosin II phosphorylation in phagocytosis. First, antibodies to myosin light chain kinase (MLCK), the enzyme that phosphorylates PMLC, were electroinjected into J774 cells. These antibodies, which inhibit MLCK activity, inhibited chemotaxis as previously described but had no effect on phagocytosis. Second, quantitation of phagocytosis and chemotaxis following treatment with the phosphoprotein phosphatase inhibitor okadaic acid demonstrated that chemotaxis was much more sensitive than phagocytosis to okadaic acid treatment; at 0.3 muM okadaic acid, there is a substantial increase in myosin phosphorylation and chemotaxis is inhibited by 60%, whereas phagocytosis is unaffected. These data indicate that PMLC phosphorylation and, by implication, myosin II are not involved in yeast phagocytosis. They also suggest that PMLC phosphorylation displays a high degree of specificity with respect to mediating energy-dependent cellular processes in macrophages.			DELANEROLLE, P (corresponding author), UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,901 S WOLCOTT AVE M-C 901,CHICAGO,IL 60612, USA.		Schluns, Kimberly/R-5635-2019		NHLBI NIH HHS [HL 02411, HL 35808] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002411, R01HL035808] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELSTEIN RS, 1983, J CLIN INVEST, V72, P1863, DOI 10.1172/JCI111148; BARYLKO B, 1992, P NATL ACAD SCI USA, V89, P490, DOI 10.1073/pnas.89.2.490; BEMENT WM, 1992, MOL BIOL CELL, V3, pA156; BOURGUIGNON LYW, 1981, J CELL BIOL, V91, P889, DOI 10.1083/jcb.91.3.889; CLERC P, 1987, INFECT IMMUN, V55, P2681, DOI 10.1128/IAI.55.11.2681-2688.1987; CRAIG R, 1983, NATURE, V302, P436, DOI 10.1038/302436a0; DABIRI GA, 1990, P NATL ACAD SCI USA, V87, P6068, DOI 10.1073/pnas.87.16.6068; DELANEROLLE P, 1981, P NATL ACAD SCI-BIOL, V78, P4738; DELANEROLLE P, 1991, AM J PHYSIOL, V261, pL1, DOI 10.1152/ajplung.1991.261.2.L1; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; GREENBERG S, 1991, J CELL BIOL, V113, P757, DOI 10.1083/jcb.113.4.757; HOWARD TH, 1985, CELL MOTIL CYTOSKEL, V5, P545, DOI 10.1002/cm.970050609; KITAZUMI K, 1992, BIOCHEM PHARMACOL, V43, P1701, DOI 10.1016/0006-2952(92)90699-J; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KOLOTILA MP, 1988, INFECT IMMUN, V56, P2016, DOI 10.1128/IAI.56.8.2016-2022.1988; KORN ED, 1988, ANNU REV BIOPHYS BIO, V17, P23; KORN ED, 1978, P NATL ACAD SCI USA, V75, P588, DOI 10.1073/pnas.75.2.588; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MABUCHI I, 1977, J CELL BIOL, V74, P251, DOI 10.1083/jcb.74.1.251; OHARAIMAIZUMI M, 1992, BIOCHEM BIOPH RES CO, V185, P1016, DOI 10.1016/0006-291X(92)91728-9; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; RALPH P, 1975, NATURE, V257, P393, DOI 10.1038/257393a0; SNYDERMAN R, 1977, J IMMUNOL, V119, P2060; SNYDERMAN R, 1988, INFLAMMATION BASIC P, P309; STENDAHL OI, 1980, J CELL BIOL, V84, P215, DOI 10.1083/jcb.84.2.215; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; VALERIUS NH, 1981, CELL, V24, P195, DOI 10.1016/0092-8674(81)90515-8; WESSELS D, 1990, J CELL BIOL, V111, P1137, DOI 10.1083/jcb.111.3.1137; WILSON AK, 1992, CANCER METAST REV, V11, P79, DOI 10.1007/BF00047605; WILSON AK, 1991, J CELL BIOL, V114, P277, DOI 10.1083/jcb.114.2.277; WILSON AK, 1991, AM J PHYSIOL, V260, pC355, DOI 10.1152/ajpcell.1991.260.2.C355; WILSON AK, 1991, AM J PHYSIOL, V260, pL105, DOI 10.1152/ajplung.1991.260.2.L105; ZIGMOND SH, 1972, EXP CELL RES, V73, P383, DOI 10.1016/0014-4827(72)90062-6	38	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16883	16886						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349578				2022-12-27	WOS:A1993LQ98800004
J	HAYASHI, I; HOSHIKO, S; MAKABE, O; OHISHI, S				HAYASHI, I; HOSHIKO, S; MAKABE, O; OHISHI, S			A POINT MUTATION OF ALANINE-163 TO THREONINE IS RESPONSIBLE FOR THE DEFECTIVE SECRETION OF HIGH-MOLECULAR-WEIGHT KININOGEN BY THE LIVER OF BROWN-NORWAY KATHOLIEK RATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-ANTITRYPSIN DEFICIENCY; ACUTE-INFLAMMATION; PLASMA KALLIKREIN; INHIBITOR; STRAIN; SYSTEM; ACID	To clarify the mechanism of the secretion defect of high molecular weight kininogen (HK) and low molecular weight kininogen (LK) by the liver of Brown Norway (B/N) Katholiek rats causing plasma kininogen deficiency, we cloned cDNAs for HK from cDNA libraries of the livers of B/N Katholiek and B/N Kitasato rats. A point mutation of G to A at nucleotide 487 was found in the cDNA of B/N Katholiek rats by sequence analysis of the cDNAs (including the entire HK-coding region) obtained from both strains. Both B/N Katholiek and B/N Kitasato rat cDNA fragments were introduced into a eukaryotic vector, pRc/CMV, to construct their respective expression plasmid, which was used to transfect COS-1 cells. At 24 h of incubation, the culture medium of COS-1 cells transfected with the B/N Katholiek rat cDNA contained only 10% of the HK antigen that was found in COS-1 cells transfected with the B/N Kitasato rat cDNA. More HK antigen was retained in the former cells. Moreover, cells transfected with B/N Katholiek rat cDNA, in which the A at nucleotide 487 was artificially replaced by G, secreted a significant amount of HK into the medium. These results suggest that a point mutation of G to A at nucleotide 487, which causes a substitution of Ala163 to Thr in the heavy chain of HK and LK, is responsible for the defective secretion of HK and LK by the liver of B/N Katholiek rats.	KITASATO UNIV,SCH PHARMACEUT SCI,DEPT PHARMACOL,5-9-1 SHIROKANE,MINATO KU,TOKYO 108,JAPAN; MEIJI SEIKA KAISHA LTD,PHARMACEUT RES CTR,KOHOKU KU,YOKOHAMA,KANAGAWA 222,JAPAN	Kitasato University; Meiji Holdings Co., Ltd.								BRANTLY M, 1988, AM J MED, V84, P13; CHEUNG PP, 1991, BLOOD S, V78, pA391; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; CURIEL DT, 1989, J BIOL CHEM, V264, P10477; DAMAS J, 1980, EXPERIENTIA, V36, P586, DOI 10.1007/BF01965817; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELGNER PL, 1989, P NATL ACAD SCI USA, V82, P7413; FUNG WP, 1988, THROMB RES, V50, P113, DOI 10.1016/0049-3848(88)90179-X; FURUTOKATO S, 1985, J BIOL CHEM, V260, P2054; HAYASHI H, 1990, BLOOD, V75, P1296; HAYASHI I, 1993, J BIOCHEM-TOKYO, V113, P531, DOI 10.1093/oxfordjournals.jbchem.a124078; HAYASHI I, 1989, THROMB RES, V56, P179, DOI 10.1016/0049-3848(89)90160-6; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMES MD, 1990, BIOCHEM BIOPH RES CO, V170, P1013, DOI 10.1016/0006-291X(90)90493-7; KITAGAWA H, 1987, J BIOL CHEM, V262, P2190; LATTION AL, 1988, FEBS LETT, V239, P59, DOI 10.1016/0014-5793(88)80545-3; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MIURA O, 1989, J BIOL CHEM, V264, P18213; OHISHI S, 1986, AGENTS ACTIONS, V18, P450, DOI 10.1007/BF01965011; OHISHI S, 1982, THROMB RES, V28, P143, DOI 10.1016/0049-3848(82)90043-3; OHISHI S, 1987, AGENTS ACTIONS, V21, P384, DOI 10.1007/BF01966523; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463	25	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17219	17224						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349607				2022-12-27	WOS:A1993LQ98800053
J	CHAVAN, AJ; ENSOR, CM; WU, P; HALEY, BE; TAI, HH				CHAVAN, AJ; ENSOR, CM; WU, P; HALEY, BE; TAI, HH			PHOTOAFFINITY-LABELING OF HUMAN PLACENTAL NAD+-LINKED 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE WITH [ALPHA-P-32]2N3NAD+ - IDENTIFICATION OF A PEPTIDE IN THE ADENINE RING BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCOHOL; PROTEIN; SITE; PURIFICATION; PREDICTION; ENZYME; FAMILY; KINASE; ATP	Oxidation of many prostaglandins at C-15 results in the formation of 15-keto metabolites, which have reduced biological activity. This reaction is catalyzed by NAD+-dependent 15-hydroxyprostaglandin dehydrogenase. Using the photoaffinity analog of NAD+, [alpha-P-32]nicotinamide-2-azidoadenine dinucleotide, we have identified a peptide in the adenine ring binding domain of the NAD+ binding site of 15-hydroxyprostaglandin dehydrogenase. The specificity of photolabeling was demonstrated by saturation and protection experiments. Saturation of photolabeling was observed at approximately 45-50 muM with an apparent K(d) of 8-10 muM. Approximately 90% of photolabeling could be protected by 200 muM NAD+ when the protein was photolyzed in the presence of 10 muM probe. The photolabeled protein was digested with Staphylococcus aureus V8 or chymotrypsin, and the photolabeled peptides were purified by either boronate affinity chromatography or Fe+3 chelate chromatography followed by reverse phase HPLC. The photolabeled peptide region was identified to be Val32-Glu40.	UNIV KENTUCKY, COLL PHARM, DIV MED CHEM & PHARMACEUT, LEXINGTON, KY 40536 USA	University of Kentucky				Ensor, Mark/0000-0003-3065-688X	NHLBI NIH HHS [HL-46296] Funding Source: Medline; NIGMS NIH HHS [GM-35766] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035766] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGGARD E, 1966, ACTA PHYSIOL SCAND, V66, P509, DOI 10.1111/j.1748-1716.1966.tb03231.x; ANGGARD E, 1964, J BIOL CHEM, V239, P4097; BRAITHWAITE SS, 1975, J BIOL CHEM, V250, P2315; CHAVAN AJ, 1992, J BIOL CHEM, V267, P14866; Chavan AJ, 1990, BIOCONJUGATE CHEM, V1, P337, DOI 10.1021/bc00005a007; ENSOR CM, 1990, J BIOL CHEM, V265, P14888; ENSOR CM, 1991, PROSTAGLANDINS LEUKO, P39; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; HALEY BE, 1991, METHOD ENZYMOL, V200, P477; HONES J, 1987, FEBS LETT, V212, P193, DOI 10.1016/0014-5793(87)81343-1; JORNVALL H, 1981, P NATL ACAD SCI-BIOL, V78, P4226, DOI 10.1073/pnas.78.7.4226; KIM H, 1991, BIOCONJUGATE CHEM, V2, P142, DOI 10.1021/bc00009a002; KNOLL DA, 1992, BIOCHIM BIOPHYS ACTA, V1121, P252, DOI 10.1016/0167-4838(92)90154-6; KROOK M, 1990, BIOCHEMISTRY-US, V29, P738, DOI 10.1021/bi00455a021; MIMURA CS, 1990, J BIOL CHEM, V265, P19535; PERSSON B, 1991, EUR J BIOCHEM, V200, P537, DOI 10.1111/j.1432-1033.1991.tb16215.x; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SALVUCCI ME, 1992, BIOCHEMISTRY-US, V31, P4479, DOI 10.1021/bi00133a014; SHOEMAKER MT, 1993, BIOCHEMISTRY-US, V32, P1883, DOI 10.1021/bi00058a023; Thatcher D.R., 1980, Biochemical Journal, V187, P884; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; XUN CQ, 1991, BIOCHEM J, V279, P553, DOI 10.1042/bj2790553	23	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16437	16442						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344929				2022-12-27	WOS:A1993LQ33600053
J	ITO, W; IBA, Y; KUROSAWA, Y				ITO, W; IBA, Y; KUROSAWA, Y			EFFECTS OF SUBSTITUTIONS OF CLOSELY-RELATED AMINO-ACIDS AT THE CONTACT SURFACE IN AN ANTIGEN-ANTIBODY COMPLEX ON THERMODYNAMIC PARAMETERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; MONOCLONAL-ANTIBODY; PHAGE-LAMBDA; BINDING; REPERTOIRE; D1.3; DNA; FV; RESOLUTION	We constructed a library of 512 kinds of Fv fragment, derivatives of a monoclonal antibody, D1.3, specific for hen egg-white lysozyme, in which a total of nine of the original amino acids were replaced by closely related amino acids at positions in the complementarity-determining regions of the H chain. More than 80% of the clones in the library produced Fv fragments in Escherichia coli. Two wild-type and 13 mutant Fv fragments were prepared in large quantities and subjected to analysis by differential titration calorimetry. The association constants of the 15 Fv fragments with hen egg-white lysozyme were distributed between 0.12 x 10(7) and 1.59 x 10(8) M-1. The changes in DELTAH-0 and -TDELTAS0 caused by one-point mutation at each position did not have intrinsic values for each change. The same changes at one position had different effects on K(A), DELTAH-0, and -TDELTAS0 when differences had been introduced in other regions. The DELTA(DELTAG0) caused by a single-point mutation ranged from -0.56 to 1.56 kcal/mol. By contrast, the DELTA(DELTAH-0) and DELTA(-TDELTAS0) caused by a single-point mutation ranged from -3.5 to 3.4 and from -3.8 to 3.4 kcal/mol, respectively. When antibodies gain the binding energy contributed by the effects of enthalpy, they lose the binding energy contributed by the effects of entropy and vice versa. In general, changes in entropy compensate for changes in enthalpy.	FUJITA HLTH UNIV,INST COMPREHENS MED SCI,TOYOAKE,AICHI 47011,JAPAN	Fujita Health University				Ito, Wataru/0000-0002-5631-8267				AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; AUSUBEL FM, 1989, CURRENT PROTOCOLS MO, pCH10; BEREK C, 1988, IMMUNOL REV, V105, P5, DOI 10.1111/j.1600-065X.1988.tb00763.x; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BOULOT G, 1990, J MOL BIOL, V213, P617, DOI 10.1016/S0022-2836(05)80248-7; CHEETHAM JC, 1991, P NATL ACAD SCI USA, V88, P7968, DOI 10.1073/pnas.88.18.7968; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DAVIES DR, 1988, J BIOL CHEM, V263, P10541; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; FINKELSTEIN AV, 1989, PROTEIN ENG, V3, P1, DOI 10.1093/protein/3.1.1; FISCHMANN TO, 1991, J BIOL CHEM, V266, P12915; FOOTE J, 1992, J MOL BIOL, V224, P487, DOI 10.1016/0022-2836(92)91010-M; GRONENBORN B, 1976, MOL GEN GENET, V148, P243, DOI 10.1007/BF00332898; HARLOW E, 1988, ANTIBODIES LABORATOR, P513; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; Kabat EA, 1991, SEQUENCES PROTEINS I; LEI SP, 1987, J BACTERIOL, V169, P4379, DOI 10.1128/jb.169.9.4379-4383.1987; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; Miller J. H., 1972, EXPT MOL GENETICS, P431; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; OGASAHARA K, 1992, J BIOL CHEM, V267, P5222; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; RIALDI G, 1984, MOL IMMUNOL, V21, P945, DOI 10.1016/0161-5890(84)90151-2; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; ROBERTS S, 1987, NATURE, V328, P731, DOI 10.1038/328731a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SIGURSKJOLD BW, 1991, EUR J BIOCHEM, V197, P239, DOI 10.1111/j.1432-1033.1991.tb15904.x; SIGURSKJOLD BW, 1992, J BIOL CHEM, V267, P8371; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	39	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16639	16647						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344944				2022-12-27	WOS:A1993LQ33600080
J	OBRIG, TG; LOUISE, CB; LINGWOOD, CA; BOYD, B; BARLEYMALONEY, L; DANIEL, TO				OBRIG, TG; LOUISE, CB; LINGWOOD, CA; BOYD, B; BARLEYMALONEY, L; DANIEL, TO			ENDOTHELIAL HETEROGENEITY IN SHIGA TOXIN RECEPTORS AND RESPONSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOLYTIC-UREMIC SYNDROME; TUMOR-NECROSIS-FACTOR; ESCHERICHIA-COLI; GLYCOLIPID GLOBOTRIOSYLCERAMIDE; SHIGELLA TOXIN; CELLS INVITRO; GLOBOTRIAOSYLCERAMIDE; IDENTIFICATION; LIPOPOLYSACCHARIDE; PATHOGENESIS	This study addresses the basis for regional microvascular susceptibility to bacterial toxins implicated in hemolytic uremic syndrome. The results indicate a relationship between the degree of Shiga toxin sensitivity of human endothelial cells from different sources and the amount of globotriaosylceramide (Gb3) glycosphingolipid receptor for Shiga toxin expressed by these cells. Cell viability and protein synthesis of renal endothelial cells were reduced to 50% by 1 pM Shiga toxin, while umbilical vein cells were not affected by >1 nM toxin. Similarly, basal levels of Gb3 were approximately 50 times higher in renal endothelial cells than in the umbilical endothelial cells. Pre-exposure of umbilical endothelial cells to tumor necrosis factor-alpha or bacterial lipopolysaccharide increased Gb3 content 4-6-fold coincident with increases in sensitivity to cytotoxic and protein synthesis inhibitory effects of Shiga toxin. Lipopolysaccharide induction of both Gb3 and sensitivity to Shiga toxin cytotoxic action in umbilical endothelial cells was dependent on the structure of lipopolysaccharide. Neither tumor necrosis factor-alpha nor lipopolysaccharide altered the Shiga toxin sensitivity or the Gb3 content of renal endothelial cells. These data indicate that differential endothelial expression of glycolipid receptors for Shiga toxins may be responsible for localized involvement of the kidney in hemolytic uremic syndrome.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT MED,DIV NEPHROL,MCN 53223,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232; UNIV ROCHESTER,SCH MED & DENT,DEPT MICROBIOL & IMMUNOL,ROCHESTER,NY 14642; HOSP SICK CHILDREN,DEPT MICROBIOL,TORONTO M5G 1X8,ONTARIO,CANADA	Vanderbilt University; Vanderbilt University; University of Rochester; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI024431, R01AI024431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039261, R01DK038517] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24431] Funding Source: Medline; NIDDK NIH HHS [P50-DK39261, R01-DK38517] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BITZAN M, 1991, J PEDIATR-US, V119, P380, DOI 10.1016/S0022-3476(05)82049-9; BOYD B, 1989, NEPHRON, V51, P207, DOI 10.1159/000185286; ENDO Y, 1988, EUR J BIOCHEM, V171, P45, DOI 10.1111/j.1432-1033.1988.tb13756.x; HABIB R, 1992, HEMOLYTIC UREMIC SYN, P315; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; JACEWICZ M, 1986, J EXP MED, V163, P1391, DOI 10.1084/jem.163.6.1391; KAPLAN BS, 1990, PEDIATR NEPHROL, V4, P276, DOI 10.1007/BF00857676; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; KARMALI MA, 1989, CLIN MICROBIOL REV, V2, P15, DOI 10.1128/CMR.2.1.15-38.1989; KONOWALCHUK J, 1977, INFECT IMMUN, V18, P775, DOI 10.1128/IAI.18.3.775-779.1977; KOSTER F, 1978, NEW ENGL J MED, V298, P927, DOI 10.1056/NEJM197804272981702; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; LINGWOOD CA, 1993, IN PRESS ADV LIPID R, V25; LOUISE CB, 1992, INFECT IMMUN, V60, P1536, DOI 10.1128/IAI.60.4.1536-1543.1992; LOUISE CB, 1991, INFECT IMMUN, V59, P4173, DOI 10.1128/IAI.59.11.4173-4179.1991; NAIKI M, 1974, BIOCHEM BIOPH RES CO, V60, P1105, DOI 10.1016/0006-291X(74)90426-4; OBRIG TG, 1988, INFECT IMMUN, V56, P2373, DOI 10.1128/IAI.56.9.2373-2378.1988; OBRIG TG, 1987, BIOCHEM J, V244, P287, DOI 10.1042/bj2440287; Obrig TG, 1992, HEMOLYTIC UREMIC SYN, P405; PUDYMAITIS A, 1991, ARCH BIOCHEM BIOPHYS, V286, P448, DOI 10.1016/0003-9861(91)90064-P; REISBIG R, 1981, J BIOL CHEM, V256, P8739; RICHARDSON SE, 1988, HUM PATHOL, V19, P1102, DOI 10.1016/S0046-8177(88)80093-5; RIDDELL RR, FOOD CHEM TOXICOL, V24, P469; SAKAKIBARA N, 1991, CANCER LETT, V57, P187, DOI 10.1016/0304-3835(91)90155-B; SAMUEL JE, 1990, INFECT IMMUN, V58, P611, DOI 10.1128/IAI.58.3.611-618.1990; TANIGUCHI N, 1985, J BIOL CHEM, V260, P4908; TESH VL, 1991, J INFECT DIS, V164, P344, DOI 10.1093/infdis/164.2.344; VANDEKAR NCAJ, 1992, BLOOD, V80, P2755; WADDELL T, 1990, P NATL ACAD SCI USA, V87, P7898, DOI 10.1073/pnas.87.20.7898; WADDELL T, 1988, BIOCHEM BIOPH RES CO, V152, P674, DOI 10.1016/S0006-291X(88)80091-3; WADOLKOWSKI EA, 1990, INFECT IMMUN, V58, P3959, DOI 10.1128/IAI.58.12.3959-3965.1990; WOJTA J, 1989, J BIOL CHEM, V264, P2846; Zoja C., 1992, HEMOLYTIC UREMIC SYN, P389	34	250	258	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15484	15488						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340376				2022-12-27	WOS:A1993LN30500027
J	WANG, K; BOHREN, KM; GABBAY, KH				WANG, K; BOHREN, KM; GABBAY, KH			CHARACTERIZATION OF THE HUMAN ALDOSE REDUCTASE GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE VAS-DEFERENS; DIABETIC COMPLICATIONS; TRANSCRIPTION FACTORS; MEDULLARY CELLS; BINDING-PROTEIN; DNA-REPLICATION; EXPRESSION; SORBITOL; SEQUENCE; CLONING	The promoter region of the human aldose reductase gene has been identified upstream of the translation start ATG codon. The promoter contains a TATA box, a CCAAT promoter element, and three Sp1 protein binding consensus sequences upstream of the capsite. A 640-base pair insert spanning +31 to -609 directs expression of the reporter gene chloramphenicol acetyltransferase in an orientation-specific manner in transfected Hep G2 cells. The promoter activity remained constant with deletions from base pairs -609 to -186. The TATA and the CCAAT consensus sequences show significant promoter activity, whereas the three Sp1 binding consensus sequences, individually, have no significant promoter activity. A GA-rich region (-186 to -146) contains two CGGAAA/G motifs, which show promoter activity and interaction with Hep G2 nuclear extract and GA-binding proteins (GABPalpha and GABPbeta1) as shown by mobility shift assays and DNase I footprinting. Similar cis-elements in herpes simplex virus type 1 interact with rat liver GABP and the viral VP16 protein to mediate the induction of immediate early viral genes. A GC-rich region (87 to -31) is identified by mobility shift assay, and a consensus sequence of an androgen response element is present at -396 to -382. The human aldose reductase promoter, thus, has regulatory response elements that may be important during early development and puberty. These regulatory elements may play a significant role in the development of certain diabetic complications.	BAYLOR COLL MED,DIABET RES CTR,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine	WANG, K (corresponding author), BAYLOR COLL MED,DIABET RES CTR,DEPT PEDIAT,HOUSTON,TX 77030, USA.			Bohren, Kurt/0000-0002-3183-4118	NIDDK NIH HHS [DK-39044] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039044] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, 1988, MOL REPROD DEV; BAGNASCO SM, 1987, P NATL ACAD SCI USA, V84, P1718, DOI 10.1073/pnas.84.6.1718; BAGNASCO SM, 1988, AM J PHYSIOL, V254, pC788, DOI 10.1152/ajpcell.1988.254.6.C788; BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BOHREN KM, 1991, 1991 US JAP ALD RED; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DVORNIK D, 1973, SCIENCE, V182, P1146, DOI 10.1126/science.182.4117.1146; DVORNIK D, 1987, ALDOSE REDUCTASE INH, P153; GABBAY KH, 1966, SCIENCE, V151, P209, DOI 10.1126/science.151.3707.209; GABBAY KH, 1968, DIABETES, V17, P239, DOI 10.2337/diab.17.5.239; GABBAY KH, 1973, NEW ENGL J MED, V288, P831, DOI 10.1056/NEJM197304192881609; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; GHOSH D, 1990, NUCLEIC ACIDS RES, V18, P1749, DOI 10.1093/nar/18.7.1749; GRAHAM A, 1991, J BIOL CHEM, V266, P6872; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; Higuchi R., 1989, PCR TECHNOLOGY, P61; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADOR PF, 1988, MED RES REV, V8, P325, DOI 10.1002/med.2610080302; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KINOSHIT.JH, 1974, INVEST OPHTH VISUAL, V13, P713; KINOSHITA JH, 1979, METABOLISM, V28, P462, DOI 10.1016/0026-0495(79)90057-X; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LAMARCO KL, 1989, GENE DEV, V3, P1372, DOI 10.1101/gad.3.9.1372; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MEISTERERNST M, 1988, NUCLEIC ACIDS RES, V16, P4419, DOI 10.1093/nar/16.10.4419; NUSSINOV R, 1990, CRIT REV BIOCHEM MOL, V25, P185, DOI 10.3109/10409239009090609; PAILHOUX E, 1992, J STEROID BIOCHEM, V42, P561, DOI 10.1016/0960-0760(92)90445-O; PAILHOUX EA, 1990, J BIOL CHEM, V265, P19932; PEEK R, 1992, DEV BIOL, V152, P152, DOI 10.1016/0012-1606(92)90165-D; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHWARTZ GJ, 1992, J CLIN INVEST, V90, P1275, DOI 10.1172/JCI115991; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; UCHIDA S, 1989, AM J PHYSIOL, V256, pC614, DOI 10.1152/ajpcell.1989.256.3.C614	41	70	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					16052	16058						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340427				2022-12-27	WOS:A1993LN30500101
J	ZENZIEGREGORY, B; SHERIDAN, P; JONES, KA; SMALE, ST				ZENZIEGREGORY, B; SHERIDAN, P; JONES, KA; SMALE, ST			HIV-1 CORE PROMOTER LACKS A SIMPLE INITIATOR ELEMENT BUT CONTAINS A BIPARTITE ACTIVATOR AT THE TRANSCRIPTION START SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; TAT GENE-PRODUCT; MESSENGER-RNA; MUTATIONAL ANALYSIS; TRANS-ACTIVATION; EXPRESSION; SEQUENCES; PROTEINS; CELLS	The human immunodeficiency virus type 1 (HIV-1) core promoter region, extending approximately from nucleotides -40 to +80 relative to the transcription start site, contains a complex array of putative regulatory elements, including a TATA box, an initiator element, an element between the TATA box and start site, binding sites for LBP/UBP, the TAR element, and others. However, because of this elaborate architecture, the precise boundaries and functional roles for the individual regulatory elements have not been defined. To facilitate a detailed analysis of the HIV-1 core promoter, we employed in vitro transcription assays to identify the simplest control elements that activate RNA synthesis in the context of a synthetic, heterologous promoter. Because mutations at the start site previously were shown to diminish transcription, we anticipated finding an initiator as a basic regulator. However, we have demonstrated that the HIV-1 core promoter lacks an initiator that is functionally analogous to those found in the terminal transferase and adenovirus major late promoters. In its place, we identified two elements between -6 and +30, both of which appear to be necessary for significant transcriptional activation. Unlike a strong initiator, the activity of these elements was dependent on the presence of a TATA box and on their position relative to TATA. We have called the region containing these two elements the HIV-1 SSR to distinguish it from the simple transcriptional initiator elements found in other genes.	UNIV CALIF LOS ANGELES,SCH MED,HOWARD HUGHES MED INST,INST MOLEC BIOL,MACDONALD RES LABS 5748,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024; SALK INST BIOL STUDIES,LA JOLLA,CA 92037	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Salk Institute					NIDDK NIH HHS [DK-43726] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043726, R01DK043726] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYER DE, 1988, MOL CELL BIOL, V8, P2021, DOI 10.1128/MCB.8.5.2021; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; GARCIA JA, 1987, EMBO J, V6, P3761, DOI 10.1002/j.1460-2075.1987.tb02711.x; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HAUBER J, 1987, P NATL ACAD SCI USA, V84, P6364, DOI 10.1073/pnas.84.18.6364; HAUBER J, 1988, J VIROL, V62, P673, DOI 10.1128/JVI.62.3.673-679.1988; JAKOBOVITS A, 1988, MOL CELL BIOL, V8, P2555, DOI 10.1128/MCB.8.6.2555; JONES K A, 1989, New Biologist, V1, P127; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KLIEWER S, 1989, J VIROL, V63, P4616, DOI 10.1128/JVI.63.11.4616-4625.1989; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LU YC, 1989, J VIROL, V63, P4115, DOI 10.1128/JVI.63.9.4115-4119.1989; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OKAMOTO T, 1986, CELL, V47, P29, DOI 10.1016/0092-8674(86)90363-6; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; RATNASABAPATHY R, 1990, GENE DEV, V4, P2061, DOI 10.1101/gad.4.12a.2061; RICE AP, 1988, NATURE, V332, P551, DOI 10.1038/332551a0; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SADAIE MR, 1988, SCIENCE, V239, P910, DOI 10.1126/science.3277284; SELBY MJ, 1989, GENE DEV, V3, P547, DOI 10.1101/gad.3.4.547; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SMALE ST, 1985, MOL CELL BIOL, V5, P352, DOI 10.1128/MCB.5.2.352; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x; ZEICHNER SL, 1991, J VIROL, V65, P2436, DOI 10.1128/JVI.65.5.2436-2444.1991; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823	34	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15823	15832						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340407				2022-12-27	WOS:A1993LN30500073
J	BASSE, CW; FATH, A; BOLLER, T				BASSE, CW; FATH, A; BOLLER, T			HIGH-AFFINITY BINDING OF GLYCOPEPTIDE ELICITOR TO TOMATO CELLS AND MICROSOMAL-MEMBRANES AND DISPLACEMENT BY SPECIFIC GLYCAN SUPPRESSORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOYBEAN GLYCINE-MAX; ETHYLENE BIOSYNTHESIS; PLANT-CELLS; TRANSDUCTION; FRACTIONS; INVITRO; SIGNAL; INVIVO	We have previously isolated glycopeptides derived from yeast invertase that acted as highly potent elicitors in suspension-cultured tomato cells, inducing ethylene biosynthesis and phenylalanine ammonia-lyase activity, and we have found that the high mannose oligosaccharides released from the pure glycopeptide elicitors by endo-beta-N-acetylglucosaminidase H acted as suppressors of elicitor activity (Basse, C. W., Bock, K., and Boller, T. (1992) J. Biol. Chem. 267, 10258-10265). One of the elicitor-active glycopeptides (gp 8c) was labeled with t-butoxycarbonyl-L-[S-35]methionine and purified by reversed phase high performance liquid chromatography resulting in a specific radioactivity of the derivative of about 900 Ci/mmol. This radiolabeled glycopeptide showed specific, saturable, and reversible binding to whole tomato cells under conditions in which cells are responsive to elicitors as well as to microsomal membranes derived from these cells. Ligand saturation experiments, performed with microsomal membranes, gave a dissociation constant (K(d)) of 3.3 nm as determined by Scatchard analysis. Various glycopeptide elicitors and preparations from yeast invertase were compared with respect to their abilities to compete for binding of S-35-labeled gp 8c to tomato membranes and to induce ethylene biosynthesis in tomato cells. These studies revealed a high degree of correlation between elicitor activities in vivo and displacement activities in vitro. In both tests, a high activity depended on the presence of glycan side chains consisting of more than 8 mannosyl residues. The high mannose oligosaccharides that acted as suppressors of elicitor activity in vivo competed for binding of the labeled elicitor also. The suppressor-active glycan Man11GlcNAc and the elicitor-active gp 8c exhibited very similar displacement activities, and the inhibitory constant (K(i)) of the glycan Man11GlcNAc was very similar to the K(d) value calculated for S-35-labeled gp 8c, indicating that the glycopeptide elicitors and the glycan suppressors derived from these elicitors competed with similar affinities for the same binding site. The suppressor-inactive glycan Man8GlcNAc had a 200-fold lower capacity to compete for binding of S-35-labeled gp 8c to tomato membranes compared with the suppressor-active glycan Man11GlcNAc. Our results demonstrate the existence of a specific elicitor binding site in tomato cell membranes and suggest that glycopeptides and glycans act as agonists and antagonists for induction of the stress response, respectively, by competing for this binding site.	FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research			Boller, Thomas/G-3500-2012	Boller, Thomas/0000-0001-6768-7503				BASSE CW, 1992, J BIOL CHEM, V267, P10258; BASSE CW, 1992, PLANT PHYSIOL, V98, P1239, DOI 10.1104/pp.98.4.1239; BOLLER T, 1990, POLYAMINES ETHYLENE, P138; Boller T., 1986, PLANT PROTEOLYTIC EN, V2, P67; Boller T., 1991, PLANT HORMONE ETHYLE; Cantor C. R., 1980, BIOPHYSICAL CHEM 3; CHEONG JJ, 1991, PLANT CELL, V3, P137, DOI 10.1105/tpc.3.2.137; COSIO EG, 1992, EUR J BIOCHEM, V204, P1115, DOI 10.1111/j.1432-1033.1992.tb16736.x; COSIO EG, 1990, FEBS LETT, V271, P223, DOI 10.1016/0014-5793(90)80411-B; COSIO EG, 1988, EUR J BIOCHEM, V175, P309, DOI 10.1111/j.1432-1033.1988.tb14198.x; DIXON RA, 1990, ANNU REV PLANT PHYS, V41, P339, DOI 10.1146/annurev.pp.41.060190.002011; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; EBEL J, 1992, PLANT GENE RES GENES, P183; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; FELIX G, 1991, P NATL ACAD SCI USA, V88, P8831, DOI 10.1073/pnas.88.19.8831; FELIX G, 1991, PLANT PHYSIOL, V97, P19, DOI 10.1104/pp.97.1.19; GALLAGHER SR, 1982, PLANT PHYSIOL, V70, P1335, DOI 10.1104/pp.70.5.1335; GROSSKOPF DG, 1990, FEBS LETT, V275, P177, DOI 10.1016/0014-5793(90)81466-2; HORN MA, 1989, PLANT CELL, V1, P1003, DOI 10.1105/tpc.1.10.1003; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; RODRIGO I, 1991, PLANT PHYSIOL, V95, P616, DOI 10.1104/pp.95.2.616; SCHEEL D, 1990, Z NATURFORSCH C, V45, P569; SCHMIDT WE, 1987, P NATL ACAD SCI USA, V84, P4117, DOI 10.1073/pnas.84.12.4117; SHARON N, 1989, LECTINS; SPANU P, 1990, PLANT PHYSIOL, V93, P1482, DOI 10.1104/pp.93.4.1482; TANNER W, 1987, BIOCHIM BIOPHYS ACTA, V906, P81, DOI 10.1016/0304-4157(87)90006-2; VERA P, 1989, PHYSIOL MOL PLANT P, V34, P323, DOI 10.1016/0885-5765(89)90029-5; WEI ZM, 1992, SCIENCE, V257, P85, DOI 10.1126/science.1621099; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103	29	100	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14724	14731						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325850				2022-12-27	WOS:A1993LL75900032
J	BERGFUSSMAN, A; GRACE, ME; IOANNOU, Y; GRABOWSKI, GA				BERGFUSSMAN, A; GRACE, ME; IOANNOU, Y; GRABOWSKI, GA			HUMAN ACID BETA-GLUCOSIDASE - N-GLYCOSYLATION SITE OCCUPANCY AND THE EFFECT OF GLYCOSYLATION ON ENZYMATIC-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; GAUCHER DISEASE TYPE-1; DIRECTED MUTAGENESIS; GENETIC-HETEROGENEITY; CULTURED FIBROBLASTS; CATALYTIC ACTIVITY; BINDING-SITES; GLUCOCEREBROSIDASE; SEQUENCE; DNA	The five potential N-glycosylation sites (sequons) of human acid beta-glucosidase were individually mutated to determine site occupancy and the effect of site occupancy on selected catalytic and stability properties of this enzyme. Each N-glycosylation consensus sequence [Asn-Xaa-(Ser/Thr)] was obliterated by individually substituting glutamine (Q) for asparagine (N). By expression of the normal and mutated cDNAs in insect (Sf9) and COS-1 cells and subsequent immunoblotting with anti-human acid beta-glucosidase antibodies, the four sequons at Asn-19, Asn-59, Asn-146, and Asn-270 were shown to be glycosylated in either source. The sequon at Asn-462 was never occupied. The mutant enzymes N59Q, N146Q, and N270Q were catalytically active and had normal interactions with active site-directed inhibitors as well as with the activators, phosphatidylserine and saposin C. Of the occupied sequons, N-glycosylation of the first was critical to the synthesis of a catalytically active enzyme. Alteration of this sequon, Asn-19-Ala-20-Thr-21, by the substitutions N19Q, N19D, N19E, or T21G led to a lack of glycosylation at this site. Enzymes containing N19Q, N19E, or T21G had significant decreases (3- to 60-fold) in intrinsic enzyme activity. The N19D enzyme had nearly normal catalytic activity and had enhanced activation by phosphatidylserine. These results show that sequon occupancy as well as steric effects at residue 19 are important for the development of an active conformer of this enzyme. This is the first example of a lysosomal hydrolase that requires sequon occupancy for the synthesis of a catalytically active	CHILDRENS HOSP MED CTR,DIV HUMAN GENET,ELLAND & BETHESDA AVE,CINCINNATI,OH 45229; CUNY MT SINAI SCH MED,DEPT PEDIAT,DIV MED & MOLEC GENET,NEW YORK,NY 10029	Cincinnati Children's Hospital Medical Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NCRR NIH HHS [RR-71] Funding Source: Medline; NIDDK NIH HHS [DK 36729] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036729] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGMANN JE, 1989, AM J HUM GENET, V44, P741; BEUTLER E, 1985, AM J HUM GENET, V37, P1062; BEUTLER E, 1993, METABOLIC BASIS INHE; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BRADY RO, 1965, BIOCHEM BIOPH RES CO, V18, P221, DOI 10.1016/0006-291X(65)90743-6; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DINUR T, 1986, P NATL ACAD SCI USA, V83, P1660, DOI 10.1073/pnas.83.6.1660; DINUR T, 1984, ANAL BIOCHEM, V136, P223, DOI 10.1016/0003-2697(84)90329-4; DOEBBER TW, 1982, J BIOL CHEM, V257, P2193; ERICKSON AH, 1985, J BIOL CHEM, V260, P4319; FABBRO D, 1987, AM J HUM GENET, V40, P15; FABBRO D, 1991, J BIOL CHEM, V266, P15021; FALLET S, 1992, PEDIATR RES, V31, P496, DOI 10.1203/00006450-199205000-00018; GINNS EI, 1982, P NATL ACAD SCI-BIOL, V79, P5607, DOI 10.1073/pnas.79.18.5607; GLEW RH, 1988, LAB INVEST, V58, P5; GRABOWSKI GA, 1990, CRIT REV BIOCHEM MOL, V25, P385, DOI 10.3109/10409239009090616; GRABOWSKI GA, 1984, ANAL BIOCHEM, V141, P267, DOI 10.1016/0003-2697(84)90456-1; GRABOWSKI GA, 1985, AM J MED GENET, V21, P529, DOI 10.1002/ajmg.1320210316; GRACE ME, 1990, BIOCHEM BIOPH RES CO, V168, P771, DOI 10.1016/0006-291X(90)92388-G; GRACE ME, 1990, J BIOL CHEM, V265, P6827; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HONG CM, 1990, DNA CELL BIOL, V9, P233, DOI 10.1089/dna.1990.9.233; Martin B M, 1989, Adv Pediatr, V36, P277; OHASHI T, 1991, J BIOL CHEM, V266, P3661; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; OSIECKINEWMAN K, 1988, ENZYME, V40, P173, DOI 10.1159/000469161; PAREKH RB, 1989, BIOCHEMISTRY-US, V28, P7670, DOI 10.1021/bi00445a023; PAREKH RB, 1989, BIOCHEMISTRY-US, V28, P7644, DOI 10.1021/bi00445a021; ROITSCH T, 1989, EUR J BIOCHEM, V181, P525, DOI 10.1111/j.1432-1033.1989.tb14755.x; SAMBROOK J, 1988, MOL CLONING LABORATO; SANO A, 1988, J BIOL CHEM, V263, P19597; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P1224; SEMENKOVICH CF, 1990, J BIOL CHEM, V265, P5429; TAKASAKI S, 1984, J BIOL CHEM, V259, P112; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; VANWEELY S, 1991, BIOCHIM BIOPHYS ACTA, V1096, P301, DOI 10.1016/0925-4439(91)90066-I; WEINREB NJ, 1968, BIOCHIM BIOPHYS ACTA, V159, P141, DOI 10.1016/0005-2744(68)90251-9; WITTWER AJ, 1989, BIOCHEMISTRY-US, V28, P7662, DOI 10.1021/bi00445a022; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	41	87	107	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14861	14866						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325864				2022-12-27	WOS:A1993LL75900051
J	HIDALGO, C; JORQUERA, J; TAPIA, V; DONOSO, P				HIDALGO, C; JORQUERA, J; TAPIA, V; DONOSO, P			TRIADS AND TRANSVERSE TUBULES ISOLATED FROM SKELETAL-MUSCLE CONTAIN HIGH-LEVELS OF INOSITOL 1,4,5-TRISPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL FOOT PROTEIN; SARCOPLASMIC-RETICULUM; CALCIUM CHANNELS; RABBIT SKELETAL; FROG; TRISPHOSPHATE; MEMBRANES; RELEASE; FIBERS; 1,3,4,5-TETRAKISPHOSPHATE	We measured the content of inositol 1,4,5-trisphosphate in sarcoplasmic reticulum, transverse tubules, and triads isolated from frog skeletal muscle, as well as in triads isolated from rabbit skeletal muscle. We found that acid extracts of both transverse tubules and triads contained significant amounts of inositol 1,4,5-trisphosphate, in the range of 300-400 pmol/mg of protein as determined by a radioreceptor assay, whereas no detectable amounts were found in sarcoplasmic reticulum vesicles. The identity of inositol 1,4,5-trisphosphate in the extracts was confirmed by comigration with [H-3]inositol 1,4,5-trisphosphate on polyethyleneimine-cellulose plates, and by phosphorylation to inositol 1,3,4,5-tetrakisphosphate using the inositol 1,4,5-trisphosphate 3-kinase present in muscle extracts. These findings may have important physiological implications. First, the results indicate that the muscle plasma membrane regions differentiated as transverse tubules contain high amounts of inositol 1,4,5-trisphosphate, suggesting that they might possess a high density of binding sites for this compound. Second, since inositol 1,4,5-trisphosphate has been proposed as a chemical transmitter in excitation-contraction coupling in skeletal muscle, our finding that this second messenger is present in high density at the site of coupling may contribute to the understanding of its role in this process.	UNIV CHILE,FAC MED,DEPT FISIOL & BIOFIS,SANTIAGO,CHILE	Universidad de Chile	HIDALGO, C (corresponding author), CTR ESTUDIOS CIENT SANTIAGO,CASILLA 16443,SANTIAGO 9,CHILE.		HIDALGO, Cecilia/H-7107-2013					BATTY IR, 1985, BIOCHEM J, V232, P211, DOI 10.1042/bj2320211; BRANDT NR, 1990, J MEMBRANE BIOL, V113, P237, DOI 10.1007/BF01870075; BREDT DS, 1989, BIOCHEM BIOPH RES CO, V159, P976, DOI 10.1016/0006-291X(89)92204-3; BULL R, 1989, BIOPHYS J, V56, P749, DOI 10.1016/S0006-3495(89)82722-5; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; CARRASCO MA, 1993, BIOPHYS J, V64, pA154; DEWAARD M, 1992, NEURON, V9, P497, DOI 10.1016/0896-6273(92)90187-I; DONALDSON SK, 1988, P NATL ACAD SCI USA, V85, P5749, DOI 10.1073/pnas.85.15.5749; FADOOL DA, 1992, NEURON, V9, P907, DOI 10.1016/0896-6273(92)90243-7; FOSTER PS, 1989, LANCET, V2, P124, DOI 10.1016/S0140-6736(89)90182-7; HANNON JD, 1992, J MUSCLE RES CELL M, V13, P447, DOI 10.1007/BF01738039; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HIDALGO C, 1986, FEBS LETT, V202, P69, DOI 10.1016/0014-5793(86)80651-2; HIDALGO C, 1986, BIOCHIM BIOPHYS ACTA, V855, P79, DOI 10.1016/0005-2736(86)90191-4; HIDALGO C, 1989, J BIOENERG BIOMEMBR, V21, P267, DOI 10.1007/BF00812072; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; JAIMOVICH E, 1991, J MUSCLE RES CELL M, V12, P316, DOI 10.1007/BF01738586; JAIMOVICH E, 1986, BIOCHIM BIOPHYS ACTA, V855, P89, DOI 10.1016/0005-2736(86)90192-6; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZ JR, 1991, CELL CALCIUM, V12, P543, DOI 10.1016/0143-4160(91)90074-O; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MAYR GW, 1991, BIOCHEM J, V280, P631, DOI 10.1042/bj2800631; OLIVARES EB, 1991, BIOPHYS J, V59, P1153, DOI 10.1016/S0006-3495(91)82331-1; PETERSEN OH, 1992, NEW PHYSL, V7, P193; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; ROJAS C, 1990, PFLUG ARCH EUR J PHY, V416, P296, DOI 10.1007/BF00392066; SCHOLZ J, 1991, LANCET, V337, P1361, DOI 10.1016/0140-6736(91)93052-B; SPENCER CEL, 1990, METHODS INOSITIDE RE, P39; Stephens L. R., 1990, METHODS INOSITIDE RE, P9; SUAREZISLA BA, 1991, J PHYSIOL-LONDON, V441, P575, DOI 10.1113/jphysiol.1991.sp018768; THEIBERT AB, 1990, BIOCHEM J, V267, P441, DOI 10.1042/bj2670441; THIELECZEK R, 1989, J BIOL CHEM, V264, P7349; VALDIVIA C, 1992, BIOPHYS J, V61, P1184, DOI 10.1016/S0006-3495(92)81927-6; VARSANYI M, 1986, BIOCHEM BIOPH RES CO, V138, P1395, DOI 10.1016/S0006-291X(86)80438-7; VERGARA J, 1985, P NATL ACAD SCI USA, V82, P6352, DOI 10.1073/pnas.82.18.6352; VILVEN J, 1988, NATURE, V336, P587, DOI 10.1038/336587a0; VOLPE P, 1985, NATURE, V316, P347, DOI 10.1038/316347a0	39	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15111	15117						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325886				2022-12-27	WOS:A1993LL75900083
J	LOW, PS; RATHINAVELU, P; HARRISON, ML				LOW, PS; RATHINAVELU, P; HARRISON, ML			REGULATION OF GLYCOLYSIS VIA REVERSIBLE ENZYME BINDING TO THE MEMBRANE-PROTEIN, BAND-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL MEMBRANE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; ERYTHROCYTE-MEMBRANES; TYROSINE PHOSPHORYLATION; BLOOD-CELL; ASSOCIATION; ALDOLASE; PHOSPHOFRUCTOKINASE; SITE; ATP	Most metabolic pathways are regulated by feedback inhibition/activation or by covalent modification of a regulatory enzyme. In erythrocytes, however, we demonstrate that glycolysis can be modulated over 30-fold by controlling the availability of glycolytic enzyme binding sites at the extreme N terminus of the anion transporter, band 3. Direct obstruction of these inhibitory sites by anti-peptide Fab's against residues 1-15 of band 3 promotes an approximately 3-fold increase in the rate of lactate production. In contrast, enrichment of the erythrocyte cytoplasm with the band 3 peptide against which the above antibodies were raised results in a more than 10-fold decrease in the rate of lactate accumulation. Control peptides and their derived antipeptide antibodies corresponding to other sequences of band 3 or glycophorin were found to have no effect on lactate production. Analysis of changes in glycolytic intermediates during Fab treatments suggests that hexokinase may be one enzyme that is modulated by association with band 3. We conclude that the extreme N terminus of band 3 can bind and inhibit glycolytic enzymes in vivo and that it probably participates in control of red cell glycolysis.	PURDUE UNIV,DEPT MEDICINAL CHEM & PHARMACOGNOSY,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus	LOW, PS (corresponding author), PURDUE UNIV,DEPT CHEM,W LAFAYETTE,IN 47907, USA.			Low, Philip/0000-0001-9042-5528	NIGMS NIH HHS [GM40983] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040983] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN DP, 1988, THESIS PURDUE U, P15; ARESE P, 1977, ACTA BIOL MED GER, V36, P481; BERGMEYER HU, 1965, METHODS ENZYMATIC AN; Beutler E, 1982, GLUTATHIONE RED CELL, V3 rd; CHEUNG CW, 1989, J BIOL CHEM, V264, P4038; DEMUTH DR, 1986, EMBO J, V5, P1205, DOI 10.1002/j.1460-2075.1986.tb04348.x; DURRIEU C, 1987, ARCH BIOCHEM BIOPHYS, V252, P32, DOI 10.1016/0003-9861(87)90005-1; FOSSEL ET, 1978, BIOCHIM BIOPHYS ACTA, V510, P99, DOI 10.1016/0005-2736(78)90133-5; FUNDER J, 1967, ACTA PHYSIOL SCAND, V71, P113, DOI 10.1111/j.1748-1716.1967.tb03716.x; HARRIS SJ, 1990, BIOCHIM BIOPHYS ACTA, V1038, P306, DOI 10.1016/0167-4838(90)90242-8; HARRISON ML, 1991, J BIOL CHEM, V266, P4106; HIGASHI T, 1979, J BIOL CHEM, V254, P9542; JENKINS JD, 1984, J BIOL CHEM, V259, P9374; KLIMAN HJ, 1980, J BIOL CHEM, V255, P6314; LOMBARDO CR, 1992, J BIOL CHEM, V267, P9540; LOW PS, 1987, J BIOL CHEM, V262, P4592; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARETZKI D, 1989, TRENDS BIOCHEM SCI, V14, P93, DOI 10.1016/0968-0004(89)90128-X; MASTERS CJ, 1981, CRC CR REV BIOCH MOL, V11, P105, DOI 10.3109/10409238109108700; MERCER RW, 1981, J GEN PHYSIOL, V78, P547, DOI 10.1085/jgp.78.5.547; MISHRA RK, 1969, J MEMBRANE BIOL, V1, P214, DOI 10.1007/BF01869782; MURTHY SNP, 1981, J BIOL CHEM, V256, P1203; OVADI J, 1988, TRENDS BIOCHEM SCI, V13, P486, DOI 10.1016/0968-0004(88)90237-X; PROVERBIO F, 1977, J GEN PHYSIOL, V69, P605, DOI 10.1085/jgp.69.5.605; ROGALSKI AA, 1989, J BIOL CHEM, V264, P6438; SOLTI M, 1976, MOL CELL BIOCHEM, V10, P145, DOI 10.1007/BF01731685; SRERE PA, 1990, TRENDS BIOCHEM SCI, V15, P411, DOI 10.1016/0968-0004(90)90273-E; STECK TL, 1974, J CELL BIOL, V62, P1, DOI 10.1083/jcb.62.1.1; THIELECZEK R, 1989, J BIOL CHEM, V264, P7349; TSAI IH, 1982, J BIOL CHEM, V257, P1438; WALSH JL, 1987, BIOCHIM BIOPHYS ACTA, V952, P83; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893	33	157	159	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14627	14631						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325839				2022-12-27	WOS:A1993LL75900018
J	RAO, KS; PRAKASH, V				RAO, KS; PRAKASH, V			INTERACTION OF SODIUM DODECYL-SULFATE WITH MULTISUBUNIT PROTEINS - A CASE-STUDY WITH CARMIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEED CARTHAMUS-TINCTORIUS; CIRCULAR-DICHROISM; COMPLEXES; CONFORMATION; DISSOCIATION; FRACTION; BOVINE	Sodium dodecyl sulfate (SDS) dissociates the multimeric protein, carmin, into its monomers (2 S) at low concentration. Dissociation begins at and above 1.6 mm SDS concentration and reaches 50% at 5 mM SDS concentration. Denaturation occurs above 5 mM SDS concentration. The dissociation step involves binding of 540 +/- 50 mol of SDS/mol of protein with an association constant, K(a) of 6.90 +/- 0.35 x 10(2) M-1. The interaction reflects a DELTAG0 = -4.0 +/- 0.1 kcal mol-1. In the denaturation step, the K(a) has the same value, and the gamma value is nearly 2-fold higher. Dissociation of carmin thus begins only above a binding of 0.60 g of SDS/g of protein. Analysis of the binding data at 37-degrees-C indicates a maximum of 1030 +/- 90 mol of SDS bound/mol of protein, which is equivalent to 1.14 +/- 0.10 g of SDS/g of protein. Upon denaturation, the alpha-helix content of the protein increases from 4 to 15%. Kinetically, the denaturation process consists of a two-step process (a fast and a slow step). The first order rate constants for these steps are 89.6 +/- 8.1 and 15.8 +/- 1.5 min-1, respectively, at 6.3 mM SDS concentration. The processes of dissociation and denaturation occur sequentially. Dissociation of the protein is reversible, whereas the process of denaturation is only partially reversible as reflected by sedimentation velocity and conformational analysis. These data are taken as a model for general understanding of the dissociation and/or denaturation processes, which could be either sequential or simultaneous in multimeric proteins.	CENT FOOD TECHNOL RES INST, DEPT PROT TECHNOL, MYSORE 570013, KARNATAKA, INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Food Technological Research Institute (CFTRI)								BRADBURY JH, 1970, PHYSICAL PRINCIPLE B, P99; CHEN YH, 1971, BIOCHEM BIOPH RES CO, V44, P1285, DOI 10.1016/S0006-291X(71)80225-5; Donovan J W, 1973, Methods Enzymol, V27, P525; Hiromi K., 1979, KINETICS FAST ENZYME; HUNT AH, 1973, BIOCHEMISTRY-US, V12, P4435, DOI 10.1021/bi00746a021; JIRGENSONS B, 1966, J BIOL CHEM, V241, P4855; JIRGENSONS B, 1982, J PROTEIN CHEM, V1, P71; JONES MN, 1982, BIOCHEM J, V203, P285, DOI 10.1042/bj2030285; JONES MN, 1982, BIOPOLYMERS, V21, P1435, DOI 10.1002/bip.360210712; KLOTZ IM, 1975, PROTEINS, V1, P294; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHA TS, 1986, NAHRUNG, V30, P833; LATHA TS, 1984, J AGR FOOD CHEM, V32, P1412, DOI 10.1021/jf00126a048; LUNDAHL P, 1986, BIOCHIM BIOPHYS ACTA, V873, P20, DOI 10.1016/0167-4838(86)90184-6; MATTICE WL, 1976, BIOCHEMISTRY-US, V15, P4264, DOI 10.1021/bi00664a020; MUKERJEE P, 1956, ANAL CHEM, V28, P870, DOI 10.1021/ac60113a026; NOZAKI Y, 1974, J BIOL CHEM, V249, P4452; PITTRIVE.R, 1968, BIOCHEM J, V109, P825, DOI 10.1042/bj1090825; PRAKASH V, 1986, CRC CR REV BIOCH MOL, V20, P265, DOI 10.3109/10409238609083736; PRAKASH V, 1988, J BIOSCIENCE, V13, P171, DOI 10.1007/BF02903099; PRAKASH V, 1980, INT J PEPT PROT RES, V15, P305; PRAKASH V, 1976, INT J PEPT PROT RES, V8, P385; PRAKASH V, 1986, INT J PEPT PROT RES, V28, P192; RAJENDRAN S, 1988, J PROTEIN CHEM, V7, P689, DOI 10.1007/BF01025578; RAO KS, 1989, J PROTEIN CHEM, V8, P529; RAY A, 1966, BIOCHEMISTRY-US, V5, P2606, DOI 10.1021/bi00872a019; REYNOLDS JA, 1967, BIOCHEMISTRY-US, V6, P937, DOI 10.1021/bi00855a038; REYNOLDS JA, 1970, P NATL ACAD SCI USA, V66, P1002, DOI 10.1073/pnas.66.3.1002; REYNOLDS JA, 1970, J BIOL CHEM, V245, P5161; SCHACHMAN HK, 1959, ULTRACENTRIFUGATION, P75; SHIRAHAMA K, 1974, J BIOCHEM, V75, P309, DOI 10.1093/oxfordjournals.jbchem.a130398; STEINHAR.J, 1973, BIOCHEMISTRY-US, V12, P1789, DOI 10.1021/bi00733a020; SURESHCHANDRA BR, 1987, J AGR FOOD CHEM, V35, P244, DOI 10.1021/jf00074a019; TAKEDA K, 1990, J PROTEIN CHEM, V9, P573, DOI 10.1007/BF01025010; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; TEALE FWJ, 1957, BIOCHEM J, V65, P476, DOI 10.1042/bj0650476; TEALE FWJ, 1960, BIOCHEM J, V76, P381, DOI 10.1042/bj0760381; VANHOLDE KE, 1971, PHYSICAL BIOCH, P51; WEBER K, 1969, J BIOL CHEM, V244, P4406; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019; ZIRWER D, 1989, NAHRUNG, V33, P929, DOI 10.1002/food.19890331004	41	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14769	14775						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325854				2022-12-27	WOS:A1993LL75900038
